FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Carlson, C Merel, SE Yukawa, M AF Carlson, Charlotte Merel, Susan E. Yukawa, Michi TI Geriatric Syndromes and Geriatric Assessment for the Generalist SO MEDICAL CLINICS OF NORTH AMERICA LA English DT Article DE Geriatric syndromes; Geriatric assessment; Frailty; Care delivery systems; Primary care ID RANDOMIZED CONTROLLED-TRIAL; MILD COGNITIVE IMPAIRMENT; OLDER-ADULTS; URINARY-INCONTINENCE; CARE MANAGEMENT; TRANSITIONAL CARE; CLINICAL-PRACTICE; ELDERLY-PATIENTS; TASK-FORCE; TAI CHI AB Geriatric assessment is an increasingly important area of outpatient medicine, given the unprecedented aging of the US population. Screening and evaluation for geriatric syndromes, particularly falls, urinary incontinence, frailty, and cognitive impairment, are crucial aspects of outpatient geriatric assessment. Innovative models of care are emerging to improve quality of care and enhance cost savings for the geriatric patient. High-value features of geriatric care systems include providing increased 24/7 access to care, a multidisciplinary team-based approach to care, performing medication reconciliation and comprehensive geriatric assessments, and integrating palliative care into treatment planning. C1 [Carlson, Charlotte] Inst Aging, On Lok Senior Hlth, San Francisco, CA 94118 USA. [Merel, Susan E.] Univ Washington, Dept Med, Div Gen Internal Med, Seattle, WA 98195 USA. [Yukawa, Michi] San Francisco VA Med Ctr, San Francisco, CA 93121 USA. RP Carlson, C (reprint author), Inst Aging, On Lok Senior Hlth, 3575 Geary Blvd, San Francisco, CA 94118 USA. EM Charlotte.carlson@ucsf.edu NR 69 TC 9 Z9 9 U1 5 U2 17 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0025-7125 EI 1557-9859 J9 MED CLIN N AM JI Med. Clin. N. Am. PD MAR PY 2015 VL 99 IS 2 BP 263 EP + DI 10.1016/j.mcna.2014.11.003 PG 18 WC Medicine, General & Internal SC General & Internal Medicine GA CD8CH UT WOS:000351322300005 PM 25700583 ER PT J AU Lum, HD Sudore, RL Bekelman, DB AF Lum, Hillary D. Sudore, Rebecca L. Bekelman, David B. TI Advance Care Planning in the Elderly SO MEDICAL CLINICS OF NORTH AMERICA LA English DT Article DE Advance care planning; Advance directives; Surrogate decision maker; Patient-doctor relationship; Communication ID OF-LIFE CARE; RANDOMIZED CONTROLLED-TRIAL; SURROGATE DECISION-MAKING; SUSTAINING TREATMENT; TREATMENT PREFERENCES; NURSING FACILITIES; PHYSICIAN ORDERS; OLDER-ADULTS; END; DIRECTIVES AB Key components of advance care planning (ACP) for the elderly include choosing a surrogate decision maker, identifying personal values, communicating with surrogates and clinicians, documenting wishes in advance directives, and translating values and preferences for future medical care into medical orders. ACP often involves multiple brief discussions over time. This article outlines common benefits and barriers to ACP in primary care, and provides practical approaches to integrating key ACP components into primary care for older adults. Opportunities for multidisciplinary teams to incorporate ACP into brief clinic visits are highlighted. C1 [Lum, Hillary D.] Univ Colorado, Sch Med, Dept Med, Div Geriatr Med, Aurora, CO 80045 USA. [Lum, Hillary D.] VA Eastern Colorado Healthcare Syst, Dept Med, Denver, CO 80220 USA. [Sudore, Rebecca L.] Univ Calif San Francisco, Div Geriatr, San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Bekelman, David B.] Univ Colorado, Sch Med, Dept Med, Div Gen Internal Med, Aurora, CO 80045 USA. [Bekelman, David B.] VA Eastern Colorado Healthcare Syst, Dept Med, Denver, CO 80220 USA. RP Lum, HD (reprint author), Univ Colorado, Sch Med, Dept Med, Div Geriatr Med, 12631 East 17th Ave,B-179, Aurora, CO 80045 USA. EM Hillary.Lum@ucdenver.edu NR 48 TC 6 Z9 7 U1 7 U2 19 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0025-7125 EI 1557-9859 J9 MED CLIN N AM JI Med. Clin. N. Am. PD MAR PY 2015 VL 99 IS 2 BP 391 EP + DI 10.1016/j.mcna.2014.11.010 PG 14 WC Medicine, General & Internal SC General & Internal Medicine GA CD8CH UT WOS:000351322300012 PM 25700590 ER PT J AU Rodriguez, JC Dzierzewski, JM Alessi, CA AF Carlos Rodriguez, Juan Dzierzewski, Joseph M. Alessi, Cathy A. TI Sleep Problems in the Elderly SO MEDICAL CLINICS OF NORTH AMERICA LA English DT Article DE Sleep problems; Sleep apnea; Insomnia; Older adults; Diagnosis and treatment ID RANDOMIZED CONTROLLED-TRIAL; OLDER-ADULTS; INSOMNIA; APNEA; COMPLAINTS; PRESSURE AB Epidemiologic studies have shown that approximately 50% of older adults have sleep problems, many of which carry deleterious consequences that affect physical and mental health and also social functioning. However, sleep problems in late life are often unrecognized, and are inadequately treated in clinical practice. This article focuses on the diagnosis and treatment of the 2 most common sleep problems in older patients: sleep apnea and insomnia. C1 [Carlos Rodriguez, Juan; Dzierzewski, Joseph M.; Alessi, Cathy A.] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, North Hills, CA 91343 USA. [Carlos Rodriguez, Juan; Dzierzewski, Joseph M.; Alessi, Cathy A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Carlos Rodriguez, Juan] Pontificia Univ Catolica Chile, Dept Med, Santiago, Chile. RP Rodriguez, JC (reprint author), VA Greater Los Angeles Healthcare Syst, 16111 Plummer St 11E, North Hills, CA 91343 USA. EM juan.rodrigueztapia@va.gov FU UCLA Claude D. Pepper Older Americans Independence Center [NIA 5P30 AG028748]; NIH/NCATS UCLA CM [UL1TR000124]; VA Advanced Geriatrics Fellowship Program; Geriatric Research, Education, and Clinical Center (GRECC); VA Greater Los Angeles Healthcare System FX This work was supported by UCLA Claude D. Pepper Older Americans Independence Center (NIA 5P30 AG028748); NIH/NCATS UCLA CM (UL1TR000124); the VA Advanced Geriatrics Fellowship Program; the Geriatric Research, Education, and Clinical Center (GRECC); and the VA Greater Los Angeles Healthcare System. NR 19 TC 8 Z9 11 U1 3 U2 15 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0025-7125 EI 1557-9859 J9 MED CLIN N AM JI Med. Clin. N. Am. PD MAR PY 2015 VL 99 IS 2 BP 431 EP + DI 10.1016/j.mcna.2014.11.013 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA CD8CH UT WOS:000351322300015 PM 25700593 ER PT J AU Win, AZ Aparici, CM AF Win, A. Z. Aparici, C. M. TI Non-traumatic radiation-induced avascular necrosis of the femoral neck SO QJM-AN INTERNATIONAL JOURNAL OF MEDICINE LA English DT Editorial Material ID HIP C1 [Win, A. Z.] San Francisco VA Med Ctr, Dept Radiol, San Francisco, CA 94121 USA. [Aparici, C. M.] UCSF, Dept Radiol, San Francisco, CA 94143 USA. RP Win, AZ (reprint author), San Francisco VA Med Ctr, Dept Radiol, 4150 Clement St, San Francisco, CA 94121 USA. EM aungzwin@gmail.com NR 5 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1460-2725 EI 1460-2393 J9 QJM-INT J MED JI QJM-An Int. J. Med. PD MAR 1 PY 2015 VL 108 IS 3 BP 257 EP 258 DI 10.1093/qjmed/hcu190 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA CE0UN UT WOS:000351522900018 PM 25208894 ER PT J AU Win, AZ Aparici, CM AF Win, A. Z. Aparici, C. M. TI Distant bone metastasis from supraglottic squamous cell carcinoma SO QJM-AN INTERNATIONAL JOURNAL OF MEDICINE LA English DT Editorial Material ID NECK C1 [Win, A. Z.] San Francisco VA Med Ctr, Dept Radiol, San Francisco, CA 94121 USA. [Aparici, C. M.] UCSF, Dept Radiol, San Francisco, CA 94143 USA. RP Win, AZ (reprint author), San Francisco VA Med Ctr, Dept Radiol, 4150 Clement St, San Francisco, CA 94121 USA. EM aungzwin@gmail.com NR 5 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1460-2725 EI 1460-2393 J9 QJM-INT J MED JI QJM-An Int. J. Med. PD MAR 1 PY 2015 VL 108 IS 3 BP 259 EP 260 DI 10.1093/qjmed/hcu199 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA CE0UN UT WOS:000351522900019 PM 25223573 ER PT J AU Tiourin, E Velasco, VS Rosales, MA Sullivan, PS Janzen, DM Memarzadeh, S AF Tiourin, Ekaterina Velasco, Victor S. Rosales, Miguel A. Sullivan, Peggy S. Janzen, Deanna M. Memarzadeh, Sanaz TI Tubal Ligation May Induce Quiescence of Distal Fallopian Tube Epithelia: A Potential Mechanism for Risk Reduction of Serous Carcinomas SO REPRODUCTIVE SCIENCES LA English DT Meeting Abstract C1 [Tiourin, Ekaterina; Velasco, Victor S.; Rosales, Miguel A.; Janzen, Deanna M.; Memarzadeh, Sanaz] Univ Calif Los Angeles, David Geffen Sch Med, Obstet & Gynecol, Los Angeles, CA 90095 USA. [Sullivan, Peggy S.] Univ Calif Los Angeles, David Geffen Sch Med, Pathol & Lab Med, Los Angeles, CA 90095 USA. [Memarzadeh, Sanaz] Univ Calif Los Angeles, Broad Ctr Regenerat Med & Stem Cell Res, Los Angeles, CA USA. [Memarzadeh, Sanaz] VA Greater Los Angeles Hlth Care Syst, Gynecol Oncol, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1933-7191 EI 1933-7205 J9 REPROD SCI JI Reprod. Sci. PD MAR PY 2015 VL 22 SU 1 MA O-017 BP 62A EP 62A PG 1 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA CD9GW UT WOS:000351407200018 ER PT J AU Chattergoon, NN Louey, S Scanlan, T Giraud, GD Thornburg, KL AF Chattergoon, N. N. Louey, S. Scanlan, T. Giraud, G. D. Thornburg, K. L. TI Blockade of T-3 Reveals the Maturation of p21 Signaling in Fetal Cardiomyocytes SO REPRODUCTIVE SCIENCES LA English DT Meeting Abstract C1 [Chattergoon, N. N.; Louey, S.; Giraud, G. D.; Thornburg, K. L.] Oregon Hlth & Sci Univ, Knight Cardiovasc Inst, Portland, OR 97201 USA. [Louey, S.; Scanlan, T.; Thornburg, K. L.] Oregon Hlth & Sci Univ, Physiol & Pharmacol, Portland, OR 97201 USA. [Giraud, G. D.] Portland VA Med Ctr, Cardiol, Portland, OR USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1933-7191 EI 1933-7205 J9 REPROD SCI JI Reprod. Sci. PD MAR PY 2015 VL 22 SU 1 MA O-090 BP 85A EP 86A PG 2 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA CD9GW UT WOS:000351407200091 ER PT J AU Crevensten, H AF Crevensten, Henry TI Patients Recovering from Abdominal Surgery Who Walked with Volunteers Exhibited Improved Postoperative Recovery Profiles During Hospitalization: Reply SO WORLD JOURNAL OF SURGERY LA English DT Letter C1 San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Crevensten, H (reprint author), San Francisco VA Med Ctr, San Francisco, CA 94121 USA. EM hcrevensten@medicine.ucsf.edu NR 2 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0364-2313 EI 1432-2323 J9 WORLD J SURG JI World J.Surg. PD MAR PY 2015 VL 39 IS 3 BP 807 EP 807 DI 10.1007/s00268-014-2907-2 PG 1 WC Surgery SC Surgery GA CD6WM UT WOS:000351230900041 PM 25575459 ER PT J AU Beristianos, M Maguen, S Neylan, T Byers, AL AF Beristianos, Matthew Maguen, Shira Neylan, Thomas Byers, Amy L. TI The Association of Traumatic Experiences with Suicidal Ideation in Older Adults SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-for-Geriatric-Psychiatry CY MAR 27-30, 2015 CL New Orleans, LA SP Amer Assoc Geriatr Psychiat C1 [Beristianos, Matthew; Maguen, Shira; Neylan, Thomas; Byers, Amy L.] San Francisco VA Med Ctr, San Francisco, CA USA. [Beristianos, Matthew; Maguen, Shira; Neylan, Thomas; Byers, Amy L.] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2015 VL 23 IS 3 SU S MA EI 14 BP S81 EP S82 PG 4 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA CD1IV UT WOS:000350829500074 ER PT J AU Byers, AL Lai, A Arean, P Nelson, C Yaffe, K AF Byers, Amy L. Lai, Amy Arean, Patricia Nelson, Craig Yaffe, Kristine TI Mental Health Services Use Across the Lifespan in Adults at High Risk of Suicide SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-for-Geriatric-Psychiatry CY MAR 27-30, 2015 CL New Orleans, LA SP Amer Assoc Geriatr Psychiat C1 [Byers, Amy L.; Arean, Patricia; Nelson, Craig; Yaffe, Kristine] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Byers, Amy L.; Lai, Amy; Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2015 VL 23 IS 3 SU S MA NR 29 BP S173 EP S175 PG 4 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA CD1IV UT WOS:000350829500174 ER PT J AU Cummings, J Lyketsos, CG Tariot, P Peskind, E Nguyen, U Knowles, N Shin, P Siffert, J AF Cummings, Jeffrey Lyketsos, Constantine G. Tariot, Pierre Peskind, Elaine Nguyen, Uyen Knowles, Nadine Shin, Paul Siffert, Joao TI Dextromethorphan/quinidine (AVP-923) Efficacy and Safety for Treatment of Agitation in Persons with Alzheimer's Disease: Results from a Phase 2 Study (NCT01584440) SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-for-Geriatric-Psychiatry CY MAR 27-30, 2015 CL New Orleans, LA SP Amer Assoc Geriatr Psychiat C1 [Cummings, Jeffrey] Cleveland Clin, Lou Ruvo Ctr Brain Hlth, Las Vegas, NV USA. [Lyketsos, Constantine G.] Johns Hopkins Med, Baltimore, MD USA. [Tariot, Pierre] Banner Alzheimers Inst, Phoenix, AZ USA. [Peskind, Elaine] Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Nguyen, Uyen; Knowles, Nadine; Shin, Paul; Siffert, Joao] Avanir Pharmaceut Inc, Aliso Viejo, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2015 VL 23 IS 3 SU S MA NR 18 BP S164 EP S165 PG 3 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA CD1IV UT WOS:000350829500163 ER PT J AU Kasckow, J Cohen, C Rajii, T Hendrie, HC AF Kasckow, John Cohen, Carl Rajii, Tarek Hendrie, Hugh C. TI RECENT ADVANCES IN LATE LIFE SCHIZOPHRENIA RESEARCH SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-for-Geriatric-Psychiatry CY MAR 27-30, 2015 CL New Orleans, LA SP Amer Assoc Geriatr Psychiat C1 [Kasckow, John] VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. [Kasckow, John] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Cohen, Carl] Suny Downstate Med Ctr, New York, NY USA. [Rajii, Tarek] Univ Toronto, Toronto, ON, Canada. [Hendrie, Hugh C.] Indiana Univ, Sch Med, Indianapolis, IN USA. NR 0 TC 0 Z9 0 U1 4 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2015 VL 23 IS 3 SU S MA 407 BP S40 EP S41 PG 3 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA CD1IV UT WOS:000350829500057 ER PT J AU Kasckow, J Waern, M Szanto, K Conwell, Y AF Kasckow, John Waern, Margda Szanto, Katalin Conwell, Yeates TI RECENT RESEARCH IN LATE LIFE SUICIDE SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-for-Geriatric-Psychiatry CY MAR 27-30, 2015 CL New Orleans, LA SP Amer Assoc Geriatr Psychiat C1 [Kasckow, John; Szanto, Katalin] VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. [Kasckow, John; Szanto, Katalin] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Waern, Margda] Univ Gothenburg, Gothenburgh, Sweden. [Conwell, Yeates] Univ Rochester, Rochester, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2015 VL 23 IS 3 SU S MA 108 BP S9 EP S10 PG 4 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA CD1IV UT WOS:000350829500009 ER PT J AU Levine, K Koenig, AM Leong, SH Benson, A Streim, J Oslin, D AF Levine, Katherine Koenig, Aaron M. Leong, Shirley H. Benson, Amy Streim, Joel Oslin, David TI Benzodiazepine Prescription Patterns for Older Adults in Pennsylvania SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-for-Geriatric-Psychiatry CY MAR 27-30, 2015 CL New Orleans, LA SP Amer Assoc Geriatr Psychiat C1 [Levine, Katherine; Koenig, Aaron M.; Benson, Amy; Streim, Joel; Oslin, David] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Leong, Shirley H.; Benson, Amy; Streim, Joel; Oslin, David] Philadelphia VA Med Ctr, VISN Mental Illness Res Educ & Clin Ctr 4, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2015 VL 23 IS 3 SU S MA EI 16 BP S83 EP S84 PG 3 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA CD1IV UT WOS:000350829500076 ER PT J AU Mintzer, J Steinberg, ES Pearson, JL AF Mintzer, Jacobo Steinberg, Ellen S. Pearson, Joseph L. TI ELDER COURTS: A NEW WAY TO PROTECT THE FRAIL ELDERLY POPULATION SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-for-Geriatric-Psychiatry CY MAR 27-30, 2015 CL New Orleans, LA SP Amer Assoc Geriatr Psychiat C1 [Mintzer, Jacobo] Roper St Francis Healthcare, Charleston, SC USA. [Steinberg, Ellen S.] Charleston Cty Magistrate, Charleston, SC USA. [Pearson, Joseph L.] SC Inst Med & Publ Hlth, Columbia, SC USA. [Mintzer, Jacobo] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2015 VL 23 IS 3 SU S MA 315 BP S31 EP S31 PG 1 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA CD1IV UT WOS:000350829500042 ER PT J AU Blevins, JE Graham, JL Morton, GJ Bales, KL Schwartz, MW Baskin, DG Havel, PJ AF Blevins, James E. Graham, James L. Morton, Gregory J. Bales, Karen L. Schwartz, Michael W. Baskin, Denis G. Havel, Peter J. TI Chronic oxytocin administration inhibits food intake, increases energy expenditure, and produces weight loss in fructose-fed obese rhesus monkeys SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Article DE obesity; food intake; energy expenditure; oxytocin ID SUGAR-SWEETENED BEVERAGES; PARAVENTRICULAR NUCLEUS; INSULIN-RESISTANCE; METABOLIC SYNDROME; VISCERAL ADIPOSITY; RECEPTOR AGONIST; GENE-EXPRESSION; DEFICIENT MICE; ONSET OBESITY; NEURONS AB Despite compelling evidence that oxytocin (OT) is effective in reducing body weight (BW) in diet-induced obese (DIO) rodents, studies of the effects of OT in humans and rhesus monkeys have primarily focused on noningestive behaviors. The goal of this study was to translate findings in DIO rodents to a preclinical translational model of DIO. We tested the hypothesis that increased OT signaling would reduce BW in DIO rhesus monkeys by inhibiting food intake and increasing energy expenditure (EE). Male DIO rhesus monkeys from the California National Primate Research Center were adapted to a 12-h fast and maintained on chow and a daily 15% fructose-sweetened beverage. Monkeys received 2 x daily subcutaneous vehicle injections over 1 wk. We subsequently identified doses of OT (0.2 and 0.4 mg/kg) that reduced food intake and BW in the absence of nausea or diarrhea. Chronic administration of OT for 4 wk (0.2 mg/kg for 2 wk; 0.4 mg/kg for 2 wk) reduced BW relative to vehicle by 3.3 +/- 0.4% (approximate to 0.6 kg; P < 0.05). Moreover, the low dose of OT suppressed 12-h chow intake by 26 +/- 7% (P < 0.05). The higher dose of OT reduced 12-h chow intake by 27 +/- 5% (P < 0.05) and 8-h fructose-sweetened beverage intake by 18 +/- 8% (P < 0.05). OT increased EE during the dark cycle by 14 +/- 3% (P < 0.05) and was associated with elevations of free fatty acids and glycerol and reductions in triglycerides suggesting increased lipolysis. Together, these data suggest that OT reduces BW in DIO rhesus monkeys through decreased food intake as well as increased EE and lipolysis. C1 [Blevins, James E.; Baskin, Denis G.] Dept Vet Affairs Med Ctr, Med Res Serv, Off Res & Dev, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Blevins, James E.; Morton, Gregory J.; Schwartz, Michael W.; Baskin, Denis G.] Univ Washington, Med Ctr, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. [Morton, Gregory J.; Schwartz, Michael W.] Univ Washington, Sch Med, Diabet & Obes Ctr Excellence, Seattle, WA USA. [Graham, James L.; Havel, Peter J.] Univ Calif Davis, Sch Vet Med, Dept Nutr, Davis, CA 95616 USA. [Graham, James L.; Havel, Peter J.] Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, Davis, CA 95616 USA. [Bales, Karen L.] Univ Calif Davis, Dept Psychol, Davis, CA 95616 USA. RP Blevins, JE (reprint author), VA Puget Sound Hlth Care Syst, Res 151,1660 South Columbian Way, Seattle, WA 98108 USA. EM jeblevin@u.washington.edu FU Office of Research and Development, Medical Research Service, Department of Veterans Affairs (VA); California National Primate Research Center (CNPRC) Pilot Award [0D011107]; Department of VA Merit Review Research Program; National Institutes of Health [DK-095980, HL-091333, HL-107256]; University of California Office of the President; VA Senior Research Career Scientist award FX This material is based upon work supported by the Office of Research and Development, Medical Research Service, Department of Veterans Affairs (VA). The research in our laboratory has been supported by the California National Primate Research Center (CNPRC) Pilot Award (core grant no. 0D011107) and the Department of VA Merit Review Research Program. The research program of P. J. Havel also receives research support from National Institutes of Health grants DK-095980, HL-091333, HL-107256, HL-107256, and a Multi-campus grant from the University of California Office of the President. D. G. Baskin is the recipient of a VA Senior Research Career Scientist award. NR 72 TC 24 Z9 24 U1 3 U2 12 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 EI 1522-1490 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD MAR 1 PY 2015 VL 308 IS 5 BP R431 EP R438 DI 10.1152/ajpregu.00441.2014 PG 8 WC Physiology SC Physiology GA CD1EC UT WOS:000350816100010 PM 25540103 ER PT J AU Kuang, SY Wang, ZH Huang, T Wei, LN Xi, TF Kindy, M Gao, BZ AF Kuang, Serena Y. Wang, Zhonghai Huang, Ting Wei, Lina Xi, Tingfei Kindy, Mark Gao, Bruce Z. TI Prolonging life in chick forebrain-neuron culture and acquiring spontaneous spiking activity on a microelectrode array SO BIOTECHNOLOGY LETTERS LA English DT Article DE Biosensor; Chick forebrain neuron; Lifespan; Microelectrode array; Spontaneous spiking activity ID EMBRYO; HEALTH AB Various types of animal neurons were cultured on a microelectrode array (MEA) platform to form biosensors to detect potential environmental neurotoxins. For a large-scale screening tool, rodent MEA-based cortical-neuron biosensors would be very costly but chick forebrain neurons (FBNs) are abundant, cost-effective, and easy to dissect. However, chick FBNs have a lifespan of similar to 14 days in vitro and their spontaneous spike activity (SSA) has been difficult to develop and detect. We used a high-density neuron-glia co-culture on an MEA to prolong chick FBN lifetime to 3 months with lifetime-long SSA. A remarkable embryonic age-dependency in the culture's morphology, lifespan, and most features of SSA signal was discovered. Our results show the feasibility of developing a chick FBN-MEA biosensor and also establish a new electrophysiological platform for functional study of an in vitro neuronal network. C1 [Kuang, Serena Y.; Wang, Zhonghai; Kindy, Mark; Gao, Bruce Z.] Clemson Univ, Dept Bioengn, Clemson, SC 29634 USA. [Huang, Ting; Wei, Lina; Xi, Tingfei] Peking Univ, Acad Adv Interdisciplinary Studies, Ctr Biomed Mat & Tissue Engn, Beijing 100871, Peoples R China. [Kindy, Mark] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29466 USA. [Kindy, Mark] Med Univ S Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC 29466 USA. [Gao, Bruce Z.] Ralph H Johnson VA Med Ctr, Charleston, SC 29403 USA. RP Gao, BZ (reprint author), Clemson Univ, Dept Bioengn, 201-5 Rhodes Res Hall, Clemson, SC 29634 USA. EM zgao@clemson.edu FU National Institutes of Health through SC COBRE [P20RR021949]; National Natural Science Foundation of China [31070847, 31370956]; Strategic New Industry Development Special Foundation of Shenzhen [JCYJ20130402172114948] FX This work was partially supported by funding from the National Institutes of Health through SC COBRE (P20RR021949), the National Natural Science Foundation of China (Nos. 31070847 and 31370956), and the Strategic New Industry Development Special Foundation of Shenzhen (No. JCYJ20130402172114948). Serena Y. Kuang designed the study, did most of the forebrain tissue dissection, cell culturing, MEA recording, data processing tasks, and wrote the manuscript. Zhonghai Wang was responsible for MEA technical support and programmed the MatLab-based software (NeuroMEA) for MEA data processing. Ting Huang translated all MEA data processing requirements into a flowchart with programming logic that oriented the development of the NeuroMEA software. Lina Wei contributed to chick forebrain and spinal cord dissection and some MEA recordings. Mark Kindy served as a senior researcher in this study and modified the manuscript. As PIs of the Project, Drs. Tingfei Xi and Bruce Z. Gao supervised the overall experimental design and data interpretation and modified and finalized the manuscript. NR 17 TC 3 Z9 3 U1 1 U2 7 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0141-5492 EI 1573-6776 J9 BIOTECHNOL LETT JI Biotechnol. Lett. PD MAR PY 2015 VL 37 IS 3 BP 499 EP 509 DI 10.1007/s10529-014-1704-1 PG 11 WC Biotechnology & Applied Microbiology SC Biotechnology & Applied Microbiology GA CC5JL UT WOS:000350394800003 PM 25344105 ER PT J AU Hong, SZ Banks, WA AF Hong, Suzi Banks, William A. TI Role of the immune system in HIV-associated neuroinflammation and neurocognitive implications SO BRAIN BEHAVIOR AND IMMUNITY LA English DT Review DE Blood brain barrier; Cognition; HIV; Inflammation; Microglia; NeuroAIDS; Neuroinflammation; Virus ID BLOOD-BRAIN-BARRIER; HUMAN-IMMUNODEFICIENCY-VIRUS; CENTRAL-NERVOUS-SYSTEM; RECONSTITUTION INFLAMMATORY SYNDROME; COMBINATION ANTIRETROVIRAL THERAPY; POLYMERASE-CHAIN-REACTION; ENHANCED TRANSCELLULAR TRANSPORT; MICROVASCULAR ENDOTHELIAL-CELLS; CHEMOKINE RECEPTOR EXPRESSION; CNS PENETRATION-EFFECTIVENESS AB Individuals living with HIV who are optimally treated with combination antiretroviral therapy (cART) can now lead an extended life. In spite of this remarkable survival benefit from viral suppression achieved by cART in peripheral blood, the rate of mild to moderate cognitive impairment remains high. A cognitive decline that includes impairments in attention, learning and executive function is accompanied by increased rates of mood disorders that together adversely impact the daily life of those with chronic HIV infection. The evidence is clear that cells in the brain are infected with HIV that has crossed the blood brain barrier both as cell-free virus and within infected monocytes and T cells. Viral proteins that circulate in blood can induce brain endothelial cells to release cytokines, invoking another source of neuroinflammation. The difficulty of efficient delivery of cART to the central nervous system (CNS) contributes to elevated viral load in the CNS, resulting in a persistent HIV-associated neurocognitive disorders (HAND). The pathogenesis of HAND is multifaceted, and mounting evidence indicates that immune cells play a major role. HIV-infected monocytes and T cells not only infect brain resident cells upon migration into the CNS but also produce proinflammatory cytokines such as TNF and IL-1 beta, which in turn, further activate microglia and astrocytes. These activated brain resident cells, along with perivascular macrophages, are the main contributors to neuroinflammation in HIV infection and release neurotoxic factors such as excitatory amino acids and inflammatory mediators, resulting in neuronal dysfunction and death. Cytokines, which are elevated in the blood of patients with HIV infection, may also contribute to brain inflammation by entering the brain from the blood. Host factors such as aging and co-morbid conditions such as cytomegalovirus co-infection and vascular pathology are important factors that affect the HIV-host immune interactions in HAND pathogenesis. By these diverse mechanisms, HIV-1 induces a neuro-inflammatory response that is likely to be a major contributor to the cognitive and behavior changes seen in HIV infection. (C) 2014 Elsevier Inc. All rights reserved. C1 [Hong, Suzi] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Banks, William A.] Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Clin & Educ Ctr, Seattle, WA 98195 USA. [Banks, William A.] Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. RP Hong, SZ (reprint author), Univ Calif San Diego, Dept Psychiat, 9500 Gilman Dr MC0804, La Jolla, CA 92093 USA. EM suzihong@ucsd.edu FU NIH [R01HL090975, R01 MH92225, R01AG029834]; VA merit review FX Authors express sincere appreciation to Randy Brooks for his assistance with Fig. 1. Writing of this work was supported in part by the grants R01HL090975 (SH), R01 MH92225 and R01AG029834 (WAB) from the NIH and VA merit review (WAB). NR 168 TC 28 Z9 30 U1 3 U2 15 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0889-1591 EI 1090-2139 J9 BRAIN BEHAV IMMUN JI Brain Behav. Immun. PD MAR PY 2015 VL 45 BP 1 EP 12 DI 10.1016/j.bbi.2014.10.008 PG 12 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA CC7BX UT WOS:000350523800001 PM 25449672 ER PT J AU Buman, MP Kline, CE Youngstedt, SD Phillips, B de Mello, MT Hirshkowitz, M AF Buman, Matthew P. Kline, Christopher E. Youngstedt, Shawn D. Phillips, Barbara de Mello, Marco Tulio Hirshkowitz, Max TI Sitting and Television Viewing Novel Risk Factors for Sleep Disturbance and Apnea Risk? Results from the 2013 National Sleep Foundation Sleep in America Poll SO CHEST LA English DT Article ID ACTIVITY QUESTIONNAIRE IPAQ; SEDENTARY BEHAVIORS; CARDIOVASCULAR-DISEASE; EXERCISE; MORTALITY; QUALITY; HEALTH; ADULTS; METAANALYSIS; DURATION AB BACKGROUND: Excess sitting is emerging as a novel risk factor for cardiovascular disease, diabetes, mental illness, and all-cause mortality. Physical activity, distinct from sitting, is associated with better sleep and lower risk for OSA, yet relationships among sitting behaviors and sleep/OSA remain unknown. We examined whether total sitting time and sitting while viewing television were associated with sleep duration and quality, OSA risk, and sleepiness. METHODS: The 2013 National Sleep Foundation Sleep in America Poll was a cross-sectional study of 1,000 adults aged 23 to 60 years. Total sitting time, time watching television while sitting, sleep duration and quality, OSA risk, and daytime sleepiness were assessed. RESULTS: After adjusting for confounding factors (including BMI and physical activity), each additional hour per day of total sitting was associated with greater odds of poor sleep quality (OR [95% CI] = 1.06 [1.01, 1.11]) but not with other sleep metrics (including sleep duration), OSA risk, or daytime sleepiness. For television viewing while sitting, each additional hour per day was associated with greater odds of long sleep onset latency (>= 30 min) (OR = 1.15 [1.04, 1.27]), waking up too early in the morning (OR = 1.12 [1.03, 1.23]), poor sleep quality (OR = 1.12 [1.02, 1.24]), and "high risk" for OSA (OR = 1.15 [1.04, 1.28]). Based upon an interaction analysis, regular physical activity was protective against OSA risk associated with television viewing (P = .04). CONCLUSIONS: Excess sitting was associated with relatively poor sleep quality. Sitting while watching television was associated with relatively poor sleep quality and OSA risk and may be an important risk factor for sleep disturbance and apnea risk. C1 [Buman, Matthew P.; Youngstedt, Shawn D.] Arizona State Univ, Sch Nutr & Hlth Promot, Phoenix, AZ 85004 USA. [Kline, Christopher E.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Youngstedt, Shawn D.] Arizona State Univ, Phoenix VA Hlth Care Syst, Coll Nursing & Hlth Innovat, Phoenix, AZ 85004 USA. [Phillips, Barbara] Univ Kentucky, Coll Med, Div Pulm Crit Care & Sleep Med, Lexington, KY USA. [de Mello, Marco Tulio] Univ Fed Sao Paulo, Dept Psicobiol, Sao Paulo, Brazil. [Hirshkowitz, Max] Baylor Coll Med, Sleep Ctr, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Hirshkowitz, Max] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. RP Buman, MP (reprint author), Arizona State Univ, Sch Nutr & Hlth Promot, 500 N 3rd St,Mail Code 3020, Phoenix, AZ 85004 USA. EM matthew.buman@asu.edu RI Kline, Christopher/B-1477-2012; de Mello, Marco Tulio/G-3237-2010 OI Kline, Christopher/0000-0003-1025-9430; de Mello, Marco Tulio/0000-0003-3896-2208 FU National Sleep Foundation; National Institutes of Health [K23HL118318, R01HL095799] FX This study was funded by the National Sleep Foundation and by the National Institutes of Health [Grants K23HL118318 to Dr Kline and R01HL095799 to Dr Youngstedt]. NR 38 TC 4 Z9 4 U1 1 U2 8 PU AMER COLL CHEST PHYSICIANS PI GLENVIEW PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA SN 0012-3692 J9 CHEST JI Chest PD MAR PY 2015 VL 147 IS 3 BP 728 EP 734 DI 10.1378/chest.14-1187 PG 7 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA CC5RC UT WOS:000350419200051 PM 25633255 ER PT J AU Hall, RK Toles, M Massing, M Jackson, E Peacock-Hinton, S O'Hare, AM Colon-Emeric, C AF Hall, Rasheeda K. Toles, Mark Massing, Mark Jackson, Eric Peacock-Hinton, Sharon O'Hare, Ann M. Colon-Emeric, Cathleen TI Utilization of Acute Care among Patients with ESRD Discharged Home from Skilled Nursing Facilities SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID STAGE RENAL-DISEASE; TRANSITIONAL CARE; HOSPITAL READMISSIONS; CONTROLLED-TRIAL; HEART-FAILURE; DIALYSIS; OUTCOMES; PROGRAM; QUALITY; OLDER AB Background and objectives Older adults with ESRD often receive care in skilled nursing facilities (SNFs) after an acute hospitalization; however, little is known about acute care use after SNF discharge to home. Design, setting, participants, & measurements This study used Medicare claims for North and South Carolina to identify patients with ESRD who were discharged home from a SNF between January 1, 2010 and August 31, 2011. Nursing Home Compare data were used to ascertain SNF characteristics. The primary outcome was time from SNF discharge to first acute care use (hospitalization or emergency department visit) within 30 days. Cox proportional hazards models were used to identify patient and facility characteristics associated with the outcome. Results Among 1223 patients with ESRD discharged home from a SNP after an acute hospitalization, 531 (43%) had at least one rehospitalization or emergency department visit within 30 days. The median time to first acute care use was 37 days. Characteristics associated with a shorter time to acute care use were black race (hazard ratio [HRL 1.25; 95% confidence interval [95% CI], 1.04 to 1.51), dual Medicare-Medicaid coverage (HR, 1.24; 95% CI, 1.03 to 1.50), higher Charlson comorbidity score (HR, 1.07; 95% CI, 1.01 to 1.12), number of hospitalizations during the 90 days before SNF admission (HR, 1.12; 95% CI, 1.03 to 1.22), and index hospital discharge diagnoses of cellulitis, abscess, and/or skin ulcer (HR, 2.59; 95% CI, 1.36 to 4.45). Home health use after SNP discharge was associated with a lower rate of acute care use (HR, 0.72; 95% CI, 0.59 to 0.87). There were no statistically significant associations between SNF characteristics and time to first acute care use. Conclusions Almost one in every two older adults with ESRD discharged home after a post acute SNF stay used acute care services within 30 days of discharge. Strategies to reduce acute care utilization in these patients are needed. C1 [Hall, Rasheeda K.; Colon-Emeric, Cathleen] Durham Vet Affairs Geriatr Res Educ & Clin Ctr, Durham, NC USA. [Hall, Rasheeda K.] Duke Univ, Med Ctr, Dept Med, Div Nephrol, Durham, NC 27710 USA. [Colon-Emeric, Cathleen] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA. [Toles, Mark; Massing, Mark] Univ N Carolina, Chapel Hill, NC USA. [Jackson, Eric; Peacock-Hinton, Sharon] Carolinas Ctr Med Excellence Inc, Cary, NC USA. [O'Hare, Ann M.] Vet Affairs Puget Sound Healthcare Syst, Hosp & Specialty Med, Seattle, WA USA. [O'Hare, Ann M.] Vet Affairs Puget Sound Healthcare Syst, Hlth Serv R&D Ctr Excellence, Seattle, WA USA. [O'Hare, Ann M.] Univ Washington, Dept Med, Div Nephrol, Seattle, WA USA. RP Hall, RK (reprint author), Duke Univ, Med Ctr, Dept Med, Div Nephrol, Box DUMC 2747,2424 Erwin Rd,Suite 605, Durham, NC 27710 USA. EM rasheeda.stephens@duke.edu FU Carolinas Center for Medical Excellence - Centers for Medicare & Medicaid Services, an agency of the U.S. Department of Health and Human Services [500-2011-NC10C, 500-2011-SC10C]; National Institute on Aging of the National Institutes of Health [P30AG028716]; Office of Academic Affiliations, U.S. Department of Veterans Affairs FX This publication is based on analyses performed by The Carolinas Center for Medical Excellence under contract number 500-2011-NC10C (Utilization and Quality Control Peer Review Organization for the State of North Carolina) and contract number 500-2011-SC10C (Utilization and Quality Control Peer Review Organization for the State of South Carolina), funded by the Centers for Medicare & Medicaid Services, an agency of the U.S. Department of Health and Human Services. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. government. The authors assume full responsibility for the accuracy and completeness of the ideas presented.; Research reported in this publication was supported by the National Institute on Aging of the National Institutes of Health under Award Number P30AG028716. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Dr. Hall was also supported by the Office of Academic Affiliations, U.S. Department of Veterans Affairs. The content of this manuscript does not reflect the views of the Department of Veterans Affairs. NR 25 TC 8 Z9 8 U1 1 U2 2 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD MAR PY 2015 VL 10 IS 3 BP 428 EP 434 DI 10.2215/CJN.03510414 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA CC9QH UT WOS:000350705200013 PM 25649158 ER PT J AU Honda, JR Knight, V Chan, ED AF Honda, Jennifer R. Knight, Vijaya Chan, Edward D. TI Pathogenesis and Risk Factors for Nontuberculous Mycobacterial Lung Disease SO CLINICS IN CHEST MEDICINE LA English DT Article DE Nontuberculous mycobacteria; Lung disease; Risk factors; Pathogenesis ID RAPIDLY GROWING MYCOBACTERIA; AVIUM COMPLEX; PULMONARY-DISEASE; CLINICAL-FEATURES; TNF-ALPHA; CELL-WALL; ABSCESSUS INFECTION; GLYCOPEPTIDOLIPIDS; INTRACELLULARE; DEFICIENCY AB Nontuberculous mycobacteria (NTM) infections are broadly classified as skin and soft tissue infections, isolated lung disease, and visceral or disseminated disease. The degree of underlying immune abnormalities varies between each classification. Skin and soft tissue infections are usually the result of iatrogenic or accidental inoculation of NTM in otherwise normal hosts. Visceral and disseminated NTM disease invariably occurs in individuals with more severe immunosuppression. Although the focus of this article is to discuss the pathogenesis of NTM lung disease, the risk factors of visceral/disseminated NTM disease are also summarized, as they provide insights into host-defense mechanisms against these organisms. C1 [Honda, Jennifer R.; Chan, Edward D.] Univ Colorado Denver, Div Pulm Sci & Crit Care Med, Aurora, CO 80045 USA. [Honda, Jennifer R.; Knight, Vijaya; Chan, Edward D.] Natl Jewish Hlth, Dept Med, Cell Biol Program, Denver, CO 80206 USA. [Honda, Jennifer R.; Chan, Edward D.] Denver Vet Affairs Med Ctr, Denver, CO 80220 USA. RP Chan, ED (reprint author), Natl Jewish Hlth, 0509,Neustadt Bldg,1400 Jackson St, Denver, CO 80206 USA. EM chane@njhealth.org NR 70 TC 15 Z9 15 U1 0 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-5231 EI 1557-8216 J9 CLIN CHEST MED JI Clin. Chest Med. PD MAR PY 2015 VL 36 IS 1 BP 1 EP 11 DI 10.1016/j.ccm.2014.10.001 PG 11 WC Respiratory System SC Respiratory System GA CC8IW UT WOS:000350612700003 PM 25676515 ER PT J AU Nolan, CJ Ruderman, NB Kahn, SE Pedersen, O Prentki, M AF Nolan, Christopher J. Ruderman, Neil B. Kahn, Steven E. Pedersen, Oluf Prentki, Marc TI Insulin Resistance as a Physiological Defense Against Metabolic Stress: Implications for the Management of Subsets of Type 2 Diabetes SO DIABETES LA English DT Article ID ACUTE MYOCARDIAL-INFARCTION; BLOOD-GLUCOSE CONTROL; ACTIVATED PROTEIN-KINASE; MALONYL-COA; MULTIFACTORIAL INTERVENTION; SUBSTRATE METABOLISM; INTENSIVE INSULIN; TREATED PATIENTS; ACCORD TRIAL; FOLLOW-UP AB Stratifying the management of type 2 diabetes (T2D) has to take into account marked variability in patient phenotype due to heterogeneity in its pathophysiology, different stages of the disease process, and multiple other patient factors including comorbidities. The focus here is on the very challenging subgroup of patients with T2D who are overweight or obese with insulin resistance (IR) and the most refractory hyperglycemia due to an inability to change lifestyle to reverse positive energy balance. For this subgroup of patients with T2D, we question the dogma that IR is primarily harmful to the body and should be counteracted at any cost. Instead we propose that IR, particularly in this high-risk subgroup, is a defense mechanism that protects critical tissues of the cardiovascular system from nutrient-induced injury. Overriding IR in an effort to lower plasma glucose levels, particularly with intensive insulin therapy, could therefore be harmful. Treatments that nutrient off-load to lower glucose are more likely to be beneficial. The concepts of IR as an adaptive defense mechanism and insulin-induced metabolic stress may provide explanation for some of the unexpected outcomes of recent major clinical trials in T2D. Potential molecular mechanisms underlying these concepts; their clinical implications for stratification of T2D management, particularly in overweight and obese patients with difficult glycemic control; and future research requirements are discussed. C1 [Nolan, Christopher J.] Canberra Hosp, Dept Endocrinol, Canberra, ACT, Australia. [Nolan, Christopher J.] Australian Natl Univ, Sch Med, Canberra, ACT, Australia. [Ruderman, Neil B.] Boston Univ, Med Ctr, Diabet Res Unit, Boston, MA USA. [Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Seattle, WA USA. [Kahn, Steven E.] Univ Washington, Seattle, WA 98195 USA. [Pedersen, Oluf] Univ Copenhagen, Fac Hlth & Med Sci, Novo Nordisk Fdn Ctr Basic Metab Res, Copenhagen, Denmark. [Prentki, Marc] Univ Montreal, CRCHUM, Quebec City, PQ, Canada. [Prentki, Marc] Univ Montreal, Montreal Diabet Res Ctr, Quebec City, PQ, Canada. [Prentki, Marc] Univ Montreal, Dept Nutr, Quebec City, PQ, Canada. [Prentki, Marc] Univ Montreal, Dept Biochem & Mol Med, Quebec City, PQ, Canada. RP Nolan, CJ (reprint author), Canberra Hosp, Dept Endocrinol, Canberra, ACT, Australia. EM christopher.nolan@anu.edu.au RI Nolan, Christopher/B-2026-2008 OI Kahn, Steven/0000-0001-7307-9002 FU National Institutes of Health [R01-DK019514, P01-HL068758, P30-DK017047]; Canadian Institutes of Health Research; National Health and Medical Research Council [1028108]; Department of Veterans Affairs FX Work was supported in part by grants from the National Institutes of Health (R01-DK019514, [N.B.R. and M.P.], P01-HL068758 [N.B.R.], and P30-DK017047 [S.E.K.]), the Canadian Institutes of Health Research (M.P.), the National Health and Medical Research Council (project grant 1028108 [C.J.N.]), and the Department of Veterans Affairs (S.E.K.). NR 73 TC 28 Z9 28 U1 2 U2 18 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 EI 1939-327X J9 DIABETES JI Diabetes PD MAR PY 2015 VL 64 IS 3 BP 673 EP 686 DI 10.2337/db14-0694 PG 14 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CC3GX UT WOS:000350235900003 PM 25713189 ER PT J AU Marshall, BDL Operario, D Bryant, KJ Cook, RL Edelman, EJ Gaither, JR Gordon, AJ Kahler, CW Maisto, SA McGinnis, KA van den Berg, JJ Zaller, ND Justice, AC Fiellin, DA AF Marshall, Brandon D. L. Operario, Don Bryant, Kendall J. Cook, Robert L. Edelman, E. Jennifer Gaither, Julie R. Gordon, Adam J. Kahler, Christopher W. Maisto, Stephen A. McGinnis, Kathleen A. van den Berg, Jacob J. Zaller, Nickolas D. Justice, Amy C. Fiellin, David A. TI Drinking trajectories among HIV-infected men who have sex with men: A cohort study of United States veterans SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Alcohol; Men who have sex with men; Veterans; HIV infection; Trajectories; Trends ID POSTTRAUMATIC-STRESS-DISORDER; ALCOHOL-RELATED PROBLEMS; VA HEALTH-CARE; SUBSTANCE USE; POSITIVE MEN; AUDIT-C; SUPPORTED EMPLOYMENT; INVERSE PROBABILITY; MINORITY VETERANS; BINGE DRINKING AB Background: Although high rates of alcohol consumption and related problems have been observed among HIV-infected men who have sex with men (MSM), little is known about the long-term patterns of and factors associated with hazardous alcohol use in this population. We sought to identify alcohol use trajectories and correlates of hazardous alcohol use among HIV-infected MSM. Methods: Sexually active, HIV-infected MSM participating in the Veterans Aging Cohort Study were eligible for inclusion. Participants were recruited from VA infectious disease clinics in Atlanta, Baltimore, New York, Houston, Los Angeles, Pittsburgh, and Washington, DC. Data from annual self-reported assessments and group-based trajectory models were used to identify distinct alcohol use trajectories over an eight-year study period (2002-2010). We then used generalized estimate equations (GEE) to examine longitudinal correlates of hazardous alcohol use (defined as an AUDIT-C score >= 4). Results: Among 1065 participants, the mean age was 45.5 (SD = 9.2) and 606 (58.2%) were African American. Baseline hazardous alcohol use was reported by 309 (29.3%). Group-based trajectory modeling revealed a distinct group (12.5% of the sample) with consistently hazardous alcohol use, characterized by a mean AUDIT-C score of >5 at every time point. In a GEE-based multivariable model, hazardous alcohol use was associated with earning <$6000 annually, having an alcohol-related diagnosis, using cannabis, and using cocaine. Conclusions: More than 1 in 10 HIV-infected MSM US veterans reported consistent, long-term hazardous alcohol use. Financial insecurity and concurrent substance use were predictors of consistently hazardous alcohol use, and may be modifiable targets for intervention. (C) 2014 Elsevier Ireland Ltd. All rights reserved. C1 [Marshall, Brandon D. L.] Brown Univ, Sch Publ Hlth, Dept Epidemiol, Providence, RI 02912 USA. [Operario, Don; Kahler, Christopher W.; van den Berg, Jacob J.] Brown Univ, Sch Publ Hlth, Dept Behav & Social Sci, Providence, RI 02912 USA. [Bryant, Kendall J.] NIAAA, Rockville, MD 20852 USA. [Cook, Robert L.] Univ Florida, Dept Epidemiol, Gainesville, FL 32610 USA. [Edelman, E. Jennifer; Justice, Amy C.; Fiellin, David A.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA. [Edelman, E. Jennifer; Gaither, Julie R.; Justice, Amy C.; Fiellin, David A.] Yale Univ, Ctr Interdisciplinary Res AIDS, New Haven, CT 06510 USA. [Gaither, Julie R.] Yale Univ, Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT 06520 USA. [Gordon, Adam J.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15206 USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. [Kahler, Christopher W.] Brown Univ, Sch Publ Hlth, Ctr Alcohol & Addict Studies, Providence, RI 02912 USA. [Kahler, Christopher W.] Brown Univ, Sch Publ Hlth, Alcohol Res Ctr HIV ARCH, Providence, RI 02912 USA. [Maisto, Stephen A.] Syracuse Univ, Dept Psychol, Syracuse, NY 13244 USA. [Maisto, Stephen A.] Syracuse VA Med Ctr, VA Ctr Integrated Healthcare, Syracuse, NY 13210 USA. [McGinnis, Kathleen A.; Justice, Amy C.] VA Connecticut Healthcare Syst, West Haven, CT 06516 USA. [van den Berg, Jacob J.] Miriam Hosp, Div Infect Dis, Providence, RI 02906 USA. [Zaller, Nickolas D.] Univ Arkansas Med Sci, Dept Hlth Behav & Hlth Educ, Little Rock, AR 72205 USA. RP Marshall, BDL (reprint author), Brown Univ, Sch Publ Hlth, Dept Epidemiol, 121 South Main St,Box G-S-121-2, Providence, RI 02912 USA. EM brandon_marshall@brown.edu OI Fiellin, David/0000-0002-4006-010X; Justice, Amy/0000-0003-0139-5502 FU National Institute on Alcohol Abuse and Alcoholism [U24-AA022000, U10-AA013566, U01-AA020795, U01-AA020790, U24-AA020794, P01-AA019072]; National Institute of Allergy and Infectious Diseases [P30-AI042853]; NIAAA [U24-AA022002, K05-AA16928]; National Institute on Drug Abuse [F31-DA035567] FX This work was supported by grants from the National Institute on Alcohol Abuse and Alcoholism (NIAAA: U24-AA022000, U10-AA013566, U01-AA020795, U01-AA020790, U24-AA020794, U10-AA013566, and P01-AA019072), the National Institute of Allergy and Infectious Diseases (P30-AI042853), and in kind by the U.S. Department of Veterans Affairs. Dr. Robert Cook is supported by the NIAAA (U24-AA022002). Ms. Julie Gaither is supported by the National Institute on Drug Abuse (F31-DA035567). Dr. Stephen Maisto is supported by the NIAAA (K05-AA16928). Dr. E. Jennifer Edelman is a Yale-Drug Abuse, Addiction, and HIV Research Scholar (K12-DA033312). The sponsors had no role in the study design; the collection, analysis and interpretation of data; the writing of the report; and in the decision to submit the article for publication. NR 65 TC 3 Z9 3 U1 4 U2 8 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 EI 1879-0046 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD MAR 1 PY 2015 VL 148 BP 69 EP 76 DI 10.1016/j.drugalcdep.2014.12.023 PG 8 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA CC7DF UT WOS:000350527200009 PM 25596785 ER PT J AU Williams, EC Frasco, MA Jacobson, IG Maynard, C Littman, AJ Seelig, AD Crum-Cianflone, NF Nagel, A Boyko, EJ AF Williams, Emily C. Frasco, Melissa A. Jacobson, Isabel G. Maynard, Charles Littman, Alyson J. Seelig, Amber D. Crum-Cianflone, Nancy F. Nagel, Anna Boyko, Edward J. TI Risk factors for relapse to problem drinking among current and former US military personnel: A prospective study of the Millennium Cohort SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Problem drinking; Alcohol use disorders; Millennium Cohort Study; Military; Relapse prospective study; Risk factors ID ALCOHOL-RELATED PROBLEMS; MENTAL-HEALTH PROBLEMS; PRIMARY-CARE; FOLLOW-UP; COMBAT EXPOSURE; SERVICE MEMBERS; BINGE DRINKING; UNITED-STATES; USE DISORDERS; SUBSTANCE USE AB Background: Military service members may be prone to relapse to problem drinking after remission, given a culture of alcohol use as a coping mechanism for stressful or traumatic events associated with military duties or exposures. However, the prevalence and correlates of relapse are unknown. We sought to identify socio-demographic, military, behavioral, and health characteristics associated with relapse among current and former military members with remittent problem drinking. Methods: Participants in the longitudinal Millennium Cohort Study who reported problem drinking at baseline (2001-2003) and were remittent at first follow-up (2004-2006) were included (n = 6909). Logistic regression models identified demographic, military service, behavioral, and health characteristics that predicted relapse (report of >= 1 past-year alcohol-related problem on the validated Patient Health Questionnaire) at the second follow-up (2007-2008). Results: Sixteen percent of those with remittent problem drinking relapsed. Reserve/National Guard members compared with active-duty members (odds ratio [OR] = 1.71,95% confidence interval [CI]: 1.45-2.01), members separated from the military during follow-up (OR= 1.46, 95% CI: 1.16-1.83), and deployers who reported combat exposure (OR = 1.32, 95% CI: 1.07-1.62, relative to non-deployers) were significantly more likely to relapse. Those with multiple deployments were significantly less likely to relapse (OR= 0.73,95% CI: 0.58-0.92). Behavioral factors and mental health conditions also predicted relapse. Conclusion: Relapse was common and associated with military and non-military factors. Targeted intervention to prevent relapse may be indicated for military personnel in particular subgroups, such as Reservists, veterans, and those who deploy with combat exposure. (C) 2015 Published by Elsevier Ireland Ltd. C1 [Williams, Emily C.; Maynard, Charles] Denver Seattle Ctr Innovat Veteran Ctr & Value Dr, Dept Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res Dev, Seattle, WA 98101 USA. [Williams, Emily C.; Maynard, Charles] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA. [Frasco, Melissa A.; Jacobson, Isabel G.; Crum-Cianflone, Nancy F.; Nagel, Anna] Naval Hlth Res Ctr, Deployment Hlth Res Dept, San Diego, CA 92106 USA. [Maynard, Charles; Littman, Alyson J.; Seelig, Amber D.; Boyko, Edward J.] Seattle Epidemiol Res & Informat Ctr, Dept Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Littman, Alyson J.; Boyko, Edward J.] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA. [Crum-Cianflone, Nancy F.] Naval Med Ctr San Diego, San Diego, CA 92134 USA. [Boyko, Edward J.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. RP Williams, EC (reprint author), VA Puget Sound Hlth Care Syst, Dept Vet Affairs Puget Sound Hlth Care Syst, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM emily.williams3@va.gov; Frasco.Melissa@gmail.com; isabeljacobson@yahoo.com; cmaynard@u.washington.edu; Alyson.Littman@va.gov; Amber.Seelig@va.gov; nancy32red@yahoo.com; anna.nagel@med.navy.mil; Edward.Boyko@va.gov RI Maynard, Charles/N-3906-2015 OI Maynard, Charles/0000-0002-1644-7814; Boyko, Edward/0000-0002-3695-192X; Frasco, Melissa/0000-0002-3437-1518 FU HSRD VA [IK2 HX001161] NR 71 TC 2 Z9 2 U1 3 U2 8 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 EI 1879-0046 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD MAR 1 PY 2015 VL 148 BP 93 EP 101 DI 10.1016/j.drugalcdep.2014.12.031 PG 9 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA CC7DF UT WOS:000350527200012 PM 25599962 ER PT J AU Sansoni, ER Sautter, NB Mace, JC Smith, TL Yawn, JR Lawrence, LA Schlosser, RJ Soler, ZM Mulligan, JK AF Sansoni, E. Ritter Sautter, Nathan B. Mace, Jess C. Smith, Timothy L. Yawn, James R. Lawrence, Lauren A. Schlosser, Rodney J. Soler, Zachary M. Mulligan, Jennifer K. TI Vitamin D-3 as a novel regulator of basic fibroblast growth factor in chronic rhinosinusitis with nasal polyposis SO INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY LA English DT Article DE sinusitis; vitamin D; 25-dihydroxyvitamin D3; fibroblast growth factor-2; polyps ID ALLERGIC FUNGAL RHINOSINUSITIS; SINUS MUCOSA; DENDRITIC CELLS; MURINE MODEL; IN-VITRO; EXPRESSION; ANALOGS; RANTES; INFLAMMATION; DEFICIENCY AB BackgroundThe immunopathogenesis of chronic rhinosinusitis (CRS) is largely unknown, but it is thought that different inflammatory profiles are responsible for the different CRS subtypes. 25-Hydroxyvitamin-D (25-VD3) has been shown to alter inflammatory mediators in other disease processes and 25-VD3 deficiency is associated with CRS with nasal polyps (CRSwNP), but it is unknown if 25-VD3 levels impact local inflammation in CRS. This study investigated the correlation between plasma 25-VD3 and sinonasal mucus monocyte chemoattractant protein-1 (MCP-1), regulated upon activation normal T cell expressed and secreted (RANTES), and basic fibroblast growth factor (bFGF) levels in patients with CRS. MethodsStudy subjects undergoing endoscopic sinus surgery (ESS) for CRS were prospectively enrolled from January 2012 to August 2014. Control subjects included patients undergoing ESS for noninflammatory pathology. Blood and sinonasal mucus were collected at the time of ESS. Plasma 25-VD3 was measured by enzyme-linked immunosorbent assay (ELISA) and mucus levels of MCP-1, RANTES, and bFGF by cytometric bead array (CBA). ResultsA total of 57 patients were enrolled and categorized as CRS without nasal polyps (CRSsNP) (n = 31), CRSwNP (n = 14), and controls (n = 12). No significant correlation was found between MCP-1 and 25-VD3. There was a significant negative correlation between 25-VD3 and RANTES (r = -0.612; p = 0.026) and bFGF (r = -0.578; p = 0.039) in CRSwNP patients; however, there was no significant correlation in CRSsNP patients. ConclusionThis data suggests that 25-VD3 may play a role in regulation of RANTES and bFGF expression in CRSwNP. This may occur through regulation of NP fibroblasts or other immune cells. Further investigation is warranted to better elucidate the role of RANTES, bFGF, and 25-VD3 in CRSwNP. C1 [Sansoni, E. Ritter; Sautter, Nathan B.; Mace, Jess C.; Smith, Timothy L.] Oregon Hlth & Sci Univ, Dept Otolaryngol Head & Neck Surg, Portland, OR 97201 USA. [Yawn, James R.] Med Univ S Carolina, Sch Med, Charleston, SC 29425 USA. [Lawrence, Lauren A.; Schlosser, Rodney J.; Soler, Zachary M.; Mulligan, Jennifer K.] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA. [Schlosser, Rodney J.; Mulligan, Jennifer K.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Mulligan, Jennifer K.] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. RP Mulligan, JK (reprint author), 135 Rutledge Ave,MSC 550, Charleston, SC 29425 USA. EM konopa@musc.edu FU NIH, National Institute on Deafness and Other Communication Disorders (NIDCD) [R01 DC005805]; American Academy of Otolaryngology-Head and Neck Surgery Foundation/American Rhinologic Society (AAO-HNSF/ARS) Centralized Otolaryngology Research Efforts (CORE) [313516] FX Funding sources for the study: NIH, National Institute on Deafness and Other Communication Disorders (NIDCD) (R01 DC005805 to T.L.S.); American Academy of Otolaryngology-Head and Neck Surgery Foundation/American Rhinologic Society (AAO-HNSF/ARS) Centralized Otolaryngology Research Efforts (CORE, #313516). NR 28 TC 4 Z9 4 U1 1 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2042-6976 EI 2042-6984 J9 INT FORUM ALLERGY RH JI Int. Forum Allergy Rhinol. PD MAR PY 2015 VL 5 IS 3 BP 191 EP 196 DI 10.1002/alr.21474 PG 6 WC Otorhinolaryngology SC Otorhinolaryngology GA CD0NG UT WOS:000350770400003 PM 25561293 ER PT J AU Zhang, Z Adappa, ND Lautenbach, E Chiu, AG Doghramji, LJ Cohen, NA Palmer, JN AF Zhang, Zi Adappa, Nithin D. Lautenbach, Ebbing Chiu, Alexander G. Doghramji, Laurel J. Cohen, Noam A. Palmer, James N. TI Coagulase-negative Staphylococcus culture in chronic rhinosinusitis SO INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY LA English DT Article DE chronic rhinosinusitis; infection; coagulase-negative Staphylococcus; endoscopic sinus surgery; culture ID CHRONIC SINUSITIS; BACTERIOLOGY; SURGERY; STRAINS AB BackgroundCoagulase-negative Staphylococcus (CoNS) is commonly isolated from patients with chronic rhinosinusitis (CRS). However, the role of CoNS in CRS remains controversial. We aimed to determine the association between positive CoNS culture at functional endoscopic sinus surgery (FESS) and CRS severity. MethodsAdult CRS patients who underwent FESS between October 1, 2007 to December 31, 2011 were recruited. Patient demographics, disease characteristics, medication use, Lund-Mackay computed tomography (CT) scores, and 22-item Sino-Nasal Outcome Test (SNOT-22) scores were collected at baseline before FESS. Intraoperative cultures were obtained in a standard manner. Patients were placed into 2 groups based on culture findings: patients with CoNS as the sole positive culture result and patients with all other positive culture results, including CoNS, as part of a polymicrobial culture. ResultsA total of 376 CRS patients met the criteria; 106 patients (28%) had CoNS as their only isolate, 260 (69%) had other positive cultures, and 10 (3%) had no bacterial growth. Compared to patients with other positive cultures, patients with the sole result of CoNS were significantly less likely to have a history of FESS (52% vs 65%, p = 0.019), nasal polyps (50% vs 65%, p = 0.006), and had a better Lund-Mackay CT score (11.95 vs 14.18, p = 0.020). After adjusting for all factors in the multiple logistic regression model, CoNS as the sole positive culture result was independently associated with having no history of FESS (odds ratio [OR] = 0.45; 95% confidence interval [CI], 0.22 to 0.94; p = 0.034). ConclusionPositive intraoperative CoNS cultures alone do not result in increased CRS disease burden by objective or subjective measures as compared to patients with other bacterial or polymicrobial culture isolates. C1 [Zhang, Zi; Lautenbach, Ebbing] Univ Penn, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Adappa, Nithin D.; Doghramji, Laurel J.; Cohen, Noam A.; Palmer, James N.] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Perelman Sch Med, Philadelphia, PA 19104 USA. [Lautenbach, Ebbing] Univ Penn, Dept Med, Perelman Sch Med, Div Infect Dis, Philadelphia, PA 19104 USA. [Chiu, Alexander G.] Univ Arizona, Dept Surg, Tucson, AZ USA. [Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Zhang, Z (reprint author), 8th Floor,Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM zizhang@mail.med.upenn.edu OI Cohen, Noam/0000-0002-9462-3932 FU National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health [K24 AI080942] FX Funding source for the study: National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (K24 AI080942 to E.L.). NR 19 TC 2 Z9 2 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2042-6976 EI 2042-6984 J9 INT FORUM ALLERGY RH JI Int. Forum Allergy Rhinol. PD MAR PY 2015 VL 5 IS 3 BP 204 EP 213 DI 10.1002/alr.21439 PG 10 WC Otorhinolaryngology SC Otorhinolaryngology GA CD0NG UT WOS:000350770400005 PM 25367456 ER PT J AU Lipska, KJ Ross, JS Miao, YH Shah, ND Lee, SJ Steinman, MA AF Lipska, Kasia J. Ross, Joseph S. Miao, Yinghui Shah, Nilay D. Lee, Sei J. Steinman, Michael A. TI Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control SO JAMA INTERNAL MEDICINE LA English DT Article ID SEVERE HYPOGLYCEMIA; EPIDEMIOLOGIC ANALYSIS; CLINICAL COMPLEXITY; GLUCOSE CONTROL; RISK; MORTALITY; ASSOCIATION; DEMENTIA; COMPLICATIONS; PREVALENCE AB IMPORTANCE In older adults with multiple serious comorbidities and functional limitations, the harms of intensive glycemic control likely exceed the benefits. OBJECTIVES To examine glycemic control levels among older adults with diabetes mellitus by health status and to estimate the prevalence of potential overtreatment of diabetes. DESIGN, SETTING, AND PARTICIPANTS Cross-sectional analysis of the data on 1288 older adults (>= 65 years) with diabetes from the National Health and Nutrition Examination Survey (NHANES) from 2001 through 2010 who had a hemoglobin A(1c) (HbA(1c)) measurement. All analyses incorporated complex survey design to produce nationally representative estimates. EXPOSURES Health status categories: very complex/poor, based on difficulty with 2 or more activities of daily living or dialysis dependence; complex/intermediate, based on difficulty with 2 or more instrumental activities of daily living or presence of 3 or more chronic conditions; and relatively healthy if none of these were present. MAIN OUTCOMES AND MEASURES Tight glycemic control (HbA(1c) level, <7%) and use of diabetes medications likely to result in hypoglycemia (insulin or sulfonylureas). RESULTS Of 1288 older adults with diabetes, 50.7%(95% CI, 46.6%-54.8%), representing 3.1 million (95% CI, 2.7-3.5), were relatively healthy, 28.1%(95% CI, 24.8%-31.5%), representing 1.7 million (95% CI, 1.4-2.0), had complex/intermediate health, and 21.2%(95% CI, 18.3%-24.4%), representing 1.3 million (95% CI, 1.1-1.5), had very complex/poor health. Overall, 61.5%(95% CI, 57.5%-65.3%), representing 3.8 million (95% CI, 3.4-4.2), had an HbA1c level of less than 7%; this proportion did not differ across health status categories (62.8%[95% CI, 56.9%-68.3%]) were relatively healthy, 63.0%(95% CI, 57.0%-68.6%) had complex/intermediate health, and 56.4%(95% CI, 49.7%-62.9%) had very complex/poor health (P = .26). Of the older adults with an HbA(1c) level of less than 7%, 54.9% (95% CI, 50.4%-59.3%) were treated with either insulin or sulfonylureas; this proportion was similar across health status categories (50.8%[95% CI, 45.1%-56.5%] were relatively healthy, 58.7% [95% CI, 49.4%-67.5%] had complex/intermediate health, and 60.0%[95% CI, 51.4%-68.1%] had very complex/poor health; P = .14). During the 10 study years, there were no significant changes in the proportion of older adults with an HbA(1c) level of less than 7% (P = .34), the proportion with an HbA(1c) level of less than 7% who had complex/intermediate or very complex/poor health (P = .27), or the proportion with an HbA(1c) level of less than 7% who were treated with insulin or sulfonylureas despite having complex/intermediate or very complex/poor health (P = .65). CONCLUSIONS AND RELEVANCE Although the harms of intensive treatment likely exceed the benefits for older patients with complex/intermediate or very complex/poor health status, most of these adults reached tight glycemic targets between 2001 and 2010. Most of them were treated with insulin or sulfonylureas, which may lead to severe hypoglycemia. Our findings suggest that a substantial proportion of older adults with diabetes were potentially overtreated. C1 Yale Univ, Sch Med, Dept Internal Med, Endocrinol Sect, New Haven, CT 06510 USA. [Lipska, Kasia J.; Ross, Joseph S.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA. [Ross, Joseph S.] Yale Univ, Sch Med, Dept Internal Med, Gen Internal Med Sect, New Haven, CT 06510 USA. [Ross, Joseph S.] Yale Univ, Sch Med, Dept Internal Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT 06510 USA. [Ross, Joseph S.] Yale Univ, Dept Hlth Policy & Management, Sch Publ Hlth, New Haven, CT 06520 USA. [Miao, Yinghui; Lee, Sei J.; Steinman, Michael A.] San Francisco VA Med Ctr, Div Geriatr, Dept Med, San Francisco, CA USA. [Shah, Nilay D.] Mayo Clin, Knowledge & Evaluat Res Unit, Dept Hlth Sci Res, Rochester, MN USA. [Shah, Nilay D.] Mayo Clin, Div Hlth Care Policy & Res, Dept Hlth Sci Res, Rochester, MN USA. [Lee, Sei J.; Steinman, Michael A.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. RP Lipska, KJ (reprint author), Yale Univ, Endocrinol Sect, Dept Internal Med, Sch Med, POB 208020, New Haven, CT 06520 USA. EM kasia.lipska@yale.edu FU Pepper Center Career Development Award [P30 AG21342]; National Institute on Aging [R03 AG045086, K23-AG048359, K08 AG032886]; Yale Center for Investigation Scholar Award Clinical and Translational Science Award [UL1 TR000142]; American Federation for Aging Research through the Paul B. Beeson Career Development Program (Drs Lipska and Ross); National Institutes of Health and the American Federation for Aging Research [1K23-AG030999, P30-AG044281] FX This study was supported by grant P30 AG21342 from the Pepper Center Career Development Award, Grants for Early Medical/Surgical Specialists' Transition to Aging Research No. R03 AG045086 from the National Institute on Aging, Yale Center for Investigation Scholar Award Clinical and Translational Science Award number UL1 TR000142, and National Institute on Aging grant K23-AG048359 (Dr Lipska); the American Federation for Aging Research through the Paul B. Beeson Career Development Program (Drs Lipska and Ross); National Institute on Aging grant K08 AG032886 (Dr Ross); and National Institutes of Health and the American Federation for Aging Research grants 1K23-AG030999 and P30-AG044281 (Dr Steinman). NR 33 TC 60 Z9 60 U1 2 U2 6 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD MAR PY 2015 VL 175 IS 3 BP 356 EP 362 DI 10.1001/jamainternmed.2014.7345 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA CD0YF UT WOS:000350799600011 PM 25581565 ER PT J AU Schmajuk, G Bozic, KJ Yazdany, J AF Schmajuk, Gabriela Bozic, Kevin J. Yazdany, Jinoos TI Using Medicare Data to Understand Health Care Value: Measures of Incremental Cost and Effectiveness are Both Needed to Estimate Value Reply SO JAMA INTERNAL MEDICINE LA English DT Letter C1 [Schmajuk, Gabriela; Yazdany, Jinoos] Univ Calif San Francisco, Dept Med Rheumatol, San Francisco, CA 94143 USA. [Schmajuk, Gabriela] San Francisco Vet Affairs VA Med Ctr, San Francisco, CA USA. [Bozic, Kevin J.] Univ Calif San Francisco, Dept Orthoped Surg, Philip R Lee Inst Hlth Policy Studies, San Francisco, CA 94143 USA. RP Schmajuk, G (reprint author), San Francisco VA Med Ctr, 4150 Clement St,Mailstop 111R, San Francisco, CA 94121 USA. EM gabriela.schmajuk@ucsf.edu FU NIAMS NIH HHS [K23 AR060259, K23 AR063770] NR 3 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD MAR PY 2015 VL 175 IS 3 BP 462 EP 463 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA CD0YF UT WOS:000350799600041 PM 25730567 ER PT J AU Grady, D Redberg, RF AF Grady, Deborah Redberg, Rita F. TI Advancing Medical Professionalism and the Choosing Wisely Campaign Reply SO JAMA INTERNAL MEDICINE LA English DT Letter C1 [Grady, Deborah; Redberg, Rita F.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94158 USA. [Grady, Deborah] San Francisco VA Med Ctr, San Francisco, CA USA. RP Grady, D (reprint author), Univ Calif San Francisco, Dept Med, 550 16th St, San Francisco, CA 94158 USA. EM Deborah.Grady@ucsf.edu NR 1 TC 0 Z9 0 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD MAR PY 2015 VL 175 IS 3 BP 465 EP 465 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA CD0YF UT WOS:000350799600045 PM 25730572 ER PT J AU Howard, RG Samuels, J Gyftopoulos, S Krasnokutsky, S Leung, J Swearingen, CJ Pillinger, MH AF Howard, Rennie G. Samuels, Jonathan Gyftopoulos, Soterios Krasnokutsky, Svetlana Leung, Joseph Swearingen, Christopher J. Pillinger, Michael H. TI Presence of Gout Is Associated With Increased Prevalence and Severity of Knee Osteoarthritis Among Older Men Results of a Pilot Study SO JCR-JOURNAL OF CLINICAL RHEUMATOLOGY LA English DT Article DE gout; hyperuricemia; knee osteoarthritis; biomarker; musculoskeletal ultrasound ID RANDOMIZED CONTROLLED-TRIAL; URIC-ACID; ASYMPTOMATIC HYPERURICEMIA; OCCUPATIONAL ACTIVITY; MONOSODIUM URATE; DANGER SIGNAL; RISK-FACTORS; ARTHRITIS; POPULATION; ULTRASOUND AB Background: Gout and osteoarthritis (OA) are the most prevalent arthritides, but their relationship is neither well established nor well understood. Objectives: We assessed whether a diagnosis of gout or asymptomatic hyperuricemia(AH) is associated with increased prevalence/severity of knee OA. Methods: One hundred nineteen male patients aged 55 to 85 years were sequentially enrolled from the primary care clinics of an urban Veterans Affairs hospital, assessed and categorized into 3 groups: gout (American College of Rheumatology Classification Criteria), AH (serum urate >= 6.8 mg/dL, no gout), and control (serum urate <6.8 mg/dL, no gout). Twenty-five patients from each group subsequently underwent formal assessment of knee OA presence and severity (American College of Rheumatology Clinical/Radiographic Criteria, Kellgren-Lawrence grade). Musculoskeletal ultrasound was used to detect monosodium urate deposition at the knees and first metatarsophalangeal joints. Results: The study showed 68.0% of gout, 52.0% of AH, and 28.0% of age-matched control subjects had knee OA (gout vs control, P = 0.017). Odds ratio for knee OA in gout versus control subjects was 5.46 prior to and 3.80 after adjusting for body mass index. Gout subjects also had higher Kellgren-Lawrence grades than did the control subjects (P = 0.001). Subjects with sonographically detected monosodium urate crystal deposition on cartilage were more likely to have OA than those without (60.0 vs 27.5%, P = 0.037), with crystal deposition at the first metatarsophalangeal joints correlating most closely with OA knee involvement. Conclusions: Knee OA was more prevalent in gout patients versus control subjects and intermediate in AH. Knee OA was more severe in gout patients versus control subjects. C1 [Howard, Rennie G.; Samuels, Jonathan; Krasnokutsky, Svetlana; Pillinger, Michael H.] NYU, NYU Langone Med Ctr, Sch Med, Div Rheumatol, New York, NY USA. [Howard, Rennie G.; Samuels, Jonathan; Krasnokutsky, Svetlana; Leung, Joseph; Pillinger, Michael H.] US Dept Vet Affairs, Dept Med, New York Harbor Hlth Care Syst, New York, NY USA. [Gyftopoulos, Soterios] NYU, Dept Radiol, Sch Med, NYU Langone Med Ctr, New York, NY 10016 USA. [Leung, Joseph] NYU, Div Gen Internal Med, Sch Med, NYU Langone Med Ctr, New York, NY 10016 USA. [Swearingen, Christopher J.] Univ Arkansas Med Sci, Dept Pediat, Biostat Sect, Little Rock, AR 72205 USA. RP Pillinger, MH (reprint author), NYU Hosp Joint Dis, 301 E 17th St,Room 1410, New York, NY 10003 USA. EM michael.pillinger@nyumc.org OI samuels, jonathan/0000-0002-1513-770X; Pillinger, Michael/0000-0003-3168-1542 FU National Institutes of Health T32 Training Grant [5T32AR007176]; Arthritis Foundation New York Chapter; Clinical and Translational Science Institute of NYU School of Medicine; CTSA from the National Center for the Advancement of Translational Science, National Institutes of Health [UL1TR000038] FX This work was supported by a National Institutes of Health T32 Training Grant 5T32AR007176 (R.G.H.; principal investigator Steven B. Abramson, MD), a Fellowship Award in Osteoarthritis from the Arthritis Foundation New York Chapter (R.G.H.) and Pilot Award from the Clinical and Translational Science Institute of NYU School of Medicine (R.G.H.). M.H.P. is supported in part by CTSA grant UL1TR000038 from the National Center for the Advancement of Translational Science, National Institutes of Health. NR 49 TC 4 Z9 4 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1076-1608 EI 1536-7355 J9 JCR-J CLIN RHEUMATOL JI JCR-J. Clin. Rheumatol. PD MAR PY 2015 VL 21 IS 2 BP 63 EP 71 DI 10.1097/RHU.0000000000000217 PG 9 WC Rheumatology SC Rheumatology GA CD0KX UT WOS:000350762600003 PM 25710856 ER PT J AU Metra, M Cotter, G El-Khorazaty, J Davison, BA Milo, O Carubelli, V Bourge, RC Cleland, JG Jondeau, G Krum, H O'Connor, CM Parker, JD Torre-Amione, G van Veldhuisen, DJ Rainisio, M Kobrin, I Mcmurray, JJ Teerlink, JR AF Metra, Marco Cotter, Gad El-Khorazaty, Jill Davison, Beth A. Milo, Olga Carubelli, Valentina Bourge, Robert C. Cleland, John G. Jondeau, Guillaume Krum, Henry O'Connor, Christopher M. Parker, John D. Torre-Amione, Guillermo van Veldhuisen, Dirk J. Rainisio, Maurizio Kobrin, Isaac Mcmurray, John J. Teerlink, John R. TI Acute Heart Failure in the Elderly: Differences in Clinical Characteristics, Outcomes, and Prognostic Factors in the VERITAS Study SO JOURNAL OF CARDIAC FAILURE LA English DT Article DE Heart failure; age; outcomes ID ACUTE MYOCARDIAL-INFARCTION; NATRIURETIC-PEPTIDE; RELAX-AHF; TROPONIN ELEVATION; RENAL DYSFUNCTION; TASK-FORCE; HIGH-RISK; ASSOCIATION; TRIAL; HOSPITALIZATION AB Background: Acute heart failure (HF) is common in the elderly, but the association of age with clinical outcomes and prognostic factors has not been examined thoroughly. Methods and Results: We analyzed the clinical and laboratory characteristics and the outcomes of 1,347 patients with acute HF enrolled in the VERITAS trial. Subjects were subdivided based on their median age of 72 years. Older patients had a higher prevalence of comorbidities and a higher prevalence of hypertension and atrial fibrillation. During a mean follow-up of 149 +/- 61 days, 432 patients (32.1%) reached the composite end point of death, in-hospital worsening HF, or HF rehospitalization by 30 days, and 135 patients (10.4%) died by 90 days, with a worse outcome in elderly patients in both cases. At multivariable analysis, different variables were related with each of these outcomes in elderly compared with younger patients. Regarding deaths at 90 days, plasma urea nitrogen and hemoglobin levels were predictive only in the younger patients, whereas respiratory rate and albumin levels were associated with mortality only in the older patients. Conclusions: Elderly patients with acute HF have different clinical characteristics and poorer outcomes. Prognostic variables differ in elderly compared with younger patients. C1 [Metra, Marco; Carubelli, Valentina] Univ Brescia, Dept Med & Surg Specialties, Radiol Sci & Publ Hlth, Cardiol, Brescia, Italy. [Cotter, Gad; El-Khorazaty, Jill; Davison, Beth A.; Milo, Olga] Momentum Res Inc, Durham, NC USA. [Bourge, Robert C.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [Cleland, John G.] Royal Bronzpton & Harefield Hosp Trust, Natl Heart & Lung Inst, London, England. [Cleland, John G.] Univ Hull, Hull York Med Sch, Kingston Upon Hull, Yorks, England. [Jondeau, Guillaume] Hop Bichat Claude Bernard, Serv Cardiol, F-75877 Paris, France. [Krum, Henry] Monash Univ, Alfred Hosp, Dept Epidemiol & Prevent Med, Monash Ctr Cardiovasc Res & Educ Therapeut, Melbourne, Vic 3004, Australia. [O'Connor, Christopher M.] Duke Univ, Duke Clin Res Inst, Durham, NC USA. [Parker, John D.] Mt Sinai Hosp, Dept Med, Div Cardiol, New York, NY USA. [Parker, John D.] Univ Toronto, Toronto, ON M5S 1A1, Canada. [Torre-Amione, Guillermo] Houston Methodist Hosp, Houston, TX USA. [Torre-Amione, Guillermo] Tecnol Monterrey, Monterrey, Mexico. [van Veldhuisen, Dirk J.] Univ Groningen, Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands. [Rainisio, Maurizio] AbaNovus, San Remo, Italy. [Kobrin, Isaac] Actel Pharmaceut, Allschwil, Switzerland. [Mcmurray, John J.] Univ Glasgow, Glasgow, Lanark, Scotland. [Teerlink, John R.] San Francisco VA Med Ctr, Sect Cardiol, San Francisco, CA USA. [Teerlink, John R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Metra, M (reprint author), Spedali Civil Brescia, Cardiol, Piazza Spedali Civili 1, I-25123 Brescia, Italy. EM metramarco@libero.it OI Cleland, John/0000-0002-1471-7016; Parker, John/0000-0003-1949-2669; Metra, Marco/0000-0001-6691-8568; mcmurray, john/0000-0002-6317-3975 NR 41 TC 9 Z9 9 U1 0 U2 4 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 EI 1532-8414 J9 J CARD FAIL JI J. Card. Fail. PD MAR PY 2015 VL 21 IS 3 BP 179 EP 188 DI 10.1016/j.cardfail.2014.12.012 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CD1ML UT WOS:000350838900001 PM 25573829 ER PT J AU Mallipattu, SK Horne, SJ D'Agati, V Narla, G Liu, RJ Frohman, MA Dickman, K Chen, EY Ma'ayan, A Bialkowska, AB Ghaleb, AM Nandan, MO Jain, MK Daehn, I Chuang, PY Yang, VW He, JC AF Mallipattu, Sandeep K. Horne, Sylvia J. D'Agati, Vivette Narla, Goutham Liu, Ruijie Frohman, Michael A. Dickman, Kathleen Chen, Edward Y. Ma'ayan, Avi Bialkowska, Agnieszka B. Ghaleb, Amr M. Nandan, Mandayam O. Jain, Mukesh K. Daehn, Ilse Chuang, Peter Y. Yang, Vincent W. He, John C. TI Kruppel-like factor 6 regulates mitochondrial function in the kidney SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID FOCAL SEGMENTAL GLOMERULOSCLEROSIS; HIV-ASSOCIATED NEPHROPATHY; NEPHROTIC SYNDROME; OXIDATIVE STRESS; GENE-EXPRESSION; RETINOIC ACID; DOXORUBICIN; APOPTOSIS; PODOCYTES; INJURY AB Maintenance of mitochondrial structure and function is critical for preventing podocyte apoptosis and eventual glomerulosclerosis in the kidney; however, the transcription factors that regulate mitochondrial function in podocyte injury remain to be identified. Here, we identified Kruppel-like factor 6 (KLF6), a zinc finger domain transcription factor, as an essential regulator of mitochondrial function in podocyte apoptosis. We observed that podocyte-specific deletion of Klf6 increased the susceptibility of a resistant mouse strain to adriamycin-induced (ADR-induced) focal segmental glomerulosclerosis (FSGS). KLF6 expression was induced early in response to ADR in mice and cultured human podocytes, and prevented mitochondrial dysfunction and activation of intrinsic apoptotic pathways in these podocytes. Promoter analysis and chromatin immunoprecipitation studies revealed that putative KLF6 transcriptional binding sites are present in the promoter of the mitochondrial cytochrome c oxidase assembly gene (SCO2), which is critical for preventing cytochrome c release and activation of the intrinsic apoptotic pathway. Additionally, KLF6 expression was reduced in podocytes from HIV-1 transgenic mice as well as in renal biopsies from patients with HIV-associated nephropathy (HIVAN) and FSGS. Together, these findings indicate that KLF6-dependent regulation of the cytochrome c oxidase assembly gene is critical for maintaining mitochondrial function and preventing podocyte apoptosis. C1 [Mallipattu, Sandeep K.; Horne, Sylvia J.] SUNY Stony Brook, Dept Med, Div Nephrol, Stony Brook, NY 11790 USA. [D'Agati, Vivette] Columbia Univ, Dept Pathol, New York, NY USA. [Narla, Goutham] Case Western Reserve Univ, Inst Transformat Mol Med, Cleveland, OH 44106 USA. [Liu, Ruijie; Daehn, Ilse; Chuang, Peter Y.; He, John C.] Mt Sinai Sch Med, Dept Med, Div Nephrol, New York, NY 10029 USA. [Frohman, Michael A.; Dickman, Kathleen] SUNY Stony Brook, Dept Pharmacol, Stony Brook, NY 11790 USA. [Chen, Edward Y.; Ma'ayan, Avi; He, John C.] Mt Sinai Sch Med, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA. [Bialkowska, Agnieszka B.; Ghaleb, Amr M.; Nandan, Mandayam O.; Yang, Vincent W.] SUNY Stony Brook, Dept Med, Stony Brook, NY 11790 USA. [Jain, Mukesh K.] Case Western Reserve Univ, Dept Med, Res Inst, Case Cardiovasc Inst, Cleveland, OH 44106 USA. [He, John C.] James J Peters VA Med Ctr, Renal Sect, New York, NY USA. RP He, JC (reprint author), Mt Sinai Sch Med, Dept Med Nephrol, One Gustave L Levy Pl,Box 1243m, New York, NY 10029 USA. EM sandeep.mallipattu@stonybrookmedicine.edu; cijiang.he@mssm.edu OI daehn, ilse/0000-0001-9915-5376 FU NIH/NIDDK [1 R01 DK078897-01, 1K0801DK102519-01]; Chinese 973 fund [2012CB517601]; Dialysis Clinic Inc. (Paul Teschan Research Grant) FX This work was supported by NIH/NIDDK 1 R01 DK078897-01 and Chinese 973 fund 2012CB517601 to J.C. He; and NIH/NIDDK 1K0801DK102519-01 and Dialysis Clinic Inc. (Paul Teschan Research Grant) to S.K. Mallipattu. We thank Ali Gharavi, Natalia Papeta, and Roel Sterken (Division of Nephrology, Department of Medicine, Columbia University, New York, New York, USA) for their guidance and constructive feedback on the data presented in this article. NR 46 TC 10 Z9 13 U1 1 U2 10 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 EI 1558-8238 J9 J CLIN INVEST JI J. Clin. Invest. PD MAR PY 2015 VL 125 IS 3 BP 1347 EP 1361 DI 10.1172/JCI77084 PG 15 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA CC8KF UT WOS:000350616500045 PM 25689250 ER PT J AU Zuchowski, JL Rose, DE Hamilton, AB Stockdale, SE Meredith, LS Yano, EM Rubenstein, LV Cordasco, KM AF Zuchowski, Jessica L. Rose, Danielle E. Hamilton, Alison B. Stockdale, Susan E. Meredith, Lisa S. Yano, Elizabeth M. Rubenstein, Lisa V. Cordasco, Kristina M. TI Challenges in Referral Communication Between VHA Primary Care and Specialty Care SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE primary care; specialty care; communication; electronic health records; veterans ID CENTERED MEDICAL HOME; HEALTH-CARE; DISPERSED COLLABORATION; PHYSICIAN REFERRALS; UNITED-STATES; COORDINATION; SYSTEM; DETERMINANTS; CONSULTATION; NEIGHBOR AB Poor communication between primary care providers (PCPs) and specialists is a significant problem and a detriment to effective care coordination. Inconsistency in the quality of primary-specialty communication persists even in environments with integrated delivery systems and electronic medical records (EMRs), such as the Veterans Health Administration (VHA). The purpose of this study was to measure ease of communication and to characterize communication challenges perceived by PCPs and primary care personnel in the VHA, with a particular focus on challenges associated with referral communication. The study utilized a convergent mixed-methods design: online cross-sectional survey measuring PCP-reported ease of communication with specialists, and semi-structured interviews characterizing primary-specialty communication challenges. 191 VHA PCPs from one regional network were surveyed (54 % response rate), and 41 VHA PCPs and primary care staff were interviewed. PCP-reported ease of communication mean score (survey) and recurring themes in participant descriptions of primary-specialty referral communication (interviews) were analyzed. Among PCPs, ease-of-communication ratings were highest for women's health and mental health (mean score of 2.3 on a scale of 1-3 in both), and lowest for cardiothoracic surgery and neurology (mean scores of 1.3 and 1.6, respectively). Primary care personnel experienced challenges communicating with specialists via the EMR system, including difficulty in communicating special requests for appointments within a certain time frame and frequent rejection of referral requests due to rigid informational requirements. When faced with these challenges, PCPs reported using strategies such as telephone and e-mail contact with specialists with whom they had established relationships, as well as the use of an EMR-based referral innovation called "eConsults" as an alternative to a traditional referral. Primary-specialty communication is a continuing challenge that varies by specialty and may be associated with the likelihood of an established connection already in place between specialty and primary care. Improvement in EMR systems is needed, with more flexibility for the communication of special requests. Building relationships between PCPs and specialists may also facilitate referral communication. C1 [Zuchowski, Jessica L.; Rose, Danielle E.; Hamilton, Alison B.; Stockdale, Susan E.; Meredith, Lisa S.; Yano, Elizabeth M.; Rubenstein, Lisa V.; Cordasco, Kristina M.] VA Greater Angeles Healthcare Syst, Ctr Study Healthcare Innovat, Implementat & Policy, Sepulveda, CA USA. [Hamilton, Alison B.; Stockdale, Susan E.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Meredith, Lisa S.; Rubenstein, Lisa V.] RAND Corp, Santa Monica, CA USA. [Yano, Elizabeth M.] UCLA Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA. [Rubenstein, Lisa V.; Cordasco, Kristina M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. RP Zuchowski, JL (reprint author), VA Greater Los Angeles Healthcare Syst, Ctr Study Healthcare Innovat Implementat & Policy, Bldg 25,16111 Plummer St, Sepulveda, CA 91343 USA. EM jessica.zuchowski@va.gov FU VHA Office of Patient Care Services [XVA 65-018]; VA HSRD Service [RCS 05-195] FX Funding for the VAIL-PCC PACT Demonstration Laboratory initiative was provided to Drs. Lisa V. Rubenstein, Elizabeth M. Yano, and Lisa Altman from the VHA Office of Patient Care Services (Project #XVA 65-018). Dr. Yano's time was supported by a Senior Research Career Scientist Award from the VA HSR&D Service (Project #RCS 05-195). The views expressed within are solely those of the authors, and do not necessarily represent the views of the Department of Veterans Affairs or the United States government. NR 32 TC 7 Z9 7 U1 2 U2 10 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2015 VL 30 IS 3 BP 305 EP 311 DI 10.1007/s11606-014-3100-x PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA CD2EG UT WOS:000350886500010 PM 25410884 ER PT J AU Parast, L Doyle, B Damberg, CL Shetty, K Ganz, DA Wenger, NS Shekelle, PG AF Parast, Layla Doyle, Brian Damberg, Cheryl L. Shetty, Kanaka Ganz, David A. Wenger, Neil S. Shekelle, Paul G. TI Challenges in Assessing the Process-Outcome Link in Practice SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE quality improvement; program evaluation; medicare; preventive care; randomized trials ID ACUTE MYOCARDIAL-INFARCTION; SENSITIVITY-ANALYSIS; BETA-BLOCKADE; MORTALITY; QUALITY; CARE; CONFOUNDERS; ASSOCIATION; ADHERENCE; TRIALS AB The expanded use of clinical process-of-care measures to assess the quality of health care in the context of public reporting and pay-for-performance applications has led to a desire to demonstrate the value of such efforts in terms of improved patient outcomes. The inability to observe associations between improved delivery of clinical processes and improved clinical outcomes in practice has raised concerns about the value of holding providers accountable for delivery of clinical processes of care. Analyses that attempt to investigate this relationship are fraught with many challenges, including selection of an appropriate outcome, the proximity of the outcome to the receipt of the clinical process, limited power to detect an effect, small expected effect sizes in practice, potential bias due to unmeasured confounding factors, and difficulties due to changes in measure specification over time. To avoid potentially misleading conclusions about an observed or lack of observed association between a clinical process of care and an outcome in the context of observational studies, individuals conducting and interpreting such studies should carefully consider, evaluate, and acknowledge these types of challenges. C1 [Parast, Layla; Damberg, Cheryl L.; Shetty, Kanaka; Ganz, David A.; Wenger, Neil S.; Shekelle, Paul G.] RAND Corp, Santa Monica, CA 90407 USA. [Doyle, Brian; Ganz, David A.; Wenger, Neil S.; Shekelle, Paul G.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Ganz, David A.; Shekelle, Paul G.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Parast, L (reprint author), RAND Corp, 1776 Main St,POB 2138, Santa Monica, CA 90407 USA. EM parast@rand.org OI Doyle, Brian/0000-0003-2782-2306 FU Centers for Medicare and Medicaid Services [HHSM-500-2011-AZ0S.SIP.02] FX This project was funded by the Centers for Medicare and Medicaid Services under contract number HHSM-500-2011-AZ0S.SIP.02. NR 31 TC 5 Z9 5 U1 1 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2015 VL 30 IS 3 BP 359 EP 364 DI 10.1007/s11606-014-3150-0 PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA CD2EG UT WOS:000350886500022 PM 25564435 ER PT J AU Hanson, JT Leykum, LK Pugh, JA McDaniel, RR AF Hanson, Joshua T. Leykum, Luci K. Pugh, Jacqueline A. McDaniel, Reuben R. TI Nighttime Clinical Encounters: How Residents Perceive and Respond to Calls at Night SO JOURNAL OF HOSPITAL MEDICINE LA English DT Article ID SIGN-OUT; HANDOFF PROGRAM; PATIENT-CARE; HEALTH-CARE; QUALITY; IMPROVEMENT AB BACKGROUNDCare fragmentation is common and contributes to communication errors and adverse events. Handoff tools were developed to reduce the potential for these errors. Despite their widespread adoption, there is little information describing their impact on clinical work. Understanding their impact could be helpful in improving handoffs and transitions. OBJECTIVETo better understand what clinical work is done overnight, the housestaff perceptions of overnight clinical work, and how handoff instruments support this work. DESIGNReal-time data collection and survey. PARTICIPANTSInternal medicine resident physicians. MAIN MEASURESData collection measured information related to nighttime clinical encounters, including the information sources and actions taken. Surveys assessed resident perceptions toward care transitions. KEY RESULTSOf 299 encounters, 289 contained complete data. The tool was used as an information source in 27.7% of encounters, whereas the information source was either the nurse or the chart in 94.4% of encounters. Many encounters resulted in a new order for a medication, whereas 3.8% resulted in documentation. In the survey data, 73.6% residents reported the sign-out procedure was safe. CONCLUSIONThese data suggest that a handoff tool is not sufficient to address nighttime clinical issues and suggest that effective care requires more than just the information transfer. It may also reflect that electronic medical records have become a readily available information source at the point of care. Sign-out should support residents' ability to make sense of what is happening and integrate care of day and night teams, rather than solely transfer information. Journal of Hospital Medicine 2015;10:142-146. 2015 Society of Hospital Medicine C1 [Hanson, Joshua T.; Leykum, Luci K.; Pugh, Jacqueline A.] South Texas Vet Hlth Care Syst, Dept Med, San Antonio, TX USA. [Hanson, Joshua T.; Leykum, Luci K.; Pugh, Jacqueline A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Sch Med, San Antonio, TX 78229 USA. [McDaniel, Reuben R.] Univ Texas Austin, McCombs Sch Business, Dept Informat Risk & Operat Management, Austin, TX 78712 USA. RP Hanson, JT (reprint author), 7703 Floyd Curl Dr,MC 7982, San Antonio, TX 78229 USA. EM hansonj4@uthscsa.edu OI Pugh, Jacqueline/0000-0003-4933-141X FU Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service [CDA 07-022]; South Texas Veterans Health Care System FX The research reported here was supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service (CDA 07-022). Investigator salary support was provided through this funding, and through the South Texas Veterans Health Care System. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. Parts of these data were presented at the 2013 SGIM National Meeting in Denver, Colorado. The authors report no conflicts of interest. NR 24 TC 3 Z9 3 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1553-5592 EI 1553-5606 J9 J HOSP MED JI J. Hosp. Med. PD MAR PY 2015 VL 10 IS 3 BP 142 EP 146 DI 10.1002/jhm.2315 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA CC8XX UT WOS:000350653000002 PM 25736614 ER PT J AU Singh, JA Dalbeth, N AF Singh, Jasvinder A. Dalbeth, Nicola TI Is the Double Contour Sign Specific for Gout? Or Only for Crystal Arthritis? SO JOURNAL OF RHEUMATOLOGY LA English DT Editorial Material ID ASYMPTOMATIC HYPERURICEMIA; ULTRASOUND; DEPOSITION; INVOLVEMENT; DIAGNOSIS C1 [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham VA Med Ctr, Birmingham, AL 35233 USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. [Dalbeth, Nicola] Univ Auckland, Auckland 1, New Zealand. [Dalbeth, Nicola] Auckland Dist Hlth Board, Auckland, New Zealand. RP Singh, JA (reprint author), Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham VA Med Ctr, Birmingham, AL 35233 USA. NR 8 TC 1 Z9 1 U1 0 U2 2 PU J RHEUMATOL PUBL CO PI TORONTO PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA SN 0315-162X EI 1499-2752 J9 J RHEUMATOL JI J. Rheumatol. PD MAR PY 2015 VL 42 IS 3 BP 353 EP 354 DI 10.3899/jrheum.141322 PG 2 WC Rheumatology SC Rheumatology GA CD0FM UT WOS:000350746000003 PM 25729038 ER PT J AU Shi, M Movius, J Dator, R Aro, P Zhao, YC Pan, C Lin, XM Bammler, TK Stewart, T Zabetian, CP Peskind, ER Hu, SC Quinn, JF Galasko, DR Zhang, J AF Shi, Min Movius, James Dator, Romel Aro, Patrick Zhao, Yanchun Pan, Catherine Lin, Xiangmin Bammler, Theo K. Stewart, Tessandra Zabetian, Cyrus P. Peskind, Elaine R. Hu, Shu-Ching Quinn, Joseph F. Galasko, Douglas R. Zhang, Jing TI Cerebrospinal Fluid Peptides as Potential Parkinson Disease Biomarkers: A Staged Pipeline for Discovery and Validation SO MOLECULAR & CELLULAR PROTEOMICS LA English DT Article ID PRECURSOR-LIKE PROTEIN-1; NEURODEGENERATIVE DISEASES; MATRIX METALLOPROTEINASES; ALZHEIMERS-DISEASE; ALPHA-SYNUCLEIN; CLINICAL-FEATURES; SUBSTANTIA-NIGRA; TISSUE INHIBITOR; AMYLOID-BETA; IDENTIFICATION AB Finding robust biomarkers for Parkinson disease (PD) is currently hampered by inherent technical limitations associated with imaging or antibody-based protein assays. To circumvent the challenges, we adapted a staged pipeline, starting from our previous proteomic profiling followed by high-throughput targeted mass spectrometry (MS), to identify peptides in human cerebrospinal fluid (CSF) for PD diagnosis and disease severity correlation. In this multicenter study consisting of training and validation sets, a total of 178 subjects were randomly selected from a retrospective cohort, matching age and sex between PD patients, healthy controls, and neurological controls with Alzheimer disease (AD). From similar to 14,000 unique peptides displaying differences between PD and healthy control in proteomic investigations, 126 peptides were selected based on relevance and observability in CSF using bioinformatic analysis and MS screening, and then quantified by highly accurate and sensitive selected reaction monitoring (SRM) in the CSF of 30 PD patients versus 30 healthy controls (training set), followed by diagnostic (receiver operating characteristics) and disease severity correlation analyses. The most promising candidates were further tested in an independent cohort of 40 PD patients, 38 AD patients, and 40 healthy controls (validation set). A panel of five peptides (derived from SPP1, LRP1, CSF1R, EPHA4, and TIMP1) was identified to provide an area under curve (AUC) of 0.873 (sensitivity = 76.7%, specificity = 80.0%) for PD versus healthy controls in the training set. The performance was essentially confirmed in the validation set (AUC = 0.853, sensitivity = 82.5%, specificity = 82.5%). Additionally, this panel could also differentiate the PD and AD groups (AUC = 0.990, sensitivity = 95.0%, specificity = 97.4%). Furthermore, a combination of two peptides belonging to proteins TIMP1 and APLP1 significantly correlated with disease severity as determined by the Unified Parkinson's Disease Rating Scale motor scores in both the training (r = 0.381, p = 0.038) j and the validation (r = 0.339, p = 0.032) sets. The novel panel of CSF peptides, if validated in independent cohorts, could be used to assist in clinical diagnosis of PD and has the potential to help monitoring or predicting disease progression. C1 [Shi, Min; Movius, James; Dator, Romel; Aro, Patrick; Zhao, Yanchun; Pan, Catherine; Lin, Xiangmin; Stewart, Tessandra; Zhang, Jing] Univ Washington, Dept Pathol, Sch Med, Seattle, WA 98104 USA. [Lin, Xiangmin] Fujian Agr & Forestry Univ, Sch Life Sci, Fuzhou 350002, Fujian, Peoples R China. [Bammler, Theo K.] Univ Washington, Dept Environm & Occupat Hlth Sci, Seattle, WA 98195 USA. [Zabetian, Cyrus P.; Hu, Shu-Ching] Vet Affairs Puget Sound Hlth Care Syst, Geriatr & Parkinsons Dis Res Ctr, Seattle, WA 98108 USA. [Zabetian, Cyrus P.; Hu, Shu-Ching] Vet Affairs Puget Sound Hlth Care Syst, Geriatr & Parkinsons Educ Ctr, Seattle, WA 98108 USA. [Zabetian, Cyrus P.; Hu, Shu-Ching] Vet Affairs Puget Sound Hlth Care Syst, Geriatr & Parkinsons Clin Ctr, Seattle, WA 98108 USA. [Zabetian, Cyrus P.; Hu, Shu-Ching] Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA. [Peskind, Elaine R.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Peskind, Elaine R.] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Quinn, Joseph F.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Galasko, Douglas R.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA. RP Zhang, J (reprint author), Univ Washington, Dept Pathol, Sch Med, HMC Box 359635,325 9th Ave, Seattle, WA 98104 USA. EM zhangj@u.washington.edu RI Shi, Min/G-6165-2012 OI Shi, Min/0000-0002-6901-2558; , xiangmin/0000-0001-9128-689X; Lin, Xiangmin/0000-0003-2216-0198 FU National Institutes of Health (NIH) [U01 NS082137, P42 ES004696-5897, P30 ES007033-6364, R01 AG033398, R01 ES016873, R01 ES019277, R01 NS057567, P50 NS062684-6221, R01 NS065070, P50 AG005131]; NIH [P50 AG003156-30]; National Institute of Neurological Disorders and Stroke/NIH [R21 NS085425]; University of Washington's Proteomics Resource [UWPR95794]; National Institute Of Environmental Health Sciences of the NIH [P30 ES007033]; National Natural Science Foundation of China (NSFC) [31200105, 31470238] FX This study was supported by generous grants from the National Institutes of Health (NIH) (U01 NS082137, P42 ES004696-5897, P30 ES007033-6364, R01 AG033398, R01 ES016873, R01 ES019277, R01 NS057567, and P50 NS062684-6221 to JZ, R01 NS065070 to CPZ, and P50 AG005131 to DRG), and partially by a pilot study award from the NIH-sponsored ADRC at the UW (P50 AG003156-30) and a National Institute of Neurological Disorders and Stroke/NIH award R21 NS085425 to MS. It was also supported in part by the University of Washington's Proteomics Resource (UWPR95794), the National Institute Of Environmental Health Sciences of the NIH under Award Number P30 ES007033, and the National Natural Science Foundation of China (NSFC) projects (31200105 and 31470238). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH and other sponsors. NR 58 TC 12 Z9 12 U1 2 U2 18 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 1535-9476 EI 1535-9484 J9 MOL CELL PROTEOMICS JI Mol. Cell. Proteomics PD MAR PY 2015 VL 14 IS 3 BP 544 EP 555 DI 10.1074/mcp.M114.040576 PG 12 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA CC9EP UT WOS:000350671300009 PM 25556233 ER PT J AU Liu, CQ Cholerton, B Shi, M Ginghina, C Cain, KC Auinger, P Zhang, J AF Liu, Changqin Cholerton, Brenna Shi, Min Ginghina, Carmen Cain, Kevin C. Auinger, Peggy Zhang, Jing CA Parkinson Study Grp DATATOP TI CSF tau and tau/A beta(42) predict cognitive decline in Parkinson's disease SO PARKINSONISM & RELATED DISORDERS LA English DT Article DE Biomarkers; Cerebrospinal fluid; Cognition; Neuropsychological tests; Parkinson disease; tau proteins ID CEREBROSPINAL-FLUID; AMYLOID-BETA; ALPHA-SYNUCLEIN; T-TAU; DEMENTIA; ASSOCIATION; PERFORMANCE; IMPAIRMENT; BIOMARKERS; MUTATIONS AB Introduction: A substantial proportion of patients with Parkinson's disease (PD) have concomitant cognitive dysfunction. Identification of biomarker profiles that predict which PD patients have a greater likelihood for progression of cognitive symptoms is pressingly needed for future treatment and prevention approaches. Methods: Subjects were drawn from the Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP) study, a large clinical trial that enrolled initially untreated PD patients. For the current study, Phase One encompassed trial baseline until just prior to levodopa administration (n = 403), and Phase Two spanned the initiation of levodopa treatment until the end of cognitive follow-up (n = 305). Correlations and linear mixed models were performed to determine cross-sectional and longitudinal associations between baseline amyloid beta(1-42) (A beta(42)), total tau (t-tau), and phosphorylated tau (p-tau) in cerebrospinal fluid (CSF) and measures of memory and executive function. Analyses also considered APOE genotype and tremor- vs. rigidity-dominant phenotype. Results: No association was found between baseline CSF biomarkers and cognitive test performance during Phase One. However, once levodopa treatment was initiated, higher p-tau and p-tau/A beta(42) predicted subsequent decline on cognitive tasks involving both memory and executive functions. The interactions between biomarkers and cognition decline did not appear to be influenced by levodopa dosage, APOE genotype or motor phenotype. Conclusions: The current study has, for the first time, demonstrated the possible involvement of tau species, whose gene (MAPT) has been consistently linked to the risk of PD by genome-wide association studies, in the progression of cognitive symptoms in PD. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Liu, Changqin; Shi, Min; Ginghina, Carmen; Zhang, Jing] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98104 USA. [Liu, Changqin] Xiamen Univ, Affiliated Hosp 1, Dept Endocrinol & Diabet, Xiamen, Peoples R China. [Cholerton, Brenna] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98104 USA. [Cholerton, Brenna] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Cain, Kevin C.] Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98104 USA. [Auinger, Peggy] Univ Rochester, Sch Med & Dent, Dept Neurol, Ctr Human Expt Therapeut, Rochester, NY 14642 USA. RP Zhang, J (reprint author), Univ Washington, Sch Med, Dept Pathol, HMC Box 359635,325 9th Ave, Seattle, WA 98104 USA. EM liuchangqin@126.com; bchol@uw.edu; mshi70@uw.edu; ginghina@uw.edu; cain@uw.edu; peggy.auinger@chet.rochester.edu; zhangj@uw.edu RI Shi, Min/G-6165-2012 OI Shi, Min/0000-0002-6901-2558 FU Michael J. Fox Foundation; NIH [AG10124, ES004696-5897, ES007033-6364, AG033398, ES016873, ES019277, NS057567, NS062684-6221, NS082137] FX The study is supported by generous grants from the Michael J. Fox Foundation as well as NIH (AG10124, ES004696-5897, ES007033-6364, AG033398, ES016873, ES019277, NS057567, NS062684-6221 and NS082137). We thank Karen Marder, Lorraine Clark, and the Parkinson's Disease Foundation Weill Family Fund for providing the APOE data for this study. NR 29 TC 18 Z9 19 U1 1 U2 10 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1353-8020 EI 1873-5126 J9 PARKINSONISM RELAT D JI Parkinsonism Relat. Disord. PD MAR PY 2015 VL 21 IS 3 BP 271 EP 276 DI 10.1016/j.parkreldis.2014.12.027 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA CD2SU UT WOS:000350930100019 PM 25596881 ER PT J AU Fang, JY Perez, A Christine, CW Leehey, M Aminoff, MJ Boyd, JT Morgan, JC Dhall, R Nicholas, AP Bodis-Wollner, I Zweig, RM Goudreau, JL AF Fang, John Y. Perez, Adriana Christine, Chadwick W. Leehey, Maureen Aminoff, Michael J. Boyd, James T. Morgan, John C. Dhall, Rohit Nicholas, Anthony P. Bodis-Wollner, Ivan Zweig, Richard M. Goudreau, John L. CA NINDS NET-PD Investigators TI Parkinson's disease severity and use of dopaminergic medications SO PARKINSONISM & RELATED DISORDERS LA English DT Article DE Parkinson's disease; Levodopa; Dopamine agonist; Clinical trial; Disability; Cognition ID TRIAL; LEVODOPA; DESIGN AB Background: The effects of dopaminergic therapy in parkinson's disease (PD) can vary depending on the class of medication selected. Objective: The aim of this post hoc study was to determine if the class of dopaminergic therapy correlated with disease severity in persons with early, treated PD. Methods: A non-parametric global statistical test (GST) was used to assess the status of participants treated with dopamine agonist (DA) monotherapy, levodopa (LD) monotherapy or combined LD and DA therapy on multiple PD outcomes encompassing motor, cognitive, psychiatric and autonomic function, as well as disability and quality of life. Results: The outcomes measured at the beginning of the study showed lower disease burden for participants on initial DA monotherapy compared to those taking combined LD and DA therapy after controlling for age, education, taking cog-meds and amantadine. Conclusion: This observation suggests that clinicians treating early PD patients favor combined LD and DA therapy in patients with more disabling features over DA monotherapy. As such, studies of PD progression in treated PD patients may be affected by the class of symptomatic dopaminergic therapy. Published by Elsevier Ltd. C1 [Fang, John Y.] Vanderbilt Univ, Dept Neurol, Nashville, TN 37232 USA. [Perez, Adriana] Univ Texas Sch Publ Hlth, UTHlth, Austin, TX 78701 USA. [Christine, Chadwick W.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Leehey, Maureen] Univ Colorado, Sch Med, Dept Neurol, Aurora, CO 80045 USA. [Aminoff, Michael J.] Univ Calif San Francisco, Sch Med, Dept Neurol, San Francisco, CA 94143 USA. [Boyd, James T.] Univ Vermont, Dept Neurol Sci, Coll Med, Burlington, VT 05401 USA. [Morgan, John C.] Georgia Regents Univ, Dept Neurol, Med Coll Georgia, Movement & Cognit Disorders Ctr, Augusta, GA 30912 USA. [Dhall, Rohit] Barrow Neurol Inst, Phoenix, AZ 85013 USA. [Nicholas, Anthony P.] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA. [Nicholas, Anthony P.] Birmingham VA Med Ctr, Birmingham, AL 35294 USA. [Bodis-Wollner, Ivan] Suny Downstate Med Ctr, Dept Neurol, Brooklyn, NY 11203 USA. [Bodis-Wollner, Ivan] Suny Downstate Med Ctr, Dept Ophthalmol, Brooklyn, NY 11203 USA. [Zweig, Richard M.] LSU Hlth Sci Ctr Shreveport, Dept Neurol, Shreveport, LA 71130 USA. [Goudreau, John L.] Michigan State Univ, Dept Neurol, E Lansing, MI 48824 USA. RP Fang, JY (reprint author), Vanderbilt Univ, Dept Neurol, 1161 21st Ave South,A-0118, Nashville, TN 37232 USA. EM john.y.fang@vanderbilt.edu FU NIMHD NIH HHS [R24 MD001779]; NINDS NIH HHS [U10 NS044555] NR 7 TC 1 Z9 1 U1 0 U2 6 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1353-8020 EI 1873-5126 J9 PARKINSONISM RELAT D JI Parkinsonism Relat. Disord. PD MAR PY 2015 VL 21 IS 3 BP 297 EP 299 DI 10.1016/j.parkreldis.2014.10.016 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA CD2SU UT WOS:000350930100024 PM 25541182 ER PT J AU Pang, CE Sarraf, D Freund, KB AF Pang, Claudine E. Sarraf, David Freund, K. Bailey TI EXTREME CHOROIDAL THINNING IN HIGH MYOPIA SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES LA English DT Article DE extreme choroidal thinning; leptochoroid; high myopia; subfoveal choroidal thickness; retinal thickness; visual acuity; age-related choroidal atrophy ID OPTICAL COHERENCE TOMOGRAPHY; THICKNESS MEASUREMENTS; AXIAL LENGTH; POSTERIOR STAPHYLOMA; RETINAL-DETACHMENT; VISUAL IMPAIRMENT; BEIJING EYE; LOW-VISION; BLINDNESS; POPULATION AB Purpose: To describe the spectral domain optical coherence tomography characteristics of extreme choroidal thinning in high myopia and demonstrate its compatibility with good visual acuity. Methods: This was a retrospective observational case review of nonconsecutive myopic patients with extreme choroidal thinning, defined as a subfoveal choroidal thickness of 20 mm or less as measured with spectral domain optical coherence tomography. Clinical features, such as visual acuity, axial length, and spectral domain optical coherence tomography characteristics including choroidal and retinal thicknesses in four quadrants were analyzed. Results: Thirty-six eyes of 20 patients with extreme choroidal thinning were included. Mean subfoveal choroidal thickness was 13.9 +/- 6.0 mu m, mean age was 71 years (range, 32-85 years), mean axial length was 30.7 +/- 2.2 mm, and mean follow-up duration was 44.7 +/- 15.4 months. Of these, 25 eyes (70%) had visual acuity of 20/40 or better (mean visual acuity was 20/30), whereas the remaining eyes had mean visual acuity of 20/193. All eyes with extreme choroidal thinning had prominent choroidal vessels seen under the macula documented on color fundus photography and near-infrared reflectance imaging. All eyes with visual acuity poorer than 20/40 had fovea-involving choroidal neovascularization and/or atrophy. In the 25 eyes with good visual acuity, the mean choroidal thickness was thinnest at the nasal zone, followed by inferior, superior, and temporal zones (P = 0.01); and there was no detectable decrease in choroidal thickness over time. The mean retinal thickness was thinner in the fovea and parafoveal zones when compared with highly myopic eyes without extreme choroidal thinning. Conclusion: Extreme choroidal thinning in myopic eyes is compatible with good visual acuity of 20/40 or better, may be present in a wide age range, and may not demonstrate any progressive decline over up to 70 months of follow-up; suggesting that choroidal thickness alone is not a reliable indicator of visual function. C1 [Pang, Claudine E.; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY 10022 USA. [Pang, Claudine E.; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY USA. [Sarraf, David] Univ Calif Los Angeles, Jules Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, Los Angeles, CA 90024 USA. [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. [Freund, K. Bailey] NYU, Dept Ophthalmol, Sch Med, New York, NY 10016 USA. RP Pang, CE (reprint author), Vitreous Retina Macula Consultants New York, 460 Pk Ave,Fifth Floor, New York, NY 10022 USA. EM kbfnyf@aol.com FU LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear and Throat Hospital, New York, NY; Macula Foundation, Inc, New York, NY; Regeneron; Heidelberg; Genentech FX Supported by LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear and Throat Hospital, New York, NY and the Macula Foundation, Inc, New York, NY.; K. B. Freund is a consultant at Genentech, Regeneron, Optos, Bayer HealthCare, Thrombogneics, and Heidelberg Engineering. D. Sarraf has received research support from Regeneron and Heidelberg, and is a speaker. C. E. Pang has no financial/conflicting interests to disclose. D. Sarraf has received research support from Regeneron and Genentech, and is a consultant for Genentech. NR 47 TC 6 Z9 6 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0275-004X EI 1539-2864 J9 RETINA-J RET VIT DIS JI Retin.-J. Retin. Vitr. Dis. PD MAR PY 2015 VL 35 IS 3 BP 407 EP 415 PG 9 WC Ophthalmology SC Ophthalmology GA CC4AO UT WOS:000350293100016 PM 25313711 ER PT J AU Daskalakis, NP Binder, EB AF Daskalakis, Nikolaos P. Binder, Elisabeth B. TI Schizophrenia in the Spectrum of Gene-Stress Interactions: The FKBP5 Example SO SCHIZOPHRENIA BULLETIN LA English DT Article ID PITUITARY-ADRENAL AXIS; RECEPTOR MESSENGER-RNA; EARLY-LIFE ADVERSITY; CHILDHOOD TRAUMA; BIPOLAR DISORDER; ENVIRONMENT INTERACTIONS; PSYCHOSOCIAL STRESS; HIPPOCAMPAL VOLUME; CORTISOL-LEVELS; 1ST-EPISODE PSYCHOSIS AB Many studies have demonstrated that genotype (G) interacts with adverse life experiences (E) to produce individual differences in vulnerability and resilience to mental disorders, including schizophrenia. Genetic susceptibility to stress and the timing of the environmental exposure(s) are relevant for these interactions and represent common risk factors. We take the example of the FKBP5 gene to illustrate G x E interactions that predict pleiotropic psychiatric outcomes, including schizophrenia. C1 [Daskalakis, Nikolaos P.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Daskalakis, Nikolaos P.] James J Peters Vet Affairs Med Ctr, Mental Hlth Care Ctr, Bronx, NY USA. [Binder, Elisabeth B.] Max Planck Inst Psychiat, Dept Translat Res Psychiat, D-80804 Munich, Germany. [Binder, Elisabeth B.] Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA USA. RP Daskalakis, NP (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. EM nikolaos.daskalakis@mssm.edu RI Daskalakis, Nikolaos/B-7930-2014 OI Daskalakis, Nikolaos/0000-0003-1660-9112 FU Dutch Top-Institute Pharma [T5-209] FX NPD was supported by the Dutch Top-Institute Pharma T5-209. EBB is co-inventor of the following patent application: "FKBP5: a novel target for antidepressant therapy. European Patent# EP 1687443 B1." The authors have declared that there are no other conflicts of interest in relation to the subject of this study. NR 91 TC 3 Z9 3 U1 4 U2 13 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 EI 1745-1701 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2015 VL 41 IS 2 BP 323 EP 329 DI 10.1093/schbul/sbu189 PG 7 WC Psychiatry SC Psychiatry GA CD3LI UT WOS:000350979500005 PM 25592294 ER PT J AU Song, YS Blackwell, T Yaffe, K Ancoli-Israel, S Redline, S Stone, KL AF Song, Yeonsu Blackwell, Terri Yaffe, Kristine Ancoli-Israel, Sonia Redline, Susan Stone, Katie L. CA Osteoporotic Fractures Men MrOS S TI Relationships Between Sleep Stages and Changes in Cognitive Function in Older Men: The MrOS Sleep Study SO SLEEP LA English DT Article DE aging; cognitive function; cohort study; sleep stages ID SLOW-WAVE SLEEP; CARDIOVASCULAR HEALTH COGNITION; VISUAL-DISCRIMINATION TASK; EYE-MOVEMENT SLEEP; OSTEOPOROTIC FRACTURES; ALZHEIMERS-DISEASE; DEMENTIA; ADULTS; PERFORMANCE; POPULATION AB Study Objective: To investigate the associations between sleep stage distributions and subsequent decline in cognitive function in older men over time. Design: A population-based prospective substudy of the Osteoporotic Fractures in Men Study. Settings: Six sites in the United States. Participants: Community-dwelling men aged 67 y or older (n = 2,601), who were free of probable dementia at sleep visit. Follow-up averaged 3.4 y. Measurement and Results: Sleep stages were identified by in-home polysomnography at the initial sleep visit (2003-2005). Cognitive outcomes were assessed with the Trail Making Test Part B and Modified Mini-Mental State Examination (3MS) at sleep visit and two follow-up visits. After adjusting for multiple confounders compared with men in the lowest quartile of percent of sleep time spent in Stage N1, those in the highest quartile had a twofold increase in cognitive decline for both cognitive tests (adjusted annualized percent change/y: Trail Making Test Part B Q1 = 1.06, Q4 = 2.45, P = 0.01; 3MS Q1 = -0.27, Q4 = -0.48, P = 0.03). In addition, compared with men in the highest quartile, men in the lowest quartile of percent of sleep time in Stage R revealed more cognitive decline on the 3MS (adjusted annualized percent change/y: Q1 = -0.49, Q4 = -0.22, P = 0.003). These findings were consistent even after further adjustment of total sleep time and sleep disordered breathing. No significant relationships between other sleep stages (N2, N3) and cognitive change were found. Conclusion: Increased time in Stage N1 sleep and less time in Stage REM sleep are associated with worsening cognitive performance in older men over time. C1 [Song, Yeonsu] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Blackwell, Terri; Stone, Katie L.] San Francisco Coordinating Ctr, San Francisco, CA 94107 USA. [Blackwell, Terri; Stone, Katie L.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Sch Med, Dept Psychiat Neurol & Epidemiol, San Francisco, CA 94143 USA. [Ancoli-Israel, Sonia] Univ Calif San Diego, Sch Med, Dept Psychiat, San Diego, CA 92103 USA. [Redline, Susan] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Redline, Susan] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA. RP Stone, KL (reprint author), San Francisco Coordinating Ctr, 185 Berry St,Lobby 5,Suite 5700, San Francisco, CA 94107 USA. EM kstone@sfcc-cpmc.net FU National Institutes of Health; National Institute on Aging (NIA); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); National Center for Advancing Translational Sciences (NCATS); NIH Roadmap for Medical Research [U01 AG027810, U01 AG042124, U01 AG042139, U01 AG042140, U01 AG042143, U01 AG042145, U01 AG042168, U01 AR066160, UL1 TR000128]; National Heart, Lung, and Blood Institute [R01 HL071194, R01 HL070848, R01 HL070847, R01 HL070842, R01 HL070841, R01 HL070837, R01 HL070838, R01 HL070839]; ResMed Foundation; NIH FX This was not an industry supported study. The Osteoporotic Fractures in Men (MrOS) Study is supported by National Institutes of Health funding. The following institutes provide support: the National Institute on Aging (NIA), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Center for Advancing Translational Sciences (NCATS), and NIH Roadmap for Medical Research under the following grant numbers: U01 AG027810, U01 AG042124, U01 AG042139, U01 AG042140, U01 AG042143, U01 AG042145, U01 AG042168, U01 AR066160, and UL1 TR000128. The National Heart, Lung, and Blood Institute provides funding for the ancillary MrOS Sleep Study, "Outcomes of Sleep Disorders in Older Men," under the following grant numbers: R01 HL071194, R01 HL070848, R01 HL070847, R01 HL070842, R01 HL070841, R01 HL070837, R01 HL070838, and R01 HL070839. The analysis was performed at California Pacific Medical Center Research Institute, San Francisco, CA. Dr. Ancoli-Israel is a consultant and on the scientific advisory board for Arena, Ferring Pharmaceuticals Inc., Jansen, Merck, NeuroVigil, Inc., and Purdue Pharma LP. Dr. Redline received research grants from ResMed Foundation and equipment for use in research from ResMed Inc and Philips-Respironics. Dr. Yaffe serves on data safety monitoring boards for Takeda Pharmaceuticals, Inc. and an NIH sponsored study. She is a consultant for Novartis and Pfizer and serves on the Beeson Scientific Advisory Board. The other authors have indicated no financial conflicts of interest. NR 71 TC 8 Z9 8 U1 4 U2 13 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 EI 1550-9109 J9 SLEEP JI Sleep PD MAR PY 2015 VL 38 IS 3 BP 411 EP 421 DI 10.5665/sleep.4500 PG 11 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CC8WE UT WOS:000350648500012 PM 25325465 ER PT J AU Shan, L Bao, AM Swaab, DF AF Shan, Ling Bao, Ai-Min Swaab, Dick F. TI The human histaminergic system in neuropsychiatric disorders SO TRENDS IN NEUROSCIENCES LA English DT Review DE histamine; Parkinson's disease; Alzheimer's disease; Huntington's disease; narcolepsy; Tourette's syndrome ID MELANIN-CONCENTRATING HORMONE; CEREBROSPINAL-FLUID HISTAMINE; RECEPTOR-MEDIATED INHIBITION; L-HISTIDINE DECARBOXYLASE; ALZHEIMERS-DISEASE BRAIN; PARKINSONS-DISEASE; H-3 RECEPTOR; HUMAN HYPOTHALAMUS; TUBEROMAMMILLARY NUCLEUS; INVERSE AGONIST AB Histaminergic neurons are exclusively located in the hypothalamic tuberomamillary nucleus, from where they project to many brain areas. The histaminergic system is involved in basic physiological functions, such as the sleep-wake cycle, energy and endocrine homeostasis, sensory and motor functions, cognition, and attention, which are all severely affected in neuropsychiatric disorders. Here, we present recent postmortem findings on the alterations in this system in neuropsychiatric disorders, including Parkinson's disease (PD), Alzheimer's disease (AD), Huntington's disease (HD), depression, and narcolepsy. In addition, we highlight the need to validate animal models for these diseases and also for burette's syndrome (TS) in relation to alterations in the histaminergic system. Moreover, we discuss the potential for, and concerns over, the use of novel histamine 3 receptor (H3R) antagonists/inverse agonists as treatment for such disorders. C1 [Shan, Ling; Bao, Ai-Min] Zhejiang Univ, Dept Neurobiol, Sch Med, Hangzhou 310058, Zhejiang, Peoples R China. [Shan, Ling; Swaab, Dick F.] Netherlands Inst Neurosci, NL-1105 BA Amsterdam, Netherlands. [Shan, Ling] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Shan, Ling] Vet Adm Greater Los Angeles Hlth Care Syst, Neurobiol Res, North Hills, CA 91343 USA. RP Bao, AM (reprint author), Zhejiang Univ, Dept Neurobiol, Sch Med, Hangzhou 310058, Zhejiang, Peoples R China. EM baoaimin@zju.edu.cn OI Shan, Ling/0000-0002-4765-2474 FU Program of Introducing Talents of Discipline to Universities of China [B13026]; Zhejiang University K.P. Chao's Hi-Tech Foundation for Scholars and Scientists; China Scholarship Council [30201]; European Histamine Research Society; NARSAD Young Investigator Grant from the Brain & Behavior Research Foundation FX This work was supported by the Program of Introducing Talents of Discipline to Universities of China (Nr. B13026) to D.S. and A-M.B., and supported by Zhejiang University K.P. Chao's Hi-Tech Foundation for Scholars and Scientists to D.S. It was also supported by the China Scholarship Council for State Scholarship Fund [grant number (2007) 30201 to L.S. The work has been presented and awarded a Young Investigators Award by the European Histamine Research Society to L.S. L.S. is currently supported by a (2014) NARSAD Young Investigator Grant from the Brain & Behavior Research Foundation. The authors also thank The Netherlands Brain Bank (Director Inge Huitinga) for providing human brain material and clinical data, and W.T.P. Verweij for secretarial assistance, NR 112 TC 23 Z9 24 U1 3 U2 16 PU ELSEVIER SCIENCE LONDON PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 0166-2236 J9 TRENDS NEUROSCI JI Trends Neurosci. PD MAR PY 2015 VL 38 IS 3 BP 167 EP 177 DI 10.1016/j.tins.2014.12.008 PG 11 WC Neurosciences SC Neurosciences & Neurology GA CD2UA UT WOS:000350933300006 PM 25575625 ER PT J AU Shamitoff, A Lamba, R Bennett, GL Catanzano, T Moshiri, M Katz, DS Bhargava, P AF Shamitoff, Anna Lamba, Ramit Bennett, Genevieve L. Catanzano, Tara Moshiri, Mariam Katz, Douglas S. Bhargava, Puneet TI Practice Patterns in Imaging of the Abdomen and Pelvis of the Pregnant Patient A Survey from the 2012 Radiological Society of North America Annual Meeting Controversies Session SO ULTRASOUND QUARTERLY LA English DT Editorial Material ID ABDOMINAL-PAIN; UROLITHIASIS; COMPLICATIONS; MANAGEMENT; DIAGNOSIS C1 [Shamitoff, Anna; Moshiri, Mariam; Bhargava, Puneet] Univ Washington, Sch Med, Dept Radiol, Seattle, WA 98195 USA. [Lamba, Ramit] Univ Calif, Dept Radiol, Sacramento, CA USA. [Bennett, Genevieve L.] NYU, Dept Radiol, Langone Med Ctr, New York, NY 10016 USA. [Bennett, Genevieve L.] Sch Med, New York, NY USA. [Catanzano, Tara] Baystate Med Ctr, Dept Radiol, Springfield, MA USA. [Katz, Douglas S.] Winthrop Univ Hosp, Dept Radiol, Mineola, NY 11501 USA. [Bhargava, Puneet] VA Puget Sound Hlth Care Syst, Dept Radiol, Seattle, WA 98108 USA. RP Bhargava, P (reprint author), VA Puget Sound Hlth Care Syst, Dept Radiol, 1660 S ColumbianWay, Seattle, WA 98108 USA. EM bhargp@uw.edu NR 15 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0894-8771 EI 1536-0253 J9 ULTRASOUND Q JI Ultrasound Q. PD MAR PY 2015 VL 31 IS 1 BP 2 EP 4 PG 3 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CC3XO UT WOS:000350284800002 PM 25706359 ER PT J AU Slade, EP Goldman, HH AF Slade, Eric P. Goldman, Howard H. TI The Dynamics of Psychiatric Bed Use in General Hospitals SO ADMINISTRATION AND POLICY IN MENTAL HEALTH AND MENTAL HEALTH SERVICES RESEARCH LA English DT Article DE Psychiatric inpatient care; Scatter beds; Length-of-stay ID EMERGENCY-DEPARTMENT; CARE AB This study examines general hospitals' adjustments in psychiatric bed utilization practices in response to increases in psychiatric inpatient admissions. Using panel data from 439 hospitals, monthly observations (N = 7,831) between 2007 and 2010 on psychiatric admissions, psychiatric bed occupancy rates, and average length-of-stay were created for psychiatric inpatients. In fixed-effects regressions, an increase in psychiatric admissions was associated with an increase in the probability of psychiatric bed use exceeding 100 % occupancy and with a reduction of mean length-of-stay. These results were confirmed in instrumental variables models. General hospitals may dynamically adjust bed utilization practices in response to changing psychiatric bed needs. An implication of this dynamic adjustment model is that bed shortages are likely to be local, transitory events. C1 [Slade, Eric P.] US Dept Vet Affairs, VA Capitol Healthcare Network Mental Illness Res, Baltimore, MD 21201 USA. [Slade, Eric P.; Goldman, Howard H.] Univ Maryland, Sch Med, Dept Psychiat, Baltimore, MD 21227 USA. RP Slade, EP (reprint author), US Dept Vet Affairs, VA Capitol Healthcare Network Mental Illness Res, 10 N Greene St, Baltimore, MD 21201 USA. EM eslade@psych.umaryland.edu; hh.goldman@verizon.net FU NIMH NIH HHS [R21 MH096285] NR 18 TC 2 Z9 2 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0894-587X EI 1573-3289 J9 ADM POLICY MENT HLTH JI Adm. Policy. Ment. Health PD MAR PY 2015 VL 42 IS 2 BP 139 EP 146 DI 10.1007/s10488-014-0554-4 PG 8 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA CC4DR UT WOS:000350301500003 PM 24756929 ER PT J AU Maria, MMMS Baker, NL Ramakrishnan, V Brady, KT McRae-Clark, A AF Maria, Megan M. Moran-Santa Baker, Nathaniel L. Ramakrishnan, Viswanathan Brady, Kathleen T. McRae-Clark, Aimee TI Impact of acute guanfacine administration on stress and cue reactivity in cocaine-dependent individuals SO AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE LA English DT Article DE Cocaine; cocaine cues; guanfacine; stress ID INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; ALPHA-2-ADRENERGIC RECEPTOR AGONISTS; ANXIOGENIC DRUG YOHIMBINE; GENDER-DIFFERENCES; INDUCED REINSTATEMENT; DSM-IV; SEEKING; CLONIDINE; RATS; WITHDRAWAL AB Background: Stress and drug-paired cues increase drug craving and noradrenergic activity in cocaine-dependent individuals. Thus, medications that attenuate noradrenergic activity may be effective therapeutic treatment options for cocaine-dependent individuals. Objectives: To examine the impact of acute administration of the alpha 2 adrenergic receptor agonist guanfacine on responses to multiple risk factors for relapse in cocaine-dependent individuals. Methods: In a double-blind, placebo-controlled study, cocaine-dependent individuals (n = 84), were randomized to receive either 2 mg guanfacine (n = 50) or placebo (n = 34). Within each treatment arm, subjects were randomized to either a stress (guanfacine n = 26; placebo n = 15) or a no-stress (guanfacine n = 24; placebo n = 19) group. Participants in the stress group performed the Trier Social Stress Test. Subjects in each group were exposed to a neutral cue and then to cocaine-related cues. Plasma cortisol and subjective responses were compared between the four groups. Results: The no-stress guanfacine group reported greater craving in response to cocaine cues as compared to the neutral cue (p<0.001). The guanfacine stress group reported greater subjective stress at the neutral cue than at baseline (p = 0.032). The cocaine cue increased subjective stress in the guanfacine (p<0.001) no-stress group. There were no effects of guanfacine on cortisol levels in either the stress or no stress groups (all >40.70). Conclusion: This study found no effects of a single 2mg dose of guanfacine on reactivity to stress and cues alone or on the interaction of stress and drug cues. In cocaine-dependent individuals an acute 2mg dose of guanfacine may not be an effective therapeutic treatment strategy. C1 [Maria, Megan M. Moran-Santa; Brady, Kathleen T.; McRae-Clark, Aimee] Med Univ S Carolina, Dept Psychiat & Behav Neurosci, Clin Neurosci Div, Charleston, SC 29425 USA. [Baker, Nathaniel L.; Ramakrishnan, Viswanathan] Med Univ S Carolina, Dept Publ Hlth Sci, Clin Neurosci Div, Charleston, SC 29425 USA. [Brady, Kathleen T.] Ralph H Johnson VAMC, Charleston, SC USA. RP Maria, MMMS (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, Clin Neurosci Div, 125 Doughty St, Charleston, SC 29425 USA. EM moranm@musc.edu FU National Institutes of Health; National Institute on Drug Abuse [R01DA021690]; National Institute of Child Health and Human Development [K12HD055885]; National Center for Advancing Translational Sciences [UL1TR000062] FX This work was supported by National Institutes of Health; National Institute on Drug Abuse (R01DA021690), National Institute of Child Health and Human Development K12HD055885, National Center for Advancing Translational Sciences (UL1TR000062). NR 44 TC 0 Z9 0 U1 2 U2 5 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0095-2990 EI 1097-9891 J9 AM J DRUG ALCOHOL AB JI Am. J. Drug Alcohol Abuse PD MAR PY 2015 VL 41 IS 2 BP 146 EP 152 DI 10.3109/00952990.2014.945590 PG 7 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA CC2XW UT WOS:000350209500006 ER PT J AU Neuner, J Fedders, M Caravella, M Bradford, L Schapira, M AF Neuner, Joan Fedders, Megan Caravella, Mary Bradford, Lisa Schapira, Marilyn TI Meaningful Use and the Patient Portal: Patient Enrollment, Use, and Satisfaction With Patient Portals at a Later-Adopting Center SO AMERICAN JOURNAL OF MEDICAL QUALITY LA English DT Article DE meaningful use; electronic health records; patient satisfaction; medical informatics ID MEDICAL-RECORD; HEALTH RECORD; USE CRITERIA; ACCESS; SERVICES; MODEL; WILL; CARE AB Many physicians are adopting patient portals in response to governmental incentives for meaningful use (MU), but the stage 2 requirements for portal use may be particularly challenging for newer electronic health record (EHR) users. This study examined enrollment, use based on MU requirements, and satisfaction in a recently adopting fee-for-service multispecialty system. Between 2010 and 2012, overall portal enrollment increased from 13.2% to 23.1% but varied substantially by physician specialty. In 2013, more than 97% of physicians would have met requirements for a stage 2 MU utilization measure requiring that patients download personal health information, but only 38% of all physicians (87% of primary care physicians [PCPs] and 37% of other specialists) would have met e-mail requirements. Satisfaction with the portal overall and with portal-based e-mails was high. These results suggest that later-adopting PCPs can succeed in providing satisfactory record and e-mail access but specialists may find reaching e-mail thresholds more difficult. C1 [Neuner, Joan; Bradford, Lisa] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Fedders, Megan] Med Coll Wisconsin, Froedtert Hosp, Milwaukee, WI 53226 USA. [Caravella, Mary] Univ Connecticut, Sch Business, Storrs, CT USA. [Schapira, Marilyn] Univ Penn, Perleman Sch Med, Philadelphia, PA 19104 USA. [Schapira, Marilyn] Philadelphia VA Med Ctr, CHERP, Philadelphia, PA USA. RP Neuner, J (reprint author), Med Coll Wisconsin, Ctr Patient Care & Outcomes Res, 8701 Watertown Plank Rd,Suite H3100, Milwaukee, WI 53226 USA. EM jneuner@mcw.edu FU CTSI (Clinical and Translational Science Institute) [5520204]; AHW (Advancing a Healthier Wisconsin) award [9520196]; AHW FX The authors received the following financial support for the research, authorship, and/or publication of this article: CTSI (Clinical and Translational Science Institute) Grant Number: 5520204; and AHW (Advancing a Healthier Wisconsin) award Project Number: 9520196. The CTSI Pilot and Collaborative Clinical and Translational Research Grant is supported by AHW. NR 21 TC 8 Z9 8 U1 4 U2 13 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1062-8606 EI 1555-824X J9 AM J MED QUAL JI Am. J. Med. Qual. PD MAR-APR PY 2015 VL 30 IS 2 BP 105 EP 113 DI 10.1177/1062860614523488 PG 9 WC Health Care Sciences & Services SC Health Care Sciences & Services GA CC6IE UT WOS:000350467800001 PM 24563085 ER PT J AU Turner, AP Hartoonian, N Maynard, C Leipertz, SL Haselkorn, JK AF Turner, Aaron P. Hartoonian, Narineh Maynard, Charles Leipertz, Steven L. Haselkorn, Jodie K. TI Smoking and Physical Activity: Examining Health Behaviors and 15-Year Mortality Among Individuals With Multiple Sclerosis SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Exercise; Mortality; Multiple sclerosis; Physical activity; Rehabilitation; Smoking ID QUALITY-OF-LIFE; UNITED-STATES; EXERCISE; POPULATION; PREVALENCE; VETERANS; VALIDITY; FITNESS; PEOPLE; RISK AB Objectives: To examine 2 modifiable health behaviors smoking and physical activity and their relationship to mortality among individuals with multiple sclerosis (MS). Design: Secondary analysis of Large Health Survey. Setting: Data were obtained from a linkage of the Veterans Affairs (VA) MS National Data Repository, containing information on service provision to all individuals with MS receiving health services within the U.S. Department of Veterans Affairs; the VA 1999 Large Health Survey, containing information on smoking and physical activity; and the VA Vital Status File. All-cause mortality was examined for the 15-year period from 1999 through 2013. Participants: Participants (N=2994) with MS who completed the Large Health Survey containing information on smoking and physical activity. Interventions: Not applicable. Main Outcome Measure: Survival. Results: There were 1500 deaths (50.1%) during the study period. Cox proportional hazard analyses were conducted to examine the association between smoking and physical activity and 15-year mortality. After adjusting for demographic factors, physical functioning, mental health, and comorbid medical conditions, baseline smoking was associated with greater mortality (hazard ratio [HR.] = 1.38; 95% confidence interval [CI], 1.184-1.60). Higher levels of baseline physical activity were associated with lower mortality (activity 1-2 times/wk: HR=.64; 95% CI,.518-.798; activity >= 3 times/wk: HR=.53; 95% CI, .388.715). Conclusions: Results suggest that modifiable health behaviors represent a promising opportunity for intervention to improve the lives of individuals with MS. (C) 2015 by the American Congress of Rehabilitation Medicine C1 [Turner, Aaron P.; Hartoonian, Narineh; Maynard, Charles; Leipertz, Steven L.; Haselkorn, Jodie K.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Turner, Aaron P.; Hartoonian, Narineh; Leipertz, Steven L.; Haselkorn, Jodie K.] VA Multiple Sclerosis Ctr Excellence West, Seattle, WA USA. [Turner, Aaron P.] VA Ctr Excellence Subst Abuse Treatment & Ed, Seattle, WA USA. [Turner, Aaron P.; Hartoonian, Narineh; Haselkorn, Jodie K.] Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA. [Haselkorn, Jodie K.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. RP Turner, AP (reprint author), VA Puget Sound Hlth Care Syst, Rehabil Care Serv, S-117-RCS,1660 S Columbian Way, Seattle, WA 98108 USA. EM Aaron.Turner@med.va.gov RI Maynard, Charles/N-3906-2015 OI Maynard, Charles/0000-0002-1644-7814; Turner, Aaron/0000-0001-6897-8003 FU Veterans Affairs (VA) Rehabilitation Research and Development Service Career Development Award [B33I9VA]; VA Center of Excellence in Substance Abuse Treatment and Education; VA Multiple Sclerosis Center of Excellence West; VA Office of Quality and Performance; National Multiple Sclerosis Society [MB0026] FX Supported by a Veterans Affairs (VA) Rehabilitation Research and Development Service Career Development Award (grant no. B33I9VA), the VA Center of Excellence in Substance Abuse Treatment and Education, the VA Multiple Sclerosis Center of Excellence West, VA Office of Quality and Performance, and National Multiple Sclerosis Society (grant no. MB0026). NR 35 TC 5 Z9 5 U1 2 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 EI 1532-821X J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD MAR PY 2015 VL 96 IS 3 BP 402 EP 409 DI 10.1016/j.apmr.2014.10.014 PG 8 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA CC3QZ UT WOS:000350265400004 PM 25448246 ER PT J AU Rauch, SAM King, AP Abelson, J Tuerk, PW Smith, E Rothbaum, BO Clifton, E Defever, A Liberzon, I AF Rauch, Sheila A. M. King, Anthony P. Abelson, James Tuerk, Peter W. Smith, Erin Rothbaum, Barbara O. Clifton, Erin Defever, Andrew Liberzon, Israel TI BIOLOGICAL AND SYMPTOM CHANGES IN POSTTRAUMATIC STRESS DISORDER TREATMENT: A RANDOMIZED CLINICAL TRIAL SO DEPRESSION AND ANXIETY LA English DT Article DE PTSD; cortisol; treatment; exposure therapy; cognitive behavioral therapy; veteran ID CORTISOL-LEVELS; PROLONGED EXPOSURE; FOLLOW-UP; PTSD; THERAPY; RESPONSES; VETERANS; NEUROENDOCRINE; VALIDATION; SURVIVORS AB BackgroundUnderstanding cognitive and biological mechanisms of PTSD treatment can help refine treatments and increase rates of response. MethodsThirty-six veterans with PTSD were randomly assigned to receive Prolonged exposure therapy (PE) or Present-Centered therapy (PCT). We examined symptoms, trauma-related cognitions, and two indices of HPA axis function (cortisol awakening response and cortisol response to a script-driven imagery task). ResultsThirty veterans started treatment and 26 completed. PE resulted in significantly more symptom reduction than PCT (P=.008). High treatment responders collapsed across treatments showed nominally higher cortisol levels measured at pretreatment 30 min after trauma script exposure compared to low responders (P=.08). At midtreatment, high treatment responders showed higher cortisol levels throughout the imagery task (Ps=.03-.04). There were no differences between high and low treatment responders at posttreatment. Thoughts of incompetence (F (1.6, 35.8)=16.8, P=.000) and a dangerous world (F (1.3, 29.9)=8.2, P=.004) significantly improved over time in high treatment responders but showed no change in low responders. Script-associated cortisol response prior to treatment and reductions in thoughts of incompetence accounted for 83% of the variance in reductions in PTSD severity with PE. ConclusionsBoth increased cortisol response to personal trauma script prior to PTSD therapy and reductions in cognitive symptoms of PTSD were significantly and uniquely related to reductions in the core symptoms of PTSD in PE. However, contrary to our hypotheses, cortisol measures were not related to cognitive changes. C1 [Rauch, Sheila A. M.; King, Anthony P.; Smith, Erin; Clifton, Erin; Defever, Andrew; Liberzon, Israel] VA Ann Arbor Healthcare Syst, PTSD Clin Team, Ann Arbor, MI USA. [Rauch, Sheila A. M.; King, Anthony P.; Abelson, James; Liberzon, Israel] Univ Michigan Med Sch, Dept Psychiat, Ann Arbor, MI USA. [Tuerk, Peter W.] Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA. [Tuerk, Peter W.] Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA. [Rothbaum, Barbara O.] Emory Univ, Dept Psychiat, Atlanta, GA 30322 USA. RP Rauch, SAM (reprint author), VA Ann Arbor Healthcare Syst, PTSD Clin Team, 2215 Fuller Rd 116c, Ann Arbor, MI 48105 USA. EM sherauch@med.umich.edu RI Rauch, Sheila/K-4450-2015 OI Rauch, Sheila/0000-0001-9686-4011; King, Anthony/0000-0002-0764-9625; Liberzon, Israel/0000-0002-4990-556X FU VA Office of Research and Development Clinical Sciences Research and Development (PI: Rauch); VHA; DOD FX This article was based on work supported by a Career Development Award (CDA-2) from the VA Office of Research and Development Clinical Sciences Research and Development (PI: Rauch). Dr. Rauch has received grant funding from VHA and DOD. Dr. Liberzon has received grant funding from DOD and NIH. Preliminary results from this study were presented at 2010 and 2011 Annual Meeting of the American College of Neuropsychopharmacology and the 2011 Anxiety Disorders Association of America Conference. Erin Clifton's affiliation has changed since her work on this project. Her current affiliation is Department of Psychology, Case Western Reserve University. NR 37 TC 10 Z9 11 U1 3 U2 13 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1091-4269 EI 1520-6394 J9 DEPRESS ANXIETY JI Depress. Anxiety PD MAR PY 2015 VL 32 IS 3 BP 204 EP 212 DI 10.1002/da.22331 PG 9 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA CC6LD UT WOS:000350475500007 PM 25639570 ER PT J AU Kapoor, S Thorn, BE Bandy, O Clements, KL AF Kapoor, S. Thorn, B. E. Bandy, O. Clements, K. L. TI Pain referents used to respond to the Pain Catastrophizing Scale SO EUROPEAN JOURNAL OF PAIN LA English DT Article ID COGNITIVE-BEHAVIORAL TREATMENT; BACK-PAIN; PREDICTORS; MEMORIES; HEADACHE; THERAPY; TRIAL AB BackgroundPain catastrophizing has emerged as a highly important construct in pain research. The Pain Catastrophizing Scale (PCS) is a widely used self-report measure used to determine a person's level of pain catastrophizing, assumed to be associated with an ongoing, recalled or anticipated pain experience. In practice, instructions for self-reporting catastrophizing typically do not provide a specific pain referent, even when assessing patients with chronic pain. Researchers have noted that it is not known what type of pain participants are referring to when responding to a catastrophizing questionnaire. MethodIn the current study, 182 presumably healthy undergraduate students completed the PCS followed by a query regarding the pain referent used to complete the scale. In addition, they were asked if they have ever experienced chronic pain and to list their worst pain experience. ResultsThe most commonly used primary referents included pain due to acute injury (26.4%), headache (18.0%) and general physical pain (11.5%). The type of primary referent and the number of referents did not influence the catastrophizing scores. However, the catastrophizing scores were influenced by the context of the primary pain referent, i.e., whether the primary pain referent was non-chronic worst pain, both chronic and worst pain, chronic pain or unrelated to either chronic or worst pain. Notably, a larger than expected proportion of participants reported having experienced chronic pain (44.5%; n=81). ConclusionThe examination of pain referents while responding to a catastrophizing measure would add to our understanding of a person's pain experience and related catastrophic cognitions. C1 [Kapoor, S.; Thorn, B. E.; Bandy, O.] Univ Alabama, Dept Psychol, Tuscaloosa, AL 35487 USA. [Clements, K. L.] Birmingham Vet Affairs Med Ctr, Dept Behav & Mental Hlth, Birmingham, AL USA. RP Thorn, BE (reprint author), Univ Alabama, Dept Psychol, Box 870348, Tuscaloosa, AL 35487 USA. EM bthorn@as.ua.edu NR 33 TC 3 Z9 3 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1090-3801 EI 1532-2149 J9 EUR J PAIN JI Eur. J. Pain PD MAR PY 2015 VL 19 IS 3 BP 400 EP 407 DI 10.1002/ejp.561 PG 8 WC Anesthesiology; Clinical Neurology; Neurosciences SC Anesthesiology; Neurosciences & Neurology GA CC6HK UT WOS:000350465800013 PM 25059471 ER PT J AU Gukovsky, I Gukovskaya, AS AF Gukovsky, Ilya Gukovskaya, Anna S. TI Impaired Autophagy Triggers Chronic Pancreatitis: Lessons From Pancreas- Specific Atg5 Knockout Mice SO GASTROENTEROLOGY LA English DT Editorial Material ID CANCER; CELLS; INFLAMMATION; TRYPSINOGEN; ACTIVATION C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Los Angeles, CA USA. RP Gukovsky, I (reprint author), West Los Angeles VA Healthcare Ctr, Pancreat Res Grp, 11301 Wilshire Blvd,Bldg 258,Rm 340, Los Angeles, CA 90073 USA. EM igukovsk@ucla.edu FU NCI NIH HHS [P01 CA163200]; NIAAA NIH HHS [AA019730, R01 AA019730]; NIDDK NIH HHS [P01 DK098108, DK059936, P30 DK041301, DK098108, R01 DK059936] NR 28 TC 6 Z9 6 U1 0 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 EI 1528-0012 J9 GASTROENTEROLOGY JI Gastroenterology PD MAR PY 2015 VL 148 IS 3 BP 501 EP 505 DI 10.1053/j.gastro.2015.01.012 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CB9QX UT WOS:000349968200017 PM 25613315 ER PT J AU Martins, M Williams, AH Comeau, M Marion, M Ziegler, JT Freedman, BI Merrill, JT Glenn, SB Kelly, JA Sivils, KM James, JA Guthridge, JM Alarcon-Riquelme, ME Bae, SC Kim, JH Kim, D Anaya, JM Boackle, SA Criswell, LA Kimberly, RP Alarcon, GS Brown, EE Vila, LM Petri, MA Ramsey-Goldman, R Niewold, TB Tsao, BP Gilkeson, GS Kamen, DL Jacob, CO Stevens, AM Gaffney, PM Harley, JB Langefeld, CD Fesel, C AF Martins, M. Williams, A. H. Comeau, M. Marion, M. Ziegler, J. T. Freedman, B. I. Merrill, J. T. Glenn, S. B. Kelly, J. A. Sivils, K. M. James, J. A. Guthridge, J. M. Alarcon-Riquelme, M. E. Bae, S-C Kim, J-H Kim, D. Anaya, J-M Boackle, S. A. Criswell, L. A. Kimberly, R. P. Alarcon, G. S. Brown, E. E. Vila, L. M. Petri, M. A. Ramsey-Goldman, R. Niewold, T. B. Tsao, B. P. Gilkeson, G. S. Kamen, D. L. Jacob, C. O. Stevens, A. M. Gaffney, P. M. Harley, J. B. Langefeld, C. D. Fesel, C. TI Genetic association of CD247 (CD3 zeta) with SLE in a large-scale multiethnic study SO GENES AND IMMUNITY LA English DT Article ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; GENOME-WIDE ASSOCIATION; RECEPTOR ZETA-CHAIN; T-CELLS; SUSCEPTIBILITY LOCI; DOWN-REGULATION; EXPRESSION; REPLICATION; VARIANTS; PHOSPHORYLATION AB A classic T-cell phenotype in systemic lupus erythematosus (SLE) is the downregulation and replacement of the CD3. chain that alters T-cell receptor signaling. However, genetic associations with SLE in the human CD247 locus that encodes CD3. are not well established and require replication in independent cohorts. Our aim was therefore to examine, localize and validate CD247-SLE association in a large multiethnic population. We typed 44 contiguous CD247 single-nucleotide polymorphisms (SNPs) in 8922 SLE patients and 8077 controls from four ethnically distinct populations. The strongest associations were found in the Asian population (11 SNPs in intron 1, 4.99 x 10(-4) < P < 4.15 x 10(-2)), where we further identified a five-marker haplotype (rs12141731-rs2949655-rs16859085- rs12144621-rs858554; G-G-A-G-A; P-hap = 2.12 x 10(-5)) that exceeded the most associated single SNP rs858554 (minor allele frequency in controls = 13%; P = 4.99 x 10(-4), odds ratio = 1.32) in significance. Imputation and subsequent association analysis showed evidence of association (P < 0.05) at 27 additional SNPs within intron 1. Cross-ethnic meta-analysis, assuming an additive genetic model adjusted for population proportions, showed five SNPs with significant P-values (1.40 x 10(-3) < P < 3.97 x 10(-2)), with one (rs704848) remaining significant after Bonferroni correction (P-meta = 2.66 x 10(-2)). Our study independently confirms and extends the association of SLE with CD247, which is shared by various autoimmune disorders and supports a common T-cell-mediated mechanism. C1 [Martins, M.] Inst Mol Med, P-1649028 Lisbon, Portugal. [Martins, M.; Fesel, C.] Inst Gulbenkian Ciencias, Oeiras, Portugal. [Williams, A. H.; Comeau, M.; Marion, M.; Ziegler, J. T.] Wake Forest Sch Med, Ctr Publ Hlth Genom, Winston Salem, NC USA. [Williams, A. H.; Comeau, M.; Marion, M.; Ziegler, J. T.] Wake Forest Sch Med, Dept Biostat Sci, Winston Salem, NC USA. [Freedman, B. I.] Wake Forest Sch Med, Nephrol Sect, Dept Internal Med, Winston Salem, NC USA. [Merrill, J. T.; Glenn, S. B.; Kelly, J. A.] Oklahoma Med Res Fdn, Clin Pharmacol Res Program, Oklahoma City, OK 73104 USA. [James, J. A.; Guthridge, J. M.; Alarcon-Riquelme, M. E.] Oklahoma Med Res Fdn, Arthritis & Clin Immunol Program, Oklahoma City, OK 73104 USA. [James, J. A.] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA. [Alarcon-Riquelme, M. E.] Pfizer Univ Granada Junta de Andalucia, Ctr Genom & Invest Oncol GENYO, Granada, Spain. [Bae, S-C; Kim, J-H; Kim, D.] Hanyang Univ, Hosp Rheumat Dis, Dept Rheumatol, Seoul 133791, South Korea. [Anaya, J-M] Univ Rosario, Ctr Autoimmune Dis Res CREA, Bogota, Colombia. [Boackle, S. A.] Univ Colorado, Sch Med, Div Rheumatol, Aurora, CO USA. [Criswell, L. A.] Univ Calif San Francisco, Dept Med, Rosalind Russell Med Res Ctr Arthrit, San Francisco, CA USA. [Kimberly, R. P.; Alarcon, G. S.] Univ Alabama Birmingham, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA. [Brown, E. E.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Brown, E. E.] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USA. [Vila, L. M.] Univ Puerto Rico Med Sci Campus, Dept Med, Div Rheumatol, San Juan, PR USA. [Petri, M. A.] Johns Hopkins Univ, Sch Med, Div Rheumatol, Baltimore, MD USA. [Ramsey-Goldman, R.] Northwestern Univ, Sch Med, Div Rheumatol, Chicago, IL 60611 USA. [Niewold, T. B.] Mayo Clin, Div Rheumatol, Rochester, MN USA. [Niewold, T. B.] Mayo Clin, Dept Immunol, Rochester, MN USA. [Tsao, B. P.] Univ Calif Los Angeles, Div Rheumatol, Los Angeles, CA USA. [Gilkeson, G. S.; Kamen, D. L.] Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, Charleston, SC 29425 USA. [Jacob, C. O.] Univ So Calif, Dept Med, Los Angeles, CA USA. [Stevens, A. M.] Seattle Childrens Res Inst Arthrit Fdn, Ctr Immun & Immunotherapies, Seattle, WA USA. [Harley, J. B.] Cincinnati Childrens Hosp Med Ctr, Div Rheumatol, Cincinnati, OH 45229 USA. [Harley, J. B.] Cincinnati Childrens Hosp Med Ctr, Ctr Autoimmune Genom & Etiol, Cincinnati, OH 45229 USA. [Harley, J. B.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA. RP Martins, M (reprint author), Inst Mol Med, Av Prof Egas Moniz,Edificio Egas Moniz,P1C74, P-1649028 Lisbon, Portugal. EM mcmartins227@gmail.com RI Anaya, Juan-Manuel/J-1960-2016 OI Anaya, Juan-Manuel/0000-0002-6444-1249 FU National Institutes of Health [UL1RR025741] FX We thank the SLE patients and healthy controls for their collaboration in this study. We also thank the entire OMRF team for organizing this study. We thank all the authors of the 'Genome-Wide Association Study in Asian Populations Identifies Variants in ETS1 and WDFY4 Associated with Systemic Lupus Erythematosus' (Yang et al. 2010) paper for sharing the data information on the GWAS results on the CD247 region. We also thank the University of Alabama Birmingham Center for Clinical and Translational Science (CCTS). This study was supported by the: National Institutes of Health grants (UL1RR025741) to RRG, Northwestern University Feinberg School of Medicine (K24AR002138, P602AR30692, P01AR49084) to RPK, GSA and EEB, University of Alabama Birmingham to LMP, National Institute of Arthritis and Musculoskeletal and Skin Diseases to RRG, UL1TR000165 and P01AI083194 to RPK, RO1AR43814 to BPT, University of California Los Angeles (P60AR053308, UL1TR000004) to LC, University of California San Francisco (AR43727) to MAP, Johns Hopkins University (R21AI070304) to SAB, University of Colorado School of Medicine (RO1AR057172) to COJ, University of Southern California (UL1RR025014 and R01AR051545-03) to AMS, Seattle Children's Research Institute Arthritis Foundation (UL1RR029882 and P60AR062755) to GSG and DLK, Medical University of South Carolina (P30AR53483, U19AI082714, P30GM103510, U01AI101934) to JAJ and JMG, AI063274, AR056360 and AI083194 to PMG, Oklahoma Medical Research Foundation (R37AI024717, P01083194, P01AR049084) to JH, Cincinnati Children's Hospital Medical Center; the US Departments of Defense (PR094002) to JH and Veterans Affairs to JH; the Alliance for Lupus Research to LC and BPT; a Kirkland Scholar Award to LC; Korea Healthcare technology R & D project (A121983) funded by the Ministry for Health and Welfare, Republic of Korea to SCB; the Swedish Research Council and Instituto de Salud Carlos III grant (PS09/ 00129) cofinanced by FEDER funds of the European Union to MEAR; Funda~ao para a Cincia e Tecnologia (FCT, Portugal) fellowships (SFRH/ BPD/ 29354/ 2006) to M Martins and (SFRH/ BPD/ 34648/ 2007) to CF. NR 44 TC 2 Z9 2 U1 1 U2 9 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1466-4879 EI 1476-5470 J9 GENES IMMUN JI Genes Immun. PD MAR PY 2015 VL 16 IS 2 BP 142 EP 150 DI 10.1038/gene.2014.73 PG 9 WC Genetics & Heredity; Immunology SC Genetics & Heredity; Immunology GA CD0BV UT WOS:000350736100006 PM 25569266 ER PT J AU Dorman, C Wong, M Khan, A AF Dorman, Christina Wong, Mark Khan, Aazib TI Cholestatic Hepatitis From Prolonged Kratom Use: A Case Report SO HEPATOLOGY LA English DT Article C1 [Dorman, Christina; Wong, Mark] Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA. [Dorman, Christina; Wong, Mark] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Wong, Mark] Audie L Murphy VA Hosp, San Antonio, TX 78229 USA. [Wong, Mark] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Khan, Aazib] Univ Texas Hlth Sci Ctr San Antonio, Internal Med, San Antonio, TX 78229 USA. RP Dorman, C (reprint author), 4114 Med Dr,Apt 19205, San Antonio, TX 78229 USA. EM christina.b.dorman@gmail.com NR 4 TC 6 Z9 6 U1 1 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD MAR PY 2015 VL 61 IS 3 BP 1086 EP 1087 DI 10.1002/hep.27612 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CC2BS UT WOS:000350150300039 PM 25418457 ER PT J AU Pietrzak, RH Lim, YY Neumeister, A Ames, D Ellis, KA Harrington, K Lautenschlager, NT Restrepo, C Martins, RN Masters, CL Villemagne, VL Rowe, CC Maruff, P AF Pietrzak, Robert H. Lim, Yen Ying Neumeister, Alexander Ames, David Ellis, Kathryn A. Harrington, Karra Lautenschlager, Nicola T. Restrepo, Carolina Martins, Ralph N. Masters, Colin L. Villemagne, Victor L. Rowe, Christopher C. Maruff, Paul CA Australian Imaging Biomarkers & Li TI Amyloid-beta, Anxiety, and Cognitive Decline in Preclinical Alzheimer Disease A Multicenter, Prospective Cohort Study SO JAMA PSYCHIATRY LA English DT Article ID HEALTHY OLDER-ADULTS; RANDOMIZED-CONTROLLED-TRIAL; LATE-LIFE ANXIETY; MEMORY DECLINE; NEUROPSYCHIATRIC SYMPTOMS; CLINICAL-TRIAL; DOUBLE-BLIND; STYLE AIBL; IMPAIRMENT; DEPRESSION AB IMPORTANCE Alzheimer disease (AD) is now known to have a long preclinical phase in which pathophysiologic processes develop many years, even decades, before the onset of clinical symptoms. Although the presence of abnormal levels of amyloid-beta (A beta) is associated with higher rates of progression to clinically classified mild cognitive impairment or dementia, little research has evaluated potentially modifiable moderators of A beta-related cognitive decline, such as anxiety and depressive symptoms. OBJECTIVE To evaluate the association between A beta status and cognitive changes, and the role of anxiety and depressive symptoms in moderating A beta-related cognitive changes in the preclinical phase of AD. DESIGN, SETTING, AND PARTICIPANTS In this multicenter, prospective cohort study with baseline and 18-, 36-, and 54-month follow-up assessments, we studied 333 healthy, older adults at hospital-based research clinics. MAIN OUTCOMES AND MEASURES Carbon 11-labeled Pittsburgh Compound B (PiB)-, florbetapir F 18-, or flutemetamol F 18-derived measures of A beta, Hospital Anxiety and Depression Scale scores, and comprehensive neuropsychological evaluation that yielded measures of global cognition, verbal memory, visual memory, attention, language, executive function, and visuospatial ability. RESULTS A positive A beta (A beta+) status at baseline was associated with a significant decline in global cognition, verbal memory, language, and executive function, and elevated anxiety symptoms moderated these associations. Compared with the A beta+, low-anxiety group, slopes of cognitive decline were significantly more pronounced in the A beta+, high-anxiety group, with Cohen d values of 0.78 (95% CI, 0.33-1.23) for global cognition, 0.54 (95% CI, 0.10-0.98) for verbal memory, 0.51 (95% CI, 0.07-0.96) for language, and 0.39 (95% CI, 0.05-0.83) for executive function. These effects were independent of age, educational level, IQ, APOE genotype, subjective memory complaints, vascular risk factors, and depressive symptoms; furthermore, depressive symptoms and subjective memory complaints did not moderate the association between A beta and cognitive decline. CONCLUSIONS AND RELEVANCE These results provide additional support for the deleterious effect of elevated A beta levels on cognitive function in preclinical AD. They further suggest that elevated anxiety symptoms moderate the effect of A beta on cognitive decline in preclinical AD, resulting in more rapid decline in several cognitive domains. Given that there is currently no standard antiamyloid therapy and that anxiety symptoms are amenable to treatment, these findings may help inform risk stratification and management of the preclinical phase of AD. C1 [Pietrzak, Robert H.] US Dept Vet Affairs, Vet Affairs Connecticut Healthcare Syst, Clin Neurosci Div, West Haven, CT 06516 USA. [Pietrzak, Robert H.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Lim, Yen Ying; Ellis, Kathryn A.; Harrington, Karra; Restrepo, Carolina; Masters, Colin L.; Villemagne, Victor L.; Maruff, Paul] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Parkville, Vic 3052, Australia. [Lim, Yen Ying] Brown Univ, Warren Alpert Sch Med, Dept Neurol, Providence, RI 02912 USA. [Neumeister, Alexander] NYU, Sch Med, Dept Psychiat, New York, NY USA. [Neumeister, Alexander] NYU, Sch Med, Dept Radiol, New York, NY USA. [Ames, David; Ellis, Kathryn A.; Lautenschlager, Nicola T.] Univ Melbourne, St Vincents Hlth, Dept Psychiat, Acad Unit Psychiat Old Age, Kew, Vic, Australia. [Ames, David; Ellis, Kathryn A.; Lautenschlager, Nicola T.] Univ Western Australia, Sch Psychiat & Clin Neurosci, Perth, WA 6009, Australia. [Ames, David; Ellis, Kathryn A.; Lautenschlager, Nicola T.] Univ Western Australia, Western Australia Ctr Hlth & Ageing, Perth, WA 6009, Australia. [Martins, Ralph N.] Edith Cowan Univ, Ctr Excellence Alzheimers Dis Res & Care, Sch Exercise Biomed & Hlth Sci, Perth, WA, Australia. [Villemagne, Victor L.; Rowe, Christopher C.] Austin Hlth, Dept Nucl Med, Heidelberg, Vic, Australia. [Villemagne, Victor L.; Rowe, Christopher C.] Austin Hlth, Ctr Positron Emiss Tomog, Heidelberg, Vic, Australia. [Villemagne, Victor L.; Rowe, Christopher C.] Univ Melbourne, Austin Hlth, Dept Med, Heidelberg, Vic, Australia. [Maruff, Paul] Cogstate Ltd, Melbourne, Vic, Australia. RP Pietrzak, RH (reprint author), US Dept Vet Affairs, Vet Affairs Connecticut Healthcare Syst, Clin Neurosci Div, 950 Campbell Ave,Mail Code 161E, West Haven, CT 06516 USA. EM robert.pietrzak@yale.edu RI Laws, Simon/C-2858-2014 OI Laws, Simon/0000-0002-4355-7082; Hone, Eugene/0000-0001-6708-3718 FU Commonwealth Scientific Industrial and Research Organization; Edith Cowan University; Mental Health Research Institute; National Ageing Research Institute; Austin Health; National Health and Medical Research Council; Dementia Collaborative Research Centres program; Science and Industry Endowment Fund; Cooperative Research Centre for Mental Health; Cogstate Ltd FX Funding for the Australian Imaging, Biomarkers, and Lifestyle Study was provided in part by the study partners (Commonwealth Scientific Industrial and Research Organization, Edith Cowan University, Mental Health Research Institute, National Ageing Research Institute, Austin Health, and Cogstate Ltd). The study also received support from the National Health and Medical Research Council and the Dementia Collaborative Research Centres program, as well as funding from the Science and Industry Endowment Fund and the Cooperative Research Centre for Mental Health. NR 51 TC 17 Z9 17 U1 2 U2 18 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-622X EI 2168-6238 J9 JAMA PSYCHIAT JI JAMA Psychiatry PD MAR PY 2015 VL 72 IS 3 BP 284 EP 291 DI 10.1001/jamapsychiatry.2014.2476 PG 8 WC Psychiatry SC Psychiatry GA CC7UJ UT WOS:000350573600012 PM 25629787 ER PT J AU Blosnich, JR AF Blosnich, John R. TI Adverse Childhood Experiences and Military Service Reply SO JAMA PSYCHIATRY LA English DT Letter C1 VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. RP Blosnich, JR (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Univ Dr C 151C-U,Bldg 30, Pittsburgh, PA 15240 USA. EM john.blosnich@va.gov NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-622X EI 2168-6238 J9 JAMA PSYCHIAT JI JAMA Psychiatry PD MAR PY 2015 VL 72 IS 3 BP 296 EP 297 PG 3 WC Psychiatry SC Psychiatry GA CC7UJ UT WOS:000350573600016 PM 25738693 ER PT J AU Glass, NE Pinna, A Masi, A Rosman, AS Neihaus, D Okochi, S Saunders, JK Hatzaras, I Cohen, S Berman, R Newman, E Pachter, HL Gouge, TH Melis, M AF Glass, Nina E. Pinna, Antonio Masi, Antonio Rosman, Alan S. Neihaus, Dena Okochi, Shunpei Saunders, John K. Hatzaras, Ioannis Cohen, Steven Berman, Russell Newman, Elliot Pachter, H. Leon Gouge, Thomas H. Melis, Marcovalerio TI The Surgical Apgar Score Predicts Postoperative ICU Admission SO JOURNAL OF GASTROINTESTINAL SURGERY LA English DT Article DE Risk assessment; Scoring systems; Surgery; Surgical Apgar score ID SURGERY; SYSTEMS; VETERAN; POSSUM C1 [Glass, Nina E.; Pinna, Antonio; Masi, Antonio; Neihaus, Dena; Okochi, Shunpei; Saunders, John K.; Hatzaras, Ioannis; Cohen, Steven; Berman, Russell; Newman, Elliot; Pachter, H. Leon; Gouge, Thomas H.; Melis, Marcovalerio] New York Harbor Healthcare Syst, Dept Surg, New York, NY 10044 USA. [Glass, Nina E.; Pinna, Antonio; Masi, Antonio; Saunders, John K.; Hatzaras, Ioannis; Cohen, Steven; Berman, Russell; Newman, Elliot; Pachter, H. Leon; Gouge, Thomas H.; Melis, Marcovalerio] NYU, Sch Med, Dept Surg, Brooklyn, NY USA. [Pinna, Antonio] Univ Sassari, I-07100 Sassari, Italy. [Rosman, Alan S.] Mt Sinai Sch Med, Gastroenterol Sect, New York, NY USA. [Rosman, Alan S.] Mt Sinai Sch Med, Program Med, New York, NY USA. [Rosman, Alan S.] James J Peters VAMC, New York, NY USA. RP Melis, M (reprint author), New York Harbor Healthcare Syst, Dept Surg, 423 E 23RD ST 4153 N, New York, NY 10044 USA. EM marcovalerio.melis@nyumc.org OI Gouge, Thomas/0000-0001-8381-4146; Pinna, Antonio/0000-0002-2187-6744; Berman, Russell/0000-0002-5026-5651 NR 14 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1091-255X EI 1873-4626 J9 J GASTROINTEST SURG JI J. Gastrointest. Surg. PD MAR PY 2015 VL 19 IS 3 BP 445 EP 450 DI 10.1007/s11605-014-2733-8 PG 6 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA CB9PV UT WOS:000349965000008 PM 25572972 ER PT J AU Hill, AL Sumra, KK Russell, MM Yoo, J Ko, CY Hart, S Wainberg, Z Hecht, JR Lin, AY AF Hill, Amy L. Sumra, Kirandeep K. Russell, Marcia M. Yoo, James Ko, Clifford Y. Hart, Steven Wainberg, Zev Hecht, J. Randolph Lin, Anne Y. TI A Single Institution Experience in Compliance with Universal Screening for Lynch Syndrome in Colorectal Cancer SO JOURNAL OF GASTROINTESTINAL SURGERY LA English DT Article DE Lynch syndrome; Universal screening; Microsatellite instability; Immunohistochemistry ID MICROSATELLITE INSTABILITY; IMMUNOHISTOCHEMISTRY; IMPLEMENTATION AB Detection of Lynch syndrome has the potential to reduce morbidity and mortality among patients and their family members due to beneficial screening and treatment options. Several institutions have begun to adopt universal rather than risk-stratified screening protocols, but the lack of 100 % compliance rates requires identification of system-level interventions to improve screening practices. We aimed to identify patient, tumor, and system factors associated with lack of screening and identify system-based interventions to improve Lynch syndrome screening. This study is a retrospective analysis of Lynch syndrome screening among colorectal cancer patients undergoing surgery in a single healthcare system. Two hundred and sixty-two patients who underwent surgery for colorectal cancer were studied. Rate of Lynch syndrome screening. We identified that 75 % of the total cohort was screened for Lynch syndrome. Of patients under the age of 50, 78 % percent were screened. Lower screening rates were found among patients with complete pathologic tumor response and lower pathologic stage of tumor. Higher screening rates were found at the academic hospital and with colorectal surgeons. In multivariable logistic regression analysis, lower screening rates were associated with community hospital location (OR, 0.22; 95 % CI, 0.08-0.56). Results may not be generalizable to different hospital settings. Several potential system-level interventions were identified to improve screening rates including an emphasis on improved provider communication. C1 [Hill, Amy L.; Lin, Anne Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Sumra, Kirandeep K.] Univ Arizona, Coll Med, Phoenix, AZ USA. [Russell, Marcia M.; Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. [Yoo, James] Tufts Med Ctr, Boston, MA 02111 USA. [Hart, Steven] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA 90095 USA. [Wainberg, Zev; Hecht, J. Randolph] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. RP Lin, AY (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, 10833 Le Conte Ave,72-247 CHS, Los Angeles, CA 90095 USA. EM aylin@mednet.ucla.edu NR 15 TC 5 Z9 5 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1091-255X EI 1873-4626 J9 J GASTROINTEST SURG JI J. Gastrointest. Surg. PD MAR PY 2015 VL 19 IS 3 BP 543 EP 550 DI 10.1007/s11605-014-2687-x PG 8 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA CB9PV UT WOS:000349965000020 PM 25504462 ER PT J AU Escobar, DA Botero-Quintero, AM Kautza, BC Luciano, J Loughran, P Darwiche, S Rosengart, MR Zuckerbraun, BS Gomez, H AF Escobar, Daniel A. Botero-Quintero, Ana M. Kautza, Benjamin C. Luciano, Jason Loughran, Patricia Darwiche, Sophie Rosengart, Matthew R. Zuckerbraun, Brian S. Gomez, Hernando TI Adenosine monophosphate-activated protein kinase activation protects against sepsis-induced organ injury and inflammation SO JOURNAL OF SURGICAL RESEARCH LA English DT Article DE Sepsis; AMPK; Energy; Inflammation; Endothelium; Organ injury ID NF-KAPPA-B; VEIN ENDOTHELIAL-CELLS; 5-AMINOIMIDAZOLE-4-CARBOXAMIDE RIBONUCLEOSIDE; MITOCHONDRIAL BIOGENESIS; ENERGY SENSOR; IN-VITRO; ACADESINE; AUTOPHAGY; AMPK; REPERFUSION AB Background: Mortality in sepsis is most often attributed to the development of multiple organ failure. In sepsis, inflammation-mediated endothelial activation, defined as a proinflammatory and procoagulant state of the endothelial cells, has been associated with severity of disease. Thus, the objective of this study was to test the hypothesis that adenosine monophosphate-activated protein kinase (AMPK) activation limits inflammation and endothelium activation to protect against organ injury in sepsis. 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), which is an adenosine monophosphate analog, has been used to upregulate activity of AMPK. Compound C is a cell-permeable pyrrazolopyrimidine compound that inhibits AMPK activity. Methods: Wild-type mice underwent cecal ligation and puncture (CLP) or sham surgery. Mice were randomized to vehicle, AICAR, or compound C. Mouse kidney endothelial cells were used for in vitro experiments. Renal and liver function were determined by serum cystatin C, blood urea nitrogen (BUN), creatinine, and alanine aminotransferase. Serum cytokines were measured by enzyme-linked immunosorbent assay. Microvascular injury was determined using Evans blue dye and electron microscopy. Immunohistochemistry was used to measure protein levels of phospho-AMPK (p-AMPK), microtubule-associated protein 1A/1B-light chain 3 (LC3), and intracellular adhesion molecule. LC3 levels were used as a measure of autophagosome formation. Results: AICAR decreased liver and kidney injury induced by CLP and minimized cytokine elevation in vivo and in vitro. CLP increased renal and hepatic phosphorylation of AMPK and autophagic signaling as determined by LC3. Inhibition of AMPK with compound C prevented CLP-induced autophagy and exacerbated tissue injury. Additionally, CLP led to endothelial injury as determined by electron microscopy and Evans blue dye extravasation, and AICAR limited this injury. Furthermore, AICAR limited CLP and lipopolysaccharide (LPS)-induced upregulation of intracellular adhesion molecule in vivo and in vitro and decreased LPS-induced neutrophil adhesion in vitro. Conclusions: In this model, activation of AMPK was protective, and AICAR minimized organ injury by decreasing inflammatory cytokines and endothelial activation. These data suggest that AMPK signaling influences sepsis or LPS-induced endothelial activation and organ injury. (C) 2015 Elsevier Inc. All rights reserved. C1 [Escobar, Daniel A.; Botero-Quintero, Ana M.; Kautza, Benjamin C.; Luciano, Jason; Loughran, Patricia; Darwiche, Sophie; Rosengart, Matthew R.; Zuckerbraun, Brian S.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA. [Rosengart, Matthew R.; Gomez, Hernando] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15261 USA. [Zuckerbraun, Brian S.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Dept Surg, Pittsburgh, PA USA. [Zuckerbraun, Brian S.; Gomez, Hernando] Univ Pittsburgh, Dept Crit Care Med, Ctr Crit Care Nephrol, Pittsburgh, PA USA. RP Gomez, H (reprint author), Univ Pittsburgh, Dept Crit Care Med, 640A Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA. EM gomezh@upmc.edu FU National Institutes of Health [R01 GM082830, 1K12HL109068-02]; Veterans Affairs Merit Award [1I01BX000566]; Department of Defense [DM102439] FX No conflict of interest is declared. This work is supported by National Institutes of Health grants R01 GM082830 (B.S.Z.), 1K12HL109068-02 (H.G.), Veterans Affairs Merit Award 1I01BX000566 (B.S.Z.), and Department of Defense DM102439 (B.S.Z.). NR 43 TC 14 Z9 16 U1 0 U2 10 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 EI 1095-8673 J9 J SURG RES JI J. Surg. Res. PD MAR PY 2015 VL 194 IS 1 BP 262 EP 272 DI 10.1016/j.jss.2014.10.009 PG 11 WC Surgery SC Surgery GA CC5FH UT WOS:000350384000034 PM 25456115 ER PT J AU Caroff, SN Campbell, EC AF Caroff, Stanley N. Campbell, E. Cabrina TI Risk of neuroleptic malignant syndrome in patients with NMDAR encephalitis SO NEUROLOGICAL SCIENCES LA English DT Letter DE Neuroleptic malignant syndrome; Encephalitis; Neuroleptics; Antipsychotics; Psychosis C1 [Caroff, Stanley N.; Campbell, E. Cabrina] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Caroff, Stanley N.; Campbell, E. Cabrina] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Caroff, SN (reprint author), Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. EM stanley.caroff@va.gov NR 5 TC 3 Z9 3 U1 0 U2 3 PU SPRINGER-VERLAG ITALIA SRL PI MILAN PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY SN 1590-1874 EI 1590-3478 J9 NEUROL SCI JI Neurol. Sci. PD MAR PY 2015 VL 36 IS 3 BP 479 EP 480 DI 10.1007/s10072-014-2022-z PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CC4ZG UT WOS:000350365000021 PM 25480349 ER PT J AU Dicianno, BE Parmanto, B Fairman, AD Crytzer, TM Yu, DXH Pramana, G Coughenour, D Petrazzi, AA AF Dicianno, Brad E. Parmanto, Bambang Fairman, Andrea D. Crytzer, Theresa M. Yu, Daihua X. Pramana, Gede Coughenour, Derek Petrazzi, Alan A. TI Perspectives on the Evolution of Mobile (mHealth) Technologies and Application to Rehabilitation SO PHYSICAL THERAPY LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; HEALTH-CARE; SELF-MANAGEMENT; WEIGHT-LOSS; RELIABILITY; SYSTEM; INTERVENTION; VALIDITY; PROGRAM; SMARTPHONE AB Individuals with chronic conditions and disabilities who are vulnerable to secondary complications often require complex habilitative and rehabilitative services to prevent and treat these complications. This perspective article reviews the evolution of mHealth technologies and presents insights as to how this evolution informed our development of a novel mHealth system, iMHere (interactive mobile health and rehabilitation), and other technologies, including those used by the Veterans Administration. This article will explain the novel applications of In Health for rehabilitation and specifically physical therapy. Perspectives on the roles of rehabilitation professionals in the delivery of health care using mHealth systems are included. Challenges to mHealth, including regulatory and funding issues, are discussed. This article also describes how mHealth can be used to improve patient satisfaction and delivery of care and to promote health and wellness. C1 [Dicianno, Brad E.] Human Engn Res Lab, Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Dicianno, Brad E.] Univ Pittsburgh, Dept Phys Med & Rehabil, Sch Med, Pittsburgh, PA 15206 USA. [Dicianno, Brad E.; Parmanto, Bambang; Yu, Daihua X.; Pramana, Gede] Univ Pittsburgh, Dept Hlth Informat Management, Sch Hlth & Rehabil Sci, Pittsburgh, PA 15206 USA. [Fairman, Andrea D.; Crytzer, Theresa M.] Univ Pittsburgh, Sch Hlth & Rehabil Sci, Dept Rehabil Sci & Technol, Pittsburgh, PA 15206 USA. [Fairman, Andrea D.] Duquesne Univ, Dept Occupat Therapy, Pittsburgh, PA 15219 USA. [Coughenour, Derek] Vet Affairs Pittsburgh Healthcare Syst, Rehabil Dept, Clin Support Serv Line, Pittsburgh, PA USA. [Petrazzi, Alan A.] Vet Affairs Pittsburgh Healthcare Syst, Primary Care Serv Line, Pittsburgh, PA USA. RP Dicianno, BE (reprint author), Univ Pittsburgh, Human Engn Res Lab, 6425 Penn Ave,Suite 400, Pittsburgh, PA 15206 USA. EM dicianno@pitt.edu RI Emchi, Karma/Q-1952-2016 FU National Institute on Disability and Rehabilitation Research (NIDRR) [H133E090002]; Rehabilitation Engineering Research Center on Telerehabilitatiori (RERC-TR); Verizon Foundation FX This research was supported, in part, by grants from the National Institute on Disability and Rehabilitation Research (NIDRR) grant H133E090002, the Rehabilitation Engineering Research Center on Telerehabilitatiori (RERC-TR), and the Verizon Foundation. NR 72 TC 9 Z9 10 U1 5 U2 27 PU AMER PHYSICAL THERAPY ASSOC PI ALEXANDRIA PA 1111 N FAIRFAX ST, ALEXANDRIA, VA 22314 USA SN 0031-9023 EI 1538-6724 J9 PHYS THER JI Phys. Ther. PD MAR PY 2015 VL 95 IS 3 BP 397 EP 405 DI 10.2522/ptj.20130534 PG 9 WC Orthopedics; Rehabilitation SC Orthopedics; Rehabilitation GA CC3RK UT WOS:000350266800011 PM 24925075 ER PT J AU Bieraugel, K Oehler, D NeSmith, M Chiovaro, J AF Bieraugel, Karen Oehler, Drew NeSmith, Meghan Chiovaro, Joseph TI Cat Got Your Spleen? Hepatosplenic Bartonella Infection SO AMERICAN JOURNAL OF MEDICINE LA English DT Editorial Material ID SCRATCH-DISEASE; HENSELAE INFECTION C1 [Bieraugel, Karen; Oehler, Drew; NeSmith, Meghan; Chiovaro, Joseph] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Chiovaro, Joseph] Portland VA Med Ctr, Dept Med, Portland, OR 97239 USA. RP Chiovaro, J (reprint author), Portland VA Med Ctr, Dept Med MED P3, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM jchiovaro@gmail.com NR 11 TC 1 Z9 1 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 EI 1555-7162 J9 AM J MED JI Am. J. Med. PD MAR PY 2015 VL 128 IS 3 BP 246 EP 249 DI 10.1016/j.amjmed.2014.11.003 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA CC0DC UT WOS:000350004200021 PM 25460524 ER PT J AU Cavusoglu, E Marmur, JD Hegde, S Yanamadala, S Batuman, OA Chopra, V Ay, G Eng, C AF Cavusoglu, Erdal Marmur, Jonathan D. Hegde, Sudhanva Yanamadala, Sunitha Batuman, Olcay A. Chopra, Vineet Ay, Gonca Eng, Calvin TI Relation of baseline plasma MMP-1 levels to long-term all-cause mortality in patients with known or suspected coronary artery disease referred for coronary angiography SO ATHEROSCLEROSIS LA English DT Article DE Matrix metalloproteinase 1; Biomarkers; Acute coronary syndrome; Prognosis; Mortality ID INDEPENDENT PREDICTOR; HEART-FAILURE; METALLOPROTEINASE EXPRESSION; MATRIX METALLOPROTEINASES; MYOCARDIAL-INFARCTION; REGIONS; PLAQUES; RISK; PAR1 AB Objectives: To investigate the long-term prognostic significance of baseline plasma MMP-1 levels in a group of well-characterized male patients with known or suspected coronary artery disease, including those presenting with acute coronary syndrome. Background: MMP-1 is an interstitial collagenase that is considered the primary enzyme responsible for collagen degradation. In addition, MMP-1 can lead to platelet activation through the PAR1 pathway that is independent of thrombin. Methods: Baseline plasma MMP-1 levels were measured in 364 male patients who were referred for coronary angiography and followed prospectively for five years for the development of all-cause mortality. Results: After adjustment for a variety of baseline clinical, angiographic and laboratory parameters, baseline plasma MMP-1 levels (analyzed as a continuous variable) were an independent predictor of all-cause mortality at 5 years (HR, 1.49; 95% CI, 1.23-1.80; P < 0.0001). Furthermore, in 3 additional multivariate models that included a wide variety of contemporary biomarkers with established prognostic efficacy (i.e., ST2, GDF-15, Cystatin C, hs-CRP, Myeloperoxidase, NT-proBNP, TIMP-1, Adiponectin, RDW, hemoglobin, and Erythropoietin), MMP-1 remained an independent predictor of all-cause mortality at 5 years. Similar results were obtained when the analyses were restricted to the subpopulation of patients presenting with acute coronary syndrome. Conclusions: Elevated levels of MMP-1 are associated with an increased risk of long-term all-cause mortality in patients with known or suspected coronary disease that is independent of a variety of clinical, angiographic, and laboratory variables, including a whole host of contemporary biomarkers with established prognostic efficacy representing multiple different pathophysiologic processes. (C) 2015 Elsevier Ireland Ltd. All rights reserved. C1 [Cavusoglu, Erdal; Chopra, Vineet; Eng, Calvin] Bronx Vet Affairs Med Ctr, Dept Med, Div Cardiol, Bronx, NY USA. [Cavusoglu, Erdal; Marmur, Jonathan D.; Hegde, Sudhanva; Yanamadala, Sunitha] Suny Downstate Med Ctr, Dept Med, Div Cardiol, Brooklyn, NY 11203 USA. [Batuman, Olcay A.] Suny Downstate Med Ctr, Dept Med, Div Hematol, Brooklyn, NY 11203 USA. [Ay, Gonca] Mersin Univ, Dept Biol Sci, Mersin, Turkey. RP Cavusoglu, E (reprint author), Suny Downstate Med Ctr, 450 Clarkson Ave,Box 1199, Brooklyn, NY 11203 USA. EM ECavusoglu@aol.com FU American Heart Association [10GRNT3700003]; NIH-NHLBI [5R21HL098661-02] FX This study was sponsored, in part, by grants related to biomarkers from the American Heart Association (Grant-in-Aid 10GRNT3700003) and the NIH-NHLBI (5R21HL098661-02). NR 23 TC 1 Z9 2 U1 2 U2 3 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0021-9150 EI 1879-1484 J9 ATHEROSCLEROSIS JI Atherosclerosis PD MAR PY 2015 VL 239 IS 1 BP 268 EP 275 DI 10.1016/j.atherosclerosis.2015.01.003 PG 8 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA CB6RH UT WOS:000349753800039 PM 25635325 ER PT J AU Hershenberg, R Goldfried, MR AF Hershenberg, Rachel Goldfried, Marvin R. TI Implications of RDoC for the Research and Practice of Psychotherapy SO BEHAVIOR THERAPY LA English DT Article DE evidence-based practice; empirically supported treatments; clinical trials; psychotherapy research; research domain criteria ID RESEARCH DOMAIN CRITERIA; CONTROLLED CLINICAL-TRIALS; PRACTICE RESEARCH NETWORK; BEHAVIORAL ACTIVATION; PSYCHIATRIC-DIAGNOSIS; COGNITIVE THERAPY; PSYCHOPATHOLOGY; DEPRESSION; MODEL; EXPERIENCES AB The field of psychotherapy is at an important juncture. Recent changes in the field include (a) the skeptical reception of the fifth edition of the Diagnostic and Statistical Manual and (b) NIMH's prioritization of an alternative classification system to guide translational and intervention research. Moreover, (c) the field continues to be held accountable to governmental agencies and third-party payers to demonstrate its empirical basis. Thus, psychological research as it relates to the practice of psychotherapy is at a crossroads. In this article, we provide a brief overview of several generations of psychotherapy outcome research, including the consequences that followed in the 1980s as psychotherapy research moved toward randomized controlled trials for clinical disorders. We delineate the inherent strengths and limitations of this movement and address how the NIMH has recently responded with the Research Domain Criteria (RDoC). We then address philosophical and practical implications of the emphasis on a neuroscientific conceptualization of psychological problems. Finally, we discuss opportunities for a next generation of convergent science that incorporates, rather than replaces, psychosocial variables across stages of translational research and treatment development. C1 [Hershenberg, Rachel] Philadelphia VA Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA 19104 USA. [Hershenberg, Rachel] Univ Penn, Philadelphia, PA 19104 USA. [Goldfried, Marvin R.] SUNY Stony Brook, Stony Brook, NY USA. RP Hershenberg, R (reprint author), Philadelphia VA Med Ctr, 3900 Woodland Ave,Mailstop 116, Philadelphia, PA 19104 USA. EM rhersh@mail.med.upenn.edu NR 67 TC 8 Z9 8 U1 2 U2 11 PU ASSOC ADV BEHAVIOR THERAPY PI NEW YORK PA 305 7TH AVE #16A, NEW YORK, NY 10001-6008 USA SN 0005-7894 EI 1878-1888 J9 BEHAV THER JI Behav. Therapy PD MAR PY 2015 VL 46 IS 2 BP 156 EP 165 PG 10 WC Psychology, Clinical SC Psychology GA CC0FX UT WOS:000350012300002 PM 25645165 ER PT J AU Ding, XB Zhou, XH Wang, QH AF Ding, Xiaobo Zhou, Xiao-Hua Wang, Qihua TI A partially linear single-index transformation model and its nonparametric estimation SO CANADIAN JOURNAL OF STATISTICS-REVUE CANADIENNE DE STATISTIQUE LA English DT Article DE Basis function; Cross validation; linear inequality restriction; local linear regression; minimum average variance estimation ID DIMENSION REDUCTION; SEMIPARAMETRIC ESTIMATION; REGRESSION-MODEL AB In this paper, we consider the nonparametric estimation of the partially linear single-index transformation model, where the transformation function, single-index function and error distribution are all completely unknown. We first use the minimum average variance estimation method to estimate the regression coefficients, and then propose a new incorporated local linear regression estimator for the derivative function of the single-index function. Accordingly by integration we can obtain the estimator of the single-index function. Finally we propose a constrained least square estimator for the transformation function, where basis function approximation is employed and cross validation method is proposed to select suitable sets of basis functions. Asymptotical properties of the estimators are established. Simulation studies show that our proposed estimators work well. A real-world data analysis of total health care charges was used to illustrate the proposed procedure. The Canadian Journal of Statistics 43: 97-117; 2015 (c) 2015 Statistical Society of Canada Resume Les auteurs traitent de l'estimation non parametrique du modele de transformation partiellement lineaire a un indice dans le cas oU la transformation, la fonction d'indice et la distribution de l'erreur sont toutes completement inconnues. Ils estiment d'abord les coefficients de regression par la methode de la variance moyenne minimale, puis ils proposent un nouvel estimateur local de regression lineaire pour la derivee de la fonction d'indice, menant a l'estimation de cette fonction par integration. Finalement, ils proposent un estimateur aux moindres carres avec contraintes pour la fonction de transformation dont une approximation est effectuee a l'aide de fonctions de base, elles-memes selectionnees par une procedure de validation croisee. Les auteurs etablissent les proprietes asymptotiques de leurs estimateurs et montrent a l'aide de simulations que ceux-ci donnent de bons resultats. Ils illustrent egalement leur methode en analysant un jeu de donnees reelles portant sur les couts des soins de sante. La revue canadienne de statistique 43: 97-117; 2015 (c) 2015 Societe statistique du Canada C1 [Ding, Xiaobo; Wang, Qihua] Chinese Acad Sci, Acad Math & Syst Sci, Beijing, Peoples R China. [Ding, Xiaobo; Zhou, Xiao-Hua] Vet Affairs Puget Sound Hlth Care Syst, HSR& Ctr Excellence, Seattle, WA 98108 USA. [Ding, Xiaobo; Zhou, Xiao-Hua] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Wang, Qihua] Shenzhen Univ, Inst Stat Sci, Shenzhen, Guangdong, Peoples R China. RP Zhou, XH (reprint author), Vet Affairs Puget Sound Hlth Care Syst, HSR& Ctr Excellence, Seattle, WA 98108 USA. EM azhou@u.washington.edu FU U.S. Department of Veterans Affairs, Veterans Affairs Health Administration, Health Science Research and Development grant [RCS 05-196]; National Natural Science Foundation of China; Key Laboratory of Random Complex Structures and Data Science, Chinese Academy of Sciences; National Science Fund for Creative Research Groups in China; Natural Science Foundation of Shenzhen University FX The authors thank the review editor and the two anonymous reviewers for their useful comments and suggestions, which led to a great improvement of the paper. Xiao-Hua (Andrew) Zhou, Ph.D., is presently a Core Investigator and Biostatistics Unit Director at the Seattle/Denver Center of Innovation for Veteran-Centered and Value-Driven Care, Department of Veterans Affairs Medical Center, Seattle, WA. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. Dr. Zhou's work was supported in part by U.S. Department of Veterans Affairs, Veterans Affairs Health Administration, Health Science Research and Development grant (RCS 05-196). Ding's research was supported in part by a research grant from the National Natural Science Foundation of China. Ding and Wang's research was also supported by the Key Laboratory of Random Complex Structures and Data Science, Chinese Academy of Sciences. Wang's research was supported by the National Natural Science Foundation of China, the National Science Fund for Creative Research Groups in China, and Natural Science Foundation of Shenzhen University. NR 27 TC 1 Z9 1 U1 4 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0319-5724 EI 1708-945X J9 CAN J STAT JI Can. J. Stat.-Rev. Can. Stat. PD MAR PY 2015 VL 43 IS 1 BP 97 EP 117 DI 10.1002/cjs.11239 PG 21 WC Statistics & Probability SC Mathematics GA CC1YF UT WOS:000350140600006 ER PT J AU Elvington, M Schepp-Berglind, J Tomlinson, S AF Elvington, M. Schepp-Berglind, J. Tomlinson, S. TI Regulation of the alternative pathway of complement modulates injury and immunity in a chronic model of dextran sulphate sodium-induced colitis SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY LA English DT Article DE colon; complement; inflammation; inflammatory bowel disease ID INFLAMMATORY-BOWEL-DISEASE; DECAY-ACCELERATING FACTOR; ULCERATIVE-COLITIS; CROHNS-DISEASE; ACTIVATED COMPLEMENT; DENDRITIC CELLS; MURINE MODEL; MICE; C5A; EXPRESSION AB The role of complement in inflammatory bowel disease (IBD) has been studied primarily using acute models, and it is unclear how complement affects processes in more relevant chronic models of IBD in which modulation of adaptive immunity and development of fibrosis have pathogenic roles. Using mice deficient in C1q/mannose-binding lectin (MBL) or C3, we demonstrated an important role for these opsonins and/or the classical pathway C3 convertase in providing protection against mucosal injury and infection in a model of chronic dextran sulphate sodium (DSS)-induced colitis. In contrast, deficiency of the alternative pathway (fB(-/-) mice) had significantly less impact on injury profiles. Consequently, the effect of a targeted inhibitor of the alternative pathway was investigated in a therapeutic protocol. Following the establishment of colitis, mice were treated with CR2-fH during subsequent periods of DSS treatment and acute injury (modelling relapse). CR2-fH significantly reduced complement activation, inflammation and injury in the colon, and additionally reduced fibrosis. Alternative pathway inhibition also altered the immune response in the chronic state in terms of reducing numbers of B cells, macrophages and mature dendritic cells in the lamina propria. This study indicates an important role for the alternative pathway of complement in the pathogenesis and the shaping of an immune response in chronic DSS-induced colitis, and supports further investigation into the use of targeted alternative pathway inhibition for the treatment of IBD. C1 [Elvington, M.; Schepp-Berglind, J.; Tomlinson, S.] Med Univ S Carolina, Dept Microbiol & Immunol, Childrens Res Inst, Charleston, SC 29425 USA. [Tomlinson, S.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Tomlinson, S (reprint author), Med Univ S Carolina, Dept Microbiol & Immunol, 173 Ashley Ave,BSB 201, Charleston, SC 29425 USA. EM tomlinss@musc.edu FU Crohn's and Colitis Foundation of America; National Institutes of Health [T32 AR050958] FX This work was supported by a grant from the Crohn's and Colitis Foundation of America (to ST) and National Institutes of Health Training Grant T32 AR050958 (to J. S. B.). We thank Emily Paulling for histology work and expert technical assistance. NR 34 TC 4 Z9 4 U1 1 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0009-9104 EI 1365-2249 J9 CLIN EXP IMMUNOL JI Clin. Exp. Immunol. PD MAR PY 2015 VL 179 IS 3 BP 500 EP 508 DI 10.1111/cei.12464 PG 9 WC Immunology SC Immunology GA CC0PQ UT WOS:000350038400013 PM 25293413 ER PT J AU Shao, JX Nguyen, KL Natsuaki, Y Spottiswoode, B Hu, P AF Shao, Jiaxin Nguyen, Kim-Lien Natsuaki, Yutaka Spottiswoode, Bruce Hu, Peng TI Instantaneous Signal Loss Simulation (InSiL): An Improved Algorithm for Myocardial T-1 Mapping Using the MOLLI Sequence SO JOURNAL OF MAGNETIC RESONANCE IMAGING LA English DT Article DE T-1 mapping; MR relaxometry; quantitative MRI; myocardial scar imaging ID INVERSION-RECOVERY MOLLI; MAGNETIZATION-TRANSFER; LOOK-LOCKER; PULSE SEQUENCE; HEART-FAILURE; T1; QUANTIFICATION; VOLUME; ATHEROSCLEROSIS; RELAXATION AB PurposeTo propose a T-1 mapping algorithm for the modified Look-Locker inversion-recovery (MOLLI) sequence that can improve T-1 estimation accuracy. Materials and MethodsThe modified T-1 mapping algorithm (InSiL) is based on the simulation of MOLLI signal evolution and simulates the longitudinal magnetization signal perturbation by each single-shot image acquisition in MOLLI as an instantaneous signal loss. InSiL was evaluated against original MOLLI using Bloch simulations, phantom studies, and in 15 healthy volunteers at 1.5T. ResultsIn phantom studies, the maximum absolute error by InSiL is less than 2%, while that by MOLLI is more than 20% for T-1 values from 221 msec to 1539 msec. The benefit of InSiL is greatest at heart rate (HR) >80 bpm and T-1 >1000 msec, and InSiL reduced MOLLI T-1 error from 14.94.5% to 0.4 +/- 0.3%. Average InSiL-derived native myocardial T-1 values at 1.5T in healthy volunteers were significantly higher than MOLLI-derived values by 236.9 +/- 11.7 msec (1160.3 +/- 25.1 msec vs. 923.4 +/- 22.3 msec, P<0.001) at an average HR of 65.1 +/- 14.7 bpm. ConclusionThe proposed InSiL approach yields better T-1 mapping accuracy than MOLLI, and is less sensitive to HR variation in tissues with longer T-1 values. J. Magn. Reson. Imaging 2015;41:721-729. (c) 2014 Wiley Periodicals, Inc. C1 [Shao, Jiaxin; Nguyen, Kim-Lien; Hu, Peng] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol Sci, Los Angeles, CA 90095 USA. [Nguyen, Kim-Lien] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Cardiol, Los Angeles, CA 90095 USA. [Nguyen, Kim-Lien] Vet Affairs Greater Los Angeles Healthcare Syst, Div Cardiol, Los Angeles, CA USA. [Natsuaki, Yutaka; Spottiswoode, Bruce] Siemens Healthcare, Chicago, IL USA. [Hu, Peng] Univ Calif Los Angeles, Biomed Phys Interdept Grad Program, Los Angeles, CA USA. RP Hu, P (reprint author), Dept Radiol Sci, 300 UCLA Med Plaza Suite B119, Los Angeles, CA 90095 USA. EM penghu@mednet.ucla.edu RI Shao, Jiaxin/S-3993-2016 OI Shao, Jiaxin/0000-0001-9998-3622 NR 31 TC 3 Z9 3 U1 2 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1053-1807 EI 1522-2586 J9 J MAGN RESON IMAGING JI J. Magn. Reson. Imaging PD MAR PY 2015 VL 41 IS 3 BP 721 EP 729 DI 10.1002/jmri.24599 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CB9QT UT WOS:000349967700018 PM 24677371 ER PT J AU Stey, AM Russell, MM Hall, BL Lin, A Gibbons, MM Lawson, EH Zingmond, DS Ko, CY AF Stey, Anne M. Russell, Marcia M. Hall, Bruce L. Lin, Andy Gibbons, Melinda M. Lawson, Elise H. Zingmond, David S. Ko, Clifford Y. TI Is There Hospital Variation in Long-Term Incisional Hernia Repair after Abdominal Surgery? SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Article ID QUALITY-OF-LIFE; ADMINISTRATIVE DATABASES; VETERANS-AFFAIRS; CLAIMS DATA; SURGICAL CARE; FOLLOW-UP; OUTCOMES; MEDICARE; COST; COMPLICATIONS AB BACKGROUND: Currently, hospital benchmarking organizations are often limited to short-term surgical quality comparisons among hospitals. The goal of this study was to determine whether long-term rates of incisional hernia repair after common abdominal operations could be used to compare hospital long-term surgical quality. STUDY DESIGN: This was a cohort study with up to 4 years of follow-up. Patients who underwent 1 of 5 common inpatient abdominal operations were identified in 2005-2008 American College of Surgeons NSQIP data linked to Medicare inpatient records. The main outcomes included occurrence of an incisional hernia repair. A multivariable, shared frailty Cox proportional hazards regression was used to compare each hospital's incisional hernia rate with the overall mean rate for all hospitals and control for American College of Surgeons NSQIP preoperative clinical variables. RESULTS: A total of 37,134 patients underwent 1 of 5 common inpatient abdominal operations, including colectomy, small bowel resection, ventral hernia repair, pancreatic resection, or cholecystectomy, at 1 of 216 hospitals participating in American College of Surgeons NSQIP during the 4-year period. There were 1,474 (4.0%) patients who underwent an incisional hernia repair, at a median follow-up time of 16 months (interquartile range 8 to 25 months) after initial abdominal surgery. After risk adjustment, there was no significant difference in the ratio of any one hospital's adjusted hazard rate for incisional hernia repair vs the average hospital adjusted hazard rate. CONCLUSIONS: Risk-adjusted hospital rates of incisional hernia repair do not vary significantly from the average. This suggests that incisional hernia repair might not be sensitive enough as a long-term quality metric for benchmarking hospital performance. (C) 2015 by the American College of Surgeons C1 [Stey, Anne M.] Mt Sinai Med Ctr, Icahn Sch Med, New York, NY 10029 USA. [Stey, Anne M.; Russell, Marcia M.; Lin, Andy; Gibbons, Melinda M.; Lawson, Elise H.; Zingmond, David S.; Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Russell, Marcia M.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Hall, Bruce L.] Washington Univ, Sch Med St Louis, Dept Surg, St Louis, MO USA. [Hall, Bruce L.] Olin Business Sch, St Louis, MO 63130 USA. [Hall, Bruce L.] Washington Univ St Louis, St Louis VA Med Ctr, Washington, DC USA. [Hall, Bruce L.] BJC Healthcare, St Louis, MO USA. [Hall, Bruce L.; Ko, Clifford Y.] Amer Coll Surg, Chicago, IL USA. RP Stey, AM (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, 10940 Wilshire Blvd,Ste 710, Los Angeles, CA 90024 USA. EM as013j@gmail.com FU Robert Wood Johnson Foundation Clinical Scholars Program; US Department of Veterans Affairs [70039]; American College of Surgeons FX Supported by the Robert Wood Johnson Foundation Clinical Scholars Program and the US Department of Veterans Affairs (grant no. 70039). Drs Hall and Ko are paid consultants for the American College of Surgeons. NR 41 TC 0 Z9 0 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD MAR PY 2015 VL 220 IS 3 BP 313 EP U192 DI 10.1016/j.jamcollsurg.2014.11.011 PG 12 WC Surgery SC Surgery GA CB8WI UT WOS:000349912300010 PM 25542281 ER PT J AU Levy, C White, H AF Levy, Cari White, Heidi TI The AMDA Foundation Futures Program: Inspiring the Next Generation of Postacute and Long-Term Care Medical Directors SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION LA English DT Editorial Material C1 [Levy, Cari] Denver Vet Affairs Med Ctr, Dept Med, Div Hlth Care Policy & Res, Denver, CO 80220 USA. [Levy, Cari] Univ Colorado, Denver, CO 80220 USA. [White, Heidi] Duke Univ, Dept Med, Div Geriatr, Durham, NC USA. RP Levy, C (reprint author), Denver Vet Affairs Med Ctr, Dept Med, Div Hlth Care Policy & Res, 1055 Clermont St, Denver, CO 80220 USA. EM cari.levy@va.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-8610 EI 1538-9375 J9 J AM MED DIR ASSOC JI J. Am. Med. Dir. Assoc. PD MAR 1 PY 2015 VL 16 IS 3 BP 179 EP 180 DI 10.1016/j.jamda.2014.12.011 PG 2 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA CC2LQ UT WOS:000350176900004 PM 25659619 ER PT J AU Mohajer, MA Darouiche, RO AF Mohajer, M. Al Darouiche, R. O. TI Re: Infections Associated with Inflatable Penile Prostheses SO JOURNAL OF UROLOGY LA English DT Editorial Material C1 [Mohajer, M. Al; Darouiche, R. O.] Univ Arizona, Dept Med, Tucson, AZ 85724 USA. [Mohajer, M. Al; Darouiche, R. O.] Baylor Coll Med, Spinal Cord Injury & Med Care Lines, Infect Dis Sect, Michael E DeBakey & Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Mohajer, MA (reprint author), Univ Arizona, Dept Med, Tucson, AZ 85724 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 EI 1527-3792 J9 J UROLOGY JI J. Urol. PD MAR PY 2015 VL 193 IS 3 BP 907 EP 907 DI 10.1016/j.juro.2014.12.043 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA CB8IX UT WOS:000349873300051 ER PT J AU Koyama, A Houston, DK Simonsick, EM Lee, JS Ayonayon, HN Shahar, DR Rosano, C Satterfield, S Yaffe, K AF Koyama, Alain Houston, Denise K. Simonsick, Eleanor M. Lee, Jung Sun Ayonayon, Hilsa N. Shahar, Danit R. Rosano, Caterina Satterfield, Suzanne Yaffe, Kristine TI Association Between the Mediterranean Diet and Cognitive Decline in a Biracial Population SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE Epidemiology; Nutrition; Cognitive aging; Alzheimers; Cognition ID MENTAL-STATE-EXAM; ALZHEIMERS-DISEASE; CARDIOVASCULAR-DISEASE; ADHERENCE; RISK; DEMENTIA; HEALTH; MEDDIETSCORE; IMPAIRMENT; AMERICANS AB Background. Results from numerous studies suggest protective effects of the Mediterranean diet for cardiovascular disease, cancer, and mortality. Evidence for an association with a decreased risk of cognitive decline is less consistent and studies are limited by a lack of diversity in their populations. Methods. We followed 2,326 older adults (38.2% black, 51.3% female, aged 70-79 at baseline) over 8 years in a prospective cohort study in the United States (Health, Aging and Body Composition study). To measure adherence to a Mediterranean diet, we calculated race-specific tertiles of the MedDiet score (range: 0-55) using baseline food frequency questionnaires. Cognitive decline was assessed using repeated Modified Mini Mental State Examination scores over the study. We used linear mixed models to assess the association between MedDiet score and trajectory of cognitive decline. Results. Among blacks, participants with high MedDiet scores had a significantly lower mean rate of decline on the Modified Mini Mental State Examination score compared with participants with lower MedDiet scores (middle and bottom tertiles). The mean difference in points per year was 0.22 (95% confidence interval: 0.05-0.39; p = .01) after adjustment for age, sex, education, body mass index, current smoking, physical activity, depression, diabetes, total energy intake, and socioeconomic status. No association between MedDiet scores and change in Modified Mini Mental State Examination score was seen among white participants (p = .14). Conclusions. Stronger adherence to the Mediterranean diet may reduce the rate of cognitive decline among black, but not white older adults. Further studies in diverse populations are needed to confirm this association and pinpoint mechanisms that may explain these results. C1 [Koyama, Alain] Northern Calif Inst Res & Educ, San Francisco, CA USA. [Koyama, Alain; Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Houston, Denise K.] Wake Forest Univ, Bowman Gray Sch Med, Sticht Ctr Aging, Winston Salem, NC USA. [Simonsick, Eleanor M.] NIA, Intramural Res Program, Baltimore, MD 21224 USA. [Lee, Jung Sun] Univ Georgia, Athens, GA 30602 USA. [Ayonayon, Hilsa N.; Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Shahar, Danit R.] Ben Gurion Univ Negev, Fac Hlth Sci, Dept Epidemiol & Hlth Evaluat, S Daniel Int Ctr Hlth & Nutr, IL-84105 Beer Sheva, Israel. [Rosano, Caterina] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15260 USA. [Satterfield, Suzanne] Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. RP Koyama, A (reprint author), San Francisco VA Med Ctr, 4150 Clement St,VAMC 116H, San Francisco, CA 94121 USA. EM akk412@mail.harvard.edu OI Rosano, Caterina/0000-0002-0909-1506; Rosano, Caterina/0000-0002-4271-6010 FU National Institute of Aging [K24 AG 031155, R01 AG 026720]; Alzheimer's Association [IIRG-08-88872]; National Institute on Aging (NIA) [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106, R01-AG028050]; NINR [R01-NR012459]; Intramural Research Program of the NIH, National Institute on Aging FX Funded in part by grants K24 AG 031155 and R01 AG 026720 from the National Institute of Aging and grant IIRG-08-88872 from the Alzheimer's Association. This research was supported by National Institute on Aging (NIA) Contracts N01-AG-6-2101; N01-AG-6-2103; N01-AG-6-2106, NIA grant R01-AG028050, and NINR grant R01-NR012459. This research was supported in part by the Intramural Research Program of the NIH, National Institute on Aging. NR 39 TC 4 Z9 4 U1 1 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5006 EI 1758-535X J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD MAR PY 2015 VL 70 IS 3 BP 352 EP 357 DI 10.1093/gerona/glu097 PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA CC1RZ UT WOS:000350122200011 PM 24994847 ER PT J AU Chen, W Xiong, S Li, J Li, XY Liu, Y Zou, CB Mallampalli, RK AF Chen, Wei Xiong, Sheng Li, Jin Li, Xiuying Liu, Yuan Zou, Chunbin Mallampalli, Rama K. TI The Ubiquitin E3 Ligase SCF-FBXO24 Recognizes Deacetylated Nucleoside Diphosphate Kinase A To Enhance Its Degradation SO MOLECULAR AND CELLULAR BIOLOGY LA English DT Article ID F-BOX PROTEINS; METASTATIC SUPPRESSOR NM23-H1; TUMOR-METASTASIS; PROTEASOMAL DEGRADATION; SUBSTRATE RECOGNITION; DEPENDENT REGULATION; CELL-PROLIFERATION; STRUCTURAL BASIS; COMPLEX; BINDING AB The Skp-Cul-F box (SCF) ubiquitin E3 ligase machinery recognizes predominantly phosphodegrons or, less commonly, an (I/L) Q molecular signature within substrates to facilitate their recruitment in mediating protein ubiquitination and degradation. Here, we examined the molecular signals that determine the turnover of the multifunctional enzyme nucleoside diphosphate kinase A (NDPK-A) that controls cell proliferation. NDPK-A protein exhibits a half-life of similar to 6 h in HeLa cells and is targeted for ubiquitylation through actions of the F-box protein FBXO24. SCF-FBXO24 polyubiquitinates NDPK-A at K85, and two NH2-terminal residues, L55 and K56, were identified as important molecular sites for FBXO24 interaction. Importantly, K56 acetylation impairs its interaction with FBXO24, and replacing K56 with Q56, an acetylation mimic, reduces NDPK-A FBXO24 binding capacity. The acetyltransferase GCN5 catalyzes K56 acetylation within NDPK-A, thereby stabilizing NDPK-A, whereas GCN5 depletion in cells accelerates NDPK-A degradation. Cellular expression of an NDPK-A acetylation mimic or FBXO24 silencing increases NDPK-A life span which, in turn, impairs cell migration and wound healing. We propose that lysine acetylation when presented in the appropriate context may be recognized by some F-box proteins as a unique inhibitory molecular signal for their recruitment to restrict substrate degradation. C1 [Chen, Wei; Xiong, Sheng; Li, Xiuying] Jinan Univ, Coll Life Sci & Technol, Inst Biomed, Guangzhou, Guangdong, Peoples R China. [Chen, Wei; Xiong, Sheng; Li, Xiuying] Jinan Univ, Coll Life Sci & Technol, Natl Engn Res Ctr Genet Med, Guangzhou, Guangdong, Peoples R China. [Li, Jin; Liu, Yuan; Zou, Chunbin; Mallampalli, Rama K.] Univ Pittsburgh, Acute Lung Injury Ctr Excellence, Dept Med, Pittsburgh, PA 15260 USA. [Mallampalli, Rama K.] Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA USA. [Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Zou, CB (reprint author), Univ Pittsburgh, Acute Lung Injury Ctr Excellence, Dept Med, Pittsburgh, PA 15260 USA. EM zouc@upmc.edu; mallampallirk@upmc.edu FU National Institutes of Health R01 [HL096376, HL097376, HL098174, HL081784, 1UH2HL123502, P01 HL114453]; American Heart Association Award [12SDG12040330]; U.S. Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development; U.S. Department of Veterans Affairs; National Project for Significant New Drugs Development of the MOST of China [2012ZX09103-301-033, 2012ZX09202-301-001]; Natural Science Foundation of China [30873082]; Major Biotech Industrialization Projects from the Guangzhou Municipal Science and Technology Bureau [2010U1-E00541] FX This work was supported, in part, by National Institutes of Health R01 grants HL096376, HL097376, HL098174, HL081784, 1UH2HL123502, P01 HL114453 (to R.K.M.) and American Heart Association Award 12SDG12040330 (to C.Z.). This work was also supported in part by the U.S. Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development, and a Merit Review Award from the U.S. Department of Veterans Affairs. This work was also supported, in part, by grants from the National Project for Significant New Drugs Development of the MOST of China (2012ZX09103-301-033 and 2012ZX09202-301-001), the Natural Science Foundation of China (30873082), and the Major Biotech Industrialization Projects from the Guangzhou Municipal Science and Technology Bureau (2010U1-E00541) to W.C., S.X., and X.L. NR 46 TC 1 Z9 2 U1 1 U2 8 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0270-7306 EI 1098-5549 J9 MOL CELL BIOL JI Mol. Cell. Biol. PD MAR PY 2015 VL 35 IS 6 BP 1001 EP 1013 DI 10.1128/MCB.01185-14 PG 13 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA CB9KS UT WOS:000349951100007 PM 25582197 ER PT J AU Tabak, NT Green, MF Wynn, JK Proudfit, GH Altshuler, L Horan, WP AF Tabak, Naomi T. Green, Michael F. Wynn, Jonathan K. Proudfit, Greg H. Altshuler, Lori Horan, William P. TI Perceived emotional intelligence is impaired and associated with poor community functioning in schizophrenia and bipolar disorder SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Schizophrenia; Bipolar disorder; Emotion; Emotional intelligence ID META-MOOD SCALE; RATING-SCALE; LIFE SATISFACTION; NEGATIVE SYMPTOMS; BEHAVIOR-THERAPY; I DISORDER; MINDFULNESS; VALIDITY; INDIVIDUALS; RELIABILITY AB Schizophrenia and bipolar disorder have been associated with shared and distinct emotion processing abnormalities. Initial findings indicate that these disorders differ with respect to the domain of emotional intelligence (EI). Individuals with schizophrenia display deficits on performance measures of EI, whereas those with bipolar disorder do not. However, no research has examined patients' subjective beliefs about their own EI (referred to as "perceived EI"). This study examined perceived EI, assessed with the Trait Meta-Mood Scale (TMMS), and its clinical and functional correlates in outpatients with schizophrenia (n = 35) or bipolar disorder I (n = 38) and matched healthy controls (n = 35). The TMMS includes three subscales that assess beliefs about one's ability to attend to (Attention to Feelings), understand (Clarity of Feelings), and repair emotions (Mood Repair). Participants in the clinical groups also completed community functioning and symptom assessments. Both clinical groups reported significantly lower perceived EI than controls, but did not differ from each other. Higher total TMMS correlated with higher levels of independent living in the schizophrenia group (r =. 36) and better social functioning in the bipolar group (r = .61). In addition, although higher Attention to Feelings scores correlated with greater psychiatric symptoms in the schizophrenia group, higher scores across all subscales correlated with less manic symptoms in the bipolar group. The findings suggest that perceived EI is impaired and related to community functioning in both disorders. Published by Elsevier B.V. C1 [Tabak, Naomi T.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90073 USA. [Tabak, Naomi T.; Green, Michael F.; Wynn, Jonathan K.; Horan, William P.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Green, Michael F.; Wynn, Jonathan K.; Altshuler, Lori; Horan, William P.] UCLA Semel Inst Neurosci & Human Behav, Los Angeles, CA USA. [Proudfit, Greg H.] SUNY Stony Brook, Dept Psychol, Stony Brook, NY USA. RP Horan, WP (reprint author), Univ Calif Los Angeles, MIRECC 210A,Bldg 210,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM horan@ucla.edu RI Wynn, Jonathan/H-3749-2014 OI Wynn, Jonathan/0000-0002-1763-8540 FU NIMH [MH091468, MH065707, MH43292] FX Funding for the current study was provided by NIMH Grants MH091468 (William P. Horan, Ph.D.) and MH065707 and MH43292 (Michael F. Green, PhD). NR 55 TC 5 Z9 5 U1 1 U2 12 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 EI 1573-2509 J9 SCHIZOPHR RES JI Schizophr. Res. PD MAR PY 2015 VL 162 IS 1-3 BP 189 EP 195 DI 10.1016/j.schres.2014.12.005 PG 7 WC Psychiatry SC Psychiatry GA CB9QI UT WOS:000349966400031 PM 25579055 ER PT J AU Marcum, ZA Driessen, J Thorpe, CT Donohue, JM Gellad, WF AF Marcum, Zachary A. Driessen, Julia Thorpe, Carolyn T. Donohue, Julie M. Gellad, Walid F. TI Regional Variation in Use of a New Class of Antidiabetic Medication Among Medicare Beneficiaries: The Case of Incretin Mimetics SO ANNALS OF PHARMACOTHERAPY LA English DT Article DE Medicare; diabetes; pharmacoepidemiology; regional variation ID PRESCRIPTION DRUG-USE; GEOGRAPHIC-VARIATION; PART-D; CLINICAL-USE; PATIENT; DETERMINANTS; PHYSICIANS; INHIBITORS; THERAPIES; COHORT AB Background: When incretin mimetic (IM) medications were introduced in 2005, their effectiveness compared with other less-expensive second-line diabetes therapies was unknown, especially for older adults. Physicians likely had some uncertainty about the role of IMs in the diabetes treatment armamentarium. Regional variation in uptake of IMs may be a marker of such uncertainty. Objective: To investigate the extent of regional variation in the use of IMs among beneficiaries and estimate the cost implications for Medicare. Methods: This was a cross-sectional analysis of 2009-2010 claims data from a nationally representative sample of 238 499 Medicare Part D beneficiaries aged >= 65 years, who were continuously enrolled in fee-for-service Medicare and Part D and filled >= 1 antidiabetic prescription. Beneficiaries were assigned to I of 306 hospital-referral regions (HRRs) using ZIP codes. The main outcome was adjusted proportion of antidiabetic users in an HRR receiving an IM. Results: Overall, 29 933 beneficiaries (12.6%) filled an IM prescription, including 26 939 (11.3%) for sitagliptin or saxagliptin and 3718 (1.6%) for exenatide or liraglutide. The adjusted proportion of beneficiaries using IMs varied more than 3-fold across HRRs, from 5th and 95th percentiles of 5.2% to 17.0%. Compared with non-1M users, IM users faced a 155% higher annual Part D plan ($1067 vs $418) and 144% higher patient ($369 vs $151) costs for antidiabetic prescriptions. Conclusion: Among older Part D beneficiaries using antidiabetic drugs, substantial regional variation exists in the use of IMs, not accounted for by sociodemographics and health status. IM use was associated with substantially greater costs for Part D plans and beneficiaries. C1 [Marcum, Zachary A.; Driessen, Julia; Thorpe, Carolyn T.; Donohue, Julie M.; Gellad, Walid F.] Univ Pittsburgh, Pittsburgh, PA 15213 USA. [Thorpe, Carolyn T.; Gellad, Walid F.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Marcum, ZA (reprint author), Univ Pittsburgh, Sch Med, Div Geriatr Med, 3471 Fifth Ave Suite 500, Pittsburgh, PA 15213 USA. EM zam12@pitt.edu OI Donohue, Julie/0000-0003-2418-6017 FU National Institute on Aging [P30 AG024827, K07AG033174, R01AG027017]; AHRQ [R01HS018721]; VA HSR&D Career Development Award [CDA 09-207]; NHLBI, a pilot grant from the RAND-University of Pittsburgh Health Institute (RUPHI) [R01HL119246]; National Center for Research Resources (NCRR), a component of the National Institutes of Health [UL1 RR024153] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was funded by National Institute on Aging Grants (P30 AG024827; K07AG033174; R01AG027017), and an AHRQ grant (R01HS018721). WFG was supported by a VA HSR&D Career Development Award (CDA 09-207). JMD and WFG were partially supported by R01HL119246 from NHLBI, a pilot grant from the RAND-University of Pittsburgh Health Institute (RUPHI), and Grant Number UL1 RR024153 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health. NR 27 TC 1 Z9 1 U1 1 U2 9 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1060-0280 EI 1542-6270 J9 ANN PHARMACOTHER JI Ann. Pharmacother. PD MAR PY 2015 VL 49 IS 3 BP 285 EP 292 DI 10.1177/1060028014563951 PG 8 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA CB6NI UT WOS:000349743300003 PM 25515869 ER PT J AU Robinson, TN Rosenthal, RA AF Robinson, Thomas N. Rosenthal, Ronnie A. TI Optimizing the Geriatric Preoperative Assessment The Use of Functional Dependence and Beyond SO ANNALS OF SURGERY LA English DT Editorial Material ID SURGICAL OUTCOMES; INTENSITY; CARE; LIFE; END C1 [Robinson, Thomas N.] Denver VA Med Ctr, Dept Surg, Denver, CO 80220 USA. [Rosenthal, Ronnie A.] Yale Univ, Sch Med, Dept Surg, West Haven, CT 06516 USA. RP Robinson, TN (reprint author), Denver VA Med Ctr, Dept Surg, 1055 Clermont St 112, Denver, CO 80220 USA. EM thomas.robinson@ucclenver.edu NR 9 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-4932 EI 1528-1140 J9 ANN SURG JI Ann. Surg. PD MAR PY 2015 VL 261 IS 3 BP 438 EP 439 DI 10.1097/SLA.0000000000001132 PG 2 WC Surgery SC Surgery GA CB3WK UT WOS:000349559900036 PM 25654561 ER PT J AU Artinyan, A Orcutt, ST Anaya, DA Richardson, P Chen, GJ Berger, DH AF Artinyan, Avo Orcutt, Sonia T. Anaya, Daniel A. Richardson, Peter Chen, G. John Berger, David H. TI Infectious Postoperative Complications Decrease Long-term Survival in Patients Undergoing Curative Surgery for Colorectal Cancer A Study of 12,075 Patients SO ANNALS OF SURGERY LA English DT Article DE colorectal cancer; postoperative complications; surgery; surgical site infections; survival ID QUALITY IMPROVEMENT PROGRAM; ANASTOMOTIC LEAKAGE; RECTAL-CANCER; COLON-CANCER; RISK-FACTORS; SURGICAL COMPLICATIONS; RESECTION; MORTALITY; MORBIDITY; IMPACT AB Objective: We sought to characterize the effect of postoperative complications on long-term survival after colorectal cancer (CRC) resection. Background: The impact of early morbidity on long-term survival after curative-intent CRC surgery remains controversial. Methods: The Veterans Affairs Surgical Quality Improvement Program and Central Cancer Registry databases were linked to acquire perioperative and cancer-specific data for 12,075 patients undergoing resection for nonmetastatic CRC (1999-2009). Patients were categorized by presence of any complication within 30 days and by type of complication (noninfectious vs infectious). Univariate and multivariate survival analyses adjusted for patient, disease, and treatment factors were performed, excluding early deaths (<90 days). Subset analysis was performed to determine the specific impact of severe postoperative infections. Results: The overall morbidity and infectious complication rates were 27.8% and 22.5%, respectively. Patients with noninfectious postoperative complications were older, had lower preoperative serum albumin, had worse functional status, and had higher American Society of Anesthesiologists scores than patients with infectious complications and without complications (all P < 0.001). The presence of any complication was independently associated with decreased long-term survival [hazard ratio, 1.24; 95% confidence interval (1.15-1.34)]. Multivariate analysis by complication type demonstrated increased risk only with infectious complications [hazard ratio, 1.31; 95% confidence interval (1.21-1.42)]. Subset analysis demonstrated this effect predominantly in patients with severe infections [hazard ratio, 1.41; 95% confidence interval (1.15-1.73)]. Conclusions: The presence of postoperative complications after CRC resection is associated with decreased long-term survival, independent of patient, disease, and treatment factors. The impact on long-term outcome is primarily driven by infectious complications, particularly severe postoperative infections. C1 [Artinyan, Avo; Anaya, Daniel A.; Berger, David H.] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Artinyan, Avo; Orcutt, Sonia T.; Anaya, Daniel A.; Berger, David H.] Baylor Coll Med, Dept Surg, Div Gen Surg & Surg Oncol, Houston, TX 77030 USA. [Anaya, Daniel A.; Richardson, Peter; Chen, G. John; Berger, David H.] Vet Affairs Ctr Innovat Qual Effectiveness & Safe, Houston, TX USA. [Richardson, Peter; Chen, G. John] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. RP Artinyan, A (reprint author), Baylor Coll Med, Dept Surg, Michael E DeBakey Vet Affairs Med Ctr, 2002 Holcombe Blvd,OCL 112, Houston, TX 77030 USA. EM artinyan@bcm.edu NR 39 TC 33 Z9 34 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-4932 EI 1528-1140 J9 ANN SURG JI Ann. Surg. PD MAR PY 2015 VL 261 IS 3 BP 497 EP 505 DI 10.1097/SLA.0000000000000854 PG 9 WC Surgery SC Surgery GA CB3WK UT WOS:000349559900046 PM 25185465 ER PT J AU Sonnenberg, A AF Sonnenberg, Amnon TI Modeling Lengthy Work-ups in Gastrointestinal Bleeding SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article DE Gastrointestinal Bleeding; Markov Chain; Medical Decision Analysis; Modeling ID DOUBLE-BALLOON ENTEROSCOPY; COST-EFFECTIVENESS; CAPSULE ENDOSCOPY; COLORECTAL-CANCER; DECISION-ANALYSIS; METAANALYSIS; COLONOSCOPY; MANAGEMENT; DIAGNOSIS; DISEASE AB Multiple procedures and medical devices are being used in a complex interplay to diagnose and treat gastrointestinal bleeding. The aim of the study was to develop a mathematical model that helps in estimating the average number of procedures to be expected in the general management of gastrointestinal bleeding. The modeling process serves as an example of how mathematical analysis in general can be used to answer unresolved clinical questions, lead to a better understanding of the underlying influences in a disease process, and provide a starting point for future clinical trials. The analysis uses a Markov chain to model the transition probabilities among consecutive interventions used to find and treat a bleeding site. The results show that starting a work-up of gastrointestinal bleeding with an esophagogastroduodenoscopy will lead on average to 2.69 procedures per patient. Of these expected procedures, 1.46 will be esophagogastroduodenoscopies, 0.69 colonoscopies, 0.25 video capsule endoscopies, 0.14 double-balloon enteroscopies, and 0.14 procedures from interventional radiology. Management chains initiated with a colonoscopy result in similar outcomes. Among 10,000 simulated individual patients, the number of procedures varies between 1 and 16 consecutive procedures, with 95% of all patients undergoing 6 procedures or less. The outcomes of the model suggest that the published success rates of endoscopic and radiographic procedures are overly optimistic. The results also point to the need to generate clinical data through future studies that more reliably account for treatment failures and the interchange among various complementary diagnostic modalities. C1 [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR 97239 USA. [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 29 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 EI 1542-7714 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD MAR PY 2015 VL 13 IS 3 BP 433 EP 439 DI 10.1016/j.cgh.2014.01.019 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CB6RJ UT WOS:000349754000011 PM 24440338 ER PT J AU Berry, K Taylor, J Liou, IW Ioannou, GN AF Berry, Kristin Taylor, Justin Liou, Iris W. Ioannou, George N. TI Portal Vein Thrombosis Is Not Associated With Increased Mortality Among Patients With Cirrhosis SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article DE Portal Vein Thrombosis; Cirrhosis; Mortality; Liver Transplantation; UNOS; Survival; MELD ID LIVER; SURVIVAL; ANTICOAGULATION; OUTCOMES AB BACKGROUND & AIMS: Portal vein thrombosis (PVT) is common in patients with cirrhosis and may have adverse clinical consequences. We investigated whether PVT is associated with survival in patients with cirrhosis. METHODS: Using the United Network for Organ Sharing registries from 2002 through 2013, we followed a cohort of transplant-naive adults with cirrhosis without hepatocellular carcinoma (N = 66,506) from the time of transplant listing until the time of liver transplantation or death before transplantation. We used Cox proportional hazards analysis and competing risks analysis to compare patients who had PVT at the time of listing (n = 2207) with those who did not (n = 64,299) with regard to the risk of transplantation or death before transplantation, after adjusting for important baseline characteristics. RESULTS: During a mean follow-up period of 1.78 years, 17,757 (27%) patients died before liver transplantation, 29,179 (44%) patients underwent transplantation, and 19,570 (29%) patients were still alive without having undergone transplantation. Compared with patients who did not have PVT, patients with PVT had lower mortality (adjusted hazard ratio [AHR], 0.88; 95% confidence interval [CI], 0.81-0.96), a similar risk of transplantation (AHR, 0.95; 95% CI, 0.89-1.02), and a lower risk of the combined outcome of death or transplantation (AHR, 0.95; 95% CI, 0.88-0.97). Similar results were found by competing risks analyses. Independent predictors of mortality included age, model for end-stage liver disease score, serum albumin level, ascites, encephalopathy, diabetes, hepatitis C virus infection, and low body mass index (<24.4 kg/m(2)). CONCLUSIONS: Among patients with cirrhosis on liver transplant waiting lists, patients with PVT have lower mortality than patients without PVT. C1 [Berry, Kristin; Ioannou, George N.] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Seattle, WA 98195 USA. [Taylor, Justin; Liou, Iris W.; Ioannou, George N.] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Gastroenterol, Seattle, WA 98195 USA. RP Ioannou, GN (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Div Gastroenterol, Dept Med, S-111-Gastro,1660 S Columbian Way, Seattle, WA 98108 USA. EM georgei@medicine.washington.edu FU Health Resources and Services Administration [231-00-0115] FX Supported in part by Health Resources and Services Administration contract 231-00-0115. The content is the responsibility of the authors alone and does not necessarily reflect the views or policies of the Department of Health and Human Services. NR 18 TC 13 Z9 14 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 EI 1542-7714 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD MAR PY 2015 VL 13 IS 3 BP 585 EP 593 DI 10.1016/j.cgh.2014.10.010 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CB6RJ UT WOS:000349754000031 PM 25459555 ER PT J AU Herbrecht, R Patterson, TF Slavin, MA Marchetti, O Maertens, J Johnson, EM Schlamm, HT Donnelly, JP Pappas, PG AF Herbrecht, Raoul Patterson, Thomas F. Slavin, Monica A. Marchetti, Oscar Maertens, Johan Johnson, Elizabeth M. Schlamm, Haran T. Donnelly, J. Peter Pappas, Peter G. TI Application of the 2008 Definitions for Invasive Fungal Diseases to the Trial Comparing Voriconazole Versus Amphotericin B for Therapy of Invasive Aspergillosis: A Collaborative Study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE voriconazole; amphotericin B; neutropenia; allogeneic hematopoietic stem cell transplantation; preemptive therapy ID RANDOMIZED-TRIAL; 1ST-LINE THERAPY; DIAGNOSIS; CASPOFUNGIN; CONSENSUS AB Background. Strict definition of invasive aspergillosis (IA) cases is required to allow precise conclusions about the efficacy of antifungal therapy. The Global Comparative Aspergillus Study (GCAS) compared voriconazole to amphotericin B (AmB) deoxycholate for the primary therapy of IA. Because predefined definitions used for this trial were substantially different from the consensus definitions proposed by the European Organization for Research and Treatment of Cancer/Mycoses Study Group in 2008, we recategorized the 379 episodes of the GCAS according to the later definitions. Methods. The objectives were to assess the impact of the current definitions on the classification of the episodes and to provide comparative efficacy for probable/proven and possible IA in patients treated with either voriconazole or AmB. In addition to original data, we integrated the results of baseline galactomannan serum levels obtained from 249 (65.7%) frozen samples. The original response assessment was accepted unchanged. Results. Recategorization allowed 59 proven, 178 probable, and 106 possible IA cases to be identified. A higher favorable 12-week response rate was obtained with voriconazole (54.7%) than with AmB (29.9%) (P < .0001). Survival was higher for voriconazole for mycologically documented (probable/proven) IA (70.2%) than with AmB (54.9%) (P = .010). Higher response rates were obtained in possible IA treated with voriconazole vs AmB with the same magnitude of difference (26.2%; 95% confidence interval [CI], 7.2%-45.3%) as in mycologically documented episodes (24.3%; 95% CI, 11.9%-36.7%), suggesting that possible cases are true IA. Conclusions. Recategorization resulted in a better identification of the episodes and confirmed the higher efficacy of voriconazole over AmB deoxycholate in mycologically documented IA. C1 [Herbrecht, Raoul] Hop Hautepierre, Dept Hematol & Oncol, Strasbourg, France. [Herbrecht, Raoul] Univ Strasbourg, F-67098 Strasbourg, France. [Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Patterson, Thomas F.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Slavin, Monica A.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia. [Slavin, Monica A.] Univ Melbourne, Melbourne, Vic 3010, Australia. [Marchetti, Oscar] Lausanne Univ Hosp CHUV, Dept Med, Infect Dis Serv, Lausanne, Switzerland. [Maertens, Johan] Katholieke Univ Leuven, Univ Ziekenhuizen Leuven, Louvain, Belgium. [Johnson, Elizabeth M.] Publ Hlth England Mycol Reference Lab, Bristol, Avon, England. [Johnson, Elizabeth M.] Natl Collect Pathogen Fungi, Bristol, Avon, England. [Schlamm, Haran T.] Pfizer Global Res & Dev, New York, NY USA. [Donnelly, J. Peter] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands. [Pappas, Peter G.] Univ Alabama Birmingham, Div Infect Dis, Dept Med, Birmingham, AL USA. RP Herbrecht, R (reprint author), Univ Strasbourg, Hop Hautepierre, Dept Hematol & Oncol, F-67098 Strasbourg, France. EM raoul.herbrecht@chru-strasbourg.fr OI Herbrecht, Raoul/0000-0002-9381-4876 FU Pfizer Inc. FX The Global Comparative Aspergillosis Study and this recategorization study were sponsored by Pfizer Inc. NR 15 TC 13 Z9 14 U1 0 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAR 1 PY 2015 VL 60 IS 5 BP 713 EP 720 DI 10.1093/cid/ciu911 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CB6VY UT WOS:000349766100008 PM 25414266 ER PT J AU Cutrona, SL Mazor, KM Vieux, SN Luger, TM Volkman, JE Rutten, LJF AF Cutrona, Sarah L. Mazor, Kathleen M. Vieux, Sana N. Luger, Tana M. Volkman, Julie E. Rutten, Lila J. Finney TI Health Information-Seeking on Behalf of Others: Characteristics of "Surrogate Seekers" SO JOURNAL OF CANCER EDUCATION LA English DT Article DE Internet; Health information-seeking; Social network; Peer group; Caregiver ID ONLINE; BEHAVIOR AB Understanding the behaviors of surrogate seekers (those who seek health information for others) may guide efforts to improve health information transmission. We used 2011-2012 data from the Health Information National Trends Survey to describe behaviors of online surrogate seekers. Respondents were asked about use of the Internet for surrogate-seeking over the prior 12 months. Data were weighted to calculate population estimates. Two thirds (66.6 %) reported surrogate-seeking. Compared to those who sought health information online for only themselves, surrogate seekers were more likely to live in households with others (weighted percent 89.4 vs. 82.5 % of self-seekers; p < 0.05); no significant differences in sex, race, income or education were observed. Surrogate seekers were more likely to report activities requiring user-generated content: email communication with healthcare providers; visits to social networking sites to read and share about medical topics and participation in online health support groups. On multivariate analysis, those who had looked online for healthcare providers were more likely to be surrogate seekers (OR 1.67, 95 % CI 1.08-2.59). In addition to seeking health information, surrogate seekers create and pass along communications that may influence medical care decisions. Research is needed to identify ways to facilitate transmission of accurate health information. C1 [Cutrona, Sarah L.] Univ Massachusetts, Sch Med, Worcester, MA 01605 USA. [Mazor, Kathleen M.] Univ Massachusetts, Sch Med, Meyers Primary Care Inst, Worcester, MA 01605 USA. [Vieux, Sana N.] PCORI, Res Integrat & Evaluat Program, Washington, DC 20036 USA. [Luger, Tana M.] Edith Nourse Rogers Mem Vet Hosp, Ctr Healthcare Org & Implementat Res, Bedford, MA 01730 USA. [Volkman, Julie E.] US Dept Vet Affairs, ENR Mem Hosp, Bedford, MA USA. [Rutten, Lila J. Finney] Mayo Clin, Robert D & Patricia E Kern Ctr Sci Hlth Care Deli, Rochester, MN 55905 USA. RP Cutrona, SL (reprint author), Univ Massachusetts, Sch Med, 365 Plantat St,Biotech 1,Suite 100, Worcester, MA 01605 USA. EM sarah.cutrona@umassmemorial.org FU NCATS NIH HHS [KL2 TR000160] NR 20 TC 6 Z9 6 U1 1 U2 9 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0885-8195 EI 1543-0154 J9 J CANCER EDUC JI J. Cancer Educ. PD MAR PY 2015 VL 30 IS 1 BP 12 EP 19 DI 10.1007/s13187-014-0701-3 PG 8 WC Oncology; Education, Scientific Disciplines; Public, Environmental & Occupational Health SC Oncology; Education & Educational Research; Public, Environmental & Occupational Health GA CB6TJ UT WOS:000349759300003 PM 24989816 ER PT J AU Sheppard, KD Ford, CR Sawyer, P Foley, KT Harada, CN Brown, CJ Ritchie, CS AF Sheppard, Kendra D. Ford, Channing R. Sawyer, Patricia Foley, Kathleen T. Harada, Caroline N. Brown, Cynthia J. Ritchie, Christine S. TI The interprofessional clinical experience: interprofessional education in the nursing home SO JOURNAL OF INTERPROFESSIONAL CARE LA English DT Article DE Health and social care; interprofessional education; interdisciplinary ID ATTITUDES; RESIDENTS; SCALE AB The interprofessional clinical experience (ICE) was designed to introduce trainees to the roles of different healthcare professionals, provide an opportunity to participate in an interprofessional team, and familiarize trainees with caring for older adults in the nursing home setting. Healthcare trainees from seven professions (dentistry, medicine, nursing, nutrition, occupational therapy, optometry and social work) participated in ICE. This program consisted of individual patient interviews followed by a team meeting to develop a comprehensive care plan. To evaluate the impact of ICE on attitudinal change, the UCLA Geriatric Attitudes Scale and a post-experience assessment were used. The post-experience assessment evaluated the trainees' perception of potential team members' roles and attitudes about interprofessional team care of the older adult. Attitudes toward interprofessional teamwork and the older adult were generally positive. ICE is a novel program that allows trainees across healthcare professions to experience interprofessional teamwork in the nursing home setting. C1 [Sheppard, Kendra D.; Ford, Channing R.; Sawyer, Patricia; Harada, Caroline N.; Brown, Cynthia J.] Univ Alabama Birmingham, Div Gerontol Geriatr & Palliat Care, Dept Med, Birmingham, AL 35294 USA. [Foley, Kathleen T.] Brenau Univ North Atlanta Campus, Sch Occupat Therapy, Norcross, GA USA. [Harada, Caroline N.; Brown, Cynthia J.] GRECC, Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Ritchie, Christine S.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA USA. [Ritchie, Christine S.] Jewish Home San Francisco Ctr Res Aging, San Francisco, CA USA. RP Sheppard, KD (reprint author), Univ Alabama Birmingham, Div Gerontol Geriatr & Palliat Care, Dept Med, 1720 2nd Ave South,CH19,218H, Birmingham, AL 35294 USA. EM ksheppard@uabmc.edu FU Health Resources and Services Administration (HRSA) [UB4HP19045]; Southeast Center of Excellence in Geriatric Medicine; VA Rehabilitation Research and Development Merit Review Award [E7036R]; Donald W. Reynolds Foundation; Geriatric Academic Leadership Award from the National Institute on Aging [1K07AG31779]; HRSA FX The authors received support for their individual roles in the Interprofessional Clinical Experience from the Health Resources and Services Administration (HRSA)-funded Geriatric Education Center Grant (UB4HP19045). K.D.S. received support as a John A. Hartford Foundation Scholar Award from the Southeast Center of Excellence in Geriatric Medicine. C.J.B. received support from the VA Rehabilitation Research and Development Merit Review Award (E7036R). C.N.H. received support from the Donald W. Reynolds Foundation. C.S.R is supported by a Geriatric Academic Leadership Award from the National Institute on Aging (1K07AG31779) and was previously supported by the HRSA-funded Geriatric Education Center grant while she was at the University of Alabama at Birmingham. K.T.F has no disclosures and no conflicts of interest. The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of any of the funding agencies. NR 7 TC 2 Z9 2 U1 1 U2 13 PU INFORMA HEALTHCARE PI NEW YORK PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA SN 1356-1820 EI 1469-9567 J9 J INTERPROF CARE JI J. Interprofessional Care PD MAR PY 2015 VL 29 IS 2 BP 170 EP 172 DI 10.3109/13561820.2014.942776 PG 3 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA CB5IP UT WOS:000349661000017 PM 25140581 ER PT J AU Scherzer, R Bacchetti, P Messerlian, G Goderre, J Maki, PM Seifer, DB Anastos, K Karim, R Greenblatt, RM AF Scherzer, Rebecca Bacchetti, Peter Messerlian, Geralyn Goderre, Johanna Maki, Pauline M. Seifer, David B. Anastos, Kathryn Karim, Roksana Greenblatt, Ruth M. TI Impact of CD4+Lymphocytes and HIV Infection on Anti-Mullerian Hormone Levels in a Large Cohort of HIV-infected and HIV-uninfected Women SO AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY LA English DT Article DE Anti-Mullerian hormone; CD4 lymphocytes; HIV; menopause; ovarian follicle ID POLYCYSTIC-OVARY-SYNDROME; REPRODUCTIVE-AGED WOMEN; ANTRAL FOLLICLE COUNT; ANTIMULLERIAN HORMONE; PREMENOPAUSAL WOMEN; INTERAGENCY HIV; MENSTRUAL-CYCLE; AMH LEVEL; MENOPAUSE; RESERVE AB ProblemEffects of HIV infection on ovarian function and aging are unclear. Method of studyAnti-Mullerian Hormone (AMH) levels were analyzed in 2621 HIV-infected and 941 uninfected participants using left-censored longitudinal models. ResultsAge-adjusted AMH levels were 16% lower in women with undetectable viraemia and 26% lower in detectable viraemia, relative to uninfected women. Current CD4 count associated with higher AMH in both HIV-infected and HIV-uninfected women. After controlling for current and nadir CD4, AMH was 15% higher in HIV-infected relative to uninfected women, regardless of HIV viraemia. Gravidity, amenorrhea, and nadir total lymphocyte counts associated with higher AMH; hormonal contraceptive use and past weight loss associated with lower AMH. ConclusionsCD4+ lymphocyte counts were associated with AMH in both HIV-infected and uninfected women. After adjustment for CD4 counts and age, HIV infection was associated with higher AMH. CD4 T cells and cellular activation may influence ovarian granulosa cell function. C1 [Scherzer, Rebecca; Greenblatt, Ruth M.] Univ Calif San Francisco, Dept Med, San Francisco Sch Med, San Francisco, CA 94143 USA. [Scherzer, Rebecca] San Francisco VA Med Ctr, San Francisco, CA USA. [Bacchetti, Peter; Greenblatt, Ruth M.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco Sch Med, San Francisco, CA 94143 USA. [Messerlian, Geralyn] Brown Univ, Women & Infants Hosp, Providence, RI USA. [Goderre, Johanna] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Maki, Pauline M.] Univ Illinois, Dept Psychiat, Coll Med, Chicago, IL 60612 USA. [Maki, Pauline M.] Univ Illinois, Dept Psychol, Coll Med, Chicago, IL 60680 USA. [Seifer, David B.] Maimonides Hosp, Brooklyn, NY 11219 USA. [Anastos, Kathryn] Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA. [Anastos, Kathryn] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA. [Karim, Roksana] Univ So Calif, Los Angeles, CA USA. [Greenblatt, Ruth M.] Univ Calif San Francisco, Dept Clin Pharm, San Francisco Sch Pharm, San Francisco, CA 94143 USA. RP Greenblatt, RM (reprint author), Univ Calif San Francisco, Box 1352, San Francisco, CA 94143 USA. EM ruth.greenblatt@ucsf.edu OI Messerlian, Geralyn/0000-0002-9440-3411 FU National Institute of Allergy and Infectious Diseases [UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, UO1-AI-42590]; Eunice Kennedy Shriver National Institute of Child Health and Human Development [UO1-HD-32632]; National Cancer Institute; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Center for Research Resources (UCSF-CTSI) [UL1 RR024131] FX Data in this manuscript were collected by the Women's Interagency HIV Study (WIHS) Collaborative Study Group with centers (Principal Investigators) at New York City/Bronx Consortium (Kathryn Anastos); Brooklyn, NY (Howard Minkoff); Washington DC Metropolitan Consortium (Mary Young); The Connie Wofsy Study Consortium of Northern California (Ruth Greenblatt); Los Angeles County/Southern California Consortium (Alexandra Levine); Chicago Consortium (Mardge Cohen); Data Coordinating Center (Stephen Gange). The WIHS is funded by the National Institute of Allergy and Infectious Diseases (UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, and UO1-AI-42590) and by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (UO1-HD-32632). The study is cofunded by the National Cancer Institute, the National Institute on Drug Abuse, and the National Institute on Deafness and Other Communication Disorders. Funding is also provided by the National Center for Research Resources (UCSF-CTSI Grant Number UL1 RR024131). The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health. These funding sources had no involvement in the design or execution of this study. NR 50 TC 4 Z9 4 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1046-7408 EI 1600-0897 J9 AM J REPROD IMMUNOL JI Am. J. Reprod. Immunol. PD MAR PY 2015 VL 73 IS 3 BP 273 EP 284 DI 10.1111/aji.12332 PG 12 WC Immunology; Reproductive Biology SC Immunology; Reproductive Biology GA CB4SJ UT WOS:000349618000009 PM 25339186 ER PT J AU Bryant, MS Workman, CD Jackson, GR AF Bryant, Mon S. Workman, Craig D. Jackson, George R. TI Multidirectional walk test in individuals with Parkinson's disease: a validity study SO INTERNATIONAL JOURNAL OF REHABILITATION RESEARCH LA English DT Article DE backward walk; forward walk; GAITRite; Parkinson's disease; sideways walk; validity ID GAIT ASSESSMENT; RELIABILITY; SYSTEM; PARAMETERS AB Gait parameters of forward, backward, and sideways walk were studied when the participants walked overground in four directions at their self-selected speed and were compared with walking in the four directions on an instrumented GAITRite walkway. Intraclass correlation coefficients between the overground walk test measures and the instrumented walkway measures of gait speed, cadence, and stride length for the forward walk were 0.85, 0.88, and 0.87, respectively. For the backward walk, the coefficients were 0.91 for gait speed, 0.75 for cadence, and 0.93 for stride length. For the sideways walk, the coefficients were 0.92 for gait speed, 0.93 for cadence, and 0.94 for stride length. Gait parameters of forward, backward, and sideways walk obtained by the overground walk test had excellent agreement with those obtained by the instrumented walkway. The quick timed test provided quantitative data for gait evaluation and was valid for clinical use. Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved. C1 [Bryant, Mon S.; Workman, Craig D.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Res Serv, Houston, TX 77030 USA. [Bryant, Mon S.] Univ Houston, Dept Phys Med & Rehabil, Houston, TX USA. [Workman, Craig D.] Univ Houston, Dept Hlth & Human Performance, Houston, TX USA. [Jackson, George R.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Houston, TX 77030 USA. [Jackson, George R.] Baylor Coll Med, Houston, TX 77030 USA. RP Bryant, MS (reprint author), Michael E DeBakey VA Med Ctr, Res Serv, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM msbryant@bcm.edu FU RRD VA [IK2 RX000734] NR 17 TC 1 Z9 1 U1 3 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0342-5282 EI 1473-5660 J9 INT J REHABIL RES JI Int. J. Rehabil. Res. PD MAR PY 2015 VL 38 IS 1 BP 88 EP 91 DI 10.1097/MRR.0000000000000091 PG 4 WC Rehabilitation SC Rehabilitation GA CB1NY UT WOS:000349395900013 PM 25371075 ER PT J AU Balbale, SN Turcios, S LaVela, SL AF Balbale, Salva Najib Turcios, Stephanie LaVela, Sherri L. TI Health Care Employee Perceptions of Patient-Centered Care SO QUALITATIVE HEALTH RESEARCH LA English DT Article DE health care; health care professionals; photography; photovoice; quality improvement; research; qualitative ID PHOTOVOICE; OUTCOMES; SATISFACTION; QUALITY; TRANSFORMATION; EMPOWERMENT; EXPERIENCE; PROMOTION; SYSTEM; NEEDS AB Given the importance of health care employees in the delivery of patient-centered care, understanding their unique perspectives is essential for quality improvement. The purpose of this study was to use photovoice to evaluate perceptions and experiences around patient-centered care among U.S. Veterans Affairs (VA) health care employees. We asked participants to take photographs of salient features in their environment related to patient-centered care. We used the photographs to facilitate dialogue during follow-up interviews. Twelve VA health care employees across two VA sites participated in the project. Although most participants felt satisfied with their work environment and experiences at the VA, they identified several areas for improvement. These included a need for more employee health and wellness initiatives and a need for enhanced opportunities for training and professional growth. Application of photovoice enabled us to learn about employees' unique perspectives around patient-centered care while engaging them in an evaluation of care delivery. C1 [Balbale, Salva Najib; Turcios, Stephanie; LaVela, Sherri L.] US Dept Vet Affairs, Ctr Evaluat Practices & Experiences Patient Ctr C, Hines, IL USA. RP Balbale, SN (reprint author), Edward Hines Jr VA Hosp, 5000 S 5th Ave 151H, Hines, IL 60141 USA. EM Salva.Balbale@va.gov FU HSRD VA [I50 HX001171] NR 34 TC 3 Z9 3 U1 0 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1049-7323 EI 1552-7557 J9 QUAL HEALTH RES JI Qual. Health Res. PD MAR PY 2015 VL 25 IS 3 BP 417 EP 425 DI 10.1177/1049732314553011 PG 9 WC Information Science & Library Science; Social Sciences, Interdisciplinary; Social Sciences, Biomedical SC Information Science & Library Science; Social Sciences - Other Topics; Biomedical Social Sciences GA CB1FO UT WOS:000349372600011 PM 25274626 ER PT J AU Kelley, PW Kenny, DJ Gordon, DR Benner, P AF Kelley, Patricia Watts Kenny, Deborah J. Gordon, Deborah R. Benner, Patricia TI The Evolution of Case Management for Service Members Injured in Iraq and Afghanistan SO QUALITATIVE HEALTH RESEARCH LA English DT Article DE brain injury; caregivers; caregiving; discharge planning; health care; managed; interpretative phenomenological analysis (IPA); posttraumatic stress disorder (PTSD); rehabilitation; trauma; war; victims of ID CARE AB In this article we describe the nursing care needs of wounded service members (WSMs) from the wars in Iraq and Afghanistan and the evolving role of the nurse case manager (CM). New types of injuries, in-field treatment, immediate transport to multiple care centers, and new technologies have created a new patient population of WSMs that requires new types of nursing care and knowledge. We interviewed 235 nurses, including CMs from nine military treatment facilities (MTFs) and the Veterans Administration (VA), on actual patient care experiences and new knowledge development, and 67 WSMs about their experiences of care. New military and VA nurse case management roles are essential for the effective functioning of the evolving, highly specialized, and transport-based health care system. Working effectively with WSMs required that the CM role be expanded beyond health care management to include family support, re-entry, and life coaching for the extremely altered life circumstances of WSMs. C1 [Kelley, Patricia Watts] US Dept Vet Affairs, Washington, DC 20420 USA. [Kenny, Deborah J.] Univ Colorado, Beth El Coll Nursing & Hlth Sci, Colorado Springs, CO 80907 USA. [Gordon, Deborah R.; Benner, Patricia] Univ Calif San Francisco, Dept Anthropol Hist & Social Med, San Francisco, CA 94143 USA. [Benner, Patricia] Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA. RP Kelley, PW (reprint author), US Dept Vet Affairs, Off Res & Dev Hlth Serv Res & Dev, 810 Vermont Ave NW, Washington, DC 20420 USA. EM Patricia.kelley2@va.gov NR 19 TC 0 Z9 0 U1 2 U2 8 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1049-7323 EI 1552-7557 J9 QUAL HEALTH RES JI Qual. Health Res. PD MAR PY 2015 VL 25 IS 3 BP 426 EP 439 DI 10.1177/1049732314553228 PG 14 WC Information Science & Library Science; Social Sciences, Interdisciplinary; Social Sciences, Biomedical SC Information Science & Library Science; Social Sciences - Other Topics; Biomedical Social Sciences GA CB1FO UT WOS:000349372600012 PM 25288405 ER PT J AU Maria, MMMS Hartwell, KJ Hanlon, CA Canterberry, M Lematty, T Owens, M Brady, KT George, MS AF Maria, Megan M. Moran-Santa Hartwell, Karen J. Hanlon, Colleen A. Canterberry, Melanie Lematty, Todd Owens, Max Brady, Kathleen T. George, Mark S. TI Right anterior insula connectivity is important for cue-induced craving in nicotine-dependent smokers SO ADDICTION BIOLOGY LA English DT Article DE Craving; cues; functional connectivity; insula; nicotine-dependence; tobacco cigarettes ID SUSTAINED-RELEASE BUPROPION; FUNCTIONAL CONNECTIVITY; DEFAULT-MODE; TOBACCO WITHDRAWAL; SMOKING-CESSATION; CIGARETTE-SMOKING; CONTROLLED-TRIAL; RESTING BRAIN; NETWORKS; ADDICTION AB The insula has been implicated in cue-induced craving and relapse in nicotine-dependent tobacco cigarette smokers. The aims of the present study were to identify brain regions that exhibit greater functional connectivity with the right anterior insula in response to smoking cues than to neutral cues and the role of functional connectivity between these regions in mediating cue-induced craving in healthy (free of axis I psychiatric disorders) nicotine-dependent tobacco cigarette smokers. Functional magnetic resonance imaging data were collected from 63 healthy nicotine-dependent smokers viewing blocks of smoking and neutral cues. Craving ratings were obtained after each block. A psychophysiologic interaction approach was used to identify regions that exhibited significantly greater functional connectivity with the right anterior insula (seed) during the smoking cues than during the neutral (corrected cluster thresholding, Z>2.3, P=0.05). Parameter estimates of the interaction effects from each region were regressed against the mean cue-induced craving scores. Significant task by seed interactions were observed in two clusters centered in the bilateral precuneus and left angular gyrus. The strength of connectivity between the right anterior insula and the precuneus, which is involved interoceptive processing and self-awareness, was positively correlated with the magnitude of the craving response to the smoking cues (r(2)=0.15; P<0.01). These data suggest that among smokers, cue-induced craving may be a function of connectivity between two regions involved in interoception and self-awareness. Moreover, treatment strategies that incorporate mindful attention may be effective in attenuating cue-induced craving and relapse in nicotine-dependent smokers. C1 [Maria, Megan M. Moran-Santa; Hartwell, Karen J.; Hanlon, Colleen A.; Canterberry, Melanie; Lematty, Todd; Owens, Max; Brady, Kathleen T.; George, Mark S.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Clin Neurosci Div, Charleston, SC 29425 USA. [Hartwell, Karen J.; Brady, Kathleen T.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Maria, MMMS (reprint author), Med Univ S Carolina, Inst Psychiat, Clin Neurosci Div, 67 President St, Charleston, SC 29425 USA. EM moranm@musc.edu NR 46 TC 7 Z9 7 U1 6 U2 16 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1355-6215 EI 1369-1600 J9 ADDICT BIOL JI Addict. Biol. PD MAR PY 2015 VL 20 IS 2 BP 407 EP 414 DI 10.1111/adb.12124 PG 8 WC Biochemistry & Molecular Biology; Substance Abuse SC Biochemistry & Molecular Biology; Substance Abuse GA CB0HG UT WOS:000349305900020 ER PT J AU Stein, CH Faigin, DA AF Stein, Catherine H. Faigin, David A. TI Community-Based Arts Initiatives: Exploring the Science of the Arts SO AMERICAN JOURNAL OF COMMUNITY PSYCHOLOGY LA English DT Article DE Community-based arts; Arts-based research; Social action AB In this introduction to the special issue, we describe some of the rewards and challenges of community-based arts initiatives for our discipline. We explore the inherent tensions between art and science that are reflected in community-based arts activities. We pose larger questions about researching community-based arts activities and defining the arts as a means of promoting social change. The diversity of populations, settings, and issues represented by the papers in the special issue are described and a common set of values, methods of inquiry and action are discussed. C1 [Stein, Catherine H.] Bowling Green State Univ, Dept Psychol, Bowling Green, OH 43404 USA. [Faigin, David A.] VA Maine Hlth Care Syst, US Dept Vet Affairs, Lewiston, ME USA. RP Stein, CH (reprint author), Bowling Green State Univ, Dept Psychol, Bowling Green, OH 43404 USA. EM cstein@bgsu.edu NR 13 TC 1 Z9 1 U1 1 U2 7 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0091-0562 EI 1573-2770 J9 AM J COMMUN PSYCHOL JI Am. J. Community Psychol. PD MAR PY 2015 VL 55 IS 1-2 BP 70 EP 73 DI 10.1007/s10464-014-9698-3 PG 4 WC Public, Environmental & Occupational Health; Psychology, Multidisciplinary; Social Work SC Public, Environmental & Occupational Health; Psychology; Social Work GA CA6KW UT WOS:000349023400007 PM 25586502 ER PT J AU Faigin, DA Stein, CH AF Faigin, David A. Stein, Catherine H. TI Community-Based Theater and Adults with Psychiatric Disabilities: Social Activism, Performance and Community Engagement SO AMERICAN JOURNAL OF COMMUNITY PSYCHOLOGY LA English DT Article DE Theater; Community-based theater; Psychiatric disabilities; Mental health activism; Qualitative research; Grounded theory ID MENTAL-HEALTH NEEDS; DRAMA THERAPY; RECOVERY; SELF; PEOPLE; CONSUMER; ILLNESS; SCHIZOPHRENIA; EMPOWERMENT; PROVIDERS AB The present study is an in-depth qualitative inquiry with an established theater troupe composed of adults living with psychiatric disabilities known as The Stars of Light. A grounded theory methodology is used to describe dimensions of social activism and characteristics of theater as a medium of engagement at the individual, setting/troupe, and community levels of analysis. Analysis of a broad scope of interview data, performance content, community contacts, and historical data from the troupe's 19-year history led to the identification of eight emergent theoretical concepts formulated from 17 supporting associated themes. The theoretical concepts characterize the impacts of community-based theater in the lives of participants, and theater troupe processes that contribute to community education and positive social change for adults living with psychiatric disabilities. Advantages, limitations, and future directions for research and action in community-based theater settings are discussed within the context of present research findings. C1 [Faigin, David A.] US Dept Vet Affairs, VA Maine Heath Care Syst, Lewiston, ME 04240 USA. [Stein, Catherine H.] Bowling Green State Univ, Dept Psychol, Bowling Green, OH 43403 USA. RP Faigin, DA (reprint author), US Dept Vet Affairs, VA Maine Heath Care Syst, Lewiston, ME 04240 USA. EM dfaigin@gmail.com NR 58 TC 0 Z9 0 U1 3 U2 17 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0091-0562 EI 1573-2770 J9 AM J COMMUN PSYCHOL JI Am. J. Community Psychol. PD MAR PY 2015 VL 55 IS 1-2 BP 148 EP 163 DI 10.1007/s10464-014-9695-6 PG 16 WC Public, Environmental & Occupational Health; Psychology, Multidisciplinary; Social Work SC Public, Environmental & Occupational Health; Psychology; Social Work GA CA6KW UT WOS:000349023400014 PM 25520209 ER PT J AU Gelernter, J Kranzler, HR Sherva, R Almasy, L Herman, AI Koesterer, R Zhao, HY Farrer, LA AF Gelernter, Joel Kranzler, Henry R. Sherva, Richard Almasy, Laura Herman, Aryeh I. Koesterer, Ryan Zhao, Hongyu Farrer, Lindsay A. TI Genome-Wide Association Study of Nicotine Dependence in American Populations: Identification of Novel Risk Loci in Both African-Americans and European-Americans SO BIOLOGICAL PSYCHIATRY LA English DT Article DE AMPK pathway; DISC1; DLC1; eNOS pathway; FTND; GWAS; Nicotine dependence; Population differences ID REGULAR TOBACCO USE; SMOKING INITIATION; ALCOHOL DEPENDENCE; TWIN; METAANALYSES; DISORDER; BEHAVIOR; CALCIUM; GENES AB BACKGROUND: We report a genome-wide association study (GWAS) of nicotine dependence defined on the basis of scores on the Fagerstrom Test for Nicotine Dependence in European-American (EA) and African-American (AA) populations. METHODS: Our sample, from the one used in our previous GWAS, included only subjects who had smoked >100 cigarettes lifetime (2114 EA and 2602 AA subjects) and an additional 927 AA and 2003 EA subjects from the Study of Addiction: Genetics and Environment project [via the database of Genotypes and Phenotypes (dbGAP)]. GWAS analysis considered Fagerstrom Test for Nicotine Dependence score as an ordinal trait, separately in each population and sample and by combining the results in meta-analysis. We also conducted analyses that were adjusted for other substance use disorder criteria in a single nucleotide polymorphism (SNP) subset. RESULTS: In EAs, one chromosome 7 intergenic region was genome-wide significant (GWS): rs13225753, p = 3.48 x 10(-8) (adjusted). In AAs, GWS associations were observed at numerous SNPs mapped to a region on chromosome 14 of >305,000 base pairs (minimal p = 4.74 x 10(-10)). Two chromosome 8 regions were associated: p = 4.45 x 10(-8) at DLC1 SNP rs289519 (unadjusted) and p = 1.10 x 10(-9) at rs6996964 (adjusted for other substances), located between CSGALNACT1 and INTS10. No GWS associations were observed at the chromosome 15 nicotinic receptor gene cluster (CHRNA5-CHRNA3-CHRNB4) previously associated with nicotine dependence and smoking quantity traits. TSNAX-DISC1 SNP rs821722 (p = 1.46 x 10(-7)) was the most significant result with substantial contributions from both populations; we previously identified DISC1 associations with opioid dependence. Pathway analysis identified association with nitric oxide synthase and adenosine monophosphate-activated protein kinase pathways in EAs. CONCLUSIONS: The key risk loci identified, which require replication, offer novel insights into nicotine dependence biology. C1 [Gelernter, Joel; Herman, Aryeh I.] Yale Univ, Sch Med, Dept Psychiat, Div Human Genet, New Haven, CT USA. [Gelernter, Joel; Herman, Aryeh I.] Vet Affairs Connecticut Healthcare Ctr, Dept Genet, West Haven, CT USA. [Gelernter, Joel; Herman, Aryeh I.] Vet Affairs Connecticut Healthcare Ctr, Dept Neurobiol, West Haven, CT USA. [Kranzler, Henry R.] Univ Penn, Perelman Sch Med, Dept Psychiat, Ctr Studies Addict, Philadelphia, PA 19104 USA. [Kranzler, Henry R.] Philadelphia Vet Affairs Med Ctr, Vet Integrated Serv Network, Mental Illness Res Educ and Clin Ctr 4, Philadelphia, PA USA. [Sherva, Richard; Koesterer, Ryan; Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Med Biomed Genet, Boston, MA 02118 USA. [Almasy, Laura] Texas Biomed Res Inst, Dept Genet, San Antonio, TX USA. [Zhao, Hongyu] Yale Univ, Dept Biostat, Sch Publ Hlth, New Haven, CT USA. [Zhao, Hongyu] Yale Univ, Dept Genet, Sch Publ Hlth, New Haven, CT USA. [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA. [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA. [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Genet & Genom, Boston, MA 02118 USA. [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Epidemiol & Biostat, Boston, MA 02118 USA. [Farrer, Lindsay A.] Sch Publ Hlth, Boston, MA USA. RP Gelernter, J (reprint author), Yale Univ, Sch Med, Dept Psychiat, VA CT 116A2,950 Campbell Ave, West Haven, CT 06516 USA. EM joel.gelernter@yale.edu OI Farrer, Lindsay/0000-0001-5533-4225 FU National Institutes of Health [RC2 DA028909, R01 DA12690, R01 DA12849, R01 DA18432, R01 AA11330, R01 AA017535]; Veterans Affairs Connecticut and Philadelphia Veterans Affairs Mental Illness Research, Educational, and Clinical Centers FX This study was supported by National Institutes of Health Grants RC2 DA028909, R01 DA12690, R01 DA12849, R01 DA18432, R01 AA11330, and R01 AA017535 and the Veterans Affairs Connecticut and Philadelphia Veterans Affairs Mental Illness Research, Educational, and Clinical Centers. NR 39 TC 18 Z9 19 U1 3 U2 19 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAR 1 PY 2015 VL 77 IS 5 BP 493 EP 503 DI 10.1016/j.biopsych.2014.08.025 PG 11 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA CA8XH UT WOS:000349203800012 PM 25555482 ER PT J AU Salazar, R Royall, DR Palmer, RF AF Salazar, Ricardo Royall, Donald R. Palmer, Raymond F. TI Neuropsychiatric symptoms in community-dwelling Mexican-Americans: results from the Hispanic Established Population for Epidemiological Study of the Elderly (HEPESE) study SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE Neuropsychiatric Inventory (NPI); neuropsychiatric symptoms (NPS); Hispanics; population-based study; Mexican-Americans ID ALZHEIMERS-DISEASE; COGNITIVE IMPAIRMENT; FAMILY CAREGIVERS; DEMENTIA SEVERITY; CACHE COUNTY; PREVALENCE; DEPRESSION; SAMPLE; CARE; PSYCHOPATHOLOGY AB ObjectiveThe Neuropsychiatric Inventory (NPI) is a well-established measure of psychopathology and frequently used in dementia studies. Little is known about its psychometric characteristics at a population level, particularly among Hispanics. We report the frequency of NPI symptoms in a community-dwelling older Mexican-American (MA) population cohort and the degree of symptom-related distress experienced by participant informants. MethodsParticipants were 1079 MA age 80years and over residing in five southwestern states who were administered the NPI as part of wave-7 of the Hispanic Established Population for Epidemiological Study of the Elderly (HEPESE) conducted from 2010 to 2011. ResultsNine hundred twenty-five informants rated NPI domains. Prevalence of neuropsychiatric symptoms (NPS) varied by symptom domain and ranged from agitation/aggression (32%) to euphoria/elation (5%). The overall rate of behavioral disturbances was 62.7%. On the other hand, 37.3% of informants reported no NPS. A significant fraction of the informants reported distress from the mood disorder cluster of the scale. ConclusionsA large percentage (>60%) of community-dwelling older MA have one or more informant-reported NPS. These symptoms have diagnostic, prognostic, and therapeutic implications. Although neuropsychiatric disorders may be the initial clinical manifestation of dementia and often appear before cognitive alterations, the high frequency of these symptoms in the HEPESE cohort may reflect a high prevalence of these disorders among community-dwelling MA. The pattern we observed also suggests relatively advanced stages of dementia. Copyright (c) 2014 John Wiley & Sons, Ltd. C1 [Salazar, Ricardo; Royall, Donald R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat & Behav Med, San Antonio, TX 78229 USA. [Royall, Donald R.; Palmer, Raymond F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, San Antonio, TX 78229 USA. [Royall, Donald R.] South Texas Vet Hlth Care Syst, GRECC, San Antonio, TX USA. RP Salazar, R (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat & Behav Med, San Antonio, TX 78229 USA. EM salazarr1@uthscsa.edu FU NIA NIH HHS [R01 AG010939] NR 45 TC 3 Z9 3 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-6230 EI 1099-1166 J9 INT J GERIATR PSYCH JI Int. J. Geriatr. Psychiatr. PD MAR PY 2015 VL 30 IS 3 BP 300 EP 307 DI 10.1002/gps.4141 PG 8 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA CA7ER UT WOS:000349081000009 PM 24838594 ER PT J AU Karlin, BE Trockel, M Spira, AP Taylor, CB Manber, R AF Karlin, Bradley E. Trockel, Mickey Spira, Adam P. Taylor, C. Barr Manber, Rachel TI National evaluation of the effectiveness of cognitive behavioral therapy for insomnia among older versus younger veterans SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE cognitive behavioral therapy; insomnia; older adults; geriatrics; veterans; US Department of Veterans Affairs; dissemination; implementation; evidence-based psychotherapy ID RANDOMIZED CONTROLLED-TRIAL; WORKING ALLIANCE INVENTORY; BECK DEPRESSION INVENTORY; QUALITY-OF-LIFE; PSYCHOMETRIC PROPERTIES; COMPARATIVE METAANALYSIS; PERSISTENT INSOMNIA; SLEEP DISTURBANCE; DISORDERS; HEALTH AB ObjectivesLimited research has examined the effects of cognitive behavioral therapy for insomnia (CBT-I) among older adults (age >65years) receiving treatment in real-world clinical settings and even less has examined effects on outcomes beyond reducing insomnia, such as improved quality of life. The current article examines and compares outcomes of older versus younger (age 18-64years) veterans receiving CBT-I nationally in nonsleep specialty settings. MethodPatient outcomes were assessed using the Insomnia Severity Index, Beck Depression Inventory-II, and the World Health Organization Quality of Life-BREF. Therapeutic alliance was assessed using the Working Alliance InventoryShort Revised. ResultsA total of 536 younger veterans and 121 older veterans received CBT-I; 77% of older and 64% of younger patients completed all sessions or finished early due to symptom relief. Mean insomnia scores declined from 19.5 to 9.7 in the older group and from 20.9 to 11.1 in the younger group. Within-group effect sizes were d=2.3 and 2.2 for older and younger groups, respectively. CBT-I also yielded significant improvements in depression and quality of life for both age groups. High and increasing levels of therapeutic alliance were observed for both age groups. ConclusionsOlder (and younger) patients receiving CBT-I from nonsleep specialists experienced large reductions in insomnia and improvements in depression and quality of life. Effects were similar for both age groups, and the rate of dropout was lower among older adults. The results provide strong support for the effectiveness and acceptability of CBT-I for older adults receiving care in routine treatment settings. Copyright (c) 2014 John Wiley & Sons, Ltd. C1 [Karlin, Bradley E.] US Dept Vet Affairs, Mental Hlth Serv, Cent Off, Washington, DC 20420 USA. [Karlin, Bradley E.] Educ Dev Ctr Inc, New York, NY 10014 USA. [Karlin, Bradley E.; Spira, Adam P.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD 21205 USA. [Trockel, Mickey; Taylor, C. Barr; Manber, Rachel] Stanford Univ, Med Ctr, Dept Psychiat, Stanford, CA 94305 USA. [Trockel, Mickey; Taylor, C. Barr; Manber, Rachel] Vet Affairs Palo Alto Hlth Care Syst, VISN Mental Illness Res Educ & Clin Ctr 21, Palo Alto, CA 94304 USA. RP Karlin, BE (reprint author), US Dept Vet Affairs, Mental Hlth Serv, Cent Off, Washington, DC 20420 USA. EM bradkarlin@gmail.com FU Mental Health Services, US Department of Veterans Affairs (VA) Central Office FX This project was supported by Mental Health Services, US Department of Veterans Affairs (VA) Central Office. NR 52 TC 5 Z9 5 U1 3 U2 20 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-6230 EI 1099-1166 J9 INT J GERIATR PSYCH JI Int. J. Geriatr. Psychiatr. PD MAR PY 2015 VL 30 IS 3 BP 308 EP 315 DI 10.1002/gps.4143 PG 8 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA CA7ER UT WOS:000349081000010 PM 24890708 ER PT J AU Chang, ET Wells, KB Gilmore, J Tang, LQ Morgan, AU Sanders, S Chung, BW AF Chang, Evelyn T. Wells, Kenneth B. Gilmore, James Tang, Lingqi Morgan, Anna U. Sanders, Starr Chung, Bowen TI Comorbid Depression and Substance Abuse Among Safety-Net Clients in Los Angeles: A Community Participatory Study SO PSYCHIATRIC SERVICES LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; PRIMARY MEDICAL-CARE; MENTAL-HEALTH-SERVICES; USE DISORDERS; COOCCURRING DISORDERS; PSYCHIATRIC-DISORDERS; HOMELESS ADULTS; EMERGENCY-DEPARTMENT; HOSPITAL UTILIZATION; ALCOHOL AB Objective: Depression and substance abuse are common among low-income adults from racial-ethnic minority groups who receive services in safety-net settings, although little is known about how clients differ by service setting. This study examined characteristics and service use among depressed, low-income persons from minority groups in under-resourced communities who did and did not have a substance abuse history. Methods: The study used cross-sectional baseline client data (N= 957) from Community Partners in Care, an initiative to improve depression services in Los Angeles County. Clients with probable depression (eight-item Patient Health Questionnaire) from substance abuse programs were compared with depressed clients with and without a history of substance abuse from primary care, mental health, and social and community programs. Sociodemographic, health status, and services utilization variables were examined. Results: Of the 957 depressed clients, 217 (23%) were from substance abuse programs; 269 (28%) clients from other sectors had a substance abuse history, and 471 (49%) did not. Most clients from substance abuse programs or with a substance abuse history were unemployed and impoverished, lacked health insurance, and had high rates of arrests and homelessness. They were also more likely than clients without a substance abuse history to have depression or anxiety disorders, psychosis, and mania and to use emergency rooms. Conclusions: Clients with depression and a substance abuse history had significant psychosocial stressors and high rates of service use, which suggests that communitywide approaches may be needed to address both depression and substance abuse in this safety-net population. C1 [Chang, Evelyn T.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Gen Internal Med, Los Angeles, CA USA. [Wells, Kenneth B.; Tang, Lingqi; Chung, Bowen] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat, Los Angeles, CA 90024 USA. [Wells, Kenneth B.; Chung, Bowen] RAND Corp, Santa Monica, CA 90406 USA. [Gilmore, James] Behav Hlth Serv Inc, Los Angeles, CA USA. [Morgan, Anna U.] Harbor UCLA Med Ctr, Div Gen Internal Med, Los Angeles, CA USA. [Sanders, Starr] House Uhuru, Los Angeles, CA USA. RP Chang, ET (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Dept Gen Internal Med, Los Angeles, CA USA. EM evelynchang.md@gmail.com FU Office of Academic Affiliations, Health Services Research and Development, U.S. Department of Veterans Affairs (VA) [TMP 65-020]; National Institute of Mental Health (NIMH) [R01MH078853, P30MH082760, P30MH068639]; Robert Wood Johnson Foundation [64244]; UCLA Clinical and Translational Science Institute, National Center for Advancing Translational Science [UL1TR000124]; California Community Foundation [CMCH-12-97088] FX Funding was provided through the Health Services Fellowship Training Program (TMP 65-020) by the Office of Academic Affiliations, Health Services Research and Development, U.S. Department of Veterans Affairs (VA). The study was also funded by awards R01MH078853, P30MH082760, and P30MH068639 from the National Institute of Mental Health (NIMH); award 64244 from the Robert Wood Johnson Foundation; award UL1TR000124 from the UCLA Clinical and Translational Science Institute, National Center for Advancing Translational Science; and award CMCH-12-97088 from the California Community Foundation. The content is solely the responsibility of the authors and does not necessarily represent the official views of the VA; NIMH; National Institutes of Health; UCLA Clinical and Translational Science Institute, National Center for Advancing Translational Science; California Community Foundation; or other affiliated institutions. Community Partners in Care is registered at clinical trials. gov (NCT01699789). The authors thank the 50 participating agencies and their representatives, the participating Los Angeles programs and their providers and staff, and the clients who participated. A list of community partners is at www.communitypartnersincare.org/about/partners. The authors thank the RAND Survey Research Group and trained community members who conducted client data collection. They also thank Wayne Aoki, Ph.D., for comments on the manuscript. NR 75 TC 0 Z9 0 U1 4 U2 8 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD MAR PY 2015 VL 66 IS 3 BP 285 EP 294 DI 10.1176/appi.ps.201300318 PG 10 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA DE5QL UT WOS:000370686200011 PM 25727117 ER PT J AU Gifford, E Tavakoli, S Wisdom, J Hamlett-Berry, K AF Gifford, Elizabeth Tavakoli, Sara Wisdom, Jennifer Hamlett-Berry, Kim TI Implementation of Smoking Cessation Treatment in VHA Substance Use Disorder Residential Treatment Programs SO PSYCHIATRIC SERVICES LA English DT Article ID NICOTINE REPLACEMENT THERAPY; TOBACCO DEPENDENCE; ABUSE-TREATMENT; CIGARETTE-SMOKING; TREATMENT ORGANIZATIONS; ALCOHOL DEPENDENCE; PARIHS FRAMEWORK; UNITED-STATES; HEALTH; TRIAL AB Objectives: Although the prevalence of tobacco use among individuals with substance use disorders remains high, smoking cessation (SC) has not been a focus of addiction treatment programs. Veterans Health Administration (VHA) policy requires tobacco use screening and the availability of evidence-based SC treatment in specialty care settings, including substance use disorder programs. As part of a larger quality improvement effort, this qualitative study examined how SC treatment is delivered in VHA substance use disorder residential treatment programs (SRTPs) and the barriers and opportunities for growth that exist within these settings. Methods: Twenty-five staff were interviewed across a sample of 15 SRTPs. Participants were asked to describe their knowledge and attitudes about SC treatment as well as organizational barriers and facilitators related to implementation of SC treatment in their programs. Content analysis was used to extract responses within and across programs. Results: Participants endorsed SC as a general goal and reported that SRTPs responded to patients who requested help. However, many programs did not emphasize SC as an important part of recovery from substance use disorders and did not document, reevaluate, or consistently address tobacco use. Conclusions: The results identified critical gaps in the provision of SC treatment in VHA SRTPs. These findings suggest actionable opportunities to improve SC treatment in SRTPs, including providing training opportunities, developing or enforcing policies that support SC, implementing systems to track and report tobacco-related diagnoses and treatment, and obtaining leadership support for building a culture that encourages SC. C1 [Gifford, Elizabeth; Tavakoli, Sara] US Dept Vet Affairs Palo Alto Hlth Care Syst, Subst Use Disorder Qual Enhancement Res Initiat, Menlo Pk, CA USA. [Wisdom, Jennifer] George Washington Univ, Dept Hlth Policy, Milken Inst, Sch Publ Hlth, Washington, DC USA. [Wisdom, Jennifer] George Washington Univ, Off Vice President Res, Washington, DC USA. [Hamlett-Berry, Kim] US Dept Vet Affairs, Dept Clin Publ Hlth, Washington, DC USA. RP Gifford, E (reprint author), US Dept Vet Affairs Palo Alto Hlth Care Syst, Subst Use Disorder Qual Enhancement Res Initiat, Menlo Pk, CA USA. EM elizabeth.gifford@va.gov FU Office of Tobacco and Health: Policy and Programs, U.S. Department of Veterans Affairs (VA) Office of Clinical Public Health; Substance Use Disorders Quality Enhancement Initiative Center [QLP 59-030] FX This project was supported by the Office of Tobacco and Health: Policy and Programs, U.S. Department of Veterans Affairs (VA) Office of Clinical Public Health and by Locally Initiated Project QLP 59-030 from the Substance Use Disorders Quality Enhancement Initiative Center. The views expressed are those of the authors and do not necessarily reflect the views of the VA or any other entity of the U.S. Government. NR 56 TC 5 Z9 5 U1 4 U2 7 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD MAR PY 2015 VL 66 IS 3 BP 295 EP 302 DI 10.1176/appi.ps.201400008 PG 8 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA DE5QL UT WOS:000370686200012 PM 25727118 ER PT J AU Montgomery, AE Dichter, ME Thomasson, AM Roberts, CB Byrne, T AF Montgomery, Ann Elizabeth Dichter, Melissa E. Thomasson, Arwin M. Roberts, Christopher Brent Byrne, Thomas TI Disparities in Housing Status Among Veterans With General Medical, Cognitive, and Behavioral Health Conditions SO PSYCHIATRIC SERVICES LA English DT Article ID HOMELESS VETERANS; CARE; GENDER; NEEDS; WOMEN AB Objective: The study explored disparities in housing status among veterans with general medical, cognitive, and behavioral health conditions. Methods: Multinomial mixed-effects models estimated the relationship between medical, cognitive, and behavioral health comorbidities and housing instability among veterans enrolled in the Veterans Health Administration (VHA) (N=1,582,125) who responded to the Homelessness Screening Clinical Reminder for homelessness and risk during a three-month period. Results: Veterans were two or more times as likely to screen positive for homelessness or risk if they had a diagnosis of a cognitive or behavioral health conditions in the study. Findings related to general medical conditions were inconsistent. Conclusions: The study found disparities in housing instability among VHA outpatients with cognitive and behavioral health conditions, suggesting the need to identify veterans with these conditions experiencing housing instability and the need to develop appropriate interventions to mitigate homelessness or risk. C1 [Montgomery, Ann Elizabeth] Philadelphia Dept Vet Affairs Med Ctr, Natl Ctr Homelessness Vet, Philadelphia, PA USA. [Dichter, Melissa E.; Thomasson, Arwin M.; Roberts, Christopher Brent] Philadelphia Dept Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Byrne, Thomas] Boston Univ, Sch Social Work, Boston, MA 02215 USA. RP Montgomery, AE (reprint author), Philadelphia Dept Vet Affairs Med Ctr, Natl Ctr Homelessness Vet, Philadelphia, PA USA. EM ann.montgomery2@va.gov FU U.S. Department of Veterans Affairs (VA), National Center on Homelessness Among Veterans; VA Center for Health Equity Research and Promotion [LIP 72-061] FX This study was funded by the U.S. Department of Veterans Affairs (VA), National Center on Homelessness Among Veterans and a Competitive Pilot Research Grant (LIP 72-061) by the VA Center for Health Equity Research and Promotion. The contents of this article do not necessarily represent the views of the VA or the United States Government. NR 15 TC 1 Z9 1 U1 1 U2 2 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD MAR PY 2015 VL 66 IS 3 BP 317 EP 320 DI 10.1176/appi.ps.201400014 PG 4 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA DE5QL UT WOS:000370686200016 PM 25727122 ER PT J AU Zhou, CK Littman, AJ Levine, PH Hoffman, HJ Cleary, SD White, E Cook, MB AF Zhou, Cindy Ke Littman, Alyson J. Levine, Paul H. Hoffman, Heather J. Cleary, Sean D. White, Emily Cook, Michael B. TI Male Pattern Baldness in Relation to Prostate Cancer Risks: An Analysis in the VITamins and Lifestyle (VITAL) Cohort Study SO PROSTATE LA English DT Article DE male pattern baldness; prostate cancer; androgen; cohort study ID ENDOGENOUS SEX-HORMONES; EARLY-ONSET BALDNESS; ANDROGENETIC ALOPECIA; SERUM TESTOSTERONE; HAIR LOSS; MEN; METAANALYSIS; POLYMORPHISMS; EPIDEMIOLOGY; FINASTERIDE AB BACKGROUNDMale pattern baldness and prostate cancer may share common pathophysiological mechanisms in terms of advancing age, heritability, and endogenous hormones. Results from previous epidemiologic studies are inconsistent. Therefore, we investigated the association of prostate cancer risks with male pattern baldness at age 30 years, age 45 years, and baseline (median age=60.5 years) in the VITamins And Lifestyle (VITAL) cohort study. METHODSWe included 32,583 men who were aged 50-76 years and without prior cancer diagnosis (excluding non-melanoma skin cancer) at the start of follow-up. First primary incident prostate cancers were ascertained via linkage to the western Washington Surveillance, Epidemiology, and End Results (SEER) program. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were estimated using Cox proportional hazards regressions with adjustment for potential confounders. RESULTSDuring follow-up (median=9 years), 2,306 incident prostate cancers were diagnosed. Male pattern baldness at age 30 years, age 45 years, and baseline were not statistically significantly associated with overall or subtypes of prostate cancer. CONCLUSIONThis study did not provide support for the hypothesis that male pattern baldness may be a marker for subsequent prostate cancer. Previous evidence indicates that a distinct class of frontal with vertex balding may be associated with increased risk of aggressive prostate cancer, but all such balding classes were captured as a single exposure category by the VITAL cohort questionnaire. Prostate 75:415-423, 2015. (c) 2014 Wiley Periodicals, Inc. C1 [Zhou, Cindy Ke; Cook, Michael B.] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA. [Zhou, Cindy Ke; Levine, Paul H.; Hoffman, Heather J.; Cleary, Sean D.] George Washington Univ, Dept Epidemiol & Biostat, Washington, DC USA. [Littman, Alyson J.; White, Emily] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Littman, Alyson J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA. [White, Emily] Fred Hutchinson Canc Res Ctr, Canc Prevent Program, Seattle, WA 98104 USA. RP Cook, MB (reprint author), NCI, Hormonal & Reprod Epidemiol Branch, Div Canc Epidemiol & Genet, 9609 Med Ctr Dr,Rm 7-E106,MSC 9774, Bethesda, MD 20892 USA. EM michael.cook@nih.gov RI Zhou, Cindy /H-2165-2015; Cook, Michael/A-5641-2009 OI Zhou, Cindy /0000-0003-4814-4305; Cook, Michael/0000-0002-0533-7302 FU Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health FX Grant sponsor: Intramural Program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health. NR 50 TC 3 Z9 3 U1 0 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-4137 EI 1097-0045 J9 PROSTATE JI Prostate PD MAR 1 PY 2015 VL 75 IS 4 BP 415 EP 423 DI 10.1002/pros.22927 PG 9 WC Endocrinology & Metabolism; Urology & Nephrology SC Endocrinology & Metabolism; Urology & Nephrology GA AY8OA UT WOS:000347811800008 PM 25492530 ER PT J AU Villani, TS Reichert, W Ferruzzi, MG Pasinetti, GM Simon, JE Wu, QL AF Villani, Tom S. Reichert, William Ferruzzi, Mario G. Pasinetti, Giulio M. Simon, James E. Wu, Qingli TI Chemical investigation of commercial grape seed derived products to assess quality and detect adulteration SO FOOD CHEMISTRY LA English DT Article DE Grape seed extract; LC-MS; Polyphenol; Proanthocyanidins; Adulteration; Quality control ID ALZHEIMERS-DISEASE; ANTIOXIDANT CAPACITY; DIETARY-SUPPLEMENTS; PEANUT SKINS; IN-VITRO; PROANTHOCYANIDINS; EXTRACT; BIOAVAILABILITY; ANTIBACTERIAL; PROCYANIDINS AB Fundamental concerns in quality control arise due to increasing use of grape seed extract (GSE) and the complex chemical composition of GSE. Proanthocyanidin monomers and oligomers are the major bioactive compounds in GSE. Given no standardized criteria for quality, large variation exists in the composition of commercial GSE supplements. Using HPLC/UV/MS, 21 commercial GSE containing products were purchased and chemically profiled, major compounds quantitated, and compared against authenticated grape seed extract, peanut skin extract, and pine bark extract. The antioxidant capacity and total polyphenol content for each sample was also determined and compared using standard techniques. Nine products were adulterated, found to contain peanut skin extract. A wide degree of variability in chemical composition was detected in commercial products, demonstrating the need for development of quality control standards for GSE. A TLC method was developed to allow for rapid and inexpensive detection of adulteration in GSE by peanut skin. (C) 2014 Elsevier Ltd. All rights reserved. C1 [Villani, Tom S.; Reichert, William; Simon, James E.; Wu, Qingli] Rutgers State Univ, Dept Plant Biol & Pathol, New Use Agr & Nat Plant Prod Program, New Brunswick, NJ 08901 USA. [Villani, Tom S.; Simon, James E.; Wu, Qingli] Rutgers State Univ, Ernest Mario Sch Pharm, Dept Med Chem, Piscataway, NJ 08854 USA. [Ferruzzi, Mario G.] Purdue Univ, Dept Food Sci, W Lafayette, IN 47907 USA. [Pasinetti, Giulio M.] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. [Pasinetti, Giulio M.] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY 10468 USA. RP Simon, JE (reprint author), Rutgers State Univ, Dept Plant Biol & Pathol, New Use Agr & Nat Plant Prod Program, New Brunswick, NJ 08901 USA. EM jimsimon@rci.rutgers.edu; qlwu@aesop.rutgers.edu FU National Institute of Health [PO1AT004511]; Rutgers New Use Agriculture and Natural Plant Products Program; New Jersey Agricultural Experiment Station, Rutgers, The State University of New Jersey FX This work was supported by the National Institute of Health grant PO1AT004511. We also thank the Rutgers New Use Agriculture and Natural Plant Products Program and the New Jersey Agricultural Experiment Station, Rutgers, The State University of New Jersey for their partial funding and support. We thank Xiaoyou Zhang in BannerBio Nutraceuticals Inc. (Shenzhen, China) for providing the authenticated reference materials. We thank Paul Coates, Joe Betz, Gordon Cragg and others at the NIH ODS for their interest in this work. We thank Ray Facto, Wendy Wang, and Grace Lin for their invaluable help in this work. NR 48 TC 5 Z9 5 U1 2 U2 85 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0308-8146 EI 1873-7072 J9 FOOD CHEM JI Food Chem. PD MAR 1 PY 2015 VL 170 BP 271 EP 280 DI 10.1016/j.foodchem.2014.08.084 PG 10 WC Chemistry, Applied; Food Science & Technology; Nutrition & Dietetics SC Chemistry; Food Science & Technology; Nutrition & Dietetics GA AR7SO UT WOS:000343780400036 PM 25306345 ER PT J AU Chang, K Karnad, A Zhao, SJ Freeman, JW AF Chang, Katherine Karnad, Anand Zhao, Shujie Freeman, James W. TI Roles of c-Met and RON Kinases in tumor progression and their potential as therapeutic targets SO ONCOTARGET LA English DT Article DE c-Met; RON kinase; Met inhibitors ID RECEPTOR TYROSINE KINASE; HEPATOCYTE GROWTH-FACTOR; CELL LUNG-CANCER; GLIOBLASTOMA STEM-CELLS; PANCREATIC-CANCER; BREAST-CANCER; HEPATOCELLULAR-CARCINOMA; TUMORIGENIC ACTIVITIES; SIGNALING PATHWAY; POINT MUTATIONS AB c-Met and receptor originated from nantes (RON) are structurally related transmembrane phosphotyrosine kinase receptors. c-Met and RON show increased expression or activity in a variety of tumors leading to tumor progression and may play a role in acquired resistance to therapy. Although often co-expressed, the distinct functional roles of c-Met and RON are not fully understood. c-Met and RON form both activated homodimers and heterodimers with themselves and other families of phosphotyrosine kinase receptors. Inhibitors for c-Met and RON including small molecular weigh kinase inhibitors and neutralizing antibodies are in pre-clinical investigation and clinical trials. Several of the tyrosine kinase inhibitors have activity against both c-Met and RON kinases whereas the antibodies generally are target specific. As with many targeted agents used to treat solid tumors, it is likely that c-Met/RON inhibitors will have greater benefit when used in combination with chemotherapy or other targeted agents. A careful analysis of c-Met/RON expression or activity and a better elucidation of how they influence cell signaling will be useful in predicting which tumors respond best to these inhibitors as well as determining which agents can be used with these inhibitors for combined therapy. C1 [Chang, Katherine; Karnad, Anand; Zhao, Shujie; Freeman, James W.] Univ Texas Hlth Sci Ctr San Antonio, Div Med Oncol, Dept Med, San Antonio, TX 78229 USA. [Chang, Katherine; Karnad, Anand; Freeman, James W.] Canc Therapy & Res Ctr S Texas, Expt & Dev Therapeut Program, San Antonio, TX 78229 USA. [Freeman, James W.] Audie L Murphy Mem Vet Adm Med Ctr, Res & Dev, San Antonio, TX USA. RP Freeman, JW (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Med Oncol, Dept Med, Floyd Curl Dr, San Antonio, TX 78229 USA. EM freemanjw@uthscsa.edu FU VA merit award; CPRIT; [NIH-RO1CA069122]; [NIH-P30CA054174] FX This work was supported by Grants to J.W.F., VA merit award, and NIH-RO1CA069122 and NIH-P30CA054174. The authors would like to thank Mr. David Baker for design of medical illustrations. The work was also supported by CPRIT postdoctoral fellowship to Dr. Katherine Chang. NR 91 TC 11 Z9 12 U1 1 U2 3 PU IMPACT JOURNALS LLC PI ALBANY PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA SN 1949-2553 J9 ONCOTARGET JI Oncotarget PD FEB 28 PY 2015 VL 6 IS 6 BP 3507 EP 3518 PG 12 WC Oncology; Cell Biology SC Oncology; Cell Biology GA CF6WB UT WOS:000352696200007 PM 25784650 ER PT J AU Yentes, JM Schmid, KK Blanke, D Romberger, DJ Rennard, SI Stergiou, N AF Yentes, Jennifer M. Schmid, Kendra K. Blanke, Daniel Romberger, Debra J. Rennard, Stephen I. Stergiou, Nicholas TI Gait mechanics in patients with chronic obstructive pulmonary disease SO RESPIRATORY RESEARCH LA English DT Article DE Pulmonary disease; Locomotion; Joint kinematics; Joint kinetics; Biomechanics ID VASTUS LATERALIS MUSCLE; RANDOMIZED CONTROLLED-TRIAL; TRAUMATIC BRAIN-INJURY; STEP WIDTH VARIABILITY; CEREBRAL-PALSY; CARDIORESPIRATORY DISORDERS; EXERCISE PERFORMANCE; SYMPTOM INTENSITY; PHYSICAL-ACTIVITY; FUNCTIONAL STATUS AB Background: Chronic obstructive pulmonary disease (COPD) is characterized by the frequent association of disease outside the lung. The objective of this study was to determine the presence of biomechanical gait abnormalities in COPD patients compared to healthy controls while well rested and without rest. Methods: Patients with COPD (N = 17) and aged-matched, healthy controls (N = 21) walked at their self-selected pace down a 10-meter walkway while biomechanical gait variables were collected. A one-minute rest was given between each of the five collected trials to prevent tiredness (REST condition). Patients with COPD then walked at a self-selected pace on a treadmill until the onset of self-reported breathlessness or leg tiredness. Subjects immediately underwent gait analysis with no rest between each of the five collected trials (NO REST condition). Statistical models with and without covariates age, gender, and smoking history were used. Results: After adjusting for covariates, COPD patients demonstrated more ankle power absorption in mid-stance (P = 0.006) than controls during both conditions. Both groups during NO REST demonstrated increased gait speed (P = 0.04), stride length (P = 0.03), and peak hip flexion (P = 0.04) with decreased plantarflexion moment (P = 0.04) and increased knee power absorption (P = 0.04) as compared to REST. A significant interaction revealed that peak ankle dorsiflexion moment was maintained from REST to NO REST for COPD but increased for controls (P < 0.01). Stratifying by disease severity did not alter these findings, except that step width decreased in NO REST as compared to REST (P = 0.01). Standardized effect sizes of significant effects varied from 0.5 to 0.98. Conclusions: Patients with COPD appear to demonstrate biomechanical gait changes at the ankle as compared to healthy controls. This was seen not only in increased peak ankle power absorption during no rest but was also demonstrated by a lack of increase in peak ankle dorsiflexion moment from the REST to the NO REST condition as compared to the healthy controls. Furthermore, a wider step width has been associated with fall risk and this could account for the increased incidence of falls in patients with COPD. C1 [Yentes, Jennifer M.; Blanke, Daniel; Stergiou, Nicholas] Univ Nebraska, Omaha, NE 68182 USA. [Schmid, Kendra K.; Stergiou, Nicholas] Univ Nebraska Med Ctr, Coll Publ Hlth, Omaha, NE 68198 USA. [Romberger, Debra J.] Nebraska Western Iowa Vet Hlth Care Syst, US Dept Vet Affairs, Omaha, NE 68105 USA. [Romberger, Debra J.; Rennard, Stephen I.] Univ Nebraska Med Ctr, Dept Pulm & Crit Care Med, Omaha, NE 68198 USA. RP Yentes, JM (reprint author), Univ Nebraska, Biomech Res Bldg,6001 Dodge St, Omaha, NE 68182 USA. EM jyentes@unomaha.edu OI Yentes, Jennifer/0000-0001-6550-7759 FU Nebraska Medical Center; University of Nebraska Medical Center; National Institutes of Health [P20 GM109090] FX The authors would like to thank Mary Carlson, NP for her assistance in screening all of the subjects and Jeff Kaipust, MS for his assistance with data collections. Funding provided by American Society of Biomechanics Grant-in-Aid, American Alliance for Health, Physical Education, Recreation and Dance Graduate Student Grant-in-Aid, NASA Nebraska Space Grant Fellowship program and Research Support Fund from the Nebraska Medical Center and the University of Nebraska Medical Center. Additional funding provided by the National Institutes of Health (P20 GM109090). Funding sources had no involvement in study design, data interpretation, and/or manuscript preparation. NR 82 TC 0 Z9 0 U1 2 U2 7 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1465-993X EI 1465-9921 J9 RESP RES JI Respir. Res. PD FEB 28 PY 2015 VL 16 AR 31 DI 10.1186/s12931-015-0187-5 PG 13 WC Respiratory System SC Respiratory System GA CD0VD UT WOS:000350791100001 PM 25849481 ER PT J AU Annamalai, B Won, JS Choi, S Singh, I Singh, AK AF Annamalai, Balasubramaniam Won, Je-Seong Choi, Seungho Singh, Inderjit Singh, Avtar K. TI Role of S-nitrosoglutathione mediated mechanisms in tau hyper-phosphorylation SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE Calpain; Cdk5; GSK-3 beta; p25; S-nitrosoglutathione; Tau ID NITRIC-OXIDE SYNTHASE; BETA-AMYLOID PEPTIDE; ALZHEIMERS-DISEASE; RAT MODEL; IN-VIVO; CDK5; NITROSYLATION; PEROXYNITRITE; CALPAIN; P25 AB Hyperphosphorylation and polymerization of microtubule-associated protein tau into paired helical filaments (PHFs) is one of the hallmarks of Alzheimer's disease (AD). Here we report that neuronal tau hyperphosphorylation under AD conditions is regulated by S-nitrosoglutathione (GSNO), an endogenous nitric oxide carrier molecule. In cultured rat cortical primary neurons, we observed that GSNO treatment decreased the beta-amyloid (A beta(25-35))-induced pathological tau hyperphosphorylation (Ser396, Ser404, and Ser202/Thr205). The decreased tau hyperphosphorylation correlated with decreased activity of calpain and decreased p35 proteolysis into p25 and Cdk5 activation. GSNO treatment also attenuated the Alias (-35)-induced activation of GSK-3 beta which is known to play critical role in tau hyperphosphorylation in addition to Cdk5. Consistent with above studies using cultured neurons, we also observed that systemic GSNO treatment of transgenic mouse model of AD (APP(Sw)/PS1(dE9)) attenuated calpain-mediated p35 proteolysis and Cdk5/GSK-3 beta activities as well as tau hyperphosphorylation. In addition, GSNO treatment provided neuro- and cognitive protection in APP(Sw)/PS1(dE9) mice. This study describing the GSNO-mediated regulation of tau hyperphosphorylation and cognitive function, for the first time, suggests for therapeutic potential of GSNO as neuro- and cognitive-protective agent for AD. Published by Elsevier Inc. C1 [Annamalai, Balasubramaniam; Won, Je-Seong; Singh, Avtar K.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. [Choi, Seungho; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. [Singh, Avtar K.] Ralph H Johnson Vet Adm Med Ctr, Dept Pathol & Lab Med Serv, Charleston, SC USA. RP Singh, AK (reprint author), Med Univ S Carolina, Charles P Darby Children Res Inst, 504D,173 Ashley Ave, Charleston, SC 29425 USA. EM avtar.singh@va.gov FU NIH; VA [NS072511, BX001062, NS037766, BX001072] FX This work was supported in part by grants from NIH and VA (NS072511, BX001062, NS037766 and BX001072). NR 33 TC 8 Z9 8 U1 0 U2 6 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X EI 1090-2104 J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD FEB 27 PY 2015 VL 458 IS 1 BP 214 EP 219 DI 10.1016/j.bbrc.2015.01.093 PG 6 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA CD7DB UT WOS:000351249900035 PM 25640839 ER PT J AU Tokhtaeva, E Capri, J Marcus, EA Whitelegge, JP Khuzakhmetova, V Bukharaeva, E Deiss-Yehiely, N Dada, LA Sachs, G Fernandez-Salas, E Vagin, O AF Tokhtaeva, Elmira Capri, Joe Marcus, Elizabeth A. Whitelegge, Julian P. Khuzakhmetova, Venera Bukharaeva, Ellya Deiss-Yehiely, Nimrod Dada, Laura A. Sachs, George Fernandez-Salas, Ester Vagin, Olga TI Septin Dynamics Are Essential for Exocytosis SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID EVOKED QUANTAL RELEASE; NEUROTRANSMITTER RELEASE; MICROTUBULE ORGANIZATION; SNARE-COMPLEX; NEUROMUSCULAR-JUNCTIONS; ENDOPLASMIC-RETICULUM; SYNAPTIC VESICLE; BARRIER FUNCTION; SEC6/8 COMPLEX; ALPHA-SNAP AB Septins are a family of 14 cytoskeletal proteins that dynamically form hetero-oligomers and organize membrane microdomains for protein complexes. The previously reported interactions with SNARE proteins suggested the involvement of septins in exocytosis. However, the contradictory results of up-or down-regulation of septin-5 in various cells and mouse models or septin-4 in mice suggested either an inhibitory or a stimulatory role for these septins in exocytosis. The involvement of the ubiquitously expressed septin-2 or general septin polymerization in exocytosis has not been explored to date. Here, by nano-LC with tandem MS and immunoblot analyses of the septin-2 interactome in mouse brain, we identified not only SNARE proteins but also Munc-18-1 (stabilizes assembled SNARE complexes), N-ethylmaleimide-sensitive factor (NSF) (disassembles SNARE complexes after each membrane fusion event), and the chaperones Hsc70 and synucleins (maintain functional conformation of SNARE proteins after complex disassembly). Importantly, alpha-soluble NSF attachment protein (SNAP), the adaptor protein that mediates NSF binding to the SNARE complex, did not interact with septin-2, indicating that septins undergo reorganization during each exocytosis cycle. Partial depletion of septin-2 by siRNA or impairment of septin dynamics by forchlorfenuron inhibited constitutive and stimulated exocytosis of secreted and transmembrane proteins in various cell types. Forchlorfenuron impaired the interaction between SNAP-25 and its chaperone Hsc70, decreasing SNAP-25 levels in cultured neuroendocrine cells, and inhibited both spontaneous and stimulated acetylcholine secretion in mouse motor neurons. The results demonstrate a stimulatory role of septin-2 and the dynamic reorganization of septin oligomers in exocytosis. C1 [Sachs, George] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA. [Marcus, Elizabeth A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA. [Tokhtaeva, Elmira; Marcus, Elizabeth A.; Sachs, George; Vagin, Olga] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Capri, Joe; Whitelegge, Julian P.] Univ Calif Los Angeles, Pasarow Mass Spectrometry Lab, Semel Inst, Neuropsychiat Inst, Los Angeles, CA 90024 USA. [Khuzakhmetova, Venera; Bukharaeva, Ellya] Russian Acad Sci, Kazan Sci Ctr, Kazan Inst Biochem & Biophys, Kazan 420111, Russia. [Bukharaeva, Ellya] Kazan Fed Univ, Kazan 420008, Russia. [Deiss-Yehiely, Nimrod; Dada, Laura A.] Northwestern Univ, Feinberg Sch Med, Div Pulm & Crit Care Med, Chicago, IL 60611 USA. [Fernandez-Salas, Ester] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA. RP Vagin, O (reprint author), Univ Calif Los Angeles, Dept Physiol & Med, VAGLAHS West LA, 11301 Wilshire Blvd,Bldg 113,Rm 324, Los Angeles, CA 90073 USA. EM olgav@ucla.edu FU National Institutes of Health from the NHLBI [R01HL113350]; National Institutes of Health from the NIDDK [UL1TR000124, K08DK100661-01, P30DK063491]; UCLA Children's Discovery and Innovation Institute; Program of Competitive Growth of Kazan Federal University; Russian Foundation for Basic Research [15-04-02983a] FX This work was supported, in whole or in part, by National Institutes of Health Grants R01HL113350 from the NHLBI (to L. A. D. and O. V.), UL1TR000124 (to the UCLA Clinical and Translational Science Institute and E. A. M.), and K08DK100661-01 (to E. A. M.) and P30DK063491 from the NIDDK (to J. P. W) This work was also supported by the UCLA Children's Discovery and Innovation Institute (to E. A. M.), the Program of Competitive Growth of Kazan Federal University (to E. B. and V. K.), and Russian Foundation for Basic Research Grant 15-04-02983a (to E. B. and V. K.). NR 69 TC 11 Z9 11 U1 1 U2 10 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD FEB 27 PY 2015 VL 290 IS 9 BP 5280 EP 5297 DI 10.1074/jbc.M114.616201 PG 18 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA CC0RS UT WOS:000350044200005 PM 25575596 ER PT J AU Kawabori, M Kacimi, R Kauppinen, T Calosing, C Kim, JY Hsieh, CL Nakamura, MC Yenari, MA AF Kawabori, Masahito Kacimi, Rachid Kauppinen, Tiina Calosing, Cyrus Kim, Jong Youl Hsieh, Christine L. Nakamura, Mary C. Yenari, Midori A. TI Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) Deficiency Attenuates Phagocytic Activities of Microglia and Exacerbates Ischemic Damage in Experimental Stroke SO JOURNAL OF NEUROSCIENCE LA English DT Article DE ischemia; neuroprotection; permanent ischemia; phagocytosis; stroke; triggering receptor expressed on myeloid cells-2 ID FOCAL CEREBRAL-ISCHEMIA; NASU-HAKOLA-DISEASE; SCLEROSING LEUKOENCEPHALOPATHY; IN-VITRO; MACROPHAGES; MECHANISM; DEMENTIA; NEURONS; SYSTEM; TRANSPLANTATION AB Clearing cellular debris after brain injury represents an important mechanism in regaining tissue homeostasis and promoting functional recovery. Triggering receptor expressed on myeloid cells-2 (TREM2) is a newly identified receptor expressed on microglia and is thought to phagocytose damaged brain cells. The precise role of TREM2 during ischemic stroke has not been fully understood. We explore TREM2 in both in vitro and in vivo stroke models and identify a potential endogenous TREM2 ligand. TREM2 knockdown in microglia reduced microglial activation to an amoeboid phenotype and decreased the phagocytosis of injured neurons. Phagocytosis and infarcted brain tissue resorption was reduced in TREM2 knock-out (KO) mice compared with wild-type (WT) mice. TREM2 KO mice also had worsened neurological recovery and decreased viable brain tissue in the ipsilateral hemisphere. The numbers of activated microglia and phagocytes in TREM2 KO mice were decreased compared with WT mice, and foamy macrophages were nearly absent in the TREM2 KO mice. Postischemia, TREM2 was highly expressed on microglia and TREM2-Fc fusion protein (used as a probe to identify potential TREM2 binding partners) bound to an unknown TREM2 ligand that colocalized to neurons. Oxygen glucose deprivation-exposed neuronal media, or cellular fractions containing nuclei or purified DNA, but not cytosolic fractions, stimulated signaling through TREM2. TREM2-Fc fusion protein pulled down nucleic acids from ischemic brain lysate. These findings establish the relevance of TREM2 in the phagocytosis of the infarcted brain and emphasize its role in influencing neurological outcomes following stroke. Further, nucleic acids may be one potential ligand of TREM2 in brain ischemia. C1 [Kawabori, Masahito; Kacimi, Rachid; Calosing, Cyrus; Kim, Jong Youl; Hsieh, Christine L.; Nakamura, Mary C.; Yenari, Midori A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA. [Kawabori, Masahito; Kacimi, Rachid; Calosing, Cyrus; Kim, Jong Youl; Hsieh, Christine L.; Nakamura, Mary C.; Yenari, Midori A.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA. [Kacimi, Rachid; Hsieh, Christine L.; Yenari, Midori A.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Kauppinen, Tiina] Kleysen Inst Adv Med, Winnipeg, MB R3E 0Z3, Canada. RP Yenari, MA (reprint author), Univ Calif San Francisco, Dept Neurol, 4150 Clement St,MS 127, San Francisco, CA 94121 USA. EM yenari@alum.mit.edu OI Kauppinen, Tiina/0000-0001-7219-9862 FU National Institutes of Health [NS40516, AR0038]; Veteran's Merit Awards; Uehara Foundation Research Fellowship; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development Career Development Award-2; American Heart Association [0835222N]; resources of the Veterans Affairs Medical Center, San Francisco, California; Rosalind Russell Arthritis Center FX This work was supported by National Institutes of Health Grants NS40516 to M.A.Y. and AR0038 to M.C.N.; Veteran's Merit Awards to M.A.Y. and M.C.N.; a Uehara Foundation Research Fellowship to M.K.; a Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development Career Development Award-2 to C.L.H.; and American Heart Association Grant 0835222N to T.K. Grants to M.A.Y., M.C.N., and T.K. were administered by the Northern California Institute for Research and Education, and supported by resources of the Veterans Affairs Medical Center, San Francisco, California. M.C.N. also received support from the Rosalind Russell Arthritis Center. The authors thank Dr. Nick Cairns for labeling the TREM2 fusion protein. NR 46 TC 33 Z9 33 U1 1 U2 11 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD FEB 25 PY 2015 VL 35 IS 8 BP 3384 EP 3396 DI 10.1523/JNEUROSCI.2620-14.2015 PG 13 WC Neurosciences SC Neurosciences & Neurology GA CD0CV UT WOS:000350738800010 PM 25716838 ER PT J AU Griffin, WC Ramachandra, VS Knackstedt, LA Becker, HC AF Griffin, William C. Ramachandra, Vorani S. Knackstedt, Lori A. Becker, Howard C. TI Repeated cycles of chronic intermittent ethanol exposure increases basal glutamate in the nucleus accumbens of mice without affecting glutamate transport SO FRONTIERS IN PHARMACOLOGY LA English DT Article DE alcohol; mouse; microdialysis; uptake; transport ID ALCOHOL-PREFERRING RATS; EXTRACELLULAR GLUTAMATE; INDUCED NEUROPLASTICITY; EXTRACTION FRACTION; REPEATED EPISODES; DRUG-ADDICTION; C57BL/6J MICE; P RATS; WITHDRAWAL; DRINKING AB Repeated cycles of chronic intermittent ethanol (CIE) exposure increase voluntary consumption of ethanol in mice. Previous work has shown that extracellular glutamate in the nucleus accumbens (NAc) is significantly elevated in ethanol dependent mice and that pharmacologically manipulating glutamate concentrations in the NAc will alter ethanol drinking, indicating that glutamate homeostasis plays a crucial role in ethanol drinking in this model. The present studies were designed to measure extracellular glutamate at a time point in which mice would ordinarily be allowed voluntary access to ethanol in the CIE model and, additionally, to measure glutamate transport capacity in the NAc at the same time point. Extracellular glutamate was measured using quantitative microdialysis procedures. Glutamate transport capacity was measured under Ne-dependent and Na+-independent conditions to determine whether the function of excitatory amino acid transporters (also known as system XAG) or of system X (glial cysteine glutamate exchanger) was influenced by CIE exposure. The results of the quantitative microdialysis experiment confirm increased extracellular glutamate (approximately twofold) in the NAc of CIE exposed mice (i.e., ethanol-dependent) compared to non-dependent mice in the NAc, consistent with earlier work. However, the increase in extracellular glutamate was not due to altered transporter function in the NAc of ethanol-dependent mice, because neither Na-H-dependent nor Na -independent glutamate transport was significantly altered by CIE exposure. These findings point to the possibility that hyperexcitability of cortical striatal pathways underlies the increases in extracellular glutamate found in the ethanol dependent mice. C1 [Griffin, William C.; Ramachandra, Vorani S.; Becker, Howard C.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston Alcohol Res Ctr, Charleston, SC 29464 USA. [Knackstedt, Lori A.] Univ Florida, Dept Psychol, Gainesville, FL 32611 USA. [Becker, Howard C.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [Becker, Howard C.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Griffin, WC (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston Alcohol Res Ctr, MSC 867,67 President St, Charleston, SC 29464 USA. EM griffinw@musc.edu FU NIAAA [P50 AA010761, T32 AA007474, F32 AA021321]; VA Medical Research FX NIAAA P50 AA010761, T32 AA007474, 132 AA021321, and VA Medical Research. NR 54 TC 9 Z9 9 U1 0 U2 2 PU FRONTIERS RESEARCH FOUNDATION PI LAUSANNE PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND SN 1663-9812 J9 FRONT PHARMACOL JI Front. Pharmacol. PD FEB 23 PY 2015 VL 6 AR 27 DI 10.3389/fphar.2015.00027 PG 7 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA CF8TY UT WOS:000352836000001 PM 25755641 ER PT J AU Bai, X Kinney, WH Su, WL Bai, A Ovrutsky, AR Honda, JR Netea, MG Henao-Tamayo, M Ordway, DJ Dinarello, CA Chan, ED AF Bai, Xiyuan Kinney, William H. Su, Wen-Lin Bai, An Ovrutsky, Alida R. Honda, Jennifer R. Netea, Mihai G. Henao-Tamayo, Marcela Ordway, Diane J. Dinarello, Charles A. Chan, Edward D. TI Caspase-3-independent apoptotic pathways contribute to interleukin-32 gamma-mediated control of Mycobacterium tuberculosis infection in THP-1 cells SO BMC MICROBIOLOGY LA English DT Article DE Mycobacterium tuberculosis; Interleukin-32; Apoptosis; Programmed cell death; Caspase-1; Cathepsins; Apoptosis-inducing factor ID CASPASE-INDEPENDENT PATHWAY; MACROPHAGE APOPTOSIS; ALVEOLAR MACROPHAGES; TNF-ALPHA; DEATH; VIRULENT; INFLAMMASOME; INDUCTION; MONOCYTES/MACROPHAGES; ACTIVATION AB Background: Macrophages are the primary effector cells responsible for killing Mycobacterium tuberculosis (MTB) through various mechanisms, including apoptosis. However, MTB can evade host immunity to create a favorable environment for intracellular replication. MTB-infected human macrophages produce interleukin-32 (IL-32). IL-32 is a pro-inflammatory cytokine and has several isoforms. We previously found that IL-32 gamma reduced the burden of MTB in human macrophages, in part, through the induction of caspase-3-dependent apoptosis. However, based on our previous studies, we hypothesized that caspase-3-independent death pathways may also mediate IL-32 control of MTB infection. Herein, we assessed the potential roles of cathepsin-mediated apoptosis, caspase-1-mediated pyroptosis, and apoptosis-inducing factor (AIF) in mediating IL-32 gamma control of MTB infection in THP-1 cells. Results: Differentiated human THP-1 macrophages were infected with MTB H37Rv alone or in the presence of specific inhibitors to caspase-1, cathepsin B/D, or cathepsin L for up to four days, after which TUNEL-positive cells were quantified; in addition, MTB was quantified by culture as well as by the percentage of THP-1 cells that were infected with green fluorescent protein (GFP)-labeled MTB as determined by microscopy. AIF expression was inhibited using siRNA technology. Inhibition of cathepsin B/D, cathepsin L, or caspase-1 activity significantly abrogated the IL-32 gamma-mediated reduction in the number of intracellular MTB and of the percentage of GFP-MTB-infected macrophages. Furthermore, inhibition of caspase-1, cathepsin B/D, or cathepsin L in the absence of exogenous IL-32 gamma resulted in a trend toward an increased proportion of MTB-infected THP-1 cells. Inhibition of AIF activity in the absence of exogenous IL-32 gamma also increased intracellular burden of MTB. However, since IL-32 gamma did not induce AIF and because the relative increases in MTB with inhibition of AIF were similar in the presence or absence of IL-32 gamma, our results indicate that AIF does not mediate the host-protective effect of IL-32 gamma against MTB. Conclusions: The anti-MTB effects of IL-32 gamma are mediated through classical caspase-3-dependent apoptosis as well as caspase-3-independent apoptosis. C1 [Bai, Xiyuan; Kinney, William H.; Bai, An; Honda, Jennifer R.; Chan, Edward D.] Denver Vet Affairs Med Ctr, Dept Med, Denver, CO 80220 USA. [Bai, Xiyuan; Kinney, William H.; Bai, An; Honda, Jennifer R.; Chan, Edward D.] Natl Jewish Hlth, Dept Med, Denver, CO 80206 USA. [Bai, Xiyuan; Kinney, William H.; Bai, An; Honda, Jennifer R.; Chan, Edward D.] Natl Jewish Hlth, Dept Acad Affairs, Denver, CO 80206 USA. [Bai, Xiyuan; Kinney, William H.; Ovrutsky, Alida R.; Honda, Jennifer R.; Chan, Edward D.] Univ Colorado, Sch Med, Dept Med, Aurora, CO USA. [Dinarello, Charles A.] Univ Colorado, Div Infect Dis, Aurora, CO USA. [Su, Wen-Lin] Buddhist Tzu Chi Med Fdn, Taipei Tzu Chi Hosp, Div Pulm & Crit Care Med, New Taipei, Taiwan. [Su, Wen-Lin] Triserv Gen Hosp, Natl Def Med Ctr, Taipei, Taiwan. [Netea, Mihai G.] Radboud Univ Nijmegen, Med Ctr, Dept Internal Med, NL-6525 ED Nijmegen, Netherlands. [Netea, Mihai G.] Radboud Univ Nijmegen, Med Ctr, Radboud Ctr Infect Dis, NL-6525 ED Nijmegen, Netherlands. [Henao-Tamayo, Marcela; Ordway, Diane J.] Colorado State Univ, Dept Microbiol Immunol & Pathol, Mycobacteria Res Labs, Ft Collins, CO 80523 USA. RP Bai, X (reprint author), Denver Vet Affairs Med Ctr, Dept Med, Denver, CO 80220 USA. EM BaiX@njhealth.org RI Netea, Mihai/N-5155-2014; Henao-Tamayo, Marcela/D-8189-2017 OI Henao-Tamayo, Marcela/0000-0002-4249-9650 FU Department of Veterans Affairs Veterans Health Administration, Office of Research and Development [1 I01 BX001028-01A2]; NIH [AI15614, R21 AI081959]; NIH Innovation award [1DP2OD006450]; ARRA funds FX Study funded by Department of Veterans Affairs Veterans Health Administration, Office of Research and Development 1 I01 BX001028-01A2 (EDC), NIH AI15614 (CAD), and NIH R21 AI081959, NIH Innovation award 1DP2OD006450, and ARRA funds (DJO). NR 38 TC 8 Z9 8 U1 0 U2 7 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2180 J9 BMC MICROBIOL JI BMC Microbiol. PD FEB 21 PY 2015 VL 15 AR 39 DI 10.1186/s12866-015-0366-z PG 9 WC Microbiology SC Microbiology GA CC3OI UT WOS:000350258400001 PM 25887904 ER PT J AU Salmon, AB AF Salmon, Adam B. TI About-face on the metabolic side effects of rapamycin SO ONCOTARGET LA English DT Editorial Material ID LIFE-SPAN; MICE C1 [Salmon, Adam B.] Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Salmon, Adam B.] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78229 USA. [Salmon, Adam B.] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA. RP Salmon, AB (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. EM salmona@uth-scsa.edu OI Salmon, Adam/0000-0002-1475-7843 NR 8 TC 1 Z9 1 U1 0 U2 2 PU IMPACT JOURNALS LLC PI ALBANY PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA SN 1949-2553 J9 ONCOTARGET JI Oncotarget PD FEB 20 PY 2015 VL 6 IS 5 BP 2585 EP 2586 PG 2 WC Oncology; Cell Biology SC Oncology; Cell Biology GA CF6VK UT WOS:000352694400002 PM 25691064 ER PT J AU Pride, H Yu, Z Sunchu, B Mochnick, J Coles, A Zhang, YQ Buffenstein, R Hornsby, PJ Austad, SN Perez, VI AF Pride, Harrison Yu, Zhen Sunchu, Bharath Mochnick, Jillian Coles, Alexander Zhang, Yiqiang Buffenstein, Rochelle Hornsby, Peter J. Austad, Steven N. Perez, Viviana I. TI Long-lived species have improved proteostasis compared to phylogenetically-related shorter-lived species SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE Protein homeostasis; Autophagy; Proteasome; Heat shock response; Long-lived species ID NAKED MOLE-RAT; PROTEIN HOMEOSTASIS; OXIDATIVE STRESS; LIVING RODENT; LIFE-SPAN; AUTOPHAGY; RESISTANCE; LONGEVITY; FIBROBLASTS; ELEGANS AB Our previous studies have shown that the liver from Naked Mole Rats (NMRs), a long-lived rodent, has increased proteasome activity and lower levels of protein ubiquitination compared to mice. This suggests that protein quality control might play a role in assuring species longevity. To determine whether enhanced proteostasis is a common mechanism in the evolution of other long-lived species, here we evaluated the major players in protein quality control including autophagy, proteasome activity, and heat shock proteins (HSPs), using skin fibroblasts from three phylogenetically-distinct pairs of short- and long-lived mammals: rodents, marsupials, and bats. Our results indicate that in all cases, macroautophagy was significantly enhanced in the longer-lived species, both at basal level and after induction by serum starvation. Similarly, basal levels of most HSPs were elevated in all the longer-lived species. Proteasome activity was found to be increased in the long-lived rodent and marsupial but not in bats. These observations suggest that long-lived species may have superior mechanisms to ensure protein quality, and support the idea that protein homeostasis might play an important role in promoting longevity. (C) 2015 Elsevier Inc. All rights reserved. C1 [Pride, Harrison; Yu, Zhen; Sunchu, Bharath; Mochnick, Jillian; Perez, Viviana I.] Oregon State Univ, Linus Pauling Inst, Corvallis, OR 97331 USA. [Coles, Alexander] Univ Michigan, Dept Chem & Biochem, Flint, MI 48502 USA. [Zhang, Yiqiang; Buffenstein, Rochelle; Hornsby, Peter J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA. [Zhang, Yiqiang; Buffenstein, Rochelle; Hornsby, Peter J.; Austad, Steven N.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Hornsby, Peter J.] South Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78249 USA. [Austad, Steven N.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cell & Struct Biol, San Antonio, TX 78229 USA. [Perez, Viviana I.] Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA. RP Perez, VI (reprint author), Oregon State Univ, Dept Biochem & Biophys, Linus Pauling Inst, 307 Linus Pauling Sci Ctr, Corvallis, OR 97331 USA. EM viviana.perez@oregonstate.edu FU Ellison Medical foundation; American Federation for Aging Research; Comparative Biology of Aging Core in the San Antonio Nathan Shock Center; Linus Pauling Institute; Biochemistry and Biophysics Dept., Oregon State University FX Financial support was provided by Ellison Medical foundation (V.I.P), American Federation for Aging Research (V.I.P), Comparative Biology of Aging Core in the San Antonio Nathan Shock Center, and funds from The Linus Pauling Institute, and Biochemistry and Biophysics Dept., Oregon State University. NR 24 TC 11 Z9 11 U1 2 U2 17 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X EI 1090-2104 J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD FEB 20 PY 2015 VL 457 IS 4 BP 669 EP 675 DI 10.1016/j.bbrc.2015.01.046 PG 7 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA CD1MK UT WOS:000350838800030 PM 25615820 ER PT J AU Jiang, FG Yeh, CK Wen, JC Sun, YY AF Jiang, Fuguang Yeh, Chih-Ko Wen, Jianchuan Sun, Yuyu TI N-trimethylchitosan/Alginate Layer-by-Layer Self Assembly Coatings Act as "Fungal Repellents" to Prevent Biofilm Formation on Healthcare Materials SO ADVANCED HEALTHCARE MATERIALS LA English DT Article ID CANDIDA-ALBICANS BIOFILMS; BIOMEDICAL APPLICATIONS; DRUG-DELIVERY; POLYELECTROLYTE MULTILAYERS; QUATERNIZED CHITOSAN; ALGINATE HYDROGELS; TRIMETHYL CHITOSAN; DENTURE MATERIALS; RESISTANCE; BIOMATERIALS AB Fungal biofilm formation on healthcare materials is a significant clinical concern, often leading to medical-device-related infections, which are difficult to treat. A novel fungal repellent strategy is developed to control fungal biofilm formation. Methylacrylic acid (MAA) is grated onto poly methyl methacrylate (PMMA)-based biomaterials via plasma-initiated grafting polymerization. A cationic polymer, trimethylchitosan (TMC), is synthesized by reacting chitosan with methyl iodide. Sodium alginate (SA) is used as an anionic polymer. TMC/SA multilayers are coated onto the MAA-grafted PMMA via layer-by-layer self-assembly. The TMC/SA multilayer coatings significantly reduce fungal initial adhesion, and effectively prevent fungal biofilm formation. It is concluded that the anti-adhesive property of the surface is due to its hydrophilicity, and that the biofilm-inhibiting action is attributed to the antifungal activity of TMC as well as the chelating function of TMC and SA, which may have acted as fungal repellents. Phosphate buffered saline (PBS)-immersion tests show that the biofilm-modulating effect of the multilayer coatings is stable for more than 4 weeks. Furthermore, the presence of TMC/SA multilayer coatings improves the biocompatibility of the original PMMA, offering a simple, yet effective, strategy for controlling fungal biofilm formation. C1 [Jiang, Fuguang; Wen, Jianchuan; Sun, Yuyu] Univ Massachusetts, Dept Chem, Lowell, MA 01854 USA. [Yeh, Chih-Ko] Univ Texas Hlth Sci Ctr San Antonio, Dept Comprehens Dent, San Antonio, TX 78229 USA. [Yeh, Chih-Ko] South Texas Vet Hlth Care Syst, Audie L Murphy Div, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. RP Sun, YY (reprint author), Univ Massachusetts, Dept Chem, Lowell, MA 01854 USA. EM yuyu_sun@uml.edu FU NIDCR; NIH [R01 DE021084]; VA Merit Review [1I01BX001103] FX This study was supported by NIDCR, NIH (R01 DE021084), and VA Merit Review (1I01BX001103). The authors thank Dr. David Dean (Professor, Comprehensive Dentistry, UTHSCSA) for his careful review and editing of this manuscript. NR 35 TC 8 Z9 9 U1 9 U2 49 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2192-2640 EI 2192-2659 J9 ADV HEALTHC MATER JI Adv. Healthc. Mater. PD FEB 18 PY 2015 VL 4 IS 3 DI 10.1002/adhm.201400428 PG 7 WC Engineering, Biomedical; Nanoscience & Nanotechnology; Materials Science, Biomaterials SC Engineering; Science & Technology - Other Topics; Materials Science GA CB9OQ UT WOS:000349961600015 PM 25295485 ER PT J AU Aspinall, SL Good, CB Zhao, XH Cunningham, FE Heron, BB Geraci, M Passero, V Stone, RA Smith, KJ Rogers, R Shields, J Sartore, M Boyle, DP Giberti, S Szymanski, J Smith, D Ha, A Sessions, J Depcinski, S Fishco, S Molina, I Lepir, T Jean, C Cruz-Diaz, L Motta, J Calderon-Vargas, R Maland, J Keefe, S Tague, M Leone, A Glovack, B Kaplan, B Cosgriff, S Kaster, L Tonnu-Mihara, I Nguyen, K Carmichael, J Clifford, L Lu, K Chatta, G AF Aspinall, Sherrie L. Good, Chester B. Zhao, Xinhua Cunningham, Francesca E. Heron, Bernadette B. Geraci, Mark Passero, Vida Stone, Roslyn A. Smith, Kenneth J. Rogers, Renee Shields, Jenna Sartore, Megan Boyle, D. Patrick Giberti, Sherry Szymanski, John Smith, Doug Ha, Allen Sessions, Jolynn Depcinski, Shawn Fishco, Shane Molina, Irvin Lepir, Tanja Jean, Carmela Cruz-Diaz, Lymaris Motta, Jessica Calderon-Vargas, Rebeca Maland, Janelle Keefe, Sean Tague, Marshall Leone, Alice Glovack, Brian Kaplan, Blair Cosgriff, Sean Kaster, Lindsay Tonnu-Mihara, Ivy Nguyen, Kimmai Carmichael, Jenna Clifford, Linda Lu, Kan Chatta, Gurkamal TI Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans SO BMC CANCER LA English DT Article DE Colon cancer; Chemotherapy; Relative dose intensity; Survival ID INDIVIDUAL PATIENT DATA; 18 RANDOMIZED-TRIALS; COLORECTAL-CANCER; COMORBIDITY; OXALIPLATIN; COHORT; AGE; FLUOROURACIL; BEVACIZUMAB; LEUCOVORIN AB Background: Given the paucity of information on dose intensity, the objective of this study is to describe the use of adjuvant chemotherapy for stage III colon cancer, focusing on relative dose intensity (RDI), overall survival (OS) and disease-free survival (DFS). Methods: Retrospective cohort of 367 patients diagnosed with stage III colon cancer in 2003-2008 and treated at 19 VA medical centers. Kaplan-Meier curves summarize 5-year OS and 3-year DFS by chemotherapy regimen and RDI, and multivariable Cox proportional hazards regression was used to model these associations. Results: 5-fluorouracil/leucovorin (FU/LV) was the most commonly initiated regimen in 2003 (94.4%) and 2004 (62.7%); in 2005-2008, a majority of patients (60%-74%) was started on an oxaliplatin-based regimen. Median RDI was 82.3%. Receipt of >70% RDI was associated with better 5-year OS (p < 0.001) and 3-year DFS (P = 0.009) than was receipt of <= 70% RDI, with 5-year OS rates of 66.3% and 50.5%, respectively and 3-year DFS rates of 66.1% and 52.7%, respectively. In the multivariable analysis of 5-year OS, oxaliplatin + 5-FU/LV (versus 5-FU/LV) (HR = 0.55; 95% CI = 0.34-0.91), >70% RDI at the first year (HR = 0.58; 95% CI = 0.37-0.89) and married status (HR = 0.66; 95% CI = 0.45-0.97) were associated with significantly decreased risk of death, while age >= 75 (versus 55-64) (HR = 2.06; 95% CI = 1.25-3.40), Charlson Comorbidity Index (HR = 1.17; 95% CI = 1.06-1.30), T4 tumor status (versus T1/T2) (HR = 5.88; 95% CI = 2.69-12.9), N2 node status (HR = 1.68; 95% CI = 1.12-2.50) and bowel obstruction (HR = 2.32, 95% CI = 1.36-3.95) were associated with significantly increased risk. Similar associations were observed for DFS. Conclusion: Patients with stage III colon cancer who received >70% RDI had improved 5-year OS. The association between RDI and survival needs to be examined in studies of adjuvant chemotherapy for colon cancer outside of the VA. C1 [Aspinall, Sherrie L.; Good, Chester B.; Cunningham, Francesca E.; Heron, Bernadette B.; Geraci, Mark] VA Pharm Benefits Management Serv, Hines, IL 60141 USA. [Aspinall, Sherrie L.; Good, Chester B.; Zhao, Xinhua; Stone, Roslyn A.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA 15240 USA. [Aspinall, Sherrie L.; Good, Chester B.] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA. [Good, Chester B.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Passero, Vida; Rogers, Renee; Shields, Jenna; Sartore, Megan] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Stone, Roslyn A.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA. [Smith, Kenneth J.] Univ Pittsburgh, Div Clin Modeling & Decis Sci, Pittsburgh, PA USA. [Boyle, D. Patrick; Giberti, Sherry] VA Maine Hlth Care Syst, Augusta, ME USA. [Szymanski, John] VA Connecticut Healthcare Syst, West Haven, CT USA. [Smith, Doug] Martinsburg VA Med Ctr, Martinsburg, WV USA. [Ha, Allen] Richmond VA Med Ctr, Richmond, VA USA. [Sessions, Jolynn] Asheville VA Med Ctr, Asheville, NC USA. [Depcinski, Shawn; Fishco, Shane] James Haley Vet Hosp, Tampa, FL USA. [Molina, Irvin; Lepir, Tanja; Jean, Carmela] Miami VA Med Ctr, Miami, FL USA. [Cruz-Diaz, Lymaris; Motta, Jessica; Calderon-Vargas, Rebeca] VA Caribbean Healthcare Syst, San Juan, PR USA. [Maland, Janelle] Harry S Truman VA Hosp, Columbia, MO USA. [Keefe, Sean] Kansas City VA Med Ctr, Kansas City, MO USA. [Tague, Marshall] Iowa City VA Med Ctr, Iowa City, IA USA. [Leone, Alice] Louis Stokes Cleveland VA Med Ctr, Cleveland, OH USA. [Kaplan, Blair] Jesse Brown VA Med Ctr, Chicago, IL USA. [Cosgriff, Sean] Portland VA Med Ctr, Portland, OR USA. [Kaster, Lindsay] Boise VA Med Ctr, Boise, ID USA. [Tonnu-Mihara, Ivy; Nguyen, Kimmai] Long Beach VA Med Ctr, Long Beach, CA USA. [Carmichael, Jenna; Clifford, Linda] VA Sierra Nevada Hlth Care Syst, Reno, NV USA. [Lu, Kan] Sacramento VA Med Ctr, Mather, CA USA. [Chatta, Gurkamal] Virginia Mason Med Ctr, Seattle, WA 98101 USA. RP Aspinall, SL (reprint author), VA Pharm Benefits Management Serv, Hines, IL 60141 USA. EM sherrie.aspinall@va.gov OI Jean, Carmela/0000-0003-0808-1047 FU VA Pharmacy Benefits Management Services, Hines, IL; VA Pittsburgh Healthcare System, Pittsburgh, PA FX There was no funding support for the work. These findings are the result of work supported in kind by VA Pharmacy Benefits Management Services, Hines, IL, VA Pittsburgh Healthcare System, Pittsburgh, PA, and the other VA medical centers that participated in the study. None of the authors has a relevant financial interest in this manuscript. NR 28 TC 9 Z9 9 U1 0 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2407 J9 BMC CANCER JI BMC Cancer PD FEB 18 PY 2015 VL 15 AR 62 DI 10.1186/s12885-015-1038-y PG 13 WC Oncology SC Oncology GA CC6QY UT WOS:000350493200001 PM 25884851 ER PT J AU Nettiksimmons, J Ayonayon, H Harris, T Phillips, C Rosano, C Satterfield, S Yaffe, K AF Nettiksimmons, Jasmine Ayonayon, Hilsa Harris, Tamara Phillips, Caroline Rosano, Caterina Satterfield, Suzanne Yaffe, Kristine CA Hlth ABC Study TI Development and validation of risk index for cognitive decline using blood-derived markers SO NEUROLOGY LA English DT Article ID CARDIOVASCULAR HEALTH COGNITION; C-REACTIVE PROTEIN; ALZHEIMERS-DISEASE; SERUM-ALBUMIN; OLDER-ADULTS; TELOMERE LENGTH; CYSTATIN-C; A-BETA; DEMENTIA; INTERLEUKIN-6 AB Objective:We sought to develop and validate a risk index for prospective cognitive decline in older adults based on blood-derived markers.Methods:The index was based on 8 markers that have been previously associated with cognitive aging: APOE genotype, plasma -amyloid 42/40 ratio, telomere length, cystatin C, glucose, C-reactive protein, interleukin-6, and albumin. The outcome was person-specific cognitive slopes (Modified Mini-Mental State Examination) from 11 years of follow-up. A total of 1,445 older adults comprised the development sample. An index based on dichotomized markers was divided into low-, medium-, and high-risk categories; the risk categories were validated with the remaining sample (n = 739) using linear regression. Amyloid was measured on a subsample (n = 865) and was included only in a secondary index.Results:The risk categories showed significant differences from each other and were predictive of prospective cognitive decline in the validation sample, even after adjustment for age and baseline cognitive score: the low-risk group (24.8%) declined 0.32 points/y (95% confidence interval [CI]: -0.46, -0.19), the medium-risk group (58.7%) declined 0.55 points/y (95% CI: -0.65, 0.45), and the high-risk group (16.6%) declined 0.69 points/y (95% CI: -0.85, -0.54). Using the secondary index, which included -amyloid 42/40 (validation n = 279), the low-risk group (26.9%) declined 0.20 points/y (95% CI: -0.42, 0.01), the medium-risk group (61.3%) declined 0.55 points/y (95% CI: -0.72, -0.38), and the high-risk group (11.8%) declined 0.83 points/y (95% CI: -1.14, -0.51).Conclusions:A risk index based on 8 blood-based markers was modestly able to predict cognitive decline over an 11-year follow-up. Further validation in other cohorts is necessary. C1 [Nettiksimmons, Jasmine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Ayonayon, Hilsa] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Harris, Tamara] NIA, Lab Epidemiol & Populat Sci, Intramural Res Program, Bethesda, MD 20892 USA. [Phillips, Caroline] NIA, Neuroepidemiol Sect, Bethesda, MD 20892 USA. [Rosano, Caterina] Univ Pittsburgh, Ctr Aging & Populat Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA. [Satterfield, Suzanne] Univ Tennessee, Hlth Sci Ctr, Dept Prevent Med, Knoxville, TN 37996 USA. [Yaffe, Kristine] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Psychiat, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Neurol, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Nettiksimmons, J (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. EM jasmine.nettiksimmons@ucsf.edu RI Newman, Anne/C-6408-2013 OI Newman, Anne/0000-0002-0106-1150; Rosano, Caterina/0000-0002-0909-1506; Rosano, Caterina/0000-0002-4271-6010 FU National Institute on Aging (NIA) [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106]; NIA [R01-AG028050, K24AG031155]; National Institute of Nursing Research [R01-NR012459]; NIH, NIA; American Health Assistance Foundation [A201-0029] FX National Institute on Aging (NIA) contracts N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106; NIA grant R01-AG028050; National Institute of Nursing Research grant R01-NR012459. This research was supported in part by the Intramural Research Program of the NIH, NIA, and by grant A201-0029 from the American Health Assistance Foundation. Dr. Yaffe is supported in part by a NIA grant (K24AG031155). NR 36 TC 2 Z9 3 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD FEB 17 PY 2015 VL 84 IS 7 BP 696 EP 702 DI 10.1212/WNL.0000000000001263 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA CB7XV UT WOS:000349843000014 PM 25609760 ER PT J AU Apostolova, LG Hwang, KS Avila, D Elashoff, D Kohannim, O Teng, E Sokolow, S Jack, CR Jagust, WJ Shaw, L Trojanowski, JQ Weiner, MW Thompson, PM AF Apostolova, Liana G. Hwang, Kristy S. Avila, David Elashoff, David Kohannim, Omid Teng, Edmond Sokolow, Sophie Jack, Clifford R. Jagust, William J. Shaw, Leslie Trojanowski, John Q. Weiner, Michael W. Thompson, Paul M. CA Alzheimer's Dis Neuroimaging TI Brain amyloidosis ascertainment from cognitive, imaging, and peripheral blood protein measures SO NEUROLOGY LA English DT Article ID ALZHEIMERS-DISEASE; HIPPOCAMPAL ATROPHY; NEUROTROPHIC FACTOR; PLASMA CLUSTERIN; IMPAIRMENT; PROGRESSION; INFLAMMATION; BIOMARKERS; GENOTYPE; RISK AB Background:The goal of this study was to identify a clinical biomarker signature of brain amyloidosis in the Alzheimer's Disease Neuroimaging Initiative 1 (ADNI1) mild cognitive impairment (MCI) cohort.Methods:We developed a multimodal biomarker classifier for predicting brain amyloidosis using cognitive, imaging, and peripheral blood protein ADNI1 MCI data. We used CSF -amyloid 1-42 (A(42)) 192 pg/mL as proxy measure for Pittsburgh compound B (PiB)-PET standard uptake value ratio 1.5. We trained our classifier in the subcohort with CSF A(42) but no PiB-PET data and tested its performance in the subcohort with PiB-PET but no CSF A(42) data. We also examined the utility of our biomarker signature for predicting disease progression from MCI to Alzheimer dementia.Results:The CSF training classifier selected Mini-Mental State Examination, Trails B, Auditory Verbal Learning Test delayed recall, education, APOE genotype, interleukin 6 receptor, clusterin, and ApoE protein, and achieved leave-one-out accuracy of 85% (area under the curve [AUC] = 0.8). The PiB testing classifier achieved an AUC of 0.72, and when classifier self-tuning was allowed, AUC = 0.74. The 36-month disease-progression classifier achieved AUC = 0.75 and accuracy = 71%.Conclusions:Automated classifiers based on cognitive and peripheral blood protein variables can identify the presence of brain amyloidosis with a modest level of accuracy. Such methods could have implications for clinical trial design and enrollment in the near future.Classification of evidence:This study provides Class II evidence that a classification algorithm based on cognitive, imaging, and peripheral blood protein measures identifies patients with brain amyloid on PiB-PET with moderate accuracy (sensitivity 68%, specificity 78%). C1 [Apostolova, Liana G.; Hwang, Kristy S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Elashoff, David] Univ Calif Los Angeles, David Geffen Sch Med, Med Stat Core, Los Angeles, CA 90095 USA. [Sokolow, Sophie] Univ Calif Los Angeles, David Geffen Sch Med, Sch Nursing, Los Angeles, CA 90095 USA. [Thompson, Paul M.] Univ So Calif, Keck Sch Med, Inst Neuroinformat, Los Angeles, CA 90033 USA. [Teng, Edmond] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Jack, Clifford R.] Mayo Clin, Dept Diagnost Radiol, Rochester, MN USA. [Jagust, William J.] Univ Calif Berkeley, Dept Publ Hlth & Neurosci, Berkeley, CA 94720 USA. [Shaw, Leslie; Trojanowski, John Q.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. [Weiner, Michael W.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA. [Weiner, Michael W.] Dept Vet Affairs Med Ctr, San Francisco, CA USA. RP Apostolova, LG (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. EM lapostolova@mednet.ucla.edu RI Jack, Clifford/F-2508-2010 OI Jack, Clifford/0000-0001-7916-622X; Preda, Adrian /0000-0003-3373-2438 FU Alzheimer's Disease Neuroimaging Initiative (ADNI) (NIH) [U01 AG024904]; DOD ADNI (Department of Defense) [W81XWH-12-2-0012]; National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering; Canadian Institutes of Health Research; Easton Consortium for Alzheimer's Drug Discovery and Biomarker Development, NIA [R01 AG040770]; NIA [P50 AG16570, R01 AG040060]; NIMH [R01 MH097268]; UCLA Dissertation Year Fellowship; UCLA Medical Scientist Training Program FX Data collection and sharing for this project were funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (NIH grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer's Association; Alzheimer's Drug Discovery Foundation; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.; GE Healthcare; Innogenetics, N.V.; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. The analyses reported in this manuscript were funded by the Easton Consortium for Alzheimer's Drug Discovery and Biomarker Development, NIA R01 AG040770, NIA P50 AG16570. Algorithm development was also supported, in part, by NIMH R01 MH097268 and NIA R01 AG040060 (to P.T.). O.K. was supported, in part, by a UCLA Dissertation Year Fellowship, and by the UCLA Medical Scientist Training Program. NR 39 TC 10 Z9 10 U1 0 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD FEB 17 PY 2015 VL 84 IS 7 BP 729 EP 737 DI 10.1212/WNL.0000000000001231 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA CB7XV UT WOS:000349843000018 PM 25609767 ER PT J AU Zhao, QD Viswanadhapalli, S Williams, P Shi, Q Tan, CY Yi, XL Bhandari, B Abboud, HE AF Zhao, Qingwei David Viswanadhapalli, Suryavathi Williams, Paul Shi, Qian Tan, Chunyan Yi, Xiaolan Bhandari, Basant Abboud, Hanna E. TI NADPH Oxidase 4 Induces Cardiac Fibrosis and Hypertrophy Through Activating Akt/mTOR and NF kappa B Signaling Pathways SO CIRCULATION LA English DT Article DE fibrosis; hypertrophy; mTORC1; NADPH oxidase; NF kappa B; reactive oxygen species ID ENDOTHELIAL GROWTH-FACTOR; TUBULAR EPITHELIAL-CELLS; ANGIOTENSIN-II; OXIDATIVE STRESS; TRANSCRIPTION FACTORS; PROMOTES APOPTOSIS; GENE-EXPRESSION; UP-REGULATION; RAT-HEART; IN-VIVO AB Background-NADPH oxidase 4 (Nox4) has been implicated in cardiac remodeling, but its precise role in cardiac injury remains controversial. Furthermore, little is known about the downstream effector signaling pathways activated by Nox4-derived reactive oxygen species in the myocardium. We investigated the role of Nox4 and Nox4-associated signaling pathways in the development of cardiac remodeling. Methods and Results-Cardiac-specific human Nox4 transgenic mice (c-hNox4Tg) were generated. Four groups of mice were studied: (1) control mice, littermates that are negative for hNox4 transgene but Cre positive; (2) c-hNox4 Tg mice; (3) angiotensin II (AngII)-infused control mice; and (4) c-hNox4Tg mice infused with AngII. The c-hNox4Tg mice exhibited an approximate to 10-fold increase in Nox4 protein expression and an 8-fold increase in the production of reactive oxygen species, and manifested cardiac interstitial fibrosis. AngII infusion to control mice increased cardiac Nox4 expression and induced fibrosis and hypertrophy. The Tg mice receiving AngII exhibited more advanced cardiac remodeling and robust elevation in Nox4 expression, indicating that AngII worsens cardiac injury, at least in part by enhancing Nox4 expression. Moreover, hNox4 transgene and AngII infusion induced the expression of cardiac fetal genes and activated the Akt-mTOR and NF kappa B signaling pathways. Treatment of AngII-infused c-hNox4Tg mice with GKT137831, a Nox4/Nox1 inhibitor, abolished the increase in oxidative stress, suppressed the Akt-mTOR and NF kappa B signaling pathways, and attenuated cardiac remodeling. Conclusions-Upregulation of Nox4 in the myocardium causes cardiac remodeling through activating Akt-mTOR and NF kappa B signaling pathways. Inhibition of Nox4 has therapeutic potential to treat cardiac remodeling. C1 Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Zhao, QD (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Sch Med, Dept Med, 7703 Floyd Curl Dr,MC 7882, San Antonio, TX 78229 USA. EM zhaoq3@uthscsa.edu FU JDRF [4-2010-511]; AHA [11SDG5380002]; [RO1DK033665] FX This work was supported in part by grants from JDRF (Multi-Project grant 4-2010-511), AHA (11SDG5380002), and RO1DK033665. NR 56 TC 28 Z9 29 U1 3 U2 14 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD FEB 17 PY 2015 VL 131 IS 7 BP 643 EP U152 DI 10.1161/CIRCULATIONAHA.114.011079 PG 38 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA CB3OZ UT WOS:000349539200012 PM 25589557 ER PT J AU Torres, A Sibila, O Ferrer, M Polverino, E Menendez, R Mensa, J Gabarrus, A Sellares, J Restrepo, MI Anzueto, A Niederman, MS Agusti, C AF Torres, Antoni Sibila, Oriol Ferrer, Miguel Polverino, Eva Menendez, Rosario Mensa, Josep Gabarrus, Albert Sellares, Jacobo Restrepo, Marcos I. Anzueto, Antonio Niederman, Michael S. Agusti, Caries TI Effect of Corticosteroids on Treatmmt Failure Among Hospitalized Patients With Severe Community-Acquired Pneumonia and High Inflammatory Response A Randomized Clinical Trial SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID HYDROCORTISONE THERAPY; RISK; PROGNOSIS; OUTCOMES; GLUCOCORTICOIDS; DEXAMETHASONE; PREDICTION; GUIDELINES; MORTALITY; PATTERNS AB IMPORTANCE In patients with severe community-acquired pneumonia, treatment failure is associated with excessive inflammatory response and worse outcomes. Corticosteroids may modulate cytokine release in these patients, but the benefit of this adjunctive therapy remains controversial. OBJECTIVE To assess the effect of corticosteroids in patients with severe community-acquired pneumonia and high associated inflammatory response. DESIGN, SETTING, AND PARTICIPANTS Multicenter, randomized, double-blind, placebo-controlled trial conducted in 3 Spanish teaching hospitals involving patients with both severe community-acquired pneumonia and a high inflammatory response, which was defined as a level of C-reactive protein greater than 150 mg/L at admission. Patients were recruited and followed up from June 2004 through February 2012. INTERVENTIONS Patients were randomized to receive either an intravenous bolus of 0.5 mg/kg per 12 hours of methylprednisolone (n = 61) or placebo (n = 59) for 5 days started within 36 hours of hospital admission. MAIN OUTCOMES AND MEASURES The primary outcome was treatment failure (composite outcome of early treatment failure defined as [1] clinical deterioration indicated by development of shock, [2] need for invasive mechanical ventilation not present at baseline, or [3] death within 72 hours of treatment; or composite outcome of late treatment failure defined as [1] radiographic progression, [2] persistence of severe respiratory failure, [3] development of shock, [4] need for invasive mechanical ventilation not present at baseline, or [5] death between 72 hours and 120 hours after treatment initiation; or both early and late treatment failure). In-hospital mortality was a secondary outcome and adverse events were assessed. RESULTS There was less treatment failure among patients from the methylprednisolone group (8 patients [13%]) compared with the placebo group (18 patients [31%]) (P = .02), with a difference between groups of 18% (95% CI, 3% to 32%). Corticosteroid treatment reduced the risk of treatment failure (odds ratio, 0.34 [95% CI, 0.14 to 0.87]; P = .02). In-hospital mortality did not differ between the 2 groups (6 patients [10%] in the methylprednisolone group vs 9 patients [15%] in the placebo group; P = .37); the difference between groups was 5% (95% CI, -6% to 17%). Hyperglycemia occurred in 11 patients (18%) in the methylprednisolone group and in 7 patients (12%) in the placebo group (P = .34). CONCLUSIONS AND RELEVANCE Among patients with severe community-acquired pneumonia and high initial inflammatory response, the acute use of methylprednisolone compared with placebo decreased treatment failure. If replicated, these findings would support the use of corticosteroids as adjunctive treatment in this clinical population. C1 [Torres, Antoni; Ferrer, Miguel; Polverino, Eva; Gabarrus, Albert; Sellares, Jacobo; Agusti, Caries] Hosp Clin Barcelona, Serv Pneumol, Inst Clin Torax, E-08036 Barcelona, Spain. [Torres, Antoni; Ferrer, Miguel; Polverino, Eva; Mensa, Josep; Gabarrus, Albert; Sellares, Jacobo; Agusti, Caries] Inst Invest Biomed August Pi & Sunyer, Barcelona, Spain. [Torres, Antoni; Ferrer, Miguel; Polverino, Eva; Menendez, Rosario; Gabarrus, Albert; Sellares, Jacobo; Agusti, Caries] Ctr Invest Biomed Red Enfermedades Resp, Islas Baleares, Spain. [Torres, Antoni] Univ Barcelona, Barcelona, Spain. [Sibila, Oriol] Hosp Santa Creu & Sant Pau, Serv Pneumol, Barcelona, Spain. [Sibila, Oriol] Inst Invest Biomed St Pau, Barcelona, Spain. [Menendez, Rosario] Hosp Univ La Fe, Serv Neumol, Valencia, Spain. [Mensa, Josep] Hosp Clin Barcelona, Serv Malalties Infeccioses, E-08036 Barcelona, Spain. [Restrepo, Marcos I.; Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Restrepo, Marcos I.; Anzueto, Antonio] South Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. [Restrepo, Marcos I.] VERDICT, San Antonio, TX USA. [Niederman, Michael S.] Winthrop Univ Hosp, Mineola, NY 11501 USA. RP Torres, A (reprint author), Hosp Clin Barcelona, Serv Pneumol, C Villarroel 170, E-08036 Barcelona, Spain. EM atorres@ub.edu RI Menendez, Rosario/G-9723-2016 OI Menendez, Rosario/0000-0002-3592-3839 FU Sociedad Espanola de Neumologia; Societat Catalana de Pneumologia; Fundacio Catalana de Pneumologia; Grup de Recerca de Qualitat de la Generalitat de Catalunya [SGR-2011]; Fondo de Investigacion Sanitaria [PI030113]; Institut dInvestigacions Biomediques August Pi i Sunyer; Centro de Investigacion Biomedica En Red-Enfermedades Respiratorias [CB06/06/0028] FX This study was supported by the Sociedad Espanola de Neumologia, the Societat Catalana de Pneumologia, the Fundacio Catalana de Pneumologia, the Grup de Recerca de Qualitat de la Generalitat de Catalunya (grant SGR-2011), the Fondo de Investigacion Sanitaria (grant PI030113), the Institut dInvestigacions Biomediques August Pi i Sunyer, and the Centro de Investigacion Biomedica En Red-Enfermedades Respiratorias (grant CB06/06/0028). NR 37 TC 91 Z9 102 U1 2 U2 26 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD FEB 17 PY 2015 VL 313 IS 7 BP 677 EP 686 DI 10.1001/jama.2015.88 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA CB2RQ UT WOS:000349476100013 PM 25688779 ER PT J AU Althoff, KN McGinnis, KA Wyatt, CM Freiberg, MS Gilbert, C Oursler, KK Rimland, D Rodriguez-Barradas, MC Dubrow, R Park, LS Skanderson, M Shiels, MS Gange, SJ Gebo, KA Justice, AC AF Althoff, Keri N. McGinnis, Kathleen A. Wyatt, Christina M. Freiberg, Matthew S. Gilbert, Cynthia Oursler, Krisann K. Rimland, David Rodriguez-Barradas, Maria C. Dubrow, Robert Park, Lesley S. Skanderson, Melissa Shiels, Meredith S. Gange, Stephen J. Gebo, Kelly A. Justice, Amy C. CA VACS TI Comparison of Risk and Age at Diagnosis of Myocardial Infarction, End-Stage Renal Disease, and Non-AIDS-Defining Cancer in HIV-Infected Versus Uninfected Adults SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE HIV infection; aging; myocardial infarction; end-stage renal disease; non-AIDS-defining cancers ID HUMAN-IMMUNODEFICIENCY-VIRUS; HIGH PREVALENCE; UNITED-STATES; VETERANS; INDIVIDUALS; COINFECTION; POPULATION; COHORT; CARE; MEN AB Background. Although it has been shown that human immunodeficiency virus (HIV)-infected adults are at greater risk for aging-associated events, it remains unclear as to whether these events happen at similar, or younger ages, in HIV-infected compared with uninfected adults. The objective of this study was to compare the median age at, and risk of, incident diagnosis of 3 age-associated diseases in HIV-infected and demographically similar uninfected adults. Methods. The study was nested in the clinical prospective Veterans Aging Cohort Study of HIV-infected and demographically matched uninfected veterans, from 1 April 2003 to 31 December 2010. The outcomes were validated diagnoses of myocardial infarction (MI), end-stage renal disease (ESRD), and non-AIDS-defining cancer (NADC). Differences in mean age at, and risk of, diagnosis by HIV status were estimated using multivariate linear regression models and Cox proportional hazards models, respectively. Results. A total of 98 687 (31% HIV-infected and 69% uninfected) adults contributed >450 000 person-years and 689 MI, 1135 ESRD, and 4179 NADC incident diagnoses. Mean age at MI (adjusted mean difference, -0.11; 95% confidence interval [CI], -.59 to .37 years) and NADC (adjusted mean difference, -0.10 [95% CI, -.30 to .10] years) did not differ by HIV status. HIV-infected adults were diagnosed with ESRD at an average age of 5.5 months younger than uninfected adults (adjusted mean difference, -0.46 [95% CI, -.86 to -.07] years). HIV-infected adults had a greater risk of all 3 outcomes compared with uninfected adults after accounting for important confounders. Conclusions. HIV-infected adults had a higher risk of these age-associated events, but they occurred at similar ages than those without HIV. C1 [Althoff, Keri N.; Gange, Stephen J.; Gebo, Kelly A.] Johns Hopkins Univ, Baltimore, MD USA. [McGinnis, Kathleen A.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Wyatt, Christina M.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Freiberg, Matthew S.] Vanderbilt Univ Sch Med, Nashville, TN USA. [Gilbert, Cynthia] Vet Affairs Med Ctr, Washington, DC 20422 USA. [Gilbert, Cynthia] George Washington Univ, Med Ctr, Washington, DC 20037 USA. [Oursler, Krisann K.] Salem Vet Affairs Med Ctr, Salem, VA USA. [Oursler, Krisann K.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Rimland, David] Atlanta Vet Affairs Med Ctr, Atlanta, GA USA. [Rimland, David] Emory Univ, Sch Med, Atlanta, GA 30322 USA. [Rodriguez-Barradas, Maria C.] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Houston, TX 77030 USA. [Dubrow, Robert; Park, Lesley S.; Skanderson, Melissa; Justice, Amy C.] Vet Affairs Connecticut Healthcare Syst, New Haven, CT USA. [Dubrow, Robert; Park, Lesley S.; Skanderson, Melissa; Justice, Amy C.] Yale Univ, Sch Med, New Haven, CT USA. [Dubrow, Robert; Park, Lesley S.; Skanderson, Melissa; Justice, Amy C.] Yale Univ, Sch Publ Hlth, New Haven, CT USA. [Shiels, Meredith S.] NCI, Div Canc Epidemiol & Genet, Rockville, MD USA. RP Althoff, KN (reprint author), Johns Hopkins Univ, 615 N Wolfe St,Rm E7142, Baltimore, MD 21231 USA. EM kalthoff@jhu.edu OI Justice, Amy/0000-0003-0139-5502 FU National Institutes of Health: National Institute on Alcohol Abuse and Alcoholism [U24-AA020794, U01-AA020790, U01-AA020795, U01-AA020799, U24-AA022001, U24 AA022007, U10 AA013566-]; National Heart, Lung, and Blood Institute [R01-HL095136, R01-HL090342]; National Institute of Allergy and Infectious Diseases (NIAID) [U01-A1069918]; National Institute of Mental Health [P30-MH062294]; National Institute on Drug Abuse [R01DA035616]; National Cancer Institute (NCI) [R01 CA173754]; Agency for Healthcare Research and Quality [R01-HS018372]; Veterans Health Administration Office of Research and Development [VA REA 08-266]; Office of Academic Affiliations (Medical Informatics Fellowship); NIAID [K01-AI093197]; NCI [F31-CA180775]; National Institute of Diabetes and Digestive and Kidney Diseases [P01-DK056492]; Department of Veterans Affairs, Veterans Health Administration [VA I01 RX000667]; National Cancer Institute FX The Veterans Aging Cohort Study is supported by the National Institutes of Health: National Institute on Alcohol Abuse and Alcoholism (grant numbers U24-AA020794, U01-AA020790, U01-AA020795, U01-AA020799, U24-AA022001, U24 AA022007, U10 AA013566-completed); National Heart, Lung, and Blood Institute (grant numbers R01-HL095136; R01-HL090342); National Institute of Allergy and Infectious Diseases (NIAID) (grant number U01-A1069918); National Institute of Mental Health (grant number P30-MH062294); National Institute on Drug Abuse (grant number R01DA035616); National Cancer Institute (NCI) (grant number R01 CA173754); Agency for Healthcare Research and Quality (grant number R01-HS018372); and the Veterans Health Administration Office of Research and Development (grant number VA REA 08-266, VA IRR Merit Award) and Office of Academic Affiliations (Medical Informatics Fellowship). Additional funding for this work includes K01-AI093197 funded by the NIAID (to K. N. A.), F31-CA180775 funded by the NCI (to L. S. P.), P01-DK056492 funded by the National Institute of Diabetes and Digestive and Kidney Diseases (to C. M. W.), VA I01 RX000667 funded by the Department of Veterans Affairs, Veterans Health Administration (to K. K. O.), and the Intramural Research Program of the National Cancer Institute (to M. S. S.). NR 38 TC 41 Z9 43 U1 1 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB 15 PY 2015 VL 60 IS 4 BP 627 EP 638 DI 10.1093/cid/ciu869 PG 12 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CB6VI UT WOS:000349764400020 PM 25362204 ER PT J AU Estrella, MM Li, M Tin, A Abraham, AG Shlipak, MG Penugonda, S Hussain, SK Palella, FJ Wolinsky, SM Martinson, JJ Parekh, RS Kao, WHL AF Estrella, Michelle M. Li, Man Tin, Adrienne Abraham, Alison G. Shlipak, Michael G. Penugonda, Sudhir Hussain, Shehnaz K. Palella, Frank J., Jr. Wolinsky, Steven M. Martinson, Jeremy J. Parekh, Rulan S. Kao, W. H. Linda TI The Association Between APOL1 Risk Alleles and Longitudinal Kidney Function Differs by HIV Viral Suppression Status SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE HIV; antiretroviral therapy; genetic; kidney disease ID ACTIVE ANTIRETROVIRAL THERAPY; ALLOGRAFT SURVIVAL; AFRICAN-AMERICANS; DISEASE; VARIANTS; NEPHROPATHY; PROGRESSION; GENOTYPE; COHORT; INFECTION AB Background. Existing data suggest that human immunodeficiency virus (HIV)-infected African Americans carrying 2 copies of the APOL1 risk alleles have greater risk of kidney disease than noncarriers. We sought to determine whether HIV RNA suppression mitigates APOL1-related kidney function decline among African Americans enrolled in the Multicenter AIDS Cohort Study. Methods. We genotyped HIV-infected men for the G1 and G2 risk alleles and ancestry informative markers. Mixed-effects models were used to estimate the annual rate of estimated glomerular filtration rate (eGFR) decline, comparing men carrying 2 (high-risk) vs 0-1 risk allele (low-risk). Effect modification by HIV suppression status (defined as HIV type 1 RNA level <400 copies/mL for >90% of follow-up time) was evaluated using interaction terms and stratified analyses. Results. Of the 333 African American men included in this study, 54 (16%) carried the APOL1 high-risk genotype. Among HIV-infected men with unsuppressed viral loads, those with the high-risk genotype had a 2.42 mL/minute/1.73 m(2) (95% confidence interval [CI], -3.52 to -1.32) faster annual eGFR decline than men with the low-risk genotype. This association was independent of age, comorbid conditions, baseline eGFR, ancestry, and HIV-related factors. In contrast, the rate of decline was similar by APOL1 genotype among men with sustained viral suppression (-0.16 mL/minute/1.73 m(2)/year; 95% CI, -.59 to .27; P for interaction <.001). Conclusions. Unsuppressed HIV-infected African Americans with the APOL1 high-risk genotype experience an accelerated rate of kidney function decline; HIV suppression with antiretroviral therapy may reduce these deleterious renal effects. C1 [Estrella, Michelle M.; Parekh, Rulan S.] Johns Hopkins Univ, Dept Med, Sch Med, Baltimore, MD 21205 USA. [Li, Man; Tin, Adrienne; Abraham, Alison G.; Parekh, Rulan S.; Kao, W. H. Linda] Johns Hopkins Univ, Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA. [Shlipak, Michael G.] San Francisco VA Med Ctr, Dept Gen Internal Med, San Francisco, CA USA. [Penugonda, Sudhir; Palella, Frank J., Jr.; Wolinsky, Steven M.] Northwestern Univ, Dept Med, Feinberg Sch Med, Chicago, IL 60611 USA. [Hussain, Shehnaz K.] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA. [Hussain, Shehnaz K.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA USA. [Martinson, Jeremy J.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Infect Dis & Microbiol, Pittsburgh, PA 15260 USA. [Parekh, Rulan S.] Hosp Sick Children, Univ Hlth Network, Toronto, ON M5G 1X8, Canada. [Parekh, Rulan S.] Univ Toronto, Toronto, ON M5S 1A1, Canada. RP Estrella, MM (reprint author), Johns Hopkins Univ, Dept Med, Sch Med, 1830 E Monument St,Ste 416, Baltimore, MD 21205 USA. EM mestrel1@jhmi.edu OI Martinson, Jeremy/0000-0003-4673-7238; Wolinsky, Steven/0000-0002-9625-6697 FU National Institute of Diabetes and Digestive and Kidney Diseases [K23DK081317]; National Kidney Foundation of Maryland; National Heart, Lung, and Blood Institute (NHLBI) [T32HL007024]; Johns Hopkins University Bloomberg School of Public Health [U01-AI35042]; Northwestern University [U01-AI35039]; University of California, Los Angeles [U01-AI35040]; University of Pittsburgh [U01-AI35041]; Center for Analysis and Management of MACS, Johns Hopkins University Bloomberg School of Public Health [UM1-AI35043]; National Institute of Allergy and Infectious Diseases; National Cancer Institute; NHLBI; National Institute on Deafness and Communication Disorders; Johns Hopkins University Institute for Clinical and Translational Research [UL1-TR000424] FX M. M. E. received support for this work from the National Institute of Diabetes and Digestive and Kidney Diseases (grant number K23DK081317) and the National Kidney Foundation of Maryland. A. T. is supported by the National Heart, Lung, and Blood Institute (NHLBI) (Cardiovascular Epidemiology Training grant number T32HL007024). Data in this manuscript were collected by the MACS with centers (principal investigators) at Johns Hopkins University Bloomberg School of Public Health (Joseph Margolick) (grant number U01-AI35042); Northwestern University (Steven M. Wolinsky) (grant number U01-AI35039); University of California, Los Angeles (Roger Detels) (grant number U01-AI35040); University of Pittsburgh (Charles Rinaldo) (grant number U01-AI35041); the Center for Analysis and Management of MACS, Johns Hopkins University Bloomberg School of Public Health (Lisa Jacobson) (grant number UM1-AI35043). The MACS is funded primarily by the National Institute of Allergy and Infectious Diseases, with additional cofunding from the National Cancer Institute. Targeted supplemental funding for specific projects was also provided by the NHLBI and the National Institute on Deafness and Communication Disorders. MACS data collection is also supported by the Johns Hopkins University Institute for Clinical and Translational Research (grant number UL1-TR000424; website located at http://www.statepi.jhsph.edu/macs/macs.html). NR 26 TC 7 Z9 7 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB 15 PY 2015 VL 60 IS 4 BP 646 EP 652 DI 10.1093/cid/ciu765 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CB6VI UT WOS:000349764400022 PM 25281610 ER PT J AU O'Connell, G Guo, G Stricker, J Quinn, LS Ma, A Pistilli, EE AF O'Connell, Grant Guo, Ge Stricker, Janelle Quinn, LeBris S. Ma, Averil Pistilli, Emidio E. TI Muscle-specific deletion of exons 2 and 3 of the IL15RA gene in mice: effects on contractile properties of fast and slow muscles SO JOURNAL OF APPLIED PHYSIOLOGY LA English DT Article DE myokine; fatigue; isometric contractile properties; interleukin ID RECEPTOR-ALPHA-CHAIN; MEMORY T-CELLS; SKELETAL-MUSCLE; INTERLEUKIN-15 RECEPTOR; SOLUBLE IL-15R-ALPHA; IL-15 ACTIVITY; MESSENGER-RNA; MOTOR UNITS; PPAR-DELTA; MDX MICE AB Interleukin-15 (IL-15) is a putative myokine hypothesized to induce an oxidative skeletal muscle phenotype. The specific IL-15 receptor alpha subunit (IL-15R alpha) has also been implicated in specifying this contractile phenotype. The purposes of this study were to determine the muscle-specific effects of IL-15R alpha functional deficiency on skeletal muscle isometric contractile properties, fatigue characteristics, spontaneous cage activity, and circulating IL-15 levels in male and female mice. Muscle creatine kinase (MCK)-driven IL-15R alpha knockout mice (mIl15ra(fl/fl)/Cre(+)) were generated using the Cre-loxP system. We tested the hypothesis that IL-15R alpha functional deficiency in skeletal muscle would increase resistance to contraction-induced fatigue, cage activity, and circulating IL-15 levels. There was a significant effect of genotype on the fatigue curves obtained in extensor digitorum longus (EDL) muscles from female mIl15ra(fl/fl)/Cre(+) mice, such that force output was greater during the repeated contraction protocol compared with mIl15ra(fl/fl)/Cre(+) control mice. Muscles from female mIl15ra(fl/fl)/Cre(+) mice also had a twofold greater amount of the mitochondrial genome-specific COXII gene compared with muscles from mIl15ra(fl/fl)/Cre(+) control mice, indicating a greater mitochondrial density in these skeletal muscles. There was a significant effect of genotype on the twitch: tetanus ratio in EDL and soleus muscles from mIl15ra(fl/fl)/Cre(+) mice, such that the ratio was lower in these muscles compared with mIl15ra(fl/fl)/Cre(+) control mice, indicating a pro-oxidative shift in muscle phenotype. However, spontaneous cage activity was not different and IL-15 protein levels were lower in male and female mIl15ra(fl/fl)/Cre(+) mice compared with control. Collectively, these data support a direct effect of muscle IL-15R alpha deficiency in altering contractile properties and fatigue characteristics in skeletal muscles. C1 [O'Connell, Grant; Guo, Ge; Stricker, Janelle; Pistilli, Emidio E.] W Virginia Univ, Div Exercise Physiol, Morgantown, WV 26506 USA. [Pistilli, Emidio E.] W Virginia Univ, Ctr Cardiovasc & Resp Sci, Morgantown, WV 26506 USA. [Pistilli, Emidio E.] W Virginia Univ, West Virginia Clin & Translat Sci Inst, Morgantown, WV 26506 USA. [Stricker, Janelle] W Virginia Univ, Dept Physiol & Pharmacol, Morgantown, WV 26506 USA. [Quinn, LeBris S.] Geriatr Res Educ & Clin Ctr, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Quinn, LeBris S.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. [Ma, Averil] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. RP Pistilli, EE (reprint author), W Virginia Univ, West Virginia Clin & Translat Sci Inst, Dept Human Performance & Appl Exercise Sci, Ctr Cardiovasc & Resp Sci,Div Exercise Physiol, Morgantown, WV 26506 USA. EM epistilli2@hsc.wvu.edu OI O'Connell, Grant/0000-0002-2642-6670 FU West Virginia University Research Funding Development Grant FX This work was partially supported by the West Virginia University Research Funding Development Grant (E. E. Pistilli). NR 52 TC 3 Z9 3 U1 1 U2 5 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 8750-7587 EI 1522-1601 J9 J APPL PHYSIOL JI J. Appl. Physiol. PD FEB 15 PY 2015 VL 118 IS 4 BP 437 EP 448 DI 10.1152/japplphysiol.00704.2014 PG 12 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA CB6QR UT WOS:000349752100006 PM 25505029 ER PT J AU Roy, A Goodman, JH Begum, G Donnelly, BF Pittman, G Weinman, EJ Sun, D Subramanya, AR AF Roy, Ankita Goodman, Joshua H. Begum, Gulnaz Donnelly, Bridget F. Pittman, Gabrielle Weinman, Edward J. Sun, Dandan Subramanya, Arohan R. TI Generation of WNK1 knockout cell lines by CRISPR/Cas-mediated genome editing SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE WNK1; SLC12 cotransporters; genome editing; CRISPR/Cas system ID K-CL COTRANSPORTER; KELCH-LIKE 3; RETICULUM-ASSOCIATED DEGRADATION; CATION-CHLORIDE COTRANSPORTERS; SENSITIVE NACL COTRANSPORTER; PROTEIN-KINASE; BLOOD-PRESSURE; ANGIOTENSIN-II; HYPERTENSION; MUTATIONS AB Sodium-coupled SLC12 cation chloride cotransporters play important roles in cell volume and chloride homeostasis, epithelial fluid secretion, and renal tubular salt reabsorption. These cotransporters are phosphorylated and activated indirectly by With-No-Lysine (WNK) kinases through their downstream effector kinases, Ste20-and SPS1-related proline alanine-rich kinase (SPAK) and oxidative stress-responsive kinase 1 (OSR1). Multiple WNK kinases can coexist within a single cell type, although their relative contributions to SPAK/OSR1 activation and salt transport remain incompletely understood. Deletion of specific WNKs from cells that natively express a functional WNK-SPAK/OSR1 network will help resolve these knowledge gaps. Here, we outline a simple method to selectively knock out full-length WNK1 expression from mammalian cells using RNA-guided clustered regularly interspaced short palindromic repeats/Cas9 endonucleases. Two clonal cell lines were generated by using a single-guide RNA (sgRNA) targeting exon 1 of the WNK1 gene, which produced indels that abolished WNK1 protein expression. Both cell lines exhibited reduced endogenous WNK4 protein abundance, indicating that WNK1 is required for WNK4 stability. Consistent with an on-target effect, the reduced WNK4 abundance was associated with increased expression of the KLHL3/cullin-3 E3 ubiquitin ligase complex and was rescued by exogenous WNK1 overexpression. Although the morphology of the knockout cells was indistinguishable from control, they exhibited low baseline SPAK/OSR1 activity and failed to trigger regulatory volume increase after hypertonic stress, confirming an essential role for WNK1 in cell volume regulation. Collectively, our data show how this new, powerful, and accessible gene-editing technology can be used to dissect and analyze WNK signaling networks. C1 [Roy, Ankita; Goodman, Joshua H.; Donnelly, Bridget F.; Pittman, Gabrielle; Subramanya, Arohan R.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15261 USA. [Begum, Gulnaz; Sun, Dandan] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA. [Subramanya, Arohan R.] Univ Pittsburgh, Sch Med, Dept Cell Biol, Pittsburgh, PA 15261 USA. [Weinman, Edward J.] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA. [Sun, Dandan; Subramanya, Arohan R.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Subramanya, AR (reprint author), Univ Pittsburgh, Sch Med, Dept Med, Div Renal Electrolyte, S828A Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA. EM ars129@pitt.edu FU National Institute of Health [R01DK098145, P30DK79307, R01 NS038118, NS075995, R01DK55881]; Mid-Level Career Development Award from the US Department of Veterans Affairs; US Department of Veterans Affairs Middleton Award FX The study was supported by National Institute of Health Grants R01DK098145 (to A. R. Subramanya), P30DK79307 (Pittsburgh Center for Kidney Research), R01 NS038118, and NS075995 (to D. Sun), and R01DK55881 (to E.J. Weinman), a Mid-Level Career Development Award from the US Department of Veterans Affairs (to A. R. Subramanya), and funds from a US Department of Veterans Affairs Middleton Award (to E. J. Weinman). NR 54 TC 10 Z9 10 U1 4 U2 24 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X EI 1522-1466 J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD FEB 15 PY 2015 VL 308 IS 4 BP F366 EP F376 DI 10.1152/ajprenal.00612.2014 PG 11 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA CB0CB UT WOS:000349291200010 PM 25477473 ER PT J AU Yehuda, R Flory, JD Bierer, LM Henn-Haase, C Lehrner, A Desarnaud, F Makotkine, I Daskalakis, NP Marmar, CR Meaney, MJ AF Yehuda, Rachel Flory, Janine D. Bierer, Linda M. Henn-Haase, Clare Lehrner, Amy Desarnaud, Frank Makotkine, Iouri Daskalakis, Nikolaos P. Marmar, Charles R. Meaney, Michael J. TI Lower Methylation of Glucocorticoid Receptor Gene Promoter 1(F) in Peripheral Blood of Veterans with Posttraumatic Stress Disorder SO BIOLOGICAL PSYCHIATRY LA English DT Article DE Biomarkers; Combat; Cortisol; Glucocorticoid receptor; HPA axis; Methylation; NR3C1 gene; NR3C1-1(F) promoter; PTSD ID DNA METHYLATION; MAJOR DEPRESSION; CHILDHOOD ABUSE; CORTISOL; DEXAMETHASONE; TRAUMA; NR3C1; SENSITIVITY; SUPPRESSION; INSTRUMENT AB BACKGROUND: Enhanced glucocorticoid receptor (GR) sensitivity is present in people with posttraumatic stress disorder (PTSD), but the molecular mechanisms of GR sensitivity are not understood. Epigenetic factors have emerged as one potential mechanism that account for how trauma exposure leads to sustained PTSD symptoms given that PTSD develops in only a subset of trauma survivors. METHODS: Cytosine methylation of a relevant promoter of the GR gene (NR3C1-1(F) promoter) and three functional neuroendocrine markers of hypothalamic-pituitary-adrenal axis function were examined in a sample of 122 combat veterans. RESULTS: Lower NR3C1-1(F) promoter methylation in peripheral blood mononuclear cells (PBMCs) was observed in combat veterans with PTSD compared with combat-exposed veterans who did not develop PTSD. NR3C1-1(F) promoter methylation was also associated with three functional measures of glucocorticoid activity that have been associated with PTSD in combat veterans: PBMCs' lysozyme inhibition on the lysozyme suppression test, plasma cortisol decline on the low-dose (.50 mg) dexamethasone suppression test, and 24-hour urinary cortisol excretion. Finally, NR3C1-1(F) promoter methylation was inversely correlated with clinical markers and symptoms associated with PTSD. CONCLUSIONS: Alterations in NR3C1-1(F) promoter methylation may reflect enduring changes resulting from combat exposure that lead to functional neuroendocrine alterations. Because epigenetic measures are thought to reflect enduring effects of environmental exposures, they may be useful in distinguishing combat-exposed veterans who do or do not develop PTSD. C1 [Yehuda, Rachel; Flory, Janine D.; Bierer, Linda M.; Lehrner, Amy; Desarnaud, Frank; Makotkine, Iouri; Daskalakis, Nikolaos P.] James J Peters Vet Affairs Med Ctr, Mental Hlth Care Ctr, Bronx, NY USA. [Yehuda, Rachel; Flory, Janine D.; Bierer, Linda M.; Lehrner, Amy; Desarnaud, Frank; Makotkine, Iouri; Daskalakis, Nikolaos P.] Icahn Sch Med Mt Sinai, Traumat Stress Studies Div, New York, NY 10029 USA. [Yehuda, Rachel; Flory, Janine D.; Bierer, Linda M.; Lehrner, Amy; Desarnaud, Frank; Makotkine, Iouri; Daskalakis, Nikolaos P.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Yehuda, Rachel] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA. [Henn-Haase, Clare; Marmar, Charles R.] NYU, Sch Med, Steven & Alexandra Cohen Vet Ctr Study Posttrauma, New York, NY USA. [Henn-Haase, Clare; Marmar, Charles R.] NYU, Sch Med, Dept Psychiat, New York, NY USA. [Meaney, Michael J.] McGill Univ, Sackler Program Epigenet Psychobiol, Montreal, PQ, Canada. [Meaney, Michael J.] McGill Univ, Dept Psychiat & Neurol, Montreal, PQ, Canada. [Meaney, Michael J.] McGill Univ, Dept Neurosurg, Montreal, PQ H3A 2T5, Canada. [Meaney, Michael J.] Singapore Inst Clin Sci, Singapore, Singapore. RP Yehuda, R (reprint author), Icahn Sch Med Mt Sinai, James J Peters Vet Affairs Med Ctr, Traumat Stress Studies Div, Dept Psychiat, 526 OOMH PTSD 116-A,130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM rachel.yehuda@va.gov RI Daskalakis, Nikolaos/B-7930-2014 OI Daskalakis, Nikolaos/0000-0003-1660-9112 FU Department of Defense [W911NF-09-1-0298, W81XWH-09-2-0044, W81XWH-10-1-0021] FX This work was supported by grant funding from the Department of Defense (Grant No. W911NF-09-1-0298 to RY and Grant No. W81XWH-09-2-0044 to CRM). We thank Dr. Owen Wolkowitz for scientific collaboration and for funding that permitted additional recruitment (Department of Defense Grant No. W81XWH-10-1-0021). NR 44 TC 57 Z9 59 U1 5 U2 48 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD FEB 15 PY 2015 VL 77 IS 4 BP 356 EP 364 DI 10.1016/j.biopsych.2014.02.006 PG 9 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA AY9ZL UT WOS:000347906200010 PM 24661442 ER PT J AU O'Donovan, A Cohen, BE Seal, KH Bertenthal, D Margaretten, M Nishimi, K Neylan, TC AF O'Donovan, Aoife Cohen, Beth E. Seal, Karen H. Bertenthal, Dan Margaretten, Mary Nishimi, Kristen Neylan, Thomas C. TI Elevated Risk for Autoimmune Disorders in Iraq and Afghanistan Veterans with Posttraumatic Stress Disorder SO BIOLOGICAL PSYCHIATRY LA English DT Article DE Autoimmune disorders; Glucocorticoids; Immune system; Inflammation; Military sexual trauma; Posttraumatic stress disorder; Traumatic stress; Veterans ID MENTAL-HEALTH DIAGNOSES; SYSTEMIC-LUPUS-ERYTHEMATOSUS; QUALITY-OF-LIFE; RHEUMATOID-ARTHRITIS; MULTIPLE-SCLEROSIS; SEX-DIFFERENCES; HEART-DISEASE; GENDER-DIFFERENCES; IMMUNE FUNCTION; CORTISOL-LEVELS AB BACKGROUND: Posttraumatic stress disorder (PTSD) is associated with endocrine and immune abnormalities that could increase risk for autoimmune disorders. However, little is known about the risk for autoimmune disorders among individuals with PTSD. METHODS: We conducted a retrospective cohort study of 666,269 Iraq and Afghanistan veterans under age 55 who were enrolled in the Department of Veterans Affairs health care system between October 7, 2001, and March 31, 2011. Generalized linear models were used to examine if PTSD, other psychiatric disorders, and military sexual trauma exposure increased risk for autoimmune disorders, including thyroiditis, inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis, and lupus erythematosus, adjusting for age, gender, race, and primary care visits. RESULTS: PTSD was diagnosed in 203,766 veterans (30.6%), and psychiatric disorders other than PTSD were diagnosed in an additional 129,704 veterans (19.5%). Veterans diagnosed with PTSD had significantly higher adjusted relative risk (ARR) for diagnosis with any of the autoimmune disorders alone or in combination compared with veterans with no psychiatric diagnoses (ARR - 2.00; 95% confidence interval, 1.91-2.09) and compared with veterans diagnosed with psychiatric disorders other than PTSD (ARR = 1.51; 95% confidence interval, 1.43-1.59; p < .001). The magnitude of the PTSD-related increase in risk for autoimmune disorders was similar in women and men, and military sexual trauma exposure was independently associated with increased risk in both women and men. CONCLUSIONS: Trauma exposure and PTSD may increase risk for autoimmune disorders. Altered immune function, lifestyle factors, or shared etiology may underlie this association. C1 [O'Donovan, Aoife; Neylan, Thomas C.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. [Cohen, Beth E.; Seal, Karen H.; Margaretten, Mary] Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA. [O'Donovan, Aoife; Cohen, Beth E.; Seal, Karen H.; Bertenthal, Dan; Nishimi, Kristen; Neylan, Thomas C.] San Francisco VA Med Ctr, San Francisco, CA USA. [O'Donovan, Aoife; Cohen, Beth E.; Seal, Karen H.; Bertenthal, Dan; Nishimi, Kristen; Neylan, Thomas C.] Northern Calif Inst Res & Educ, San Francisco, CA USA. RP O'Donovan, A (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, 4150 Clement St 116H, San Francisco, CA 94121 USA. EM aoife.odonovan@ucsf.edu FU Society in Science-The Branco Weiss Fellowship; Mental Illness Research, Education and Clinical Centers Program Director Dr. Thomas Neylan; [NIH-K23 HL 094765-0]; [NIH-KL2TR000143] FX We acknowledge support for the present manuscript from The Mental Illness Research, Education and Clinical Centers; Society in Science-The Branco Weiss Fellowship; and the National Institutes of Health, as well as the Department of Veterans Affairs and the NCIRE-The Veterans Health Research Institute. We also thank Ashkan Ahmadian for his excellent assistance with this manuscript.; Dr. Aoife O'Donovan received salary support from Society in Science-The Branco Weiss Fellowship. Dr. Beth Cohen received salary support through NIH-K23 HL 094765-0. Mr. Dan Bertenthal received grant salary support through grants to Dr. Karen Seal and The Mental Illness Research, Education and Clinical Centers Program Director Dr. Thomas Neylan. Dr. Mary Margaretten received grant support through NIH-KL2TR000143. All other authors reported no biomedical financial interests or potential conflicts of interest. NR 65 TC 22 Z9 22 U1 0 U2 22 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD FEB 15 PY 2015 VL 77 IS 4 BP 365 EP 374 DI 10.1016/j.biopsych.2014.06.015 PG 10 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA AY9ZL UT WOS:000347906200011 PM 25104173 ER PT J AU McLaughlin, KA Koenen, KC Friedman, MJ Ruscio, AM Karam, EG Shahly, V Stein, DJ Hill, ED Petukhova, M Alonso, J Andrade, LH Angermeyer, MC Borges, G de Girolamo, G de Graaf, R Demyttenaere, K Florescu, SE Mladenova, M Posada-Villa, J Scott, KM Takeshima, T Kessler, RC AF McLaughlin, Katie A. Koenen, Karestan C. Friedman, Matthew J. Ruscio, Ayelet Meron Karam, Elie G. Shahly, Victoria Stein, Dan J. Hill, Eric D. Petukhova, Maria Alonso, Jordi Andrade, Laura Helena Angermeyer, Matthias C. Borges, Guilherme de Girolamo, Giovanni de Graaf, Ron Demyttenaere, Koen Florescu, Silvia E. Mladenova, Maya Posada-Villa, Jose Scott, Kate M. Takeshima, Tadashi Kessler, Ronald C. TI Subthreshold Posttraumatic Stress Disorder in the World Health Organization World Mental Health Surveys SO BIOLOGICAL PSYCHIATRY LA English DT Article DE Epidemiology; Nosology; Partial PTSD; Posttraumatic stress disorder; PTSD; Subthreshold PTSD ID PARTIAL PTSD; RISK-FACTORS; FULL PTSD; SYMPTOMS; VETERANS; PREVALENCE; COMMUNITY; WAR; COMORBIDITY; PREDICTORS AB BACKGROUND: Although only a few people exposed to a traumatic event (TE) develop posttraumatic stress disorder (PTSD), symptoms that do not meet full PTSD criteria are common and often clinically significant. Individuals with these symptoms sometimes have been characterized as having subthreshold PTSD, but no consensus exists on the optimal definition of this term. Data from a large cross-national epidemiologic survey are used in this study to provide a principled basis for such a definition. METHODS: The World Health Organization World Mental Health Surveys administered fully structured psychiatric diagnostic interviews to community samples in 13 countries containing assessments of PTSD associated with randomly selected TEs. Focusing on the 23,936 respondents reporting lifetime TE exposure, associations of approximated DSM-5 PTSD symptom profiles with six outcomes (distress-impairment, suicidality, comorbid feardistress disorders, PTSD symptom duration) were examined to investigate implications of different subthreshold definitions. RESULTS: Although consistently highest outcomes for distress-impairment, suicidality, comorbidity, and PTSD symptom duration were observed among the 3.0% of respondents with DSM-5 PTSD rather than other symptom profiles, the additional 3.6% of respondents meeting two or three of DSM-5 criteria B-E also had significantly elevated scores for most outcomes. The proportion of cases with threshold versus subthreshold PTSD varied depending on TE type, with threshold PTSD more common following interpersonal violence and subthreshold PTSD more common following events happening to loved ones. CONCLUSIONS: Subthreshold DSM-5 PTSD is most usefully defined as meeting two or three of DSM-5 criteria B-E. Use of a consistent definition is critical to advance understanding of the prevalence, predictors, and clinical significance of subthreshold PTSD. C1 [McLaughlin, Katie A.] Univ Washington, Dept Psychol, Seattle, WA 98195 USA. [Koenen, Karestan C.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA. [Friedman, Matthew J.] US Dept Vet Affairs, Natl Ctr PTSD, Hanover, NH USA. [Friedman, Matthew J.] Geisel Sch Med Dartmouth, Hanover, NH USA. [Ruscio, Ayelet Meron] Univ Penn, Dept Psychol, Philadelphia, PA 19104 USA. [Karam, Elie G.] Balamand Univ, St George Hosp Univ Med Ctr, Inst Dev Res Advocacy & Appl Care, Med Inst Neuropsychol Disorders,Fac Med, Beirut, Lebanon. [Shahly, Victoria; Hill, Eric D.; Petukhova, Maria; Kessler, Ronald C.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA. [Stein, Dan J.] Univ Cape Town, Dept Psychiat & Mental Hlth, ZA-7925 Cape Town, South Africa. [Alonso, Jordi] Univ Pompeu Fabra, Hlth Serv Res Unit, Inst Hosp Mar Invest Med, Consorcio Invest Biomed Red Epidemiol & Salud Pub, Barcelona, Spain. [Andrade, Laura Helena] Univ Sao Paulo, Sch Med, Sect Psychiat Epidemiology LIM 23, Dept Psychiat, Sao Paulo, Brazil. [Andrade, Laura Helena] Univ Sao Paulo, Sch Med, Inst Psychiat, Sao Paulo, Brazil. [Angermeyer, Matthias C.] Ctr Publ Mental Hlth, Gosing Am Wagram, Austria. [Borges, Guilherme] Natl Inst Psychiat Mexico, Dept Epidemiol Res, Div Epidemiol & Psychosocial Res, Mexico City, DF, Mexico. [Borges, Guilherme] Metropolitan Autonomous Univ, Mexico City, DF, Mexico. [de Girolamo, Giovanni] Ctr S Giovanni di Dio Fatebenefratelli, Ist Ricovero & Cura Carattere Sci, Brescia, Italy. [de Graaf, Ron] Netherlands Inst Mental Hlth & Addict, Utrecht, Netherlands. [Demyttenaere, Koen] Univ Hosp Gasthuisberg, Dept Psychiat, Leuven, Belgium. [Florescu, Silvia E.] Natl Sch Publ Hlth Management & Profess Dev, Hlth Serv Res & Evaluat Ctr, Bulgarian Ctr Human Relat, Bucharest, Romania. [Mladenova, Maya] New Bulgarian Univ, Sofia, Bulgaria. [Posada-Villa, Jose] Univ Colegio Mayor Cundinamarca, Dept Psychiat, Bogota, Colombia. [Scott, Kate M.] Univ Otago, Dept Psychol Med, Dunedin, New Zealand. [Takeshima, Tadashi] Natl Ctr Neurol & Psychiat, Natl Inst Mental Hlth, Kodaira, Tokyo, Japan. RP Kessler, RC (reprint author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA. EM Kessler@hcp.med.harvard.edu RI Alonso, Jordi/A-5514-2010; Koenen, Karestan/K-5402-2014; Andrade, Laura Helena/F-3023-2010 OI Alonso, Jordi/0000-0001-8627-9636; Koenen, Karestan/0000-0003-3293-4281; Andrade, Laura Helena/0000-0002-2362-3521; Borges, Guilherme/0000-0002-3269-0507; McLaughlin, Katie/0000-0002-1362-2410; Stein, Dan/0000-0001-7218-7810 FU National Institute of Mental Health [R01 MH070884, R01 MH093612-01, U01-MH60220]; John D. and Catherine T. MacArthur Foundation; Pfizer Foundation; United States Public Health Service [R13-MH066849, R01-MH069864, R01 DA016558]; Fogarty International Center [FIRCA R03-TW006481]; Pan American Health Organization; Eli Lilly and Company; Ortho-McNeil Pharmaceutical; GlaxoSmithKline; Bristol-Myers Squibb; State of Sao Paulo Research Foundation Thematic Project [03/00204-3]; Ministry of Social Protection; Ministry of Health; National Center for Public Health Protection; European Commission [QLG5-1999-01042, 2004123, 20081308]; Piedmont Region, Italy; Fondo de Investigacion Sanitaria; Instituto de Salud Carlos III, Spain [00/0028]; Ministerio de Ciencia y Tecnologia, Spain [SAF 2000-158-CE]; Departament de Salut, Generalitat de Catalunya, Spain; Instituto de Salud Carlos III [CB06/02/0046, RD06/0011 REM-TAP]; Grant for Research on Psychiatric and Neurological Diseases and Mental Health [H13-SHOGAI-023, H14-TOKUBETSU-026, H16-KOKORO-013]; Japan Ministry of Health, Labour and Welfare; National Institute of Psychiatry Ramon de la Fuente [INPRFMDIES 4280]; National Council on Science and Technology [CONACyT-G30544-H]; PanAmerican Health Organization; New Zealand Ministry of Health, Alcohol Advisory Council; Health Research Council; Ministry of Public Health (former Ministry of Health); Substance Abuse and Mental Health Services Administration; Robert Wood Johnson Foundation [044708]; John W. Alden Trust; Abbott Laboratories; AstraZeneca; Jazz Pharmaceuticals; Johnson Johnson; Lundbeck; Orion; Pfizer; Pharmacia; Roche; Servier; Solvay; Sumitomo; Takeda; Tikvah; Wyeth; Analysis Group; EPIQ; Johnson & Johnson Pharmaceuticals; Ortho-McNeil Janssen Scientific Affairs; Sanofi-Aventis Groupe; Shire; Walgreens; DataStat, Inc FX This work, carried out in conjunction with the World Health Organization World Mental Health (WMH) Survey Initiative, was supported by the National Institute of Mental Health (Grant Nos. R01 MH070884 and R01 MH093612-01), the John D. and Catherine T. MacArthur Foundation, the Pfizer Foundation, the United States Public Health Service (Grant Nos. R13-MH066849, R01-MH069864, and R01 DA016558), the Fogarty International Center (Grant No. FIRCA R03-TW006481), the Pan American Health Organization, Eli Lilly and Company, Ortho-McNeil Pharmaceutical, GlaxoSmithKline, and Bristol-Myers Squibb. We thank the staff of the WMH Data Collection and Data Analysis Coordination Centres for assistance with instrumentation, fieldwork, and consultation on data analysis. None of the funders had any role in the design, analysis, interpretation of results, or preparation of this article. A complete list of all within-country and crossnational WMH publications can be found at http://www.hcp.med.harvard.edu/wmh/.; The Sao Paulo Megacity Mental Health Survey is supported by the State of Sao Paulo Research Foundation Thematic Project Grant No. 03/00204-3. The Colombian National Study of Mental Health is supported by the Ministry of Social Protection. The Bulgarian Epidemiological Study of common mental disorders (EPIBUL) is supported by the Ministry of Health and the National Center for Public Health Protection. The European Study of the Epidemiology of Mental Disorders (ESEMeD) project is funded by the European Commission (Contracts QLG5-1999-01042, Health and Consumer Affairs (SANCO) 2004123, and Executive Agency for Health and Consumers (EACH) 20081308); the Piedmont Region, Italy; Fondo de Investigacion Sanitaria, Instituto de Salud Carlos III, Spain (Grant No. Fund for Health of Spain (FIS) 00/0028); Ministerio de Ciencia y Tecnologia, Spain (Grant No. SAF 2000-158-CE); Departament de Salut, Generalitat de Catalunya, Spain; Instituto de Salud Carlos III (Grant Nos. Networked Biomedical Research Centres (CIBER) CB06/02/0046 and Cooperative Health Research Thematic Networks (RETICS) RD06/0011 REM-TAP); and other local agencies and by an unrestricted educational grant from GlaxoSmithKline. The World Mental Health Japan Survey is supported by the Grant for Research on Psychiatric and Neurological Diseases and Mental Health (Grant Nos. H13-SHOGAI-023, H14-TOKUBETSU-026, and H16-KOKORO-013) from the Japan Ministry of Health, Labour and Welfare. The Mexican National Comorbidity Survey is supported by The National Institute of Psychiatry Ramon de la Fuente (Grant No. INPRFMDIES 4280) and by the National Council on Science and Technology (Grant No. CONACyT-G30544-H), with supplemental support from the PanAmerican Health Organization. Te Rau Hinengaro: The New Zealand Mental Health Survey is supported by the New Zealand Ministry of Health, Alcohol Advisory Council, and Health Research Council. The Romania WMH study projects "Policies in Mental Health Area" and "National Study regarding Mental Health and Services Use" were carried out by the National School of Public Health & Health Services Management (former National Institute for Research & Development in Health, present National School of Public Health Management & Professional Development, Bucharest), with technical support of Metro Media Transilvania, the National Institute of Statistics-National Centre for Training in Statistics, SC, Cheyenne Services SRL, and Statistics Netherlands, and were funded by the Ministry of Public Health (former Ministry of Health) with supplemental support of Eli Lilly Romania SRL. The U.S. National Comorbidity Survey Replication is supported by the National Institute of Mental Health (Grant No. U01-MH60220) with supplemental support from the National Institute of Drug Abuse, the Substance Abuse and Mental Health Services Administration, the Robert Wood Johnson Foundation (Grant No. 044708), and the John W. Alden Trust.; DJS has received research grants or consultancy honoraria or both from Abbott Laboratories, AstraZeneca, Eli Lilly and Company, GlaxoSmithKline, Jazz Pharmaceuticals, Johnson & Johnson, Lundbeck, Orion, Pfizer, Pharmacia, Roche, Servier, Solvay, Sumitomo, Takeda, Tikvah, and Wyeth. KD has served on advisory boards and speaker bureaus for and has research grants from AstraZeneca, Eli Lilly and Company, GlaxoSmithKline, Lundbeck, Takeda, and Servier. RCK has been a consultant for AstraZeneca, Analysis Group, Bristol-Myers Squibb, Cerner Galt, Eli Lilly and Company, GlaxoSmithKline, HealthCore, Health Dialog, Hoffmann-LaRoche, Integrated Benefits Institute, Wellness & Prevention, Inc., John Snow, Inc., Kaiser Permanente, Lake Nona Institute, Matria Healthcare, Mensante, Merck & Co, Ortho-McNeil Janssen Scientific Affairs, Pfizer, Primary Care Network, Research Triangle Institute, Sanofi-Aventis Groupe, Shire, SRA International, Inc., Takeda Global Research & Development, Transcept Pharmaceuticals, and Wyeth-Ayerst; has served on advisory boards for Appliance Computing Ii, Eli Lilly and Company, Mindsite, Ortho-McNeil Janssen Scientific Affairs, Johnson & Johnson, Plus One Health Management, and Wyeth-Ayerst; has had research support for epidemiologic studies from Analysis Group, Bristol-Myers Squibb, Eli Lilly and Company, EPIQ, GlaxoSmithKline, Johnson & Johnson Pharmaceuticals, Ortho-McNeil Janssen Scientific Affairs, Pfizer, Sanofi-Aventis Groupe, Shire, and Walgreens; and owns 25% share in DataStat, Inc. All other authors report no biomedical financial interests or potential conflicts of interest. NR 42 TC 15 Z9 15 U1 3 U2 25 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD FEB 15 PY 2015 VL 77 IS 4 BP 375 EP 384 DI 10.1016/j.biopsych.2014.03.028 PG 10 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA AY9ZL UT WOS:000347906200012 PM 24842116 ER PT J AU McMurray, J Packer, M Desai, A Gong, JJ Greenlaw, N Lefkowitz, M Rizkala, A Shi, V Rouleau, J Solomon, S Swedberg, K Zile, MR Andersen, K Arango, JL Arnold, M Belohlavek, J Bohm, M Boytsov, S Burgess, L Cabrera, W Chen, CH Erglis, A Fu, M Gomez, E Gonzalez, A Hagege, AA Katova, T Kiatchoosakun, S Kim, KS Bayram, E Martinez, F Merkely, B Mendoza, I Mosterd, A Negrusz-Kawecka, M Peuhkurinen, K Ramires, F Refsgaard, J Senni, M Sibulo, AS Silva-Cardoso, J Squire, I Starling, RC Vinereanu, D Teerlink, JR Wong, R AF McMurray, John Packer, Milton Desai, Akshay Gong, Jianjian Greenlaw, Nicola Lefkowitz, Martin Rizkala, Adel Shi, Victor Rouleau, Jean Solomon, Scott Swedberg, Karl Zile, Michael R. Andersen, Karl Arango, Juan Luis Arnold, Malcolm Belohlavek, Jan Boehm, Michael Boytsov, Sergey Burgess, Lesley Cabrera, Walter Chen, Chen-Huan Erglis, Andrejs Fu, Michael Gomez, Efrain Gonzalez, Angel Hagege, Albert-Alain Katova, Tzvetana Kiatchoosakun, Songsak Kim, Kee-Sik Bayram, Edmundo Martinez, Felipe Merkely, Bela Mendoza, Ivan Mosterd, Arend Negrusz-Kawecka, Marta Peuhkurinen, Keijo Ramires, Felix Refsgaard, Jens Senni, Michele Sibulo, Antonio S., Jr. Silva-Cardoso, Jose Squire, Iain Starling, Randall C. Vinereanu, Dragos Teerlink, John R. Wong, Raymond CA PARADIGM-HF Comm Investigators TI A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure SO EUROPEAN HEART JOURNAL LA English DT Article DE Heart failure; Angiotensin II; Natriuretic peptides ID ACTIVE-CONTROL TRIALS; MYOCARDIAL-INFARCTION; RANDOMIZED-TRIAL; NON-INFERIORITY; CAPTOPRIL; INHIBITION; ENALAPRIL; MORTALITY; SURVIVAL; LOSARTAN AB Aims Although active-controlled trials with reninangiotensin inhibitors are ethically mandated in heart failure with reduced ejection fraction, clinicians and regulators often want to know how the experimental therapy would perform compared with placebo. The angiotensin receptor-neprilysin inhibitor LCZ696 was compared with enalapril in PARADIGM-HF. We made indirect comparisons of the effects of LCZ696 with putative placebos. Methods and results We used the treatment-arm of the Studies Of Left Ventricular Dysfunction (SOLVD-T) as the reference trial for comparison of an ACE inhibitor to placebo and the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity-Alternative trial (CHARM-Alternative) as the reference trial for comparison of an ARB to placebo. The hazard ratio of LCZ696 vs. a putative placebo was estimated through the product of the hazard ratio of LCZ696 vs. enalapril (active-control) and that of the historical active-control (enalapril or candesartan) vs. placebo. For the primary composite outcome of cardiovascular death or heart failure hospitalization in PARADIGM-HF, the relative risk reduction with LCZ696 vs. a putative placebo from SOLVD-T was 43% (95%CI 3450%; P < 0.0001) with similarly large effects on cardiovascular death (34%, 2144%; P < 0.0001) and heart failure hospitalization (49%, 3958%; P < 0.0001). For all-cause mortality, the reduction compared with a putative placebo was 28% (95%CI 1539%; P < 0.0001). Putative placebo analyses based on CHARM-Alternative gave relative risk reductions of 39% (95%CI 2748%; P < 0.0001) for the composite outcome of cardiovascular death or heart failure hospitalization, 32% (95%CI 1645%; P < 0.0001) for cardiovascular death, 46% (3356%; P < 0.0001) for heart failure hospitalization, and 26% (95%CI 1139%; P < 0.0001) for all-cause mortality. Conclusion These indirect comparisons of LCZ696 with a putative placebo show that the strategy of combined angiotensin receptor blockade and neprilysin inhibition led to striking reductions in cardiovascular and all-cause mortality, as well as heart failure hospitalization. These benefits were obtained even though LCZ696 was added to comprehensive background beta-blocker and mineralocorticoid receptor antagonist therapy. C1 [McMurray, John] Univ Glasgow, British Heart Fdn Cardiovasc Res Ctr, Glasgow G12 8TA, Lanark, Scotland. [Packer, Milton] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Desai, Akshay; Solomon, Scott] Brigham & Womens Hosp, Cardiovasc Med, Boston, MA 02115 USA. [Gong, Jianjian; Lefkowitz, Martin; Rizkala, Adel; Shi, Victor] Novartis Pharmaceut, E Hanover, NJ USA. [Greenlaw, Nicola] Univ Glasgow, Robertson Ctr Biostat, Glasgow, Lanark, Scotland. [Rouleau, Jean] Univ Montreal, Inst Cardiol, Montreal, PQ, Canada. [Swedberg, Karl] Univ Gothenburg, Dept Mol & Clin Med, Gothenburg, Sweden. [Swedberg, Karl] Univ London Imperial Coll Sci Technol & Med, London, England. [Zile, Michael R.] Med Univ S Carolina, Charles Ezra Daniel Prof Med, RHJ Dept VA Med Ctr, Charleston, SC 29425 USA. [Andersen, Karl] Univ Iceland, Sch Hlth Sci, Cardiovasc Res Ctr, Reykjavik, Iceland. [Arango, Juan Luis] Guatemalan Heart Inst, Guatemala City, Guatemala. [Arnold, Malcolm] Western Univ, Schulich Sch Med & Dent, London Hlth Sci Ctr, Ottawa, ON, Canada. [Belohlavek, Jan] Charles Univ Prague, Dept Med 2, Cardiovasc Med, Gen Teaching Hosp, Prague, Czech Republic. [Belohlavek, Jan] Charles Univ Prague, Sch Med 1, Prague, Czech Republic. [Boehm, Michael] Univ Saarland, Dept Cardiol, Homburg, Germany. [Boytsov, Sergey] Natl Res Ctr Prevent Med, Moscow, Russia. [Burgess, Lesley] Univ Stellenbosch, Cardiol Trial Unit, ZA-7600 Stellenbosch, South Africa. [Cabrera, Walter] Clin Vesalio, Lima, Peru. [Chen, Chen-Huan] Natl Yang Ming Univ, Fac Med, Taipei 112, Taiwan. [Chen, Chen-Huan] Taipei Vet Gen Hosp, Dept Med Educ, Div Fac Dev, Taipei, Taiwan. [Erglis, Andrejs] Univ Latvia, Fac Med, Riga, Latvia. [Fu, Michael] Sahlgrens Univ Hosp, Dept Med, Ostra Hosp, Gothenburg, Sweden. [Gomez, Efrain] Clin Shaio, Bogota, Colombia. [Gonzalez, Angel] Inst Dominicano Cardiol, Santo Domingo, Dominican Rep. [Hagege, Albert-Alain] Georges Pompidou European Hosp, Dept Cardiol, Paris, France. [Katova, Tzvetana] Natl Cardiol Hosp, Dept Noninvas Cardiovasc Imaging & Funct Diagnost, Sofia, Bulgaria. [Kiatchoosakun, Songsak] Khon Kaen Univ, Div Cardiol, Khon Kaen, Thailand. [Kim, Kee-Sik] Daegu Catholic Univ, Med Ctr, Dept Cardiol, Daegu, South Korea. [Bayram, Edmundo] Fdn Cardiovasc Aguascalientes, Ags, Mexico. [Martinez, Felipe] Inst DAMIC Fdn Rusculleda, Cordoba, Argentina. [Merkely, Bela] Semmelweis Univ, Heart & Vasc Ctr, H-1085 Budapest, Hungary. [Mendoza, Ivan] Cent Univ Venezuela, Caracas, Venezuela. [Mosterd, Arend] Meander Med Ctr, Dept Cardiol, Amsterdam, Netherlands. [Negrusz-Kawecka, Marta] Wroclaw Med Univ, Dept & Clin Cardiol, Wroclaw, Poland. [Peuhkurinen, Keijo] Univ Kuopio, Finnish Fdn Cardiovasc Res, FIN-70211 Kuopio, Finland. [Ramires, Felix] Univ Sao Paulo, Sch Med, Heart Inst InCor, Sao Paulo, SP, Brazil. [Refsgaard, Jens] Viborg Hosp, Dept Cardiol, Viborg, Denmark. [Senni, Michele] Osped Papa Giovanni XXIII, Cardiovasc Dept, Cardiol 1, Bergamo, Italy. [Sibulo, Antonio S., Jr.] St Lukes Heart Inst, Manila, Philippines. [Silva-Cardoso, Jose] Porto Med Sch, Oporto, Portugal. [Squire, Iain] Univ Leicester, Leicester, Leics, England. [Squire, Iain] NIHR Cardiovasc Res Unit, Leicester, Leics, England. [Mendoza, Ivan; Starling, Randall C.] Cleveland Clin, Kaufman Ctr Heart Failure, Inst Heart & Vasc, Cleveland, OH 44106 USA. [Vinereanu, Dragos] Univ Med & Pharm Carol Davila Emergency & Univ Ho, Bucharest, Romania. [Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA USA. [Teerlink, John R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Belohlavek, Jan] Natl Univ Hearty Ctr, Dept Cardiol, Singapore, Singapore. RP McMurray, J (reprint author), Univ Glasgow, British Heart Fdn Cardiovasc Res Ctr, 126 Univ Pl, Glasgow G12 8TA, Lanark, Scotland. EM john.mcmurray@glasgow.ac.uk; milton.packer@utsouthwestern.edu RI Ramires, Felix/D-5996-2012; Boytsov, Sergey/M-4486-2014; Drapkina, Oxana/G-8443-2016 OI Ramires, Felix/0000-0003-2437-2485; Boytsov, Sergey/0000-0001-6998-8406; Drapkina, Oxana/0000-0002-4453-8430; mcmurray, john/0000-0002-6317-3975 FU Novartis; University of Glasgow FX The PARADIGM-HF trial with LCZ696 (ClinicalTrials.gov number, NCT01035255) was funded by Novartis. Funding to pay the Open Access publication charges for this article was provided by University of Glasgow. NR 15 TC 25 Z9 27 U1 1 U2 22 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X EI 1522-9645 J9 EUR HEART J JI Eur. Heart J. PD FEB 14 PY 2015 VL 36 IS 7 BP 434 EP 439 DI 10.1093/eurheartj/ehu455 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CE1RG UT WOS:000351589000015 PM 25416329 ER PT J AU McCullough, MB Chou, AF Solomon, JL Petrakis, BA Kim, B Park, AM Benedict, AJ Hamilton, AB Rose, AJ AF McCullough, Megan B. Chou, Ann F. Solomon, Jeffrey L. Petrakis, Beth Ann Kim, Bo Park, Angela M. Benedict, Ashley J. Hamilton, Alison B. Rose, Adam J. TI The interplay of contextual elements in implementation: an ethnographic case study SO BMC HEALTH SERVICES RESEARCH LA English DT Article DE Organizational context; Contextual elements; Quality improvement; Interplay; PARIHS; Implementation ID PARIHS FRAMEWORK; HEALTH-CARE; ANTICOAGULATION CONTROL; QUALITY; WARFARIN; SCIENCE; TRIAL AB Background: Contextual elements have significant impact on uptake of health care innovations. While existing conceptual frameworks in implementation science suggest contextual elements interact with each other, little research has described how this might look in practice. To bridge this gap, this study identifies the interconnected patterns among contextual elements that influence uptake of an anticoagulation clinic improvement initiative. Methods: We completed 51 semi-structured interviews and ethnographic observations across five case study sites involved in an evidence-based practice (EBP) quality improvement initiative. We analyzed data in NVivo 10 using an a priori approach based on the Promoting Action on Research Implementation in Health Services (PARIHS) model and an emergent thematic analysis. Results: Key contextual elements, such as leadership, teamwork, and communication, interacted with each other in contributing to site-level uptake of the EBP, often yielding results that could not be predicted by looking at just one of these elements alone. Sites with context conducive to change in these areas predictably had high uptake, while sites with uniformly weak contextual elements had low uptake. Most sites presented a mixed picture, with contextual elements being strongly supportive of change in some areas and weak or moderate in others. In some cases, we found that sites with strong context in at least one area only needed to have adequate context in other areas to yield high uptake. At other sites, weak context in just one area had the potential to contribute to low uptake, despite countervailing strengths. Even a site with positive views of EBPs could not succeed when context was weak. Conclusion: Interrelationships among different contextual elements can act as barriers to uptake at some sites and as facilitators at others. Accounting for interconnections among elements enables PARIHS to more fully describe the determinants of successful implementation as they operate in real-world settings. C1 [McCullough, Megan B.; Solomon, Jeffrey L.; Petrakis, Beth Ann; Kim, Bo; Rose, Adam J.] ENRM Vet Hosp, VA HSR&D Ctr Healthcare Org & Implementat Res, Bedford, MA 01730 USA. [Chou, Ann F.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA. [Park, Angela M.] VA New England Healthcare Syst, Bedford, MA USA. [Benedict, Ashley J.] VA Sunshine Healthcare Network, St Petersburg, FL USA. [Hamilton, Alison B.] VA Greater Los Angeles, VA HSR&D Ctr Study Healthcare Innovat Implementat, Los Angeles, CA USA. [Hamilton, Alison B.] Univ Calif Los Angeles, Los Angeles, CA USA. [Rose, Adam J.] Boston Univ, Sch Med, Boston, MA 02118 USA. RP McCullough, MB (reprint author), ENRM Vet Hosp, VA HSR&D Ctr Healthcare Org & Implementat Res, Bedford, MA 01730 USA. EM Megan.Mccullough@va.gov FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development [SDP 12-249] FX The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the U.S. government. Funding is from Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development SDP 12-249 (Rose, PI). We would also like to acknowledge the assistance of CHOIR faculty, especially Dr. Carol VanDeusen Lukas as well as Drs. Barbara Bokhour and Rani Elwy. NR 25 TC 2 Z9 2 U1 2 U2 7 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6963 J9 BMC HEALTH SERV RES JI BMC Health Serv. Res. PD FEB 14 PY 2015 VL 15 DI 10.1186/s12913-015-0713-7 PG 12 WC Health Care Sciences & Services SC Health Care Sciences & Services GA CC5WR UT WOS:000350436200001 PM 25890333 ER PT J AU Bokhour, BG Saifu, H Goetz, MB Fix, GM Burgess, J Fletcher, MD Knapp, H Asch, SM AF Bokhour, Barbara G. Saifu, Hemen Goetz, Matthew Bidwell Fix, Gemmae M. Burgess, Jane Fletcher, Michael D. Knapp, Herschel Asch, Steven M. TI The role of evidence and context for implementing a multimodal intervention to increase HIV testing SO IMPLEMENTATION SCIENCE LA English DT Article DE HIV/AIDS; Health promotion/prevention; Qualitative research; Technology adoption/diffusion; Primary care; Implementation ID CLINICAL REMINDERS; BARRIERS AB Background: Increasing the use of routine preventive care such as HIV testing is important, yet implementation of such evidence-based clinical care is complex. The Promoting Action on Research Implementation in Health Services (PARiHS) model for implementation posits that implementation will be most successful when the evidence, context, and facilitation strategies are strong for the clinical practice. We evaluated the relative importance of perceived evidence, context, and facilitation of HIV testing during the implementation of a multimodal intervention in US Department of Veterans Affairs primary care clinics. Methods: A multimodal intervention including clinical reminders (CRs), academic detailing-providing education sessions for providers-and social marketing to improve HIV testing was implemented in 15 VA primary care clinics in three regions. We conducted qualitative formative and process evaluations using semi-structured interviews with HIV lead clinicians, primary care lead clinicians, nurse managers, and social workers. Interviews were analyzed thematically to identify barriers and facilitators to implementation of HIV testing and how these were addressed by the intervention. Sites were then rated high, medium, or low on the dimensions of perceived evidence and the context for testing. We then assessed the relationship of these ratings to improvements in HIV testing rates found in earlier quantitative analyses. Results: Sites that showed greatest improvements in HIV testing rates also rated high on evidence and context. Conversely, sites that demonstrated the poorest improvements in testing rates rated low on both dimensions. Perceptions of evidence and several contextual aspects resulted in both barriers and facilitators to implementing testing. Evidence barriers included provider perceptions of evidence for routine testing as irrelevant to their population. Contextual barriers included clinical reminder overload, insufficient resources, onerous consent processes, stigma, provider discomfort, and concerns about linking individuals who test positive to HIV treatment. While most barriers were ameliorated by the intervention, HIV stigma in particular regions and concerns about linkage to care persisted. Conclusions: Interventions to implement evidence-based practices such as HIV testing can be successful when utilizing proven quality improvement techniques. However, it is critical to address providers' perceptions of evidence and consider aspects of the local context in order to fully implement new routine clinical practices such as HIV testing. C1 [Bokhour, Barbara G.; Saifu, Hemen; Goetz, Matthew Bidwell; Fix, Gemmae M.; Burgess, Jane; Fletcher, Michael D.; Asch, Steven M.] US Dept Vet Affairs, Qual Enhancement Res Initiat HIV & Hepatitis C, Bedford, MA 01730 USA. [Bokhour, Barbara G.; Fix, Gemmae M.] Ctr Healthcare Org & Implementat Res, Concord, MA 01742 USA. [Bokhour, Barbara G.; Fix, Gemmae M.; Fletcher, Michael D.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA. [Saifu, Hemen; Goetz, Matthew Bidwell; Knapp, Herschel] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Burgess, Jane] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA. [Asch, Steven M.] VA Palo Alto Hlth Care Syst, Menlo Pk, CA USA. [Asch, Steven M.] Stanford Univ, Sch Med, Div Gen Med Disciplines, Palo Alto, CA 94304 USA. RP Bokhour, BG (reprint author), US Dept Vet Affairs, Qual Enhancement Res Initiat HIV & Hepatitis C, Bedford, MA 01730 USA. EM Barbara.Bokhour@va.gov OI Fix, Gemmae/0000-0001-6055-4177 NR 22 TC 1 Z9 1 U1 1 U2 8 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1748-5908 J9 IMPLEMENT SCI JI Implement. Sci. PD FEB 13 PY 2015 VL 10 AR 22 DI 10.1186/s13012-015-0214-4 PG 12 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA CC3OV UT WOS:000350259700001 PM 25889388 ER PT J AU Barnes, DE Mehling, W Wu, E Beristianos, M Yaffe, K Skultety, K Chesney, MA AF Barnes, Deborah E. Mehling, Wolf Wu, Eveline Beristianos, Matthew Yaffe, Kristine Skultety, Karyn Chesney, Margaret A. TI Preventing Loss of Independence through Exercise (PLIE): A Pilot Clinical Trial in Older Adults with Dementia SO PLOS ONE LA English DT Article ID MINI-MENTAL-STATE; QUALITY-OF-LIFE; MODERATE ALZHEIMERS-DISEASE; RANDOMIZED-CONTROLLED-TRIAL; TAI CHI; COGNITIVE IMPAIRMENT; OUTCOMES; METAANALYSIS; PERFORMANCE; INVENTORY AB Background Current dementia medications have small effect sizes, many adverse effects and do not change the disease course. Therefore, it is critically important to study alternative treatment strategies. The goal of this study was to pilot-test a novel, integrative group exercise program for individuals with mild-to-moderate dementia called Preventing Loss of Independence through Exercise (PLIE), which focuses on training procedural memory for basic functional movements (e.g., sit-to-stand) while increasing mindful body awareness and facilitating social connection. Methods We performed a 36-week cross-over pilot clinical trial to compare PLIE with usual care (UC) at an adult day program for individuals with dementia in San Francisco, CA. Assessments of physical performance, cognitive function, physical function, dementia-related behaviors, quality of life and caregiver burden were performed by blinded assessors at baseline, 18 weeks (cross-over) and 36 weeks. Our primary outcomes were effect sizes based on between-group comparisons of change from baseline to 18 weeks; secondary outcomes were within-group comparisons of change before and after cross-over. Results Twelve individuals enrolled (7 PLIE, 5 UC) and 2 withdrew (1 PLIE, 18 weeks; 1 UC, 36 weeks). Participants were 82% women (mean age, 84 +/- 4 years); caregivers were 82% daughters (mean age, 56 +/- 13 years). Effect sizes were not statistically significant but suggested potentially clinically meaningful (>= 0.25 SDs) improvement with PLIE versus UC for physical performance (Cohen's D: 0.34 SDs), cognitive function (0.76 SDs) and quality of life (0.83 SDs) as well as for caregiver measures of participant's quality of life (0.33 SDs) and caregiver burden (0.49 SDs). Results were similar when within-group comparisons were made before and after cross-over. Conclusions PLIE is a novel, integrative exercise program that shows promise for improving physical function, cognitive function, quality of life and caregiver burden in individuals with mild-to-moderate dementia. Larger randomized, controlled trials are warranted. C1 [Barnes, Deborah E.; Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Barnes, Deborah E.; Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Barnes, Deborah E.; Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. [Mehling, Wolf] Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA. [Mehling, Wolf; Wu, Eveline; Chesney, Margaret A.] Univ Calif San Francisco, Osher Ctr Integrat Med, San Francisco, CA 94143 USA. [Wu, Eveline] Calif Inst Integral Studies, San Francisco, CA USA. [Beristianos, Matthew] Northern Calif Inst Res & Educ, San Francisco, CA USA. [Beristianos, Matthew] Calif Sch Profess Psychol, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Skultety, Karyn] Inst Aging, San Francisco, CA USA. [Chesney, Margaret A.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. RP Barnes, DE (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. EM Deborah.barnes@ucsf.edu FU UCSF Osher Center for Integrative Medicine FX We thank Drew and Ellen Bradley for their generous support of the UCSF Osher Center for Integrative Medicine, which enabled the development and pilot-testing of the Preventing Loss of Independence through Exercise (PLIE) program. NR 63 TC 4 Z9 4 U1 5 U2 28 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 11 PY 2015 VL 10 IS 2 AR UNSP e0113367 DI 10.1371/journal.pone.0113367 PG 19 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CB3RF UT WOS:000349545300002 PM 25671576 ER PT J AU Tamrat, R Peralta, CA Tajuddin, SM Evans, MK Zonderman, AB Crews, DC AF Tamrat, Ruth Peralta, Carmen A. Tajuddin, Salman M. Evans, Michele K. Zonderman, Alan B. Crews, Deidra C. TI Apolipoprotein L1, income and early kidney damage SO BMC NEPHROLOGY LA English DT Article DE APOL1; Chronic kidney disease; Socioeconomic status; African American; Renal; Albuminuria ID AFRICAN-AMERICANS; APOL1 VARIANTS; SOCIOECONOMIC-STATUS; RACIAL-DIFFERENCES; FUNCTION DECLINE; RENAL-DISEASE; UNITED-STATES; CYSTATIN C; RISK; ASSOCIATION AB Background: The degree to which genetic or environmental factors are associated with early kidney damage among African Americans (AAs) is unknown. Methods: Among 462 AAs in the Healthy Aging in Neighborhoods of Diversity across the Life Span (HANDLS) study, we examined the cross-sectional association between apolipoprotein L1 (APOL1) risk variants and income with: 1) mildly reduced eGFR (<75 mL/min/1.73 m(2), creatinine-cystatin C equation) and 2) elevated urine albumin-to-creatinine ratio (ACR) (>= 17 in men and >= 25 mg/g in women). High risk APOL1 status was defined by 2 copies of high-risk variants; low risk if 0 or 1 copy. Income groups were dichotomized as < $ 14,000/year (lowest income group) or >= $ 14,000/year. Logistic regression models were adjusted for age, sex, and % European ancestry. Results: Overall, participants' mean age was 47 years and 16% (n = 73) had high risk APOL1 status. Mean eGFR was 99 mL/min/1.73 m(2). Mildly reduced eGFR was prevalent among 11% (n = 51). The lowest income group had higher adjusted odds (aOR) of mildly reduced eGFR than the higher income group (aOR 1.8, 95% CI 1.2-2.7). High-risk APOL1 was not significantly associated with reduced eGFR (aOR 1.5, 95% CI 0.9-2.5). Among 301 participants with ACR data, 7% (n = 21) had elevated ACR. Compared to low-risk, persons with high-risk APOL1 had higher odds of elevated ACR (aOR 3.8, 95% CI 2.0-7.3). Income was not significantly associated with elevated ACR (aOR 1.8, 95% CI 0.7-4.5). There were no significant interactions between APOL1 and income. Conclusions: Both genetic and socioeconomic factors may be important determinants of early kidney damage among AAs. C1 [Tamrat, Ruth; Crews, Deidra C.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA. [Peralta, Carmen A.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Peralta, Carmen A.] San Francisco VA Med Ctr, San Francisco, CA USA. [Tajuddin, Salman M.; Evans, Michele K.; Zonderman, Alan B.] NIA, Lab Epidemiol & Populat Sci, NIH, Baltimore, MD 21224 USA. [Crews, Deidra C.] Johns Hopkins Med Inst, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD 21205 USA. [Crews, Deidra C.] Johns Hopkins Med Inst, Ctr Aging & Hlth, Baltimore, MD 21205 USA. [Crews, Deidra C.] Johns Hopkins Univ, Sch Med, Johns Hopkins Bayview Med Ctr, Div Nephrol, Baltimore, MD 21224 USA. RP Crews, DC (reprint author), Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA. EM dcrews1@jhmi.edu OI Zonderman, Alan B/0000-0002-6523-4778; Tajuddin, Salman M./0000-0002-7919-8528 FU Intramural Research Program of the National Institute on Aging, National Institutes of Health (NIH); Robert Wood Johnson Foundation; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [K23DK097184]; Gilbert S. Omenn Anniversary Fellowship of the Institute of Medicine FX This work was supported by the Intramural Research Program of the National Institute on Aging, National Institutes of Health (NIH). Dr. Crews was supported by the Harold Amos Medical Faculty Development Program of the Robert Wood Johnson Foundation, grant K23DK097184 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, and the Gilbert S. Omenn Anniversary Fellowship of the Institute of Medicine. NR 32 TC 2 Z9 2 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2369 J9 BMC NEPHROL JI BMC Nephrol. PD FEB 10 PY 2015 VL 16 AR 14 DI 10.1186/s12882-015-0008-6 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA CD3ET UT WOS:000350961400001 PM 25884165 ER PT J AU Li, CW Concepcion, E Tomer, Y AF Li, Cheuk Wun Concepcion, Erlinda Tomer, Yaron TI Dissecting the role of the foxp3 gene in the joint genetic susceptibility to autoimmune thyroiditis and diabetes: A genetic and functional analysis SO GENE LA English DT Article DE Autoimmune thyroiditis; Type 1 diabetes; FOXP3; Gene splicing; Transcription ID REGULATORY T-CELLS; ORGAN-SPECIFIC AUTOANTIBODIES; LEUCINE-ZIPPER; HASHIMOTOS-THYROIDITIS; 1ST-DEGREE RELATIVES; SPLICE VARIANTS; GRAVES-DISEASE; TARGET GENES; FORK HEAD; TYPE-1 AB We have previously shown that a (TC)(n) microsatellite in intron 5 of the Forkhead Box Protein 3 (FOXP3) gene was associated with a variant of the autoimmune polyglandular syndrome type 3 (APS3v), that is defined as the co-occurrence of type 1 diabetes (T1D) and autoimmune thyroiditis (AITD). Allele 10, containing 25 repeats of the microsatellite (long repeats), is preferentially transmitted to offspring with APS3v, while allele 2, containing 14 repeats of the microsatellite (short repeats), is protective. We hypothesized that the long repeats of the intron 5 microsatellite decrease FOXP3 splicing and function, thereby reducing regulatory T cell activity and promoting the development of APS3v. We cloned genomic DNA from two males hemizygous for the long and short repeats of the microsatellite on their X-chromosomes and transfected them into human embryonic kidney 293 (HEK 293) cells to perform direct splicing analysis. We identified a novel splice variant of FOXP3 lacking exon 6, and showed that it is expressed in human thymus and lymph node. However, the length of the repeats in the microsatellite did not significantly influence the expression of this FOXP3 splice variant in vitro. Interestingly, this splice variant was expressed in human regulatory T cells, suggesting that it may play a role in their function. In conclusion, we identified a novel splice variant FOXP3 Delta 6. The role of its expression in regulatory T cells in the development of autoimmunity remains to be determined. (C) 2014 Elsevier B.V. All rights reserved. C1 [Li, Cheuk Wun; Concepcion, Erlinda; Tomer, Yaron] Icahn Sch Med Mt Sinai, Div Endocrinol, New York, NY 10029 USA. [Tomer, Yaron] James J Peters VA Med Ctr, Bronx, NY USA. RP Li, CW (reprint author), Icahn Sch Med Mt Sinai, Div Endocrinol, One Gustave L Levy Pl,Box 1055, New York, NY 10029 USA. EM cheukwunli@mssm.edu FU NIDDK [DK061659, DK067555, DK073681]; Department of Veterans Affairs FX This work was supported in part by grants DK061659, DK067555 & DK073681 from NIDDK. In addition this material is based upon the work supported in part by the Department of Veterans Affairs. We also thank Dr. Peter Heeger's lab for their generous help on isolating regulatory T cells. NR 78 TC 4 Z9 4 U1 0 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0378-1119 EI 1879-0038 J9 GENE JI Gene PD FEB 10 PY 2015 VL 556 IS 2 BP 142 EP 148 DI 10.1016/j.gene.2014.11.064 PG 7 WC Genetics & Heredity SC Genetics & Heredity GA CB4HW UT WOS:000349589800009 PM 25481456 ER PT J AU Case, MA Burwick, HA Volpp, KG Patel, MS AF Case, Meredith A. Burwick, Holland A. Volpp, Kevin G. Patel, Mitesh S. TI Accuracy of Smartphone Applications and Wearable Devices for Tracking Physical Activity Data SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter C1 [Case, Meredith A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Burwick, Holland A.] Amherst Coll, Amherst, MA 01002 USA. [Volpp, Kevin G.; Patel, Mitesh S.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Patel, MS (reprint author), Univ Penn, 13th Floor Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM mpatel@upenn.edu FU NIA NIH HHS [RC4 AG039114-01] NR 5 TC 71 Z9 72 U1 14 U2 50 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD FEB 10 PY 2015 VL 313 IS 6 BP 625 EP 626 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA CA7AZ UT WOS:000349070700024 PM 25668268 ER PT J AU Chrystal, JG Glover, DL Young, AS Whelan, F Austin, EL Johnson, NK Pollio, DE Holt, CL Stringfellow, E Gordon, AJ Kim, TA Daigle, SG Steward, JL Kertesz, SG AF Chrystal, Joya G. Glover, Dawn L. Young, Alexander S. Whelan, Fiona Austin, Erika L. Johnson, Nancy K. Pollio, David E. Holt, Cheryl L. Stringfellow, Erin Gordon, Adam J. Kim, Theresa A. Daigle, Shanette G. Steward, Jocelyn L. Kertesz, Stefan G. TI Experience of Primary Care among Homeless Individuals with Mental Health Conditions SO PLOS ONE LA English DT Article ID MEDICAL-CARE; PROSPECTIVE COHORT; LOS-ANGELES; ADULTS; QUALITY; ILLNESS; VETERANS; SERVICES; ACCESS; DETOXIFICATION AB The delivery of primary care to homeless individuals with mental health conditions presents unique challenges. To inform healthcare improvement, we studied predictors of favorable primary care experience among homeless persons with mental health conditions treated at sites that varied in degree of homeless-specific service tailoring. This was a multi-site, survey-based comparison of primary care experiences at three mainstream primary care clinics of the Veterans Administration (VA), one homeless-tailored VA clinic, and one tailored non-VA healthcare program. Persons who accessed primary care service two or more times from July 2008 through June 2010 (N = 366) were randomly sampled. Predictor variables included patient and organization characteristics suggested by the patient perception model developed by Sofaer and Firminger (2005), with an emphasis on mental health. The primary care experience was assessed with the Primary Care Quality-Homeless (PCQ-H) questionnaire, a validated survey instrument. Multiple regression identified predictors of positive experiences (i.e. higher PCQ-H total score). Significant predictors of a positive experience included a site offering tailored service design, perceived choice among providers, and currently domiciled status. There was an interaction effect between site and severe psychiatric symptoms. For persons with severe psychiatric symptoms, a homeless-tailored service design was significantly associated with a more favorable primary care experience. For persons without severe psychiatric symptoms, this difference was not significant. This study supports the importance of tailored healthcare delivery designed for homeless persons' needs, with such services potentially holding special relevance for persons with mental health conditions. To improve patient experience among the homeless, organizations may want to deliver services that are tailored to homelessness and offer a choice of providers. C1 [Chrystal, Joya G.; Glover, Dawn L.; Young, Alexander S.] Vet Affairs Greater Los Angeles Healthcare Syst, MIRECC, Los Angeles, CA 90073 USA. [Young, Alexander S.; Whelan, Fiona] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Austin, Erika L.; Johnson, Nancy K.; Daigle, Shanette G.; Steward, Jocelyn L.; Kertesz, Stefan G.] Birmingham Vet Affairs Med Ctr, Ctr Surg Med Acute Care Res & Transit C SMART, Birmingham, AL USA. [Pollio, David E.] Univ Alabama, Sch Social Work, Tuscaloosa, AL USA. [Holt, Cheryl L.] Univ Maryland, Dept Behav & Community Hlth, College Pk, MD 20742 USA. [Stringfellow, Erin] Boston Hlth Care Homeless Program, Boston, MA USA. [Gordon, Adam J.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Gordon, Adam J.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Kim, Theresa A.] Boston Med Ctr, Boston, MA USA. [Kim, Theresa A.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Kertesz, Stefan G.] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA. RP Chrystal, JG (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, MIRECC, Los Angeles, CA 90073 USA. EM Joya.Chrystal@va.gov OI Kim, Theresa/0000-0001-6043-0721; Kertesz, Stefan/0000-0001-6101-8421 FU Department of Veterans Affairs, Health Services Research Development [SDR-11-233, IAA-07-06902]; Desert Pacific Mental Illness Research, Education and Clinical Center (MIRECC); United States Department of Veterans Affairs Research and Development (RD) branch FX Support was provided by the Department of Veterans Affairs, Health Services Research & Development Grants SDR-11-233 and IAA-07-06902, and the Desert Pacific Mental Illness Research, Education and Clinical Center (MIRECC). The United States Department of Veterans Affairs Research and Development (R&D) branch funded this project as part of its competitive merit review program. The Department''s R&D branch functions in a manner similar to the National Institutes of Health (USA), assembling peer review and acting as "funder" and it has no role in design, data collection, analysis or preparation of manuscripts. By regulation the principal investigator must be an employee of the United States Department of Veterans Affairs (typically within a VA Medical Center). Applicable US federal regulations require a formal disclaimer by the author of any VAfunded research, that underscores the separation of the researcher from VA official views: "The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government." Applicants for R&D funds include VA employees (noted with asterisks below) who are eligible to serve as investigator. However, the funder is VA Research and Development. J.G. Chrystal* conceptualized this study, collected data, analyzed and interpreted results, wrote the primary draft of results, and wrote revisions of the article. D.L. Glover* analyzed and interpreted results, and contributed to revisions of the article. A.S. Young* analyzed and interpreted results, and contributed to revisions of the article. F. Whelan* analyzed and interpreted results, and contributed to the primary draft of the article. E.L. Austin* and N.K. Johnson* designed data collection procedures, collected data, analyzed and interpreted results, and contributed to the primary draft of the article. D.E. Pollio designed data collection procedures, analyzed and interpreted results, and contributed to the primary draft of the article. C.L. Holt conceptualized and designed data collection procedures, analyzed and interpreted results, and contributed to the primary draft of the article. E. Stringfellow designed data collection procedures, collected data, analyzed and interpreted results, and contributed to the primary draft of the article. A. J. Gordon* and T.A. Kim conceptualized and designed the primary study, analyzed and interpreted results, and contributed to the primary draft of the article. S.G. Daigle* designed data collection procedures, collected data, analyzed and interpreted results, and contributed to the primary draft of the article. J.L. Steward designed data collection procedures, collected data, and analyzed and interpreted results. S.G. Kertesz* conceptualized and designed the primary study where, designed the data collection procedures, analyzed and interpreted results, and wrote revisions of the article. All authors gave final approval of the article. NR 51 TC 0 Z9 0 U1 1 U2 20 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 6 PY 2015 VL 10 IS 2 AR e0117395 DI 10.1371/journal.pone.0117395 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CB2GK UT WOS:000349444900141 PM 25659142 ER PT J AU Morinelli, TA Walker, LP Velez, JCQ Ullian, ME AF Morinelli, Thomas A. Walker, Linda P. Velez, Juan Carlos Q. Ullian, Michael E. TI Clathrin-dependent internalization of the angiotensin II AT(1A) receptor links receptor internalization to COX-2 protein expression in rat aortic vascular smooth muscle cells SO EUROPEAN JOURNAL OF PHARMACOLOGY LA English DT Article DE Angiotensin II; AT(1A) receptor; NF-kappa B; Cyclooxygenase 2; Clathrin-mediated endocytosis; Vascular smooth muscle cells ID ARRESTIN-BIASED LIGAND; BETA-ARRESTIN; NUCLEAR ACCUMULATION; SIGNAL-TRANSDUCTION; COUPLED RECEPTORS; HEART-FAILURE; ACTIVATION; ENDOCYTOSIS; TRV120027 AB The major effects of Angiutensin II (AngII) in vascular tissue are mediated by AngII AT(1A) receptor activation. Certain effects initiated by AT(1A) receptor activation require receptor internalization. In rat aortic vascular smooth muscle cells (RASMC). AngII stimulates cyclooxygenase 2 protein expression. We have previously shown this is mediated by beta-arrestin-dependent receptor internalization and NF-kappa B activation. In this study, a specific inhibitor of clathrin-mediated endocytosis (CME), pitstop-2, was used to test the hypothesis that clathrin-dependent internalization or activated AT(1A) receptor mediates NF-kappa B activation and subsequent cyclooxygenase 2 expression. Radioligand binding assays, real time qt-PCR and immunoblotting were used to document the effects of pitstop-2 on AngII binding and signaling in RASMC. Laser scanning confocal microscopy (LSCM) was used to image pitstop-2's effects on AT(1) receptor/GFP internalization in HEK-293 cells and p65 NF-kappa B nuclear localization in RASMC. Pitstop-2 significantly inhibited internalization of AT(1A) receptor (44.7% +/- 3.1% Control vs. 13.2% perpendicular to 8.3% Pitstop-2; n=3) as determined by radioligand binding studies in RASMC. Studies utilizing AT(1A) receptor/GFP expressed in HEK 293 cells and LSCM confirmed these findings. Pitstop-2 significantly inhibited AngII-induced p65 NE-kappa B phosphorylation and nuclear localization, COX-2 message and protein expression in RASMC without altering activation of p42/44 ERK or TNF alpha signaling. Pitstop-2, a specific inhibitor of clathrin-mediated endocytosis, confirms that internalization of activated AT(1A) receptor mediates AngII activation of cyclooxygenase 2 expression in RASMC. These data provide support for additional intracellular signaling pathways activated through beta-arrestin mediated internalization of G protein-coupled receptors, such as AT(1A) receptors. (C) 2014 Elsevier By. All rights reserved, C1 [Morinelli, Thomas A.; Walker, Linda P.; Velez, Juan Carlos Q.; Ullian, Michael E.] Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA. [Velez, Juan Carlos Q.; Ullian, Michael E.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Morinelli, TA (reprint author), Med Univ S Carolina, Dept Med, Div Nephrol, 96 Jonathan Lucas St,MSC 629, Charleston, SC 29425 USA. EM morinelt@musc.edu RI Velez, Juan Carlos/N-3782-2016 FU Dialysis Clinic, Incorporated [C-3175] FX This project was supported by funds provided by Dialysis Clinic, Incorporated (#C-3175). The technical assistance of Jessalyn L. Rodgers is gratefully acknowledged. NR 26 TC 1 Z9 1 U1 0 U2 9 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0014-2999 EI 1879-0712 J9 EUR J PHARMACOL JI Eur. J. Pharmacol. PD FEB 5 PY 2015 VL 748 BP 143 EP 148 DI 10.1016/j.ejphar.2014.12.018 PG 6 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA CA3YH UT WOS:000348840500018 PM 25542758 ER PT J AU Rao, VR Lim, LE Fong, D Garga, NI Parko, KL AF Rao, Vikram R. Lim, Leland E. Fong, Dean Garga, Nina I. Parko, Karen L. TI Multicentric Castleman's disease with voltage-gated potassium channel antibody-positive limbic encephalitis: a case report SO BMC NEUROLOGY LA English DT Article DE Castleman's disease; Lymphoproliferative; Limbic encephalitis; Voltage-gated potassium channel; VGKC; Paraneoplastic; Seizure AB Background: Castleman's disease is a rare lymphoproliferative disorder which occurs in localized and multicentric forms and can mimic lymphoma. Despite its well-known association with certain autoimmune diseases, including paraneoplastic pemphigus and myasthenia gravis, Castleman's disease has not previously been associated with limbic encephalitis. Case presentation: We report the case of a 47-year old Caucasian man who presented with subacute onset of constitutional symptoms, diffuse lymphadenopathy, and stereotyped spells involving olfactory aura, nausea, disorientation, and unresponsiveness. He was found to have focal dyscognitive seizures of temporal lobe origin, cerebrospinal fluid with lymphocytic pleocytosis, hyponatremia, and serum positive for voltage-gated potassium channel antibodies, consistent with limbic encephalitis. An extensive infectious workup was unrevealing, but lymph node biopsy revealed multicentric Castleman's disease. His symptoms improved with antiepileptic drugs and immunotherapy. Conclusion: This case highlights the clinical diversity of voltage-gated potassium channel autoimmunity and expands the association of Castleman's disease and autoimmune syndromes to include limbic encephalitis. Clinicians should be aware that paraneoplastic disorders of the central nervous system can be related to underlying hematologic disorders such as Castleman's disease. C1 [Rao, Vikram R.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Lim, Leland E.] Palo Alto Hlth Care Syst, Dept Vet Affairs, Neurol Serv, Palo Alto, CA 94304 USA. [Lim, Leland E.] Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA. [Fong, Dean] Palo Alto Hlth Care Syst 113, Dept Vet Affairs, Pathol & Lab Med Serv, Palo Alto, CA 94304 USA. [Garga, Nina I.; Parko, Karen L.] San Francisco VA Med Ctr, Epilepsy Ctr Excellence, San Francisco, CA 94121 USA. RP Rao, VR (reprint author), Univ Calif San Francisco, Dept Neurol, 400 Parnassus Ave,8th Floor, San Francisco, CA 94143 USA. EM vikram.rao@ucsf.edu NR 17 TC 0 Z9 0 U1 1 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2377 J9 BMC NEUROL JI BMC Neurol. PD FEB 4 PY 2015 VL 15 AR 4 DI 10.1186/s12883-015-0266-8 PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA CB0YA UT WOS:000349352400001 PM 25648431 ER PT J AU Cheng, VWT Piragasam, RS Rothery, RA Maklashina, E Cecchini, G Weiner, JH AF Cheng, Victor W. T. Piragasam, Ramanaguru Siva Rothery, Richard A. Maklashina, Elena Cecchini, Gary Weiner, Joel H. TI Redox State of Flavin Adenine Dinucleotide Drives Substrate Binding and Product Release in Escherichia coli Succinate Dehydrogenase SO BIOCHEMISTRY LA English DT Article ID COVALENTLY BOUND FLAVIN; QUINOL-FUMARATE REDUCTASE; SHEWANELLA-FRIGIDIMARINA NCIMB400; WOLINELLA-SUCCINOGENES QUINOL; VANILLYL-ALCOHOL OXIDASE; IRON-SULFUR CLUSTERS; COMPLEX-II; RESPIRATORY COMPLEX; ELECTRON-TRANSFER; ACTIVE-SITE AB The Complex II family of enzymes, comprising respiratory succinate dehydrogenases and fumarate reductases, catalyzes reversible interconversion of succinate and fumarate. In contrast to the covalent flavin adenine dinucleotide (FAD) cofactor assembled in these enzymes, soluble fumarate reductases (e.g., those from Shewanella frigidimarina) that assemble a noncovalent FAD cannot catalyze succinate oxidation but retain the ability to reduce fumarate. In this study, an SdhA-H45A variant that eliminates the site of the 8 alpha-N3-histidyl covalent linkage between the protein and FAD was examined. Variants SdhA-R286A/K/Y and -H242A/Y that target residues thought to be important for substrate binding and catalysis were also studied. The variants SdhA-H45A and -R286A/K/Y resulted in the assembly of a noncovalent FAD cofactor, which led to a significant decrease (-87 mV or more) in its reduction potential. The variant enzymes were studied by electron paramagnetic resonance spectroscopy following stand-alone reduction and potentiometric titrations. The free and occupied states of the active site were linked to the reduced and oxidized states of FAD, respectively. Our data allow for a proposed model of succinate oxidation that is consistent with tunnel diode effects observed in the succinate dehydrogenase enzyme and a preference for fumarate reduction catalysis in fumarate reductase homologues that assemble a noncovalent FAD. C1 [Cheng, Victor W. T.; Piragasam, Ramanaguru Siva; Rothery, Richard A.; Weiner, Joel H.] Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada. [Maklashina, Elena; Cecchini, Gary] San Francisco VA Med Ctr, Div Mol Biol, San Francisco, CA 94121 USA. [Maklashina, Elena; Cecchini, Gary] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94158 USA. RP Weiner, JH (reprint author), Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada. EM joel.weiner@UAlberta.ca OI Rothery, Richard/0000-0003-3265-1783 FU Canadian Institutes of Health Research [MDP98735]; Department of Veterans Affairs [BX001077]; National Institutes of Health [GM61606] FX This work was supported by the Canadian Institutes of Health Research (Grant MDP98735 to J.H.W.), the Department of Veterans Affairs (Merit Grant BX001077 to G.C.), and the National Institutes of Health (Grant GM61606 to G.C.). NR 68 TC 5 Z9 5 U1 1 U2 28 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0006-2960 J9 BIOCHEMISTRY-US JI Biochemistry PD FEB 3 PY 2015 VL 54 IS 4 BP 1043 EP 1052 DI 10.1021/bi501350j PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA CA6WZ UT WOS:000349059400009 PM 25569225 ER PT J AU Shireman, PK Rasmussen, TE Jaramillo, CA Pugh, MJ AF Shireman, Paula K. Rasmussen, Todd E. Jaramillo, Carlos A. Pugh, Mary Jo TI VA Vascular Injury Study (VAVIS): VA-DoD extremity injury outcomes collaboration SO BMC SURGERY LA English DT Article DE Extremity vascular injury; Limb salvage; Outcomes; Transitions of care; Service members; Veterans; Iraq; Afghanistan ID POPLITEAL ARTERY TRAUMA; ASSESSMENT PROJECT LEAP; DEPRESSIVE SYMPTOMS; CHALLENGING INJURY; BYPASS-SURGERY; MEDICAL-CARE; GLOBAL WAR; AMPUTATION; VETERANS; STATINS AB Background: Limb injuries comprise 50-60% of U.S. Service member's casualties of wars in Afghanistan and Iraq. Combat-related vascular injuries are present in 12% of this cohort, a rate 5 times higher than in prior wars. Improvements in medical and surgical trauma care, including initial in-theatre limb salvage approaches (IILS) have resulted in improved survival and fewer amputations, however, the long-term outcomes such as morbidity, functional decline, and risk for late amputation of salvaged limbs using current process of care have not been studied. The long-term care of these injured warfighters poses a significant challenge to the Department of Defense (DoD) and Department of Veterans Affairs (VA). Methods/Design: The VA Vascular Injury Study (VAVIS): VA-DoD Extremity Injury Outcomes Collaborative, funded by the VA, Health Services Research and Development Service, is a longitudinal cohort study of Veterans with vascular extremity injuries. Enrollment will begin April, 2015 and continue for 3 years. Individuals with a validated extremity vascular injury in the Department of Defense Trauma Registry will be contacted and will complete a set of validated demographic, social, behavioral, and functional status measures during interview and online/mailed survey. Primary outcome measures will: 1) Compare injury, demographic and geospatial characteristics of patients with IILS and identify late vascular surgery related limb complications and health care utilization in Veterans receiving VA vs. non-VA care, 2) Characterize the preventive services received by individuals with vascular repair and related outcomes, and 3) Describe patient-reported functional outcomes in Veterans with traumatic vascular limb injuries. Discussion: This study will provide key information about the current process of care for Active Duty Service members and Veterans with polytrauma/vascular injuries at risk for persistent morbidity and late amputation. The results of this study will be the first step for clinicians in VA and military settings to generate evidence-based treatment and care approaches to these injuries. It will identify areas where rehabilitation medicine and vascular specialty care or telehealth options are needed to allow for better planning, resource utilization, and improved DoD-to-VA care transitions. C1 [Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, Sam & Ann Barshop Inst Longev & Aging Studies, Dept Surg, San Antonio, TX 78229 USA. [Rasmussen, Todd E.] US Combat Casualty Care Res Program, Frederick, MD 20814 USA. [Rasmussen, Todd E.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA. [Jaramillo, Carlos A.] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Healthcare Syst, Dept Rehabil Med, Merton Minter BLVD 7400,Polytrauma Rehabil Ctr, San Antonio, TX 78229 USA. [Pugh, Mary Jo] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Healthcare Syst, Dept Epidemiol & Biostat, 7400 Merton Minter BLVD,Polytrauma Rehabil Ctr, San Antonio, TX 78229 USA. RP Shireman, PK (reprint author), Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, Sam & Ann Barshop Inst Longev & Aging Studies, Dept Surg, San Antonio, TX 78229 USA. EM Shireman@uthscsa.edu; maryjo.pugh2@va.gov FU Veterans Administration [IO1 HX001304]; Department of Defense FX This study is funded by the Veterans Administration IO1 HX001304 and the Department of Defense. In addition to the authors on this manuscript, the VAVIS Collaborators include:; The University of Texas Health Science Center and the South Texas Veterans Health Care System: Mary Bolinger, PhD, Jacqueline A Pugh, MD, Judith Gail Walden, MPH, Polly H Noel, PhD, Blessen Eapen, MD, Lori Pounds, MD, Animesh Agarwal, MD, Chen-Pin Wang, PhD; Central Texas Veterans Health Care System: Laurel Copeland, PhD Veterans Administration Puget Sound: Gayle Reiber, PhD Department of Defense: Jessica Cross Rivera, MD, Diane Miller, BSN, Jean Orman, ScD. NR 57 TC 0 Z9 0 U1 1 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2482 J9 BMC SURG JI BMC Surg. PD FEB 3 PY 2015 VL 15 AR 13 DI 10.1186/1471-2482-15-13 PG 12 WC Surgery SC Surgery GA CA9QW UT WOS:000349260900001 PM 25644593 ER PT J AU Zlatar, ZZ McGregor, KM Towler, S Nocera, JR Dzierzewski, JM Crosson, B AF Zlatar, Zvinka Z. McGregor, Keith M. Towler, Stephen Nocera, Joer R. Dzierzewski, Joseph M. Crosson, Bruce TI Self-reported physical activity and objective aerobic fitness: differential associations with gray matter density in healthy aging SO FRONTIERS IN AGING NEUROSCIENCE LA English DT Article DE physical activity; aerobic fitness; voxel based morphometry; healthy aging; MRI; gray matter density ID OLDER-ADULTS; ALZHEIMERS-DISEASE; MR-IMAGES; EXERCISE; BRAIN; VOLUME; SEDENTARY; RISK; EDUCATION; BEHAVIOR AB Aerobic fitness (AF) and self-reported physical activity (srPA) do not represent the same construct. However, many exercise and brain aging studies interchangeably use AF and srPA measures, which may be problematic with regards to how these metrics are associated with brain outcomes, such as morphology. If AF and PA measures captured the same phenomena, regional brain volumes associated with these measures should directly overlap. This study employed the general linear model to examine the differential association between objectively-measured AF (treadmill assessment) and srPA (questionnaire) with gray matter density (GMd) in 29 cognitively unimpaired community-dwelling older adults using voxel based morphometry. The results show significant regional variance in terms of GMd when comparing AF and srPA as predictors. Higher AF was associated with greater GMd in the cerebellum only, while srPA displayed positive associations with GMd in occipito-temporal, left perisylvian, and frontal regions after correcting for age. Importantly, only AF level, and not srPA, modified the relationship between age and GMd, such that higher levels of AF were associated with increased GMd in older age, while decreased GMd was seen in those with lower AF as a function of age. These results support existing literature suggesting that both AF and PA exert beneficial effects on GMd, but only AF served as a buffer against age-related GMd loss. Furthermore, these results highlight the need for use of objective PA measurement and comparability of tools across studies, since results vary dependent upon the measures used and whether these are objective or subjective in nature. C1 [Zlatar, Zvinka Z.] Univ Calif San Diego, Dept Psychiat, Stein Inst Res Aging, La Jolla, CA 92093 USA. [McGregor, Keith M.; Towler, Stephen; Nocera, Joer R.; Crosson, Bruce] Emory Univ, Dept Neurol, Atlanta, GA 30322 USA. [McGregor, Keith M.; Towler, Stephen; Nocera, Joer R.; Crosson, Bruce] Atlanta VA Med Ctr, Ctr Visual & Neurocognit Rehabil, Decatur, GA USA. [Dzierzewski, Joseph M.] Ctr Geriatr Res Educ & Clin Ctr, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Dzierzewski, Joseph M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Crosson, Bruce] Georgia State Univ, Dept Psychol, Atlanta, GA 30303 USA. RP Zlatar, ZZ (reprint author), Univ Calif San Diego, Dept Psychiat, Stein Inst Res Aging, La Jolla, CA 92093 USA. EM zzlatar@ucsd.edu OI McGregor, Keith/0000-0003-3654-351X FU National Institutes of Health [T32 MH019934-21, T32 AG020499-08, P30 AG028740-03]; Department of Veteran Affairs (VA) Rehabilitation R&D Center of Excellence [F2182C]; Senior Research Career Scientist [B6364L] FX This work was supported by the National Institutes of Health grants T32 MH019934-21; T32 AG020499-08, and P30 AG028740-03 to Zvinka Z. Zlatar. This work was also supported by a Department of Veteran Affairs (VA) Rehabilitation R&D Center of Excellence #F2182C and Senior Research Career Scientist (Bruce Crosson: #B6364L) award. We thank Michael Marsiske, Ph.D. and Todd M. Manini, Ph.D. for their help with this project and all the individuals who participated in this study. NR 50 TC 1 Z9 1 U1 1 U2 17 PU FRONTIERS RESEARCH FOUNDATION PI LAUSANNE PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND SN 1663-4365 J9 FRONT AGING NEUROSCI JI Front. Aging Neurosci. PD FEB 3 PY 2015 VL 7 AR 5 DI 10.3389/fnagi.2015.00005 PG 8 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA CA5XF UT WOS:000348981000001 PM 25691866 ER PT J AU Patel, MS Asch, DA Volpp, KG AF Patel, Mitesh S. Asch, David A. Volpp, Kevin G. TI Wearable Devices as Facilitators, Not Drivers, of Health Behavior Change SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material ID APPS C1 [Patel, Mitesh S.; Asch, David A.; Volpp, Kevin G.] Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. RP Patel, MS (reprint author), 423 Guardian Dr,Blockley Hall,12th Floor, Philadelphia, PA 19104 USA. EM mpatel@upenn.edu NR 6 TC 82 Z9 82 U1 7 U2 40 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD FEB 3 PY 2015 VL 313 IS 5 BP 459 EP 460 DI 10.1001/jama.2014.14781 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA CA7AV UT WOS:000349070300005 PM 25569175 ER PT J AU Merkow, RP Ju, MH Chung, JW Hall, BL Cohen, ME Williams, MV Tsai, TC Ko, CY Bilimoria, KY AF Merkow, Ryan P. Ju, Mila H. Chung, Jeanette W. Hall, Bruce L. Cohen, Mark E. Williams, Mark V. Tsai, Thomas C. Ko, Clifford Y. Bilimoria, Karl Y. TI Underlying Reasons Associated With Hospital Readmission Following Surgery in the United States SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID QUALITY IMPROVEMENT PROGRAM; SURGICAL-CARE; MEDICARE BENEFICIARIES; 30-DAY READMISSION; AMERICAN-COLLEGE; PATIENT EXPERIENCE; HEART-FAILURE; RISK-FACTORS; RATES; SITE AB IMPORTANCE Financial penalties for readmission have been expanded beyond medical conditions to include surgical procedures. Hospitals are working to reduce readmissions; however, little is known about the reasons for surgical readmission. OBJECTIVE To characterize the reasons, timing, and factors associated with unplanned postoperative readmissions. DESIGN, SETTING, AND PARTICIPANTS Patients undergoing surgery at one of 346 continuously enrolled US hospitals participating in the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) between January 1, 2012, and December 31, 2012, had clinically abstracted information examined. Readmission rates and reasons (ascertained by clinical data abstractors at each hospital) were assessed for all surgical procedures and for 6 representative operations: bariatric procedures, colectomy or proctectomy, hysterectomy, total hip or knee arthroplasty, ventral hernia repair, and lower extremity vascular bypass. MAIN OUTCOMES AND MEASURES Unplanned 30day readmission and reason for readmission. RESULTS The unplanned readmission rate for the 498 875 operations was 5.7%. For the individual procedures, the readmission rate ranged from 3.8% for hysterectomy to 14.9% for lower extremity vascular bypass. The most common reason for unplanned readmission was surgical site infection (SSI) overall (19.5%) and also after colectomy or proctectomy (25.8%), ventral hernia repair (26.5%), hysterectomy (28.8%), arthroplasty (18.8%), and lower extremity vascular bypass (36.4%). Obstruction or ileus was the most common reason for readmission after bariatric surgery (24.5%) and the second most common reason overall (10.3%), after colectomy or proctectomy (18.1%), ventral hernia repair (16.7%), and hysterectomy (13.4%). Only 2.3% of patients were readmitted for the same complication they had experienced during their index hospitalization. Only 3.3% of patients readmitted for SSIs had experienced an SSI during their index hospitalization. There was no time pattern for readmission, and early (<= 7 days postdischarge) and late (> 7 days postdischarge) readmissions were associated with the same 3 most common reasons: SSI, ileus or obstruction, and bleeding. Patient comorbidities, index surgical admission complications, nonhome discharge (hazard ratio [HR], 1.40 [95% CI, 1.351.46]), teaching hospital status (HR, 1.14 [95% CI 1.071.21]), and higher surgical volume (HR, 1.15 [95% CI, 1.071.25]) were associated with a higher risk of hospital readmission. CONCLUSIONS AND RELEVANCE Readmissions after surgery were associated with new postdischarge complications related to the procedure and not exacerbation of prior index hospitalization complications, suggesting that readmissions after surgery are a measure of postdischarge complications. These data should be considered when developing quality indicators and any policies penalizing hospitals for surgical readmission. C1 [Merkow, Ryan P.; Ju, Mila H.; Hall, Bruce L.; Cohen, Mark E.; Ko, Clifford Y.; Bilimoria, Karl Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL USA. [Merkow, Ryan P.; Ju, Mila H.; Chung, Jeanette W.; Bilimoria, Karl Y.] Northwestern Univ, Feinberg Sch Med, Dept Surg, SOQIC, Chicago, IL 60611 USA. [Merkow, Ryan P.; Ju, Mila H.; Chung, Jeanette W.; Bilimoria, Karl Y.] Northwestern Univ, Feinberg Sch Med, Ctr Healthcare Studies, Chicago, IL 60611 USA. [Merkow, Ryan P.; Ju, Mila H.; Chung, Jeanette W.; Bilimoria, Karl Y.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Northwestern Inst Comparat Effectiveness Res Onco, SOQIC, Chicago, IL 60611 USA. [Merkow, Ryan P.] Univ Chicago, Dept Surg, Div Biol Sci, Chicago, IL 60637 USA. [Hall, Bruce L.] Washington Univ, Sch Med, Dept Surg, Barnes Jewish Hosp, St Louis, MO 63110 USA. [Hall, Bruce L.] Washington Univ, Ctr Hlth Policy, Olin Business Sch, St Louis, MO USA. [Hall, Bruce L.] John Cochran Vet Affairs Med Ctr, Dept Surg, St Louis, MO USA. [Hall, Bruce L.] BJC Healthcare, St Louis, MO USA. [Williams, Mark V.] Univ Kentucky, Dept Internal Med, Ctr Hlth Serv Res, Lexington, KY 40506 USA. [Tsai, Thomas C.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA. [Tsai, Thomas C.] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Bilimoria, KY (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Surg, SOQIC, 633 N St Clair St,20th Floor, Chicago, IL 60611 USA. EM k-bilimoria@northwestern.edu FU American College of Surgeons Clinical Scholars in Residence Program; Northwestern Institute for Comparative Effectiveness Research in Oncology (NICER-Onc); National Institutes of Health (NIH) [5T32HL094293]; NIH; Agency for Healthcare Research and Quality; American Cancer Society; National Comprehensive Cancer Network; American College of Surgeons; American Board of Surgery; Accreditation Council for Graduate Medical Education; Health Care Services Corporation; Robert H. Lurie Cancer Center of Northwestern University FX Dr Merkow is supported by the American College of Surgeons Clinical Scholars in Residence Program and the Northwestern Institute for Comparative Effectiveness Research in Oncology (NICER-Onc). Dr Ju is supported by the American College of Surgeons Clinical Scholars in Residence Program and National Institutes of Health (NIH) grant 5T32HL094293. Dr Hall is a consultant to the American College of Surgeons. Dr Bilimoria reported support from the NIH, Agency for Healthcare Research and Quality, American Cancer Society, National Comprehensive Cancer Network, American College of Surgeons, American Board of Surgery, Accreditation Council for Graduate Medical Education, Health Care Services Corporation, and the Robert H. Lurie Cancer Center of Northwestern University. NR 48 TC 116 Z9 116 U1 1 U2 23 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD FEB 3 PY 2015 VL 313 IS 5 BP 483 EP 495 DI 10.1001/jama.2014.18614 PG 13 WC Medicine, General & Internal SC General & Internal Medicine GA CA7AV UT WOS:000349070300012 PM 25647204 ER PT J AU Nguyen, VH Roger, BA Dergalust, S Wasterlain, CG AF Nguyen, V. -H. Roger, B. A. Dergalust, S. Wasterlain, C. G. TI TIME-DEPENDENT EFFECTS OF LACOSAMIDE, KETAMINE AND COMBINATION KETAMINE AND DIAZEPAM TREATMENT IN A RAT LITHIUM-PILOCARPINE MODEL OF STATUS EPILEPTICUS SO EPILEPSIA LA English DT Meeting Abstract CT 31st International Epilepsy Congress CY SEP 05-09, 2015 CL Istanbul, TURKEY C1 [Nguyen, V. -H.; Dergalust, S.] VA Greater Los Angeles Healthcare Syst, Neurol & Pharm, Los Angeles, CA USA. [Roger, B. A.; Wasterlain, C. G.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Wasterlain, C. G.] Univ Calif Los Angeles, Neurol, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0013-9580 EI 1528-1167 J9 EPILEPSIA JI Epilepsia PD FEB PY 2015 VL 56 SU 1 SI SI MA p1054 BP 258 EP 258 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA CX5QG UT WOS:000365756500783 ER PT J AU Lee, JXW Patel, AM Pham, AQ Lee, ST Flores, JB Yusin, JS AF Lee, Joyce X. W. Patel, Anil M. Pham, Andrew Q. Lee, Sabrina T. Flores, Jeffrey B. Yusin, Joseph S. TI Long-Term Adherence to Self-Injectable Epinephrine Prescription SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI) CY FEB 20-24, 2015 CL Houston, TX SP Amer Acad Allergy, Asthma & Immunol C1 [Lee, Joyce X. W.; Patel, Anil M.; Pham, Andrew Q.; Lee, Sabrina T.; Flores, Jeffrey B.; Yusin, Joseph S.] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2015 VL 135 IS 2 SU S MA 762 BP AB236 EP AB236 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA CR2BN UT WOS:000361129600761 ER PT J AU Olson, AA Manthei, DM Kim, C Mathur, SK AF Olson, Ashleigh A. Manthei, David M. Kim, Chloe Mathur, Sameer K. TI Significance of Food Skin Prick Testing in Adult Eosinophilic Esophagitis Patients SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI) CY FEB 20-24, 2015 CL Houston, TX SP Amer Acad Allergy, Asthma & Immunol C1 [Olson, Ashleigh A.; Manthei, David M.; Kim, Chloe; Mathur, Sameer K.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA. [Mathur, Sameer K.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2015 VL 135 IS 2 SU S MA 131 BP AB42 EP AB42 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA CR2BN UT WOS:000361129600132 ER PT J AU Patel, AM Yusin, JS AF Patel, Anil M. Yusin, Joseph S. TI Role of Patient Education in the Management and Control of Asthma in the Adult Population SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI) CY FEB 20-24, 2015 CL Houston, TX SP Amer Acad Allergy, Asthma & Immunol C1 [Patel, Anil M.; Yusin, Joseph S.] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2015 VL 135 IS 2 SU S MA 220 BP AB68 EP AB68 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA CR2BN UT WOS:000361129600221 ER PT J AU Heisler, JM Morales, J Donegan, JJ Jett, JD Redus, L O'Connor, JC AF Heisler, Jillian M. Morales, Juan Donegan, Jennifer J. Jett, Julianne D. Redus, Laney O'Connor, Jason C. TI The Attentional Set Shifting Task: A Measure of Cognitive Flexibility in Mice SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS LA English DT Article DE Behavior; Issue 96; cognitive flexibility; prefrontal cortex; behavior; attention; mouse; neuropsychiatric symptom; cognitive dysfunction ID PREFRONTAL CORTEX; LESIONS; RAT AB Cognitive impairment, particularly involving dysfunction of circuitry within the prefrontal cortex (PFC), represents a core feature of many neuropsychiatric and neurodevelopmental disorders, including depression, post-traumatic stress disorder, schizophrenia and autism spectrum disorder. Deficits in cognitive function also represent the most difficult symptom domain to successfully treat, as serotonin reuptake inhibitors and tricyclic antidepressants have only modest effects. Functional neuroimaging studies and postmortem analysis of human brain tissue implicate the PFC as being a primary region of dysregulation in patients with these disorders. However, preclinical behavioral assays used to assess these deficits in mouse models which can be readily manipulated genetically and could provide the basis for studies of new treatment avenues have been underutilized. Here we describe the adaptation of a behavioral assay, the attentional set shifting task (AST), to be performed in mice to assess prefrontal cortex mediated cognitive deficits. The neural circuits underlying behavior during the AST are highly conserved across humans, nonhuman primates and rodents, providing excellent face, construct and predictive validity. C1 [Heisler, Jillian M.; Morales, Juan; Donegan, Jennifer J.; Jett, Julianne D.; Redus, Laney; O'Connor, Jason C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. [O'Connor, Jason C.] South Texas Vet Hlth Care Syst, Audie L Murphy VA Hosp, San Antonio, TX USA. RP O'Connor, JC (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. EM oconnorj@uthscsa.edu FU National Institute of Mental Health [R01-MH090127, P30-MH089868]; National Center for Advancing Translational Sciences [UL1TR001120] FX This research was supported by grants R01-MH090127, P30-MH089868 from the National Institute of Mental Health and award number UL1TR001120 from the National Center for Advancing Translational Sciences. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIMH or NCATS. Additionally, we would like to gratefully acknowledge Dr. David Morilak for his valuable expertise in guiding the early method development. NR 15 TC 0 Z9 0 U1 4 U2 8 PU JOURNAL OF VISUALIZED EXPERIMENTS PI CAMBRIDGE PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA SN 1940-087X J9 JOVE-J VIS EXP JI J. Vis. Exp. PD FEB PY 2015 IS 96 AR e51944 DI 10.3791/51944 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CR7MH UT WOS:000361533700006 ER PT J AU Bhise, V Singh, H AF Bhise, Viraj Singh, Hardeep TI Measuring diagnostic safety of inpatients: time to set sail in uncharted waters SO DIAGNOSIS LA English DT Editorial Material C1 [Singh, Hardeep] VA Med Ctr 152, Houston, TX 77030 USA. [Bhise, Viraj; Singh, Hardeep] Michael E DeBakey VA Med Ctr, Houston Vet Affairs Ctr Innovat Qual Effectivenes, Houston, TX USA. [Bhise, Viraj; Singh, Hardeep] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [Bhise, Viraj] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Div Management Policy & Community Hlth, Houston, TX 77030 USA. RP Singh, H (reprint author), VA Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM hardeeps@bcm.edu FU AHRQ HHS [R01 HS022087]; NCI NIH HHS [K23 CA125585] NR 10 TC 0 Z9 0 U1 0 U2 0 PU WALTER DE GRUYTER GMBH PI BERLIN PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY SN 2194-8011 EI 2194-802X J9 DIAGNOSIS JI Diagnosis PD FEB PY 2015 VL 2 IS 1 BP 1 EP 2 DI 10.1515/dx-2015-0003 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA CL9FA UT WOS:000357280000002 PM 26955511 ER PT J AU Dodson, MV Allen, RE Du, M Bergen, WG Velleman, SG Poulos, SP Fernyhough-Culver, M Wheeler, MB Duckett, SK Young, MRI Voy, BH Jiang, Z Hausman, GJ AF Dodson, M. V. Allen, R. E. Du, M. Bergen, W. G. Velleman, S. G. Poulos, S. P. Fernyhough-Culver, M. Wheeler, M. B. Duckett, S. K. Young, M. R. I. Voy, B. H. Jiang, Z. Hausman, G. J. TI INVITED REVIEW: Evolution of meat animal growth research during the past 50 years: Adipose and muscle stem cells SO JOURNAL OF ANIMAL SCIENCE LA English DT Review DE adipocytes; adipose tissue; animal growth; satellite cells; skeletal muscle tissue; stem cells ID SYNDECAN-4 CYTOPLASMIC DOMAIN; COMBINED TRENBOLONE ACETATE; BOVINE ADIPOCYTE CULTURES; BETA-ADRENERGIC AGONISTS; ADULT SKELETAL-MUSCLE; SATELLITE CELLS; FIBROBLAST-GROWTH; IN-VITRO; REGENERATIVE MEDICINE; ADIPONECTIN RECEPTORS AB If one were to compare today's animal growth research to research from a mere 50 yr ago, one would see programs with few similarities. The evolution of this research from whole-animal through cell-based and finally molecular and genomic studies has been enhanced by the identification, isolation, and in vitro evaluation of adipose- and muscle-derived stem cells. This paper will highlight the struggles and the milestones that make this evolving area of research what it is today. The contribution of adipose and muscle stem cell research to development and growth, tissue regeneration, and final carcass composition are reviewed. C1 [Dodson, M. V.; Du, M.; Jiang, Z.] Washington State Univ, Dept Anim Sci, Pullman, WA 99164 USA. [Allen, R. E.] Univ Arizona, Dept Anim Sci, Tucson, AZ 85721 USA. [Bergen, W. G.] Auburn Univ, Dept Anim Sci, Program Cell & Mol Biosci, Auburn, AL 36849 USA. [Velleman, S. G.] Ohio State Univ, OARDC, Wooster, OH 44691 USA. [Poulos, S. P.] Akeso Hlth LLC, Decatur, GA 30033 USA. [Fernyhough-Culver, M.] Abitec Corp, Columbus, OH 43215 USA. [Wheeler, M. B.] Univ Illinois, Inst Genom Biol, Urbana, IL 61801 USA. [Duckett, S. K.] Clemson Univ, Anim & Vet Sci, Clemson, SC 29634 USA. [Young, M. R. I.] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC 29401 USA. [Young, M. R. I.] Med Univ S Carolina, Dept Otolaryngol, Charleston, SC 29401 USA. [Voy, B. H.] Univ Tennessee, Dept Anim Sci, Knoxville, TN 37996 USA. [Hausman, G. J.] Univ Georgia, Dept Anim & Dairy Sci, Athens, GA 30602 USA. RP Dodson, MV (reprint author), Washington State Univ, Dept Anim Sci, Pullman, WA 99164 USA. EM dodson@wsu.edu RI Du, Min/H-4311-2011; Jiang, Zhihua/A-3378-2008 OI Du, Min/0000-0002-7232-072X; Jiang, Zhihua/0000-0003-1986-088X NR 263 TC 2 Z9 2 U1 1 U2 20 PU AMER SOC ANIMAL SCIENCE PI CHAMPAIGN PA PO BOX 7410, CHAMPAIGN, IL 61826-7410 USA SN 0021-8812 EI 1525-3163 J9 J ANIM SCI JI J. Anim. Sci. PD FEB PY 2015 VL 93 IS 2 BP 457 EP 481 DI 10.2527/jas2014-8221 PG 25 WC Agriculture, Dairy & Animal Science SC Agriculture GA CL6OO UT WOS:000357086600001 PM 26020737 ER PT J AU Bettcher, BM Yaffe, K Boudreau, RM Neuhaus, J Aizenstein, H Ding, J Kritchevsky, SB Launer, LJ Liu, Y Satterfield, S Rosano, C AF Bettcher, Brianne Magouirk Yaffe, Kristine Boudreau, Robert M. Neuhaus, John Aizenstein, Howard Ding, Jingzhong Kritchevsky, Stephen B. Launer, Lenore J. Liu, Yongmei Satterfield, Suzanne Rosano, Caterina CA Health ABC Study TI Declines in inflammation predict greater white matter microstructure in older adults SO NEUROBIOLOGY OF AGING LA English DT Article DE CRP; Pro-inflammatory; Diffusion tensor imaging; Longitudinal ID C-REACTIVE PROTEIN; MILD COGNITIVE IMPAIRMENT; NECROSIS-FACTOR-ALPHA; ALZHEIMERS-DISEASE; NEURODEGENERATIVE DISEASE; CARDIOVASCULAR-DISEASE; VASCULAR DYSFUNCTION; DIFFUSION TENSOR; HEALTH ABC; TNF-ALPHA AB Protracted systemic inflammation has been associated with adverse effects on cognition and brain structure and may accelerate neurodegenerative disease processes; however, it is less clear whether changes in inflammation are associated with brain structure. We studied 276 black and white older adults (mean age = 83 years at time of imaging) enrolled in a prospective study of aging. Inflammation (measured with c-reactive protein, CRP) was assessed repeatedly over 6 years (i.e., year 2, 4, 6, and 8). Brain magnetic resonance imaging (MRIs) were obtained at years 10-11 with diffusion tensor imaging; regions of interest included late-myelinating areas vulnerable to aging, including frontal-parietal (superior longitudinal fasciculus [SLF]-dorsal) and temporal (SLF-temporal; uncinate) white matter tracts. Mean CRP values significantly declined (t = -5.54, p < 0.0001) over 6 years, and subject-specific slopes (best linear unbiased predictors of slopes) all showed a decline (mean = -0.57, standard deviation = 0.53) for our participant sample. More than 50% of study participants were still in the moderate to high cardiovascular risk range based on CRP values at year 8. After controlling for demographics, vascular risk factors and MRI white matter hyperintensities, larger decreases in CRP values over time were significantly associated with higher fractional anisotropy in the SLF-dorsal (beta = -0.0052, standard error [SE] = 0.003; 95% confidence interval [CI] = -0.0103 to -0.0025, p = 0.04), SLF-temporal (beta = -0.0109, SE = 0.004; 95% CI = -0.0189 to -0.0029, p = 0.008), and uncinate (beta = -0.0067, SE = 0.003; 95% CI = -0.0132 to -0.0001, p = 0.05) fasciculi. Results suggest that in a prospective cohort of older individuals, faster declines in inflammation over time are related to indicators of white matter health, even after accounting for vascular risk factors. (C) 2015 Elsevier Inc. All rights reserved. C1 [Bettcher, Brianne Magouirk; Neuhaus, John] Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Boudreau, Robert M.; Rosano, Caterina] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. [Aizenstein, Howard] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Ding, Jingzhong; Kritchevsky, Stephen B.; Liu, Yongmei] Wake Forest Sch Med, Sticht Ctr Aging, Winston Salem, NC USA. [Launer, Lenore J.] NIA, Lab Epidemiol & Populat Sci, Bethesda, MD 20892 USA. [Satterfield, Suzanne] Univ Tennessee, Ctr Hlth Sci, Dept Prevent Med, Memphis, TN 38163 USA. RP Bettcher, BM (reprint author), Memory & Aging Ctr, Dept Neurol, 675 Nelson Rising Ln,Suite 190,MC 1207, San Francisco, CA 94158 USA. EM bbettcher@memory.ucsf.edu OI Rosano, Caterina/0000-0002-0909-1506; Rosano, Caterina/0000-0002-4271-6010; Boudreau, Robert/0000-0003-0162-5187 FU National Institute on Aging (NIA) [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106]; NIA [R01-AG028050, K23 AG042492-01, RO1-AG028288]; NINR [R01-NR012459]; Intramural Research Program of the NIH, National Institute on Aging; Alzheimer's Association [NIRP-12-259223] FX This research was supported by National Institute on Aging (NIA) Contracts N01-AG-6-2101; N01-AG-6-2103; N01-AG-6-2106; NIA grant R01-AG028050, K23 AG042492-01 (Brianne Magouirk Bettcher), RO1-AG028288 (Yongmei Liu), and NINR grant R01-NR012459. This research was supported in part by the Intramural Research Program of the NIH, National Institute on Aging, as well as an Alzheimer's Association New Investigator Grant (NIRP-12-259223; Brianne Magouirk Bettcher). NR 56 TC 3 Z9 3 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 EI 1558-1497 J9 NEUROBIOL AGING JI Neurobiol. Aging PD FEB PY 2015 VL 36 IS 2 BP 948 EP 954 DI 10.1016/j.neurobiolaging.2014.11.004 PG 7 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA CF3MZ UT WOS:000352454400040 PM 25554492 ER PT J AU Finley, EP Bollinger, M Noel, PH Amuan, ME Copeland, LA Pugh, JA Dassori, A Palmer, R Bryan, C Pugh, MJV AF Finley, Erin P. Bollinger, Mary Noel, Polly H. Amuan, Megan E. Copeland, Laurel A. Pugh, Jacqueline A. Dassori, Albana Palmer, Raymond Bryan, Craig Pugh, Mary Jo V. TI A National Cohort Study of the Association Between the Polytrauma Clinical Triad and Suicide-Related Behavior Among US Veterans Who Served in Iraq and Afghanistan SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH DIAGNOSES; SUBSTANCE USE DISORDERS; DEPLOYED MILITARY PERSONNEL; PSYCHIATRIC DIAGNOSES; COMMUNITY SAMPLE; WAR VETERANS; RISK; IDEATION AB Objectives. We examined the association of posttraumatic stress disorder (PTSD), traumatic brain injury, and chronic pain-the polytrauma clinical triad (PCT)-independently and with other conditions, with suicide-related behavior (SRB) risk among Operation Enduring Freedom (OEF; Afghanistan) and Operation Iraqi Freedom (OIF) veterans. Methods. We used Department of Veterans Affairs (VA) administrative data to identify OEF and OIF veterans receiving VA care in fiscal years 2009-2011; we used International Classification of Diseases, Ninth Revision, Clinical Modification codes to characterize 211 652 cohort members. Descriptive statistics were followed by multinomial logistic regression analyses predicting SRB. Results. Co-occurrence of PCT conditions was associated with significant increase in suicide ideation risk (odds ratio [OR] = 1.9; 95% confidence interval [CI] = 1.5, 2.4) or attempt and ideation (OR = 2.6; 95% CI = 1.5, 4.6), but did not exceed increased risk with PTSD alone (ideation: OR = 2.3; 95% CI = 2.0, 2.6; attempt: OR = 2.0; 95% CI = 1.4, 2.9; ideation and attempt: OR = 1.8; 95% CI = 1.2, 2.8). Ideation risk was significantly elevated when PTSD was comorbid with depression (OR = 4.2; 95% CI = 3.6, 4.8) or substance abuse (OR = 4.7; 95% CI = 3.9, 5.6). Conclusions. Although PCT was a moderate SRB predictor, interactions among PCT conditions, particularly PTSD, and depression or substance abuse had larger risk increases. C1 [Finley, Erin P.; Bollinger, Mary; Noel, Polly H.; Pugh, Jacqueline A.; Dassori, Albana; Pugh, Mary Jo V.] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Palmer, Raymond] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [Amuan, Megan E.] Edith Nourse Rogers Mem VA Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. [Copeland, Laurel A.] Hlth Care Syst, Cent Texas Vet, Ctr Appl Hlth Res, Temple, TX USA. [Copeland, Laurel A.] Scott & White Healthcare Syst, Temple, TX USA. [Bryan, Craig] Univ Utah, Natl Ctr Vet Studies, Salt Lake City, UT USA. [Bryan, Craig] Univ Utah, Dept Psychol, Salt Lake City, UT 84112 USA. RP Finley, EP (reprint author), South Texas Vet Hlth Care Syst, Audie L Murphy Mem Vet Hosp, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM finleye@uthscsa.edu OI Pugh, Jacqueline/0000-0003-4933-141X; Pugh, Mary Jo/0000-0003-4196-7763; Bryan, Craig/0000-0002-9714-0733; Copeland, Laurel/0000-0002-9478-0209; Finley, Erin/0000-0003-4497-7721 FU Department of Veterans Affairs, Office of Research and Development, VA Health Services Research and Development Service [DHI 09-237]; South Texas Veterans Health Care System; National Institute of Mental Health [R25 MH080916-01A2]; Department of Veterans Affairs, Health Services Research and Development Service, Quality Enhancement Research Initiative FX This study was funded by Department of Veterans Affairs, Office of Research and Development, VA Health Services Research and Development Service (DHI 09-237). J. A. Pugh's and A. Dassori's salaries were funded by the South Texas Veterans Health Care System. E. P. Finley is an investigator with the Implementation Research Institute, at the George Warren Brown School of Social Work, Washington University in St Louis, through an award from the National Institute of Mental Health (R25 MH080916-01A2) and the Department of Veterans Affairs, Health Services Research and Development Service, Quality Enhancement Research Initiative. NR 59 TC 11 Z9 11 U1 4 U2 17 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD FEB PY 2015 VL 105 IS 2 BP 380 EP 387 DI 10.2105/AJPH.2014.301957 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CE6CD UT WOS:000351922500046 PM 25033126 ER PT J AU Broytman, O Braun, RK Morgan, BJ Pegelow, DF Hsu, PN Mei, LS Koya, AK Eldridge, M Teodorescu, M AF Broytman, Oleg Braun, Rudolf K. Morgan, Barbara J. Pegelow, David F. Hsu, Pei-Ning Mei, Linda S. Koya, Ajay K. Eldridge, Marlowe Teodorescu, Mihaela TI Effects of Chronic Intermittent Hypoxia on Allergen-Induced Airway Inflammation in Rats SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY LA English DT Article DE airway remodeling, immunology; disease models, animal; fibrosis; lung immunology, metabolism, pathology; rats ID OBSTRUCTIVE SLEEP-APNEA; PULMONARY-FIBROSIS; ASTHMATIC-PATIENTS; LUNG INFLAMMATION; INDUCIBLE FACTORS; ACTIVATION; MACROPHAGES; DYSFUNCTION; HIF-1-ALPHA; EXPRESSION AB Obstructive sleep apnea aggravates asthma, but its mechanisms are unknown. Chronic intermittent hypoxia is one hallmark feature of sleep apnea. In this study, we tested the effects of chronic intermittent hypoxia on allergen-induced inflammation in rats. Four groups (n = 9-11/group) of ovalbumin (OVA)-sensitized Brown-Norway rats underwent intermittent hypoxia (10% oxygen, 30 cycles/h, 10 h/d) or normoxia for 30 days concurrent with weekly OVA or vehicle challenges. Lung physiology, differential leukocyte counts from bronchoalveolar lavage, and histology (Picro Sirius Red staining for collagen content) were compared between groups 2 days after the last challenge. Gene expression in bronchoalveolar lavage cells was quantified by quantitative PCR. Compared with normoxia, chronic intermittent hypoxia reduced the FEV0.1/FVC ratio (P = 0.005), peak expiratory flow (P = 0.002), and mean midexpiratory flow (P = 0.004), predominantly in medium and large airways; decreased the baseline eosinophil number (P = 0.01) and amplified the effect of OVA on monocyte number (P = 0.02 for the interaction); in proximal airways, increased (P = 0.008), whereas in distal airways it decreased (P = 0.004), collagen density; induced qualitative emphysematous changes in lung periphery; and increased expression of the M2 macrophage marker YM-1 and augmented OVA-induced expression of plasminogen activator inhibitor-1. Chronic intermittent hypoxia alters immune response to allergen toward a more T-H-1-predominant cellular phenotype with collagen deposition and matrix degradation, leading to airflow limitation. These findings highlight the potential of sleep apnea to aggravate airway dysfunction in patients with preexistent asthma. C1 [Broytman, Oleg; Hsu, Pei-Ning; Mei, Linda S.; Koya, Ajay K.; Teodorescu, Mihaela] Univ Wisconsin Hosp & Clin, William S Middleton Mem Vet Adm Hosp, Med Serv, James B Skatrud Pulm Sleep Res Lab, Madison, WI 53792 USA. [Broytman, Oleg; Teodorescu, Mihaela] Univ Wisconsin, Div Allergy Pulm & Crit Care Med, Sch Med & Publ Hlth, Madison, WI USA. [Braun, Rudolf K.; Pegelow, David F.; Eldridge, Marlowe] Univ Wisconsin, John Rankin Pulm Res Lab, Sch Med & Publ Hlth, Madison, WI USA. [Braun, Rudolf K.; Pegelow, David F.; Eldridge, Marlowe] Univ Wisconsin, Dept Pediat, Sch Med & Publ Hlth, Madison, WI USA. [Morgan, Barbara J.] Univ Wisconsin, Dept Orthoped & Rehabil, Sch Med & Publ Hlth, Madison, WI USA. RP Teodorescu, M (reprint author), B5056 VA Hosp,2500 Overlook Terrace, Madison, WI 53705 USA. EM mt3@medicine.wisc.edu FU Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin FX This work was supported by funding from the Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. NR 50 TC 10 Z9 10 U1 3 U2 8 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1044-1549 EI 1535-4989 J9 AM J RESP CELL MOL JI Am. J. Respir. Cell Mol. Biol. PD FEB PY 2015 VL 52 IS 2 BP 162 EP 170 DI 10.1165/rcmb.2014-0213OC PG 9 WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System GA CF0BK UT WOS:000352207300003 PM 25004109 ER PT J AU Friedlander, AH AF Friedlander, Arthur H. TI ETHICAL CONCERNS Response SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION LA English DT Letter C1 VA Greater Los Angeles Healthcare Syst, Grad Med Educ, Los Angeles, CA 90073 USA. RP Friedlander, AH (reprint author), VA Greater Los Angeles Healthcare Syst, Grad Med Educ, Los Angeles, CA 90073 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER DENTAL ASSOC PI CHICAGO PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA SN 0002-8177 EI 1943-4723 J9 J AM DENT ASSOC JI J. Am. Dent. Assoc. PD FEB PY 2015 VL 146 IS 2 BP 75 EP 75 DI 10.1016/j.adaj.2014.12.005 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA CE9GM UT WOS:000352152100003 PM 25637203 ER PT J AU Kaji, I Iwanaga, T Watanabe, M Guth, PH Engel, E Kaunitz, JD Akiba, Y AF Kaji, Izumi Iwanaga, Toshihiko Watanabe, Masahiko Guth, Paul H. Engel, Eli Kaunitz, Jonathan D. Akiba, Yasutada TI SCFA transport in rat duodenum SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY LA English DT Article DE acetate; monocarboxylate transporter; sodium-coupled monocarboxylate transporter; short-chain fatty acid ID CHAIN FATTY-ACIDS; NA+-COUPLED TRANSPORTER; BICARBONATE SECRETION; ENTEROENDOCRINE CELLS; HEALTHY-SUBJECTS; DISTAL COLON; MONOCARBOXYLATE TRANSPORTERS; GASTROINTESTINAL-TRACT; CELLULAR EXPRESSION; DIGESTIVE-TRACT AB Bacterial or ingested food-derived short-chain fatty acids (SCFAs) are present in the duodenal lumen. Acetate, the most abundant SCFA in the foregut lumen, is absorbed immediately after ingestion, although the mechanism by which this absorption occurs is not fully understood. We investigated the distribution and function of candidate SCFA transporters in rat duodenum. The Na+ -coupled monocarboxylate transporter-1 (SMCT1) was localized to the brush border, whereas the pH-dependent monocarboxylate transporter (MCT) 1 and MCT4 were localized to the duodenocyte basolateral membrane. In Ussing chambered duodenal mucosa, luminal acetate dose-dependently increased short-circuit current (I-sc) in the presence of serosal bumetanide and indomethacin by a luminal Na+ -dependent, ouabain-sensitive mechanism. The Isc response was inhibited dose-dependently by the SMCT1 nonsubstrate inhibitor ibuprofen, consistent with net electrogenic absorption of acetate via SMCT1. Other SCFAs and lactate also increased Isc. Furthermore, duodenal loop perfusion of acetate increased portal venous acetate concentration, inhibited by coperfusion of ibuprofen or a MCT inhibitor. Luminal acetate perfusion increased duodenal HCO3 secretion via capsaicin-sensitive afferent nerve activation and cyclooxygenase activity, consistent with absorption-mediated HCO3- secretion. These results suggest that absorption of luminal SCFA via SMCT1 and MCTs increases duodenal HCO3- secretion. In addition to SCFA sensing via free fatty acid receptors, the presence of rapid duodenal SCFA absorption may be important for the suppression of luminal bacterial colonization and implicated in the generation of functional dyspepsia due to bacterial overgrowth. C1 [Guth, Paul H.; Kaunitz, Jonathan D.; Akiba, Yasutada] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. [Kaji, Izumi; Guth, Paul H.; Kaunitz, Jonathan D.; Akiba, Yasutada] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA. [Kaunitz, Jonathan D.] Univ Calif Los Angeles, Sch Med, Dept Surg, Los Angeles, CA 90024 USA. [Engel, Eli] Univ Calif Los Angeles, Sch Med, Dept Biomath, Los Angeles, CA 90024 USA. [Kaji, Izumi; Iwanaga, Toshihiko; Watanabe, Masahiko] Hokkaido Univ, Grad Sch Med, Dept Anat, Sapporo, Hokkaido, Japan. [Kaji, Izumi; Kaunitz, Jonathan D.; Akiba, Yasutada] Brentwood Biomed Res Inst, Los Angeles, CA USA. RP Kaunitz, JD (reprint author), West Los Angeles VA Med Ctr, Bldg 114,Suite 217,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jake@ucla.edu RI WATANABE, Masahiko/A-4055-2012 FU Department of Veterans Affairs Merit Review Award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [R01-DK-54221]; NIDDK [P30-DK-0413]; [24-5317] FX This study was supported by a Grant-in-Aid for the Japan Society for the Promotion of Science Fellows to I. Kaji (no. 24-5317), a Department of Veterans Affairs Merit Review Award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (R01-DK-54221 to J. Kaunitz), and the animal core of the NIDDK (P30-DK-0413 to J. E. Rozengurt). NR 60 TC 8 Z9 9 U1 1 U2 13 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1857 EI 1522-1547 J9 AM J PHYSIOL-GASTR L JI Am. J. Physiol.-Gastroint. Liver Physiol. PD FEB 1 PY 2015 VL 308 IS 3 BP G188 EP G197 DI 10.1152/ajpgi.00298.2014 PG 10 WC Gastroenterology & Hepatology; Physiology SC Gastroenterology & Hepatology; Physiology GA CB6PV UT WOS:000349749900004 PM 25394661 ER PT J AU Ubel, PA Asch, DA AF Ubel, Peter A. Asch, David A. TI Creating Value In Health By Understanding And Overcoming Resistance To De-Innovation SO HEALTH AFFAIRS LA English DT Editorial Material ID CARE; CHALLENGE; GUIDELINE AB As hard as it may be for clinicians to adopt new practices, it is often harder for them to "de-innovate," or give up old practices, even when new evidence reveals that those practices offer little value. In this article we explore recent controversies over screening for breast and prostate cancer and testing for sleep disorders. We show that these controversies are not caused solely by a lack of clinical data on the harms and benefits of these tests but are also influenced by several psychological biases that make it difficult for clinicians to de-innovate. De-innovation could be fostered by making sure that advisory panels and guideline committees include experts who have competing biases; emphasizing evidence over clinical judgment; resisting " indication creep," or the premature extension of innovations into unproven areas; and encouraging clinicians to explicitly consider how their experiences bias their interpretations of clinical evidence. C1 [Ubel, Peter A.] Duke Univ, Fuqua Sch Business, Dept Med, Durham, NC 27706 USA. [Ubel, Peter A.] Duke Univ, Sanford Sch Publ Policy, Durham, NC 27706 USA. [Asch, David A.] Univ Penn, Ctr Hlth Care Innovat, Philadelphia, PA 19104 USA. [Asch, David A.] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. [Asch, David A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Asch, David A.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Ubel, PA (reprint author), Duke Univ, Fuqua Sch Business, Dept Med, Durham, NC 27706 USA. EM asch@wharton.upenn.edu FU Health Policy Investigator Award from the Robert Wood Johnson Foundation FX Peter Ubel is supported by a Health Policy Investigator Award from the Robert Wood Johnson Foundation. The opinions expressed are those of the authors and not of the Department of Veterans Affairs. NR 22 TC 14 Z9 14 U1 0 U2 3 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD FEB PY 2015 VL 34 IS 2 BP 239 EP 244 DI 10.1377/hlthaff.2014.0983 PG 6 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA CE3HA UT WOS:000351716100009 PM 25646103 ER PT J AU Trivedi, R Gerrity, M Rumsfeld, JS Spertus, JA Sun, HL McDonell, M Doak, M Lucas, L Fihn, SD AF Trivedi, Ranak Gerrity, Martha Rumsfeld, John S. Spertus, John A. Sun, Haili McDonell, Mary Doak, Melanie Lucas, Linda Fihn, Stephan D. TI Angina Symptom Burden Associated with Depression Status Among Veterans with Ischemic Heart Disease SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Article DE Angina; Depression; Quality of life; Patient-reported outcomes ID CORONARY-ARTERY-DISEASE; QUALITY-OF-LIFE; CHRONIC STABLE ANGINA; FUNCTIONAL STATUS; MAJOR DEPRESSION; UNSTABLE ANGINA; RISK-FACTOR; MORTALITY; OUTPATIENTS; PHQ-9 AB Angina and depression are common in ischemic heart disease (IHD), but their association remains understudied. This study was conducted in order to evaluate the association of 1 year change in depression with change in patient-reported outcomes of stable angina. Five hundred sixty-nine stable angina patients completed the Seattle Angina Questionnaire and Patient Health Questionnaire (PHQ) at baseline and 1 year. Participants were divided into four groups: not depressed, new onset of depression at 1 year, remitted at 1 year, and persistently depressed. Associations between depression and angina symptoms were evaluated using regression models. Compared to those not depressed, newly depressed participants reported more angina (beta = -11.7, p < 0.001) and physical limitations (beta = -11.8, p < 0.001) and lower treatment satisfaction (beta = -15.03, p < 0.001) and quality of life (beta = -15.4, p < 0.001). Persistently depressed participants reported physical limitations (beta = -7.4, p < 0.05), lower treatment satisfaction (beta = -10.1, p < 0.001), and poorer quality of life (beta = -10.03, p < 0.001). Changes in depression scores and angina outcomes were significantly associated. C1 [Trivedi, Ranak; Sun, Haili; McDonell, Mary] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Gerrity, Martha; Doak, Melanie; Lucas, Linda] Portland VA Med Ctr, Portland, OR USA. [Gerrity, Martha; Doak, Melanie; Lucas, Linda] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Rumsfeld, John S.] VA Eastern Colorado Hlth Care Syst, Denver, CO USA. [Spertus, John A.] Univ Missouri, Dept Med, Kansas City, KS USA. [Fihn, Stephan D.] Univ Washington, Dept Med, Off Analyt & Business Intelligence, Dept Vet Affairs, Seattle, WA USA. [Trivedi, Ranak] Stanford Univ, Ctr Innovat Implementat, VA Palo Alto Hlth Care Syst, Dept Psychiat & Behav Sci, Menlo Pk, CA 94025 USA. RP Trivedi, R (reprint author), Stanford Univ, Ctr Innovat Implementat, VA Palo Alto Hlth Care Syst, Dept Psychiat & Behav Sci, 795 Willow Rd MPD 42,Bldg 324, Menlo Pk, CA 94025 USA. EM ranak.trivedi@va.gov FU Department of Veterans Affairs (VA); Veterans Health Administration, Health Services Research and Development (HSRD) Service [IHI 02-062]; VA HSR&D Career Development Award (CDA) [09-206] FX This work was supported by the Department of Veterans Affairs (VA), Veterans Health Administration, Health Services Research and Development (HSR&D) Service, IHI 02-062. Dr. Trivedi is supported by a VA HSR&D Career Development Award (CDA 09-206). VA Puget Sound Health Care System and the VA Palo Alto Health Care System provided resources to support this research. The views expressed in this manuscript are those of the authors and do not necessarily represent the opinions of the Department of Veterans Affairs. Dr. Trivedi and Dr. Sun had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. NR 25 TC 3 Z9 3 U1 2 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 EI 1532-4796 J9 ANN BEHAV MED JI Ann. Behav. Med. PD FEB PY 2015 VL 49 IS 1 BP 58 EP 65 DI 10.1007/s12160-014-9629-4 PG 8 WC Psychology, Multidisciplinary SC Psychology GA CC0TX UT WOS:000350050800009 PM 25008432 ER PT J AU Perez-Rodrigueza, MM Mahon, K Russo, M Ungar, AK Burdick, KE AF Mercedes Perez-Rodrigueza, M. Mahon, Katie Russo, Manuela Ungar, Allison K. Burdick, Katherine E. TI Oxytocin and social cognition in affective and psychotic disorders SO EUROPEAN NEUROPSYCHOPHARMACOLOGY LA English DT Article DE Oxytocin; Schizophrenia; Major depressive disorder; Bipolar disorder; Social cognition ID BORDERLINE PERSONALITY-DISORDER; INTERACTION TRAINING SCIT; FACIAL-AFFECT RECOGNITION; SCHIZOPHRENIA SPECTRUM DISORDERS; ADJUNCTIVE INTRANASAL OXYTOCIN; RANDOMIZED CONTROLLED-TRIAL; VISUAL SCANNING BEHAVIOR; BIPOLAR DISORDER; ATTRIBUTIONAL STYLE; MAJOR DEPRESSION AB Impairments in social cognition are now recognized as core illness features in psychotic and affective disorders. Despite the significant disability caused by social cognitive abnormalities, treatments for this symptom dimension are lacking. Here, we describe the evidence demonstrating abnormalities in social cognition in schizophrenia, major depressive disorder, and bipolar disorder, as well as the neurobiology of social cognition including the role of oxytocin. We then review clinical trials of oxytocin administration in psychotic and affective disorders and the impact of this agent on social cognition. To date, several studies have demonstrated that oxytocin may improve social cognition in schizophrenia; too few studies have been conducted in affective disorders to determine the effect of oxytocin on social cognition in these disorders. Future work is needed to clarify which aspects of social cognition may be improved with oxytocin treatment in psychotic and affective disorders. (C) 2014 Elsevier B.V. and ECNP. All rights reserved. C1 [Mercedes Perez-Rodrigueza, M.; Mahon, Katie; Russo, Manuela; Ungar, Allison K.; Burdick, Katherine E.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Mercedes Perez-Rodrigueza, M.] James J Peters Vet Affairs Med Ctr, Mental Hlth Patient Care Ctr, Bronx, NY 10468 USA. [Mercedes Perez-Rodrigueza, M.] James J Peters Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Bronx, NY 10468 USA. [Mercedes Perez-Rodrigueza, M.] Univ Autonoma Madrid, CIBERSAM, Fdn Jimenez Diaz Hosp, E-28049 Madrid, Spain. RP Perez-Rodrigueza, MM (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, Psychiat Box 1230,One Gustave L Levy Pl, New York, NY 10029 USA. EM mercedes.perez@mssm.edu FU Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness Research and Treatment; Medical Research Service of the Veterans Affairs James J Peters VAMC; Department of Veterans Affairs NY/NJ (VISN3) Mental Illness Research, Education, and Clinical Center (MIRECC); Brain and Behavior Research Foundation NARSAD Young Investigator Award; NIMH [R01 MH100125, UL1TR000067] FX This research is supported by the Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness Research and Treatment, the Medical Research Service of the Veterans Affairs James J Peters VAMC; the Department of Veterans Affairs NY/NJ (VISN3) Mental Illness Research, Education, and Clinical Center (MIRECC); a Brain and Behavior Research Foundation NARSAD Young Investigator Award to Dr. Perez Rodriguez, and the NIMH (R01 MH100125 to Dr. Burdick, CTSA grant UL1TR000067 awarded to the Mt. Sinai School of Medicine). NR 193 TC 10 Z9 10 U1 7 U2 21 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0924-977X EI 1873-7862 J9 EUR NEUROPSYCHOPHARM JI Eur. Neuropsychopharmacol. PD FEB PY 2015 VL 25 IS 2 BP 265 EP 282 PG 18 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA CD4DB UT WOS:000351031700013 ER PT J AU O'Malley, SS Corbin, WR Leeman, RF DeMartini, KS Fucito, LM Ikomi, J Romano, DM Wu, R Toll, BA Sher, KJ Gueorguieva, R Kranzler, HR AF O'Malley, Stephanie S. Corbin, William R. Leeman, Robert F. DeMartini, Kelly S. Fucito, Lisa M. Ikomi, Jolomi Romano, Denise M. Wu, Ran Toll, Benjamin A. Sher, Kenneth J. Gueorguieva, Ralitza Kranzler, Henry R. TI Reduction of Alcohol Drinking in Young Adults by Naltrexone: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial of Efficacy and Safety SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID EARLY PROBLEM DRINKERS; US COLLEGE-STUDENTS; TARGETED NALTREXONE; HEAVY DRINKING; INTERVENTION; DEPENDENCE; ADOLESCENTS; OUTCOMES AB Objective: Naltrexone, an opioid antagonist, may facilitate reduction in drinking among young adults. We compared the efficacy and safety of naltrexone administered daily plus targeted dosing with placebo to reduce drinking in young adults who engage in heavy drinking. Method: A randomized, double-blind, placebo-controlled study was conducted in an outpatient research center in March 2008-January 2012. Participants were aged 18-25 years and reported >= 4 heavy drinking days in the prior 4 weeks. Interventions included naltrexone 25 mg daily plus 25 mg targeted (at most daily) in anticipation of drinking (n = 61) or daily/targeted placebo (n = 67). All participants received a personalized feedback session and brief counseling every other week. Primary outcomes were percent heavy drinking days and percent days abstinent over the 8-week treatment period. Secondary outcomes included number of drinks per drinking day and percentage of days with estimated blood alcohol concentration (BAC) levels >= 0.08 g/dL. Results: Of 140 randomized patients, 128 began treatment, comprising the evaluable sample. During treatment, percent heavy drinking days (naltrexone: mean = 21.60, SD = 16.05; placebo: mean = 22.90, SD = 13.20) (P = .58) and percent days abstinent (naltrexone: mean = 56.60, SD = 22.52; placebo: mean = 62.50, SD = 15.75) (P = .39) did not differ by group. Naltrexone significantly reduced the number of drinks per drinking day (naltrexone: mean = 4.90, SD = 2.28; placebo: mean = 5.90, SD = 2.51) (P = .009) and percentage of drinking days with estimated BAC >= 0.08 g/dL (naltrexone: mean = 35.4, SD = 28.40; placebo: mean = 45.7, SD = 26.80) (P = .042). There were no serious adverse events. Sleepiness was more common with naltrexone. Conclusions: Naltrexone did not reduce frequency of drinking or heavy drinking days, but reduced secondary measures of drinking intensity. While effects were modest, the risk-benefit ratio favors offering naltrexone to help young adult heavy drinkers reduce the amount of alcohol they drink. (C) Copyright 2015 Physicians Postgraduate Press, Inc. C1 [O'Malley, Stephanie S.; Leeman, Robert F.; DeMartini, Kelly S.; Fucito, Lisa M.; Ikomi, Jolomi; Romano, Denise M.; Wu, Ran; Toll, Benjamin A.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [O'Malley, Stephanie S.; Toll, Benjamin A.] Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT USA. [Gueorguieva, Ralitza] Yale Univ, Sch Publ Hlth, New Haven, CT USA. [Gueorguieva, Ralitza] Yale Univ, Sch Med, New Haven, CT USA. [Corbin, William R.] Arizona State Univ, Dept Psychol, Tempe, AZ 85287 USA. [Sher, Kenneth J.] Univ Missouri, Dept Psychol, Columbia, MO 65211 USA. [Kranzler, Henry R.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Kranzler, Henry R.] Philadelphia VA Med Ctr, Philadelphia, PA USA. RP O'Malley, SS (reprint author), Connecticut Mental Hlth Ctr, 34 Pk St, New Haven, CT 06519 USA. EM Stephanie.omalley@yale.edu OI Gueorguieva, Ralitza/0000-0003-0944-5973 FU State of Connecticut, Department of Mental Health and Addictions Services (DMHAS) from National Institute on Alcohol Abuse and Alcoholism (NIAAA), Bethesda, Maryland [R01 AA016621, K05 AA014715, K24 AA013736, K05 AA01742, K01 AA019694, K23 AA020000] FX The project described was supported by the State of Connecticut, Department of Mental Health and Addictions Services (DMHAS) and grant numbers R01 AA016621 and K05 AA014715 to Dr O'Malley, K24 AA013736 to Dr Kranzler, K05 AA01742 to Dr Sher, K01 AA019694 to Dr Leeman, and K23 AA020000 to Dr Fucito from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), Bethesda, Maryland. NR 36 TC 13 Z9 13 U1 1 U2 8 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 EI 1555-2101 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD FEB PY 2015 VL 76 IS 2 BP E207 EP + DI 10.4088/JCP.13m08934 PG 10 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA CD3KG UT WOS:000350976600002 PM 25742208 ER PT J AU Armstrong, EJ AF Armstrong, Ehrin J. TI Does Gender Influence Outcomes After Femoropopliteal Stenting? SO JOURNAL OF ENDOVASCULAR THERAPY LA English DT Article ID PERIPHERAL ARTERIAL-DISEASE; PACLITAXEL-ELUTING STENTS; CRITICAL LIMB ISCHEMIA; PERCUTANEOUS INTERVENTION; RISK-FACTORS; PREVALENCE; WOMEN; POPULATION; MEN C1 [Armstrong, Ehrin J.] Denver VA Med Ctr, Cardiol Sect, Denver, CO USA. [Armstrong, Ehrin J.] Univ Colorado, Sch Med, Denver, CO 80202 USA. RP Armstrong, EJ (reprint author), Univ Colorado, Sch Med, Div Cardiol, VA Eastern Colorado Healthcare Syst, 1250 14th St, Denver, CO 80202 USA. EM ehrin.armstrong@gmail.com NR 19 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1526-6028 EI 1545-1550 J9 J ENDOVASC THER JI J. Endovascular Ther. PD FEB PY 2015 VL 22 IS 1 BP 38 EP 40 DI 10.1177/1526602814565774 PG 3 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA CD9JE UT WOS:000351413800007 PM 25775678 ER PT J AU Liu, Y Lear, T Zhao, Y Zhao, J Zou, C Chen, BB Mallampalli, RK AF Liu, Y. Lear, T. Zhao, Y. Zhao, J. Zou, C. Chen, B. B. Mallampalli, R. K. TI F-box protein Fbxl18 mediates polyubiquitylation and proteasomal degradation of the pro-apoptotic SCF subunit Fbxl7 SO CELL DEATH & DISEASE LA English DT Article ID UBIQUITIN LIGASE; CANCER; IDENTIFICATION; INFLAMMATION; STABILITY; MECHANISM; COMPLEX; BINDING; SYSTEM; FAMILY AB Fbxl7, a subunit of the SCF (Skp-Cul1-F-box protein) complex induces mitotic arrest in cells; however, molecular factors that control its cellular abundance remain largely unknown. Here, we identified that an orphan F-box protein, Fbxl18, targets Fbxl7 for its polyubiquitylation and proteasomal degradation. Lys 109 within Fbxl7 is an essential acceptor site for ubiquitin conjugation by Fbxl18. An FQ motif within Fbxl7 serves as a molecular recognition site for Fbxl18 interaction. Ectopically expressed Fbxl7 induces apoptosis in Hela cells, an effect profoundly accentuated after cellular depletion of Fbxl18 protein or expression of Fbxl7 plasmids encoding mutations at either Lys 109 or within the FQ motif. Ectopic expression of Fbxl18 plasmid-limited apoptosis caused by overexpressed Fbxl7 plasmid. Thus, Fbxl18 regulates apoptosis by mediating ubiquitin-dependent proteasomal degradation of the pro-apoptotic protein Fbxl7 that may impact cellular processes involved in cell cycle progression. C1 [Liu, Y.; Lear, T.; Zhao, Y.; Zhao, J.; Zou, C.; Chen, B. B.; Mallampalli, R. K.] Univ Pittsburgh, Acute Lung Injury Ctr Excellence, Dept Med, Pittsburgh, PA 15213 USA. [Mallampalli, R. K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA USA. RP Mallampalli, RK (reprint author), Univ Pittsburgh, UPMC Montefiore, Dept Med, RK Mallampalli Pulm Allergy & Crit Care Med,NW628, Pittsburgh, PA 15213 USA. EM mallampallirk@upmc.edu OI Lear, Travis/0000-0001-9156-0844 FU United States Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development; United States Department of Veterans Affairs; National Institutes of Health [HL096376, HL097376, HL098174, HL081784, 1UH2HL123502, P01 HL114453, HL116472, HL01916]; American Heart Association Award [12SDG9050005, 12SDG12040330] FX The authors thank Wei Chen and Jin Li for cells. This work was supported in part by the United States Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development and by a Merit Review award from the United States Department of Veterans Affairs (to RKM). This work was also supported, in part, by National Institutes of Health R01 grants HL096376, HL097376, HL098174, HL081784, 1UH2HL123502 and P01 HL114453 (to RKM), HL116472 (to BBC), HL01916 (to YZ), and American Heart Association Award 12SDG9050005 (to JZ) and 12SDG12040330 (to CZ). NR 29 TC 6 Z9 6 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-4889 J9 CELL DEATH DIS JI Cell Death Dis. PD FEB PY 2015 VL 6 AR e1630 DI 10.1038/cddis.2014.585 PG 9 WC Cell Biology SC Cell Biology GA CC7VF UT WOS:000350575800004 PM 25654763 ER PT J AU Hall, DE Hanusa, BH Stone, RA Ling, BS Arnold, RM AF Hall, Daniel E. Hanusa, Barbara H. Stone, Roslyn A. Ling, Bruce S. Arnold, Robert M. TI Time Required for Institutional Review Board Review at One Veterans Affairs Medical Center SO JAMA SURGERY LA English DT Article ID CLINICAL-TRIALS; MULTICENTER; QUALITY; EVENTS; COSTS AB IMPORTANCE Despite growing concern that institutional review boards (IRBs) impose burdensome delays on research, little is known about the time required for IRB review across different types of research. OBJECTIVE To measure the overall and incremental process times for IRB review as a process of quality improvement. DESIGN, SETTING, AND PARTICIPANTS After developing a detailed process flowchart of the IRB review process, 2 analysts abstracted temporal data from the records pertaining to all 103 protocols newly submitted to the IRB at a large urban Veterans Affairs medical center from June 1, 2009, through May 31, 2011. Disagreements were reviewed with the principal investigator to reach consensus. We then compared the review times across review types using analysis of variance and post hoc Scheffe tests after achieving normally distributed data through logarithmic transformation. MAIN OUTCOMES AND MEASURES Calendar days from initial submission to final approval of research protocols. RESULTS Initial IRB review took 2 to 4 months, with expedited and exempt reviews requiring less time (median [range], 85 [23-631] and 82 [16-437] days, respectively) than full board reviews (median [range], 131 [64-296] days; P = .008). The median time required for credentialing of investigators was 1 day (range, 0-74 days), and review by the research and development committee took a median of 15 days (range, 0-184 days). There were no significant differences in credentialing or research and development times across review types (exempt, expedited, or full board). Of the extreme delays in IRB review, 80.0% were due to investigators' slow responses to requested changes. There were no systematic delays attributable to the information security officer, privacy officer, or IRB chair. CONCLUSIONS AND RELEVANCE Measuring and analyzing review times is a critical first step in establishing a culture and process of continuous quality improvement among IRBs that govern research programs. The review times observed at this IRB are substantially longer than the 60-day target recommended by expert panels. Themethod described here could be applied to other IRBs to begin identifying and improving inefficiencies. C1 [Hall, Daniel E.; Hanusa, Barbara H.; Stone, Roslyn A.; Ling, Bruce S.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. [Hall, Daniel E.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA. [Stone, Roslyn A.] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA. [Ling, Bruce S.; Arnold, Robert M.] Univ Pittsburgh, Dept Gen Internal Med, Pittsburgh, PA 15261 USA. RP Hall, DE (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Bldg 30,Univ Dr 151C, Pittsburgh, PA 15240 USA. EM hallde@upmc.edu OI Hall, Daniel/0000-0001-6382-0522 FU US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development [CDA 08-281, SDR 11-399-1] FX This research was supported by grants CDA 08-281 and SDR 11-399-1 from the US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development (Dr Hall). NR 14 TC 4 Z9 4 U1 0 U2 5 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6254 EI 2168-6262 J9 JAMA SURG JI JAMA Surg. PD FEB PY 2015 VL 150 IS 2 BP 103 EP 109 DI 10.1001/jamasurg.2014.956 PG 7 WC Surgery SC Surgery GA CC7JF UT WOS:000350542800004 PM 25494359 ER PT J AU Rao, VR Parko, KL AF Rao, Vikram R. Parko, Karen L. TI Clinical Approach to Posttraumatic Epilepsy SO SEMINARS IN NEUROLOGY LA English DT Article DE traumatic brain injury; epilepsy; posttraumatic epilepsy; seizure; neuromodulation ID TRAUMATIC BRAIN-INJURY; PSYCHOGENIC NONEPILEPTIC SEIZURES; VAGUS NERVE-STIMULATION; TEMPORAL-LOBE EPILEPSY; HEAD-INJURY; REFRACTORY EPILEPSY; CONCUSSIVE CONVULSIONS; NEUROLOGIC EXAMINATION; INTRACTABLE EPILEPSY; AMERICAN-ACADEMY AB Traumatic brain injury (TBI) is one of the most common causes of acquired epilepsy, and posttraumatic epilepsy (PTE) results in significant somatic and psychosocial morbidity. The risk of developing PTE relates directly to TBI severity, but the latency to first seizure can be decades after the inciting trauma. Given this "silent period," much work has focused on identification of molecular and radiographic biomarkers for risk stratification and on development of therapies to prevent epileptogenesis. Clinical management requires vigilant neurologic surveillance and recognition of the heterogeneous endophenotypes associated with PTE. Appropriate treatment of patients who have or are at risk for seizures varies as a function of time after TBI, and the clinician's armamentarium includes an ever-expanding diversity of pharmacological and surgical options. Most recently, neuromodulation with implantable devices has emerged as a promising therapeutic strategy for some patients with refractory PTE. Here, we review the epidemiology, diagnostic considerations, and treatment options for PTE and develop a roadmap for providers encountering this challenging clinical entity. C1 [Rao, Vikram R.; Parko, Karen L.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Parko, Karen L.] San Francisco VA Med Ctr, Dept Neurol, San Francisco, CA USA. RP Rao, VR (reprint author), Univ Calif San Francisco, Epilepsy Ctr, 400 Parnassus Ave,8th Floor, San Francisco, CA 94143 USA. EM vikram.rao@ucsf.edu NR 120 TC 4 Z9 4 U1 1 U2 6 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 0271-8235 EI 1098-9021 J9 SEMIN NEUROL JI Semin. Neurol. PD FEB PY 2015 VL 35 IS 1 BP 57 EP 63 DI 10.1055/s-0035-1544239 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA CC4AP UT WOS:000350293300009 PM 25714868 ER PT J AU Jain, S Keys, D Nydam, T Plenter, RJ Edelstein, CL Jani, A AF Jain, Swati Keys, Daniel Nydam, Trevor Plenter, Robert J. Edelstein, Charles L. Jani, Alkesh TI Inhibition of autophagy increases apoptosis during re-warming after cold storage in renal tubular epithelial cells SO TRANSPLANT INTERNATIONAL LA English DT Article DE apoptosis; autophagy; cold storage; re-warming ID KIDNEY-TRANSPLANTATION; INJURY; PRESERVATION; PROTECTS; FAILURE; MICE; RAT; PARTICIPATION; BIOFLAVONOIDS; DEGENERATION AB Prolonged cold storage and re-warming (CS/REW) of kidneys are risk factors for delayed graft function (DGF). Studies in renal tubular epithelial cells (RTECs) have determined apoptosis and autophagy in models of either cold storage (CS) or re-warming alone. The effect of both cold storage and re-warming on apoptosis and autophagy, in RTECS is not known and is relevant to DGF as the kidney is subjected to both CS and re-warming. We hypothesized that CS/REW of RTECs would induce autophagy that protects against apoptosis. In CS/REW, there was increased autophagic flux of RTECs. Autophagy inhibition using an Atg5 siRNA resulted in increased cleaved caspase-3 and increased apoptotic cells (on both morphology and annexin V staining) during CS/REW. The effect of autophagy inhibition on necrosis in RTECs is unknown. There were increased necrosis and caspase-1, a mediator of necrosis, during CS/REW, and the Atg5 siRNA had no effect on necrosis and caspase-1. In a kidney transplant model, there was an increase in LC3 II, a marker of autophagy, in kidneys transplanted after cold storage. In summary, autophagic flux is increased during CS/REW. Autophagy inhibition resulted in increased cleaved caspase-3 and increased apoptosis during CS/REW without an effect on necrosis or caspase-1. In conclusion, autophagy inhibition in RTECs after CS/REW induces apoptotic cell death and may be deleterious as a therapy to decrease DGF. C1 [Jain, Swati; Keys, Daniel; Nydam, Trevor; Plenter, Robert J.; Edelstein, Charles L.; Jani, Alkesh] Univ Colorado, Denver, CO 80202 USA. [Edelstein, Charles L.; Jani, Alkesh] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Edelstein, CL (reprint author), Univ Colorado, Denver Div Renal Dis & Hypertens, 12700 East 19th Ave,C281, Aurora, CO 80045 USA. EM Charles.edelstein@ucdenver.edu FU NIDDK NIH HHS [1 R03 DK96151-01, T32 DK007135] NR 32 TC 3 Z9 3 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0934-0874 EI 1432-2277 J9 TRANSPL INT JI Transpl. Int. PD FEB PY 2015 VL 28 IS 2 BP 214 EP 223 DI 10.1111/tri.12465 PG 10 WC Surgery; Transplantation SC Surgery; Transplantation GA CD3MQ UT WOS:000350983200012 PM 25270002 ER PT J AU Tanner, CM Comella, CL AF Tanner, Caroline M. Comella, Cynthia L. TI When brawn benefits brain: physical activity and Parkinson's disease risk SO BRAIN LA English DT Editorial Material C1 [Tanner, Caroline M.] Univ Calif San Francisco, Parkinsons Dis Res Educ & Clin Ctr, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. [Tanner, Caroline M.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Comella, Cynthia L.] Rush Presbyterian St Lukes Med Ctr, Neurol Sci, Chicago, IL USA. RP Tanner, CM (reprint author), Univ Calif San Francisco, Parkinsons Dis Res Educ & Clin Ctr, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. EM caroline.tanner@ucsf.edu FU NCATS NIH HHS [U54 TR001456]; NINDS NIH HHS [U54 NS065701, U54NS065701, R01NS074343] NR 10 TC 3 Z9 3 U1 0 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0006-8950 EI 1460-2156 J9 BRAIN JI Brain PD FEB 1 PY 2015 VL 138 BP 238 EP 239 DI 10.1093/brain/awu351 PN 2 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CC2YA UT WOS:000350209900012 PM 25627233 ER PT J AU Fling, BW Nutt, JG Horak, FB AF Fling, Brett W. Nutt, John G. Horak, Fay B. TI Reply: Does dominant pedunculopontine nucleus exist? SO BRAIN LA English DT Letter ID PARKINSONS-DISEASE; GAIT; CONNECTIVITY; INHIBITION C1 [Fling, Brett W.; Nutt, John G.; Horak, Fay B.] Oregon Hlth & Sci Univ, Dept Neurol, Sch Med, Portland, OR 97239 USA. [Fling, Brett W.; Horak, Fay B.] Portland VA Med Ctr, Portland, OR 97239 USA. RP Fling, BW (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, Sch Med, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM fling@ohsu.edu FU NIA NIH HHS [R01 AG006457]; RRD VA [I01 RX001075] NR 15 TC 2 Z9 2 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0006-8950 EI 1460-2156 J9 BRAIN JI Brain PD FEB 1 PY 2015 VL 138 AR e324 DI 10.1093/brain/awu226 PN 2 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CC2YA UT WOS:000350209900002 PM 25125613 ER PT J AU Deniger, A Troller, P Kennelty, KA AF Deniger, Amanda Troller, Peggy Kennelty, Korey A. TI Geriatric Transitional Care and Readmissions Review SO JNP-JOURNAL FOR NURSE PRACTITIONERS LA English DT Review DE 30 days; care coordination; discharge; geriatrics; nurse; nurse practitioner; readmissions; transitional care; transitions AB Geriatric patients are a highly vulnerable population and are at increased risk for hospital admission and readmission. A university hospital implemented the Geriatric Transitional Care program, aimed at improving quality of care and reducing 30-day hospital readmission rates. Enrolled patients received telephone calls, and, if there was high risk for readmission, home visits from a nurse practitioner. Twenty-six (6.6%) inpatient-to-inpatient readmissions occurred, which was a 48% reduction from the hospital-wide readmission rate. Causes of readmissions fell into 6 categories. Transitional care can reduce frequency, serve as a point of contact, and monitor discharge follow-up. C1 [Deniger, Amanda; Troller, Peggy] Univ Wisconsin Hosp & Clin, Madison, WI 53792 USA. [Kennelty, Korey A.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA. [Kennelty, Korey A.] Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA. RP Deniger, A (reprint author), Univ Wisconsin Hosp & Clin, Madison, WI 53792 USA. EM adeniger@uwhealth.org FU University of Wisconsin Hospital and Clinics FX The authors thank the University of Wisconsin Hospital and Clinics, specifically Dr. Steven Barczi, Dr. Amy Kind, Julie Christofferson, Kathy Scott, Donna Cole, and Maria Brenny-Fitzpatrick, for guidance and support through the development and implementation of the program. NR 4 TC 1 Z9 1 U1 4 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1555-4155 EI 1878-058X J9 JNP-J NURSE PRACT JI JNP-J. Nurse Pract. PD FEB PY 2015 VL 11 IS 2 BP 248 EP 252 DI 10.1016/j.nurpra.2014.08.014 PG 5 WC Nursing SC Nursing GA CC7IA UT WOS:000350539700022 ER PT J AU Huttner, B Jones, M Madaras-Kelly, K Neuhauser, MM Rubin, MA Goetz, MB Samore, MH AF Huttner, Benedikt Jones, Makoto Madaras-Kelly, Karl Neuhauser, Melinda M. Rubin, Michael A. Goetz, Matthew Bidwell Samore, Matthew H. TI Initiation and termination of antibiotic regimens in Veterans Affairs hospitals SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY LA English DT Article DE antibiotic use; practice variation; infectious diseases ID ANTIBACTERIAL DRUG-USE; CONSUMPTION AB Objectives: To assess rates of starting or stopping antibiotics across different hospitals. Methods: We used barcode medication administration data to measure antibiotic use on acute-care wards in 128 Veterans Affairs medical centres (VAMCs) in 2010. A treatment day (TD) was defined as the administration of any antibiotic on a given day. A treatment period (TP) was defined as an interval of inpatient antimicrobial therapy with gaps of <= 1 day in TDs. The rate of starting antibiotics was calculated for inpatients who had not yet started antibiotics, as the number of start events divided by the 'person-time at risk'. The rate of stopping antibiotics was calculated analogously for inpatients that were on antibiotics. Once individuals had stopped antibiotics they were removed from further analysis. Per-day start and stop rates were also calculated for each day of hospitalization. Results: The hospital mean rate of starting the first TP was 18.1 start events/100 days at risk (range 8.4-25.6/100 days at risk). The mean hospital stopping rate was 21.1 stop events/100 days at risk (range 13.3-29.5/100 days at risk). The ratio of a facility's starting and stopping rates was highly correlated with overall antibiotic use in TDs/1000 patient-days (r(s) = 0.92, P<0.001), while starting and stopping rates individually were only moderately correlated (r(s) = 0.39, P<0.001). Conclusions: VAMCs with similar antibiotic use showed marked differences in their starting and stopping rates of antibiotics. It may be useful to target empirical therapy when starting rates are high and definitive therapy when stopping rates are low. C1 [Huttner, Benedikt; Jones, Makoto; Rubin, Michael A.; Samore, Matthew H.] VA Salt Lake City Hlth Care Syst, IDEAS Ctr, Salt Lake City, UT 84148 USA. [Huttner, Benedikt; Jones, Makoto; Rubin, Michael A.; Samore, Matthew H.] Univ Utah, Div Epidemiol, Salt Lake City, UT 84132 USA. [Madaras-Kelly, Karl] Boise VA Med Ctr, Boise, ID 83702 USA. [Madaras-Kelly, Karl] Idaho State Univ, Coll Pharm, Meridian, ID 83713 USA. [Neuhauser, Melinda M.] Dept Vet Affairs Pharm Benefit Management Serv, Hines, IL USA. [Goetz, Matthew Bidwell] VA Greater LA Healthcare Syst, Los Angeles, CA 90073 USA. [Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA. RP Huttner, B (reprint author), VA Salt Lake City Hlth Care Syst, 500 Foothill Dr, Salt Lake City, UT 84148 USA. EM makoto.jones@va.gov RI Huttner, Benedikt/M-5616-2014 OI Huttner, Benedikt/0000-0002-1749-9464; Goetz, Matthew/0000-0003-4542-992X FU VA Informatics and Computing Infrastructure [VA HSR HIR 08-204]; Consortium for Healthcare Informatics Research [VA HSR HIR 08-374]; Centers for Disease Control and Prevention's Prevention Epicenters Program [5U01CI000334, 07FED706504]; career development award [CDA 10-030-02]; Geneva University Hospitals, Switzerland FX This work was supported by: the VA Informatics and Computing Infrastructure (grant number VA HSR HIR 08-204); the Consortium for Healthcare Informatics Research (grant number VA HSR HIR 08-374); the Centers for Disease Control and Prevention's Prevention Epicenters Program (grant numbers 5U01CI000334 and 07FED706504); a career development award (CDA 10-030-02 to M. J.); and a fellowship grant from Geneva University Hospitals, Switzerland (to B. H.). NR 11 TC 1 Z9 1 U1 1 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-7453 EI 1460-2091 J9 J ANTIMICROB CHEMOTH JI J. Antimicrob. Chemother. PD FEB PY 2015 VL 70 IS 2 BP 598 EP 601 DI 10.1093/jac/dku388 PG 4 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA CC2YR UT WOS:000350211600035 PM 25288680 ER PT J AU Barnes, SM Russell, LM Hostetter, TA Forster, JE Devore, MD Brenner, LA AF Barnes, Sean M. Russell, Leah M. Hostetter, Trisha A. Forster, Jeri E. Devore, Maria D. Brenner, Lisa A. TI Characteristics of Traumatic Brain Injuries Sustained Among Veterans Seeking Homeless Services SO JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED LA English DT Article DE Traumatic brain injuries; homeless; Veterans ID PEOPLE; HEALTH AB This hypothesis-generating research describes the characteristics of traumatic brain injuries (TBIs) sustained among 229 Veterans seeking homeless services. Nearly all participants (83%) had sustained at least one TBI prior to their first episode of homelessness. Among participants with a TBI, assaults, transportation-related accidents, and falls were the most common causes of these injuries. Thirty percent of individuals sustained injuries with severity levels that would be expected to be associated with ongoing TBI-related deficits. Forty-three percent of the Veterans sustained at least one brain injury following their first episode of homelessness. Median lifetime number of TBIs was three. The severity of TBIs was similar among Veterans who sustained injuries before or after their first incident of homelessness. Findings suggest that future research should directly examine the potential bi-directional relationship between TBI and homelessness, as well as the impact of TBI-related deficits on Veterans' ability to benefit from homeless services and/or maintain stable housing. C1 [Barnes, Sean M.; Russell, Leah M.; Hostetter, Trisha A.; Forster, Jeri E.; Devore, Maria D.; Brenner, Lisa A.] Vet Integrated Serv Network 19 Mental Illness Res, Denver, CO USA. RP Barnes, SM (reprint author), Denver VA Med Ctr, MIRECC, 1055 Clermont St, Denver, CO 80220 USA. EM Sean.Barnes2@va.gov FU National Center on Homelessness FX The authors are associated with the Veterans Integrated Service Network 19 Mental Illness Research, Education, and Clinical Center, Denver, CO. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. We wish to thank the National Center on Homelessness for their support of this project. Correspondence should be sent to Sean M. Barnes, Denver VA Medical Center, MIRECC, 1055 Clermont Street, Denver, CO 80220 (e-mail: Sean.Barnes2@va.gov). NR 26 TC 2 Z9 2 U1 0 U2 1 PU JOHNS HOPKINS UNIV PRESS PI BALTIMORE PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD 21218-4363 USA SN 1049-2089 EI 1548-6869 J9 J HEALTH CARE POOR U JI J. Health Care Poor Underserved PD FEB PY 2015 VL 26 IS 1 BP 92 EP 105 PG 14 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA CC7BO UT WOS:000350522900011 PM 25702730 ER PT J AU Zhi, DG Shendre, A Scherzer, R Irvin, MR Perry, RT Levy, S Arnett, DK Grunfeld, C Shrestha, S AF Zhi, Degui Shendre, Aditi Scherzer, Rebecca Irvin, Marguerite R. Perry, Rodney T. Levy, Shawn Arnett, Donna K. Grunfeld, Carl Shrestha, Sadeep TI Deep sequencing of RYR3 gene identifies rare and common variants associated with increased carotid intima-media thickness (cIMT) in HIV-infected individuals SO JOURNAL OF HUMAN GENETICS LA English DT Article ID GENOME-WIDE ASSOCIATION; MICROBIAL TRANSLOCATION; ATHEROSCLEROSIS; PREDICTION; HERITABILITY; ACTIVATION; DISEASE; EVENTS; WOMEN; RISK AB Carotid intima-media thickness (cIMT) is a subclinical measure of atherosclerosis with mounting evidence that higher cIMT confers an increased risk of cardiovascular disease. The ryanodine receptor 3 gene (RYR3) has previously been linked to increased cIMT; however, the causal variants have not yet been localized. Therefore, we sequenced 339 480 bp encompassing 104 exons and 2 kb flanking region of the RYR3 gene in 96 HIV-positive white men from the extremes of the distribution of common cIMT from the Fat Redistribution and Metabolic Changes in HIV infection study (FRAM). We identified 2710 confirmed variants (2414 single-nucleotide polymorphisms (SNPs) and 296 insertion/deletions (indels)), with a mean count of 736 SNPs (ranging from 528 to 1032) and 170 indels (ranging from 128 to 214) distributed in each individual. There were 39 variants in the exons and 15 of these were non-synonymous, of which with only 4 were common variants and the remaining 11 were rare variants, one was a novel SNP. We confirmed that the common variant rs2229116 was significantly associated with cIMT in this design (P<7.9 x 10(-9)), and observed seven other significantly associated SNPs (P<10(-8)). These variants including the private non-synonymous SNPs need to be followed up in a larger sample size and also tested with clinical atherosclerotic outcomes. C1 [Zhi, Degui] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA. [Shendre, Aditi; Irvin, Marguerite R.; Perry, Rodney T.; Arnett, Donna K.; Shrestha, Sadeep] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL 35294 USA. [Scherzer, Rebecca; Grunfeld, Carl] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. [Scherzer, Rebecca; Grunfeld, Carl] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Levy, Shawn] HudsonAlpha Inst Biotechnol, Huntsville, AL USA. RP Shrestha, S (reprint author), Univ Alabama Birmingham, Dept Epidemiol, 1665 Univ Blvd,RPHB Room 217L, Birmingham, AL 35294 USA. EM sshrestha@uab.edu FU NIH [RO1-DK57508, RO1-HL74814, RO1-HL53359, K23-AI66943, UL1 RR024131, M01-RR00036, M01-RR00051, M01-RR00052, M01-RR00054, M01-RR00083, M01-RR0636, M01-RR00865]; UAB Center for AIDS Research (CFAR) developmental project (NIAID) [P30 AI027767]; Albert L. and Janet A. Schultz Supporting Foundation FX We thank investigators and staff of the Fat Redistribution and Metabolic Change in HIV Infection (FRAM) study. The FRAM study was supported by NIH grants RO1-DK57508, -HL74814 and -HL53359, K23-AI66943 and UL1 RR024131; NIH GCRC grants M01-RR00036, -RR00051, -RR00052, -RR00054, -RR00083, -RR0636 and -RR00865; the Albert L. and Janet A. Schultz Supporting Foundation and with resources and the use of facilities of the Veterans Affairs Medical Centers of Atlanta, District of Columbia, New York and San Francisco. Sequencing experiments were conducted at HudsonAlpha Institute for Biotechnology, Huntsville, AL and the genetic sub-study was supported by UAB Center for AIDS Research (CFAR; P30 AI027767) developmental project (NIAID Supplement PI: Shrestha). NR 29 TC 0 Z9 0 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1434-5161 EI 1435-232X J9 J HUM GENET JI J. Hum. Genet. PD FEB PY 2015 VL 60 IS 2 BP 63 EP 67 DI 10.1038/jhg.2014.104 PG 5 WC Genetics & Heredity SC Genetics & Heredity GA CC4WA UT WOS:000350354100002 PM 25500725 ER PT J AU Bauman, WA Cardozo, CP AF Bauman, William A. Cardozo, Christopher P. TI Osteoporosis in Individuals with Spinal Cord Injury SO PM&R LA English DT Review ID BONE-MINERAL DENSITY; QUANTITATIVE COMPUTED-TOMOGRAPHY; VITAMIN-D DEFICIENCY; PULSED ELECTROMAGNETIC-FIELDS; LOWER-EXTREMITY FRACTURES; LOW-INTENSITY VIBRATION; POSTMENOPAUSAL WOMEN; DISUSE OSTEOPOROSIS; PREVENTS BONE; MUSCLE LOSS AB The pathophysiology, clinical considerations, and relevant experimental findings with regard to osteoporosis in individuals with spinal cord injury (SCI) will be discussed. The bone loss that occurs acutely after more neurologically motor complete SCI is unique for its sublesional skeletal distribution and rate, at certain skeletal sites approaching 1% of bone mineral density per week, and its resistance to currently available treatments. The areas of high bone loss include the distal femur, proximal tibia, and more distal boney sites. Evidence from a study performed in monozygotic twins discordant for SCI indicates that sublesional bone loss in the twin with SCI increases for several decades, strongly suggesting that the heightened net bone loss after SCI may persist for an extended period of time. The increased frequency of fragility fracture after paralysis will be discussed, and a few risk factors for such fractures after SCI will be examined. Because vitamin D deficiency, regardless of disability, is a relevant consideration for bone health, as well as an easily reversible condition, the increased prevalence of and treatment target values for vitamin D in this deficiency state in the SCI population will be reviewed. Pharmacological and mechanical approaches to preserving bone integrity in persons with acute and chronic SCI will be reviewed, with emphasis placed on efficacy and practicality. Emerging osteoanabolic agents that improve functioning of WNT/beta-catenin signaling after paralysis will be introduced as therapeutic interventions that may hold promise. C1 [Bauman, William A.; Cardozo, Christopher P.] James J Peters Vet Affairs Med Ctr, Dept Vet Affairs Rehabil Res & Dev Serv, Natl Ctr Excellence Med Consequences Spinal Cord, Bronx, NY 10468 USA. [Bauman, William A.; Cardozo, Christopher P.] James J Peters VA Med Ctr, Med Serv, Bronx, NY USA. [Bauman, William A.; Cardozo, Christopher P.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [Bauman, William A.; Cardozo, Christopher P.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA. RP Bauman, WA (reprint author), James J Peters Vet Affairs Med Ctr, Dept Vet Affairs Rehabil Res & Dev Serv, Natl Ctr Excellence Med Consequences Spinal Cord, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM william.bauman@va.gov FU Veterans Affairs Rehabilitation Research and Development Service [B9212C]; James J. Peters VA Medical Center FX Supported by the Veterans Affairs Rehabilitation Research and Development Service (grant no. B9212C) and the James J. Peters VA Medical Center. NR 99 TC 11 Z9 12 U1 1 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1934-1482 EI 1934-1563 J9 PM&R JI PM&R PD FEB PY 2015 VL 7 IS 2 BP 188 EP 201 DI 10.1016/j.pmrj.2014.08.948 PG 14 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA CB9ZZ UT WOS:000349995500011 PM 25171878 ER PT J AU Maguen, S Skopp, NA Zhang, Y Smolenski, DJ AF Maguen, Shira Skopp, Nancy A. Zhang, Ying Smolenski, Derek J. TI Gender differences in suicide and suicide attempts among US Army soldiers SO PSYCHIATRY RESEARCH LA English DT Article DE Suicide; Military personnel; Female; Mental Health; Risk ID MALE VETERANS; RISK-FACTORS; MILITARY PERSONNEL; IDEATION; SERVICE; PERSPECTIVE; POPULATION; STATES; WORK AB In order to best tailor suicide prevention initiatives and programs, it is critical to gain an understanding of how service members' suicide risk factors may differ by gender. We aimed to better understand gender differences in suicide and suicide attempts among soldiers, including demographic, military, mental health, and other risk factors. We also examined risk factors uniquely associated with suicide and suicide attempts. We conducted a retrospective study of 1857 US Army soldiers who died by suicide or attempted suicide between 2008 and 2010 and had a Department of Defense Suicide Event Report. Female and male soldiers had more similarities than differences when examining risk factors associated with suicide. The only gender difference approaching significance was workplace difficulties, which was more strongly associated with suicide for female soldiers, compared to their male counterparts. Among suicide decedents, the most common risk factor was having a failed intimate relationship in the 90 days prior to suicide. Among those who attempted suicide, the most common risk factor was a major psychiatric diagnosis. Better understanding both gender differences and risk factors uniquely associated with suicide has critical prevention and public health implications as we work to better understand preventable mortality in our youngest generation of service members. Published by Elsevier Ireland Ltd. C1 [Maguen, Shira] San Francisco VA Med Ctr, San Francisco, CA USA. [Maguen, Shira] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Skopp, Nancy A.; Zhang, Ying; Smolenski, Derek J.] Natl Ctr Telehlth & Technol, Def Ctr Excellence Psychol Hlth, Joint Base Lewis McChord, Tacoma, WA USA. [Skopp, Nancy A.; Zhang, Ying; Smolenski, Derek J.] Natl Ctr Telehlth & Technol, Def Ctr Traumat Brain Injury, Joint Base Lewis McChord, Tacoma, WA USA. [Skopp, Nancy A.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Maguen, S (reprint author), San Francisco VA Med Ctr, PTSD Program 116 P, 4150 Clement St, San Francisco, CA 94121 USA. EM Shira.Maguen@va.gov NR 24 TC 1 Z9 1 U1 4 U2 10 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD FEB PY 2015 VL 225 IS 3 BP 545 EP 549 DI 10.1016/j.psychres.2014.11.050 PG 5 WC Psychiatry SC Psychiatry GA CC2NI UT WOS:000350181500048 PM 25530416 ER PT J AU Hartoonian, N Terrill, AL Of, MLBUOWS Turner, AP Day, MA Alschuler, KN AF Hartoonian, Narineh Terrill, Alexandra L. Beier, Meghan L. Turner, Aaron P. Day, Melissa A. Alschuler, Kevin N. TI Predictors of Anxiety in Multiple Sclerosis SO REHABILITATION PSYCHOLOGY LA English DT Article DE multiple sclerosis; anxiety; depression ID QUALITY-OF-LIFE; NEGATIVE AFFECTIVITY; DEPRESSION SCALE; HOSPITAL ANXIETY; COMORBID ANXIETY; RISK-FACTORS; DISORDERS; SEVERITY; FATIGUE; PREVALENCE AB Purpose/Objectives: The aims of this study were to (1) identify the predictors of symptoms of anxiety, and (2) evaluate the differential association of somatic and nonsomatic symptoms of depression on anxiety over time in persons with multiple sclerosis (MS). Method/Design: Participants were 513 persons with MS who previously enrolled in a study exploring the experience of living with MS and completed a 4-month follow-up survey. The main outcome measure used was the Hospital Anxiety and Depression Scale-Anxiety. Demographic, disease-associated variables (time since onset of MS, Expanded Disability Status Scale Mobility, pain, and fatigue), and Time 1 psychological variables were entered into a hierarchical regression model to examine predictors at baseline for anxiety symptoms at Time 2. Results: A large portion of the sample was White (92%), female (82%), and had relapsing-remitting MS (57%). After adjusting for demographic and disease related variables, anxiety (beta = .001), employment (beta = .07), and nonsomatic depressive symptoms (beta = .10) at baseline significantly predicted anxiety at Time 2, ps < .05. Interactions revealed significant effects for time since onset of MS and somatic symptoms as well as time since onset and nonsomatic symptoms, ps < .05. Nonsomatic symptoms were more linked to anxiety early in the disease and somatic symptoms were more prominently linked to anxiety later in the disease. Conclusions: Findings suggest that nonsomatic symptoms of depression and employment predict anxiety in MS. The relationship between different aspects of depression and anxiety may change over the course of the disease. C1 [Hartoonian, Narineh; Turner, Aaron P.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Hartoonian, Narineh; Turner, Aaron P.] Vet Affairs Multiple Sclerosis Ctr Excellence Wes, Seattle, WA USA. [Hartoonian, Narineh; Terrill, Alexandra L.; Beier, Meghan L.; Turner, Aaron P.; Alschuler, Kevin N.] Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA. [Day, Melissa A.] Australian Catholic Univ, Sch Psychol, Sydney, NSW 2059, Australia. RP Hartoonian, N (reprint author), Univ Washington, Sch Med, Dept Rehabil Med, VA Puget Sound Hlth Care Syst, S-117-MSCOE,1660 South Columbia Way, Seattle, WA 98108 USA. EM narhart@uw.edu OI Turner, Aaron/0000-0001-6897-8003 FU Department of Education, NIDRR [H133B031129, H133B080025]; National Institutes of Health through the NIH Roadmap for Medical Research [5U01AR052171-03]; National Multiple Sclerosis Society [MB 0008, MB0026] FX Portions of this article were presented at the 16th annual Rehabilitation Psychology Conference in San Antonio, Texas, March 1, 2014. The contents of this article were developed under grants from the Department of Education, NIDRR Grants H133B031129 and H133B080025. However, these contents do not necessarily represent the policy of the Department of Education, and you should not assume endorsement by the Federal Government. In addition, the work reported in this article was supported by a grant from the National Institutes of Health through the NIH Roadmap for Medical Research, Grant 5U01AR052171-03 to University of Washington, Amtmann (PI), and by grants from the National Multiple Sclerosis Society Grant MB 0008 (Dawn Ehde, PI) and MB0026 (Aaron Turner, PI). NR 40 TC 3 Z9 3 U1 0 U2 7 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 0090-5550 EI 1939-1544 J9 REHABIL PSYCHOL JI Rehabil. Psychol. PD FEB PY 2015 VL 60 IS 1 BP 91 EP 98 DI 10.1037/rep0000019 PG 8 WC Psychology, Clinical; Rehabilitation SC Psychology; Rehabilitation GA CC4VV UT WOS:000350353600010 PM 25496434 ER PT J AU Tipps, ME Raybuck, JD Buck, KJ Lattal, KM AF Tipps, Megan E. Raybuck, Jonathan D. Buck, Kari J. Lattal, K. Matthew TI Acute Ethanol Withdrawal Impairs Contextual Learning and Enhances Cued Learning SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE Acute Ethanol Withdrawal; Fear Conditioning; Strain Comparison; Hippocampus ID INDUCED MEMORY IMPAIRMENT; QUANTITATIVE TRAIT LOCI; ALCOHOL HANGOVER; C57BL/6 MICE; RAT HIPPOCAMPUS; MOUSE STRAINS; INBRED MICE; DBA/2 MICE; FEAR; TRACE AB BackgroundAlcohol affects many of the brain regions and neural processes that support learning and memory, and these effects are thought to underlie, at least in part, the development of addiction. Although much work has been done regarding the effects of alcohol intoxication on learning and memory, little is known about the effects of acute withdrawal from a single alcohol exposure. MethodsWe assess the effects of acute ethanol withdrawal (6hours postinjection with 4g/kg ethanol) on 2 forms of fear conditioning (delay and trace fear conditioning) in C57BL/6J and DBA/2J mice. The influence of a number of experimental parameters (pre- and post training withdrawal exposure; foreground/background processing; training strength; and nonassociative effects) is also investigated. ResultsAcute ethanol withdrawal during training had a bidirectional effect on fear-conditioned responses, decreasing contextual responses and increasing cued responses. These effects were apparent for both trace and delay conditioning in DBA/2J mice and for trace conditioning in C57BL/6J mice; however, C57BL/6J mice were selectively resistant to the effects of acute withdrawal on delay cued responses. ConclusionsOur results show that acute withdrawal from a single, initial ethanol exposure is sufficient to alter long-term learning in mice. In addition, the differences between the strains and conditioning paradigms used suggest that specific learning processes can be differentially affected by acute withdrawal in a manner that is distinct from the reported effects of both alcohol intoxication and withdrawal following chronic alcohol exposure. Thus, our results suggest a unique effect of acute alcohol withdrawal on learning and memory processes. C1 [Tipps, Megan E.; Buck, Kari J.] Portland VA Med Ctr, Portland Alcohol Res Ctr, Portland, OR USA. [Tipps, Megan E.; Raybuck, Jonathan D.; Buck, Kari J.; Lattal, K. Matthew] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. RP Tipps, ME (reprint author), VA Med Ctr, Dept Behav Neurosci, Mail Code L470, Portland, OR 97239 USA. EM metipps@gmail.com FU NIH [F32 AA022011, T32 AA07468, F32 DA031537, T32 DA07262, R01 AA011114, P60 AA10760, R24 AA020245, R01 DA005228, R01 DA025922]; VA; US Department of the Army/DOD-TAT-RC [W81XWH-12-2-0048] FX This work was supported by NIH F32 AA022011 and T32 AA07468 (MET); NIH F32 DA031537 and T32 DA07262 (JDR); NIH R01 AA011114, P60 AA10760, R24 AA020245, R01 DA005228, and the VA (KJB); and NIH R01 DA025922 and US Department of the Army/DOD-TAT-RC:W81XWH-12-2-0048 (KML). NR 50 TC 5 Z9 6 U1 2 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD FEB PY 2015 VL 39 IS 2 BP 282 EP 290 DI 10.1111/acer.12614 PG 9 WC Substance Abuse SC Substance Abuse GA CC1KZ UT WOS:000350100900009 PM 25684050 ER PT J AU Gaddikeri, S Andre, JB Benjert, J Hippe, DS Anzai, Y AF Gaddikeri, S. Andre, J. B. Benjert, J. Hippe, D. S. Anzai, Y. TI Impact of Model-Based Iterative Reconstruction on Image Quality of Contrast-Enhanced Neck CT SO AMERICAN JOURNAL OF NEURORADIOLOGY LA English DT Article ID FILTERED BACK-PROJECTION; MULTIDETECTOR ROW CT; COMPUTED-TOMOGRAPHY; DOSE REDUCTION; RADIATION-EXPOSURE; HELICAL CT; OPTIMIZATION; STRATEGIES; 64-MDCT; CANCER AB BACKGROUND AND PURPOSE: Improved image quality is clinically desired for contrast-enhanced CT of the neck. We compared 30% adaptive statistical iterative reconstruction and model-based iterative reconstruction algorithms for the assessment of image quality of contrast-enhanced CT of the neck. MATERIALS AND METHODS: Neck contrast-enhanced CT data from 64 consecutive patients were reconstructed retrospectively by using 30% adaptive statistical iterative reconstruction and model-based iterative reconstruction. Objective image quality was assessed by comparing SNR, contrast-to-noise ratio, and background noise at levels 1 (mandible) and 2 (superior mediastinum). Two independent blinded readers subjectively graded the image quality on a scale of 1-5, (grade 5 = excellent image quality without artifacts and grade 1 = nondiagnostic image quality with significant artifacts). The percentage of agreement and disagreement between the 2 readers was assessed. RESULTS: Compared with 30% adaptive statistical iterative reconstruction, model-based iterative reconstruction significantly improved the SNR and contrast-to-noise ratio at levels 1 and 2. Model-based iterative reconstruction also decreased background noise at level] (P = .016), though there was no difference at level 2 (P = .61). Model-based iterative reconstruction was scored higher than 30% adaptive statistical iterative reconstruction by both reviewers at the nasopharynx (P < .001) and oropharynx (P < .001) and for overall image quality (P < .001) and was scored lower at the vocal cords (P < .001) and sternoclavicular junction (P < .001), due to artifacts related to thyroid shielding that were specific for model-based iterative reconstruction. CONCLUSIONS: Model-based iterative reconstruction offers improved subjective and objective image quality as evidenced by a higher SNR and contrast-to-noise ratio and lower background noise within the same dataset for contrast-enhanced neck CT. Model-based iterative reconstruction has the potential to reduce the radiation dose while maintaining the image quality, with a minor downside being prominent artifacts related to thyroid shield use on model-based iterative reconstruction. C1 [Gaddikeri, S.; Andre, J. B.; Anzai, Y.] Univ Washington, Med Ctr, Dept Neuroradiol, Seattle, WA 98195 USA. [Benjert, J.] Univ Washington, Dept Neuroradiol, Seattle, WA 98195 USA. VA Puget Sound, Seattle, WA USA. [Hippe, D. S.] Univ Washington, Dept Radiol, Seattle, WA 98195 USA. RP Gaddikeri, S (reprint author), Univ Washington, Med Ctr, Dept Radiol, 1959 NE Pacific St,Box 357115, Seattle, WA 98195 USA. EM sg272@uw.edu OI Andre, Jalal/0000-0002-0896-183X NR 31 TC 5 Z9 5 U1 0 U2 3 PU AMER SOC NEURORADIOLOGY PI DENVILLE PA PO BOX 3000, DENVILLE, NJ 07834-9349 USA SN 0195-6108 EI 1936-959X J9 AM J NEURORADIOL JI Am. J. Neuroradiol. PD FEB PY 2015 VL 36 IS 2 BP 391 EP 396 DI 10.3174/ajnr.A4123 PG 6 WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA CB5GR UT WOS:000349656000027 PM 25300982 ER PT J AU Meerwijk, EL Ford, JM Weiss, SJ AF Meerwijk, Esther L. Ford, Judith M. Weiss, Sandra J. TI Resting-state EEG delta power is associated with psychological pain in adults with a history of depression SO BIOLOGICAL PSYCHOLOGY LA English DT Article DE Psychological pain; Mental pain; EEG; Depression; Nonlinear measures; Default mode network ID DEFAULT-MODE NETWORK; TRANSCRANIAL MAGNETIC STIMULATION; HEART-RATE-VARIABILITY; ALPHA ASYMMETRY; MENTAL PAIN; MAJOR DEPRESSION; FUNCTIONAL CONNECTIVITY; CONTROLLED-TRIALS; HEALTHY CONTROLS; BRAIN ACTIVITY AB Psychological pain is a prominent symptom of clinical depression. We asked if frontal alpha asymmetry, frontal EEG power, and frontal fractal dimension asymmetry predicted psychological pain in adults with a history of depression. Resting-state frontal EEG (F3/F4) was recorded while participants (N=35) sat upright with their eyes closed. Frontal delta power predicted psychological pain while controlling for depressive symptoms, with participants who exhibited less power experiencing greater psychological pain. Frontal fractal dimension asymmetry, a nonlinear measure of complexity, also predicted psychological pain, such that greater left than right complexity was associated with greater psychological pain. Frontal alpha asymmetry did not contribute unique variance to any regression model of psychological pain. As resting-state delta power is associated with the brain's default mode network, results suggest that the default mode network was less activated during high psychological pain. Findings are consistent with a state of arousal associated with psychological pain. (C) 2015 Elsevier B.V. All rights reserved. C1 [Meerwijk, Esther L.; Weiss, Sandra J.] Univ Calif San Francisco, Dept Community Hlth Syst, San Francisco, CA 94143 USA. [Ford, Judith M.] San Francisco VA Med Ctr, San Francisco, CA USA. [Ford, Judith M.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. RP Meerwijk, EL (reprint author), Univ Calif San Francisco, Dept Family Hlth Care Nursing, 2 Koret Way N411Y, San Francisco, CA 94143 USA. EM esther.meerwijk@ucsf.edu FU American Psychiatric Nursing Foundation; Sigma Theta Tau International Honor Society of Nursing, Alpha Eta Chapter; National Institute of Nursing Research [T32 NR07088]; U.S. Department of Veterans Affairs [I01CX000497]; Research Career Scientist award; Robert C & Delphine Wentland Eschbach Endowment FX We thank Gwendolyn van der Linden for her assistance in data management and implementation of the fractal dimension algorithm. Source code of the box-counting algorithm is available from the first author upon request. This study was supported by research grants from the American Psychiatric Nursing Foundation and Sigma Theta Tau International Honor Society of Nursing, Alpha Eta Chapter. Esther Meerwijk received additional support during preparation of this manuscript from the National Institute of Nursing Research Grant No. T32 NR07088. Additional support to Judith Ford during preparation of this manuscript was provided by U.S. Department of Veterans Affairs (I01CX000497) and a Research Career Scientist award. Additional support to Sandra Weiss was provided by the Robert C & Delphine Wentland Eschbach Endowment. Funding organizations were not involved in study design, data collection, analysis, or interpretation, or the decision to submit the article for publication. NR 88 TC 5 Z9 5 U1 3 U2 17 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0301-0511 EI 1873-6246 J9 BIOL PSYCHOL JI Biol. Psychol. PD FEB PY 2015 VL 105 BP 106 EP 114 DI 10.1016/j.biopsycho.2015.01.003 PG 9 WC Psychology, Biological; Behavioral Sciences; Psychology; Psychology, Experimental SC Psychology; Behavioral Sciences GA CB8WH UT WOS:000349912100012 PM 25600291 ER PT J AU Hay, RA Roach, BJ Srihari, VH Woods, SW Ford, JM Mathalon, DH AF Hay, Rachel A. Roach, Brian J. Srihari, Vinod H. Woods, Scott W. Ford, Judith M. Mathalon, Daniel H. TI Equivalent mismatch negativity deficits across deviant types in early illness schizophrenia-spectrum patients SO BIOLOGICAL PSYCHOLOGY LA English DT Article DE Event related potential; Schizophrenia spectrum; Mismatch negativity; Auditory cortex; MMN ID AUDITORY CHANGE-DETECTION; CLINICAL HIGH-RISK; 1ST-EPISODE PSYCHOSIS; HUMAN BRAIN; FEATURE CONJUNCTIONS; STIMULUS DEVIANCE; SPEECH SOUNDS; 1ST EPISODE; MMN; DURATION AB Neurophysiological abnormalities in auditory deviance processing, as reflected by the mismatch negativity (MMN), have been observed across the course of schizophrenia. Studies in early schizophrenia patients have typically shown varying degrees of MMN amplitude reduction for different deviant types, suggesting that different auditory deviants are uniquely processed and may be differentially affected by duration of illness. To explore this further, we examined the MMN response to 4 auditory deviants (duration, frequency, duration + frequency "double deviant", and intensity) in 24 schizophrenia-spectrum patients early in the illness (ESZ) and 21 healthy controls. ESZ showed significantly reduced MMN relative to healthy controls for all deviant types (p < 0.05), with no significant interaction with deviant type. No correlations with clinical symptoms were present (all ps > 0.05). These findings support the conclusion that neurophysiological mechanisms underlying processing of auditory deviants are compromised early in illness, and these deficiencies are not specific to the type of deviant presented. (C) 2015 Elsevier B.V. All rights reserved. C1 [Ford, Judith M.; Mathalon, Daniel H.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Hay, Rachel A.; Roach, Brian J.; Ford, Judith M.; Mathalon, Daniel H.] San Francisco VA Med Ctr, San Francisco, CA USA. [Srihari, Vinod H.; Woods, Scott W.] Yale Univ, Sch Med, New Haven, CT USA. RP Mathalon, DH (reprint author), San Francisco VA Med Ctr, Mental Hlth Serv 116D,4150 Clement St, San Francisco, CA 94121 USA. EM daniel.mathalon@ucsf.edu FU National Institute of Mental Health [MH076989, MH058262]; U.S. Department of Veterans Affairs [I01 CX000497] FX This work was supported by the National Institute of Mental Health (MH076989, MH058262) and the U.S. Department of Veterans Affairs (I01 CX000497). NR 88 TC 6 Z9 6 U1 0 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0301-0511 EI 1873-6246 J9 BIOL PSYCHOL JI Biol. Psychol. PD FEB PY 2015 VL 105 BP 130 EP 137 DI 10.1016/j.biopsycho.2015.01.004 PG 8 WC Psychology, Biological; Behavioral Sciences; Psychology; Psychology, Experimental SC Psychology; Behavioral Sciences GA CB8WH UT WOS:000349912100015 PM 25603283 ER PT J AU Sonnenberg, A Genta, RM AF Sonnenberg, Amnon Genta, Robert M. TI Prevalence of benign gastric polyps in a large pathology database SO DIGESTIVE AND LIVER DISEASE LA English DT Article DE Epidemiology; Fundic gland polyps; Gastric adenomas; Gastric atrophy; Gastric hyperplastic polyps; Gastric neuroendocrine tumours; Intestinal metaplasia ID PROTON-PUMP INHIBITORS; GASTROESOPHAGEAL-REFLUX DISEASE; HELICOBACTER-PYLORI; ESOPHAGEAL EOSINOPHILIA; SYDNEY SYSTEM; RISK; CLASSIFICATION; GUIDELINES; MANAGEMENT; INFECTION AB Aims: The aim of the study was to utilize a large national histopathology database for the analysis of the clinical epidemiology of gastric polyps. Methods: In a case-control study, 71,575 case subjects with gastric polyps were compared to 741,351 control subjects without gastric polyps. Results: Of all patients, 7.72% harboured fundic gland polyps, 1.79% gastric hyperplastic polyps, 0.09% gastric adenomas, and 0.06% type I neuroendocrine tumours. All types showed a clear-cut age-dependent rise. Reflux disease was significantly more common in patients with fundic gland polyps and significantly less common in patients with gastric adenomas or neuroendocrine tumours. Anaemia was more common in patients with gastric hyperplastic polyps, gastric adenomas, or neuroendocrine tumours. Helicobacter pylon was found significantly less frequently in all subjects with gastric polyps than in controls. Intestinal metaplasia and gastric atrophy were both more common in gastric adenoma and neuroendocrine tumours and less common in fundic gland polyps than in controls. Different polyp types tended to coincide in the same patients. Conclusions: Gastric hyperplastic polyps appeared to mark the beginning of a progression from chronic gastritis to intestinal metaplasia and gastric atrophy, which leads to diminished gastric acid output and increased gastrin secretion. Gastric adenoma and neuroendocrine tumours reflect later stages of this process. Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l. C1 [Sonnenberg, Amnon; Genta, Robert M.] Miraca Life Sci, Res Inst, Irving, TX USA. [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR 97239 USA. [Genta, Robert M.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 32 TC 5 Z9 5 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1590-8658 EI 1878-3562 J9 DIGEST LIVER DIS JI Dig. Liver Dis. PD FEB PY 2015 VL 47 IS 2 BP 164 EP 169 DI 10.1016/j.dld.2014.10.004 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CB9RY UT WOS:000349971300013 PM 25458775 ER PT J AU Pugh, MJ Parko, K AF Pugh, Mary Jo Parko, Karen TI Research using archival health care data: Let the buyer beware SO EPILEPSIA LA English DT Letter ID NEW-ONSET EPILEPSY; RISK-FACTORS; POPULATION; ADULTS C1 [Pugh, Mary Jo] South Texas Vet Hlth Care Syst, VA Epilepsy Ctr Excellence, San Antonio, TX 78229 USA. [Parko, Karen] San Francisco VA Med Ctr, VA Epilepsy Ctr Excellence, San Francisco, CA USA. RP Pugh, MJ (reprint author), South Texas Vet Hlth Care Syst, VA Epilepsy Ctr Excellence, San Antonio, TX 78229 USA. EM maryjo.pugh2@va.gov OI Pugh, Mary Jo/0000-0003-4196-7763 FU HSRD VA [I01 HX000717] NR 9 TC 2 Z9 2 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0013-9580 EI 1528-1167 J9 EPILEPSIA JI Epilepsia PD FEB PY 2015 VL 56 IS 2 BP 321 EP 322 DI 10.1111/epi.12873 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA CC2AH UT WOS:000350146300033 PM 25708477 ER PT J AU Gries, CJ Bhadriraju, S Edelman, JD Goss, CH Raghu, G Mulligan, MS AF Gries, Cynthia J. Bhadriraju, Sudha Edelman, Jeffrey D. Goss, Christopher H. Raghu, Ganesh Mulligan, Michael. S. TI Obese patients with idiopathic pulmonary fibrosis have a higher 90-day mortality risk with bilateral lung transplantation SO JOURNAL OF HEART AND LUNG TRANSPLANTATION LA English DT Article DE idiopathic pulmonary fibrosis; body mass index; lung transplantation; obesity; transplant type ID OFFICIAL ADULT LUNG; INTERNATIONAL-SOCIETY; MULTIPLE IMPUTATION; REGISTRY; HEART; SURVIVAL AB BACKGROUND: Obese patients with idiopathic pulmonary fibrosis (IPF) have higher 90-day mortality after lung transplantation. We sought to determine whether body mass index (BMI) differentially modified the effect of transplant procedure type on 90-day mortality in IPF patients. METHODS: We analyzed data from the Organ Procurement and Transplantation Network (OPTN) for all patients with IPF who were transplanted between 2000 and 2010. Post-transplant survival was examined using Kaplan Meier estimates. Multivariable logistic regression modeling was used to determine the difference in 90-day survival. The primary variable of interest was the interaction term between body mass index (BMI) and transplant type. RESULTS: A total of 3,389 (58% single-lung transplant [SLT] and 42% bilateral lung transplant [BLT]) subjects were included. Multivariable logistic regression modeling demonstrated a statistically significant interaction between BIVII and transplant type (p = 0.047). Patients with a BMI > 30 kg/m(2) who received a BLT are 1.71 times (95% CI [1.03 to 2.85], p = 0.038) more likely to die within 90 days than BLT recipients with a BMI of 18.5 to 30 kg/m(2). CONCLUSIONS: Our results suggest that obese patients who receive a BLT may be at higher risk of 90-day mortality compared with patients of normal weight. Further study is needed to obtain more detailed information about comorbidities and other risk factors for early death that are not included in the OPTN database. (C) 2015 International Society for Heart and Lung Transplantation. All rights reserved. C1 [Gries, Cynthia J.] Univ Pittsburgh, Med Ctr, Div Allergy Pulm & Crit Care Med, Pittsburgh, PA 15213 USA. [Bhadriraju, Sudha] Univ Pittsburgh, Med Ctr, Dept Internal Med, Pittsburgh, PA 15213 USA. [Edelman, Jeffrey D.] VA Puget Sound Healthcare Syst, Div Pulm & Crit Care Med, Seattle, WA USA. [Goss, Christopher H.; Raghu, Ganesh] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA. [Mulligan, Michael. S.] Univ Washington, Dept Surg, Seattle, WA 98195 USA. RP Gries, CJ (reprint author), Univ Pittsburgh, Med Ctr, Div Allergy Pulm & Crit Care Med, 628 NW Montefiore,3459 Fifth Ave, Pittsburgh, PA 15213 USA. EM griescj@upmc.edu FU National Institutes of Health (NIH); National Center for Research Resources (NCRR); NIH Roadmap for Medical Research [5KL2RR025015] FX The authors have no conflicts of interest to disclose. This study was supported by the National Center for Research Resources (NCRR) from a component of the National Institutes of Health (NIH) and NIH Roadmap for Medical Research (5KL2RR025015). NR 18 TC 6 Z9 6 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1053-2498 EI 1557-3117 J9 J HEART LUNG TRANSPL JI J. Heart Lung Transplant. PD FEB PY 2015 VL 34 IS 2 BP 241 EP 246 DI 10.1016/j.healun.2014.09.031 PG 6 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery; Transplantation SC Cardiovascular System & Cardiology; Respiratory System; Surgery; Transplantation GA CC1DV UT WOS:000350082300015 PM 25447567 ER PT J AU Marcus, BS McAvay, G Gill, TM Fragoso, CAV AF Marcus, Brian S. McAvay, Gail Gill, Thomas M. Fragoso, Carlos A. Vaz TI Respiratory Symptoms, Spirometric Respiratory Impairment, and Respiratory Disease in Middle-Aged and Older Persons SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE spirometry; Z-scores; respiratory impairment; respiratory symptoms ID OBSTRUCTIVE PULMONARY-DISEASE; LUNG-FUNCTION; CHRONIC-BRONCHITIS; PREVALENCE; DYSPNEA; GUIDELINES; MANAGEMENT; VALUES; ADULTS; COPD AB ObjectivesTo evaluate whether a novel definition of spirometric respiratory impairment from the Global Lung Initiative (GLI) is strongly associated with respiratory symptoms and, in turn, frequently establishes symptomatic respiratory disease. DesignCross-sectional. SettingThird National Health and Nutrition Examination Survey. ParticipantsCommunity-dwelling individuals aged 40 to 80 (N=7,115). MeasurementsGLI-defined spirometric respiratory impairment (airflow obstruction and restrictive pattern), dyspnea on exertion (DOE), chronic bronchitis (CB), and wheezing. ResultsPrevalence rates were 12.7% for airflow obstruction, 6.2% for restrictive pattern, 28.6% for DOE, 12.6% for CB, and 12.9% for wheezing. Airflow obstruction was associated with DOE (adjusted odds ratio (aOR)=1.69, 95% confidence interval (CI)=1.42-2.02), CB (aOR=1.92, 95% CI=1.62-2.29), and wheezing (aOR=2.50, 95% CI=2.08-3.00), and restrictive pattern was associated with DOE (aOR=1.75, 95% CI=1.36-2.25), CB (aOR=1.39, 95% CI=1.08-1.78), and wheezing (aOR=1.53, 95% CI=1.15-2.04). Nonetheless, among participants who had airflow obstruction and restrictive pattern, only a minority had DOE (38.6% and 45.5%), CB (23.3% and 15.9%), and wheezing (24.4% and 19.1%), yielding a positive predictive value (PPV) of only 53% for any respiratory symptom in the setting of any spirometric respiratory impairment. In addition, most participants who had DOE (73.0%), CB (67.8%), and wheezing (66.8%) did not have airflow obstruction or restrictive pattern, yielding a PPV of only 26% for any spirometric respiratory impairment in the setting of any respiratory symptom. The results differed only modestly when stratified according to age (40-64 vs 65-80). ConclusionGLI-defined spirometric respiratory impairment increased the likelihood of respiratory symptoms but was nonetheless a poor predictor of respiratory symptoms. Similarly, respiratory symptoms were poor predictors of GLI-defined spirometric respiratory impairment. Hence, a comprehensive assessment is needed when evaluating respiratory symptoms, even in the presence of spirometric respiratory impairment. C1 [Marcus, Brian S.; McAvay, Gail; Gill, Thomas M.; Fragoso, Carlos A. Vaz] Yale Univ, Sch Med, New Haven, CT USA. [Fragoso, Carlos A. Vaz] US Dept Vet Affairs, Clin Epidemiol Res Ctr, West Haven, CT USA. RP Fragoso, CAV (reprint author), VA Connecticut Healthcare Syst, Clin Epidemiol Res Ctr, 950 Campbell Ave,Mailcode 151B, West Haven, CT 06516 USA. EM carlos.fragoso@yale.edu FU Yale Claude D. Pepper Older Americans Independence Center [P30AG021342]; Veterans Administration Merit Award; National Institute on Aging [K07AG043587]; START@Yale Program FX The study was conducted at the Yale Claude D. Pepper Older Americans Independence Center (Grant P30AG021342). Dr. Vaz Fragoso is the recipient of a Veterans Administration Merit Award. Dr. Gill is the recipient of Academic Leadership Award K07AG043587 from the National Institute on Aging. Mr. Brian Marcus is the recipient of support from the START@Yale Program. NR 38 TC 6 Z9 6 U1 2 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD FEB PY 2015 VL 63 IS 2 BP 251 EP 257 DI 10.1111/jgs.13242 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA CB8PP UT WOS:000349893300005 PM 25643966 ER PT J AU Jennings, LA Reuben, DB Evertson, LC Serrano, KS Ercoli, L Grill, J Chodosh, J Tan, Z Wenger, NS AF Jennings, Lee A. Reuben, David B. Evertson, Leslie Chang Serrano, Katherine S. Ercoli, Linda Grill, Joshua Chodosh, Joshua Tan, Zaldy Wenger, Neil S. TI Unmet Needs of Caregivers of Individuals Referred to a Dementia Care Program SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE dementia; primary care; caregiver strain ID QUALITY-OF-LIFE; SELF-EFFICACY; ALZHEIMERS-DISEASE; FAMILY CAREGIVERS; BEHAVIORAL-PROBLEMS; MANAGING DEMENTIA; STRAIN INDEX; OLDER-ADULTS; HEALTH; STRESS AB ObjectivesTo characterize caregiver strain, depressive symptoms, and self-efficacy for managing dementia-related problems and the relationship between these and referring provider type. DesignCross-sectional observational cohort. SettingUrban academic medical center. ParticipantsCaregivers of community-dwelling adults with dementia referred to a dementia care management program. MeasurementsCaregivers were surveyed and completed the Patient Health Questionnaire (PHQ-9) about themselves; the Modified Caregiver Strain Index; the Neuropsychiatric Inventory Questionnaire, which measures patient symptom severity and related caregiver distress; and a nine-item caregiver self-efficacy scale developed for the study. ResultsOf 307 patient-caregiver dyads surveyed over a 1-year period, 32% of caregivers reported confidence in managing dementia-related problems, 19% knew how to access community services to help provide care, and 28% agreed that the individual's provider helped them work through dementia care problems. Thirty-eight percent reported high levels of caregiver strain, and 15% reported moderate to severe depressive symptoms. Caregivers of individuals referred by geriatricians more often reported having a healthcare professional to help work through dementia care problems than those referred by internists, family physicians, or other specialists, but self-efficacy did not differ. Low caregiver self-efficacy was associated with higher caregiver strain, more caregiver depressive symptoms, and caring for an individual with more-severe behavioral symptoms. ConclusionMost caregivers perceived inadequate support from the individual's provider in managing dementia-related problems, reported strain, and had low confidence in managing caregiving. New models of care are needed to address the complex care needs of individuals with dementia and their caregivers. C1 [Jennings, Lee A.; Reuben, David B.; Evertson, Leslie Chang; Serrano, Katherine S.; Chodosh, Joshua; Tan, Zaldy] Univ Calif Los Angeles, Multicampus Program Geriatr Med & Gerontol, Los Angeles, CA 90095 USA. [Wenger, Neil S.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. [Ercoli, Linda] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Grill, Joshua] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA. [Grill, Joshua] Univ Calif Los Angeles, Mary Easton Ctr Alzheimers Dis Res, Los Angeles, CA 90095 USA. [Chodosh, Joshua] Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. RP Jennings, LA (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr, 10945 Le Conte Ave,Suite 2339, Los Angeles, CA 90095 USA. EM lajennings@mednet.ucla.edu OI Chodosh, Joshua/0000-0001-7784-4306 FU Avanir; Bristol-Myers Squibb; Eli Lilly; Genentech; Janssen Alzheimer Immunotherapy; Medivation; Merck; Alzheimer's Disease Cooperative Study; Centers for Medicare and Medicaid Services Centers for Medicare and Medicaid Innovation [CMS-1C1-12-0001, 1C1CMS330982-01-00]; UCLA Claude Pepper Older Americans Independence Center - National Institute on Aging [5P30AG028748]; National Institutes of Health, National Center for Advancing Translational Science FX All authors report no conflict of interest associated with this paper. Dr. Joshua Grill has received grant and research support as a site investigator for clinical trials sponsored by Avanir, Bristol-Myers Squibb, Eli Lilly, Genentech, Janssen Alzheimer Immunotherapy, Medivation, Merck, and the Alzheimer's Disease Cooperative Study.; The project described was supported by Funding Opportunity CMS-1C1-12-0001 from the Centers for Medicare and Medicaid Services (1C1CMS330982-01-00) Centers for Medicare and Medicaid Innovation and the UCLA Claude Pepper Older Americans Independence Center funded by the National Institute on Aging (5P30AG028748) and the National Institutes of Health, National Center for Advancing Translational Science. The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the Department of Health and Human Services or any of its agencies. NR 44 TC 7 Z9 8 U1 3 U2 13 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD FEB PY 2015 VL 63 IS 2 BP 282 EP 289 DI 10.1111/jgs.13251 PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA CB8PP UT WOS:000349893300009 PM 25688604 ER PT J AU Ghosh, S Lertwattanarak, R Garduno, JD Galeana, JJ Li, JQ Zamarripa, F Lancaster, JL Mohan, S Hussey, S Musi, N AF Ghosh, Sangeeta Lertwattanarak, Raweewan Garduno, Jose de Jesus Galeana, Joaquin Joya Li, Jinqi Zamarripa, Frank Lancaster, Jack L. Mohan, Sumathy Hussey, Sophie Musi, Nicolas TI Elevated Muscle TLR4 Expression and Metabolic Endotoxemia in Human Aging SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE Aging; LPS; TLR4; NF kappa B; JNK; Sarcopenia ID INDUCED INSULIN-RESISTANCE; NF-KAPPA-B; TYPE-2 DIABETIC SUBJECTS; RODENT SKELETAL-MUSCLE; FREE FATTY-ACID; GLUCOSE-TOLERANCE; OXIDATIVE STRESS; ACUTE EXERCISE; INFLAMMATORY MARKERS; ELDERLY SUBJECTS AB Aging is associated with alterations in glucose metabolism and sarcopenia that jointly contribute to a higher risk of developing type 2 diabetes. Because aging is considered as a state of low-grade inflammation, in this study we examined whether older, healthy (lean, community-dwelling) participants have altered signaling flux through toll-like receptor 4 (TLR4), a key mediator of innate and adaptive immune responses. We also examined whether a 4-month aerobic exercise program would have an anti-inflammatory effect by reducing TLR4 expression and signaling. At baseline, muscle TLR4, nuclear factor kappa B p50 and nuclear factor kappa B p65 protein content, and c-Jun N-terminal kinase phosphorylation were significantly elevated in older versus young participants. The plasma concentration of the TLR4 agonist lipopolysaccharide and its binding protein also were significantly elevated in older participants, indicative of metabolic endotoxemia, which is a recently described phenomenon of increased plasma endotoxin level in metabolic disease. These alterations in older participants were accompanied by decreased insulin sensitivity, quadriceps muscle volume, and muscle strength. The exercise training program increased insulin sensitivity, without affecting quadriceps muscle volume or strength. Muscle TLR4, nuclear factor kappa B, and c-Jun N-terminal kinase, and plasma lipopolysaccharide and lipopolysaccharide binding protein were not changed by exercise. In conclusion, insulin resistance and sarcopenia of aging are associated with increased TLR4 expression/signaling, which may be secondary to metabolic endotoxemia. C1 [Ghosh, Sangeeta; Hussey, Sophie; Musi, Nicolas] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Audie L Murphy VA Hosp, San Antonio, TX 78229 USA. [Ghosh, Sangeeta; Hussey, Sophie; Musi, Nicolas] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Ghosh, Sangeeta; Lertwattanarak, Raweewan; Garduno, Jose de Jesus; Galeana, Joaquin Joya; Hussey, Sophie; Musi, Nicolas] Univ Texas Hlth Sci Ctr San Antonio, Ctr Hlth Aging, San Antonio, TX 78229 USA. [Li, Jinqi; Zamarripa, Frank; Lancaster, Jack L.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA. [Mohan, Sumathy] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. RP Musi, N (reprint author), South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Audie L Murphy VA Hosp, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM musi@uthscsa.edu FU American Diabetes Association; National Institutes of Health [DK-80157, DK-089229]; San Antonio Nathan Shock Center [AG-013319]; American Federation for Aging Research [AG-030979]; National Institute on Aging; Institutional Ruth L. Kirchstein National research Service Award (NRSA) [T32-HL-04776] FX This study was supported by grants from the American Diabetes Association (N.M.), the National Institutes of Health (DK-80157 and DK-089229 to N.M.), the San Antonio Nathan Shock Center (AG-013319). N.M. was the recipient of a Paul B. Beeson Career Development Award (AG-030979) from the American Federation for Aging Research and the National Institute on Aging. S.G. was supported by an Institutional Ruth L. Kirchstein National research Service Award (NRSA) (T32-HL-04776). NR 75 TC 18 Z9 18 U1 1 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5006 EI 1758-535X J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD FEB PY 2015 VL 70 IS 2 BP 232 EP 246 DI 10.1093/gerona/glu067 PG 15 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA CC1RR UT WOS:000350121100013 PM 24846769 ER PT J AU Lee, T Phan, R Nham, P Moatamed, N AF Lee, Thomas Phan, Ryan Nham, Phillipp Moatamed, Neda TI Post Hoc Assessment of B-Cell and T-Cell Gene Rearrangements From Cytology Smears SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2015 VL 28 SU 2 MA 375 BP 96A EP 96A PG 1 WC Pathology SC Pathology GA CB3BF UT WOS:000349502200376 ER PT J AU Malec, M Weiner, DK Shega, JW AF Malec, Monica Weiner, Debra K. Shega, Joseph W. TI Optimal Pharmacologic Pain Management in the Older Adult: An Ongoing Quagmire SO PAIN MEDICINE LA English DT Editorial Material C1 [Malec, Monica] Univ Chicago, Dept Med, Sect Geriatr & Palliat Med, Chicago, IL 60637 USA. [Weiner, Debra K.] VA Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Med, Div Geriatr Med, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Anesthesiol, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA USA. [Shega, Joseph W.] Vitas Healthcare, Miami, FL USA. RP Malec, M (reprint author), Univ Chicago, Dept Med, Sect Geriatr & Palliat Med, 5841 S Maryland Ave, Chicago, IL 60637 USA. NR 3 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1526-2375 EI 1526-4637 J9 PAIN MED JI Pain Med. PD FEB PY 2015 VL 16 IS 2 BP 217 EP 218 DI 10.1111/pme.12653 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA CB9UU UT WOS:000349979600001 PM 25521331 ER PT J AU Steinman, MA Komaiko, KDR Fung, KZ Ritchie, CS AF Steinman, Michael A. Komaiko, Kiya D. R. Fung, Kathy Z. Ritchie, Christine S. TI Use of Opioids and Other Analgesics by Older Adults in the United States, 1999-2010 SO PAIN MEDICINE LA English DT Article DE Opioid Analgesics; Aged; Physician's Practice Patterns; Pharmacoepidemiology; Analgesics; United States ID EMERGENCY-DEPARTMENTS; COMPARATIVE SAFETY; NONMALIGNANT PAIN; NONCANCER PAIN; TRENDS; PRESCRIPTION; WORKERS; RISK; CARE; AGE AB Background and ObjectiveThere has been concern over rising use of prescription opioids in young and middle-aged adults. Much less is known about opioid prescribing in older adults, for whom clinical recommendations and the balance of risks and benefits differ from younger adults. We evaluated changes in use of opioids and other analgesics in a national sample of clinic visits made by older adults between 1999 and 2010. Design, Setting, and SubjectsObservational study of adults aged 65 and older from the 1999-2010 National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey, serial cross-sectional surveys of outpatient visits in the United States. MethodsMedication use was assessed at each study visit and included medications in use prior to the visit and medications newly prescribed at the visit. Results were adjusted for survey weights and design factors to provide nationally representative estimates. ResultsMean age was 757 years, and 45% of visits occurred in primary care settings. Between 1999-2000 and 2009-2010, the percent of clinic visits at which an opioid was used rose from 4.1% to 9.0% (P<0.001). Although use of all major opioid classes increased, the largest contributor to increased use was hydrocodone-containing combination opioids, which rose from 1.1% to 3.5% of visits over the study period (P<0.001). Growth in opioid use was observed across a wide range of patient and clinic characteristics, including in visits for musculoskeletal problems (10.7% of visits in 1999-2000 to 17.0% in 2009-2010, P<0.001) and in visits for other reasons (2.8% to 7.3%, P<0.001). ConclusionsOpioid use by older adults visiting clinics more than doubled between 1999 and 2010, and occurred across a wide range of patient characteristics and clinic settings. C1 [Steinman, Michael A.; Komaiko, Kiya D. R.; Fung, Kathy Z.; Ritchie, Christine S.] Univ Calif San Francisco, San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA 94141 USA. RP Steinman, MA (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, Div Geriatr, 4150 Clement St,VA Box 181G, San Francisco, CA 94141 USA. EM mike.steinman@ucsf.edu FU National Institute of Aging; American Federation for Aging Research [1K23-AG030999, 1K07AG31779] FX Funding sources: This study was supported by the National Institute of Aging and by the American Federation for Aging Research (1K23-AG030999 [MAS] and 1K07AG31779 [CSR]). The sponsors had no role in the design, analysis, authorship, or decision to publish this work. NR 26 TC 12 Z9 12 U1 1 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1526-2375 EI 1526-4637 J9 PAIN MED JI Pain Med. PD FEB PY 2015 VL 16 IS 2 BP 319 EP 327 DI 10.1111/pme.12613 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA CB9UU UT WOS:000349979600016 PM 25352175 ER PT J AU Ganzini, L Rakoski, A Cohn, S Mularski, RA AF Ganzini, Linda Rakoski, Alexa Cohn, Sharilyn Mularski, Richard A. TI Family members' views on the benefits of harp music vigils for terminally-ill or dying loved ones SO PALLIATIVE & SUPPORTIVE CARE LA English DT Article DE Music; palliative care; family; dyspnea; spirituality AB Objectives: Music-thanatology is a palliative modality that uses harp and voice to provide bedside vigils, particularly for terminally ill or actively dying. We sought to determine the benefits of music vigils for terminally ill patients. Methods: Survey of 55 family members, whose terminally ill loved one experienced a music vigil during hospitalization, regarding effects on the patient's breathing, relaxation, comfort, pain and ability to sleep. Written comments on negative and positive results of the vigils were coded using content analysis. Results: Family members perceived that the vigils resulted in modest improvement in the patients' breathing, relaxation, comfort, and ability to sleep, with fewer positive effects on pain, and almost no negative effects. Open ended comments focused on the positive benefit in increasing calm, relaxation, comfort. Comments on the positive effects for the family were almost as common as comments on the positive results for the patient. Significance of Results: The use of music-vigils in palliative care should be investigated more extensively as our study supports that this intervention has benefits, almost no risk, minimal cost, and may improve patient-family experience of the dying process. C1 [Ganzini, Linda] Portland VA Med Ctr, Hlth Serv Res & Dev, Portland, OR USA. [Ganzini, Linda] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Rakoski, Alexa] Univ Notre Dame, Notre Dame, IN 46556 USA. [Cohn, Sharilyn] SacredFlight, Portland, OR USA. [Mularski, Richard A.] Kaiser Permanente, Portland, OR USA. RP Ganzini, L (reprint author), Portland VA Med Ctr, R&D 66, POB 1034, Portland, OR 97207 USA. EM Linda.Ganzini@va.gov NR 6 TC 0 Z9 0 U1 4 U2 8 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1478-9515 EI 1478-9523 J9 PALLIAT SUPPORT CARE JI Palliat. Support Care PD FEB PY 2015 VL 13 IS 1 BP 41 EP 44 DI 10.1017/S1478951513000564 PG 4 WC Health Policy & Services SC Health Care Sciences & Services GA CB6TA UT WOS:000349758400006 PM 24128665 ER PT J AU Colombero, C Catano, G Rocco, CA Mecikovsky, D Bologna, R Aulicino, PC Sen, LS Mangano, A AF Colombero, Cecilia Catano, Gabriel Rocco, Carlos A. Mecikovsky, Debora Bologna, Rosa Aulicino, Paula C. Sen, Luisa Mangano, Andrea TI Role of 3 Lipoprotein Lipase Variants in Triglycerides in Children Receiving Highly Active Antiretroviral Therapy SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE lipoprotein lipase; triglycerides; highly active antiretroviral therapy; children; human immunodeficiency virus-1 infection ID HUMAN-IMMUNODEFICIENCY-VIRUS; CORONARY-ARTERY-DISEASE; CARDIOVASCULAR RISK-FACTORS; HIV PROTEASE INHIBITORS; MIDDLE-AGED MEN; GENE POLYMORPHISMS; INFECTED CHILDREN; HEART-DISEASE; YOUNG-ADULTS; LIPID-LEVELS AB Background: Lipoprotein lipase is a key enzyme in lipid metabolism, especially for plasma triglycerides (TGs). Genetic variants have been associated with lipid levels in healthy individuals, cardiovascular disease, obesity and diabetes. Our aim was to evaluate the influence of 3 polymorphisms: Hind III, Pvu II and S447X in plasma TG levels in human immunodeficiency virus-1-infected children under highly active antiretroviral therapy (HAART). Methods: Fifty-two children diagnosed with human immunodeficiency virus-1 between 2005 and 2009 were retrospectively selected with at least 1 plasma TG level assessment. TG levels were examined before and after 1 year of HAART. Hypertriglyceridemia was defined as TG > 150 mg/dL. Hind III (H+/H-), Pvu II (P+/P-) and S447X (S/X) were determined by polymerase chain reaction and restricted fragment length polymorphism. The Wilcoxon sum-rank test was used to compare median plasma TG among groups. Also, allelic frequencies were estimated for these variants in an Argentinean population. Results: Allelic frequencies for human immunodeficiency virus-1-infected children were: H-, 0.21; P-, 0.53; and X, 0.05 with no significant differences to controls. After 1 year of HAART, median TG levels were significantly lower in P-/P-(98.5 mg/dL) when compared with P+/P+ (180 mg/dL) (P = 0.039). The presence of the P-allele was associated with an 11-fold lower risk of hypertriglyceridemia. Hind III and S447X were not associated with TG at the selected time points. Conclusions: Our findings suggest a protective effect of lipoprotein lipase polymorphisms against hypertriglyceridemia in children after 1 year of HAART. These results could endorse a prompt nutritional or pharmacological intervention in patients lacking the P-allele. C1 [Colombero, Cecilia; Rocco, Carlos A.; Aulicino, Paula C.; Sen, Luisa; Mangano, Andrea] Hosp Pediat Dr JP Garrahan, Lab Biol Celular & Retrovirus, RA-1245 Buenos Aires, DF, Argentina. [Catano, Gabriel] South Texas Vet Hlth Care Syst, Vet Affairs Res Ctr AIDS & HIV Infect 1, San Antonio, TX USA. [Catano, Gabriel] South Texas Vet Hlth Care Syst, Ctr Personalized Med, San Antonio, TX USA. [Catano, Gabriel] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Mecikovsky, Debora; Bologna, Rosa; Mangano, Andrea] Hosp Pediat Dr JP Garrahan, Serv Epidemiol & Infectol, Buenos Aires, DF, Argentina. [Aulicino, Paula C.; Sen, Luisa; Mangano, Andrea] Consejo Nacl Invest Cient & Tecn CONICET, Buenos Aires, DF, Argentina. RP Mangano, A (reprint author), Hosp Pediat Dr JP Garrahan, Lab Biol Celular & Retrovirus, Combate Pozos 1881, RA-1245 Buenos Aires, DF, Argentina. EM amangano@garrahan.gov.ar FU Fogarty AITRP [D43TW001037]; Fondo Nacional para Ciencia y Tecnologia (FONCYT-ANPCyT, PICT) [1235] FX This work was supported, in part, by Fogarty AITRP grant #D43TW001037 and by Fondo Nacional para Ciencia y Tecnologia (FONCYT-ANPCyT, PICT 2006 No. 1235). NR 72 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0891-3668 EI 1532-0987 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD FEB PY 2015 VL 34 IS 2 BP 155 EP 161 DI 10.1097/INF.0000000000000474 PG 7 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA CB8VE UT WOS:000349908800011 PM 24988117 ER PT J AU Crytzer, TM Dicianno, BE Robertson, RJ Cheng, YT AF Crytzer, T. M. Dicianno, B. E. Robertson, R. J. Cheng, Yu-Ting TI VALIDITY OF A WHEELCHAIR PERCEIVED EXERTION SCALE (WHEEL SCALE) FOR ARM ERGOMETRY EXERCISE IN PEOPLE WITH SPINA BIFIDA SO PERCEPTUAL AND MOTOR SKILLS LA English DT Article ID CHILDRENS OMNI SCALE; PHYSICAL-ACTIVITY; YOUNG-ADULTS; RESISTANCE EXERCISE; HEART-RATE; STEPPING EXERCISE; AEROBIC FITNESS; RPE SCALE; VALIDATION; ADOLESCENTS AB This study assessed the concurrent and construct validity of the Borg 6-20 Scale and WHEEL Scale during arm ergometry exercise stress testing in (n = 24) adolescents and adults with spina bifida. Significant, moderate, positive correlations were observed between power output and relative heart rate and power output to relative VO(2)peak. Further, a moderate, significant correlation between physiologic criterion variables and the rating of perceived exertion derived from the Borg Scale and the WHEEL Scale was found. Concurrent validity was supported by the following findings: (1) relative heart rate was significantly correlated with the Borg (Kendall's tau =.41) and WHEEL Scales (tau =.44), and relative VO2 was significantly correlated with the Borg (tau =.46) and WHEEL Scales (tau =.47); (2) content validity was supported by the finding that the Borg and WHEEL Scales shared significant variance (tau =.70), demonstrating internal consistency. The WHEEL Scale shows strong potential for use in this cohort subsequent to further testing and validation. C1 [Crytzer, T. M.] Vet Affairs Pittsburgh Healthcare Syst, Sch Hlth & Rehabil Sci, Human Engn Res Labs, Pittsburgh, PA USA. [Crytzer, T. M.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Crytzer, T. M.] Univ Pittsburgh, Med Ctr, Ctr Assist Technol, Pittsburgh, PA USA. [Dicianno, B. E.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Dicianno, B. E.] Univ Pittsburgh, Med Ctr, UPMC Mercy Hosp, Adult Outpatient Spina Bifida Clin, Pittsburgh, PA USA. [Dicianno, B. E.] Univ Pittsburgh, Med Ctr, Childrens Hosp Pittsburgh, Pittsburgh, PA USA. [Robertson, R. J.] Univ Pittsburgh, Sch Educ, Ctr Exercise & Hlth Fitness Res, Pittsburgh, PA 15260 USA. [Cheng, Yu-Ting] Chung Shan Med Univ, Sch Phys Therapy, Taichung, Taiwan. RP Crytzer, TM (reprint author), 6425 Bakery Sq,Suite 400, Pittsburgh, PA 15206 USA. EM tmc38@pitt.edu FU Spina Bifida Association; Ashley Rose Foundation through the Spina Bifida Association Young Investigators Award FX This study was funded by the Spina Bifida Association and Ashley Rose Foundation through the Spina Bifida Association 2011 Young Investigators Award. The authors wish to thank our participants, without whom this study would not have been possible. We thank the exercise physiologists who conducted the exercise testing, Mr. Steve Anthony and Ms. Shannon Speight, Division of Endocrinology and Metabolism, University of Pittsburgh. We thank Mr. and Mrs. Pitek who provided funding for this project through the Ashley Rose Foundation with love and honor of their daughter Ashley Rose. Without their generous support and the support of the Spina Bifida Association, we would not have been able to conduct this study. NR 49 TC 0 Z9 0 U1 0 U2 3 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0031-5125 EI 1558-688X J9 PERCEPT MOTOR SKILL JI Percept. Mot. Skills PD FEB PY 2015 VL 120 IS 1 BP 304 EP 322 DI 10.2466/15.08.PMS.120v12x8 PG 19 WC Psychology, Experimental SC Psychology GA CC4RP UT WOS:000350341200023 PM 25650508 ER PT J AU Bush, NE Dobscha, SK Crumpton, R Denneson, LM Hoffman, JE Crain, A Cromer, R Kinn, JT AF Bush, Nigel E. Dobscha, Steven K. Crumpton, Rosa Denneson, Lauren M. Hoffman, Julia E. Crain, Aysha Cromer, Risa Kinn, Julie T. TI A Virtual Hope Box Smartphone App as an Accessory to Therapy: Proof-of-Concept in a Clinical Sample of Veterans SO SUICIDE AND LIFE-THREATENING BEHAVIOR LA English DT Article ID COGNITIVE THERAPY; SUICIDE ATTEMPTS; INTERVENTION; PREVENTION; INJURY AB A Hope Box is a therapeutic tool employed by clinicians with patients who are having difficulty coping with negative thoughts and stress, including patients who may be at risk of suicide or nonsuicidal self-harm. We conducted a proof-of-concept test of a Virtual Hope Box (VHB)a smartphone app that delivers patient-tailored coping tools. Compared with a conventional hope box integrated into VA behavioral health treatment, high-risk patients and their clinicians used the VHB more regularly and found the VHB beneficial, useful, easy to set up, and said they were likely to use the VHB in the future and recommend the VHB to peers. C1 [Bush, Nigel E.; Crumpton, Rosa; Kinn, Julie T.] US Dept Def, Natl Ctr Telehlth & Technol T2, Tacoma, WA USA. [Dobscha, Steven K.; Denneson, Lauren M.; Crain, Aysha; Cromer, Risa] Portland VA Med Ctr, Portland Ctr Improve Vet Involvement Care CIVIC, Portland, OR USA. [Dobscha, Steven K.; Denneson, Lauren M.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Hoffman, Julia E.] VA Palo Alto Hlth Care Syst, Natl Ctr PTSD, Palo Alto, CA USA. RP Bush, NE (reprint author), Natl Ctr Telehlth & Technol T2, OMAMC, Joint Base Lewis McChord, 9933 West Hayes St, Tacoma, WA 98431 USA. EM nigel.e.bush.civ@mail.mil FU Military Suicide Research Consortium (MSRC); Office of the Assistant Secretary of Defense for Health Affairs [W81XWH-10-2-0178] FX The views expressed are those of the authors and do not reflect the official policy of the Department of Defense or the U.S. Government. This work was in part supported by the Military Suicide Research Consortium (MSRC), an effort supported by the Office of the Assistant Secretary of Defense for Health Affairs under Award No. W81XWH-10-2-0178. Opinions, interpretations, conclusions and recommendations are those of the authors and are not necessarily endorsed by the MSRC or the Department of Defense. NR 18 TC 6 Z9 7 U1 3 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0363-0234 EI 1943-278X J9 SUICIDE LIFE-THREAT JI Suicide Life-Threat. Behav. PD FEB PY 2015 VL 45 IS 1 BP 1 EP 9 DI 10.1111/sltb.12103 PG 9 WC Psychiatry; Psychology, Multidisciplinary SC Psychiatry; Psychology GA CC0BA UT WOS:000349998700001 PM 24828126 ER PT J AU Lee, P Murphy, B Miller, R Menon, V Banik, NL Giglio, P Lindhorst, SM Varma, AK Vandergrift, WA Patel, SJ Das, A AF Lee, Philip Murphy, Ben Miller, Rickey Menon, Vivek Banik, Naren L. Giglio, Pierre Lindhorst, Scott M. Varma, Abhay K. Vandergrift, William A., III Patel, Sunil J. Das, Arabinda TI Mechanisms and Clinical Significance of Histone Deacetylase Inhibitors: Epigenetic Glioblastoma Therapy SO ANTICANCER RESEARCH LA English DT Review DE Clinical trials; epigenetics; glioblastoma; histone deacetylase inhibitor; preclinical trials; review ID CEREBROSPINAL-FLUID PHARMACOKINETICS; HUMAN GLIOMA-CELLS; PHASE-II TRIAL; HDAC INHIBITORS; VALPROIC ACID; IN-VIVO; QUISINOSTAT JNJ-26481585; NONHUMAN-PRIMATES; CANCER-TREATMENT; UP-REGULATION AB Glioblastoma is the most common and deadliest of malignant primary brain tumors (Grade IV astrocytoma) in adults. Current standard treatments have been improving but patient prognosis still remains unacceptably devastating. Glioblastoma recurrence is linked to epigenetic mechanisms and cellular pathways. Thus, greater knowledge of the cellular, genetic and epigenetic origin of glioblastoma is the key for advancing glioblastoma treatment. One rapidly growing field of treatment, epigenetic modifiers; histone deacetylase inhibitors (HDACis), has now shown much promise for improving patient outcomes through regulation of the acetylation states of histone proteins (a form of epigenetic modulation) and other non-histone protein targets. HDAC inhibitors have been shown, in a pre-clinical setting, to be effective anticancer agents via multiple mechanisms, by up-regulating expression of tumor suppressor genes, inhibiting oncogenes, inhibiting tumor angiogenesis and up-regulating the immune system. There are many HDAC inhibitors that are currently in pre-clinical and clinical stages of investigation for various types of cancers. This review will explain the theory of epigenetic cancer therapy, identify HDAC inhibitors that are being investigated for glioblastoma therapy, explain the mechanisms of therapeutic effects as demonstrated by pre-clinical and clinical studies and describe the current status of development of these drugs as they pertain to glioblastoma therapy. C1 [Lee, Philip; Murphy, Ben; Miller, Rickey; Menon, Vivek; Banik, Naren L.; Giglio, Pierre; Lindhorst, Scott M.; Varma, Abhay K.; Vandergrift, William A., III; Patel, Sunil J.; Das, Arabinda] Med Univ S Carolina, Dept Neurol & Neurosurg, Charleston, SC 29425 USA. [Lee, Philip; Murphy, Ben; Miller, Rickey; Menon, Vivek; Banik, Naren L.; Giglio, Pierre; Lindhorst, Scott M.; Varma, Abhay K.; Vandergrift, William A., III; Patel, Sunil J.; Das, Arabinda] Med Univ S Carolina, MUSC Brain & Spine Tumor Program, Charleston, SC 29425 USA. [Banik, Naren L.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Giglio, Pierre] Ohio State Univ, Wexner Med Coll, Dept Neurol Surg, Columbus, OH 43210 USA. RP Das, A (reprint author), Med Univ S Carolina, Dept Neurol & Neurosurg, Charleston, SC 29425 USA. EM dasa@musc.edu FU Office of Research and Development; Department of Veterans Affairs [101BX001262, SC SCIRF-11-002]; Jerry Zucker Fund for Brain Tumor Research at the MUSC Foundation; American Brain Tumor Association Medical Student Summer Fellowship in Honor of Paul Fabri; [NS-38146]; [NS-41088] FX Completion of this investigation was made possible in part by the grants NS-38146, NS-41088. This work in part was supported by a merit award from the Office of Research and Development, Department of Veterans Affairs (101BX001262) and SC SCIRF-11-002), the Jerry Zucker Fund for Brain Tumor Research at the MUSC Foundation and the American Brain Tumor Association Medical Student Summer Fellowship in Honor of Paul Fabri. We thank the Medical University of South Carolina, Department of Neurosurgery and College of Medicine, for assistance. We appreciate consultation for illustration by Lane Brown. NR 77 TC 10 Z9 10 U1 2 U2 13 PU INT INST ANTICANCER RESEARCH PI ATHENS PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE SN 0250-7005 EI 1791-7530 J9 ANTICANCER RES JI Anticancer Res. PD FEB PY 2015 VL 35 IS 2 BP 615 EP 625 PG 11 WC Oncology SC Oncology GA CB4LG UT WOS:000349598600002 PM 25667438 ER PT J AU Kristensen, SL Jhund, PS Kober, L Preiss, D Kjekshus, J McKelvie, RS Zile, MR Anand, IS Wikstrand, J Wedel, H Komajda, M Carson, PE Cleland, JGF McMurray, JJV AF Kristensen, Soren L. Jhund, Pardeep S. Kober, Lars Preiss, David Kjekshus, John McKelvie, Robert S. Zile, Michael R. Anand, Inder S. Wikstrand, John Wedel, Hans Komajda, Michel Carson, Peter E. Cleland, John G. F. McMurray, John J. V. TI Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction SO EUROPEAN JOURNAL OF HEART FAILURE LA English DT Article DE Heart failure; Clinical trials; HF-PEF; HF-REF; Mortality ID ROSUVASTATIN; TRIAL; PROGRESSION; IRBESARTAN; DESIGN; CORONA AB AimsTo investigate the prognostic significance of hospitalization for worsening heart failure (WHF), myocardial infarction (MI), and stroke in patients with chronic heart failure (HF). Methods and resultsWe studied 5011 patients with HF and reduced EF (HF-REF) in the CORONA trial and 4128 patients with HF and preserved EF (HF-PEF) in the I-Preserve trial. Adjusted hazard ratios (HRs) for death were estimated for 0-30 days and 31 days after first post-randomization WHF, MI, or stroke used as a time-dependent variable, compared with patients with none of these events. In CORONA, 1616 patients (32%) had post-randomization first events (1223 WHF, 216 MI, 177 stroke), and the adjusted HR for mortality 30 days after an event was: WHF 7.21 [95% confidence interval (CI) 2.05-25.40], MI 23.08 (95% CI 6.44-82.71), and stroke 32.15 (95% CI 8.93-115.83). The HR for mortality at >30 days was: WHF 3.62 (95% CI 3.11-4.21), MI 4.41 (95% CI 3.23-6.02), and stroke 3.19 (95% CI 2.21-4.61). In I-Preserve, 896 patients (22%) experienced a post-randomization event (638 WHF, 111 MI, 147 stroke). The HR for mortality 30 days was WHF 31.77 (95% CI 7.60-132.81), MI 154.77 (95% CI 34.21-700.17), and stroke 223.30 (95% CI 51.42-969.78); for >30 days it was WHF 3.36 (95% CI 2.79-4.05), MI 3.29 (95% CI 2.14-5.06), and stroke 5.13 (95% CI 3.61-7.29). ConclusionsIn patients with both HF-REF and HF-PEF, hospitalization for WHF was associated with high early and late mortality. The early relative risk of death was not as great as following MI or stroke, but the longer term relative risk of death was similar following all three types of event. Numerically, more deaths occurred following WHF because it was a much more common event. C1 [Kristensen, Soren L.; Jhund, Pardeep S.; Preiss, David; McMurray, John J. V.] Univ Glasgow, BHF Cardiovasc Res Ctr, Glasgow G12 8TA, Lanark, Scotland. [Kristensen, Soren L.] Gentofte Univ Hosp, Dept Cardiol, Copenhagen, Denmark. [Kober, Lars] Univ Copenhagen, Rigshosp, Dept Cardiol, DK-2100 Copenhagen, Denmark. [Kjekshus, John] Univ Oslo, Rikshosp, Dept Cardiol, N-0027 Oslo, Norway. [McKelvie, Robert S.] McMaster Univ, Hamilton Hlth Sci, Hamilton, ON, Canada. [Zile, Michael R.] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. [Zile, Michael R.] Med Univ S Carolina, Charleston, SC 29425 USA. [Anand, Inder S.] Vet Affairs Med Ctr, Minneapolis, MN USA. [Anand, Inder S.] Univ Minnesota, Minneapolis, MN USA. [Wikstrand, John] Gothenburg Univ, Wallenberg Lab Cardiovasc Res, Sahlgrenska Acad, Gothenburg, Sweden. [Wedel, Hans] Nord Sch Publ Hlth, Gothenburg, Sweden. [Komajda, Michel] Univ Paris 06, Hosp Pitie Salpetriere, Paris, France. [Komajda, Michel] Inst ICAN, Paris, France. [Carson, Peter E.] Georgetown Univ, Washington, DC USA. [Carson, Peter E.] Washington DC Vet Affairs Med Ctr, Washington, DC USA. [Cleland, John G. F.] Univ London Imperial Coll Sci Technol & Med, Royal Brompton Hosp, Natl Heart & Lung Inst, London, England. [Cleland, John G. F.] Univ London Imperial Coll Sci Technol & Med, Harefield Hosp, Natl Heart & Lung Inst, London, England. RP McMurray, JJV (reprint author), Univ Glasgow, BHF Cardiovasc Res Ctr, Inst Cardiovasc & Med Sci, Glasgow G12 8TA, Lanark, Scotland. EM john.mcmurray@glasgow.ac.uk OI Cleland, John/0000-0002-1471-7016; Preiss, David/0000-0003-3139-1836; Jhund, Pardeep/0000-0003-4306-5317; mcmurray, john/0000-0002-6317-3975 NR 17 TC 4 Z9 4 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1388-9842 EI 1879-0844 J9 EUR J HEART FAIL JI Eur. J. Heart Fail. PD FEB PY 2015 VL 17 IS 2 BP 169 EP 176 DI 10.1002/ejhf.211 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CB5NT UT WOS:000349675200010 PM 25756844 ER PT J AU Goedecke, JH Chorell, E Livingstone, DEW Stimson, RH Hayes, P Adams, K Dave, JA Victor, H Levitt, NS Kahn, SE Seckl, JR Walker, BR Olsson, T AF Goedecke, J. H. Chorell, E. Livingstone, D. E. W. Stimson, R. H. Hayes, P. Adams, K. Dave, J. A. Victor, H. Levitt, N. S. Kahn, S. E. Seckl, J. R. Walker, B. R. Olsson, T. TI Glucocorticoid receptor gene expression in adipose tissue and associated metabolic risk in black and white South African women SO INTERNATIONAL JOURNAL OF OBESITY LA English DT Article ID 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1; INSULIN-RESISTANCE; VISCERAL OBESITY; MESSENGER-RNA; INFLAMMATION; SENSITIVITY; FAT; BETA; ADIPOGENESIS; REGULATOR AB BACKGROUND: Black women have lower visceral adipose tissue (VAT) but are less insulin sensitive than white women; the mechanisms responsible are unknown. OBJECTIVE: The study aimed to test the hypothesis that variation in subcutaneous adipose tissue (SAT) sensitivity to glucocorticoids might underlie these differences. METHODS: Body fatness (dual energy X-ray absorptiometry) and distribution (computerized tomography), insulin sensitivity (SI, intravenous and oral glucose tolerance tests), and expression of 11 beta-hydroxysteroid dehydrogenase-1 (11HSD1), hexose-6-phosphate dehydrogenase and glucocorticoid receptor-alpha (GR alpha), as well as genes involved in adipogenesis and inflammation were measured in abdominal deep SAT, superficial SAT and gluteal SAT (GLUT) depots of 56 normal-weight or obese black and white premenopausal South African (SA) women. We used a combination of univariate and multivariate statistics to evaluate ethnic-specific patterns in adipose gene expression and related body composition and insulin sensitivity measures. RESULTS: Although 11HSD1 activity and mRNA did not differ by ethnicity, GRa mRNA levels were significantly lower in SAT of black compared with white women, particularly in the GLUT depot (0.52 +/- 0.21 vs 0.91 +/- 0.26 AU, respectively, P < 0.01). In black women, lower SAT GRa mRNA levels were associated with increased inflammatory gene transcript levels and abdominal SAT area, and reduced adipogenic gene transcript levels, VAT/SAT ratio and SI. Abdominal SAT 11HSD1 activity associated with increased VAT area and decreased SI in white, but not in black women. CONCLUSIONS: In black SA women, downregulation of GRa mRNA levels with obesity and reduced insulin sensitivity, possibly via increased SAT inflammation, is associated with reduced VAT accumulation. C1 [Goedecke, J. H.] S African MRC, Noncommunicable Dis Res Unit, ZA-7505 Cape Town, South Africa. [Goedecke, J. H.; Victor, H.] UCT MRC Res Unit Exercise Sci & Sports Med, Dept Human Biol, Cape Town, South Africa. [Chorell, E.; Olsson, T.] Umea Univ, Dept Publ Hlth & Clin Med, Umea, Sweden. [Livingstone, D. E. W.; Stimson, R. H.; Seckl, J. R.; Walker, B. R.] Univ Edinburgh, Univ British Heart Fdn Ctr Cardiovasc Sci, Endocrinol Unit, Edinburgh, Midlothian, Scotland. [Hayes, P.; Adams, K.] Univ Cape Town, Dept Plast Surg, Div Surg, ZA-7925 Cape Town, South Africa. [Dave, J. A.; Levitt, N. S.] Univ Cape Town, Dept Med, Div Diabet & Endocrinol, ZA-7925 Cape Town, South Africa. [Kahn, S. E.] VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA USA. [Kahn, S. E.] Univ Washington, Seattle, WA 98195 USA. RP Goedecke, JH (reprint author), S African MRC, Noncommunicable Dis Res Unit, POB 19070, ZA-7505 Cape Town, South Africa. EM julia.goedecke@mrc.ac.za RI Goedecke, Julia/E-1820-2016 OI Goedecke, Julia/0000-0001-6795-4771; Kahn, Steven/0000-0001-7307-9002 FU South African Medical Research Council; International Atomic Energy Agency; National Research Foundation of South Africa; Royal Society SA-UK Science Networks Program; University of Cape Town; British Heart Foundation; Welcome Trust; United States Department of Veterans Affairs; Swedish Heart and Lung Foundation FX We thank the research volunteers for their participation in this study. J Bergman and N Fenton of Symington Radiology are thanked for performing the computerized tomography scans and L Bewerunge is thanked for performing the dual-energy X-ray absorptiometry scans. S West is acknowledged for her clinical support. This study was funded by the South African Medical Research Council, the International Atomic Energy Agency, the National Research Foundation of South Africa and Royal Society SA-UK Science Networks Program, the University of Cape Town, the British Heart Foundation, the Welcome Trust, the United States Department of Veterans Affairs and the Swedish Heart and Lung Foundation. NR 41 TC 1 Z9 1 U1 0 U2 5 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0307-0565 EI 1476-5497 J9 INT J OBESITY JI Int. J. Obes. PD FEB PY 2015 VL 39 IS 2 BP 303 EP 311 DI 10.1038/ijo.2014.94 PG 9 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA CB3UA UT WOS:000349553200016 PM 24854429 ER PT J AU Cook, JW Piper, ME Leventhal, AM Schlam, TR Fiore, MC Baker, TB AF Cook, Jessica W. Piper, Megan E. Leventhal, Adam M. Schlam, Tanya R. Fiore, Michael C. Baker, Timothy B. TI Anhedonia as a Component of the Tobacco Withdrawal Syndrome SO JOURNAL OF ABNORMAL PSYCHOLOGY LA English DT Article DE anhedonia; tobacco withdrawal; tobacco dependence; smoking cessation ID SMOKING-CESSATION PHARMACOTHERAPIES; BRAIN REWARD FUNCTION; NICOTINE DEPENDENCE; NEGATIVE AFFECT; BEHAVIORAL ACTIVATION; DEPRESSIVE SYMPTOMS; RESPONSE-INHIBITION; WISCONSIN INVENTORY; HEDONIC CAPACITY; OPPONENT-PROCESS AB Animal research suggests that anhedonia is a tobacco withdrawal symptom, but this topic has not been addressed definitively in research with humans. This research sought to determine whether anhedonia is (a) an element of the tobacco withdrawal syndrome in humans and (b) an impediment to successful tobacco cessation. Data were from 1,175 smokers (58.3% women; 85.5% White) participating in a randomized double-blind, placebo-controlled trial of smoking cessation pharmacotherapies. Ecological momentary assessments for 5 days before and 10 days after the target quit day were used to assess anhedonia and other established withdrawal symptoms. Consistent with drug withdrawal, anhedonia showed an inverted-U pattern of change in response to tobacco cessation and was associated with the severity of other withdrawal symptoms and tobacco dependence. Postquit anhedonia was associated with decreased latency to relapse (hazard ratio = 1.09, 95% confidence interval [CI] [1.02, 1.17]) and with lower 8-week point-prevalence abstinence (odds ratio = .91, 95% CI [.86, .97])-relations that remained significant when other withdrawal symptoms were included as predictors. Finally, nicotine replacement therapy nearly fully suppressed the increase in abstinence-related anhedonia (beta = -.66, p < .001), suggesting agonist suppression of withdrawal. Results suggest that anhedonia is a unique and motivationally significant element of the tobacco withdrawal syndrome in humans. These results have implications for defining and assessing tobacco use disorder and for understanding and treating tobacco addiction. C1 [Cook, Jessica W.; Piper, Megan E.; Schlam, Tanya R.; Fiore, Michael C.; Baker, Timothy B.] Ctr Tobacco Res & Intervent, Madison, WI 53711 USA. [Cook, Jessica W.; Piper, Megan E.; Schlam, Tanya R.; Fiore, Michael C.; Baker, Timothy B.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53706 USA. [Cook, Jessica W.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Leventhal, Adam M.] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA. [Leventhal, Adam M.] Univ So Calif, Keck Sch Med, Dept Psychol, Los Angeles, CA 90033 USA. RP Cook, JW (reprint author), Ctr Tobacco Res & Intervent, 1930 Monroe St,Suite 200, Madison, WI 53711 USA. EM jwcook@ctri.medicine.wisc.edu FU National Cancer Institute [9P50CA143188]; General Clinical Research Centers Program of the National Center for Research Resources, National Institutes of Health (NIH) [M01 RR03186]; NIH [K08DA02131, K08DA025041, K05CA139871]; Health Resources and Services Administration [T32HP10010]; Wisconsin Partnership Program FX This research was supported in part by Grant 9P50CA143188 from the National Cancer Institute to the University of Wisconsin Center for Tobacco Research and Intervention; Grant M01 RR03186 from the General Clinical Research Centers Program of the National Center for Research Resources, National Institutes of Health (NIH); Grants K08DA02131, K08DA025041, and K05CA139871 from NIH; a National Research Service Award (T32HP10010) from the Health Resources and Services Administration to the University of Wisconsin Department of Family Medicine; and by the Wisconsin Partnership Program. Medication was provided to participants at no cost under a research agreement with GlaxoSmithKline; no part of this article was written or edited by anyone employed by GlaxoSmithKline. The authors have no conflicts of interest to declare. NR 77 TC 12 Z9 12 U1 13 U2 20 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0021-843X EI 1939-1846 J9 J ABNORM PSYCHOL JI J. Abnorm. Psychol. PD FEB PY 2015 VL 124 IS 1 BP 215 EP 225 DI 10.1037/abn0000016 PG 11 WC Psychology, Clinical; Psychology, Multidisciplinary SC Psychology GA CB6QY UT WOS:000349752800020 PM 25384069 ER PT J AU Keo-Meier, CL Herman, LI Reisner, SL Pardo, ST Sharp, C Babcock, JC AF Keo-Meier, Colton L. Herman, Levi I. Reisner, Sari L. Pardo, Seth T. Sharp, Carla Babcock, Julia C. TI Testosterone Treatment and MMPI-2 Improvement in Transgender Men: A Prospective Controlled Study SO JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY LA English DT Article DE transgender; psychopathology; hormonal sex-reassignment therapy; female-to-male; testosterone ID GENDER IDENTITY DISORDER; TO-MALE TRANSSEXUALS; CROSS-SEX HORMONES; PSYCHIATRIC COMORBIDITY; REPLACEMENT THERAPY; ENDOCRINE TREATMENT; HEALTH; DEPRESSION; STRESS; ADULT AB Objective: Most transgender men desire to receive testosterone treatment in order to masculinize their bodies. In this study, we aimed to investigate the short-term effects of testosterone treatment on psychological functioning in transgender men. This is the 1st controlled prospective follow-up study to examine such effects. Method: We examined a sample of transgender men (n = 48) and nontransgender male (n = 53) and female (n = 62) matched controls (mean age = 26.6 years; 74% White). We asked participants to complete the Minnesota Multiphasic Personality Inventory (2nd ed., or MMPI-2; Butcher, Graham, Tellegen, Dahlstrom, & Kaemmer, 2001) to assess psychological functioning at baseline and at the acute posttreatment follow-up (3 months after testosterone initiation). Regression models tested (a) Gender x Time interaction effects comparing divergent mean response profiles across measurements by gender identity; (b) changes in psychological functioning scores for acute postintervention measurements, adjusting for baseline measures, comparing transgender men with their matched nontransgender male and female controls and adjusting for baseline scores; and (c) changes in meeting clinical psychopathological thresholds. Results: Statistically significant changes in MMPI-2 scale scores were found at 3-month follow-up after initiating testosterone treatment relative to baseline for transgender men compared with female controls (female template): reductions in Hypochondria (p = .05), Depression (p = .05), Hysteria (p = .05), and Paranoia (p = .01); and increases in Masculinity-Femininity scores (p = .01). Gender = Time interaction effects were found for Hysteria (p = .05) and Paranoia (p = .01) relative to female controls (female template) and for Hypochondria (p = .05), Depression (p = .01), Hysteria (p = .01), Psychopathic Deviate (p = .05), Paranoia (p = .01), Psychasthenia (p = .01), and Schizophrenia (p = .01) compared with male controls (male template). In addition, the proportion of transgender men presenting with co-occurring psychopathology significantly decreased from baseline compared with 3-month follow-up relative to controls (p = .05). Conclusions: Findings suggest that testosterone treatment resulted in increased levels of psychological functioning on multiple domains in transgender men relative to nontransgender controls. These findings differed in comparisons of transgender men with female controls using the female template and with male controls using the male template. No iatrogenic effects of testosterone were found. These findings suggest a direct positive effect of 3 months of testosterone treatment on psychological functioning in transgender men. C1 [Keo-Meier, Colton L.] Univ Houston, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77204 USA. [Keo-Meier, Colton L.] Baylor Coll Med, Houston, TX 77030 USA. [Herman, Levi I.; Sharp, Carla; Babcock, Julia C.] Univ Houston, Houston, TX 77204 USA. [Herman, Levi I.] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Reisner, Sari L.] Harvard Sch Publ Hlth & Fenway Hlth, Boston, MA USA. [Pardo, Seth T.] Alliant Int Univ, San Diego, CA USA. RP Keo-Meier, CL (reprint author), Univ Houston, Dept Psychol, 126 Heyne Bldg, Houston, TX 77204 USA. EM ckeo-meier@uh.edu OI Babcock, Julia/0000-0001-6049-8988; Sharp, Carla/0000-0001-8349-4701 FU American Psychological Association Division 44 Matthew W. Scholarship Award; University of Houston Women, Gender, & Sexuality Studies Blanche Espy Chenoweth Graduate Fellowship award; University of Houston Small Grants Program; University of Houston; University of Houston College of Liberal Arts and Sciences Graduate Scholarship; Parents, Families, and Friends of Lesbians and Gays (PFLAG) HATCH Scholarship; Houston Transgender Unity Committee Peggy Rudd Scholarship; National Institutes of Mental Health [1R01MH094323-01] FX Funding for this study was provided by the American Psychological Association Division 44 Matthew W. Scholarship Award for Female to Male Transgender Research; the University of Houston Women, Gender, & Sexuality Studies Blanche Espy Chenoweth Graduate Fellowship award; the University of Houston Small Grants Program awarded to Julia C. Babcock; the University of Houston Start-Up Funding awarded to Carla Sharp; the University of Houston College of Liberal Arts and Sciences Graduate Scholarship; the Parents, Families, and Friends of Lesbians and Gays (PFLAG) HATCH Scholarship; and the Houston Transgender Unity Committee Peggy Rudd Scholarship. Sari L. Reisner was supported by National Institutes of Mental Health Grant 1R01MH094323-01. NR 69 TC 10 Z9 10 U1 4 U2 18 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0022-006X EI 1939-2117 J9 J CONSULT CLIN PSYCH JI J. Consult. Clin. Psychol. PD FEB PY 2015 VL 83 IS 1 BP 143 EP 156 DI 10.1037/a0037599 PG 14 WC Psychology, Clinical SC Psychology GA CB4PY UT WOS:000349611500013 PM 25111431 ER PT J AU Cicero, DC Docherty, AR Becker, TM Martin, EA Kerns, JG AF Cicero, David C. Docherty, Anna R. Becker, Theresa M. Martin, Elizabeth A. Kerns, John G. TI ABERRANT SALIENCE, SELF-CONCEPT CLARITY, AND INTERVIEW-RATED PSYCHOTIC-LIKE EXPERIENCES SO JOURNAL OF PERSONALITY DISORDERS LA English DT Article ID HIGH-RISK; 1ST-EPISODE PSYCHOSIS; PERSONALITY-DISORDERS; STRUCTURED INTERVIEW; MAGICAL IDEATION; 5-FACTOR MODEL; SCHIZOPHRENIA; SCHIZOTYPY; SYMPTOMS; ESTEEM AB Many social-cognitive models of psychotic-like symptoms posit a role for self-concept and aberrant salience. Previous work has shown that the interaction between aberrant salience and self-concept clarity is associated with self-reported psychotic-like experiences. In the current research with two structured interviews, the interaction between aberrant salience and self-concept clarity was found to be associated with interview-rated psychotic-like experiences. The interaction was associated with psychotic-like experiences composite scores, delusional ideation, grandiosity, and perceptual anomalies. In all cases, self-concept clarity was negatively associated with psychotic-like experiences at high levels of aberrant salience, but unassociated with psychotic-like experiences at low levels of aberrant salience. The interaction was specific to positive psychotic-like experiences and not present for negative or disorganized ratings. The interaction was not mediated by self-esteem levels. These results provide further evidence that aberrant salience and self-concept clarity play an important role in the generation of psychotic-like experiences. C1 [Cicero, David C.] Univ Hawaii Manoa, Honolulu, HI 96822 USA. [Docherty, Anna R.] Virginia Commonwealth Univ, Richmond, VA 23284 USA. [Becker, Theresa M.] Univ Washington, Seattle, WA 98195 USA. [Martin, Elizabeth A.] Vet Affairs Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. [Kerns, John G.] Univ Missouri, Columbia, MO 65211 USA. RP Cicero, DC (reprint author), Univ Hawaii Manoa, Dept Psychol, Sakamaki Hall,D406,2530 Dole St, Honolulu, HI 96822 USA. EM dcicero@hawaii.edu RI Cicero, David/E-2046-2016 OI Cicero, David/0000-0002-5666-9139; Docherty, Anna/0000-0001-7139-7007 FU National Research Service Award from the National Institute of Mental Health FX Work on this article was supported by a National Research Service Award from the National Institute of Mental Health. NR 75 TC 3 Z9 3 U1 3 U2 9 PU GUILFORD PUBLICATIONS INC PI NEW YORK PA 72 SPRING STREET, NEW YORK, NY 10012 USA SN 0885-579X EI 1943-2763 J9 J PERS DISORD JI J. Pers. Disord. PD FEB PY 2015 VL 29 IS 1 BP 79 EP 99 PG 21 WC Psychiatry SC Psychiatry GA CB6MS UT WOS:000349741700006 PM 25102085 ER PT J AU Xu, K Krystal, JH Ning, YP Chen, DC He, HB Wang, DP Ke, XY Zhang, XF Ding, Y Liu, YP Gueorguieva, R Wang, ZH Limoncelli, D Pietrzak, RH Petrakis, IL Zhang, XY Fan, N AF Xu, Ke Krystal, John H. Ning, Yuping Chen, Da Chun He, Hongbo Wang, Daping Ke, Xiaoyin Zhang, Xifan Ding, Yi Liu, Yuping Gueorguieva, Ralitza Wang, Zuoheng Limoncelli, Diana Pietrzak, Robert H. Petrakis, Ismene L. Zhang, Xiangyang Fan, Ni TI Preliminary analysis of positive and negative syndrome scale in ketamine-associated psychosis in comparison with schizophrenia SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE Ketamine psychosis; Schizophrenia; Positive and Negative Syndrome Scale (PANSS); Factor analysis; Symptom severity ID GENDER-DIFFERENCES; WORKING-MEMORY; SUBANESTHETIC KETAMINE; RECEPTOR HYPOFUNCTION; COGNITIVE IMPAIRMENT; HEALTHY-VOLUNTEERS; THOUGHT-DISORDER; NMDA ANTAGONIST; 5-FACTOR MODEL; ANIMAL-MODEL AB Objective: Studies of the effects of the N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, ketamine, have suggested similarities to the symptoms of schizophrenia. Our primary goal was to evaluate the dimensions of the Positive and Negative Syndrome Scale (PANSS) in ketamine users (acute and chronic) compared to schizophrenia patients (early and chronic stages). Method: We conducted exploratory factor analysis for the PANSS from four groups: 135 healthy subject administrated ketamine or saline, 187 inpatients of ketamine abuse; 154 inpatients of early course schizophrenia and 522 inpatients of chronic schizophrenia. Principal component factor analyses were conducted to identify the factor structure of the PANSS. Results: Factor analysis yielded five factors for each group: positive, negative, cognitive, depressed, excitement or dissociation symptoms. The symptom dimensions in two schizophrenia groups were consistent with the established five-factor model (Wallwork et al., 2012). The factor structures across four groups were similar, with 19 of 30 symptoms loading on the same factor in at least 3 of 4 groups. The factors in the chronic ketamine group were more similar to the factors in the two schizophrenia groups rather than to the factors in the acute ketamine group. Symptom seventies were significantly different across the groups (Kruskal Wallis chi(2)(4) = 540.6, p < 0.0001). Symptoms in the two ketamine groups were milder than in the two schizophrenia groups (Cohen's d = 0.7). Conclusion: Our results provide the evidence of similarity in symptom dimensions between ketamine psychosis and schizophrenia psychosis. The interpretations should be cautious because of potential confounding factors. (C) 2014 Elsevier Ltd. All rights reserved. C1 [Xu, Ke; Krystal, John H.; Gueorguieva, Ralitza; Pietrzak, Robert H.; Petrakis, Ismene L.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Ning, Yuping; He, Hongbo; Wang, Daping; Ke, Xiaoyin; Ding, Yi; Liu, Yuping; Fan, Ni] Guangzhou Med Univ, Guangzhou Brain Hosp, Affiliated Brain Hosp, Guangzhou 510370, Guangdong, Peoples R China. [Xu, Ke; Krystal, John H.; Limoncelli, Diana; Pietrzak, Robert H.; Petrakis, Ismene L.] US Dept Vet Affairs, VA Connecticut Healthcare Syst, West Haven, CT USA. [Zhang, Xifan] Guangzhou Baiyun Mental Hlth Hosp, Guangzhou, Guangdong, Peoples R China. [Gueorguieva, Ralitza; Wang, Zuoheng] Yale Univ, Dept Biostat, Sch Publ Hlth, New Haven, CT USA. [Chen, Da Chun; Zhang, Xiangyang] Peking Univ, Beijing Hui Long Guan Hosp, Biol Psychiat Ctr, Beijing 100096, Peoples R China. RP Fan, N (reprint author), Guangzhou Brain Hosp, 36 Mingxin Rd, Guangzhou 510370, Guangdong, Peoples R China. EM fanni2005@126.com OI Gueorguieva, Ralitza/0000-0003-0944-5973 FU Chinese National Key Clinical Program in Psychiatry to Guangzhou Brain Hospital; Health Bureau of Guangzhou, China [20131A011091]; National Institute on Drug Abuse, US [K12 DA000167]; APA/Merck Early Academic Career Award, US FX This work is supported by grants from Chinese National Key Clinical Program in Psychiatry to Guangzhou Brain Hospital and from Health Bureau of Guangzhou (No: 20131A011091), China, the grant K12 DA000167 from National Institute on Drug Abuse, US, and APA/Merck Early Academic Career Award, US. NR 55 TC 7 Z9 7 U1 2 U2 8 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 EI 1879-1379 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD FEB PY 2015 VL 61 BP 64 EP 72 DI 10.1016/j.jpsychires.2014.12.012 PG 9 WC Psychiatry SC Psychiatry GA CB6IP UT WOS:000349731000010 PM 25560772 ER PT J AU Zvolensky, MJ Kotov, R Schechter, CB Gonzalez, A Vujanovic, A Pietrzak, RH Crane, M Kaplan, J Moline, J Southwick, SM Feder, A Udasin, I Reissman, DB Luft, BJ AF Zvolensky, Michael J. Kotov, Roman Schechter, Clyde B. Gonzalez, Adam Vujanovic, Anka Pietrzak, Robert H. Crane, Michael Kaplan, Julia Moline, Jacqueline Southwick, Steven M. Feder, Adriana Udasin, Iris Reissman, Dori B. Luft, Benjamin J. TI Post-disaster stressful life events and WTC-related posttraumatic stress, depressive symptoms, and overall functioning among responders to the World Trade Center disaster SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE Stress exposure; Stress generation; Depression; Disaster; Trauma ID PTSD CHECKLIST PCL; RISK-FACTORS; PSYCHOMETRIC PROPERTIES; RECOVERY WORKERS; VICTIMS SPEAK; CENTER RESCUE; FIT INDEXES; DISORDER; EXPOSURE; RESILIENCE AB Background: The current study examined contributions of post-disaster stressful life events in relation to the maintenance of WTC-related posttraumatic stress, depressive symptoms, and overall functioning among rescue, recovery, and clean-up workers who responded to the September 11, 2001 World Trade Center (WTC) terrorist attacks. Methods: Participants were 18,896 WTC responders, including 8466 police officers and 10,430 non-traditional responders (85.8% male; 86.4% Caucasian; M-age = 39.5, SD = 8.8) participating in the WTC Health Program who completed an initial examination between July, 2002 and April, 2010 and who were reassessed, on average, 2.5 years later. Results: Path analyses were conducted to evaluate contributions of life events to the maintenance of WTC-related posttraumatic stress, depressive symptoms, and overall functioning. These analyses were stratified by police and non-traditional responder groups and adjusted for age, sex, time from 9/11 to initial visit, WTC exposures (three WTC contextual exposures: co-worker, friend, or a relative died in the disaster; co-worker, friend, or a relative injured in the disaster; and responder was exposed to the dust cloud on 9/11), and interval from initial to first follow-up visit. In both groups, WTC-related posttraumatic stress, depressive symptoms, and overall functioning were stable over the follow-up period. WTC exposures were related to these three outcomes at the initial assessment. WTC-related posttraumatic stress, depressive symptoms, and overall functioning, at the initial assessment each predicted the occurrence of post-disaster stressful life events, as measured by Disaster Supplement of the Diagnostic Interview Schedule. Post-disaster stressful life events, in turn, were associated with subsequent mental health, indicating partial mediation of the stability of observed mental health. Conclusions: The present findings suggest a dynamic interplay between exposure, post-disaster stressful life events, and WTC-related posttraumatic stress, depressive symptoms, and overall functioning among WTC disaster responders. Published by Elsevier Ltd. C1 [Zvolensky, Michael J.] Univ Houston, Dept Psychol, Houston, TX 77204 USA. [Zvolensky, Michael J.] Univ Texas MD Anderson Canc Ctr, Dept Behav Sci, Houston, TX 77030 USA. [Kotov, Roman; Gonzalez, Adam] SUNY Stony Brook, Dept Psychiat, Stony Brook, NY 11794 USA. [Schechter, Clyde B.] Albert Einstein Coll Med, Dept Family & Social Med, Bronx, NY 10467 USA. [Vujanovic, Anka] Univ Texas Hlth Sci Ctr Houston, Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Pietrzak, Robert H.; Southwick, Steven M.] US Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, VA Connecticut Healthcare Syst, West Haven, CT USA. [Pietrzak, Robert H.; Southwick, Steven M.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Crane, Michael; Kaplan, Julia] Icahn Sch Med Mt Sinai, Dept Prevent Med, New York, NY 10029 USA. [Moline, Jacqueline] North Shore LIJ Hlth Syst, Dept Populat Hlth, Great Neck, NY USA. [Feder, Adriana] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Udasin, Iris] Univ Med & Dent New Jersey, Environm & Occupat Hlth Sci Inst, Piscataway, NJ 08854 USA. [Reissman, Dori B.] NIOSH, WTC Hlth Program, Washington, DC USA. [Luft, Benjamin J.] SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA. RP Zvolensky, MJ (reprint author), Univ Houston, 126 Heyne Bldg,Suite 104, Houston, TX 77204 USA. EM mjzvolen@central.uh.edu OI Luft, Benjamin/0000-0001-9008-7004 FU National Institute of Occupational Safety and Health [200-2011-42057, 200-201139410] FX This project was supported by National Institute of Occupational Safety and Health awards (200-2011-42057 and 200-201139410). NIOSH had no direct role in the study design, collection, analysis, or interpretation of the data, writing of the manuscript, or the decision to submit the paper for publication. NR 59 TC 3 Z9 3 U1 4 U2 18 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 EI 1879-1379 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD FEB PY 2015 VL 61 BP 97 EP 105 DI 10.1016/j.jpsychires.2014.11.010 PG 9 WC Psychiatry SC Psychiatry GA CB6IP UT WOS:000349731000014 PM 25499737 ER PT J AU Armour, C Tsai, J Durham, TA Charak, R Biehn, TL Elhai, JD Pietrzak, RH AF Armour, Cherie Tsai, Jack Durham, Tory A. Charak, Ruby Biehn, Tracey L. Elhai, Jon D. Pietrzak, Robert H. TI Dimensional structure of DSM-5 posttraumatic stress symptoms: Support for a hybrid Anhedonia and Externalizing Behaviors model SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE Posttraumatic stress disorder; DSM-5; 7-Factor hybrid model; Confirmatory factor analysis; Latent structure ID CONFIRMATORY FACTOR-ANALYSIS; DYSPHORIC AROUSAL MODEL; TRAUMA HISTORY; ANXIETY DISORDERS; PTSD SYMPTOMS; SAMPLE; VETERANS; EXPOSURE; SYMPTOMATOLOGY; ADOLESCENTS AB Several revisions to the symptom clusters of posttraumatic stress disorder (PTSD) have been made in the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Central to the focus of this study was the revision of PTSD's tripartite structure in DSM-IV into four symptom clusters in DSM-5. Emerging confirmatory factor analytic (CFA) studies have suggested that DSM-5 PTSD symptoms may be best represented by one of two 6-factor models: (1) an Externalizing Behaviors model characterized by a factor which combines the irritability/anger and self-destructive/reckless behavior items; and (2) an Anhedonia model characterized by items of loss of interest, detachment, and restricted affect. The current study conducted CFAs of DSM-5 PTSD symptoms assessed using the PTSD Checklist for DSM-5 (PCL-5) in two independent and diverse trauma-exposed samples of a nationally representative sample of 1484 U.S. veterans and a sample of 497 Midwestern U.S. university undergraduate students. Relative fits of the DSM-5 model, the DSM-5 Dysphoria model, the DSM-5 Dysphoric Arousal model, the two 6-factor models, and a newly proposed 7-factor Hybrid model, which consolidates the two 6-factor models, were evaluated. Results revealed that, in both samples, both 6-factor models provided significantly better fit than the 4-factor DSM-5 model, the DSM-5 Dysphoria model and the DSM-5 Dysphoric Arousal model. Further, the 7-factor Hybrid model, which incorporates key features of both 6-factor models and is comprised of re-experiencing, avoidance, negative affect, anhedonia, externalizing behaviors, and anxious and dysphoric arousal symptom clusters, provided superior fit to the data in both samples. Results are discussed in light of theoretical and empirical support for the latent structure of DSM-5 PTSD symptoms. (C) 2014 Elsevier Ltd. All rights reserved. C1 [Armour, Cherie] Univ Ulster, Psychol Res Inst, Coleraine BT52 1SA, Londonderry, North Ireland. [Tsai, Jack] US Dept Vet Affairs, New England Mental Illness Res Educ & Clin Ctr, West Haven, CT USA. [Tsai, Jack; Pietrzak, Robert H.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Durham, Tory A.; Biehn, Tracey L.] Univ Toledo, Dept Psychol, Toledo, OH USA. [Charak, Ruby] Univ Nebraska, Dept Psychol, Lincoln, NE 68588 USA. [Elhai, Jon D.] Univ Toledo, Dept Psychiat, Toledo, OH USA. [Pietrzak, Robert H.] US Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, Clin Neurosci Div, VA Connecticut Healthcare Syst, West Haven, CT USA. RP Armour, C (reprint author), Univ Ulster, Psychol Res Inst, Coleraine Campus,Cromore Rd, Coleraine BT52 1SA, Londonderry, North Ireland. EM armour.cherie@gmail.com OI Armour, Cherie/0000-0001-7649-3874 FU U.S. Department of Veterans Affairs National Center for Posttraumatic Stress Disorder (PTSD); Clinical Neurosciences Division of the National Center for PTSD FX The National Health and Resilience in Veterans Study was funded by the U.S. Department of Veterans Affairs National Center for Posttraumatic Stress Disorder (PTSD). Preparation of this report was supported in part by the Clinical Neurosciences Division of the National Center for PTSD and a private donation. The views and opinions expressed in this report are those of the authors and should not be construed to represent the views of sponsoring organizations, agencies, or the U.S. government. NR 56 TC 43 Z9 44 U1 4 U2 30 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 EI 1879-1379 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD FEB PY 2015 VL 61 BP 106 EP 113 DI 10.1016/j.jpsychires.2014.10.012 PG 8 WC Psychiatry SC Psychiatry GA CB6IP UT WOS:000349731000015 PM 25479765 ER PT J AU Jung, M Parrinello, CM Xue, XN Mack, WJ Anastos, K Lazar, JM Selzer, RH Shircore, AM Plankey, M Tien, P Cohen, M Gange, SJ Hodis, HN Kaplan, RC AF Jung, Molly Parrinello, Christina M. Xue, Xiaonan Mack, Wendy J. Anastos, Kathryn Lazar, Jason M. Selzer, Robert H. Shircore, Anne M. Plankey, Michael Tien, Phyllis Cohen, Mardge Gange, Stephen J. Hodis, Howard N. Kaplan, Robert C. TI Echolucency of the Carotid Artery Intima-Media Complex and Intima-Media Thickness Have Different Cardiovascular Risk Factor Relationships: The Women's Interagency HIV Study SO JOURNAL OF THE AMERICAN HEART ASSOCIATION LA English DT Article DE carotid arteries; epidemiology; immune system; risk factors; ultrasonics ID ACTIVE ANTIRETROVIRAL THERAPY; UPPSALA SENIORS PIVUS; OXIDATIVE STRESS; INFECTED WOMEN; LIPID-RICH; ATHEROSCLEROSIS; ULTRASOUND; PLAQUES; COHORT; LIPOPROTEINS AB Background-Adults infected with HIV have increased atherosclerosis potentially associated with both HIV and non-HIV associated factors. We characterized risk factors for atherosclerosis as measured by noninvasive vascular imaging. Methods and Results-We used B-mode ultrasound to examine levels and correlates of echogenicity and vessel wall thickness of the carotid artery intima-media complex in 1282 HIV-infected and 510 HIV-uninfected women of the Women's Interagency HIV Study. Levels of gray scale median (GSM, a measure of echogenicity) did not vary between HIV infection groups. In both groups, smokers had increased GSM, whereas age, diabetes, elevated blood pressure, and high BMI were associated with lower (rather than higher) GSM. Each of these non-lipid CVD risk factors, especially age and blood pressure, was also associated with higher levels of carotid artery intima-media thickness (cIMT). Higher serum triglyceride levels were associated with lower GSM in both HIV-infected and HIV-uninfected groups. Additional lipid risk factors for low GSM including high LDL cholesterol and low HDL cholesterol levels were identified in HIV uninfected but not in HIV infected women. In contrast to findings for GSM, among the lipid parameters only LDL cholesterol level had an association with cIMT, which was observed only in the HIV uninfected group. Conclusions-Lipid and non-lipid risk factor associations with echolucency of the carotid artery and the thickness of the common carotid artery intima-media layer suggest that these measures capture different aspects of atherosclerosis. C1 [Jung, Molly; Xue, Xiaonan; Anastos, Kathryn; Kaplan, Robert C.] Albert Einstein Coll Med, Dept Epidemiol, Bronx, NY 10461 USA. [Parrinello, Christina M.; Gange, Stephen J.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Mack, Wendy J.; Selzer, Robert H.; Shircore, Anne M.; Hodis, Howard N.] Univ So Calif, Dept Med, Atherosclerosis Res Unit, Los Angeles, CA USA. [Lazar, Jason M.] Suny Downstate Med Ctr, Dept Med, Brooklyn, NY 11203 USA. [Plankey, Michael] Georgetown Univ, Med Ctr, Dept Med, Washington, DC 20007 USA. [Tien, Phyllis] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Tien, Phyllis] San Francisco VA Med Ctr, San Francisco, CA USA. [Cohen, Mardge] Stroger Hosp, Dept Med, Chicago, IL USA. [Cohen, Mardge] Rush Univ, Chicago, IL 60612 USA. RP Kaplan, RC (reprint author), Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, 1300 Morris Pk Ave,Room 1315, Bronx, NY 10461 USA. EM robert.kaplan@einstein.yu.edu FU National Institute of Allergy and Infectious Diseases [UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, UO1-AI-42590]; Eunice Kennedy Shriver National Institute of Child Health and Human Development [UO1-HD-32632]; National Cancer Institute; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Center for Research Resources (UCSF-CTSI grant) [UL1 RR024131]; National Heart, Lung and Blood Institute [1R01HL095140, 1R01HL083760, R21HL120394, R01HL126543] FX The WIHS is funded by the National Institute of Allergy and Infectious Diseases (UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, and UO1-AI-42590) and by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (UO1-HD-32632). The study is co-funded by the National Cancer Institute, the National Institute on Drug Abuse, and the National Institute on Deafness and Other Communication Disorders. Funding is also provided by the National Center for Research Resources (UCSF-CTSI grant number UL1 RR024131). Additional co-funding is provided by the National Heart, Lung and Blood Institute (1R01HL095140, 1R01HL083760, R21HL120394 and R01HL126543 to Kaplan). NR 22 TC 1 Z9 1 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2047-9980 J9 J AM HEART ASSOC JI J. Am. Heart Assoc. PD FEB PY 2015 VL 4 IS 2 AR e001405 DI 10.1161/JAHA.114.001405 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CB5LG UT WOS:000349668000009 ER PT J AU Seidman, MD Gurgel, RK Lin, SY Schwartz, SR Baroody, FM Bonner, JR Dawson, DE Dykewicz, MS Hackell, JM Han, JK Ishman, SL Krouse, HJ Malekzadeh, S Mims, JW Omole, FS Reddy, WD Wallace, DV Walsh, SA Warren, BE Wilson, MN Nnacheta, LC AF Seidman, Michael D. Gurgel, Richard K. Lin, Sandra Y. Schwartz, Seth R. Baroody, Fuad M. Bonner, James R. Dawson, Douglas E. Dykewicz, Mark S. Hackell, Jesse M. Han, Joseph K. Ishman, Stacey L. Krouse, Helene J. Malekzadeh, Sonya Mims, James (Whit) W. Omole, Folashade S. Reddy, William D. Wallace, Dana V. Walsh, Sandra A. Warren, Barbara E. Wilson, Meghan N. Nnacheta, Lorraine C. TI Clinical Practice Guideline: Allergic Rhinitis Executive Summary SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article DE allergic rhinitis; runny nose; nasal congestion; rhinitis; allergies ID DIAGNOSIS; IMPACT AB The American Academy of OtolaryngologyHead and Neck Surgery Foundation (AAO-HNSF) has published a supplement to this issue featuring the new Clinical Practice Guideline: Allergic Rhinitis. To assist in implementing the guideline recommendations, this article summarizes the rationale, purpose, and key action statements. The 14 recommendations developed address the evaluation of patients with allergic rhinitis, including performing and interpretation of diagnostic testing and assessment and documentation of chronic conditions and comorbidities. It will then focus on the recommendations to guide the evaluation and treatment of patients with allergic rhinitis, to determine the most appropriate interventions to improve symptoms and quality of life for patients with allergic rhinitis. C1 [Seidman, Michael D.] Henry Ford West Bloomfield Hosp, Dept Otolaryngol Head & Neck Surg, West Bloomfield, MI 48322 USA. [Gurgel, Richard K.] Univ Utah, Dept Surg Otolaryngol Head & Neck Surg, Salt Lake City, UT USA. [Lin, Sandra Y.] Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA. [Schwartz, Seth R.] Virginia Mason Med Ctr, Seattle, WA 98101 USA. [Baroody, Fuad M.] Univ Chicago, Med Ctr, Dept Otolaryngol, Chicago, IL 60637 USA. [Bonner, James R.] Birmingham VA Med Ctr, Birmingham, AL USA. [Dykewicz, Mark S.] St Louis Univ, Sch Med, Dept Internal Med, St Louis, MO USA. [Hackell, Jesse M.] Pomona Pediat, Pomona, NY USA. [Han, Joseph K.] Eastern Virginia Med Sch, Norfolk, VA 23501 USA. [Ishman, Stacey L.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [Krouse, Helene J.] Wayne State Univ, Philadelphia, PA USA. [Malekzadeh, Sonya] Georgetown Univ Hosp, Washington, DC 20007 USA. [Mims, James (Whit) W.] Wake Forest Baptist Hlth, Winston Salem, NC USA. [Omole, Folashade S.] Morehouse Sch Med, East Point, GA USA. [Reddy, William D.] Acupuncture & Oriental Med AAAOM, Annandale, VA USA. [Wallace, Dana V.] Florida Atlantic Univ, Boca Raton, FL 33431 USA. [Wallace, Dana V.] Nova SE Univ, Davie, FL USA. [Walsh, Sandra A.; Warren, Barbara E.] Consumers United Evidence Based Healthcare, Fredericton, NB, Canada. [Wilson, Meghan N.] Louisiana State Univ, Sch Med, New Orleans, LA USA. [Nnacheta, Lorraine C.] Amer Acad Otolaryngol Head & Neck Surg, Dept Res & Qual, Alexandria, VA USA. RP Seidman, MD (reprint author), Henry Ford West Bloomfield Hosp, 6777 West Maple Rd, West Bloomfield, MI 48322 USA. EM mseidma1@hfhs.org FU American Academy of Otolaryngology-Head and Neck Surgery Foundation FX Funding Source: American Academy of Otolaryngology-Head and Neck Surgery Foundation. NR 10 TC 14 Z9 17 U1 4 U2 20 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0194-5998 EI 1097-6817 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD FEB PY 2015 VL 152 IS 2 BP 197 EP 206 DI 10.1177/0194599814562166 PG 10 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA CB2OU UT WOS:000349468100003 PM 25645524 ER PT J AU Willson, TJ Lospinoso, J Weitzel, E McMains, K AF Willson, Thomas J. Lospinoso, Joshua Weitzel, Erik McMains, Kevin TI Correlating Regional Aeroallergen Effects on Internet Search Activity SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article DE aeroallergen; allergen; allergic rhinitis ID ALLERGIC RHINITIS AB Objective To investigate the correlation between the change in regional aeroallergen levels and Internet search activity related to allergies. Study Design A retrospective time series analysis using a graphical analytical approach and statistical modeling was used. Setting Tertiary academic hospital setting. Subjects and Methods There were no specific enrolled subjects. Data from Google Trends were obtained (google.com/trends) for the following search terms: allergy, allergies, pollen, runny nose, congestion, and post nasal drainage. Daily pollen and mold spore count data were obtained for the same period from throughout Texas. Graphical analysis, correlation, and autoregressive integrated moving average (ARIMA) were employed to assess the relationship between aeroallergens on Google search activity. Results A strong positive correlation was observed between observed pollen counts and search activity for the terms allergies (r(pollen) = 0.798), allergy (r(pollen) = 0.781), and pollen (r(pollen) = 0.849). Symptom term searches were weakly correlated with pollen and mold counts. Also, ARIMA modeling supported the relationships indicated by the correlations. Conclusion Search activities for surrogate terms such as allergy, allergies, and pollen correlate strongly with observed pollen counts but not mold counts. These data demonstrate the usefulness of Google Trends search data in assessing regional disease burdens and offer insight into how the public seeks information about their own illness. C1 [Willson, Thomas J.; Weitzel, Erik] San Antonio Mil Med Ctr, Dept Otolaryngol Head & Neck Surg, San Antonio, TX 78234 USA. [Lospinoso, Joshua] Portia Stat Consulting LLC, San Antonio, TX USA. [McMains, Kevin] South Texas Vet Hlth Care Syst, Otolaryngol Sect, San Antonio, TX USA. RP Willson, TJ (reprint author), San Antonio Mil Med Ctr, Dept Otolaryngol Head & Neck Surg, 3551 Roger Brooke Dr, San Antonio, TX 78234 USA. EM S10twillson@gmail.com NR 12 TC 4 Z9 4 U1 0 U2 4 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0194-5998 EI 1097-6817 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD FEB PY 2015 VL 152 IS 2 BP 228 EP 232 DI 10.1177/0194599814560149 PG 5 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA CB2OU UT WOS:000349468100007 PM 25505261 ER PT J AU Bromley, EG May, FP Federer, L Spiegel, BMR van Oijen, MGH AF Bromley, Erica G. May, Folasade P. Federer, Lisa Spiegel, Brennan M. R. van Oijen, Martijn G. H. TI Explaining persistent under-use of colonoscopic cancer screening in African Americans: A systematic review SO PREVENTIVE MEDICINE LA English DT Review DE Barriers; Colorectal cancer; Screening; Colonoscopy; Race; Ethnicity; African-American ID DIGITAL RECTAL EXAMINATION; COLORECTAL-CANCER; PRACTICE GUIDELINES; PREVENTIVE SERVICES; BARRIERS; DISPARITIES; COLON; MEN; FACILITATORS; PHYSICIANS AB Introduction. Although African Americans have the highest incidence and mortality from colorectal cancer (CRC), they are less likely than other racial groups to undergo CRC screening. Previous research has identified barriers to CRC screening among African Americans. However we lack a systematic review that synthesizes contributing factors and informs interventions to address persistent disparities. Methods. We conducted a systematic review to evaluate barriers to colonoscopic CRC screening in African Americans. We developed a conceptual model to summarize the patient-, provider-, and system-level barriers and suggest strategies to address these barriers. Results. Nineteen studies met inclusion criteria. Patient barriers to colonoscopy included fear, poor knowledge of CRC risk, and low perceived benefit of colonoscopy. Provider-level factors included failure to recommend screening and knowledge deficits about guidelines and barriers to screening. System barriers included financial obstacles, lack of insurance and access to care, and intermittent primary care visits. Conclusions. There are modifiable barriers to colonoscopic CRC screening among African Americans. Future interventions should confront patient fear, patient and physician knowledge about barriers, and access to healthcare services. As the Affordable Care Act aims to improve uptake of preventive services, focused interventions to increase CRC screening in African Americans are essential and timely. (C) 2014 Elsevier Inc. All rights reserved. C1 [Bromley, Erica G.; May, Folasade P.; Spiegel, Brennan M. R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90073 USA. [May, Folasade P.; Spiegel, Brennan M. R.; van Oijen, Martijn G. H.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Digest Dis, Los Angeles, CA 90073 USA. [May, Folasade P.; Spiegel, Brennan M. R.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. [May, Folasade P.; Spiegel, Brennan M. R.] UCLA VA Ctr Outcomes Res & Educ CORE, Los Angeles, CA USA. [van Oijen, Martijn G. H.] Univ Utrecht, NL-3508 TC Utrecht, Netherlands. [Federer, Lisa] Univ Calif Los Angeles, Los Angeles, CA 90073 USA. RP May, FP (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, VA Ctr Outcomes Res & Educ, 11301 Wilshire Blvd,Bldg 115,Room 215, Los Angeles, CA 90073 USA. EM fmay@mednet.ucla.edu FU NIDDK NIH HHS [P30 DK041301, T32 DK007180] NR 51 TC 13 Z9 14 U1 2 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 EI 1096-0260 J9 PREV MED JI Prev. Med. PD FEB PY 2015 VL 71 BP 40 EP 48 DI 10.1016/j.ypmed.2014.11.022 PG 9 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CB6NL UT WOS:000349743600009 PM 25481094 ER PT J AU Davidson, TM Soltis, K Albia, CM de Arellano, M Ruggiero, KJ AF Davidson, Tatiana M. Soltis, Kathryn Albia, Christina MinHee de Arellano, Michael Ruggiero, Kenneth J. TI Providers' Perspectives Regarding the Development of a Web-Based Depression Intervention for Latina/o Youth SO PSYCHOLOGICAL SERVICES LA English DT Article DE Latina/o adolescents; depression; cultural adaptation; Internet-based intervention ID COGNITIVE-BEHAVIORAL THERAPY; CHILD INTERACTION THERAPY; PUERTO-RICAN ADOLESCENTS; ETHNIC-MINORITY YOUTH; MENTAL-HEALTH-CARE; MEXICAN-AMERICANS; CULTURAL-ADAPTATION; CONTROLLED-TRIAL; LOW-INCOME; ACTIVATION AB Latina/o youth appear to be at significant risk for depression and, of concern, is the high underutilization of mental health services observed in this population. There is a tremendous need for novel intervention methods to better serve the unique needs of this population. This article describes the development of Rise Above (Siempre Sale el Sol), a Web-based, self-help, depression intervention for Latina/o adolescents funded by the National Institute of Mental Health. We applied a cultural adaptation model to an evidence-based depression treatment to reduce potential service barriers and increase the relevance and potential efficacy of the intervention for Latina/o youth. We conducted thematic interviews with 32 national experts to obtain feedback that would inform our application of the cultural adaptation model, the potential efficacy of the intervention, and the feasibility of implementation. Future directions for the evaluation of Rise Above (Siempre Sale el Sol) are described. C1 [Davidson, Tatiana M.; Soltis, Kathryn; de Arellano, Michael; Ruggiero, Kenneth J.] Med Univ S Carolina, Charleston, SC 29425 USA. [Albia, Christina MinHee] Coll Charleston, Charleston, SC USA. [Ruggiero, Kenneth J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Davidson, TM (reprint author), Med Univ S Carolina, Mental Hlth Dispar & Divers Program, 67 President St IOP 4 South,MSC 861, Charleston, SC 29425 USA. EM davidst@musc.edu FU NIMH NIH HHS [R01 MH081056-03S2, P60 MH082598, R01 MH081056, R01 MH81056, R34 MH077149, R34 MH77149] NR 69 TC 1 Z9 1 U1 3 U2 11 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1541-1559 EI 1939-148X J9 PSYCHOL SERV JI Psychol. Serv. PD FEB PY 2015 VL 12 IS 1 BP 37 EP 48 DI 10.1037/a0037686 PG 12 WC Psychology, Clinical SC Psychology GA CB3TK UT WOS:000349551400006 PM 25133417 ER PT J AU Dismuke, CE Egede, LE Saunders, L Krause, JS AF Dismuke, C. E. Egede, L. E. Saunders, L. Krause, J. S. TI Diabetes increases financial burden of individuals with traumatic spinal cord injury (TSCI) SO SPINAL CORD LA English DT Article ID RACE AB Study design: Secondary analysis of existing data. Objective: To estimate the association of diabetes with family income in a pooled 15-year cohort of individuals with TSCI. Setting: A large specialty hospital in the southeastern United States. Methods: A total number of 1408 individuals identified with TSCI were surveyed regarding family income as well as clinical and demographic factors. Due to income being reported in censored intervals rather than individual dollar values, interval regression was used to estimate models of the association of family income with diabetes. Results: Approximately 12% of individuals with TSCI reported being diagnosed with diabetes. The most frequent family income interval in our sample was <$10 000, lower than the poverty threshold. The family income interval with the highest rate of diabetes was $15000-$20 000. In an unadjusted model, diabetes was associated with a significant reduction of $8749 and in a fully adjusted model, diabetes was significantly associated with a reduction of $8560 in family income. Being a minority was also significantly associated with a reduction whereas educational attainment was associated with increased family income. TSCI severity was not significantly related to family income. Conclusion: Diabetes imposes an additional financial burden on individuals with TSCI an already vulnerable population with high health care costs. The burden is more pronounced in minorities with TSCI. Providers should be aware of the higher prevalence of diabetes among patients with TSCI and pursue a policy of testing early and vigilant management. Further studies are needed regarding special interventions for managing diabetes in the TSCI population. C1 [Dismuke, C. E.; Egede, L. E.] Ralph H Johnson Vet Affairs Med Ctr, Hlth Equ & Rural Outreach Innovat Ctr, Charleston, SC USA. [Dismuke, C. E.; Egede, L. E.] Med Univ S Carolina, Ctr Hlth Dispar Res, Div Gen Internal Med, Charleston, SC 29425 USA. [Saunders, L.; Krause, J. S.] Med Univ S Carolina, Dept Hlth Sci & Res, Coll Hlth Profess, Charleston, SC 29425 USA. RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,MSC 593, Charleston, SC 29425 USA. EM egedel@musc.edu FU Department of Education, NIDRR [H133G050165, H133A080064]; National Institutes of Health [1R01 NS 48117] FX The contents of this presentation were developed under grants from the Department of Education, NIDRR Grant numbers H133G050165 and H133A080064 and a Grant from the National Institutes of Health, 1R01 NS 48117. However, those contents do not necessarily represent the policy of the Department of Education or the NIH, and one should not assume endorsement by the Federal Government. We thank the following persons who contributed to the work reported in the manuscript: Richard Aust, Jennifer Coker, Melinda Jarnecke and D'Andra Roper. NR 11 TC 0 Z9 0 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1362-4393 EI 1476-5624 J9 SPINAL CORD JI Spinal Cord PD FEB PY 2015 VL 53 IS 2 BP 135 EP 138 DI 10.1038/sc.2014.200 PG 4 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA CB3WW UT WOS:000349561100011 PM 25403503 ER PT J AU Sankari, A Martin, JL Bascom, AT Mitchell, MN Badr, MS AF Sankari, A. Martin, J. L. Bascom, A. T. Mitchell, M. N. Badr, M. S. TI Identification and treatment of sleep-disordered breathing in chronic spinal cord injury SO SPINAL CORD LA English DT Article ID POSITIVE AIRWAY PRESSURE; HIGH BLOOD-PRESSURE; CARDIOVASCULAR-DISEASE; APNEA SYNDROME; RISK-FACTOR; QUALITY INDEX; PREVALENCE; QUESTIONNAIRE; DISTURBANCES; TETRAPLEGIA AB Study design: A follow up on an ongoing prospective cohort study. Objective: Spinal cord injury or disorder (SCI/D) patients have higher rates of sleep-disordered breathing (SDB) than the general population. The objectives of this study were to examine predictors of SDB diagnosis and to estimate rates of SDB treatment in SCI/D patients. Setting: A SCI clinical sleep research laboratory. Methods: Twenty-eight SCI/D patients (7 women, age 42.8 +/- 15.8 years; 16 cervical and 12 thoracic level injuries) completed a battery of questionnaires (Epworth Sleepiness Scale (ESS), Pittsburgh Sleep Quality Index (PSQI), Berlin questionnaire (BQ) and fatigue severity scale (FSS)) and had one night of attended laboratory polysomnography (PSG). Participants were then notified of the results of their PSG and were interviewed approximately 1 year later to assess clinical outcomes. Results: The majority of patients reported poor sleep quality on all questionnaires. On the basis of PSG, 22 (79%) patients had SDB (apnea-hypopnea index (AHI)>= 5 events per hour), and 17 (61%) had moderate/severe SDB (AHI >= 15 events per hour). Higher ESS scores were associated with a higher risk of AHI >= 5; however, other questionnaires did not distinguish between those with and without SDB using either AHI cutoff. In follow-up interviews, only 50% of patients had spoken to a health-care provider about SDB and only six patients with SDB were prescribed treatment, four of whom were using the treatment at follow-up. Conclusion: SDB is common and severe among SCI/D patients. Screening questionnaires do not appear to differentiate between those with and without SDB. Even when SDB was recognized, many patients remained untreated. The increased prevalence of cardiovascular disease in SCI/D patients could represent a consequence of untreated SDB, and improving diagnosis and management of SDB has the potential to improve outcomes for these patients. C1 [Sankari, A.; Badr, M. S.] Dingell VA Med Ctr, Detroit, MI USA. [Sankari, A.; Bascom, A. T.; Badr, M. S.] Wayne State Univ, Dept Med, Detroit, MI 48202 USA. [Martin, J. L.; Mitchell, M. N.] VA Greater Los Angeles Healthcare Syst, North Hills, CA USA. [Martin, J. L.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Sankari, A (reprint author), Div Pulm Crit Care & Sleep Med, 3990 John R,3 Hudson, Detroit, MI 48201 USA. EM atarbich@med.wayne.edu FU United States Department of Veterans Affairs Merit Review [1I01CX001040]; Clinical Science Research & Development Service of the VA Office of Research and Development [1IK2CX000547] FX The research was supported by the United States Department of Veterans Affairs Merit Review # 1I01CX001040 and Career Development Award # 1IK2CX000547 from the Clinical Science Research & Development Service of the VA Office of Research and Development. NR 36 TC 6 Z9 6 U1 2 U2 4 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1362-4393 EI 1476-5624 J9 SPINAL CORD JI Spinal Cord PD FEB PY 2015 VL 53 IS 2 BP 145 EP 149 DI 10.1038/sc.2014.216 PG 5 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA CB3WW UT WOS:000349561100013 PM 25510191 ER PT J AU Taber, DJ Palanisamy, AP Srinivas, TR Gebregziabher, M Odeghe, J Chavin, KD Egede, LE Baliga, PK AF Taber, David J. Palanisamy, Arun P. Srinivas, Titte R. Gebregziabher, Mulugeta Odeghe, John Chavin, Kenneth D. Egede, Leonard E. Baliga, Prabhakar K. TI Inclusion of Dynamic Clinical Data Improves the Predictive Performance of a 30-Day Readmission Risk Model in Kidney Transplantation SO TRANSPLANTATION LA English DT Article ID EARLY HOSPITAL READMISSION; ELECTRONIC HEALTH RECORDS; BIG-DATA; UNITED-STATES; CARE; RECIPIENTS; QUALITY; PATIENT; REHOSPITALIZATIONS; CHALLENGES AB Background. Thirty-day readmissions (30DRA) are a highly scrutinized measure of healthcare quality and relatively frequent among kidney transplants (KTX). Development of predictive risk models is critical to reducing 30DRA and improving outcomes. Current approaches rely on fixed variables derived from administrative data. These models may not capture clinical evolution that is critical to predicting outcomes. Methods. We directed a retrospective analysis toward: (1) developing parsimonious risk models for 30DRA and (2) comparing efficiency of models based on the use of immutable versus dynamic data. Baseline and in-hospital clinical and outcomes data were collected from adult KTX recipients between 2005 and 2012. Risk models were developed using backward logistic regression and compared for predictive efficacy using receiver operating characteristic curves. Results. Of 1147 KTX patients, 123 had 30DRA. Risk factors for 30DRA included recipient comorbidities, transplant factors, and index hospitalization patient level clinical data. The initial fixed variable model included 9 risk factors and was modestly predictive (area under the curve, 0.64; 95% confidence interval [95% CI], 0.58-0.69). The model was parsimoniously reduced to 6 risks, which remained modestly predictive (area under the curve, 0.63; 95% CI, 0.58-0.69). The initial predictive model using 13 fixed and dynamic variables was significantly predictive (AUC, 0.73; 95% CI, 0.67-0.80), with parsimonious reduction to 9 variables maintaining predictive efficacy (AUC, 0.73; 95% CI, 0.67-0.79). The final model using dynamically evolving clinical data outperformed the model using static variables (P = 0.009). Internal validation demonstrated that the final model was stable with minimal bias. Conclusions. We demonstrate that modeling dynamic clinical data outperformed models using immutable data in predicting 30DRA. C1 [Taber, David J.; Palanisamy, Arun P.; Chavin, Kenneth D.; Baliga, Prabhakar K.] Med Univ S Carolina, Div Transplant Surg, Charleston, SC 29425 USA. [Taber, David J.] Ralph H Johnson VAMC, Dept Pharm, Charleston, SC USA. [Srinivas, Titte R.] Med Univ S Carolina, Div Transplant Nephrol, Charleston, SC 29425 USA. [Gebregziabher, Mulugeta] Med Univ S Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA. [Odeghe, John] Med Univ S Carolina, Coll Med, Charleston, SC 29425 USA. [Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. [Egede, Leonard E.] Ralph H Johnson VAMC, Ctr Innovat COIN, Charleston, SC USA. RP Taber, DJ (reprint author), Med Univ S Carolina, Div Transplant Surg, 96 Jonathan Lucas St,CSB 409, Charleston, SC 29425 USA. EM taberd@musc.edu OI Gebregziabher, Mulugeta/0000-0002-4826-481X FU National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health [K23DK099440, T35 DK007431] FX D.J.T.'s efforts preparing this study were supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under Award Number K23DK099440. J.O.'s efforts conducting this analysis were supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under Award Number T35 DK007431. L.E.'s efforts conducting this analysis were supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under Award Number T35 DK007431. NR 34 TC 6 Z9 6 U1 3 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD FEB PY 2015 VL 99 IS 2 BP 324 EP 330 DI 10.1097/TP.0000000000000565 PG 7 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA CB2YH UT WOS:000349493900021 PM 25594549 ER PT J AU Mannis, G Wu, D Dea, T Mauro, T Hsu, G AF Mannis, Gabriel Wu, Davina Dea, Tiffany Mauro, Theodora Hsu, Gerald TI Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia SO AMERICAN JOURNAL OF HEMATOLOGY LA English DT Editorial Material ID TARGETING BTK; LYMPHOMA C1 [Mannis, Gabriel; Hsu, Gerald] San Francisco VA Med Ctr, Dept Med, Div Hematol Oncol, San Francisco, CA 94121 USA. [Wu, Davina; Mauro, Theodora] San Francisco VA Med Ctr, Dept Dermatol, San Francisco, CA USA. [Dea, Tiffany] San Francisco VA Med Ctr, Dept Clin Pharm, San Francisco, CA USA. RP Mannis, G (reprint author), San Francisco VA Med Ctr, Dept Med, Div Hematol Oncol, San Francisco, CA 94121 USA. EM gabriel.mannis@ucsf.edu FU NIA NIH HHS [R01 AG028492]; NIAMS NIH HHS [R01 AR051930] NR 3 TC 1 Z9 1 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0361-8609 EI 1096-8652 J9 AM J HEMATOL JI Am. J. Hematol. PD FEB PY 2015 VL 90 IS 2 BP 179 EP 179 DI 10.1002/ajh.23775 PG 1 WC Hematology SC Hematology GA CA4AL UT WOS:000348846600022 PM 24890909 ER PT J AU Zellmer, C Zimdars, P Parker, S Safdar, N AF Zellmer, Caroline Zimdars, Peggy Parker, Sarah Safdar, Nasia TI Evaluating the usefulness of patient education materials on surgical site infection: A systematic assessment SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Patient education; Surgical site infection ID HEALTH-CARE; INFORMATION AB Patient education is important for the prevention of surgical site infections (SSIs). The usefulness of available patient education materials is unclear. Using a validated evaluation tool, the Patient Education Materials Assessment Tool, we systematically assessed patient education materials for SSI. We found that available materials performed poorly, and further research is needed in this area. Published by Elsevier Inc. on behalf of the Association for Professionals in Infection Control and Epidemiology, Inc. C1 [Zellmer, Caroline; Zimdars, Peggy; Parker, Sarah; Safdar, Nasia] Univ Wisconsin, Dept Med, Infect Dis Sect, Madison, WI 53792 USA. [Safdar, Nasia] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Safdar, N (reprint author), Univ Wisconsin, Dept Med, Madison, WI 53792 USA. EM ns2@medicine.wisc.edu NR 10 TC 2 Z9 2 U1 0 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD FEB 1 PY 2015 VL 43 IS 2 BP 167 EP 168 DI 10.1016/j.ajic.2014.10.020 PG 2 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CA2KK UT WOS:000348737200015 PM 25541334 ER PT J AU Luon, DK Gushiken, F Zigmond, M AF Luon, Darren K. Gushiken, Francisca Zigmond, Megan TI Contributing Factors to Renal Dysfunction during Engraftment Syndrome SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 11-15, 2015 CL San Diego, CA C1 [Luon, Darren K.] South Texas VA Hlth Care Syst, Pharm, San Antonio, TX USA. [Gushiken, Francisca] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Zigmond, Megan] South Texas Vet Hlth Care Syst, Pharm, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2015 VL 21 IS 2 SU 1 MA 161 BP S141 EP S141 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA CA0UZ UT WOS:000348633000166 ER PT J AU Toro, JJ Cadena, JA Meinzen, S Shaw, S McKee, M Neumon, B Gushiken, F Haile, DJ Freytes, CO AF Toro, Juan J. Cadena, Jose A. Meinzen, Sarah Shaw, Sandra McKee, Megan Neumon, Bonita Gushiken, Francisca Haile, David J. Freytes, Cesar O. TI A Quality Improvement Project to Decrease Clostridium Difficile Associated Infection in a Bone Marrow Transplant Unit: A Multidisciplinary Approach SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 11-15, 2015 CL San Diego, CA C1 [Toro, Juan J.; Cadena, Jose A.; Meinzen, Sarah; Shaw, Sandra; McKee, Megan; Neumon, Bonita; Gushiken, Francisca; Haile, David J.; Freytes, Cesar O.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2015 VL 21 IS 2 SU 1 MA 366 BP S259 EP S260 PG 2 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA CA0UZ UT WOS:000348633000368 ER PT J AU Partin, MR Burgess, DJ Burgess, JF Gravely, A Haggstrom, D Lillie, SE Nugent, S Powell, AA Shaukat, A Walter, LC Nelson, DB AF Partin, Melissa R. Burgess, Diana J. Burgess, James F., Jr. Gravely, Amy Haggstrom, David Lillie, Sarah E. Nugent, Sean Powell, Adam A. Shaukat, Aasma Walter, Louise C. Nelson, David B. TI Organizational Predictors of Colonoscopy Follow-up for Positive Fecal Occult Blood Test Results: An Observational Study SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID AMERICAN-CANCER-SOCIETY; ON-COLORECTAL-CANCER; HEALTH-CARE-SYSTEMS; SCREENING COLONOSCOPY; WAIT TIMES; PATIENT; GASTROENTEROLOGY; PROGRAM; INTERVENTION; SURVEILLANCE AB Background: This study assessed the contribution of organizational structures and processes identified from facility surveys to follow-up for positive fecal occult blood tests [FOBT-positive (FOBT+)]. Methods: We identified 74,104 patients with FOBT+ results from 98 Veterans Health Administration (VHA) facilities between August 16, 2009 and March 20, 2011, and followed them until September 30, 2011, for completion of colonoscopy. We identified patient characteristics from VHA administrative records, and organizational factors from facility surveys completed by primary care and gastroenterology chiefs. We estimated predictors of colonoscopy completion within 60 days and six months using hierarchical logistic regression models. Results: Thirty percent of patients with FOBT+ results received colonoscopy within 60 days and 49% within six months. Having gastroenterology or laboratory staff notify gastroenterology providers directly about FOBT+ cases was a significant predictor of 60-day [odds ratio (OR), 1.85; P = 0.01] and six-month follow-up (OR, 1.25; P = 0.008). Additional predictors of 60-day follow-up included adequacy of colonoscopy appointment availability (OR, 1.43; P = 0.01) and frequent individual feedback to primary care providers about FOBT+ referral timeliness (OR, 1.79; P = 0.04). Additional predictors of six-month follow-up included using guideline-concordant surveillance intervals for low-risk adenomas (OR, 1.57; P = 0.01) and using group appointments and combined verbal-written methods for colonoscopy preparation instruction (OR, 1.48; P = 0.0001). Conclusion: Directly notifying gastroenterology providers about FOBT+ results, using guideline-concordant adenoma surveillance intervals, and using colonoscopy preparations instruction methods that provide both verbal and written information may increase overall follow-up rates. Enhancing follow-up within 60 days may require increased colonoscopy capacity and feedback to primary care providers. Impact: These findings may inform organizational-level interventions to improve FOBT+ follow-up. (C)2014 AACR. C1 [Partin, Melissa R.; Burgess, Diana J.; Gravely, Amy; Lillie, Sarah E.; Nugent, Sean; Powell, Adam A.; Shaukat, Aasma; Nelson, David B.] Minneapolis Vet Affairs Hlth Care Syst, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA. [Partin, Melissa R.; Burgess, Diana J.; Lillie, Sarah E.; Shaukat, Aasma; Nelson, David B.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA. [Burgess, James F., Jr.] Boston Vet Affairs Hlth Care Syst, Ctr Healthcare Org & Implementat Res, Boston, MA USA. [Burgess, James F., Jr.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA. [Haggstrom, David] Roudebush VAMC, VA Hlth Serv Res & Dev Ctr Hlth Informat & Commun, Indianapolis, IN USA. [Haggstrom, David] Indiana Univ Sch Med, Dept Med, Div Gen Internal Med & Geriatr, Indianapolis, IN 46202 USA. [Walter, Louise C.] San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA USA. [Walter, Louise C.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Partin, MR (reprint author), Minneapolis Vet Affairs Med Ctr, 1 Vet Dr, Minneapolis, MN 55417 USA. EM Melissa.partin@va.gov RI Burgess, Diana/A-1946-2016 OI Lillie, Sarah/0000-0001-9854-7191 FU Department of Veterans Affairs Health Services Research and Development (VA HSRD) [IIR 08-334-2]; VA HSR&D Research Career Scientist award [RCS 10-185]; VA HSR&D Career Development Award (CDA) [CDA 07-016]; VA HSRD CDA [CDA 08-024]; VA Clinical Science Research and Development Career Development Award [CDA-2]; National Institute on Aging at the NIH [K24AG041180] FX This research was funded by the Department of Veterans Affairs Health Services Research and Development (VA HSR&D) grant IIR 08-334-2 (to M.R. Partin), VA HSR&D Research Career Scientist award RCS 10-185 (to M.R. Partin), VA HSR&D Career Development Award (CDA) #CDA 07-016 (to D. Haggstrom), VA HSR&D CDA #CDA 08-024 (to A.A. Powell), VA Clinical Science Research and Development Career Development Award CDA-2 (to A. Shaukat), and National Institute on Aging at the NIH grant K24AG041180 (to L.C. Walter). NR 47 TC 9 Z9 9 U1 1 U2 3 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 EI 1538-7755 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD FEB PY 2015 VL 24 IS 2 BP 422 EP 434 DI 10.1158/1055-9965.EPI-14-1170 PG 13 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA CB1XY UT WOS:000349422500014 PM 25471345 ER PT J AU Honda, JR Bernhard, JN Chan, ED AF Honda, Jennifer R. Bernhard, Jon N. Chan, Edward D. TI Natural Disasters and Nontuberculous Mycobacteria A Recipe for Increased Disease? SO CHEST LA English DT Article ID SOFT-TISSUE INFECTIONS; UNITED-STATES; ACANTHAMOEBA-KERATITIS; GROWING MYCOBACTERIA; TSUNAMI SURVIVORS; PUBLIC-HEALTH; EPIDEMIOLOGY; TRENDS; LUNG AB Infectious diseases acquired by survivors of large-scale natural disasters complicate the recovery process. During events such as tsunamis, hurricanes, earthquakes, and tornados and well into the recovery period, victims often are exposed to water-soil mixtures that have relocated with indigenous microbes. Because nontuberculous mycobacteria (NTM) are ubiquitous in water and soil, there is potential for increased exposure to these organisms during natural disasters. In this hypothesis-driven commentary, we discuss the rise in NTM lung disease and natural disasters and examine the geographic overlap of NTM infections and disaster frequencies in the United States. Moreover, we show an increased number of positive NTM cultures from Louisiana residents in the years following three of the relatively recent epic hurricanes and posit that such natural disasters may help to drive the increased number of NTM infections. Finally, we advocate for increased environmental studies and surveillance of NTM infections before and after natural disasters. C1 [Honda, Jennifer R.; Chan, Edward D.] Univ Colorado, Div Pulm Sci & Crit Care Med, Aurora, CO 80045 USA. [Honda, Jennifer R.; Chan, Edward D.] Denver Vet Affairs Med Ctr, Natl Jewish Hlth, Denver, CO USA. RP Honda, JR (reprint author), Univ Colorado, Div Pulm Sci & Crit Care Med, Anschutz Med Campus,RC2,Box C272, Aurora, CO 80045 USA. EM Jennifer.Honda@ucdenver.edu FU National Institutes of Health National Research Service Award for Pulmonary and Critical Care Medicine Training [T32 HL 7085-83]; Potts Memorial Foundation FX Dr Honda is supported by a National Institutes of Health National Research Service Award for Pulmonary and Critical Care Medicine Training [T32 HL 7085-83] and by the Potts Memorial Foundation. NR 36 TC 1 Z9 1 U1 0 U2 6 PU AMER COLL CHEST PHYSICIANS PI GLENVIEW PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA SN 0012-3692 J9 CHEST JI Chest PD FEB PY 2015 VL 147 IS 2 BP 304 EP 308 DI 10.1378/chest.14-0974 PG 5 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA CB1YF UT WOS:000349423200009 PM 25644904 ER PT J AU Bakal, K Danckers, M Denson, JL Sauthoff, H AF Bakal, Keren Danckers, Mauricio Denson, Joshua L. Sauthoff, Harald TI Therapeutic Hypothermia After Cardiac Arrest in a Patient With Systemic Sclerosis and Raynaud Phenomenon SO CHEST LA English DT Editorial Material ID LEFT-VENTRICULAR DYSFUNCTION; DIGITAL ULCERS; SCLERODERMA; HEART AB Therapeutic hypothermia favorably impacts neurologic outcomes in patients after cardiopulmonary arrest, although the appropriate target temperature is less clear. Its safety profile in patients with systemic sclerosis (SSc) and Raynaud phenomenon (RP), who may be at increased risk for ischemic complications, has not been addressed in the literature, to our knowledge. Digital lesions are commonly seen in patients with SSc, and cold-induced myocardial ischemia has also been reported. We describe a case of a man with SSc, RP, and digital ulcers who underwent therapeutic hypothermia after cardiopulmonary arrest. He regained full neurologic function, and except for digital necrosis, no hypothermia-associated adverse events were observed. Other risk factors for ischemia, such as cocaine use, may have contributed to the development of the digital necrosis. However, clinicians should be aware of the risk for ischemic complications in patients with SSc and RP when considering the appropriate target temperature after cardiopulmonary arrest. C1 [Bakal, Keren; Danckers, Mauricio; Denson, Joshua L.; Sauthoff, Harald] NYU, Sch Med, Dept Med, New York, NY 10010 USA. [Sauthoff, Harald] US Dept Vet Affairs, VA NY Harbor Healthcare Syst, New York, NY USA. RP Sauthoff, H (reprint author), NYU, Sch Med, Dept Med, 423 E 23rd St, New York, NY 10010 USA. EM Harald.sauthoff@nyumc.org OI Sauthoff, Harald/0000-0001-9258-4135 NR 16 TC 0 Z9 0 U1 0 U2 1 PU AMER COLL CHEST PHYSICIANS PI GLENVIEW PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA SN 0012-3692 J9 CHEST JI Chest PD FEB PY 2015 VL 147 IS 2 BP E27 EP E30 DI 10.1378/chest.14-1184 PG 4 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA CB1YF UT WOS:000349423200040 PM 25644911 ER PT J AU Cooke, CR Wiener, RS Slatore, CG AF Cooke, Colin R. Wiener, Renda Soylemez Slatore, Christopher G. TI Critical Care Use in Patients With Lung Cancer Response SO CHEST LA English DT Letter ID INTENSIVE-CARE; END C1 [Cooke, Colin R.] Univ Michigan, Div Pulm & Crit Care Med, Ctr Healthcare Outcomes & Policy, Inst Healthcare Policy & Innovat,Michigan Ctr Int, Ann Arbor, MI 48109 USA. [Wiener, Renda Soylemez] Edith Nourse Rogers Mem VA Hosp, Ctr Healthcare Org & Implementat Res, Boston, MA USA. [Wiener, Renda Soylemez] Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02118 USA. [Slatore, Christopher G.] Portland VA Med Ctr, Hlth Serv Res & Dev, Portland, VA USA. [Slatore, Christopher G.] Portland VA Med Ctr, Sect Pulm & Crit Care Med, Portland, VA USA. [Slatore, Christopher G.] Oregon Hlth & Sci Univ, Dept Med, Div Pulm & Crit Care Med, Portland, OR 97201 USA. RP Cooke, CR (reprint author), Univ Michigan, Ctr Healthcare Outcomes & Policy, 2800 Plymouth Rd,Bldg 16,Rm 127W, Ann Arbor, MI 48109 USA. EM cookecr@umich.edu FU AHRQ HHS [K08 HS020672]; NCI NIH HHS [K07 CA138772] NR 4 TC 0 Z9 0 U1 0 U2 1 PU AMER COLL CHEST PHYSICIANS PI GLENVIEW PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA SN 0012-3692 J9 CHEST JI Chest PD FEB PY 2015 VL 147 IS 2 BP E57 EP E57 DI 10.1378/chest.14-2507 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA CB1YF UT WOS:000349423200048 PM 25644919 ER PT J AU Paisible, AL Chang, CCH So-Armah, KA Butt, AA Leaf, DA Budoff, M Rimland, D Bedimo, R Goetz, MB Rodriguez-Barradas, MC Crane, HM Gibert, CL Brown, ST Tindle, HA Warner, AL Alcorn, C Skanderson, M Justice, AC Freiberg, MS AF Paisible, Anne-Lise Chang, Chung-Chou H. So-Armah, Kaku A. Butt, Adeel A. Leaf, David A. Budoff, Matthew Rimland, David Bedimo, Roger Goetz, Matthew B. Rodriguez-Barradas, Maria C. Crane, Heidi M. Gibert, Cynthia L. Brown, Sheldon T. Tindle, Hilary A. Warner, Alberta L. Alcorn, Charles Skanderson, Melissa Justice, Amy C. Freiberg, Matthew S. CA VACS Project Team TI HIV Infection, Cardiovascular Disease Risk Factor Profile, and Risk for Acute Myocardial Infarction SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE HIV; optimal cardiovascular health; myocardial infarction ID CORONARY-HEART-DISEASE; ANTIRETROVIRAL THERAPY; HYPERTENSIVE PATIENTS; LIFETIME RISK; VETERANS; COHORT; INDIVIDUALS; POPULATION; PREVALENCE; MORTALITY AB Background:Traditional cardiovascular disease risk factors (CVDRFs) increase the risk of acute myocardial infarction (AMI) among HIV-infected (HIV+) participants. We assessed the association between HIV and incident AMI within CVDRF strata.Methods:Cohort81,322 participants (33% HIV+) without prevalent CVD from the Veterans Aging Cohort Study Virtual Cohort (prospective study of HIV+ and matched HIV- veterans) participated in this study. Veterans were followed from first clinical encounter on/after April 1, 2003, until AMI/death/last follow-up date (December 31, 2009). PredictorsHIV, CVDRFs (total cholesterol, cholesterol-lowering agents, blood pressure, blood pressure medication, smoking, diabetes) used to create 6 mutually exclusive profiles: all CVDRFs optimal, 1+ nonoptimal CVDRFs, 1+ elevated CVDRFs, and 1, 2, 3+ major CVDRFs. OutcomeIncident AMI [defined using enzyme, electrocardiogram (EKG) clinical data, 410 inpatient ICD-9 (Medicare), and/or death certificates]. StatisticsCox models adjusted for demographics, comorbidity, and substance use.Results:Of note, 858 AMIs (42% HIV+) occurred over 5.9 years (median). Prevalence of optimal cardiac health was <2%. Optimal CVDRF profile was associated with the lowest adjusted AMI rates. Compared with HIV- veterans, AMI rates among HIV+ veterans with similar CVDRF profiles were higher. Compared with HIV- veterans without major CVDRFs, HIV+ veterans without major CVDRFs had a 2-fold increased risk of AMI (HR: 2.0; 95% confidence interval: 1.0 to 3.9; P = 0.044).Conclusions:The prevalence of optimal cardiac health is low in this cohort. Among those without major CVDRFs, HIV+ veterans have twice the AMI risk. Compared with HIV- veterans with high CVDRF burden, AMI rates were still higher in HIV+ veterans. Preventing/reducing CVDRF burden may reduce excess AMI risk among HIV+ people. C1 [Paisible, Anne-Lise; Butt, Adeel A.; Tindle, Hilary A.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA. [Chang, Chung-Chou H.; Alcorn, Charles] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA. [So-Armah, Kaku A.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Butt, Adeel A.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA. [Leaf, David A.; Goetz, Matthew B.] VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA. [Leaf, David A.; Goetz, Matthew B.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Budoff, Matthew] Harbor UCLA Med Ctr, Los Angeles, CA USA. [Budoff, Matthew] Los Angeles Biomed Res Inst, Los Angeles, CA USA. [Rimland, David] VA Med Ctr, Atlanta, GA USA. [Rimland, David] Emory Univ, Sch Med, Dept Med, Atlanta, GA USA. [Bedimo, Roger] UT Southwestern Med Ctr, VA North Texas Hlth Care Syst, Dept Med, Infect Dis Sect, Dallas, TX USA. [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Michael E DeBakey VA Med Ctr, Infect Dis Sect, Houston, TX 77030 USA. [Crane, Heidi M.] Univ Washington, Dept Med, Seattle, WA USA. [Gibert, Cynthia L.] VA Med Ctr, Washington, DC USA. [Gibert, Cynthia L.] George Washington Univ, Med Ctr, Washington, DC 20037 USA. [Brown, Sheldon T.] Mt Sinai Med Ctr, Dept Internal Med, New York, NY USA. [Brown, Sheldon T.] Bronx Vet Affairs Med Ctr, Bronx, NY USA. [Warner, Alberta L.] Univ Calif Los Angeles, Dept Med, Div Cardiol, Los Angeles, CA 90024 USA. [Skanderson, Melissa; Justice, Amy C.] VA Connecticut Healthcare Syst, West Haven, CT USA. [Justice, Amy C.] Yale Univ, Sch Med, Sect Gen Med, New Haven, CT USA. [Freiberg, Matthew S.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. [Freiberg, Matthew S.] Nashville Vet Affairs Med Ctr, Nashville, TN USA. RP Freiberg, MS (reprint author), Vanderbilt Univ, Med Ctr, Div Cardiovasc Med, 2525 West End,Suite 300-A, Nashville, TN 37203 USA. EM matthew.s.freiberg@vanderbilt.edu OI Butt, Adeel/0000-0002-1118-1826; Goetz, Matthew/0000-0003-4542-992X; Justice, Amy/0000-0003-0139-5502 FU National Heart, Lung, and Blood Institute [HL095136-04]; National Institute on Alcohol Abuse and Alcoholism at the National Institutes of Health [AA013566-10, AA020790, AA020794]; National Institutes of Health; Merck; Pfizer; Merck Co, Inc; Janssen Therapeutics; Bristol-Myers Squibb FX Supported by grant HL095136-04 from the National Heart, Lung, and Blood Institute and grant Nos. AA013566-10, AA020790, and AA020794 from the National Institute on Alcohol Abuse and Alcoholism at the National Institutes of Health. M.B., H.C., S.B., A.J., and M.F. received funding from the National Institutes of Health related to this work; A.B. has received Investigator Initiated Research Support from Merck and Pfizer; and R.B. has received grants and research support awarded to the VA North TX Healthcare System from Merck & Co, Inc, Janssen Therapeutics, and Bristol-Myers Squibb. NR 34 TC 27 Z9 28 U1 0 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD FEB 1 PY 2015 VL 68 IS 2 BP 209 EP 216 DI 10.1097/QAI.0000000000000419 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AZ8IF UT WOS:000348458200018 PM 25588033 ER PT J AU Simonetti, JA Mackelprang, JL Rowhani-Rahbar, A Zatzick, D Rivara, FR AF Simonetti, Joseph A. Mackelprang, Jessica L. Rowhani-Rahbar, Ali Zatzick, Douglas Rivara, Frederick R. TI Psychiatric Comorbidity, Suicidality, and In-Home Firearm Access Among a Nationally Representative Sample of Adolescents SO JAMA PSYCHIATRY LA English DT Article ID SUPPLEMENT NCS-A; STORAGE PRACTICES; UNITED-STATES; DEPRESSIVE SYMPTOMS; CONTROLLED-TRIAL; CLINICAL-TRIAL; SUBSTANCE USE; RISK; CHILDREN; GUN AB IMPORTANCE Suicide is the second leading cause of death among US adolescents, and in-home firearm access is an independent risk factor for suicide. Given recommendations to limit firearm access by those with mental health risk factors for suicide, we hypothesized that adolescents with such risk factors would be less likely to report in-home firearm access. OBJECTIVES To estimate the prevalence of self-reported in-home firearm access among US adolescents, to quantify the lifetime prevalence of mental illness and suicidality (ie, suicidal ideation, planning, or attempt) among adolescents living with a firearm in the home, and to compare the prevalence of in-home firearm access between adolescents with and without specific mental health risk factors for suicide. DESIGN, SETTING, AND PARTICIPANTS Cross-sectional analysis of data from the National Comorbidity Survey-Adolescent Supplement, a nationally representative survey of 10 123 US adolescents (age range, 13-18 years) who were interviewed between February 2001 and January 2004 (response rate 82.9%). EXPOSURES Risk factors for suicide, including a history of any mental health disorder, suicidality, or any combination of the 2. MAIN OUTCOMES AND MEASURES Self-reported access to a firearm in the home. RESULTS One in three respondents (2778 [29.1%]) of the weighted survey sample reported living in a home with a firearm and responded to a question about firearm access; 1089 (40.9%) of those adolescents reported easy access to and the ability to shoot that firearm. Among adolescents with a firearm in home, those with access were significantly more likely to be older (15.6 vs 15.1 years), male (70.1% vs 50.9%), of non-Hispanic white race/ethnicity (86.6% vs 78.3%), and living in high-income households (40.0% vs 31.8%), and in rural areas (28.1% vs 22.6%) (P < .05 for all). Adolescents with firearm access also had a higher lifetime prevalence of alcohol abuse (10.1% vs 3.8%, P < .001) and drug abuse (11.4% vs 6.9%, P < .01) compared with those without firearm access. In multivariable analyses, adolescents with a history of mental illness without a history of suicidality (prevalence ratio [PR], 1.13; 95% CI, 0.98-1.29) and adolescents with a history of suicidality with or without a history of mental illness (PR, 1.20; 95% CI, 0.96-1.51) were as likely to report in-home firearm access as those without such histories. CONCLUSIONS AND RELEVANCE Adolescents with risk factors for suicide were just as likely to report in-home firearm access as those without such risk factors. Given that firearms are the second most common means of suicide among adolescents, further attention to developing and implementing evidence-based strategies to decrease firearm access in this age group is warranted. C1 [Simonetti, Joseph A.] Univ Washington, Div Gen Internal Med, Dept Med, Seattle, WA 98195 USA. [Simonetti, Joseph A.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA. [Simonetti, Joseph A.; Mackelprang, Jessica L.; Rowhani-Rahbar, Ali; Zatzick, Douglas; Rivara, Frederick R.] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA. RP Simonetti, JA (reprint author), Vet Affairs Puget Sound Hlth Care Syst, 1100 OliveWay,Ste 1400, Seattle, WA 98101 USA. EM simonja@uw.edu OI Mackelprang, Jessica/0000-0001-9135-7811 FU Ruth L. Kirschstein National Research Service Award [T32HP10002]; Eunice Kennedy Shriver National Institute of Child Health and Human Development [T32HD057822]; National Institute of Mental Health [R01 MH/DA46376, R01 MH49098]; National Institute on Drug Abuse [R01 MH/DA46376]; William T. Grant Foundation [90135190] FX During the preparation of the manuscript, Dr Simonetti received fellowship support by grant T32HP10002 from the Ruth L. Kirschstein National Research Service Award, administered by the Health Resources and Services Administration, and Dr Mackelprang received fellowship support by grant T32HD057822 from The Eunice Kennedy Shriver National Institute of Child Health and Human Development. The National Comorbidity Survey is funded by grants R01 MH/DA46376 and R01 MH49098 from the National Institute of Mental Health, by a supplement to grant R01 MH/DA46376 from the National Institute on Drug Abuse, and by grant 90135190 from the William T. Grant Foundation. NR 63 TC 10 Z9 10 U1 6 U2 18 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-622X EI 2168-6238 J9 JAMA PSYCHIAT JI JAMA Psychiatry PD FEB PY 2015 VL 72 IS 2 BP 152 EP 159 DI 10.1001/jamapsychiatry.2014.1760 PG 8 WC Psychiatry SC Psychiatry GA CB2JH UT WOS:000349452800011 PM 25548879 ER PT J AU AlJaroudi, WA Hage, FG AF AlJaroudi, Wael A. Hage, Fadi G. TI Review of Cardiovascular Literature SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Article ID CORONARY-ARTERY-DISEASE; RISK C1 [AlJaroudi, Wael A.] Amer Univ Beirut, Med Ctr, Div Cardiovasc Med, Beirut, Lebanon. [Hage, Fadi G.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL USA. RP Hage, FG (reprint author), Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Lyons Harrison Res Bldg 314,1900 Univ BLVD, Birmingham, AL 35294 USA. EM fadihage@uab.edu OI Hage, Fadi/0000-0002-1397-4942 NR 6 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 EI 1532-6551 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD FEB PY 2015 VL 22 IS 1 BP 6 EP 8 DI 10.1007/s12350-014-0043-x PG 3 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA CA3EZ UT WOS:000348790400003 PM 25515422 ER PT J AU Chatterjee, A Hage, FG AF Chatterjee, Arka Hage, Fadi G. TI Guidelines in review: 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Article C1 [Chatterjee, Arka; Hage, Fadi G.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Med, Birmingham, AL 35294 USA. [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL USA. RP Chatterjee, A (reprint author), Univ Alabama Birmingham, Dept Med, Div Cardiovasc Med, Lyons Harrison Res Bldg 314,1900 Univ BLVD, Birmingham, AL 35294 USA. EM arkachatterjee2608@gmail.com NR 2 TC 2 Z9 2 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 EI 1532-6551 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD FEB PY 2015 VL 22 IS 1 BP 158 EP 161 DI 10.1007/s12350-014-9992-3 PG 4 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA CA3EZ UT WOS:000348790400021 PM 25208531 ER PT J AU Pierre, JF Heneghan, AF Wang, XY Roenneburg, DA Groblewski, GE Kudsk, KA AF Pierre, Joseph F. Heneghan, Aaron F. Wang, Xinying Roenneburg, Drew A. Groblewski, Guy E. Kudsk, Kenneth A. TI Bombesin Improves Adaptive Immunity of the Salivary Gland During Parenteral Nutrition SO JOURNAL OF PARENTERAL AND ENTERAL NUTRITION LA English DT Article DE parenteral nutrition; salivary glands; parotid; submandibular; sIgA; amylase ID POLYMERIC IMMUNOGLOBULIN RECEPTOR; ENTERIC NERVOUS-SYSTEM; MUCOSAL IMMUNITY; LYMPHOID-TISSUE; FED MICE; BACTERIAL PNEUMONIA; IGA LEVELS; CELLS; IMPAIRMENT; TRANSPORT AB Background: The parotid and submandibular salivary glands are gut-associated lymphoid tissues (GALTs) that secrete immune compounds into the oral cavity. Parenteral nutrition (PN) without enteral stimulation decreases GALT function, including intestinal lymphocyte counts and secretory immunoglobulin A (sIgA) levels. Since the neuropeptide bombesin (BBS), a gastrin-releasing peptide analogue, stimulates intestinal function and restores GALT parameters, we hypothesized that PN + BBS would stimulate parotid and salivary gland IgA levels, T lymphocytes, and IgA plasma cell counts compared with PN alone. Methods: Male (Institute of Cancer Research) ICR mice received intravenous catheters and were randomized to chow with saline, PN, or PN + BBS (15 mu g/tid/mouse) for 5 days (8/group), 2 days after cannulation. Salivary glands were weighed and either frozen for IgA and amylase analysis or fixed for histological analysis of acinar cells, IgA+ plasma cells, and T lymphocytes. Small intestinal wash fluid was collected for IgA regression analysis with salivary glands. Results: PN reduced organ weight, acinar cell size, and amylase activity compared with chow; BBS had no significant effects on these parameters. Compared with chow, PN significantly reduced salivary gland IgA levels, IgA+ plasma cells, and T lymphocytes. PN + BBS significantly elevated IgA and restored cellularity compared with PN. Salivary gland tissue homogenate IgA levels significantly correlated with intestinal fluid IgA levels. Conclusions: Compared with chow, PN results in atrophy of the salivary glands characterized by reduced amylase, IgA, and immune cellularity. BBS has no effect on acinar cells or amylase activity compared with PN but maintains tissue IgA and plasma cells and T-lymphocyte numbers compared with chow. C1 [Pierre, Joseph F.; Heneghan, Aaron F.; Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, Madison, WI USA. [Pierre, Joseph F.; Heneghan, Aaron F.; Wang, Xinying; Roenneburg, Drew A.; Kudsk, Kenneth A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Madison, WI 53792 USA. [Wang, Xinying] Nanjing Univ, Sch Med, Jinling Hosp, Dept Surg, Nanjing 210008, Jiangsu, Peoples R China. [Groblewski, Guy E.] Univ Wisconsin, Dept Nutr Sci, Madison, WI 53792 USA. RP Kudsk, KA (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, G5-341 Clin Sci Ctr,600 Highland Ave, Madison, WI 53792 USA. EM kudsk@surgery.wisc.edu FU Biomedical Laboratory Research & Development Service of the VA Office of Research and Development [I01BX001672] FX This study was supported by Award Number I01BX001672 from the Biomedical Laboratory Research & Development Service of the VA Office of Research and Development. The contents of this article do not represent the views of the Veterans Affairs or the US government. NR 43 TC 6 Z9 6 U1 0 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0148-6071 EI 1941-2444 J9 JPEN-PARENTER ENTER JI J. Parenter. Enter. Nutr. PD FEB PY 2015 VL 39 IS 2 BP 190 EP 199 DI 10.1177/0148607113507080 PG 10 WC Nutrition & Dietetics SC Nutrition & Dietetics GA CA7HK UT WOS:000349088200010 PM 24121183 ER PT J AU Lee, T Phan, R Nham, P Moatamed, N AF Lee, Thomas Phan, Ryan Nham, Phillipp Moatamed, Neda TI Post Hoc Assessment of B-Cell and T-Cell Gene Rearrangements From Cytology Smears SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 104th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 21-27, 2015 CL Boston, MA SP US & Canadian Acad Pathol C1 Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2015 VL 95 SU 1 MA 375 BP 96A EP 96A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA CA5KT UT WOS:000348948000376 ER PT J AU Weintraub, D David, AS Evans, AH Grant, JE Stacy, M AF Weintraub, Daniel David, Anthony S. Evans, Andrew H. Grant, Jon E. Stacy, Mark TI Clinical Spectrum of Impulse Control Disorders in Parkinson's Disease SO MOVEMENT DISORDERS LA English DT Review DE Parkinson's disease; impulse control disorder; dopamine agonists ID DOPAMINE AGONIST USE; COMPULSIVE BEHAVIORS; DYSREGULATION SYNDROME; REPETITIVE BEHAVIORS; WITHDRAWAL SYNDROME; UNITED-STATES; RATING-SCALE; MDS-UPDRS; PREVALENCE; ASSOCIATION AB Impulse control disorders (ICDs), including compulsive gambling, buying, sexual behavior, and eating, are a serious and increasingly recognized psychiatric complication in Parkinson's disease (PD). Other impulsive-compulsive behaviors (ICBs) have been described in PD, including punding (stereotyped, repetitive, purposeless behaviors) and dopamine dysregulation syndrome (DDS; compulsive PD medication overuse). ICDs have been most closely related to the use of dopamine agonists (DAs), perhaps more so at higher doses; in contrast, DDS is primarily associated with shorter-acting, higher-potency dopaminergic medications, such as apomorphine and levodopa. Possible risk factors for ICDs include male sex, younger age and younger age at PD onset, a pre-PD history of ICDs, and a personal or family history of substance abuse, bipolar disorder, or gambling problems. Given the paucity of treatment options and potentially serious consequences, it is critical for PD patients to be monitored closely for development of ICDs as part of routine clinical care. (c) 2014 International Parkinson and Movement Disorder Society C1 [Weintraub, Daniel] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Univ Penn, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [David, Anthony S.] Kings Coll London, Inst Psychiat, London WC2R 2LS, England. [Evans, Andrew H.] Royal Melbourne Hosp, Dept Neurol, Parkville, Vic 3050, Australia. [Grant, Jon E.] Univ Chicago, Sch Med, Dept Psychiat, Chicago, IL 60637 USA. [Stacy, Mark] Duke Univ, Sch Med, Dept Neurol, Durham, NC USA. RP Weintraub, D (reprint author), Univ Penn, Perelman Sch Med, 3615 Chestnut St,330, Philadelphia, PA 19104 USA. EM daniel.weintraub@uphs.upenn.edu RI David, Anthony/C-1315-2011 OI David, Anthony/0000-0003-0967-774X FU Parkinson's UK [J-0705] NR 77 TC 46 Z9 47 U1 2 U2 23 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD FEB PY 2015 VL 30 IS 2 BP 121 EP 127 DI 10.1002/mds.26016 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA CB0IZ UT WOS:000349310600001 PM 25370355 ER PT J AU Rowland, NC Starr, PA Larson, PS Ostrem, JL Marks, WJ Lim, DA AF Rowland, Nathan C. Starr, Philip A. Larson, Paul S. Ostrem, Jill L. Marks, William J., Jr. Lim, Daniel A. TI Combining Cell Transplants or Gene Therapy With Deep Brain Stimulation for Parkinson's Disease SO MOVEMENT DISORDERS LA English DT Article DE Parkinson's disease; stem cell technology; gene therapy; clinical trial design; deep brain stimulation ID RANDOMIZED CONTROLLED-TRIAL; DOUBLE-BLIND; OPEN-LABEL; SUBTHALAMIC NUCLEUS; MEDICAL THERAPY; AAV2-NEURTURIN; DELIVERY; MOTOR AB Cell transplantation and gene therapy each show promise to enhance the treatment of Parkinson's disease (PD). However, because cell transplantation and gene therapy generally require direct delivery to the central nervous system, clinical trial design involves unique scientific, ethical, and financial concerns related to the invasive nature of the procedure. Typically, such biologics have been tested in PD patients who have not received any neurosurgical intervention. Here, we suggest that PD patients undergoing deep brain stimulation (DBS) device implantation are an ideal patient population for the clinical evaluation of cell transplantation and gene therapy. Randomizing subjects to an experimental group that receives the biologic concurrently with the DBS implantationor to a control group that receives the DBS treatment alonehas several compelling advantages. First, this study design enables the participation of patients likely to benefit from DBS, many of whom simultaneously meet the inclusion criteria of biologic studies. Second, the need for a sham neurosurgical procedure is eliminated, which may reduce ethical concerns, promote patient recruitment, and enhance the blinding of surgical trials. Third, testing the biologic by piggybacking onto an established, reimbursable procedure should reduce the cost of clinical trials, which may allow a greater number of biologics to reach this critical stage of research translation. Finally, this clinical trial design may lead to combinatorial treatment strategies that provide PD patients with more durable control over disabling motor symptoms. By combining neuromodulation with biologics, we may also reveal important treatment paradigms relevant to other diseases of the brain. (c) 2014 International Parkinson and Movement Disorder Society C1 [Rowland, Nathan C.; Starr, Philip A.; Larson, Paul S.; Lim, Daniel A.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA. [Ostrem, Jill L.; Marks, William J., Jr.] Univ Calif San Francisco, Dept Neurol, San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. [Starr, Philip A.; Larson, Paul S.; Ostrem, Jill L.; Marks, William J., Jr.; Lim, Daniel A.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, San Francisco, CA 94143 USA. RP Lim, DA (reprint author), 35 Med Ctr Way,RMB 1037, San Francisco, CA 94143 USA. EM LimD@neurosurg.ucsf.edu FU NIH [DP2OD006505-01]; CIRM [RT2-01975] FX DAL is supported by NIH DP2OD006505-01 and CIRM RT2-01975. NR 34 TC 7 Z9 7 U1 0 U2 13 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD FEB PY 2015 VL 30 IS 2 BP 190 EP 195 DI 10.1002/mds.26083 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA CB0IZ UT WOS:000349310600010 PM 25521796 ER PT J AU Nabli, F Ben Sassi, S Amouri, R Duda, JE Farrer, MJ Hentati, F AF Nabli, Fatma Ben Sassi, Samia Amouri, Rim Duda, John E. Farrer, Matthew J. Hentati, Faycal TI Motor Phenotype of LRRK2-Associated Parkinson's Disease: A Tunisian Longitudinal Study SO MOVEMENT DISORDERS LA English DT Article DE Parkinson's disease; PARK8; LRRK2 gene; G2019S mutation; longitudinal study ID TREMOR-DOMINANT PARKINSONISM; LRRK2 G2019S MUTATION; PROGRESSION; PENETRANCE; IMPAIRMENT; ONSET AB Mutations in the leucine-rich repeat kinase 2 gene (LRRK2) were found to be a significant cause of late-onset autosomal dominant forms of Parkinson's disease (PD). To determine the motor characteristics of LRRK2-related disease, we conducted a longitudinal study of 58 G2019S LRRK2-associated PD patients and compared them with genetically undefined (GU) PD patients. Fifty-eight patients diagnosed with PD-related LRRK2 G2019S mutation were included in the study and compared with 54 sporadic PD patients with negative tests for LRRK2 G2019S, PINK1, SNCA, PRKN, and DJ1 mutations. Patients were assessed at baseline and after a follow-up period of 6 years. The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), the Hoehn and Yahr, and the Schwab and England scores were determined. Logistic regression was used to examine associations of G2019S mutation status with motor phenotype and rate of motor decline. The LRRK2-associated PD patients had a mean age of onset of 56.25 +/- 12.05 years and in most cases (58.6%) a postural instability gait difficulty (PIGD) phenotype. The mean annual decline in the MDS-UDRS III motor score and the Hoehn and Yahr staging was of 1.3% and 2%, respectively. The PIGD phenotype predicted a more rapid progression of motor impairment. The PD motor phenotype and motor scores were similar in the LRRK2-associated PD group and in the GU PD group, with no significant differences in the progression rate of motor impairment. Motor phenotype seems to be similar in LRRK2-related PD and idiopathic PD. (c) 2014 International Parkinson and Movement Disorder Society C1 [Nabli, Fatma; Ben Sassi, Samia; Amouri, Rim; Hentati, Faycal] Univ Tunis El Manar, Natl Inst Mongi Ben Hmida Neurol, Fac Med Tunis, Dept Neurol, Tunis, Tunisia. [Duda, John E.] Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA USA. [Farrer, Matthew J.] Univ British Columbia, Djavad Mowafhaghian Ctr Brain Hlth, Vancouver, BC V5Z 1M9, Canada. RP Nabli, F (reprint author), Inst Natl Mongi Ben Hmida Neurol, Tunis 1007, Tunisia. EM fatmafatnassi@yahoo.fr FU Department of Research and Development; GlaxoSmithKline; Michael. J. Fox Foundation FX This study was supported by the Department of Research and Development, GlaxoSmithKline, and by the Michael. J. Fox Foundation. NR 23 TC 6 Z9 6 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD FEB PY 2015 VL 30 IS 2 BP 253 EP 258 DI 10.1002/mds.26097 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA CB0IZ UT WOS:000349310600020 PM 25487881 ER PT J AU Sharp, ME Caccappolo, E Mejia-Santana, H Tang, MX Rosado, L Reilly, MO Ruiz, D Louis, ED Comella, C Nance, M Bressman, S Scott, WK Tanner, C Waters, C Fahn, S Cote, L Ford, B Rezak, M Novak, K Friedman, JH Pfeiffer, R Payami, H Molho, E Factor, SA Nutt, J Serrano, C Arroyo, M Pauciulo, MW Nichols, WC Clark, LN Alcalay, RN Marder, KS AF Sharp, Madeleine E. Caccappolo, Elise Mejia-Santana, Helen Tang, Ming-X. Rosado, Llency Reilly, Martha Orbe Ruiz, Diana Louis, Elan D. Comella, Cynthia Nance, Martha Bressman, Susan Scott, William K. Tanner, Caroline Waters, Cheryl Fahn, Stanley Cote, Lucien Ford, Blair Rezak, Michael Novak, Kevin Friedman, Joseph H. Pfeiffer, Ronald Payami, Haydeh Molho, Eric Factor, Stuart A. Nutt, John Serrano, Carmen Arroyo, Maritza Pauciulo, Michael W. Nichols, William C. Clark, Lorraine N. Alcalay, Roy N. Marder, Karen S. TI The Relationship Between Obsessive-Compulsive Symptoms and PARKIN Genotype: The CORE-PD Study SO MOVEMENT DISORDERS LA English DT Article DE Parkinson's; neuropsychological; obsessive-compulsive; parkin ID DISEASE; MUTATIONS; GENE; DISORDER; CARRIERS; VALIDATION; DEPRESSION AB BackgroundFew studies have systematically investigated the association between PARKIN genotype and psychiatric co-morbidities of Parkison's disease (PD). PARKIN-associated PD is characterized by severe nigral dopaminergic neuronal loss, a finding that may have implications for behaviors rooted in dopaminergic circuits such as obsessive-compulsive symptoms (OCS). MethodsThe Schedule of Compulsions and Obsessions Patient Inventory (SCOPI) was administered to 104 patients with early-onset PD and 257 asymptomatic first-degree relatives. Carriers of one and two PARKIN mutations were compared with noncarriers. ResultsAmong patients, carriers scored lower than noncarriers in adjusted models (one-mutation: 13.9 point difference, P=0.03; two-mutation: 24.1, P=0.001), where lower scores indicate less OCS. Among asymptomatic relatives, a trend toward the opposite was seen: mutation carriers scored higher than noncarriers (one mutation, P=0.05; two mutations, P=0.13). ConclusionsFirst, a significant association was found between PARKIN mutation status and obsessive-compulsive symptom level in both PD and asymptomatic patients, suggesting that OCS might represent an early non-motor dopamine-dependent feature. Second, irrespective of disease status, heterozygotes were significantly different from noncarriers, suggesting that PARKIN heterozygosity may contribute to phenotype. (c) 2014 International Parkinson and Movement Disorder Society C1 [Sharp, Madeleine E.; Caccappolo, Elise; Mejia-Santana, Helen; Tang, Ming-X.; Rosado, Llency; Reilly, Martha Orbe; Ruiz, Diana; Louis, Elan D.; Waters, Cheryl; Fahn, Stanley; Cote, Lucien; Ford, Blair; Alcalay, Roy N.; Marder, Karen S.] Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA. [Tang, Ming-X.; Louis, Elan D.; Clark, Lorraine N.; Alcalay, Roy N.; Marder, Karen S.] Columbia Univ, Coll Phys & Surg, Taub Inst Res Alzheimers & Aging Brain, New York, NY 10032 USA. [Louis, Elan D.; Cote, Lucien; Marder, Karen S.] Columbia Univ, Coll Phys & Surg, Gertrude H Sergievsky Ctr, New York, NY 10032 USA. [Louis, Elan D.] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY 10032 USA. [Comella, Cynthia] Rush Univ, Dept Neurol Sci, Med Ctr, Chicago, IL 60612 USA. [Nance, Martha] Struthers Parkinsons Ctr, Pk Nicollet Clin, Golden Valley, MN USA. [Bressman, Susan] Beth Israel Deaconess Med Ctr, Alan & Barbara Mirken Dept Neurol, New York, NY 10003 USA. [Bressman, Susan] Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA. [Scott, William K.] Univ Miami, Miller Sch Med, Miami Inst Human Genom, Dr John T Macdonald Fdn,Dept Human Genet, Miami, FL 33136 USA. [Tanner, Caroline] Parkinsons Inst, Sunnyvale, CA USA. [Tanner, Caroline] San Francisco VA Med Ctr, San Francisco, CA USA. [Tanner, Caroline] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Rezak, Michael] Cent DuPage Hosp, Movement Disorders Ctr, Neurosci Inst, Winfield, IL USA. [Novak, Kevin] NorthShore Univ Hlth Syst, Dept Neurol, Evanston, IL USA. [Novak, Kevin] Univ Chicago, Pritzker Sch Med, Dept Neurol, Chicago, IL 60637 USA. [Friedman, Joseph H.] Butler Hosp, Providence, RI 02906 USA. [Friedman, Joseph H.] Brown Univ, Dept Neurol, Alpert Med Sch, Providence, RI 02912 USA. [Pfeiffer, Ronald] Univ Tennessee, Ctr Hlth Sci, Coll Med, Dept Neurol, Memphis, TN 38163 USA. [Payami, Haydeh] New York State Dept Hlth, Wadsworth Ctr, Albany, NY USA. [Molho, Eric] Albany Med Ctr, Parkinsons Dis & Movement Disorders Ctr, Albany, NY USA. [Factor, Stuart A.] Emory Univ, Dept Neurol, Atlanta, GA 30322 USA. [Nutt, John] Portland VA Med Ctr Parkinson Dis Res Educ & Clin, Portland, OR USA. [Nutt, John] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Serrano, Carmen; Arroyo, Maritza] Univ Puerto Rico, San Juan, PR 00936 USA. [Pauciulo, Michael W.; Nichols, William C.] Cincinnati Childrens Hosp Med Ctr, Div Human Genet, Cincinnati, OH 45229 USA. [Pauciulo, Michael W.; Nichols, William C.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45221 USA. [Clark, Lorraine N.] Columbia Univ, Coll Phys & Surg, Dept Pathol & Cell Biol, New York, NY 10032 USA. [Clark, Lorraine N.] Columbia Univ, Coll Phys & Surg, Ctr Human Genet, New York, NY 10032 USA. [Marder, Karen S.] Columbia Univ, Dept Psychiat, Med Ctr, New York, NY 10032 USA. RP Marder, KS (reprint author), Columbia Univ, Coll Phys & Surg, Taub Inst Res Alzheimers & Aging Brain, 630 West 168th St,Unit 16, New York, NY 10032 USA. EM ksm1@cumc.columbia.edu FU NIH [NS036630, UL1 RR024156, NS050487, NS060113, K02NS080915]; Parkinson's Disease Foundation [P50 NS039764, P50 NS071674, NS36960]; University of British Columbia Clinician Investigator Program FX This study was supported by NIH NS036630, UL1 RR024156 (K.S.M.), NS050487, NS060113 (L.N.C.), K02NS080915 (R.N.A) the Parkinson's Disease Foundation (K.S.M., S.F., and L.N.C.), P50 NS039764 and P50 NS071674 (W.K.S), NS36960 (H.P) and the University of British Columbia Clinician Investigator Program (M.E.S). NR 30 TC 2 Z9 3 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD FEB PY 2015 VL 30 IS 2 BP 278 EP 283 DI 10.1002/mds.26065 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA CB0IZ UT WOS:000349310600026 PM 25393808 ER PT J AU Bilousova, T Taylor, K Emirzian, A Gylys, R Frautschy, SA Cole, GM Teng, E AF Bilousova, Tina Taylor, Karen Emirzian, Ana Gylys, Raymond Frautschy, Sally A. Cole, Gregory M. Teng, Edmond TI Parallel age-associated changes in brain and plasma neuronal pentraxin receptor levels in a transgenic APP/PS1 rat model of Alzheimer's disease SO NEUROBIOLOGY OF DISEASE LA English DT Article DE Plasma; Cortex; Hippocampus; Biomarker; Neuronal pentraxin; Transgenic; Alzheimer's disease; Synaptic function ID LONG-TERM DEPRESSION; MILD COGNITIVE IMPAIRMENT; DEVELOPING VISUAL-SYSTEM; BINDING PROTEIN 49; CEREBROSPINAL-FLUID; AMYLOID-BETA; IN-VIVO; SYNAPTIC PLASTICITY; MOUSE MODEL; A-BETA AB Neuronal pentraxin receptor (NPR) is a synaptic protein implicated in AMPA receptor trafficking at excitatory synapses. Since glutamate neurotransmission is disrupted in Alzheimer's disease (AD), NPR levels measured from plasma represent a potential biomarker for synaptic dysfunction associated with AD. We sought to determine the relationship between AD pathology and brain and plasma NPR levels by examining age-associated NPR levels in these compartments in a transgenic APP/PS1 rat model of AD. NPR levels in cortical homogenate were similar in wild-type (Wt) and APP/PS1 rats at 3 months of age (prior to A beta plaque deposition), but significantly increased in APP/PS1 rats by 9 and 18-20 months of age (after the onset of plaque deposition). These age-dependent differences were driven by proportional increases in NPR in membrane-associated cortical fractions. Genotype-related differences in NPR expression were also seen in the hippocampus, which exhibits significant A beta pathology, but not in the cerebellum, which does not. Plasma analyses revealed increased levels of a 26 kDa NPR fragment in APP/PS1 rats relative to Wt rats by 18-20 months of age, which correlated with the levels of full-length NPR in cortex. Our findings indicate that cerebral accumulation of NPR and A beta occurs with similar temporal and regional patterns in the APP/PS1 model, and suggest that a 26 kDa plasma NPR fragment may represent a peripheral biomarker of this process. (C) 2014 Elsevier Inc. All rights reserved. C1 [Bilousova, Tina; Taylor, Karen; Emirzian, Ana; Gylys, Raymond; Frautschy, Sally A.; Cole, Gregory M.; Teng, Edmond] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Bilousova, Tina; Taylor, Karen; Frautschy, Sally A.; Cole, Gregory M.; Teng, Edmond] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Teng, E (reprint author), West Angeles VA Healthcare Ctr, Neurobehav Serv, 116AF,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM eteng@ucla.edu FU National Institute on Aging [K08 AG34628]; NIA; AFAR; John A. Hartford Foundation; Atlantic Philanthropies; Starr Foundation; anonymous donor [RC1 AG035878]; National Center for Research Resources; National Center for Advancing Translational Sciences [UL1 TR000124]; UCLA Clinical and Translational Science Institute FX This work was supported by the National Institute on Aging (K08 AG34628 [to ET; jointly sponsored by NIA, AFAR, the John A. Hartford Foundation, the Atlantic Philanthropies, the Starr Foundation and an anonymous donor] and RC1 AG035878 [to GMC]), the National Center for Research Resources and the National Center for Advancing Translational Sciences (UL1 TR000124), and the UCLA Clinical and Translational Science Institute. NR 49 TC 1 Z9 1 U1 0 U2 5 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0969-9961 EI 1095-953X J9 NEUROBIOL DIS JI Neurobiol. Dis. PD FEB PY 2015 VL 74 BP 32 EP 40 DI 10.1016/j.nbd.2014.11.006 PG 9 WC Neurosciences SC Neurosciences & Neurology GA CB5GQ UT WOS:000349655900004 PM 25449907 ER PT J AU Seidman, MD Gurgel, RK Lin, SY Schwartz, SR Baroody, FM Bonner, JR Dawson, DE Dykewicz, MS Hackell, JM Han, JK Ishman, SL Krouse, HJ Malekzadeh, S Mims, JWW Omole, FS Reddy, WD Wallace, DV Walsh, SA Warren, BE Wilson, MN Nnacheta, LC AF Seidman, Michael D. Gurgel, Richard K. Lin, Sandra Y. Schwartz, Seth R. Baroody, Fuad M. Bonner, James R. Dawson, Douglas E. Dykewicz, Mark S. Hackell, Jesse M. Han, Joseph K. Ishman, Stacey L. Krouse, Helene J. Malekzadeh, Sonya Mims, James Whit W. Omole, Folashade S. Reddy, William D. Wallace, Dana V. Walsh, Sandra A. Warren, Barbara E. Wilson, Meghan N. Nnacheta, Lorraine C. TI Clinical Practice Guideline: Allergic Rhinitis SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article DE allergic rhinitis; allergic rhinitis immunotherapy; surgical management of allergic rhinitis; medical management of allergic rhinitis; allergic rhinitis and steroid use; antihistamine use; decongestant use; allergic rhinitis and complementary; alternative; integrative medicine; acupuncture; herbal therapies; diagnosis of allergic rhinitis; nasal allergies; hay fever; atopic rhinitis; atrophic rhinitis; pollinosis; catarrh ID AQUEOUS NASAL SPRAY; PLACEBO-CONTROLLED TRIAL; PITUITARY-ADRENAL AXIS; INTRANASAL FLUTICASONE PROPIONATE; ENVIRONMENTAL EXPOSURE UNIT; LONG-TERM SAFETY; LEUKOTRIENE RECEPTOR ANTAGONISTS; ONCE-DAILY TREATMENT; SKIN PRICK TESTS; QUALITY-OF-LIFE AB Objective Allergic rhinitis (AR) is one of the most common diseases affecting adults. It is the most common chronic disease in children in the United States today and the fifth most common chronic disease in the United States overall. AR is estimated to affect nearly 1 in every 6 Americans and generates $2 to $5 billion in direct health expenditures annually. It can impair quality of life and, through loss of work and school attendance, is responsible for as much as $2 to $4 billion in lost productivity annually. Not surprisingly, myriad diagnostic tests and treatments are used in managing this disorder, yet there is considerable variation in their use. This clinical practice guideline was undertaken to optimize the care of patients with AR by addressing quality improvement opportunities through an evaluation of the available evidence and an assessment of the harm-benefit balance of various diagnostic and management options. Purpose The primary purpose of this guideline is to address quality improvement opportunities for all clinicians, in any setting, who are likely to manage patients with AR as well as to optimize patient care, promote effective diagnosis and therapy, and reduce harmful or unnecessary variations in care. The guideline is intended to be applicable for both pediatric and adult patients with AR. Children under the age of 2 years were excluded from the clinical practice guideline because rhinitis in this population may be different than in older patients and is not informed by the same evidence base. The guideline is intended to focus on a limited number of quality improvement opportunities deemed most important by the working group and is not intended to be a comprehensive reference for diagnosing and managing AR. The recommendations outlined in the guideline are not intended to represent the standard of care for patient management, nor are the recommendations intended to limit treatment or care provided to individual patients. Action Statements The development group made a strong recommendation that clinicians recommend intranasal steroids for patients with a clinical diagnosis of AR whose symptoms affect their quality of life. The development group also made a strong recommendation that clinicians recommend oral second-generation/less sedating antihistamines for patients with AR and primary complaints of sneezing and itching. The panel made the following recommendations: (1) Clinicians should make the clinical diagnosis of AR when patients present with a history and physical examination consistent with an allergic cause and 1 or more of the following symptoms: nasal congestion, runny nose, itchy nose, or sneezing. Findings of AR consistent with an allergic cause include, but are not limited to, clear rhinorrhea, nasal congestion, pale discoloration of the nasal mucosa, and red and watery eyes. (2) Clinicians should perform and interpret, or refer to a clinician who can perform and interpret, specific IgE (skin or blood) allergy testing for patients with a clinical diagnosis of AR who do not respond to empiric treatment, or when the diagnosis is uncertain, or when knowledge of the specific causative allergen is needed to target therapy. (3) Clinicians should assess patients with a clinical diagnosis of AR for, and document in the medical record, the presence of associated conditions such as asthma, atopic dermatitis, sleep-disordered breathing, conjunctivitis, rhinosinusitis, and otitis media. (4) Clinicians should offer, or refer to a clinician who can offer, immunotherapy (sublingual or subcutaneous) for patients with AR who have inadequate response to symptoms with pharmacologic therapy with or without environmental controls. The panel recommended against (1) clinicians routinely performing sinonasal imaging in patients presenting with symptoms consistent with a diagnosis of AR and (2) clinicians offering oral leukotriene receptor antagonists as primary therapy for patients with AR. The panel group made the following options: (1) Clinicians may advise avoidance of known allergens or may advise environmental controls (ie, removal of pets; the use of air filtration systems, bed covers, and acaricides [chemical agents formulated to kill dust mites]) in patients with AR who have identified allergens that correlate with clinical symptoms. (2) Clinicians may offer intranasal antihistamines for patients with seasonal, perennial, or episodic AR. (3) Clinicians may offer combination pharmacologic therapy in patients with AR who have inadequate response to pharmacologic monotherapy. (4) Clinicians may offer, or refer to a surgeon who can offer, inferior turbinate reduction in patients with AR with nasal airway obstruction and enlarged inferior turbinates who have failed medical management. (5) Clinicians may offer acupuncture, or refer to a clinician who can offer acupuncture, for patients with AR who are interested in nonpharmacologic therapy. The development group provided no recommendation regarding the use of herbal therapy for patients with AR. C1 [Seidman, Michael D.] Henry Ford West Bloomfield Hosp, Dept Otolaryngol Head & Neck Surg, West Bloomfield, MI 48322 USA. [Gurgel, Richard K.] Univ Utah, Dept Surg Otolaryngol Head & Neck Surg, Salt Lake City, UT USA. [Lin, Sandra Y.] Johns Hopkins Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD USA. [Schwartz, Seth R.] Virginia Mason Med Ctr, Seattle, WA 98101 USA. [Baroody, Fuad M.] Univ Chicago, Med Ctr, Dept Otolaryngol, Chicago, IL 60637 USA. [Bonner, James R.] Birmingham VA Med Ctr, Birmingham, AL USA. [Dykewicz, Mark S.] St Louis Univ, Sch Med, Dept Internal Med, St Louis, MO USA. [Hackell, Jesse M.] Pomona Pediat, Pomona, NY USA. [Han, Joseph K.] Eastern Virginia Med Sch, Norfolk, VA 23501 USA. [Ishman, Stacey L.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [Krouse, Helene J.] Wayne State Univ, Philadelphia, PA USA. [Malekzadeh, Sonya] Georgetown Univ Hosp, Washington, DC 20007 USA. [Mims, James Whit W.] Wake Forest Baptist Hlth, Winston Salem, NC USA. [Omole, Folashade S.] Morehouse Sch Med, East Point, GA USA. [Reddy, William D.] Acupuncture & Oriental Med AAAOM, Annandale, VA USA. [Wallace, Dana V.] Florida Atlantic Univ, Boca Raton, FL 33431 USA. [Wallace, Dana V.] Nova SE Univ, Davie, FL USA. [Walsh, Sandra A.; Warren, Barbara E.] Consumers United Evidence Based Healthcare, Fredericton, NB, Canada. [Wilson, Meghan N.] Louisiana State Univ, Sch Med, New Orleans, LA USA. [Nnacheta, Lorraine C.] Amer Acad Otolaryngol Head & Neck Surg Fdn, Dept Res & Qual, Alexandria, VA USA. RP Seidman, MD (reprint author), Henry Ford West Bloomfield Hosp, 6777 West Maple Rd, West Bloomfield, MI 48322 USA. EM mseidma1@hfhs.org FU American Academy of Otolaryngology-Head and Neck Surgery Foundation FX American Academy of Otolaryngology-Head and Neck Surgery Foundation. NR 365 TC 50 Z9 59 U1 15 U2 50 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0194-5998 EI 1097-6817 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD FEB PY 2015 VL 152 SU 1 BP S1 EP S43 DI 10.1177/0194599814561600 PG 43 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA CA9GP UT WOS:000349230300001 PM 25644617 ER PT J AU Fisher, MB Belkin, NS Milby, AH Henning, EA Bostrom, M Kim, M Pfeifer, C Meloni, G Dodge, GR Burdick, JA Schaer, TP Steinberg, DR Mauck, RL AF Fisher, Matthew B. Belkin, Nicole S. Milby, Andrew H. Henning, Elizabeth A. Bostrom, Marc Kim, Minwook Pfeifer, Christian Meloni, Gregory Dodge, George R. Burdick, Jason A. Schaer, Thomas P. Steinberg, David R. Mauck, Robert L. TI Cartilage Repair and Subchondral Bone Remodeling in Response to Focal Lesions in a Mini-Pig Model: Implications for Tissue Engineering SO TISSUE ENGINEERING PART A LA English DT Article ID AUTOLOGOUS CHONDROCYTE IMPLANTATION; ARTICULAR-CARTILAGE; IN-VIVO; STEM-CELL; KNEE ARTHROSCOPIES; ANIMAL-MODELS; FOLLOW-UP; DEFECTS; MATRIX; TRANSPLANTATION AB Objective: Preclinical large animal models are essential for evaluating new tissue engineering (TE) technologies and refining surgical approaches for cartilage repair. Some preclinical animal studies, including the commonly used minipig model, have noted marked remodeling of the subchondral bone. However, the mechanisms underlying this response have not been well characterized. Thus, our objective was to compare in-vivo outcomes of chondral defects with varied injury depths and treatments. Design: Trochlear chondral defects were created in 11 Yucatan minipigs (6 months old). Groups included an untreated partial-thickness defect (PTD), an untreated full-thickness defect (FTD), and FTDs treated with microfracture, autologous cartilage transfer (FTD-ACT), or an acellular hyaluronic acid hydrogel. Six weeks after surgery, micro-computed tomography (mu CT) was used to quantitatively assess defect fill and subchondral bone remodeling. The quality of cartilage repair was assessed using the ICRS-II histological scoring system and immunohistochemistry for type II collagen. A finite element model (FEM) was developed to assess load transmission. Results: Using mu CT, substantial bone remodeling was observed for all FTDs, but not for the PTD group. The best overall histological scores and greatest type II collagen staining was found for the FTD-ACT and PTD groups. The FEM confirmed that only the FTD-ACT group could initially restore appropriate transfer of compressive loads to the underlying bone. Conclusions: The bony remodeling observed in this model system appears to be a biological phenomena and not a result of altered mechanical loading, with the depth of the focal chondral defect (partial vs. full thickness) dictating the bony remodeling response. The type of cartilage injury should be carefully controlled in studies utilizing this model to evaluate TE approaches for cartilage repair. C1 [Fisher, Matthew B.; Belkin, Nicole S.; Milby, Andrew H.; Henning, Elizabeth A.; Bostrom, Marc; Kim, Minwook; Pfeifer, Christian; Meloni, Gregory; Dodge, George R.; Steinberg, David R.; Mauck, Robert L.] Univ Penn, McKay Orthopaed Res Lab, Dept Orthopaed Surg, Perelman Sch Med, Philadelphia, PA 19104 USA. [Fisher, Matthew B.; Belkin, Nicole S.; Milby, Andrew H.; Henning, Elizabeth A.; Bostrom, Marc; Kim, Minwook; Pfeifer, Christian; Meloni, Gregory; Dodge, George R.; Burdick, Jason A.; Steinberg, David R.; Mauck, Robert L.] Philadelphia VA Med Ctr, Translat Musculoskeletal Res Ctr, Philadelphia, PA USA. [Burdick, Jason A.; Mauck, Robert L.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA. [Schaer, Thomas P.] Univ Penn, Sch Vet Med, Comparat Orthoped Res Lab, Philadelphia, PA 19104 USA. RP Mauck, RL (reprint author), Univ Penn, McKay Orthopaed Res Lab, Dept Orthopaed Surg, Perelman Sch Med, 424 Stemmler Hall,36th St & Hamilton Walk, Philadelphia, PA 19104 USA. EM lemauck@mail.med.upenn.edu RI Fisher, Matthew/M-5809-2016 OI Fisher, Matthew/0000-0002-3212-0870 FU National Institutes of Health [R01 EB008722, F32 AR062971]; Department of Veterans Affairs [I01 RX000700]; AO Foundation; Orthopedic Research and Education Foundation (Resident Clinician Scientist Training Grant) FX The authors thank Nicole Soegaard for her technical assistance. This work was supported by the National Institutes of Health (R01 EB008722 and F32 AR062971), the Department of Veterans Affairs (I01 RX000700), the AO Foundation, and the Orthopedic Research and Education Foundation (Resident Clinician Scientist Training Grant). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Department of Veterans Affairs. No funding source had a role in the study design, collection, analysis and interpretation of data, writing of this article, or the decision to submit this article for publication. NR 54 TC 13 Z9 13 U1 4 U2 26 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1937-3341 EI 1937-335X J9 TISSUE ENG PT A JI Tissue Eng. Part A PD FEB 1 PY 2015 VL 21 IS 3-4 BP 850 EP 860 DI 10.1089/ten.tea.2014.0384 PG 11 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology SC Cell Biology; Biotechnology & Applied Microbiology GA CB4PZ UT WOS:000349611600040 PM 25318414 ER PT J AU Levkovitz, Y Isserles, M Padberg, F Lisanby, SH Bystritsky, A Xia, GH Tendler, A Daskalakis, ZJ Winston, JL Dannon, P Hafez, HM Reti, IM Morales, OG Schlaepfer, TE Hollander, E Berman, JA Husain, MM Sofer, U Stein, A Adler, S Deutsch, L Deutsch, F Roth, Y George, MS Zangen, A AF Levkovitz, Yechiel Isserles, Moshe Padberg, Frank Lisanby, Sarah H. Bystritsky, Alexander Xia, Guohua Tendler, Aron Daskalakis, Zafiris J. Winston, Jaron L. Dannon, Pinhas Hafez, Hisham M. Reti, Irving M. Morales, Oscar G. Schlaepfer, Thomas E. Hollander, Eric Berman, Joshua A. Husain, Mustafa M. Sofer, Uzi Stein, Ahava Adler, Shmulik Deutsch, Lisa Deutsch, Frederic Roth, Yiftach George, Mark S. Zangen, Abraham TI Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial SO WORLD PSYCHIATRY LA English DT Article DE Deep transcranial magnetic stimulation; major depressive disorder; treatment resistance; response; remission; maintenance treatment ID FUNCTIONAL CONNECTIVITY; PREFRONTAL CORTEX; BRAIN-REGIONS; H-COIL; DISORDER; METAANALYSIS; FIGURE-8; THERAPY; TMS AB Major depressive disorder (MDD) is a prevalent and disabling condition, and many patients do not respond to available treatments. Deep transcranial magnetic stimulation (dTMS) is a new technology allowing non-surgical stimulation of relatively deep brain areas. This is the first double-blind randomized controlled multicenter study evaluating the efficacy and safety of dTMS in MDD. We recruited 212 MDD outpatients, aged 22-68 years, who had either failed one to four antidepressant trials or not tolerated at least two antidepressant treatments during the current episode. They were randomly assigned to monotherapy with active or sham dTMS. Twenty sessions of dTMS (18 Hz over the prefrontal cortex) were applied during 4 weeks acutely, and then biweekly for 12 weeks. Primary and secondary efficacy endpoints were the change in the Hamilton Depression Rating Scale (HDRS-21) score and response/remission rates at week 5, respectively. dTMS induced a 6.39 point improvement in HDRS-21 scores, while a 3.28 point improvement was observed in the sham group (p=0.008), resulting in a 0.76 effect size. Response and remission rates were higher in the dTMS than in the sham group (response: 38.4 vs. 21.4%, p=0.013; remission: 32.6 vs. 14.6%, p=0.005). These differences between active and sham treatment were stable during the 12-week maintenance phase. dTMS was associated with few and minor side effects apart from one seizure in a patient where a protocol violation occurred. These results suggest that dTMS constitutes a novel intervention in MDD, which is efficacious and safe in patients not responding to antidepressant medications, and whose effect remains stable over 3 months of maintenance treatment. C1 [Levkovitz, Yechiel] Tel Aviv Univ, Shalvata Mental Hlth Ctr, Hod Hasharon, Israel. [Isserles, Moshe] Hadassah Hebrew Univ Med Ctr, Dept Psychiat, Jerusalem, Israel. [Padberg, Frank] Univ Munich, Dept Psychiat & Psychotherapy, Munich, Germany. [Lisanby, Sarah H.] Duke Univ, Dept Psychiat & Behav Sci, Durham, NC USA. [Lisanby, Sarah H.] Duke Univ, Dept Psychol & Neurosci, Durham, NC USA. [Bystritsky, Alexander] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Xia, Guohua] Univ Calif Davis, UC Davis Ctr Mind & Brain, Davis, CA 95616 USA. [Xia, Guohua] Univ Calif Davis, Dept Psychiat & Behav Sci, Davis, CA 95616 USA. [Tendler, Aron] Adv Mental Hlth Care Inc, Royal Palm Beach, FL USA. [Daskalakis, Zafiris J.] Univ Toronto, Ctr Addict & Mental Hlth, Toronto, ON, Canada. [Winston, Jaron L.] Senior Adult Specialty Healthcare, Austin, TX USA. [Dannon, Pinhas] Tel Aviv Univ, Beer Yaakov Mental Hlth Ctr, Beer Yaagov, Israel. [Hafez, Hisham M.] Greater Nashua Mental Hlth Ctr, Nashua, NH USA. [Reti, Irving M.] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA. [Morales, Oscar G.] McLean Hosp, Belmont, MA 02178 USA. [Morales, Oscar G.] Harvard Univ, Sch Med, Belmont, MA 02178 USA. [Schlaepfer, Thomas E.] Univ Hosp, Dept Psychiat & Psychotherapy, Bonn, Germany. [Hollander, Eric] Spectrum Neurosci & Treatment Ctr, New York, NY USA. [Berman, Joshua A.] Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, Dept Psychiat, New York, NY 10032 USA. [Husain, Mustafa M.] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA. [Sofer, Uzi] Brainsway Ltd, Jerusalem, Israel. [Stein, Ahava; Adler, Shmulik] A Stein Regulatory Affairs Consulting Ltd, Kefar Sava, Israel. [Roth, Yiftach; Zangen, Abraham] Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel. [George, Mark S.] Med Univ S Carolina, Dept Psychiat, Brain Stimulat Lab, Charleston, SC 29425 USA. [George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Levkovitz, Y (reprint author), Tel Aviv Univ, Shalvata Mental Hlth Ctr, Hod Hasharon, Israel. OI Tendler, Aron/0000-0001-8587-7335 NR 29 TC 35 Z9 36 U1 4 U2 14 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1723-8617 EI 2051-5545 J9 WORLD PSYCHIATRY JI World Psychiatry PD FEB PY 2015 VL 14 IS 1 BP 64 EP 73 DI 10.1002/wps.20199 PG 10 WC Psychiatry SC Psychiatry GA CB0FC UT WOS:000349300000019 PM 25655160 ER PT J AU Carnes, M Devine, PG Manwell, LB Byars-Winston, A Fine, E Ford, CE Forscher, P Isaac, C Kaatz, A Magua, W Palta, M Sheridan, J AF Carnes, Molly Devine, Patricia G. Manwell, Linda Baier Byars-Winston, Angela Fine, Eve Ford, Cecilia E. Forscher, Patrick Isaac, Carol Kaatz, Anna Magua, Wairimu Palta, Mari Sheridan, Jennifer TI The Effect of an Intervention to Break the Gender Bias Habit for Faculty at One Institution: A Cluster Randomized, Controlled Trial SO ACADEMIC MEDICINE LA English DT Article ID ACADEMIC MEDICINE; SEX-DISCRIMINATION; CONSORT STATEMENT; CAUTIONARY TALE; BASE-LINE; WOMEN; PREJUDICE; STEREOTYPES; LEADERSHIP; CULTURE AB Purpose Despite sincere commitment to egalitarian, meritocratic principles, subtle gender bias persists, constraining women's opportunities for academic advancement. The authors implemented a pair-matched, single-blind, cluster randomized, controlled study of a gender-bias-habit-changing intervention at a large public university. Method Participants were faculty in 92 departments or divisions at the University of Wisconsin Madison. Between September 2010 and March 2012, experimental departments were offered a gender-bias-habit-changing intervention as a 2.5-hour workshop. Surveys measured gender bias awareness; motivation, self-efficacy, and outcome expectations to reduce bias; and gender equity action. A timed word categorization task measured implicit gender/leadership bias. Faculty completed a work life survey before and after all experimental departments received the intervention. Control departments were offered workshops after data were collected. Results Linear mixed-effects models showed significantly greater changes post intervention for faculty in experimental versus control departments on several outcome measures, including self-efficacy to engage in gender-equity-promoting behaviors (P=.013). When 25% of a department's faculty attended the workshop (26 of 46 departments), significant increases in self-reported action to promote gender equity occurred at three months (P =.007). Post intervention, faculty in experimental departments expressed greater perceptions of fit (P=.024), valuing of their research (P=.019), and comfort in raising personal and professional conflicts (P =.025). Conclusions An intervention that facilitates intentional behavioral change can help faculty break the gender bias habit and change department climate in ways that should support the career advancement of women in academic medicine, science, and engineering. C1 [Carnes, Molly; Kaatz, Anna; Magua, Wairimu] Univ Wisconsin, Ctr Womens Hlth Res, Madison, WI 53715 USA. [Carnes, Molly; Manwell, Linda Baier; Byars-Winston, Angela] Univ Wisconsin, Dept Med, Madison, WI 53715 USA. [Carnes, Molly] Univ Wisconsin, Dept Psychiat, Madison, WI 53715 USA. [Carnes, Molly] Univ Wisconsin, Dept Ind & Syst Engn, Madison, WI 53715 USA. [Carnes, Molly] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Devine, Patricia G.; Forscher, Patrick] Univ Wisconsin, Dept Psychol, Madison, WI 53715 USA. [Manwell, Linda Baier] Vet Hlth Adm Cent Off, Womens Hlth Serv, Washington, DC USA. [Fine, Eve; Sheridan, Jennifer] Univ Wisconsin, Women Sci & Engn Leadership Inst, Madison, WI 53715 USA. [Ford, Cecilia E.] Univ Wisconsin, Dept English & Sociol, Madison, WI 53715 USA. [Isaac, Carol] Mercer Univ, Atlanta, GA USA. [Palta, Mari] Univ Wisconsin, Dept Biostat, Madison, WI 53715 USA. [Palta, Mari] Univ Wisconsin, Dept Populat Hlth Sci, Madison, WI 53715 USA. RP Carnes, M (reprint author), Univ Wisconsin, 700 Regent St,Suite 301, Madison, WI 53715 USA. EM mlcarnes@wisc.edu FU National Institutes of Health [R01 GM088477, DP4 GM096822, R25 GM083252] FX This work was supported by National Institutes of Health grants R01 GM088477, DP4 GM096822, and R25 GM083252. NR 76 TC 32 Z9 32 U1 5 U2 33 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1040-2446 EI 1938-808X J9 ACAD MED JI Acad. Med. PD FEB PY 2015 VL 90 IS 2 BP 221 EP 230 DI 10.1097/ACM.0000000000000552 PG 10 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA CA3LL UT WOS:000348808000029 PM 25374039 ER PT J AU Lowe, JR Raugi, G Reiber, GE Whitney, JD AF Lowe, Jeanne R. Raugi, Greg Reiber, Gayle E. Whitney, JoAnne D. TI Changes in Classifications of Chronic Lower-Limb Wound Codes in Patients with Diabetes: ICD-9-CM Versus ICD-10-CM SO ADVANCES IN SKIN & WOUND CARE LA English DT Article DE ICD-9; ICD-10; diabetes and foot ulcers; wound classification ID ADMINISTRATIVE DATA; AMPUTATION; VALIDITY AB OBJECTIVE: To determine the sensitivity and specificity of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM) and ICD-10-CM codes for individuals with diabetes and foot ulcers. DESIGN AND METHODS: Wound care providers and researchers are concerned about the potential impacts when the United States transitions from ICD-9-CM to ICD-10-CM. To identify the impact on diabetic foot ulcers, health history and wound variables were prospectively assessed with criterion-standard data from a prospective study of 49 patients with 65 foot ulcer episodes representing 81 incident foot ulcers. The ICD-9-CM and ICD-10-CM code sets were mapped to correctly classify individuals with diabetes and foot ulcers. RESULTS: Frequencies for health history variables were similar in both systems. The ICD-9 code did not capture any data on laterality (left or right) or ulcer depth/severity. The ICD-9 captured 69 of 81 incident ulcers (85%) and 94% of heel and midfoot ulcers, whereas the ICD-10 code captured 78 of 81 incident ulcers (96%) and all incident heel or midfoot ulcers. Sensitivity and specificity for ulcer characteristics were consistently lower in ICD-9 than in ICD-10. CONCLUSIONS: The ICD-9 and ICD-10 are similar for data capture on health history variables, but wound variables are captured more accurately using ICD-10. The increased specificity of ICD-10 for ulcer location and severity improves identification and tracking ulcers during an episode of care. C1 [Lowe, Jeanne R.; Whitney, JoAnne D.] Univ Washington, Sch Nursing, Seattle, WA 98195 USA. [Lowe, Jeanne R.] UW Med Hlth Syst, Dept Finance, Pay For Performance, Seattle, WA USA. [Raugi, Greg] VA Puget Sound Med, Ctr, Teledermatol, Seattle, WA USA. [Reiber, Gayle E.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Lowe, JR (reprint author), Univ Washington, Sch Nursing, Seattle, WA 98195 USA. FU Biobehavioral Nursing Research Training Program, NIH/NINR University of Washington, Seattle [NR007106]; VA Health Services and Research Development Project [IBA 09061]; VA Senior Career Scientist Award [98-353] FX This study is funded in part by the Biobehavioral Nursing Research Training Program, NR007106 NIH/NINR University of Washington, Seattle. Funding was also provided by the VA Health Services and Research Development Project IBA 09061. Dr Reiber's salary is supported by VA Senior Career Scientist Award 98-353. NR 15 TC 0 Z9 0 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1527-7941 EI 1538-8654 J9 ADV SKIN WOUND CARE JI Adv. Skin Wound Care PD FEB PY 2015 VL 28 IS 2 BP 84 EP 92 PG 9 WC Dermatology; Nursing; Surgery SC Dermatology; Nursing; Surgery GA CA0GS UT WOS:000348595600006 PM 25608014 ER PT J AU Brothers, TE AF Brothers, Thomas E. TI Failure of Patients with Peripheral Arterial Disease to Accept the Recommended Treatment Results in Worse Outcomes SO ANNALS OF VASCULAR SURGERY LA English DT Article ID QUALITY-OF-LIFE; PROSPECTIVE DECISION-ANALYSIS; VASCULAR-SURGERY; SEVERE ISCHEMIA; GRADING SYSTEM; LIMB ISCHEMIA; LEGS SCORE; BYPASS; QUESTIONNAIRE; AMPUTATION AB Background: Strategies available to facilitate decision making for patients with peripheral arterial disease (PAD) include a Markov-based decision analysis (DA) model and the Lower Extremity Grading System (LEGS) score. Both have suggested inferior outcomes when the actual treatment received (ATX) differs from that predicted. This study focuses on patient outcomes when such discordance exists. Methods: All patients referred for symptomatic lower extremity PAD over a 3-year period were evaluated using the DA model and the LEGS score. Calculated quality of life (cQOL) values were assigned before treatment based on patient symptom, perfusion, and amputation status and at follow-up (range 1.000 [perfect health] to .000 [death]). The primary outcome of cQOL was compared according to whether the ATX matched that proposed by the surgeon or predicted by the DA model or LEGS score. Secondary outcomes for revascularized patients included major adverse limb event with perioperative death (MALE + POD) and amputation-free survival (AFS). Results: Among 375 procedures in 345 consecutive patients, the greatest improvement in cQOL at last follow-up (median 16 months) was observed with endovascular (0.23 +/- 0.16, n=93) or open (0.21 +/- 0.17, n=137) revascularization compared with primary amputation (0.10 +/- 0.07, n=23) or medical therapy (0.04 +/- 0.09, n = 122). Multivariate regression showed discordance with the surgeon's recommendation (P<0.05) and/or the DA model (P<0.05) to be independent predictors of improvement failure. ATX did not always agree with that proposed by the surgeon (89% agree, kappa = 0.84), the DA model (68% agree, kappa = 0.53), or the LEGS score (53% agree, kappa = 0.32). Improvement in cQOL was greatest when ATX was concordant with treatment proposed by the surgeon (0.18 vs. 0.08, P < 0.01), the DA model (0.19 vs. 0.13, P < 0.01), or the LEGS score (0.23 vs. 0.10, P < 0.01). Patient refusal to follow the surgeon's recommendations and continued smoking were associated with minimal improvement (cQOL ranges 0.05-0.07 and 0.00-0.02, respectively), while pursuing a less morbid procedure was associated with greater improvement (cQOL range 0.28-0.38). Among revascularized patients, MALE + POD was lower at 36 months after endovascular than open surgery (21% +/- 5% vs. 36% +/- 4%, P < 0.05), while AFS was not significantly different. Only discordance with the surgeon's recommendation was an independent predictor of MALE + POD, possibly because of limitations in sample subset size. Conclusions: Mean cQOL improved most with direct revascularization, especially when the treatment received matched that predicted by the models or proposed by the surgeon. Type of treatment received was an independent predictor of agreement of treatment with recommendations. Patient refusal to follow the recommended treatment as well as the strategy not to revascularize claudicants who persist in smoking were associated with much less patient benefit from treatment. C1 Med Univ S Carolina, Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC 29425 USA. RP Brothers, TE (reprint author), Med Univ S Carolina, Ralph H Johnson Dept Vet Affairs Med Ctr, 25 Courtenay Dr, Charleston, SC 29425 USA. EM brothete@musc.edu OI Brothers, Thomas/0000-0001-9780-9559 NR 22 TC 2 Z9 2 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0890-5096 EI 1615-5947 J9 ANN VASC SURG JI Ann. Vasc. Surg. PD FEB PY 2015 VL 29 IS 2 BP 244 EP 259 DI 10.1016/j.avsg.2014.08.006 PG 16 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA CA8VY UT WOS:000349200200011 PM 25305420 ER PT J AU Lepak, AJ Marchillo, K Craig, WA Andes, DR AF Lepak, Alexander J. Marchillo, Karen Craig, William A. Andes, David R. TI In Vivo Pharmacokinetics and Pharmacodynamics of the Lantibiotic NAI-107 in a Neutropenic Murine Thigh Infection Model SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID RESISTANT STAPHYLOCOCCUS-AUREUS; PRECURSOR LIPID II; DISEASES-SOCIETY; BAD BUGS; STREPTOCOCCUS-PNEUMONIAE; HEALTH-CARE; ANTIBIOTICS; VANCOMYCIN; AMERICA; NISIN AB NAI-107 is a novel lantibiotic compound with potent in vitro activity against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). The purpose of this study was to examine the activity of NAI-107 against S. aureus strains, including MRSA, in the neutropenic murine thigh infection model. Serum pharmacokinetics were determined and timekill studies were performed following administration of single subcutaneous doses of 5, 20, and 80 mg/kg body weight. The dose fractionation included total doses ranging from 1.56 to 400 mg/kg/72 h, divided into 1, 2, 3, or 6 doses. Studies of treatment effects against 9 S. aureus strains (4 methicillin-susceptible Staphylococcus aureus [MSSA] and 5 MRSA) using a 12-h dosing interval and total dose range of 1.56 to 400 mg/kg/72 h were also performed. A maximum effect (E-max) model was used to determine the pharmacokinetic/pharmacodynamic (PK/PD) index that best described the dose-response data and to estimate the doses required to achieve a net bacteriostatic dose (SD) and a 1-log reduction in CFU/thigh. The pharmacokinetic studies demonstrated an area under the concentration-time curve (AUC) range of 26.8 to 276 mg.h/liter and half-lives of 4.2 to 8.2 h. MICs ranged from 0.125 to 0.5 mu g/ml. The 2 highest single doses produced more than a 2-log kill and prolonged postantibiotic effects (PAEs) ranging from 36 to > 72 h. The dose fractionation-response curves were similar, and the AUC/MIC ratio was the most predictive PD index (AUC/MIC, coefficient of determination [R-2] = 0.89; maximum concentration of drug in serum [C-max]/MIC, R-2 = 0.79; time [T] > MIC, R-2 = 0.63). A >= 2-log kill was observed against all 9 S. aureus strains. The total drug 24-h AUC/MIC values associated with stasis and a 1-log kill for the 9 S. aureus strains were 371 +/- 130 and 510 +/- 227, respectively. NAI-107 demonstrated concentration-dependent killing and prolonged PAEs. The AUC/MIC ratio was the predictive PD index. Extensive killing was observed for S. aureus organisms, independent of the MRSA status. The AUC/MIC target should be useful for the design of clinical dosing regimens. C1 [Lepak, Alexander J.; Craig, William A.; Andes, David R.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53706 USA. [Andes, David R.] Univ Wisconsin, Dept Med Microbiol & Immunol, Madison, WI USA. [Marchillo, Karen; Andes, David R.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Andes, DR (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53706 USA. EM dra@medicine.wisc.edu FU Sentinella Pharmaceuticals, Inc. FX This study was funded by Sentinella Pharmaceuticals, Inc. NR 47 TC 14 Z9 14 U1 0 U2 11 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD FEB PY 2015 VL 59 IS 2 BP 1258 EP 1264 DI 10.1128/AAC.04444-14 PG 7 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA CA0LT UT WOS:000348610000062 PM 25512404 ER PT J AU Wiederhold, NP Najvar, LK Fothergill, AW Bocanegra, R Olivo, M McCarthy, DI Kirkpatrick, WR Fukuda, Y Mitsuyama, J Patterson, TF AF Wiederhold, Nathan P. Najvar, Laura K. Fothergill, Annette W. Bocanegra, Rosie Olivo, Marcos McCarthy, Dora I. Kirkpatrick, William R. Fukuda, Yoshiko Mitsuyama, Junichi Patterson, Thomas F. TI The Novel Arylamidine T-2307 Maintains In Vitro and In Vivo Activity against Echinocandin-Resistant Candida albicans SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID BLOOD-STREAM INFECTIONS; SURVEILLANCE; EFFICACY AB We evaluated the in vitro and in vivo activities of the investigational arylamidine T-2307 against echinocandin-resistant Candida albicans. T-2307 demonstrated potent in vitro activity, and daily subcutaneous doses between 0.75 and 6 mg/kg of body weight significantly improved survival and reduced fungal burden compared to placebo control and caspofungin (10 mg/kg/day) in mice with invasive candidiasis caused by an echinocandin-resistant strain. Thus, T-2307 may have potential use in the treatment of echinocandin-resistant C. albicans infections. C1 [Wiederhold, Nathan P.; Najvar, Laura K.; Fothergill, Annette W.; Bocanegra, Rosie; Olivo, Marcos; McCarthy, Dora I.; Kirkpatrick, William R.; Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Najvar, Laura K.; Bocanegra, Rosie; Olivo, Marcos; Kirkpatrick, William R.; Patterson, Thomas F.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Fukuda, Yoshiko; Mitsuyama, Junichi] Toyama Chem Co Ltd, Toyama, Japan. RP Wiederhold, NP (reprint author), Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. EM wiederholdn@uthscsa.edu OI Wiederhold, Nathan/0000-0002-2225-5122 FU National Institute of Allergy and Infectious Diseases, National Institutes of Health; Department of Health and Human Services [HHS272201000018I, HHSN272201000038I]; Astellas; Dow; F2G; Merck; Merz; Viamet FX This project utilized preclinical services funded by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, and Department of Health and Human Services under contract no. HHS272201000018I and HHSN272201000038I, Task Orders A03 and A13, respectively.; N.P.W. has received research support from Astellas, Dow, F2G, Merck, Merz, and Viamet and has served on advisory boards for Merck, Astellas, Toyama, and Viamet. T.F.P. has received research grants to UT Health Science Center San Antonio from Astellas and Merck and has served as a consultant for Astellas, Merck, Toyama, Viamet, and SCYN-EXIS. L.K.N. has received travel support from Viamet. Y.F. and J.M. are employees of Toyama Chemical Co., Ltd. NR 13 TC 3 Z9 3 U1 1 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD FEB PY 2015 VL 59 IS 2 BP 1341 EP 1343 DI 10.1128/AAC.04228-14 PG 3 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA CA0LT UT WOS:000348610000074 PM 25451054 ER PT J AU Borrero, S Nikolajski, C Steinberg, JR Freedman, L Akers, AY Ibrahim, S Schwarz, EB AF Borrero, Sonya Nikolajski, Cara Steinberg, Julia R. Freedman, Lori Akers, Aletha Y. Ibrahim, Said Schwarz, Eleanor Bimla TI "It just happens": a qualitative study exploring low-income women's perspectives on pregnancy intention and planning SO CONTRACEPTION LA English DT Article DE Pregnancy intention; Race; Pregnancy planning; Reproductive coercion ID UNINTENDED PREGNANCY; CONTRACEPTIVE USE; UNPROTECTED INTERCOURSE; PARTNER VIOLENCE; AVOID PREGNANCY; UNITED-STATES; YOUNG-ADULTS; ATTITUDES; AMBIVALENCE; ADOLESCENTS AB Objective: Unintended pregnancy is common and disproportionately occurs among low-income women. We conducted a qualitative study with low-income women to better typologize pregnancy intention, understand the relationship between pregnancy intention and contraceptive use, and identify the contextual factors that shape pregnancy intention and contraceptive behavior. Study design: Semistructured interviews were conducted with low-income, African American and white women aged 18-45 recruited from reproductive health clinics in Pittsburgh, PA, to explore factors that influence women's pregnancy-related behaviors. Narratives were analyzed using content analysis and the constant comparison method. Results: Among the 66 participants (36 African American and 30 white), we identified several factors that may impede our public health goal of increasing the proportion of pregnancies that are consciously desired and planned. First, women do not always perceive that they have reproductive control and therefore do not necessarily formulate clear pregnancy intentions. Second, the benefits of a planned pregnancy may not be evident. Third, because preconception intention and planning do not necessarily occur, decisions about the acceptability of a pregnancy are often determined after the pregnancy has already occurred. Finally, even when women express a desire to avoid pregnancy, their contraceptive behaviors are not necessarily congruent with their desires. We also identified several clinically relevant and potentially modifiable factors that help to explain this intention behavior discrepancy, including women's perceptions of low fecundity and their experiences with male partner contraceptive sabotage. Conclusion: Our findings suggest that the current conceptual framework that views pregnancy-related behaviors from a strict planned behavior perspective may be limited, particularly among low-income populations. Implications: This study identified several cognitive and interpersonal pathways to unintended pregnancy among low-income women in Pittsburgh, PA, including perceptions of low reproductive control, perceptions of low fecundity and male partner reproductive coercion. Published by Elsevier Inc. C1 [Borrero, Sonya; Nikolajski, Cara] Univ Pittsburgh, Dept Med, Ctr Res Hlth Care, Pittsburgh, PA 15213 USA. [Borrero, Sonya] VA Pittsburgh Healthcare Syst, VA Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Steinberg, Julia R.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Freedman, Lori] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA. [Akers, Aletha Y.] Magee Womens Hosp, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA USA. [Akers, Aletha Y.] Univ Pittsburgh, Pittsburgh, PA 15213 USA. [Ibrahim, Said] Philadelphia VA Med Ctr, VA Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Ibrahim, Said] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Schwarz, Eleanor Bimla] Univ Calif Davis, Davis Sch Med, Dept Med, Sacramento, CA USA. RP Borrero, S (reprint author), Univ Pittsburgh, Ctr Res Hlth Care, 230 McKee Pl,Suite 600, Pittsburgh, PA 15213 USA. EM borrerosp@upmc.edu OI Freedman, Lori/0000-0002-7919-9520; Schwarz, Eleanor Bimla/0000-0002-9912-8236 FU Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) [1 R21 HD068736-01]; a component of the National Institutes of Health (NIH); K01 [K01HD075834] FX This study was funded by Dr. Borrero's grant (1 R21 HD068736-01) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), a component of the National Institutes of Health (NIH). The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of NICHD or NIH. Dr. Steinberg's effort on this study was supported by her K01 grant (K01HD075834). NR 39 TC 30 Z9 30 U1 1 U2 16 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 EI 1879-0518 J9 CONTRACEPTION JI Contraception PD FEB PY 2015 VL 91 IS 2 BP 150 EP 156 DI 10.1016/j.contraception.2014.09.014 PG 7 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA CA4TD UT WOS:000348896300009 PM 25477272 ER PT J AU Furlong, M Tanner, CM Goldman, SM Bhudhikanok, GS Blair, A Chade, A Comyns, K Hoppin, JA Kasten, M Korell, M Langston, JW Marras, C Meng, C Richards, M Ross, GW Umbach, DM Sandler, DP Kamel, F AF Furlong, Melissa Tanner, Caroline M. Goldman, Samuel M. Bhudhikanok, Grace S. Blair, Aaron Chade, Anabel Comyns, Kathleen Hoppin, Jane A. Kasten, Meike Korell, Monica Langston, J. William Marras, Connie Meng, Cheryl Richards, Marie Ross, G. Webster Umbach, David M. Sandler, Dale P. Kamel, Freya TI Protective glove use and hygiene habits modify the associations of specific pesticides with Parkinson's disease SO ENVIRONMENT INTERNATIONAL LA English DT Article DE Personal protective equipment; Parkinson's disease; Pesticides; Neurodegenerative diseases; Movement disorders ID AGRICULTURAL HEALTH; INCOMPLETE REMOVAL; EXPOSURE; RISK; DETERMINANTS; APPLICATORS; FARMWORKERS; CALIFORNIA; CAPTAN; SKIN AB Pesticides have been associated with Parkinson's disease (PD), and protective gloves and workplace hygiene can reduce pesticide exposure. We assessed whether use of gloves and workplace hygiene modified associations between pesticides and PD. The Farming and Movement Evaluation (FAME) study is a nested case-control study within the Agricultural Health Study. Use of protective gloves, other PPE, and hygiene practices were determined by questionnaire (69 cases and 237 controls were included). We considered interactions of gloves and hygiene with ever-use of pesticides for all pesticides with >= 5 exposed and unexposed cases and controls in each glove-use stratum (paraquat, permethrin, rotenone, and trifluralin). 61% of respondents consistently used protective gloves and 87% consistently used >= 2 hygiene practices. Protective glove use modified the associations of paraquat and permethrin with PD: neither pesticide was associated with PD among protective glove users, while both pesticides were associated with PD among non-users (paraquat OR 3.9 [95% CI 13, 11.7], interaction p = 0.15; permethrin OR 4.3 [95% CI 1.2, 15.6] interaction p = 0.05). Rotenone was associated with PD regardless of glove use. Trifluralin was associated with PD among participants who used <2 hygiene practices (OR 5.5 [95% CI 1.1, 27.1]) but was not associated with PD among participants who used 2 or more practices (interaction p = 0.02). Although sample size was limited in the FAME study, protective glove use and hygiene practices appeared to be important modifiers of the association between pesticides and PD and may reduce risk of PD associated with certain pesticides. Published by Elsevier Ltd C1 [Furlong, Melissa] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27599 USA. [Tanner, Caroline M.; Meng, Cheryl] San Francisco VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, San Francisco, CA USA. [Tanner, Caroline M.; Goldman, Samuel M.; Comyns, Kathleen; Korell, Monica; Meng, Cheryl] Univ Calif San Francisco, Sch Med, Dept Neurol, San Francisco, CA 94143 USA. [Bhudhikanok, Grace S.; Langston, J. William] Parkinsons Inst & Clin Ctr, Sunnyvale, CA USA. [Blair, Aaron] NCI, Occupat & Environm Epidemiol Branch, Bethesda, MD 20892 USA. [Chade, Anabel] Favaloro Univ, Inst Neurosci, Buenos Aires, DF, Argentina. [Hoppin, Jane A.] N Carolina State Univ, Dept Biol Sci, Raleigh, NC 27695 USA. [Kasten, Meike] Univ Lubeck, Dept Psychiat, Lubeck, Germany. [Marras, Connie] Univ Toronto, Toronto, ON, Canada. [Richards, Marie] Westat Corp, Durham, NC USA. [Ross, G. Webster] VA Pacific Isl Hlth Care Syst, Honolulu, HI USA. [Umbach, David M.] NIEHS, Biostat Branch, Res Triangle Pk, NC 27709 USA. [Sandler, Dale P.; Kamel, Freya] NIEHS, Epidemiol Branch, Res Triangle Pk, NC 27709 USA. RP Furlong, M (reprint author), Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, Box 7435, Chapel Hill, NC 27599 USA. EM furlongm@med.unc.edu OI Kamel, Freya/0000-0001-5052-6615; Sandler, Dale/0000-0002-6776-0018 FU NIEHS [R01-ES10803, ES07018]; National Institutes of Health [National Institute of Environmental Health Sciences (NIEHS)] [Z01-ES044007, Z01-ES049030]; National Institutes of Health [National Cancer Institute] [Z01-CP010119] FX This study was supported by the NIEHS grant R01-ES10803, the James and Sharron Clark, and the Intramural Research Program of the National Institutes of Health [National Institute of Environmental Health Sciences (NIEHS) grants Z01-ES044007 and Z01-ES049030, and the National Cancer Institute grant Z01-CP010119]. M Furlong was partly supported by the NIEHS institutional training grant ES07018. The authors would also like to thank the participants and the research team. We are indebted to Kent Thomas at the US EPA for valuable discussions about PPE and hygiene. NR 36 TC 8 Z9 8 U1 0 U2 15 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0160-4120 EI 1873-6750 J9 ENVIRON INT JI Environ. Int. PD FEB PY 2015 VL 75 BP 144 EP 150 DI 10.1016/j.envint.2014.11.002 PG 7 WC Environmental Sciences SC Environmental Sciences & Ecology GA CA2OD UT WOS:000348746600014 PM 25461423 ER PT J AU Kunisaki, KM Akgun, KM Fiellin, DA Gibert, CL Kim, JW Rimland, D Rodriguez-Barradas, MC Yaggi, HK Crothers, K AF Kunisaki, K. M. Akguen, K. M. Fiellin, D. A. Gibert, C. L. Kim, J. W. Rimland, D. Rodriguez-Barradas, M. C. Yaggi, H. K. Crothers, K. TI Prevalence and correlates of obstructive sleep apnoea among patients with and without HIV infection SO HIV MEDICINE LA English DT Article DE fatigue; HIV; obesity; obstructive; sleep apnoea; sleep apnoea syndromes ID POSITIVE AIRWAY PRESSURE; RISK-FACTOR; HYPERTENSION; ASSOCIATION; DISEASE; MEN; VETERANS; PATTERNS; OUTCOMES; COHORT AB ObjectivesIn HIV-uninfected populations, obstructive sleep apnoea (OSA) is commonly associated with cardiovascular disease, metabolic syndrome, and cognitive impairment. These comorbidities are common in HIV-infected patients, but there are scarce data regarding OSA in HIV-infected patients. Therefore, we examined the prevalence and correlates of OSA in a cohort of HIV-infected and uninfected patients. MethodsAn observational cohort study was carried out. Electronic medical record and self-report data were examined in patients enrolled in the Veterans Aging Cohort Study (VACS) between 2002 and 2008 and followed until 2010. The primary outcome was OSA diagnosis, determined using International Classification of Diseases, 9th edition (ICD-9) codes, in HIV-infected compared with uninfected individuals. We used regression analyses to determine the association between OSA diagnosis, symptoms and comorbidities in adjusted models. ResultsOf 3683 HIV-infected and 3641 uninfected patients, 143 (3.9%) and 453 (12.4%) had a diagnosis of OSA (p<0.0001), respectively. HIV-infected patients were more likely to report symptoms associated with OSA such as tiredness and fatigue. Compared with uninfected patients with OSA, HIV-infected patients with OSA were younger, had lower body mass indexes (BMIs), and were less likely to have hypertension. In models adjusting for these traditional OSA risk factors, HIV infection was associated with markedly reduced odds of OSA diagnosis (odds ratio 0.48; 95% confidence interval 0.39-0.60). ConclusionsHIV-infected patients are less likely to receive a diagnosis of OSA. Future studies are needed to determine whether the lower prevalence of OSA diagnoses in HIV-infected patients is attributable to decreased screening and detection or to a truly decreased likelihood of OSA in the setting of HIV infection. C1 [Kunisaki, K. M.] Minneapolis VA Hlth Care Syst, Minneapolis, MN 55417 USA. [Kunisaki, K. M.] Univ Minnesota, Minneapolis, MN USA. [Akguen, K. M.; Yaggi, H. K.] VA Connecticut Hlth Care Syst, West Haven, CT USA. [Akguen, K. M.; Fiellin, D. A.; Yaggi, H. K.] Yale Univ, Sch Med, New Haven, CT USA. [Gibert, C. L.] Washington DC VA Med Ctr, Washington, DC USA. [Gibert, C. L.] George Washington Univ, Washington, DC USA. [Kim, J. W.] James J Peters VA Med Ctr, Bronx, NY USA. [Rimland, D.] Atlanta VA Med Ctr, Atlanta, GA USA. [Rimland, D.] Emory Univ, Atlanta, GA 30322 USA. [Rodriguez-Barradas, M. C.] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Rodriguez-Barradas, M. C.] Baylor Coll Med, Houston, TX 77030 USA. [Crothers, K.] Univ Washington, Seattle, WA 98195 USA. RP Kunisaki, KM (reprint author), Minneapolis VA Hlth Care Syst, Pulm Crit Care & Sleep Apnea 111N, One Vet Dr, Minneapolis, MN 55417 USA. EM kunis001@umn.edu OI Kunisaki, Ken/0000-0001-8644-2827; Fiellin, David/0000-0002-4006-010X FU Department of Veterans Affairs, Veterans Health Administration, VISN 1 Career Development Award [VA HSRD V1CDA2012-20]; National Heart Lung and Blood Institute [R01-HL090342]; National Institute on Alcohol Abuse and Alcoholism [U10-AA13566, U24-AA020794, U01-AA020790] FX The research reported/outlined here was supported by the Department of Veterans Affairs, Veterans Health Administration, VISN 1 Career Development Award (VA HSR&D V1CDA2012-20), the National Heart Lung and Blood Institute (R01-HL090342), and the National Institute on Alcohol Abuse and Alcoholism (U10-AA13566, U24-AA020794 and U01-AA020790). NR 26 TC 4 Z9 4 U1 3 U2 13 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1464-2662 EI 1468-1293 J9 HIV MED JI HIV Med. PD FEB PY 2015 VL 16 IS 2 BP 105 EP 113 DI 10.1111/hiv.12182 PG 9 WC Infectious Diseases SC Infectious Diseases GA CA2AW UT WOS:000348712300005 PM 25230851 ER PT J AU Teo, AR Fetters, MD Stufflebam, K Tateno, M Balhara, Y Choi, TY Kanba, S Mathews, CA Kato, TA AF Teo, Alan R. Fetters, Michael D. Stufflebam, Kyle Tateno, Masaru Balhara, Yatan Choi, Tae Young Kanba, Shigenobu Mathews, Carol A. Kato, Takahiro A. TI Identification of the hikikomori syndrome of social withdrawal: Psychosocial features and treatment preferences in four countries SO INTERNATIONAL JOURNAL OF SOCIAL PSYCHIATRY LA English DT Article DE Social isolation; cross-national; culture ID CULTURE-BOUND SYNDROME; COMMUNITY POPULATION; PRIMARY-CARE; MECHANISMS; DISORDERS; VERSION; SCALE; JAPAN; RISK AB Background: Hikikomori, a form of social withdrawal first reported in Japan, may exist globally but cross-national studies of cases of hikikomori are lacking. Aims: To identify individuals with hikikomori in multiple countries and describe features of the condition. Method: Participants were recruited from sites in India, Japan, Korea and the United States. Hikikomori was defined as a 6-month or longer period of spending almost all time at home and avoiding social situations and social relationships, associated with significant distress/impairment. Additional measures included the University of California, Los Angeles (UCLA) Loneliness Scale, Lubben Social Network Scale (LSNS-6), Sheehan Disability Scale (SDS) and modified Cornell Treatment Preferences Index. Results: A total of 36 participants with hikikomori were identified, with cases detected in all four countries. These individuals had high levels of loneliness (UCLA Loneliness Scale M = 55.4, SD = 10.5), limited social networks (LSNS-6 M = 9.7, SD = 5.5) and moderate functional impairment (SDS M = 16.5, SD = 7.9). Of them 28 (78%) desired treatment for their social withdrawal, with a significantly higher preference for psychotherapy over pharmacotherapy, in-person over telepsychiatry treatment and mental health specialists over primary care providers. Across countries, participants with hikikomori had similar generally treatment preferences and psychosocial features. Conclusion: Hikikomori exists cross-nationally and can be assessed with a standardized assessment tool. Individuals with hikikomori have substantial psychosocial impairment and disability, and some may desire treatment. C1 [Teo, Alan R.] Portland VA Med Ctr, Portland, OR 97239 USA. [Fetters, Michael D.] Univ Michigan, Dept Family Med, Japanese Family Hlth Program, Ann Arbor, MI 48109 USA. [Stufflebam, Kyle] Univ Michigan, Robert Wood Johnson Fdn, Clin Scholars Program, Ann Arbor, MI 48109 USA. [Tateno, Masaru] Sapporo Med Univ, Dept Neuropsychiat, Sapporo Hana Dev Psychiat Clin, Sapporo, Hokkaido, Japan. [Balhara, Yatan] All India Inst Med Sci, Natl Drug Dependence Treatment Ctr, New Delhi, India. [Choi, Tae Young] Catholic Univ Daegu, Sch Med, Dept Psychiat, Taegu, South Korea. [Kanba, Shigenobu; Kato, Takahiro A.] Kyushu Univ, Grad Sch Med Sci, Dept Neuropsychiat, Fukuoka 812, Japan. [Mathews, Carol A.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Kato, Takahiro A.] Kyushu Univ, Innovat Ctr Med Redox Nav, Fukuoka 812, Japan. RP Teo, AR (reprint author), Portland VA Med Ctr, 3710 SW US Vet Hosp Rd R&D 66, Portland, OR 97239 USA. EM teoa@ohsu.edu; takahiro@npsych.med.kyushu-u.ac.jp NR 35 TC 11 Z9 11 U1 6 U2 19 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0020-7640 EI 1741-2854 J9 INT J SOC PSYCHIATR JI Int. J. Soc. Psychiatr. PD FEB PY 2015 VL 61 IS 1 BP 64 EP 72 DI 10.1177/0020764014535758 PG 9 WC Psychiatry SC Psychiatry GA CA8CD UT WOS:000349143200009 PM 24869848 ER PT J AU Teo, AR Kato, TA AF Teo, Alan R. Kato, Takahiro A. TI The prevalence and correlates of severe social withdrawal in Hong Kong SO INTERNATIONAL JOURNAL OF SOCIAL PSYCHIATRY LA English DT Letter C1 [Teo, Alan R.] Portland VA Med Ctr, Portland, OR 97239 USA. [Teo, Alan R.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Kato, Takahiro A.] Kyushu Univ, Grad Sch Med Sci, Dept Neuropsychiat, Fukuoka 812, Japan. [Kato, Takahiro A.] Kyushu Univ, Innovat Ctr Med Redox Nav, Fukuoka 812, Japan. RP Teo, AR (reprint author), Portland VA Med Ctr, 3710 SW US Vet Hosp Rd R&D 66, Portland, OR 97239 USA. EM teoa@ohsu.edu NR 3 TC 1 Z9 1 U1 0 U2 5 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0020-7640 EI 1741-2854 J9 INT J SOC PSYCHIATR JI Int. J. Soc. Psychiatr. PD FEB PY 2015 VL 61 IS 1 BP 102 EP 102 DI 10.1177/0020764014554923 PG 1 WC Psychiatry SC Psychiatry GA CA8CD UT WOS:000349143200013 PM 25323493 ER PT J AU Butt, AA Yan, P Lo Re, V Rimland, D Goetz, MB Leaf, D Freiberg, MS Klein, MB Justice, AC Sherman, KE AF Butt, Adeel A. Yan, Peng Lo Re, Vincent, III Rimland, David Goetz, Matthew B. Leaf, David Freiberg, Matthew S. Klein, Marina B. Justice, Amy C. Sherman, Kenneth E. CA ERCHIVES Elect Retrieved Cohort HC TI Liver Fibrosis Progression in Hepatitis C Virus Infection After Seroconversion SO JAMA INTERNAL MEDICINE LA English DT Article ID NON-B-HEPATITIS; TERM-FOLLOW-UP; NON-A; POSTTRANSFUSION HEPATITIS; NATURAL-HISTORY; HCV; COINFECTION; VETERANS; SURVIVAL; COHORT AB IMPORTANCE Knowing the rate of liver fibrosis progression in hepatitis C virus (HCV)-infected persons can help inform patients and providers (clinicians, medical institutions or organizations, and third-party payers) in making treatment decisions. OBJECTIVE To determine the rate and factors associated with liver fibrosis progression and hepatic decompensation in persons after acquiring HCV infection. DESIGN, SETTING, AND PARTICIPANTS Secondary data analysis of persons in the Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES), a national Veterans Affairs (VA) database, between 2002 and 2012. Among 610 514 persons in ERCHIVES (half were HCV positive), we identified those with an initial negative and subsequent positive test result for HCV antibody and positive HCV RNA test result (HCV+). Controls had 2 negative HCV antibody test results (HCV-) in a comparable time frame and were matched 1: 1 on age (in 5-year blocks), race, and sex. We excluded persons with human immunodeficiency virus, hepatitis B, less than 24 months of follow-up, hepatocellular carcinoma, and cirrhosis at baseline. MAIN OUTCOMES AND MEASURES Progression of liver fibrosis as estimated by the Fibrosis-4 (FIB-4) index; development of cirrhosis, defined by a FIB-4 score greater than 3.5; and development of hepatic decompensation. RESULTS The evaluable data set consisted of 1840 persons who were HCV+ and 1840 HCV-controls. The HCV+ persons were younger and had a lower mean (SD) body mass index (27.39 [5.51] vs 29.49 [6.16]; P <.001), a higher prevalence of alcohol and drug abuse and dependence diagnoses, and higher serum aminotransferase levels, but had a lower prevalence of diabetes and hypertension. Fibrosis progression started early after infection among HCV+ persons and tapered off after 5 years. A total of 452 cirrhosis and 85 hepatic decompensation events were recorded. After 10 years of follow-up, HCV+ persons were more likely to have a diagnosis of cirrhosis compared with HCV-controls (18.4% vs 6.1%). Nine years after diagnosis of cirrhosis, hepatic decompensation events were uncommon but had a higher rate in the HCV+ group (1.79% vs 0.33%). CONCLUSIONS AND RELEVANCE Persons who seroconverted for HCV have a more rapid progression of liver fibrosis and accelerated time to development of cirrhosis after seroconversion compared with HCV-controls. Fibrosis progression occurs early after infection; however, hepatic decompensation is uncommon after diagnosis of cirrhosis. C1 [Butt, Adeel A.; Freiberg, Matthew S.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA. [Butt, Adeel A.; Yan, Peng; Freiberg, Matthew S.] Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Lo Re, Vincent, III] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Rimland, David] Atlanta VA Med Ctr, Dept Med, Decatur, GA USA. [Goetz, Matthew B.; Leaf, David] VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA. [Klein, Marina B.] McGill Univ, Dept Med, Ctr Hlth, Montreal, PQ, Canada. [Justice, Amy C.] VA Connecticut Healthcare Syst, West Haven, CT USA. [Justice, Amy C.] Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA. [Sherman, Kenneth E.] Univ Cincinnati, Med Ctr, Dept Med, Cincinnati, OH 45267 USA. RP Butt, AA (reprint author), Univ Pittsburgh, Sch Med, Div Infect Dis, 3601 Fifth Ave,Ste 3A, Pittsburgh, PA 15213 USA. EM aabutt@pitt.edu RI Lo Re, Vincent/N-7817-2015 OI Butt, Adeel/0000-0002-1118-1826; Goetz, Matthew/0000-0003-4542-992X; Justice, Amy/0000-0003-0139-5502 FU National Institutes of Health (NIH) [U24 AA020794, U01 AA020790] FX Dr Justice's time was supported by grants U24 AA020794 and U01 AA020790 from the National Institutes of Health (NIH). This material is the result of work supported with resources and the use of facilities at the VA Pittsburgh Healthcare System and the central data repositories maintained by the VA Information Resource Center, including the National Patient Care Database, Decisions Support System Database and Pharmacy Benefits Management Database. NR 30 TC 27 Z9 27 U1 1 U2 6 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD FEB PY 2015 VL 175 IS 2 BP 178 EP 185 DI 10.1001/jamainternmed.2014.6502 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA CA7TL UT WOS:000349120100012 PM 25485735 ER PT J AU Burke, RE Juarez-Colunga, E Levy, C Prochazka, AV Coleman, EA Ginde, AA AF Burke, Robert E. Juarez-Colunga, Elizabeth Levy, Cari Prochazka, Allan V. Coleman, Eric A. Ginde, Adit A. TI Rise of Post-Acute Care Facilities as a Discharge Destination of US Hospitalizations SO JAMA INTERNAL MEDICINE LA English DT Letter C1 [Burke, Robert E.; Prochazka, Allan V.] Eastern Colorado Hlth Care Syst, Dept Vet Affairs Med Ctr, Denver, CO USA. [Burke, Robert E.; Prochazka, Allan V.] Univ Colorado, Sch Med, Dept Med, Div Gen Internal Med, Aurora, CO USA. [Juarez-Colunga, Elizabeth] Univ Colorado, Sch Med, Dept Biostat & Informat, Aurora, CO USA. [Levy, Cari; Coleman, Eric A.] Univ Colorado, Sch Med, Div Hlth Care Policy & Res, Aurora, CO USA. [Ginde, Adit A.] Univ Colorado, Sch Med, Dept Emergency Med, Aurora, CO USA. RP Burke, RE (reprint author), Denver VA Med Ctr, 1055 Clermont St, Denver, CO 80220 USA. EM robert.burke5@va.gov RI bebarta, vikhyat/K-3476-2015 FU NCATS NIH HHS [UL1 TR001082]; NIA NIH HHS [K23AG040708] NR 6 TC 15 Z9 15 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD FEB PY 2015 VL 175 IS 2 BP 295 EP 296 DI 10.1001/jamainternmed.2014.6383 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA CA7TL UT WOS:000349120100034 PM 25437642 ER PT J AU Keller, AC Knaub, LA Miller, MW Birdsey, N Klemm, DJ Reusch, JEB AF Keller, Amy C. Knaub, Leslie A. Miller, Matthew W. Birdsey, Nicholas Klemm, Dwight J. Reusch, Jane E. B. TI Saxagliptin Restores Vascular Mitochondrial Exercise Response in the Goto-Kakizaki Rat SO JOURNAL OF CARDIOVASCULAR PHARMACOLOGY LA English DT Article DE mitochondria; exercise; saxagliptin; type 2 diabetes; GLP-1; eNOS ID GLUCAGON-LIKE PEPTIDE-1; NITRIC-OXIDE SYNTHASE; CHRONIC HEART-FAILURE; PHYSICAL-ACTIVITY; SKELETAL-MUSCLE; SMOOTH-MUSCLE; CARDIOVASCULAR-DISEASE; INSULIN-RESISTANCE; DIABETES-MELLITUS; ENDOTHELIAL-CELLS AB Cardiovascular disease risk and all-cause mortality are largely predicted by physical fitness. Exercise stimulates vascular mitochondrial biogenesis through endothelial nitric oxide synthase (eNOS), sirtuins, and PPAR gamma coactivator 1 alpha (PGC-1 alpha), a response absent in diabetes and hypertension. We hypothesized that an agent regulating eNOS in the context of diabetes could reconstitute exercise-mediated signaling to mitochondrial biogenesis. Glucagon-like peptide 1 (GLP-1) stimulates eNOS and blood flow; we used saxagliptin, an inhibitor of GLP-1 degradation, to test whether vascular mitochondrial adaptation to exercise in diabetes could be restored. Goto-Kakizaki (GK) rats, a nonobese, type 2 diabetes model, and Wistar controls were exposed to an 8-day exercise intervention with or without saxagliptin (10 mg.kg(-1).d(-1)). We evaluated the impact of exercise and saxagliptin on mitochondrial proteins and signaling pathways in aorta. Mitochondrial protein expression increased with exercise in the Wistar aorta and decreased or remained unchanged in the GK animals. GK rats treated with saxagliptin plus exercise showed increased expression of mitochondrial complexes, cytochrome c, eNOS, nNOS, PGC-1 alpha, and UCP3 proteins. Notably, a 3-week saxagliptin plus exercise intervention significantly increased running time in the GK rats. These data suggest that saxagliptin restores vascular mitochondrial adaptation to exercise in a diabetic rodent model and may augment the impact of exercise on the vasculature. C1 [Keller, Amy C.; Knaub, Leslie A.; Miller, Matthew W.; Birdsey, Nicholas; Reusch, Jane E. B.] Univ Colorado Denver, Div Endocrinol Metab & Diabet, Aurora, CO 80045 USA. [Keller, Amy C.; Knaub, Leslie A.; Miller, Matthew W.; Birdsey, Nicholas; Reusch, Jane E. B.] Denver VA Med Ctr, Dept Med, Denver, CO USA. [Klemm, Dwight J.] Univ Colorado Denver, Div Pulm Sci & Crit Care Med, Aurora, CO 80045 USA. RP Reusch, JEB (reprint author), Univ Colorado Denver, Div Endocrinol Metab & Diabet, Anschutz Med Campus,12801 E 17th Ave,MS8106, Aurora, CO 80045 USA. EM jane.reusch@ucdenver.edu FU VA Merit; Denver Research Institue; Bristol-Myers Squibb; CCTSI [UL1RR025780]; Center for Women's Health Research; [NIH-5T32HL007171]; [NIH-5P01HL014985] FX Funded by VA Merit, Denver Research Institute, Bristol-Myers Squibb, NIH-5T32HL007171, NIH-5P01HL014985, CCTSI (UL1RR025780), and the Center for Women's Health Research. NR 54 TC 4 Z9 4 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0160-2446 EI 1533-4023 J9 J CARDIOVASC PHARM JI J. Cardiovasc. Pharmacol. PD FEB PY 2015 VL 65 IS 2 BP 137 EP 147 PG 11 WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy GA CB0KE UT WOS:000349313800007 PM 25264749 ER PT J AU Jones, J Nowels, CT Sudore, R Ahluwalia, S Bekelman, DB AF Jones, Jacqueline Nowels, Carolyn T. Sudore, Rebecca Ahluwalia, Sangeeta Bekelman, David B. TI The Future as a Series of Transitions: Qualitative Study of Heart Failure Patients and Their Informal Caregivers SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE advance care planning; transitions; palliative care; decision making; patient-centered care ID ADVANCE DIRECTIVES; LIFE; CARE; END; COMMUNICATION; ADJUSTMENT; PEOPLE; HOPE AB Advance care planning often only focuses on written advance directives rather than on future goals important to patients and families. Heart failure has a particularly uncertain future with variable clinical trajectories. A better understanding of patient and family concerns about and perceptions of the future could improve advance care planning. We aimed to identify how patients with heart failure and their informal (family) caregivers perceive their future. This was a cross-sectional study using qualitative methods. Thirty-three patients from an academic health care system with New York Heart Association class II-IV heart failure and 20 of their informal caregivers participated in the study. We used a purposive sampling strategy to include patients within a range of ages and health statuses. Participants were asked in individual, semi-structured interviews: "When you think about what lies ahead, what comes to mind?" Qualitative analysis used an inductive approach. Early in the analysis, it became clear that participants' narratives about the future were described in terms of past transitions. This led us to use transition theory to further guide analysis. Transition theory describes how people restructure their reality and resolve uncertainty during change. Patients and their caregivers talked about past and present transitions when asked about the future: "The present gets in the way of talking about the future." We identified four common pivotal transitions, including the shock of first being diagnosed with heart failure; learning to adjust to life with heart failure; reframing and taking back control of one's life; and understanding and accepting that death is inevitable. Concerns about the future were framed based on the most recent transition. Heart failure is a series of transitions according to patients and caregivers. By recognizing and educating patients about transitions, identifying transition-specific concerns, and supporting patients and caregivers through transitions, the process of planning for the future as part of advance care planning may be improved. C1 [Jones, Jacqueline] Univ Colorado, Coll Nursing, Aurora, CO 80045 USA. [Nowels, Carolyn T.; Bekelman, David B.] Univ Colorado, Sch Med, Aurora, CO 80045 USA. [Nowels, Carolyn T.; Bekelman, David B.] Eastern Colorado Hlth Care Syst, Dept Vet Affairs, Denver, CO USA. [Sudore, Rebecca] Univ Calif San Francisco, Sch Med, Div Geriatr, San Francisco, CA USA. [Sudore, Rebecca] San Francisco VA Med Ctr, San Francisco, CA USA. [Ahluwalia, Sangeeta] Oregon State Univ, Coll Publ Hlth & Human Sci, Corvallis, OR 97331 USA. RP Jones, J (reprint author), Univ Colorado, Coll Nursing, Campus Box C-288-19,13120 E 19th Ave, Aurora, CO 80045 USA. EM jacqueline.jones@ucdenver.edu FU University of Colorado Hartford/Jahnigen Center for Excellence in Geriatric Medicine; Mordecai Palliative Care Grants Fund; Department of Veterans Affairs [HSRD CDA 08-022] FX Funders: This research was funded by the University of Colorado Hartford/Jahnigen Center for Excellence in Geriatric Medicine and the Mordecai Palliative Care Grants Fund. Dr. Bekelman is funded by a Department of Veterans Affairs Career Development Award (HSR&D CDA 08-022). The funding organizations had no role in any part of the study. The views expressed in this paper are those of the authors and do not necessarily reflect the views of the Department of Veterans Affairs. NR 31 TC 5 Z9 5 U1 2 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD FEB PY 2015 VL 30 IS 2 BP 176 EP 182 DI 10.1007/s11606-014-3085-5 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA CA9HX UT WOS:000349234300009 PM 25385209 ER PT J AU Chiovaro, J AF Chiovaro, Joseph TI Capsule Commentary on Turner et al., Chronic Opioid Therapy Urine Drug Testing in Primary Care: Prevalence and Predictors of Aberrant Results SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material C1 Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97239 USA. RP Chiovaro, J (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97239 USA. EM jchiovaro@gmail.com NR 4 TC 1 Z9 1 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD FEB PY 2015 VL 30 IS 2 BP 241 EP 241 DI 10.1007/s11606-014-3091-7 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA CA9HX UT WOS:000349234300022 PM 25387440 ER PT J AU Ozieh, MN Bishu, KG Dismuke, CE Egede, LE AF Ozieh, M. N. Bishu, K. G. Dismuke, C. E. Egede, L. E. TI TREND OF HEALTH CARE EXPENDITURE IN UNITED STATES ADULTS WITH CHRONIC KIDNEY DISEASE: 2002-2011 SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Southern Regional Meeting of the American-Federation-for-Medical-Research CY FEB 26-28, 2015 CL New Orleans, LA SP Amer Federat Med Res C1 [Ozieh, M. N.; Bishu, K. G.; Dismuke, C. E.; Egede, L. E.] MUSC, Charleston, SC USA. [Dismuke, C. E.; Egede, L. E.] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1081-5589 EI 1708-8267 J9 J INVEST MED JI J. Invest. Med. PD FEB PY 2015 VL 63 IS 2 MA 447 BP 453 EP 454 PG 2 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA CA0GM UT WOS:000348595000454 ER PT J AU Swenson, C Sadikot, R AF Swenson, C. Sadikot, R. TI DIFFERENTIAL INDUCTION OF HOST GENES BY ACHROMOBACTER SPECIES SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Southern Regional Meeting of the American-Federation-for-Medical-Research CY FEB 26-28, 2015 CL New Orleans, LA SP Amer Federat Med Res C1 [Swenson, C.] Univ Florida, Gainesville, FL USA. [Sadikot, R.] Emory Univ, Atlanta, GA 30322 USA. [Sadikot, R.] US Dept Vet Affairs, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1081-5589 EI 1708-8267 J9 J INVEST MED JI J. Invest. Med. PD FEB PY 2015 VL 63 IS 2 MA 517 BP 474 EP 474 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA CA0GM UT WOS:000348595000524 ER PT J AU Ioannou, GN Van Rooyen, DM Savard, C Haigh, WG Yeh, MM Teoh, NC Farrell, GC AF Ioannou, George N. Van Rooyen, Derrick M. Savard, Christopher Haigh, W. Geoffrey Yeh, Matthew M. Teoh, Narci C. Farrell, Geoffrey C. TI Cholesterol-lowering drugs cause dissolution of cholesterol crystals and disperse Kupffer cell crown-like structures during resolution of NASH SO JOURNAL OF LIPID RESEARCH LA English DT Article DE crown-like structure; caspase 1; lipotoxicity; nonalcoholic steatohepatitis ID FATTY LIVER-DISEASE; RECEPTOR-DEFICIENT MICE; NONALCOHOLIC STEATOHEPATITIS; NALP3 INFLAMMASOME; DIETARY-CHOLESTEROL; METABOLIC SYNDROME; CONTROLLED-TRIAL; ADIPOCYTE DEATH; ADIPOSE-TISSUE; DIABETIC MICE AB Cholesterol crystals form within hepatocyte lipid droplets in human and experimental nonalcoholic steatohepatitis (NASH) and are the focus of crown-like structures (CLSs) of activated Kupffer cells (KCs). Obese, diabetic Alms1 mutant (foz/foz) mice were a fed high-fat (23%) diet containing 0.2% cholesterol for 16 weeks and then assigned to four intervention groups for 8 weeks: a) vehicle control, b) ezetimibe (5 mg/kg/day), c) atorvastatin (20 mg/kg/day), or d) ezetimibe and atorvastatin. Livers of vehicle-treated mice developed fibrosing NASH with abundant cholesterol crystallization within lipid droplets calculated to extend over 3.3% (SD, 2.2%) of liver surface area. Hepatocyte lipid droplets with prominent cholesterol crystallization were surrounded by TNF-positive (activated) KCs forming CLSs (3 per high-power field). KCs that formed CLSs stained positive for NLRP3, implicating activation of the NLRP3 inflammasome in response to cholesterol crystals. In contrast, foz/foz mice treated with ezetimibe and atorvastatin showed near-complete resolution of cholesterol crystals [0.01% (SD, 0.02%) of surface area] and CLSs (0 per high-power field), with amelioration of fibrotic NASH. Ezetimibe or atorvastatin alone had intermediate effects on cholesterol crystallization, CLSs, and NASH. These findings are consistent with a causative link between exposure of hepatocytes and KCs to cholesterol crystals and with the development of NASH possibly mediated by NLRP3 activation. C1 [Ioannou, George N.; Savard, Christopher; Haigh, W. Geoffrey] Vet Affairs Puget Sound Hlth Care Syst, Div Gastroenterol, Dept Med, Seattle, WA 98108 USA. Univ Washington, Seattle, WA 98195 USA. [Van Rooyen, Derrick M.; Teoh, Narci C.; Farrell, Geoffrey C.] Australian Natl Univ, Sch Med, Canberra Hosp, Liver Res Grp, Garran, ACT, Australia. [Yeh, Matthew M.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. RP Ioannou, GN (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Div Gastroenterol, Dept Med, Seattle, WA 98108 USA. EM georgei@medicine.washington.edu FU Diabetes Research Center, University of Washington FX This work was supported by a grant from the Diabetes Research Center, University of Washington (G.N.I.) and by resources from VAPSHCS Research and Development. NR 41 TC 15 Z9 15 U1 1 U2 8 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0022-2275 EI 1539-7262 J9 J LIPID RES JI J. Lipid Res. PD FEB PY 2015 VL 56 IS 2 BP 277 EP 285 DI 10.1194/jlr.M053785 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA CA4VR UT WOS:000348905000008 PM 25520429 ER PT J AU Burhans, MS Flowers, MT Harrington, KR Bond, LM Guo, CA Anderson, RM Ntambi, JM AF Burhans, Maggie S. Flowers, Matthew T. Harrington, Kristin R. Bond, Laura M. Guo, Chang-An Anderson, Rozalyn M. Ntambi, James M. TI Hepatic oleate regulates adipose tissue lipogenesis and fatty acid oxidation SO JOURNAL OF LIPID RESEARCH LA English DT Article DE -oxidation; de novo lipogenesis; fatty acid; desaturases; fatty acid; metabolism; lipids; liver; triglycerides; white adipose tissue ID STEAROYL-COA DESATURASE-1; DE-NOVO LIPOGENESIS; LIVER-DISEASE; INSULIN-RESISTANCE; PROTECTS MICE; DIACYLGLYCEROL ACYLTRANSFERASE; OBESITY; DEFICIENCY; HUMANS; GENE AB Hepatic steatosis is associated with detrimental metabolic phenotypes including enhanced risk for diabetes. Stearoyl-CoA desaturases (SCDs) catalyze the synthesis of MUFAs. In mice, genetic ablation of SCDs reduces hepatic de novo lipogenesis (DNL) and protects against diet-induced hepatic steatosis and adiposity. To understand the mechanism by which hepatic MUFA production influences adipose tissue stores, we created two liver-specific transgenic mouse models in the SCD1 knockout that express either human SCD5 or mouse SCD3, that synthesize oleate and palmitoleate, respectively. We demonstrate that hepatic de novo synthesized oleate, but not palmitoleate, stimulate hepatic lipid accumulation and adiposity, reversing the protective effect of the global SCD1 knockout under lipogenic conditions. Unexpectedly, the accumulation of hepatic lipid occurred without induction of the hepatic DNL program. Changes in hepatic lipid composition were reflected in plasma and in adipose tissue. Importantly, endogenously synthesized hepatic oleate was associated with suppressed DNL and fatty acid oxidation in white adipose tissue. Regression analysis revealed a strong correlation between adipose tissue lipid fuel utilization and hepatic and adipose tissue lipid storage. These data suggest an extrahepatic mechanism where endogenous hepatic oleate regulates lipid homeostasis in adipose tissues. C1 [Burhans, Maggie S.; Ntambi, James M.] Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA. [Flowers, Matthew T.; Harrington, Kristin R.; Bond, Laura M.; Guo, Chang-An; Ntambi, James M.] Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA. [Anderson, Rozalyn M.] Univ Wisconsin, Dept Med, Madison, WI 53706 USA. [Anderson, Rozalyn M.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI 53705 USA. RP Ntambi, JM (reprint author), Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA. EM jmntambi@wisc.edu FU National Institutes of Health (NIH) [R01 DK062388]; ADA [7-13-BS-118]; USDA Hatch [W2005]; NIH [RO1 AG037000, T32 DK007665, T32 GM07215]; American Heart Association FX This work was supported by National Institutes of Health (NIH) Grant R01 DK062388, ADA 7-13-BS-118, and USDA Hatch W2005 (to J.M.N.), and NIH Grant RO1 AG037000 (to R.M.A.). M.S.B was supported by NIH Predoctoral Training Grant T32 DK007665, M.T.F was supported by NIH Postdoctoral Training Grant T32 DK007665 and an American Heart Association postdoctoral fellowship, L.M.B. was supported by NIH National Research Service Award T32 GM07215. NR 47 TC 7 Z9 7 U1 2 U2 15 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0022-2275 EI 1539-7262 J9 J LIPID RES JI J. Lipid Res. PD FEB PY 2015 VL 56 IS 2 BP 304 EP 318 DI 10.1194/jlr.M054429 PG 15 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA CA4VR UT WOS:000348905000011 PM 25555387 ER PT J AU Kvale, E Bailey, AA Dionne-Odom, J Redden, D Burgio, A AF Kvale, Elizabeth Bailey, Al F. Amos Dionne-Odom, James Redden, David Burgio, Al Kathryn TI Predictors of Physical Restraint Use in Hospitalized Veterans at End of Life in the Acute Care Setting: An Analysis of Data from the BEACON Trial SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 25-28, 2015 CL Philadelphia, PA SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Kvale, Elizabeth; Burgio, Al Kathryn] Birmingham VAMC, Birmingham, AL USA. [Bailey, Al F. Amos] Birmingham VAMC, Denver, CO USA. [Dionne-Odom, James; Redden, David] Univ Alabama Birmingham, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2015 VL 49 IS 2 MA TH318-C BP 341 EP 342 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AZ8PU UT WOS:000348478200031 ER PT J AU Cooke, K Franklin, J AF Cooke, Kelly Franklin, John TI Paying Homage to Unsung Heroes: Understanding and Honoring Military Service at the End of Life SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 25-28, 2015 CL Philadelphia, PA SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Cooke, Kelly] Prohlth Care, Eagle, WI USA. [Franklin, John] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2015 VL 49 IS 2 MA FR453 BP 373 EP 373 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AZ8PU UT WOS:000348478200094 ER PT J AU Vig, E Wocial, L AF Vig, Elizabeth Wocial, Lucia TI Recognizing and Responding to Moral Distress SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 25-28, 2015 CL Philadelphia, PA SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Vig, Elizabeth] Univ Washington, Mercer Isl, WA USA. [Vig, Elizabeth] VA Puget Sound Hlth Care Syst, Mercer Isl, WA USA. [Wocial, Lucia] Indiana Univ, Indianapolis, IN 46204 USA. [Wocial, Lucia] Fairbanks Ctr Med Eth, Indianapolis, IN USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2015 VL 49 IS 2 MA FR463 BP 378 EP 379 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AZ8PU UT WOS:000348478200106 ER PT J AU Gilbert, A Dubeansky, D Garrido, M Howe, J Chang, V AF Gilbert, Amanda Dubeansky, Debbie Garrido, Melissa Howe, Judith Chang, Victor TI Palliative Social Work Services for Hepatocellular Cancer Patients at a VA Medical Center SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 25-28, 2015 CL Philadelphia, PA SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Gilbert, Amanda] James J Peters VAMC, New York, NY USA. [Dubeansky, Debbie; Garrido, Melissa; Howe, Judith] James J Peters VAMC, Bronx, NY USA. [Garrido, Melissa; Howe, Judith] Icahn Sch Med, Bronx, NY USA. [Chang, Victor] New Jersey Hlth Care Syst, E Orange, NJ USA. [Chang, Victor] Rutgers NJMS, E Orange, NJ USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2015 VL 49 IS 2 MA S717 BP 415 EP 416 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AZ8PU UT WOS:000348478200177 ER PT J AU Goebel, J Guo, W Chong, K AF Goebel, Joy Guo, William Chong, Kelly TI A Team of Experts or an Expert Team: Interdisciplinary Teamwork and Perceptions of Palliative Care Quality SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 25-28, 2015 CL Philadelphia, PA SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Goebel, Joy] Calif State Univ Long Beach, Long Beach, CA 90840 USA. [Guo, William] Master Quick Bridge Funding, Walnut, CA USA. [Chong, Kelly] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2015 VL 49 IS 2 MA S742 BP 429 EP 429 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AZ8PU UT WOS:000348478200201 ER PT J AU Hagiwara, Y Ross, J Aagaard, H Lee, S Sanchez-Reilly, S AF Hagiwara, Yuya Ross, Jeanette Aagaard, Hannah Lee, Shuko Sanchez-Reilly, Sandra TI As Real as It Gets: Enhancing Medical Student's Palliative Communication Skills Through Standardized Family Meetings with Onsite-Feedback SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 25-28, 2015 CL Philadelphia, PA SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Hagiwara, Yuya; Ross, Jeanette; Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Ross, Jeanette; Sanchez-Reilly, Sandra] GEC GRECC South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Aagaard, Hannah; Lee, Shuko] South Texas Vet Hlth Care Syst, San Antonio, TX USA. High Sch Student South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2015 VL 49 IS 2 MA S743 BP 429 EP 430 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AZ8PU UT WOS:000348478200202 ER PT J AU Azuero, C Huang, CH Bae, S Kvale, E Ritchie, C AF Azuero, Casey Huang, Chao-Hui Bae, Sejong Kvale, Elizabeth Ritchie, Christine TI Concordance Between Structured and Unstructured Debriefing on Symptom Burden in Breast Cancer: A Mixed Methods Analysis SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 25-28, 2015 CL Philadelphia, PA SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Azuero, Casey; Bae, Sejong] Univ Alabama Birmingham, Birmingham, AL USA. [Huang, Chao-Hui] Univ Alabama, Tuscaloosa, AL USA. [Kvale, Elizabeth] Birmingham VAMC, Birmingham, AL USA. [Ritchie, Christine] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2015 VL 49 IS 2 MA S755 BP 436 EP 436 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AZ8PU UT WOS:000348478200214 ER PT J AU Mireles, C Ross, J Lee, S Noble, S Healy, A AF Mireles, Christina Ross, Jeanette Lee, Shuko Noble, Sara Healy, Amanda TI Facebook as a Resource for Caregivers of Hospice Patients SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 25-28, 2015 CL Philadelphia, PA SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Mireles, Christina; Ross, Jeanette; Noble, Sara] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Lee, Shuko] South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2015 VL 49 IS 2 MA S769 BP 443 EP 443 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AZ8PU UT WOS:000348478200227 ER PT J AU Singer, A Kim, Y Goebel, J Ahluwalia, S Lapham, C AF Singer, Adam Kim, Yan Goebel, Joy Ahluwalia, Sangeeta Lapham, Carrie TI A Systematic Review of Palliative Interventions: Populations, Intervention Components, and Healthcare Use and Cost SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 25-28, 2015 CL Philadelphia, PA SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Singer, Adam] RAND Corp, Santa Monica, CA USA. [Kim, Yan] Kaiser Permanente No Calif, Millbrae, CA USA. [Goebel, Joy] Calif State Univ Long Beach, Long Beach, CA 90840 USA. [Ahluwalia, Sangeeta] Oregon State Univ, Corvallis, OR 97331 USA. [Lapham, Carrie] VA Greater Los Angeles Healthcare Syst, La Crosse, WI USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2015 VL 49 IS 2 MA S790 BP 454 EP 455 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AZ8PU UT WOS:000348478200248 ER PT J AU Wachterman, M Ersek, M Gilbert, D Keating, N AF Wachterman, Melissa Ersek, Mary Gilbert, Dawn Keating, Nancy TI Quality of End-of-Life Care Provided to Patients with Different Life-Limiting Conditions in the Veterans Health Administration SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY FEB 25-28, 2015 CL Philadelphia, PA SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Wachterman, Melissa] VA Boston Healthcare Syst, Brookline, MA USA. [Ersek, Mary] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Gilbert, Dawn] Philadelphia VA Med Ctr, Bellmawr, NJ USA. [Keating, Nancy] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2015 VL 49 IS 2 MA S797 BP 458 EP 458 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AZ8PU UT WOS:000348478200255 ER PT J AU Loke, W Girvan, T Ingmundson, P Verrett, R Schoolfield, J Mealey, BL AF Loke, Weiqiang Girvan, Thomas Ingmundson, Paul Verrett, Ronald Schoolfield, John Mealey, Brian L. TI Investigating the Association Between Obstructive Sleep Apnea and Periodontitis SO JOURNAL OF PERIODONTOLOGY LA English DT Article DE Chronic periodontitis; sleep apnea; obstructive ID C-REACTIVE PROTEIN; BREATHING DISORDERS; ADULTS; INFLAMMATION; PREVALENCE; MECHANISMS; DISEASE; STATES; CARE AB Background: Obstructive sleep apnea (OSA) is a sleep disorder characterized by disruptions of normal sleep architecture. Chronic periodontitis is a chronic disease of the periodontium that elicits a general inflammatory response to local dental plaque. It has been suggested that periodontal disease may increase in severity with increasingly severe OSA because both disease entities share common inflammatory pathways, acting synergistically to alter the host response. The aim of this study is to analyze the association between severity of OSA and the prevalence/severity of periodontitis. Methods: One hundred patients from a large veterans administration sleep study center (n = 26 normal, n = 21 mild, n = 19 moderate, n = 34 severe) diagnosed with an overnight polysomnogram underwent a comprehensive periodontal examination. Periodontal parameters measured included the following: 1) mean periodontal probing depth (PD); 2) clinical attachment level (CAL); 3) gingival recession; and 4) percentage of sites with bleeding on probing, plaque, PD >= 5 mm, and CAL >= 3 mm. Results: Seventy-three percent of the sampled population had moderate/severe periodontal disease. chi(2) analyses revealed no significant differences in the prevalence of periodontal disease between the apnea-hypopnea index (AHI) groups, with a negligible Spearman correlation coefficient of 0.246 between AHI severity and periodontal disease severity categories. Analysis of covariance indicated a significant association between AHI severity categories and percentage of sites with plaque, after adjusting for age. Multivariable logistic regression analysis predicting moderate/severe periodontitis with AHI score, age, and smoking status indicated a significant association with age (P = 0.028) but no significant association with the other two predictors. Conclusion: OSA was not significantly associated with the prevalence of moderate/severe periodontitis and the periodontal parameters examined, except percentage plaque. C1 [Loke, Weiqiang; Schoolfield, John; Mealey, Brian L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Periodont, San Antonio, TX 78229 USA. [Girvan, Thomas] Vet Adm Facil, South Texas Vet Hlth Care Syst, Sleep Clin, San Antonio, TX USA. [Ingmundson, Paul] Vet Adm Facil, South Texas Vet Hlth Care Syst, Dent Clin, San Antonio, TX USA. [Verrett, Ronald] Univ Texas Hlth Sci Ctr San Antonio, Dept Comprehens Dent, San Antonio, TX 78229 USA. RP Mealey, BL (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Periodont, MSC 7894,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM mealey@uthscsa.edu NR 33 TC 3 Z9 4 U1 0 U2 2 PU AMER ACAD PERIODONTOLOGY PI CHICAGO PA 737 NORTH MICHIGAN AVENUE, SUITE 800, CHICAGO, IL 60611-2690 USA SN 0022-3492 EI 1943-3670 J9 J PERIODONTOL JI J. Periodont. PD FEB PY 2015 VL 86 IS 2 BP 232 EP 243 DI 10.1902/jop.2014.140229 PG 12 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA CB1IK UT WOS:000349380500009 PM 25299385 ER PT J AU Akiba, Y Inoue, T Kaji, I Higashiyama, M Narimatsu, K Iwamoto, K Watanabe, M Guth, PH Engel, E Kuwahara, A Kaunitz, JD AF Akiba, Yasutada Inoue, Takuya Kaji, Izumi Higashiyama, Masaaki Narimatsu, Kazuyuki Iwamoto, Ken-ichi Watanabe, Masahiko Guth, Paul H. Engel, Eli Kuwahara, Atsukazu Kaunitz, Jonathan D. TI Short-chain fatty acid sensing in rat duodenum SO JOURNAL OF PHYSIOLOGY-LONDON LA English DT Article ID GLUCAGON-LIKE PEPTIDE-2; ENTEROENDOCRINE CELLS; FUNCTIONAL DYSPEPSIA; BICARBONATE SECRETION; HEALTHY-SUBJECTS; GASTROINTESTINAL-TRACT; BACTERIAL OVERGROWTH; MOUSE INTESTINE; ENTERIC NEURONS; RECEPTOR GPR40 AB Key points Luminal lipid in the duodenum modulates gastroduodenal functions via the release of gut hormones and mediators such as cholecystokinin and 5-HT. The effects of luminal short-chain fatty acids (SCFAs) in the foregut are unknown. Free fatty acid receptors (FFARs) for long-chain fatty acids (LCFAs) and SCFAs are expressed in enteroendocrine cells. SCFA receptors, termed FFA2 and FFA3, are expressed in duodenal enterochromaffin cells and L cells, respectively. Activation of LCFA receptor (FFA1) and presumed FFA3 stimulates duodenal HCO3- secretion via a glucagon-like peptide (GLP)-2 pathway, whereas FFA2 activation induces HCO3- secretion via muscarinic and 5-HT4 receptor activation. The presence of SCFA sensing in the duodenum with GLP-2 and 5-HT signals further supports the hypothesis that luminal SCFA in the foregut may contribute towards the generation of functional symptoms. Intraduodenal fatty acids (FA) and bacterial overgrowth, which generate short-chain FAs (SCFAs), have been implicated in the generation of functional dyspepsia symptoms. We studied the mechanisms by which luminal SCFA perfusion affects duodenal HCO3- secretion (DBS), a measure of mucosal neurohumoral activation. Free fatty acid receptor (FFAR) 1 (FFA1), which binds long-chain FA (LCFA), and SCFA receptors FFA2 and FFA3 were immunolocalised to duodenal enteroendocrine cells. FFA3 colocalised with glucagon-like peptide (GLP)-1, whereas FFA2 colocalised with 5-HT. Luminal perfusion of the SCFA acetate or propionate increased DBS, enhanced by dipeptidyl peptidase-IV (DPPIV) inhibition, at the same time as increasing GLP-2 portal blood concentrations. Acetate-induced DBS was partially inhibited by monocarboxylate/HCO3- exchanger inhibition without affecting GLP-2 release, implicating acetate absorption in the partial mediation of DBS. A selective FFA2 agonist dose-dependently increased DBS, unaffected by DPPIV inhibition or by cholecystokinin or 5-HT3 receptor antagonists, but was inhibited by atropine and a 5-HT4 antagonist. By contrast, a selective FFA1 agonist increased DBS accompanied by GLP-2 release, enhanced by DPPIV inhibition and inhibited by a GLP-2 receptor antagonist. Activation of FFA1 by LCFA and presumably FFA3 by SCFA increased DBS via GLP-2 release, whereas FFA2 activation stimulated DBS via muscarinic and 5-HT4 receptor activation. SCFA/HCO3- exchange also appears to be present in the duodenum. The presence of duodenal fatty acid sensing receptors that signal hormone release and possibly signal neural activation may be implicated in the pathogenesis of functional dyspepsia. C1 [Akiba, Yasutada; Guth, Paul H.; Kaunitz, Jonathan D.] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA 90073 USA. [Akiba, Yasutada; Inoue, Takuya; Kaji, Izumi; Higashiyama, Masaaki; Narimatsu, Kazuyuki; Kaunitz, Jonathan D.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA. [Akiba, Yasutada; Kaji, Izumi; Kaunitz, Jonathan D.] Brentwood Biomed Res Inst, Los Angeles, CA 90073 USA. [Kaji, Izumi; Watanabe, Masahiko] Hokkaido Univ, Dept Anat, Grad Sch Med, Kita Ku, Sapporo, Hokkaido 0608638, Japan. [Iwamoto, Ken-ichi] Sch Pharmaceut Sci, Organ Chem Lab, Suruga Ku, Shizuoka 4228526, Japan. [Engel, Eli; Kaunitz, Jonathan D.] Univ Calif Los Angeles, Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Kuwahara, Atsukazu] Univ Shizuoka, Inst Environm Sci, Physiol Lab, Suruga Ku, Shizuoka 4228526, Japan. RP Kaunitz, JD (reprint author), West Los Angeles VA Med Ctr, Bldg 114,Suite 217,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jake@ucla.edu RI WATANABE, Masahiko/A-4055-2012 FU Department of Veterans Affairs; NIH-NIDDK [R01 DK54221, P30 DK0413]; [24-5317] FX This work was supported by a Department of Veterans Affairs Merit Review Award, NIH-NIDDK R01 DK54221 (J. Kaunitz), a Grant-in-aid for Japanese Society for the Promotion of Science Fellow (I. Kaji, 24-5317) and the animal core of NIH-NIDDK P30 DK0413 (J. E. Rozengurt). NR 54 TC 9 Z9 9 U1 1 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-3751 EI 1469-7793 J9 J PHYSIOL-LONDON JI J. Physiol.-London PD FEB 1 PY 2015 VL 593 IS 3 BP 585 EP 599 DI 10.1113/jphysiol.2014.280792 PG 15 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA CB0CP UT WOS:000349292900011 PM 25433076 ER PT J AU Huckans, M Fuller, B Wheaton, V Jaehnert, S Ellis, C Kolessar, M Kriz, D Anderson, JR Berggren, K Olavarria, H Sasaki, AW Chang, M Flora, KD Loftis, JM AF Huckans, Marilyn Fuller, Bret Wheaton, Viva Jaehnert, Sarah Ellis, Carilyn Kolessar, Michael Kriz, Daniel Anderson, Jeanne Renee Berggren, Kristin Olavarria, Hannah Sasaki, Anna W. Chang, Michael Flora, Kenneth D. Loftis, Jennifer M. TI A longitudinal study evaluating the effects of interferon-alpha therapy on cognitive and psychiatric function in adults with chronic hepatitis C SO JOURNAL OF PSYCHOSOMATIC RESEARCH LA English DT Article DE Anxiety; Cognition; Depression; Fatigue; Interferon; Hepatitis C; Pain ID INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; CHRONIC VIRAL-HEPATITIS; FATIGUE SEVERITY SCALE; GENOTYPE 1 INFECTION; VIRUS-INFECTION; INDUCED DEPRESSION; PEGYLATED INTERFERON; ANTIVIRAL TREATMENT; RANDOMIZED-TRIAL; SOMATIC SYMPTOMS AB Objective: To prospectively evaluate for changes in objective cognitive performance (attention, memory, and executive function) and psychiatric symptom severity (depression, anxiety, fatigue, and pain) in patients before, during and after interferon-alpha based therapy (IFN) for chronic hepatitis C virus infection (HCV). Methods: 33 HCV+ adults were evaluated two months before IFN initiation (baseline), three months into IFN, and six months following IFN termination (IFN+ Group). 31 HCV+ adults who did not undergo IFN therapy were evaluated at baseline and six months later (IFN - Group). At each evaluation, participants completed the Neuropsychological Assessment Battery (NAB) Attention, Memory and Executive Functions Modules, the Beck Depression Inventory, Second Edition (BDI), Generalized Anxiety Disorder Inventory (GADO, Fatigue Severity Scale (FSS), and Brief Pain Inventory (BPI). Results: Compared with the IFN - Group, the IFN + Group experienced significantly (p < 0.050) increased symptoms of depression, anxiety, fatigue and pain during IFN therapy relative to baseline. In the IFN + Group, psychiatric symptoms generally returned to baseline levels following IFN termination. Sustained viral response was associated with significantly lower depression and fatigue. No significant changes in cognitive performance were observed. Conclusions: During IFN, patients with HCV evidence significantly increased psychiatric symptoms, including symptoms of depression, anxiety, fatigue and pain. These psychiatric symptoms are generally short-term and remit following IFN termination, with increased benefit if viral clearance is achieved. However, IFN is not associated with significant declines in objective cognitive performance during or following IFN. (c) 2014 Published by Elsevier Inc. C1 [Huckans, Marilyn; Wheaton, Viva; Jaehnert, Sarah; Ellis, Carilyn; Kolessar, Michael; Kriz, Daniel; Anderson, Jeanne Renee; Berggren, Kristin; Olavarria, Hannah; Loftis, Jennifer M.] Portland VA Med Ctr, Res & Dev Serv, Portland, OR 97239 USA. [Huckans, Marilyn; Fuller, Bret] Portland VA Med Ctr, Mental Hlth & Clin Neurosci Div, Portland, OR 97239 USA. [Huckans, Marilyn; Fuller, Bret; Loftis, Jennifer M.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97239 USA. [Wheaton, Viva; Jaehnert, Sarah; Kolessar, Michael; Kriz, Daniel; Anderson, Jeanne Renee] Univ Pacific, Sch Profess Psychol, Hillsboro, OR 97123 USA. [Ellis, Carilyn; Berggren, Kristin] George Fox Univ, Grad Dept Clin Psychol, Newberg, OR 97132 USA. [Sasaki, Anna W.; Chang, Michael] Portland VA Med Ctr, Gastroenterol Serv, Portland, OR 97239 USA. [Sasaki, Anna W.; Chang, Michael] Oregon Hlth & Sci Univ, Dept Internal Med, Portland, OR 97239 USA. [Flora, Kenneth D.] Oregon Clin, Portland Gastroenterol Div, Clackamas, OR 97015 USA. RP Huckans, M (reprint author), Portland VA Med Ctr, P3MHN,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM marilyn.huckans@va.gov FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development Clinical Sciences Research and Development FX This work was supported by career development awards to M.H. (Staff Psychologist and Neuropsychologist) and J.M.L (Research Scientist) from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development Clinical Sciences Research and Development This material is the result of work supported with resources and the use of facilities at the Portland Veterans Affairs Medical Center, Portland, Oregon. The authors thank the study participants and staff at each of the recruitment sites, especially Betsy Zucker and Janice Voukidis. The authors also acknowledge Arthur Vandenbark, Peter Hauser, William Hoffman, Diane Howieson, Daniel Storzbach, and Alexander Stevens for consultation regarding study design and implementation. All authors read and approved the final contents of the manuscript. The authors have no competing interests to report. NR 69 TC 9 Z9 9 U1 3 U2 10 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3999 EI 1879-1360 J9 J PSYCHOSOM RES JI J. Psychosomat. Res. PD FEB PY 2015 VL 78 IS 2 BP 184 EP 192 DI 10.1016/j.jpsychores.2014.07.020 PG 9 WC Psychiatry SC Psychiatry GA CA0US UT WOS:000348632400014 PM 25219976 ER PT J AU Unroe, KT Ersek, M Cagle, J AF Unroe, Kathleen T. Ersek, Mary Cagle, John TI The IOM Report on Dying in America: A Call to Action for Nursing Homes SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION LA English DT Editorial Material ID OF-LIFE CARE; PALLIATIVE CARE; HOSPICE ENROLLMENT; DEMENTIA; PROGRAM; INTERVENTION; PERSPECTIVES; SETTINGS; PLACE; DEATH C1 [Unroe, Kathleen T.] Indiana Univ, Sch Med, Indianapolis, IN 46202 USA. [Unroe, Kathleen T.] Indiana Univ, Ctr Aging Res, Indianapolis, IN 46202 USA. [Unroe, Kathleen T.] Regenstrief Inst Hlth Care, Indianapolis, IN USA. [Ersek, Mary] Philadelphia Vet Affairs Med Ctr, Natl PROMISE Ctr, Philadelphia, PA USA. [Ersek, Mary] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [Cagle, John] Univ Maryland, Sch Social Work, Baltimore, MD 21201 USA. RP Unroe, KT (reprint author), Indiana Univ, Ctr Aging Res, 410 West 10th St,Suite 2000, Indianapolis, IN 46202 USA. EM kunroe@iupui.edu NR 31 TC 6 Z9 6 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-8610 EI 1538-9375 J9 J AM MED DIR ASSOC JI J. Am. Med. Dir. Assoc. PD FEB 1 PY 2015 VL 16 IS 2 BP 90 EP 92 DI 10.1016/j.jamda.2014.11.010 PG 3 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA CA2KR UT WOS:000348738000002 PM 25512213 ER PT J AU Obedin-Maliver, J AF Obedin-Maliver, Juno TI Time for OBGYNs to Care for People of All Genders SO JOURNAL OF WOMENS HEALTH LA English DT Editorial Material ID TRANSGENDER; GAY C1 [Obedin-Maliver, Juno] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA. [Obedin-Maliver, Juno] San Francisco VA Med Ctr, Dept Internal Med, San Francisco, CA USA. [Obedin-Maliver, Juno] Stanford Univ, Sch Med, Lesbian Gay Bisexual & Transgender Med Educ Res G, Stanford, CA 94305 USA. RP Obedin-Maliver, J (reprint author), Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, 505 Parnassus Ave, San Francisco, CA 94143 USA. EM ObedinMaliverJ@obgyn.ucsf.edu NR 16 TC 1 Z9 1 U1 0 U2 2 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 EI 1931-843X J9 J WOMENS HEALTH JI J. Womens Health PD FEB 1 PY 2015 VL 24 IS 2 BP 109 EP 111 DI 10.1089/jwh.2015.1518 PG 3 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA CB0NI UT WOS:000349322700001 PM 25682814 ER PT J AU Zhong, F Chen, HB Wei, CG Zhang, WJ Li, ZZ Jain, MK Chuang, PY Chen, HY Wang, YJ Mallipattu, SK He, JC AF Zhong, Fang Chen, Habing Wei, Chengguo Zhang, Weijia Li, Zhengzhe Jain, Mukesh K. Chuang, Peter Y. Chen, Hongyu Wang, Yongjun Mallipattu, Sandeep K. He, John C. TI Reduced Kruppel-like factor 2 expression may aggravate the endothelial injury of diabetic nephropathy SO KIDNEY INTERNATIONAL LA English DT Article DE diabetic nephropathy; endothelium; podocyte ID PROTEASE-ACTIVATED RECEPTOR-1; TRANSCRIPTIONAL REGULATOR; GENE-EXPRESSION; PROINFLAMMATORY ACTIVATION; GLOMERULAR ENDOTHELIUM; UP-REGULATION; KLF2; MICE; PERMEABILITY; DEFICIENCY AB Kruppel-like factor 2 (KLF2), a shear stress-inducible transcription factor, has endoprotective effects. In streptozotocin-induced diabetic rats, we found that glomerular Klf2 expression was reduced in comparison with nondiabetic rats. However, normalization of hyperglycemia by insulin treatment increased Klf2 expression to a level higher than that of nondiabetic rats. Consistent with this, we found that Klf2 expression was suppressed by high glucose but increased by insulin in cultured endothelial cells. To determine the role of KLF2 in streptozotocin-induced diabetic nephropathy, we used endothelial cell-specific Klf2 heterozygous knockout mice and found that diabetic knockout mice developed more kidney/glomerular hypertrophy and proteinuria than diabetic wild-type mice. Glomerular expression of Vegfa, Flk1, and angiopoietin 2 increased, but expression of Flt1, Tie2, and angiopoietin 1 decreased, in diabetic knockout mice compared with diabetic wild-type mice. Glomerular expression of ZO-1, glycocalyx, and eNOS was also decreased in diabetic knockout compared with diabetic wild-type mice. These data suggest knockdown of Klf2 expression in the endothelial cells induced more endothelial cell injury. Interestingly, podocyte injury was also more prominent in diabetic knockout compared with diabetic wild-type mice, indicating a cross talk between these two cell types. Thus, KLF2 may play a role in glomerular endothelial cell injury in early diabetic nephropathy. C1 [Zhong, Fang; Chen, Habing; Wei, Chengguo; Zhang, Weijia; Li, Zhengzhe; Chuang, Peter Y.; He, John C.] Icahn Sch Med Mt Sinai, Dept Med Nephrol, New York, NY 10029 USA. [Zhong, Fang; Chen, Hongyu; Wang, Yongjun] Zhejiang Chinese Med Univ, Hang Zhou Hosp Tradit Chinese Med, Dept Nephrol, Zhejiang, Peoples R China. [Chen, Habing] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Shanghai Clin Ctr Diabet, Shanghai Diabet Inst,Dept Endocrinol & Metab,Shan, Shanghai, Peoples R China. [Jain, Mukesh K.] Case Western Reserve Univ, Case Cardiovasc Res Inst, Dept Med, Cleveland, OH 44106 USA. [Mallipattu, Sandeep K.] SUNY Stony Brook, Dept Med, Div Nephrol, Stony Brook, NY 11794 USA. [He, John C.] James J Peters VAMC, Renal Sect, Bronx, NY USA. RP He, JC (reprint author), Mt Sinai Sch Med, Div Nephrol, Box 1243,1 Gustave L Levy Pl, New York, NY 10029 USA. EM cijiang.he@mssm.edu FU Chinese 973 fund [2012CB517601]; VA Merit Award [NIH 1R01DK078897, NIH1R01DK088541, NIH P01-DK-56492] FX JCH is supported by Chinese 973 fund 2012CB517601, VA Merit Award, NIH 1R01DK078897, NIH1R01DK088541, NIH P01-DK-56492. JCH is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. NR 56 TC 9 Z9 10 U1 2 U2 9 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0085-2538 EI 1523-1755 J9 KIDNEY INT JI Kidney Int. PD FEB PY 2015 VL 87 IS 2 BP 382 EP 395 DI 10.1038/ki.2014.286 PG 14 WC Urology & Nephrology SC Urology & Nephrology GA CA5UH UT WOS:000348972800019 PM 25185079 ER PT J AU Singh, JP Yang, S Mulvey, EP AF Singh, Jay P. Yang, Suzanne Mulvey, Edward P. CA RAGEE Grp TI Reporting Guidance for Violence Risk Assessment Predictive Validity Studies: The RAGEE Statement SO LAW AND HUMAN BEHAVIOR LA English DT Article DE reporting guidance; risk assessment; violence; checklist; RAGEE ID RANDOMIZED CONTROLLED-TRIALS; DIAGNOSTIC-ACCURACY; QUALITY; CONSORT; GUIDELINES; RECOMMENDATIONS; RELIABILITY; INDICATORS; EXTENSION; STANDARDS AB Available reporting guidelines for prognostic and diagnostic accuracy studies apply primarily to biological assessment and outcomes, overlooking behavioral issues with major public health and safety implications such as violence. The present study aimed to develop the first set of reporting guidance for predictive validity studies of violence risk assessments: the Risk Assessment Guidelines for the Evaluation of Efficacy (RAGEE) Statement. A systematic search of 8 electronic databases prior to September 2012 identified 279 reporting guidelines for prognostic and diagnostic accuracy studies. Unique items were extracted and modified to make them relevant to risk assessment. A 4-wave Delphi process involving a multidisciplinary team of 37 international experts resulted in a 50-item reporting checklist. The panelists endorsed the RAGEE Statement checklist as being highly satisfactory and as indicating study features that should be reported routinely in manuscripts. Use of these proposed standards has the potential to improve the quality of the risk assessment literature. C1 [Singh, Jay P.] Singh Inst Forens Res LLC, Reston, VA 20190 USA. [Singh, Jay P.] Univ Konstanz, Dept Psychol, Constance, Germany. [Yang, Suzanne] Vet Affairs Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr VISN4, Pittsburgh, PA USA. [Yang, Suzanne; Mulvey, Edward P.] Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, Pittsburgh, PA 15260 USA. RP Singh, JP (reprint author), Singh Inst Forens Res LLC, 11700 Plaza Amer Dr,Suite 810, Reston, VA 20190 USA. EM jaysingh@sifrllc.com NR 32 TC 7 Z9 7 U1 0 U2 4 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0147-7307 EI 1573-661X J9 LAW HUMAN BEHAV JI Law Hum. Behav. PD FEB PY 2015 VL 39 IS 1 BP 15 EP 22 DI 10.1037/lhb0000090 PG 8 WC Law; Psychology, Social SC Government & Law; Psychology GA CA6KN UT WOS:000349022200002 PM 25133921 ER PT J AU Quinzanos, I Davis, L Keniston, A Nash, A Yazdany, J Fransen, R Hirsh, JM Zell, J AF Quinzanos, I. Davis, L. Keniston, A. Nash, A. Yazdany, J. Fransen, R. Hirsh, J. M. Zell, J. TI Application and feasibility of systemic lupus erythematosus reproductive health care quality indicators at a public urban rheumatology clinic SO LUPUS LA English DT Article DE Systemic lupus erythematous; quality indicators health care; reproductive health; teratogens; contraception ID PREGNANT-WOMEN; ARTHRITIS; CLASSIFICATION; PRESCRIPTION; MEDICATIONS; MOTHERS; SET; AGE AB Objectives Quality indicators (QIs) are evidence-based processes of care designed to represent the current standard of care. Reproductive health QIs for the care of patients with systemic lupus erythematosus (SLE) have recently been developed, and examine areas such as pregnancy screening for autoantibodies, treatment of pregnancy-associated antiphospholipid syndrome, and contraceptive counseling. This study was designed to investigate our performance on these QIs and to explore potential gaps in care and demographic predictors of adherence to the QIs in a safety-net hospital. Methods We performed a record review of patients with a diagnosis of SLE at Denver Health Medical Center (DH) through an electronic query of existing medical records and via chart review. Data were limited to female patients between the ages of 18 and 50 who were seen between July 2006 and August 2011. Results A total of 137 female patients between the ages of 18 and 50 were identified by ICD-9 code and confirmed by chart review to have SLE. Of these, 122 patients met the updated 1997 American College of Rheumatology SLE criteria and had intact reproductive systems. Only 15 pregnancies were documented during this five-year period, and adherence to autoantibody screening was 100 percent. We did not have any patients who were pregnant and met criteria for pregnancy-associated antiphospholipid syndrome. Sixty-five patients (53%) received potentially teratogenic medications, and 30 (46%) had documented discussions about these medications' potential risk upon their initiation. Predictors of whether patients received appropriate counseling included younger age (OR 0.92, CI 0.87-0.98) and those who did not describe English as their primary language (OR 0.24, CI 0.07-0.87) in the multivariate analysis. Conclusions We were able to detect an important gap in care regarding teratogenic medication education to SLE patients of childbearing potential in our public health academic clinic, as only one in two eligible patients had documented appropriate counseling at the initiation of a teratogenic medication. C1 [Quinzanos, I.; Davis, L.; Hirsh, J. M.; Zell, J.] Univ Colorado, Sch Med, Dept Med, Div Rheumatol, Aurora, CO USA. [Quinzanos, I.; Davis, L.] Denver Vet Affairs Med Ctr, Dept Med, Div Rheumatol, Denver, CO 80220 USA. [Quinzanos, I.; Davis, L.; Keniston, A.; Hirsh, J. M.; Zell, J.] Denver Hlth Med Ctr, Div Rheumatol, Dept Med, Denver, CO USA. [Nash, A.] Univ Colorado, Div Gen Internal Med, Sch Med, Aurora, CO USA. [Yazdany, J.] Univ Calif San Francisco, Div Rheumatol, Dept Med, San Francisco, CA USA. [Fransen, R.] Exempla St Joseph Hosp, Denver, CO USA. [Zell, J.] Natl Jewish Hlth, Div Rheumatol, Dept Med, Denver, CO USA. RP Quinzanos, I (reprint author), Denver Vet Affairs Med Ctr, Dept Med, 1055 Clermont St, Denver, CO 80220 USA. EM itziar.quinzanos@ucdenver.edu FU NIAMS NIH HHS [K23 AR060259] NR 15 TC 3 Z9 3 U1 0 U2 2 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0961-2033 EI 1477-0962 J9 LUPUS JI Lupus PD FEB PY 2015 VL 24 IS 2 BP 203 EP 209 DI 10.1177/0961203314552832 PG 7 WC Rheumatology SC Rheumatology GA CA0YX UT WOS:000348640500013 PM 25267076 ER PT J AU Belanger, HG Barwick, F Silva, MA Kretzmer, T Kip, KE Vanderploeg, RD AF Belanger, Heather G. Barwick, Fiona Silva, Marc A. Kretzmer, Tracy Kip, Kevin E. Vanderploeg, Rodney D. TI Web-Based Psychoeducational Intervention for Postconcussion Symptoms: A Randomized Trial SO MILITARY MEDICINE LA English DT Article ID TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE-BEHAVIOR THERAPY; PSYCHOLOGICAL TREATMENTS; HEAD-INJURY; METAANALYSIS; PAPER; CONCUSSION; DEPRESSION; COMPLAINTS AB The objective of this study was to investigate the effectiveness of a web-based educational intervention for reducing postconcussion symptoms. 158 participants with self-reported symptomatic mild traumatic brain injury were randomized to intervention versus control. There was no effect of intervention on symptom severity or attributions. Subgroup analyses suggested benefit of the web-based intervention in those receiving concurrent mental health treatment and in those participants with the greatest time since injury (>1 year after mild traumatic brain injury). Web-based educational intervention was not effective overall in this sample. However, there is some suggestion of promise in those receiving concurrent mental health treatment and with more chronic symptoms. Findings also suggest potential benefit of interventions targeting self-efficacy. C1 [Belanger, Heather G.; Silva, Marc A.; Kretzmer, Tracy; Vanderploeg, Rodney D.] James A Haley VA, Dept Mental Hlth & Behav Sci, Tampa, FL 33612 USA. [Belanger, Heather G.; Vanderploeg, Rodney D.] Univ S Florida, Dept Psychol, Tampa, FL 33612 USA. [Belanger, Heather G.; Vanderploeg, Rodney D.] Univ S Florida, Dept Psychiat, Tampa, FL 33612 USA. [Belanger, Heather G.; Vanderploeg, Rodney D.] Def & Vet Brain Injury Ctr, Tampa, FL 33612 USA. [Barwick, Fiona] VA Greater Los Angeles Healthcare Syst, Dept Mental Behav Hlth, Los Angeles, CA 90073 USA. [Kip, Kevin E.] Univ S Florida, Coll Nursing, Tampa, FL USA. RP Belanger, HG (reprint author), James A Haley VA, Dept Mental Hlth & Behav Sci, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA. FU Department of Defense [W81XWH-10-1-0719]; Department of Veterans Affairs; Defense and Veterans Brain Injury Center (DVBIC); James A. Haley Veterans' Hospital; Veterans Health Administration (VHA) FX The research reported here was supported by the Department of Defense (W81XWH-10-1-0719), Department of Veterans Affairs, Veterans Health Administration (VHA), and the Defense and Veterans Brain Injury Center (DVBIC). Further support was provided by the James A. Haley Veterans' Hospital. NR 53 TC 1 Z9 1 U1 1 U2 8 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 EI 1930-613X J9 MIL MED JI Milit. Med. PD FEB PY 2015 VL 180 IS 2 BP 192 EP 200 DI 10.7205/MILMED-D-14-00388 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA CA7MR UT WOS:000349101900012 PM 25643387 ER PT J AU Knight, EM Williams, HN Stevens, AC Kim, SH Kottwitz, JC Morant, AD Steele, JW Klein, WL Yanagisawa, K Boyd, RE Lockhart, DJ Sjoberg, ER Ehrlich, ME Wustman, BA Gandy, S AF Knight, E. M. Williams, H. N. Stevens, A. C. Kim, S. H. Kottwitz, J. C. Morant, A. D. Steele, J. W. Klein, W. L. Yanagisawa, K. Boyd, R. E. Lockhart, D. J. Sjoberg, E. R. Ehrlich, M. E. Wustman, B. A. Gandy, S. TI Evidence that small molecule enhancement of beta-hexosaminidase activity corrects the behavioral phenotype in Dutch APP(E693Q) mice through reduction of ganglioside-bound A beta SO MOLECULAR PSYCHIATRY LA English DT Article ID ALZHEIMERS-DISEASE; GM1 GANGLIOSIDE; PHARMACOLOGICAL CHAPERONE; SANDHOFF-DISEASE; TAY-SACHS; PROTEIN; BRAIN; CHOLESTEROL; GLUCOCEREBROSIDASE; MUTATIONS AB Certain mutant Alzheimer's amyloid-beta (A beta) peptides (that is, Dutch mutant APP(E693Q)) form complexes with gangliosides (GA beta). These mutant A beta peptides may also undergo accelerated aggregation and accumulation upon exposure to GM2 and GM3. We hypothesized that increasing beta-hexosaminidase (beta-hex) activity would lead to a reduction in GM2 levels, which in turn, would cause a reduction in A beta aggregation and accumulation. The small molecule OT1001 is a beta-hex-targeted pharmacological chaperone with good bioavailability, blood-brain barrier penetration, high selectivity for beta-hex and low cytotoxicity. Dutch APP(E693Q) transgenic mice accumulate oligomeric A beta as they age, as well as A beta oligomer-dose-dependent anxiety and impaired novel object recognition (NOR). Treatment of Dutch APP(E693Q) mice with OT1001 caused a dose-dependent increase in brain beta-hex levels up to threefold over those observed at baseline. OT1001 treatment was associated with reduced anxiety, improved learning behavior in the NOR task and dramatically reduced GA beta accumulation in the subiculum and perirhinal cortex, both of which are brain regions required for normal NOR. Pharmacological chaperones that increase beta-hex activity may be useful in reducing accumulation of certain mutant species of A beta and in preventing the associated behavioral pathology. C1 [Knight, E. M.; Kim, S. H.; Kottwitz, J. C.; Morant, A. D.; Ehrlich, M. E.; Gandy, S.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. [Knight, E. M.; Kim, S. H.; Kottwitz, J. C.; Morant, A. D.; Ehrlich, M. E.; Gandy, S.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Knight, E. M.; Kim, S. H.; Gandy, S.] Icahn Sch Med Mt Sinai, Alzheimers Dis Res Ctr, New York, NY 10029 USA. [Williams, H. N.; Boyd, R. E.] Amicus Therapeut, Cranbury, NJ USA. [Stevens, A. C.; Steele, J. W.; Lockhart, D. J.; Sjoberg, E. R.; Wustman, B. A.] OrPhi Therapeut, Carlsbad, CA USA. [Klein, W. L.] Northwestern Univ, Dept Neurobiol, Evanston, IL USA. [Klein, W. L.] Northwestern Univ, Dept Cognit Neurol, Evanston, IL USA. [Klein, W. L.] Northwestern Univ, Alzheimers Dis Ctr, Evanston, IL USA. [Yanagisawa, K.] Natl Ctr Geriatr Gerontol, Res Inst, Obu City, Aichi, Japan. [Gandy, S.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. RP Gandy, S (reprint author), Icahn Sch Med Mt Sinai, Dept Neurol, One Gustave L Levy Pl, New York, NY 10029 USA. EM samuel.gandy@mssm.edu FU Alzheimer's Drug Discovery Foundation [291003]; BrightFocus Foundation FX This work was supported by Alzheimer's Drug Discovery Foundation grant 291003. SHK is supported by BrightFocus Foundation. The beta-hex targeted pharmacological chaperone OT1001 was supplied by Amicus Therapeutics. We thank Drs Richie Khanna, Anadina Garcia and Michelle Frascella for their assistance in animal handling and dosing, and Drs Elfrida Benjamin and Rick Hamler for their assistance in measuring OT1001 levels in the PK and PD studies conducted in C57BL/J6 mice. NR 48 TC 8 Z9 8 U1 0 U2 16 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1359-4184 EI 1476-5578 J9 MOL PSYCHIATR JI Mol. Psychiatr. PD FEB PY 2015 VL 20 IS 1 BP 109 EP 117 DI 10.1038/mp.2014.135 PG 9 WC Biochemistry & Molecular Biology; Neurosciences; Psychiatry SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry GA CB1QR UT WOS:000349403400011 PM 25349165 ER PT J AU Buehring, B Krueger, D Fidler, E Gangnon, R Heiderscheit, B Binkley, N AF Buehring, B. Krueger, D. Fidler, E. Gangnon, R. Heiderscheit, B. Binkley, N. TI Reproducibility of jumping mechanography and traditional measures of physical and muscle function in older adults SO OSTEOPOROSIS INTERNATIONAL LA English DT Article DE DXA leanmass; Jumpingmechanography; Muscle function; Reproducibility; Sarcopenia ID LOWER-EXTREMITY FUNCTION; PERFORMANCE BATTERY; BODY-COMPOSITION; SUBSEQUENT DISABILITY; GRIP STRENGTH; SARCOPENIA; MASS; AGE; POWER; HEALTH AB A Summary Improved approaches to assess functional change over time are needed to optimally reduce fall/fracture risk; jumping mechanography (JM) may be one such methodology. In this study, JM parameters were more reproducible than traditional functional tests. JM may be better able to demonstrate efficacy of interventions to mitigate sarcopenia. Introduction Jumping mechanography (JM), a tool using maximal countermovement jumps performed on a force plate, may more reliably assess muscle function than traditional methods. The purpose of this study was to examine JM retest reliability in older adults compared with commonly used muscle and physical function assessments. Methods Community-dwelling individuals age >= 70 years performed physical and muscle function assessments including the short physical performance battery (SPPB), grip strength, and JM on multiple occasions over 3 months. JM parameters included body weight-corrected peak power and jump height. Appendicular lean mass was measured by dual energy x-ray (DXA). Mixed effects linear regression models were used to estimate between- and within-person variability summarized as intra-class correlation coefficients (ICC). Results Ninety-seven individuals (49 females, 48 males, mean age 80.7 years) participated. All testing was well tolerated; no participant sustained injury. Jump power, height, and grip strength were greater (p < 0.0001) in men than women. Grip strength, jump power, and height had excellent ICCs (0.95, 0.93, and 0.88, respectively); chair rise, SPPB score, and gait speed had lower ICCs (0.81, 0.77, and 0.76, respectively). Conclusion In older adults, JM has excellent retest reliability, is stable over time, and can be performed safely. JM retest reliability was comparable to grip strength and possibly better than SPPB and gait speed. JM is a promising tool for muscle function assessment in older adults. Comparison of this approach with traditional assessment tools in longitudinal interventional studies is needed. C1 [Buehring, B.; Krueger, D.; Fidler, E.; Binkley, N.] Univ Wisconsin, Osteoporosis Clin Res Program, Madison, WI 53705 USA. [Buehring, B.; Binkley, N.] Univ Wisconsin, William S Middleton Mem Vet Adm Hosp, GRECC, Madison, WI 53705 USA. [Gangnon, R.] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI 53705 USA. [Gangnon, R.] Univ Wisconsin, Dept Populat Hlth, Madison, WI 53705 USA. [Heiderscheit, B.] Univ Wisconsin, Dept Orthopaed & Rehabil, Madison, WI 53705 USA. [Heiderscheit, B.] Univ Wisconsin, Dept Intercollegiate Athlet, Madison, WI 53705 USA. RP Buehring, B (reprint author), Univ Wisconsin, Osteoporosis Clin Res Program, 2870 Univ Ave,Suite 100, Madison, WI 53705 USA. EM bbuehring@medicine.wisc.edu OI Buehring, Bjoern/0000-0003-3841-624X FU Merck Co., Inc.; John A. Hartford Foundation FX All authors contributed to the study concept and design, acquisition of subjects and data, analysis and interpretation of data, and preparation of manuscript. This work was sponsored by an investigator initiated research grant from Merck & Co., Inc. Merck & Co., Inc and did not have any role in the design, methods, subject recruitment, data collection, analysis, or preparation of paper. Dr. Buehring receives research funding from the John A. Hartford Foundation as a Centers of Excellence in Geriatric Medicine and Geriatric Psychiatry scholar. Dr. Binkley is participating in a multicenter trial with Lilly in functional outcomes in older adults. He also consults on the same project. NR 41 TC 4 Z9 4 U1 2 U2 16 PU SPRINGER LONDON LTD PI LONDON PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND SN 0937-941X EI 1433-2965 J9 OSTEOPOROSIS INT JI Osteoporosis Int. PD FEB PY 2015 VL 26 IS 2 BP 819 EP 825 DI 10.1007/s00198-014-2983-z PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CA6JM UT WOS:000349018700043 PM 25488806 ER PT J AU Honda, JR Wallace, RJ Chan, ED AF Honda, Jennifer R. Wallace, Richard J., Jr. Chan, Edward D. TI First you have to row a little boat SO RESPIROLOGY LA English DT Editorial Material DE infection and inflammation; pneumonia; respiratory infection (non-tuberculous) ID COMPLEX LUNG-DISEASE; NONTUBERCULOUS MYCOBACTERIAL DISEASES; AVIUM-INTRACELLULARE; ETHAMBUTOL; RIFAMPICIN; MACROLIDE; THERAPY C1 [Honda, Jennifer R.; Chan, Edward D.] Denver Vet Affairs Med Ctr, Dept Med, Denver, CO 80220 USA. [Honda, Jennifer R.; Chan, Edward D.] Natl Jewish Hlth, Dept Med & Acad Affairs, Denver, CO USA. [Honda, Jennifer R.; Chan, Edward D.] Univ Colorado, Div Pulm Sci & Crit Care Med, Aurora, CO USA. [Wallace, Richard J., Jr.] Univ Texas Hlth Sci Ctr Tyler, Dept Med, Tyler, TX USA. [Wallace, Richard J., Jr.] Univ Texas Hlth Sci Ctr Tyler, Mycobacteria Nocardia Res Lab, Tyler, TX USA. RP Honda, JR (reprint author), Denver Vet Affairs Med Ctr, Dept Med, Denver, CO 80220 USA. NR 15 TC 1 Z9 1 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1323-7799 EI 1440-1843 J9 RESPIROLOGY JI Respirology PD FEB PY 2015 VL 20 IS 2 BP 181 EP 182 DI 10.1111/resp.12465 PG 2 WC Respiratory System SC Respiratory System GA AZ3EK UT WOS:000348110300003 PM 25581353 ER PT J AU Abou Zahr, Z Spiegelman, A Cantu, M Ng, B AF Abou Zahr, Zaki Spiegelman, Andrew Cantu, Maria Ng, Bernard TI Perioperative use of anti-rheumatic agents does not increase early postoperative infection risks: a Veteran Affairs' administrative database study SO RHEUMATOLOGY INTERNATIONAL LA English DT Article DE Anti-TNF drugs; Rheumatoid arthritis; Disease-modifying anti-rheumatic drugs (DMARD); Infection; Surgery ID RHEUMATOID-ARTHRITIS PATIENTS; FACTOR-ALPHA BLOCKERS; NECROSIS-FACTOR; METHOTREXATE; COMPLICATIONS; SURGERY; DRUGS; HAND AB The aim of this study was to validate a novel technique that predicts stopping of disease-modifying anti-rheumatic drugs (DMARDs) and biologic agents (BA) from the Veterans Affairs (VA) database and compare infection risks of rheumatoid arthritis patients who stopped versus continued DMARDs/BA perioperatively. We identified 6,024 patients on 1 DMARD or BA in the perioperative period between 1999 and 2009. Time gap between medication stop date and the next start date predicted drug stoppage (X). Time gap between surgery date and stop date predicted whether stoppage was before surgery (Y). Chart review from Houston VA was used for validation. ROC analyses were performed on chart review data to obtain X and Y cutoffs. The primary endpoints were wound infections and other infections within 30 days. ROC analyses found X a parts per thousand yen 33 (AUC = 0.954) and Y a parts per thousand yen -11 (AUC = 0.846). Risk of postoperative infections was not different when stopping and continuing DMARDs/BA preoperatively. Stopping BA after surgery was associated with higher odds of postoperative wound (OR 14.15, 95 % CI 1.76-113.76) and general infection (OR 9.2, 95 % CI 1.99-42.60) compared to not stopping. Stopping DMARDs after surgery was associated with increased risk of postoperative general infection (OR 1.84, 95 % CI 1.07-3.16) compared with not stopping. There was positive association between stopping DMARDs after surgery and postoperative wound infection but failed to achieve statistical significance (OR 1.67, 95 % CI 0.96-2.91). There was no significant difference in postoperative infection risk when stopping or continuing DMARD/BA. Our new validated method can be utilized in the VA and other databases to predict drug stoppage. C1 [Abou Zahr, Zaki] Univ Minnesota, Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA. [Spiegelman, Andrew] Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA. [Cantu, Maria] Baylor Coll Med, Houston, TX 77030 USA. [Ng, Bernard] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Ng, B (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA. EM dr_zaki_abouzahr@yahoo.com; bernardng1@gmail.com FU Department of Veteran Affairs, Veterans Health Administration, Health Services Research and Development Service [VA.SCV.1010./000-00.B_N]; Veterans Affairs Health Services Research and Development Service Houston Center of Excellence [HFP90-020]; South Central VA Health Care Network Research Pilot Grant Award FX The research reported here was supported by the Department of Veteran Affairs, Veterans Health Administration, Health Services Research and Development Service, (VA.SCV.1010./000-00.B_N). This work was also partly supported by the Veterans Affairs Health Services Research and Development Service Houston Center of Excellence (HFP90-020). Dr. Bernard Ng held a South Central VA Health Care Network Research Pilot Grant Award and was a consultant to UCB Pharmaceuticals. The rest of the authors have no conflicts of interest to declare. The funding sources had no role in the study design, conduct and analysis or in the decision to submit the manuscript for publication. NR 25 TC 1 Z9 1 U1 0 U2 1 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 0172-8172 EI 1437-160X J9 RHEUMATOL INT JI Rheumatol. Int. PD FEB PY 2015 VL 35 IS 2 BP 265 EP 272 DI 10.1007/s00296-014-3121-0 PG 8 WC Rheumatology SC Rheumatology GA CA5YB UT WOS:000348983300006 PM 25187198 ER PT J AU Hazlett, EA Rothstein, EG Ferreira, R Silverman, JM Siever, LJ Olincy, A AF Hazlett, Erin A. Rothstein, Ethan G. Ferreira, Rui Silverman, Jeremy M. Siever, Larry J. Olincy, Ann TI Sensory gating disturbances in the spectrum: Similarities and differences in schizotypal personality disorder and schizophrenia SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Schizotypal personality disorder; Schizophrenia; Event-related potential; Evoked potential; P50; Psychophysiology; Sensory gating ID REPEATED AUDITORY-STIMULI; DEFICIENT ATTENTIONAL MODULATION; P50 SUPPRESSION; BIPOLAR DISORDER; EVOKED-RESPONSE; POTENTIAL ABNORMALITIES; COGNITIVE IMPAIRMENT; NICOTINIC RECEPTORS; STARTLE RESPONSE; WORKING-MEMORY AB Background: DSM-5 places schizophrenia on a continuum from severe, chronic schizophrenia to the attenuated schizophrenia-like traits of schizotypal personality disorder (SPD), the prototypic schizophrenia-related personality disorder. SPD shares common genetic and neurobiological substrates with schizophrenia, including information processing abnormalities, although they are less marked. This is the first study to directly compare the P50 evoked electroencephalographic response-a measure of sensory gating and a neurophysiological endophenotype-between schizophrenia-spectrum groups. Two hypotheses were tested: (1) Compared with healthy controls (HCs), schizophrenia patients show reduced P50 suppression and SPD patients resemble schizophrenia but exhibit less marked deficits; and (2) Deficient P50 suppression in SPD is associated with greater clinical symptom severity. Methods: P50 was assessed in 32 schizophrenia-spectrum disorder patients (12 SPD, 20 schizophrenia patients) and 25 demographically-matched HCs. The standard conditioning (C)-testing (T) paradigm was used and P50 suppression was quantified using the T-C difference and the T/C ratio. Results: All P50 measures showed a linear, stepwise pattern with the SPD group intermediate between the HC and schizophrenia groups. Compared with HCs, both patient groups had lower conditioning and T-C difference values. Among the SPD group, greater clinical symptom severity was associated with greater conditioning-response amplitude deficits. Conclusion: These findings: (1) are novel in showing that P50 deficits in SPD resemble those observed in schizophrenia, albeit less marked; (2) support the concept that the phenomenological link between SPD and schizophrenia lies in shared neurocognitive/neurophysiological pathologies; and (3) provide evidence that P50 is a neurophysiological endophenotype for schizophrenia-spectrum disorders. Published by Elsevier B.V. C1 [Hazlett, Erin A.; Rothstein, Ethan G.; Ferreira, Rui; Silverman, Jeremy M.; Siever, Larry J.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Hazlett, Erin A.; Silverman, Jeremy M.; Siever, Larry J.] James J Peters VA Med Ctr, Res & Dev, Bronx, NY 10468 USA. [Hazlett, Erin A.; Siever, Larry J.] James J Peters VA Med Ctr, Mental Illness Res Educ & Clin Ctr VISN3, Bronx, NY 10468 USA. [Olincy, Ann] Univ Colorado, Dept Psychiat, Denver, CO 80202 USA. RP Hazlett, EA (reprint author), James J Peters VA Med Ctr, Mental Illness Res Educ & Clin Ctr VISN3, 130 West Kingsbridge Rd,Room 6A-44, Bronx, NY 10468 USA. EM erin.hazlett@mssm.edu FU VA MERIT Award [I01CX000261]; NIMH Collaborative R01 grant [R01MH065554, R01MH056140]; National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH) [UL1TR000067] FX Support for this work came from a VA MERIT Award I01CX000261 to E. A. H., NIMH Collaborative R01 grants to each of the seven Consortia on Genetics of Schizophrenia (COGS) sites including R01MH065554 to L.J.S, R01MH056140 to L.J.S., and grant no. UL1TR000067 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH). NR 87 TC 4 Z9 4 U1 2 U2 9 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 EI 1573-2509 J9 SCHIZOPHR RES JI Schizophr. Res. PD FEB PY 2015 VL 161 IS 2-3 BP 283 EP 290 DI 10.1016/j.schres.2014.11.020 PG 8 WC Psychiatry SC Psychiatry GA AZ8GB UT WOS:000348452100021 PM 25482574 ER PT J AU Trockel, M Karlin, BE Taylor, CB Brown, GK Manber, R AF Trockel, Mickey Karlin, Bradley E. Taylor, C. Barr Brown, Gregory K. Manber, Rachel TI Effects of Cognitive Behavioral Therapy for Insomnia on Suicidal Ideation in Veterans SO SLEEP LA English DT Article DE cognitive behavioral therapy; insomnia; suicidal ideation; dissemination; Veterans ID RANDOMIZED CONTROLLED-TRIAL; SLEEP DISTURBANCE; NATIONAL-DISSEMINATION; PERSISTENT INSOMNIA; DEPRESSIVE SYMPTOMS; FOLLOW-UP; ADULTS; SYSTEM; PHARMACOTHERAPY; METAANALYSIS AB Objective: To examine the effects of cognitive behavioral therapy for insomnia (CBT-I) on suicidal ideation among Veterans with insomnia. Design: Longitudinal data collected in the course of an uncontrolled evaluation of a large-scale CBT-I training program. Setting: Outpatient and residential treatment facilities. Participants: Four hundred five Veterans presenting for treatment of insomnia. Interventions: Cognitive behavioral therapy for insomnia. Measurement and Results: At baseline, 32% of patients, compared with 21% at final assessment, endorsed some level of suicidal ideation [chi(2)(df = 1) = 125; P < 0.001]. After adjusting for demographic variables and baseline insomnia severity, each 7-point decrease in Insomnia Severity Index score achieved during CBT-I treatment was associated with a 65% (odds ratio = 0.35; 95% confidence intervals = 0.24 to 0.52) reduction in odds of suicidal ideation. The effect of change in insomnia severity on change in depression severity was also significant. After controlling for change in depression severity and other variables in the model, the effect of change in insomnia severity on change in suicidal ideation remained significant. Conclusion: This evaluation of the largest dissemination of cognitive behavioral therapy for insomnia (CBT-I) in the United States found a clinically meaningful reduction in suicidal ideation among Veterans receiving CBT-I. The mechanisms by which effective treatment of insomnia with CBT-I reduces suicide risk are unknown and warrant investigation. The current results may have significant public health implications for preventing suicide among Veterans. C1 [Trockel, Mickey; Manber, Rachel] Vet Affairs Palo Alto Hlth Care Syst, Sierra Pacific Mental Illness Res Educ & Clin Ctr, Palo Alto, CA USA. [Trockel, Mickey; Taylor, C. Barr; Manber, Rachel] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA. [Karlin, Bradley E.] US Dept Vet Affairs, Cent Off, Mental Hlth Serv, Washington, DC USA. [Karlin, Bradley E.] Educ Dev Ctr Inc, New York, NY 10014 USA. [Karlin, Bradley E.] Johns Hopkins Univ, Dept Mental Hlth, Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Brown, Gregory K.] Philadelphia Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA. [Brown, Gregory K.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Karlin, BE (reprint author), Educ Dev Ctr Inc, Mental Hlth & Aging, 96 Morton St,7th Floor, New York, NY 10014 USA. EM bradkarlin@gmail.com FU Mental Health Services, U.S. Department of Veterans Affairs Central Office FX This was not an industry supported study. This project was supported by Mental Health Services, U.S. Department of Veterans Affairs Central Office. Dr. Karlin is currently affiliated with the Education Development Center, Inc., and the Department of Mental Health, Bloomberg School of Public Health, Johns Hopkins University. Dr. Manber is a co-author of a workbook related to the treatment described in this paper from which she receives royalties. The other authors have indicated no financial conflicts of interest. NR 47 TC 17 Z9 17 U1 1 U2 12 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 EI 1550-9109 J9 SLEEP JI Sleep PD FEB 1 PY 2015 VL 38 IS 2 BP 259 EP 265 DI 10.5665/sleep.4410 PG 7 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CA2SO UT WOS:000348757800014 PM 25515115 ER PT J AU Stey, AM Russell, MM Ko, CY Sacks, GD Dawes, AJ Gibbons, MM AF Stey, Anne M. Russell, Marcia M. Ko, Clifford Y. Sacks, Greg D. Dawes, Aaron J. Gibbons, Melinda M. TI Clinical registries and quality measurement in surgery: A systematic review SO SURGERY LA English DT Review ID OUTCOMES LONGITUDINAL DATABASE; SURGICAL-SITE-INFECTION; RISK-ADJUSTED OUTCOMES; ARTERY-BYPASS-SURGERY; OF-VETERANS-AFFAIRS; ABDOMINAL AORTIC-ANEURYSM; NORTHERN NEW-ENGLAND; VENA-CAVA FILTERS; TRAUMA DATA-BANK; BARIATRIC-SURGERY AB Background. Surgical clinical registries provide clinical information with the intent of measuring and improving quality. This study aimed to describe how surgical clinical registries have been used to measure surgical quality, the reported findings, and the limitations of registry measurements. Methods. Medline, CINAHL, and Cochrane were queried for English articles with the terms: "registry AND surgery AND quality. "Eligibility criteria were studies explicitly assessing quality measurement with registries as the primary data source. Studies were abstracted to identify registries, define registry structure, uses for quality measurement, and limitations of the measurements used. Results. A total of 111 studies of 18 registries were identified for data abstraction. Two registries were financed privately, and 5 registries were financed by a governmental organization. Across registries, the most common uses of process measures were for monitoring providers and as platforms for quality improvement initiatives. The most common uses of outcome measures were to improve quality modeling and to identify preoperative risk factors for poor outcomes. Eight studies noted improvements in risk-adjusted mortality with registry participation; one found no change. A major limitation is bias from context and means of data collection threatening internal validity of registry quality measurement. Conversely, the other major limitation is the cost of participation, which threatens the external validity of registry quality measurement. Conclusion. Clinical registries have advanced surgical quality definition, measurement, and modeling as well as having served as platforms for local initiatives for quality improvement. The implication of this finding is that subsidizing registry participation may improve data validity as well as engage providers in quality improvement. C1 [Stey, Anne M.] Mt Sinai Med Ctr, Icahn Sch Med, Los Angeles, CA 90024 USA. [Stey, Anne M.; Russell, Marcia M.; Ko, Clifford Y.; Sacks, Greg D.; Dawes, Aaron J.; Gibbons, Melinda M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Russell, Marcia M.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Ko, Clifford Y.] Amer Coll Surg, Chicago, IL USA. RP Stey, AM (reprint author), Mt Sinai Med Ctr, Icahn Sch Med, 10940 Wilshire Blvd,Suite 710, Los Angeles, CA 90024 USA. EM astey@mednet.ucla.edu OI Stey, Anne/0000-0002-8334-0304; Dawes, Aaron/0000-0003-4574-6765 FU Robert Wood Johnson Foundation Clinical Scholars program; U.S. Department of Veterans Affairs [70039] FX A.M.S., A.D., G.D.S. time was supported for this publication by The Robert Wood Johnson Foundation Clinical Scholars program and the U.S. Department of Veterans Affairs Grant number 70039. NR 140 TC 11 Z9 11 U1 3 U2 7 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0039-6060 J9 SURGERY JI Surgery PD FEB PY 2015 VL 157 IS 2 BP 381 EP 395 DI 10.1016/j.surg.2014.08.097 PG 15 WC Surgery SC Surgery GA CA5TX UT WOS:000348971800025 PM 25616951 ER PT J AU Goy, ER Bohlig, A Carter, J Ganzini, L AF Goy, Elizabeth R. Bohlig, Amanda Carter, Julie Ganzini, Linda TI Identifying Predictors of Hospice Eligibility in Patients With Parkinson Disease SO AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE LA English DT Article DE Parkinson disease; hospice; palliative ID BODY-WEIGHT; PROGRESSION; MORTALITY; LIFE; CARE; END AB This study aims to improve recognition of hospice eligibility for patients with Parkinson disease (PD) by ascertaining which variables have a higher probability of occurring uniquely in 6 to 12 months before death when compared to 18 to 24 months before death. Participants were 339 patients who died who were diagnosed with PD or Parkinsonism and treated with dopaminergic prescriptions for at least 3 years in northwestern US Veterans Affairs medical centers. A range of indicators were compared across 3 time periods (30-36 months, 24-18 months, and 12-6 months before death) using within-subjects repeated measures design. Results indicate that body mass index less than 18, alone or combined with a shift in prescribing (when benefits of dopaminergic medications no longer outweigh their risk of side effects), may signal appropriate timing for hospice referral. C1 [Goy, Elizabeth R.; Bohlig, Amanda; Ganzini, Linda] Portland VA Med Ctr, Div Mental Hlth, Portland, OR 97239 USA. [Carter, Julie] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. RP Goy, ER (reprint author), Portland VA Med Ctr, 3710 SW US Vet Hosp Rd P3MHDC, Portland, OR 97239 USA. EM Elizabeth.Goy@va.gov FU Health Services Research and Development (HSR&D) Career Development Award [RCD 04326]; HSR&D Portland Center for the Study of Chronic, Comorbid Mental and Physical Disorders, at the Portland VA Medical Center [REA 06-174] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research is funded in part by a Health Services Research and Development (HSR&D) Career Development Award for Dr. Goy (RCD 04326), and the HSR&D Portland Center for the Study of Chronic, Comorbid Mental and Physical Disorders (REA 06-174), at the Portland VA Medical Center. NR 18 TC 1 Z9 1 U1 1 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1049-9091 EI 1938-2715 J9 AM J HOSP PALLIAT ME JI Am. J. Hosp. Palliat. Med. PD FEB PY 2015 VL 32 IS 1 BP 29 EP 33 DI 10.1177/1049909113502119 PG 5 WC Health Care Sciences & Services SC Health Care Sciences & Services GA AZ4MQ UT WOS:000348196000004 PM 23975684 ER PT J AU Balch, C Arias-Pulido, H Banerjee, S Lancaster, AK Clark, KB Perilstein, M Hawkins, B Rhodes, J Sliz, P Wilkins, J Chittenden, TW AF Balch, Curt Arias-Pulido, Hugo Banerjee, Soumya Lancaster, Alex K. Clark, Kevin B. Perilstein, Michael Hawkins, Brian Rhodes, John Sliz, Piotr Wilkins, Jon Chittenden, Thomas W. TI Science and technology consortia in US biomedical research: A paradigm shift in response to unsustainable academic growth SO BIOESSAYS LA English DT Editorial Material C1 [Balch, Curt; Arias-Pulido, Hugo; Banerjee, Soumya; Lancaster, Alex K.; Clark, Kevin B.; Perilstein, Michael; Hawkins, Brian; Rhodes, John; Sliz, Piotr; Wilkins, Jon; Chittenden, Thomas W.] Complex Biol Syst Alliance, N Andover, MA 01845 USA. [Balch, Curt; Arias-Pulido, Hugo; Banerjee, Soumya; Lancaster, Alex K.; Wilkins, Jon; Chittenden, Thomas W.] Ronin Inst, Montclair, NJ USA. [Banerjee, Soumya] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Banerjee, Soumya] Broad Inst MIT & Harvard, Cambridge, MA USA. [Lancaster, Alex K.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Pathol, Boston, MA 02215 USA. [Clark, Kevin B.] Vet Affairs Greater Los Angeles Healthcare Syst, Res & Dev Serv, Los Angeles, CA USA. [Clark, Kevin B.] Univ Illinois, Natl Ctr Supercomp Applicat, Urbana, IL USA. [Hawkins, Brian] Univ Washington, Sch Med, Mitochondria & Metab Ctr, Seattle, WA USA. [Rhodes, John] Yale Univ, Sch Med, Yale Cardiovasc Res Ctr, New Haven, CT USA. [Sliz, Piotr] Harvard Univ, Sch Med, SBGrid Consortium, Boston, MA USA. [Wilkins, Jon] Santa Fe Inst, Santa Fe, NM 87501 USA. [Chittenden, Thomas W.] Harvard Univ, Sch Med, Res Comp Grp, Boston, MA USA. RP Chittenden, TW (reprint author), Complex Biol Syst Alliance, N Andover, MA 01845 USA. EM tom_chittenden@hms.harvard.edu RI ; Lancaster, Alexander/K-2855-2013 OI Wilkins, Jon/0000-0001-6405-6538; Lancaster, Alexander/0000-0002-0002-9263; Sliz, Piotr/0000-0002-6522-0835 NR 10 TC 2 Z9 2 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0265-9247 EI 1521-1878 J9 BIOESSAYS JI Bioessays PD FEB PY 2015 VL 37 IS 2 BP 119 EP 122 DI 10.1002/bies.201400167 PG 4 WC Biochemistry & Molecular Biology; Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics GA AZ9AQ UT WOS:000348504100004 PM 25387399 ER PT J AU Vij, R Kumar, S Zhang, MJ Zhong, XB Huang, JX Dispenzieri, A Abidi, MH Bird, JM Freytes, CO Gale, RP Kindwall-Keller, TL Kyle, RA Landsburg, DJ Lazarus, HM Munker, R Roy, V Sharma, M Vogl, DT Wirk, B Hari, PN AF Vij, Ravi Kumar, Shaji Zhang, Mei-Jie Zhong, Xiaobo Huang, Jiaxing Dispenzieri, Angela Abidi, Muneer H. Bird, Jennifer M. Freytes, Cesar O. Gale, Robert Peter Kindwall-Keller, Tamila L. Kyle, Robert A. Landsburg, Daniel J. Lazarus, Hillard M. Munker, Reinhold Roy, Vivek Sharma, Manish Vogl, Dan T. Wirk, Baldeep Hari, Parameswaran N. TI Impact of Pretransplant Therapy and Depth of Disease Response before Autologous Transplantation for Multiple Myeloma SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Article DE Myeloma; Primary refractory; Autologous transplant ID STEM-CELL TRANSPLANTATION; HIGH-DOSE THERAPY; COMPLETE REMISSION; INTENSIVE THERAPY; CHEMOTHERAPY; SURVIVAL; INDUCTION; OUTCOMES; BENEFIT AB Patients with multiple myeloma (MM) who are eligible for autologous stem cell transplantation (ASCT) typically receive a finite period of initial therapy before ASCT. It is not clear if patients with suboptimal (less than a partial) response to initial therapy benefit from additional alternative therapy with intent to maximize pretransplant response. We identified 539 patients with MM who had an ASCT after having achieved less than a partial response (PR) to first-line induction chemotherapy between 1995 and 2010. These patients were then divided into 2 groups: those who received additional salvage chemotherapy before ASCT (n = 324) and those who had no additional salvage chemotherapy immediately before ASCT (n = 215). Additional pretransplant chemotherapy resulted in deepening responses in 68% (complete response in 8% and PR in 60%). On multivariate analysis there was no impact of pretransplant salvage chemotherapy on treatment-related mortality, risk for relapse, progression-free survival, or overall survival. In conclusion, for patients achieving less than a PR to initial induction therapy, including with novel agent combinations, additional pre-ASCT salvage chemotherapy improved the depth of response and pre-ASCT disease status but was not associated with survival benefit. (C) 2015 American Society for Blood and Marrow Transplantation. C1 [Vij, Ravi] Washington Univ, Sch Med, Div Hematol & Oncol, St Louis, MO USA. [Kumar, Shaji; Dispenzieri, Angela; Kyle, Robert A.] Mayo Clin, Dept Hematol, Rochester, MN USA. [Zhang, Mei-Jie; Zhong, Xiaobo; Huang, Jiaxing; Hari, Parameswaran N.] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Div Hematol & Oncol, Milwaukee, WI 53226 USA. [Zhang, Mei-Jie] Inst Hlth & Soc, Div Biostat, Milwaukee, WI USA. [Abidi, Muneer H.] Wayne State Univ, Karmanos Canc Inst, Dept Oncol, Div BMT, Detroit, MI USA. [Bird, Jennifer M.] Univ Hosp Bristol NHS, Dept Haematol, Bristol, Avon, England. [Freytes, Cesar O.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Freytes, Cesar O.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Gale, Robert Peter] Univ London Imperial Coll Sci Technol & Med, Hematol Res Ctr, Div Expt Med, London, England. [Kindwall-Keller, Tamila L.] Univ Virginia Hlth Syst, Div Hematol Oncol, Charlottesville, VA USA. [Landsburg, Daniel J.; Vogl, Dan T.] Univ Penn, Abramson Canc Ctr, Div Hematol Oncol, Philadelphia, PA 19104 USA. [Lazarus, Hillard M.] Univ Hosp Case Med Ctr, Seidman Canc Ctr, Cleveland, OH USA. [Munker, Reinhold] Louisiana State Univ Hlth Shreveport, Dept Internal Med, Div Hematol Oncol, Shreveport, LA USA. [Roy, Vivek] Mayo Clin, Blood & Marrow Transplant Program, Jacksonville, FL 32224 USA. [Sharma, Manish] Thomas Jefferson Univ, Dept Internal Med, Philadelphia, PA 19107 USA. [Wirk, Baldeep] SUNY Stony Brook, Med Ctr, Dept Internal Med, Stony Brook, NY 11794 USA. RP Hari, PN (reprint author), Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Div Hematol & Oncol, 9200 W Wisconsin Ave,Suite C5500, Milwaukee, WI 53226 USA. EM phari@mcw.edu RI Kumar, Shaji/A-9853-2008 OI Kumar, Shaji/0000-0001-5392-9284; Abidi, Muneer/0000-0002-9936-6031; Dispenzieri, Angela/0000-0001-8780-9512; Hari, Parameswaran/0000-0002-8800-297X FU National Cancer Institute (NCI) [U24-CA076518]; National Heart, Lung, and Blood Institute (NHLBI); National Institute of Allergy and Infectious Diseases (NIAID); NHLBI and NCI [5U10HL069294]; Health Resources and Services Administration [HHSH250201200016C]; Office of Naval Research [N00014-12-1-0142, N00014-13-1-0039]; Office of Naval Research; *Actinium Pharmaceuticals; Allos Therapeutics, Inc.; Amgen, Inc.; Anonymous donation to the Medical College of Wisconsin; Ariad; Be The Match Foundation; *Blue Cross and Blue Shield Association; *Celgene Corporation; Chimerix, Inc.; Fred Hutchinson Cancer Research Center; Fresenius-Biotech North America, Inc.; *Gamida Cell Teva Joint Venture Ltd.; Genentech, Inc.; Gentium SpA; Genzyme Corporation; GlaxoSmithKline; Health Research, Inc. Roswell Park Cancer Institute; HistoGenetics, Inc.; Incyte Corporation; Jeff Gordon Children's Foundation; Kiadis Pharma; Leukemia & Lymphoma Society; Medac GmbH; Medical College of Wisconsin; Merck Co, Inc.; Millennium: The Takeda Oncology Co.; Milliman USA, Inc.; *Miltenyi Biotec, Inc.; National Marrow Donor Program; Onyx Pharmaceuticals; Optum Healthcare Solutions, Inc.; Osiris Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; Perkin Elmer, Inc.; *Remedy Informatics; Sanofi US; Seattle Genetics; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; St. Baldrick's Foundation; StemCyte, A Global Cord Blood Therapeutics Co.; Stemsoft Software, Inc.; Swedish Orphan Biovitrum; *Tarix Pharmaceuticals; *Terumo BCT; *Teva Neuroscience, Inc.; *Therakos; University of Minnesota; University of Utah; WellPoint FX Financial disclosure: The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA076518 from the National Cancer Institute (NCI), the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases (NIAID); Grant/Cooperative Agreement 5U10HL069294 from NHLBI and NCI; contract HHSH250201200016C with the Health Resources and Services Administration; 2 grants (N00014-12-1-0142 and N00014-13-1-0039) from the Office of Naval Research; and grants from *Actinium Pharmaceuticals; Allos Therapeutics, Inc.; *Amgen, Inc.; Anonymous donation to the Medical College of Wisconsin; Ariad; Be The Match Foundation; *Blue Cross and Blue Shield Association; *Celgene Corporation; Chimerix, Inc.; Fred Hutchinson Cancer Research Center; Fresenius-Biotech North America, Inc.; *Gamida Cell Teva Joint Venture Ltd.; Genentech, Inc.; *Gentium SpA; Genzyme Corporation; GlaxoSmithKline; Health Research, Inc. Roswell Park Cancer Institute; HistoGenetics, Inc.; Incyte Corporation; Jeff Gordon Children's Foundation; Kiadis Pharma; The Leukemia & Lymphoma Society; Medac GmbH; The Medical College of Wisconsin; Merck & Co, Inc.; Millennium: The Takeda Oncology Co.; *Milliman USA, Inc.; *Miltenyi Biotec, Inc.; National Marrow Donor Program; Onyx Pharmaceuticals; Optum Healthcare Solutions, Inc.; Osiris Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; Perkin Elmer, Inc.; *Remedy Informatics; *Sanofi US; Seattle Genetics; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; St. Baldrick's Foundation; StemCyte, A Global Cord Blood Therapeutics Co.; Stemsoft Software, Inc.; Swedish Orphan Biovitrum; *Tarix Pharmaceuticals; *Terumo BCT; *Teva Neuroscience, Inc.; *Therakos; University of Minnesota; University of Utah; and *WellPoint The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration; or any other agency of the U.S. Government. Asterisk (*) indicates corporate members. NR 19 TC 14 Z9 14 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2015 VL 21 IS 2 BP 335 EP 341 DI 10.1016/j.bbmt.2014.10.023 PG 7 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA CA0UW UT WOS:000348632700019 PM 25445028 ER PT J AU Billen, A Madrigal, JA Strydom, A Szydlo, RM Switzer, GE Shaw, BE AF Billen, Annelies Madrigal, J. Alejandro Strydom, Andre Szydlo, Richard M. Switzer, Galen E. Shaw, Bronwen E. TI Predonation Health-Related Quality of Life Scores Predict Time to Recovery in Hematopoietic Stem Cell Donors SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Article DE Peripheral blood stem cells; Bone marrow; Donation experience; Health-related quality of life ID COLONY-STIMULATING FACTOR; UNRELATED BONE-MARROW; ADVERSE EVENTS; PROSPECTIVE TRIAL; FOLLOW-UP; BLOOD; DONATION; PAIN; DEPRESSION; EXPERIENCE AB The physical reactions to hematopoietic stem cell donation have been extensively studied, but less is known about factors that predict poorer donation experiences. The aim of this prospective study was to examine demographic and health-related quality of life (HRQOL) factors that might be associated with recovery and side effects. We also described the changes in HRQOL during the donation process. In total, 275 peripheral blood stem cell (PBSC) and 37 bone marrow (BM) consecutive donors completed the SF-36 questionnaire predonation and 4 weeks, and 3 months postdonation. Predonation HRQOL markers were the strongest predictors of time to recovery. Poorer predonation physical health was associated with longer recovery (P = .017) and certain side effects in PBSC donors. Poorer predonation mental health was associated with longer recovery in BM donors (P = .03) and pain after PBSC donation (P = .003). Physical HRQOL scores declined significantly from predonation to 4 weeks postdonation. This was shown both for PBSC and BM donors (P < .001 and P = .009, respectively), but the decline was much greater for BM donors. There was a return to predonation HRQOL values 3 months after donation in both groups with values well above the mean of the general population (P < .001). (C) 2015 American Society for Blood and Marrow Transplantation. C1 [Billen, Annelies; Madrigal, J. Alejandro; Shaw, Bronwen E.] UCL, Inst Canc, London, England. [Billen, Annelies; Madrigal, J. Alejandro; Shaw, Bronwen E.] Anthony Nolan Res Inst, London, England. [Strydom, Andre] UCL, Mental Hlth Sci Unit, London, England. [Szydlo, Richard M.] Univ London Imperial Coll Sci Technol & Med, Dept Med, London, England. [Switzer, Galen E.] Univ Pittsburgh, Dept Gen Internal Med, Pittsburgh, PA USA. [Switzer, Galen E.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. [Shaw, Bronwen E.] Royal Marsden Hosp, Dept Haematol, London SW3 6JJ, England. RP Billen, A (reprint author), Anthony Nolan,2 Heathgate Pl,75-87 Agincourt Rd, London NW3 2N, England. EM Annelies.billen@anthonynolan.org RI Szydlo, Richard/C-6678-2012 OI Szydlo, Richard/0000-0003-1102-8298 NR 36 TC 3 Z9 4 U1 2 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2015 VL 21 IS 2 BP 350 EP 356 DI 10.1016/j.bbmt.2014.10.028 PG 7 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA CA0UW UT WOS:000348632700021 PM 25452034 ER PT J AU Sosenko, JM Skyler, JS DiMeglio, LA Beam, CA Krischer, JP Greenbaum, CJ Boulware, D Rafkin, LE Matheson, D Herold, KC Mahon, J Palmer, JP AF Sosenko, Jay M. Skyler, Jay S. DiMeglio, Linda A. Beam, Craig A. Krischer, Jeffrey P. Greenbaum, Carla J. Boulware, David Rafkin, Lisa E. Matheson, Della Herold, Kevan C. Mahon, Jeffrey Palmer, Jerry P. CA Type 1 Diabet TrialNet Diabet Prevention Trial-Type 1 TI A New Approach for Diagnosing Type 1 Diabetes in Autoantibody-Positive Individuals Based on Prediction and Natural History SO DIABETES CARE LA English DT Article ID TRIAL-TYPE 1; IMPAIRED GLUCOSE-TOLERANCE; RISK SCORE; PREVENTION TRIAL-TYPE-1; INSULIN-RESISTANCE; MELLITUS; PARTICIPANTS; PROGRESSION; CHILDREN; PUBERTY AB OBJECTIVEWe assessed whether type 1 diabetes (T1D) can be diagnosed earlier using a new approach based on prediction and natural history in autoantibody-positive individuals.RESEARCH DESIGN AND METHODSDiabetes Prevention Trial-Type 1 (DPT-1) and TrialNet Natural History Study (TNNHS) participants were studied. A metabolic index, the T1D Diagnostic Index60 (Index60), was developed from 2-h oral glucose tolerance tests (OGTTs) using the log fasting C-peptide, 60-min C-peptide, and 60-min glucose. OGTTs with Index60 2.00 and 2-h glucose <200 mg/dL (Ind60+Only) were compared with Index60 <2.00 and 2-h glucose 200 mg/dL (2hglu+Only) OGTTs as criteria for T1D. Individuals were assessed for C-peptide loss from the first Ind60+Only OGTT to diagnosis.RESULTSAreas under receiver operating characteristic curves were significantly higher for Index60 than for the 2-h glucose (P < 0.001 for both DPT-1 and the TNNHS). As a diagnostic criterion, sensitivity was higher for Ind60+Only than for 2hglu+Only (0.44 vs. 0.15 in DPT-1; 0.26 vs. 0.17 in the TNNHS) OGTTs. Specificity was somewhat higher for 2hglu+Only OGTTs in DPT-1 (0.97 vs. 0.91) but equivalent in the TNNHS (0.98 for both). Positive and negative predictive values were higher for Ind60+Only OGTTs in both studies. Postchallenge C-peptide levels declined significantly at each OGTT time point from the first Ind60+Only OGTT to the time of standard diagnosis (range -22 to -34% in DPT-1 and -14 to -27% in the TNNHS). C-peptide and glucose patterns differed markedly between Ind60+Only and 2hglu+Only OGTTs.CONCLUSIONSAn approach based on prediction and natural history appears to have utility for diagnosing T1D. C1 [Sosenko, Jay M.; Skyler, Jay S.; Rafkin, Lisa E.; Matheson, Della] Univ Miami, Div Endocrinol, Miami, FL 33132 USA. [DiMeglio, Linda A.] Indiana Univ, Sect Pediat Endocrinol Diabetol, Indianapolis, IN 46204 USA. [Beam, Craig A.] Western Michigan Univ, Sch Med, Div Epidemiol & Biostat, Kalamazoo, MI 49008 USA. [Krischer, Jeffrey P.; Boulware, David] Univ S Florida, Div Informat & Biostat, Tampa, FL USA. [Greenbaum, Carla J.] Benaroya Res Inst Virginia Mason, Seattle, WA USA. [Herold, Kevan C.] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT USA. [Mahon, Jeffrey] Univ Western Ontario, Dept Epidemiol & Biostat, London, ON, Canada. [Palmer, Jerry P.] Univ Washington, VA Puget Sound Hlth Care Syst, Div Endocrinol Metab & Nutr, Seattle, WA 98195 USA. RP Sosenko, JM (reprint author), Univ Miami, Div Endocrinol, Miami, FL 33132 USA. EM jsosenko@med.miami.edu RI Skyler, Jay/F-4211-2016 OI DiMeglio, Linda/0000-0002-8033-6078 FU National Institutes of Health through the National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Allergy and Infectious Diseases; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Center for Research Resources; JDRF; American Diabetes Association FX This work was funded by the National Institutes of Health through the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Center for Research Resources, JDRF, and the American Diabetes Association. NR 16 TC 8 Z9 8 U1 0 U2 8 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD FEB PY 2015 VL 38 IS 2 BP 271 EP 276 DI 10.2337/dc14-1813 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AZ8JK UT WOS:000348461400027 PM 25519451 ER PT J AU Li, Y Lu, Z Zhang, X Yu, H Kirkwood, KL Lopes-Virella, MF Huang, Y AF Li, Y. Lu, Z. Zhang, X. Yu, H. Kirkwood, K. L. Lopes-Virella, M. F. Huang, Y. TI Metabolic Syndrome Exacerbates Inflammation and Bone Loss in Periodontitis SO JOURNAL OF DENTAL RESEARCH LA English DT Article DE lipopolysaccharide; palmitic acid; high-fat diet; osteoclast; cytokines; gene expression ID FREE FATTY-ACIDS; INSULIN-RESISTANCE; AGGRESSIVE PERIODONTITIS; DISEASE; ASSOCIATION; OBESITY; MACROPHAGES; EXPRESSION; MICROBIOTA; PALMITATE AB Clinical studies have shown that metabolic syndrome (MetS) is associated with increased risk of developing periodontitis. However, the underlying mechanisms remain largely unknown. Since it is known that lipopolysaccharide (LPS)-activated toll-like receptor 4 signaling pathways play a crucial role in periodontitis, we hypothesized that MetS enhances LPS-induced periodontal inflammation and alveolar bone loss. In this study, we induced MetS in C57BL/6 mice by feeding them high-fat diet (HFD), and we induced periodontitis by periodontal injection of Aggregatibacter actinomycetemcomitans LPS. We found that mice fed a HFD had significantly increased body weight, plasma lipids, insulin, and insulin resistance when compared with mice fed regular chow, indicating that the mice developed MetS. We also found that a HFD markedly increased LPS-induced alveolar bone loss, osteoclastogenesis, and inflammatory infiltration. Analysis of gene expression in periodontal tissue revealed that HFD and LPS injection cooperatively stimulated expression of cytokines that are known to be involved in periodontal tissue inflammation and osteoclastogenesissuch as interleukin 6, monocyte-chemotactic protein 1, receptor activator of nuclear factor kappa-B ligand, and macrophage colony-stimulating factor. To further understand the potential mechanisms involved in MetS-boosted tissue inflammation, our in vitro studies showed that palmitic acidthe most abundant saturated fatty acid (SFA) and the major SFA in the HFD used in our animal studypotently enhanced LPS-induced proinflammatory gene expression in macrophages. In sum, this study demonstrated that MetS was associated with increased periodontal inflammation and alveolar bone loss in an LPS-induced periodontitis animal model. This study also suggests that SFA palmitic acid may play an important role in MetS-associated periodontitis by enhancing LPS-induced expression of inflammatory cytokines in macrophages. C1 [Li, Y.; Lu, Z.; Zhang, X.; Lopes-Virella, M. F.; Huang, Y.] Med Univ S Carolina, Div Endocrinol Diabet & Med Genet, Dept Med, Coll Med, Charleston, SC 29403 USA. [Yu, H.; Kirkwood, K. L.; Huang, Y.] Med Univ S Carolina, Dept Oral Hlth Sci, Coll Dent Med, Charleston, SC 29403 USA. [Lopes-Virella, M. F.; Huang, Y.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Huang, Y (reprint author), Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Dept Med, 114 Doughty St, Charleston, SC 29403 USA. EM huangyan@musc.edu FU National Institutes of Health [DE016353]; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development [5I01BX000854]; National Institute of General Medical Sciences [P30GM103331] FX This work was supported by grant DE016353 from the National Institutes of Health and grant 5I01BX000854 from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development (to Y.H.). This study utilized the facilities and resources of the Medical University of South Carolina Center for Oral Health Research, which is partially supported by grant P30GM103331 from the National Institute of General Medical Sciences. The authors declare no potential conflicts of interest with respect to the authorship and/or publication of this article. NR 35 TC 6 Z9 7 U1 2 U2 14 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0022-0345 EI 1544-0591 J9 J DENT RES JI J. Dent. Res. PD FEB PY 2015 VL 94 IS 2 BP 362 EP 370 DI 10.1177/0022034514561658 PG 9 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA CA1BO UT WOS:000348647900016 PM 25503900 ER PT J AU Xiong, GX Redding, K Chen, B Cohen, AS Cohen, NA AF Xiong, Guoxiang Redding, Kevin Chen, Bei Cohen, Akiva S. Cohen, Noam A. TI Non-specific Immunostaining by a Rabbit Antibody against Gustducin alpha Subunit in Mouse Brain SO JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY LA English DT Article DE taste bud; immunohistochemistry; peptide neutralization; axonal terminal; polyclonal antibody ID BITTER TASTE RECEPTORS; SOLITARY CHEMOSENSORY CELLS; GASTROINTESTINAL-TRACT; BURKHOLDERIA-CEPACIA; SWEET TASTE; RAT-BRAIN; IMMUNOHISTOCHEMISTRY; EXPRESSION; BUDS; SPECIFICITY AB Gustducin is a guanosine nucleotide-binding protein functionally coupled with taste receptors and thus originally identified in taste cells of the tongue. Recently, bitter taste receptors and gustducin have been detected in the airways, digestive tracts and brain. The existing studies showing taste receptors and gustducin in the brain were carried out exclusively on frozen sections. In order to avoid the technical shortcomings associated with frozen sectioning, we performed immunofluorescence staining using vibratome-cut sections from mouse brains. Using a rabbit gustducin antibody, we could not detect neurons or astrocytes as reported previously. Rather, we found dense fibers in the nucleus accumbens and periventricular areas. We assumed these staining patterns to be specific after confirmation with conventional negative control staining. For the verification of this finding, we stained gustducin knockout mouse brain and tongue sections with the same rabbit gustducin antibody. Whereas negative staining was confirmed in the tongue, intensive fibers were constantly stained in the brain. Moreover, immunostaining with a goat gustducin antibody could not demonstrate the fibers in the brain tissue. The present study implies a cross immunoreaction that occurs with the rabbit gustducin antibody in mouse brain samples, suggesting that the conventional negative controls may not be sufficient when an immunostaining pattern is to be verified. C1 [Xiong, Guoxiang; Cohen, Akiva S.] Childrens Hosp Philadelphia, Div Neurol, Philadelphia, PA 19104 USA. [Redding, Kevin] Monell Chem Senses Ctr, Philadelphia, PA 19104 USA. [Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Chen, Bei; Cohen, Noam A.] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA. [Cohen, Akiva S.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Xiong, GX (reprint author), Childrens Hosp Philadelphia, Div Neurol, Philadelphia, PA 19104 USA. EM xiong@email.chop.edu FU Flight Attendants Medical Research Institute FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by a grant from The Flight Attendants Medical Research Institute and a philanthropic contribution from the RLG Foundation, Inc. (to NAC). NR 39 TC 2 Z9 2 U1 0 U2 5 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0022-1554 EI 1551-5044 J9 J HISTOCHEM CYTOCHEM JI J. Histochem. Cytochem. PD FEB PY 2015 VL 63 IS 2 BP 79 EP 87 DI 10.1369/0022155414562838 PG 9 WC Cell Biology SC Cell Biology GA AZ9JP UT WOS:000348529900001 PM 25411190 ER PT J AU Hagiwara, Y Villarreal, D Sanchez-Reilly, S AF Hagiwara, Yuya Villarreal, Deborah Sanchez-Reilly, Sandra TI Present Planning versus Future Planning: We Need a Shift Toward Goals of Care Education for Physicians SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Letter C1 [Hagiwara, Yuya; Villarreal, Deborah; Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, Div Geriatr Gerontol & Palliat Med, San Antonio, TX 78229 USA. [Villarreal, Deborah; Sanchez-Reilly, Sandra] South Texas Vet Hlth Care Syst, Geriatr Res Educ Clin Ctr, San Antonio, TX USA. RP Hagiwara, Y (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Geriatr Gerontol & Palliat Med, 7703 Floyd Curl Dr,MSC 7875, San Antonio, TX 78229 USA. EM hagiwara@uthscsa.edu NR 4 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 EI 1557-7740 J9 J PALLIAT MED JI J. Palliat. Med. PD FEB 1 PY 2015 VL 18 IS 2 BP 99 EP 99 DI 10.1089/jpm.2014.0394 PG 1 WC Health Care Sciences & Services SC Health Care Sciences & Services GA AZ9IE UT WOS:000348526300004 PM 25546816 ER PT J AU Kamat, SS Camara, K Parsons, WH Chen, DH Dix, MM Bird, TD Howell, AR Cravatt, BF AF Kamat, Siddhesh S. Camara, Kaddy Parsons, William H. Chen, Dong-Hui Dix, Melissa M. Bird, Thomas D. Howell, Amy R. Cravatt, Benjamin F. TI Immunomodulatory lysophosphatidylserines are regulated by ABHD16A and ABHD12 interplay SO NATURE CHEMICAL BIOLOGY LA English DT Article ID MAJOR HISTOCOMPATIBILITY COMPLEX; SERINE HYDROLASES; ENDOCANNABINOID 2-ARACHIDONOYLGLYCEROL; PHOSPHOLIPASE A(1); HISTAMINE-RELEASE; GRAVES-DISEASE; X-CHROMOSOME; MAST-CELLS; BRAIN; PHOSPHATIDYLSERINE AB Lysophosphatidylserines (lyso-PSs) are a class of signaling lipids that regulate immunological and neurological processes. The metabolism of lyso-PSs remains poorly understood in vivo. Recently, we determined that ABHD12 is a major brain lyso-PS lipase, implicating lyso-PSs in the neurological disease polyneuropathy, hearing loss, ataxia, retinitis pigmentosa and cataract (PHARC), which is caused by null mutations in the ABHD12 gene. Here, we couple activity-based profiling with pharmacological and genetic methods to annotate the poorly characterized enzyme ABHD16A as a phosphatidylserine (PS) lipase that generates lyso-PS in mammalian systems. We describe a small-molecule inhibitor of ABHD16A that depletes lyso-PSs from cells, including lymphoblasts derived from subjects with PHARC. In mouse macrophages, disruption of ABHD12 and ABHD16A respectively increases and decreases both lyso-PSs and lipopolysaccharide-induced cytokine production. Finally, Abhd16a(-/-) mice have decreased brain lyso-PSs, which runs counter to the elevation in lyso-PS in Abhd12(-/-) mice. Our findings illuminate an ABHD16A-ABHD12 axis that dynamically regulates lyso-PS metabolism in vivo, designating these enzymes as potential targets for treating neuroimmunological disorders. C1 [Kamat, Siddhesh S.; Parsons, William H.; Dix, Melissa M.; Cravatt, Benjamin F.] Scripps Res Inst, Dept Physiol Chem, La Jolla, CA 92037 USA. [Kamat, Siddhesh S.; Parsons, William H.; Dix, Melissa M.; Cravatt, Benjamin F.] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA. [Camara, Kaddy; Howell, Amy R.] Univ Connecticut, Dept Chem, Storrs, CT USA. [Chen, Dong-Hui; Bird, Thomas D.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Bird, Thomas D.] Univ Washington, Dept Med, Seattle, WA USA. [Bird, Thomas D.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Cravatt, BF (reprint author), Scripps Res Inst, Dept Physiol Chem, La Jolla, CA 92037 USA. EM cravatt@scripps.edu OI Parsons, William/0000-0001-6065-2340 FU US National Institutes of Health [DA033760]; American Chemical Society; Hewitt Foundation for Medical Research fellowship; Department of Veterans Affairs Research Funds; US National Science Foundation [CHE-0809753, CHE-1048717] FX We are grateful to K. Masuda, A. Viader and K.-L. Hsu for their helpful discussions, guidance and technical expertise in harvesting tissues; G. Simon and J. Blankman for helpful discussions; M. Niphakis for advice on the SAR studies on the beta-lactone scaffolds; O. Ulanovskaya for advice on generating the shRNA knockdown cell lines; B. Correia for the guidance on using CIMAGE; C. Joslyn and T. Takei for technical assistance; and M. Lau for contributions to initial synthetic studies. This work was supported by the US National Institutes of Health (DA033760) and the ninth Irving S. Sigal postdoctoral fellowship from the American Chemical Society (to S.S.K.), a Hewitt Foundation for Medical Research fellowship (to W.H.P.), the Department of Veterans Affairs Research Funds (to T.D.B.) and the US National Science Foundation (CHE-0809753 and CHE-1048717 to A.R.H.). NR 49 TC 21 Z9 21 U1 0 U2 17 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1552-4450 EI 1552-4469 J9 NAT CHEM BIOL JI Nat. Chem. Biol. PD FEB PY 2015 VL 11 IS 2 BP 164 EP U116 DI 10.1038/NCHEMBIO.1721 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA AZ6WN UT WOS:000348358800015 PM 25580854 ER PT J AU Koffel, EA Koffel, JB Gehrman, PR AF Koffel, Erin A. Koffel, Jonathan B. Gehrman, Philip R. TI A meta-analysis of group cognitive behavioral therapy for insomnia SO SLEEP MEDICINE REVIEWS LA English DT Review DE Group therapy; CBT-I; Insomnia ID RANDOMIZED CONTROLLED-TRIAL; PSYCHIATRIC-DISORDERS; PERSISTENT INSOMNIA; SLEEP DISTURBANCE; STEPPED CARE; OLDER-ADULTS; EFFICACY; INTERVENTION; SEVERITY; DISEASE AB Insomnia is the most common sleep disorder among the general population. Although cognitive behavioral therapy for insomnia (CBT-I) is the psychological treatment of choice, the availability of individual therapy is often not sufficient to meet the demand for treatment. Group treatment can increase the efficiency of delivery, but its efficacy has not been well-established. Randomized controlled trials (RCfs) comparing group CBT-I to a control group in patients with insomnia were identified. A review of 670 unique citations resulted in eight studies that met criteria for analysis. Outcome variables included both qualitative (e.g., sleep quality) and quantitative (e.g., sleep diary) outcomes, as well as depression and pain severity, at both pre- to post-treatment and follow-up (3-12 mo post-treatment). Overall, we found medium to large effect sizes for sleep onset latency, sleep efficiency, and wake after sleep onset and small effect sizes for pain outcomes. Effect sizes remained significant at follow-up, suggesting that treatment gains persist over time. Other variables, including total sleep time, sleep quality, and depression, showed significant improvements, but these findings were limited to the within treatment group analyses. It is clear that group CBT-I is an efficacious treatment. Implications for stepped care models for insomnia are discussed. Published by Elsevier Ltd. C1 [Koffel, Erin A.] Univ Minnesota, Minneapolis Vet Affairs Med Ctr, Minneapolis, MN USA. [Koffel, Erin A.] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA. [Koffel, Jonathan B.] Univ Minnesota, Biomed Lib, Minneapolis, MN USA. [Gehrman, Philip R.] Univ Penn, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Gehrman, Philip R.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. RP Koffel, EA (reprint author), Dept Vet Affairs Med Ctr, 1 Vet Dr, Minneapolis, MN 55417 USA. EM Erin.Koffel@va.gov OI Koffel, Jonathan/0000-0003-1723-5087 FU VA [VA999999] NR 46 TC 26 Z9 27 U1 7 U2 35 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 1087-0792 EI 1532-2955 J9 SLEEP MED REV JI Sleep Med. Rev. PD FEB PY 2015 VL 19 BP 6 EP 16 DI 10.1016/j.smrv.2014.05.001 PG 11 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA AZ6NP UT WOS:000348336600003 PM 24931811 ER PT J AU Antebi, B Zhang, ZL Wang, Y Lu, ZD Chen, XD Ling, J AF Antebi, Ben Zhang, ZhiLiang Wang, Yu Lu, ZhongDing Chen, Xiao-Dong Ling, Jian TI Stromal-Cell-Derived Extracellular Matrix Promotes the Proliferation and Retains the Osteogenic Differentiation Capacity of Mesenchymal Stem Cells on Three-Dimensional Scaffolds SO Tissue Engineering Part C-Methods LA English DT Article ID PERFUSION BIOREACTOR SYSTEM; BONE-MARROW-CELLS; IN-VITRO; EX-VIVO; CONSTRUCT DEVELOPMENT; SEEDING DENSITY; SELF-RENEWAL; CULTURE; NICHE; MICROENVIRONMENT AB To date, expansion of bone-marrow-derived mesenchymal stem cells (MSCs) is typically carried out on two-dimensional (2D) tissue culture plastic. Since this 2D substratum is very different from the physiological situation, MSCs gradually lose their unique multipotent properties during expansion. Recently, the role of the extracellular matrix (ECM) microenvironment ("niche") in facilitating and regulating stem cell behavior in vivo has been elucidated. As a result, investigators have shifted their efforts toward developing three-dimensional (3D) scaffolds capable of functioning like the native tissue ECM. In this study, we demonstrated that stromal-cell-derived ECM, formed within a collagen/hydroxyapatite (Col/HA) scaffold to mimic the bone marrow "niche," promoted MSC proliferation and preserved their differentiation capacity. The ECM was synthesized by MSCs to reconstitute the tissue-specific 3D microenvironment in vitro. Following deposition of the ECM inside Col/HA scaffold, the construct was decellularized and reseeded with MSCs to study their behavior. The data showed that MSCs cultured on the ECM-Col/HA scaffolds grew significantly faster than the cells from the same batch cultured on the regular Col/HA scaffolds. In addition, MSCs cultured on the ECM-Col/HA scaffolds retained their "stemness" and osteogenic differentiation capacity better than MSCs cultured on regular Col/HA scaffolds. When ECM-Col/HA scaffolds were implanted into immunocompromised mice, with or without loading MSCs, it was found that those scaffolds formed less bone as compared with regular Col/HA scaffolds (i.e., without ECM), in both cases of with or without loading MSCs. The in vivo study further confirmed that the ECM-Col/HA scaffold was a suitable mimic of the bone marrow "niche." This novel 3D stromal-cell-derived ECM system has the potential to be developed into a biomedical platform for regenerative medicine applications. C1 [Antebi, Ben; Ling, Jian] SW Res Inst, Microencapsulat & Nanomat Dept, San Antonio, TX 78238 USA. [Antebi, Ben; Ling, Jian] Univ Texas Hlth Sci Ctr San Antonio, Univ Texas San Antonio, Biomed Engn Program, San Antonio, TX 78229 USA. [Zhang, ZhiLiang; Wang, Yu; Lu, ZhongDing; Chen, Xiao-Dong] Univ Texas Hlth Sci Ctr San Antonio, Dept Comprehens Dent, San Antonio, TX 78229 USA. [Chen, Xiao-Dong] South Texas Vet Hlth Care Syst, Audie L Murphy Div Hosp, San Antonio, TX USA. RP Ling, J (reprint author), SW Res Inst, Microencapsulat & Nanomat Dept, 6220 Culebra Rd, San Antonio, TX 78238 USA. EM chenx4@uthscsa.edu; jling@swri.org FU National Heart, Lung, and Blood Institute [R21 HL102775] FX This work was supported by the National Heart, Lung, and Blood Institute: R21 HL102775. NR 46 TC 7 Z9 7 U1 4 U2 16 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1937-3384 EI 1937-3392 J9 TISSUE ENG PART C-ME JI Tissue Eng. Part C-Methods PD FEB 1 PY 2015 VL 21 IS 2 BP 171 EP 181 DI 10.1089/ten.tec.2014.0092 PG 11 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology SC Cell Biology; Biotechnology & Applied Microbiology GA CA6HR UT WOS:000349012400007 PM 24965227 ER PT J AU Singh, H Sittig, DF AF Singh, Hardeep Sittig, Dean F. TI Advancing the science of measurement of diagnostic errors in healthcare: the Safer Dx framework SO BMJ QUALITY & SAFETY LA English DT Article ID ADVERSE EVENTS; MALPRACTICE CLAIMS; PATIENT SAFETY; HOSPITALIZED-PATIENTS; AMBULATORY-CARE; MEDICAL-RECORD; ORGANIZATIONS; SURVEILLANCE; SETTINGS; IMPROVE AB Diagnostic errors are major contributors to harmful patient outcomes, yet they remain a relatively understudied and unmeasured area of patient safety. Although they are estimated to affect about 12 million Americans each year in ambulatory care settings alone, both the conceptual and pragmatic scientific foundation for their measurement is under-developed. Health care organizations do not have the tools and strategies to measure diagnostic safety and most have not integrated diagnostic error into their existing patient safety programs. Further progress toward reducing diagnostic errors will hinge on our ability to overcome measurement-related challenges. In order to lay a robust groundwork for measurement and monitoring techniques to ensure diagnostic safety, we recently developed a multifaceted framework to advance the science of measuring diagnostic errors (The Safer Dx framework). In this paper, we describe how the framework serves as a conceptual foundation for system-wide safety measurement, monitoring and improvement of diagnostic error. The framework accounts for the complex adaptive sociotechnical system in which diagnosis takes place (the structure), the distributed process dimensions in which diagnoses evolve beyond the doctor's visit (the process) and the outcomes of a correct and timely "safe diagnosis" as well as patient and health care outcomes (the outcomes). We posit that the Safer Dx framework can be used by a variety of stakeholders including researchers, clinicians, health care organizations and policymakers, to stimulate both retrospective and more proactive measurement of diagnostic errors. The feedback and learning that would result will help develop subsequent interventions that lead to safer diagnosis, improved value of health care delivery and improved patient outcomes. C1 [Singh, Hardeep] Michael E DeBakey VA Med Ctr, Houston Vet Affairs Ctr Innovat Qual Effectivenes, Houston, TX USA. [Singh, Hardeep] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [Sittig, Dean F.] Univ Texas Sch Biomed Informat, Houston, TX USA. [Sittig, Dean F.] UT Mem Hermann Ctr Healthcare Qual & Safety, Houston, TX USA. RP Singh, H (reprint author), VA Med Ctr 152,2002 Holcombe Blvd, Houston, TX 77030 USA. EM hardeeps@bcm.edu FU VA Health Services Research and Development Service [CRE 12-033]; VA National Center for Patient Safety; Agency for Health Care Research and Quality [R01HS022087]; Houston VA HSR&D Center for Innovations in Quality, Effectiveness and Safety [CIN 13-413] FX HS is supported by the VA Health Services Research and Development Service (CRE 12-033; Presidential Early Career Award for Scientists and Engineers USA 14-274), the VA National Center for Patient Safety and the Agency for Health Care Research and Quality (R01HS022087). This work is supported in part by the Houston VA HSR&D Center for Innovations in Quality, Effectiveness and Safety (CIN 13-413). HS presented the Safer Dx framework to the Institute of Medicine Diagnostic Error in Health Care Consensus Study Committee on 6 August 2014. NR 59 TC 17 Z9 17 U1 2 U2 12 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-5415 EI 2044-5423 J9 BMJ QUAL SAF JI BMJ Qual. Saf. PD FEB PY 2015 VL 24 IS 2 BP 103 EP 110 DI 10.1136/bmjqs-2014-003675 PG 8 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA AZ4PC UT WOS:000348203800005 PM 25589094 ER PT J AU Gillern, SM Mahmoud, NN Paulson, EC AF Gillern, Suzanne M. Mahmoud, Najjia N. Paulson, E. Carter TI Local Excision for Early Stage Rectal Cancer in Patients Over Age 65 Years: 2000-2009 SO DISEASES OF THE COLON & RECTUM LA English DT Article DE Local excision; Patterns of care; Rectal cancer; Survey of Epidemiology and End Results-Medicare ID LYMPH-NODE METASTASIS; TRANSANAL ENDOSCOPIC MICROSURGERY; LONG-TERM SURVIVAL; COLORECTAL-CANCER; RADICAL SURGERY; T1; CARCINOMA; THERAPY; RISK; ADENOCARCINOMA AB BACKGROUND: Local excision of rectal cancer is an attractive option because it avoids the morbidity of radical resection. Concerns have arisen during the past decade, however, regarding substandard oncologic results. OBJECTIVE: Using the most recent Survey of Epidemiology and End Results-Medicare data, we examined the change in the use of local excision for rectal cancer from 2000 to 2009 and examined patient, surgeon, and hospital factors related to its use. DESIGN: This study is a retrospective cohort study. SETTINGS: This study was conducted at a tertiary care medical center using Survey of Epidemiology and End Results-Medicare data. PATIENTS: Patients with pathologic Tis, T1, or T2 rectal cancer who were >65 years of age and underwent primary radical resection or local excision between 2000 and 2009 were included in this study. MAIN OUTCOME MEASURES: The change in the use of local excision for rectal cancer from 2000 to 2009 was the main outcome measured. RESULTS: A total of 8966 patients were identified. The use of local excision decreased significantly between 2000 and 2009. Women and patients who were older and had more comorbidities were significantly more likely to undergo local excision. Having a colorectal surgeon perform the surgery increased the odds of local excision by 1.5 times (p < 0.001). Similar trends were seen in patients operated on at the National Cancer Institute (OR, 1.7; p < 0.001) and teaching hospitals (OR, 1.2; p = 0.003). Younger surgeons were more likely to perform local excisions. For surgeons graduating in 1980-1989 or 1990 and after, the odds of local excision were 1.40 (p = 0.001) and 2.1 (p < 0.001) compared with surgeons graduating before 1970. LIMITATIONS: The study was limited by the retrospective design, and the data were collected by multiple healthcare officials in their representative institutions. CONCLUSIONS: In patient >65 years of age, the odds of undergoing local excision for early stage rectal cancer decreased significantly between 2000 and 2009, coincident with evidence of oncologic inferiority. However, there was still significant variation in its use. More studies are needed to better understand these variations in an attempt to bring more uniformity to the use of local excision in early stage rectal cancer. C1 [Gillern, Suzanne M.; Mahmoud, Najjia N.; Paulson, E. Carter] Hosp Univ Penn, Dept Gen Surg, Div Colon & Rectal Surg, Philadelphia, PA 19104 USA. [Paulson, E. Carter] Philadelphia VA Med Ctr, Dept Gen Surg, Philadelphia, PA USA. RP Paulson, EC (reprint author), Surg Business Off, 3900 Woodland Ave,PVAMC 5th Floor, Philadelphia, PA 19104 USA. EM paulsone@uphs.upenn.edu FU Thomas B. and Jeannette E. Laws McCabe Fund FX Funding for this research was provided by the Thomas B. and Jeannette E. Laws McCabe Fund. NR 33 TC 3 Z9 4 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0012-3706 EI 1530-0358 J9 DIS COLON RECTUM JI Dis. Colon Rectum PD FEB PY 2015 VL 58 IS 2 BP 172 EP 178 DI 10.1097/DCR.0000000000000279 PG 7 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA AZ4IZ UT WOS:000348186000008 PM 25585074 ER PT J AU Han, SH Mallampalli, RK AF Han, SeungHye Mallampalli, Rama K. TI The Acute Respiratory Distress Syndrome: From Mechanism to Translation SO JOURNAL OF IMMUNOLOGY LA English DT Review ID ACUTE LUNG INJURY; NEUTROPHIL EXTRACELLULAR TRAPS; MESENCHYMAL STEM-CELLS; PATTERN-RECOGNITION RECEPTORS; DIAGNOSED MULTIPLE-MYELOMA; TOLL-LIKE RECEPTORS; MOLECULAR-PATTERNS; MITOCHONDRIAL-DNA; NLRP3 INFLAMMASOME; UBIQUITIN LIGASE AB The acute respiratory distress syndrome (ARDS) is a form of severe hypoxemic respiratory failure that is characterized by inflammatory injury to the alveolar capillary barrier, with extravasation of protein-rich edema fluid into the airspace. Although many modalities to treat ARDS have been investigated over the past several decades, supportive therapies remain the mainstay of treatment. In this article, we briefly review the definition, epidemiology, and pathophysiology of ARDS and present emerging aspects of ARDS pathophysiology that encompass modulators of the innate immune response, damage signals, and aberrant proteolysis that may serve as a foundation for future therapeutic targets. C1 [Han, SeungHye; Mallampalli, Rama K.] Univ Pittsburgh, Dept Med, Acute Lung Injury Ctr Excellence, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15213 USA. [Mallampalli, Rama K.] Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15213 USA. [Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA 15240 USA. RP Mallampalli, RK (reprint author), Univ Pittsburgh, UPMC Montefiore, Dept Med, Div Pulm Allergy & Crit Care Med, NW 628, Pittsburgh, PA 15213 USA. EM mallampallirk@upmc.edu FU National Institutes of Health [R01 HL096376, R01 HL097376, R01 HL098174, R01 HL081784, 1UH2HL123502, P01 HL114453]; U.S. Department of Veterans Affairs FX This work was supported by a Merit Review Award from the U.S. Department of Veterans Affairs and National Institutes of Health Grants R01 HL096376, R01 HL097376, R01 HL098174, R01 HL081784, 1UH2HL123502, and P01 HL114453 (to R.K.M.). This material is based upon work that was supported in part by the Biomedical Laboratory Research and Development, Office of Research and Development, Veterans Health Administration, U.S. Department of Veterans Affairs. NR 89 TC 26 Z9 32 U1 6 U2 25 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD FEB 1 PY 2015 VL 194 IS 3 BP 855 EP 860 DI 10.4049/jimmunol.1402513 PG 6 WC Immunology SC Immunology GA AZ3NK UT WOS:000348134000003 PM 25596299 ER PT J AU Mossanen, M Calvert, JK Holt, SK James, AC Wright, JL Harper, JD Krieger, JN Gore, JL AF Mossanen, Matthew Calvert, Joshua K. Holt, Sarah K. James, Andrew C. Wright, Jonathan L. Harper, Jonathan D. Krieger, John N. Gore, John L. TI Overuse of Antimicrobial Prophylaxis in Community Practice Urology SO JOURNAL OF UROLOGY LA English DT Article DE urologic surgical procedures; antibiotic prophylaxis; physician's practice patterns; drug resistance; bacterial; quality of health care ID CLOSTRIDIUM-DIFFICILE COLITIS; INFECTION-PREVENTION-PROJECT; LENGTH-OF-STAY; SURGERY; MORTALITY; RISK AB Purpose: We examined index urological surgeries to assess utilization patterns of antimicrobial prophylaxis in a large, community based population. Materials and Methods: From the Premier Perspectives Database we identified patients who underwent inpatient urological surgeries that are considered index procedures by the ABU (American Board of Urology), including radical prostatectomy, partial or radical nephrectomy, radical cystectomy, ureteroscopy, shock wave lithotripsy, transurethral resection of the prostate, percutaneous nephrostolithotomy, transvaginal surgery, inflatable penile prosthesis, brachytherapy, transurethral resection of bladder tumor and cystoscopy. Procedures were identified based on ICD-9 procedure codes for 2007 to 2012. Antimicrobial administration, class and duration were abstracted from patient billing data. The class and duration of antimicrobials concordant with the 2008 AUA Best Practice Policy Statement was used to determine compliance. Results: The overall compliance rate was 53%, ranging from 0.6% for radical cystectomy to 97% for shock wave lithotripsy. Antimicrobial use consistent with AUA Best Practices included the appropriate class in 67% of cases (range 34% to 80%) and the recommended duration in 78% (range 1.2% to 98%). Average prophylaxis duration for procedures for which it is recommended ranged from 1.1 days after brachytherapy to 10.3 days after radical cystectomy. The compliance rate increased from 46% overall in 2007 to 59% overall in 2012. Conclusions: We documented considerable variation in antimicrobial prophylaxis for urological surgery. Compliance with AUA Best Practices increased with time but overall rates remain less than 60%. Efforts are needed to better understand the reasons for variation from recommended antimicrobial prophylaxis for common inpatient urological procedures to help decrease resultant complications and improve outcomes. C1 [Mossanen, Matthew] Univ Washington, Dept Urol, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Div Urol, Seattle, WA USA. RP Mossanen, M (reprint author), Univ Washington, Dept Urol, 1959 Northeast Pacific St,BB-1115,Box 356510, Seattle, WA 98195 USA. EM mnmoss@uw.edu FU NIDDK NIH HHS [P01 DK043881] NR 21 TC 10 Z9 10 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 EI 1527-3792 J9 J UROLOGY JI J. Urol. PD FEB PY 2015 VL 193 IS 2 BP 543 EP 547 DI 10.1016/j.juro.2014.08.107 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA AY6YZ UT WOS:000347709800042 PM 25196654 ER PT J AU Swanson, RA AF Swanson, Raymond A. TI Brain glycogen - vestigial no more SO METABOLIC BRAIN DISEASE LA English DT Editorial Material ID IN-VIVO; GLUCOSE DEPRIVATION; ENERGY-METABOLISM; CEREBRAL GLYCOGEN; NEURONAL-ACTIVITY; WHITE-MATTER; ASTROCYTES; NEUROTRANSMITTERS; HYPOGLYCEMIA; STIMULATION C1 [Swanson, Raymond A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Swanson, Raymond A.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Swanson, RA (reprint author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. EM Raymond.Swanson@ucsf.edu NR 24 TC 0 Z9 0 U1 0 U2 4 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0885-7490 EI 1573-7365 J9 METAB BRAIN DIS JI Metab. Brain Dis. PD FEB PY 2015 VL 30 IS 1 BP 251 EP 253 DI 10.1007/s11011-014-9596-2 PG 3 WC Endocrinology & Metabolism; Neurosciences SC Endocrinology & Metabolism; Neurosciences & Neurology GA AZ2GS UT WOS:000348053100032 PM 25060966 ER PT J AU Nassour, I Kautza, B Rubin, M Escobar, D Luciano, J Loughran, P Gomez, H Scott, J Gallo, D Brumfield, J Otterbein, LE Zuckerbraun, BS AF Nassour, Ibrahim Kautza, Benjamin Rubin, Mark Escobar, Daniel Luciano, Jason Loughran, Patricia Gomez, Hernando Scott, Jeffrey Gallo, David Brumfield, John Otterbein, Leo E. Zuckerbraun, Brian S. TI CARBON MONOXIDE PROTECTS AGAINST HEMORRHAGIC SHOCK AND RESUSCITATION-INDUCED MICROCIRCULATORY INJURY AND TISSUE INJURY SO SHOCK LA English DT Article DE Endothelium; carbon monoxide-releasing molecule; sinusoid; adhesion molecule ID HEME OXYGENASE-1; ORGAN FAILURE; P-SELECTIN; EXPRESSION; ACTIVATION; STRESS; APOPTOSIS; ADHESION; LIVER; DYSFUNCTION AB Traumatic injury is a significant cause of morbidity and mortality worldwide. Microcirculatory activation and injury from hemorrhage contribute to organ injury. Many adaptive responses occur within the microcirculatory beds to limit injury including upregulation of heme oxygenase (HO) enzymes, the rate-limiting enzymes in the breakdown of heme to carbon monoxide (CO), iron, and biliverdin. Here we tested the hypothesis that CO abrogates trauma-induced injury and inflammation protecting the microcirculatory beds. Methods: C57Bl/6 mice underwent sham operation or hemorrhagic shock to a mean arterial pressure of 25 mmHg for 120 minutes. Mice were resuscitated with lactated Ringer's at 2x the volume of maximal shed blood. Mice were randomized to receive CO-releasing molecule or inactive CO-releasing molecule at resuscitation. A cohort of mice was pretreated with tin protoporphyrin-IX to inhibit endogenous CO generation by HOs. Primary mouse liver sinusoidal endothelial cells were cultured for in vitro experiments. Results: Carbon monoxide-releasing molecule protected against hemorrhagic shock/resuscitation organ injury and systemic inflammation and reduced hepatic sinusoidal endothelial injury. Inhibition of HO activity with tin protoporphyrin-IX exacerbated liver hepatic sinusoidal injury. Hemorrhagic shock/resuscitation in vivo or cytokine stimulation in vitro resulted in increased endothelial expression of adhesion molecules that was associated with decreased leukocyte adhesion in vivo and in vitro. Conclusions: Hemorrhagic shock/resuscitation is associated with endothelial injury. Heme oxygenase enzymes and CO are involved in part in diminishing this injury and may prove useful as a therapeutic adjunct that can be harnessed to protect against endothelial activation and damage. C1 [Nassour, Ibrahim; Kautza, Benjamin; Rubin, Mark; Escobar, Daniel; Luciano, Jason; Loughran, Patricia; Gomez, Hernando; Brumfield, John; Zuckerbraun, Brian S.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Scott, Jeffrey; Gallo, David; Otterbein, Leo E.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA. [Brumfield, John; Zuckerbraun, Brian S.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Zuckerbraun, BS (reprint author), F1200PUH,200 Lothrop St, Pittsburgh, PA 15213 USA. EM zuckerbraunbs@upmc.edu OI Nassour, Ibrahim/0000-0002-9845-1074 FU National Institutes of Health [R01 GM082830]; Veterans Affairs Merit Award [1I01BX000566]; Department of Defense [DM102439, 5R01GM088666]; CIMIT Center for Integration of Medicine and Innovative Technology FX This work is supported by National Institutes of Health grants R01 GM082830 (B.S.Z.), Veterans Affairs Merit Award 1I01BX000566 (B.S.Z.), and Department of Defense DM102439 (B.S.Z.), 5R01GM088666 (L.E.O.) and CIMIT Center for Integration of Medicine and Innovative Technology (L.E.O.). NR 34 TC 6 Z9 6 U1 2 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1073-2322 EI 1540-0514 J9 SHOCK JI Shock PD FEB PY 2015 VL 43 IS 2 BP 166 EP 171 DI 10.1097/SHK.0000000000000264 PG 6 WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology GA AZ3PS UT WOS:000348139900010 PM 25243427 ER PT J AU Tian, HJ Li, CS Scott, TP Montgomery, SR Phan, K Lao, LF Zhang, W Li, YW Hayashi, T Takahashi, S Alobaidaan, R Ruangchainikom, M Zhao, KW Brochmann, EJ Murray, SS Wang, JC Daubs, MD AF Tian, Haijun Li, Chen-Shuang Scott, Trevor P. Montgomery, Scott R. Phan, Kevin Lao, Lifeng Zhang, Wei Li, Yawei Hayashi, Tetsuo Takahashi, Shinji Alobaidaan, Raed Ruangchainikom, Monchai Zhao, Ke-Wei Brochmann, Elsa J. Murray, Samuel S. Wang, Jeffrey C. Daubs, Michael D. TI Secreted phosphoprotein 24 kD inhibits nerve root inflammation induced by bone morphogenetic protein-2 SO SPINE JOURNAL LA English DT Article DE Secreted phosphoprotein 24 kD; Bone morphogenetic protein-2; Nerve root inflammation; Spine surgery; Posterior lumbar fusion; Complications ID GENE-RELATED PEPTIDE; BINDING PEPTIDE; SENSORY NEURONS; RODENT MODEL; SURGERY; FUSION; ARTHRODESIS; EXPRESSION; RECOVERY; INJURY AB BACKGROUND CONTEXT: Bone morphogenetic protein-2 (BMP-2) has been used to successfully promote spine fusion, but side-effects including nerve inflammation have been observed. PURPOSE: To investigate the direct neurotoxic effects of BMP-2 and test the hypotheses that the use of BMP binding proteins, such as secreted phosphoprotein 24 kD (Spp24), can reduce or eliminate these effects. STUDY DESIGN: In vitro experiments and in vivo analysis in a rodent model. METHODS: In vitro, dorsal root ganglion cells were cultured in the presence of BMP-2 with and without Spp24 and calcitonin gene-related peptide and Substance P, markers of neuroinflammation, were measured by immunohistochemistry. In vivo, rats underwent a left-sided laminotomy at L5 to expose the S1 nerve root and were randomized into four different groups according to the intervention at the laminotomy site: collagen sponge only (no BMP-2 or Spp24), BMP-2 in a collagen sponge only, BMP-2 in a collagen sponge+an empty collagen sponge to act as a barrier, and BMP-2 in a collagen sponge+Spp24 in a collagen sponge to act as a barrier. Functional evaluation was done using the Basso, Beattie, and Bresnahan scale and immunohistochemical analyses were performed using calcitonin gene-related peptide and Substance P staining. RESULTS: The neuroinflammatory effects of BMP-2 in vitro were ameliorated by the addition of Spp24. Similarly, in vivo, Spp24 reduced the expression of markers on neuroinflammation in animals treated with BMP-2 and also improved the function after BMP-2 administration. CONCLUSIONS: These results confirm that BMP binding proteins have great potential as adjuvant therapies to limit BMP-2 related side-effects in spine surgery. (C) 2015 Elsevier Inc. All rights reserved. C1 [Tian, Haijun] Second Mil Med Univ, Shanghai Changzheng Hosp, Dept Orthopaed Surg, Shanghai 200003, Peoples R China. [Tian, Haijun; Scott, Trevor P.; Montgomery, Scott R.; Phan, Kevin; Lao, Lifeng; Zhang, Wei; Li, Yawei; Hayashi, Tetsuo; Takahashi, Shinji; Alobaidaan, Raed; Ruangchainikom, Monchai] Univ Calif Los Angeles, Dept Orthopaed Surg, Los Angeles, CA 90024 USA. [Li, Chen-Shuang] Peking Univ, Sch & Hosp Stomatol, Dept Orthodont, Beijing 100081, Peoples R China. [Zhao, Ke-Wei; Brochmann, Elsa J.; Murray, Samuel S.] VA Greater Los Angeles Healthcare Syst, Res Serv, North Hills, CA 91343 USA. [Brochmann, Elsa J.; Murray, Samuel S.] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, North Hills, CA 91343 USA. [Brochmann, Elsa J.; Murray, Samuel S.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Wang, Jeffrey C.] Univ So Calif, Keck Sch Med, Dept Orthopaed Surg, Los Angeles, CA 90033 USA. [Daubs, Michael D.] Univ Nevada, Sch Med, Dept Surg, Div Orthopaed Surg, Las Vegas, NV 89102 USA. RP Tian, HJ (reprint author), Second Mil Med Univ, Shanghai Changzheng Hosp, Dept Orthopaed Surg, 415 Fengyang Rd, Shanghai 200003, Peoples R China. EM haijuntianmd@gmail.com FU AO Spine; Dept. VA; AO Foundation; Cervical Spine Research Society; AO Spine of North America FX HT: Nothing to disclose. C-SL: Nothing to disclose. TPS: Nothing to disclose. SRM: Nothing to disclose. KP: Nothing to disclose. LL: Nothing to disclose. WZ: Nothing to disclose. YL: Nothing to disclose. TH: Nothing to disclose. ST: Fellowship Support: AO Spine (B). RA: Nothing to disclose. MR: Nothing to disclose. K-WZ: Nothing to disclose. EJB: Grants: Dept. VA (G, Paid directly to institution). SSM: Grants: Dept. VA (F, Paid directly to institution). JCW: Royalties: Stryker (B), Osprey (C), Aesculap (B), Biomet (F), Amedica (D), Seaspine (D), Synthes (C), Alphatech (E); Stock Ownership: Fziomed (2,500 shares, less than 1%), Alphatech (14,619 shares, less than 1%); Private Investments: Promethean Spine (B investment, less than 1% of entity, unknown amount of shares), Paradigm Spine (B investment, less than 1% of entity, unknown amount of shares), Benevenue (C investment, less than 1% of entity, unknown amount of shares), Nexgen (B investment, less than 1% of entity, unknown amount of shares), Pioneer (B investment, less than 1% of entity, unknown amount of shares), Amedica (D investment, less than 1% of entity, unknown amount of shares), Vertiflex (B investment, less than 1% of entity, unknown amount of shares), Electrocore (C investment, less than 1% of entity, unknown amount of shares), Surgitech (C investment, less than 1% of entity, unknown amount of shares), Axiomed (25,000 shares, less than 1% of entity), VG Innovations (5,000 options, less than 1% of entity), Corespine (2,000 options valued at less than 1% of company), Expanding Ortho (33,000 options valued at less than 1% of company), Syndicom (66,125 shares valued at less than 1% of company), Osprey (10 options, less than 1% of company), Amedica (35,416 options, less than 1% of company), Bone Biologics (51,255 shares, less than 1% of company), Curative Biosciences (1,875 options, less than 1% of company), Pearldriver (25,000 options, less than 1% of company); Board of Directors: NASS (nonfinancial, reimbursement for travel for board meetings), CSRS (nonfinancial, reimbursement for travel for board meetings), AO Foundation (E, combined for honorariums for educational activities and reimbursements for international travel for this nonprofit foundation, which requires me to travel internationally on multiple trips and allows for business class travel on international trips), Collaborative Spine Research Foundation (nonfinancial, reimbursement for travel for board meetings); Fellowship Support: AO Foundation (E, Paid directly to institution). MDD: Grant: Cervical Spine Research Society (C, Paid directly to institution); Royalties: Depuy-Synthes Spine (F); Consulting: Depuy-Synthes Spine (B); Fellowship Support: AO Spine of North America (E, Paid directly to institution). NR 25 TC 3 Z9 3 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1529-9430 EI 1878-1632 J9 SPINE J JI Spine Journal PD FEB 1 PY 2015 VL 15 IS 2 BP 314 EP 321 DI 10.1016/j.spinee.2014.09.021 PG 8 WC Clinical Neurology; Orthopedics SC Neurosciences & Neurology; Orthopedics GA AZ2DX UT WOS:000348045900019 PM 25264179 ER PT J AU Zhu, WB Casper, A Libal, NL Murphy, SJ Bodhankar, S Offner, H Alkayed, NJ AF Zhu, Wenbin Casper, Amanda Libal, Nicole L. Murphy, Stephanie J. Bodhankar, Sheetal Offner, Halina Alkayed, Nabil J. TI Preclinical Evaluation of Recombinant T Cell Receptor Ligand RTL1000 as a Therapeutic Agent in Ischemic Stroke SO TRANSLATIONAL STROKE RESEARCH LA English DT Article DE Ischemic stroke; Neurobehavioral evaluation; Immunotherapy; Recombinant T cell receptor ligand; HLA-DR2 transgenic mice ID CLASS-II CONSTRUCTS; FUNCTIONAL RECOVERY; MICE; ACTIVATION; MYELIN; RECOMMENDATIONS; INFLAMMATION; LYMPHOCYTES; TOLERANCE; SEVERITY AB Recombinant T cell Receptor Ligand 1000 (RTL1000), a partial human major histocompatibility complex (MHC) molecule coupled to a human myelin peptide, reduces infarct size after experimental stroke in HLA-DRB1*1502 transgenic (DR2-Tg) mice. In this study, we characterized the therapeutic time window of opportunity for RTL1000; we explored the efficacy of a single dose of RTL1000 administration and determined if RTL1000 affords long-term neurobehavioral functional improvement after ischemic stroke. Male DR2-Tg mice underwent 60 min of intraluminal reversible middle cerebral artery occlusion (MCAO). RTL1000 or vehicle was injected 4, 6, or 8 h after MCAO, followed by three daily injections. In the single-dose study, one-time injection of RTL1000 was applied 4 h after MCAO. Cortical, striatal, and hemispheric infarct sizes were measured 24 or 96 h after stroke. Behavioral testing, including neuroscore evaluation, open field, paw preference, and novel object recognition, was performed up to 28 days after stroke. Our data showed that RTL1000 significantly reduced the infarct size 96 h after MCAO when the first injection was given at 4 and 6 h, but not 8 h, after the onset of stroke. A single dose of 400 or 100 mu g RTL1000 also significantly reduced the infarct size 24 h after MCAO. Behavioral testing showed that RTL1000 treatment used 4 h after MCAO improved long-term cognitive outcome 28 days after stroke. Taken together, RTL1000 protects against acute injury if applied within a 6-h time window and improves long-term functional recovery after experimental stroke in DR2-Tg mice. C1 [Zhu, Wenbin; Casper, Amanda; Libal, Nicole L.; Murphy, Stephanie J.; Offner, Halina; Alkayed, Nabil J.] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97239 USA. [Bodhankar, Sheetal; Offner, Halina; Alkayed, Nabil J.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Murphy, Stephanie J.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. [Alkayed, Nabil J.] Oregon Hlth & Sci Univ, Knight Cardiovasc Inst, Portland, OR 97239 USA. [Bodhankar, Sheetal; Offner, Halina] Portland VA Med Ctr, Portland, OR 97239 USA. RP Alkayed, NJ (reprint author), Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97239 USA. EM alkayedn@ohsu.edu FU NIH [NS076013]; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development FX This work was supported by NIH Grants #NS076013 (STTR) and by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. NR 32 TC 10 Z9 10 U1 1 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1868-4483 EI 1868-601X J9 TRANSL STROKE RES JI Transl. Stroke Res. PD FEB PY 2015 VL 6 IS 1 BP 60 EP 68 DI 10.1007/s12975-014-0373-7 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA AZ3IT UT WOS:000348121500008 PM 25270354 ER PT J AU Malte, CA Dennis, PA Saxon, AJ McFall, M Carmody, TP Unger, W Beckham, JC AF Malte, Carol A. Dennis, Paul A. Saxon, Andrew J. McFall, Miles Carmody, Timothy P. Unger, William Beckham, Jean C. TI Tobacco use trajectories among a large cohort of treated smokers with posttraumatic stress disorder SO ADDICTIVE BEHAVIORS LA English DT Article DE Smoking cessation; Posttraumatic stress disorder; Veterans; Major depressive disorder; Relapse ID MENTAL-HEALTH-CARE; SMOKING-CESSATION; NICOTINE DEPENDENCE; GENERAL-POPULATION; CIGARETTE-SMOKING; MAJOR DEPRESSION; ELECTRONIC DIARY; FOLLOW-UP; RELAPSE; ABSTINENCE AB Introduction: This study identified distinct tobacco use trajectories across 18 months in 943 veteran smokers with posttraumatic stress disorder (PTSD) in order to describe quit and relapse patterns, examine associations between trajectory groups on baseline characteristics and cessation service utilization, and explore group differences in mental health outcomes. Methods: Veterans who participated in a muldsite, randomized trial of integrated smoking cessation care were grouped using k-means clustering based on reported daily tobacco use between baseline and 18 months. Four trajectory clusters were identified: no reduction (62%), temporary reduction (11%), late sustained reduction (9%) and early sustained reduction (18%). Results: Median quit times in the early, late, temporary, and no reduction groups were 451, 141.5, 97, and 2 days, respectively. Compared to the early reduction group, the temporary reduction group exhibited higher baseline depression (p < 0.01) and anxiety (p < 0.01), but did not differ in treatment received, with both groups attending significantly more cessation visits (p < 0.001) and more likely to receive recommended pharmacotherapy (p < 0.001) than the no reduction group-between baseline and 6 months. The early reduction group exhibited lower depression relative to the no reduction (p < 0.01) and temporary reduction (p < 0.01) groups across all assessments between baseline and 18 months. Differences were not observed between groups in depressive or PTSD symptom change over time between baseline and 18 months. Conclusions: Tobacco use trajectories among treated smokers with PTSD vary distinctly. Characteristics of identified subgroups may lead to targeted interventions among smokers with PTSD and potentially other psychiatric disorders. Published by Elsevier Ltd. C1 [Malte, Carol A.; Saxon, Andrew J.; McFall, Miles] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Dennis, Paul A.] Durham Vet Affairs Med Ctr, Res & Dev Serv, Durham, NC USA. [Saxon, Andrew J.; McFall, Miles] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Carmody, Timothy P.] Vet Affairs Med Ctr, San Francisco, CA 94121 USA. [Carmody, Timothy P.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Unger, William] Providence Vet Affairs Med Ctr, Providence, RI USA. [Beckham, Jean C.] Vet Affairs Mid Atlantic Reg Mental Illness Res E, Durham, NC USA. [Beckham, Jean C.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA. RP Malte, CA (reprint author), VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, 1660 S Columbian Way,S-116 ATC, Seattle, WA 98108 USA. EM Carol.Malte@va.gov FU U.S. Department of Veterans Affairs, Office of Research and Development Cooperative Studies Program (CSP) [519]; Veterans Affairs Puget Sound Center of Excellence in Substance Abuse Treatment and Education; U.S. Department of Veterans Affairs, Office of Clinical Research and Development; Veterans Affairs Mid-Atlantic Mental Illness Research, Education, and Clinical Center FX This material is based upon work supported by the U.S. Department of Veterans Affairs, Office of Research and Development Cooperative Studies Program (CSP #519). The Veterans Affairs Puget Sound Center of Excellence in Substance Abuse Treatment and Education, the U.S. Department of Veterans Affairs, Office of Clinical Research and Development, and the Veterans Affairs Mid-Atlantic Mental Illness Research, Education, and Clinical Center provided additional support. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the U.S. Department of Veterans Affairs. NR 37 TC 2 Z9 2 U1 4 U2 11 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4603 EI 1873-6327 J9 ADDICT BEHAV JI Addict. Behav. PD FEB PY 2015 VL 41 BP 238 EP 246 DI 10.1016/j.addbeh.2014.10.034 PG 9 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA AY3PZ UT WOS:000347496500037 PM 25452071 ER PT J AU Gottlieb, LM Tirozzi, KJ Manchanda, R Burns, AR Sandel, MT AF Gottlieb, Laura M. Tirozzi, Karen J. Manchanda, Rishi Burns, Abby R. Sandel, Megan T. TI Moving Electronic Medical Records Upstream Incorporating Social Determinants of Health SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID NUTRITION EXAMINATION SURVEY; HOUSEHOLD FOOD INSECURITY; NATIONAL-HEALTH; CHILDREN; BEHAVIOR; ADOLESCENTS; ADULTHOOD; SECURITY; RISKS AB Background: Knowledge of the biological pathways and mechanisms connecting social factors with health has increased exponentially over the past 25 years, yet in most clinical settings, screening and intervention around social determinants of health are not part of standard clinical care. Electronic medical records provide new opportunities for assessing and managing social needs in clinical settings, particularly those serving vulnerable populations. Purpose: To illustrate the feasibility of capturing information and promoting interventions related to social determinants of health in electronic medical records. Methods: Three case studies were examined in which electronic medical records have been used to collect data and address social determinants of health in clinical settings. Results: From these case studies, we identified multiple functions that electronic medical records can perform to facilitate the integration of social determinants of health into clinical systems, including screening, triaging, referring, tracking, and data sharing. Conclusions: If barriers related to incentives, training, and privacy can be overcome, electronic medical record systems can improve the integration of social determinants of health into health care delivery systems. More evidence is needed to evaluate the impact of such integration on health care outcomes before widespread adoption can be recommended. (C) 2015 American Journal of Preventive Medicine C1 [Gottlieb, Laura M.] Univ Calif San Francisco, Sch Med, Dept Family & Community Med, San Francisco, CA 94118 USA. [Burns, Abby R.] Univ Calif Berkeley, Sch Social Welf, Berkeley, CA 94720 USA. [Manchanda, Rishi] HealthBegins, Los Angeles, CA USA. [Manchanda, Rishi] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Tirozzi, Karen J.] Hlth Leads, Res & Dev, Boston, MA USA. [Sandel, Megan T.] George Washington Univ, Sch Publ Hlth & Hlth Serv, Dept Hlth Policy, Natl Ctr Med Legal Partnership, Washington, DC USA. RP Gottlieb, LM (reprint author), Univ Calif San Francisco, Sch Med, 3333 Calif St,Suite 465, San Francisco, CA 94118 USA. EM gottliebl@chc.ucsf.edu FU Lisa and John Pritzker Family Fund; Kresge Foundation; Robert Wood Johnson Foundation FX Laura Gottlieb's work on this project was supported by the Lisa and John Pritzker Family Fund. The funding agency played no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript. Gottlieb is employed by the University of California, San Francisco and is Co-Founder of HealthBegins.; Megan Sandel's work on this project was supported by the Kresge and Robert Wood Johnson Foundations. Neither funding agency played a role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript. Sandel is also Medical Director of the National Center for Medical-Legal Partnership. NR 26 TC 16 Z9 16 U1 2 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD FEB PY 2015 VL 48 IS 2 BP 215 EP 218 DI 10.1016/j.amepre.2014.07.009 PG 4 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA AZ2YY UT WOS:000348096300015 PM 25217095 ER PT J AU Evans, AT Loeb, KR Shulman, HM Hassan, S Qiu, WC Hockenbery, DM Ioannou, GN Chauncey, TR Gretch, DR McDonald, GB AF Evans, Ashley T. Loeb, Keith R. Shulman, Howard M. Hassan, Sajida Qiu, Wan Chong Hockenbery, David M. Ioannou, George N. Chauncey, Thomas R. Gretch, David R. McDonald, George B. TI Fibrosing Cholestatic Hepatitis C After Hematopoietic Cell Transplantation Report of 3 Fatal Cases SO AMERICAN JOURNAL OF SURGICAL PATHOLOGY LA English DT Article DE hepatitis C virus; fibrosing cholestatic hepatitis; hematopoietic cell transplantation; liver disease; mycophenolate mofetil; in situ hybridization ID BONE-MARROW-TRANSPLANTATION; MYCOPHENOLATE-MOFETIL; VIRUS-INFECTION; LIVER-TRANSPLANTATION; BILIARY OBSTRUCTION; PREVENTION; RECIPIENTS; DISEASE; COMPLICATIONS; TRANSMISSION AB Development of liver disease after hematopoietic cell transplantation is common and the causes diverse. Infection by hepatitis C virus (HCV) can be seen in patients who are chronically infected before transplant or from passage of virus from an infected donor; the normal 10-year course of hepatitis C after transplant is one of waxing and waning of serum aminotransferase enzymes, with little morbidity. In the series of 3 patients reported here, the course of hepatitis C was rapidly fatal, with the onset of jaundice at day 60 to 80 after transplant and liver histology typical of fibrosing cholestatic hepatitis (marked bile ductular proliferation, ballooned hepatocytes, and associated collagenous fibrosis centered around ductules). The bile ductular reaction pattern varied from elongated structures without a recognizable lumen to a pattern of cuboidal cells with a clear lumen. There was significant cholestasis with bile within hepatocytes and canalicular bile plugs. In situ HCV RNA hybridization studies from 1 patient showed a robust infection with high levels of HCV-infected hepatocytes and active viral replication. All 3 patients were on immunosuppressive drugs after transplant, including mycophenolate mofetil (MMF), which irreversibly inhibits inosine monophosphate dehydrogenase, on which T and B lymphocytes are dependent. We speculate that fatal fibrosing cholestatic hepatitis C in these cases was related to the immunosuppressive effects of MMF, as we had not recognized this presentation of HCV infection before the introduction of MMF. C1 [Evans, Ashley T.; Hockenbery, David M.; Ioannou, George N.; Chauncey, Thomas R.; McDonald, George B.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Loeb, Keith R.; Shulman, Howard M.] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA. [Qiu, Wan Chong; Gretch, David R.] Univ Washington, Sch Med, Dept Lab Med, Seattle, WA 98195 USA. [Loeb, Keith R.; Shulman, Howard M.; Hassan, Sajida; Hockenbery, David M.; McDonald, George B.] Fred Hutchinson Canc Res Ctr, Clin Res Div, Seattle, WA 98104 USA. [Ioannou, George N.; Chauncey, Thomas R.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP McDonald, GB (reprint author), Fred Hutchinson Canc Res Ctr, Gastroenterol Hepatol Sect D5 114, 1100 Fairview Ave North, Seattle, WA 98109 USA. EM gmcdonal@fhcrc.org NR 38 TC 6 Z9 6 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0147-5185 EI 1532-0979 J9 AM J SURG PATHOL JI Am. J. Surg. Pathol. PD FEB PY 2015 VL 39 IS 2 BP 212 EP 220 PG 9 WC Pathology; Surgery SC Pathology; Surgery GA AZ0SP UT WOS:000347955200008 PM 25517948 ER PT J AU Lawson, EH Zingmond, DS Hall, BL Louie, R Brook, RH Ko, CY AF Lawson, Elise H. Zingmond, David S. Hall, Bruce Lee Louie, Rachel Brook, Robert H. Ko, Clifford Y. TI Comparison Between Clinical Registry and Medicare Claims Data on the Classification of Hospital Quality of Surgical Care SO ANNALS OF SURGERY LA English DT Article DE surgery; quality measurement; clinical registry; administrative claims ID POSTOPERATIVE ADVERSE EVENTS; IMPROVEMENT PROGRAM; ADMINISTRATIVE DATA; RISK ADJUSTMENT; HEALTH-CARE; NSQIP; ASSOCIATION; MORTALITY; OUTCOMES; VOLUME AB Objective: To compare the classification of hospital statistical outlier status as better or worse performance than expected for postoperative complications using Medicare claims versus clinical registry data. Background: Controversy remains as to the most favorable data source for measuring postoperative complications for pay-for-performance and public reporting polices. Methods: Patient-level records (2005-2008) were linked between the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) and Medicare inpatient claims. Hospital statistical outlier status for better or worse performance than expected was assessed using each data source for superficial surgical site infection (SSI), deep/organ-space SSI, any SSI, urinary tract infection, pneumonia, sepsis, deep venous thrombosis, pulmonary embolism, venous thromboembolism, and myocardial infarction by developing hierarchical multivariable logistic regression models. Kappa statistics and correlation coefficients assessed agreement between the data sources. Results: A total of 192 hospitals with 110,987 surgical patients were included. Agreement on hospital rank for complication rates between Medicare claims and ACS-NSQIP was poor-to-moderate (weighted kappa: 0.18-0.48). Of hospitals identified as statistical outliers for better or worse performance by Medicare claims, 26% were also identified as outliers by ACS-NSQIP. Of outliers identified by ACS-NSQIP, 16% were also identified as outliers by Medicare claims. Agreement between the data sources on hospital outlier status classification was uniformly poor (weighted kappa: -0.02-0.34). Conclusions: Despite using the same statistical methodology with each data source, classification of hospital outlier status as better or worse performance than expected for postoperative complications differed substantially between ACS-NSQIP and Medicare claims. C1 [Lawson, Elise H.; Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Lawson, Elise H.; Hall, Bruce Lee; Ko, Clifford Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL USA. [Lawson, Elise H.; Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Zingmond, David S.; Louie, Rachel; Brook, Robert H.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Hall, Bruce Lee] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA. [Hall, Bruce Lee] Barnes Jewish Hosp, St Louis, MO 63110 USA. [Hall, Bruce Lee] Washington Univ, Ctr Hlth Policy, St Louis, MO USA. [Hall, Bruce Lee] Washington Univ, Olin Business Sch, St Louis, MO USA. [Hall, Bruce Lee] John Cochran Vet Affairs Med Ctr, Dept Surg, St Louis, MO USA. [Brook, Robert H.] RAND Corp, Santa Monica, CA USA. [Brook, Robert H.] UCLA Jonathan & Karin Fielding Sch Publ Hlth, Los Angeles, CA USA. RP Lawson, EH (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, 10833 Le Conte Ave,72-215 CHS, Los Angeles, CA 90095 USA. EM elawson@mednet.ucla.edu FU VA Health Services Research and Development program [RWJ 65-020]; American College of Surgeons through the Robert Wood Johnson Foundation Clinical Scholars Program; Centers for Medicare and Medicaid Services (CMS) FX E.H.L.'s time was supported by the VA Health Services Research and Development program (RWJ 65-020) and the American College of Surgeons through the Robert Wood Johnson Foundation Clinical Scholars Program. This study was funded by a contract from the Centers for Medicare and Medicaid Services (CMS). The remaining authors have nothing to declare. NR 26 TC 7 Z9 7 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-4932 EI 1528-1140 J9 ANN SURG JI Ann. Surg. PD FEB PY 2015 VL 261 IS 2 BP 290 EP 296 DI 10.1097/SLA.0000000000000707 PG 7 WC Surgery SC Surgery GA AY8AP UT WOS:000347777100038 PM 25569029 ER PT J AU Smith, JA Stallons, LJ Collier, JB Chavin, KD Schnellmann, RG AF Smith, Joshua A. Stallons, L. Jay Collier, Justin B. Chavin, Kenneth D. Schnellmann, Rick G. TI Suppression of Mitochondrial Biogenesis through Toll-Like Receptor 4-Dependent Mitogen-Activated Protein Kinase Kinase/Extracellular Signal-Regulated Kinase Signaling in Endotoxin-Induced Acute Kidney Injury SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS LA English DT Article ID ACUTE-RENAL-FAILURE; PERITUBULAR CAPILLARY DYSFUNCTION; ISCHEMIA-REPERFUSION INJURY; CRITICALLY-ILL PATIENTS; MEK1/2 INHIBITOR; TNF-ALPHA; SEPSIS; CELLS; LPS; INFLAMMATION AB Although disruption of mitochondrial homeostasis and biogenesis (MB) is a widely accepted pathophysiologic feature of sepsis-induced acute kidney injury (AKI), the molecular mechanisms responsible for this phenomenon are unknown. In this study, we examined the signaling pathways responsible for the suppression of MB in a mouse model of lipopolysaccharide (LPS)-induced AKI. Downregulation of peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1 alpha), a master regulator of MB, was noted at the mRNA level at 3 hours and protein level at 18 hours in the renal cortex, and was associated with loss of renal function after LPS treatment. LPS-mediated suppression of PGC-1 alpha led to reduced expression of downstream regulators of MB and electron transport chain proteins along with a reduction in renal cortical mitochondrial DNA content. Mechanistically, Toll-like receptor 4 (TLR4) knockout mice were protected from renal injury and disruption of MB after LPS exposure. Immunoblot analysis revealed activation of tumor progression locus 2/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (TPL-2/MEK/ERK) signaling in the renal cortex by LPS. Pharmacologic inhibition of MEK/ERK signaling attenuated renal dysfunction and loss of PGC-1 alpha, and was associated with a reduction in proinflammatory cytokine (e.g., tumor necrosis factor-alpha [TNF-alpha], interleukin-1 beta) expression at 3 hours after LPS exposure. Neutralization of TNF-alpha also blocked PGC-1 alpha suppression, but not renal dysfunction, after LPS-induced AKI. Finally, systemic administration of recombinant tumor necrosis factor-alpha alone was sufficient to produce AKI and disrupt mitochondrial homeostasis. These findings indicate an important role for the TLR4/MEK/ERK pathway in both LPS-induced renal dysfunction and suppression of MB. TLR4/MEK/ERK/TNF-alpha signaling may represent a novel therapeutic target to prevent mitochondrial dysfunction and AKI produced by sepsis. C1 [Smith, Joshua A.; Stallons, L. Jay; Collier, Justin B.; Schnellmann, Rick G.] Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA. [Chavin, Kenneth D.] Med Univ S Carolina, Div Transplant Surg, Dept Surg, Charleston, SC 29425 USA. [Schnellmann, Rick G.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. RP Schnellmann, RG (reprint author), Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, 280 Calhoun St,MSC140, Charleston, SC 29425 USA. EM schnell@musc.edu FU National Institutes of Health National Institute of General Medical Sciences [GM084147, P20-GM103542-02]; National Institutes of Health National Center for Research Resources [UL1-RR029882, C06-RR015455]; Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs [5I01 BX-000851]; South Carolina Clinical and Translational Research Institute at the Medical University of South Carolina FX This work was supported in part by the National Institutes of Health National Institute of General Medical Sciences [Grants GM084147 (to R.G.S.) and P20-GM103542-02 (to South Carolina COBRE in Oxidants, Redox Balance, and Stress Signaling]; the National Institutes of Health National Center for Research Resources [Grant UL1-RR029882]; the Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs [Grant 5I01 BX-000851 (to R.G.S.)]; and the South Carolina Clinical and Translational Research Institute at the Medical University of South Carolina. Animal facilities were funded by the National Institutes of Health National Center for Research Resources [Grant C06-RR015455]. NR 59 TC 11 Z9 11 U1 0 U2 5 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA SN 0022-3565 EI 1521-0103 J9 J PHARMACOL EXP THER JI J. Pharmacol. Exp. Ther. PD FEB PY 2015 VL 352 IS 2 BP 346 EP 357 DI 10.1124/jpet.114.221085 PG 12 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA AY8RY UT WOS:000347822200018 PM 25503387 ER PT J AU Codella, J Safdar, N Heffernan, R Alagoz, O AF Codella, James Safdar, Nasia Heffernan, Rick Alagoz, Oguzhan TI An Agent-based Simulation Model for Clostridium difficile Infection Control SO MEDICAL DECISION MAKING LA English DT Article DE Clostridium difficile; simulation methods; agent-based simulation; infectious disease control; hospital-acquired infections ID PSEUDOMEMBRANOUS COLITIS; ORAL VANCOMYCIN; ENVIRONMENTAL SURFACES; HOSPITALIZED-PATIENTS; REDUCE TRANSMISSION; RISK-FACTORS; DISEASE; DIARRHEA; CONTAMINATION; MORTALITY AB Background. Control of Clostridium difficile infection (CDI) is an increasingly difficult problem for health care institutions. There are commonly recommended strategies to combat CDI transmission, such as oral vancomycin for CDI treatment, increased hand hygiene with soap and water for health care workers, daily environmental disinfection of infected patient rooms, and contact isolation of diseased patients. However, the efficacy of these strategies, particularly for endemic CDI, has not been well studied. The objective of this research is to develop a valid, agent-based simulation model (ABM) to study C. difficile transmission and control in a midsized hospital. Methods. We develop an ABM of a midsized hospital with agents such as patients, health care workers, and visitors. We model the natural progression of CDI in a patient using a Markov chain and the transmission of CDI through agent and environmental interactions. We derive input parameters from aggregate patient data from the 2007-2010 Wisconsin Hospital Association and published medical literature. We define a calibration process, which we use to estimate transition probabilities of the Markov model by comparing simulation results to benchmark values found in published literature. Results. In a comparison of CDI control strategies implemented individually, routine bleach disinfection of CDI-positive patient rooms provides the largest reduction in nosocomial asymptomatic colonization (21.8%) and nosocomial CDIs (42.8%). Additionally, vancomycin treatment provides the largest reduction in relapse CDIs (41.9%), CDI-related mortalities (68.5%), and total patient length of stay (21.6%). Conclusion. We develop a generalized ABM for CDI control that can be customized and further expanded to specific institutions and/or scenarios. Additionally, we estimate transition probabilities for a Markov model of natural CDI progression in a patient through calibration. C1 [Codella, James; Alagoz, Oguzhan] Univ Wisconsin, Dept Ind & Syst Engn, Madison, WI 53706 USA. [Heffernan, Rick] Bur Communicable Dis & Emergency Response, Wisconsin Div Publ Hlth, Madison, WI USA. [Safdar, Nasia] Univ Wisconsin Hosp & Clin, Dept Med, Madison, WI 53792 USA. [Safdar, Nasia] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Alagoz, O (reprint author), Univ Wisconsin, Dept Ind & Syst Engn, 3242 Mech Engn Bldg,1513 Univ Ave, Madison, WI 53706 USA. EM alagoz@engr.wisc.edu FU CTSA program of NCRR NIH [2UL1TR000427]; National Science Foundation, Division of Civil, Mechanical and Manufacturing Innovation [CMMI-0844423]; VA MERIT award FX Supported through grant 2UL1TR000427 from the CTSA program of NCRR NIH and grant CMMI-0844423 from the National Science Foundation, Division of Civil, Mechanical and Manufacturing Innovation. Nasia Safdar is supported by a VA MERIT award. Revision accepted for publication 18 June 2014. NR 55 TC 3 Z9 3 U1 1 U2 14 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0272-989X EI 1552-681X J9 MED DECIS MAKING JI Med. Decis. Mak. PD FEB PY 2015 VL 35 IS 2 BP 211 EP 229 DI 10.1177/0272989X14545788 PG 19 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA AZ2HF UT WOS:000348054300011 PM 25112595 ER PT J AU Beste, LA Green, PK Ioannou, GN AF Beste, Lauren A. Green, Pamela K. Ioannou, George N. TI Boceprevir and telaprevir-based regimens for the treatment of hepatitis C virus in HIV/HCV coinfected patients SO EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY LA English DT Article DE hepatitis C virus; hepatitis C virus; HIV; protease inhibitor; veterans ID HUMAN-IMMUNODEFICIENCY-VIRUS; TREATMENT-NAIVE PATIENTS; ALPHA-2A PLUS RIBAVIRIN; HEPATOCELLULAR-CARCINOMA; PEGINTERFERON ALPHA-2A; PHASE-2 TRIAL; VIROLOGICAL RESPONSE; INTERFERON ALPHA-2A; HIV COINFECTION; TRIPLE THERAPY AB Background and aim Hepatitis C virus (HCV) treatment in patients coinfected with HIV has historically been limited by poor efficacy and medication toxicities. Direct-acting antivirals (e.g. boceprevir and telaprevir) improve treatment results in clinical trials, but little is known about the outcomes in community-based coinfected populations. This project aimed to describe the real-world effectiveness of boceprevir-based or telaprevir-based therapies in HIV/HCV coinfected patients. Materials and methods We identified HIV/HCV coinfected patients of all genotypes in the Veterans Affairs healthcare system who initiated pegylated interferon and ribavirin with or without boceprevir or telaprevir from June 2011 to November 2012 (n = 134). Results Sustained virologic response (SVR) was higher in genotype 1 patients receiving boceprevir or telaprevir [ n = 62, SVR = 50.0%, 95% confidence interval (CI) 37-63] versus pegylated interferon/ribavirin alone (n = 48, SVR = 33.3%, 95% CI 20-47). Patients with genotypes 2/3 treated with pegylated interferon/ribavirin (n = 24) achieved an SVR of 41.7% (95% CI 20-63). Only a few patients (15-25%) of each genotype completed more than 44 of 48 projected weeks. Treatment with boceprevir or telaprevir was the only characteristic independently associated with SVR in genotype 1 (adjusted odds ratio 2.2, 95% CI 1.1-4.7). Conclusion Addition of boceprevir or telaprevir to pegylated interferon/ribavirin improves treatment response in genotype 1 HIV/HCV coinfected patients. Treatment response is similar to reports from HCV monoinfected Veterans Affairs patients but lower than those reported in clinical trials. Early treatment discontinuation was common. (C) 2015 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins. C1 [Beste, Lauren A.] Vet Affairs Puget Sound Hlth Care Syst, Primary Care Serv, Seattle, WA 98108 USA. [Beste, Lauren A.; Green, Pamela K.] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98108 USA. [Beste, Lauren A.] Univ Washington, Dept Internal Med, Div Gen Internal Med, Seattle, WA 98195 USA. [Ioannou, George N.] Univ Washington, Dept Internal Med, Div Gastroenterol, Seattle, WA 98195 USA. [Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Gastroenterol Sect, Seattle, WA 98108 USA. RP Beste, LA (reprint author), Vet Affairs Puget Sound Hlth Care Syst, 1660 S Columbian Way,S-111-GI, Seattle, WA 98108 USA. EM lauren.beste@va.gov FU VA Puget Sound Health Care System (Seattle, Washington); Clinical Science Research and Development, Office of Research and Development, Veterans Affairs [I01CX000320] FX This material is the result of work supported by resources from the VA Puget Sound Health Care System (Seattle, Washington). The study was funded by a Merit Review grant (I01CX000320), Clinical Science Research and Development, Office of Research and Development, Veterans Affairs (GNI). NR 23 TC 4 Z9 4 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0954-691X EI 1473-5687 J9 EUR J GASTROEN HEPAT JI Eur. J. Gastroenterol. Hepatol. PD FEB PY 2015 VL 27 IS 2 BP 123 EP 129 DI 10.1097/MEG.0000000000000241 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AX9UZ UT WOS:000347248700002 PM 25503739 ER PT J AU Rosendorff, C AF Rosendorff, Clive TI Diuretics and potassium SO JOURNAL OF HYPERTENSION LA English DT Letter C1 [Rosendorff, Clive] Icahn Sch Med Mt Sinai, Mt Sinai Heart, Bronx, NY USA. [Rosendorff, Clive] Icahn Sch Med Mt Sinai, Dept Med, Bronx, NY USA. [Rosendorff, Clive] James J Peters VA Med Ctr, Bronx, NY 10468 USA. RP Rosendorff, C (reprint author), James J Peters VA Med Ctr, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM clive.rosendorff@va.gov NR 4 TC 1 Z9 1 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0263-6352 EI 1473-5598 J9 J HYPERTENS JI J. Hypertens. PD FEB PY 2015 VL 33 IS 2 BP 421 EP 422 DI 10.1097/HJH.0000000000000457 PG 2 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA AY2CM UT WOS:000347396100030 PM 25535881 ER PT J AU Lee, RJ Cohen, NA AF Lee, Robert J. Cohen, Noam A. TI Role of the bitter taste receptor T2R38 in upper respiratory infection and chronic rhinosinusitis SO CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Review DE acyl-homoserine lactone; bacterial infection; host-pathogen interactions; interkingdom signaling; nitric oxide ID SOLITARY CHEMOSENSORY CELLS; QUORUM-SENSING MOLECULES; NITRIC-OXIDE; PSEUDOMONAS-AERUGINOSA; BRUSH CELLS; ANTIMICROBIAL ACTIVITY; CYSTIC-FIBROSIS; AIRWAY; PERCEPTION; EXPRESSION AB Purpose of review Taste receptor family 2 (T2R) bitter taste receptors were originally identified and named on the basis of their role in type 2 taste cells of the tongue, in which they serve to detect the presence of potentially harmful ingested chemicals. In 2009, researchers demonstrated that airway epithelial cells also express T2R receptors, but their role in airway physiology and human disease has only recently begun to be identified. Recent findings Recent research has demonstrated that at least one airway T2R receptor, taste receptor family 2 isoform 38 protein (T2R38) is activated by secreted bacterial products. Activation of T2R38 in sinonasal epithelial cells stimulates nitric oxide production, increasing ciliary beating and directly killing bacteria. Clinical studies have also found correlations of TAS2R38 genotype with susceptibility to gram-negative upper respiratory infection and established T2R38 as an independent risk factor for chronic rhinosinusitis requiring sinus surgery. Summary These recent studies identify a role for T2R38 in sinonasal innate immunity and chronic rhinosinusitis. Clinical implications include the potential development of T2R38-directed topical therapies, as well as using taste testing and/or genotyping to predict susceptibility to infection. Further studies are needed to more clearly determine how TAS2R38 genotype affects patient outcomes in chronic rhinosinusitis and other upper airway diseases. C1 [Lee, Robert J.; Cohen, Noam A.] Univ Penn, Perelman Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA. [Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Surg Serv, Philadelphia, PA USA. RP Cohen, NA (reprint author), Univ Penn, Perelman Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Div Rhinol, Hosp Univ Penn Ravdin Bldg,5th Floor,3400 Spruce, Philadelphia, PA 19104 USA. EM noam.cohen@uphs.upenn.edu OI Cohen, Noam/0000-0002-9462-3932; Lee, Robert/0000-0001-5826-6686 FU Flight Attendants Medical Research Institute [082478] FX Some of the research described here was supported by a grant from the Flight Attendants Medical Research Institute (082478) and a philanthropic contribution from the RLG Foundation, Inc., both to N.A.C. NR 77 TC 13 Z9 14 U1 9 U2 35 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1528-4050 EI 1473-6322 J9 CURR OPIN ALLERGY CL JI Curr. Opin. Allergy Clin. Immunol. PD FEB PY 2015 VL 15 IS 1 BP 14 EP 20 DI 10.1097/ACI.0000000000000120 PG 7 WC Allergy; Immunology SC Allergy; Immunology GA AX9ZX UT WOS:000347258500002 PM 25304231 ER PT J AU Denny, BT Fan, J Liu, X Ochsner, KN Guerreri, S Mayson, SJ Rimsky, L McMaster, A New, AS Goodman, M Siever, LJ Koenigsberg, HW AF Denny, Bryan T. Fan, Jin Liu, Xun Ochsner, Kevin N. Guerreri, Stephanie Mayson, Sarah Jo Rimsky, Liza McMaster, Antonia New, Antonia S. Goodman, Marianne Siever, Larry J. Koenigsberg, Harold W. TI Elevated amygdala activity during reappraisal anticipation predicts anxiety in avoidant personality disorder SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Avoidant personality disorder; Reappraisal; Anticipation; Anxiety; FMRI; Amygdala ID GENERALIZED SOCIAL PHOBIA; COGNITIVE REAPPRAISAL; EMOTION REGULATION; BORDERLINE; PICTURES; BRAIN AB Background: Avoidant personality disorder is characterized by pervasive anxiety, fear of criticism, disapproval, and rejection, particularly in anticipation of exposure to social situations. An important but underexplorecl question concerns whether anxiety in avoidant patients is associated with an impaired ability to engage emotion regulatory strategies in anticipation of and during appraisal of negative social stimuli. Methods: We examined the use of an adaptive emotion regulation strategy, cognitive reappraisal, in avoidant patients. In addition to assessing individual differences in state and trait anxiety levels, self-reported affect as well as measures of neural activity were compared between 17 avoidant patients and 21 healthy control participants both in anticipation of and during performance of a reappraisal task. Results: Avoidant patients showed greater state and trait related anxiety relative to healthy participants. In addition, relative to healthy participants, avoidant patients showed pronounced amygdala hyper-reactivity during reappraisal anticipation, and this hyper reactivity effect was positively associated with increasing self reported anxiety levels. Limitations: Our finding of exaggerated amygdala activity during reappraisal anticipation could reflect anxiety about the impending need to reappraise, anxiety about the certainty of an upcoming negative image, or anxiety relating to anticipated scrutiny of task responses by the experimenters. While we believe that all of these possibilities are consistent with the phenomenology of avoidant personality disorder, future research may clarify this ambiguity. Conclusions: These results suggest that amygclala reactivity in anticipation of receiving negative social information may represent a key component of the neural mechanisms underlying the heightened anxiety present in avoidant patients. Published by Elsevier B.V. C1 [Denny, Bryan T.; Fan, Jin; Guerreri, Stephanie; Mayson, Sarah Jo; Rimsky, Liza; McMaster, Antonia; New, Antonia S.; Goodman, Marianne; Siever, Larry J.; Koenigsberg, Harold W.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Fan, Jin] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA. [Fan, Jin] CUNY Queens Coll, Dept Psychol, New York, NY 11367 USA. [Liu, Xun] Chinese Acad Sci, Inst Psychol, Beijing 100101, Peoples R China. [Ochsner, Kevin N.] Columbia Univ, Dept Psychol, New York, NY 10027 USA. RP Koenigsberg, HW (reprint author), James J Peters VA Med Ctr, Mental Hlth Patient Care Ctr, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM HWarrenK@nyc.rr.com RI Fan, Jin/A-6716-2009 OI Fan, Jin/0000-0001-9630-8330 FU National Institute of Mental Health; James J Peters VA Medical Center; National Center for Advancing Translational Sciences (a component of the National Institutes of Health) FX This research was funded by the National Institute of Mental Health, the James J Peters VA Medical Center, and the National Center for Advancing Translational Sciences (a component of the National Institutes of Health). This publication is solely the work of the authors. The study sponsors had no role in the collection, analysis, or interpretation of data, in the writing of the manuscript, or in the decision to submit the manuscript for publication. NR 36 TC 3 Z9 3 U1 2 U2 17 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 EI 1573-2517 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD FEB 1 PY 2015 VL 172 BP 1 EP 7 DI 10.1016/j.jad.2014.09.017 PG 7 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA AX0LD UT WOS:000346643000001 PM 25451388 ER PT J AU Pietrzak, RH Rosenheck, RA Cramer, JA Vessichio, JC Tsai, J Southwick, SM Krystal, JH AF Pietrzak, Robert H. Rosenheck, Robert A. Cramer, Joyce A. Vessichio, Jennifer C. Tsai, Jack Southwick, Steven M. Krystal, John H. CA VA CSP 504 Collaborative Grp TI Elucidating the transdiagnostic dimensional structure of trauma-related psychopathology: Findings from VA cooperative study 504-risperidone treatment for military service related chronic post traumatic stress disorder SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Posttraumatic stress disorder; Depression; Generalized anxiety disorder; Veterans; Exploratory factor analysis; Functioning ID RESEARCH DOMAIN CRITERIA; 5-FACTOR MODEL; SYMPTOMS; VETERANS; ANXIETY; DEPRESSION; SCALE; PTSD; RDOC; DISTRESS AB Background: Three of the most common trauma-related mental disorders posttraumatic stress disorder (PTSD), major depressive disorder (MDD), and generalized anxiety disorder (GAD) are highly comorbid and share common transdiagnostic symptom dimensions of threat (i.e., fear) and loss (i.e., dysphoria) symptomatology. However, empirical evaluation of the dimensional structure of component aspects of these disorders is lacking. Methods: Using structured clinical interview data from U.S. military veterans with chronic military related PTSD, we evaluated the transdiagnostic dimensional structure of PTSD, MDD, and GAD symptoms. We then examined the relationship between the best-fitting transdiagnostic model of these symptoms, and measures of physical and mental functioning, and life satisfaction and well-being. Results: Exploratory factor analysis revealed that a 3-factor transdiagnostic model comprised of loss (i.e., dysphoria), threat (i.e., anxious arousal, re-experiencing, and avoidance symptoms), and somatic anxiety (i.e., physiological manifestations of anxiety) symptoms provided the best representation of trauma related PTSD, MDD, and GAD symptoms. Somatic anxiety symptoms were independently associated with physical functioning, while loss symptoms were independently associated with mental functioning and life satisfaction and well-being. Limitations: Evaluation of study aims in a relatively homogeneous sample of veterans with chronic, military related PTSD. Conclusions: Results of this study suggest that a 3-factor transdiagnostic model best characterizes the dimensional structure of PTSD, MDD, and GAD symptoms in military veterans with chronic military-related PTSD. This model evidenced external validity in demonstrating differential associations with measures of physical and mental functioning, and life satisfaction and well-being. Results provide support for emerging contemporary models of psychopathology, which emphasize transdiagnostic and dimensional conceptualizations of mental disorders. Such models may have utility in understanding the Functional status of trauma survivors. Published by Elsevier B.V. C1 [Pietrzak, Robert H.; Southwick, Steven M.; Krystal, John H.] VA Connecticut Healthcare Syst, Clin Neurosci Div, US Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, West Haven, CT USA. [Pietrzak, Robert H.; Rosenheck, Robert A.; Cramer, Joyce A.; Vessichio, Jennifer C.; Tsai, Jack; Southwick, Steven M.; Krystal, John H.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06516 USA. [Rosenheck, Robert A.; Tsai, Jack; Krystal, John H.] New England Mental Illness Res Educ & Clin Ctr, US Dept Vet Affairs, West Haven, CT USA. [Cramer, Joyce A.; Vessichio, Jennifer C.] VA Connecticut Healthcare Syst, Psychiat Serv, West Haven, CT USA. [Krystal, John H.] Yale New Haven Med Ctr, Psychiat Serv, New Haven, CT 06504 USA. RP Pietrzak, RH (reprint author), Yale Univ, Sch Med, US Dept Vet Affairs,Dept Psychiat, Natl Ctr Posttraumat Stress Disorder,VA Connectic, 950 Campbell Ave,151E, West Haven, CT 06516 USA. EM robert.pietrzak@yale.edu FU U.S. Department of Veterans Affairs [504]; National Institute on Alcohol Abuse and Alcoholism [2P50AA012870-14] FX This study was supported by the U.S. Department of Veterans Affairs through its support of VA Cooperative Study #504, Clinical Neuroscience Division of the VA National Center for PTSD, and the Consortium to Alleviate PTSD. Johnson and Johnson provided medication and some financial support to the U.S. Department of Veterans Affairs to facilitate the initiation and conduct of the study. Additionally Dr. Krystal received support from the National Institute on Alcohol Abuse and Alcoholism grant (2P50AA012870-14) and the National Center for Advancing Translational Science grants (UL1RR024139, PI: R. Sherwin, UH2TR000960, PI: JHK). NR 30 TC 0 Z9 0 U1 0 U2 10 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 EI 1573-2517 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD FEB 1 PY 2015 VL 172 BP 331 EP 336 DI 10.1016/j.jad.2014.10.025 PG 6 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA AX0LD UT WOS:000346643000047 PM 25451434 ER PT J AU Arterburn, D Wellman, R Westbrook, EO Ross, TR McCulloch, D Handley, M Lowe, M Cable, C Zeliadt, SB Hoffman, RM AF Arterburn, David Wellman, Robert Westbrook, Emily O. Ross, Tyler R. McCulloch, David Handley, Matt Lowe, Marc Cable, Chris Zeliadt, Steven B. Hoffman, Richard M. TI Decision Aids for Benign Prostatic Hyperplasia and Prostate Cancer SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID CLINICAL-PRACTICE; MANAGEMENT; UPDATE; HEALTH; GUIDELINE; BARRIERS; CARE; MEN AB Objectives To examine the relationships among implementing decision aids (DAs) for benign prostatic hyperplasia (BPH) and prostate cancer (PRCA), and treatment rates and costs. Study Design A pre-post observational evaluation of a quality improvement initiative in a healthcare system in Washington state. Methods Men with BPH seen in urology clinics and all men diagnosed with localized PRCA were identified for an intervention period, in which urologists were instructed to order a DA for every patient with those conditions, and a historical control period. Outcomes were 6-month rates of surgery for BPH, any active treatment (hormone therapy, radiation, or surgery) for PRCA, and total healthcare costs. Results During the intervention, DAs were delivered to 22% of men with recent BPH drug treatment, 24% of men with untreated BPH, and 56% of men with PRCA. DA implementation was associated with a 32% lower rate of surgery among men with treated BPH (rate ratio [RR], 0.68; 95% CI, 0.49-0.94) and a nonsignificant 22% lower rate of surgery among men with previously untreated BPH (RR, 0.78; 95% CI, 0.50-1.22). For PRCA, DA implementation was associated with a 27% lower rate of active treatment (RR, 0.73; 95% CI, 0.57-0.93). We found no significant associations between DA implementation and costs of care for either condition. Conclusions Implementing patient DAs was associated with lower rates of elective surgery for previously treated BPH and active treatment for localized PRCA; however, implementation of these DAs was not associated with lower costs of care. C1 [Arterburn, David; Wellman, Robert; Westbrook, Emily O.; Ross, Tyler R.] Grp Hlth Res Inst, 1730 Minor Ave,Ste 1600, Seattle, WA 98101 USA. [McCulloch, David; Handley, Matt; Lowe, Marc; Cable, Chris] Grp Hlth Phys, Seattle, WA USA. [Zeliadt, Steven B.] VA Puget Sound Hlth Care Syst, Northwest HSR&D Ctr Excellence, Seattle, WA USA. [Hoffman, Richard M.] Univ New Mexico, Dept Med, Albuquerque, NM 87131 USA. [Hoffman, Richard M.] New Mexico VA Hlth Care Syst, Med Serv, Albuquerque, NM USA. RP Arterburn, D (reprint author), Grp Hlth Res Inst, 1730 Minor Ave,Ste 1600, Seattle, WA 98101 USA. EM arterburn.d@ghc.org FU The Commonwealth Fund [20080479]; Informed Medical Decisions Foundation [0103]; Group Health Foundation FX This work was funded by The Commonwealth Fund (Grant #20080479), the Informed Medical Decisions Foundation (Grant #0103), and the Group Health Foundation. The decision aids used in this study were provided by Health Dialog, Inc. The authors had full access to all of the data and the funders did not have control over manuscript drafting or publication. NR 25 TC 0 Z9 1 U1 0 U2 0 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD FEB PY 2015 VL 21 IS 2 BP E130 EP + PG 13 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA DR4XM UT WOS:000379906800006 PM 25880488 ER PT J AU Kimerling, R Bastian, LA Bean-Mayberry, BA Bucossi, MM Carney, DV Goldstein, KM Phibbs, CS Pomernacki, A Sadler, AG Yano, EM Frayne, SM AF Kimerling, Rachel Bastian, Lori A. Bean-Mayberry, Bevanne A. Bucossi, Meggan M. Carney, Diane V. Goldstein, Karen M. Phibbs, Ciaran S. Pomernacki, Alyssa Sadler, Anne G. Yano, Elizabeth M. Frayne, Susan M. TI Patient-Centered Mental Health Care for Female Veterans SO PSYCHIATRIC SERVICES LA English DT Article ID COLLABORATIVE CARE; WOMEN VETERANS; DEPRESSION; VALIDATION; DISORDERS; SERVICES; QUALITY; VA; INTERVENTIONS; QUESTIONNAIRE AB Objective: Mental health services for women vary widely across the Veterans Health Administration (VHA) system, without consensus on the need for, or organization of, specialized services for women. Understanding women's needs and priorities is essential to guide the implementation of patient-centered behavioral health services. Methods: In a cross-sectional, multisite survey of female veterans using primary care, potential stakeholders were identified for VHA mental health services by assessing perceived or observed need for mental health services. These stakeholders (N=484) ranked priorities for mental health care among a wide range of possible services. The investigators then quantified the importance of having designated women's mental health services for each of the mental health services that emerged as key priorities. Results: Treatment for depression, pain management, coping with chronic general medical conditions, sleep problems, weight management, and posttraumatic stress disorder (PTSD) emerged as women's key priorities. Having mental health services specialized for women was rated as extremely important to substantial proportions of women for each of the six prioritized services. Preference for primary care colocation was strongly associated with higher importance ratings for designated women's mental health services. For specific types of services, race, ethnicity, sexual orientation, PTSD symptoms, and psychiatric comorbidity were also associated with higher importance ratings for designated women's services. Conclusions: Female veterans are a diverse population whose needs and preferences for mental health services vary along demographic and clinical factors. These stakeholder perspectives can help prioritize structural and clinical aspects of designated women's mental health care in the VHA. C1 [Kimerling, Rachel] Vet Affairs VA Palo Alto Hlth Care Syst, Natl Ctr PTSD, Menlo Pk, CA USA. [Kimerling, Rachel; Bucossi, Meggan M.; Carney, Diane V.; Pomernacki, Alyssa; Frayne, Susan M.] Vet Affairs VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, Menlo Pk, CA USA. [Frayne, Susan M.] Stanford Univ, Sch Med, Div Gen Med Disciplines, Stanford, CA 94305 USA. [Bastian, Lori A.] VA Connecticut Healthcare Syst, Hlth Serv Res & Dev HSR&D Pain Res Informat Multi, West Haven, CT USA. [Bastian, Lori A.] Univ Connecticut, Ctr Hlth, Div Gen Internal Med, Farmington, CT USA. [Bean-Mayberry, Bevanne A.] VA Greater Los Angeles Healthcare Syst, HSR&D Ctr Study Healthcare Innovat Implementat &, Sepulveda, CA USA. [Bean-Mayberry, Bevanne A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Yano, Elizabeth M.] Univ Calif Los Angeles, Fielding Sch Publ Health, Dept Hlth Policy & Management, Los Angeles, CA 90024 USA. [Goldstein, Karen M.] Durham VA Med Ctr, HSR&D Ctr Hlth Serv Res Primary Care, Durham, NC USA. [Goldstein, Karen M.] Duke Univ, Dept Med, Durham, NC USA. [Phibbs, Ciaran S.] VA Palo Alto Hlth Care Syst, HSR&D Hlth Econ Resource Ctr, Menlo Pk, CA USA. [Phibbs, Ciaran S.] Stanford Univ, Dept Pediat, Stanford, CA 94305 USA. [Sadler, Anne G.] Iowa City VA Hlth Care Syst, HSR&D Ctr Comprehens Access & Delivery Res & Eval, Iowa City, IA USA. [Sadler, Anne G.] Univ Iowa Hosp & Clin, Dept Psychiat, Iowa City, IA 52242 USA. RP Kimerling, R (reprint author), Vet Affairs VA Palo Alto Hlth Care Syst, Natl Ctr PTSD, Menlo Pk, CA USA. EM rachel.kimerling@va.gov OI Kimerling, Rachel/0000-0003-0996-4212 FU VA HSRD grant [SDR 10-012] FX This study was funded by VA HSR&D grant SDR 10-012 (Women's Health Research Network). The authors thank Joanne Pavao, M.P.H., Deborah Nazarian, Ph.D., Shannan Sonnicksen, L.C.S.W., M.P.H., Caitlin McLean, M.S., and Julia Lin, Ph.D., of the VA Palo Alto Health Care System; Jill Blakeney, R.N., of Durham VA Medical Center; Ruth Klap, Ph.D., and Julia Yosef, M.S., R.N., of VA Greater Los Angeles Healthcare System; and Brittany D. Martin, M.A., M. Litt., and Holly J. Erschens, B.A., of Iowa City VA Health Care System. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the VA or the U.S. government. NR 41 TC 6 Z9 6 U1 1 U2 4 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD FEB PY 2015 VL 66 IS 2 BP 155 EP 162 DI 10.1176/appi.ps.201300551 PG 8 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA DE3TC UT WOS:000370552100013 PM 25642611 ER PT J AU Mayeda, ER Whitmer, RA Yaffe, K AF Mayeda, Elizabeth Rose Whitmer, Rachel A. Yaffe, Kristine TI Diabetes and Cognition SO CLINICS IN GERIATRIC MEDICINE LA English DT Article DE Type 2 diabetes; Cognition; Cognitive decline; Dementia; Aging; Epidemiology ID VASCULAR RISK-FACTORS; ALZHEIMERS-DISEASE; DEMENTIA RISK; OLDER PERSONS; SEVERE HYPOGLYCEMIA; OXIDATIVE DAMAGE; FOLLOW-UP; LATE-LIFE; MELLITUS; DECLINE AB Dementia is a major cause of disability and death among older adults. Those with type 2 diabetes (T2D) are 50-100% more likely to develop dementia than those without T2D, but it is unknown whether this association reflects a causal relationship. Proposed mechanisms through which T2D could cause dementia include the effects of insulin dysregulation and chronic hyperglycemia on features of Alzheimer's disease and macrovascular and microvascular disorders in the brain. More research is needed to elucidate the link between T2D and dementia and identify strategies to maintain cognitive function among people with T2D. C1 [Mayeda, Elizabeth Rose] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94107 USA. [Whitmer, Rachel A.] Kaiser Permanente, Div Res, Oakland, CA 94612 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Mayeda, ER (reprint author), Univ Calif San Francisco, Dept Epidemiol & Biostat, 185 Berry St,Lobby 5,Suite 5700, San Francisco, CA 94107 USA. EM elizabeth.mayeda@ucsf.edu FU National Institute on Aging grant [K24 AG031155]; National Institute of Diabetes and Digestive and Kidney Diseases grant [R01DK081796]; BrightFocus Foundation FX The authors were supported by funding from National Institute on Aging grant K24 AG031155, National Institute of Diabetes and Digestive and Kidney Diseases grant R01DK081796, and grant support from the BrightFocus Foundation. NR 92 TC 16 Z9 17 U1 0 U2 24 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0749-0690 EI 1879-8853 J9 CLIN GERIATR MED JI Clin. Geriatr. Med. PD FEB PY 2015 VL 31 IS 1 BP 101 EP + DI 10.1016/j.cger.2014.08.021 PG 16 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA AX1CX UT WOS:000346686900010 PM 25453304 ER PT J AU Richard, MLL Nowling, TK Brandon, D Watson, DK Zhang, XK AF Richard, Mara L. Lennard Nowling, Tamara K. Brandon, Danielle Watson, Dennis K. Zhang, Xian K. TI Fli-1 controls transcription from the MCP-1 gene promoter, which may provide a novel mechanism for chemokine and cytokine activation SO MOLECULAR IMMUNOLOGY LA English DT Article DE Transcriptional factors; Gene regulation; Chemokines; Inflammation; Fli-1; MCP-1 ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; SYSTEMIC-LUPUS-ERYTHEMATOSUS; NF-KAPPA-B; ETS FAMILY; RENAL-DISEASE; GROWTH-FACTOR; T-CELLS; EXPRESSION; BINDING; MICE AB Regulation of proinflammatory cytokines and chemokines is a primary role of the innate immune response. MCP-1 is a chemokine that recruits immune cells to sites of inflammation. Expression of MCP-1 is reduced in primary kidney endothelial cells from mice with a heterozygous knockout of the Fli-1 transcription factor. Fli-1 is a member of the Ets family of transcription factors, which are evolutionarily conserved across several organisms including Drosophilla, Xenopus, mouse and human. Ets family members bind DNA through a consensus sequence GGAA/T, or Ets binding site (EBS). Fli-1 binds to EBSs within the endogenous MCP-1 promoter by ChIP assay. In this study, transient transfection assays indicate that the Fli-1 gene actively promotes transcription from the MCP-1 gene promoter in a dose-dependent manner. Mutation of the DNA binding domain of Fli-1 demonstrated that Fli-1 activates transcription of MCP-1 both directly, by binding to the promoter, and indirectly, likely through interactions with other transcription factors. Another-Ets-transcription-factor, Ets-1, was also tested, but failed to promote transcription. While Ets-1 failed to drive transcription independently, a weak synergistic activation of the MCP-1 promoter was observed between Ets-1 and FR-1. In addition, Fli-1 and the NF kappa B family member p65 were found to interact synergistically to activate transcription from the MCP-1 promoter, while Sp1 and p50 inhibit this interaction. Deletion studies identified that EBSs in the distal and proximal MCP-1 promoter are critical for Fli-1 activation from the MCP-1 promoter. Together, these results demonstrate that Fli-1 is a novel regulator of the proinflammatory chemokine MCP-1, that interacts with other transcription factors to form a complex transcriptional mechanism for the activation of MCP-1 and mediation of the inflammatory response. (C) 2014 Elsevier Ltd. All rights reserved. C1 [Richard, Mara L. Lennard; Nowling, Tamara K.; Brandon, Danielle; Zhang, Xian K.] Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, Charleston, SC 29425 USA. [Nowling, Tamara K.; Zhang, Xian K.] Ralph H Johnson Vet Affairs Med Ctr, Med Res Serv, Charleston, SC 29403 USA. [Watson, Dennis K.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. [Watson, Dennis K.] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA. RP Zhang, XK (reprint author), Div Rheumatol & Immunol, Suite 912,96 Jonathan Lucas St,MSC637, Charleston, SC 29425 USA. EM zhangjo@musc.edu OI Watson, Dennis/0000-0003-3448-7657 FU National Institute of Health (NIAMS) [AR056670] FX This research study was supported by the National Institute of Health grant (NIAMS, AR056670 to X.K.Z.). We would like to thank Dr. Jeremy Boss from the Emory University School of Medicine for providing us with the pJECAT2.6 vector and the p50, p65 and Sp1 expression constructs. We would also like to thank Dr. Maria Trojanowska from the Boston University School of Medicine Arthritis Center for the Fli-1 DNA binding mutant expression construct. NR 45 TC 3 Z9 3 U1 0 U2 10 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0161-5890 J9 MOL IMMUNOL JI Mol. Immunol. PD FEB PY 2015 VL 63 IS 2 SI SI BP 566 EP 573 DI 10.1016/j.molimm.2014.07.013 PG 8 WC Biochemistry & Molecular Biology; Immunology SC Biochemistry & Molecular Biology; Immunology GA AW8WT UT WOS:000346540900053 ER PT J AU Scandrett, KG Zuckerbraun, BS Peitzman, AB AF Scandrett, Karen G. Zuckerbraun, Brian S. Peitzman, Andrew B. TI Operative Risk Stratification in the Older Adult SO SURGICAL CLINICS OF NORTH AMERICA LA English DT Article DE Geriatric; Frailty; Goals of care; Cognitive function ID AMERICAN GERIATRICS SOCIETY; COLLEGE-OF-PHYSICIANS; SERVICES-TASK-FORCE; ELDER LIFE PROGRAM; SURGICAL OUTCOMES; POSTOPERATIVE COMPLICATIONS; NONCARDIOTHORACIC SURGERY; PULMONARY COMPLICATIONS; PREOPERATIVE ASSESSMENT; ASPIRATION PNEUMONIA AB As the population ages, the health care system must to adapt to the needs of the older population. Hospitalization risks are particularly significant in the frail geriatric patients, with costly and morbid consequences. Appropriate preoperative assessment can identify sources of increased risk and enable the surgical team to manage this risk, through "prehabilitation," intraoperative modification, and postoperative care. Geriatric preoperative assessment expands usual risk stratification and careful medication review to include screening for functional disability, cognitive impairment, nutritional deficiency, and frailty. The information gathered can also equip the surgeon to develop a patient-centered and realistic treatment plan. C1 [Scandrett, Karen G.] Univ Pittsburgh, Dept Geriatr Med, Pittsburgh, PA USA. [Zuckerbraun, Brian S.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Zuckerbraun, Brian S.; Peitzman, Andrew B.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA. RP Peitzman, AB (reprint author), UPMC Presbyterian, Dept Surg, F-1281, Pittsburgh, PA 15213 USA. EM peitzmanab@upmc.edu NR 84 TC 4 Z9 4 U1 6 U2 13 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0039-6109 EI 1558-3171 J9 SURG CLIN N AM JI Surg. Clin.-North Am. PD FEB PY 2015 VL 95 IS 1 BP 149 EP + DI 10.1016/j.suc.2014.09.014 PG 26 WC Surgery SC Surgery GA AW9AF UT WOS:000346549500014 PM 25459549 ER PT J AU Micheletti, RG Werth, VP AF Micheletti, Robert G. Werth, Victoria P. TI Small Vessel Vasculitis of the Skin SO RHEUMATIC DISEASE CLINICS OF NORTH AMERICA LA English DT Article DE Small vessel vasculitis of the skin; Cutaneous vasculitis; Leukocytoclastic vasculitis; Hypersensitivity vasculitis; IgA vasculitis; Henoch-Schonlein purpura ID HENOCH-SCHONLEIN PURPURA; CUTANEOUS LEUKOCYTOCLASTIC VASCULITIS; URTICARIAL-VASCULITIS; CLINICAL-FEATURES; HYPERSENSITIVITY VASCULITIS; DIRECT IMMUNOFLUORESCENCE; LUPUS-ERYTHEMATOSUS; ETIOLOGIC FACTORS; CONTROLLED-TRIAL; THERAPY AB Small vessel vasculitis in the skin manifests with palpable purpura on the lower extremities. This clinical presentation prompts a complete physical examination, history, and review of systems, as well as biopsies for routine processing and direct immunofluorescence to confirm the diagnosis. The presence of vasculitis in other organs, associated underlying conditions, and the severity of cutaneous manifestations dictate management. The majority of cases are self-limited, and overall the prognosis is favorable. Still, a subset of patients can have serious complications and chronic or recurrent disease. C1 [Micheletti, Robert G.; Werth, Victoria P.] Univ Penn, Perelman Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA. [Micheletti, Robert G.; Werth, Victoria P.] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Werth, Victoria P.] Univ Penn, Perelman Sch Med, Philadelphia Vet Affairs Med Ctr, Dept Dermatol, Philadelphia, PA 19104 USA. [Werth, Victoria P.] Univ Penn, Perelman Sch Med, Philadelphia Vet Affairs Med Ctr, Dept Med, Philadelphia, PA 19104 USA. RP Micheletti, RG (reprint author), Univ Penn, Perelman Sch Med, Dept Dermatol, 3400 Spruce St, Philadelphia, PA 19104 USA. EM Robert.Micheletti@uphs.upenn.edu NR 43 TC 7 Z9 7 U1 2 U2 14 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-857X EI 1558-3163 J9 RHEUM DIS CLIN N AM JI Rheum. Dis. Clin. North Am. PD FEB PY 2015 VL 41 IS 1 BP 21 EP + DI 10.1016/j.rdc.2014.09.006 PG 13 WC Rheumatology SC Rheumatology GA AW3XS UT WOS:000346217100004 PM 25399937 ER PT J AU Stewart, T Sossi, V Aasly, JO Wszolek, ZK Uitti, RJ Hasegawa, K Yokoyama, T Zabetian, CP Leverenz, JB Stoessl, AJ Wang, Y Ginghina, C Liu, CQ Cain, KC Auinger, P Kang, UJ Jensen, PH Shi, M Zhang, J AF Stewart, Tessandra Sossi, Vesna Aasly, Jan O. Wszolek, Zbigniew K. Uitti, Ryan J. Hasegawa, Kazuko Yokoyama, Teruo Zabetian, Cyrus P. Leverenz, James B. Stoessl, Alexander Jon Wang, Yu Ginghina, Carmen Liu, Changqin Cain, Kevin C. Auinger, Peggy Kang, Un Jung Jensen, Poul Henning Shi, Min Zhang, Jing TI Phosphorylated alpha-synuclein in Parkinson's disease: correlation depends on disease severity SO ACTA NEUROPATHOLOGICA COMMUNICATIONS LA English DT Article DE Parkinson's disease; Cerebrospinal fluid; Biomarker; alpha-synuclein; Phosphorylation; DATATOP ID CEREBROSPINAL-FLUID; RAT MODEL; BLOOD-PLASMA; AMYLOID-BETA; IN-VIVO; SER-129; DEMENTIA; NEURODEGENERATION; NEUROTOXICITY; PROGRESSION AB Introduction: alpha a-Synuclein (alpha-syn) is a key protein in Parkinson's disease (PD), and one of its phosphorylated forms, pS129, is higher in PD patients than healthy controls. However, few studies have examined its levels in longitudinally collected cerebrospinal fluid (CSF) or in preclinical cases. In this study, CSF and clinical data were contributed by >300 subjects from three cohorts (the longitudinal DATATOP cohort, a large cross-sectional cohort, and a cohort of LRRK2 mutation carriers). Results: Consistent with our previous observation that CSF pS129 positively correlated with Unified Parkinson's Disease Rating Scale (UPDRS) scores, CSF pS129 in the DATATOP cohort increased over approximately two years of disease progression (mean change 5.60 pg/ml, p = 0.050). Intriguingly, in the DATATOP cohort, pS129 negatively correlated with UPDRS scores at the baseline (R = -0.244, p = 0.017), but not final point, suggesting that this association may depend on disease stage. Reanalysis of our previous cohort with stratification by PD stage, and addition of a cohort of LRRK2 mutation carriers with very early/preclinical PD, supported the idea that the relationship between CSF pS129 and disease severity over a wider range of PD stages might be represented with a U-shaped curve, in which lower pS129 levels correlated with worse clinical condition at early stages, but better condition at later stages. Conclusion: The observation of a negative-to-positive transition of correlation of pS129 to disease severity as PD progresses could have profound impact on how pS129 is used as a biomarker clinically as well as in modeling PD experimentally. C1 [Stewart, Tessandra; Ginghina, Carmen; Liu, Changqin; Shi, Min; Zhang, Jing] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98104 USA. [Sossi, Vesna] Univ British Columbia, Vancouver Hosp & Hlth Sci Ctr, Dept Phys & Astron, Vancouver, BC V5Z 1M9, Canada. [Aasly, Jan O.] St Olavs Hosp, Dept Neurol, Trondheim, Norway. [Wszolek, Zbigniew K.] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA. [Hasegawa, Kazuko; Yokoyama, Teruo] Sagamihara Natl Hosp, Natl Hosp Org, Dept Neurol, Kanagawa, Japan. [Zabetian, Cyrus P.] Vet Affairs Puget Sound Hlth Care Syst, Educ & Clin Ctr, Geriatr Res, Seattle, WA USA. [Zabetian, Cyrus P.; Leverenz, James B.] Affairs Puget Sound Hlth Care Syst, Parkinsons Dis Res Educ & Clin Ctr, Seattle, WA USA. [Zabetian, Cyrus P.; Leverenz, James B.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98104 USA. [Leverenz, James B.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA USA. [Leverenz, James B.] Vet Affairs Puget Sound Hlth Care Syst, Educ & Clin Ctr, Mental Illness Res, Seattle, WA USA. [Stoessl, Alexander Jon] Univ British Columbia, Pacific Parkinsons Res Ctr, Vancouver Coastal Hlth, Vancouver, BC V5Z 1M9, Canada. [Wang, Yu] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Neurosurg, Wuhan 430030, Hubei, Peoples R China. [Liu, Changqin] Xiamen Univ, Affiliated Hosp 1, Dept Endocrinol & Metab, Xiamen, Peoples R China. [Liu, Changqin] Xiamen Univ, Affiliated Hosp 1, Xiamen Diabet Inst, Xiamen, Peoples R China. [Cain, Kevin C.] Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA. [Auinger, Peggy] Univ Rochester, Sch Med & Dent, Ctr Human Expt Therapeut, Dept Neurol, Rochester, NY USA. [Kang, Un Jung] Univ Chicago Med & Biol Sci, Dept Neurol, Chicago, IL USA. [Jensen, Poul Henning] Aarhus Univ, Dept Biomed, DK-8000 Aarhus C, Denmark. RP Zhang, J (reprint author), Univ Washington, Sch Med, Dept Pathol, 325 9th Ave,HMC Box 359635, Seattle, WA 98104 USA. EM zhangj@uw.edu FU NIA NIH HHS [R01 AG033398]; NIEHS NIH HHS [R01 ES016873, P30 ES007033-6364, P42 ES004696-5897, R01 ES019277, T32 ES007032, T32 ES015459]; NINDS NIH HHS [P50 NS062684-6221, P50 NS072187, R01 NS057567, R01 NS065070, U01 NS082137] NR 35 TC 12 Z9 12 U1 1 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 2051-5960 J9 ACTA NEUROPATHOL COM JI Acta Neuropathol. Commun. PD JAN 31 PY 2015 VL 3 AR 7 DI 10.1186/s40478-015-0185-3 PG 11 WC Neurosciences SC Neurosciences & Neurology GA CS6AI UT WOS:000362159000003 PM 25637461 ER PT J AU Zamani, P Rawat, D Shiva-Kumar, P Geraci, S Bhuva, R Konda, P Doulias, PT Ischiropoulos, H Townsend, RR Margulies, KB Cappola, TP Poole, DC Chirinos, JA AF Zamani, Payman Rawat, Deepa Shiva-Kumar, Prithvi Geraci, Salvatore Bhuva, Rushik Konda, Prasad Doulias, Paschalis-Thomas Ischiropoulos, Harry Townsend, Raymond R. Margulies, Kenneth B. Cappola, Thomas P. Poole, David C. Chirinos, Julio A. TI Effect of Inorganic Nitrate on Exercise Capacity in Heart Failure With Preserved Ejection Fraction SO CIRCULATION LA English DT Article DE exercise; heart failure; nitrates; nitric oxide ID NEAR-INFRARED SPECTROSCOPY; SOCIETY-OF-CARDIOLOGY; O-2 UPTAKE KINETICS; DIETARY NITRATE; SKELETAL-MUSCLE; NITRIC-OXIDE; OXIDATIVE CAPACITY; INTENSITY EXERCISE; OXYGEN-CONSUMPTION; WAVE REFLECTIONS AB Background-Inorganic nitrate (NO3-), abundant in certain vegetables, is converted to nitrite by bacteria in the oral cavity. Nitrite can be converted to nitric oxide in the setting of hypoxia. We tested the hypothesis that NO3- supplementation improves exercise capacity in heart failure with preserved ejection fraction via specific adaptations to exercise. Methods and Results-Seventeen subjects participated in this randomized, double-blind, crossover study comparing a single dose of NO3- rich beetroot juice (NO3-, 12.9 mmol) with an identical nitrate-depleted placebo. Subjects performed supine-cycle maximal-effort cardiopulmonary exercise tests, with measurements of cardiac output and skeletal muscle oxygenation. We also assessed skeletal muscle oxidative function. Study end points included exercise efficiency (total work/total oxygen consumed), peak Vo(2), total work performed, vasodilatory reserve, forearm mitochondrial oxidative function, and augmentation index (a marker of arterial wave reflections, measured via radial arterial tonometry). Supplementation increased plasma nitric oxide metabolites (median, 326 versus 10 mu mol/L; P=0.0003), peak (V) over doto(2) (12.6 +/- 3.7 versus 11.6 +/- 3.1 mL O-2.min(-1).kg(-1); P=0.005), and total work performed (55.6 +/- 35.3 versus 49.2 +/- 28.9 kJ; P=0.04). However, efficiency was unchanged. NO3- led to greater reductions in systemic vascular resistance (-42.4 +/- 16.6% versus -31.8 +/- 20.3%; P=0.03) and increases in cardiac output (121.2 +/- 59.9% versus 88.7 +/- 53.3%; P=0.006) with exercise. NO3- reduced aortic augmentation index (132.2 +/- 16.7% versus 141.4 +/- 21.9%; P=0.03) and tended to improve mitochondrial oxidative function. Conclusions-NO3- increased exercise capacity in heart failure with preserved ejection fraction by targeting peripheral abnormalities. Efficiency did not change as a result of parallel increases in total work and (V)over doto(2). NO3- increased exercise vasodilatory and cardiac output reserves. NO3- also reduced arterial wave reflections, which are linked to left ventricular diastolic dysfunction and remodeling. C1 [Zamani, Payman; Shiva-Kumar, Prithvi; Konda, Prasad; Margulies, Kenneth B.; Cappola, Thomas P.; Chirinos, Julio A.] Hosp Univ Penn, Perelman Sch Med, Div Cardiovasc Med, Philadelphia, PA 19104 USA. [Rawat, Deepa; Shiva-Kumar, Prithvi; Geraci, Salvatore; Bhuva, Rushik; Chirinos, Julio A.] Philadelphia Vet Affairs Med Ctr, Div Cardiol, Philadelphia, PA USA. [Doulias, Paschalis-Thomas; Ischiropoulos, Harry] Childrens Hosp Philadelphia, Res Inst, Philadelphia, PA 19104 USA. [Townsend, Raymond R.] Univ Penn, Perelman Sch Med, Div Nephrol Hypertens, Philadelphia, PA 19104 USA. [Poole, David C.] Kansas State Univ, Dept Kinesiol, Manhattan, KS 66506 USA. [Poole, David C.] Kansas State Univ, Dept Anat, Manhattan, KS 66506 USA. [Poole, David C.] Kansas State Univ, Dept Physiol, Manhattan, KS 66506 USA. RP Chirinos, JA (reprint author), 3800 Woodland Ave,Room 8B111, Philadelphia, PA 19104 USA. EM Julio.Chirinos@uphs.upenn.edu FU Gilead Life Sciences; Atcor Medical; Cardiodynamics; APC Cardiovascular; National Institutes of Health [HL54926, HL105993, HL110338, HL113777]; Juventis Therapeutics; Celladon Corp; Thoratec Corp; Innolign Biomedical, LLC FX Dr Zamani performed prior research in HFpEF that was funded by Gilead Life Sciences. Dr Chirinos is named as inventor in a patent application for the use of inorganic nitrate in HFpEF. Dr Chirinos has received minor support (equipment loans) from Atcor Medical, Cardiodynamics, and APC Cardiovascular. Dr Ischiropoulos is the Gisela and Dennis Alter Chair in Pediatric Neonatology at the Children's Hospital of Philadelphia and is supported by National Institutes of Health grant HL54926. Dr Margulies reports advisory committee membership for Novo Nordisk and AstraZeneca, as well as research grant support from Juventis Therapeutics, Celladon Corp, Thoratec Corp, Innolign Biomedical, LLC, and the National Institutes of Health (HL105993, HL110338, HL113777). The other authors report no conflicts. NR 54 TC 57 Z9 59 U1 6 U2 21 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD JAN 27 PY 2015 VL 131 IS 4 BP 371 EP U1184 DI 10.1161/CIRCULATIONAHA.114.012957 PG 17 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA AZ7YR UT WOS:000348432100014 PM 25533966 ER PT J AU Ho, PM O'Donnell, CI Bradley, SM Grunwald, GK Helfrich, C Chapko, M Liu, CF Maddox, TM Tsai, TT Jesse, RL Fihn, SD Rumsfeld, JS AF Ho, P. Michael O'Donnell, Colin I. Bradley, Steven M. Grunwald, Gary K. Helfrich, Christian Chapko, Michael Liu, Chuan-Fen Maddox, Thomas M. Tsai, Thomas T. Jesse, Robert L. Fihn, Stephan D. Rumsfeld, John S. TI 1-Year Risk-Adjusted Mortality and Costs of Percutaneous Coronary Intervention in the Veterans Health Administration Insights From the VA CART Program SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article DE costs; health care delivery; ischemic heart disease; PCI; outcomes; value ID CARDIOVASCULAR DATA REGISTRY; ACUTE MYOCARDIAL-INFARCTION; REPEAT REVASCULARIZATION; QUALITY; PCI; PREDICTION; EFFICIENCY; OUTCOMES; DISEASE; SURGERY AB BACKGROUND There is significant interest in measuring health care value, but this concept has not been operationalized in specific patient cohorts. The longitudinal outcomes and costs for patients after percutaneous coronary intervention (PCI) provide an opportunity to measure an aspect of health care value. OBJECTIVES This study evaluated variations in 1-year outcomes (risk-adjusted mortality) and risk-standardized costs of care for all patients undergoing PCI in the Veterans Affairs (VA) system from 2007 to 2010. METHODS This retrospective cohort study evaluated all veterans undergoing PCI at any of 60 hospitals in the VA health care system, using data from the national VA Clinical Assessment, Reporting, and Tracking (CART) program. Primary outcomes were 1-year mortality and costs following PCI. Risk-standardized mortality and cost ratios were calculated, adjusting for cardiac and noncardiac comorbidities. RESULTS A median of 261 PCIs were performed in the 60 hospitals during the study period. Median 1-year unadjusted hospital mortality rate was 6.13%. Four hospitals were significantly above the 1-year risk-standardized median mortality rate, with median mortality ratios ranging from 1.23 to 1.28. No hospitals were significantly below median mortality. Median 1-year total unadjusted hospital costs were $46,302 per patient. There were 16 hospitals above and 19 hospitals below the risk-standardized median cost, with risk-standardized ratios ranging from 0.45 to 2.09, reflecting a much larger magnitude of variability in costs than in mortality. CONCLUSIONS There is much smaller variation in 1-year risk adjusted mortality than in risk-standardized costs after PCI in the VA. These findings suggest that there are opportunities to improve PCI value by reducing costs without compromising outcomes. This approach to evaluating outcomes and costs together may be a model for other health systems and accountable care organizations interested in operationalizing value measurement. (C) 2015 by the American College of Cardiology Foundation. C1 [Ho, P. Michael; O'Donnell, Colin I.; Bradley, Steven M.; Grunwald, Gary K.; Maddox, Thomas M.; Tsai, Thomas T.; Rumsfeld, John S.] Vet Affairs Eastern Colorado Hlth Care Syst, Denver, CO USA. [Ho, P. Michael; O'Donnell, Colin I.; Bradley, Steven M.; Grunwald, Gary K.; Maddox, Thomas M.; Tsai, Thomas T.; Rumsfeld, John S.] Univ Colorado, Div Cardiol, Denver, CO 80220 USA. [Helfrich, Christian; Chapko, Michael; Liu, Chuan-Fen; Fihn, Stephan D.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Jesse, Robert L.] Dept Vet Affairs, Vet Hlth Adm, Washington, DC USA. [Fihn, Stephan D.] Vet Affairs Off Analyt & Business Intelligence, Washington, DC USA. RP Ho, PM (reprint author), Univ Colorado, Sect Cardiol, Denver Vet Affairs Med Ctr, 1055 Clermont St 111B, Denver, CO 80220 USA. EM michael.ho@va.gov RI Helfrich, Christian/D-2382-2016 OI Helfrich, Christian/0000-0002-9827-4768 FU Career Development Awards from VA Health Services Research and Development FX Drs. Bradley and Maddox are supported by Career Development Awards from VA Health Services Research and Development. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. NR 19 TC 6 Z9 6 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD JAN 27 PY 2015 VL 65 IS 3 BP 236 EP 242 DI 10.1016/j.jacc.2014.10.048 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AZ2EA UT WOS:000348046200003 PM 25614420 ER PT J AU Samarendra, P Mangione, MP AF Samarendra, Padmaraj Mangione, Michael P. TI Aortic Stenosis and Perioperative Risk With Noncardiac Surgery SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Review DE clinical outcomes; heart failure; hypotension; intraoperative monitoring; phenylephrine ID CORONARY-ARTERY-DISEASE; LOW MORTALITY-RATES; VALVE-REPLACEMENT; CARDIAC RISK; SURGICAL-PROCEDURES; PERFORM WELL; COMPLICATIONS; OUTCOMES; HEMODYNAMICS; HOSPITALS AB Aortic stenosis (AS) is characterized as a high-risk index for cardiac complications during noncardiac surgery. The American College of Cardiology/American Heart Association guidelines define severe AS as aortic valve area <= 1 cm(2), mean gradient of >= 40 mm Hg, and peak velocity of >= 4 m/s. As per current clinical practice, any of these characteristic features label a patient as at high risk for noncardiac surgery. However, these parameters appear inconsistent, particularly with respect to the aortic valve area cutoff value. The perioperative risk associated with AS during noncardiac surgery depends upon its severity (moderate vs. severe), clinical status, and the complexity of the surgical procedure (low to intermediate risk vs. high risk). A critical analysis of old and new data from published studies indicates that the significance of the presence of AS in patients undergoing noncardiac surgery is overemphasized in studies that predate the more recent advances in echocardiography and cardiac catheterization in assessment of aortic stenosis, anesthetic and surgical techniques, as well as post-operative patient care. (C) 2015 by the American College of Cardiology Foundation. C1 [Samarendra, Padmaraj] VA Med Ctr, Noninvas Cardiol & Echocardiog Lab, Pittsburgh, PA 15240 USA. [Samarendra, Padmaraj] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA. [Mangione, Michael P.] VA Pittsburgh Hlth Care Syst, Dept Anesthesia, Pittsburgh, PA USA. [Mangione, Michael P.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15261 USA. RP Samarendra, P (reprint author), VA Med Ctr, Univ Dr C, Pittsburgh, PA 15240 USA. EM Padmaraj@aol.com NR 40 TC 0 Z9 0 U1 1 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD JAN 27 PY 2015 VL 65 IS 3 BP 295 EP 302 DI 10.1016/j.jacc.2014.10.051 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AZ2EA UT WOS:000348046200012 PM 25614427 ER PT J AU Sea, K Sohn, SH Durazo, A Sheng, YW Shaw, BF Cao, XH Taylor, AB Whitson, LJ Holloway, SP Hart, PJ Cabelli, DE Gralla, EB Valentine, JS AF Sea, Kevin Sohn, Se Hui Durazo, Armando Sheng, Yuewei Shaw, Bryan F. Cao, Xiaohang Taylor, Alexander B. Whitson, Lisa J. Holloway, Stephen P. Hart, P. John Cabelli, Diane E. Gralla, Edith Butler Valentine, Joan Selverstone TI Insights into the Role of the Unusual Disulfide Bond in Copper-Zinc Superoxide Dismutase SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID AMYOTROPHIC-LATERAL-SCLEROSIS; CU,ZN-SUPEROXIDE DISMUTASE; SACCHAROMYCES-CEREVISIAE; ATOMIC-RESOLUTION; PULSE-RADIOLYSIS; REDUCED FORM; METAL; AGGREGATION; YEAST; ALS AB The functional and structural significance of the intrasubunit disulfide bond in copper-zinc superoxide dismutase (SOD1) was studied by characterizing mutant forms of human SOD1 (hSOD) and yeast SOD1 lacking the disulfide bond. We determined x-ray crystal structures of metal-bound and metal-deficient hC57S SOD1. C57S hSOD1 isolated from yeast contained four zinc ions per protein dimer and was structurally very similar to wild type. The addition of copper to this four-zinc protein gave properly reconstituted 2Cu, 2Zn C57S hSOD, and its spectroscopic properties indicated that the coordination geometry of the copper was remarkably similar to that of holo wild type hSOD1. In contrast, the addition of copper and zinc ions to apo C57S human SOD1 failed to give proper reconstitution. Using pulse radiolysis, we determined SOD activities of yeast and human SOD1s lacking disulfide bonds and found that they were enzymatically active at similar to 10% of the wild type rate. These results are contrary to earlier reports that the intrasubunit disulfide bonds in SOD1 are essential for SOD activity. Kinetic studies revealed further that the yeast mutant SOD1 had less ionic attraction for superoxide, possibly explaining the lower rates. Saccharomyces cerevisiae cells lacking the sod1 gene do not grow aerobically in the absence of lysine, but expression of C57S SOD1 increased growth to 30-50% of the growth of cells expressing wild type SOD1, supporting that C57S SOD1 retained a significant amount of activity. C1 [Sea, Kevin; Sohn, Se Hui; Durazo, Armando; Sheng, Yuewei; Shaw, Bryan F.; Gralla, Edith Butler; Valentine, Joan Selverstone] Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA. [Sea, Kevin] Santa Rosa Jr Coll, Dept Wine Studies, Santa Rosa, CA 95401 USA. [Sohn, Se Hui] LG Chem Ltd, Taejon 305380, South Korea. [Durazo, Armando] Univ Arizona, Dept Chem & Environm Engn, Tucson, AZ 85721 USA. [Cabelli, Diane E.] Brookhaven Natl Lab, Dept Chem, Upton, NY 11973 USA. [Shaw, Bryan F.] Baylor Univ, Dept Chem & Biochem, Waco, TX 76798 USA. [Cao, Xiaohang; Taylor, Alexander B.; Whitson, Lisa J.; Holloway, Stephen P.; Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. [Hart, P. John] South Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX 78229 USA. [Valentine, Joan Selverstone] Ewha Womans Univ, Dept Bioinspired Sci, Seoul 120750, South Korea. RP Sea, K (reprint author), Santa Rosa Jr Coll, Dept Wine Studies, 1501 Mendocino Ave, Santa Rosa, CA 95401 USA. EM kevinsea@yahoo.com; jsv@chem.ucla.edu RI Shaw, Bryan/A-7001-2008 FU National Institutes of Health [DK46828, GM28222, GM08496, NS39112]; Veterans Affairs [VA 101 BX00506]; U.S. Department of Energy Division of Chemical Sciences, Geosciences, and Biosciences [DE-AC02-98CH10886] FX This work was supported, in whole or in part, by National Institutes of Health Grants DK46828 and GM28222 (to J. S. V.), GM08496 (to K. S.), and NS39112 (to P. J. H.). This work was also supported by Veterans Affairs Grant VA 101 BX00506 (to P. J. H.) and Contract DE-AC02-98CH10886 from the U.S. Department of Energy Division of Chemical Sciences, Geosciences, and Biosciences (to Brookhaven National Laboratory). NR 63 TC 7 Z9 7 U1 4 U2 29 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD JAN 23 PY 2015 VL 290 IS 4 BP 2405 EP 2418 DI 10.1074/jbc.M114.588798 PG 14 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA CA0EH UT WOS:000348588000043 PM 25433341 ER PT J AU Copik, AJ Baldys, A Nguyen, K Sahdeo, S Ho, H Kosaka, A Dietrich, PJ Fitch, B Raymond, JR Ford, APDW Button, D Milla, ME AF Copik, Alicja J. Baldys, Aleksander Nguyen, Khanh Sahdeo, Sunil Ho, Hoangdung Kosaka, Alan Dietrich, Paul J. Fitch, Bill Raymond, John R. Ford, Anthony P. D. W. Button, Donald Milla, Marcos E. TI Isoproterenol Acts as a Biased Agonist of the Alpha-1A-Adrenoceptor that Selectively Activates the MAPK/ERK Pathway SO PLOS ONE LA English DT Article ID PROTEIN-KINASE PATHWAYS; PAROTID ACINAR-CELLS; ALPHA(1)-ADRENERGIC RECEPTOR SUBTYPES; BETA-ADRENERGIC-RECEPTORS; TRANSFECTED PC12 CELLS; BETA(2)-ADRENERGIC RECEPTOR; ALPHA(1A)-ADRENERGIC RECEPTORS; INTERNALIZATION PROPERTIES; SYMPATHOMIMETIC AMINES; FUNCTIONAL SELECTIVITY AB The alpha(1A)-AR is thought to couple predominantly to the G alpha(q)/PLC pathway and lead to phosphoinositide hydrolysis and calcium mobilization, although certain agonists acting at this receptor have been reported to trigger activation of arachidonic acid formation and MAPK pathways. For several G protein-coupled receptors (GPCRs) agonists can manifest a bias for activation of particular effector signaling output, i.e. not all agonists of a given GPCR generate responses through utilization of the same signaling cascade(s). Previous work with G alpha(q) coupling-defective variants of alpha(1A)-AR, as well as a combination of Ca2+ channel blockers, uncovered cross-talk between alpha(1A)-AR and beta(2)-AR that leads to potentiation of a G alpha(q)-independent signaling cascade in response to alpha(1A)-AR activation. We hypothesized that molecules exist that act as biased agonists to selectively activate this pathway. In this report, isoproterenol (Iso), typically viewed as beta-AR-selective agonist, was examined with respect to activation of alpha(1A)-AR. alpha(1A)-AR selective antagonists were used to specifically block Iso evoked signaling in different cellular backgrounds and confirm its action at alpha(1A)-AR. Iso induced signaling at alpha(1A)-AR was further interrogated by probing steps along the G alpha(q)/PLC, G alpha(s) and MAPK/ERK pathways. In HEK-293/EBNA cells transiently transduced with alpha(1A)-AR, and CHO_alpha(1A)-AR stable cells, Iso evoked low potency ERK activity as well as Ca2+ mobilization that could be blocked by alpha(1A)-AR selective antagonists. The kinetics of Iso induced Ca2+ transients differed from typical G alpha(q)-mediated Ca2+ mobilization, lacking both the fast IP3R mediated response and the sustained phase of Ca2+ re-entry. Moreover, no inositol phosphate (IP) accumulation could be detected in either cell line after stimulation with Iso, but activation was accompanied by receptor internalization. Data are presented that indicate that Iso represents a novel type of alpha(1A)-AR partial agonist with signaling bias toward MAPK/ERK signaling cascade that is likely independent of coupling to G alpha(q). C1 [Copik, Alicja J.; Sahdeo, Sunil; Ford, Anthony P. D. W.; Button, Donald; Milla, Marcos E.] Roche Palo Alto LLC, Biochem Pharmacol Inflammat Discovery, Palo Alto, CA 94304 USA. [Nguyen, Khanh; Ho, Hoangdung; Kosaka, Alan; Dietrich, Paul J.; Fitch, Bill] Roche Palo Alto LLC, Discovery Technol, Palo Alto, CA 94304 USA. [Baldys, Aleksander; Raymond, John R.] Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA. [Baldys, Aleksander; Raymond, John R.] Ralph H Johnson Vet Affairs Med Ctr, Med & Res Serv, Charleston, SC 29425 USA. RP Milla, ME (reprint author), Roche Palo Alto LLC, Biochem Pharmacol Inflammat Discovery, 3401 Hillview Dr, Palo Alto, CA 94304 USA. EM mmilla22@its.jnj.com FU Department of Veterans Affairs Merit and Research Enhancement Award Program grants; National Institutes of Health [DK052448, GM063909]; Medical University of South Carolina Division of Nephrology, and Dialysis Clinics, Inc.; Roche Palo Alto LLC FX Most of this work was performed at Roche Palo Alto LLC. Immunofluorescence microscopy studies were performed with support from the Department of Veterans Affairs Merit and Research Enhancement Award Program grants, by National Institutes of Health Grants DK052448 and GM063909, by laboratory endowment jointly supported by the Medical University of South Carolina Division of Nephrology, and Dialysis Clinics, Inc. (to JRR). Roche Palo Alto LLC, the funder, provided support in the form of salaries for authors AJC, KN, SS, HH, AK, PJD, BF, APDWF, DB and MEM, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section. NR 69 TC 2 Z9 2 U1 1 U2 8 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JAN 21 PY 2015 VL 10 IS 1 AR e0115701 DI 10.1371/journal.pone.0115701 PG 31 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA AZ4PR UT WOS:000348205300018 PM 25606852 ER PT J AU Penagarikano, O Lazaro, MT Lu, XH Gordon, A Dong, HM Lam, HA Peles, E Maidment, NT Murphy, NP Yang, XW Golshani, P Geschwind, DH AF Penagarikano, Olga Lazaro, Maria T. Lu, Xiao-Hong Gordon, Aaron Dong, Hongmei Lam, Hoa A. Peles, Elior Maidment, Nigel T. Murphy, Niall P. Yang, X. William Golshani, Peyman Geschwind, Daniel H. TI Exogenous and evoked oxytocin restores social behavior in the Cntnap2 mouse model of autism SO SCIENCE TRANSLATIONAL MEDICINE LA English DT Article ID RECEPTOR GENE OXTR; SPECTRUM DISORDER; PLASMA OXYTOCIN; PRAIRIE VOLES; AFFILIATIVE BEHAVIOR; MICROTUS-OCHROGASTER; HYPERPHAGIC OBESITY; MICE; VASOPRESSIN; RELEASE AB Mouse models of neuropsychiatric diseases provide a platform for mechanistic understanding and development of new therapies. We previously demonstrated that knockout of the mouse homolog of CNTNAP2 (contactin-associated protein-like 2), in which mutations cause cortical dysplasia and focal epilepsy (CDFE) syndrome, displays many features that parallel those of the human disorder. Because CDFE has high penetrance for autism spectrum disorder (ASD), we performed an in vivo screen for drugs that ameliorate abnormal social behavior in Cntnap2 mutant mice and found that acute administration of the neuropeptide oxytocin improved social deficits. We found a decrease in the number of oxytocin immunoreactive neurons in the para-ventricular nucleus (PVN) of the hypothalamus in mutant mice and an overall decrease in brain oxytocin levels. Administration of a selective melanocortin receptor 4 agonist, which causes endogenous oxytocin release, also acutely rescued the social deficits, an effect blocked by an oxytocin antagonist. We confirmed that oxytocin neurons mediated the behavioral improvement by activating endogenous oxytocin neurons in the paraventricular hypothalamus with Designer Receptors Exclusively Activated by Designer Drugs (DREADD). Last, we showed that chronic early postnatal treatment with oxytocin led to more lasting behavioral recovery and restored oxytocin immunoreactivity in the PVN. These data demonstrate dysregulation of the oxytocin system in Cntnap2 knockout mice and suggest that there may be critical developmental windows for optimal treatment to rectify this deficit. C1 [Penagarikano, Olga; Lazaro, Maria T.; Dong, Hongmei; Golshani, Peyman; Geschwind, Daniel H.] Univ Calif Los Angeles, David Geffen Sch Med, Program Neurogenet, Dept Neurol, Los Angeles, CA 90095 USA. [Penagarikano, Olga; Geschwind, Daniel H.] Univ Calif Los Angeles, Ctr Autism Res & Treament, Los Angeles, CA 90095 USA. [Penagarikano, Olga; Geschwind, Daniel H.] Univ Calif Los Angeles, Ctr Neurobehav Genet, Jane & Terry Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA. [Lu, Xiao-Hong; Yang, X. William; Geschwind, Daniel H.] Univ Calif Los Angeles, Ctr Neurobehav Genet, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Gordon, Aaron; Peles, Elior] Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel. [Lam, Hoa A.; Maidment, Nigel T.; Murphy, Niall P.] Univ Calif Los Angeles, Jane & Terry Semel Inst Neurosci & Human Behav, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Golshani, Peyman] Univ Calif Los Angeles, Integrat Ctr Learning & Memory, Los Angeles, CA 90095 USA. [Golshani, Peyman] W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP Geschwind, DH (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Program Neurogenet, Dept Neurol, Los Angeles, CA 90095 USA. EM dhg@ucla.edu OI Penagarikano, Olga/0000-0001-8153-8221 FU NIH/National Institute of Mental Health (NIMH) [R01 MH081754-02R, NIH/NS50220]; NIH Autism Centers of Excellence (ACE) (Project II) [1P50-HD055784-01]; Simons Foundation Autism Research Initiative; UCLA Center for Autism Research and Treatment (CART) Pilot Grant; Autism Speaks grant in translational research [7657]; NIH/National Institute of Neurological Disorders and Stroke (NINDS) [R01 NS049501, R01 NS074312]; McKnight Foundation; [5R01-MH081754-04] FX This work was supported by grants NIH/National Institute of Mental Health (NIMH) R01 MH081754-02R to D.H.G., NIH/NS50220 to E.P., NIH Autism Centers of Excellence (ACE) 1P50-HD055784-01 to D.H.G. (Project II), Network grant 5R01-MH081754-04 to D.H.G., Simons Foundation Autism Research Initiative to E.P. and D.H.G., UCLA Center for Autism Research and Treatment (CART) Pilot Grant to N.T.M. and N.P.M., and Autism Speaks grant in translational research 7657 to O.P. X.W.Y. is supported by the NIH/National Institute of Neurological Disorders and Stroke (NINDS) grants R01 NS049501 and R01 NS074312, and the Brain Disorder Award from McKnight Foundation. NR 76 TC 50 Z9 51 U1 3 U2 32 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 1946-6234 EI 1946-6242 J9 SCI TRANSL MED JI Sci. Transl. Med. PD JAN 21 PY 2015 VL 7 IS 271 AR 271ra8 DI 10.1126/scitranslmed.3010257 PG 11 WC Cell Biology; Medicine, Research & Experimental SC Cell Biology; Research & Experimental Medicine GA AZ6TS UT WOS:000348353900002 PM 25609168 ER PT J AU Corrales-Medina, VF Alvarez, KN Weissfeld, LA Angus, DC Chirinos, JA Chang, CCH Newman, A Loehr, L Folsom, AR Elkind, MS Lyles, MF Kronmal, RA Yende, S AF Corrales-Medina, Vicente F. Alvarez, Karina N. Weissfeld, Lisa A. Angus, Derek C. Chirinos, Julio A. Chang, Chung-Chou H. Newman, Anne Loehr, Laura Folsom, Aaron R. Elkind, Mitchell S. Lyles, Mary F. Kronmal, Richard A. Yende, Sachin TI Association Between Hospitalization for Pneumonia and Subsequent Risk of Cardiovascular Disease SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID ACUTE CORONARY SYNDROMES; HEART-DISEASE; INFLAMMATORY MARKERS; ATHEROSCLEROSIS RISK; OLDER AMERICANS; ACUTE INFECTION; SEVERE SEPSIS; SURVIVAL; MORTALITY; STROKE AB IMPORTANCE The risk of cardiovascular disease (CVD) after infection is poorly understood. OBJECTIVE To determine whether hospitalization for pneumonia is associated with an increased short-term and long-term risk of CVD. DESIGN, SETTINGS, AND PARTICIPANTS We examined 2 community-based cohorts: the Cardiovascular Health Study (CHS, n = 5888; enrollment age, >= 65 years; enrollment period, 1989-1994) and the Atherosclerosis Risk in Communities study (ARIC, n = 15 792; enrollment age, 45-64 years; enrollment period, 1987-1989). Participants were followed up through December 31, 2010. We matched each participant hospitalized with pneumonia to 2 controls. Pneumonia cases and controls were followed for occurrence of CVD over 10 years after matching. We estimated hazard ratios (HRs) for CVD at different time intervals, adjusting for demographics, CVD risk factors, subclinical CVD, comorbidities, and functional status. EXPOSURES Hospitalization for pneumonia. MAIN OUTCOMES AND MEASURES Incident CVD (myocardial infarction, stroke, and fatal coronary heart disease). RESULTS Of 591 pneumonia cases in CHS, 206 had CVD events over 10 years after pneumonia hospitalization. Compared with controls, CVD risk among pneumonia cases was highest during the first year after hospitalization and remained significantly higher than among controls through 10 years. In ARIC, of 680 pneumonia cases, 112 had CVD events over 10 years after hospitalization. After the second year, CVD risk among pneumonia cases was not significantly higher than among controls. [GRAPHICS] CONCLUSIONS AND RELEVANCE Hospitalization for pneumonia was associated with increased short-term and long-term risk of CVD, suggesting that pneumonia may be a risk factor for CVD. C1 [Corrales-Medina, Vicente F.] Univ Ottawa, Dept Med, Ottawa, ON, Canada. [Corrales-Medina, Vicente F.] Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada. [Alvarez, Karina N.; Weissfeld, Lisa A.; Angus, Derek C.; Yende, Sachin] Univ Pittsburgh, Dept Crit Care Med, Clin Res Invest & Syst Modeling Acute Illness CRI, Pittsburgh, PA 15261 USA. [Weissfeld, Lisa A.; Chang, Chung-Chou H.] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA. [Chirinos, Julio A.] Univ Penn, Philadelphia, PA 19104 USA. [Chirinos, Julio A.] Philadelphia Vet Affairs Med Ctr, Div Cardiol, Philadelphia, PA USA. [Chang, Chung-Chou H.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15261 USA. [Newman, Anne] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. [Loehr, Laura] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA. [Folsom, Aaron R.] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN USA. [Elkind, Mitchell S.] Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY USA. [Elkind, Mitchell S.] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY USA. [Lyles, Mary F.] Wake Forest Univ, Dept Med, Winston Salem, NC 27109 USA. [Kronmal, Richard A.] Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA. [Yende, Sachin] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Yende, S (reprint author), Univ Pittsburgh, Dept Crit Care Med, Clin Res Invest & Syst Modeling Acute Illness CRI, 606D Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA. EM angusdc@upmc.edu; yendes@upmc.edu RI Newman, Anne/C-6408-2013; Angus, Derek/E-9671-2012 OI Newman, Anne/0000-0002-0106-1150; Corrales-Medina, Vicente/0000-0002-9691-491X FU National Heart, Lung, and Blood Institute (NHLBI) [HHSN268201200036C, HHSN268200800007C, N01 HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, HL080295]; National Institute on Aging (NIA) [AG023629]; NHLBI [HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, HHSN268201100012C]; Department of Medicine of The Ottawa Hospital; Ottawa Hospital Research Institute in Ottawa, Ontario, Canada; National Institute of General Medical Sciences [K23GM083215, R01GM097471] FX The Cardiovascular Health Study (CHS) was supported by contracts HHSN268201200036C, HHSN268200800007C, N01 HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, and grant HL080295 from the National Heart, Lung, and Blood Institute (NHLBI), with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided by grant AG023629 from the National Institute on Aging (NIA). A full list of principal CHS investigators and institutions can be found at CHS- NHLBI. org. The Atherosclerosis Risk in Communities study was supported by contracts HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C from the NHLBI. This article is also supported by a Junior Investigator Award from the Department of Medicine of The Ottawa Hospital and the Ottawa Hospital Research Institute in Ottawa, Ontario, Canada (Dr Corrales- Medina) and by K23GM083215 and R01GM097471 from the National Institute of General Medical Sciences (Dr Yende). NR 41 TC 51 Z9 51 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 20 PY 2015 VL 313 IS 3 BP 264 EP 274 DI 10.1001/jama.2014.18229 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA AZ3RS UT WOS:000348145000018 PM 25602997 ER PT J AU Dotson, AL Wang, JM Saugstad, J Murphy, SJ Offner, H AF Dotson, Abby L. Wang, Jianming Saugstad, Julie Murphy, Stephanie J. Offner, Halina TI Splenectomy reduces infarct volume and neuroinflammation in male but not female mice in experimental stroke SO JOURNAL OF NEUROIMMUNOLOGY LA English DT Article DE Experimental stroke; Sex difference; Immune response; Neuroinflammation; Infarct volume; Splenectomy ID REGULATORY T-CELLS; ACUTE ISCHEMIC-STROKE; NECROSIS-FACTOR-ALPHA; BRAIN-INJURY; CEREBRAL-ISCHEMIA; INFLAMMATION; SEX; EXPRESSION; PROTECTS; ESTROGEN AB The peripheral immune response contributes to neurodegeneration after stroke yet little is known about how this process differs between males and females. The current study demonstrates that splenectomy prior to experimental stroke eliminates sex differences in infarct volume and activated brain monocytes/microglia. In the periphery of both sexes, activated T cells correlate directly with stroke outcome while monocytes are reduced by splenectomy only in males. This study provides new information about the sex specific mechanisms of the peripheral immune response in neurodegeneration after stroke and demonstrates the need for representation of both sexes in basic and clinical stroke research. (C) 2014 Elsevier B.V. All rights reserved. C1 [Dotson, Abby L.; Offner, Halina] VA Med Ctr, Portland, OR USA. [Dotson, Abby L.; Offner, Halina] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Wang, Jianming; Saugstad, Julie; Murphy, Stephanie J.; Offner, Halina] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA. RP Offner, H (reprint author), Portland VA Med Ctr, R&D 31, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM offnerva@ohsu.edu FU NIH [NS076013]; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development FX The authors wish to thank Gail Kent for assistance with manuscript submission. This work was supported by NIH Grant # NS076013 and by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. The contents do not represent the views of the Department of Veterans Affairs or the United States Government. NR 37 TC 9 Z9 9 U1 2 U2 7 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-5728 EI 1872-8421 J9 J NEUROIMMUNOL JI J. Neuroimmunol. PD JAN 15 PY 2015 VL 278 BP 289 EP 298 DI 10.1016/j.jneuroim.2014.11.020 PG 10 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA CA9UC UT WOS:000349269300037 PM 25434281 ER PT J AU Kim, DH Martin, JT Elliott, DM Smith, LJ Mauck, RL AF Kim, Dong Hwa Martin, John T. Elliott, Dawn M. Smith, Lachlan J. Mauck, Robert L. TI Phenotypic stability, matrix elaboration and functional maturation of nucleus pulposus cells encapsulated in photocrosslinkable hyaluronic acid hydrogels SO ACTA BIOMATERIALIA LA English DT Article DE Intervertebral disc degeneration; Cell therapy; Three-dimensional culture; Mechanical properties; Tissue engineering ID INTERVERTEBRAL DISC CELLS; IN-VITRO; ARTICULAR-CARTILAGE; ENGINEERED CARTILAGE; REGENERATION; CHONDROCYTES; EXPRESSION; GENE; GELS; DIFFERENTIATION AB Degradation of the nucleus pulposus (NP) is an early hallmark of intervertebral disc degeneration. The capacity for endogenous regeneration in the NP is limited due to the low cellularity and poor nutrient and vascular supply. Towards restoring the NP, a number of biomaterials have been explored for cell delivery. These materials must support the NP cell phenotype while promoting the elaboration of an NP-like extracellular matrix in the shortest possible time. Our previous work with chondrocytes and mesenchymal stem cells demonstrated that hydrogels based on hyaluronic acid (HA) are effective at promoting matrix production and the development of functional material properties. However, this material has not been evaluated in the context of NP cells. Therefore, to test this material for NP regeneration, bovine NP cells were encapsulated in 1% w/vol HA hydrogels at either a low seeding density (20 x 10(6) cells ml(-1)) or a high seeding density (60 x 10(6) cells ml(-1)), and constructs were cultured over an 8 week period. These NP cell-laden HA hydrogels showed functional matrix accumulation, with increasing matrix content and mechanical properties with time in culture at both seeding densities. Furthermore, encapsulated cells showed NP-specific gene expression profiles that were significantly higher than expanded NP cells prior to encapsulation, suggesting a restoration of phenotype. Interestingly, these levels were higher at the lower seeding density compared to the higher seeding density. These findings support the use of HA-based hydrogels for NP tissue engineering and cellular therapies directed at restoration or replacement of the endogenous NP. (C) 2014 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved. C1 [Kim, Dong Hwa; Martin, John T.; Smith, Lachlan J.; Mauck, Robert L.] Univ Penn, McKay Orthopaed Res Lab, Dept Orthopaed Surg, Philadelphia, PA 19104 USA. [Kim, Dong Hwa; Martin, John T.; Smith, Lachlan J.; Mauck, Robert L.] Philadelphia VA Med Ctr, Translat Musculoskeletal Res Ctr, Philadelphia, PA 19104 USA. [Martin, John T.; Mauck, Robert L.] Univ Penn, Dept Mech Engn & Appl Mech, Philadelphia, PA 19104 USA. [Elliott, Dawn M.] Univ Delaware, Dept Biomed Engn, Newark, DE 19716 USA. [Smith, Lachlan J.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA. [Mauck, Robert L.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA. RP Mauck, RL (reprint author), Univ Penn, McKay Orthopaed Res Lab, Dept Orthopaed Surg, 36th St & Hamilton Walk,424 Stemmler Hall, Philadelphia, PA 19104 USA. EM lemauck@mail.med.upenn.edu FU Department of Defense [OR090090]; Department of Veterans Affairs [101 RX000211]; Penn Center for Musculoskeletal Disorders [P30 AR050950] FX This work was supported by the Department of Defense (Grant OR090090), the Department of Veterans Affairs (Grant 101 RX000211) and the Penn Center for Musculoskeletal Disorders (Grant P30 AR050950). NR 51 TC 9 Z9 10 U1 0 U2 12 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1742-7061 EI 1878-7568 J9 ACTA BIOMATER JI Acta Biomater. PD JAN 15 PY 2015 VL 12 BP 21 EP 29 DI 10.1016/j.actbio.2014.10.030 PG 9 WC Engineering, Biomedical; Materials Science, Biomaterials SC Engineering; Materials Science GA CA1QF UT WOS:000348686100003 PM 25448344 ER PT J AU Konhilas, JP Chen, H Luczak, E Mckee, LA Regan, J Watson, PA Stauffer, BL Khalpey, ZI Mckinsey, TA Horn, T LaFleur, B Leinwand, LA AF Konhilas, John P. Chen, Hao Luczak, Elizabeth Mckee, Laurel A. Regan, Jessica Watson, Peter A. Stauffer, Brian L. Khalpey, Zain I. Mckinsey, Timothy A. Horn, Todd LaFleur, Bonnie Leinwand, Leslie A. TI Diet and sex modify exercise and cardiac adaptation in the mouse SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE cardiac hypertrophy; sex and exercise; diet; soy ID ACTIVATED PROTEIN-KINASE; ENDURANCE EXERCISE; SKELETAL-MUSCLE; HYPERTROPHIC CARDIOMYOPATHY; GENDER-DIFFERENCES; HEART-FAILURE; MICE; WHEEL; SUBSTRATE; PATHWAY AB The heart adapts to exercise stimuli in a sex-dimorphic manner when mice are fed the traditional soy-based chow. Females undergo more voluntary exercise (4 wk) than males and exhibit more cardiac hypertrophy per kilometer run (18, 32). We have found that diet plays a critical role in cage wheel exercise and cardiac adaptation to the exercise stimulus in this sex dimorphism. Specifically, feeding male mice a casein-based, soy-free diet increases daily running distance over soy-fed counterparts to equal that of females. Moreover, casein-fed males have a greater capacity to increase their cardiac mass in response to exercise compared with soy-fed males. To further explore the biochemical mechanisms for these differences, we performed a candidate-based RT-PCR screen on genes previously implicated in diet-or exercise-based cardiac hypertrophy. Of the genes screened, many exhibit significant exercise, diet, or sex effects but only transforming growth factor-beta 1 shows a significant three-way interaction with no genes showing a two-way interaction. Finally, we show that the expression and activity of adenosine monophosphate-activated kinase-alpha 2 and acetyl-CoA carboxylase is dependent on exercise, diet, and sex. C1 [Konhilas, John P.; Luczak, Elizabeth; Stauffer, Brian L.; Leinwand, Leslie A.] Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA. [Konhilas, John P.; Chen, Hao; Mckee, Laurel A.; Regan, Jessica] Univ Arizona, Dept Physiol, Sarver Mol Cardiovasc Res Program, Tucson, AZ 85721 USA. [Watson, Peter A.] Univ Colorado, Denver, CO 80202 USA. [Watson, Peter A.; Stauffer, Brian L.; Mckinsey, Timothy A.; Horn, Todd] Denver Vet Affairs Med Ctr, Denver, CO USA. [Watson, Peter A.; Stauffer, Brian L.; Mckinsey, Timothy A.; Horn, Todd] Univ Colorado, Dept Med, Div Cardiol, Denver, CO USA. [Stauffer, Brian L.] Denver Hlth Med Ctr, Dept Med, Div Cardiol, Denver, CO USA. [Khalpey, Zain I.] Univ Arizona, Dept Surg, Tucson, AZ 85721 USA. [LaFleur, Bonnie] Univ Arizona, Mel & Enid Zuckerman Coll Publ Hlth, Tucson, AZ 85721 USA. RP Konhilas, JP (reprint author), Univ Arizona, Dept Physiol, Sarver Mol Cardiovasc Res Program, 1656 E Mabel St,Med Res Bldg,Rm 320, Tucson, AZ 85721 USA. EM konhilas@arizona.edu OI Stauffer, Brian/0000-0003-3418-7750 FU National Heart, Lung, and Blood Institute [HL-50560, HL-098256]; National and Mentored Research Science Development Award [K01-AR-052840]; National Heart, Lung, and Blood Institute Independent Scientist Award [K02-HL-105799] FX This work was supported by National Heart, Lung, and Blood Institute Grants HL-50560 (to L. A. Leinwand) and HL-098256, National and Mentored Research Science Development Award K01-AR-052840, and National Heart, Lung, and Blood Institute Independent Scientist Award K02-HL-105799 (to J. P. Konhilas). NR 43 TC 5 Z9 5 U1 0 U2 7 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 EI 1522-1539 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD JAN 15 PY 2015 VL 308 IS 2 BP H135 EP H145 DI 10.1152/ajpheart.00532.2014 PG 11 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA AY0WW UT WOS:000347315900008 PM 25398983 ER PT J AU McCleery, A Lee, J Joshi, A Wynn, JK Hellemann, GS Green, MF AF McCleery, Amanda Lee, Junghee Joshi, Aditi Wynn, Jonathan K. Hellemann, Gerhard S. Green, Michael F. TI Meta-Analysis of Face Processing Event-Related Potentials in Schizophrenia SO BIOLOGICAL PSYCHIATRY LA English DT Article DE Emotion identification; ERP; Face processing; N170; N250; Schizophrenia ID FACIAL AFFECT RECOGNITION; SOCIAL COGNITION; EMOTION RECOGNITION; PERCEPTION; N170; DEFICITS; EXPRESSIONS; PSYCHOSIS; REPRESENTATIONS; STANDARDIZATION AB BACKGROUND: Schizophrenia is associated with impaired face processing. N170 and N250 are two event-related potentials that have been studied in relation to face processing in schizophrenia, but the results have been mixed. The aim of this article was to conduct a meta-analysis of N170 and N250 in schizophrenia to evaluate trends and resolve the inconsistencies. METHODS: Twenty-one studies of N170 (n = 438 schizophrenia patients, n = 418 control subjects) and six studies of N250 (n = 149 schizophrenia patients, n = 151 control subjects) were evaluated. Hedges' g was calculated for each study, and the overall weighted mean effect size (ES) was calculated for N170 and N250. Homogeneity of the ES distributions, potential publication bias, and impact of potential moderators were also assessed. RESULTS: The amplitude of both N170 and N250 to face stimuli was smaller in patients than control subjects (N170 ES = .64; N250 ES = .49; ps < .001). The distributions of the ES were homogeneous (ps > .90), and there was no indication of a publication bias. We found no significant effect of task requirements regarding judgments of the face stimuli. Moreover, we found no significant difference between the ES for N170 and N250. CONCLUSIONS: Though findings of individual studies have been mixed, the results of the meta-analysis strongly support disruption of N170 and N250 in schizophrenia. The comparable effect sizes across the two waveforms suggest that the well-established behavioral deficit in face emotion processing is mirrored in an underlying neural impairment for processing faces. C1 [McCleery, Amanda; Lee, Junghee; Wynn, Jonathan K.; Hellemann, Gerhard S.; Green, Michael F.] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA. [Joshi, Aditi] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Wynn, Jonathan K.; Green, Michael F.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP McCleery, A (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat, UCLA Semel Inst Neurosci & Human Behav, 300 Med Plaza,Room 2213, Los Angeles, CA 90095 USA. EM amccleery@mednet.ucla.edu RI Lee, Junghee/C-5226-2014; McCleery, Amanda/D-5471-2016; Wynn, Jonathan/H-3749-2014 OI Lee, Junghee/0000-0001-9567-8700; McCleery, Amanda/0000-0003-2714-6897; Wynn, Jonathan/0000-0002-1763-8540 FU Canadian Institutes of Health Research fellowship award; Amgen FX Dr. McCleery is supported by the Canadian Institutes of Health Research fellowship award.; Dr. Green has been a consultant to AbbVie, Biogen, DSP, EnVivo, and Roche, and he is on the scientific advisory board of Mnemosyne. He has received research funds from Amgen. All other authors declare no biomedical financial interests or potential conflicts of interest. NR 63 TC 9 Z9 10 U1 4 U2 21 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD JAN 15 PY 2015 VL 77 IS 2 BP 116 EP 126 DI 10.1016/j.biopsych.2014.04.015 PG 11 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA AW6NQ UT WOS:000346386600007 PM 24923618 ER PT J AU Dowling, NM Johnson, SC Gleason, CE Jagust, WJ AF Dowling, N. Maritza Johnson, Sterling C. Gleason, Carey E. Jagust, William J. CA Alzheimers Dis Neuroimaging Initia TI The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function SO NEUROIMAGE LA English DT Article DE CSF biomarkers; Beta amyloid; FDG-PET; Tau; Alzheimer's disease; Longitudinal mediation; Parallel process latent growth; Structural equation modeling ID MILD COGNITIVE IMPAIRMENT; POSITRON-EMISSION-TOMOGRAPHY; PRECLINICAL ALZHEIMERS-DISEASE; BRAIN GLUCOSE-METABOLISM; MINI-MENTAL-STATE; APOLIPOPROTEIN-E; CSF BIOMARKERS; MEASUREMENT INVARIANCE; AMYLOID BURDEN; GENETIC RISK AB Positive cerebrospinal fluid (CSF) biomarkers of tau and amyloid beta42 suggest possible active underlying Alzheimer's disease (AD) including neurometabolic dysfunction and neurodegeneration leading to eventual cognitive decline. But the temporal relationship between CSF, imagingmarkers of neural function, and cognition has not been described. Using a statistical mediation model, we examined relationships between cerebrospinal fluid (CSF) analytes (hyperphosphorylated tau (p-Tau(181p)), beta-amyloid peptides 1-42 (A beta(1-42)), total tau (t-Tau), and their ratios); change in cognitive function; and change in [18F] fluorodeoxyglucose (FDG) uptake using positron emission tomography (PET). We hypothesized that a) abnormal CSF protein values at baseline, result in cognitive declines by decreasing neuronal glucose metabolism across time, and b) the role of altered glucose metabolism in the assumed causal chain varies by brain region and the nature of CSF protein alteration. Data from 412 individuals participating in Alzheimer's Disease Neuroimaging (ADNI) cohort studies were included in analyses. At baseline, individuals were cognitively normal (N = 82), or impaired: 241 with mild cognitive impairment, and 89 with Alzheimer's disease. A parallel-process latent growth curve model was used to test mediational effects of changes in regional FDG-PET uptake over time in relation to baseline CSF biomarkers and changes in cognition, measured with the 13-item Alzheimer Disease's Assessment Scale-cognitive subscale (ADAS-Cog). Findings suggested a causal sequence of events; specifically, FDG hypometabolism acted as a mediator between antecedent CSF biomarker alterations and subsequent cognitive impairment. Higher baseline concentrations of t-Tau, and p-Tau181p were more predictive of decline in cerebral glucose metabolism than lower baseline concentrations of A beta(1-42). FDG-PET changes appeared to mediate t-Tau or t-Tau/A beta(1-42)-associated cognitive change across all brain regions examined. Significant direct effects of alterations in A beta(1-42) levels on hypometabolism were observed in a single brain region: middle/inferior temporal gyrus. Results support a temporal framework model in which reduced CSF amyloid-related biomarkers occur earlier in the pathogenic pathway, ultimately leading to detrimental cognitive effects. Also consistent with this temporal framework model, baseline markers of neurofibrillary degeneration predicted changes in brain glucose metabolism in turn causing longitudinal cognitive changes, suggesting that tau-related burden precedes neurometabolic dysfunction. While intriguing, the hypothesized mediational relationships require further validation. Published by Elsevier Inc. C1 [Dowling, N. Maritza] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI 53792 USA. [Dowling, N. Maritza; Johnson, Sterling C.; Gleason, Carey E.] Univ Wisconsin, Alzheimers Dis Res Ctr, Madison, WI 53792 USA. [Johnson, Sterling C.; Gleason, Carey E.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA. [Jagust, William J.] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA. [Jagust, William J.] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA. RP Dowling, NM (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI 53792 USA. EM nmdowlin@biostat.wisc.edu RI Kowall, Neil/G-6364-2012 OI Kowall, Neil/0000-0002-6624-0213; Preda, Adrian /0000-0003-3373-2438 FU Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]; DOD ADNI (Department of Defense) [W81XWH-12-2-0012]; National Institute on Aging; National Institute of Biomedical Imaging and Bioengineering; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; Takeda Pharmaceutical Company; Canadian Institutes of Health Research; Alzheimer's Association [NIRG-12-242799]; National Institutes of Health [NIH-AG021155] FX Data collection and sharing for this project were funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare;; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.; This research also was partially supported by a grant from the Alzheimer's Association (NIRG-12-242799, Dowling) and the National Institutes of Health (NIH-AG021155, Johnson). NR 81 TC 8 Z9 9 U1 4 U2 28 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 EI 1095-9572 J9 NEUROIMAGE JI Neuroimage PD JAN 15 PY 2015 VL 105 BP 357 EP 368 DI 10.1016/j.neuroimage.2014.10.050 PG 12 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA AW1LG UT WOS:000346050300034 PM 25450107 ER PT J AU Wheeler, AL Tien, PC Grunfeld, C Schafer, AL AF Wheeler, Amber L. Tien, Phyllis C. Grunfeld, Carl Schafer, Anne L. TI Teriparatide treatment of osteoporosis in an HIV-infected man: a case report and literature review SO AIDS LA English DT Letter ID BONE; THERAPY; MEN C1 Univ Calif San Francisco, Dept Med, San Francisco, CA USA. San Francisco VA Med Ctr, San Francisco, CA USA. RP Wheeler, AL (reprint author), Vet Affairs Med Ctr, Metab Sect, 111F,4150 Clement St, San Francisco, CA 94121 USA. EM amber.wheeler@ucsf.edu OI Wheeler, Amber/0000-0002-9926-1301 FU CSRD VA [IK2 CX000549]; NCATS NIH HHS [KL2 TR000143, KL2TR000143]; NIAID NIH HHS [K24 AI108516]; NICHD NIH HHS [5K12HD052163-15, K12 HD052163]; NIDDK NIH HHS [T32 DK007418] NR 6 TC 5 Z9 5 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0269-9370 EI 1473-5571 J9 AIDS JI Aids PD JAN 14 PY 2015 VL 29 IS 2 BP 245 EP 246 DI 10.1097/QAD.0000000000000529 PG 2 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA AX8HE UT WOS:000347149900014 PM 25532609 ER PT J AU Daskalakis, NP Yehuda, R AF Daskalakis, Nikolaos P. Yehuda, Rachel TI Early maternal influences on stress circuitry: implications for resilience and susceptibility to physical and mental disorders SO FRONTIERS IN ENDOCRINOLOGY LA English DT Editorial Material DE early life stress; HPA axis; vulnerability; resilience; maternal ID HOLOCAUST SURVIVORS; PTSD; EXPOSURE; TRAUMA C1 [Daskalakis, Nikolaos P.; Yehuda, Rachel] Icahn Sch Med Mt Sinai, Traumat Stress Studies Div, Dept Psychiat, New York, NY 10029 USA. [Daskalakis, Nikolaos P.; Yehuda, Rachel] James J Peters Vet Affairs Med Ctr, Mental Hlth Patient Care Ctr, Bronx, NY USA. [Daskalakis, Nikolaos P.] Icahn Sch Med Mt Sinai, Dept Psychiat, Lab Mol Neuropsychiat, New York, NY 10029 USA. [Yehuda, Rachel] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA. RP Daskalakis, NP (reprint author), Icahn Sch Med Mt Sinai, Traumat Stress Studies Div, Dept Psychiat, New York, NY 10029 USA.; Daskalakis, NP (reprint author), James J Peters Vet Affairs Med Ctr, Mental Hlth Patient Care Ctr, Bronx, NY USA.; Daskalakis, NP (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, Lab Mol Neuropsychiat, New York, NY 10029 USA. EM nikolaos.daskalakis@mssm.edu OI Daskalakis, Nikolaos/0000-0003-1660-9112 NR 22 TC 1 Z9 1 U1 0 U2 3 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1664-2392 J9 FRONT ENDOCRINOL JI Front. Endocrinol. PD JAN 14 PY 2015 VL 5 AR 244 DI 10.3389/fendo.2014.00244 PG 3 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DP3KL UT WOS:000378392100001 ER PT J AU Teodorescu, M Barnet, JH Hagen, EW Palta, M Young, TB Peppard, PE AF Teodorescu, Mihaela Barnet, Jodi H. Hagen, Erika W. Palta, Mari Young, Terry B. Peppard, Paul E. TI Association Between Asthma and Risk of Developing Obstructive Sleep Apnea SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID UPPER AIRWAY; GASTROESOPHAGEAL-REFLUX; SYSTEMIC INFLAMMATION; INCREASED PREVALENCE; DAYTIME SLEEPINESS; SELF-REPORT; ADULTS; POPULATION; STEROIDS; DISEASE AB IMPORTANCE Obstructive sleep apnea (OSA) is more common among patients with asthma; whether asthma is associated with the development of OSA is unknown. OBJECTIVE To examine the prospective relationship of asthma with incident OSA. DESIGN, SETTING, AND PARTICIPANTS Population-based prospective epidemiologic study (the Wisconsin Sleep Cohort Study) beginning in 1988. Adult participants were recruited from a random sample of Wisconsin state employees to attend overnight polysomnography studies at 4-year intervals. Asthma and covariate information were assessed during polysomnography studies through March 2013. Eligible participants were identified as free of OSA (apnea-hypopnea index [AHI] of <5 events/h and not treated) by 2 baseline polysomnography studies. There were 1105 4-year follow-up intervals provided by 547 participants (52% women; mean [SD] baseline age, 50 [8] years). EXPOSURES Questionnaire-assessed presence and duration of self-reported physician-diagnosed asthma. MAIN OUTCOMES AND MEASURES The associations of presence and duration of asthma with 4-year incidences of both OSA (AHI of >= 5 or positive airway pressure treatment) and OSA concomitant with habitual daytime sleepiness were estimated using repeated-measures Poisson regression, adjusting for confounders. RESULTS Twenty-two of 81 participants (27%[95% CI, 17%-37%]) with asthma experienced incident OSA over their first observed 4-year follow-up interval compared with 75 of 466 participants (16%[95% CI, 13%-19%]) without asthma. Using all 4-year intervals, participants with asthma experienced 45 cases of incident OSA during 167 4-year intervals (27%[95% CI, 20%-34%]) and participants without asthma experienced 160 cases of incident OSA during 938 4-year intervals (17%[95% CI, 15%-19%]); the corresponding adjusted relative risk (RR) was 1.39 (95% CI, 1.06-1.82), controlling for sex, age, baseline and change in body mass index, and other factors. Asthma was also associated with new-onset OSA with habitual sleepiness (RR, 2.72 [95% CI, 1.26-5.89], P = .045). Asthma duration was related to both incident OSA (RR, 1.07 per 5-year increment in asthma duration [95% CI, 1.02-1.13], P = .01) and incident OSA with habitual sleepiness (RR, 1.18 [95% CI, 1.07-1.31], P = .02). CONCLUSIONS AND RELEVANCE Asthma was associated with an increased risk of new-onset OSA. Studies investigating the mechanisms underlying this association and the value of periodic OSA evaluation in patients with asthma are warranted. C1 [Teodorescu, Mihaela] William S Middleton Mem Vet Adm Med Ctr, James B Skatrud Pulm Sleep Res Lab, Madison, WI USA. [Teodorescu, Mihaela] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53792 USA. [Teodorescu, Mihaela] Univ Wisconsin, Sch Med & Publ Hlth, Ctr Sleep Med & Sleep Res, Madison, WI 53792 USA. [Barnet, Jodi H.; Hagen, Erika W.; Palta, Mari; Young, Terry B.; Peppard, Paul E.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53792 USA. RP Teodorescu, M (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, K4-910 CSC 9988,600 Highland Ave, Madison, WI 53792 USA. EM mt3@medicine.wisc.edu FU National Heart, Lung, and Blood Institute [R01HL62252]; National Institute on Aging [R01AG036838]; National Center for Research Resources at the National Institutes of Health (NIH) [1UL1RR025011] FX This work was funded by the National Heart, Lung, and Blood Institute (R01HL62252), National Institute on Aging (R01AG036838), and the National Center for Research Resources (1UL1RR025011) at the National Institutes of Health (NIH); additional resources were from the William S. Middleton Memorial VA Hospital, Madison. This work was performed at the University of Wisconsin and William S. Middleton Memorial VA Hospital, Madison. NR 34 TC 33 Z9 35 U1 3 U2 10 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 13 PY 2015 VL 313 IS 2 BP 156 EP 164 DI 10.1001/jama.2014.17822 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA AY6MC UT WOS:000347679300015 PM 25585327 ER PT J AU Naghavi, M Wang, HD Lozano, R Davis, A Liang, XF Zhou, MG Vollset, SE Ozgoren, AA Abdalla, S Abd-Allah, F Aziz, MIA Abera, SF Aboyans, V Abraham, B Abraham, JP Abuabara, KE Abubakar, I Abu-Raddad, LJ Abu-Rmeileh, NME Achoki, T Adelekan, A Ademi, ZN Adofo, K Adou, AK Adsuar, JC Aernlov, J Agardh, EE Akena, D Al Khabouri, MJ Alasfoor, D Albittar, M Alegretti, MA Aleman, AV Alemu, ZA Alfonso-Cristancho, R Alhabib, S Ali, MK Ali, R Alla, F Al Lami, F Allebeck, P AlMazroa, MA Salman, RAS Alsharif, U Alvarez, E Alviz-Guzman, N Amankwaa, AA Amare, AT Ameli, O Amini, H Ammar, W Anderson, HR Anderson, BO Antonio, CAT Anwari, P Apfel, H Cunningham, SA Arsenijevic, VSA Al Artaman Asad, MM Asghar, RJ Assadi, R Atkins, LS Atkinson, C Badawi, A Bahit, MC Bakfalouni, T Balakrishnan, K Balalla, S Banerjee, A Barber, RM Barker-Collo, SL Barquera, S Barregard, L Barrero, LH Barrientos-Gutierrez, T Basu, A Basu, S Basulaiman, MO Beardsley, J Bedi, N Beghi, E Bekele, T Bell, ML Benjet, C Bennett, DA Bensenor, IM Benzian, H Bertozzi-Villa, A Beyene, TJ Bhala, N Bhalla, A Bhutta, ZA Bikbov, B Bin Abdulhak, A Biryukov, S Blore, JD Blyth, FM Bohensky, MA Borges, G Bose, D Boufous, S Bourne, RR Boyers, LN Brainin, M Brauer, M Brayne, CEG Brazinova, A Breitborde, N Brenner, H Briggs, ADM Brown, JC Brugha, TS Buckle, GC Bui, LN Bukhman, G Burch, M Nonato, IRC Carabin, H Cardenas, R Carapetis, J Carpenter, DO Caso, V Castaneda-Orjuela, CA Castro, RE Catala-Lopez, F Cavalleri, F Chang, JC Charlson, FC Che, X Chen, HL Chen, YY Chen, JS Chen, ZM Chiang, PPC Chimed-Ochir, O Chowdhury, R Christensen, H Christophi, CA Chuang, TW Chugh, SS Cirillo, M Coates, MM Coffeng, LE Coggeshall, MS Cohen, A Colistro, V Colquhoun, SM Colomar, M Cooper, LT Cooper, C Coppola, LM Cortinovis, M Courville, K Cowie, BC Criqui, MH Crump, JA Cuevas-Nasu, L Leite, IDC Dabhadkar, KC Dandona, L Dandona, R Dansereau, E Dargan, PI Dayama, A De la Cruz-Gongora, V de la Vega, SF De Leo, D Degenhardt, L del Pozo-Cruz, B Dellavalle, RP Deribe, K Jarlais, DCD Dessalegn, M deVeber, GA Dharmaratne, SD Dherani, M Diaz-Ortega, JL Diaz-Torne, C Dicker, D Ding, EL Dokova, K Dorsey, ER Driscoll, TR Duan, LL Duber, HC Durrani, AM Ebel, BE Edmond, KM Ellenbogen, RG Elshrek, Y Ermakov, SP Erskine, HE Eshrati, B Esteghamati, A Estep, K Furst, T Fahimi, S Fahrion, AS Faraon, EJA Farzadfar, F Fay, DFJ Feigl, AB Feigin, VL Felicio, MM Fereshtehnejad, SM Fernandes, JG Ferrari, AJ Fleming, TD Foigt, N Foreman, K Forouzanfar, MH Fowkes, FGR Paleo, UF Franklin, RC Futran, ND Gaffikin, L Gambashidze, K Gankpe, FG Garcia-Guerra, FA Garcia, AC Geleijnse, JM Gessner, BD Gibney, KB Gillum, RF Gilmour, S Abdelmageem, I Ginawi, M Giroud, M Glaser, EL Goenka, S Dantes, HG Gona, P Gonzalez-Medina, D Guinovart, C Gupta, R Gupta, R Gosselin, RA Gotay, CC Goto, A Gowda, HN Graetz, N Greenwell, KF Gugnani, HC Gunnell, D Gutierrez, RA Haagsma, J Hafezi-Nejad, N Hagan, H Hagstromer, M Halasa, YA Hamadeh, RR Hamavid, H Hammami, M Hancock, J Hankey, GJ Hansen, GM Harb, HL Harewood, H Haro, JM Havmoeller, R Hay, RJ Hay, SI Hedayati, MT Pi, IBH Heuton, KR Heydarpour, P Higashi, H Hijar, M Hoek, HW Hoffman, HJ Hornberger, JC Hosgood, HD Hossain, M Hotez, PJ Hoy, DG Hsairi, M Hu, GQ Huang, JJ Huffman, MD Hughes, AJ Husseini, A Huynh, C Iannarone, M Iburg, KM Idrisov, BT Ikeda, N Innos, K Inoue, M Islami, F Ismayilova, S Jacobsen, KH Jassal, S Jayaraman, SP Jensen, PN Jha, V Jiang, GH Jiang, Y Jonas, JB Joseph, J Juel, K Kabagambe, EK Kan, HD Karch, A Karimkhani, C Karthikeyan, G Kassebaum, N Kaul, A Kawakami, N Kazanjan, K Kazi, DS Kemp, AH Kengne, AP Keren, A Kereselidze, M Khader, YS Khalifa, SEAH Khan, EA Khan, G Khang, YH Kieling, C Kinfu, Y Kinge, JM Kim, D Kim, S Kivipelto, M Knibbs, L Knudsen, AK Kokubo, Y Kosen, S Kotagal, M Kravchenko, MA Krishnaswami, S Krueger, H Defo, BK Kuipers, EJ Bicer, BK Kulkarni, C Kulkarni, VS Kumar, K Kumar, RB Kwan, GF Kyu, H Lai, T Balaji, AL Lalloo, R Lallukka, T Lam, H Lan, Q Lansingh, VC Larson, HJ Larsson, A Lavados, PM Lawrynowicz, AEB Leasher, JL Lee, JT Leigh, J Leinsalu, M Leung, R Levitz, C Li, B Li, YC Li, YM Liddell, C Lim, SS de Lima, GMF Lind, ML Lipshultz, SE Liu, SW Liu, Y Lloyd, BK Lofgren, KT Logroscino, G London, SJ Lortet-Tieulent, J Lotufo, PA Lucas, RM Lunevicius, R Lyons, RA Ma, S Machado, VMP MacIntyre, MF Mackay, MT MacLachlan, JH Magis-Rodriguez, C Mahdi, AA Majdan, M Malekzadeh, R Mangalam, S Mapoma, CC Marape, M Marcenes, W Margono, C Marks, GB Marzan, MB Masci, JR Mashal, MTQ Masiye, F Mason-Jones, AJ Matzopolous, R Mayosi, BM Mazorodze, TT McGrath, JJ Mckay, AC Mckee, M McLain, A Meaney, PA Mehndiratta, MM Mejia-Rodriguez, F Melaku, YA Meltzer, M Memish, ZA Mendoza, W Mensah, GA Meretoja, A Mhimbira, FA Miller, TR Mills, EJ Misganaw, A Mishra, SK Mock, CN Moffitt, TE Ibrahim, NM Mohammad, KA Mokdad, AH Mola, GL Monasta, L Monis, JD Hernandez, JCM Montico, M Montine, TJ Mooney, MD Moore, AR Moradi-Lakeh, M Moran, AE Mori, R Moschandreas, J Moturi, WN Moyer, ML Mozaffarian, D Mueller, UO Mukaigawara, M Mullany, EC Murray, J Mustapha, A Naghavi, P Naheed, A Naidoo, KS Naldi, L Nand, D Nangia, V Narayan, KMV Nash, D Nasher, J Nejjari, C Nelson, RG Neuhouser, M Neupane, SP Newcomb, PA Newman, L Newton, CR Ng, M Ngalesoni, FN Nguyen, G Nguyen, NTT Nisar, MI Nolte, S Norheim, OF Norman, RE Norrving, B Nyakarahuka, L Odell, S O'Donnell, M Ohkubo, T Ohno, SL Olusanya, BO Omer, SB Opio, JN Orisakwe, OE Ortblad, KF Ortiz, A Otayza, MLK Pain, AW Pandian, JD Panelo, CI Panniyammakal, J Papachristou, C Caicedo, AJP Patten, SB Patton, GC Paul, VK Pavlin, B Pearce, N Pellegrini, CA Pereira, DM Peresson, SC Perez-Padilla, R Perez-Ruiz, FP Perico, N Pervaiz, A Pesudovs, K Peterson, CB Petzold, M Phillips, BK Phillips, DE Phillips, MR Plass, D Piel, FB Poenaru, D Polinder, S Popova, S Poulton, RG Pourmalek, F Prabhakaran, D Qato, D Quezada, AD Quistberg, DA Rabito, F Rafay, A Rahimi, K Rahimi-Movaghar, V Rahman, SUR Raju, M Rakovac, I Rana, SM Refaat, A Remuzzi, G Ribeiro, AL Ricci, S Riccio, PM Richardson, L Richardus, JH Roberts, B Roberts, DA Robinson, M Roca, A Rodriguez, A Rojas-Rueda, D Ronfani, L Room, R Roth, GA Rothenbacher, D Rothstein, DH Rowley, JT Roy, N Ruhago, GM Rushton, L Sambandam, S Soreide, K Saeedi, MY Saha, S Sahathevan, R Sahraian, MA Sahle, BW Salomon, JA Salvo, D Samonte, GMJ Sampson, U Sanabria, JR Sandar, L Santos, IS Satpathy, M Sawhney, M Saylan, M Scarborough, P Schottker, B Schmidt, JC Schneider, IJC Schumacher, AE Schwebel, DC Scott, JG Sepanlou, SG Servan-Mori, EE Shackelford, K Shaheen, A Shahraz, S Shakh-Nazarova, M Shangguan, S She, J Sheikhbahaei, S Shepard, DS Shibuya, K Shinohara, Y Shishani, K Shiue, I Shivakoti, R Shrime, MG Sigfusdottir, ID Silberberg, DH Silva, AP Simard, EP Sindi, S Singh, JA Singh, L Sioson, E Skirbekk, V Sliwa, K So, S Soljak, M Soneji, S Soshnikov, SS Sposato, LA Sreeramareddy, CT Stanaway, JRD Stathopoulou, VK Steenland, K Stein, C Steiner, C Stevens, A Stoeckl, H Straif, K Stroumpoulis, K Sturua, L Sunguya, BF Swaminathan, S Swaroop, M Sykes, BL Tabb, KM Takahashi, K Talongwa, RT Tan, F Tanne, D Tanner, M Tavakkoli, M Ao, BT Teixeira, CM Templin, T Tenkorang, EY Terkawi, AS Thomas, BA Thorne-Lyman, AL Thrift, AG Thurston, GD Tillmann, T Tirschwell, DL Tleyjeh, IM Tonelli, M Topouzis, F Towbin, JA Toyoshima, H Traebert, J Tran, BX Truelsen, T Trujillo, U Trillini, M Dimbuene, ZT Tsilimbaris, M Tuzcu, EM Ubeda, C Uchendu, US Ukwaja, KN Undurraga, EA Vallely, AJ van de Vijver, S van Gool, CH Varakin, YY Vasankari, TJ Vasconcelos, AMN Vavilala, MS Venketasubramanian, N Vijayakumar, L Villalpando, S Violante, FS Vlassov, VV Wagner, GR Waller, SG Wang, JL Wang, L Wang, XR Wang, YP Warouw, TS Weichenthal, S Weiderpass, E Weintraub, RG Wenzhi, W Werdecker, A Wessells, KRR Westerman, R Whiteford, HA Wilkinson, JD Williams, TN Woldeyohannes, SM Wolfe, CDA Wolock, TM Woolf, AD Wong, JQ Wright, JL Wulf, S Wurtz, B Xu, GL Yang, YC Yano, Y Yatsuya, H Yip, P Yonemoto, N Yoon, SJ Younis, M Yu, CH Jin, KY Zaki, MES Zamakhshary, MF Zeeb, H Zhang, Y Zhao, Y Zheng, YF Zhu, J Zhu, S Zonies, D Zou, XN Zunt, JR Vos, T Lopez, AD Murray, CJL AF Naghavi, Mohsen Wang, Haidong Lozano, Rafael Davis, Adrian Liang, Xiaofeng Zhou, Maigeng Vollset, Stein Emil Ozgoren, Ayse Abbasoglu Abdalla, Safa Abd-Allah, Foad Aziz, Muna I. Abdel Abera, Semaw Ferede Aboyans, Victor Abraham, Biju Abraham, Jerry P. Abuabara, Katrina E. Abubakar, Ibrahim Abu-Raddad, Laith J. Abu-Rmeileh, Niveen M. E. Achoki, Tom Adelekan, Ademola Ademi, Zanfi Na Adofo, Koranteng Adou, Arsene Kouablan Adsuar, Jose C. Aernlov, Johan Agardh, Emilie Elisabet Akena, Dickens Al Khabouri, Mazin J. Alasfoor, Deena Albittar, Mohammed Alegretti, Miguel Angel Aleman, Alicia V. Alemu, Zewdie Aderaw Alfonso-Cristancho, Rafael Alhabib, Samia Ali, Mohammed K. Ali, Raghib Alla, Francois Al Lami, Faris Allebeck, Peter AlMazroa, Mohammad A. Salman, Rustam Al-Shahi Alsharif, Ubai Alvarez, Elena Alviz-Guzman, Nelson Amankwaa, Adansi A. Amare, Azmeraw T. Ameli, Omid Amini, Hassan Ammar, Walid Anderson, H. Ross Anderson, Benjamin O. Antonio, Carl Abelardo T. Anwari, Palwasha Apfel, Henry Cunningham, Solveig Argeseanu Arsenijevic, Valentina S. Arsic Al Artaman Asad, Majed Masoud Asghar, Rana J. Assadi, Reza Atkins, Lydia S. Atkinson, Charles Badawi, Alaa Bahit, Maria C. Bakfalouni, Talal Balakrishnan, Kalpana Balalla, Shivanthi Banerjee, Amitava Barber, Ryan M. Barker-Collo, Suzanne L. Barquera, Simon Barregard, Lars Barrero, Lope H. Barrientos-Gutierrez, Tonatiuh Basu, Arindam Basu, Sanjay Basulaiman, Mohammed Omar Beardsley, Justin Bedi, Neeraj Beghi, Ettore Bekele, Tolesa Bell, Michelle L. Benjet, Corina Bennett, Derrick A. Bensenor, Isabela M. Benzian, Habib Bertozzi-Villa, Amelia Beyene, Tariku Jibat Bhala, Neeraj Bhalla, Ashish Bhutta, Zulfiqar A. Bikbov, Boris Bin Abdulhak, Aref Biryukov, Stan Blore, Jed D. Blyth, Fiona M. Bohensky, Megan A. Borges, Guilherme Bose, Dipan Boufous, Soufiane Bourne, Rupert R. Boyers, Lindsay N. Brainin, Michael Brauer, Michael Brayne, Carol E. G. Brazinova, Alexandra Breitborde, Nicholas Brenner, Hermann Briggs, Adam D. M. Brown, Jonathan C. Brugha, Traolach S. Buckle, Geoffrey C. Bui, Linh Ngoc Bukhman, Gene Burch, Michael Nonato, Ismael Ricardo Campos Carabin, Helesne Cardenas, Rosario Carapetis, Jonathan Carpenter, David O. Caso, Valeria Castaneda-Orjuela, Carlos A. Castro, Ruben Estanislao Catala-Lopez, Ferrn Cavalleri, Fiorella Chang, Jung-Chen Charlson, Fiona C. Che, Xuan Chen, Honglei Chen, Yingyao Chen, Jian Sheng Chen, Zhengming Chiang, Peggy Pei-Chia Chimed-Ochir, Odgerel Chowdhury, Rajiv Christensen, Hanne Christophi, Costas A. Chuang, Ting-Wu Chugh, Sumeet S. Cirillo, Massimo Coates, Matthew M. Coffeng, Luc Edgar Coggeshall, Megan S. Cohen, Aaron Colistro, Valentina Colquhoun, Samantha M. Colomar, Mercedes Cooper, Leslie Trumbull Cooper, Cyrus Coppola, Luis M. Cortinovis, Monica Courville, Karen Cowie, Benjamin C. Criqui, Michael H. Crump, John A. Cuevas-Nasu, Lucia Leite, Iuri da Costa Dabhadkar, Kaustubh C. Dandona, Lalit Dandona, Rakhi Dansereau, Emily Dargan, Paul I. Dayama, Anand De la Cruz-Gongora, Vanessa de la Vega, Shelley F. De Leo, Diego Degenhardt, Louisa del Pozo-Cruz, Borja Dellavalle, Robert P. Deribe, Kebede Jarlais, Don C. Des Dessalegn, Muluken deVeber, Gabrielle A. Dharmaratne, Samath D. Dherani, Mukesh Diaz-Ortega, Jose-Luis Diaz-Torne, Cesar Dicker, Daniel Ding, Eric L. Dokova, Klara Dorsey, E. Ray Driscoll, Tim R. Duan, Leilei Duber, Herbert C. Durrani, Adnan M. Ebel, Beth E. Edmond, Karen M. Ellenbogen, Richard G. Elshrek, Yousef Ermakov, Sergey Petrovich Erskine, Holly E. Eshrati, Babak Esteghamati, Alireza Estep, Kara Fuerst, Thomas Fahimi, Saman Fahrion, Anna S. Faraon, Emerito Jose A. Farzadfar, Farshad Fay, Derek F. J. Feigl, Andrea B. Feigin, Valery L. Felicio, Manuela Mendonca Fereshtehnejad, Seyed-Mohammad Fernandes, Jefferson G. Ferrari, Alize J. Fleming, Thomas D. Foigt, Nataliya Foreman, Kyle Forouzanfar, Mohammad H. Fowkes, F. Gerry R. Fra Paleo, Urbano Franklin, Richard C. Futran, Neal D. Gaffikin, Lynne Gambashidze, Ketevan Gankpe, Fortune Gbetoho Garcia-Guerra, Francisco Armando Garcia, Ana Cristina Geleijnse, Johanna M. Gessner, Bradford D. Gibney, Katherine B. Gillum, Richard F. Gilmour, Stuart Abdelmageem, Ibrahim Ginawi, Mohamed Giroud, Maurice Glaser, Elizabeth L. Goenka, Shifalika Dantes, Hector Gomez Gona, Philimon Gonzalez-Medina, Diego Guinovart, Caterina Gupta, Rahul Gupta, Rajeev Gosselin, Richard A. Gotay, Carolyn C. Goto, Atsushi Gowda, Hube N. Graetz, Nicholas Greenwell, K. Fern Gugnani, Harish Chander Gunnell, David Gutierrez, Reyna A. Haagsma, Juanita Hafezi-Nejad, Nima Hagan, Holly Hagstromer, Maria Halasa, Yara A. Hamadeh, Randah Ribhi Hamavid, Hannah Hammami, Mouhanad Hancock, Jamie Hankey, Graeme J. Hansen, Gillian M. Harb, Hilda L. Harewood, Heather Haro, Josep Maria Havmoeller, Rasmus Hay, Roderick J. Hay, Simon I. Hedayati, Mohammad T. Pi, Ileana B. Heredia Heuton, Kyle R. Heydarpour, Pouria Higashi, Hideki Hijar, Martha Hoek, Hans W. Hoffman, Howard J. Hornberger, John C. Hosgood, H. Dean Hossain, Mazeda Hotez, Peter J. Hoy, Damian G. Hsairi, Mohamed Hu, Guoqing Huang, John J. Huffman, Mark D. Hughes, Andrew J. Husseini, Abdullatif Huynh, Chantal Iannarone, Marissa Iburg, Kim M. Idrisov, Bulat T. Ikeda, Nayu Innos, Kaire Inoue, Manami Islami, Farhad Ismayilova, Samaya Jacobsen, Kathryn H. Jassal, Simerjot Jayaraman, Sudha P. Jensen, Paul N. Jha, Vivekanand Jiang, Guohong Jiang, Ying Jonas, Jost B. Joseph, Jonathan Juel, Knud Kabagambe, Edmond Kato Kan, Haidong Karch, Andre Karimkhani, Chante Karthikeyan, Ganesan Kassebaum, Nicholas Kaul, Anil Kawakami, Norito Kazanjan, Konstantin Kazi, Dhruv S. Kemp, Andrew H. Kengne, Andre Pascal Keren, Andre Kereselidze, Maia Khader, Yousef Saleh Khalifa, Shams Eldin Ali Hassan Khan, Ejaz Ahmed Khan, Gulfaraz Khang, Young-Ho Kieling, Christian Kinfu, Yohannes Kinge, Jonas M. Kim, Daniel Kim, Sungroul Kivipelto, Miia Knibbs, Luke Knudsen, Ann Kristin Kokubo, Yoshihiro Kosen, Sowarta Kotagal, Meera Kravchenko, Michael A. Krishnaswami, Sanjay Krueger, Hans Defo, Barthelemy Kuate Kuipers, Ernst J. Bicer, Burcu Kucuk Kulkarni, Chanda Kulkarni, Veena S. Kumar, Kaushalendra Kumar, Ravi B. Kwan, Gene F. Kyu, Hmwe Lai, Taavi Balaji, Arjun Lakshmana Lalloo, Ratilal Lallukka, Tea Lam, Hilton Lan, Qing Lansingh, Van C. Larson, Heidi J. Larsson, Anders Lavados, Pablo M. Lawrynowicz, Alicia E. B. Leasher, Janet L. Lee, Jong-Tae Leigh, James Leinsalu, Mall Leung, Ricky Levitz, Carly Li, Bin Li, Yichong Li, Yongmei Liddell, Chelsea Lim, Stephen S. de Lima, Graca Maria Ferreira Lind, Maggie L. Lipshultz, Steven E. Liu, Shiwei Liu, Yang Lloyd, Belinda K. Lofgren, Katherine T. Logroscino, Giancarlo London, Stephanie J. Lortet-Tieulent, Joannie Lotufo, Paulo A. Lucas, Robyn M. Lunevicius, Raimundas Lyons, Ronan Anthony Ma, Stefan Machado, Vasco Manuel Pedro MacIntyre, Michael F. Mackay, Mark T. MacLachlan, Jennifer H. Magis-Rodriguez, Carlos Mahdi, Abbas A. Majdan, Marek Malekzadeh, Reza Mangalam, Srikanth Mapoma, Christopher Chabila Marape, Marape Marcenes, Wagner Margono, Christopher Marks, Guy B. Marzan, Melvin Barrientos Masci, Joseph R. Mashal, Mohammad Taufi Q. Masiye, Felix Mason-Jones, Amanda J. Matzopolous, Richard Mayosi, Bongani M. Mazorodze, Tasara T. McGrath, John J. Mckay, Abigail C. Mckee, Martin McLain, Abigail Meaney, Peter A. Mehndiratta, Man Mohan Mejia-Rodriguez, Fabiola Melaku, Yohannes Adama Meltzer, Michele Memish, Ziad A. Mendoza, Walter Mensah, George A. Meretoja, Atte Mhimbira, Francis A. Miller, Ted R. Mills, Edward J. Misganaw, Awoke Mishra, Santosh K. Mock, Charles N. Moffitt, Terrie E. Ibrahim, Norlinah Mohamed Mohammad, Karzan Abdulmuhsin Mokdad, Ali H. Mola, Glen Liddell Monasta, Lorenzo Monis, Jonathan de la Cruz Hernandez, Julio C. Montaez Montico, Marcella Montine, Thomas J. Mooney, Meghan D. Moore, Ami R. Moradi-Lakeh, Maziar Moran, Andrew E. Mori, Rintaro Moschandreas, Joanna Moturi, Wilkister Nyaora Moyer, Madeline L. Mozaffarian, Dariush Mueller, Ulrich O. Mukaigawara, Mitsuru Mullany, Erin C. Murray, Joseph Mustapha, Adetoun Naghavi, Paria Naheed, Aliya Naidoo, Kovin S. Naldi, Luigi Nand, Devina Nangia, Vinay Narayan, K. M. Venkat Nash, Denis Nasher, Jamal Nejjari, Chakib Nelson, Robert G. Neuhouser, Marian Neupane, Sudan Prasad Newcomb, Polly A. Newman, Lori Newton, Charles R. Ng, Marie Ngalesoni, Frida Namnyak Nguyen, Grant Nhung Thi Trang Nguyen Nisar, Muhammad Imran Nolte, Sandra Norheim, Ole F. Norman, Rosana E. Norrving, Bo Nyakarahuka, Luke Odell, Shaun O'Donnell, Martin Ohkubo, Takayoshi Ohno, Summer Lockett Olusanya, Bolajoko O. Omer, Saad B. Opio, John Nelson Orisakwe, Orish Ebere Ortblad, Katrina F. Ortiz, Alberto Otayza, Maria Lourdes K. Pain, Amanda W. Pandian, Jeyaraj D. Panelo, Carlo Irwin Panniyammakal, Jeemon Papachristou, Christina Paternina Caicedo, Angel J. Patten, Scott B. Patton, George C. Paul, Vinod K. Pavlin, Boris Pearce, Neil Pellegrini, Carlos A. Pereira, David M. Peresson, Sophie C. Perez-Padilla, Rogelio Perez-Ruiz, Fernando P. Perico, Norberto Pervaiz, Aslam Pesudovs, Konrad Peterson, Carrie B. Petzold, Max Phillips, Bryan K. Phillips, David E. Phillips, Michael R. Plass, Dietrich Piel, Frederic Bernard Poenaru, Dan Polinder, Suzanne Popova, Svetlana Poulton, Richie G. Pourmalek, Farshad Prabhakaran, Dorairaj Qato, Dima Quezada, Amado D. Quistberg, D. Alex Rabito, Felicia Rafay, Anwar Rahimi, Kazem Rahimi-Movaghar, Vafa Rahman, Sajjad U. R. Raju, Murugesan Rakovac, Ivo Rana, Saleem M. Refaat, Amany Remuzzi, Giuseppe Ribeiro, Antonio L. Ricci, Stefano Riccio, Patricia M. Richardson, Lee Richardus, Jan Hendrik Roberts, Bayard Roberts, D. Allen Robinson, Margaret Roca, Anna Rodriguez, Alina Rojas-Rueda, David Ronfani, Luca Room, Robin Roth, Gregory A. Rothenbacher, Dietrich Rothstein, David H. Rowley, Jane Tf Roy, Nobhojit Ruhago, George M. Rushton, Lesley Sambandam, Sankar Soreide, Kjetil Saeedi, Mohammad Yahya Saha, Sukanta Sahathevan, Ramesh Sahraian, Mohammad Ali Sahle, Berhe Weldearegawi Salomon, Joshua A. Salvo, Deborah Samonte, Genesis May J. Sampson, Uchechukwu Sanabria, Juan Ramon Sandar, Logan Santos, Itamar S. Satpathy, Maheswar Sawhney, Monika Saylan, Mete Scarborough, Peter Schoettker, Ben Schmidt, Juergen C. Schneider, Ione J. C. Schumacher, Austin E. Schwebel, David C. Scott, James G. Sepanlou, Sadaf G. Servan-Mori, Edson E. Shackelford, Katya Shaheen, Amira Shahraz, Saeid Shakh-Nazarova, Marina Shangguan, Siyi She, Jun Sheikhbahaei, Sara Shepard, Donald S. Shibuya, Kenji Shinohara, Yukito Shishani, Kawkab Shiue, Ivy Shivakoti, Rupak Shrime, Mark G. Sigfusdottir, Inga Dora Silberberg, Donald H. Silva, Andrea P. Simard, Edgar P. Sindi, Shireen Singh, Jasvinder A. Singh, Lavanya Sioson, Edgar Skirbekk, Vegard Sliwa, Karen So, Samuel Soljak, Michael Soneji, Samir Soshnikov, Sergey S. Sposato, Luciano A. Sreeramareddy, Chandrashekhar T. Stanaway, Jeff Rey D. Stathopoulou, Vasiliki Kalliopi Steenland, Kyle Stein, Claudia Steiner, Caitlyn Stevens, Antony Stoeckl, Heidi Straif, Kurt Stroumpoulis, Konstantinos Sturua, Lela Sunguya, Bruno F. Swaminathan, Soumya Swaroop, Mamta Sykes, Bryan L. Tabb, Karen M. Takahashi, Ken Talongwa, Roberto Tchio Tan, Feng Tanne, David Tanner, Marcel Tavakkoli, Mohammad Ao, Braden Te Teixeira, Carolina Maria Templin, Tara Tenkorang, Eric Yeboah Terkawi, Abdullah Sulieman Thomas, Bernadette A. Thorne-Lyman, Andrew L. Thrift, Amanda G. Thurston, George D. Tillmann, Taavi Tirschwell, David L. Tleyjeh, Imad M. Tonelli, Marcello Topouzis, Fotis Towbin, Jeffrey A. Toyoshima, Hideaki Traebert, Jefferson Tran, Bach X. Truelsen, Thomas Trujillo, Ulises Trillini, Matias Dimbuene, Zacharie Tsala Tsilimbaris, Miltiadis Tuzcu, E. Murat Ubeda, Clotilde Uchendu, Uche S. Ukwaja, Kingsley N. Undurraga, Eduardo A. Vallely, Andrew J. van de Vijver, Steven van Gool, Coen H. Varakin, Yuri Y. Vasankari, Tommi J. Vasconcelos, Ana Maria Nogales Vavilala, Monica S. Venketasubramanian, N. Vijayakumar, Lakshmi Villalpando, Salvador Violante, Francesco S. Vlassov, Vasiliy Victorovich Wagner, Gregory R. Waller, Stephen G. Wang, JianLi Wang, Linhong Wang, XiaoRong Wang, Yanping Warouw, Tati Suryati Weichenthal, Scott Weiderpass, Elisabete Weintraub, Robert G. Wenzhi, Wang Werdecker, Andrea Wessells, K. Ryan R. Westerman, Ronny Whiteford, Harvey A. Wilkinson, James D. Williams, Thomas Neil Woldeyohannes, Solomon Meseret Wolfe, Charles D. A. Wolock, Timothy M. Woolf, Anthony D. Wong, John Q. Wright, Jonathan L. Wulf, Sarah Wurtz, Brittany Xu, Gelin Yang, Yang C. Yano, Yuichiro Yatsuya, Hiroshi Yip, Paul Yonemoto, Naohiro Yoon, Seok-Jun Younis, Mustafa Yu, Chuanhua Jin, Kim Yun Zaki, Maysaa El Sayed Zamakhshary, Mohammed Fouad Zeeb, Hajo Zhang, Yong Zhao, Yong Zheng, Yingfeng Zhu, Jun Zhu, Shankuan Zonies, David Zou, Xiao Nong Zunt, Joseph R. Vos, Theo Lopez, Alan D. Murray, Christopher J. L. CA GBD Mortal 2013 Causes Death Colla TI Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013 SO LANCET LA English DT Article ID INFLUENZAE TYPE-B; PNEUMOCOCCAL CONJUGATE VACCINE; PLACEBO-CONTROLLED-TRIAL; 187 COUNTRIES; RISK-FACTORS; ENTERIC MULTICENTER; CHILDREN YOUNGER; CHILDHOOD PNEUMONIA; INTEGRATED APPROACH; POPULATION HEALTH AB Background Up-to-date evidence on levels and trends for age-sex-specifi c all-cause and cause-specifi c mortality is essential for the formation of global, regional, and national health policies. In the Global Burden of Disease Study 2013 (GBD 2013) we estimated yearly deaths for 188 countries between 1990, and 2013. We used the results to assess whether there is epidemiological convergence across countries. Methods We estimated age-sex-specifi c all-cause mortality using the GBD 2010 methods with some refinements to improve accuracy applied to an updated database of vital registration, survey, and census data. We generally estimated cause of death as in the GBD 2010. Key improvements included the addition of more recent vital registration data for 72 countries, an updated verbal autopsy literature review, two new and detailed data systems for China, and more detail for Mexico, UK, Turkey, and Russia. We improved statistical models for garbage code redistribution. We used six different modelling strategies across the 240 causes; cause of death ensemble modelling (CODEm) was the dominant strategy for causes with sufficient information. Trends for Alzheimer's disease and other dementias were informed by meta-regression of prevalence studies. For pathogen-specifi c causes of diarrhoea and lower respiratory infections we used a counterfactual approach. We computed two measures of convergence (inequality) across countries: the average relative difference across all pairs of countries (Gini coefficient) and the average absolute difference across countries. To summarise broad findings, we used multiple decrement life-tables to decompose probabilities of death from birth to exact age 15 years, from exact age 15 years to exact age 50 years, and from exact age 50 years to exact age 75 years, and life expectancy at birth into major causes. For all quantities reported, we computed 95% uncertainty intervals (UIs). We constrained cause-specific fractions within each age-sex-country-year group to sum to all-cause mortality based on draws from the uncertainty distributions. Findings Global life expectancy for both sexes increased from 65.3 years (UI 65.0-65.6) in 1990, to 71.5 years (UI 71.0-71.9) in 2013, while the number of deaths increased from 47.5 million (UI 46.8-48.2) to 54.9 million (UI 53.6-56.3) over the same interval. Global progress masked variation by age and sex: for children, average absolute diff erences between countries decreased but relative diff erences increased. For women aged 25-39 years and older than 75 years and for men aged 20-49 years and 65 years and older, both absolute and relative diff erences increased. Decomposition of global and regional life expectancy showed the prominent role of reductions in age-standardised death rates for cardiovascular diseases and cancers in high-income regions, and reductions in child deaths from diarrhoea, lower respiratory infections, and neonatal causes in low-income regions. HIV/AIDS reduced life expectancy in southern sub-Saharan Africa. For most communicable causes of death both numbers of deaths and age-standardised death rates fell whereas for most non-communicable causes, demographic shifts have increased numbers of deaths but decreased age-standardised death rates. Global deaths from injury increased by 10.7%, from 4.3 million deaths in 1990 to 4.8 million in 2013; but age-standardised rates declined over the same period by 21%. For some causes of more than 100 000 deaths per year in 2013, age-standardised death rates increased between 1990 and 2013, including HIV/AIDS, pancreatic cancer, atrial fibrillation and flutter, drug use disorders, diabetes, chronic kidney disease, and sickle-cell anaemias. Diarrhoeal diseases, lower respiratory infections, neonatal causes, and malaria are still in the top five causes of death in children younger than 5 years. The most important pathogens are rotavirus for diarrhoea and pneumococcus for lower respiratory infections. Country-specific probabilities of death over three phases of life were substantially varied between and within regions. Interpretation For most countries, the general pattern of reductions in age-sex specifi c mortality has been associated with a progressive shift towards a larger share of the remaining deaths caused by non-communicable disease and injuries. Assessing epidemiological convergence across countries depends on whether an absolute or relative measure of inequality is used. Nevertheless, age-standardised death rates for seven substantial causes are increasing, suggesting the potential for reversals in some countries. Important gaps exist in the empirical data for cause of death estimates for some countries; for example, no national data for India are available for the past decade. C1 [Naghavi, Mohsen; Wang, Haidong; Lozano, Rafael; Vollset, Stein Emil; Achoki, Tom; Apfel, Henry; Atkinson, Charles; Barber, Ryan M.; Bertozzi-Villa, Amelia; Biryukov, Stan; Brown, Jonathan C.; Catala-Lopez, Ferrn; Coates, Matthew M.; Coffeng, Luc Edgar; Coggeshall, Megan S.; Dandona, Lalit; Dansereau, Emily; Dicker, Daniel; Duber, Herbert C.; Estep, Kara; Fleming, Thomas D.; Forouzanfar, Mohammad H.; Gonzalez-Medina, Diego; Graetz, Nicholas; Haagsma, Juanita; Hamavid, Hannah; Hancock, Jamie; Hansen, Gillian M.; Heuton, Kyle R.; Higashi, Hideki; Huynh, Chantal; Iannarone, Marissa; Joseph, Jonathan; Kassebaum, Nicholas; Kyu, Hmwe; Levitz, Carly; Liddell, Chelsea; Lind, Maggie L.; Lofgren, Katherine T.; MacIntyre, Michael F.; Margono, Christopher; McLain, Abigail; Mokdad, Ali H.; Mooney, Meghan D.; Moradi-Lakeh, Maziar; Moyer, Madeline L.; Mullany, Erin C.; Naghavi, Paria; Ng, Marie; Nguyen, Grant; Odell, Shaun; Ohno, Summer Lockett; Ortblad, Katrina F.; Pain, Amanda W.; Phillips, Bryan K.; Phillips, David E.; Richardson, Lee; Roberts, D. Allen; Robinson, Margaret; Roth, Gregory A.; Sandar, Logan; Schumacher, Austin E.; Shackelford, Katya; Singh, Lavanya; Sioson, Edgar; Stanaway, Jeff Rey D.; Steiner, Caitlyn; Stevens, Antony; Templin, Tara; Thomas, Bernadette A.; Wolock, Timothy M.; Wulf, Sarah; Wurtz, Brittany; Vos, Theo; Murray, Christopher J. L.] Inst Hlth Metr & Evaluat, Seattle, WA USA. [Ellenbogen, Richard G.; Wright, Jonathan L.] Univ Washington, Sch Med, Seattle, WA USA. [Kassebaum, Nicholas] Childrens Hosp, Seattle, WA USA. [Tirschwell, David L.] Dept Neurol, Seattle, WA USA. [Ebel, Beth E.] Univ Washington, Harborview Med Ctr, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA. [Alfonso-Cristancho, Rafael; Anderson, Benjamin O.; Futran, Neal D.; Jensen, Paul N.; Kotagal, Meera; Mock, Charles N.; Montine, Thomas J.; Pellegrini, Carlos A.; Quistberg, D. Alex; Vavilala, Monica S.; Zunt, Joseph R.] Univ Washington, Seattle, WA 98195 USA. [Lozano, Rafael; Barquera, Simon; Barrientos-Gutierrez, Tonatiuh; Nonato, Ismael Ricardo Campos; Cuevas-Nasu, Lucia; De la Cruz-Gongora, Vanessa; Diaz-Ortega, Jose-Luis; Garcia-Guerra, Francisco Armando; Dantes, Hector Gomez; Pi, Ileana B. Heredia; Mejia-Rodriguez, Fabiola; Hernandez, Julio C. Montaez; Perez-Padilla, Rogelio; Quezada, Amado D.; Salvo, Deborah; Servan-Mori, Edson E.; Villalpando, Salvador] Natl Inst Publ Hlth Mexico, Mexico City, DF, Mexico. [Davis, Adrian; Fay, Derek F. J.; Schmidt, Juergen C.] Publ Hlth England, London, England. [Zhou, Maigeng; Duan, Leilei; Li, Yichong; Liu, Shiwei; Wang, Linhong] Natl Ctr Chron & Noncommunicable Dis Control & Pr, Beijing, Peoples R China. [Tan, Feng] Natl Inst Occupat Hlth & Control, Beijing, Peoples R China. [Liang, Xiaofeng] China Ctr Dis Control Prevent, Beijing, Peoples R China. [Vollset, Stein Emil; Kinge, Jonas M.; Knudsen, Ann Kristin; Skirbekk, Vegard] Norwegian Inst Publ Hlth, Oslo, Norway. [Vollset, Stein Emil; Norheim, Ole F.] Univ Bergen, Bergen, Norway. [Ozgoren, Ayse Abbasoglu; Bicer, Burcu Kucuk] Hacettepe Univ, Inst Populat Studies, Ankara, Turkey. [Abdalla, Safa] Sudanese Publ Hlth Consultancy Grp, Solihull, W Midlands, England. [Abd-Allah, Foad] Cairo Univ, Fac Med, Cairo, Egypt. [Aziz, Muna I. Abdel] Inst Publ Hlth, Khartoum, Sudan. [Abera, Semaw Ferede] Coll Hlth Sci, Sch Publ Hlth, Mekelle, Tigray, Ethiopia. [Melaku, Yohannes Adama; Sahle, Berhe Weldearegawi] Mekelle Univ, Mekelle, Tigray, Ethiopia. [Aboyans, Victor] Dupuytren Univ Hosp, Limoges, France. [Abraham, Biju] Oslo & Akershus Univ, Coll Appl Sci HiOA, Oslo, Norway. [Abraham, Jerry P.] Univ Texas San Antonio, Sch Med, San Antonio, TX USA. [Abuabara, Katrina E.; Silberberg, Donald H.] Univ Penn, Philadelphia, PA 19104 USA. [Benzian, Habib] Dept Epidemiol & Publ Hlth, London, England. [Benzian, Habib] UCL, London, England. [Abu-Raddad, Laith J.] Weill Cornell Med Coll Qatar, Doha, Qatar. [Abu-Rmeileh, Niveen M. E.] Birzeit Univ, Inst Community & Publ Hlth, Ramallah, W Bank, Israel. [Adelekan, Ademola] Publ Hlth Promot Alliance, Osogbp, Nigeria. [Chiang, Peggy Pei-Chia] Beneral Practice & Primary Hlth Care Acad Ctr, Melbourne, Vic, Australia. [Colquhoun, Samantha M.] Ctr Int Child Hlth, Melbourne, Vic, Australia. [Ademi, Zanfi Na; Blore, Jed D.; Bohensky, Megan A.; Catala-Lopez, Ferrn; Balaji, Arjun Lakshmana; Patton, George C.; Weintraub, Robert G.] Univ Melbourne, Melbourne, Vic, Australia. [Adofo, Koranteng] Kwame Nkrumah Univ Sci & Technol, Kumasi, Ashanti, Ghana. [Adou, Arsene Kouablan] Assoc Ivoirienne Bien Etre Familial, Abidjan, Cote Ivoire. [Adsuar, Jose C.; Fra Paleo, Urbano] Univ Extremadura, Caceres, Spain. [Aernlov, Johan; Larsson, Anders] Uppsala Univ, Uppsala, Sweden. [Agardh, Emilie Elisabet] Inst Publ Hlth Sci, Stockholm, Sweden. [Akena, Dickens; Nyakarahuka, Luke] Makerere Univ, Kampala, Uganda. [Al Khabouri, Mazin J.; Alasfoor, Deena] Minist Hlth, Muscat, Oman. [Al Lami, Faris] Baghdad Coll Med, Baghdad, Iraq. [Albittar, Mohammed] Independent, Damascus, Syria. Grp Invest Ciencias Salud & Neurociencias CISNEUR, Cartagena De Indias, Bolivar, Colombia. [Alegretti, Miguel Angel; Aleman, Alicia V.; Cavalleri, Fiorella; Colistro, Valentina] Univ Republica, Fac Med, Dept Prevent & Social Med, Montevideo, Uruguay. [Alemu, Zewdie Aderaw] Debre Markos Univ, Debre Markos, Amhara, Ethiopia. [Alhabib, Samia] Natl Guard Hlth Affairs, Riyadh, Saudi Arabia. [Simard, Edgar P.; Steenland, Kyle] Rollins Sch Publ Hlth, Atlanta, GA USA. [Ali, Mohammed K.; Cunningham, Solveig Argeseanu; Dabhadkar, Kaustubh C.; Liu, Yang; Narayan, K. M. Venkat; Omer, Saad B.; Phillips, Michael R.] Emory Univ, Atlanta, GA 30322 USA. [Ali, Raghib; Bennett, Derrick A.; Briggs, Adam D. M.; Chen, Zhengming; Hay, Simon I.; Piel, Frederic Bernard; Rahimi, Kazem; Scarborough, Peter] Univ Oxford, Oxford, England. [Alla, Francois] Univ Lorraine, Sch Publ Hlth, Nancy, France. [Allebeck, Peter] Dept Publ Hlth Sci, Stockholm, Sweden. [Fereshtehnejad, Seyed-Mohammad] Dept Neurobiol Care Sci & Soc NVS, Stockholm, Sweden. [Kivipelto, Miia] Aging Res Ctr, Stockholm, Sweden. [Weiderpass, Elisabete] Dept Med Epidemiol & Biostat, Stockholm, Sweden. [Hagstromer, Maria; Havmoeller, Rasmus; Sindi, Shireen] Karolinska Inst, Stockholm, Sweden. [AlMazroa, Mohammad A.; Basulaiman, Mohammed Omar; Memish, Ziad A.; Saeedi, Mohammad Yahya] Saudi Minist Hlth, Riyadh, Saudi Arabia. [Salman, Rustam Al-Shahi; Fowkes, F. Gerry R.] Univ Edinburgh, Edinburgh, Midlothian, Scotland. [Alsharif, Ubai; Nolte, Sandra; Papachristou, Christina] Charite, D-13353 Berlin, Germany. [Alvarez, Elena] Government, Madrid, Spain. [Alviz-Guzman, Nelson; Paternina Caicedo, Angel J.] Univ Cartagena, Cartagena De Indias, Colombia. [Amankwaa, Adansi A.] Albany State Univ, Albany, GA 31705 USA. [Amare, Azmeraw T.] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands. [Amare, Azmeraw T.] Bahir Dar Univ, Coll Med & Hlth Sci, Bahir Dar, Ethiopia. [Ameli, Omid] Boston Univ, Boston, MA 02215 USA. [Amini, Hassan] Kurdistan Univ Med Sci, Kurdistan Environm Hlth Res Ctr, Sanandaj, Kurdistan, Iran. [Amini, Hassan] Swiss Trop & Publ Hlth Inst, Dept Epidemiol & Publ Hlth, Basel, Switzerland. [Tanner, Marcel] Univ Basel, Basel, Switzerland. [Ammar, Walid] Minist Publ Hlth, Beirut, Lebanon. [Anderson, H. Ross] St Georges Univ London, London, England. [Antonio, Carl Abelardo T.; Faraon, Emerito Jose A.; Panelo, Carlo Irwin] Univ Philippines Manila, Coll Publ Hlth, Manila, Philippines. [Anwari, Palwasha] UNFPA, Kabul, Afghanistan. [Arsenijevic, Valentina S. Arsic] Univ Belgrade, Sch Med, Inst Microbiol & Immunol, Belgrade, Serbia. [Al Artaman] Evidera Inc, Lexington, MA USA. [Asad, Majed Masoud] Minist Hlth, Amman, Jordan. [Asghar, Rana J.] South Asian Publ Hlth Forum, Islamabad, Pakistan. [Assadi, Reza] Mashhad Univ Med Sci, Mashhad, Khorasan Razavi, Iran. [Atkins, Lydia S.] Minist Hlth Wellness Human Serv & Gender Relat, Castries, St Lucia. [Badawi, Alaa] Publ Hlth Agcy Canada, Toronto, ON, Canada. [Bahit, Maria C.] INECO Neurociencias, Santa Fe, NM USA. [Bakfalouni, Talal] Minist Hlth, Damascus, Syria. [Balakrishnan, Kalpana] Sri Ramachandra Univ, Madras, Tamil Nadu, India. [Balalla, Shivanthi; Feigin, Valery L.] Natl Inst Stroke & Appl Neurosciences, Auckland, New Zealand. [Barker-Collo, Suzanne L.] Sch Psychol, Auckland, New Zealand. [del Pozo-Cruz, Borja] Univ Auckland, Auckland 1, New Zealand. [Banerjee, Amitava] Univ Birmingham, Birmingham, W Midlands, England. [Barregard, Lars] Univ Gothenburg, Dept Environm & Occupat Hlth, Gothenburg, Sweden. [Barrero, Lope H.] Pontificia Univ Javeriana, Dept Ind Engn, Bogota, Colombia. [Basu, Arindam] Univ Canterbury, Sch Hlth Sci, Canterbury, New Zealand. [So, Samuel] Asian Liver Ctr, Palo Alto, CA USA. [Gaffikin, Lynne] Stanford Univ, Med Ctr, Sch Med, Stanford, CA 94305 USA. [Basu, Sanjay] Stanford Univ, Stanford, CA 94305 USA. [Beardsley, Justin] Univ Oxford, Ho Hi Minh City, Vietnam. [Bedi, Neeraj] Coll Publ Hlth & Trop Med, Jazan, Saudi Arabia. [Beghi, Ettore; Cortinovis, Monica; Perico, Norberto; Remuzzi, Giuseppe; Trillini, Matias] IRCCS Ist Ric Farmacol Mario Negri, Milan, Italy. [Bekele, Tolesa] Madawalabu Univ, Bale Goba, Oromia, Ethiopia. [Bell, Michelle L.; Huang, John J.] Yale Univ, New Haven, CT USA. [Benjet, Corina; Gutierrez, Reyna A.] Natl Inst Psychiat Ramon de la Fuente, Mexico City, DF, Mexico. [Bensenor, Isabela M.; Kemp, Andrew H.] Univ Hosp, Sao Paulo, Brazil. [Lotufo, Paulo A.; Santos, Itamar S.] Univ Sao Paulo, Sao Paulo, Brazil. [Beyene, Tariku Jibat; Deribe, Kebede] Univ Addis Ababa, Debre Zeit, Ethiopia. [Bhala, Neeraj] Wellington Hosp, Wellington, New Zealand. [Bhalla, Ashish] Postgrad Inst Med Educ & Res, Chandigarh 160012, UT, India. [Bhutta, Zulfiqar A.] Med Ctr, Karachi, Pakistan. [Nisar, Muhammad Imran] Aga Khan Univ, Karachi, Pakistan. [Bikbov, Boris] I Evdokimov Moscow State Univ Med & Dent, Moscow, Russia. [Bin Abdulhak, Aref] Univ Missouri, Kansas City, MO 64110 USA. [Marks, Guy B.] Woolcock Inst Med Res, Sydney, NSW, Australia. [Driscoll, Tim R.] Sydney Sch Publ Hlth, Sydney, NSW, Australia. [Blyth, Fiona M.; Leigh, James] Univ Sydney, Sydney, NSW 2006, Australia. [Borges, Guilherme] Inst Nacl Psiquiatria, Mexico City, DF, Mexico. [Bose, Dipan] World Bank, Washington, DC 20433 USA. [Boufous, Soufiane] Transport & Rd Safety TARS Res, Sydney, NSW, Australia. [Vallely, Andrew J.] Kirby Inst, Sydney, NSW, Australia. [Degenhardt, Louisa; Satpathy, Maheswar] Univ New S Wales, Sydney, NSW, Australia. [Bourne, Rupert R.] Anglia Ruskin Univ, Vis & Eye Res Unit, Cambridge, England. [Boyers, Lindsay N.] Georgetown Univ, Sch Med, Washington, DC USA. [Brainin, Michael] Danube Univ Krems, Krems, Austria. [Krueger, Hans] Sch Populat & Publ Hlth, Vancouver, BC, Canada. [Brauer, Michael; Gotay, Carolyn C.; Pourmalek, Farshad] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. [Brayne, Carol E. G.] Cambridge Inst Publ Hlth, Cambridge, England. [Brazinova, Alexandra; Majdan, Marek] Trnava Univ, Fac Hlth Sci & Social Work, Trnava, Slovakia. [Breitborde, Nicholas] Univ Arizona, Tucson, AZ USA. [Brenner, Hermann] German Canc Res Ctr, Heidelberg, Germany. [Brugha, Traolach S.] Univ Leicester, Leicester, Leics, England. [Buckle, Geoffrey C.; Gona, Philimon] Univ Massachusetts, Sch Med, Worcester, MA USA. [Bui, Linh Ngoc; Nhung Thi Trang Nguyen] Hanoi Sch Publ Hlth, Hanoi, Vietnam. [Bukhman, Gene] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Ding, Eric L.; Fahimi, Saman; Shangguan, Siyi] Harvard Univ, Sch Publ Hlth, Cambridge, MA 02138 USA. [Feigl, Andrea B.; Salomon, Joshua A.; Shrime, Mark G.] Harvard Univ, Cambridge, MA 02138 USA. [Burch, Michael] Great Ormond St Hosp Sick Children, London WC1N 3JH, England. [Cardenas, Rosario] Univ Autonoma Metropolitana, Mexico City, DF, Mexico. [Carabin, Helesne] Univ Oklahoma, Hlth Sci Ctr, Dept Biostat & Epidemiol, Oklahoma City, OK USA. [Carapetis, Jonathan] Telethon Inst Child Hlth Res, Subiaco, WA, Australia. [Carpenter, David O.] Univ Albany, Rensselaer, NY USA. [Caso, Valeria] Univ Perugia, Stroke Unit, I-06100 Perugia, Italy. [Castaneda-Orjuela, Carlos A.] Colombian Natl Hlth Observ, Inst Nacl Salud, Bogota, Colombia. [Castro, Ruben Estanislao] Univ Diego Portales, Santiago, Chile. [Catala-Lopez, Ferrn] Minist Hlth, Spanish Med & Healthcare Prod Agcy AEMPS, Div Pharmacoepidemiol & Pharmacovigilance, Madrid, Spain. [Chang, Jung-Chen] Natl Taiwan Univ, Taipei 10764, Taiwan. [Hoy, Damian G.] Univ Queensland, Sch Populat Hlth, Herston, Qld, Australia. [Scott, James G.] Univ Queensland, Clin Res Ctr, Herston, Qld, Australia. [Charlson, Fiona C.; Erskine, Holly E.; Ferrari, Alize J.; Knibbs, Luke; McGrath, John J.; Norman, Rosana E.; Whiteford, Harvey A.] Univ Queensland, Brisbane, Qld, Australia. [Che, Xuan] NIH, Bethesda, MD 20892 USA. [She, Jun] Zhongshan Hosp, Shanghai, Peoples R China. [Chen, Yingyao; Kan, Haidong] Fudan Univ, Shanghai 200433, Peoples R China. [Chen, Zhengming] CTSU, Nuffield Dept Populat Hlth, Oxford, England. [Chen, Honglei; London, Stephanie J.] NIEHS, Div Intramural Res, NIH, Dept Hlth & Human Serv,RTP,NC USA, Res Triangle Pk, NC 27709 USA. [Chen, Jian Sheng] Inst Bone & Joint Res, St Laonards, NSW, Australia. [Chimed-Ochir, Odgerel] Univ Occupat & Environm Hlth, Dept Environm Epidemiol, Kitakyushu, Fukuoka 807, Japan. [Chowdhury, Rajiv; Murray, Christopher J. L.] Univ Cambridge, Cambridge, England. [Christensen, Hanne] Bispebjerg Hosp, Copenhagen, Denmark. [Christophi, Costas A.] Cyprus Univ Technol, Limassol, Cyprus. [Chang, Jung-Chen] Taipei Med Univ, Sch Med, Dept Mol Parasitol & Trop Dis, Taipei, Taiwan. [Chuang, Ting-Wu] Taipei Med Univ, Ctr Int Trop Med, Coll Med, Taipei, Taiwan. [Chugh, Sumeet S.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Cirillo, Massimo] Univ Salerno, I-84081 Baronissi, SA, Italy. [Cohen, Aaron] Hlth Effects Inst, Boston, MA USA. [Colomar, Mercedes] UNICEM, Montevideo, Uruguay. [Cooper, Cyrus] Univ Southampton, MRC Lifecourse Epidemiol Unit, Southampton, Hants, England. [Cooper, Cyrus; Tleyjeh, Imad M.] Mayo Clin, Rochester, MN USA. [Coppola, Luis M.] Hosp Municipal Ramon Santamarina, Buenos Aires, DF, Argentina. [Cowie, Benjamin C.; MacLachlan, Jennifer H.] Victorian Infect Dis Reference Lab, North Melbourne, Vic, Australia. [Criqui, Michael H.; Jassal, Simerjot] Univ Calif San Diego, La Jolla, CA 92093 USA. [Crump, John A.] Dunedin Sch Med, Ctr Int Hlth, Dunedin, Otago, New Zealand. [Poulton, Richie G.] Univ Otago, Dunedin, Otago, New Zealand. [Leite, Iuri da Costa] Natl Sch Publ Hlth ENSP Fiocruz, Rio De Janeiro, Brazil. [Dandona, Lalit; Dandona, Rakhi; Goenka, Shifalika] Publ Hlth Fdn India, New Delhi, India. [Dandona, Rakhi; Goenka, Shifalika] Indian Inst Publ Hlth, New Delhi, India. [Dargan, Paul I.] Guys & St Thomas NHS Fdn Trust, London, England. [Dayama, Anand] Jacobi Med Ctr, Dept Surg, Atlanta, GA USA. [de la Vega, Shelley F.] Univ Philippines, Inst Aging, Manila, Philippines. [Lam, Hilton] Univ Philippines, Natl Inst Hlth, Inst Hlth Policy & Dev Studies, Manila, Philippines. [De Leo, Diego] Griffith Univ, Brisbane, Qld 4111, Australia. [Uchendu, Uche S.] US Dept Vet Affairs, Washington, DC USA. [Dellavalle, Robert P.] Eastern Colorado Healthcare Syst, Denver, CO USA. [Jarlais, Don C. Des] Beth Israel Deaconess Med Ctr, New York, NY 10003 USA. [Dessalegn, Muluken] Africa Med & Res Fdn Ethiopia, Addis Ababa, Ethiopia. [deVeber, Gabrielle A.] Univ Toronto, Hosp Sick Children, Toronto, ON M5G 1X8, Canada. [Dharmaratne, Samath D.] Univ Peradeniya, Peradeniya, Sri Lanka. [Dherani, Mukesh] Univ Liverpool, Liverpool L69 3BX, Merseyside, England. [Diaz-Torne, Cesar] Hosp Santa Creu & Sant Pau, Barcelona, Spain. [Dokova, Klara] Med Univ Varna, Fac Publ Hlth, Dept Social Med, Varna, Bulgaria. [Dorsey, E. Ray] Univ Rochester, Med Ctr, Rochester, NY 14642 USA. [Durrani, Adnan M.] NIH, Montgomery, MD USA. [Hankey, Graeme J.] Sch Med & Pharmacol, Perth, WA, Australia. [Kabagambe, Edmond Kato] Univ Western Australia, Perth, WA 6009, Australia. [Elshrek, Yousef] Univ Tripoli, Fac Agr, Dept Food Sci, Tripoli, Libya. [Ermakov, Sergey Petrovich] Russian Acad Sci, Inst Social & Econ Studies Populat, Moscow, Russia. [Eshrati, Babak] Arak Univ Med Sci & Hlth Affairs, Arak, Markazi, Iran. [Esteghamati, Alireza; Hafezi-Nejad, Nima; Sheikhbahaei, Sara] Endocrinol & Metab Res Ctr, Tehran, Iran. [Farzadfar, Farshad] Noncommunicable Dis Reesearch Ctr, Tehran, Iran. [Malekzadeh, Reza; Sepanlou, Sadaf G.] Digest Dis Res Ctr, Tehran, Iran. [Rahimi-Movaghar, Vafa] Sina Trauma & Surg Res Ctr, Tehran, Iran. [Sahraian, Mohammad Ali] Res Ctr, Tehran, Iran. [Moradi-Lakeh, Maziar] Dept Community Med, Tehran, Iran. [Heydarpour, Pouria] Univ Tehran Med Sci, Tehran, Iran. [Fuerst, Thomas] Ctr Hlth Policy, London, England. [Fuerst, Thomas] Dept Infect Dis Epidemiol, London, England. [Mustapha, Adetoun] MRC PHE Ctr Hlth & Environm, London, England. [Foreman, Kyle; Rodriguez, Alina; Rushton, Lesley; Soljak, Michael; Williams, Thomas Neil] Univ London Imperial Coll Sci Technol & Med, London, England. [Vollset, Stein Emil] Div Informat Evidence Res & Innovat, Copenhagen, Denmark. [Fahrion, Anna S.; Rakovac, Ivo] WHO, Reg Off Europe, DK-2100 Copenhagen, Denmark. [Newman, Lori] WHO, CH-1211 Geneva, Switzerland. [Teixeira, Carolina Maria] ARS Norte, Oporto, Portugal. [Felicio, Manuela Mendonca; de Lima, Graca Maria Ferreira; Machado, Vasco Manuel Pedro] IP Dept Saude Publ, Oporto, Portugal. [Fernandes, Jefferson G.] German Hosp Oswaldo Cruz, Inst Educ & Sci, Sao Paulo, Brazil. [Foigt, Nataliya] Ukraine Acad Med Sci, Inst Gerontol, UA-252655 Kiev, Ukraine. [Franklin, Richard C.] James Cook Univ, Townsville, Qld 4811, Australia. [Gambashidze, Ketevan; Kazanjan, Konstantin; Kereselidze, Maia; Shakh-Nazarova, Marina; Sturua, Lela] Natl Ctr Dis Control & Publ Hlth, Tbilisi, Rep of Georgia. [Gankpe, Fortune Gbetoho] Clin Cooperat Parakou, Parakou, Borgou, Benin. [Garcia, Ana Cristina] Publ Hlth Unit Primary Hlth Care Grp Almada Seixa, Almada, Setubal, Portugal. [Geleijnse, Johanna M.] Wageningen Univ, Div Human Nutr, NL-6700 AP Wageningen, Netherlands. [Gessner, Bradford D.] Agence Med Prevent, Paris, France. [Lloyd, Belinda K.] Eastern Hlth Clin Sch, Melbourne, Vic, Australia. [Gibney, Katherine B.; Thrift, Amanda G.] Monash Univ, Melbourne, Vic 3004, Australia. [Gillum, Richard F.] Howard Univ, Washington, DC 20059 USA. [Inoue, Manami] Grad Sch Med, Tokyo, Japan. [Kawakami, Norito] Sch Publ Hlth, Tokyo, Japan. [Gilmour, Stuart; Shibuya, Kenji] Univ Tokyo, Tokyo, Japan. [Ginawi, Mohamed] Univ Hail, Coll Med, Hail, Saudi Arabia. [Giroud, Maurice] Univ Hosp Dijon, Dijon France, Region Of Burgo, France. [Glaser, Elizabeth L.; Halasa, Yara A.; Idrisov, Bulat T.; Shahraz, Saeid; Shepard, Donald S.; Undurraga, Eduardo A.] Brandeis Univ, Waltham, MA USA. [Gosselin, Richard A.; Kazi, Dhruv S.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Goto, Atsushi] Natl Ctr Global Hlth & Med, Dept Diabet Res, Tokyo, Japan. [Gugnani, Harish Chander] St James Sch Med, Kralendijk, Bonaire, Netherlands. [Guinovart, Caterina] PATH, Seattle, WA USA. [Gunnell, David] Univ Bristol, Bristol, Avon, England. [Gupta, Rahul] Fortis Escorts Hosp, Jaipur, Rajasthan, India. [Gupta, Rajeev] Kanawha Charleston Hlth Dept, Charleston, WV USA. [Thurston, George D.] NYU, Nelson Inst Environm Med, Tuxedo Pk, NY USA. [Hagan, Holly] NYU, New York, NY USA. [Hamadeh, Randah Ribhi] Arabian Gulf Univ, Manama, Bahrain. [Hammami, Mouhanad] Wayne Cty Dept Hlth & Human Serv, Detroit, MI USA. [Harewood, Heather] Eunice Gibson Polyclin, Bridgetown, St Michael, Barbados. [Haro, Josep Maria] Univ Barcelona, CIBERSAM, Barcelona, Spain. [Hay, Roderick J.] Int Fdn Dermatol, London, England. [Hedayati, Mohammad T.] Mazandaran Univ Med Sci, Sari, Mazandaran, Iran. [Hijar, Martha] Fdn Entornos AC, Cuernavaca, Morelos, Mexico. [Hoek, Hans W.] Parnassia Psychiat Inst, The Hague, Netherlands. [Hoffman, Howard J.] Natl Inst Deafness & Other Commun Disorders, NIH, Bethesda, MD USA. [Hornberger, John C.] Cedar Associates, Menlo Pk, CA USA. [Hosgood, H. Dean] Albert Einstein Coll Med, Bronx, NY 10467 USA. [Hossain, Mazeda; Larson, Heidi J.; Mckee, Martin; Pearce, Neil; Roberts, Bayard; Stoeckl, Heidi; Tillmann, Taavi] London Sch Hyg & Trop Med, London WC1, England. [Hotez, Peter J.] Baylor Coll Med, Houston, TX 77030 USA. [Hoy, Damian G.] Secretariat Pacific Commun, Publ Hlth Div, Herston, Qld, Australia. [Hsairi, Mohamed] Natl Inst Publ Hlth MOH, Tunis, Tunisia. [Hu, Guoqing] Univ Toronto, Toronto, ON, Canada. [Hu, Guoqing] Cent S Univ, Changsha, Hunan, Peoples R China. [Huffman, Mark D.] Feinberg Sch Med, Chicago, IL USA. [Swaroop, Mamta] Northwestern Univ, Chicago, IL 60611 USA. [Husseini, Abdullatif] Qatar Univ, Publ Hlth Program, Birzeit, Ramallah, Israel. [Iburg, Kim M.] Aarhus Univ, Aarhus, Denmark. [Ikeda, Nayu] Natl Inst Hlth & Nutr, Bunkyo Ku, Tokyo 162, Japan. [Innos, Kaire; Leinsalu, Mall] Natl Inst Hlth Dev, Tallinn, Estonia. [Islami, Farhad] Amer Canc Soc, New York, NY USA. [Ismayilova, Samaya] Self Employed, Baku, Azerbaijan. [Jacobsen, Kathryn H.] George Mason Univ, Fairfax, VA 22030 USA. [Jassal, Simerjot] VA San Diego, San Diego, CA USA. [Jayaraman, Sudha P.] Virginia Commonwealth Univ, Richmond, VA USA. [Jha, Vivekanand] Postgrad Inst Med Educ & Res, Chandigarh 160012, India. [Jiang, Guohong] Tianjin Ctr Dis Control & Prevent, Tianjin, Peoples R China. [Jiang, Ying] Univ Occupat & Environm Hlth, Inst Ind Ecol Sci, Dept Hlth Dev, Dept Environm Epidemiol, Kitakyushu, Fukuoka 807, Japan. [Jonas, Jost B.] Heidelberg Univ, Med Fac Mannheim, Dept Ophthalmol, Mannheim, Germany. [Juel, Knud] Natl Inst Publ Hlth, Copenhagen, Denmark. [Kabagambe, Edmond Kato; Sampson, Uchechukwu] Vanderbilt Univ, Nashville, TN 37235 USA. Univ Balamand, Beirut, Lebanon. [Karch, Andre] Helmholtz Ctr Infect Res, Braunschweig, Germany. [Karch, Andre] German Ctr Infect Res DZIF, Braunschweig, Germany. [Karimkhani, Chante] Columbia Univ, Coll Phys & Surg, New York, NY USA. [Moran, Andrew E.] Columbia Univ, New York, NY USA. [Karthikeyan, Ganesan; Paul, Vinod K.] All India Inst Med Sci, New Delhi, India. [Kaul, Anil] Oklahoma State Univ, Tulsa, OK USA. [Kengne, Andre Pascal; Matzopolous, Richard] South African Med Res Council, Cape Town, Western Cape, South Africa. [Keren, Andre] Hadassah Kerem Univ Hosp, Jerusalem, Israel. [Khader, Yousef Saleh] Jordan Univ Sci & Technol, Irbid, Jordan. [Khalifa, Shams Eldin Ali Hassan] Supreme Council Hlth, Doha, Qatar. [Khan, Ejaz Ahmed] Hlth Serv Acad, Islamabad, Punjab, Pakistan. [Khan, Gulfaraz] UAE Univ, Abu Dhabi, U Arab Emirates. [Khang, Young-Ho] Seoul Natl Univ, Coll Med, Inst Hlth Policy & Management, Seoul, South Korea. [Kieling, Christian] Univ Fed Rio Grande do Sul, Porto Alegre, RS, Brazil. [Kim, Daniel] Northeastern Univ, Boston, MA 02115 USA. [Kim, Sungroul] Soonchunhyang Univ, Asan, South Korea. [Kinfu, Yohannes] Univ Canberra, Canberra, ACT 2601, Australia. [Kokubo, Yoshihiro] Natl Cerebral & Cardiovasc Ctr, Dept Prevent Cardiol, Suita, Osaka, Japan. [Kosen, Sowarta] Ctr Community Empowerment Hlth Policy & Humanitie, Jakarta, Indonesia. [Warouw, Tati Suryati] NIHRD, Jakarta, Special Provinc, Indonesia. [Kravchenko, Michael A.; Varakin, Yuri Y.] Res Ctr Neurol, Moscow, Russia. [Krishnaswami, Sanjay] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Krishnaswami, Sanjay] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Defo, Barthelemy Kuate] Univ Montreal, Montreal, PQ, Canada. [Polinder, Suzanne] Dept Publ Hlth, Rotterdam, Netherlands. [Kuipers, Ernst J.; Richardus, Jan Hendrik] Erasmus MC Univ Med Ctr, Rotterdam, Netherlands. [Kulkarni, Chanda] Rajrajeshwari Med Coll & Hosp, Bangalore, Karnataka, India. [Kulkarni, Veena S.] Arkansas State Univ, State Univ, AR 72467 USA. [Kumar, Kaushalendra] Int Inst Populat Sci, Bombay, Maharashtra, India. [Kwan, Gene F.] Boston Med Ctr, Boston, MA USA. [Lai, Taavi] Fourth View Consulting, Tallinn, Estonia. [Lalloo, Ratilal] Australian Res Ctr Populat Oral Hlth, Gold Coast, Qld, Australia. [Lalloo, Ratilal] Univ Adelaide, Sch Dent, Gold Coast, Qld, Australia. [Lallukka, Tea] Finnish Inst Occupat Hlth, Helsinki, Finland. [Lallukka, Tea] Univ Helsinki, Fac Med, Hjelt Inst, FIN-00014 Helsinki, Finland. [Lan, Qing] NCI, Rockville, MD USA. [Lansingh, Van C.] IAPB & Vis 2020 LA, Weston, FL USA. [Lavados, Pablo M.] Univ Desarrollo, Serv Neurol Clin Alemana, Santiago, RM, Chile. [Lawrynowicz, Alicia E. B.; Silva, Andrea P.; Ubeda, Clotilde] Inst Nacl Epidemiol Dr Juan H Jara, Buenos Aires, DF, Argentina. [Leasher, Janet L.] Nova SE Univ, Ft Lauderdale, FL 33314 USA. [Lee, Jong-Tae; Yoon, Seok-Jun] Korea Univ, Seoul, South Korea. [Leung, Ricky] SUNY Albany, Rensselaer, NY USA. [Zhang, Yong] Dept Gerontol, Jinan, Shandong, Peoples R China. [Li, Bin] Jinan Cent Hosp, Jinan, Shandong, Peoples R China. [Li, Yichong] Genentech Inc, San Francisco, CA USA. [Lipshultz, Steven E.] Wayne State Univ, Miami, FL USA. [Lloyd, Belinda K.; Room, Robin] Eastern Hlth, Turning Point Alcohol & Drug Ctr, Fitzroy, Vic, Australia. [Logroscino, Giancarlo] Univ Bari, Bari, Italy. Australian Natl Univ, Canberra, ACT, Australia. [Lunevicius, Raimundas] Aintree Univ Hosp NHS Fdn Trust, NHS Fdn Trust, Liverpool L9 7AL, Merseyside, England. [Lyons, Ronan Anthony] Swansea Univ, swauni, Swansea, W Glam, Wales. [Ma, Stefan] Minist Hlth Singapore, Singapore, Singapore. [Mackay, Mark T.] Royal Childrens Hosp, Melbourne, Vic, Australia. [Magis-Rodriguez, Carlos] Ctr Prevenc & Control VIH SIDA, Mexico City, DF, Mexico. [Mahdi, Abbas A.] King Georges Med Univ, Lucknow, Uttar Pradesh, India. [Mangalam, Srikanth] Tech Stand & Safety Author, Toronto, ON, Canada. [Mapoma, Christopher Chabila; Masiye, Felix] Univ Zambia, Lusaka, Zambia. [Marape, Marape] Botswana Baylor Childrens Clin Ctr Excellence, Gaborone, Botswana. [Marcenes, Wagner] Univ London, London, England. [Marzan, Melvin Barrientos] Univ East Ramon Magsaysay, Med Ctr, Quezon City, Metro Manila, Philippines. [Masci, Joseph R.] Elmhurst Hosp Ctr, Mt Sinai Serv, Elmhurst, NY USA. [Mashal, Mohammad Taufi Q.] Minist Publ Hlth, Kabul, Afghanistan. [Mason-Jones, Amanda J.] Univ York, York YO10 5DD, N Yorkshire, England. [Sliwa, Karen] Hatter Inst Cardiovasc Res Africa, Fac Hlth Sci, Cape Town, Western Cape, South Africa. [Mayosi, Bongani M.] Univ Cape Town, Cape Town, Western Cape, South Africa. [Mazorodze, Tasara T.] AIDC EC, Port Elizabeth, Eastern Cape, South Africa. [Mckay, Abigail C.] EmergentCorp, Belize City, Belize District, Belize. [Mehndiratta, Man Mohan] Janakpuri Superspecialty Hosp, Delhi, India. [Meltzer, Michele] Thomas Jefferson Univ, Philadelphia, PA 19107 USA. [Mendoza, Walter] UNFPA, Lima, Peru. [Mensah, George A.] NHLBI, Ctr Translat Res & Implementat Sci, NIH, Bethesda, MD 20892 USA. [Mhimbira, Francis A.] Ifakara Hlth Inst, Dar Es Salaam, Tanzania. [Miller, Ted R.] Pacific Inst Res & Evaluat, Calverton, MD USA. [Miller, Ted R.] Curtin Univ, Ctr Populat Hlth Res, Perth, WA 6845, Australia. [Mills, Edward J.] Univ Ottawa, Ottawa, ON, Canada. [Mishra, Santosh K.] SNDT Womens Univ, Populat Educ Resource Ctr, Dept Continuing & Adult Educ & Extens, Bombay, Maharashtra, India. [Moffitt, Terrie E.] Duke Univ, Durham, NC USA. [Ibrahim, Norlinah Mohamed] Univ Kebangsaan Malaysia, Med Ctr, Dept Med, Kuala Lumpur, Malaysia. [Mohammad, Karzan Abdulmuhsin] Univ Salahaddin, Erbil, Iraq. [Mola, Glen Liddell] Univ Papua New Guinea, Port Moresby, NCD, Papua N Guinea. [Monasta, Lorenzo; Montico, Marcella; Ronfani, Luca] Inst Maternal & Child Health IRCCS Burlo Garofolo, Trieste, Italy. [Monis, Jonathan de la Cruz] Bur Int Hlth Cooperat, Manila, Philippines. [Moore, Ami R.] Univ N Texas, Denton, TX 76203 USA. [Mori, Rintaro] Natl Ctr Child Hlth & Dev, Tokyo, Japan. [Tsilimbaris, Miltiadis] Dept Med, Iraklion, Greece. [Moschandreas, Joanna] Univ Crete, Iraklion, NE, Greece. [Moturi, Wilkister Nyaora] Egerton Univ, Egerton, Rift Valley, Kenya. [Mozaffarian, Dariush] Tufts Univ, Friedman Sch Nutr Sci & Policy, Boston, MA 02111 USA. [Mueller, Ulrich O.] Univ Marburg, Marburg, Germany. [Mukaigawara, Mitsuru] Tokyo Med & Dent Univ, Bunkyo Ku, Tokyo, Japan. [Naheed, Aliya] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh. [Naidoo, Kovin S.] Univ KwaZulu Natal, Durban, KwaZulu Natal, South Africa. [Naldi, Luigi] Azienda Osped Papa Giovanni XXIII, Bergamo, Italy. [Nand, Devina] Minist Hlth Fiji, Suva, Fiji. [Nangia, Vinay] Suraj Eye Inst, Nagpur, Maharashtra, India. [Nash, Denis] CUNY, Sch Publ Hlth, New York, NY 10021 USA. [Nasher, Jamal] Minist Publ Hlth & Populat, Sanaa, Yemen. [Nejjari, Chakib] Fac Med, Fes, Morocco. [Nelson, Robert G.] Natl Inst Diabet & Digest & Kidney Dis, Phoenix, AZ USA. [Neuhouser, Marian; Newcomb, Polly A.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Neupane, Sudan Prasad] Univ Oslo, Norwegian Ctr Addict Res SERAF, N-0316 Oslo, Norway. [Ngalesoni, Frida Namnyak] Minist Hlth & Social Welf, Dar Es Salaam, Tanzania. [Norrving, Bo] Lund Univ, Fac Med, Dept Clin Sci, Lund, Sweden. [O'Donnell, Martin] Natl Univ Ireland Galway, Galway, Ireland. [Ohkubo, Takayoshi] Teikyo Univ, Sch Med, Tokyo 173, Japan. [Olusanya, Bolajoko O.] Ctr Hlth Start Initiat, Lagos, Nigeria. [Opio, John Nelson] Lira Municipal Council, Lira Dist Local Govt, Northern Uganda, Uganda. [Orisakwe, Orish Ebere] Univ Port Harcourt, Fac Pharm, Toxicol Unit, Port Harcourt, Rivers State, Nigeria. [Ortiz, Alberto] IIS Fdn Jimenez Diaz, Madrid, Spain. [Otayza, Maria Lourdes K.] Mariano Marcos Mem Hosp, City Of Batac, Ilocos Norte, Philippines. [Otayza, Maria Lourdes K.] Med Ctr, City Of Batac, Ilocos Norte, Philippines. [Pandian, Jeyaraj D.] Christian Med Coll Ludhiana, Ludhiana, Punjab, India. [Panniyammakal, Jeemon] Ctr Chron Dis Control, Delhi, India. [Patten, Scott B.; Wang, JianLi] Univ Calgary, Calgary, AB, Canada. [Pavlin, Boris] Independent Researcher, Waigani, NCD, Papua N Guinea. [Pereira, David M.] Univ Porto, REQUIMTE, Fac Farm, Dept Quim,Lab Farmacognosia, P-4100 Oporto, Portugal. [Peresson, Sophie C.] Int Diabet Federat, Brussels, Belgium. [Perez-Ruiz, Fernando P.] Hosp Univ Cruces, Baracaldo, Spain. [Pervaiz, Aslam] Postgrad Med Inst, Lahore, Punjab, Pakistan. [Pesudovs, Konrad] Flinders Univ S Australia, Adelaide, SA 5001, Australia. [Peterson, Carrie B.] Aalborg Univ, Aalborg, Denmark. [Petzold, Max] Univ Gothenburg, Sahlgrenska Acad, Ctr Appl Biostat, Gothenburg, Sweden. [Phillips, Michael R.] Shanghai Jiao Tong Univ, Shanghai 200030, Peoples R China. [Plass, Dietrich] Fed Environm Agcy, Exposure Assessment & Environm Hlth Indicators, Bielefeld, North Rhine Wes, Germany. [Poenaru, Dan] McMaster Univ, Hamilton, ON, Canada. [Popova, Svetlana] Ctr Addict & Mental Hlth, Toronto, ON, Canada. [Prabhakaran, Dorairaj] Ctr Chron Dis Control, Delhi, India. [Qato, Dima] Univ Illinois, Coll Pharm, Chicago, IL USA. [Tabb, Karen M.] Univ Illinois, Chicago, IL USA. [Rabito, Felicia] Tulane Univ, Sch Publ Hlth & Trop Med, New Orleans, LA USA. [Rafay, Anwar] Contech Intl, Lahore, Punjab, Pakistan. [Rahman, Sajjad U. R.] Hamad Med Corp, Doha, Qatar. [Raju, Murugesan] Univ Missouri, Columbia, MS USA. [Rana, Saleem M.] Univ Punjab, Dept Publ Hlth, Lahore, Punjab, Pakistan. [Refaat, Amany] Walden Univ, Minneapolis, MN USA. [Ribeiro, Antonio L.] Univ Fed Minas Gerais, Hosp Clin, Belo Horizonte, MG, Brazil. [Ricci, Stefano] UO Neurol USL Umbria 1, Perugia, Italy. [Riccio, Patricia M.] Univ Western Ontario, Dept Clin Neurol Sci, London Hlth Sci Ctr, London, ON, Canada. [Roca, Anna] MRC Unit, Fajara, Gambia. [Rojas-Rueda, David] Ctr Res Environm Epidemiol CREAL, Barcelona, Catalonia, Spain. [Rothenbacher, Dietrich] Univ Ulm, Inst Epidemiol & Med Biometry, D-89069 Ulm, Germany. [Rothstein, David H.] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL USA. [Roy, Nobhojit] BARC Hosp, Bombay, Maharashtra, India. [Ruhago, George M.; Sunguya, Bruno F.] Muhimbili Univ Hlth & Allied Sci, Dar Es Salaam, Tanzania. Rwanda Biomed Ctr, Kigali, Rwanda. [Soreide, Kjetil] Stavanger Univ Hosp, Stavanger, Norway. [Saha, Sukanta] Queensland Ctr Mental Hlth Res, Brisbane, Qld, Australia. [Sahathevan, Ramesh] UKM Med Ctr, Kuala Lumpur, Malaysia. [Samonte, Genesis May J.] Natl Epidemiol Ctr, HIV AIDS & STI Surveillance & Strateg Informat Un, Dept Hlth, Manila, National Capita, Philippines. [Sanabria, Juan Ramon] Case Western Reserve Univ, Cleveland, OH 44106 USA. [Sawhney, Monika] Marshall Univ, Huntington, WV USA. [Saylan, Mete] Novartis, Istanbul, Turkey. [Schoettker, Ben] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, Baden Wurttembe, Switzerland. [Schneider, Ione J. C.] Univ Fed Santa Catarina, Florianopolis, SC, Brazil. [Schwebel, David C.; Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham, AL USA. [Shaheen, Amira] An Najah Univ, Nablus, Palestine, Israel. [Shinohara, Yukito] Tachikawa Hosp, Tokyo, Japan. [Shishani, Kawkab] Washington State Univ, Spokane, WA USA. [Shiue, Ivy] Heriot Watt Univ, Edinburgh, Midlothian, Scotland. [Shivakoti, Rupak] Ctr Clin Global Hlth Educ, Baltimore, MD USA. [Tran, Bach X.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Sigfusdottir, Inga Dora] Reykjavik Univ, Reykjavik, Iceland. [Soneji, Samir] Dartmouth Coll, Lebanon, NH 03756 USA. [Soshnikov, Sergey S.] Minist Hlth Russian Federat, Fed Res Inst Hlth Org & Informat, Moscow, Russia. [Sposato, Luciano A.] Univ Western Ontario, Dept Clin Neurol Sci, London, ON, Canada. [Sreeramareddy, Chandrashekhar T.] Univ Tunku Abdul Rahman, Fac Med & Hlth Sci, Kajang, Selangor, Malaysia. [Stathopoulou, Vasiliki Kalliopi] Ctr Hosp Nord Deux Sevres, Bressuire, France. [Straif, Kurt] IARC WHO, Lyon, France. [Stroumpoulis, Konstantinos] Alexandra Gen Hosp Athens, KEELPNO, Ctr Dis Control, Athens, Greece. [Swaminathan, Soumya] Natl Inst Res TB, Madras, Tamil Nadu, India. [Sykes, Bryan L.] Univ Calif Irvine, Dept Criminol Law & Soc & Sociol, Irvine, CA USA. [Takahashi, Ken] Univ Occupat & Environm Hlth, Inst Ind Ecol Sci, Dept Environm Epidemiol, Kitakyushu, Fukuoka 807, Japan. [Talongwa, Roberto Tchio] Minist Hlth MINSANTE, Yaounde, Cameroon. [Tanne, David] Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel. [Tanne, David] Tel Aviv Univ, Tel Hashomer, Israel. [Tavakkoli, Mohammad] Westchester Med Ctr, Valhalla, NY USA. [Ao, Braden Te] Auckland Univ Technol, Auckland, New Zealand. Jhpiego, Addis Ababa, Ethiopia. [Tenkorang, Eric Yeboah] Mem Univ Newfoundland, St John, NF, Canada. [Terkawi, Abdullah Sulieman] Univ Virginia, Dept Anesthesiol, Charlottesville, VA USA. [Terkawi, Abdullah Sulieman; Tleyjeh, Imad M.] King Fahad Med City, Dept Anesthesiol, Riyadh, Saudi Arabia. [Thorne-Lyman, Andrew L.] WorldFish, New York, NY USA. [Tleyjeh, Imad M.] Alfasial Univ, Coll Med, Riyadh, Saudi Arabia. [Tonelli, Marcello] Univ Alberta, Edmonton, AB, Canada. [Topouzis, Fotis] Aristotle Univ Thessaloniki, GR-54006 Thessaloniki, Greece. [Towbin, Jeffrey A.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [Toyoshima, Hideaki] Hlth Care Ctr Anjo Kosei Hosp, Anjo, Aichi, Japan. [Traebert, Jefferson] Univ Southern Santa Catarina, Palhoca, SC, Brazil. [Truelsen, Thomas] Univ Copenhagen, Herlev Hosp, Dept Neurol, Copenhagen, Denmark. [Trujillo, Ulises] Serv Canario Salud, Tenerife, Spain. [Dimbuene, Zacharie Tsala] Univ Kinshasa, Fac Econ & Management, Dept Populat Sci & Dev, Kinshasa, Zaire. [Ukwaja, Kingsley N.] Fed Teaching Hosp Abakaliki, Dept Internal Med, Abakailiki, Ebonyi State, Nigeria. [van de Vijver, Steven] African Populat & Hlth Res Ctr, Nairobi, Kenya. [van Gool, Coen H.] Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands. [Vasankari, Tommi J.] UKK Inst Hlth Promot Res, Tampere, Finland. [Vasconcelos, Ana Maria Nogales] Univ Brasilia, Brasilia, DF, Brazil. [Venketasubramanian, N.] Raffles Hosp, Ctr Neurosci, Singapore, Singapore. [Vijayakumar, Lakshmi] Voluntary Hlth Serv, Madras, Tamil Nadu, India. [Violante, Francesco S.] Univ Bologna, Bologna, Italy. [Vlassov, Vasiliy Victorovich] Higher Sch Econ, Moscow, Russia. [Wagner, Gregory R.] Natl Inst Occupat Safety & Hlth, Washington, DC USA. [Waller, Stephen G.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA. [Wang, Yanping; Zhu, Jun] Natl Off Maternal & Childs Hlth Surveillance, Chengdu, Peoples R China. [Weichenthal, Scott] Hlth Canada, Ottawa, ON K1A 0L2, Canada. [Weintraub, Robert G.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia. [Wenzhi, Wang] Beijing Neurosurg Inst, Beijing, Peoples R China. [Werdecker, Andrea] Inst Med Sociol & Social Med, Marburg, Hessen, Germany. [Wessells, K. Ryan R.] Univ Calif Davis, Davis, CA 95616 USA. [Wilkinson, James D.] Univ Miami, Miami, FL USA. [Woldeyohannes, Solomon Meseret] Univ Gondar, Inst Publ Hlth, Gondar, Amhara, Ethiopia. [Wong, John Q.] Ateneo Sch Med & Publ Hlth, Pasig, Metro Manila, Philippines. [Woolf, Anthony D.] Royal Cornwall Hosp, Truro, Cornwall, England. [Xu, Gelin] Nanjing Univ, Sch Med, Jinling Hosp, Nanjing 210008, Jiangsu, Peoples R China. [Yang, Yang C.] Univ N Carolina, Chapel Hill, NC USA. [Yano, Yuichiro] Jichi Med Univ, Sch Med, Div Cardiovasc Med, Shimotsuke, Tochigi, Japan. [Yatsuya, Hiroshi] Fujita Hlth Univ, Toyoake, Aichi, Japan. [Yip, Paul] Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China. [Yonemoto, Naohiro] Natl Ctr Neurol & Psychiat, Tokyo, Japan. [Younis, Mustafa] Jackson State Univ, Jackson, MS USA. [Yu, Chuanhua] Wuhan Univ, Sch Publ Hlth, Global Hlth Inst, Dept Epidemiol & Biostat, Wuhan 430072, Hubei, Peoples R China. [Jin, Kim Yun] TCM Med TK SDN BHD, Nusajaya, Johor Bahru, Malaysia. [Zaki, Maysaa El Sayed] Mansoura Fac Med, Mansoura, Egypt. [Zamakhshary, Mohammed Fouad] Minist Planning & Training, Riyadh, Saudi Arabia. [Zeeb, Hajo] Leibniz Inst Prevent Res & Epidemiol BIPS, Bremen, Germany. [Zhao, Yong] Chongqing Med Univ, Chongqing, Peoples R China. [Zheng, Yingfeng] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, Guangzhou 510275, Guangdong, Peoples R China. [Zhu, Shankuan] Zhejiang Univ, Sch Publ Hlth, Hangzhou 310003, Zhejiang, Peoples R China. [Zonies, David] Landstuhl Reg Med Ctr, Landstuhl, NY USA. [Zou, Xiao Nong] Chinese Acad Med Sci, Canc Inst Hosp, Beijing 100730, Peoples R China. RP Murray, CJL (reprint author), 2301 5th Ave,Suite 600, Seattle, WA 98121 USA. EM cjlm@uw.edu RI ; Whiteford, Harvey/A-4840-2009; Charlson, Fiona/F-5290-2011; Ronfani, Luca/B-6668-2013; LOGROSCINO, GIANCARLO/K-5148-2016; Moffitt, Terrie/D-5295-2011; McGrath, John/G-5493-2010; Hankey, Graeme /H-4968-2014; wang, YA XING/K-9671-2016; Naldi, Luigi/K-6343-2016; Osborne, Nicholas/N-4915-2015; Thrift, Amanda/I-6251-2012; Weiderpass, Elisabete/M-4029-2016; Tonelli, Marcello/B-3028-2009; Rahimi, Kazem/Q-1279-2015; Haro, Josep Maria/D-1423-2011; Degenhardt, Louisa/D-4515-2012; Kaul, Anil/B-2075-2016; Carabin, Helene/B-7600-2016; Patten, Scott/B-4434-2011; Monasta, Lorenzo/B-1388-2012; Sepanlou, Sadaf/H-9343-2016; Kravchenko, Michael/B-2596-2012; Ribeiro, Antonio/C-2707-2009; Castro, Ruben/J-1948-2015; CSTFA, ResearcherID/P-1067-2014; Research ID, CTBCC /O-3564-2014; Nolte, Sandra/B-7498-2008; Ameli, Omid/G-1583-2013; Rakovac, Ivo/A-7678-2013; Tanne, David/F-2560-2010; Adsuar, Jose C/C-6558-2008; Majdan, Marek/K-5017-2012; Higashi, Hideki/D-3797-2011; Lavados, Pablo/E-9918-2016; Undurraga, Eduardo/I-3739-2014; Alsharif, Ubai/C-6527-2017; Amini, Heresh/B-3076-2010; Lotufo, Paulo/A-9843-2008; Karch, Andre/D-6973-2017; Hedayati, Mohammad T./E-2304-2017; Scott, James/D-5900-2012; Franklin, Richard/H-1731-2012; Ermakov, Sergey/G-1709-2016; Pereira, David/M-9286-2013; NORMAN, ROSANA/F-2774-2010; Dokova, Klara/N-2448-2016; Montico, Marcella/B-5290-2013; Jacobsen, Kathryn/B-5857-2008; Lalloo, Ratilal/O-5624-2014; Tillmann, Taavi/R-6026-2016; Soshnikov, Sergey/R-7352-2016; Salomon, Joshua/D-3898-2009; Beyene, Tariku Jibat/A-6875-2017; Santos, Itamar/K-7055-2012; Patton, George/B-5246-2013; Varakin, Yuriy/C-8634-2012; Brenner, Hermann/B-4627-2017 OI Hay, Simon/0000-0002-0611-7272; Wessells, K. Ryan/0000-0002-5485-7144; London, Stephanie/0000-0003-4911-5290; Heydarpour, Pouria/0000-0001-5644-7555; Whiteford, Harvey/0000-0003-4667-6623; Charlson, Fiona/0000-0003-2876-5040; Ronfani, Luca/0000-0001-5710-3914; LOGROSCINO, GIANCARLO/0000-0003-0423-3242; Moffitt, Terrie/0000-0002-8589-6760; McGrath, John/0000-0002-4792-6068; Hankey, Graeme /0000-0002-6044-7328; wang, YA XING/0000-0003-2749-7793; Naldi, Luigi/0000-0002-3160-2835; Osborne, Nicholas/0000-0002-6700-2284; Thrift, Amanda/0000-0001-8533-4170; Weiderpass, Elisabete/0000-0003-2237-0128; Rahimi, Kazem/0000-0002-4807-4610; Haro, Josep Maria/0000-0002-3984-277X; Degenhardt, Louisa/0000-0002-8513-2218; Patten, Scott/0000-0001-9871-4041; Monasta, Lorenzo/0000-0001-7774-548X; Sepanlou, Sadaf/0000-0002-3669-5129; Kravchenko, Michael/0000-0001-5187-5518; Ribeiro, Antonio/0000-0002-2740-0042; Nolte, Sandra/0000-0001-6185-9423; Ameli, Omid/0000-0001-7878-0551; Rakovac, Ivo/0000-0003-3462-2636; Tanne, David/0000-0002-6699-2220; Adsuar, Jose C/0000-0001-7203-3168; Majdan, Marek/0000-0001-8037-742X; Moradi-Lakeh, Maziar/0000-0001-7381-5305; Olusanya, Bolajoko/0000-0002-3826-0583; Goenka, Shifalika/0000-0001-6993-2883; Deribe, Kebede/0000-0002-8526-6996; Khang, Young-Ho/0000-0002-9585-8266; Ortiz Arduan, Alberto/0000-0002-9805-9523; Kemp, Andrew/0000-0003-1146-3791; Erskine, Holly/0000-0003-3119-9211; Aboyans, Victor/0000-0002-0322-9818; Brauer, Michael/0000-0002-9103-9343; Glaser, Elizabeth/0000-0002-1918-057X; Chen, Honglei/0000-0003-3446-7779; Perez-Ruiz, Fernando/0000-0002-5268-1894; Catala-Lopez, Ferran/0000-0002-3833-9312; Norheim, Ole F./0000-0002-5748-5956; Quistberg, Alex/0000-0001-9730-2686; Liu, Zhi-Hong/0000-0001-6093-0726; Kieling, Christian/0000-0001-7691-4149; Sindi, Shireen/0000-0002-3786-0552; Husseini, Abdullatif/0000-0001-8767-5956; Benjet, Corina/0000-0002-4569-6094; Al-Shahi Salman, Rustam/0000-0002-2108-9222; Prabhakaran, Dorairaj/0000-0002-3172-834X; Mhimbira, Francis/0000-0001-8989-6832; Tabb Dina, Karen/0000-0002-4722-9502; Higashi, Hideki/0000-0002-5534-0905; Vallely, Andrew/0000-0003-1558-4822; Xu, Gelin/0000-0002-6194-0341; Goto, Atsushi/0000-0003-0669-654X; Soreide, Kjetil/0000-0001-7594-4354; Balakrishnan, Kalpana/0000-0002-5905-1801; Paternina-Caicedo, Angel/0000-0002-6332-5174; Newton, Charles/0000-0002-6999-5507; Cowie, Benjamin/0000-0002-7087-5895; O'Donnell, Martin/0000-0002-7347-7761; O'donnell, Colm/0000-0002-8004-450X; Rodriguez, Alina/0000-0003-1209-8802; Naghavi, Paria/0000-0002-8908-7952; Lavados, Pablo/0000-0002-9118-9093; Davis, Adrian/0000-0001-7134-7528; Banerjee, Amitava/0000-0001-8741-3411; Hotez, Peter/0000-0001-8770-1042; Abubakar, Ibrahim/0000-0002-0370-1430; Schottker, Ben/0000-0002-1217-4521; Pourmalek, Farshad/0000-0002-2134-0771; Undurraga, Eduardo/0000-0002-4425-1253; Bohensky, Megan/0000-0001-8370-1408; Khan, Ejaz/0000-0002-7072-8035; Hagstromer, Maria/0000-0002-4607-8677; Bikbov, Boris/0000-0002-1925-7506; MacLachlan, Jennifer/0000-0002-7654-4536; Gibney, Katherine/0000-0001-5851-5339; Stockl, Heidi/0000-0002-0907-8483; Kwan, Gene/0000-0002-0929-6800; Piel, Frederic B./0000-0001-8131-7728; Ukwaja, Kingsley N./0000-0002-1974-8735; Alsharif, Ubai/0000-0002-4024-3950; Amini, Heresh/0000-0002-4825-1322; Lotufo, Paulo/0000-0002-4856-8450; Karch, Andre/0000-0003-3014-8543; Hedayati, Mohammad T./0000-0001-6415-4648; Scott, James/0000-0002-0744-0688; Franklin, Richard/0000-0003-1864-4552; Ermakov, Sergey/0000-0003-1072-1162; Pereira, David/0000-0003-0384-7592; NORMAN, ROSANA/0000-0002-9742-1957; Montico, Marcella/0000-0003-0377-8232; Jacobsen, Kathryn/0000-0002-4198-6246; Lalloo, Ratilal/0000-0001-5822-1269; Tillmann, Taavi/0000-0002-8428-3719; Soshnikov, Sergey/0000-0002-6983-7066; Salomon, Joshua/0000-0003-3929-5515; Beyene, Tariku Jibat/0000-0002-7474-1966; Santos, Itamar/0000-0003-3212-8466; Patton, George/0000-0001-5039-8326; Brenner, Hermann/0000-0002-6129-1572 FU British Heart Foundation [RG/08/014/24067]; Department of Health [CDF-2013-06-012, RP-PG-0407-10184]; Medical Research Council [G9806489, MC_U137686851, MC_U147585819, MC_UP_A620_1014, MC_UU_12011/1, MR/K006525/1, MR/L003120/1]; NCATS NIH HHS [KL2 TR001088]; NIA NIH HHS [P30 AG017253]; NIEHS NIH HHS [P30 ES000260]; Wellcome Trust [089276, 089963, 099876] NR 122 TC 977 Z9 1022 U1 221 U2 792 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 EI 1474-547X J9 LANCET JI Lancet PD JAN 10 PY 2015 VL 385 IS 9963 BP 117 EP 171 DI 10.1016/S0140-6736(14)61682-2 PG 55 WC Medicine, General & Internal SC General & Internal Medicine GA AY7BI UT WOS:000347715900024 PM 25530442 ER PT J AU Leak, RK Li, PY Zhang, F Sulaiman, HH Weng, ZF Wang, GH Stetler, RA Shi, YJ Cao, GD Gao, YQ Chen, J AF Leak, Rehana K. Li, Peiying Zhang, Feng Sulaiman, Hassan H. Weng, Zhongfang Wang, Guohua Stetler, R. Anne Shi, Yejie Cao, Guodong Gao, Yanqin Chen, Jun TI Apurinic/Apyrimidinic Endonuclease 1 Upregulation Reduces Oxidative DNA Damage and Protects Hippocampal Neurons from Ischemic Injury SO ANTIOXIDANTS & REDOX SIGNALING LA English DT Article ID BASE-EXCISION-REPAIR; GLOBAL CEREBRAL-ISCHEMIA; STRANDED DEOXYRIBONUCLEIC-ACID; CELLULAR STRESS RESPONSES; HUMAN ABASIC ENDONUCLEASE; TRANSIENT FOCAL ISCHEMIA; RAT-BRAIN; CRITICAL DETERMINANTS; SUPEROXIDE-DISMUTASE; IONIZING-RADIATION AB Aims: Apurinic/apyrimidinic endonuclease 1 (APE1) is a multifunctional enzyme that participates in base-excision repair of oxidative DNA damage and in the redox activation of transcription factors. We tested the hypothesis that APE1 upregulation protects neuronal structure and function against transient global cerebral ischemia (tGCI). Results: Upregulation of APE1 by low-dose proton irradiation (PI) or by transgene overexpression protected hippocampal CA1 neurons against tGCI-induced cell loss and reduced apurinic/apyrimidinic sites and DNA fragmentation. Conversely, APE1 knockdown attenuated the protection afforded by PI and ischemic preconditioning. APE1 overexpression inhibited the DNA damage response, as evidenced by lower phospho-histone H2A and p53-upregulated modulator of apoptosis levels. APE1 overexpression also partially rescued dendritic spines and attenuated the decrease in field excitatory postsynaptic potentials in hippocampal CA1. Presynaptic and postsynaptic markers were reduced after tGCI, and this effect was blunted in APE1 transgenics. The Morris water maze test revealed that APE1 protected against learning and memory deficits for at least 27 days post-injury. Animals expressing DNA repair-disabled mutant APE1 (D210A) exhibited more DNA damage than wild-type controls and were not protected against tGCI-induced cell loss. Innovation: This is the first study that thoroughly characterizes structural and functional protection against ischemia after APE1 upregulation by measuring synaptic markers, electrophysiological function, and long-term neurological deficits in vivo. Furthermore, disabling the DNA repair activity of APE1 was found to abrogate its protective impact. Conclusion: APE1 upregulation, either endogenously or through transgene overexpression, protects DNA, neuronal structures, synaptic function, and behavioral output from ischemic injury. Antioxid. Redox Signal. 22, 135-148. C1 [Leak, Rehana K.; Li, Peiying; Zhang, Feng; Wang, Guohua; Stetler, R. Anne; Cao, Guodong; Gao, Yanqin; Chen, Jun] Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200433, Peoples R China. [Leak, Rehana K.; Li, Peiying; Zhang, Feng; Wang, Guohua; Stetler, R. Anne; Cao, Guodong; Gao, Yanqin; Chen, Jun] Fudan Univ, Inst Brain Sci, Shanghai 200433, Peoples R China. [Leak, Rehana K.; Li, Peiying; Zhang, Feng; Sulaiman, Hassan H.; Weng, Zhongfang; Wang, Guohua; Stetler, R. Anne; Shi, Yejie; Cao, Guodong; Chen, Jun] Univ Pittsburgh, Sch Med, Ctr Cerebrovasc Dis Res, Pittsburgh, PA USA. [Leak, Rehana K.] Duquesne Univ, Div Pharmaceut Sci, Pittsburgh, PA 15219 USA. [Leak, Rehana K.; Li, Peiying; Zhang, Feng; Sulaiman, Hassan H.; Weng, Zhongfang; Stetler, R. Anne; Shi, Yejie; Cao, Guodong; Chen, Jun] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Zhang, Feng; Weng, Zhongfang; Stetler, R. Anne; Cao, Guodong; Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. RP Chen, J (reprint author), Univ Pittsburgh, Dept Neurol, S507 Biomed Sci Tower, Pittsburgh, PA 15213 USA. EM yqgao@shmu.edu.cn; chenj2@upmc.edu RI Gao, Yanqin/I-6790-2016 OI Gao, Yanqin/0000-0002-4915-9819; Leak, Rehana/0000-0003-2817-7417; Shi, Yejie/0000-0001-7502-9201 FU NIH [NS036736, NS043802, NS045048]; AHA [10SDG2560122]; Chinese Natural Science Foundation [30870794, 81020108021, 81171149, 81371306, 81228008]; VA; UPMC FX These studies were supported by NIH grants NS036736, NS043802, and NS045048 (to J.C.) and AHA grant 10SDG2560122 (to F.Z.). Y.G. was supported by Chinese Natural Science Foundation grant numbers 30870794, 81020108021, 81171149, and 81371306. J.C. is the recipient of the Research Career Scientist award from the VA and of the Richard King Mellon Endowed Professorship from UPMC and was also supported by Chinese Natural Science Foundation grant number 81228008. The authors are indebted to Pat Strickler for outstanding administrative support. NR 67 TC 5 Z9 6 U1 1 U2 7 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1523-0864 EI 1557-7716 J9 ANTIOXID REDOX SIGN JI Antioxid. Redox Signal. PD JAN 10 PY 2015 VL 22 IS 2 BP 135 EP 148 DI 10.1089/ars.2013.5511 PG 14 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA AX6NC UT WOS:000347037800004 PM 24180454 ER PT J AU Brennan-Minnella, AM Won, SJ Swanson, RA AF Brennan-Minnella, Angela M. Won, Seok Joon Swanson, Raymond A. TI NADPH Oxidase-2: Linking Glucose, Acidosis, and Excitotoxicity in Stroke SO ANTIOXIDANTS & REDOX SIGNALING LA English DT Review ID METHYL-D-ASPARTATE; CYTOSOLIC PHOSPHOLIPASE A(2); FOCAL CEREBRAL-ISCHEMIA; NMDA RECEPTOR ACTIVATION; TISSUE-PLASMINOGEN ACTIVATOR; KINASE-C-ZETA; NEUTROPHIL RESPIRATORY BURST; CEREBELLAR GRANULE CELLS; EXCITATORY AMINO-ACIDS; REACTIVE-OXYGEN AB Significance: Neuronal superoxide production contributes to cell death in both glutamate excitotoxicity and brain ischemia (stroke). NADPH oxidase-2 (NOX2) is the major source of neuronal superoxide production in these settings, and regulation of NOX2 activity can thereby influence outcome in stroke. Recent Advances: Reduced NOX2 activity can rescue cells from oxidative stress and cell death that otherwise occur in excitotoxicity and ischemia. NOX2 activity is regulated by several factors previously shown to affect outcome in stroke, including glucose availability, intracellular pH, protein kinase zeta/delta, casein kinase 2, phosphoinositide-3-kinase, Rac1/2, and phospholipase A2. The newly identified functions of these factors as regulators of NOX2 activity suggest alternative mechanisms for their effects on ischemic brain injury. Critical Issues: Key aspects of these regulatory influences remain unresolved, including the mechanisms by which rac1 and phospholipase activities are coupled to N-methyl-D-aspartate (NMDA) receptors, and whether superoxide production by NOX2 triggers subsequent superoxide production by mitochondria. Future Directions: It will be important to establish whether interventions targeting the signaling pathways linking NMDA receptors to NOX2 in brain ischemia can provide a greater neuroprotective efficacy or a longer time window to treatment than provided by NMDA receptor blockade alone. It will likewise be important to determine whether dissociating superoxide production from the other signaling events initiated by NMDA receptors can mitigate the deleterious effects of NMDA receptor blockade. Antioxid. Redox Signal. 22, 161-174. C1 [Brennan-Minnella, Angela M.; Won, Seok Joon; Swanson, Raymond A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA. [Brennan-Minnella, Angela M.; Won, Seok Joon; Swanson, Raymond A.] San Francisco VA Med Ctr, Neurol & Rehabil Serv, San Francisco, CA USA. RP Swanson, RA (reprint author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA. EM raymond.swanson@ucsf.edu OI Swanson, Raymond/0000-0002-3664-5359 FU U.S. Dept. of Veterans Affairs; National Institutes of Health [NS081149] FX This work was supported by the U.S. Dept. of Veterans Affairs and National Institutes of Health (grant NS081149). We thank Colleen Hefner for assistance with the article preparation. NR 196 TC 9 Z9 9 U1 4 U2 12 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1523-0864 EI 1557-7716 J9 ANTIOXID REDOX SIGN JI Antioxid. Redox Signal. PD JAN 10 PY 2015 VL 22 IS 2 BP 161 EP 174 DI 10.1089/ars.2013.5767 PG 14 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA AX6NC UT WOS:000347037800006 PM 24628477 ER PT J AU Konadhode, RR Pelluru, D Shiromani, PJ AF Konadhode, Roda Rani Pelluru, Dheeraj Shiromani, Priyattam J. TI Neurons containing orexin or melanin concentrating hormone reciprocally regulate wake and sleep SO FRONTIERS IN SYSTEMS NEUROSCIENCE LA English DT Article DE sleep; melanin concentrating hormone; optogenetics; hypothalamus ID EYE-MOVEMENT SLEEP; VENTROLATERAL PREOPTIC NUCLEUS; LATERAL HYPOTHALAMIC AREA; WAKING DISCHARGE PATTERNS; LOCUS-COERULEUS NEURONS; SLOW-WAVE SLEEP; REM-SLEEP; MCH NEURONS; KNOCKOUT MICE; GENE-TRANSFER AB Neurons containing orexin (hypocretin), or melanin concentrating hormone (MCH) are intermingled with each other in the perifornical and lateral hypothalamus. Each is a separate and distinct neuronal population, but they project to similar target areas in the brain. Orexin has been implicated in regulating arousal since loss of orexin neurons is associated with the sleep disorder narcolepsy. Microinjections of orexin into the brain or optogenetic stimulation of orexin neurons increase waking. Orexin neurons are active in waking and quiescent in sleep, which is consistent with their role in promoting waking. On the other hand, the MCH neurons are quiet in waking but active in sleep, suggesting that they could initiate sleep. Recently, for the first time the MCH neurons were stimulated optogenetically and it increased sleep. Indeed, optogenetic activation of MCH neurons induced sleep in both mice and rats at a circadian time when they should be awake, indicating the powerful effect that MCH neurons have in suppressing the wake-promoting effect of not only orexin but also of all of the other arousal neurotransmitters. Gamma-Aminobutyric acid (GABA) is coexpressed with MCH in the MCH neurons, although MCH is also inhibitory. The inhibitory tone of the MCH neurons is opposite to the excitatory tone of the orexin neurons. We hypothesize that strength in activity of each determines wake vs. sleep. C1 [Konadhode, Roda Rani; Pelluru, Dheeraj; Shiromani, Priyattam J.] Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA. [Konadhode, Roda Rani; Pelluru, Dheeraj; Shiromani, Priyattam J.] Med Univ S Carolina, Dept Behav Sci, Charleston, SC 29425 USA. [Shiromani, Priyattam J.] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. RP Shiromani, PJ (reprint author), Med Univ S Carolina, Ralph H Johnson VA Med Ctr, 114 Doughty St,Room 404, Charleston, SC 29425 USA. EM shiroman@musc.edu NR 101 TC 7 Z9 7 U1 1 U2 6 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1662-5137 J9 FRONT SYST NEUROSCI JI Front. Syst. Neurosci. PD JAN 8 PY 2015 VL 8 AR UNSP 244 DI 10.3389/fnsys.2014.00244 PG 9 WC Neurosciences SC Neurosciences & Neurology GA CU6SM UT WOS:000363663800001 ER PT J AU Sauna, ZE Lozier, JN Kasper, CK Yanover, C Nichols, T Howard, TE AF Sauna, Zuben E. Lozier, Jay N. Kasper, Carol K. Yanover, Chen Nichols, Timothy Howard, Tom E. TI The intron-22-inverted F8 locus permits factor VIII synthesis: explanation for low inhibitor risk and a role for pharmacogenomics SO BLOOD LA English DT Article ID SEVERE HEMOPHILIA-A; ENDOGENOUS FACTOR-VIII; MHC CLASS-II; CENTRAL TOLERANCE; GENE; MUTATION; MILD; CELLS; IMMUNOGENICITY; INVERSIONS AB Intron-22-inversion patients express the entire Factor VIII (FVIII)-amino-acid sequence intracellularly as 2 non-secreted polypeptides and have a positive "intracellular (I)-FVIII-CRM" status. Mutations conferring a positive I-FVIII-CRM status are associated with low inhibitor risk and are pharmacogenetically relevant because inhibitor risk may be affected by the nature of the therapeutic FVIII-protein (tFVIII), the affinity of any tFVIII-derived foreign peptide (tFVIII-fp) for anyHLAclass-II isomer (HLA-II) comprising individual major histocompatibility complex (MHC) repertoires, and the stability of any tFVIII-fp/HLA-II complex. We hypothesize that mutations conferring a completely or substantially negative I-FVIII-CRM status are pharmacogenetically irrelevant because inhibitor risk is high with any tFVIII and individual MHC repertoire. C1 [Sauna, Zuben E.] US FDA, Lab Hemostasis, Div Hematol Res & Review, Ctr Biol Evaluat & Res, Silver Spring, MD 20993 USA. [Lozier, Jay N.] NIH, Hematol Sect, Dept Lab Med, Ctr Clin, Bethesda, MD 20892 USA. [Kasper, Carol K.] Orthopaed Hemophilia Treatment Ctr, Los Angeles, CA USA. [Kasper, Carol K.] Univ So Calif, Keck Sch Med, Dept Med, Div Hematol, Los Angeles, CA 90033 USA. [Yanover, Chen] IBM Res Lab, Machine Learning Healthcare & Life Sci, Haifa, Israel. [Nichols, Timothy] Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC USA. [Nichols, Timothy] Univ N Carolina, Sch Med, Dept Pathol & Lab Med, Chapel Hill, NC USA. [Howard, Tom E.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA 90073 USA. [Howard, Tom E.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol & Oncol, Los Angeles, CA 90095 USA. [Howard, Tom E.] Univ So Calif, Keck Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90033 USA. RP Howard, TE (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Bldg 500,Room 1258, Los Angeles, CA 90073 USA. EM zuben.sauna@fda.hhs.gov; Tom.Howard@va.gov RI Yanover, Chen/A-3754-2012 OI Yanover, Chen/0000-0003-3663-4286 FU Modernization of Science Program of the Center for Biologics Evaluation and Research, United States Food and Drug Administration; National Heart, Lung and Blood Institute, National Institutes of Health [1RC2-HL101851, HL-71130, HL-72533]; Bayer Healthcare Corporation; Bayer Hemophilia Awards Program; Baxter Healthcare Corporation; Clinical Translational Science Institute at the University of Southern California FX This study was supported by the Modernization of Science Program of the Center for Biologics Evaluation and Research, United States Food and Drug Administration (Z.E.S.); and grants from the National Heart, Lung and Blood Institute, National Institutes of Health (1RC2-HL101851, HL-71130, HL-72533), the Bayer Healthcare Corporation, Bayer Hemophilia Awards Program, Baxter Healthcare Corporation, and the Clinical Translational Science Institute at the University of Southern California (T.E.H.). NR 31 TC 3 Z9 4 U1 0 U2 4 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD JAN 8 PY 2015 VL 125 IS 2 BP 223 EP 228 DI 10.1182/blood-2013-12-530113 PG 6 WC Hematology SC Hematology GA CD1CA UT WOS:000350810200010 PM 25406352 ER PT J AU Guo, YM Wang, Z Mayer, EA Holschneider, DP AF Guo, Yumei Wang, Zhuo Mayer, Emeran A. Holschneider, Daniel P. TI Neonatal stress from limited bedding elicits visceral hyperalgesia in adult rats SO NEUROREPORT LA English DT Article DE abdominal pain; colorectal distension; early life stress; irritable bowel syndrome; nesting behavior; nociception; sex differences; visceral pain ID EARLY-LIFE STRESS; IRRITABLE-BOWEL-SYNDROME; MATERNAL SEPARATION; ESTROUS-CYCLE; COLONIC DISTENSION; SEX-DIFFERENCES; MODEL; VISCEROMOTOR; RESPONSES; ABUSE AB Early life stress is a risk factor for developing functional pain disorders. The 'limited bedding' (LB) model elicits psychological stress in the dam and her pups by providing minimal nesting material following delivery. Little is known about the effects of LB on visceral pain. Rats (female, male) were exposed to LB on postnatal days 2-9. Electromyographic visceromotor responses were recorded at the age of 11-12 weeks during titrated colorectal distension. LB exposure resulted in significant visceral hyperalgesia in both sexes. Sex differences were demonstrated only in nonstressed controls, with females showing a greater visceromotor response. Our results prepare the way for use of the LB model in studying the development of visceral pain in adults with functional gastrointestinal disorders. (C) 2014 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins. C1 [Guo, Yumei; Wang, Zhuo; Holschneider, Daniel P.] Univ So Calif, Dept Psychiat & Behav Sci, Los Angeles, CA 90089 USA. [Holschneider, Daniel P.] Univ So Calif, Dept Neurol Cell & Neurobiol, Los Angeles, CA 90089 USA. [Wang, Zhuo; Mayer, Emeran A.; Holschneider, Daniel P.] Univ Calif Los Angeles, Dept Med, Ctr Neurobiol Stress, Los Angeles, CA 90024 USA. [Mayer, Emeran A.] Univ Calif Los Angeles, Dept Physiol, Los Angeles, CA 90024 USA. [Mayer, Emeran A.] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA USA. [Mayer, Emeran A.] Univ Calif Los Angeles, Dept Biobehav Sci, Los Angeles, CA USA. [Mayer, Emeran A.] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Holschneider, DP (reprint author), Univ So Calif, Dept Psychiat & Behav Sci, 1975 Zonal Ave,KAM 400,MC 9037, Los Angeles, CA 90089 USA. EM holschne@usc.edu FU United States National Institutes of Health [P50DK064539] FX The research was supported by United States National Institutes of Health grants P50DK064539 (Mayer). NR 25 TC 10 Z9 10 U1 1 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0959-4965 EI 1473-558X J9 NEUROREPORT JI Neuroreport PD JAN 7 PY 2015 VL 26 IS 1 BP 13 EP 16 DI 10.1097/WNR.0000000000000292 PG 4 WC Neurosciences SC Neurosciences & Neurology GA AU7OW UT WOS:000345790900003 PM 25426824 ER PT J AU Packer, M McMurray, JJV Desai, AS Gong, J Lefkowitz, MP Rizkala, AR Rouleau, JL Shi, VC Solomon, SD Swedberg, K Zile, M Andersen, K Arango, JL Arnold, JM Belohlavek, J Bohm, M Boytsov, S Burgess, LJ Cabrera, W Calvo, C Chen, CH Dukat, A Duarte, YC Erglis, A Fu, M Gomez, E Gonzalez-Medina, A Hagege, AA Huang, J Katova, T Kiatchoosakun, S Kim, KS Kozan, O Llamas, EB Martinez, F Merkely, B Mendoza, I Mosterd, A Negrusz-Kawecka, M Peuhkurinen, K Ramires, FJA Refsgaard, J Rosenthal, A Senni, M Jr, ASS Silva-Cardoso, J Squire, IB Starling, RC Teerlink, JR Vanhaecke, J Vinereanu, D Wong, RCC AF Packer, Milton McMurray, John J. V. Desai, Akshay S. Gong, Jianjian Lefkowitz, Martin P. Rizkala, Adel R. Rouleau, Jean L. Shi, Victor C. Solomon, Scott D. Swedberg, Karl Zile, Michael Andersen, Karl Arango, Juan Luis Arnold, J. Malcolm Belohlavek, Jan Boehm, Michael Boytsov, Sergey Burgess, Lesley J. Cabrera, Walter Calvo, Carlos Chen, Chen-Huan Dukat, Andrej Duarte, Yan Carlos Erglis, Andrejs Fu, Michael Gomez, Efrain Gonzalez-Medina, Angel Hagege, Albert A. Huang, Jun Katova, Tzvetana Kiatchoosakun, Songsak Kim, Kee-Sik Kozan, Oemer Llamas, Edmundo Bayram Martinez, Felipe Merkely, Bela Mendoza, Ivan Mosterd, Arend Negrusz-Kawecka, Marta Peuhkurinen, Keijo Ramires, Felix J. A. Refsgaard, Jens Rosenthal, Arvo Senni, Michele Jr, Antonio S. Sibulo Silva-Cardoso, Jose Squire, Iain B. Starling, Randall C. Teerlink, John R. Vanhaecke, Johan Vinereanu, Dragos Wong, Raymond Ching-Chiew CA PARADIGM-HF Investigators TI Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure SO CIRCULATION LA English DT Article DE heart failure; neprilysin; receptors, angiotensin ID LEFT-VENTRICULAR DYSFUNCTION; NATRIURETIC-PEPTIDE; NEUTRAL ENDOPEPTIDASE; CONVERTING ENZYME; MYOCARDIAL-INFARCTION; MILD SYMPTOMS; MORTALITY; TRIAL; ADRENOMEDULLIN; BRADYKININ AB Background-Clinical trials in heart failure have focused on the improvement in symptoms or decreases in the risk of death and other cardiovascular events. Little is known about the effect of drugs on the risk of clinical deterioration in surviving patients. Methods and Results-We compared the angiotensin-neprilysin inhibitor LCZ696 (400 mg daily) with the angiotensin-converting enzyme inhibitor enalapril (20 mg daily) in 8399 patients with heart failure and reduced ejection fraction in a double-blind trial. The analyses focused on prespecified measures of nonfatal clinical deterioration. In comparison with the enalapril group, fewer LCZ696-treated patients required intensification of medical treatment for heart failure (520 versus 604; hazard ratio, 0.84; 95% confidence interval, 0.74-0.94; P=0.003) or an emergency department visit for worsening heart failure (hazard ratio, 0.66; 95% confidence interval, 0.52-0.85; P=0.001). The patients in the LCZ696 group had 23% fewer hospitalizations for worsening heart failure (851 versus 1079; P<0.001) and were less likely to require intensive care (768 versus 879; 18% rate reduction, P=0.005), to receive intravenous positive inotropic agents (31% risk reduction, P<0.001), and to have implantation of a heart failure device or cardiac transplantation (22% risk reduction, P=0.07). The reduction in heart failure hospitalization with LCZ696 was evident within the first 30 days after randomization. Worsening of symptom scores in surviving patients was consistently more common in the enalapril group. LCZ696 led to an early and sustained reduction in biomarkers of myocardial wall stress and injury (N-terminal pro-B-type natriuretic peptide and troponin) versus enalapril. Conclusions-Angiotensin-neprilysin inhibition prevents the clinical progression of surviving patients with heart failure more effectively than angiotensin-converting enzyme inhibition. C1 [Packer, Milton] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA. [McMurray, John J. V.] Univ Glasgow, BHF Cardiovasc Res Ctr, Glasgow, Lanark, Scotland. [Desai, Akshay S.; Solomon, Scott D.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Gong, Jianjian; Lefkowitz, Martin P.; Rizkala, Adel R.; Shi, Victor C.] Novartis Pharmaceut, E Hanover, NJ USA. [Rouleau, Jean L.] Univ Montreal, Inst Cardiol, Montreal, PQ, Canada. [Swedberg, Karl] Dept Mol & Clin Med, Gothenburg, Sweden. [Zile, Michael] Med Univ S Carolina, Charleston, SC 29425 USA. [Zile, Michael] Vet Adm Med Ctr, RHJ Dept, Charleston, SC 29403 USA. [Andersen, Karl] Univ Iceland, Fac Med, Sch Hlth Sci, Reykjavik, Iceland. [Arango, Juan Luis] Unidad Cirugia Cardiovasc Guatemala, Guatemala City, Guatemala. [Arnold, J. Malcolm] Univ Western Ontario, Dept Physiol & Med, London, ON N6A 3K7, Canada. [Belohlavek, Jan] Charles Univ Prague, Gen Univ Hosp, Dept Med 2, Prague, Czech Republic. [Belohlavek, Jan] Charles Univ Prague, Sch Med 1, Dept Med 2, Prague, Czech Republic. [Boehm, Michael] Univ Saarland, Dept Cardiol, Homburg, Germany. [Boytsov, Sergey] Natl Res Ctr Prevent Med, Moscow, Russia. [Burgess, Lesley J.] Univ Stellenbosch, Dept Internal Med, Cardiol Unit, TREAD Res, Parow, South Africa. [Burgess, Lesley J.] Tygerberg Hosp, Parow, South Africa. [Cabrera, Walter] Clin Vesalio, Lima, Peru. [Calvo, Carlos] Hosp Clin Univ, Unidad Hipertens Arterial & Riesgo Vasc, La Coruna, Spain. [Chen, Chen-Huan] Natl Yang Ming Univ, Dept Med, Taipei, Taiwan. [Dukat, Andrej] Comenius Univ, Dept Internal Med 2, Bratislava, Slovakia. [Duarte, Yan Carlos] Luis Vernaza Hosp, Guayaquil, Ecuador. [Erglis, Andrejs] Univ Latvia, Inst Cardiol, Fac Med, Riga, Latvia. [Fu, Michael] Ostra Hosp, Sahlgrenska Univ Hosp, Dept Med, S-41685 Gothenburg, Sweden. [Gomez, Efrain] Clin Shaio, Bogota, Colombia. [Gonzalez-Medina, Angel] Univ Autonoma Santo Domingo, Hosp Santo Domingo, Santo Domingo, Dominican Rep. [Hagege, Albert A.] Hop Europeen Georges Pompidou, AP HP, Dept Cardiol, Paris, France. [Hagege, Albert A.] Paris Descartes Univ, Sorbonne Paris Cite, Paris, France. [Hagege, Albert A.] INSERM, U970, Paris Cardiovasc Res Ctr, Paris, France. [Huang, Jun] Nanjing Med Univ, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China. [Katova, Tzvetana] Natl Hosp Cardiol, Sofia, Bulgaria. [Kiatchoosakun, Songsak] Khon Kaen Univ, Khon Kaen, Thailand. [Kim, Kee-Sik] Daegu Catholic Univ Hosp, Taegu, South Korea. [Kozan, Oemer] Dokuz Eylul Univ, Fac Med, Izmir, Turkey. [Llamas, Edmundo Bayram] Fdn Cardiovasc Aguascalientes AC, Hidalgo, Mexico. [Martinez, Felipe] Univ Nacl Cordoba, Fdn Rusculleda, Inst DAMIC, RA-5000 Cordoba, Argentina. [Merkely, Bela] Semmelweis Univ, H-1085 Budapest, Hungary. [Mendoza, Ivan] Cent Univ Venezuela, Venezuela Inst Trop Med, Caracas, Venezuela. [Mosterd, Arend] Meander Med Ctr, Dept Cardiol, Amersfoort, Netherlands. [Mosterd, Arend] WCN Dutch Network Cardiovasc Res, Utrecht, Netherlands. [Negrusz-Kawecka, Marta] Wroclaw Med Univ, Dept & Clin Cardiol, Wroclaw, Poland. [Peuhkurinen, Keijo] Kuopio Univ Hosp, Dept Med, SF-70210 Kuopio, Finland. [Ramires, Felix J. A.] Univ Sao Paulo, Sch Med, Heart Inst InCor, BR-05508 Sao Paulo, Brazil. [Refsgaard, Jens] Viborg Hosp, Dept Cardiol, Viborg, Denmark. [Senni, Michele] Azienda Osped Papa Giovanni XXIII, Bergamo, Italy. [Jr, Antonio S. Sibulo] St Lukes Heart Inst, Quezon City, Philippines. [Silva-Cardoso, Jose] Univ Porto, Porto Med Sch, Ctr Hlth Technol & Serv Res CINTESIS, P-4100 Oporto, Portugal. [Squire, Iain B.] Univ Leicester, Dept Cardiovasc Sci, Leicester, Leics, England. [Squire, Iain B.] Glenfield Hosp, NIHR Cardiovasc Biomed Res Unit, Leicester, Leics, England. [Starling, Randall C.] Cleveland Clin, Inst Heart & Vasc, Cleveland, OH 44106 USA. [Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA USA. [Teerlink, John R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Vanhaecke, Johan] Univ Hosp KU Leuven, Dept Cardiovasc Dis, Leuven, Belgium. [Vinereanu, Dragos] Carol Davila Univ & Emergency Hosp, Univ Med & Pharm, Bucharest, Romania. [Wong, Raymond Ching-Chiew] Natl Univ Singapore, Ctr Heart, Dept Cardiol, Singapore 117548, Singapore. RP Packer, M (reprint author), Univ Texas SW Med Ctr Dallas, Dept Clin Sci, 5323 Harry Hines Blvd, Dallas, TX 75390 USA. EM milton.packer@utsouthwestern.edu; john.mcmurray@glasgow.ac.uk RI Ramires, Felix/D-5996-2012; Libis, Roman/O-9193-2015; Rafalskiy, Vladimir/G-3172-2013; FMUP, CINTESIS/C-6631-2014; Zhilyaev, Evgeny/E-3774-2016; Urina, Miguel/H-2605-2016; Boytsov, Sergey/M-4486-2014; Drapkina, Oxana/G-8443-2016; Krupicka, Jan/F-6916-2017 OI Ramires, Felix/0000-0003-2437-2485; Libis, Roman/0000-0003-0130-990X; Rafalskiy, Vladimir/0000-0002-2503-9580; FMUP, CINTESIS/0000-0001-7248-2086; Zhilyaev, Evgeny/0000-0002-9443-1164; Urina, Miguel/0000-0001-6003-4622; Boytsov, Sergey/0000-0001-6998-8406; Drapkina, Oxana/0000-0002-4453-8430; Krupicka, Jan/0000-0002-0849-7395; Nightingale, Angus/0000-0001-9435-726X; Mohindra, Raj/0000-0002-8437-5066; Danzi, Gian Battista/0000-0003-0897-8006; mcmurray, john/0000-0002-6317-3975; Martinez-Selles, Manuel/0000-0003-0289-6229 FU Novartis FX The study was funded by Novartis. NR 42 TC 88 Z9 95 U1 5 U2 53 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD JAN 6 PY 2015 VL 131 IS 1 BP 54 EP 61 DI 10.1161/CIRCULATIONAHA.114.013748 PG 8 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA AY0PW UT WOS:000347299900017 PM 25403646 ER PT J AU Qin, WP Pan, JP Wu, Y Bauman, WA Cardozo, C AF Qin, Weiping Pan, Jiangping Wu, Yong Bauman, William A. Cardozo, Christopher TI Anabolic steroids activate calcineurin-NFAT signaling and thereby increase myotube size and reduce denervation atrophy SO MOLECULAR AND CELLULAR ENDOCRINOLOGY LA English DT Article DE Muscle atrophy; Myotubes; Androgens; Denervation; Calcineurin-NFAT signaling ID SKELETAL-MUSCLE HYPERTROPHY; SPINAL-CORD-INJURY; GENE-EXPRESSION; NERVE ACTIVITY; AMYLOID NEUROPATHOLOGY; CALORIE RESTRICTION; CARDIAC-HYPERTROPHY; STRIATED-MUSCLES; RECEPTOR-BINDING; CYCLOSPORINE-A AB Anabolic androgens have been shown to reduce muscle loss due to immobilization, paralysis and many other medical conditions, but the molecular basis for these actions is poorly understood. We have recently demonstrated that nandrolone, a synthetic androgen, slows muscle atrophy after nerve transection associated with down-regulation of regulator of calcineurin 2 (RCAN2), a calcineurin inhibitor, suggesting a possible role of calcineurin-NFAT signaling. To test this possibility, rat gastrocnemius muscle was analyzed at 56 days after denervation. In denervated muscle, calcineurin activity declined and NFATc4 was excluded from the nucleus and these effects were reversed by nandrolone. Similarly, nandrolone increased calcineurin activity and nuclear NFATc4 levels in cultured L6 myotubes. Nandrolone also induced cell hypertrophy that was blocked by cyclosporin A or overexpression of RCAN2. Finally protection against denervation atrophy by nandrolone in rats was blocked by cyclosporin A. These results demonstrate for the first time that nandrolone activates calcineurin-NFAT signaling, and that such signaling is important in nandrolone-induced cell hypertrophy and protection against paralysis-induced muscle atrophy. Published by Elsevier Ireland Ltd. C1 [Qin, Weiping; Pan, Jiangping; Wu, Yong; Bauman, William A.; Cardozo, Christopher] James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Bronx, NY 10468 USA. [Qin, Weiping; Bauman, William A.; Cardozo, Christopher] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA. [Bauman, William A.; Cardozo, Christopher] Mt Sinai Sch Med, New York, NY 10029 USA. RP Qin, WP (reprint author), James J Peters VA Med Ctr, Ctr Excellence Med Consequences SCI, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM weiping.qin@mssm.edu; Chris.cardozo@mssm.edu FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service [B4162C, B3347K, F6997R, B0687R, B1313-R] FX We thank Kel Morin for critical reading of the manuscript and Jianwei Hou for assistance with the animal studies. Sources of research support: The Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service grants B4162C, B3347K, F6997R, B0687R and B1313-R. NR 59 TC 3 Z9 3 U1 1 U2 7 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0303-7207 J9 MOL CELL ENDOCRINOL JI Mol. Cell. Endocrinol. PD JAN 5 PY 2015 VL 399 IS C BP 336 EP 345 DI 10.1016/j.mce.2014.09.025 PG 10 WC Cell Biology; Endocrinology & Metabolism SC Cell Biology; Endocrinology & Metabolism GA CA4MI UT WOS:000348877700036 PM 25450864 ER PT J AU Jenkins, JA Gordon, AJ AF Jenkins, Jennifer A. Gordon, Adam J. TI Substance Use Disorder Prevention and Treatment in Stigmatized Patient Populations: Ripe for Innovation SO SUBSTANCE ABUSE LA English DT Editorial Material C1 [Jenkins, Jennifer A.] VA Puget Sound Hlth Care Syst, Ctr Innovat Vet Ctr & Value Driven Care, Seattle, WA USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC, Pittsburgh, PA 15240 USA. [Gordon, Adam J.] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA. RP Gordon, AJ (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Univ Dr C,Bldg 30, Pittsburgh, PA 15240 USA. EM adam.gordon@va.gov NR 4 TC 0 Z9 0 U1 1 U2 4 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0889-7077 EI 1547-0164 J9 SUBST ABUS JI Subst. Abus. PD JAN 2 PY 2015 VL 36 IS 1 BP 1 EP 2 DI 10.1080/08897077.2015.1009266 PG 2 WC Substance Abuse SC Substance Abuse GA CD7MW UT WOS:000351275600001 PM 25607933 ER PT J AU Rittmueller, SE Frey, MS Williams, EC Sun, HL Bryson, CL Bradley, KA AF Rittmueller, Stacey E. Frey, Madeleine S. Williams, Emily C. Sun, Haili Bryson, Chris L. Bradley, Katharine A. TI Association Between Alcohol Use and Cardiovascular Self-Care Behaviors Among Male Hypertensive Veterans Affairs Outpatients: A Cross-Sectional Study SO SUBSTANCE ABUSE LA English DT Article DE Alcohol; cardiovascular; hypertension; self-care ID RANDOMIZED CONTROLLED-TRIALS; SERVICES TASK-FORCE; BLOOD-PRESSURE; SCREENING SCORES; PROBLEM DRINKING; UNITED-STATES; AUDIT-C; CONSUMPTION; RISK; POPULATION AB Background: Alcohol use is associated with health behaviors that impact cardiovascular outcomes in patients with hypertension, including avoiding salt, exercising, weight management, and not smoking. This study examined associations between varying levels of alcohol use and self-reported cardiovascular health behaviors among hypertensive Veterans Affairs (VA) outpatients. Methods: Male outpatients with self-reported hypertension from 7 VA sites who returned mailed questionnaires (N = 11,927) were divided into 5 levels of alcohol use: nondrinking, low-level use, and mild, moderate, and severe alcohol misuse based on AUDIT-C (Alcohol Use Disorders Identification Test-Consumption) scores (0, 1-3, 4-5, 6-7, and 8-12, respectively). For each category, adjusted logistic regression models estimated the prevalence of patients who self-reported avoiding salt, exercising, controlling weight, or not smoking, and the composite of all four. Results: Increasing level of alcohol use was associated with decreasing prevalence of avoiding salt, controlling weight, not smoking, and the combination of all 4 behaviors (P values all <.001). A linear trend was not observed for exercise (P =.83), which was most common among patients with mild alcohol misuse (P =.01 relative to nondrinking). Conclusions: Alcohol consumption is inversely associated with adherence to cardiovascular self-care behaviors among hypertensive VA outpatients. Clinicians should be especially aware of alcohol use level among hypertensive patients. C1 [Rittmueller, Stacey E.] Pacific Northwest Univ Hlth Sci, Yakima, WA USA. [Frey, Madeleine S.; Bradley, Katharine A.] Grp Hlth Res Inst, Ctr Community Hlth & Evaluat, Seattle, WA USA. [Williams, Emily C.; Sun, Haili; Bryson, Chris L.] Vet Affairs VA Puget Sound Hlth Care Syst, Denver Seattle Ctr Innovat Vet Ctr & Value Driven, Seattle, WA USA. [Williams, Emily C.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Bryson, Chris L.] Vet Affairs VA Puget Sound Hlth Care Syst, Primary & Specialty Med Care Serv, Seattle, WA USA. [Bryson, Chris L.; Bradley, Katharine A.] Univ Washington, Dept Med, Seattle, WA USA. [Bradley, Katharine A.] Vet Affairs VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA USA. [Bradley, Katharine A.] Grp Hlth Res Inst, Seattle, WA USA. RP Williams, EC (reprint author), VA Puget Sound Hlth Care Syst, Denver Seattle Ctr Innovat Vet Ctr & Value Driven, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM Emily.williams3@va.gov FU VA HSRD IIR grant [IAC 05-206-1]; VA Health Services Research and Development [CDA 12-276]; VA Center of Excellence for Substance Abuse Treatment and Education; VA HSRD grants [SDR96-002, IIR99-376]; National Institute of Mental Health [R25 MH080916-01A2]; Department of Veterans Affairs, Health Services Research & Development Service, Quality Enhancement Research Initiative (QUERI) FX This work was funded by VA HSR&D IIR grant IAC 05-206-1 and conducted with support from VA Health Services Research and Development and VA Center of Excellence for Substance Abuse Treatment and Education. The VA Ambulatory Care Quality Improvement Project (ACQUIP) was funded by VA HSR&D grants SDR96-002 and IIR99-376. Dr. Williams is supported by a Career Development Award from VA Health Services Research & Development (CDA 12-276) and is an investigator with the Implementation Research Institute (IRI) at the George Warren Brown School of Social Work at Washington University in St. Louis. IRI is supported through an award from the National Institute of Mental Health (R25 MH080916-01A2) and the Department of Veterans Affairs, Health Services Research & Development Service, Quality Enhancement Research Initiative (QUERI). Views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs, the University of Washington, or Group Health Research Institute. NR 37 TC 2 Z9 2 U1 1 U2 5 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0889-7077 EI 1547-0164 J9 SUBST ABUS JI Subst. Abus. PD JAN 2 PY 2015 VL 36 IS 1 BP 6 EP 12 DI 10.1080/08897077.2014.932318 PG 7 WC Substance Abuse SC Substance Abuse GA CD7MW UT WOS:000351275600003 PM 24964087 ER PT J AU Collins, SE Duncan, MH Smart, BF Saxon, AJ Malone, DK Jackson, TR Ries, RK AF Collins, Susan E. Duncan, Mark H. Smart, Brian F. Saxon, Andrew J. Malone, Daniel K. Jackson, T. Ron Ries, Richard K. TI Extended-Release Naltrexone and Harm Reduction Counseling for Chronically Homeless People With Alcohol Dependence SO SUBSTANCE ABUSE LA English DT Article DE extended-release naltrexone; Alcohol dependence; homelessness; harm reduction ID SUBSTANCE-ABUSE TREATMENT; COGNITIVE-BEHAVIORAL TREATMENT; RANDOMIZED CONTROLLED-TRIALS; HOUSING 1ST; ETHYL GLUCURONIDE; PHARMACOTHERAPY TRIALS; CONTROLLED DRINKING; MENTAL-ILLNESS; HEAVY DRINKING; USE DISORDERS AB Background: Abstinence-based alcohol interventions are minimally desirable to and effective for chronically homeless individuals with alcohol dependence who have multimorbidity and high publicly funded service utilization and associated costs. Lower-barrier, patient-centered combined pharmacobehavioral interventions may more effectively treat this population. Harm reduction counseling involves a nonjudgmental, empathic style and patient-driven goal setting that requires neither abstinence nor use reduction. Extended-release naltrexone (XR-NTX), a monthly injectable formulation of an opioid receptor antagonist, reduces craving, is safe and effective for active drinkers, and may thereby support harm reduction goal setting. The aims of this 12-week, single-arm pilot were to initially document some aspects of feasibility, acceptability, and alcohol outcomes following XR-NTX administration and harm reduction counseling for chronically homeless individuals with alcohol dependence. Methods: Participants were currently/formerly chronically homeless, alcohol-dependent individuals (N = 31) from 2 community-based agencies in the US Pacific Northwest. Measures included self-reported alcohol craving, quantity/frequency, problems, and biomarkers (ethyl glucuronide [EtG], liver transaminases). XR-NTX and harm reduction counseling were administered monthly over the 3-month treatment course. Results: Of the 45 individuals approached, 43 were interested in participation. The first injection was received by 31 participants, and 24 complied with all study procedures. Participants reported the treatment was acceptable. Participants evinced decreases in alcohol craving (33%), typical (25%) and peak (34%) use, frequency (17%), problems (60%), and EtG from the baseline to the 12-week follow-up (Ps < .05). Conclusions: XR-NTX and harm reduction counseling are promising means of supporting reductions in alcohol use and alcohol-related harm among chronically homeless, alcohol-dependent individuals. C1 [Collins, Susan E.; Duncan, Mark H.; Smart, Brian F.; Saxon, Andrew J.; Ries, Richard K.] Univ Washington, Harborview Med Ctr, Dept Psychiat & Behav Sci, Seattle, WA 98104 USA. [Saxon, Andrew J.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Malone, Daniel K.] Downtown Emergency Serv Ctr, Seattle, WA USA. [Jackson, T. Ron] Evergreen Treatment Serv, Seattle, WA USA. RP Collins, SE (reprint author), Univ Washington, Harborview Med Ctr, Dept Psychiat & Behav Sci, 325 Ninth Ave,Box 359911, Seattle, WA 98104 USA. EM collinss@uw.edu FU Alcohol and Drug Abuse Institute; Center for Healthcare Improvement for Addictions, Mental Illness and Medically Vulnerable Populations (CHAMMP); National Institute on Alcohol Abuse and Alcoholism [K22AA018384] FX This research was supported by small grants from the Alcohol and Drug Abuse Institute (Principal Investigator [PI]: Collins) and the Center for Healthcare Improvement for Addictions, Mental Illness and Medically Vulnerable Populations (CHAMMP; PI: Collins) as well as a Career Transition Award from the National Institute on Alcohol Abuse and Alcoholism (K22AA018384; PI: Collins). These agencies were not directly involved in the work reported on in the article or in the composition of the submission. Dr. Saxon serves on the Scientific Advisory Board for Alkermes and as speaker for Reckitt Benckiser. Dr. Ries serves as speaker for Alkermes, Janssen Pharmaceuticals, and has served in the past as speaker for Reckitt Benckiser. All other authors declare that they have no conflicts of interest pertaining to this article. NR 100 TC 6 Z9 6 U1 2 U2 8 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0889-7077 EI 1547-0164 J9 SUBST ABUS JI Subst. Abus. PD JAN 2 PY 2015 VL 36 IS 1 BP 21 EP 33 DI 10.1080/08897077.2014.904838 PG 13 WC Substance Abuse SC Substance Abuse GA CD7MW UT WOS:000351275600005 PM 24779575 ER PT J AU Chandra, A Lin, T Zhu, J Tong, W Huo, YY Jia, HR Zhang, YJ Liu, XS Cengel, K Xia, B Qin, L AF Chandra, Abhishek Lin, Tiao Zhu, Ji Tong, Wei Huo, Yanying Jia, Haoruo Zhang, Yejia Liu, X. Sherry Cengel, Keith Xia, Bing Qin, Ling TI PTH1-34 Blocks Radiation-induced Osteoblast Apoptosis by Enhancing DNA Repair through Canonical Wnt Pathway SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article DE Apoptosis; DNA Repair; Osteoblast; Parathyroid Hormone; Wnt Pathway; Ionizing Radiation ID PELVIC INSUFFICIENCY FRACTURES; PARATHYROID-HORMONE; BONE-FORMATION; IONIZING-RADIATION; INTERMITTENT PTH; PROTEIN-KINASE; IN-VITRO; CELLS; IRRADIATION; EXPRESSION AB Background: PTH1-34 alleviates radiation-induced osteoporosis in a preclinical radiotherapy model. Results: PTH1-34 attenuates radiation damage on osteoblasts by increasing Ku70 amount, accelerating DNA repair, and suppressing osteoblast apoptosis. Pathway analyses identify canonical Wnt pathway as an important mediator. Conclusion: PTH1-34 blocks radiation-induced osteoblast apoptosis through activation of -catenin. Significance: PTH1-34 or Wnt agonist could be possible therapy for radiation-induced osteoporosis. Focal radiotherapy for cancer patients has detrimental effects on bones within the radiation field and the primary clinical signs of bone damage include the loss of functional osteoblasts. We reported previously that daily injection of parathyroid hormone (PTH, 1-34) alleviates radiation-induced osteopenia in a preclinical radiotherapy model by improving osteoblast survival. To elucidate the molecular mechanisms, we irradiated osteoblastic UMR 106-01 cells and calvarial organ culture and demonstrated an anti-apoptosis effect of PTH1-34 on these cultures. Inhibitor assay indicated that PTH exerts its radioprotective action mainly through protein kinase A/-catenin pathway. -H2AX foci staining and comet assay revealed that PTH efficiently promotes the repair of DNA double strand breaks (DSBs) in irradiated osteoblasts via activating the -catenin pathway. Interestingly, Wnt3a alone also blocked cell death and accelerated DNA repair in primary osteoprogenitors, osteoblastic and osteocytic cells after radiation through the canonical signaling. Further investigations revealed that both Wnt3a and PTH increase the amount of Ku70, a core protein for initiating the assembly of DSB repair machinery, in osteoblasts after radiation. Moreover, down-regulation of Ku70 by siRNA abrogated the prosurvival effect of PTH and Wnt3a on irradiated osteoblasts. In summary, our results identify a novel role of PTH and canonical Wnt signaling in regulating DSB repair machinery and apoptosis in osteoblasts and shed light on using PTH1-34 or Wnt agonist as possible therapy for radiation-induced osteoporosis. C1 [Chandra, Abhishek; Lin, Tiao; Zhu, Ji; Tong, Wei; Jia, Haoruo; Liu, X. Sherry; Qin, Ling] Univ Penn, Dept Orthopaed Surg, Perelman Sch Med, Philadelphia, PA 19104 USA. [Zhang, Yejia] Univ Penn, Dept Phys Med & Rehabil, Perelman Sch Med, Philadelphia, PA 19104 USA. [Zhang, Yejia] Univ Penn, Dept Orthoped Surg, Perelman Sch Med, Philadelphia, PA 19104 USA. [Cengel, Keith] Univ Penn, Dept Radiat Oncol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Lin, Tiao] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Orthopaed Surg, Hangzhou 310009, Zhejiang, Peoples R China. [Tong, Wei] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Orthopaed Surg, Wuhan 430022, Hubei, Peoples R China. [Xia, Bing] Rutgers State Univ, Dept Radiat Oncol, Rutgers Canc Inst New Jersey, New Brunswick, NJ 08903 USA. [Xia, Bing] Rutgers State Univ, Dept Radiat Oncol, Robert Wood Johnson Med Sch, New Brunswick, NJ 08903 USA. [Zhang, Yejia] Philadelphia Vet Affairs Med Ctr, Translat Musculoskeletal Res Ctr, Philadelphia, PA 19104 USA. RP Qin, L (reprint author), Univ Penn, Dept Orthopaed Surg, Perelman Sch Med, 424 Stemmler Hall,36th St & Hamilton Walk, Philadelphia, PA 19104 USA. EM qinling@mail.med.upenn.edu RI Liu, Xiaowei/H-1664-2017 OI Liu, Xiaowei/0000-0001-7247-2232; Chandra, Abhishek/0000-0001-9423-9669 FU National Institutes of Health [R01DK095803, R01CA138804]; Penn Center for Musculoskeletal Disorder [P30AR050950]; ASBMR Junior Faculty Osteoporosis Basic Research Award; McCabe Pilot Award FX This work was supported by National Institutes of Health Grants R01DK095803 (to L. Q.) and R01CA138804 (to B. X.), Penn Center for Musculoskeletal Disorder Grant P30AR050950 (NIAMS, National Institutes of Health), the ASBMR Junior Faculty Osteoporosis Basic Research Award (to L. Q.), and the McCabe Pilot Award (to X. S. L.). NR 53 TC 7 Z9 7 U1 2 U2 5 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD JAN 2 PY 2015 VL 290 IS 1 BP 157 EP 167 DI 10.1074/jbc.M114.608158 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA AX9OG UT WOS:000347231200014 PM 25336648 ER PT J AU Hoggatt, KJ Prescott, MR Goldmann, E Tamburrino, M Calabrese, JR Liberzon, I Galea, S AF Hoggatt, Katherine J. Prescott, Marta R. Goldmann, Emily Tamburrino, Marijo Calabrese, Joseph R. Liberzon, Israel Galea, Sandro TI The Prevalence and Correlates of Risky Driving Behavior Among National Guard Soldiers SO TRAFFIC INJURY PREVENTION LA English DT Article DE combat; mental health; risky driving; military medicine; veterans of war; trauma ID GULF-WAR-I; ACTIVE-DUTY; DEPLOYMENT STRESSORS; MILITARY PERSONNEL; COMBAT RETURNEES; PTSD CHECKLIST; VETERANS; INJURY; DISORDER; PHQ-9 AB Objective: Previous studies have reported that risky driving is associated with deployment and combat exposure in military populations, but there is limited research on risky driving among soldiers in the National Guard and Reserves, a group increasingly deployed to active international conflicts. The goal of this analysis was to assess the prevalence of risky driving and its demographic, mental health, and deployment-related correlates among members of the Ohio Army National Guard (OHARNG). Methods: The study group comprised 2,616 eligible OHARNG soldiers enlisted as of June 2008, or who enlisted between June 2008 and February 2009. The main outcome of interest was the prevalence of risky driving behavior assessed using six questions: "How often do you use seat belts when you drive or ride in a car?"; "In the past 30days, how many times have you driven when you've had perhaps too much to drink?"; "In the past year, have you ever become impatient with a slow driver in the fast lane and passed them on the right?"; "In the past year have you crossed an intersection knowing that the traffic lights have already changed from yellow to red?"; "In the past year have you disregarded speed limits late at night or early in the morning?"; and "In the past year have you underestimated the speed of an oncoming vehicle when attempting to pass a vehicle in your own lane?" We fit multiple logistic regression models and derived the adjusted prevalence of risky driving behavior for soldiers with mental health conditions, deployment experience, exposure to combat or trauma, and psychosocial stressors or supports. Results: The prevalence of risky driving was higher in soldiers with a history of mental health conditions, deployment to a conflict area, deployment-related traumatic events, and combat or post-combat stressors. In contrast, the prevalence of risky driving was lower for soldiers who reported high levels of psychosocial support. Conclusions: Efforts to mitigate risky driving in military populations may be more effective if they incorporate both targeted messages to remediate dangerous learned driving behaviors and psychosocial interventions to build resilience and address underlying stressors and mental health symptoms. C1 [Hoggatt, Katherine J.] CSHIIP, VA Greater Los Angeles Healthcare Syst, VA Hlth Serv Res & Dev HSR&D, Sepulveda, CA 91343 USA. [Hoggatt, Katherine J.] UCLA Fielding Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA USA. [Prescott, Marta R.; Goldmann, Emily; Galea, Sandro] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA. [Tamburrino, Marijo] Univ Toledo, Dept Psychiat, Toledo, OH 43606 USA. [Calabrese, Joseph R.] Case Western Reserve Univ, Dept Psychiat, Cleveland, OH 44106 USA. [Liberzon, Israel] VA Ann Arbor, Ann Arbor, MI USA. [Liberzon, Israel] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. RP Hoggatt, KJ (reprint author), CSHIIP, VA Greater Los Angeles Healthcare Syst, VA Hlth Serv Res & Dev HSR&D, 16111 Plummer St. 152), Sepulveda, CA 91343 USA. EM khoggatt@ucla.edu OI Liberzon, Israel/0000-0002-4990-556X FU Department of Defense Congressionally Directed Medical Research Program [W81XWH-O7-1-0409/W81XWH-10-1-0579]; Combat Mental Health Initiative; Department of Veterans Affairs, Veterans Health Administration (VA), Health Services Research and Development (HSRD) Service; VA HSR&D/QUERI Career Development Award at the VA Greater Los Angeles [CDA 11-261]; VA Office of Academic Affiliations; Department of Defense; Health Resources Services Administration; National Institute of Mental Health; Abbott; AstraZeneca; Bristol-Myers Squibb; Cephalon; Cleveland Foundation; Eli Lilly; GlaxoSmithKline; Janssen; NARSAD; Repligen; Stanley Medical Research Institute; Takeda; Wyeth FX This research was supported by Department of Defense Congressionally Directed Medical Research Program: W81XWH-O7-1-0409/W81XWH-10-1-0579, the "Combat Mental Health Initiative" and the Department of Veterans Affairs, Veterans Health Administration (VA), Health Services Research and Development (HSR&D) Service. Dr. Hoggatt was funded through a VA HSR&D/QUERI Career Development Award (CDA 11-261) at the VA Greater Los Angeles and received additional support from the VA Office of Academic Affiliations. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs.; Joseph R. Calabrese has received federal funding from the Department of Defense, Health Resources Services Administration, and National Institute of Mental Health; has received research support from Abbott, AstraZeneca, Bristol-Myers Squibb, Cephalon, Cleveland Foundation, Eli Lilly, GlaxoSmithKline, Janssen, NARSAD, Repligen, Stanley Medical Research Institute, Takeda, and Wyeth; has consulted to or served on advisory boards of Abbott, AstraZeneca, Bristol-Myers Squibb, Cephalon, Dainippon Sumitomo, EPI-Q, Inc, Forest, France Foundation, GlaxoSmithKline, Janssen, Johnson and Johnson, Lundbeck, Neurosearch, OrthoMcNeil, Otsuka, Pfizer, Repligen, Schering-Plough, Servier, Solvay, Supernus, Synosia, and Wyeth; has provided CME lectures supported by Abbott, AstraZeneca, Bristol-Myers Squibb, France Foundation, GlaxoSmithKline, Janssen, Johnson & Johnson, Sanofi Aventis, Schering-Plough, Pfizer, Solvay, and Wyeth; and has not been on a speakers bureau for the past 8 years. Past speaker bureaus included Abbott, AstraZeneca, Eli Lilly, and GlaxoSmithKline. He has no related stock, equity, or patents. The other authors have no financial disclosures. NR 36 TC 3 Z9 3 U1 3 U2 46 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1538-9588 EI 1538-957X J9 TRAFFIC INJ PREV JI Traffic Inj. Prev. PD JAN 2 PY 2015 VL 16 IS 1 BP 17 EP 23 DI 10.1080/15389588.2014.896994 PG 7 WC Public, Environmental & Occupational Health; Transportation SC Public, Environmental & Occupational Health; Transportation GA AQ4ZO UT WOS:000342811100004 PM 25260973 ER PT S AU Gordon, AJ Conley, JW Gordon, JM AF Gordon, Adam J. Conley, James W. Gordon, Joanne M. BE Sartorius, N Holt, RIG Maj, M TI Physical Diseases and Addictive Disorders: Associations and Implications SO COMORBIDITY OF MENTAL AND PHYSICAL DISORDERS SE Key Issues in Mental Health LA English DT Article; Book Chapter ID ACUTE MARIJUANA INTOXICATION; AMERICAN ADOLESCENT FEMALES; ACUTE MYOCARDIAL-INFARCTION; RECREATIONAL DRUG-USE; CHEST-WALL RIGIDITY; GERM-CELL TUMORS; CANNABIS USE; COCAINE USE; SPONGIFORM LEUKOENCEPHALOPATHY; MENINGOCOCCAL DISEASE AB Increasingly, the identification, assessment and treatment of unhealthy use of alcohol and other drugs often occur within general medical settings. Within this climate, there is a growing awareness of the physical effects connected to acute or chronic use of substances of abuse. By examining these associations and their purported biological causative mechanisms, greater clinical attention in the form of screening, identification and treatment - to co-occurring medical conditions as well as to the use of illicit substances itself may be possible. In this review, we examine recent peer-reviewed literature regarding three substances of abuse (cocaine, marijuana and opioids) and their direct associations with physical disorders. We group the association of diseases based on organ systems and critically examine the literature regarding the evidence to supporting those associations and causative mechanisms. There is good evidence to support the association of cocaine, marijuana and opioid use with a variety of physical health conditions. Unfortunately, while the causative evidence of these associations is preliminary, we could conclude that the use of these substances can incite a host of medical illnesses or complicate their treatment. When combined with societal, mental health and public health harms associated with the use of illicit substances, co-occurring or incident physical health conditions associated with substance use may present a substantial healthcare cost to the individual as well as to the healthcare system at large, resulting in a debilitating strain on often limited time and resources. (C) 2015 S. Karger AG, Basel C1 [Gordon, Adam J.; Conley, James W.] Univ Pittsburgh, Sch Med, CHERP, Pittsburgh, PA 15240 USA. [Gordon, Adam J.; Conley, James W.] Univ Pittsburgh, Sch Med, MIRECC, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. [Gordon, Adam J.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA 15240 USA. [Gordon, Joanne M.] Missouri State Univ, Biomed Sci, Springfield, MO USA. RP Gordon, AJ (reprint author), Univ Pittsburgh, Sch Med, Ctr Hlth Equ Res & Promot, VA Pittsburgh Healthcare Syst, CHERP 151-C,Univ Dr C, Pittsburgh, PA 15240 USA. EM gordona@medschool.pitt.edu NR 122 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 1662-4874 BN 978-3-318-02604-7; 978-3-318-02603-0 J9 KEY ISSUES MENT HEAL JI Key Iss. Ment. Health PY 2015 VL 179 BP 114 EP 128 DI 10.1159/000365543 PG 15 WC Public, Environmental & Occupational Health; Psychiatry SC Public, Environmental & Occupational Health; Psychiatry GA BG3GT UT WOS:000387942800013 ER PT B AU Pfeiffer, CD Wong, B AF Pfeiffer, Christopher D. Wong, Brian BE Hospenthal, DR Rinaldi, MG TI Diagnostic Immunology SO DIAGNOSIS AND TREATMENT OF FUNGAL INFECTIONS, SECOND EDITION SE Infectious Disease-Series LA English DT Article; Book Chapter ID INVASIVE FUNGAL-INFECTIONS; BRONCHOALVEOLAR LAVAGE FLUID; LATEX-AGGLUTINATION-TEST; BETA-D-GLUCAN; GALACTOMANNAN ENZYME-IMMUNOASSAY; BLASTOMYCES-DERMATITIDIS ANTIGEN; CLINICAL-PRACTICE GUIDELINES; ORGAN TRANSPLANT RECIPIENTS; SERUM CRYPTOCOCCAL ANTIGEN; LINKED-IMMUNOSORBENT-ASSAY C1 [Pfeiffer, Christopher D.; Wong, Brian] Oregon Hlth & Sci Univ, Div Infect Dis, Dept Med, 3181 SW Sam Jackson Pk Rd,L457, Portland, OR 97239 USA. [Pfeiffer, Christopher D.] Portland VA Med Ctr, Div Hosp & Specialty Med, Portland, OR 97239 USA. RP Wong, B (reprint author), Oregon Hlth & Sci Univ, Div Infect Dis, Dept Med, 3181 SW Sam Jackson Pk Rd,L457, Portland, OR 97239 USA. EM wongbri@ohsu.edu NR 96 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER INT PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND BN 978-3-319-13090-3; 978-3-319-13089-7 J9 INFECT DIS-SER PY 2015 BP 45 EP 64 DI 10.1007/978-3-319-13090-3_5 D2 10.1007/978-3-319-13090-3 PG 20 WC Infectious Diseases SC Infectious Diseases GA BF9SL UT WOS:000385855800006 ER PT B AU Boucher, HW Patterson, TF AF Boucher, Helen W. Patterson, Thomas F. BE Hospenthal, DR Rinaldi, MG TI Aspergillosis SO DIAGNOSIS AND TREATMENT OF FUNGAL INFECTIONS, SECOND EDITION SE Infectious Disease-Series LA English DT Article; Book Chapter ID INVASIVE PULMONARY ASPERGILLOSIS; LIPOSOMAL AMPHOTERICIN-B; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; CELL TRANSPLANT RECIPIENTS; POLYMERASE-CHAIN-REACTION; GUINEA-PIG MODEL; BETA-D-GLUCAN; FUNGAL-INFECTIONS; ANTIFUNGAL THERAPY; CONTROLLED-TRIAL C1 [Boucher, Helen W.] Tufts Med Ctr, Div Infect Dis & Geog Med, 800 Washington St,Box 238, Boston, MA 02111 USA. [Patterson, Thomas F.] Tufts Med Ctr, Div Infect Dis & Geog Med, 800 Washington St,Box 238, Boston, MA 02111 USA. Univ Texas Hlth Sci Ctr San Antonio, Audie L Murphy Div, South Texas Vet Hlth Care Syst, Dept Med,Div Infect Dis, San Antonio, TX 78229 USA. EM hboucher@tuftsmedicalcenter.org NR 107 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER INT PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND BN 978-3-319-13090-3; 978-3-319-13089-7 J9 INFECT DIS-SER PY 2015 BP 129 EP 140 DI 10.1007/978-3-319-13090-3_10 D2 10.1007/978-3-319-13090-3 PG 12 WC Infectious Diseases SC Infectious Diseases GA BF9SL UT WOS:000385855800011 ER PT S AU Berenji, GR Li, YX Gonzalez-Odriozola, R Thenkondar, A AF Berenji, Gholam R. Li, Yuxin Gonzalez-Odriozola, Roberto Thenkondar, Anurada BE Preedy, VR TI Sodium Fluoride and PET Bone Scans SO FLUORINE: CHEMISTRY, ANALYSIS, FUNCTION AND EFFECTS SE Food and Nutritional Components in Focus LA English DT Article; Book Chapter ID POSITRON-EMISSION-TOMOGRAPHY; F-18-FLUORIDE PET; BREAST-CANCER; METABOLIC-ACTIVITY; SKELETAL KINETICS; PAGETS-DISEASE; ION; METASTASES; GRAFTS C1 [Berenji, Gholam R.; Li, Yuxin; Gonzalez-Odriozola, Roberto; Thenkondar, Anurada] VA Greater Los Angeles Healthcare Syst, Dept Nucl Med, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. RP Berenji, GR (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Nucl Med, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM Gholam.Berenji@va.gov NR 36 TC 0 Z9 0 U1 0 U2 0 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, CAMBRIDGE CB4 4WF, CAMBS, ENGLAND SN 2045-1695 BN 978-1-78262-850-7; 978-1-84973-888-0 J9 FOOD NUTR COMPON FOC PY 2015 IS 6 BP 236 EP 254 D2 10.1039/9781782628507 PG 19 WC Chemistry, Analytical; Nutrition & Dietetics SC Chemistry; Nutrition & Dietetics GA BG3RW UT WOS:000388175200015 ER PT S AU Pfefferbaum, B Deshpande, SN Allen, SF Sherrieb, K AF Pfefferbaum, B. Deshpande, S. N. Allen, S. F. Sherrieb, K. BE Watson, RR Tabor, JA Ehiri, JE Preedy, VR TI Children's reactions and adjustment to natural disasters SO HANDBOOK OF PUBLIC HEALTH IN NATURAL DISASTERS: NUTRITION, FOOD, REMEDIATION AND PREPARATION SE Human Health Handbooks LA English DT Article; Book Chapter DE children; disaster; exposure; mental health; posttraumatic stress ID POSTTRAUMATIC-STRESS-DISORDER; HURRICANE KATRINA; MENTAL-HEALTH; NORWEGIAN CHILDREN; FOLLOW-UP; SRI-LANKA; ADOLESCENTS; TSUNAMI; TERRORISM; EXPOSURE AB This chapter reviews children's reactions to natural disasters and the factors which influence those reactions. Commonly-studied post-disaster outcomes in children include posttraumatic stress disorder, posttraumatic stress reactions, anxiety, depression, behavior problems, and substance use, and an emerging literature describes posttraumatic growth. In addition to exposure, a number of individual, family, and social factors influence children's reactions and recovery. Given that children have been identified as a vulnerable population in the context of disasters, systematic public health preparedness and response efforts as well as clinical services should address their special needs. C1 [Pfefferbaum, B.; Deshpande, S. N.; Allen, S. F.] Univ Oklahoma, Hlth Sci Ctr, Dept Psychiat & Behav Sci, Terrorism & Disaster Ctr,Coll Med, POB 26901, Oklahoma City, OK 73126 USA. [Sherrieb, K.] Geisel Sch Med Dartmouth, Dept Psychiat, Lebanon, NH 03756 USA. [Sherrieb, K.] US Dept Vet Affairs, Natl Ctr PTSD, White River Jct, VT 05001 USA. RP Pfefferbaum, B (reprint author), Univ Oklahoma, Hlth Sci Ctr, Dept Psychiat & Behav Sci, Terrorism & Disaster Ctr,Coll Med, POB 26901, Oklahoma City, OK 73126 USA. EM betty-pfefferbaum@ouhsc.edu NR 42 TC 0 Z9 0 U1 1 U2 1 PU WAGENINGEN ACAD PUBL PI WAGENINGEN PA POSTBUS 220, 6700 AE WAGENINGEN, NETHERLANDS SN 2212-375X BN 978-90-8686-806-3; 978-90-8686-257-3 J9 HUM HEALT HANDB PY 2015 VL 10 BP 113 EP 124 DI 10.3920/978-90-8686-806-3_6 D2 10.3920/ 978-90-8686-806-3 PG 12 WC Health Policy & Services; Public, Environmental & Occupational Health; Nutrition & Dietetics SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Nutrition & Dietetics GA BF9IH UT WOS:000385640500006 ER PT J AU Taneli, T Guo, YH Mushtaq, S AF Taneli, Tolga Guo, Yu-Heng Mushtaq, Sabina BE Ascher, MS Levounis, P TI Internet Gaming Disorder Virtual or Real? SO BEHAVIORAL ADDICTIONS LA English DT Article; Book Chapter ID VIDEO GAMES; ADDICTION C1 [Taneli, Tolga; Mushtaq, Sabina] Rutgers New Jersey Med Sch, Div Child & Adolescent Psychiat, Dept Psychiat, New Brunswick, NJ 08903 USA. [Guo, Yu-Heng] Hosp Univ Penn, Dept Psychiat, Psychiat, Philadelphia, PA 19104 USA. [Guo, Yu-Heng] Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Taneli, T (reprint author), Rutgers New Jersey Med Sch, Div Child & Adolescent Psychiat, Dept Psychiat, New Brunswick, NJ 08903 USA. NR 17 TC 1 Z9 1 U1 0 U2 0 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209 USA BN 978-1-58562-485-0 PY 2015 BP 67 EP 80 PG 14 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA BF6IT UT WOS:000383141300007 ER PT J AU Zaman, T Lache, D AF Zaman, Tauheed Lache, Daniel BE Ascher, MS Levounis, P TI Texting and E-mail Problem Use SO BEHAVIORAL ADDICTIONS LA English DT Article; Book Chapter ID MOBILE PHONE USE; YOUNG-ADULTS; INTERNET C1 [Zaman, Tauheed] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Lache, Daniel] Univ Penn, Philadelphia VA Med Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Zaman, T (reprint author), Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 18 TC 1 Z9 1 U1 1 U2 1 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209 USA BN 978-1-58562-485-0 PY 2015 BP 101 EP 112 PG 12 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA BF6IT UT WOS:000383141300009 ER PT J AU Ratzliff, AH Unutzer, J Pascualy, M AF Ratzliff, Anna H. Unutzer, Jurgen Pascualy, Marcella BE Raney, LE TI Training Psychiatrists for Integrated Care SO INTEGRATED CARE: WORKING AT THE INTERFACE OF PRIMARY CARE AND BEHAVIORAL HEALTH LA English DT Article; Book Chapter ID PRIMARY MEDICAL-CARE; MENTAL-HEALTH-CARE; COLLABORATIVE CARE; INTERPROFESSIONAL EDUCATION; RESIDENTS; DEPRESSION; SETTINGS; ILLNESS; SERVICES; PROGRAMS C1 [Ratzliff, Anna H.; Unutzer, Jurgen] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Unutzer, Jurgen] Univ Washington, Hlth Serv & Global Hlth, Seattle, WA 98195 USA. [Unutzer, Jurgen] Univ Washington, Div Integrated Care & Publ Hlth, Seattle, WA 98195 USA. [Unutzer, Jurgen] Univ Washington, AIMS Adv Integrated Mental Hlth Solut Ctr, Seattle, WA 98195 USA. [Pascualy, Marcella] VA Puget Sound Hlth Care Syst, Psychiat & Behav Sci, Seattle, WA USA. RP Ratzliff, AH (reprint author), Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. NR 33 TC 1 Z9 1 U1 1 U2 1 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209 USA BN 978-1-58562-480-5 PY 2015 BP 113 EP 138 PG 26 WC Health Care Sciences & Services; Health Policy & Services; Primary Health Care; Psychiatry SC Health Care Sciences & Services; General & Internal Medicine; Psychiatry GA BF6IR UT WOS:000383139600008 ER PT J AU Parks, AC Kleiman, EM Kashdan, TB Hausmann, LRM Meyer, PS Day, AM Spillane, NS Kahler, CW AF Parks, Acacia C. Kleiman, Evan M. Kashdan, Todd B. Hausmann, Leslie R. M. Meyer, Piper S. Day, Anne M. Spillane, Nichea S. Kahler, Christopher W. BE Jeste, DV Palmer, BW TI Positive Psychotherapeutic and Behavioral Interventions SO POSITIVE PSYCHIATRY: A CLINICAL HANDBOOK LA English DT Article; Book Chapter ID SMOKING-CESSATION TREATMENT; DEPRESSIVE SYMPTOMS; MAJOR DEPRESSION; METAANALYSIS; HAPPINESS; LIFE; SCHIZOPHRENIA; FEASIBILITY; EXPERIENCE; GRATITUDE C1 [Parks, Acacia C.] Hiram Coll, Psychol, Hiram, OH 44234 USA. [Kleiman, Evan M.] Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA. [Kashdan, Todd B.] George Mason Univ, Dept Psychol, Fairfax, VA 22030 USA. [Kashdan, Todd B.] George Mason Univ, Ctr Consciousness & Transformat, Fairfax, VA 22030 USA. [Hausmann, Leslie R. M.] VA Pittsburgh Healthcare Syst, CHERP, Pittsburgh, PA USA. [Hausmann, Leslie R. M.] Univ Pittsburgh, Sch Med, Med, Pittsburgh, PA USA. [Meyer, Piper S.] Univ Minnesota, Minnesota Ctr Mental Hlth, St Paul, MN 55108 USA. [Day, Anne M.] Brown Univ, Ctr Alcohol & Addict Studies, Providence, RI 02912 USA. [Spillane, Nichea S.] Brown Univ, Ctr Alcohol & Addict Studies, Res, Providence, RI 02912 USA. [Kahler, Christopher W.] Brown Univ, Dept Behav & Social Sci, Providence, RI 02912 USA. RP Parks, AC (reprint author), Hiram Coll, Psychol, Hiram, OH 44234 USA. NR 37 TC 1 Z9 1 U1 1 U2 1 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209 USA BN 978-1-58562-495-9 PY 2015 BP 147 EP 165 D2 10.1176/appi.books.9781615370818 PG 19 WC Psychiatry SC Psychiatry GA BF6IU UT WOS:000383142600009 ER PT S AU Tuerk, PW Ronzio, JL Shore, P AF Tuerk, Peter W. Ronzio, Joseph L. Shore, Peter BE Tuerk, PW Shore, P TI Technologies and Clinical Videoconferencing Infrastructures: A Guide to Selecting Appropriate Systems SO CLINICAL VIDEOCONFERENCING IN TELEHEALTH: PROGRAM DEVELOPMENT AND PRACTICE SE Behavioral Telehealth LA English DT Article; Book Chapter AB Purpose This chapter provides basic and intermediate-level key concepts related to clinical videoconferencing (CV) technologies for the purposes of assisting clinical administrators in choosing a CV system. It defines the common types of CV systems and considers the strengths and limitations of hardware-based vs. software-based platforms, as well as web-based vs. cellular-based signal transmission. The chapter also highlights the importance of defining the specific needs of a clinical ecology on a hierarchy to help achieve a balance between optimizing clinical utility and available budget when choosing CV systems. Context The information is helpful to clinical managers or administrators who are in charge of choosing/purchasing a CV solution for their facility or practice. The field of telehealth, and the availability of accompanying commercial technology options, is expanding rapidly with no end in sight. Both the development of new technologies and the daily identification of novel clinical demands for technologies are fueling continued growth in the field. Accordingly, administrators new to CV purchasing and decision making need a concise starting place to get a handle on relevant issues. The chapter is also helpful to clinicians, as they are ultimately the driving force in the identification of new ways to use technology in the service of public health needs. Tools The chapter provides the following tools: a summary overview of CV system options, including hardware-based, software-based and mixed strategies; a checklist of issues to research when choosing CV systems, a beginners guide to network capacity issues relevant to purchasing CV systems; three vignettes outlining helpful issues related to choosing specific telehealth hardware; a guide for selecting CV software, including the requirements of existing hardware; information on mobile tablets in the CV environment; a detailed discussion regarding health insurance portability and accountability (HIPPA) and FIPS 140-2 encoding; considerations regarding the integration of supporting technologies for CV systems; and a checklist of questions to address basic system needs before consulting with vendors. C1 [Tuerk, Peter W.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Tuerk, Peter W.] Vet Hlth Adm, Ralph H Johnson VA Med Ctr, Mental Hlth Serv, Charleston, SC USA. [Ronzio, Joseph L.] Vet Hlth Adm, Dept Vet Affairs, Washington, DC USA. [Shore, Peter] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Shore, Peter] Dept Vet Affairs, VA NW Hlth Network VISN 20, Portland, OR USA. RP Tuerk, PW (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. EM Tuerk@musc.edu; joe@ronzio.org; shore@ohsu.edu NR 19 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER INT PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 2199-8604 BN 978-3-319-08765-8; 978-3-319-08764-1 J9 BEHAV TELEHEALTH PY 2015 BP 3 EP 22 DI 10.1007/978-3-319-08765-8_1 D2 10.1007/978-3-319-08765-8 PG 20 WC Psychology, Clinical; Health Care Sciences & Services; Health Policy & Services; Medical Informatics; Psychiatry SC Psychology; Health Care Sciences & Services; Medical Informatics; Psychiatry GA BF0EP UT WOS:000378626900003 ER PT S AU Tuerk, PW Shore, P AF Tuerk, Peter W. Shore, Peter BE Tuerk, PW Shore, P TI Clinical Videoconferencing in Telehealth Program Development and Practice Preface SO CLINICAL VIDEOCONFERENCING IN TELEHEALTH: PROGRAM DEVELOPMENT AND PRACTICE SE Behavioral Telehealth LA English DT Editorial Material; Book Chapter C1 [Tuerk, Peter W.] Med Univ S Carolina, Dept Psychiat & Behav Sci, 171 Ashley Ave, Charleston, SC 29425 USA. [Tuerk, Peter W.] Ralph H Johnson VA Med Ctr, Dept Vet Affairs, Charleston, SC USA. [Shore, Peter] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Shore, Peter] Dept Vet Affairs, VA NW Hlth Network VISN 20, Portland, OR USA. RP Tuerk, PW (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, 171 Ashley Ave, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER INT PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 2199-8604 BN 978-3-319-08765-8; 978-3-319-08764-1 J9 BEHAV TELEHEALTH PY 2015 BP IX EP X D2 10.1007/978-3-319-08765-8 PG 2 WC Psychology, Clinical; Health Care Sciences & Services; Health Policy & Services; Medical Informatics; Psychiatry SC Psychology; Health Care Sciences & Services; Medical Informatics; Psychiatry GA BF0EP UT WOS:000378626900002 ER PT S AU Williams, JL Tuerk, PW Acierno, R AF Williams, Joah L. Tuerk, Peter W. Acierno, Ron BE Tuerk, PW Shore, P TI Common Elements of the Expert Consensus Guidelines for Clinical Videoconferencing SO CLINICAL VIDEOCONFERENCING IN TELEHEALTH: PROGRAM DEVELOPMENT AND PRACTICE SE Behavioral Telehealth LA English DT Article; Book Chapter AB Purpose This chapter identifies common elements of various expert consensus guidelines for clinical videoconferencing (CV) services. We broadly conceptualize common elements as shared recommendations or themes addressed in the majority of published organizational guidelines (in this case, as identified in at least five of the nine major sets of national-level guidelines). Practice recommendations are discussed in the context of these common elements, specific guidelines are highlighted that represent the shared intention of common themes, and basic core requirements of CV programming are synthesized. We close the chapter by discussing notable variability among the guidelines pertaining to specific issues. Context Several professional organizations and agencies have published guides addressing the clinical, technical, and administrative standards applicable to CV-based health services. This information is useful for clinic managers and clinicians attempting to integrate CV into their practice in that these guidelines offer practical strategies for developing safe, patient-centered programs. Yet, a large amount of content related to expert consensus guidelines is available and not all guidelines are agreed on or pertinent to specific contexts. Accordingly, care is taken to represent commonalities of the various guidelines in order to provide a brief synopsis of the core recommendations considered to be essential across a majority of contexts. It is expected that managers and clinicians developing CV programming might use this information as a quick-reference base to begin considering CV procedures and policies, and then judge the merits of additional components from individual guidelines based on local programming needs and circumstances. Tools The chapter identifies and provides links to the expert consensus guidelines relevant to CV practice. Summary checklists of core similarities in the guidelines are provided related to CV technical considerations, physical set-up at the provider-and patient-end, clinical and administrative responsibilities, and specific provider behaviors that facilitate successful CV programming. Differences between the guidelines are also highlighted. While efforts have been taken in this volume to minimize the repetition of similar information presented across chapters, the current chapter represents somewhat of a departure from that rule given the overarching content matter. Accordingly, please note that most of the information summarized here is surveyed in much greater detail by the individually themed chapters. C1 [Williams, Joah L.] Med Univ S Carolina, Charleston, SC 29425 USA. [Tuerk, Peter W.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Tuerk, Peter W.] Vet Hlth Adm, Ralph H Johnson VA Med Ctr, Mental Hlth Serv, Charleston, SC USA. [Acierno, Ron] Med Univ S Carolina, Coll Nursing, Charleston, SC 29425 USA. RP Williams, JL (reprint author), Med Univ S Carolina, Charleston, SC 29425 USA. EM wiljoah@musc.edu; Tuerk@musc.edu NR 11 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER INT PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 2199-8604 BN 978-3-319-08765-8; 978-3-319-08764-1 J9 BEHAV TELEHEALTH PY 2015 BP 55 EP 67 DI 10.1007/978-3-319-08765-8_3 D2 10.1007/978-3-319-08765-8 PG 13 WC Psychology, Clinical; Health Care Sciences & Services; Health Policy & Services; Medical Informatics; Psychiatry SC Psychology; Health Care Sciences & Services; Medical Informatics; Psychiatry GA BF0EP UT WOS:000378626900005 ER PT S AU Hilty, DM Yellowlees, PM Tuerk, PW Nasatir-Hilty, SEH Shoemaker, EZ Johnston, B Pato, MT AF Hilty, Donald M. Yellowlees, Peter M. Tuerk, Peter W. Nasatir-Hilty, Sarah E. H. Shoemaker, Erica Z. Johnston, Barb Pato, Michele T. BE Tuerk, PW Shore, P TI Program Evaluation and Modification: Supporting Pragmatic Data-Driven Clinical Videoconferencing (CV) Services SO CLINICAL VIDEOCONFERENCING IN TELEHEALTH: PROGRAM DEVELOPMENT AND PRACTICE SE Behavioral Telehealth LA English DT Article; Book Chapter ID POSTTRAUMATIC-STRESS-DISORDER; PRIMARY-CARE; TELEPSYCHIATRY CONSULTATION; TELEMENTAL HEALTH; DEVELOPMENTAL-DISABILITIES; ADOLESCENT TELEPSYCHIATRY; PATIENT SATISFACTION; MANAGEMENT-SYSTEM; RANDOMIZED-TRIAL; DEPRESSION AB Purpose This chapter discusses the prioritization of desired outcomes and ongoing program evaluation in the provision of clinical videoconferencing (CV) services. It provides an overall organizing framework to consider program evaluation from the very early stages of planning. Emphasis is placed on crafting evaluation fitted to specific needs and available resources. Context Understanding the fundamentals of program evaluation is necessary for clinical managers, clinicians, and telehealth experts because the processes of sound evaluation are essential for goal-directed programming and innovation with new CV services. Program evaluation may require a fundamental shift in philosophy-from measuring what happens with services, to planning for specific desired outcomes, and then gathering support for and designing services around those specific outcomes-in advance. The foundation for high-quality evaluation is a program with organizational support and an interdisciplinary team that shares responsibilities for overlapped roles. Tools The chapter provides a number of concrete tools to assist in planning for and implementing CV program evaluation. Included is a list of team-based resources which should be evaluated during the program development stage; a list of team qualities that can be planned for and assessed; examples for identifying multidimensional goals and alignment of goals across facilities; resources highlighting types of cost analyses; a list of cost-related outcomes and questions relevant to CV programming; a list of satisfaction-related CV outcomes for patients, providers, and support staff; examples of relevant process-oriented evaluation measures; a table organizing different types of reference groups for comparing CV program outcomes; and a list of program evaluation do's and don'ts. References and resources for information are also provided for further review. C1 [Hilty, Donald M.; Shoemaker, Erica Z.; Pato, Michele T.] USC, Keck Sch Med, Dept Psychiat, Los Angeles, CA USA. [Yellowlees, Peter M.] Hlth Informat Fellowship Program UC Davis, UC Davis Dept Psychiat, Sacramento, CA USA. [Tuerk, Peter W.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Tuerk, Peter W.] Vet Hlth Adm, Ralph H Johnson VA Med Ctr, Mental Hlth Serv, Charleston, SC USA. [Nasatir-Hilty, Sarah E. H.] USC, Keck Sch Med, Dept Psychiat, Los Angeles, CA USA. [Johnston, Barb] HealthLinkNow, Sacramento, CA USA. RP Hilty, DM (reprint author), USC, Keck Sch Med, Dept Psychiat, Los Angeles, CA USA. EM hilty@usc.edu NR 53 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER INT PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 2199-8604 BN 978-3-319-08765-8; 978-3-319-08764-1 J9 BEHAV TELEHEALTH PY 2015 BP 105 EP 130 DI 10.1007/978-3-319-08765-8_6 D2 10.1007/978-3-319-08765-8 PG 26 WC Psychology, Clinical; Health Care Sciences & Services; Health Policy & Services; Medical Informatics; Psychiatry SC Psychology; Health Care Sciences & Services; Medical Informatics; Psychiatry GA BF0EP UT WOS:000378626900008 ER PT S AU Shore, P Lu, M AF Shore, Peter Lu, Mary BE Tuerk, PW Shore, P TI Patient Safety Planning and Emergency Management SO CLINICAL VIDEOCONFERENCING IN TELEHEALTH: PROGRAM DEVELOPMENT AND PRACTICE SE Behavioral Telehealth LA English DT Article; Book Chapter AB Purpose This chapter provides practice guidelines and resources for patient risk evaluation and emergency response when providing clinical videoconferencing (CV) services to clinic-based and nonclinic-based settings. It contains information regarding provider preparation for both behavioral and medical emergencies. Additionally, this chapter provides information regarding the identification of suitable patients for CV services. Context This chapter is useful for clinicians because although behavioral and medical emergencies in mental health settings have been addressed in the literature for decades, guidelines for handling emergencies via CV are somewhat new. Providers offering or preparing to offer CV services must necessarily attend to the specifics of risk evaluation and emergency response protocols in CV settings. Tools This chapter provides an overview of available recommendations regarding emergency planning and response in CV settings, identifies specific procedures for selecting suitable patients and for conducting emergency planning prior to and during treatment for both clinic-based and nonclinic-based settings. This chapter also includes the following tools in the appendices: Pre-treatment checklists, pre-session checklists, emergency planning templates, clinical note template for documenting emergency plans, the Assessment for Suitability Home-Based Telemental Health (ASH-25)-a suicide risk assessment tool, and a list of additional resources related to chapter topics. C1 [Shore, Peter; Lu, Mary] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Shore, Peter] Dept Vet Affairs, VA NW Hlth Network VISN 20, Portland, OR USA. [Lu, Mary] Portland VA Med Ctr, Dept Vet Affairs, Portland, OR USA. RP Shore, P (reprint author), Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. EM shore@ohsu.edu NR 22 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER INT PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 2199-8604 BN 978-3-319-08765-8; 978-3-319-08764-1 J9 BEHAV TELEHEALTH PY 2015 BP 167 EP 201 DI 10.1007/978-3-319-08765-8_8 D2 10.1007/978-3-319-08765-8 PG 35 WC Psychology, Clinical; Health Care Sciences & Services; Health Policy & Services; Medical Informatics; Psychiatry SC Psychology; Health Care Sciences & Services; Medical Informatics; Psychiatry GA BF0EP UT WOS:000378626900010 ER PT S AU Lozano, BE Birks, AH Kloezeman, K Cha, N Morland, LA Tuerk, PW AF Lozano, Brian E. Birks, Anna Hynes Kloezeman, Karen Cha, Nancy Morland, Leslie A. Tuerk, Peter W. BE Tuerk, PW Shore, P TI Therapeutic Alliance in Clinical Videoconferencing: Optimizing the Communication Context SO CLINICAL VIDEOCONFERENCING IN TELEHEALTH: PROGRAM DEVELOPMENT AND PRACTICE SE Behavioral Telehealth LA English DT Article; Book Chapter ID FACE-TO-FACE; POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE-BEHAVIOR THERAPY; OBSESSIVE-COMPULSIVE DISORDER; RANDOMIZED CONTROLLED-TRIAL; HEALTH-CARE-UTILIZATION; PATIENT-SATISFACTION; TELEMENTAL HEALTH; WORKING ALLIANCE; TELECOMMUNICATIONS TECHNOLOGY AB Purpose This chapter addresses methods to establish or bolster therapeutic alliance with patients engaged in clinical videoconferencing (CV). The chapter will present a brief summary of the existing literature on therapeutic alliance to support a discussion of how therapeutic alliance may be impacted when conducting CV services. The chapter will also denote modifications to standard clinical behaviors which have been linked to strong therapeutic alliance in CV settings. Context The information is helpful for clinicians and managers because alliance has been demonstrated to be related to clinical outcomes for behavioral treatments. Stakeholders and clinicians new to CV contexts often question the ability of CV services to facilitate appropriate levels of alliance; accordingly, it is helpful to have access to a quick-reference summary in order to provide support for programming. Moreover, though the scientific literature base regarding CV provides broad evidence that appropriate alliance is most often achieved via CV, it is still important to convey specialized nuances of alliance in CV contexts. The authors have logged over 10,000 clinical hours via CV and have amassed a significant amount of highly-specific procedural knowledge regarding at-distance relationship building through practical experience and trial and error. Accordingly, the information is helpful in preventing those new to CV from starting from scratch or recreating the wheel when considering alliance in CV contexts. Tools The chapter provides the following tools: a brief review of the literature regarding therapeutic alliance and the effects of alliance on clinical outcomes in CV contexts, a list of psychotherapy contexts in which CV treatment has been associated with strong or adequate patient-provider alliance, a separate list of more general health care domains in which CV treatment has been associated with strong or adequate patient-provider satisfaction, a list of clinical techniques and clinician attributes that have been empirically associated with alliance, a more targeted list of suggestions to bolster alliance in CV contexts, a provider-oriented checklist of tasks to complete before initial CV sessions to safeguard alliance, a provider-oriented checklist of tasks to complete during initial CV sessions to safeguard alliance, and a checklist of procedures for when patients express concerns regarding receiving treatment via CV modalities. Finally, links to resources documenting technical and physical configurations to support alliance in CV contexts are provided, as are sample videos of provider/patient interactions over the modality. C1 [Lozano, Brian E.; Tuerk, Peter W.] Med Univ S Carolina, Dept Psychiat & Behav Sci, 171 Ashley Ave, Charleston, SC 29425 USA. [Lozano, Brian E.; Tuerk, Peter W.] Vet Hlth Adm, Ralph H Johnson VA Med Ctr, Mental Hlth Serv, Charleston, SC USA. [Birks, Anna Hynes] Vet Hlth Adm, Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Kloezeman, Karen; Cha, Nancy; Morland, Leslie A.] Dept Vet Affairs Pacific Isl Healthcare Syst, Natl Ctr PTSD, Pacific Isl Div, Honolulu, HI USA. RP Lozano, BE (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, 171 Ashley Ave, Charleston, SC 29425 USA. EM Lozano@musc.edu; anna.birks@va.gov NR 90 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER INT PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 2199-8604 BN 978-3-319-08765-8; 978-3-319-08764-1 J9 BEHAV TELEHEALTH PY 2015 BP 221 EP 251 DI 10.1007/978-3-319-08765-8_10 D2 10.1007/978-3-319-08765-8 PG 31 WC Psychology, Clinical; Health Care Sciences & Services; Health Policy & Services; Medical Informatics; Psychiatry SC Psychology; Health Care Sciences & Services; Medical Informatics; Psychiatry GA BF0EP UT WOS:000378626900012 ER PT J AU Ahluwalia, S Mularski, RA Lendon, J Prendergast, T Neville, TH Lorenz, K AF Ahluwalia, S. Mularski, R. A. Lendon, J. Prendergast, T. Neville, T. H. Lorenz, K. TI Improving Icu Family Meetings: Do The Experts Agree With The Evidence? SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 15-20, 2015 CL Denver, CO SP Amer Thorac Soc C1 [Ahluwalia, S.] RAND Corp, Santa Monica, CA USA. [Mularski, R. A.] Kaiser Permanente Northwest, Portland, OR USA. [Lendon, J.; Lorenz, K.] VA Greater Los Angeles, Los Angeles, CA USA. [Lendon, J.; Lorenz, K.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. [Prendergast, T.] Portland VA Med Ctr, Portland, CA USA. [Prendergast, T.] Oregon Hlth & Sci Univ, Portland, CA USA. [Neville, T. H.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2015 VL 191 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DO2AW UT WOS:000377582800006 ER PT J AU Akgun, KM Tate, JP Womack, J Brown, TT Leaf, DA Crystal, S Justice, AC Crothers, KA Oursler, KK AF Akgun, K. M. Tate, J. P. Womack, J. Brown, T. T. Leaf, D. A. Crystal, S. Justice, A. C. Crothers, K. A. Oursler, K. K. TI Is Chronic Obstructive Pulmonary Disease (COPD) An Independent Risk Factor For An Adapted Frailty-Related Phenotype In Hiv-Infected Compared With Uninfected Persons? SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 15-20, 2015 CL Denver, CO SP Amer Thorac Soc C1 [Akgun, K. M.; Tate, J. P.; Womack, J.; Justice, A. C.] VA Connecticut, West Haven, CT USA. [Akgun, K. M.; Tate, J. P.; Justice, A. C.] Yale Univ, Sch Med, West Haven, CT 06516 USA. [Womack, J.] Yale Univ, Sch Nursing, West Haven, CT USA. [Brown, T. T.] Johns Hopkins Univ, Baltimore, MD USA. [Leaf, D. A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Leaf, D. A.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. [Crystal, S.] Rutgers State Univ, New Brunswick, NJ 08903 USA. [Crothers, K. A.] Univ Washington, Sch Med, Seattle, WA USA. [Oursler, K. K.] Salem VA Med Ctr, Salem, VA USA. [Oursler, K. K.] Univ Maryland, SOM, Salem, VA USA. EM kathleen.akgun@yale.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2015 VL 191 MA A4713 PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DO2AW UT WOS:000377582806148 ER PT J AU Au, DH Berger, D Carvalho, PG Collins, M Goodman, RB Gunnink, E McDowell, J Moss, BR Nelson, K Plumley, R Reinke, LF Weppner, W Woo, D Feemster, LC AF Au, D. H. Berger, D. Carvalho, P. G. Collins, M. Goodman, R. B. Gunnink, E. McDowell, J. Moss, B. R. Nelson, K. Plumley, R. Reinke, L. F. Weppner, W. Woo, D. Feemster, L. C. TI COPD Hospital Readmissions Penalites: Do Patients Discharged With COPD Diagnoses Have COPD? SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 15-20, 2015 CL Denver, CO SP Amer Thorac Soc C1 [Au, D. H.; Berger, D.; Collins, M.; Goodman, R. B.; Gunnink, E.; McDowell, J.; Moss, B. R.; Nelson, K.; Plumley, R.; Reinke, L. F.; Woo, D.; Feemster, L. C.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Carvalho, P. G.; Weppner, W.] Boise VA Med Ctr, Boise, ID USA. EM margaret.collins@va.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2015 VL 191 MA A6478 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DO2AW UT WOS:000377582808556 ER PT J AU Bai, X Shang, S Henao-Tamayo, M Basaraba, R Ovrutsky, A Matsuda, J Takeda, K Chan, M Dakhama, A Kinney, W Trostel, J Bai, A Achcar, R Hartney, J Kim, SH Dinarello, C Orme, I Ordway, DJ Chan, ED AF Bai, X. Shang, S. Henao-Tamayo, M. Basaraba, R. Ovrutsky, A. Matsuda, J. Takeda, K. Chan, M. Dakhama, A. Kinney, W. Trostel, J. Bai, A. Achcar, R. Hartney, J. Kim, S. -H. Dinarello, C. Orme, I. Ordway, D. J. Chan, E. D. TI Human Il-32 Expression Protects Mice Against A Hypervirulent Strain Of Mycobacterium Tuberculosis SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 15-20, 2015 CL Denver, CO SP Amer Thorac Soc C1 [Bai, X.; Ovrutsky, A.; Matsuda, J.; Takeda, K.; Chan, M.; Dakhama, A.; Kinney, W.; Trostel, J.; Bai, A.; Achcar, R.; Hartney, J.; Kim, S. -H.] Natl Jewish Hlth, Denver, CO USA. [Shang, S.; Henao-Tamayo, M.; Basaraba, R.; Orme, I.; Ordway, D. J.] Colorado State Univ, Ft Collins, CO 80523 USA. [Dinarello, C.] Univ Colorado, Aurora, CO USA. [Chan, E. D.] Denver VAMC, Denver, CO USA. RI Shang, Shaobin/K-5669-2015; Henao-Tamayo, Marcela/D-8189-2017 OI Shang, Shaobin/0000-0003-4407-1911; Henao-Tamayo, Marcela/0000-0002-4249-9650 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2015 VL 191 MA A3249 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DO2AW UT WOS:000377582803524 ER PT J AU Bann, M Lacy, M Ash, S Swenson, E AF Bann, M. Lacy, M. Ash, S. Swenson, E. TI Non-Invasive Total Hemoglobin Measurement: Can A Finger Probe Replace A Blood Draw? SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 15-20, 2015 CL Denver, CO SP Amer Thorac Soc C1 [Bann, M.] Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA. [Lacy, M.] Univ New Mexico, Albuquerque, NM 87131 USA. [Ash, S.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Swenson, E.] Univ Washington, VA Puget Sound, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2015 VL 191 MA A1654 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DO2AW UT WOS:000377582801053 ER PT J AU Beane, J Mazzili, S Tassinari, A Geshalter, Y Mascaux, C Liu, G Zhang, S Liu, H Alexandrov, Y Reid, M Merrick, D Lam, S Lenburg, M Spira, A AF Beane, J. Mazzili, S. Tassinari, A. Geshalter, Y. Mascaux, C. Liu, G. Zhang, S. Liu, H. Alexandrov, Y. Reid, M. Merrick, D. Lam, S. Lenburg, M. Spira, A. TI Airway Gene-Expression Alterations Associated With Premalignancy: New Paradigms For Lung Cancer Chemoprevention SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 15-20, 2015 CL Denver, CO SP Amer Thorac Soc C1 [Beane, J.; Mazzili, S.; Tassinari, A.; Geshalter, Y.; Liu, G.; Zhang, S.; Liu, H.; Alexandrov, Y.; Lenburg, M.; Spira, A.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Beane, J.; Mascaux, C.] Ontario Canc Inst, Toronto, ON M4X 1K9, Canada. [Reid, M.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. [Merrick, D.] Denver VA Med Ctr, Denver, CO USA. [Lam, S.] BC Canc Agcy, Vancouver, BC, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2015 VL 191 MA A5158 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DO2AW UT WOS:000377582806592 ER PT J AU Betancourt, J Patel, A Jun, D Lulla, A Patel, K Oh, SS AF Betancourt, J. Patel, A. Jun, D. Lulla, A. Patel, K. Oh, S. S. TI Clozapine-Induced Cardiovascular Collapse SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 15-20, 2015 CL Denver, CO SP Amer Thorac Soc C1 [Betancourt, J.; Oh, S. S.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Betancourt, J.; Oh, S. S.] West Los Angeles VA Med Ctr, Los Angeles, CA USA. [Patel, A.; Jun, D.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Lulla, A.; Patel, K.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. EM jaimebetancourt@yahoo.com NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2015 VL 191 MA A3178 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DO2AW UT WOS:000377582803453 ER PT J AU Chan, ED Rizque, M Langston, L AF Chan, E. D. Rizque, M. Langston, L. TI Unusual Cause Of Upper Gastrointestinal Bleeding In An Immunocompromised Patient SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 15-20, 2015 CL Denver, CO SP Amer Thorac Soc C1 [Chan, E. D.] Natl Jewish Hlth, Denver, CO USA. [Chan, E. D.; Rizque, M.; Langston, L.] Denver VAMC, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2015 VL 191 MA A4645 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DO2AW UT WOS:000377582806080 ER PT J AU Chan, ED Frazer-Abel, A Woroch, E Bohn, M Giclas, P Bishokarma, P AF Chan, E. D. Frazer-Abel, A. Woroch, E. Bohn, M. Giclas, P. Bishokarma, P. TI Heparin Significantly Restores C1 Esterase Inhibitor (c1-Inh) Activity Ex Vivo In Patients With Hereditary Angioedema SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 15-20, 2015 CL Denver, CO SP Amer Thorac Soc C1 [Chan, E. D.; Frazer-Abel, A.; Woroch, E.; Giclas, P.; Bishokarma, P.] Natl Jewish Hlth, Denver, CO USA. [Bohn, M.] Denver VAMC, Denver, CO USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2015 VL 191 MA A4208 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DO2AW UT WOS:000377582805267 ER PT J AU Chan, ED Oberley-Deegan, R Bai, A Ovrutsky, A Kinney, W Weaver, M Honda, J Pott, G Shapiro, L Bai, X AF Chan, E. D. Oberley-Deegan, R. Bai, A. Ovrutsky, A. Kinney, W. Weaver, M. Honda, J. Pott, G. Shapiro, L. Bai, X. TI Curcumin Enhances Macrophage Control Of Mycobacterium Tuberculosis Infection SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 15-20, 2015 CL Denver, CO SP Amer Thorac Soc C1 [Chan, E. D.; Oberley-Deegan, R.; Bai, A.; Ovrutsky, A.; Kinney, W.; Weaver, M.; Honda, J.; Bai, X.] Natl Jewish Hlth, Denver, CO USA. [Chan, E. D.; Pott, G.; Shapiro, L.] Denver VAMC, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2015 VL 191 MA A3250 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DO2AW UT WOS:000377582803525 ER PT J AU Fleehart, S Nguyen, HQ Fan, VS Hunter, C Chen, Z Reinke, LF AF Fleehart, S. Nguyen, H. Q. Fan, V. S. Hunter, C. Chen, Z. Reinke, L. F. TI The Effect Of Psychosocial Behavioral Therapy For Patients With COPD And Depression SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 15-20, 2015 CL Denver, CO SP Amer Thorac Soc C1 [Fleehart, S.; Fan, V. S.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Nguyen, H. Q.; Hunter, C.; Chen, Z.] Univ Washington, Seattle, WA 98195 USA. [Reinke, L. F.] Dept Vet Affairs, Edmonds, WA USA. EM reinkl@u.washington.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2015 VL 191 MA A6395 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DO2AW UT WOS:000377582803352 ER PT J AU Jun, D Ghaznavi, Z Ryden, AM Warner, AL Zeidler, MR AF Jun, D. Ghaznavi, Z. Ryden, A. M. Warner, A. L. Zeidler, M. R. TI Sleep Disordered Breathing In Hospitalized Va Heart Failure Patients SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 15-20, 2015 CL Denver, CO SP Amer Thorac Soc C1 [Jun, D.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Ghaznavi, Z.; Ryden, A. M.; Warner, A. L.; Zeidler, M. R.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Ghaznavi, Z.; Warner, A. L.] West Lost Angeles VA Med Ctr, Los Angeles, CA USA. [Ryden, A. M.; Zeidler, M. R.] West Los Angeles VA Med Ctr, Los Angeles, CA USA. EM dale.jun@cshs.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2015 VL 191 MA A1245 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DO2AW UT WOS:000377582800244 ER PT J AU Karamooz, E Harriff, M Grant, WF Canfield, ET Burr, A Moita, LF Lewinsohn, DM AF Karamooz, E. Harriff, M. Grant, W. F. Canfield, E. T. Burr, A. Moita, L. F. Lewinsohn, D. M. TI Key Role For Vamp4 In Mr1 Dependent Presentation Of Mycobacterial Antigen To Mait Cells SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 15-20, 2015 CL Denver, CO SP Amer Thorac Soc C1 [Karamooz, E.; Grant, W. F.; Canfield, E. T.; Lewinsohn, D. M.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Harriff, M.; Burr, A.] Portland VA Med Ctr, Portland, OR USA. [Moita, L. F.] Inst Mol Med, Lisbon, Portugal. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2015 VL 191 MA A2183 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DO2AW UT WOS:000377582801575 ER PT J AU Kim, V Anzueto, A Han, MK Martinez, CH Black-Shinn, JL Boriek, A Porszacz, J Soler, X Wise, RA Dass, C Comellas, AP Ramsdell, JW Criner, GJ Sharafkhaneh, A Yen, A Crapo, J Make, BJ Silverman, EK Curtis, JL AF Kim, V. Anzueto, A. Han, M. K. Martinez, C. H. Black-Shinn, J. L. Boriek, A. Porszacz, J. Soler, X. Wise, R. A. Dass, C. Comellas, A. P. Ramsdell, J. W. Criner, G. J. Sharafkhaneh, A. Yen, A. Crapo, J. Make, B. J. Silverman, E. K. Curtis, J. L. CA COPDGene Investigators TI Persistent And Newly Developed Chronic Bronchitis Is Associated With Worse Outcomes And Increased Respiratory Symptoms In Smokers With And Without Chronic Obstructive Pulmonary Disease SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 15-20, 2015 CL Denver, CO SP Amer Thorac Soc C1 [Kim, V.; Dass, C.; Criner, G. J.] Temple Univ, Sch Med, Philadelphia, PA 19122 USA. [Anzueto, A.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Anzueto, A.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Han, M. K.; Martinez, C. H.] Univ Michigan Hlth Syst, Ann Arbor, MI USA. [Black-Shinn, J. L.] Univ Colorado, Colorado Sch Publ Hlth, Aurora, CO USA. [Boriek, A.; Sharafkhaneh, A.] Baylor Coll Med, Houston, TX 77030 USA. [Porszacz, J.] Harbor UCLA Med Ctr, Loas Angeles Biomed Res Inst, Torrance, CA 90509 USA. [Soler, X.; Ramsdell, J. W.; Yen, A.] Univ Calif San Diego, San Diego, CA 92103 USA. [Wise, R. A.] Johns Hopkins Med Ctr, Baltimore, MD USA. [Comellas, A. P.] Univ Iowa, Iowa City, IA USA. [Crapo, J.; Make, B. J.] Natl Jewish Hlth, Denver, CO USA. [Silverman, E. K.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Curtis, J. L.] Univ Michigan, VA Med Ctr, Ann Arbor, MI 48109 USA. EM victor.kim@tuhs.temple.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2015 VL 191 MA A2854 PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DO2AW UT WOS:000377582803098 ER PT J AU Kinney, GL Darabian, S Jacobs, MR Lambert, AA Black-Shinn, JL Anzueto, A Bon, J Boriek, AM Bowler, RP Dass, C Demeo, DL Foreman, MG Hoffman, EA Kim, V Li, D Parulekar, AD Van Beek, E Yen, A Wise, RA Curtis, JL Newell, JD Hokanson, JE Make, BJ Washko, GR Rossiter, HB Casaburi, R Rennard, SI McDonald, MLN AF Kinney, G. L. Darabian, S. Jacobs, M. R. Lambert, A. A. Black-Shinn, J. L. Anzueto, A. Bon, J. Boriek, A. M. Bowler, R. P. Dass, C. DeMeo, D. L. Foreman, M. G. Hoffman, E. A. Kim, V. Li, D. Parulekar, A. D. Van Beek, E. Yen, A. Wise, R. A. Curtis, J. L. Newell, J. D. Hokanson, J. E. Make, B. J. Washko, G. R. Rossiter, H. B. Casaburi, R. Rennard, S. I. McDonald, M. -L. N. TI Determinants Of 5-Year Change In BMI In Current And Former Smokers SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 15-20, 2015 CL Denver, CO SP Amer Thorac Soc C1 [Kinney, G. L.] Colorado Sch Publ Hlth, Aurora, CO USA. [Darabian, S.] LABiomed, Torrance, CA USA. [Jacobs, M. R.; Dass, C.] Temple Univ, Philadelphia, PA 19122 USA. [Lambert, A. A.] Johns Hopkins Univ, Baltimore, MD USA. [Black-Shinn, J. L.] Univ Colorado, Colorado Sch Publ Hlth, Aurora, CO USA. [Anzueto, A.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Anzueto, A.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Bon, J.] Univ Pittsburgh, Pittsburgh, PA USA. [Boriek, A. M.] Baylor Coll Med, Houston, TX 77030 USA. [Bowler, R. P.] Natl Jewish Hlth & Res Ctr, Denver, CO USA. [DeMeo, D. L.; Washko, G. R.; McDonald, M. -L. N.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Foreman, M. G.] Morehouse Sch Med, Atlanta, GA 30310 USA. [Hoffman, E. A.] Univ Iowa, Carver Coll Med, Iowa City, IA USA. [Kim, V.] Temple Univ Hosp & Med Sch, Philadelphia, PA 19140 USA. [Li, D.] Los Angeles Biomed Res Inst, Torrance, CA USA. [Parulekar, A. D.] Baylor Coll Med, Houston, TX 77030 USA. [Van Beek, E.] Univ Edinburgh, Edinburgh, Midlothian, Scotland. [Yen, A.] Univ Calif San Diego, San Diego, CA USA. [Wise, R. A.] Johns Hopkins Med Ctr, Baltimore, MD USA. [Curtis, J. L.] Univ Michigan, VA Med Ctr, Ann Arbor, MI 48109 USA. [Newell, J. D.] Univ Iowa, Iowa City, IA USA. [Hokanson, J. E.] Univ Colorado, Denver, CO 80202 USA. [Make, B. J.] Natl Jewish Hlth, Denver, CO USA. [Rossiter, H. B.] Harbor ULCA Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA USA. [Casaburi, R.] Harbor UCLA Med Ctr, Torrance, CA USA. [Rennard, S. I.] Univ Nebraska, Omaha, NE 68182 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2015 VL 191 MA A5702 PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DO2AW UT WOS:000377582807563 ER PT J AU Liu, Y Iannone, O Lear, T Chen, BB Mallampalli, RK AF Liu, Y. Iannone, O. Lear, T. Chen, B. B. Mallampalli, R. K. TI Pro-Apoptotic F-Box Protein Fbxl7 Regulates Mitochondrial Function By Mediating The Ubiquitylation And Proteasomal Degradation Of Survivin SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 15-20, 2015 CL Denver, CO SP Amer Thorac Soc C1 [Liu, Y.; Iannone, O.; Lear, T.; Chen, B. B.] Univ Pittsburgh, Pittsburgh, PA USA. [Mallampalli, R. K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA USA. EM yul119@pitt.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2015 VL 191 MA A5554 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DO2AW UT WOS:000377582807415 ER PT J AU Melzer, AC Au, DH AF Melzer, A. C. Au, D. H. TI Effectiveness Of Post-Discharge Smoking Cessation Management Following Exacerbation Of COPD SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 15-20, 2015 CL Denver, CO SP Amer Thorac Soc C1 [Au, D. H.] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. EM acmelzer@u.washington.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2015 VL 191 MA A5387 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DO2AW UT WOS:000377582807255 ER PT J AU Miller, M Vasquez, J Weiner, M Chapman, A Engle, M Higgins, M Quinones, A Roselli, V Yoon, C Cattamanchi, A Davis, JL Stearman, R Phang, TL Kechris, K Fingerlin, T Datta, G Garcia, BJ Strong, M Geraci, MW Reves, RR Walter, ND AF Miller, M. Vasquez, J. Weiner, M. Chapman, A. Engle, M. Higgins, M. Quinones, A. Roselli, V. Yoon, C. Cattamanchi, A. Davis, J. L. Stearman, R. Phang, T. L. Kechris, K. Fingerlin, T. Datta, G. Garcia, B. J. Strong, M. Geraci, M. W. Reves, R. R. Walter, N. D. TI Evaluation Of African Blood Expression Signatures For Tuberculosis In Us Patients SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 15-20, 2015 CL Denver, CO SP Amer Thorac Soc C1 [Miller, M.; Roselli, V.; Kechris, K.] Colorado Sch Publ Hlth, Aurora, CO USA. [Vasquez, J.; Yoon, C.; Cattamanchi, A.; Davis, J. L.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Weiner, M.; Engle, M.] Vet Adm Med Ctr, San Antonio, TX USA. [Chapman, A.; Stearman, R.; Phang, T. L.; Geraci, M. W.; Walter, N. D.] Univ Colorado Denver, Aurora, CO USA. [Higgins, M.; Reves, R. R.] Denver Publ Hlth Dept, Denver, CO USA. [Quinones, A.] Denver Hlth, Denver, CO USA. [Fingerlin, T.; Datta, G.; Garcia, B. J.; Strong, M.] Natl Jewish Hlth, Denver, CO USA. EM mikaela.miller@ucdenver.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2015 VL 191 MA A5430 PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DO2AW UT WOS:000377582807291 ER PT J AU Mortensen, EM Alvarez, C Anzueto, A AF Mortensen, E. M. Alvarez, C. Anzueto, A. TI Safety Of Azithromycin In Older Patients With COPD Hospitalized With Pneumonia SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 15-20, 2015 CL Denver, CO SP Amer Thorac Soc C1 [Mortensen, E. M.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Alvarez, C.] Tech Univ Hlth Sci Ctr, Dallas, TX USA. [Anzueto, A.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Anzueto, A.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2015 VL 191 MA A1775 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DO2AW UT WOS:000377582801174 ER PT J AU Neville, TH Ahluwalia, S Smith, I Bando, J Yamamoto, M Prendergast, T Lorenz, K AF Neville, T. H. Ahluwalia, S. Smith, I. Bando, J. Yamamoto, M. Prendergast, T. Lorenz, K. TI Implementation And Use Of An Icu Family Meeting Template SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 15-20, 2015 CL Denver, CO SP Amer Thorac Soc C1 [Neville, T. H.; Smith, I.; Bando, J.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Ahluwalia, S.] RAND Corp, Santa Monica, CA USA. [Ahluwalia, S.] UCLA, Fielding Sch Publ Hlth, Santa Monica, CA USA. [Yamamoto, M.] Univ Calif Los Angeles, Los Angeles, CA USA. [Prendergast, T.] Portland VA Med Ctr, Portland, OR USA. [Prendergast, T.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Lorenz, K.] VA Greater Los Angeles, Los Angeles, CA USA. [Lorenz, K.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2015 VL 191 MA A1086 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DO2AW UT WOS:000377582800087 ER PT J AU Novosad, S Choi, D Hedberg, K Henkle, E Schafer, S Siegel, SAR Slatore, CG Winthrop, KL AF Novosad, S. Choi, D. Hedberg, K. Henkle, E. Schafer, S. Siegel, S. A. R. Slatore, C. G. Winthrop, K. L. TI Predictors Of Death At Isolation Of Nontuberculous Mycobacteria In Respiratory Specimens SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 15-20, 2015 CL Denver, CO SP Amer Thorac Soc C1 [Novosad, S.; Choi, D.; Siegel, S. A. R.; Winthrop, K. L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Hedberg, K.; Henkle, E.; Schafer, S.] Oregon Publ Hlth Div, Portland, OR USA. [Slatore, C. G.] Portland VA Med Ctr, Portland, OR USA. EM novosad@ohsu.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2015 VL 191 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DO2AW UT WOS:000377582807082 ER PT J AU Parsons, EC Chaytor, NS Kapur, VK Caldwell, E Johnston, C Bell, K Vitiello, MV Hough, CL AF Parsons, E. C. Chaytor, N. S. Kapur, V. K. Caldwell, E. Johnston, C. Bell, K. Vitiello, M. V. Hough, C. L. TI Sleep Apnea Severity And Cognitive Function After Acute Respiratory Failure SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 15-20, 2015 CL Denver, CO SP Amer Thorac Soc C1 [Parsons, E. C.] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Parsons, E. C.; Chaytor, N. S.; Kapur, V. K.; Caldwell, E.; Johnston, C.; Bell, K.; Vitiello, M. V.] Univ Washington, Seattle, WA 98195 USA. [Hough, C. L.] Univ Washington, Harborview Med Ctr, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2015 VL 191 MA A4506 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DO2AW UT WOS:000377582805565 ER PT J AU Paul, TK Oh, SS Bando, JM Lee, JM Susanto, I AF Paul, T. K. Oh, S. S. Bando, J. M. Lee, J. M. Susanto, I. TI Central Airway Obstruction From Endobronchial Mucormycosis SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 15-20, 2015 CL Denver, CO SP Amer Thorac Soc C1 [Paul, T. K.; Bando, J. M.; Lee, J. M.; Susanto, I.] Univ Calif Los Angeles, Los Angeles, CA USA. [Paul, T. K.; Oh, S. S.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Paul, T. K.; Oh, S. S.] West Los Angeles VA Med Ctr, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2015 VL 191 MA A1856 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DO2AW UT WOS:000377582801255 ER PT J AU Prieto-Centurion, V Zaidi, F Coultas, DB Casaburi, R Rand, CS Krishnan, JA AF Prieto-Centurion, V. Zaidi, F. Coultas, D. B. Casaburi, R. Rand, C. S. Krishnan, J. A. TI Comparison Of Commercially-Available Pedometers For Potential Use For Promotion Of Lifestyle Physical Activity SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 15-20, 2015 CL Denver, CO SP Amer Thorac Soc C1 [Prieto-Centurion, V.; Zaidi, F.; Krishnan, J. A.] Univ Illinois, Chicago, IL USA. [Coultas, D. B.] Portland VA Med Ctr, Portland, OR USA. [Coultas, D. B.; Casaburi, R.] Harbor UCLA Med Ctr, Torrance, CA 90509 USA. [Rand, C. S.] Johns Hopkins Univ, Baltimore, MD USA. EM vprieto@uic.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2015 VL 191 MA A5204 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DO2AW UT WOS:000377582807024 ER PT J AU Prieto-Centurion, V Zaidi, F Bracken, NE Norwick, L Coultas, DB Casaburi, R Rand, CS Jaffe, HA Krishnan, JA AF Prieto-Centurion, V. Zaidi, F. Bracken, N. E. Norwick, L. Coultas, D. B. Casaburi, R. Rand, C. S. Jaffe, H. A. Krishnan, J. A. TI Patient Perspectives And Barriers To Pulmonary Rehabilitation Following Hospitalizations For Chronic Obstructive Pulmonary Disease Exacerbations SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 15-20, 2015 CL Denver, CO SP Amer Thorac Soc C1 [Prieto-Centurion, V.; Zaidi, F.; Bracken, N. E.; Norwick, L.; Jaffe, H. A.; Krishnan, J. A.] Univ Illinois, Chicago, IL USA. [Coultas, D. B.] Portland VA Med Ctr, Portland, OR USA. [Casaburi, R.] Harbor UCLA Med Ctr, Torrance, CA 90509 USA. [Rand, C. S.] Johns Hopkins Univ, Baltimore, MD USA. EM vprieto@uic.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2015 VL 191 MA A2222 PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DO2AW UT WOS:000377582802017 ER PT J AU Reinke, LF Feemster, LC Mc Dowell, J Gunnink, E Tartaglione, EV Udris, EM Au, DH AF Reinke, L. F. Feemster, L. C. Mc Dowell, J. Gunnink, E. Tartaglione, E. V. Udris, E. M. Au, D. H. TI Long Term Impact Of An End-Of-Life Communication Intervention Among Veterans With COPD SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 15-20, 2015 CL Denver, CO SP Amer Thorac Soc C1 [Reinke, L. F.; Mc Dowell, J.; Gunnink, E.; Tartaglione, E. V.; Udris, E. M.] VA Puget Sound, Edmonds, WA USA. [Feemster, L. C.] Univ Washington, VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98195 USA. [Au, D. H.] Univ Washington, Seattle, WA 98195 USA. EM reinkl@u.washington.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2015 VL 191 MA A3916 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DO2AW UT WOS:000377582804583 ER PT J AU Rinne, S Wong, E Hebert, P Au, DH Concato, J Liu, CF AF Rinne, S. Wong, E. Hebert, P. Au, D. H. Concato, J. Liu, C. -F. TI Average Facility Length Of Stay For COPD Hospitalizations Is Not Associated With Readmission Or Mortality SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 15-20, 2015 CL Denver, CO SP Amer Thorac Soc C1 [Rinne, S.] Yale, New Haven, CT USA. [Wong, E.; Hebert, P.; Liu, C. -F.] VA Puget Sound, Seattle, WA USA. [Au, D. H.] Dept Vet Affairs VA Puget Sound Healthcare Syst, Seattle, WA USA. [Concato, J.] Yale Univ, Sch Med, Vet Affairs Med Ctr, West Haven, CT 06516 USA. EM seppo.rinne@yale.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2015 VL 191 MA A6171 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DO2AW UT WOS:000377582808406 ER PT J AU Rinne, S Wong, E Hebert, P Au, DH Justice, AC Liu, CF AF Rinne, S. Wong, E. Hebert, P. Au, D. H. Justice, A. C. Liu, C. -F. TI Organizational Factors And Risk Of Readmission Among Patients Hospitalized For COPD SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 15-20, 2015 CL Denver, CO SP Amer Thorac Soc C1 [Rinne, S.] Yale Univ, New Haven, CT USA. [Wong, E.; Hebert, P.; Liu, C. -F.] VA Puget Sound, Seattle, WA USA. [Au, D. H.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Justice, A. C.] Yale Univ, West Haven, CT USA. EM seppo.rinne@yale.edu NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2015 VL 191 MA A3888 PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DO2AW UT WOS:000377582804555 ER PT J AU Sauler, M McGinnis, KM Berical, A Crothers, KA Akgun, KM Huang, L Goetz, MB Rimland, D Bucala, R Lee, PJ AF Sauler, M. McGinnis, K. M. Berical, A. Crothers, K. A. Akgun, K. M. Huang, L. Goetz, M. B. Rimland, D. Bucala, R. Lee, P. J. TI Differential Association Of Macrophage Migration Inhibitory Factor (mif) Promoter Polymorphisms With Chronic Obstructive Pulmonary Disease (COPD) By Hiv Status And Race SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 15-20, 2015 CL Denver, CO SP Amer Thorac Soc C1 [Sauler, M.; Berical, A.; Akgun, K. M.; Bucala, R.; Lee, P. J.] Yale Univ, Sch Med, New Haven, CT USA. [McGinnis, K. M.] Univ Pittsburgh, Pittsburgh, PA USA. [Crothers, K. A.] Univ Washington, Sch Med, Seattle, WA USA. [Huang, L.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Huang, L.] San Francisco Gen Hosp, San Francisco, CA 94110 USA. [Goetz, M. B.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Rimland, D.] Emory Univ, Decatur, GA USA. EM maor.sauler@yale.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2015 VL 191 MA A1055 PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DO2AW UT WOS:000377582800056 ER PT J AU Teerapuncharoen, K Wells, JM Dransfield, MT Rowe, SM AF Teerapuncharoen, K. Wells, J. M. Dransfield, M. T. Rowe, S. M. TI Acquired Cftr Dysfunction And Pulmonary Arterial Enlargement In Chronic Obstructive Pulmonary Disease SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 15-20, 2015 CL Denver, CO SP Amer Thorac Soc C1 [Teerapuncharoen, K.; Wells, J. M.; Rowe, S. M.] Univ Alabama Birmingham, Birmingham, AL USA. [Teerapuncharoen, K.; Dransfield, M. T.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2015 VL 191 MA A3830 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DO2AW UT WOS:000377582804472 ER PT J AU Tennis, M Nield, L Merrick, D Keith, RL AF Tennis, M. Nield, L. Merrick, D. Keith, R. L. TI Personalized Lung Cancer Chemoprevention Using Ppar gamma And Its Downstream Targets SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 15-20, 2015 CL Denver, CO SP Amer Thorac Soc C1 [Tennis, M.; Merrick, D.] Univ Colorado Denver, Aurora, CO USA. [Nield, L.] Univ Colorado, Aurora, CO USA. [Keith, R. L.] Univ Colorado, Denver Vet Affairs Med Ctr, Denver, CO 80202 USA. EM meredith.tennis@ucdenver.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2015 VL 191 MA A2431 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DO2AW UT WOS:000377582802225 ER PT J AU Wiener, RS Koppelman, E Slatore, CG Clark, JA AF Wiener, R. S. Koppelman, E. Slatore, C. G. Clark, J. A. TI Patients' Impressions Of Communication With Their Clinicians Surrounding Low-Dose CT Lung Cancer Screening: A Qualitative Study SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 15-20, 2015 CL Denver, CO SP Amer Thorac Soc C1 [Wiener, R. S.; Koppelman, E.; Clark, J. A.] Edith Nourse Rogers Mem VA Hosp, Bedford, MA USA. [Slatore, C. G.] Portland VA Med Ctr, Portland, OR USA. EM rwiener@bu.edu NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2015 VL 191 MA A6120 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DO2AW UT WOS:000377582808355 ER PT J AU Zider, A Pezeshkpour, G Betancourt, J AF Zider, A. Pezeshkpour, G. Betancourt, J. TI Combined Lung Neuroendocrine/adenocarcinoma With Pulmonary Tumor Thrombotic Microangiopathy: A Rare Cause Of Severe Hypoxemia And Pulmonary Hypertension SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 15-20, 2015 CL Denver, CO SP Amer Thorac Soc C1 [Zider, A.] Univ Calif Los Angeles, Los Angeles, CA USA. [Pezeshkpour, G.; Betancourt, J.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Pezeshkpour, G.; Betancourt, J.] West Los Angeles VA Med Ctr, Los Angeles, CA USA. EM jaimebetancourt@yahoo.com NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2015 VL 191 MA A5868 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DO2AW UT WOS:000377582808119 ER PT S AU Tipps, ME Buck, KJ AF Tipps, Megan E. Buck, Kari J. BE Slesinger, PA Wickman, K TI GIRK Channels: A Potential Link Between Learning and Addiction SO STRUCTURE TO FUNCTION OF G PROTEIN- GATED INWARDLY RECTIFYING (GIRK) CHANNELS SE International Review of Neurobiology LA English DT Review; Book Chapter ID LONG-TERM POTENTIATION; RECTIFYING POTASSIUM CHANNELS; VENTRAL TEGMENTAL AREA; RECTIFIER K+ CHANNELS; SORTING NEXIN 27; G-BETA-GAMMA; EVOKED SYNAPTIC PLASTICITY; MEDIAL PREFRONTAL CORTEX; HUMAN-CHROMOSOME 21Q22.2; LOCUS-CERULEUS NEURONS AB The ability of drug-associated cues to reinitiate drug craving and seeking, even after long periods of abstinence, has led to the hypothesis that addiction represents a form of pathological learning, in which drugs of abuse hijack normal learning and memory processes to support long-term addictive behaviors. In this chapter, we review evidence suggesting that G protein-gated inwardly rectifying potassium (GIRK/Kir3) channels are one mechanism through which numerous drugs of abuse can modulate learning and memory processes. We will examine the role of GIRK channels in two forms of experience-dependent long-term changes in neuronal function: homeostatic plasticity and synaptic plasticity. We will also discuss how drug-induced changes in GIRK-mediated signaling can lead to changes that support the development and maintenance of addiction. C1 [Tipps, Megan E.; Buck, Kari J.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA. [Tipps, Megan E.] Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA. [Buck, Kari J.] Portland VA Med Ctr, Portland Alcohol Res Ctr, Portland, OR USA. RP Tipps, ME (reprint author), Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA. EM metipps@gmail.com NR 225 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0074-7742 BN 978-0-12-802631-1; 978-0-12-802458-4 J9 INT REV NEUROBIOL JI Int. Rev. Neurobiol. PY 2015 VL 123 BP 239 EP 277 DI 10.1016/bs.irn.2015.05.012 PG 39 WC Neurosciences SC Neurosciences & Neurology GA BE8BJ UT WOS:000376196400008 PM 26422987 ER PT J AU Kalore, NV Guay, J Eastman, JM Nishimori, M Singh, JA AF Kalore, Niraj V. Guay, Joanne Eastman, Jamie M. Nishimori, Mina Singh, Jasvinder A. TI Nerve blocks or no nerve blocks for pain control after elective hip replacement (arthroplasty) surgery in adults SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS LA English DT Review ID PSOAS COMPARTMENT BLOCK; REGIONAL ANESTHESIA; POSTOPERATIVE ANALGESIA; SPINAL-ANESTHESIA; LUMBAR; COMPLICATIONS; METAANALYSES; GUIDELINES; EFFICACY; TRIALS C1 [Kalore, Niraj V.] Virginia Commonwealth Univ Hlth Syst, Dept Orthopaed Surg, 417 North 11th St, Richmond, VA 23298 USA. [Guay, Joanne] Univ Sherbrooke, Fac Med, Dept Anesthesiol, Rouyn Noranda, ON, Canada. [Eastman, Jamie M.] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA. [Nishimori, Mina] Univ Tokyo, Dept Anesthesiol, Tokyo, Japan. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Dept Med, Birmingham, AL USA. RP Kalore, NV (reprint author), Virginia Commonwealth Univ Hlth Syst, Dept Orthopaed Surg, 417 North 11th St, Richmond, VA 23298 USA. EM niraj.kalore@gmail.com FU Takeda; Savient; Allergan; Novartis; Regeneron FX Jasvinder A Singh has received research grants from Takeda (2007 to present) and Savient (2009 to 2013; bankrupt in 2013) and consultant fees from Takeda, Allergan (2004 to 2011), Savient, Novartis, and Regeneron (2009 to 2013). He is a member of the executive committee of OMERACT, an organization that develops outcome measures in rheumatology and receives arms-length funding from 36 companies. NR 38 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1469-493X EI 1361-6137 J9 COCHRANE DB SYST REV JI Cochrane Database Syst Rev. PY 2015 IS 3 AR CD011608 DI 10.1002/14651858.CD011608 PG 17 WC Medicine, General & Internal SC General & Internal Medicine GA DL3OC UT WOS:000375542100085 ER PT J AU Kalore, NV Guay, J Nishimori, M Eastman, JM Noorbaloochi, S Singh, JA AF Kalore, Niraj V. Guay, Joanne Nishimori, Mina Eastman, Jamie M. Noorbaloochi, Shahrzad Singh, Jasvinder A. TI Regional analgesia versus no regional analgesia for ambulatory hip arthroscopy in adults SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS LA English DT Review ID PSOAS COMPARTMENT BLOCK; POSTOPERATIVE PAIN; NERVE BLOCKS; ANESTHESIA; METAANALYSES; REPLACEMENT; TRIALS C1 [Kalore, Niraj V.] Virginia Commonwealth Univ Hlth Syst, Dept Orthopaed Surg, 417 North 11th St, Richmond, VA 23298 USA. [Guay, Joanne] Univ Sherbrooke, Fac Med, Dept Anesthesiol, Sherbrooke, PQ, Canada. [Nishimori, Mina] Seibo Int Catholic Hosp, Dept Anesthesiol, Tokyo, Japan. [Eastman, Jamie M.] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA. [Noorbaloochi, Shahrzad] Minneapolis VA Med Ctr, Dept Med, Minneapolis, MN USA. [Noorbaloochi, Shahrzad] Univ Minnesota, Minneapolis, MN USA. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Dept Med, Birmingham, AL USA. RP Kalore, NV (reprint author), Virginia Commonwealth Univ Hlth Syst, Dept Orthopaed Surg, 417 North 11th St, Richmond, VA 23298 USA. EM niraj.kalore@gmail.com FU University of Dalhousie; University of Quebec en Abitibi-Temiscamingue; Takeda; Savient; Allergan; Novartis; Regeneron FX Joanne Guay: I have had no direct relationship with any pharmaceutical company or equipment manufacturer in the past five years. I have not acted as expert witness in the past five years. I am not an author in any of the included or excluded studies. I do not hold any stock other than mutual funds. During the last five years, I have received fees as speaker for two lectures given at the University of Dalhousie: one on regional anaesthesia for carotid endarterectomy and the other on local-anaesthetic-related methaemoglobinaemia. My fees were paid by the University of Dalhousie. I am the editor of a multi author textbook on anaesthesia (including notions on general and regional anaesthesia). I will receive fees for a course on airway management at University of Quebec en Abitibi-Temiscamingue scheduled for February 2015.; Jasvinder A Singh: Jasvinder A Singh has received research grants from Takeda (2007 to present); Savient (2009 to 2013; bankrupt in 2013); and consultant fees from Takeda, Allergan (2004 to 2011); and Savient, Novartis and Regeneron (2009 to 2013); he is a member of the executive of OMERACT, an organization that develops outcome measures in rheumatology and receives arms-length funding from 36 companies. Novartis manufactures over-the-counter pain relief medication. The other companies manufacture gout drugs or Botox, which is approved for wrinkles, headaches and some other conditions. NR 27 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1469-493X EI 1361-6137 J9 COCHRANE DB SYST REV JI Cochrane Database Syst Rev. PY 2015 IS 3 AR CD011578 DI 10.1002/14651858.CD011578 PG 17 WC Medicine, General & Internal SC General & Internal Medicine GA DL3OC UT WOS:000375542100064 ER PT J AU Morris, AC Singh, JA Bickel, CS Ponce, BA AF Morris, Andrew C. Singh, Jasvinder A. Bickel, C. Scott Ponce, Brent A. TI Exercise therapy following surgical rotator cuff repair SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS LA English DT Review ID PROTOCOL; DISEASE; MOTION AB This is the protocol for a review and there is no abstract. The objectives are as follows: To assess the benefits and harms of exercise therapy for patients following surgical repair of rotator cuff tears. To determine the optimal time post surgery for initiation of passive and active range of motion exercises. To evaluate exercise therapy versus no therapy, exercise therapy versus nonexercise modalities, and slow versus accelerated exercise therapy protocols. C1 [Morris, Andrew C.; Ponce, Brent A.] Univ Alabama Birmingham, Dept Orthopaed, Birmingham, AL USA. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Dept Med, Fac Off Tower 805B,510 20th St South, Birmingham, AL 35294 USA. [Bickel, C. Scott] Univ Alabama Birmingham, Dept Phys Therapy, Birmingham, AL USA. RP Singh, JA (reprint author), Birmingham VA Med Ctr, Dept Med, Fac Off Tower 805B,510 20th St South, Birmingham, AL 35294 USA. EM jasvinder.md@gmail.com FU Takeda; Savient; Ardea; Regeneron; Allergan; Novartis; URL Pharmaceuticals; Arthrex; Synthes; JJ/DePuy/Mitek; Tornier FX JAS: JAS has received research grants from Takeda and Savient, and consultant fees from Ardea, Regeneron, Takeda, Allergan, Savient, Novartis, and URL Pharmaceuticals; he is a member of the executive board of OMERACT, an organization that develops outcome measures in rheumatology and receives arms-length funding from 36 companies.; BAP: BAP has received research grants from Arthrex, Synthes, J&J/DePuy/Mitek, and Tornier and is a consultant for Arthrex, Tornier, and Acumed. NR 26 TC 0 Z9 0 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1469-493X EI 1361-6137 J9 COCHRANE DB SYST REV JI Cochrane Database Syst Rev. PY 2015 IS 2 AR CD011531 DI 10.1002/14651858.CD011531 PG 13 WC Medicine, General & Internal SC General & Internal Medicine GA DL0TV UT WOS:000375346400055 ER PT J AU Wynn, JK Jimenez, AM Roach, BJ Korb, A Lee, J Horan, WP Ford, JM Green, MF AF Wynn, Jonathan K. Jimenez, Amy M. Roach, Brian J. Korb, Alexander Lee, Junghee Horan, William P. Ford, Judith M. Green, Michael F. TI Impaired target detection in schizophrenia and the ventral attentional network: Findings from a joint event-related potential-functional MRI analysis Target stimulus ERP/fMRI analysis in schizophrenia SO NEUROIMAGE-CLINICAL LA English DT Article DE ERP; fMRI; Joint ICA; Oddball; Salience network ID SUSTAINED ATTENTION; P300; FMRI; METAANALYSIS; SALIENCE; INFORMATION; BRAIN; TASK; CONNECTIVITY; DYSFUNCTION AB Schizophrenia patients have abnormal neural responses to salient, infrequent events. We integrated event-related potentials (ERP) and fMRI to examine the contributions of the ventral (salience) and dorsal (sustained) attention networks to this dysfunctional neural activation. Twenty-one schizophrenia patients and 22 healthy controls were assessed in separate sessions with ERP and fMRI during a visual oddball task. Visual P100, N100, and P300 ERP waveforms and fMRI activation were assessed. A joint independent components analysis (jICA) on the ERP and fMRI data were conducted. Patients exhibited reduced P300, but not P100 or N100, amplitudes to targets and reduced fMRI neural activation in both dorsal and ventral attentional networks compared with controls. However, the jICA revealed that the P300 was linked specifically to activation in the ventral (salience) network, including anterior cingulate, anterior insula, and temporal parietal junction, with patients exhibiting significantly lower activation. The P100 and N100 were linked to activation in the dorsal (sustained) network, with no group differences in level of activation. This joint analysis approach revealed the nature of target detection deficits that were not discernable by either imaging methodology alone, highlighting the utility of a multimodal fMRI and ERP approach to understand attentional network deficits in schizophrenia. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). C1 [Wynn, Jonathan K.; Jimenez, Amy M.; Lee, Junghee; Horan, William P.; Green, Michael F.] MIRECC, Vet Affairs Greater Los Angeles Healthcare Syst, Bldg 210,Room 131,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. [Wynn, Jonathan K.; Korb, Alexander; Lee, Junghee; Horan, William P.; Green, Michael F.] Univ Calif Los Angeles, Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Roach, Brian J.; Ford, Judith M.] Northern Calif Inst Res & Educ, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA. [Ford, Judith M.] Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA. RP Wynn, JK (reprint author), MIRECC, Vet Affairs Greater Los Angeles Healthcare Syst, Bldg 210,Room 131,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jkwynn@ucla.edu RI Wynn, Jonathan/H-3749-2014; Lee, Junghee/C-5226-2014 OI Wynn, Jonathan/0000-0002-1763-8540; Lee, Junghee/0000-0001-9567-8700 FU Veterans Affairs (VA) Career Development Award [Wynn 0001]; VA Merit Review Grant [I01CX000497]; National Institutes of Mental Health [MH58262, MH43292, MH065707]; Brain Mapping Medical Research Organization; Brain Mapping Support Foundation; Pierson-Lovelace Foundation; Ahmanson Foundation; William M. and Linda R. Dietel Philanthropic Fund at the Northern Piedmont Community Foundation; Tamkin Foundation; Jennifer Jones-Simon Foundation; Capital Group Companies Charitable Foundation; Robson Family; Northstar Fund FX This work was supported by a Veterans Affairs (VA) Career Development Award (Wynn 0001) to JKW; VA Merit Review Grant (I01CX000497) and National Institutes of Mental Health (MH58262) to JMF; and National Institutes of Mental Health grants MH43292 and MH065707 to MFG. For generous support, we also thank the Brain Mapping Medical Research Organization, Brain Mapping Support Foundation, Pierson-Lovelace Foundation, The Ahmanson Foundation, William M. and Linda R. Dietel Philanthropic Fund at the Northern Piedmont Community Foundation, Tamkin Foundation, Jennifer Jones-Simon Foundation, Capital Group Companies Charitable Foundation, Robson Family, and Northstar Fund. The funding sources had no role in: the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. NR 50 TC 6 Z9 6 U1 2 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-1582 J9 NEUROIMAGE-CLIN JI NeuroImage-Clin. PY 2015 VL 9 BP 95 EP 102 DI 10.1016/j.nicl.2015.07.004 PG 8 WC Neuroimaging SC Neurosciences & Neurology GA DI0LR UT WOS:000373188400012 PM 26448909 ER PT J AU Barron, DS Fox, PT Pardoe, H Lancaster, J Price, LR Blackmon, K Berry, K Cavazos, JE Kuzniecky, R Devinsky, O Thesen, T AF Barron, Daniel S. Fox, Peter T. Pardoe, Heath Lancaster, Jack Price, Larry R. Blackmon, Karen Berry, Kristen Cavazos, Jose E. Kuzniecky, Ruben Devinsky, Orrin Thesen, Thomas TI Thalamic functional connectivity predicts seizure laterality in individual TLE patients: Application of a biomarker development strategy SO NEUROIMAGE-CLINICAL LA English DT Article DE Epilepsy; Temporal Lobe Epilepsy; Thalamus; Resting-state fMRI; fMRI; Biomarker; Lateralization ID TEMPORAL-LOBE EPILEPSY; NETWORKS; MRI; ORGANIZATION; BRAIN AB Noninvasive markers of brain function could yield biomarkers in many neurological disorders. Disease models constrained by coordinate-based meta-analysis are likely to increase this yield. Here, we evaluate a thalamic model of temporal lobe epilepsy that we proposed in a coordinate-based meta-analysis and extended in a diffusion tractography study of an independent patient population. Specifically, we evaluated whether thalamic functional connectivity (resting-state fMRI-BOLD) with temporal lobe areas can predict seizure onset laterality, as established with intracranial EEG. Twenty-four lesional and non-lesional temporal lobe epilepsy patients were studied. No significant differences in functional connection strength in patient and control groups were observed with Mann-Whitney Tests (corrected for multiple comparisons). Notwithstanding the lack of group differences, individual patient difference scores (from control mean connection strength) successfully predicted seizure onset zone as shown in ROC curves: discriminant analysis (two-dimensional) predicted seizure onset zone with 85% sensitivity and 91% specificity; logistic regression (four-dimensional) achieved 86% sensitivity and 100% specificity. The strongest markers in both analyses were left thalamo-hippocampal and right thalamo-entorhinal cortex functional connection strength. Thus, this study shows that thalamic functional connections are sensitive and specific markers of seizure onset laterality in individual temporal lobe epilepsy patients. This study also advances an overall strategy for the programmatic development of neuroimaging biomarkers in clinical and genetic populations: a disease model informed by coordinate-based meta-analysis was used to anatomically constrain individual patient analyses. (C) 2014 The Authors. Published by Elsevier Inc. C1 [Barron, Daniel S.; Fox, Peter T.; Lancaster, Jack] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA. [Barron, Daniel S.] Yale Univ, Sch Med, New Haven, CT USA. [Fox, Peter T.; Lancaster, Jack] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA. [Fox, Peter T.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Fox, Peter T.; Cavazos, Jose E.] Univ TX Hlth Sci Ctr, Dept Neurol, San Antonio, TX USA. [Fox, Peter T.] Univ Hong Kong, State Key Lab Brain & Cognit Sci, Hong Kong, Hong Kong, Peoples R China. [Pardoe, Heath; Blackmon, Karen; Berry, Kristen; Kuzniecky, Ruben; Devinsky, Orrin; Thesen, Thomas] NYU, Dept Neurol, New York, NY 10016 USA. [Price, Larry R.] Texas State Univ, Coll Educ, San Marcos, TX USA. [Price, Larry R.] Texas State Univ, Coll Sci, San Marcos, TX USA. [Cavazos, Jose E.] South Texas Vet Hlth Care Syst, San Antonio Epilepsy Ctr Excellence, San Antonio, TX USA. RP Barron, DS (reprint author), Off Student Affairs, 367 Cedar St, New Haven, CT 06510 USA. EM daniel.s.barron@yale.edu RI Cavazos, Jose/J-4122-2016 OI Cavazos, Jose/0000-0001-5777-2608; Devinsky, Orrin/0000-0003-0044-4632; Pardoe, Heath/0000-0002-0123-2167 FU National Institute of Neurological Disorder Stroke [1-F31-NS083160-01]; National Institute of Health [RO1 MH074457]; F.A.C.E.S (Finding a cure for epilepsy and Seizures); American Epilepsy Foundation FX Funding from the National Institute of Neurological Disorder & Stroke1-F31-NS083160-01 (D.S.B.), National Institute of HealthRO1 MH074457 (P.T.F.), F.A.C.E.S (Finding a cure for epilepsy and Seizures; T.T., O.D.) and the American Epilepsy Foundation (T.T.) assisted in the collection, management, analysis, and interpretation of the data; and in the preparation and review of the manuscript. NR 29 TC 5 Z9 5 U1 0 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-1582 J9 NEUROIMAGE-CLIN JI NeuroImage-Clin. PY 2015 VL 7 BP 273 EP 280 DI 10.1016/j.nicl.2014.08.002 PG 8 WC Neuroimaging SC Neurosciences & Neurology GA DI0GE UT WOS:000373172600031 PM 25610790 ER PT J AU Fling, BW Dutta, GG Horak, FB AF Fling, Brett W. Dutta, Geetanjali Gera Horak, Fay B. TI Functional connectivity underlying postural motor adaptation in people with multiple sclerosis SO NEUROIMAGE-CLINICAL LA English DT Article ID TRANSCRANIAL MAGNETIC STIMULATION; GRAY-MATTER ATROPHY; CEREBELLAR CORTEX; VIRTUAL-REALITY; BASAL GANGLIA; LESION LOAD; BRAIN; MECHANISMS; PLASTICITY; ADULTS AB A well-characterized neural network is associated with motor learning, involving several brain regions known to have functional and structural deficits in persons with multiple sclerosis (PwMS). However, it is not known how MS affects postural motor learning or the neural networks involved. The aim of this study was to gain a better understanding of the neural networks underlying adaptation of postural responses within PwMS. Participants stood on a hydraulically driven, servo-controlled platform that translated horizontally forward and backward in a continuous sinusoidal pattern across multiple trials over two consecutive days. Our results show similar postural adaptation between PwMS and age-matched control participants despite overall deficits in postural motor control in PwMS. Moreover, PwMS demonstrated better retention the following day. PwMS had significantly reduced functional connectivity within both the cortico-cerebellar and cortico-striatal motor loops; neural networks that subserve implicit motor learning. In PwMS, greater connectivity strength within the cortico-cerebellar circuit was strongly related to better baseline postural control, but not to postural adaptation as it was in control participants. Further, anti-correlated cortico-striatal connectivity within the right hemisphere was related to improved postural adaptation in both groups. Taken together with previous studies showing a reduced reliance on cerebellar-and proprioceptive-related feedback control in PwMS, we suggest that PwMS may rely on cortico-striatal circuitry to a greater extent than cortico-cerebellar circuitry for the acquisition and retention of motor skills. (C) 2015 The Authors. Published by Elsevier Inc. C1 [Fling, Brett W.; Dutta, Geetanjali Gera; Horak, Fay B.] Oregon Hlth & Sci Univ, Sch Med, Dept Neurol, Portland, OR 97239 USA. [Fling, Brett W.; Horak, Fay B.] Portland VA Med Ctr, Portland, OR 97239 USA. RP Fling, BW (reprint author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM fling@ohsu.edu FU National Multiple Sclerosis Society [RG 5273A1/T, FG 2058-A-1, MB0011]; Medical Research Foundation of Oregon; N.L. Tartar Research Fund FX We thank the volunteers for participating in this study. We are also grateful to Heather Schlueter for assistance in participant recruitment and data collection. This work was principally supported by grants from the National Multiple Sclerosis Society (BWF: RG 5273A1/T, GGD: FG 2058-A-1 and FBH: MB0011). Additional support was provided by the Medical Research Foundation of Oregon (BWF & GGD) and the N.L. Tartar Research Fund (BWF). The authors declare no competing financial interests. NR 73 TC 3 Z9 3 U1 2 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-1582 J9 NEUROIMAGE-CLIN JI NeuroImage-Clin. PY 2015 VL 8 BP 281 EP 289 DI 10.1016/j.nicl.2015.04.023 PG 9 WC Neuroimaging SC Neurosciences & Neurology GA DI0LE UT WOS:000373187100030 PM 26106552 ER PT S AU Schopfer, DW Khera, A Levine, B Forman, DE AF Schopfer, David W. Khera, Amit Levine, Benjamin Forman, Daniel E. BE Willerson, JT Holmes, DR TI Preventive Cardiology: The Effects of Exercise SO CORONARY ARTERY DISEASE SE Cardiovascular Medicine-London LA English DT Article; Book Chapter DE Exercise training; Exercise prescription; Physical activity; Physical fitness; Cardiac Rehabilitation; Habitual exercise; Sleep; Secondary prevention; Risk Factor Modification; Central exercise effects; Peripheral exercise effects; Skeletal muscle; Vascular; Autonomic function; Coagulation; Heart failure ID CORONARY-HEART-DISEASE; C-REACTIVE PROTEIN; ACUTE MYOCARDIAL-INFARCTION; TIME PHYSICAL-ACTIVITY; SUDDEN CARDIAC DEATH; RANDOMIZED CONTROLLED-TRIAL; MIDDLE-AGED MEN; HEALTH-CARE PROFESSIONALS; QUALITY-OF-LIFE; PRESERVED EJECTION FRACTION AB Physical adaptations to dynamic exercise (i. e., exercise training) lead to increased aerobic and strength capacities (including cardiovascular reserve, endurance and velocity of movement) (Noakes et al., Clin Sports Med 3(2): 527-543, 1984). These attributes are relevant in vigorous athletes, who in addition to high performance also tend to have better metabolism and health, as well as for older adults who compared to age-matched sedentary adults enjoy better health, greater independence, and better quality of life. Exercise regimens are best tailored to the needs of individual patients, with varying emphasis on strength vs. aerobic, and with different intensities/modes based on clinical contexts. Since the 1950s, an extensive literature has described the benefits and risks of exercise, including reports by the American Heart Association (Fletcher et al., Circulation 86(1): 340-344, 1992) and the International Society and Federation of Cardiology (Bijnen et al., J Int Soc Federation Cardiol 2: 5-6, 1992). The aggregate data conveys a strong case that a sedentary lifestyle is detrimental to health, and creates high a risk for cardiovascular disease. The weight of evidence even led to a Surgeon General's report which made clear and explicit recommendations regarding physical activity (Department of Health and Human Services. Physical activity and health: a report of the Surgeon General. Atlanta: National Center for Chronic Disease Prevention and Health Promotion; 1996). Several major agencies and organizations including the National Institutes of Health, the Centers for Disease Control and Prevention, the American College of Sports Medicine, and the American Heart Association have advanced related recommendations that all adults should exercise with moderate-intensity for at least 30 min on most and preferably all day of the week (Department of Health and Human Services. Physical activity and health: a report of the Surgeon General. Atlanta: National Center for Chronic Disease Prevention and Health Promotion; 1996; Physical activity and cardiovascular health. NIH Consensus Development Panel on Physical Activity and Cardiovascular Health JAMA 276(3): 241-246, 1996; Pate et al., JAMA 273(5): 402-407, 1995; Thompson et al. Circulation 107(24): 3109-3116, 2003). Nonetheless, the majority of adults do not attain the recommended levels of exercise and they are not routinely counseled on the important health benefits of regular physical activity (Prevalence of physical activity, including lifestyle activities among adults - United States, 2000-2001 MMWR Morb Mortal Wkly Rep 52(32): 764-769, 2003; Wee et al., JAMA 282(16): 1583-1588, 1999). This chapter explores the role of occupational and recreational physical activity on morbidity and mortality from coronary heart disease (CHD). The first section will focus on healthy individuals, i. e., primary prevention, and will discuss epidemiologic evidence supporting the practice of regular exercise. The second section will discuss secondary prevention, for patients who already have had some manifestation of CHD such as angina pectoris or myocardial infarction or who have undergone revascularization. Finally, the third section will provide a pathophysiologic framework of the possible mechanisms for the beneficial effects of exercise training. Physical activity, exercise training, and physical fitness have distinct definitions (Thompson et al., Circulation 107(24): 3109-3116, 2003; Caspersen et al., Public Health Rep 100(2): 126-131, 1985). Physical activity is any bodily movement produced by skeletal muscles that results in energy expenditure, including occupational, athletic, and other activities. Exercise training refers more specifically to activity that is planned, structured, and purposeful with the intent of developing or maintaining physical fitness (Caspersen et al., Public Health Rep 100(2): 126-131, 1985). Physical fitness is a set of measurable health-related attributes, including muscle strength, flexibility, body composition, and cardiorespiratory power and endurance. While all are important facets of health, only a minority of adults of any age meet current recommendations for physical activity, exercise training, and/or achieve "optimal" physical fitness (Hansen et al., Med Sci Sports Exerc 44(2): 266-272, 2012). In this chapter, we initially focus on the distinctive health benefits of endurance and strength exercise training. Endurance or "aerobic" exercise includes activities with energy demands that are met primarily by oxidative metabolism. Strength exercise is specialized to increase muscle mass and anaerobic endurance. Strength training also can facilitate aerobic performance as it has the potential to moderate muscle atrophy (sarcopenia) that otherwise occurs with aging, deconditioning, and multimorbidity. Increasing muscle mass with strength training also has benefit of increasing weight loss by raising metabolism and caloric expenditure. Therefore, the combination of aerobic and strength training is often optimal, especially for achieving fitness goals of elderly, obese and/or deconditioned adults who benefit particularly from increased muscle mass as well as aerobic training effects (Brown and Holloszy Aging (Milano) 5(6): 427-434, 1993; McAuley J Behav Med 16(1): 103-113, 1993). While there is conceptually value for exercise regimens that are longer and more intense, this is often not feasible for adults who are frail, deconditioned, or those who may simply be averse to exercise. However, even small amounts of exercise have value; research shows that as little as 15 min of low intensity exercise may be beneficial (Wen et al., Lancet 378(9798): 1244-1253, 2011). Therefore, doing any exercise is better than no exercise, particularly because exercise-induced strength and aerobic capacities often facilitate greater physical activity in addition to exercise. C1 [Schopfer, David W.] San Francisco VA Med Ctr, Dept Med, Div Cardiol, San Francisco, CA USA. [Khera, Amit] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Div Cardiol, Dallas, TX 75390 USA. [Levine, Benjamin] Texas Hlth Presbyterian, Inst Exercise & Environm Med, S Finley Ewing Jr Chair Wellness, Dallas, TX USA. [Levine, Benjamin] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Div Cardiol, Cardiovasc Res, Dallas, TX 75390 USA. [Levine, Benjamin] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Div Cardiol, Med & Cardiol, Dallas, TX 75390 USA. [Levine, Benjamin] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Div Cardiol, Exercise Sci, Dallas, TX 75390 USA. [Forman, Daniel E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc Med,Dept Med, Boston, MA 02115 USA. [Forman, Daniel E.] VA Boston Med Ctr, Dept Med, Cardiol Sect, Boston, MA USA. RP Forman, DE (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc Med,Dept Med, Boston, MA 02115 USA. EM deforman@partners.org OI Schopfer, David/0000-0002-7244-9857 NR 364 TC 0 Z9 0 U1 2 U2 4 PU SPRINGER-VERLAG LONDON LTD PI GODALMING PA SWEETAPPLE HOUSE CATTESHALL RD FARNCOMBE, GODALMING GU7 1NH, SURREY, ENGLAND SN 2363-5061 BN 978-1-4471-2828-1; 978-1-4471-2827-4 J9 CARDIOVASC MED-LOND PY 2015 BP 737 EP 766 DI 10.1007/978-1-4471-2828-1_28 D2 10.1007/978-1-4471-2828-1 PG 30 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA BE2UY UT WOS:000370136700029 ER PT J AU Fuehrlein, BS Cowell, AJ Pollio, D Cupps, L Balfour, ME North, CS AF Fuehrlein, Brian S. Cowell, Alexander J. Pollio, David Cupps, Lori Balfour, Margaret E. North, Carol S. TI A Prospective Study of the Associations Among Housing Status and Costs of Services in a Homeless Population SO PSYCHIATRIC SERVICES LA English DT Article ID SUBSTANCE USE; COMORBIDITY; DISORDERS; ALCOHOL; PROGRAM; ADULTS; WOMEN; TIME; CARE AB Objective: The complex needs of homeless populations result in use of a wide range of services and high costs for housing programs and psychiatric and general medical care. Allocation of resources often is not congruent with assessed needs. A series of cost-congruence hypotheses was developed to test assumptions that needs are associated with resources provided for appropriate services in homeless populations. Methods: Individuals (N=255) who were homeless were followed for two years and were categorized by housing status over time (consistently housed, housed late, lost housing, or consistently homeless). Detailed information about the individuals was obtained at baseline, and follow-up data were collected one and two years later. Extensive data about the costs of services provided by type (medical, psychiatric, substance abuse, and homeless maintenance and amelioration) were derived from 23 agencies, and service use information was collected from the agencies and by self-report. Multiple regression models were used to test the hypotheses. Results: Medical, psychiatric, and homeless maintenance costs varied by housing status. Serious mental illness predicted costs for psychiatric services, as expected, but also costs for substance abuse services and acute behavioral health care and total costs. Alcohol use disorders predicted substance abuse service costs. Conclusions: This study followed a homeless cohort prospectively and provided estimates of costs of service use derived from a large number of agencies. This research increases the understanding of patterns of service use in a homeless population and informs the provision of services appropriate to the complex needs of this difficult-to-serve population. C1 [Fuehrlein, Brian S.; Balfour, Margaret E.; North, Carol S.] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA. [North, Carol S.] US Dept Vet Affairs, North Texas Hlth Care Syst, Dallas, TX USA. [Cowell, Alexander J.] RTI Int, Dept Social Stat & Environm Sci, Res Triangle Pk, NC USA. [Pollio, David] Univ Alabama, Dept Social Work, Tuscaloosa, AL USA. [Cupps, Lori] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA. RP Fuehrlein, BS (reprint author), Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA. EM fuehrlein@gmail.com OI Balfour, Margaret/0000-0002-1510-9709 FU National Institute on Drug Abuse [R01 DA10713] FX This work was funded by grant R01 DA10713 from the National Institute on Drug Abuse. NR 17 TC 2 Z9 2 U1 2 U2 5 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD JAN PY 2015 VL 66 IS 1 BP 27 EP 32 DI 10.1176/appi.ps.201400010 PG 6 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA DE3OD UT WOS:000370538700007 PM 25269783 ER PT J AU Cheng, R Azarbal, A Currier, J Thomson, LEJ Hamilton, MA Esmailian, F Azarbal, B AF Cheng, Richard Azarbal, Amir Currier, Jesse Thomson, Louise E. J. Hamilton, Michele A. Esmailian, Fardad Azarbal, Babak TI Tricuspid Regurgitation, the Forgotten Valvular Lesion-A Contemporary Review of Etiology, Prevalence, and Management Options SO REVIEWS IN CARDIOVASCULAR MEDICINE LA English DT Review DE Tricuspid regurgitation; Tricuspid valve disease; Cardiac surgery; Valvular heart disease ID IN-VALVE IMPLANTATION; DOPPLER COLOR-FLOW; HEART-TRANSPLANTATION; FOLLOW-UP; REPLACEMENT; REPAIR; DISEASE; SURGERY; PREDICTORS; STENOSIS AB Tricuspid regurgitation (TR) is a common finding. Pathologic TR is an independent risk factor for mortality. TR can be classified by etiology into functional versus organic. Organic TR is caused by structural damage to the tricuspid valve (TV) by a spectrum of etiologies, including pacemaker leads and right heart biopsies, whereas functional TR is predominantly due to elevated pulmonary pressures. Atrial fibrillation and chamber enlargement, among other risk factors, are strong predictors of functional TR. Correction of elevated pulmonary pressures improves TR, and concurrent repair of severe TR at the time of left heart valve surgery improves postoperative heart failure symptoms but does not improve survival. TR repair is associated with less operative and long-term mortality than TV replacement, and demonstrates similar improvements in heart failure symptoms. Substantial residual TR remains after repair, and reoperative mortality for residual TR is considerable. Percutaneous TV replacement may offer a rescue strategy. (C) 2015 MedReviews (R), LLC C1 [Cheng, Richard; Thomson, Louise E. J.; Hamilton, Michele A.; Esmailian, Fardad; Azarbal, Babak] Cedars Sinai Heart Inst, Los Angeles, CA USA. [Azarbal, Amir] Univ Alabama, Med Ctr, Dept Med, Huntsville, AL 35899 USA. [Currier, Jesse; Azarbal, Babak] VA Greater Los Angeles Healthcare Syst, Div Cardiol, Los Angeles, CA USA. RP Cheng, R (reprint author), Cedars Sinai Heart Inst, Los Angeles, CA USA. OI Cheng, Richard/0000-0003-2552-6773 NR 56 TC 1 Z9 1 U1 0 U2 0 PU MEDREVIEWS, LLC PI NEW YORK PA 1370 BROADWAY, STE 900, NEW YORK, NY 10018 USA SN 1530-6550 EI 2153-8174 J9 REV CARDIOVASC MED JI Rev. Cardiovasc. Med. PY 2015 VL 16 IS 3 BP 171 EP 181 DI 10.3909/ricm0766 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DD2TM UT WOS:000369775100001 PM 26451764 ER PT J AU Rao, BB Click, B Eid, G Codario, RA AF Rao, Bhavana B. Click, Benjamin Eid, George Codario, Ronald A. TI Management of Refractory Noninsulinoma Pancreatogenous Hypoglycemia Syndrome with Gastric Bypass Reversal: A Case Report and Review of the Literature SO CASE REPORTS IN ENDOCRINOLOGY LA English DT Review ID HYPERINSULINEMIC HYPOGLYCEMIA; SURGERY AB Background. Roux-en-Y gastric bypass (RYGB) is a commonly performed, effective bariatric procedure; however, rarely, complications such as postprandial hypoglycemia due to noninsulinoma pancreatogenous hypoglycemia syndrome (NIPHS) may ensue. Management of refractory NIPHS is challenging. We report a case that was successfully treated with RYGB reversal. Case Report. A 58-year-old male with history of RYGB nine months earlier for morbid obesity presented for evaluation of postprandial, hypoglycemic seizures. Testing for insulin level, insulin antibodies, oral hypoglycemic agents, pituitary axis hormone levels, and cortisol stimulation was unrevealing. Computed tomography (CT) scan of the abdomen was unremarkable. A 72-hour fast was completed without hypoglycemia. Mixed meal testing demonstrated endogenous hyperinsulinemic hypoglycemia (EHH) and selective arterial calcium stimulation testing (SACST) was positive. Strict dietary modifications, maximal medical therapy, gastrostomy tube feeding, and stomal reduction failed to alleviate symptoms. Ultimately, he underwent laparoscopic reversal of RYGB. Now, 9 months after reversal, he has markedly reduced hypoglycemia burden. Discussion. Hyperfunctioning islets secondary to exaggerated incretin response and altered intestinal nutrient delivery are hypothesized to be causative in NIPHS. For refractory cases, there is increasing skepticism about the safety and efficacy of pancreatic resection. RYGB reversal may be successful. C1 [Rao, Bhavana B.; Click, Benjamin] Univ Pittsburgh, Med Ctr, Dept Internal Med, Pittsburgh, PA 15213 USA. [Eid, George] Allegheny Hlth Network, Div Bariatr Surg, Pittsburgh, PA 15212 USA. [Codario, Ronald A.] VA Pittsburgh Healthcare Syst, Div Endocrinol, Dept Internal Med, Pittsburgh, PA 15240 USA. RP Codario, RA (reprint author), VA Pittsburgh Healthcare Syst, Div Endocrinol, Dept Internal Med, Pittsburgh, PA 15240 USA. EM ronald.codario@va.gov NR 10 TC 1 Z9 1 U1 0 U2 0 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 2090-6501 EI 2090-651X J9 CASE REP ENDOCRINOL JI Case Rep. Endocrinol. PY 2015 AR 384526 DI 10.1155/2015/384526 PG 4 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DD1DU UT WOS:000369662200001 ER PT J AU Jovanovich, AJ Chonchol, MB Sobhi, A Kendrick, JB Cheung, AK Kaufman, JS Smits, G Jablonski, KL AF Jovanovich, Anna J. Chonchol, Michel B. Sobhi, Atousa Kendrick, Jessica B. Cheung, Alfred K. Kaufman, James S. Smits, Gerard Jablonski, Kristen L. CA HOST Investigators TI Mineral Metabolites, Angiotensin II Inhibition and Outcomes in Advanced Chronic Kidney Disease SO AMERICAN JOURNAL OF NEPHROLOGY LA English DT Article DE Dialysis; Mortality; Phosphorus; Renin-angiotensin inhibition ID STAGE RENAL-DISEASE; RANDOMIZED CONTROLLED-TRIAL; CONVERTING ENZYME-INHIBITORS; LONG-TERM HEMODIALYSIS; CARDIOVASCULAR OUTCOMES; ALDOSTERONE SYSTEM; RECEPTOR BLOCKERS; ACE-INHIBITORS; MORTALITY RISK; HEART-FAILURE AB Background: Evidence suggests that the renin angiotensin aldosterone system (RAAS) interacts with the vitamin D-fibroblast growth factor 23-Klotho axis. We investigated whether circulating mineral metabolism markers modify outcomes in response to RAAS inhibition in subjects with advanced chronic kidney disease (CKD). Methods: In this retrospective cohort study, we analyzed the association of angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) use with all-cause mortality and dialysis initiation among 1,753 subjects (1,099 CKD, estimated glomerular filtration rate 18 +/- 6 ml/min/1.73 m(2) and 654 end-stage renal disease [ESRD]) from the Homocysteine in Kidney and End Stage Renal Disease (HOST) study. A propensity score analysis accounted for indication bias and Cox re-gression models adjusted for mineral metabolism markers. Results: Mean follow-up was 3.2 years; 714 (41%) subjects died and 615 (56%) initiated dialysis. In adjusted analyses, all subjects treated with ACEI/ARB had a significantly lower hazard of death (hazards ratio (HR) 0.81, 95% CI 0.70-0.95, p = 0.007). Those with CKD not on dialysis and treated with ACEI/ARB trended toward a lower hazard of dialysis initiation (HR 0.86, 95% CI 0.73-1.01, p = 0.06). The association with mortality did not differ by level of mineral metabolism marker (p for interaction >0.16); however, the relationship with dialysis initiation differed according to the median serum phosphorus level (p for interaction <0.001). Conclusions: RAAS inhibition was associated with decreased all-cause mortality independent of disordered mineral metabolism among mostly male HOST subjects with advanced CKD and ESRD. However, among those with CKD not requiring dialysis, the renoprotection associated with RAAS inhibition was attenuated by higher serum phosphorus levels. Further studies are needed to confirm this association. (C) 2015 S. Karger AG, Basel C1 [Jovanovich, Anna J.; Chonchol, Michel B.; Kendrick, Jessica B.; Smits, Gerard; Jablonski, Kristen L.] Univ Colorado Denver, Div Renal Dis & Hypertens, Mail Stop C281,13199 E Montview Blvd,Ste 495, Aurora, CO 80010 USA. [Jovanovich, Anna J.] Denver Vet Affairs Med Ctr, Med Serv, Renal Sect, Denver, CO USA. [Sobhi, Atousa] Univ Colorado, Sch Med, Denver, CO USA. [Kendrick, Jessica B.] Denver Hlth Med Ctr, Div Renal, Denver, CO USA. [Cheung, Alfred K.] Univ Utah, Div Nephrol & Hypertens, Salt Lake City, UT USA. [Cheung, Alfred K.] Vet Affairs Salt Lake City Healthcare Syst, Med Serv, Renal Sect, Salt Lake City, UT USA. [Kaufman, James S.] Vet Affairs NY Harbor Healthcare Syst, Med Serv, Renal Sect, New York, NY USA. [Kaufman, James S.] NYU, Langone Med Ctr, New York, NY USA. RP Jovanovich, AJ (reprint author), Univ Colorado Denver, Div Renal Dis & Hypertens, Mail Stop C281,13199 E Montview Blvd,Ste 495, Aurora, CO 80010 USA. EM anna.jovanovich@ucdenver.edu FU HOST executive Committee; Department of Veterans Affairs Cooperative Studies Program; American Heart Association [12POST11920023]; VA Career Development Award 2 [1IKCX001030-01A1] FX This study was supported by the HOST executive Committee and the Department of Veterans Affairs Cooperative Studies Program, by the American Heart Association (12POST11920023) and by a VA Career Development Award 2 (1IKCX001030-01A1). There are no conflicts of interest to report. NR 36 TC 1 Z9 1 U1 0 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0250-8095 EI 1421-9670 J9 AM J NEPHROL JI Am. J. Nephrol. PY 2015 VL 42 IS 5 BP 361 EP 368 DI 10.1159/000441684 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA DB9VC UT WOS:000368864800003 PM 26606453 ER PT J AU Dahl, R Calverley, PMA Anzueto, A Metzdorf, N Fowler, A Mueller, A Wise, R Dusser, D AF Dahl, Ronald Calverley, Peter M. A. Anzueto, Antonio Metzdorf, Norbert Fowler, Andy Mueller, Achim Wise, Robert Dusser, Daniel TI Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trial SO BMJ OPEN LA English DT Article DE Tiotropium; COPD; Respimat (R); HandiHaler (R); Switching; Efficacy ID OBSTRUCTIVE PULMONARY-DISEASE; RANDOMIZED CONTROLLED-TRIALS; CLINICAL-TRIALS; MIST INHALER; MORTALITY; COPD; RISK; METAANALYSIS; POWDER AB Objectives This post hoc analysis of TIOtropium Safety and Performance In Respimat (TIOSPIR) evaluated safety and exacerbation efficacy in patients with stable (2months) use of tiotropium HandiHaler 18 mu g (HH18) prior to study entry, to evaluate whether there was a difference in risk for patients who switched from HH18 to tiotropium Respimat 2.5 mu g (R2.5) or 5 mu g (R5). Setting TIOSPIR (n=17135) was an international, Phase IIIb/IV, randomised, double-blind, parallel-group, event-driven trial. Participants Patients from TIOSPIR with chronic obstructive pulmonary disease (COPD) and postbronchodilator ratio of forced expiratory volume in 1s to forced vital capacity 0.70, receiving HH18 before study entry, were analysed (n=2784). Interventions Patients were randomised to once-daily tiotropium R2.5 (n=914), R5 (n=918) or HH18 (n=952) for 2-3years. Primary and secondary outcome measures Primary outcomes: time to death (safety) and time to first COPD exacerbation (efficacy). Secondary outcomes: number of exacerbations and time to first major adverse cardiovascular event (MACE). Results Baseline characteristics were similar in all groups. Respimat had a similar mortality risk versus HH18 (vital status follow-up, HR; 95% CI R2.5: 0.87; 0.64 to 1.17; R5: 0.79; 0.58 to 1.07) with no significant differences in the risk and rates of exacerbations and severe exacerbations across treatment groups. Risk of MACE and fatal MACE was similar for Respimat versus HH18 (HR; 95% CI MACE R2.5: 0.73; 0.47 to 1.15; R5: 0.69; 0.44 to 1.08; fatal MACE R2.5: 0.57; 0.27 to 1.19; R5: 0.67; 0.33 to 1.34). Overall risk of a fatal event (on treatment) was lower for R5 versus HH18 (HR; 95% CI R2.5: 0.78; 0.55 to 1.09; R5: 0.62; 0.43 to 0.89). Conclusions This analysis indicates that it is safe to switch patients from tiotropium HandiHaler to tiotropium Respimat, and that the efficacy is maintained over the switch. Trial registration number NCT01126437; Post-results. C1 [Dahl, Ronald] Odense Univ Hosp, Allergy Ctr, DK-5000 Odense C, Denmark. [Calverley, Peter M. A.] Aintree Univ Hosp NHS Fdn Trust, Clin Sci Ctr, Inst Ageing & Chron Dis, Liverpool L9 7AL, Merseyside, England. [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, Pulm Crit Care Dept, San Antonio, TX 78229 USA. [Anzueto, Antonio] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Metzdorf, Norbert] Boehringer Ingelheim Pharma GmbH & Co KG, TA Resp Dis, Ingelheim, Germany. [Fowler, Andy] Boehringer Ingelheim Pharma Ltd, Clin Res, Bracknell, Berks, England. [Mueller, Achim] Boehringer Ingelheim Pharma GmbH & Co KG, Biometr & Data Management, Biberach, Germany. [Wise, Robert] Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD USA. [Dusser, Daniel] Univ Paris 05, Hop Cochin, Dept Pneumol, AP HP, Paris, France. RP Dahl, R (reprint author), Odense Univ Hosp, Allergy Ctr, DK-5000 Odense C, Denmark. EM Ronald.dahl2@rsyd.dk FU Boehringer Ingelheim FX The TIOSPIR trial was funded by Boehringer Ingelheim. The funding source participated in the design and conduct of the study, the analysis or interpretation of the data and the preparation of the manuscript before publication. NR 26 TC 4 Z9 4 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-6055 J9 BMJ OPEN JI BMJ Open PY 2015 VL 5 IS 12 AR e009015 DI 10.1136/bmjopen-2015-009015 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA DB9MB UT WOS:000368839100068 PM 26715479 ER PT J AU Warren, T Milburn, E Patson, ND Dickey, MW AF Warren, Tessa Milburn, Evelyn Patson, Nikole D. Dickey, Michael Walsh TI Comprehending the impossible: what role do selectional restriction violations play? SO LANGUAGE COGNITION AND NEUROSCIENCE LA English DT Article DE language comprehension; plausibility; eye tracking; sentence processing; reading ID E-Z READER; EYE-MOVEMENTS; LANGUAGE COMPREHENSION; PLAUSIBILITY; KNOWLEDGE; INTEGRATION; INFORMATION; MEMORY AB To elucidate how different kinds of knowledge are used during comprehension, readers' eye movements were monitored as they read sentences that were: plausible, impossible because of a selectional restriction violation (SRV) or impossible because of a violation of general world knowledge. Eye movements on the pre-critical, critical, and post-critical words evidenced disruption in the SRV condition compared to the other two conditions. These findings suggest that disruption associated with reading about impossible events is not directly determined by how impossible the event seems. Rather, the relationship between the verb and arguments in the sentence seems to matter. These findings are the strongest evidence to date that processing effects associated with selectional restrictions can dissociate from those associated with general world knowledge about events. C1 [Warren, Tessa; Milburn, Evelyn] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA. [Warren, Tessa; Milburn, Evelyn] Univ Pittsburgh, Learning Res & Dev Ctr, Pittsburgh, PA 15260 USA. [Patson, Nikole D.] Ohio State Univ, Dept Psychol, Marion, OH USA. [Dickey, Michael Walsh] Univ Pittsburgh, Dept Commun Sci & Disorders, Pittsburgh, PA USA. [Dickey, Michael Walsh] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Warren, T (reprint author), Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA. EM tessa@pitt.edu OI Dickey, Michael Walsh/0000-0002-9068-3313 FU National Institutes of Health [R01DC011520] FX This research was supported by the National Institutes of Health [grant number R01DC011520] to the first and fourth authors. It is the result of work supported with resources and the use of facilities at the VA Pittsburgh Healthcare System. NR 36 TC 2 Z9 2 U1 1 U2 3 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 2327-3798 EI 2327-3801 J9 LANG COGN NEUROSCI JI Lang. Cogn. Neurosci. PY 2015 VL 30 IS 8 BP 932 EP 939 DI 10.1080/23273798.2015.1047458 PG 8 WC Audiology & Speech-Language Pathology; Behavioral Sciences; Linguistics; Psychology, Experimental SC Audiology & Speech-Language Pathology; Behavioral Sciences; Linguistics; Psychology GA DC2PZ UT WOS:000369060000008 PM 26618186 ER PT S AU Chaudhuri, AR Wei, R Bhattacharya, A Hamilton, R AF Chaudhuri, Asish R. Wei, Rochelle Bhattacharya, Arunabh Hamilton, Ryan BE Shaw, AC TI Fluorescence-Based Approaches for Quantitative Assessment of Protein Carbonylation, Protein Disulfides, and Protein Conformation in Biological Tissues SO IMMUNOSENESCENCE: METHODS AND PROTOCOLS SE Methods in Molecular Biology LA English DT Article; Book Chapter DE Protein oxidation; Carbonylation; Disulfide; Oxidative stress ID METAL-CATALYZED OXIDATION; SKELETAL-MUSCLE; STRESS; STATE AB Protein oxidation and misfolding have been considered as key players for progression of aging and etiology of various pathological conditions. However, few attempts have been made to develop sensitive and reproducible assays to quantify the changes in protein oxidation and alteration in structure. Here we describe three distinct fluorescence-based assays to quantify changes in protein oxidation, namely carbonylation and disulfides and alteration in protein surface hydrophobicity as a reporter for protein conformation. These techniques will provide investigators the opportunity to address important biological questions in their experimental models. C1 [Chaudhuri, Asish R.] UT Southwestern Med Ctr, Dallas, TX USA. [Chaudhuri, Asish R.; Wei, Rochelle; Bhattacharya, Arunabh; Hamilton, Ryan] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Chaudhuri, Asish R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. [Chaudhuri, Asish R.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Bhattacharya, Arunabh; Hamilton, Ryan] Univ Texas Hlth Sci Ctr San Antonio, Cellular & Struct Biol, San Antonio, TX 78229 USA. RP Chaudhuri, AR (reprint author), UT Southwestern Med Ctr, Dallas, TX USA. NR 23 TC 0 Z9 0 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA SN 1064-3745 BN 978-1-4939-2963-4; 978-1-4939-2962-7 J9 METHODS MOL BIOL JI Methods Mol. Biol. PY 2015 VL 1343 BP 155 EP 173 DI 10.1007/978-1-4939-2963-4_13 D2 10.1007/978-1-4939-2963-4 PG 19 WC Immunology SC Immunology GA BE1RY UT WOS:000368438800014 PM 26420716 ER PT J AU Kalra, A Forman, DE Goodlin, SJ AF Kalra, Ankur Forman, Daniel E. Goodlin, Sarah J. TI Medical decision making for older adults: an international perspective comparing the United States and India SO JOURNAL OF GERIATRIC CARDIOLOGY LA English DT Article DE Advance care planning; Advance directive; End-of-life; India; Surrogate decision-making ID ADVANCE DIRECTIVES; HEALTH-CARE; LIFE; SURROGATES; EVOLUTION; FUTILITY; END; LAW AB There has been a significant decline in cardiovascular morbidity and mortality amidst pervasive advances in care, including percutaneous revascularization, mechanical circulatory support, and transcatheter valvular therapies. While advancing therapies may add significant longevity, they also bring about new end-of-life decision-making challenges for patients and their families who also must weigh the advantages of reduced mortality to the possibility of longer lives consisting of high morbidity, frailty, pain, and poor quality of living. Advance care entails options of withholding or withdrawing therapies, and has become a familiar part of cardiovascular care for older patients in Western countries. However, as advanced cardiovascular practices extend to developing countries, the interrelated concept of advance care is rarely straight forward as it is affected by local cultural traditions and mores, and can lead to very different inferences and use. This paper discusses the concepts of advance care planning, surrogate decision-making, orders for resuscitation and futility in patients with cardiac disease with comparisons of West to East, focusing particularly on the United States versus India. C1 [Goodlin, Sarah J.] Oregon Hlth & Sci Univ, Dept Geriatr Med, Portland, OR 97201 USA. [Kalra, Ankur] Beth Israel Deaconess Med Ctr, Div Intervent Cardiol, Boston, MA 02215 USA. [Kalra, Ankur] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Kalra, Ankur] Kalra Hosp SRCNC Pvt Ltd, Dept Med, Div Cardiol, New Delhi, India. [Forman, Daniel E.] Univ Pittsburgh, Med Ctr, Sect Geriatr Cardiol, Pittsburgh, PA USA. [Forman, Daniel E.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Goodlin, Sarah J.] Vet Affairs Portland Hlth Care Syst, Portland, OR USA. RP Goodlin, SJ (reprint author), Oregon Hlth & Sci Univ, Dept Geriatr Med, Portland, OR 97201 USA. EM sarah.goodlin@va.gov NR 32 TC 0 Z9 0 U1 1 U2 2 PU SCIENCE PRESS PI BEIJING PA 16 DONGHUANGCHENGGEN NORTH ST, BEIJING 100717, PEOPLES R CHINA SN 1671-5411 J9 J GERIATR CARDIOL JI J. Geriatr. Cardiol. PY 2015 VL 12 IS 4 BP 329 EP 334 PG 6 WC Cardiac & Cardiovascular Systems; Geriatrics & Gerontology SC Cardiovascular System & Cardiology; Geriatrics & Gerontology GA DB3MR UT WOS:000368416200001 PM 26346983 ER PT J AU Fujikawa, DG AF Fujikawa, Denson G. TI The Role of Excitotoxic Programmed Necrosis in Acute Brain Injury SO COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL LA English DT Review DE Excitotoxicity; Necrosis; Programmed cell death; NMDA receptor ID APOPTOSIS-INDUCING FACTOR; INTERNUCLEOSOMAL DNA CLEAVAGE; ELECTRON-MICROSCOPIC FINDINGS; POLY(ADP-RIBOSE) PAR POLYMER; TRANSIENT CEREBRAL-ISCHEMIA; HIPPOCAMPAL NEURONAL DEATH; INDUCED STATUS EPILEPTICUS; NMDA-RECEPTOR ACTIVATION; CELL-DEATH; CYTOCHROME-C AB Excitotoxicity involves the excessive release of glutamate from presynaptic nerve terminals and from reversal of astrocytic glutamate uptake, when there is excessive neuronal depolarization. N-methyl-D-aspartate (NMDA) receptors, a subtype of glutamate receptor, are activated in postsynaptic neurons, opening their receptor-operated cation channels to allow Ca2+ influx. The Ca2+ influx activates two enzymes, calpain I and neuronal nitric oxide synthase (nNOS). Calpain I activation produces mitochondrial release of cytochrome c (cyt c), truncated apoptosis-inducing factor (tAIF) and endonuclease G (endoG), the lysosomal release of cathepsins B and D and DNase II, and inactivation of the plasma membrane Na+-Ca2+ exchanger, which add to the buildup of intracellular Ca2+. tAIF is involved in large-scale DNA cleavage and cyt c may be involved in chromatin condensation; endoG produces internucleosomal DNA cleavage. The nuclear actions of the other proteins have not been determined. nNOS forms nitric oxide (NO), which reacts with superoxide (O-2(-)) to form peroxynitrite (ONOO-). These free radicals damage cellular membranes, intracellular proteins and DNA. DNA damage activates poly(ADPribose) polymerase-1 (PARP-1), which produces poly(ADP-ribose) (PAR) polymers that exit nuclei and translocate to mitochondrial membranes, also releasing AIF. Poly(ADP-ribose) glycohydrolase hydrolyzes PAR polymers into ADP-ribose molecules, which translocate to plasma membranes, activating melastatin-like transient receptor potential 2 (TRPM-2) channels, which open, allowing Ca2+ influx into neurons. NADPH oxidase (NOX1) transfers electrons across cellular membranes, producing O-2(-). The result of these processes is neuronal necrosis, which is a programmed cell death that is the basis of all acute neuronal injury in the adult brain. Fujikawa. Published by Elsevier B.V. on behalf of the Research Network of Computational and Structural Biotechnology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). C1 [Fujikawa, Denson G.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. RP Fujikawa, DG (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. EM dfujikaw@ucla.edu NR 82 TC 14 Z9 17 U1 2 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 2001-0370 J9 COMPUT STRUCT BIOTEC JI Comp. Struct. Biotechnol. J.. PY 2015 VL 13 BP 212 EP 221 DI 10.1016/j.csbj.2015.03.004 PG 10 WC Biotechnology & Applied Microbiology SC Biotechnology & Applied Microbiology GA DA4EJ UT WOS:000367752600026 PM 25893083 ER PT J AU Zeidler, MR Santiago, V Dzierzewski, JM Mitchell, MN Santiago, S Martin, JL AF Zeidler, Michelle R. Santiago, Vicente Dzierzewski, Joseph M. Mitchell, Michael N. Santiago, Silverio Martin, Jennifer L. TI Predictors of Obstructive Sleep Apnea on Polysomnography after a Technically Inadequate or Normal Home Sleep Test SO JOURNAL OF CLINICAL SLEEP MEDICINE LA English DT Article DE home sleep test; obstructive sleep apnea; polysomnography ID PREVALENCE; DIAGNOSIS AB Study Objectives: Home sleep testing (HST) is an accepted alternative to polysomnography (PSG) for diagnosing obstructive sleep apnea (OSA) in high-risk populations. Clinical guidelines recommend PSG in cases where the HST is technically inadequate (TI) or fails to establish the diagnosis of OSA in patients with high pretest probability. This retrospective study evaluated predictors of OSA on PSG within patients who had a TI or normal HST. Methods: Electronic medical records were reviewed on 1,157 patients referred for HST at our sleep center. Two hundred thirty-eight patients had a TI or normal HST with subsequent PSG. Age, BMI, Epworth score, HST result, and PSG-based apnea-hypopnea index (AHI) were abstracted. Results: Two hundred thirty-eight consecutive patients with either a normal HST (n = 127) or TI HST (n = 111) underwent subsequent PSG. Of 127 who had a normal HST, 76% had a normal PSG and 24% had OSA (23 mild, 6 moderate, 1 severe). Of 111 who had a TI HST, 29% had a normal PSG and 71% had OSA (43 mild, 19 moderate, 17 severe). Individuals younger than 50 years old with a normal HST were more likely to have a normal PSG. Older age predicted diagnosis of OSA on PSG among individuals with a TI HST. Conclusion: In this retrospective analysis of a clinical sample, when the HST is interpreted as normal in a younger patient population, the subsequent PSG is likewise normal in majority of the patients, although significant OSA is sometimes discovered. When a HST is read as TI, the majority of patients have OSA. C1 [Zeidler, Michelle R.; Santiago, Silverio] VA Greater Los Angeles Healthcare Syst, Pulm Crit Care & Sleep Med, Los Angeles, CA USA. [Zeidler, Michelle R.; Dzierzewski, Joseph M.; Martin, Jennifer L.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Santiago, Vicente] VA Cent Calif Healthcare Syst, Fresno, CA USA. [Santiago, Vicente] Univ Calif San Francisco, Fresno Med Educ Program, San Francisco, CA 94143 USA. [Dzierzewski, Joseph M.; Mitchell, Michael N.; Martin, Jennifer L.] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. RP Zeidler, MR (reprint author), UCLA Med Ctr, West Los Angeles VA, Pulm & Crit Care, 10833 Le Conte Ave,CHS 37-131, Los Angeles, CA 90095 USA. EM mzeidler@mednet.ucla.edu FU VA Greater Los Angeles Healthcare System Sleep Medicine Fellowship Program; VA Rehabilitation Research and Development [1RX000135-01]; VA Greater Los Angeles Healthcare System Geriatric Research, Education and Clinical Center; UCLA Claude Pepper Older Americans Independence Center [5P30AG028748]; NIH/NCATS UCLA [CTSI UL1TR000124]; Research Service of the VA Greater Los Angeles Healthcare System; Equinox Fitness FX This was not an industry supported study. Supported by: VA Greater Los Angeles Healthcare System Sleep Medicine Fellowship Program, VA Rehabilitation Research and Development 1RX000135-01 (Martin) the VA Greater Los Angeles Healthcare System Geriatric Research, Education and Clinical Center, UCLA Claude Pepper Older Americans Independence Center 5P30AG028748 (Dzierzewski) and NIH/NCATS UCLA CTSI UL1TR000124 (Dzierzewski), and Research Service of the VA Greater Los Angeles Healthcare System. Dr. Martin has received research support from Equinox Fitness. The other author have indicated no financial conflicts of interest. NR 14 TC 1 Z9 1 U1 2 U2 2 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 1550-9389 EI 1550-9397 J9 J CLIN SLEEP MED JI J. Clin. Sleep Med. PY 2015 VL 11 IS 11 BP 1313 EP 1318 DI 10.5664/jcsm.5194 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA DA1UM UT WOS:000367581000010 PM 26156951 ER PT J AU Watson, NF Morgenthaler, T Chervin, R Carden, K Kirsch, D Kristo, D Malhotra, R Martin, J Ramar, K Rosen, I Weaver, T Wise, M AF Watson, Nathaniel F. Morgenthaler, Timothy Chervin, Ronald Carden, Kelly Kirsch, Douglas Kristo, David Malhotra, Raman Martin, Jennifer Ramar, Kannan Rosen, Ilene Weaver, Terri Wise, Merrill CA Amer Acad Sleep Med Board TI Confronting Drowsy Driving: The American Academy of Sleep Medicine Perspective SO JOURNAL OF CLINICAL SLEEP MEDICINE LA English DT Article DE drowsy driving; sleep deprivation; undiagnosed; sleep disorders AB Drowsy driving is a serious public health concern which is often difficult for individual drivers to identify. While it is important for drivers to understand the causes of drowsy driving, there is still insufficient scientific knowledge and public education to prevent drowsy driving. As a result, the AASM is calling upon institutions and policy makers to increase public awareness and improve education on the issue, so our society can better recognize and prevent drowsy driving. The AASM has adopted a position statement to educate both healthcare providers and the general public about drowsy driving risks and countermeasures. C1 [Watson, Nathaniel F.] Univ Washington, Sleep Disorders Ctr, Seattle, WA 98195 USA. [Morgenthaler, Timothy] Mayo Clin, Mayo Ctr Sleep Med, Rochester, MN USA. [Chervin, Ronald] Univ Michigan, Sleep Disorders Ctr, Ann Arbor, MI 48109 USA. [Carden, Kelly] St Thomas Sleep Specialists, Nashville, TN USA. [Kirsch, Douglas] Carolinas Healthcare Med Grp Sleep Serv, Charlotte, NC USA. [Kristo, David] Univ Pittsburgh, Pittsburgh, PA USA. [Malhotra, Raman] SLUCare Sleep Disorders Ctr, St Louis, MO USA. [Malhotra, Raman] St Louis Univ, Dept Neurol, St Louis, MO 63103 USA. [Martin, Jennifer] Vet Affairs Greater Los Angeles Hlth Syst, North Hills, CA USA. [Ramar, Kannan] Mayo Clin, Div Pulm Sleep Crit Care, Rochester, MN USA. [Rosen, Ilene] Penn Sleep Ctr, Philadelphia, PA USA. [Rosen, Ilene] Ctr Sleep, Philadelphia, PA USA. [Weaver, Terri] Univ Illinois, Coll Nursing, Chicago, IL USA. [Wise, Merrill] Methodist Healthcare Sleep Disorders Ctr, Memphis, TN USA. RP Watson, NF (reprint author), 2510 N Frontage Rd, Darien, IL 60561 USA. EM research@aasmnet.org FU Tera, Inc.; Jazz FX This was not an industry supported study. Dr. Chervin is on the advisory board of the not-for-profit SweetDreamzzz. Dr. Weaver has received research support form Tera, Inc., and Jazz. The other authors have indicated no financial conflicts of interest. NR 5 TC 2 Z9 2 U1 1 U2 2 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 1550-9389 EI 1550-9397 J9 J CLIN SLEEP MED JI J. Clin. Sleep Med. PY 2015 VL 11 IS 11 BP 1335 EP 1336 DI 10.5664/jcsm.5200 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA DA1UM UT WOS:000367581000013 ER PT J AU Sher, L AF Sher, Leo TI PARENTAL ALIENATION AND SUICIDE IN MEN SO PSYCHIATRIA DANUBINA LA English DT Article ID ADULT CHILDREN C1 [Sher, Leo] James J Peters Vet Adm Med Ctr, New York, NY USA. [Sher, Leo] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. RP Sher, L (reprint author), James J Peters Vet Adm Med Ctr, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM Leo.Sher@mssm.edu NR 10 TC 1 Z9 1 U1 1 U2 10 PU MEDICINSKA NAKLADA PI ZAGREB PA VLASKA 69, HR-10000 ZAGREB, CROATIA SN 0353-5053 J9 PSYCHIAT DANUB JI Psychiatr. Danub. PY 2015 VL 27 IS 3 BP 288 EP 289 PG 2 WC Psychiatry SC Psychiatry GA DA1WM UT WOS:000367586300013 PM 26400140 ER PT S AU Ben-Ari, A Hammond, K AF Ben-Ari, Alon Hammond, Kenric BE Bui, TX Sprague, RH TI Text Mining the EMR for Modeling and Predicting Suicidal Behavior Among US Veterans of the 1991 Persian Gulf War SO 2015 48TH HAWAII INTERNATIONAL CONFERENCE ON SYSTEM SCIENCES (HICSS) SE Proceedings of the Annual Hawaii International Conference on System Sciences LA English DT Proceedings Paper CT 48th Annual Hawaii International Conference on System Sciences (HICSS) CY JAN 05-08, 2015 CL Kauai, HI SP IEEE Comp Soc, Univ Hawaii, Shidler Coll Business, Univ Hawaii, Dept EE, Univ Hawaii, Informat Sci Program, ONR, AFOSR, Natl Sci Fdn, IEEE Syst Sci & Cybernet Soc, ACM, SIAM, IEEE Hawaii Sect, IEEE Control Syst Soc, IEEE Grp Informat Theory, IEEE Grp Automat Control, ARO, Reg Med Program Hawaii, Univ Hawaii, Coll Business Adm, Nasdaq ID EXTRACTION; RISK AB Suicide is an important public health problem and prominent among U.S. veterans and active duty troops. Prediction of suicide and suicide attempts is problematic because these are low-frequency events and traditional clinical screening approaches have a high false positive rate. Large clinical databases extracted from electronic health records permit study of suicidal behavior in larger populations than previously possible using sampling techniques. In addition to offering structured data, text search and classification methods can identify additional risk variables. Data extracted from clinical records of 250,000 veterans were modeled using machine learning methodology. To predict suicide attempts in this population over a 10 year period. In contrast to previously reported models, our results showed high specificity and a false positive rate of 0.5%, contrasting with other studies showing false positive rates exceeding 20%. The model showed lower specificity with a true positive rate of 27% and a false negative rate of 73%. These results suggest that a machine learning approach developed with large data sets can usefully supplement current approaches to prediction of suicidal behavior. C1 [Ben-Ari, Alon; Hammond, Kenric] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Ben-Ari, A (reprint author), Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. EM alon.benari@gmail.com; khammond@uw.edu NR 15 TC 0 Z9 0 U1 2 U2 5 PU IEEE COMPUTER SOC PI LOS ALAMITOS PA 10662 LOS VAQUEROS CIRCLE, PO BOX 3014, LOS ALAMITOS, CA 90720-1264 USA SN 1060-3425 BN 978-1-4799-7367-5 J9 P ANN HICSS PY 2015 BP 3168 EP U2073 DI 10.1109/HICSS.2015.382 PG 11 WC Computer Science, Information Systems; Computer Science, Theory & Methods; Operations Research & Management Science SC Computer Science; Operations Research & Management Science GA BE0LK UT WOS:000366264103034 ER PT S AU Jarvenpaa, SL Lanham, HJ AF Jarvenpaa, Sirkka L. Lanham, Holly J. BE Bui, TX Sprague, RH TI Introduction to the Inter-Organizational Collaborative Dynamics and Role of Information Technology Minitrack SO 2015 48TH HAWAII INTERNATIONAL CONFERENCE ON SYSTEM SCIENCES (HICSS) SE Proceedings of the Annual Hawaii International Conference on System Sciences LA English DT Proceedings Paper CT 48th Annual Hawaii International Conference on System Sciences (HICSS) CY JAN 05-08, 2015 CL Kauai, HI SP IEEE Comp Soc, Univ Hawaii, Shidler Coll Business, Univ Hawaii, Dept EE, Univ Hawaii, Informat Sci Program, ONR, AFOSR, Natl Sci Fdn, IEEE Syst Sci & Cybernet Soc, ACM, SIAM, IEEE Hawaii Sect, IEEE Control Syst Soc, IEEE Grp Informat Theory, IEEE Grp Automat Control, ARO, Reg Med Program Hawaii, Univ Hawaii, Coll Business Adm, Nasdaq C1 [Jarvenpaa, Sirkka L.] Univ Texas Austin, McCombs Sch Business, Austin, TX 78712 USA. [Lanham, Holly J.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX USA. [Lanham, Holly J.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Jarvenpaa, SL (reprint author), Univ Texas Austin, McCombs Sch Business, Austin, TX 78712 USA. EM sirkka.jarvenpaa@mccombs.utexas.edu; lanham@uthscsa.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU IEEE COMPUTER SOC PI LOS ALAMITOS PA 10662 LOS VAQUEROS CIRCLE, PO BOX 3014, LOS ALAMITOS, CA 90720-1264 USA SN 1060-3425 BN 978-1-4799-7367-5 J9 P ANN HICSS PY 2015 BP 4355 EP 4355 DI 10.1109/HICSS.2015.521 PG 1 WC Computer Science, Information Systems; Computer Science, Theory & Methods; Operations Research & Management Science SC Computer Science; Operations Research & Management Science GA BE0LK UT WOS:000366264104058 ER PT J AU Skogseth, RE Bronnick, K Pereira, JB Mollenhauer, B Weintraub, D Fladby, T Aarsland, D AF Skogseth, Ragnhild E. Bronnick, Kolbjorn Pereira, Joana B. Mollenhauer, Brit Weintraub, Daniel Fladby, Tormod Aarsland, Dag TI Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease SO JOURNAL OF PARKINSONS DISEASE LA English DT Article DE Parkinson disease; cerebrospinal fluid; Mild cognitive impairment; alpha-synuclein; amyloid beta-peptides; tau Proteins ID CSF AMYLOID-BETA; ALPHA-SYNUCLEIN; ALZHEIMERS-DISEASE; DEMENTIA; IMPAIRMENT; PROGRESSION; DECLINE; TAU; COHORT; RISK AB Background: Mild cognitive impairment and dementia are common, clinically important features of Parkinson's disease (PD). The underlying disease pathology is heterogeneous and not yet well characterized. Biomarkers for cognitive impairment in PD could aid in diagnostic and prognostic evaluation and in the development of new cognitive enhancing treatments. Objective: To examine the relationship between CSF markers and cognition in a large, multicenter, cohort study of early, untreated PD, and compare marker concentrations between PD patients with and without MCI and healthy, age-matched controls. Methods: 414 early, untreated PD (34% with mild cognitive impairment) and 189 healthy, cognitively intact controls with baseline neuropsychological testing and CSF abeta42, t-tau, p-tau181 and alpha-synuclein results were included. Multiple linear regression models were constructed with a composite cognition factor, or memory-, or visuospatial- or executive-attention domains as dependent variables, and CSF markers, demographic characteristics and MDS-UPDRS III score as predictors. Results: Lower alpha-synuclein was associated with reduced performance on the executive-attention domain and the composite cognition factor in the whole PD-group. Abeta42 was significantly decreased in PD with mild cognitive impairment compared with controls after adjusting for covariates, while values in PD without MCI were identical to healthy controls. Conclusions: The association between reduced CSF alpha-synuclein concentrations and cognition suggests that alpha-synuclein pathology contributes to early cognitive impairment in PD, in particular to executive-attentional dysfunction. Longitudinal analyses are needed to determine if this and other CSF biomarkers in early Parkinson's disease are associated with the risk of future cognitive decline and dementia. C1 [Skogseth, Ragnhild E.] Haraldsplass Deaconess Hosp, Kavli Res Ctr Geriatr & Dementia, N-5892 Bergen, Norway. [Skogseth, Ragnhild E.] Univ Bergen, Dept Clin Med, N-5020 Bergen, Norway. [Bronnick, Kolbjorn] Stavanger Univ Hosp, TIPS Reg Ctr Clin Res Psychosis, Stavanger, Norway. [Bronnick, Kolbjorn] Univ Stavanger, Fac Social Sci, Stavanger, Norway. [Pereira, Joana B.] Karolinska Inst H1, Dept Neurobiol Care Sci & Soc, Div Clin Geriatr, Huddinge, Sweden. [Mollenhauer, Brit] Univ Med Ctr Gottingen, Paracelsus Elena Klin, Gottingen, Germany. [Mollenhauer, Brit] Univ Med Ctr Gottingen, Dept Neuropathol, Gottingen, Germany. [Weintraub, Daniel] Univ Penn, Perelman Sch Med, Dept Psychiat & Neurol, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Fladby, Tormod] Akershus Univ Hosp, Dept Neurol, Lorenskog, Norway. [Fladby, Tormod] Univ Oslo, Inst Clin Med, N-0316 Oslo, Norway. [Aarsland, Dag] Karolinska Inst H1, Ctr Alzheimers Dis Res, Dept Neurobiol Care Sci & Soc, Div Neurogeriatr, Huddinge, Sweden. [Aarsland, Dag] Stavanger Univ Hosp, Dept Psychiat, Ctr Age Related Med, Stavanger, Norway. RP Skogseth, RE (reprint author), Haraldsplass Deaconess Hosp, Postboks 6165 Postterminal, N-5892 Bergen, Norway. EM ragnhild.skogseth@gmail.com OI Aarsland, Dag/0000-0001-6314-216X FU Swedish non-governmental and industry independent sources; Alzheimerfonden; Stiftelsen for alderssjukdomar; Loo och Hans Ostermans stiftelse; Lindhes Advokatbyra AB; TEVA-Pharma; BMBF; EU; Deutsche Parkinson Vereinigung; Michael J. Fox Foundation for Parkinson's Research; Stifterverband fur die deutsche Wissenschaft; Teva Pharmaceuticals; Novartis Pharmaceuticals; NINDS [P50 NS053488, R01NS065087]; NIA [RO1AG031348]; University of Pennsylvania; Lundbeck Inc.; Novartis; GE Healthcare; GlaxoSmithKline; Merck Serono FX Dr. Skogseth reports no disclosures. Dr. Bronnick reports no disclosures. Dr. Pereira has received a Marie Curie Intra-European Fellowship and project grants from Swedish non-governmental and industry independent sources; Alzheimerfonden, Stiftelsen for alderssjukdomar, Loo och Hans Ostermans stiftelse and Lindhes Advokatbyra AB. Dr. Mollenhauer is member of the executive steering committee of the Parkinson Progression Marker Initiative of the Michael J. Fox Foundation for Parkinson's Research. She has received independent research grants from TEVA-Pharma, and honoraria for consultancy from GE Healthcare, Roche, AbbVie, TEVA-Pharma, for presentations from GlaxoSmithKline, Orion Pharma, TEVA-Pharma and travel costs from TEVA-Pharma. She has received grants from the BMBF, EU, Deutsche Parkinson Vereinigung, Michael J. Fox Foundation for Parkinson's Research, Stifterverband fur die deutsche Wissenschaft, and has scientific collaborations with Roche, Ely Lilly, Covance/BioLegend and Biogen Idec. Dr. Weintraub is part of the scientific advisory boards: Commercial - Pfizer, CHDI, Teva Pharmaceuticals, Avanir Pharmaceuticals, Merck, Eli Lilly and Company, Biogen, Lundbeck Inc. He is part of the Editorial Board of Movement Disorders Journal and receives: Funding for Travel or Speaker Honoraria: Commercial - Teva Pharmaceuticals; Research Support, Commercial Entities: Novartis Pharmaceuticals, PI, 2011-; Research Support from Government Entities: NINDS, P50 NS053488, Investigator, 2007- NINDS, R01NS065087, Investigator, 2009- NIA, RO1AG031348, Investigator, 2008-; Research Support, Foundations and Societies: Michael J. Fox Foundation for Parkinson's Research, PI, 2009- 2011, Michael J. Fox Foundation for Parkinson's Research, PI, 2011- Michael J. Fox Foundation for Parkinson's Research, Investigator, 2011-; License Fee Payments, Technology or Inventions: Licensing fees from the University of Pennsylvania for licensing of Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease.; Dr. Fladby reports no disclosures. Dr. Aarsland serves on scientific advisory boards for Lundbeck Inc. and Merck Serono; has received funding for travel and speaker honoraria from Lundbeck Inc., Novartis, GE Healthcare, and GlaxoSmithKline; serves on the editorial boards of International Psychogeriatrics, Movement Disorders, and the Journal of Neurology, Neurosurgery, and Psychiatry; and receives research support from Lundbeck Inc. and Merck Serono. NR 26 TC 5 Z9 5 U1 2 U2 5 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1877-7171 EI 1877-718X J9 J PARKINSON DIS JI J. Parkinsons Dis. PY 2015 VL 5 IS 4 BP 783 EP 792 DI 10.3233/JPD-150682 PG 10 WC Neurosciences SC Neurosciences & Neurology GA CZ7VL UT WOS:000367308200011 PM 26599300 ER PT J AU Borwankar, AU Willsey, BW Twu, A Hung, JJ Stover, RJ Wang, TYW Feldman, MD Milner, TE Truskett, TM Johnston, KP AF Borwankar, Ameya U. Willsey, Brian W. Twu, April Hung, Jessica J. Stover, Robert J. Wang, Tianyi W. Feldman, Marc D. Milner, Thomas E. Truskett, Thomas M. Johnston, Keith P. TI Gold nanoparticles with high densities of small protuberances on nanocluster cores with strong NIR extinction SO RSC ADVANCES LA English DT Article ID RAMAN-SCATTERING SERS; ONE-STEP SYNTHESIS; BIODEGRADABLE PLASMONIC NANOCLUSTERS; COLLOIDAL GOLD; OPTICAL-PROPERTIES; LIGHT-ABSORPTION; SHAPE EVOLUTION; PARTICLE-SIZE; NANOSTARS; CLUSTERS AB Plasmonic nanoparticles with sizes well below 100 nm and high near infrared ( NIR) extinction are of great interest in biomedical imaging. Herein we present similar to 60 nm Au nanoparticles with high NIR absorbance at wavelengths ranging from 700 nm to 1100 nm, which were synthesized under kinetic control. A high surface density of protuberances is grown on similar to 30 nm nanocluster cores, which are composed of similar to 10 nm primary particles. The high NIR extinction is produced by a combination of the close proximity of the primary particles in the cores, the high surface density of protuberances, and the high aspect ratio of the length of the protuberances to the diameter of the primary particles. When the Au precursor was reduced more slowly at a higher pH of 9.3, the growth was thermodynamically controlled and the nanocluster cores relaxed to spheres. This concept of self-assembly during reaction to change the morphology of nanoclusters and decorated nanoclusters, may be expected to be applicable to a wide variety of systems by balancing kinetic and thermodynamic control, along with the colloidal interactions. C1 [Borwankar, Ameya U.; Willsey, Brian W.; Twu, April; Hung, Jessica J.; Stover, Robert J.; Truskett, Thomas M.; Johnston, Keith P.] Univ Texas Austin, McKetta Dept Chem Engn, Austin, TX 78712 USA. [Wang, Tianyi W.; Milner, Thomas E.] Univ Texas Austin, Dept Biomed Engn, Austin, TX 78712 USA. [Feldman, Marc D.] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Feldman, Marc D.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Cardiol, San Antonio, TX 78229 USA. RP Johnston, KP (reprint author), Univ Texas Austin, McKetta Dept Chem Engn, Austin, TX 78712 USA. EM kpj@che.utexas.edu RI Truskett, Thomas/D-4624-2009 OI Truskett, Thomas/0000-0002-6607-6468 FU Welch Foundation [F-1319, F-1696]; NSF [CBET-0968038]; INSPIRE [1247945]; Veterans Hospital Administration Merit Grant FX This work is supported in part by the Welch Foundation (F-1319 (KPJ), F-1696 (TMT)), NSF CBET-0968038, INSPIRE 1247945 and the Veterans Hospital Administration Merit Grant. We would like to thank Dr Dwight Romanowicz from the Institute of Cellular and Molecular biology and Dr Shouliang Zhang from the Center for Nanomaterials both at the University of Texas for their assistance with the electron microscopy. NR 89 TC 1 Z9 1 U1 2 U2 11 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 2046-2069 J9 RSC ADV JI RSC Adv. PY 2015 VL 5 IS 127 BP 104674 EP 104687 DI 10.1039/c5ra21712a PG 14 WC Chemistry, Multidisciplinary SC Chemistry GA CZ1KY UT WOS:000366865900008 ER PT J AU Vaid, M Singh, T Prasad, R Kappes, JC Katiyar, SK AF Vaid, Mudit Singh, Tripti Prasad, Ram Kappes, John C. Katiyar, Santosh K. TI Therapeutic intervention of proanthocyanidins on the migration capacity of melanoma cells is mediated through PGE(2) receptors and beta-catenin signaling molecules SO AMERICAN JOURNAL OF CANCER RESEARCH LA English DT Article DE Grape seed proanthocyanidins; melanoma; cell migration; prostaglandin E-2; PGE(2) receptors; beta-catenin; bioluminescence imaging; metastasis ID IN-VIVO; CUTANEOUS MELANOMA; COLORECTAL-CANCER; LUNG-CANCER; MOUSE SKIN; EXPRESSION; PHOTOCARCINOGENESIS; CARCINOGENESIS; ACTIVATION; MUTATIONS AB Melanoma is a highly aggressive form of skin cancer and a leading cause of death from skin diseases mainly due to its propensity to metastasis. Due to metastatic tendency, melanoma is often associated with activation of Wnt/beta-catenin signaling mechanism. Blocking beta-catenin activation may be a good strategy to block melanoma-associated mortality. We have shown earlier that grape seed proanthocyanidins (GSPs) inhibit melanoma cell migration via targeting cyclooxygenase-2 (COX-2) overexpression. Here we explored further whether inhibition of inflammatory mediators-mediated activation of beta-catenin by GSPs is associated with the inhibition of melanoma cell migration. Our study revealed that PGE(2) receptors (EP2 and EP4) agonists promote melanoma cell migration while PGE(2) receptor antagonist suppressed the migration capacity of melanoma cells. GSPs treatment inhibit butaprost (EP2 agonist) or Cay10580 (EP4 agonist) induced migration of melanoma cells. Western blot analysis revealed that GSPs reduced cellular accumulation of beta-catenin, and decreased the expressions of matrix metalloproteinase (MMP)-2, MMP-9 and MITF, downstream targets of beta-catenin in melanoma cells. GSPs also reduced the protein expressions of PI3K and p-Akt in the same set of experiment. To verify that beta-catenin is a specific molecular target of GSPs, we compared the effect of GSPs on cell migration of beta-catenin-activated (Mel1241) and beta-catenin-inactivated (Mel1011) melanoma cells. GSPs inhibit cell migration of Mel1241 cells but not of Mel1011 cells. Additionally, in vi bioluminescence imaging data indicate that dietary administration of GSPs (0.5%, w/w) in supplementation with AIN76A control diet inhibited the migration/extravasation of intravenously injected melanoma cells in lungs of immune-compromised nude mice, and that this effect of GSPs was associated with an inhibitory effect on the activation of beta-catenin and its downstream targets, such as MMPs, in lungs as a target organ. C1 [Vaid, Mudit; Singh, Tripti; Prasad, Ram; Katiyar, Santosh K.] Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA. [Kappes, John C.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Kappes, John C.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA. [Kappes, John C.; Katiyar, Santosh K.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA. [Singh, Tripti; Prasad, Ram; Kappes, John C.; Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35233 USA. RP Katiyar, SK (reprint author), Univ Alabama Birmingham, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557, Birmingham, AL 35294 USA. EM skatiyar@uab.edu FU National Institutes of Health (NIH) [CA166883]; Veterans Administration Merit Review Award [1I01BX001410]; Virology and Genetic Sequencing cores of the UAB Center for AIDS Research (CFAR) [P30AI-27767] FX This work was supported by grants from the National Institutes of Health (NIH, CA166883) and the Veterans Administration Merit Review Award (1I01BX001410) to S. K. K. This research also used the facilities supported by of the Virology and Genetic Sequencing cores of the UAB Center for AIDS Research (CFAR), P30AI- 27767. The funding agencies had no roles in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 37 TC 2 Z9 2 U1 1 U2 1 PU E-CENTURY PUBLISHING CORP PI MADISON PA 40 WHITE OAKS LN, MADISON, WI 53711 USA SN 2156-6976 J9 AM J CANCER RES JI Am. J. Cancer Res. PY 2015 VL 5 IS 11 BP 3325 EP 3338 PG 14 WC Oncology SC Oncology GA CY8ZX UT WOS:000366698300005 PM 26807314 ER PT J AU Johansen, KL AF Johansen, Kirsten L. TI The Frail Dialysis Population: A Growing Burden for the Dialysis Community SO BLOOD PURIFICATION LA English DT Article; Proceedings Paper CT 60th Annual Meeting of the Japanese-Society-for-Dialysis-Therapy CY JUN, 2015 CL Yokohama, JAPAN SP Japanese Soc Dialysis Therapy DE Frailty; Dialysis; End-stage renal disease ID STAGE RENAL-DISEASE; CHRONIC KIDNEY-DISEASE; PHYSICAL-ACTIVITY; HEMODIALYSIS-PATIENTS; BODY-COMPOSITION; MAINTENANCE HEMODIALYSIS; AMBULATORY PATIENTS; ASSOCIATION; MORTALITY; SURVIVAL AB Background: The dialysis population is aging worldwide. It is well known that patients on dialysis have limited functional status, but only recently has frailty been considered. Summary: The prevalence of frailty among patients on dialysis ranges from 3.4-to 10-fold higher than among community- dwelling elderly, depending on the method of assessing frailty and patient characteristics. Despite its high prevalence and the high overall mortality in the dialysis population, frailty is associated with higher mortality, independent of clinical and demographic characteristics and comorbidity. The prevalence of frailty among patients with nondialysis- dependent chronic kidney disease (CKD) is also high, and cross-sectional data suggest that the prevalence may increase as CKD progresses. Thus, interventions to improve frailty have the potential to improve quality of life and mortality. Although interventions to improve physical dysfunction have been successful in the population with end-stage renal disease, no studies have specifically targeted frail individuals. Therefore, the extent to which exercise or physical activity interventions are feasible among frail patients and can improve frailty urgently needs to be examined. In the meantime, providers should refer frail patients to physical therapists and encourage them to be more active if possible. In addition, more attention should be focused on the possibility that rehabilitation among patients with earlier stages of CKD could improve dialysis outcomes. Key Messages: Frailty is extremely common among patients on dialysis and is independently associated with adverse outcomes. Providers should take advantage of available resources to improve functioning in this population, and research should address the optimal strategy for addressing frailty, including timing of intervention. (C) 2015 S. Karger AG, Basel C1 [Johansen, Kirsten L.] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA. [Johansen, Kirsten L.] San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA USA. RP Johansen, KL (reprint author), 111J San Francisco VA Med Ctr, Nephrol Sect, 4150 Clement St, San Francisco, CA 94127 USA. EM kirsten.johansen@ucsf.edu NR 34 TC 3 Z9 3 U1 0 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0253-5068 EI 1421-9735 J9 BLOOD PURIFICAT JI Blood Purif. PY 2015 VL 40 IS 4 BP 288 EP 292 DI 10.1159/000441575 PG 5 WC Hematology; Urology & Nephrology SC Hematology; Urology & Nephrology GA CY9NX UT WOS:000366734700004 PM 26656296 ER PT J AU Minzenberg, MJ Lesh, T Niendam, T Yoon, JH Cheng, YA Rhoades, RN Carter, CS AF Minzenberg, Michael J. Lesh, Tyler Niendam, Tara Yoon, Jong H. Cheng, Yaoan Rhoades, Remy N. Carter, Cameron S. TI Frontal Motor Cortex Activity During Reactive Control Is Associated With Past Suicidal Behavior in Recent-Onset Schizophrenia SO CRISIS-THE JOURNAL OF CRISIS INTERVENTION AND SUICIDE PREVENTION LA English DT Article DE suicide; schizophrenia; fMRI; cognitive control; prefrontal cortex ID DORSOLATERAL PREFRONTAL CORTEX; POSITRON-EMISSION-TOMOGRAPHY; 1ST EPISODE PSYCHOSIS; COGNITIVE-CONTROL; NEURAL MECHANISMS; CEREBRAL-CORTEX; PREMOTOR AREAS; BRAIN ACTIVITY; DYSFUNCTION; CONFLICT AB Background: Suicide is prevalent in schizophrenia (SZ), yet the neural system functions that confer suicide risk remain obscure. Circuits operated by the prefrontal cortex (PFC) are altered in SZ, including those that support reactive control, and PFC changes are observed in postmortem studies of heterogeneous suicide victims. Aims: We tested whether history of suicide attempt is associated with altered frontal motor cortex activity during reactive control processes. Method: We evaluated 17 patients with recent onset of DSM-IV-TR-defined SZ using the Columbia Suicide Severity Rating Scale and functional magnetic resonance imaging during Stroop task performance. Group-level regression models relating pas suicidal behavior to frontal activation controlled for depression, psychosis, and impulsivity. Results: Past suicidal behavior was associated with relatively higher activation in the left-hemisphere supplementary motor area (SMA), pre-SMA, premotor cortex, and dorsolateral PFC, all ipsilateral to the active primary motor cortex. Conclusion: This study provides unique evidence that suicidal behavior in patients with recent-onset SZ directly relates to frontal motor cortex activity during reactive control, in a pattern reciprocal to the relationship with proactive control found previously. Further work should address how frontal-based control functions change with risk over time, and their potential utility as a biomarker for interventions to mitigate suicide risk in SZ. C1 [Minzenberg, Michael J.; Cheng, Yaoan] Univ Calif San Francisco, Sch Med, Dept Psychiat, San Francisco, CA 94143 USA. [Lesh, Tyler; Niendam, Tara; Carter, Cameron S.] Univ Calif Davis, Sch Med, Dept Psychiat, Sacramento, CA 95817 USA. [Carter, Cameron S.] Univ Calif Davis, Ctr Neurosci, Davis, CA 95616 USA. [Yoon, Jong H.; Rhoades, Remy N.] Stanford Sch Med, Dept Psychiat, Palo Alto, CA USA. RP Minzenberg, MJ (reprint author), San Francisco VA Med Ctr, Outpatient Mental Hlth, 116C,4150 Clement St, San Francisco, CA 94121 USA. EM michael.minzenberg@ucsf.edu FU American Foundation for Suicide Prevention; Doris Duke Charitable Foundation [2009045]; [MH059883] FX This work was supported by an American Foundation for Suicide Prevention Young Investigator Award and the Doris Duke Charitable Foundation Grant # 2009045, both to MJM, and MH059883 to CSC. The authors have no disclosures to declare. NR 54 TC 1 Z9 1 U1 1 U2 7 PU HOGREFE & HUBER PUBLISHERS PI GOTTINGEN PA MERKELSTR 3, D-37085 GOTTINGEN, GERMANY SN 0227-5910 EI 2151-2396 J9 CRISIS JI Crisis PY 2015 VL 36 IS 5 BP 363 EP 370 DI 10.1027/0227-5910/a000335 PG 8 WC Psychiatry; Psychology, Multidisciplinary SC Psychiatry; Psychology GA CY2EI UT WOS:000366221200009 PM 26502787 ER PT J AU Kayman, DJ Goldstein, MF Dixon, L Goodman, M AF Kayman, Deborah J. Goldstein, Marjorie F. Dixon, Lisa Goodman, Marianne TI Perspectives of Suicidal Veterans on Safety Planning Findings From a Pilot Study SO CRISIS-THE JOURNAL OF CRISIS INTERVENTION AND SUICIDE PREVENTION LA English DT Article DE suicide; prevention; safety plan; veterans; mobile mental health ID RANDOMIZED CONTROLLED-TRIAL; EMERGENCY-DEPARTMENT; BRIEF INTERVENTION; COGNITIVE THERAPY; SELF-HARM; FOLLOW-UP; RISK; PREVENTION; MILITARY; RATIONALE AB Aims: Individual interviews were conducted and analyzed to learn about the engagement of suicidal veterans in safety planning. Method: Twenty suicidal veterans who had recently constructed safety plans were recruited at two VA hospitals. In semistructured interviews, they discussed how they felt about constructing and using the plan and suggested changes in plan content and format that might increase engagement. Results: The veterans' experiences varied widely, from reviewing plans often and noting symptom improvement to not using them at all and doubting that they would think of doing so when deeply depressed. Conclusion: The veterans suggested ways to enrich safety planning encounters and identified barriers to plan use. Their ideas were specific and practical. Safety planning was most meaningful and helpful to them when they experienced the clinician as a partner in exploring their concerns (e.g., fear of discussing and attending to warning signs) and collaborating with them to devise solutions. C1 [Kayman, Deborah J.; Dixon, Lisa; Goodman, Marianne] James J Peters Med Ctr, Dept Vet Affairs, Bronx, NY 10468 USA. [Goldstein, Marjorie F.] Natl Dev & Res Inst Inc NDRI, New York, NY USA. [Dixon, Lisa] Columbia Univ, Med Ctr, New York, NY USA. [Dixon, Lisa] New York State Psychiat Inst & Hosp, New York, NY 10032 USA. [Goodman, Marianne] Mt Sinai Hosp, Icahn Sch Med, New York, NY 10029 USA. RP Kayman, DJ (reprint author), James J Peters Med Ctr, Dept Vet Affairs, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM deborah.kayman@va.gov FU Department of Defense [W81XWH-09-1-0722]; Medical Research Service of the Department of Veterans Affairs, James J. Peters Medical Center; Department of Veterans Affairs, Veterans Integrated Service Network 3, Mental Illness Research Education and Clinical Center (MIRECC) FX This work was supported by the Department of Defense #W81XWH-09-1-0722 (M. Goodman, Principal Investigator), the Medical Research Service of the Department of Veterans Affairs, James J. Peters Medical Center, and the Department of Veterans Affairs, Veterans Integrated Service Network 3, Mental Illness Research Education and Clinical Center (MIRECC). NR 35 TC 0 Z9 0 U1 1 U2 7 PU HOGREFE & HUBER PUBLISHERS PI GOTTINGEN PA MERKELSTR 3, D-37085 GOTTINGEN, GERMANY SN 0227-5910 EI 2151-2396 J9 CRISIS JI Crisis PY 2015 VL 36 IS 5 BP 371 EP 383 DI 10.1027/0227-5910/a000348 PG 13 WC Psychiatry; Psychology, Multidisciplinary SC Psychiatry; Psychology GA CY2EI UT WOS:000366221200010 PM 26502788 ER PT J AU Auger, RR Burgess, HJ Emens, JS Deriy, LV Sharkey, KM AF Auger, R. Robert Burgess, Helen J. Emens, Jonathan S. Deriy, Ludmila V. Sharkey, Katherine M. TI Do Evidence-Based Treatments for Circadian Rhythm Sleep-Wake Disorders Make the GRADE? Updated Guidelines Point to Need for More Clinical Research SO JOURNAL OF CLINICAL SLEEP MEDICINE LA English DT Editorial Material ID PHASE SYNDROME; MELATONIN C1 [Auger, R. Robert] Mayo Ctr Sleep Med, Rochester, MN 55905 USA. [Burgess, Helen J.] Rush Univ, Med Ctr, Chicago, IL 60612 USA. [Emens, Jonathan S.] Portland VA Med Ctr, Portland, OR USA. [Deriy, Ludmila V.] Amer Acad Sleep Med, Darien, IL USA. [Sharkey, Katherine M.] Brown Univ, Providence, RI 02912 USA. RP Auger, RR (reprint author), Mayo Ctr Sleep Med, Rochester, MN 55905 USA. EM research@aasmnet.org NR 12 TC 1 Z9 1 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 1550-9389 EI 1550-9397 J9 J CLIN SLEEP MED JI J. Clin. Sleep Med. PY 2015 VL 11 IS 10 BP 1079 EP 1080 AR PII jc-00354-15 DI 10.5664/jcsm.5072 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA CY3FO UT WOS:000366294100002 PM 26414984 ER PT J AU Casey, KR Teodorescu, M AF Casey, Kenneth R. Teodorescu, Mihai TI Postoperative Complications in Patients with Obstructive Sleep Apnea: Where Do We Stand? SO JOURNAL OF CLINICAL SLEEP MEDICINE LA English DT Editorial Material ID POSITIVE AIRWAY PRESSURE; CONTROLLED-TRIAL; OUTCOMES; SURGERY; METAANALYSIS; COHORT; IMPACT C1 [Casey, Kenneth R.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. Wisconsin Sleep, Madison, WI USA. Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA. RP Casey, KR (reprint author), William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace, Madison, WI 53705 USA. EM krcasey@msn.com NR 10 TC 1 Z9 1 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 1550-9389 EI 1550-9397 J9 J CLIN SLEEP MED JI J. Clin. Sleep Med. PY 2015 VL 11 IS 10 BP 1081 EP 1082 AR PII jc-00396-15 DI 10.5664/jcsm.5074 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA CY3FO UT WOS:000366294100003 PM 26414991 ER PT J AU Auger, RR Burgess, HJ Emens, JS Deriy, LV Thomas, SM Sharkey, KM AF Auger, R. Robert Burgess, Helen J. Emens, Jonathan S. Deriy, Ludmila V. Thomas, Sherene M. Sharkey, Katherine M. TI Clinical Practice Guideline for the Treatment of Intrinsic Circadian Rhythm Sleep-Wake Disorders: Advanced Sleep-Wake Phase Disorder (ASWPD), Delayed Sleep-Wake Phase Disorder (DSWPD), Non-24-Hour Sleep-Wake Rhythm Disorder (N24SWD), and Irregular Sleep-Wake Rhythm Disorder (ISWRD). An Update for 2015 SO JOURNAL OF CLINICAL SLEEP MEDICINE LA English DT Article DE circadian rhythms; DSWPD; ASWPD; N24SWD; ISWRD ID BRIGHT-LIGHT TREATMENT; PLACEBO-CONTROLLED TRIAL; NURSING-HOME RESIDENTS; RUNNING BLIND PEOPLE; ENRICHED POLYCHROMATIC-LIGHT; CONTROLLED-RELEASE MELATONIN; RANDOMIZED CONTROLLED-TRIAL; REST-ACTIVITY DISRUPTION; SHORT-WAVELENGTH LIGHT; ALZHEIMERS-DISEASE AB A systematic literature review and meta-analyses (where appropriate) were performed and the GRADE approach was used to update the previous American Academy of Sleep Medicine Practice Parameters on the treatment of intrinsic circadian rhythm sleep-wake disorders. Available data allowed for positive endorsement (at a second-tier degree of confidence) of strategically timed melatonin (for the treatment of DSWPD, blind adults with N24SWD, and children/adolescents with ISWRD and comorbid neurological disorders), and light therapy with or without accompanying behavioral interventions (adults with ASWPD, children/adolescents with DSWPD, and elderly with dementia). Recommendations against the use of melatonin and discrete sleep-promoting medications are provided for demented elderly patients, at a second-and first-tier degree of confidence, respectively. No recommendations were provided for remaining treatments/populations, due to either insufficient or absent data. Areas where further research is needed are discussed. C1 [Auger, R. Robert] Mayo Ctr Sleep Med, Rochester, MN 55905 USA. [Burgess, Helen J.] Rush Univ, Med Ctr, Chicago, IL 60612 USA. [Emens, Jonathan S.] Portland VA Med Ctr, Portland, OR USA. [Deriy, Ludmila V.; Thomas, Sherene M.] Amer Acad Sleep Med, Darien, IL USA. [Sharkey, Katherine M.] Brown Univ, Providence, RI 02912 USA. RP Auger, RR (reprint author), Mayo Ctr Sleep Med, Rochester, MN 55905 USA. EM research@aasmnet.org FU American Academy of Sleep Medicine FX The authors acknowledge Dr. Ilene Rosen for serving as a board liaison for this project and assuring that the guideline adhered to the standards set forth by the Board of Directors of American Academy of Sleep Medicine. The authors also acknowledge the contributions of the following individuals: Christine Stepanski, MS, for performing literature searches #1 and #2; and Michelle M. Tangredi, PhD, for managing the project at the initial steps. The authors are grateful to the organizations and individuals who provided their insights and suggestions during the public comment period. Every comment was internally documented and addressed, and decisions regarding corresponding amendments in the text were left to the TF's discretion. The project was funded by the American Academy of Sleep Medicine. NR 198 TC 19 Z9 19 U1 6 U2 20 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 1550-9389 EI 1550-9397 J9 J CLIN SLEEP MED JI J. Clin. Sleep Med. PY 2015 VL 11 IS 10 BP 1199 EP 1236 AR PII jc-00358-15 DI 10.5664/jcsm.5100 PG 38 WC Clinical Neurology SC Neurosciences & Neurology GA CY3FO UT WOS:000366294100016 PM 26414986 ER PT J AU Soni, A Aspinall, SL Zhao, XH Good, CB Cunningham, FE Chatta, G Passero, V Smith, KJ AF Soni, Amy Aspinall, Sherrie L. Zhao, Xinhua Good, Chester B. Cunningham, Francesca E. Chatta, Gurkamal Passero, Vida Smith, Kenneth J. TI Cost-Effectiveness Analysis of Adjuvant Stage III Colon Cancer Treatment at Veterans Affairs Medical Centers SO ONCOLOGY RESEARCH LA English DT Article DE Colon cancer; 5-Fluorouracil (5-FU); Capecitabine; Oxaliplatin; Cost-effectiveness ID X-ACT TRIAL; COLORECTAL-CANCER; NSABP C-07; OXALIPLATIN; CAPECITABINE; FLUOROURACIL; LEUCOVORIN; SURVIVAL; CHEMOTHERAPY; 5-FLUOROURACIL/LEUCOVORIN AB The objective of this study was to evaluate the real-world cost effectiveness of adjuvant stage III colon cancer chemotherapy regimens, given that previous analyses have been based on data from clinical trials. The study was designed using integrated decision tree and Markov model, which was developed to evaluate the cost effectiveness of 5-fluorouracil/leucovorin (5-FU/LV), capecitabine, and the combination of each with oxaliplatin. The analysis was performed from a US Veterans Affairs perspective via retrospectively collected data, over a 5-year model time horizon. Outcome and cost data were used to calculate cost per quality adjusted life year (QALY), and one-way and probabilistic sensitivity analyses were performed. In the base case analysis, capecitabine and capecitabine plus oxaliplatin both cost more and were less effective than other regimens, and 5-FU/LV plus oxaliplatin, compared to 5-FU/LV alone, resulted in a cost of $25,997 per QALY gained. Model results were generally robust to parameter variation. Capecitabine plus oxaliplatin could be economically reasonable if full dosing occurred 3 76% of the time (base case 42%). In a real-world setting, the addition of oxaliplatin to 5-FU/LV is more effective but also more costly than 5-FU/LV alone. If full dosing of capecitabine-containing regimens can be assured, they may also be cost-effective strategies. C1 [Soni, Amy] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA. [Aspinall, Sherrie L.; Good, Chester B.; Cunningham, Francesca E.] VA Pharm Benefits Management Serv, Hines, IL USA. [Aspinall, Sherrie L.; Zhao, Xinhua; Good, Chester B.] VA Pittsburgh Healthcare Syst, VA Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Aspinall, Sherrie L.; Good, Chester B.] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA. [Good, Chester B.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Chatta, Gurkamal] Virginia Mason Med Ctr, Seattle, WA 98101 USA. [Passero, Vida] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Smith, Kenneth J.] Univ Pittsburgh, Div Clin Modeling & Decis Sci, Pittsburgh, PA USA. RP Soni, A (reprint author), Palo Alto Med Fdn, Sunnyvale Ctr, 301 Old San Francisco Rd,Level 1, Sunnyvale, CA 94086 USA. EM soniac@sutterhealth.org FU VA Pharmacy Benefits Management Services, Hines, IL, USA; VA Pittsburgh Healthcare System, Pittsburgh, PA, USA; VA medical centers FX The views expressed in this article are those of the authors, and no official endorsement by the Department of Veteran Affairs or the United States Government is intended or should be inferred. There was no funding support for the work. These findings are the result of work supported in kind by VA Pharmacy Benefits Management Services, Hines, IL, USA, VA Pittsburgh Healthcare System, Pittsburgh, PA, USA, and the other VA medical centers that participated in the study. None of the authors has a relevant financial interest in this manuscript. The VA Oncology Pharmacotherapy Research Group includes Bernadette B. Heron, Pharm.D. (VA Pharmacy Benefits Management Services, Hines, IL, USA); Mark Geraci, Pharm.D. (VA Pharmacy Benefits Management Services, Hines, IL, USA); Roslyn A. Stone, Ph.D. (VA Pittsburgh Healthcare System, Pittsburgh, PA, USA; University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA); Renee Rogers, Pharm.D. (VA Pittsburgh Healthcare System, Pittsburgh, PA, USA); Jenna Shields, Pharm.D. (VA Pittsburgh Healthcare System, Pittsburgh, PA, USA); Megan Sartore, Pharm.D. (VA Pittsburgh Healthcare System, Pittsburgh, PA, USA); D. Patrick Boyle, RPh (VA Maine Health Care System, Augusta, ME, USA); Sherry Giberti, CTR (VA Maine Health Care System, Augusta, ME, USA); John Szymanski, Pharm.D. (VA Connecticut Healthcare System, West Haven, CT, USA); Doug Smith, Pharm.D. (Martinsburg VA Medical Center, Martinsburg, WV, USA); Allen Ha, Pharm.D. (Richmond VA Medical Center, Richmond, VA, USA); Jolynn Sessions, Pharm.D. (Asheville VA Medical Center, Asheville, NC, USA); Shawn Depcinski, Pharm.D. (James A. Haley Veterans Hospital, Tampa, FL, USA); Shane Fishco, Pharm.D. (James A. Haley Veterans Hospital, Tampa, FL, USA); Irvin Molina, Pharm.D. (Miami VA Medical Center, Miami, FL, USA); Tanja Lepir, Pharm.D. (Miami VA Medical Center, Miami, FL, USA); Carmela Jean, Pharm.D. (Miami VA Medical Center, Miami, FL, USA); Lymaris Cruz-Diaz, Pharm.D. (VA Caribbean Healthcare System, San Juan, PR, USA); Jessica Motta, Pharm.D. (VA Caribbean Healthcare System, San Juan, PR, USA); Rebeca Calderon-Vargas, Pharm.D. (VA Caribbean Healthcare System, San Juan, PR, USA); Janelle Maland, Pharm.D. (Harry S. Truman VA Hospital, Columbia, MO, USA); Sean Keefe, Pharm.D. (Kansas City VA Medical Center, Kansas City, MO, USA); Marshall Tague, Pharm.D. (Iowa City VA Medical Center, Iowa City, IA, USA); Alice Leone, R. Ph. (Louis Stokes Cleveland VA Medical Center, Cleveland, OH, USA); Brian Glovack, Pharm.D. (Jesse Brown VA Medical Center, Chicago, IL, USA); Blair Kaplan, Pharm.D. (Jesse Brown VA Medical Center, Chicago, IL, USA); Sean Cosgriff, Pharm.D. (Portland VA Medical Center, Portland, OR, USA); Lindsay Kaster, Pharm.D. (Boise VA Medical Center, Boise, ID, USA); Ivy Tonnu-Mihara, Pharm.D. Long Beach VA Medical Center, Long Beach, CA, USA); Kimmai Nguyen, Pharm.D. (Long Beach VA Medical Center, Long Beach, CA, USA); Jenna Carmichael, Pharm.D. (VA Sierra Nevada Health Care System, Reno, NV, USA); and Kan Lu, Pharm.D. (Sacramento VA Medical Center, Mather, CA, USA). NR 31 TC 0 Z9 0 U1 0 U2 0 PU COGNIZANT COMMUNICATION CORP PI PUTNAM VALLEY PA 18 PEEKSKILL HOLLOW RD, PO BOX 37, PUTNAM VALLEY, NY 10579 USA SN 0965-0407 EI 1555-3906 J9 ONCOL RES JI Oncol. Res. PY 2015 VL 22 IS 5-6 BP 311 EP 319 DI 10.3727/096504015X14424348426152 PG 9 WC Oncology SC Oncology GA CY1UB UT WOS:000366192300009 ER PT S AU Chen, YB Yuan, KY McDonald, J AF Chen, Yabing Yuan, Kaiyu McDonald, Jay BE Bonavida, B Chouaib, S TI Pancreatic Cancer Resistance to TRAIL Therapy: Regulators of the Death Inducing Signaling Complex SO RESISTANCE OF CANCER CELLS TO CTL-MEDIATED IMMUNOTHERAPY SE Resistance to Targeted Anti-Cancer Therapeutics LA English DT Article; Book Chapter DE Pancreatic cancer; TRAIL; Resistance; Apoptosis; Death receptor; Death-inducing signaling complex ID TUMOR-NECROSIS-FACTOR; HISTONE DEACETYLASE INHIBITORS; AGONISTIC MONOCLONAL-ANTIBODY; RECEPTOR-MEDIATED APOPTOSIS; LIGAND-INDUCED APOPTOSIS; X-LINKED INHIBITOR; CELL LUNG-CANCER; METASTATIC COLORECTAL-CANCER; ADVANCED SOLID MALIGNANCIES; SMALL-MOLECULE ANTAGONISTS AB Pancreatic cancer is the fourth leading cause of cancer deaths in the United States. It is generally a fatal cancer with poor prognosis. Once pancreatic cancer becomes metastatic, it is uniformly fatal with an overall average survival of typically 6 months. The only potentially curative therapy for pancreatic cancer is surgical resection. Unfortunately, the majority of pancreatic cancer patients have advanced and inoperable disease at the time of diagnosis. Studies from our group and others have supported that modulating tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis provides potential novel avenues for cancer therapy. However, resistance of pancreatic cancer to TRAIL therapy remains a large clinical hurdle. Thus, better understanding of the molecular events regulating pancreatic cancer cell apoptosis would facilitate the development of novel strategies to enhance the efficacy of TRAIL therapy. Dysregulation of apoptosis of tumor cells plays an important role in the pancreatic cancer pathogenesis and their resistance to therapies. We and others have demonstrated that the formation of death receptor-activated death-inducing signaling complex (DISC) and the recruitment of DISC components determine both the downstream apoptotic and survival signaling pathways. We have identified several components in the death receptor-activated DISC that mediate death receptor-induced survival pathways, including FLIP and three new DISC components, calmodulin (CaM), Src and poly(ADP-ribose) polymerase (PARP-1), which contribute to the resistance of cancer cells to death receptor-activated apoptosis. This review discusses the roles of TRAIL death receptors and the molecular regulators in the DISC that contribute to the resistance to TRAIL-induced apoptosis. The specific apoptotic regulators as potential therapeutic targets for TRAIL-resistant pancreatic cancers are emphasized, including death receptor 5 (DR5), FLIP, CaM, Src and PARP-1. C1 [Chen, Yabing; Yuan, Kaiyu; McDonald, Jay] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA. [Chen, Yabing; McDonald, Jay] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA. RP Chen, YB (reprint author), Univ Alabama Birmingham, Dept Pathol, 614 Shelby Biomed Res Bldg,1825 Univ Blvd, Birmingham, AL 35294 USA. EM ybchen@uab.edu NR 226 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER INT PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 2196-5501 BN 978-3-319-17807-3; 978-3-319-17806-6 J9 RESIST TARGET ANTI-C PY 2015 VL 7 BP 235 EP 265 DI 10.1007/978-3-319-17807-3_11 D2 10.1007/978-3-319-17807-3 PG 31 WC Oncology; Pharmacology & Pharmacy SC Oncology; Pharmacology & Pharmacy GA BE0FJ UT WOS:000365951300012 ER PT J AU Tang, WHW Dupont, M Hernandez, AF Voors, AA Hsu, AP Felker, GM Butler, J Metra, M Anker, SD Troughton, RW Gottlieb, SS McMurray, JJ Armstrong, PW Massie, BM Califf, RM O'Connor, CM Starling, RC AF Tang, W. H. Wilson Dupont, Matthias Hernandez, Adrian F. Voors, Adriaan A. Hsu, Amy P. Felker, G. Michael Butler, Javed Metra, Marco Anker, Stefan D. Troughton, Richard W. Gottlieb, Stephen S. McMurray, John J. Armstrong, Paul W. Massie, Barry M. Califf, Robert M. O'Connor, Christopher M. Starling, Randall C. TI Comparative Assessment of Short-Term Adverse Events in Acute Heart Failure With Cystatin C and Other Estimates of Renal Function: Results From the ASCEND-HF Trial SO JACC-HEART FAILURE LA English DT Article DE acute heart failure; cystatin C; nesiritide; renal insufficiency ID GLOMERULAR-FILTRATION-RATE; ACUTE KIDNEY INJURY; CARDIORENAL SYNDROME; CREATININE EQUATION; SERUM CREATININE; NT-PROBNP; RISK; NESIRITIDE; MARKERS; IMPACT AB OBJECTIVES The purpose of this study was to investigate the predictive values of baseline and changes in cystatin C (CysC) and its derived equations for short-term adverse outcomes and the effect of nesiritide therapy on CysC in acute decompensated heart failure (ADHF). BACKGROUND Newer renal. biomarkers or their derived estimates of renal function have demonstrated tong-term prognostic value in chronic heart failure. METHODS CysC levels were measured in sequential plasma samples from 811 subjects with ADHF who were enrolled in the ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) biomarker sub-study (randomized to nesiritide therapy vs. placebo), and followed for all-cause death (180 days) and recurrent hospital stay (30 days). RESULTS Median CysC levels were 1.49 (interquartile range [IQR]: 1.20 to 1.96) mg/l at baseline, 1.56 (IQR: 1.28 to 2.13) mg/l. at 48 to 72 h, and 1.58 (IQR: 1.24 to 2.11) mg/l. at 30 days. Higher baseline (but not follow-up) CysC levels were associated with increased risk of 30-day adverse events and less improvement in dyspnea after 24 h as welt as 180-day mortality, although not incremental to blood urea nitrogen. Worsening renal function (defined as a 0.3 mg/l increase in CysC) occurred in 161 of 701 (23%) patients, but it was not predictive of adverse events. Changes in CysC levels were similar between the nesiritide and placebo groups. CONCLUSIONS Our findings confirmed the prognostic value of baseline CysC levels in the setting of ADHF. However, worsening renal, function based on CysC rise was not predictive of adverse events. Nesiritide did not worsen renal function compared with placebo. (C) 2015 by the American College of Cardiology Foundation. C1 [Tang, W. H. Wilson; Hsu, Amy P.; Starling, Randall C.] Cleveland Clin, Inst Heart & Vasc, Cleveland, OH 44195 USA. [Dupont, Matthias] Ziekenhuis Oost Limburg, Dept Cardiol, Genk, Belgium. [Hernandez, Adrian F.; Felker, G. Michael; Califf, Robert M.; O'Connor, Christopher M.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA. [Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands. [Butler, Javed] SUNY Stony Brook, Div Cardiovasc, Stony Brook, NY 11794 USA. [Metra, Marco] Univ Brescia, Dept Cardiol, Brescia, Italy. [Anker, Stefan D.] Univ Med Ctr Gottingen, Dept Innovat Clin Trials, Gottingen, Germany. [Troughton, Richard W.] Univ Otago, Dept Cardiol, Christchurch, New Zealand. [Gottlieb, Stephen S.] Univ Maryland, Dept Cardiol, Baltimore, MD 21201 USA. [McMurray, John J.] Univ Glasgow, Dept Cardiol, Glasgow, Lanark, Scotland. [Armstrong, Paul W.] Univ Alberta, Dept Cardiol, Edmonton, AB, Canada. [Massie, Barry M.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. RP Tang, WHW (reprint author), Cleveland Clin, 950 Euclid Ave,Desk J3-4, Cleveland, OH 44195 USA. EM tangw@ccf.org RI Hernandez, Adrian F./A-7818-2016 OI Hernandez, Adrian F./0000-0003-3387-9616; Metra, Marco/0000-0001-6691-8568; mcmurray, john/0000-0002-6317-3975 FU Janssen Pharmaceuticals, Inc.; Johnson Johnson; Roche Diagnostics; Critical Diagnostics; BG Medicine; Ortho Biotech FX The ASCEND-HF biomarker substudy is funded by Johnson & Johnson (now Janssen Pharmaceuticals, Inc.). Dr. Felker has received research grants from Johnson & Johnson, Roche Diagnostics, Critical Diagnostics, and BG Medicine. Dr. Hernandez has received a research grant from Johnson & Johnson. Drs. Gottlieb, Voors, Butler, and Massie are consultants to and on the advisory board of Johnson & Johnson. Dr. Metra is a consultant to and on the advisory board of Corthera, Daiichi, Novartis, and Servier. Dr. Anker has received honoraria from, is a consultant to, and is on the advisory board of Alere Inc., Europe, ThermoFisher Scientific, and Vifor Pharma. Dr. Troughton is a consultant to and on the advisory board of St. Jude Medical. Drs. McMurray, Califf, and O'Connor have received research grants from Johnson & Johnson. Dr. Armstrong has received research grants from Johnson & Johnson and Ortho Biotech. Dr. Starling has received other research support, is a consultant to, and on the advisory board of Johnson & Johnson. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. John R. Teerlink, MD, served as Guest Editor for this paper. NR 28 TC 10 Z9 10 U1 0 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-1779 EI 2213-1787 J9 JACC-HEART FAIL JI JACC-Heart Fail. PD JAN PY 2015 VL 3 IS 1 BP 40 EP 49 DI 10.1016/j.jchf.2014.06.014 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CX4DV UT WOS:000365649700006 PM 25453534 ER PT J AU Kholia, S Jorfi, S Thompson, PR Causey, CP Nicholas, AP Inal, JM Lange, S AF Kholia, Sharad Jorfi, Samireh Thompson, Paul R. Causey, Corey P. Nicholas, Anthony P. Inal, Jameel M. Lange, Sigrun TI A novel role for peptidylarginine deiminases in microvesicle release reveals therapeutic potential of PAD inhibition in sensitizing prostate cancer cells to chemotherapy SO JOURNAL OF EXTRACELLULAR VESICLES LA English DT Article DE peptidylarginine deiminases; chloramidine; microvesicles; microvesiculation; prostate cancer cells (PC3) ID NUCLEOSIDE DIPHOSPHATE KINASE; RHEUMATOID-ARTHRITIS; IN-VITRO; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; CIRCULATING MICROPARTICLES; PLATELET MICROPARTICLES; MEMBRANE MICROPARTICLES; CITRULLINATED EPITOPES; ARGININE METHYLATION; HISTONE DEIMINATION AB Introduction: Protein deimination, defined as the post-translational conversion of protein-bound arginine to citrulline, is carried out by a family of 5 calcium-dependent enzymes, the peptidylarginine deiminases (PADs) and has been linked to various cancers. Cellular microvesicle (MV) release, which is involved in cancer progression, and deimination have not been associated before. We hypothesize that elevated PAD expression, observed in cancers, causes increased MV release in cancer cells and contributes to cancer progression. Background: We have previously reported that inhibition of MV release sensitizes cancer cells to chemotherapeutic drugs. PAD2 and PAD4, the isozymes expressed in patients with malignant tumours, can be inhibited with the pan-PAD-inhibitor chloramidine (Cl-am). We sought to investigate whether Cl-am can inhibit MV release and whether this pathway could be utilized to further increase the sensitivity of cancer cells to drug-directed treatment. Methods: Prostate cancer cells (PC3) were induced to release high levels of MVs upon BzATP stimulation of P2X(7) receptors. Western blotting with the pan-protein deimination antibody F95 was used to detect a range of deiminated proteins in cells stimulated to microvesiculate. Changes in deiminated proteins during microvesiculation were revealed by immunoprecipitation and immunoblotting, and mass spectrometry identified deiminated target proteins with putative roles in microvesiculation. Conclusion: We report for the first time a novel function of PADs in the biogenesis of MVs in cancer cells. Our results reveal that during the stimulation of prostate cancer cells (PC3) to microvesiculate, PAD2 and PAD4 expression levels and the deimination of cytoskeletal actin are increased. Pharmacological inhibition of PAD enzyme activity using Cl-am significantly reduced MV release and abrogated the deimination of cytoskeletal actin. We demonstrated that combined Cl-am and methotrexate (MTX) treatment of prostate cancer cells increased the cytotoxic effect of MTX synergistically. Refined PAD inhibitors may form part of a novel combination therapy in cancer treatment. C1 [Kholia, Sharad; Jorfi, Samireh; Inal, Jameel M.] London Metropolitan Univ, Sch Human Sci, Cellular & Mol Immunol Res Ctr, London N7 8DB, England. [Thompson, Paul R.] Scripps Res Inst, Dept Chem, Jupiter, FL USA. [Causey, Corey P.] Univ N Florida, Dept Chem, Jacksonville, FL USA. [Nicholas, Anthony P.] Univ Alabama Birmingham, Dept Neurol, Birmingham, VA USA. [Nicholas, Anthony P.] Birmingham VA Med Ctr, Birmingham, AL USA. [Lange, Sigrun] UCL, Sch Pharm, London WC1N 1AX, England. RP Inal, JM (reprint author), London Metropolitan Univ, Sch Hlth Sci, Cellular & Mol Immunol Res Ctr, 166-220 Holloway Rd, London N7 8DB, England. EM j.inal@londonmet.ac.uk; sigrun.lange@ucl.ac.uk RI Inal, Jameel/G-2995-2010 OI Inal, Jameel/0000-0002-7200-0363 FU NCI NIH HHS [P30 CA013148]; NIGMS NIH HHS [R01 GM079357] NR 78 TC 5 Z9 5 U1 2 U2 5 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 2001-3078 J9 J EXTRACELL VESICLES JI J. Extracell. Vesicles PY 2015 VL 4 AR UNSP 26192 DI 10.3402/jev.v4.26192 PG 16 WC Cell Biology SC Cell Biology GA CW5YP UT WOS:000365073500001 PM 26095379 ER PT B AU McQuaid, JR AF McQuaid, John R. BE Mohlman, J Deckersbach, T Weissman, AS TI TREATMENT OF PHANTOM LIMB PAIN Application of Neuroscience to a Disorder of Neuroplasticity SO From Symptom to Synapse: A Neurocognitive Perspective on Clinical Psychology LA English DT Article; Book Chapter ID MIRROR THERAPY; MOTOR CORTEX; CASE SERIES; AMPUTEES; AMPUTATION; REORGANIZATION; MOVEMENTS; REPRESENTATIONS; PLASTICITY C1 UCSF, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. RP McQuaid, JR (reprint author), UCSF, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. NR 55 TC 0 Z9 0 U1 2 U2 9 PU ROUTLEDGE PI ABINGDON PA 2 PARK SQ, MILTON PARK, ABINGDON OX14 4RN, OXFORD, ENGLAND BN 978-0-415-83587-9; 978-0-203-50713-1; 978-0-415-83586-2 PY 2015 BP 303 EP 322 PG 20 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA BD8YC UT WOS:000364454700011 ER PT J AU Daveler, B Salatin, B Grindle, GG Candiotti, J Wang, HW Cooper, RA AF Daveler, Brandon Salatin, Benjamin Grindle, Garrett G. Candiotti, Jorge Wang, Hongwu Cooper, Rory A. TI Participatory design and validation of mobility enhancement robotic wheelchair SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE barriers; design; electric powered wheelchair; mobility; mobility enhancement; movement; robotics; traction control; transportation; wheelchair ID PERSONAL MOBILITY; MANIPULATION; ISSUES; INJURIES; BARRIERS; ADULTS; TRENDS; USERS AB The design of the mobility enhancement robotic wheelchair (MEBot) was based on input from electric powered wheelchair (EPW) users regarding the conditions they encounter when driving in both indoor and outdoor environments that may affect their safety and result in them becoming immobilized, tipping over, or falling out of their wheelchair. Phase I involved conducting a participatory design study to understand the conditions and barriers EPW users found to be difficult to drive in/over. Phase II consisted of creating a computer-aided design (CAD) prototype EPW to provide indoor and outdoor mobility that addressed these conditions with advanced applications. Phase III involved demonstrating the advanced applications and gathering feedback from end users about the likelihood they would use the advanced applications. The CAD prototype incorporated advanced applications, including self-leveling, curb climbing, and traction control, that addressed the challenging conditions and barriers discussed with EPW users (n = 31) during the participatory design study. Feedback on the CAD design and applications in phase III from end users (n = 12) showed a majority would use self-leveling (83%), traction control (83%), and curb climbing (75%). The overall design of MEBot received positive feedback from EPW users. However, these opinions will need to be reevaluated through user trials as the design advances. C1 [Daveler, Brandon; Grindle, Garrett G.; Candiotti, Jorge; Wang, Hongwu; Cooper, Rory A.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Daveler, Brandon; Grindle, Garrett G.; Candiotti, Jorge; Wang, Hongwu; Cooper, Rory A.] Dept Vet Affairs VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA. [Salatin, Benjamin] Hunter Holmes McGuire VA Med Ctr, Dept Phys Med & Rehabil Assist Technol, Richmond, VA USA. RP Cooper, RA (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, 6425 Penn Ave,Suite 400, Pittsburgh, PA 15206 USA. EM rcooper@pitt.edu FU Department of Veterans Affairs Rehabilitation Research and Development Center of Excellence [B9250-C]; National Science Foundation Interdisciplinary Research Training in Rehabilitation Engineering [DGE1144584]; National Science Foundation Quality of Life Engineering Research Center [EEC0540865] FX This material was based on work supported by the Department of Veterans Affairs Rehabilitation Research and Development Center of Excellence (grant B9250-C), and the National Science Foundation Interdisciplinary Research Training in Rehabilitation Engineering (grant DGE1144584), and the National Science Foundation Quality of Life Engineering Research Center (grant EEC0540865). NR 28 TC 1 Z9 1 U1 3 U2 6 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 EI 1938-1352 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2015 VL 52 IS 6 BP 739 EP 750 DI 10.1682/JRRD.2014.11.0278 PG 12 WC Rehabilitation SC Rehabilitation GA CV8BM UT WOS:000364501500010 PM 26562492 ER PT B AU Korsten, MA Ancha, HR Kaminski, M AF Korsten, Mark A. Ancha, Hanumantha R. Kaminski, Miriam BE Sands, BE TI Approach to Constipation SO Mount Sinai Expert Guides: Gastroenterology LA English DT Article; Book Chapter ID NORTH-AMERICA; TRIAL C1 [Korsten, Mark A.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [Korsten, Mark A.] James J Peters VA Med Ctr, Gastroenterol, Bronx, NY USA. [Ancha, Hanumantha R.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA. [Kaminski, Miriam] Tech Univ Munich, Klinikum Rechts Isar, Dept Neurol, D-80290 Munich, Germany. RP Korsten, MA (reprint author), Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. NR 10 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, WEST SUSSEX, ENGLAND BN 978-1-118-93275-9; 978-1-118-51996-7 PY 2015 BP 45 EP 55 PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA BD6ZK UT WOS:000362779400007 ER PT J AU Delgado, C Shieh, S Grimes, B Chertow, GM Dalrymple, LS Kaysen, GA Kornak, J Johansen, KL AF Delgado, Cynthia Shieh, Stephanie Grimes, Barbara Chertow, Glenn M. Dalrymple, Lorien S. Kaysen, George A. Kornak, John Johansen, Kirsten L. TI Association of Self-Reported Frailty with Falls and Fractures among Patients New to Dialysis SO AMERICAN JOURNAL OF NEPHROLOGY LA English DT Article DE Fracture; Frailty; Hemodialysis ID STAGE RENAL-DISEASE; HEMODIALYSIS-PATIENTS; HIP FRACTURE; ELDERLY PERSONS; INCREASED RISK; MORTALITY; OLDER; MORBIDITY; INJURIES; COMMUNITY AB Background: Although frailty has been linked to higher risk of falls and fracture in the general population, only few studies have examined the extent to which frailty is associated with these outcomes among patients with end-stage renal disease, who are at particularly high risk for these events. Methods: A total of 1,646 patients who were beginning maintenance hemodialysis in 297 dialysis units throughout the United States from September 2005 to June 2007 were enrolled in the Comprehensive Dialysis Study, and 1,053 Medicare beneficiaries were included in this study. Self-reported frailty was defined by the patients endorsing 2 or more of the following: poor physical functioning, exhaustion or low physical activity. Falls and fractures requiring medical attention were identified through Medicare claims data. We examined the association between frailty and the time to first fall or fracture using the Fine-Gray modification of Cox proportional hazards regression, adjusted for demographics, Quetelet's body mass index, diabetes mellitus, heart failure and atherosclerosis. Results: Seventy-seven percent of patients were frail by self-report. The median length of follow-up was 2.5 (1.0-3.9) years. Crude rates of first medically urgent falls or fractures were 66 and 126 per 1,000 personyears in non-frail and self-reported frail participants, respectively. After accounting for demographic factors, comorbidities and the competing risk of death, self-reported frailty was associated with a higher risk of falls or fractures requiring medical attention (hazards ratio 1.60, 95% CI 1.16-2.20). Conclusion: Participants reporting frailty experienced nearly twice the risk of medically urgent falls or fractures compared to those who did not report frailty. (C) 2015 S. Karger AG, Basel C1 [Delgado, Cynthia; Shieh, Stephanie; Johansen, Kirsten L.] Univ Calif San Francisco, Nephrol Sect, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Delgado, Cynthia; Shieh, Stephanie; Johansen, Kirsten L.] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA. [Grimes, Barbara; Kornak, John] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Chertow, Glenn M.] Stanford Univ, Div Nephrol, Sch Med, Stanford, CA 94305 USA. [Dalrymple, Lorien S.; Kaysen, George A.] Univ Calif Davis, Div Nephrol, Davis, CA 95616 USA. RP Delgado, C (reprint author), San Francisco Dept Vet Affairs, 4150 Clement St,Box 111J, San Francisco, CA 94121 USA. EM cynthia.delgado@ucsf.edu FU National Institutes of Health, National Institute of Diabetes, Digestive and Kidney Disease [N01-DK-7-0005, KD-7-5004]; Department of Veterans Affairs, Clinical Science Research and Development Program under Career Development [1IK2CX000527-01A2]; Department of Veterans Affairs; San Francisco Department of Veterans Affairs Medical Center; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [K23 DK093584]; [1K24DK085153] FX Supported by contract N01-DK-7-0005 and KD-7-5004 from the National Institutes of Health, National Institute of Diabetes, Digestive and Kidney Disease.; Dr. Delgado's work is supported by the Department of Veterans Affairs, Clinical Science Research and Development Program under Career Development Award 1IK2CX000527-01A2. Her contribution is the result of work supported with the resources and the use of facilities at the San Francisco VA Medical Center.; Dr. Shieh's work is supported by the Department of Veterans Affairs, she received fellowship funding support from the San Francisco Department of Veterans Affairs Medical Center. Her contribution is the result of work supported with the resources and the use of facilities at the San Francisco VA Medical Center.; Dr. Johansen is supported by 1K24DK085153 and Dr. Dalrymple is supported by K23 DK093584 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). NR 33 TC 5 Z9 5 U1 0 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0250-8095 EI 1421-9670 J9 AM J NEPHROL JI Am. J. Nephrol. PY 2015 VL 42 IS 2 BP 134 EP 140 DI 10.1159/000439000 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA CV0JU UT WOS:000363937800007 PM 26381744 ER PT J AU Dubner, L Wang, J Ho, L Ward, L Pasinetti, GM AF Dubner, Lauren Wang, Jun Ho, Lap Ward, Libby Pasinetti, Giulio M. TI Recommendations for Development of New Standardized Forms of Cocoa Breeds and Cocoa Extract Processing for the Prevention of Alzheimer's Disease: Role of Cocoa in Promotion of Cognitive Resilience and Healthy Brain Aging SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Review DE Amyloid; chocolate; diet therapy; Lavado; oligomerization; polyphenols; synapses ID PERFORMANCE LIQUID-CHROMATOGRAPHY; SEED POLYPHENOLIC EXTRACT; MOUSE MODEL; A-BETA; TRANSGENIC MICE; SYNAPTIC DYSFUNCTION; IMPROVES COGNITION; CONTROLLED-TRIAL; TG2576 MICE; RED WINE AB It is currently thought that the lackluster performance of translational paradigms in the prevention of age-related cognitive deteriorative disorders, such as Alzheimer's disease (AD), may be due to the inadequacy of the prevailing approach of targeting only a single mechanism. Age-related cognitive deterioration and certain neurodegenerative disorders, including AD, are characterized by complex relationships between interrelated biological phenotypes. Thus, alternative strategies that simultaneously target multiple underlying mechanisms may represent a more effective approach to prevention, which is a strategic priority of the National Alzheimer's Project Act and the National Institute on Aging. In this review article, we discuss recent strategies designed to clarify the mechanisms by which certain brain-bioavailable, bioactive polyphenols, in particular, flavan-3-ols also known as flavanols, which are highly represented in cocoa extracts, may beneficially influence cognitive deterioration, such as in AD, while promoting healthy brain aging. However, we note that key issues to improve consistency and reproducibility in the development of cocoa extracts as a potential future therapeutic agent requires a better understanding of the cocoa extract sources, their processing, and more standardized testing including brain bioavailability of bioactive metabolites and brain target engagement studies. The ultimate goal of this review is to provide recommendations for future developments of cocoa extracts as a therapeutic agent in AD. C1 [Dubner, Lauren; Wang, Jun; Ho, Lap; Ward, Libby; Pasinetti, Giulio M.] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. [Wang, Jun; Pasinetti, Giulio M.] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. RP Pasinetti, GM (reprint author), Mt Sinai Sch Med, Dept Neurol, 1 Gustave L Levy Pl,Box 1137, New York, NY 10029 USA. EM giulio.pasinetti@mssm.edu FU National Center for Complementary and Integrative Health (NCCIH) [P50 AT008661-01]; Office of Dietary Supplements (ODS) FX This publication was supported by Grant Number P50 AT008661-01, titled "Dietary Botanicals in the Preservation of Cognitive and Psychological Resilience," from the National Center for Complementary and Integrative Health (NCCIH) and the Office of Dietary Supplements (ODS). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NCCIH, ODS, or the National Institutes of Health. NR 67 TC 1 Z9 1 U1 6 U2 17 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2015 VL 48 IS 4 BP 879 EP 889 DI 10.3233/JAD-150536 PG 11 WC Neurosciences SC Neurosciences & Neurology GA CU9LZ UT WOS:000363867300001 PM 26402120 ER PT J AU Graff, JN Chamberlain, ED AF Graff, Julie N. Chamberlain, Erin D. TI Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy SO CORE EVIDENCE LA English DT Review DE prostate cancer; sipuleucel-T; efficacy; economic analysis ID QUALITY-OF-LIFE; PHASE-III TRIAL; CELLULAR IMMUNOTHERAPY; INCREASED SURVIVAL; DOUBLE-BLIND; MITOXANTRONE; DOCETAXEL; CHEMOTHERAPY; PREDNISONE; ENZALUTAMIDE AB Metastatic castration-resistant prostate cancer is the lethal form of cancer of the prostate. Five new agents that prolong survival in this group have emerged in the past 5 years, and sipuleucel-T is among them. Sipuleucel-T is the only immunotherapy shown to improve survival in prostate cancer. It is currently indicated in asymptomatic or mildly symptomatic patients, as it has never shown a direct cancer effect. This paper describes the process of creating the sipuleucel-T product from the manufacturing and patient aspects. It discusses the four placebo-controlled, randomized clinical trials (RCTs) of sipuleucel-T, focusing on survival and adverse events. There are three RCTs in metastatic castration-resistant prostate cancer, all of which showed improved overall survival without meaningful decreases in symptoms, tumor volumes, or prostate-specific antigen levels. One RCT in castration-sensitive, biochemically relapsed prostate cancer attempted to find a decrease in biochemical failure, but that endpoint was not reached. Adverse events in all four of these studies centered around cytokine release. This paper also reviews a Phase II study of sipuleucel-T given neoadjuvantly that speaks to its mechanism of action. Additionally, there is a registry study of sipuleucel-T that has been used to evaluate immunological parameters of the product in men. 80 years of age and men who had previously been treated with palliative radiation. Attempts to find early markers of response to sipuleucel-T are described. Further ongoing studies that explore the efficacy of sipuleucel-T in combination with immune checkpoint inhibitors and second-generation hormonal therapies that are summarized. Finally, the only published economic analysis of sipuleucel-T is discussed. C1 [Graff, Julie N.] Portland VA Med Ctr, Portland, OR 97239 USA. [Graff, Julie N.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA. [Chamberlain, Erin D.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. RP Graff, JN (reprint author), Portland VA Med Ctr, 3710 SW US Vet Hosp Rd,MC P3CHEMO, Portland, OR 97239 USA. EM graffj@ohsu.edu NR 43 TC 8 Z9 8 U1 1 U2 13 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1555-1741 EI 1555-175X J9 CORE EVID JI Core Evid. PY 2015 VL 10 BP 1 EP 10 DI 10.2147/CE.S54712 PG 10 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA CU6RT UT WOS:000363661600001 PM 25565923 ER PT J AU Lee, BH Lim, TH Yoon, YW Yenari, MA Jeong, Y AF Lee, Bae Hwan Lim, Tae-Hong Yoon, Young Wook Yenari, Midori A. Jeong, Yong TI Postinjury Neuroplasticity in Central Neural Networks SO NEURAL PLASTICITY LA English DT Editorial Material C1 [Lee, Bae Hwan] Yonsei Univ, Dept Physiol, Coll Med, Brain Korea PLUS Project Med Sci 21, Seoul 120752, South Korea. [Lim, Tae-Hong] Univ Iowa, Dept Biomed Engn, Coll Engn, Seamans Ctr Engn Arts & Sci, Iowa City, IA 52242 USA. [Yoon, Young Wook] Korea Univ, Dept Physiol, Coll Med, Seoul 136705, South Korea. [Yenari, Midori A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA. [Yenari, Midori A.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Jeong, Yong] Korea Adv Inst Sci & Technol, Dept Bio & Brain Engn, Daejeon 305701, South Korea. RP Lee, BH (reprint author), Yonsei Univ, Dept Physiol, Coll Med, Brain Korea PLUS Project Med Sci 21, Seoul 120752, South Korea. EM bhlee@yuhs.ac RI Jeong, Yong/C-1677-2011 OI Jeong, Yong/0000-0002-5907-3787; Lee, Bae H./0000-0003-4719-9021 NR 0 TC 0 Z9 0 U1 0 U2 0 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 2090-5904 EI 1687-5443 J9 NEURAL PLAST JI Neural. Plast. PY 2015 AR 857085 DI 10.1155/2015/857085 PG 2 WC Neurosciences SC Neurosciences & Neurology GA CV3DP UT WOS:000364138900001 ER PT J AU Foraker, J Millard, SP Leong, L Thomson, Z Chen, S Keene, CD Bekris, LM Yu, CE AF Foraker, Jessica Millard, Steven P. Leong, Lesley Thomson, Zachary Chen, Sunny Keene, C. Dirk Bekris, Lynn M. Yu, Chang-En TI The APOE Gene is Differentially Methylated in Alzheimer's Disease SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; apolipoprotein E; CGI; CpG island; DMR; DNA methylation; epigenetics; pyrosequencing ID DNA METHYLATION; HUMAN BRAIN; GENOME; HYDROXYMETHYLATION; ALLELE; CELLS; ANK1; AGE AB The epsilon 4 allele of the human apolipoprotein E gene (APOE) is a well-proven genetic risk factor for the late onset form of Alzheimer's disease (AD). However, the biological mechanisms through which the epsilon 4 allele contributes to disease pathophysiology are incompletely understood. The three common alleles of APOE, epsilon 2, epsilon 3 and epsilon 4, are defined by two single nucleotide polymorphisms (SNPs) that reside in the coding region of exon 4, which overlaps with a well-defined CpG island (CGI). Both SNPs change not only the protein codon but also the quantity of CpG dinucleotides, primary sites for DNA methylation. Thus, we hypothesize that the presence of an epsilon 4 allele changes the DNA methylation landscape of the APOE CGI and that such epigenetic alteration contributes to AD susceptibility. To explore the relationship between APOE genotype, AD risk, and DNA methylation of the APOE CGI, we applied bisulfite pyrosequencing and evaluated methylation profiles of postmortem brain from 15 AD and 10 control subjects. We observed a tissue-specific decrease in DNA methylation with AD and identified two AD-specific differentially methylated regions (DMRs), which were also associated with APOE genotype. We further demonstrated that one DMR was completely un-methylated in a sub-population of genomes, possibly due to a subset of brain cells carrying deviated APOE methylation profiles. These data suggest that the APOE CGI is differentially methylated in AD brain in a tissue-and APOE-genotype-specific manner. Such epigenetic alteration might contribute to neural cell dysfunction in AD brain. C1 [Foraker, Jessica; Leong, Lesley; Thomson, Zachary; Chen, Sunny; Yu, Chang-En] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Millard, Steven P.] VA Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Foraker, Jessica; Yu, Chang-En] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA USA. [Keene, C. Dirk] Univ Washington, Dept Pathol, Neuropathol Div, Seattle, WA 98195 USA. [Bekris, Lynn M.] Cleveland Clin Fdn, Lerner Res Inst, Genom Med Inst, Cleveland, OH 44195 USA. RP Foraker, J (reprint author), VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, 1660S Columbian Way,Box 358280, Seattle, WA 98108 USA. EM jforaker@u.washington.edu RI Keene, Christopher/N-1806-2015 FU U.S. Department of Veterans Affairs Office of Research and Development Biomedical Laboratory Research Program; National Institute of Health/National Institute on Aging grants [P50 AG05136, T32 AG000258] FX This work was supported in part by the U.S. Department of Veterans Affairs Office of Research and Development Biomedical Laboratory Research Program and National Institute of Health/National Institute on Aging grants (P50 AG05136 and T32 AG000258). NR 33 TC 3 Z9 3 U1 3 U2 14 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2015 VL 48 IS 3 BP 745 EP 755 DI 10.3233/JAD-143060 PG 11 WC Neurosciences SC Neurosciences & Neurology GA CT6YE UT WOS:000362958800017 PM 26402071 ER PT J AU Raab, PA Mackintosh, MA Gros, DF Morland, LA AF Raab, Phillip A. Mackintosh, Margaret-Anne Gros, Daniel F. Morland, Leslie A. TI Impact of comorbid depression on quality of life in male combat Veterans with posttraumatic stress disorder SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE comorbidity; depression; major depressive disorder; MDD; negative affect; numbing; posttraumatic stress disorder; PTSD; quality of life; Veterans ID COGNITIVE PROCESSING THERAPY; ADMINISTERED PTSD SCALE; ANXIETY DISORDERS; MAJOR DEPRESSION; GULF-WAR; SYMPTOMS; HEALTH; IMPAIRMENT; MILITARY; EXPOSURE AB For Veterans with posttraumatic stress disorder (PTSD), depression is a highly comorbid condition. Both conditions have been associated with decreased quality of life, and research suggests that comorbid PTSD and depression may result in worse quality of life than PTSD alone. However, research is needed to elucidate the effect of comorbidity on a broader variety of quality of life domains. In this study, we used baseline data of 158 male combat Veterans taking part in a PTSD treatment trial and examined the unique relationships between quality of life domains and PTSD symptom clusters, major depressive disorder (MDD) diagnosis, and self-reported depressive symptoms. Veterans with comorbid PTSD-MDD reported significantly worse satisfaction-related quality of life than those with PTSD alone, although this finding was largely attributable to PTSD numbing symptoms. Subsequent analyses comparing the effect of numbing symptoms to depressive symptoms revealed that depression exerted a stronger influence, although numbing symptoms were still uniquely associated with quality of life. We discuss implications for treatment and research, as well as the need to address negative affect in Veterans with PTSD. C1 [Raab, Phillip A.; Mackintosh, Margaret-Anne; Morland, Leslie A.] Dept Vet Affairs VA Pacific Isl Hlth Care Syst, Natl Ctr Posttraumat Stress Disorder, Pacific Isl Div, Honolulu, HI USA. [Gros, Daniel F.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Gros, Daniel F.] Med Univ S Carolina, Charleston, SC 29425 USA. [Morland, Leslie A.] Univ Hawaii Manoa, John A Burns Sch Med, Honolulu, HI 96822 USA. RP Raab, PA (reprint author), Natl Ctr Posttraumat Stress Disorder, Pacific Isl Div, 3375 Koapaka St,Suite I-560, Honolulu, HI 96819 USA. EM drewraab@gmail.com FU VA Office of Research and Development, Health Services Research & Development Service [DHI 07-259]; Department of Defense, Congressionally Directed Medical Research Programs [PT074516]; VA National Center for PTSD FX This material was based on work supported in part by the VA Office of Research and Development, Health Services Research & Development Service (grant DHI 07-259) and the Department of Defense, Congressionally Directed Medical Research Programs (grant PT074516). Support was also provided by the VA National Center for PTSD and with resources and the use of facilities at Spark M. Matsunaga Medical Center, VA Pacific Islands Health Care System. NR 52 TC 3 Z9 3 U1 0 U2 0 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 EI 1938-1352 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2015 VL 52 IS 5 BP 563 EP 576 DI 10.1682/JRRD.2014.05.0130 PG 14 WC Rehabilitation SC Rehabilitation GA CT2HQ UT WOS:000362623000006 PM 26466310 ER PT J AU Dean, JC Kautz, SA AF Dean, Jesse C. Kautz, Steven A. TI Foot placement control and gait instability among people with stroke SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE balance; biomechanics; foot placement; frontal plane; kinematics; motor control; muscle activity; stability; stroke; walking ID BERG BALANCE SCALE; OLDER-ADULTS; LATERAL PERTURBATIONS; DYNAMIC STABILITY; HEALTHY-ADULTS; FALL INCIDENCE; WALKING; COMMUNITY; POSTSTROKE; PREVENTION AB Gait instability is a common problem following stroke, as evidenced by increases in fall risk and fear of falling. However, the mechanism underlying gait instability is currently unclear. We recently found that young, healthy humans use a consistent gait stabilization strategy of actively controlling their mediolateral foot placement based on the concurrent mechanical state of the stance limb. In the present work, we tested whether people with stroke (n = 16) and age-matched controls (n = 19) used this neuromechanical strategy. Specifically, we used multiple linear regressions to test whether (1) swing phase gluteus medius (GM) activity was influenced by the simultaneous state of the stance limb and (2) mediolateral foot placement location was influenced by swing phase GM activity and the mechanical state of the swing limb at the start of the step. We found that both age-matched controls and people with stroke classified as having a low fall risk (Dynamic Gait Index [DGI] score >19) essentially used the stabilization strategy previously described in young controls. In contrast, this strategy was disrupted for people with stroke classified as higher fall risk (DGI 70) in a blinded random fashion. Participants then underwent cognitive testing and blood sampling for metabolic and Alzheimer's disease biomarkers. Data were analyzed using repeated measures ANOVA and Spearman correlations. Results: E4-adults with NC demonstrated lower delayed memory scores after the HIGH compared to the LOW meal, whereas normal E4+ and CI E4- groups had higher scores after the HIGH meal (ANOVA p = 0.03). These findings were associated with meal-induced changes in glucose (p = 0.05), insulin (p = 0.004), triglycerides (p < 0.01), and plasma A beta(42) (p = 0.05). Conclusions: These preliminary data suggest that cognitive performance of adults without CI mayworsen following high SF and sugar meals, whereas adults with CI or those at risk for CI due to E4 status may benefit acutely from such meals. Furthermore, plasma A beta was affected by meal type, suggesting a relationship between metabolic response and amyloid regulation. C1 [Hanson, Angela J.; Cholerton, Brenna] Univ Washington, Med Ctr, Dept Med, Seattle, WA 98195 USA. [Bayer, Jennifer L.] Univ Iowa, Iowa City, IA USA. [Baker, Laura D.; Craft, Suzanne] Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Sticht Ctr Aging, Winston Salem, NC 27157 USA. [VanFossen, Brian; Trittschuh, Emily] VA Puget Sound Healthcare Syst, Seattle, WA USA. [Rissman, Robert A.; Donohue, Michael C.; Moghadam, Setareh H.] Univ Calif San Diego, Dept Neurosci, Alzheimers Dis Cooperat Study, La Jolla, CA 92093 USA. RP Craft, S (reprint author), Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Sticht Ctr Aging, Med Ctr Blvd, Winston Salem, NC 27157 USA. EM suzcraft@wakehealth.edu FU AFAR Hartford Center of Excellence Award [AG010483, AG032755]; Alzheimer's Disease Cooperative Study (ADCS) Biomarker core from the National Institute on Aging; National Institute on Aging [R37 AG 10880]; [5T32AG000258] FX This research was supported by grant 5T32AG000258 training grant and AFAR Hartford Center of Excellence Award to Dr. Hanson, grants AG010483 and AG032755 and the Alzheimer's Disease Cooperative Study (ADCS) Biomarker core from the National Institute on Aging to Dr. Rissman and Dr. Donohue, and R37 AG 10880 from the National Institute on Aging to Dr. Craft. This article results from work supported by resources from the Veterans Affairs Puget Sound Health Care System, Seattle, Washington. NR 55 TC 4 Z9 4 U1 5 U2 11 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2015 VL 48 IS 1 BP 205 EP 218 DI 10.3233/JAD-150273 PG 14 WC Neurosciences SC Neurosciences & Neurology GA CQ9JW UT WOS:000360931700019 PM 26401941 ER PT J AU Wood, PL Medicherla, S Sheikh, N Terry, B Phillipps, A Kaye, JA Quinn, JF Woltjer, RL AF Wood, Paul L. Medicherla, Srikanth Sheikh, Naveen Terry, Bradley Phillipps, Aaron Kaye, Jeffrey A. Quinn, Joseph F. Woltjer, Randall L. TI Targeted Lipidomics of Fontal Cortex and Plasma Diacylglycerols (DAG) in Mild Cognitive Impairment and Alzheimer's Disease: Validation of DAG Accumulation Early in the Pathophysiology of Alzheimer's Disease SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; diacylglycerols; mild cognitive impairment; monoacylglycerols ID LIPOPROTEIN-LIPASE; FRONTAL-CORTEX; HUMAN BRAIN; DEMENTIA; ENZYMES; METABOLISM; ACTIVATION; PROTEINS; POLARITY; COMPLEX AB Previous studies have demonstrated augmented levels of diacylglycerols (DAG) in the frontal cortex and plasma of Alzheimer's disease (AD) patients. We extended these findings from non-targeted lipidomics studies to design a lipidomics platform to interrogate DAGs and monoacylglycerols (MAG) in the frontal cortex and plasma of MCI subjects. Control subjects included both aged normal controls and controls with normal cognition, but AD pathology at autopsy, individuals termed non-demented AD neuropathology. DAGs with saturated, unsaturated, and polyunsaturated fatty acid substituents were found to be elevated in MCI frontal cortex and plasma. Tandem mass spectrometry of the DAGs did not reveal any differences in the distributions of the fatty acid substitutions between MCI and control subjects. While triacylglycerols were not altered in MCI subjects there were increases in MAG levels both in the frontal cortex and plasma. In toto, increased levels of DAGs and MAGs appear to occur early in AD pathophysiology and require both further validation in a larger patient cohort and elucidation of the lipidomics alteration(s) that lead to the accumulation of DAGs in MCI subjects. C1 [Wood, Paul L.; Medicherla, Srikanth; Sheikh, Naveen; Terry, Bradley; Phillipps, Aaron] Lincoln Mem Univ, Lipid Unit, Dept Physiol & Pharmacol, DeBusk Coll Osteopath Med, Harrogate, TN 37752 USA. [Kaye, Jeffrey A.; Quinn, Joseph F.; Woltjer, Randall L.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR USA. [Kaye, Jeffrey A.; Quinn, Joseph F.; Woltjer, Randall L.] Portland VA Med Ctr, Portland, OR USA. RP Wood, PL (reprint author), Lincoln Mem Univ, Lipid Unit, Dept Physiol & Pharmacol, DeBusk Coll Osteopath Med, 6965 Cumberland Gap Pkwy, Harrogate, TN 37752 USA. EM paul.wood@lmunet.edu FU Lincoln Memorial University, DeBusk College of Osteopathic Medicine; [NIA-AG08017] FX We thank the participants of the aging study and their families for their valuable contribution to aging and Alzheimer's disease research. This research was funded by Lincoln Memorial University, DeBusk College of Osteopathic Medicine and by NIA-AG08017. NR 48 TC 5 Z9 5 U1 0 U2 4 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2015 VL 48 IS 2 BP 537 EP 546 DI 10.3233/JAD-150336 PG 10 WC Neurosciences SC Neurosciences & Neurology GA CR1EI UT WOS:000361066200022 PM 26402017 ER PT J AU Salameh, TS Bullock, KM Hujoel, IA Niehoff, ML Wolden-Hanson, T Kim, J Morley, JE Farr, SA Banks, WA AF Salameh, Therese S. Bullock, Kristin M. Hujoel, Isabel A. Niehoff, Michael L. Wolden-Hanson, Tami Kim, Junghyun Morley, John E. Farr, Susan A. Banks, William A. TI Central Nervous System Delivery of Intranasal Insulin: Mechanisms of Uptake and Effects on Cognition SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; cognition; insulin; intranasal administration ID BLOOD-BRAIN-BARRIER; SENESCENCE-ACCELERATED MICE; GROWTH-FACTOR EXPRESSION; AGED SAMP8 MOUSE; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; RAT-BRAIN; ANTISENSE OLIGONUCLEOTIDE; MEMORY IMPAIRMENT; APOE GENOTYPE AB Intranasal insulin has shown efficacy in patients with Alzheimer's disease (AD), but there are no preclinical studies determining whether or how it reaches the brain. Here, we showed that insulin applied at the level of the cribriform plate via the nasal route quickly distributed throughout the brain and reversed learning and memory deficits in an AD mouse model. Intranasal insulin entered the blood stream poorly and had no peripheral metabolic effects. Uptake into the brain from the cribriform plate was saturable, stimulated by PKC inhibition, and responded differently to cellular pathway inhibitors than did insulin transport at the blood-brain barrier. In summary, these results show intranasal delivery to be an effective way to deliver insulin to the brain. C1 [Salameh, Therese S.; Bullock, Kristin M.; Hujoel, Isabel A.; Wolden-Hanson, Tami; Banks, William A.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Salameh, Therese S.; Banks, William A.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA USA. [Niehoff, Michael L.; Kim, Junghyun; Morley, John E.; Farr, Susan A.] St Louis Univ, Dept Internal Med, Div Geriatr, St Louis, MO 63103 USA. [Niehoff, Michael L.; Farr, Susan A.] Vet Affairs Med Ctr St Louis, St Louis, MO USA. RP Banks, WA (reprint author), VAPSHCS, 810A-1,1660 S Columbian Way, Seattle, WA 98108 USA. EM wabanks1@uw.edu FU National Institutes of Health National Institute on Aging [R01-AG046619, T32-AG000258] FX This work was supported by the National Institutes of Health National Institute on Aging (Grant R01-AG046619). Therese S. Salameh is supported by National Institutes of Health National Institute on Aging (Grant T32-AG000258). We would like to acknowledge the Rodent Metabolic and Behavioral Phenotyping Core at the VA Puget Sound Health Care System. NR 44 TC 11 Z9 11 U1 4 U2 18 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2015 VL 47 IS 3 BP 715 EP 728 DI 10.3233/JAD-150307 PG 14 WC Neurosciences SC Neurosciences & Neurology GA CQ9JN UT WOS:000360930700017 PM 26401706 ER PT J AU Li, G Xiong, KP Korff, A Pan, C Quinn, JF Galasko, DR Liu, CF Montine, TJ Peskind, ER Zhang, J AF Li, Ge Xiong, Kangping Korff, Ane Pan, Catherine Quinn, Joseph F. Galasko, Douglas R. Liu, Chunfeng Montine, Thomas J. Peskind, Elaine R. Zhang, Jing TI Increased CSF E-Selectin in Clinical Alzheimer's Disease without Altered CSF A beta(42) and Tau SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; A beta(42); cerebrospinal fluid; biomarkers; cerebrovascular disease; E-selectin; tau; vascular cell adhesion molecule 1 ID SILENT CEREBRAL INFARCTION; SOLUBLE ADHESION MOLECULES; DEMENTIA; NEUROPATHOLOGY; ASSOCIATION; AUTOPSY; INJURY; AD AB Clinically diagnosed Alzheimer's disease (AD) is pathologically heterogeneous. In this multicenter cohort of 215 clinically diagnosed AD patients and 249 controls, E-selectin and vascular cell adhesion molecule 1 (VACM-1) were measured along with amyloid-beta peptide 1-42 (A beta(42)) and tau. We discovered that E-selectin, a biomarker of endothelial function/vascular injury, was inversely correlated with cerebrospinal fluid (CSF) tau/A beta(42) ratio and significantly elevated in clinical AD patients without the typical AD CSF biomarker signature (i.e., low tau/A beta(42) ratio) compared to those with the signature. These findings suggest that E-selectin may be an objective biomarker related to vascular mechanisms contributing to dementia. C1 [Li, Ge; Peskind, Elaine R.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Xiong, Kangping; Liu, Chunfeng] Soochow Univ, Affiliated Hosp 2, Dept Neurol, Suzhou, Peoples R China. [Korff, Ane; Pan, Catherine; Zhang, Jing] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98104 USA. [Quinn, Joseph F.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Quinn, Joseph F.] Portland VA Med Ctr, Portland, OR USA. [Galasko, Douglas R.; Montine, Thomas J.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA. [Li, Ge] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Peskind, Elaine R.] Vet Affairs Puget Sound Hlth Care Syst, VA Northwest Network Mental Illness Res Educ & Cl, Seattle, WA USA. RP Zhang, J (reprint author), Univ Washington, Dept Pathol, 325 9th Ave, Seattle, WA 98104 USA. EM zhangj@uw.edu FU Shaw endowment; Department of Veterans Affairs; [AG05136]; [AG023185]; [AG08017]; [NS082137] FX We appreciate deeply the assistance provided by Ms. Jane Shofer and Dr. Travis Cook in the preparation of the manuscript. The work was supported by several grants (AG05136, AG023185, AG08017 and NS082137), an anonymous foundation, the Shaw endowment, and the Department of Veterans Affairs. NR 20 TC 1 Z9 1 U1 0 U2 0 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2015 VL 47 IS 4 BP 883 EP 887 DI 10.3233/JAD-150420 PG 5 WC Neurosciences SC Neurosciences & Neurology GA CQ9JS UT WOS:000360931300008 PM 26401768 ER PT J AU Mendez, MF Paholpak, P Lin, A Zhang, JY Teng, E AF Mendez, Mario F. Paholpak, Pongsatorn Lin, Andrew Zhang, Jeannie Y. Teng, Edmond TI Prevalence of Traumatic Brain Injury in Early Versus Late-Onset Alzheimer's Disease SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Aging; Alzheimer's disease; concussion; dementia; epidemiology; head injury; memory loss; neurodegeneration; risk factors; traumatic brain injury ID HEAD-INJURY; RISK-FACTOR; DEMENTIA; AGE; ENCEPHALOPATHY; POPULATION; INDIVIDUALS; TAUOPATHY; AD AB Background: Traumatic brain injury (TBI) is the most established environmental risk factor for Alzheimer's disease (AD), but it is unclear if TBI is specifically associated with early-onset AD (EOAD). Objective: To evaluate the relationship between TBI and EOAD (<65 years). Methods: We identified 1,449 EOAD, 4,337 late-onset AD (LOAD), and corresponding EOAD-matched and LOAD-matched normal controls (NC) in the National Alzheimer's Coordinating Center Uniform (NACC) database and compared the prevalence of any history of TBI as well as measures of cognition, function, behavior, and neuropathology. For validation, we determined TBI prevalence among 115 well-characterized clinic patients with EOAD. Results: Part A: The prevalence of any TBI in the NACC-database EOAD participants (13.3%) was comparable to that observed in the clinic EOAD patients (13.9%) but significantly higher than in the NACC-database LOAD participants (7.7%; p < 0.0001) and trended to higher compared to EOAD-matched NC (11.1%; logistic regression p = 0.053). Part B: When we compared EOAD patients with documented non-acute and non-residually impairing TBI to EOAD without a documented history of prior TBI, those with TBI had significantly more disinhibition. Part C: Autopsies did not reveal differences in AD neuropathology based on a history of TBI. Conclusions: These findings suggest, but do not establish, that TBI is a specific risk factor for EOAD and may lead to disinhibition, a feature that often results from the frontal effects of head injury. This study recommends further research on the effects of TBI in EOAD in larger numbers of participants. C1 [Mendez, Mario F.; Paholpak, Pongsatorn; Lin, Andrew; Teng, Edmond] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. [Mendez, Mario F.; Paholpak, Pongsatorn; Lin, Andrew; Zhang, Jeannie Y.; Teng, Edmond] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Mendez, Mario F.; Paholpak, Pongsatorn; Lin, Andrew; Teng, Edmond] VA Greater Los Angeles Healthcare Syst, Neurobehav Unit, Dept Neurol, Los Angeles, CA USA. RP Mendez, MF (reprint author), VA Greater Los Angeles Healthcare Ctr, Neurobehav Unit, 691-116AF,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM mmendez@UCLA.edu FU Medical Student Training in Aging Research Program, the National Institute on Aging [T35AG026736]; John A. Hartford Foundation; Lillian R. Gleitsman Foundation; NIA [U01 AG016976, P30 AG019610, P30 AG013846, P50 AG008702, P50 AG025688, P30 AG010133, P50 AG005146, P50 AG005134, P50 AG016574, P50 AG005138, P30 AG008051, P30 AG013854, P30 AG008017]; NIA/NIH [U01 AG016976]; The NIA [P30 AG010161, P30 AG010129, P50 AG016573, P50 AG016570, P50 AG005131, P50 AG023501, P30 AG035982, P30 AG028383, P30 AG010124, P50 AG005133, P50 AG005142, P30 AG012300, P50 AG005136, P50 AG033514, P50 AG005681] FX This research was funded by The Medical Student Training in Aging Research Program, the National Institute on Aging (T35AG026736), the John A. Hartford Foundation, the Lillian R. Gleitsman Foundation, and NIA Grant U01 AG016976.; The authors thank Michelle Mather, Kate Heller, and Dr. Stephen Hawes for their contributions. The NACC database is funded by NIA/NIH Grant U01 AG016976. NACC data are contributed by the NIA funded ADCs: P30 AG019610 (PI Eric Reiman, MD), P30 AG013846 (PI Neil Kowall, MD), P50 AG008702 (PI Scott Small, MD), P50 AG025688 (PI Allan Levey, MD, PhD), P30 AG010133 (PI Andrew Saykin, PsyD), P50 AG005146 (PI Marilyn Albert, PhD), P50 AG005134 (PI Bradley Hyman, MD, PhD), P50 AG016574 (PI Ronald Petersen, MD, PhD), P50 AG005138 (PI Mary Sano, PhD), P30 AG008051 (PI Steven Ferris, PhD), P30 AG013854 (PI M. Marsel Mesulam, MD), P30 AG008017 (PI Jeffrey Kaye, MD), P30 AG010161 (PI David Bennett, MD), P30 AG010129 (PI Charles DeCarli, MD), P50 AG016573 (PI Frank LaFerla, PhD), P50 AG016570 (PI David Teplow, PhD), P50 AG005131 (PI Douglas Galasko, MD), P50 AG023501 (PI Bruce Miller, MD), P30 AG035982 (PI Russell Swerdlow, MD), P30 AG028383 (PI Linda Van Eldik, PhD), P30 AG010124 (PI John Trojanowski, MD, PhD), P50 AG005133 (PI Oscar Lopez, MD), P50 AG005142 (PI Helena Chui, MD), P30 AG012300 (PI Roger Rosenberg, MD), P50 AG005136 (PI Thomas Montine, MD, PhD), P50 AG033514 (PI Sanjay Asthana, MD, FRCP), and P50 AG005681 (PI John Morris, MD). NR 51 TC 3 Z9 3 U1 4 U2 16 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2015 VL 47 IS 4 BP 985 EP 993 DI 10.3233/JAD-143207 PG 9 WC Neurosciences SC Neurosciences & Neurology GA CQ9JS UT WOS:000360931300017 PM 26401777 ER PT J AU Gleason, CE Fischer, BL Dowling, NM Setchell, KDR Atwood, CS Carlsson, CM Asthana, S AF Gleason, Carey E. Fischer, Barbara L. Dowling, N. Maritza Setchell, Kenneth D. R. Atwood, Craig S. Carlsson, Cynthia M. Asthana, Sanjay TI Cognitive Effects of Soy Isoflavones in Patients with Alzheimer's Disease SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; clinical trial; cognition; daidzein; equol; genistein; phytoestrogens; soy isoflavones ID ESTROGEN-RECEPTOR-BETA; EQUOL-PRODUCER STATUS; POSTMENOPAUSAL WOMEN; OXIDATIVE STRESS; CONTROLLED-TRIAL; DOUBLE-BLIND; OLDER WOMEN; S-EQUOL; PHARMACOKINETICS; GENISTEIN AB Background: In a previous trial, treatment with soy isoflavones was associated with improved nonverbal memory, construction abilities, verbal fluency, and speeded dexterity compared to treatment with placebo in cognitively healthy older adults. Objective: The current trial aimed to examine the potential cognitive benefits of soy isoflavones in patients with Alzheimer's disease. Methods: Sixty-five men and women over the age of 60 were treated with 100 mg/day soy isoflavones, or matching placebo capsules for six months. APOE genotype was determined for all participants. Cognitive outcomes and plasma isoflavone levels were measured at baseline, and at two additional time points: three and six months after baseline. Results: Of the sixty-five participants enrolled, thirty-four (52.3%) were women, and 31 (47.7%) were APOE epsilon 4 positive. Average age was 76.3 (SD = 7.2) years. Fifty-nine (90.8%) subjects completed all study visits. Plasma isoflavone levels increased in subjects treated with soy isoflavones compared to baseline and to placebo, although intersubject variability in plasma levels was large. No significant differences in treatment effects for cognition emerged between treatment groups or genders. Exploratory analyses of associations between changes in cognition and plasma isoflavone levels revealed an association between equol levels, and speeded dexterity and verbal fluency. Conclusions: Six months of 100 mg/day treatment with soy isoflavones did not benefit cognition in older men and women with Alzheimer's disease. However, our results suggest the need to examine the role of isoflavone metabolism, i.e., the ability to effectively metabolize soy isoflavones by converting daidzen to equol when attempting to fully clarify the cognitive effects of isoflavones. C1 [Gleason, Carey E.; Fischer, Barbara L.; Atwood, Craig S.; Carlsson, Cynthia M.; Asthana, Sanjay] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Div Geriatr & Gerontol, Madison, WI USA. [Gleason, Carey E.; Fischer, Barbara L.; Atwood, Craig S.; Carlsson, Cynthia M.; Asthana, Sanjay] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA. [Gleason, Carey E.; Dowling, N. Maritza; Carlsson, Cynthia M.; Asthana, Sanjay] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Alzheimers Dis Res Ctr, Madison, WI USA. [Dowling, N. Maritza] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA. [Setchell, Kenneth D. R.] Univ Cincinnati, Dept Pediat, Div Pathol & Lab Med, Cincinnati, OH USA. RP Gleason, CE (reprint author), Madison VA GRECC 11G, 2500 Overlook Terrace, Madison, WI 53705 USA. EM ceg@medicine.wisc.edu FU NIH [K23 AG024302, P50 AG033514] FX This research was supported by funding from the NIH (K23 AG024302; P50 AG033514). NR 58 TC 4 Z9 4 U1 2 U2 8 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2015 VL 47 IS 4 BP 1009 EP 1019 DI 10.3233/JAD-142958 PG 11 WC Neurosciences SC Neurosciences & Neurology GA CQ9JS UT WOS:000360931300019 PM 26401779 ER PT J AU Brenes-Salazar, JA Alshawabkeh, L Schmader, KE Hanlon, JT Forman, DE AF Brenes-Salazar, Jorge A. Alshawabkeh, Laith Schmader, Kenneth E. Hanlon, Joseph T. Forman, Daniel E. TI Clinical pharmacology relevant to older adults with cardiovascular disease SO JOURNAL OF GERIATRIC CARDIOLOGY LA English DT Editorial Material DE Metabolism; Pharmacokinetics; Pharmacodynamics; Polypharmacy ID DRUG-DRUG; ADHERENCE C1 [Brenes-Salazar, Jorge A.] Mayo Clin, Dept Med, Div Cardiovasc Dis, Rochester, MN USA. [Alshawabkeh, Laith] Univ Iowa, Dept Med, Div Cardiovasc Dis, Iowa City, IA 52242 USA. [Schmader, Kenneth E.] Duke Univ, Sch Med, Dept Med, Div Geriatr, Durham, NC 27706 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Dept Med, Geriatr Res Educ & Clin Ctr, Div Geriatr Med, Pittsburgh, PA USA. [Hanlon, Joseph T.] Univ Pittsburgh, Dept Pharm, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Hanlon, Joseph T.] Univ Pittsburgh, Dept Epidemiol, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Hanlon, Joseph T.] VA Pittsburgh Hlth Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Forman, Daniel E.] Univ Pittsburgh, VA Pittsburgh Hlth Syst, Geriatr Res Educ & Clin Ctr, Dept Med,Div Geriatr Med,Med Ctr, Pittsburgh, PA 15260 USA. [Forman, Daniel E.] Univ Pittsburgh, VA Pittsburgh Hlth Syst, Geriatr Res Educ & Clin Ctr, Div Cardiol,Med Ctr, Pittsburgh, PA USA. RP Forman, DE (reprint author), Univ Pittsburgh, VA Pittsburgh Hlth Syst, Geriatr Res Educ & Clin Ctr, Dept Med,Div Geriatr Med,Med Ctr, Pittsburgh, PA 15260 USA. EM formand@pitt.edu FU NIA NIH HHS [K07 AG033174, P30 AG024827, P30 AG028716, R01 AG037451] NR 11 TC 2 Z9 2 U1 1 U2 2 PU SCIENCE PRESS PI BEIJING PA 16 DONGHUANGCHENGGEN NORTH ST, BEIJING 100717, PEOPLES R CHINA SN 1671-5411 J9 J GERIATR CARDIOL JI J. Geriatr. Cardiol. PY 2015 VL 12 IS 3 BP 192 EP 195 PG 4 WC Cardiac & Cardiovascular Systems; Geriatrics & Gerontology SC Cardiovascular System & Cardiology; Geriatrics & Gerontology GA CP6SE UT WOS:000360017600002 PM 26089839 ER PT J AU Rodriguez, KL Burkitt, KH Bayliss, NK Skoko, JE Switzer, GE Zickmund, SL Fine, MJ Macpherson, DS AF Rodriguez, Keri L. Burkitt, Kelly H. Bayliss, Nichole K. Skoko, Jennifer E. Switzer, Galen E. Zickmund, Susan L. Fine, Michael J. Macpherson, David S. TI Veteran, Primary Care Provider, and Specialist Satisfaction With Electronic Consultation SO JMIR MEDICAL INFORMATICS LA English DT Article DE access; rural health; referral and consultation; patient satisfaction; veterans ID RANDOMIZED CONTROLLED-TRIAL; PATIENT SATISFACTION; RURAL VETERANS; HEALTH-CARE; TELEMEDICINE AB Background: Access to specialty care is challenging for veterans in rural locations. To address this challenge, in December 2009, the Veterans Affairs (VA) Pittsburgh Healthcare System (VAPHS) implemented an electronic consultation (e-consult) program to provide primary care providers (PCPs) and patients with enhanced specialty care access. Objective: The aim of this quality improvement (QI) project evaluation was to: (1) assess satisfaction with the e-consult process, and (2) identify perceived facilitators and barriers to using the e-consult program. Methods: We conducted semistructured telephone interviews with veteran patients (N=15), Community Based Outpatient Clinic (CBOC) PCPs (N=15), and VA Pittsburgh specialty physicians (N=4) who used the e-consult program between December 2009 to August 2010. Participants answered questions regarding satisfaction in eight domains and identified factors contributing to their responses. Results: Most participants were white (patients=87%; PCPs=80%; specialists=75%) and male (patients=93%; PCPs=67%; specialists=75%). On average, patients had one e-consult (SD 0), PCPs initiated 6 e-consults (SD 6), and VAPHS specialists performed 17 e-consults (SD 11). Patients, PCPs, and specialty physicians were satisfied with e-consults median (range) of 5.0 (4-5) on 1-5 Likert-scale, 4.0 (3-5), and 3.5 (3-5) respectively. The most common reason why patients and specialists reported increased overall satisfaction with e-consults was improved communication, whereas improved timeliness of care was the most common reason for PCPs. Communication was the most reported perceived barrier and facilitator to e-consult use. Conclusions: Veterans and VA health care providers were satisfied with the e-consult process. Our findings suggest that while the reasons for satisfaction with e-consult differ somewhat for patients and physicians, e-consult may be a useful tool to improve VA health care system access for rural patients. C1 [Rodriguez, Keri L.; Burkitt, Kelly H.; Switzer, Galen E.; Zickmund, Susan L.; Fine, Michael J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. [Rodriguez, Keri L.; Switzer, Galen E.; Zickmund, Susan L.; Fine, Michael J.; Macpherson, David S.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA. [Rodriguez, Keri L.] VA Pittsburgh Healthcare Syst, Vet Engn Resource Ctr, Pittsburgh, PA 15240 USA. [Bayliss, Nichole K.] Chatham Univ, Dept Psychol, Pittsburgh, PA USA. [Bayliss, Nichole K.] Chatham Univ, Dept Social Work Criminol, Pittsburgh, PA USA. [Skoko, Jennifer E.] VA Pittsburgh Healthcare Syst, Facil Management Serv, Pittsburgh, PA 15240 USA. [Switzer, Galen E.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Switzer, Galen E.] Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA USA. [Macpherson, David S.] Vet Integrated Serv Network 4 VISN 4 Healthcare N, Pittsburgh, PA USA. RP Rodriguez, KL (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Bldg 30,Univ Dr C 151C, Pittsburgh, PA 15240 USA. EM keri.rodriguez@va.gov NR 24 TC 6 Z9 6 U1 1 U2 3 PU JMIR PUBLICATIONS, INC PI TORONTO PA 59 WINNERS CIRCLE, TORONTO, ON M4L 3Y7, CANADA SN 2291-9694 J9 JMIR MED INF JI JMIR Med. Inf. PD JAN-MAR PY 2015 VL 3 IS 1 AR e5 DI 10.2196/medinform.3725 PG 14 WC Medical Informatics SC Medical Informatics GA CP3ON UT WOS:000359789800009 PM 25589233 ER PT J AU Landman, A Emani, S Carlile, N Rosenthal, DI Semakov, S Pallin, DJ Poon, EG AF Landman, Adam Emani, Srinivas Carlile, Narath Rosenthal, David I. Semakov, Simon Pallin, Daniel J. Poon, Eric G. TI A Mobile App for Securely Capturing and Transferring Clinical Images to the Electronic Health Record: Description and Preliminary Usability Study SO JMIR MHEALTH AND UHEALTH LA English DT Article DE mobile phone; photographs; electronic health records; telemedicine ID DIGITAL PHOTOGRAPHY; TELEDERMATOLOGY; FACILITATORS; DIAGNOSIS; BARRIERS; SYSTEMS AB Background: Photographs are important tools to record, track, and communicate clinical findings. Mobile devices with high-resolution cameras are now ubiquitous, giving clinicians the opportunity to capture and share images from the bedside. However, secure and efficient ways to manage and share digital images are lacking. Objective: The aim of this study is to describe the implementation of a secure application for capturing and storing clinical images in the electronic health record (EHR), and to describe initial user experiences. Methods: We developed CliniCam, a secure Apple iOS (iPhone, iPad) application that allows for user authentication, patient selection, image capture, image annotation, and storage of images as a Portable Document Format (PDF) file in the EHR. We leveraged our organization's enterprise service-oriented architecture to transmit the image file from CliniCam to our enterprise clinical data repository. There is no permanent storage of protected health information on the mobile device. CliniCam also required connection to our organization's secure WiFi network. Resident physicians from emergency medicine, internal medicine, and dermatology used CliniCam in clinical practice for one month. They were then asked to complete a survey on their experience. We analyzed the survey results using descriptive statistics. Results: Twenty-eight physicians participated and 19/28 (68%) completed the survey. Of the respondents who used CliniCam, 89% found it useful or very useful for clinical practice and easy to use, and wanted to continue using the app. Respondents provided constructive feedback on location of the photos in the EHR, preferring to have photos embedded in (or linked to) clinical notes instead of storing them as separate PDFs within the EHR. Some users experienced difficulty with WiFi connectivity which was addressed by enhancing CliniCam to check for connectivity on launch. Conclusions: CliniCam was implemented successfully and found to be easy to use and useful for clinical practice. CliniCam is now available to all clinical users in our hospital, providing a secure and efficient way to capture clinical images and to insert them into the EHR. Future clinical image apps should more closely link clinical images and clinical documentation and consider enabling secure transmission over public WiFi or cellular networks. C1 [Landman, Adam; Pallin, Daniel J.] Brigham & Womens Hosp, Dept Emergency Med, Boston, MA 02115 USA. [Landman, Adam; Emani, Srinivas; Carlile, Narath; Pallin, Daniel J.] Harvard Univ, Sch Med, Boston, MA USA. [Emani, Srinivas; Carlile, Narath] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Rosenthal, David I.] Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA. [Rosenthal, David I.] US Dept Vet Affairs, West Haven, CT USA. [Semakov, Simon] Solaris Dev Inc, Newton, MA USA. [Poon, Eric G.] Boston Univ, Sch Med, Dept Med, Boston Med Ctr, Boston, MA 02118 USA. RP Landman, A (reprint author), Brigham & Womens Hosp, Dept Emergency Med, 75 Francis St, Boston, MA 02115 USA. EM alandman@partners.org RI Pallin, Daniel/H-6382-2013 OI Pallin, Daniel/0000-0002-8517-9702 NR 21 TC 14 Z9 14 U1 4 U2 22 PU JMIR PUBLICATIONS, INC PI TORONTO PA 59 WINNERS CIRCLE, TORONTO, ON M4L 3Y7, CANADA SN 2291-5222 J9 JMIR MHEALTH UHEALTH JI JMIR mHealth uHealth PD JAN-MAR PY 2015 VL 3 IS 1 AR e1 DI 10.2196/mhealth.3481 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA CP3OX UT WOS:000359791000008 PM 25565678 ER PT J AU Chen, XZ Zhao, SF Song, Y Shi, YJ Leak, RK Cao, GD AF Chen, Xinzhi Zhao, Shangfeng Song, Yang Shi, Yejie Leak, Rehana K. Cao, Guodong TI The Role of Nicotinamide Phosphoribosyltransferase in Cerebral Ischemia SO CURRENT TOPICS IN MEDICINAL CHEMISTRY LA English DT Review DE Adipokine; Brain ischemia; Intracerebroventricular; Mouse; Neuroprotection; Reperfusion injury; Stroke; Vascular biology ID COLONY-ENHANCING FACTOR; POTENT ANTITUMOR-ACTIVITY; TYPE-2 DIABETES-MELLITUS; REGULATES CELL-SURVIVAL; HUMAN FETAL MEMBRANES; VISFATIN GENE PBEF1; NAD BIOSYNTHESIS; WHITE-MATTER; MOUSE MODEL; NEUROPROTECTIVE EFFICACY AB As recombinant tissue plasminogen activator is the only drug approved for the clinical treatment of acute ischemic stroke, there is an urgent unmet need for novel stroke treatments. Endogenous defense mechanisms against stroke may hold the key to new therapies for stroke. A large number of studies suggest that nicotinamide phosphoribosyl-transferase (NAMPT) is an attractive candidate to improve post-stroke recovery. NAMPT is a multifunctional protein and plays important roles in immunity, metabolism, aging, inflammation, and stress responses. NAMPT exists in both the intracellular and extracellular space. As a rate-limiting enzyme, the intracellular form (iNAMPT) catalyzes the first step in the biosynthesis of nicotinamide adenine dinucleotide (NAD) from nicotinamide. iNAMPT closely regulates energy metabolism, enhancing the proliferation of endothelial cells, inhibiting apoptosis, regulating vascular tone, and stimulating autophagy in disease conditions such as stroke. Extracellular NAMPT (eNAMPT) is also known as visfatin (visceral fat-derived adipokine) and has pleotropic effects. It is widely believed that the diverse biological functions of eNAMPT are attributed to its NAMPT enzymatic activity. However, the effects of eNAMPT on ischemic injury are still controversial. Some authors have argued that eNAMPT exacerbates ischemic neuronal injury non-enzymatically by triggering the release of TNF-alpha from glial cells. In addition, NAMPT also participates in several pathophysiological processes such as hypertension, atherosclerosis, and ischemic heart disease. Thus, it remains unclear under what conditions NAMPT is beneficial or destructive. Recent work using in vitro and in vivo genetic/pharmacologic manipulations, including our own studies, has greatly improved our understanding of NAMPT. This review focuses on the multifaceted and complex roles of NAMPT under both normal and ischemic conditions. C1 [Chen, Xinzhi; Zhao, Shangfeng; Song, Yang; Shi, Yejie; Leak, Rehana K.; Cao, Guodong] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15260 USA. [Zhao, Shangfeng] Capital Med Univ, Beijing Tongren Hosp, Dept Neurosurg, Beijing 100053, Peoples R China. [Leak, Rehana K.] Duquesne Univ, Div Pharmaceut Sci, Pittsburgh, PA 15282 USA. [Cao, Guodong] Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15240 USA. RP Chen, XZ (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15260 USA. EM chenx5@upmc.edu OI Leak, Rehana/0000-0003-2817-7417; Shi, Yejie/0000-0001-7502-9201 FU NIH [R01 NS079345]; VA Merit Review grants [RX000199 / BX002346] FX We thank all the authors who contributed to this field of work and apologize to those whose works are not directly cited in this review. This work was supported in part by NIH grants R01 NS079345 and VA Merit Review grants RX000199 / BX002346 (Dr. Cao). NR 101 TC 0 Z9 0 U1 3 U2 8 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1568-0266 EI 1873-4294 J9 CURR TOP MED CHEM JI Curr. Top. Med. Chem. PY 2015 VL 15 IS 21 BP 2211 EP 2221 DI 10.2174/1568026615666150610142234 PG 11 WC Chemistry, Medicinal SC Pharmacology & Pharmacy GA CO7ZS UT WOS:000359384100007 PM 26059356 ER PT J AU Rinne, ST Liu, CF Feemster, LC Collins, BF Bryson, CL O'Riordan, TG Au, DH AF Rinne, Seppo T. Liu, Chuan-Fen Feemster, Laura C. Collins, Bridget F. Bryson, Christopher L. O'Riordan, Thomas G. Au, David H. TI Thiazolidinediones are associated with a reduced risk of COPD exacerbations SO INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE LA English DT Article DE peroxisome proliferator-activated receptors; glitazones; COPD exacerbation; inflammation; cohort study ID OBSTRUCTIVE PULMONARY-DISEASE; PROLIFERATOR-ACTIVATED RECEPTORS; SMOOTH-MUSCLE-CELLS; PPAR-GAMMA; HEART-FAILURE; ASTHMA; CORTICOSTEROIDS; ROSIGLITAZONE; INFLAMMATION; MANAGEMENT AB Background: Thiazolidinediones (TZDs) are oral antihyperglycemic medications that are selective agonists to peroxisome proliferator-activated receptor gamma and have been shown to have potent anti-inflammatory effects in the lung. Objective: The purpose of this study was to assess whether exposure to TZDs is associated with a decreased risk of chronic obstructive pulmonary disease (COPD) exacerbation. Methods: A cohort study was performed by collecting data on all US veterans with diabetes and COPD who were prescribed oral antihyperglycemic medications during from period of October 1, 2005 to September 30, 2007. Patients who had two or more prescriptions for TZDs were compared with patients who had two or more prescriptions for an alternative oral anti-hyperglycemic medication. Multivariable negative binomial regression was performed with adjustment for potential confounding factors. The primary outcome was COPD exacerbations, including both inpatient and outpatient exacerbations. Results: We identified 7,887 veterans who were exposed to TZD and 42,347 veterans who were exposed to non-TZD oral diabetes medications. COPD exacerbations occurred in 1,258 (16%) of the TZD group and 7,789 (18%) of the non-TZD group. In multivariable negative binomial regression, there was a significant reduction in the expected number of COPD exacerbations among patients who were exposed to TZDs with an incidence rate ratio of 0.86 (95% CI 0.81-0.92). Conclusion: Exposure to TZDs was associated with a small but significant reduction in risk for COPD exacerbation among diabetic patients with COPD. C1 [Rinne, Seppo T.] VA Connecticut Healthcare Syst, Dept Vet Affairs, West Haven, CT 06516 USA. [Rinne, Seppo T.] Yale Univ, Div Pulm & Crit Care, New Haven, CT USA. [Liu, Chuan-Fen; Feemster, Laura C.; Collins, Bridget F.; Bryson, Christopher L.; Au, David H.] VA Puget Sound Hlth Care Syst, Dept Vet Affairs, Seattle, WA USA. [Liu, Chuan-Fen; Au, David H.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Feemster, Laura C.; Collins, Bridget F.] Univ Washington, Div Pulm & Crit Care, Seattle, WA 98195 USA. [Bryson, Christopher L.] Univ Washington, Div Gen Internal Med, Seattle, WA 98195 USA. [O'Riordan, Thomas G.] Gilead Sci Inc, Seattle, WA USA. RP Rinne, ST (reprint author), VA Connecticut Healthcare Syst, Dept Vet Affairs, 950 Campbell Ave,Bldg 35a,Room 2-234, West Haven, CT 06516 USA. EM seppo.rinne@va.gov FU VA HSRD grant [IIR 07-068-2]; Gilead Sciences Inc.; NIH NHLBI [K23 HL111116] FX Research funding for this project was from a VA HSR&D grant (IIR 07-068-2) along with funding from Gilead Sciences Inc. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States Government. Dr Feemster is supported by the NIH NHLBI (K23 HL111116). NR 37 TC 1 Z9 1 U1 1 U2 2 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1178-2005 J9 INT J CHRONIC OBSTR JI Int. J. Chronic Obstr. Pulm. Dis. PY 2015 VL 10 BP 1591 EP 1597 DI 10.2147/COPD.S82643 PG 7 WC Respiratory System SC Respiratory System GA CO6ZI UT WOS:000359306500001 PM 26300638 ER PT J AU Landman, A Emani, S Carlile, N Rosenthal, DI Semakov, S Pallin, DJ Poon, EG AF Landman, Adam Emani, Srinivas Carlile, Narath Rosenthal, David I. Semakov, Simon Pallin, Daniel J. Poon, Eric G. TI A Mobile App for Securely Capturing and Transferring Clinical Images to the Electronic Health Record: Description and Preliminary Usability Study SO JOURNAL OF MEDICAL INTERNET RESEARCH LA English DT Article DE mobile phone; photographs; electronic health records; telemedicine ID DIGITAL PHOTOGRAPHY; CARE; TELEDERMATOLOGY; FACILITATORS; TECHNOLOGY; DIAGNOSIS; BARRIERS; SYSTEMS AB Background: Photographs are important tools to record, track, and communicate clinical findings. Mobile devices with high-resolution cameras are now ubiquitous, giving clinicians the opportunity to capture and share images from the bedside. However, secure and efficient ways to manage and share digital images are lacking. Objective: The aim of this study is to describe the implementation of a secure application for capturing and storing clinical images in the electronic health record (EHR), and to describe initial user experiences. Methods: We developed CliniCam, a secure Apple iOS (iPhone, iPad) application that allows for user authentication, patient selection, image capture, image annotation, and storage of images as a Portable Document Format (PDF) file in the EHR. We leveraged our organization's enterprise service-oriented architecture to transmit the image file from CliniCam to our enterprise clinical data repository. There is no permanent storage of protected health information on the mobile device. CliniCam also required connection to our organization's secure WiFi network. Resident physicians from emergency medicine, internal medicine, and dermatology used CliniCam in clinical practice for one month. They were then asked to complete a survey on their experience. We analyzed the survey results using descriptive statistics. Results: Twenty-eight physicians participated and 19/28 (68%) completed the survey. Of the respondents who used CliniCam, 89% found it useful or very useful for clinical practice and easy to use, and wanted to continue using the app. Respondents provided constructive feedback on location of the photos in the EHR, preferring to have photos embedded in (or linked to) clinical notes instead of storing them as separate PDFs within the EHR. Some users experienced difficulty with WiFi connectivity which was addressed by enhancing CliniCam to check for connectivity on launch. Conclusions: CliniCam was implemented successfully and found to be easy to use and useful for clinical practice. CliniCam is now available to all clinical users in our hospital, providing a secure and efficient way to capture clinical images and to insert them into the EHR. Future clinical image apps should more closely link clinical images and clinical documentation and consider enabling secure transmission over public WiFi or cellular networks. C1 [Landman, Adam; Pallin, Daniel J.] Brigham & Womens Hosp, Dept Emergency Med, Boston, MA 02115 USA. [Landman, Adam; Emani, Srinivas; Carlile, Narath; Pallin, Daniel J.] Harvard Univ, Sch Med, Boston, MA USA. [Emani, Srinivas; Carlile, Narath] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Rosenthal, David I.] Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA. [Rosenthal, David I.] US Dept Vet Affairs, West Haven, CT USA. [Semakov, Simon] Solaris Dev Inc, Newton, MA USA. [Poon, Eric G.] Boston Univ, Sch Med, Dept Med, Boston Med Ctr, Boston, MA 02118 USA. RP Landman, A (reprint author), Brigham & Womens Hosp, Dept Emergency Med, 75 Francis St, Boston, MA 02115 USA. EM alandman@partners.org FU Brigham and Women's Hospital Health Information Technology Innovation Program FX We thank Nina Plaks, Chioma Agbo, MD, Kara Backman, Stephen Clay, Janice Grillo, Janice Cutone, Kevin Littlefield, Jacqueline Raymond, Scott Guelich, MD, and multiple Partners Healthcare information services teams for their assistance with design and development of the application. We also appreciate assistance with the survey from Vladmir Suric (Partners Healthcare, Wellesley, MA). Generous funding for this project was provided by a grant from the Brigham and Women's Hospital Health Information Technology Innovation Program. The sponsor had no role in the design and conduct of the study; and collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. NR 22 TC 0 Z9 0 U1 4 U2 13 PU JMIR PUBLICATIONS, INC PI TORONTO PA 59 WINNERS CIRCLE, TORONTO, ON M4L 3Y7, CANADA SN 1438-8871 J9 J MED INTERNET RES JI J. Med. Internet Res. PD JAN PY 2015 VL 17 IS 1 DI 10.2196/mhealth.3481 PG 8 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA AY0YH UT WOS:000347320100004 ER PT J AU Abreo, AP Herzog, CA Kutner, NG Lea, J Johansen, KL AF Abreo, Adrian P. Herzog, Charles A. Kutner, Nancy G. Lea, Janice Johansen, Kirsten L. TI Estimated Pulmonary Artery Systolic Pressure and Self-Reported Physical Function in Patients on Hemodialysis SO AMERICAN JOURNAL OF NEPHROLOGY LA English DT Article DE Physical function; End-stage renal disease; Echocardiography; Volume status ID QUALITY-OF-LIFE; FREQUENT HEMODIALYSIS; DIALYSIS PATIENTS; KIDNEY-DISEASE; HEART-FAILURE; RISK-FACTORS; HYPERTENSION; HEALTH; EPIDEMIOLOGY; ASSOCIATION AB Background/Aims: Patients on chronic hemodialysis have a high prevalence of heart disease and poor self-reported physical function. The association between structural heart disease and self-reported physical function in patients on hemodialysis is unknown. Methods: We studied the association between elevated pulmonary artery systolic pressure (PASP) and self-reported physical function in ESRD in 253 patients in the USRDS ACTIVE/ADIPOSE study between 2009 and 2011. We used multivariate linear regression with PASP obtained from clinical echocardiogram reports as the primary predictor and the Physical Function (PF) subscale of the SF-36 as the primary outcome. To determine whether associations between PASP and PF were driven by fluid overload or left ventricular hypertrophy, we assessed whether PASP was associated with bioimpedance spectroscopy (BIS)-derived extracellular water (ECW) and with left ventricular posterior wall thickness. Results: In a multivariable model, each 10 mm Hg higher PASP was associated with a 3.32-point lower PF score (95% CI-5.95, -0.68). In a multivariable model that included BIS estimates, both left ventricular posterior wall thickness (LVPW, per 5 mm) and ECW were associated with a higher PASP (LVPW 4.21 mm Hg, 95% 0.38-8.04; ECW 1.12 mm Hg per liter, 95% CI 0.07-2.18). Higher LVPW and ECW were independently associated with a lower PF score. Conclusion: Left ventricular hypertrophy and elevated pulmonary pressure are associated with worse self-reported physical function in patients on hemodialysis. The role of chronic volume overload on PASP and PF score should be evaluated in a prospective manner. (C) 2015 S. Karger AG, Basel C1 [Abreo, Adrian P.] Univ Cincinnati, Coll Med, Div Nephrol, Cincinnati, OH 45267 USA. [Abreo, Adrian P.] Cincinnati VA Med Ctr, Nephrol Sect, Cincinnati, OH USA. [Herzog, Charles A.] Hennepin Cty Med Ctr, Div Cardiol, Minneapolis, MN 55415 USA. [Herzog, Charles A.] Univ Minnesota, Minneapolis, MN USA. [Kutner, Nancy G.] Emory Univ, Sch Med, Dept Rehabil Med, Atlanta, GA USA. [Lea, Janice] Emory Univ, Sch Med, Div Nephrol, Atlanta, GA USA. [Johansen, Kirsten L.] San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA USA. [Johansen, Kirsten L.] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA. [Johansen, Kirsten L.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Abreo, AP (reprint author), Univ Cincinnati, Coll Med, 231 Albert Sabin Way,MSB 6252, Cincinnati, OH 45267 USA. EM adrian.abreo@uc.edu FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [N01-DK-7-0005, N01-DK-7-5004]; [K24DK085153] FX This work was supported through contracts N01-DK-7-0005 and N01-DK-7-5004 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and a K24DK085153 grant. NR 37 TC 0 Z9 0 U1 2 U2 3 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0250-8095 EI 1421-9670 J9 AM J NEPHROL JI Am. J. Nephrol. PY 2015 VL 41 IS 4-5 BP 313 EP 319 DI 10.1159/000431334 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA CN6AF UT WOS:000358515000009 PM 26089100 ER PT J AU Adams, ZW Danielson, CK Sumner, JA McCauley, JL Cohen, JR Ruggiero, KJ AF Adams, Zachary W. Danielson, Carla Kmett Sumner, Jennifer A. McCauley, Jenna L. Cohen, Joseph R. Ruggiero, Kenneth J. TI Comorbidity of PTSD, Major Depression, and Substance Use Disorder Among Adolescent Victims of the Spring 2011 Tornadoes in Alabama and Joplin, Missouri SO PSYCHIATRY-INTERPERSONAL AND BIOLOGICAL PROCESSES LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED CONTROLLED-TRIAL; RISK; TRAUMA; INTERVENTION; PREVALENCE; SYMPTOMS; YOUTH; MOOD AB Objective: The purpose of this study was twofold: (1) to estimate the prevalence of comorbid posttraumatic stress disorder (PTSD), major depressive episode (MDE), and substance use disorder (SUD); and (2) to identify risk factors for patterns of comorbidity among adolescents affected by disasters. Method: A population-based sample of 2,000 adolescents (51% female; 71% Caucasian, 26% African American) aged 12 to 17 years (M = 14.5, SD = 1.7) and their parents was recruited from communities affected by the spring 2011 tornadoes in Alabama and Joplin, Missouri. Participants completed structured telephone interviews assessing demographic characteristics, impact of disaster, prior trauma history, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), symptoms of posttraumatic stress disorder (PTSD) and major depressive episode (MDE), and substance use disorder (SUD) symptoms. Prevalence estimates were calculated for PTSD + MDE, PTSD + SUD, MDE + SUD, and PTSD + MDE + SUD. Hierarchical logistic regression was used to identify risk factors for each comorbidity profile. Results: Overall prevalence since the tornado was 3.7% for PTSD + MDE, 1.1% for PTSD + SUD, 1.0% for MDE + SUD, and 0.7% for PTSD + MDE + SUD. Girls were significantly more likely than boys to meet criteria for PTSD + MDE and MDE + SUD (ps<.05). Female gender, exposure to prior traumatic events, and persistent loss of services were significant risk factors for patterns of comorbidity. Parental injury was associated with elevated risk for PTSD + MDE. Adolescents should be evaluated for comorbid problems, including SUD, following disasters so that appropriate referrals to evidence-based treatments can be made. Conclusions: Results suggest that screening procedures to identify adolescents at risk for comorbid disorders should assess demographic characteristics (gender), impact of the disaster on the family, and adolescents' prior history of stressful events. C1 [Adams, Zachary W.; Danielson, Carla Kmett; Cohen, Joseph R.] Med Univ S Carolina, Natl Crime Victims Res & Treatment Ctr, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Sumner, Jennifer A.] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY USA. [McCauley, Jenna L.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Clin Neurosci Div, Charleston, SC 29425 USA. [Ruggiero, Kenneth J.] Med Univ S Carolina, Coll Nursing, Charleston, SC 29425 USA. [Ruggiero, Kenneth J.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Adams, ZW (reprint author), Med Univ S Carolina, Natl Crime Victims Res & Treatment Ctr, 67 President St, Charleston, SC 29425 USA. EM adamsz@musc.edu FU National Institute of Mental Health [R01-MH81056, T32-MH18869]; National Institute on Drug Abuse [K12-DA031794, R01-DA031285] FX This research was supported by National Institute of Mental Health grants R01-MH81056 and T32-MH18869 and National Institute on Drug Abuse grants K12-DA031794 and R01-DA031285. The authors have no other conflicts to disclose. NR 39 TC 2 Z9 2 U1 2 U2 10 PU GUILFORD PUBLICATIONS INC PI NEW YORK PA 370 SEVENTH AVE, SUITE 1200, NEW YORK, NY 10001-1020 USA SN 0033-2747 J9 PSYCHIATRY JI Psychiatry-Interpers. Biol. Process. PY 2015 VL 78 IS 2 BP 170 EP 185 DI 10.1080/00332747.2015.1051448 PG 16 WC Psychiatry SC Psychiatry GA CN5BT UT WOS:000358445200008 PM 26168094 ER PT S AU Pillai, A Yao, JK AF Pillai, Anilkumar Yao, Jeffrey K. BE DietrichMuszalska, A Chauhan, V Grignon, S TI Antioxidant Interventions in Neuropsychiatric Disorders SO STUDIES ON PSYCHIATRIC DISORDERS SE Oxidative Stress in Applied Basic Research and Clinical Practice LA English DT Article; Book Chapter ID POLYUNSATURATED FATTY-ACIDS; RANDOMIZED CONTROLLED-TRIALS; PLACEBO-CONTROLLED-TRIAL; BLOOD-CELL MEMBRANES; VITAMIN-E TREATMENT; SERUM NITRIC-OXIDE; N-ACETYL CYSTEINE; BIPOLAR DISORDER; TARDIVE-DYSKINESIA; OXIDATIVE STRESS C1 [Pillai, Anilkumar] Georgia Hlth Sci Univ, Dept Psychiat & Hlth Behav, Augusta, GA 30901 USA. [Yao, Jeffrey K.] VA Pittsburgh Healthcare Syst, Med Res Serv, Pittsburgh, PA 15240 USA. [Yao, Jeffrey K.] Univ Pittsburgh, Sch Med, WPIC, Dept Psychiat, Pittsburgh, PA 15213 USA. [Yao, Jeffrey K.] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15216 USA. RP Yao, JK (reprint author), VA Pittsburgh Healthcare Syst, Med Res Serv, 151 Univ Dr C, Pittsburgh, PA 15240 USA. EM jkyao@pitt.edu NR 119 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES SN 2197-7224 BN 978-1-4939-0440-2; 978-1-4939-0439-6 J9 OXID STRESS APPL BAS JI Oxid. Stress Appl. Basic Res. Clin. Pract. PY 2015 BP 505 EP 520 DI 10.1007/978-1-4939-0440-2_25 D2 10.1007/978-1-4939-0440-2 PG 16 WC Biochemical Research Methods; Biochemistry & Molecular Biology; Neurosciences; Psychiatry SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry GA BD1YO UT WOS:000358504200026 ER PT J AU Bergman, AA Frankel, RM Hamilton, AB Yano, EM AF Bergman, Alicia A. Frankel, Richard M. Hamilton, Alison B. Yano, Elizabeth M. TI Challenges with Delivering Gender-Specific and Comprehensive Primary Care to Women Veterans SO WOMENS HEALTH ISSUES LA English DT Article ID HEALTH-CARE; SEXUAL TRAUMA; MEDICAL HOME; AFFAIRS; EXPERIENCES; PREFERENCES; CLINICS AB Background: The growing presence of women veterans in Veterans Administration (VA) settings has prompted the need for greater attention to clinical proficiency related to women's health (WH) primary care needs. Instead of making appointments for multiple visits or referring patients to a WH clinic or alternate site for gender-specific care, a comprehensive primary care model now allows for women veteran patients be seen by primary care providers (PCPs) who have WH training/experience and can see patients for both primary and WH care in the context of a single visit. However, little is currently known about the barriers and facilitators WH-PCPs face in using this approach to incorporate gender-specific services into women veterans' primary care services. Methods: We conducted qualitative in-depth interviews with 22 WH-PCPs at one Midwestern VA Medical Center. All participants were members of one of four outpatient primary care clinics within the main medical center, one off-site satellite clinic, or two off-site community-based outpatient clinics. Results: Inductive thematic analysis identified six themes: 1) Time constraints, 2) importance of staff support, 3) necessity of sufficient space and equipment/supplies, 4) perceptions of discomfort among patients with trauma histories, 5) lack of education/training, and 6) challenges with scheduling/logistics. Conclusion: Although adequate staff was a key facilitator, the findings suggest that there may be barriers that undermine the ability of VA WH-PCPs to provide high-quality, comprehensive primary and gender-specific care. The nature of these barriers is multifactorial and multilevel in nature, and may therefore require special policy and practice action. Published by Elsevier Inc. C1 [Bergman, Alicia A.; Frankel, Richard M.] Richard L Roudebush VA Med Ctr, Ctr Hlth Informat & Commun, Dept Vet Affairs, Vet Hlth Adm,Hlth Serv Res & Dev Serv CIN 13 416, Indianapolis, IN USA. [Bergman, Alicia A.; Hamilton, Alison B.; Yano, Elizabeth M.] VA Greater Los Angeles Healthcare Syst, Ctr Study Healthcare Innovat Implementat & Policy, Hlth Serv Res & Dev Serv CIN 13 417, North Hills, CA 91343 USA. [Frankel, Richard M.] Indiana Univ Sch Med, Med, Indianapolis, IN 46202 USA. [Frankel, Richard M.] Indiana Univ Sch Med, Geriatr, Indianapolis, IN 46202 USA. [Yano, Elizabeth M.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA. RP Bergman, AA (reprint author), VA Greater Los Angeles Healthcare Syst, 16111 Plummer St,Bldg 25 Off B-110, North Hills, CA 91343 USA. EM alicia.bergman@va.gov FU Indiana Institute for Medical Research Young Investigator Award (YIA); Department of Veterans Affairs, Veterans Health Administration Health Services Research and Development (HSR&D) Associated Health Fellowship Program; VA HSR&D Senior Research Career Scientist Award [05-195]; VA HSR&D Center of Excellence in Implementing Evidence-Based Practice, Indianapolis, Indiana [HFP 04-148] FX The project reported here was supported by the Indiana Institute for Medical Research Young Investigator Award (YIA) funding (Bergman) and the Department of Veterans Affairs, Veterans Health Administration Health Services Research and Development (HSR&D) Associated Health Fellowship Program (Bergman). Dr. Yano's effort was supported by a VA HSR&D Senior Research Career Scientist Award (Project #05-195). Dr. Frankel's efforts were supported by the VA HSR&D Center of Excellence in Implementing Evidence-Based Practice, Indianapolis, Indiana (HFP 04-148). Portions of this article were presented at the Society for General Internal Medicine Annual Conference, April, 2013, in Denver, Colorado. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or the United States Government. There are no financial conflicts of interest involving any of the coauthors. NR 28 TC 2 Z9 2 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1049-3867 EI 1878-4321 J9 WOMEN HEALTH ISS JI Womens Health Iss. PD JAN-FEB PY 2015 VL 25 IS 1 BP 28 EP 34 DI 10.1016/j.whi.2014.10.004 PG 7 WC Public, Environmental & Occupational Health; Women's Studies SC Public, Environmental & Occupational Health; Women's Studies GA CN7GN UT WOS:000358602500006 PM 25530547 ER PT J AU Montgomery, AE Dichter, ME Thomasson, AM Fu, XY Roberts, CB AF Montgomery, Ann Elizabeth Dichter, Melissa E. Thomasson, Arwin M. Fu, Xiaoying Roberts, Christopher B. TI Demographic Characteristics Associated with Homelessness and Risk Among Female and Male Veterans Accessing VHA Outpatient Care SO WOMENS HEALTH ISSUES LA English DT Article ID VIOLENCE; HEALTH; PREVALENCE AB Background: This study explored demographic influences on veterans' reports of homelessness or imminent risk of homelessness with a particular focus on gender. Methods: We analyzed data for a cohort of veterans who responded to the U.S. Department of Veterans Affairs (VA), Veterans Health Administration (VHA) universal screener for homelessness and risk during a 3-month period. Multinomial mixed effects models stratified by gender predicted veterans' reports of homelessness or risk based on age, race, marital status, and receipt of VA compensation. Findings: The proportion of positive screens homelessness or risk was 2.7% for females and 1.7% for males. Women more likely to report being at risk of homelessness were aged 35 to 54 years, Black, and unmarried; those more likely to experience homelessness were Black and unmarried. Among male veterans, the greatest predictors of both homelessness and risk were Black race and unmarried status. Among both genders, receiving VA disability compensation was associated with lesser odds of being homeless or at risk. Conclusions: The findings describe the current population of veterans using VHA health care services who may benefit from homelessness prevention or intervention services, identify racial differences in housing stability, and distinguish subpopulations who may be in particular need of intervention. Interventions to address these needs are described. Published by Elsevier Inc. C1 [Montgomery, Ann Elizabeth] US Dept Vet Affairs, Natl Ctr Homelessness Vet, Philadelphia, PA 19146 USA. [Dichter, Melissa E.; Thomasson, Arwin M.; Fu, Xiaoying; Roberts, Christopher B.] US Dept Vet Affairs, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19146 USA. RP Montgomery, AE (reprint author), US Dept Vet Affairs, Natl Ctr Homelessness Vet, 4100 Chester Ave,Suite 201, Philadelphia, PA 19146 USA. EM ann.montgomery2@va.gov FU U.S. Department of Veterans Affairs; National Center on Homelessness Among Veterans; Center for Health Equity Research and Promotion [LIP 72-061] FX This study was funded by the U.S. Department of Veterans Affairs, National Center on Homelessness Among Veterans and Center for Health Equity Research and Promotion (Grant no. LIP 72-061). The contents of this article do not necessarily represent the views of the U.S. Department of Veterans Affairs or the U.S. Government. NR 38 TC 5 Z9 5 U1 5 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1049-3867 EI 1878-4321 J9 WOMEN HEALTH ISS JI Womens Health Iss. PD JAN-FEB PY 2015 VL 25 IS 1 BP 42 EP 48 DI 10.1016/j.whi.2014.10.003 PG 7 WC Public, Environmental & Occupational Health; Women's Studies SC Public, Environmental & Occupational Health; Women's Studies GA CN7GN UT WOS:000358602500008 PM 25498763 ER PT J AU Ketch, RA Rubin, RT Baker, MR Sones, AC Ames, D AF Ketch, Robert A. Rubin, Robert T. Baker, Matthew R. Sones, Alexander C. Ames, Donna TI Art appreciation for veterans with severe mental illness in a VA Psychosocial Rehabilitation and Recovery Center SO ARTS & HEALTH LA English DT Article DE veterans; mental health; art appreciation AB Considerable research has shown the positive effects of art, music and drama therapy on mental health and well-being. In September 2012, a weekly Art Appreciation class was initiated at the Veterans Affairs (VA) West Los Angeles (WLA) Psychosocial Rehabilitation and Recovery Center (PRRC) for veterans with severe mental illness. There are 106 VA PRRCs throughout the USA, designed to be transitional learning centers with curriculum-based interventions to help veterans re-integrate into the community and develop meaningful activities independent of the hospital setting. The VA WLA PRRC Art Appreciation class includes classroom sessions and community outings to local museums and other institutions holding art works of interest. It is taught at a college level and designed to lack the stigma of being a therapy group. Preliminary evidence from self-report measures indicates positive effects on mood, self-esteem, socialization and community participation among the veteran participants and recognition among staff that the course aids the veterans' recovery process. Appreciating art thus appears to promote both subjective and objective improvement in recovery and community re-integration for veterans who are experiencing chronic and disabling emotional distress. C1 [Ketch, Robert A.; Baker, Matthew R.; Sones, Alexander C.; Ames, Donna] VA Greater Los Angeles Healthcare Syst, West LA Psychosocial Rehabil & Recovery Ctr, Los Angeles, CA USA. [Rubin, Robert T.] VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA 90073 USA. [Rubin, Robert T.] Univ Calif Los Angeles, David Geffen Sch Med, Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. RP Rubin, RT (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA 90073 USA. EM rtrubin@yahoo.com NR 18 TC 0 Z9 0 U1 0 U2 4 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1753-3015 EI 1753-3023 J9 ARTS HEALTH JI Arts Health PY 2015 VL 7 IS 2 BP 172 EP 181 DI 10.1080/17533015.2015.1019700 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CM4TS UT WOS:000357678300008 ER PT J AU Peterson, MJ Kahn, JA Kerrigan, MV Gutmann, JM Harrow, JJ AF Peterson, Matthew J. Kahn, Julie A. Kerrigan, Michael V. Gutmann, Joseph M. Harrow, Jeffrey J. TI Pressure ulcer risk of patient handling sling use SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE decubitus ulcer; interface pressure; patient handling; patient handling sling; patient lifting; patient moving and lifting; patient repositioning; pressure sore; pressure ulcer; pressure ulcer risk; spinal cord injury ID INJURIES AB Patient handling slings and lifts reduce the risk of musculoskeletal injuries for healthcare providers. However, no published evidence exists of their safety with respect to pressure ulceration for vulnerable populations, specifically persons with spinal cord injury, nor do any studies compare slings for pressure distribution. High-resolution interface pressure mapping was used to describe and quantify risks associated with pressure ulceration due to normal forces and identify at-risk anatomical locations. We evaluated 23 patient handling slings with 4 non-disabled adults. Sling-participant interface pressures were recorded while participants lay supine on a hospital bed and while they were suspended during typical patient transfers. Sling-participant interface pressures were greatest while participants were suspended for all seated and supine slings and exceeded 200 mm Hg for all seated slings. Interface pressures were greatest along the sling seams (edges), regardless of position or sling type. The anatomical areas most at risk while participants were suspended in seated slings were the posterior upper and lower thighs. For supine slings, the perisacral area, ischial tuberosities, and greater trochanters were most at risk. The duration of time spent in slings, especially while suspended, should be limited. C1 [Peterson, Matthew J.; Gutmann, Joseph M.] James A Haley Vet Hosp, Dept Vet Affairs, Hlth Serv Res & Dev Ctr Innovat Disabil & Rehabil, Tampa, FL USA. [Kahn, Julie A.] Univ S Florida, Dept Chem & Biomed Engn, Tampa, FL USA. [Kerrigan, Michael V.] US Patent & Trademark Off, Alexandria, VA USA. [Harrow, Jeffrey J.] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA. RP Peterson, MJ (reprint author), James A Haley Vet Hosp 151R, HSR&D Ctr Innovat Disabil & Rehabil Res CINDRR, 8900 Grand Oak Cir, Tampa, FL 33637 USA. EM Matthew.Peterson1@va.gov FU VA Central Office Occupational Health Strategic Healthcare Group [SPTOF00A1] FX This work was supported by the VA Central Office Occupational Health Strategic Healthcare Group (no. SPTOF00A1). NR 16 TC 0 Z9 0 U1 3 U2 4 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 EI 1938-1352 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2015 VL 52 IS 3 BP 291 EP 300 DI 10.1682/JRRD.2014.06.0140 PG 10 WC Rehabilitation SC Rehabilitation GA CN0NR UT WOS:000358111100004 PM 26237005 ER PT J AU Diamond, SJ Sonnenberg, A AF Diamond, Sarah J. Sonnenberg, Amnon TI A game theoretic approach to repeated foreign body ingestion SO ENDOSCOPY LA English DT Editorial Material ID ENDOSCOPY; BODIES C1 Portland VA Med Ctr, Portland, OR USA. [Diamond, Sarah J.; Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Div Gastroenterol Hepatol, Portland, OR 97201 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr P3 GI, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 5 TC 1 Z9 1 U1 0 U2 0 PU GEORG THIEME VERLAG KG PI STUTTGART PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY SN 0013-726X EI 1438-8812 J9 ENDOSCOPY JI Endoscopy PY 2015 VL 47 SU 1 BP E79 EP E80 DI 10.1055/s-0034-1390920 PG 2 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA CL2RC UT WOS:000356791200021 PM 25926224 ER PT J AU Hashash, JG Habib-Bein, N Khalid, A Francis, FF AF Hashash, Jana G. Habib-Bein, Nadia Khalid, Asif Francis, Fadi F. TI Recurrent bladder cancer presenting as rectal linitis plastica SO ENDOSCOPY LA English DT Editorial Material C1 [Hashash, Jana G.; Khalid, Asif; Francis, Fadi F.] Univ Pittsburgh, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA 15213 USA. [Habib-Bein, Nadia] Univ Pittsburgh, Dept Microbiol, Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15213 USA. RP Hashash, JG (reprint author), Univ Pittsburgh, Div Gastroenterol Hepatol & Nutr, 200 Lothrop St,M2,C Wing, Pittsburgh, PA 15213 USA. EM alhashashj@upmc.edu NR 2 TC 0 Z9 0 U1 0 U2 1 PU GEORG THIEME VERLAG KG PI STUTTGART PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY SN 0013-726X EI 1438-8812 J9 ENDOSCOPY JI Endoscopy PY 2015 VL 47 SU 1 BP E102 EP E103 DI 10.1055/s-0034-1391300 PG 2 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA CL2RC UT WOS:000356791200032 PM 25734804 ER PT J AU Logan, DE Koo, KH Kilmer, JR Blayney, JA Lewis, MA AF Logan, Diane E. Koo, Kelly H. Kilmer, Jason R. Blayney, Jessica A. Lewis, Melissa A. TI Use of Drinking Protective Behavioral Strategies and Sexual Perceptions and Behaviors in US College Students SO JOURNAL OF SEX RESEARCH LA English DT Article ID ALCOHOL-RELATED CONSEQUENCES; NEGATIVE CONSEQUENCES; CONDOM USE; HEAVY-DRINKING; 1ST YEAR; EXPECTANCIES; CONSUMPTION; ADOLESCENTS; RISK; GENDER AB Alcohol use among college students is linked to an increased likelihood of engaging in risky sexual behaviors, including casual sex and unprotected sex. These behaviors increase college students' risks for negative social and health-related consequences. This study examined the relationship between drinking behaviors and protective behavioral strategies (PBS), expectancies and perceptions of sexual risk, and actual alcohol-related sexual behaviors and consequences. Sexually active college students completed Web-based self-report measures of drinking behaviors and use of PBS, alcohol expectancies and perceptions of risk, and sexual behaviors and related consequences (n = 524; 57.1% women). Findings indicated that PBS were related to lower expectancies of sexual risk and sexual disinhibition, and among lighter drinkers, lower expectancies of sexual enhancement from alcohol. PBS were also related to decreased perceptions of sexual-related risks, some alcohol-related sexual behaviors, including number of drinks before/during sex, and number of sexual consequences, but were not related to abstaining during sex, frequency of alcohol-related sexual behaviors, or general condom use. These findings demonstrate a disconnect between perceived and actual risks among college students, such that decreased perceptions of risk may not be associated with protective behaviors. Prevention and intervention implications are discussed. C1 [Logan, Diane E.] Brown Univ, Dept Behav & Social Sci, Providence, RI 02912 USA. [Koo, Kelly H.] San Francisco VA Med Ctr, Dept Mental Hlth, San Francisco, CA USA. [Koo, Kelly H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Kilmer, Jason R.; Lewis, Melissa A.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Kilmer, Jason R.] Univ Washington, Div Student Life, Hlth & Wellness, Seattle, WA 98195 USA. [Blayney, Jessica A.] SUNY Buffalo, Dept Psychol, Buffalo, NY 14260 USA. RP Logan, DE (reprint author), Brown Univ, Sch Publ Hlth, Dept Behav & Social Sci, Ctr Alcohol & Addict Studies, Box G-S121-4, Providence, RI 02912 USA. EM diane_logan@brown.edu FU National Institute on Alcohol Abuse and Alcoholism [K01AA016966, 1F31AA018238-01A1, 2T32AA007459] FX Data collection and manuscript preparation was supported by National Institute on Alcohol Abuse and Alcoholism Grant K01AA016966 awarded to M. A. Lewis. Manuscript preparation was supported by National Institute on Alcohol Abuse and Alcoholism Grant 1F31AA018238-01A1 awarded to D. E. Logan and National Institute on Alcohol Abuse and Alcoholism Grant 2T32AA007459 awarded to P. Monti. NR 66 TC 2 Z9 2 U1 7 U2 14 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0022-4499 EI 1559-8519 J9 J SEX RES JI J. Sex Res. PY 2015 VL 52 IS 5 BP 558 EP 569 DI 10.1080/00224499.2014.964167 PG 12 WC Psychology, Clinical; Social Sciences, Interdisciplinary SC Psychology; Social Sciences - Other Topics GA CM1FA UT WOS:000357425100007 PM 25350078 ER PT J AU Sawatsky, AP Zickmund, SL Berlacher, K Lesky, D Granieri, R AF Sawatsky, Adam P. Zickmund, Susan L. Berlacher, Kathryn Lesky, Dan Granieri, Rosanne TI Understanding the challenges to facilitating active learning in the resident conferences: a qualitative study of internal medicine faculty and resident perspectives SO MEDICAL EDUCATION ONLINE LA English DT Article DE medical education; graduate medical education; conference; lecture; active learning; lifelong learning ID TRAINING EXAMINATION SCORES; CONFERENCE ATTENDANCE; NOON CONFERENCE; EDUCATION.; PROGRAMS AB Background: In the Next Accreditation System, the Accreditation Council for Graduate Medical Education outlines milestones for medical knowledge and requires regular didactic sessions in residency training. There are many challenges to facilitating active learning in resident conferences, and we need to better understand resident learning preferences and faculty perspectives on facilitating active learning. The goal of this study was to identify challenges to facilitating active learning in resident conferences, both through identifying specific implementation barriers and identifying differences in perspective between faculty and residents on effective teaching and learning strategies. Methods: The investigators invited core residency faculty to participate in focus groups. The investigators used a semistructured guide to facilitate discussion about learning preferences and teaching perspectives in the conference setting and used an 'editing approach' within a grounded theory framework to qualitative analysis to code the transcripts and analyze the results. Data were compared to previously collected data from seven resident focus groups. Results: Three focus groups with 20 core faculty were conducted. We identified three domains pertaining to facilitating active learning in resident conferences: barriers to facilitating active learning formats, similarities and differences in faculty and resident learning preferences, and divergence between faculty and resident opinions about effective teaching strategies. Faculty identified several setting, faculty, and resident barriers to facilitating active learning in resident conferences. When compared to residents, faculty expressed similar learning preferences; the main differences were in motivations for conference attendance and type of content. Resident preferences and faculty perspectives differed on the amount of information appropriate for lecture and the role of active participation in resident conferences. Conclusion: This study highlights several challenges to facilitating active learning in resident conferences and provides insights for residency faculty who seek to transform the conference learning environment within their residency program. C1 [Sawatsky, Adam P.] Mayo Clin, Div Gen Internal Med, Rochester, MN 55905 USA. [Zickmund, Susan L.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Berlacher, Kathryn] Univ Pittsburgh, Sch Med, Div Cardiol, Pittsburgh, PA USA. [Lesky, Dan] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Granieri, Rosanne] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA USA. RP Sawatsky, AP (reprint author), Mayo Clin, Div Gen Internal Med, 200 1st St SW, Rochester, MN 55905 USA. EM sawatsky.adam@mayo.edu FU Division of General Internal Medicine; Faculty Award at the University of Pittsburgh FX The authors thank the Division of General Internal Medicine Fellow and Faculty Award at the University of Pittsburgh for funding this project. NR 28 TC 0 Z9 0 U1 1 U2 6 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 1087-2981 J9 MED EDUC ONLINE JI Med. Educ. Online PY 2015 VL 20 AR 27289 DI 10.3402/meo.v20.27289 PG 7 WC Education & Educational Research SC Education & Educational Research GA CM3MN UT WOS:000357586500001 PM 26160805 ER PT J AU Madigan, MC McEnaney, RM Shukla, AJ Hong, GY Kelley, EE Tarpey, MM Gladwin, M Zuckerbraun, BS Tzeng, E AF Madigan, Michael C. McEnaney, Ryan M. Shukla, Ankur J. Hong, Guiying Kelley, Eric E. Tarpey, Margaret M. Gladwin, Mark Zuckerbraun, Brian S. Tzeng, Edith TI Xanthine Oxidoreductase Function Contributes to Normal Wound Healing SO MOLECULAR MEDICINE LA English DT Article ID NITRIC-OXIDE SYNTHASE; EGF-RECEPTOR PHOSPHORYLATION; ISCHEMIA-REPERFUSION INJURY; ENDOTHELIAL GROWTH-FACTOR; IMPAIRED SKIN REPAIR; MIGRATION IN-VITRO; OXIDATIVE STRESS; HYDROGEN-PEROXIDE; DEFICIENT MICE; REDOX CONTROL AB Chronic, nonhealing wounds result in patient morbidity and disability. Reactive oxygen species (ROS) and nitric oxide (NO) are both required for normal wound repair, and derangements of these result in impaired healing. Xanthine oxidoreductase (XOR) has the unique capacity to produce both ROS and NO. We hypothesize that XOR contributes to normal wound healing. Cutaneous wounds were created in C57Bl6 mice. XOR was inhibited with dietary tungsten or allopurinol. Topical hydrogen peroxide (H2O2, 0.15%) or allopurinol (30 mu g) was applied to wounds every other day. Wounds were monitored until closure or collected at d 5 to assess XOR expression and activity, cell proliferation and histology. The effects of XOR, nitrite, H2O2 and allopurinol on keratinocyte cell (KC) and endothelial cell (EC) behavior were assessed. We identified XOR expression and activity in the skin and wound edges as well as granulation tissue. Cultured human KCs also expressed XOR. Tungsten significantly inhibited XOR activity and impaired healing with reduced ROS production with reduced angiogenesis and KC proliferation. The expression and activity of other tungsten-sensitive enzymes were minimal in the wound tissues. Oral allopurinol did not reduce XOR activity or alter wound healing but topical allopurinol significantly reduced XOR activity and delayed healing. Topical H2O2 restored wound healing in tungsten-fed mice. In vitro, nitrite and H2O2 both stimulated KC and EC proliferation and EC migration. These studies demonstrate for the first time that XOR is abundant in wounds and participates in normal wound healing through effects on ROS production. C1 [Madigan, Michael C.; McEnaney, Ryan M.; Shukla, Ankur J.; Hong, Guiying; Tarpey, Margaret M.; Zuckerbraun, Brian S.; Tzeng, Edith] Dept Vet Affairs Med Ctr, Surg Serv, Pittsburgh, PA USA. [Madigan, Michael C.; McEnaney, Ryan M.; Shukla, Ankur J.; Hong, Guiying; Zuckerbraun, Brian S.; Tzeng, Edith] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA. [Kelley, Eric E.; Tarpey, Margaret M.] Univ Pittsburgh, Dept Anesthesia, Pittsburgh, PA USA. [Gladwin, Mark] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. RP Tzeng, E (reprint author), VA Pittsburgh Healthcare Syst, Vasc Surg, A1010 PUH,200 Lothrop St, Pittsburgh, PA 15213 USA. EM tzenge@upmc.edu FU Department of Veterans Affairs, Veterans Health Administration; Office of Biomedical Laboratory Research and Development - National Institutes of Health (NIH) [NIH T32 HL098036, NIH R01 HL058115]; NIH [R01HL098032, R01HL096973, PO1HL103455]; Institute for Transfusion Medicine; Hemophilia Center of Western Pennsylvania FX We gratefully acknowledge the excellent technical assistance provided by NJ Hundley, SI Zharikov and N Cantu-Medellin. This material is based on work supported in part by the Department of Veterans Affairs, Veterans Health Administration and Office of Biomedical Laboratory Research and Development (ET), through funding from the National Institutes of Health (NIH) (NIH T32 HL098036 to MC Madigan, RM McEnaney and AJ Shukla and NIH R01 HL058115 to MM Tarpey). M Gladwin received research support from NIH grants R01HL098032, R01HL096973 and PO1HL103455 as well as from the Institute for Transfusion Medicine and the Hemophilia Center of Western Pennsylvania. NR 51 TC 5 Z9 5 U1 1 U2 8 PU FEINSTEIN INST MED RES PI MANHASSET PA 350 COMMUNITY DR, MANHASSET, NY 11030 USA SN 1076-1551 EI 1528-3658 J9 MOL MED JI Mol. Med. PY 2015 VL 21 BP 313 EP 322 DI 10.2119/molmed.2014.00191 PG 10 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA CM4JW UT WOS:000357651800008 PM 25879627 ER PT J AU Yang, AM Xiao, X Zhao, MF LaRue, AC Schulte, BA Wang, GY AF Yang, Aimin Xiao, Xia Zhao, Mingfeng LaRue, Amanda C. Schulte, Bradley A. Wang, Gavin Y. TI Differential Reponses of Hematopoietic Stem and Progenitor Cells to mTOR Inhibition SO STEM CELLS INTERNATIONAL LA English DT Article ID ACUTE MYELOID-LEUKEMIA; MAMMALIAN TARGET; ANTITUMOR-ACTIVITY; RAPAMYCIN; PTEN; PATHWAY; AZD8055; CANCER; LEUKEMOGENESIS; SENESCENCE AB Abnormal activation of the mammalian target of rapamycin (mTOR) signaling pathway has been observed in a variety of human cancers. Therefore, targeting of the mTOR pathway is an attractive strategy for cancer treatment and several mTOR inhibitors, including AZD8055 (AZD), a novel dual mTORC1/2 inhibitor, are currently in clinical trials. Although bone marrow (BM) suppression is one of the primary side effects of anticancer drugs, it is not known if pharmacological inhibition of dual mTORC1/2 affects BM hematopoietic stem and progenitor cells (HSPCs) function and plasticity. Here we report that dual inhibition of mTORC1/2 by AZD or its analogue (KU-63794) depletes mouse BM Lin(-)Sca-1(+)c-Kit(+) cells in cultures via the induction of apoptotic cell death. Subsequent colony-forming unit (CFU) assays revealed that inhibition of mTORC1/2 suppresses the clonogenic function of hematopoietic progenitor cells (HPCs) in a dose-dependent manner. Surprisingly, we found that dual inhibition of mTORC1/2 markedly inhibits the growth of day-14 cobblestone area-forming cells (CAFCs) but enhances the generation of day-35 CAFCs. Given the fact that day-14 and day-35 CAFCs are functional surrogates of HPCs and hematopoietic stem cells (HSCs), respectively, these results suggest that dual inhibition of mTORC1/2 may have distinct effects on HPCs versus HSCs. C1 [Yang, Aimin; Xiao, Xia; LaRue, Amanda C.; Schulte, Bradley A.; Wang, Gavin Y.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. [Xiao, Xia; Zhao, Mingfeng] Tianjin First Ctr Hosp, Dept Hematol, Tianjin 300192, Peoples R China. [LaRue, Amanda C.] Ralph H Johnson VAMC, Res Serv, Charleston, SC USA. [LaRue, Amanda C.; Wang, Gavin Y.] Med Univ S Carolina, Hollings Canc Ctr, Canc Genes & Mol Regulat Program, Charleston, SC 29425 USA. RP Wang, GY (reprint author), Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. EM wangy@musc.edu FU National Heart, Lung and Blood Institute (NHLBI) [HL106451]; Hollings Cancer Center [P30 CA138313]; South Carolina Clinical & Translational Research (SCTR) Institute; Medical University of South Carolina CTSA, NIH/NCATS Grant [UL1TR000062] FX This study was supported, in part, by a Grant from the National Heart, Lung and Blood Institute (NHLBI) no. HL106451 (Gavin Y. Wang) and a pilot grant from the Hollings Cancer Center (Gavin Y. Wang) via P30 CA138313. This work was also supported in part by the South Carolina Clinical & Translational Research (SCTR) Institute, with an academic home at the Medical University of South Carolina CTSA, NIH/NCATS Grant no. UL1TR000062. NR 31 TC 1 Z9 1 U1 0 U2 1 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 1687-966X EI 1687-9678 J9 STEM CELLS INT JI Stem Cells Int. PY 2015 AR 561404 DI 10.1155/2015/561404 PG 9 WC Cell & Tissue Engineering SC Cell Biology GA CM6QG UT WOS:000357813000001 ER PT J AU Gustafson, DR Morris, MC Scarmeas, N Shah, RC Sijben, J Yaffe, K Zhu, XW AF Gustafson, Deborah R. Morris, Martha Clare Scarmeas, Nikolaos Shah, Raj C. Sijben, John Yaffe, Kristine Zhu, Xiongwei TI New Perspectives on Alzheimer's Disease and Nutrition SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; cognition disorders; diet therapy; neuronal membrane; nutrition ID MILD COGNITIVE IMPAIRMENT; BODY-MASS INDEX; POLYUNSATURATED FATTY-ACID; DOCOSAHEXAENOIC ACID; MEDITERRANEAN DIET; OXIDATIVE STRESS; VITAMIN-E; CONTROLLED-TRIAL; OLDER-ADULTS; CARDIOVASCULAR-DISEASE AB Accumulating evidence shows nutritional factors influence the risk of developing Alzheimer's disease (AD) and its rate of clinical progression. Dietary and lifestyle guidelines to help adults reduce their risk have been developed. However, the clinical dementia picture remains complex, and further evidence is required to demonstrate that modifying nutritional status can protect the brain and prevent, delay, or reduce pathophysiological consequences of AD. Moreover, there is a pressing need for further research because of the global epidemic of overweight and obesity combined with longer life expectancy of the general population and generally observed decreases in body weight with aging and AD. A new research approach is needed, incorporating more sophisticated models to account for complex scenarios influencing the relationship between nutritional status and AD. Systematic research should identify and address evidence gaps. Integrating longitudinal epidemiological data with biomarkers of disease, including brain imaging technology, and randomized controlled interventions may provide greater insights into progressive and subtle neurological changes associated with dietary factors in individuals at risk for or living with AD. In addition, greater understanding of mechanisms involved in nutritional influences on AD risk and progression, such as oxidative stress and loss of neuronal membrane integrity, will better inform possible interventional strategies. There is consensus among the authors that nutritional deficits, and even states of excess, are associated with AD, but more work is needed to determine cause and effect. Appropriately designed diets or nutritional interventions may play a role, but additional research is needed on their clinical-cognitive effectiveness. C1 [Gustafson, Deborah R.] Suny Downstate Med Ctr, Dept Neurol, Brooklyn, NY 11203 USA. [Gustafson, Deborah R.] Univ Gothenburg, Sect Psychiat & Neurochem, NeuroPsychiat Epidemiol Unit, Inst Neurosci & Physiol,Sahlgrenska Acad, Gothenburg, Sweden. [Morris, Martha Clare] Rush Univ, Med Ctr, Dept Internal Med, Sect Nutr & Nutr Epidemiol, Chicago, IL 60612 USA. [Scarmeas, Nikolaos] Columbia Univ, Gertrude H Sergievsky Ctr, Dept Neurol, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY 10027 USA. [Scarmeas, Nikolaos] Univ Athens, Dept Social Med Psychiat & Neurol, Athens 11528, Greece. [Shah, Raj C.] Rush Univ, Med Ctr, Dept Family Med, Chicago, IL 60612 USA. [Shah, Raj C.] Rush Univ, Med Ctr, Rush Alzheimers Dis Ctr, Chicago, IL 60612 USA. [Sijben, John] Nutricia Res, Nutricia Adv Med Nutr, Utrecht, Netherlands. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA. [Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. [Zhu, Xiongwei] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA. RP Yaffe, K (reprint author), Univ Calif San Francisco, Psychiat, 4150 Clement St, San Francisco, CA 94121 USA. EM kristine.yaffe@ucsf.edu FU Swedish Research Council for Health, Working Life and Welfare [AGECAP 2013-2300]; EU [211696]; ESPA-EU program Excellence Grant (ARISTEIA) [189 10276/8/9/2011]; European Social Fund; Greek National resources; Ministry for Health and Social Solidarity (Greece) [DeltaY2beta/oiotakappa.51657/14.4.2009]; Illinois Department of Public Health; National Institute on Aging; National Institute on Environmental Health Sciences FX The authors received the following support: Deborah R. Gustafson: Swedish Research Council for Health, Working Life and Welfare (AGECAP 2013-2300) and EU 7th framework LipiDiDiet project (FP7/2007-2015) under grant agreement no. 211696; Nikolaos Scarmeas: 189 10276/8/9/2011 from the ESPA-EU program Excellence Grant (ARISTEIA) which is co-funded by the European Social Fund and Greek National resources; and Delta Y2 beta/o iota kappa.51657/14.4.2009 from the Ministry for Health and Social Solidarity (Greece); Raj C Shah: The Illinois Department of Public Health; Morris MC: National Institute on Aging and National Institute on Environmental Health Sciences. NR 143 TC 7 Z9 7 U1 5 U2 17 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2015 VL 46 IS 4 BP 1111 EP 1127 DI 10.3233/JAD-150084 PG 17 WC Neurosciences SC Neurosciences & Neurology GA CM1GM UT WOS:000357429300026 PM 26402637 ER PT J AU McDonald, LT Mehrotra, M LaRue, AC AF McDonald, Lindsay T. Mehrotra, Meenal LaRue, Amanda C. TI Hematopoietic Origin of Murine Lung Fibroblasts SO STEM CELLS INTERNATIONAL LA English DT Article ID INDUCED PULMONARY-FIBROSIS; MESENCHYMAL STEM-CELLS; BONE-MARROW; CIRCULATING FIBROCYTES; IN-VITRO; MYOFIBROBLASTS; IDENTIFICATION; RECONSTITUTION; PROLIFERATION; PRECURSORS AB Multiple origins, including the bone marrow, have been suggested to contribute to fibroblast populations in the lung. Using bone marrow reconstitution strategies, the present study tested the hypothesis that the bone marrow hematopoietic stem cell (HSC) gives rise to lung tissue fibroblasts in vivo. Data demonstrate that the nonadherent bone marrow fraction is enriched for CD45(+) HSC-derived cells and was able to reconstitute hematopoiesis in lethally irradiated animals. Analysis of peripheral blood and lung tissues from engrafted mice demonstrated the ability of this population to give rise to CD45(+)/Discoidin-Domain Receptor-2(+) (DDR2) circulating fibroblast precursors (CFPs) in blood and fibroblast populations in lung. An HSC origin for lung fibroblasts was confirmed using a novel clonal cell transplantation method in which the bone marrow is reconstituted by a clonal population derived from a single HSC. Together, these findings provide evidence for an HSC contribution to lung fibroblasts and demonstrate a circulating intermediate through the CD45(+)/DDR2(+) HSC-derived CFP. C1 [McDonald, Lindsay T.; LaRue, Amanda C.] Ralph H Johnson Dept Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA. [McDonald, Lindsay T.; Mehrotra, Meenal; LaRue, Amanda C.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. [LaRue, Amanda C.] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA. RP LaRue, AC (reprint author), Ralph H Johnson Dept Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA. EM laruerc@musc.edu FU VA [BX-12-011] FX This work was supported by a VA merit awarded to Amanda C. LaRue (BX-12-011). The authors thank the staff of the Radiation Oncology Department of the Medical University of South Carolina in irradiation of mice, and the animal care staff of the Ralph H. Johnson VAMC. They also acknowledge the Hollings Cancer Center Flow Cytometry Core P30 CA138313. NR 41 TC 0 Z9 0 U1 0 U2 0 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 1687-966X EI 1687-9678 J9 STEM CELLS INT JI Stem Cells Int. PY 2015 AR 159713 DI 10.1155/2015/159713 PG 11 WC Cell & Tissue Engineering SC Cell Biology GA CM2EY UT WOS:000357493800001 ER PT J AU Hoggatt, KJ Jamison, AL Lehavot, K Cucciare, MA Timko, C Simpson, TL AF Hoggatt, Katherine J. Jamison, Andrea L. Lehavot, Keren Cucciare, Michael A. Timko, Christine Simpson, Tracy L. TI Alcohol and Drug Misuse, Abuse, and Dependence in Women Veterans SO EPIDEMIOLOGIC REVIEWS LA English DT Article DE alcohol; drugs; gender; military; substance-related disorders; veterans; women ID SUBSTANCE USE DISORDERS; POSTTRAUMATIC-STRESS-DISORDER; VA HEALTH-CARE; NURSING-HOME RESIDENTS; FEMALE VETERANS; MENTAL-HEALTH; AFGHANISTAN VETERANS; GENDER-DIFFERENCES; UNITED-STATES; MILITARY SERVICE AB We conducted a systematic literature review on substance misuse, abuse, and dependence in women veterans, including National Guard/reserve members. We identified 837 articles published between 1980 and 2013. Of 56 included studies, 32 reported rates of alcohol misuse, binge drinking, or other unhealthy alcohol use not meeting diagnostic criteria for abuse or dependence, and 33 reported rates of drug misuse or diagnosed alcohol or drug use disorders. Rates ranged from 4% to 37% for alcohol misuse and from 7% to 25% for binge drinking; among Veterans Health Administration (VA) health-care system outpatients, rates ranged from 3% to 16% for substance use disorder. Studies comparing women veterans and civilians reported no clear differences in binge or heavy drinking. Substance misuse rates were generally lower among women veterans than men veterans. Substance misuse was associated with higher rates of trauma, psychiatric and medical conditions, and increased mortality and suicide rates. Most studies included only VA patients, and many used only VA medical record data; therefore, the reported substance misuse rates likely do not reflect true prevalence. Rates also varied by assessment method, source of data, and the subgroups studied. Further efforts to develop epidemiologically valid prevalence estimates are needed to capture the true health burden of substance misuse in women veterans, particularly those not using VA care. C1 [Hoggatt, Katherine J.] VA Greater Los Angeles, Hlth Serv Res & Dev Ctr, Study Healthcare Innovat Implementat & Policy, Sepulveda, CA 91343 USA. RP Hoggatt, KJ (reprint author), VA Greater Los Angeles, Hlth Serv Res & Dev Ctr, Study Healthcare Innovat Implementat & Policy, 16111 Plummer St Mailstop 152, Sepulveda, CA 91343 USA. EM khoggatt@ucla.edu FU VA HSRD [SDR 10-012, CX 000867, CDA 08-004-3, RCS 00-001]; VA HSRD/QUERI [CDA 11-261] FX This work was supported by VA HSR&D (SDR 10-012), with excerpts presented at the VA Substance Use Disorder Workgroup of the Women's Health Research Consortium. Funding was also provided through a VA HSR&D/QUERI Career Development Award (CDA 11-261) to K. J. H., a VA CSR&D Career Development Award (CX 000867) to K. L., a VA HSR&D Career Development Award (CDA 08-004-3) to M. A. C., and a VA HSR&D Senior Research Career Scientist Award (RCS 00-001) to C. T. NR 119 TC 8 Z9 8 U1 4 U2 17 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0193-936X EI 1478-6729 J9 EPIDEMIOL REV JI Epidemiol. Rev. PY 2015 VL 37 IS 1 BP 23 EP 37 DI 10.1093/epirev/mxu010 PG 15 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CL3ZX UT WOS:000356892800003 PM 25608962 ER PT J AU Theodoroff, SM Lewis, MS Folmer, RL Henry, JA Carlson, KF AF Theodoroff, Sarah M. Lewis, M. Samantha Folmer, Robert L. Henry, James A. Carlson, Kathleen F. TI Hearing Impairment and Tinnitus: Prevalence, Risk Factors, and Outcomes in US Service Members and Veterans Deployed to the Iraq and Afghanistan Wars SO EPIDEMIOLOGIC REVIEWS LA English DT Article DE hearing loss; prevalence; risk factors; tinnitus; veterans' health ID TRAUMATIC BRAIN-INJURY; OPERATION ENDURING FREEDOM; COMBAT WOUNDS; BLAST INJURY; GLOBAL WAR; MECHANISM; TERROR; AIDS AB Hearing loss and tinnitus are the 2 most prevalent service-connected disabilities among veterans in the United States. Veterans of Operations Enduring Freedom, Iraqi Freedom, and New Dawn have been exposed to multiple hazards associated with these conditions, such as blasts/explosions, ototoxic chemicals, and most notably high levels of noise. We conducted a systematic literature review of evidence on 1) prevalence of, 2) risk and protective factors for, and 3) functional and quality-of-life outcomes of hearing impairment and tinnitus in US Operations Enduring Freedom, Iraqi Freedom, and New Dawn veterans and military personnel. We identified studies published from 2001 through 2013 using PubMed, PsycINFO, REHABDATA, Cochrane Library, pearling, and expert recommendation. Peer-reviewed English language articles describing studies of 30 or more adults were included if they informed one or more key questions. A total of 839 titles/abstracts were reviewed for relevance by investigators trained in critical analysis of literature; 14 studies met inclusion criteria. Of these, 13 studies presented data on prevalence and 4 on risk/protective factors, respectively. There were no included studies reporting on outcomes. Findings from this systematic review will help inform clinicians, researchers, and policy makers on future resource and research needs pertaining to hearing impairment and tinnitus in this newest generation of veterans. C1 [Theodoroff, Sarah M.] Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, Portland, OR 97239 USA. RP Theodoroff, SM (reprint author), Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, 3710 Southwest US Vet Hosp Rd, Portland, OR 97239 USA. EM sarah.theodoroff@va.gov FU Department of Defense Congressionally Directed Medical Research Programs [PR121146]; Veterans Health Administration Health Services Research and Development Service [CDA 08-025]; National Center for Rehabilitative Auditory Research - VA RR&D at the Portland VA Medical Center [C9230C] FX This work was supported, in part, by the Department of Defense Congressionally Directed Medical Research Programs (PR121146 to J. A. H.) and a career development grant from the Veterans Health Administration Health Services Research and Development Service (CDA 08-025 to K. F. C.). Additional support was provided by the National Center for Rehabilitative Auditory Research (funded by VA RR&D grant C9230C) at the Portland VA Medical Center. NR 46 TC 4 Z9 4 U1 2 U2 15 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0193-936X EI 1478-6729 J9 EPIDEMIOL REV JI Epidemiol. Rev. PY 2015 VL 37 IS 1 BP 71 EP 85 DI 10.1093/epirev/mxu005 PG 15 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CL3ZX UT WOS:000356892800006 PM 25600417 ER PT J AU Beste, LA Ioannou, GN AF Beste, Lauren A. Ioannou, George N. TI Prevalence and Treatment of Chronic Hepatitis C Virus Infection in the US Department of Veterans Affairs SO EPIDEMIOLOGIC REVIEWS LA English DT Article DE epidemiology; hepatitis C virus; United States; veterans ID SUSTAINED VIROLOGICAL RESPONSE; UNITED-STATES VETERANS; GENOTYPE 1 INFECTION; TREATMENT ELIGIBILITY; ANTIVIRAL THERAPY; VIRAL-HEPATITIS; PLUS RIBAVIRIN; RISK-FACTORS; COHORT; CARE AB Chronic hepatitis C virus (HCV) is the most common blood-borne pathogen in the United States. HCV disproportionately affects Veterans Affairs (VA) health-care users: 174,302 HCV-infected veterans were in VA care in 2013, making the VA the world's largest HCV care provider. This systematic review identified 546 articles related to HCV in the VA. After assessment by 2 independent reviewers, 28 articles describing prevalence and treatment of HCV in VA users ultimately met inclusion criteria. Most VA patients currently living with HCV infection were born between 1945 and 1965 and were infected with HCV between 1970 and 1990. To prevent HCV-related complications such as cirrhosis, hepatocellular carcinoma, and death, medical personnel must identify and treat HCV. However, antiviral therapy has historically been limited by medication side effects, contraindications, and patient acceptance. Although treatment initiation rates are higher in the VA than in the general United States, only 23% of VA HCV patients have received treatment and, of those, only a minority were cured. Recent development of more effective and tolerable antiviral agents represents a major pharmacological breakthrough. Eradication of HCV is theoretically possible for the majority of HCV patients for the first time, although new barriers, such as high drug costs, may limit future uptake. C1 [Beste, Lauren A.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Beste, LA (reprint author), Vet Affairs Puget Sound Hlth Care Syst, 1660 South Columbian Way,S-111 GI, Seattle, WA 98108 USA. EM lauren.beste@va.gov NR 60 TC 16 Z9 16 U1 2 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0193-936X EI 1478-6729 J9 EPIDEMIOL REV JI Epidemiol. Rev. PY 2015 VL 37 IS 1 BP 131 EP 143 DI 10.1093/epirev/mxu002 PG 13 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CL3ZX UT WOS:000356892800010 PM 25600415 ER PT J AU Amalakuhan, B Adams, SG AF Amalakuhan, Bravein Adams, Sandra G. TI Improving outcomes in chronic obstructive pulmonary disease: the role of the interprofessional approach SO INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE LA English DT Review DE optimal care; shared decision-making; co-morbidities ID RANDOMIZED CONTROLLED-TRIAL; SMOKING-CESSATION; LUNG TRANSPLANTATION; INTERNATIONAL SOCIETY; MANAGEMENT PROGRAM; PHYSICAL-ACTIVITY; SLEEP-APNEA; ADULT LUNG; COPD; REHABILITATION AB Chronic obstructive pulmonary disease (COPD) is associated with significant morbidity, places substantial time and cost burden on the health care system, and is now the third leading cause of death in the US. Many interventions are available to appropriately manage patients with COPD; however, fully implementing these strategies to help improve outcomes may be difficult. Collaboration between an interprofessional team of health care professionals (which includes physicians, nurses, respiratory therapists, physical therapists, dietitians, pharmacists, and many others) and COPD patients and caregivers is necessary to optimally manage these patients and to truly impact outcomes in this devastating disease. Prescribing evidence-based non-pharmacological and pharmacological therapies is an important start, but a true team-based approach is critical to successfully implement comprehensive care in patients with COPD. The goal of this review is to employ a case-based approach to provide practical information regarding the roles of the interprofessional team in implementing strategies to optimally manage COPD patients. C1 [Amalakuhan, Bravein; Adams, Sandra G.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Pulm Dis Crit Care Med, San Antonio, TX 78229 USA. [Amalakuhan, Bravein; Adams, Sandra G.] South Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. RP Adams, SG (reprint author), Audie L Murphy Mem Vet Adm Med Ctr, South Texas Vet Hlth Care Syst, Pulm Dis Sect 111E,7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM adamssg@uthscsa.edu FU National Institute of Health; Veterans Affairs Cooperative Studies Program; CHEST Foundation; University of Texas System Patient Safety Grant; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc; GlaxoSmithKline; Novartis Pharmaceuticals AG FX Sandra Adams has funded research by National Institute of Health, Veterans Affairs Cooperative Studies Program, CHEST Foundation, University of Texas System Patient Safety Grant, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals, Inc, GlaxoSmithKline, and Novartis Pharmaceuticals AG, and is the President of a not-for-profit organization entitled WipeDiseases Foundation. Bravein Amalakuhan reports no conflict of interest in this work. NR 66 TC 4 Z9 4 U1 0 U2 4 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1178-2005 J9 INT J CHRONIC OBSTR JI Int. J. Chronic Obstr. Pulm. Dis. PY 2015 VL 10 BP 1225 EP 1232 DI 10.2147/COPD.S71450 PG 8 WC Respiratory System SC Respiratory System GA CL5VV UT WOS:000357031300003 PM 26170651 ER PT J AU Laws, DA Kraft, AS Leddy, LR LaRue, AC AF Laws, Dayvia A. Kraft, Andrew S. Leddy, Lee R. LaRue, Amanda C. TI The role of circulating fibroblast precursors in promoting metastatic sarcoma SO CANCER RESEARCH LA English DT Meeting Abstract CT AACR Special Conference on Cellular Heterogeneity in the Tumor Microenvironment CY FEB 26-MAR 01, 2014 CL San Diego, CA SP AACR C1 [Laws, Dayvia A.; Kraft, Andrew S.; Leddy, Lee R.] Med Univ S Carolina, Charleston, SC 29425 USA. [LaRue, Amanda C.] Ralph H Johnson VAMC, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD JAN 1 PY 2015 VL 75 IS 1 SU S MA A46 DI 10.1158/1538-7445.CHTME14-A46 PG 1 WC Oncology SC Oncology GA CL0JZ UT WOS:000356630300031 ER PT J AU Xiong, Y Laws, DA LaRue, AC AF Xiong, Ying Laws, Dayvia A. LaRue, Amanda C. TI Hematopoietic stem cell-derived adipocytes promote tumor progression SO CANCER RESEARCH LA English DT Meeting Abstract CT AACR Special Conference on Cellular Heterogeneity in the Tumor Microenvironment CY FEB 26-MAR 01, 2014 CL San Diego, CA SP AACR C1 [Xiong, Ying; Laws, Dayvia A.] Med Univ S Carolina, Charleston, SC 29425 USA. [LaRue, Amanda C.] Ralph H Johnson VAMC, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD JAN 1 PY 2015 VL 75 IS 1 SU S MA A77 DI 10.1158/1538-7445.CHTME14-A77 PG 1 WC Oncology SC Oncology GA CL0JZ UT WOS:000356630300057 ER PT J AU Maxwell, LJ Zochling, J Boonen, A Singh, JA Veras, MMS Ghogomu, ET Jandu, MB Tugwell, P Wells, GA AF Maxwell, Lara J. Zochling, Jane Boonen, Annelies Singh, Jasvinder A. Veras, Mirella M. S. Ghogomu, Elizabeth Tanjong Jandu, Maria Benkhalti Tugwell, Peter Wells, George A. TI TNF-alpha inhibitors for ankylosing spondylitis SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS LA English DT Review ID PLACEBO-CONTROLLED TRIAL; NECROSIS-FACTOR-ALPHA; LOW-DOSE INFLIXIMAB; SOCIETY CLASSIFICATION CRITERIA; REDUCES SPINAL INFLAMMATION; PATIENT-REPORTED OUTCOMES; SHORT-TERM IMPROVEMENT; ETANERCEPT 50 MG; PHASE-III TRIAL; DOUBLE-BLIND AB Background TNF (tumor necrosis factor)-alpha inhibitors block a key protein in the inflammatory chain reaction responsible for joint inflammation, pain, and damage in ankylosing spondylitis. Objectives To assess the benefit and harms of adalimumab, etanercept, golimumab, and infliximab (TNF-alpha inhibitors) in peoplewith ankylosing spondylitis. Search methods We searched the following databases to January 26, 2009: MEDLINE (from 1966); EMBASE (from 1980); the Cochrane Central Register of Controlled Trials (CENTRAL; 2008, Issue 4); ACP Journal Club; CINAHL (from1982); and ISIWeb of Knowledge (from 1900). We ran updated searches in May 2012, October 2013, and in June 2014 for McMaster PLUS. We searched major regulatory agencies for safety warnings and clinicaltrials. gov for registered trials. Selection criteria Randomized controlled trials (RCTs) comparing adalimumab, etanercept, golimumab and infliximab to placebo, other drugs or usual care in patients with ankylosing spondylitis, reported in abstract or full-text. Data collection and analysis Two authors independently assessed search results, risk of bias, and extracted data. We conducted Bayesian mixed treatment comparison (MTC) meta-analyses using WinBUGS software. To investigate a class-effect of harms across biologics, we pooled harms data using Review Manager 5. Main results We included twenty-one, short-term(24 weeks or less) RCTs with a total of 3308 participants; 18 contributed data to the MTC analysis: adalimumab (4 studies), etanercept (8 studies), golimumab (2 studies), infliximab (3 studies), and one head-to-head study (etanercept versus infliximab) which was unblinded and considered at a higher risk of bias. The risk of selection and detection bias was low or unclear for most of the studies. The risk of selective outcome reporting was low for most studies as they reported on outcomes recommended by the Assessment of SpondyloArthritis international Society. We found little heterogeneity and no significant inconsistency in the MTC analyses. The majority of the studies were funded by pharmaceutical companies. Most studies permitted concomitant therapy of stable doses of disease-modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs, or corticosteroids, but allowances varied across studies. Compared with placebo, there was high quality evidence that patients on an anti-TNF agent were three to four times more likely to achieve an ASAS40 response (assessing spinal pain, function, and inflammation, as measured by the mean of intensity and duration of morning stiffness, and patient global assessment) by six months (adalimumab: risk ratio (RR) 3.53, 95% credible interval (Crl) 2.49 to 4.91; etanercept: RR 3.31, 95% Crl 2.38 to 4.53; golimumab: RR 2.90, 95% Crl 1.90 to 4.23; infliximab: RR 4.07, 95% Crl 2.80 to 5.74, with a 25% to 40% absolute difference between treatment and placebo groups. The number needed to treat (NNT) to achieve an ASAS 40 response ranged from 3 to 5. There was high quality evidence of improvement in physical function on a 0 to 10 scale (adalimumab: mean difference (MD) -1.6, 95% Crl -2.2 to -0.9; etanercept: MD -1.1, 95% CrI -1.6 to -0.6; golimumab: MD -1.5, 95% Crl -2.3 to -0.7; infliximab: MD 2.1, 95% Crl -2.7 to -1.4, with an 11% to 21% absolute difference between treatment and placebo groups. The NNT to achieve the minimally clinically important difference of 0.7 points ranged from 2 to 4. Compared with placebo, there was moderate quality evidence (downgraded for imprecision) that patients on an anti-TNF agent were more likely to achieve an ASAS partial remission by six months (adalimumab: RR 6.28, 95% Crl 3.13 to 12.78; etanercept: RR 4.24, 95% Crl 2.31 to 8.09; golimumab: RR 5.18, 95% Crl 1.90 to 14.79; infliximab: RR 15.41, 95% Crl 5.09 to 47.98 with a 10% to 44% absolute difference between treatment and placebo groups. The NNT to achieve an ASAS partial remission response ranged from 3 to 11. There was low to moderate level evidence of a greater reduction in spinal inflammation as measured by magnetic resonance imaging though the absolute differences were small and the clinical relevance of the difference was unclear: adalimumab (1 trial; -6% (95% confidence interval (CI) -12% to 0.05%); 1 trial: 53.6% mean decrease from baseline versus 9.4% mean increase in the placebo group), golimumab (1 trial; -2.5%, (95% CI -5.6% to -0.7%)), and infliximab (1 trial; -3% (95% CI -4% to -2.4%)). Radiographic progression was measured in one trial (N = 60) of etanercept versus placebo and it found that radiologic changes were similar in both groups (detailed data not provided). There were few events of withdrawals due to adverse events leading to imprecision around the estimates. When all the anti-TNF agents were combined against placebo, there was moderate quality evidence from 16 studies of an increased risk of withdrawals due to adverse events in the anti-TNF group (Peto odds ratio (OR) 2.44, 95% CI 1.26 to 4.72; total events: 38/1637 in biologic group; 7/986 in placebo) though the absolute increase in harm was small (1%; 95% CI 0% to 2%). Due to low event rates, evidence of the effect of individual TNF-inhibitors against placebo or for all four biologics pooled together versus placebo on serious adverse events is inconclusive (moderate quality; downgraded for imprecision). For all anti-TNF pooled versus placebo based on 16 studies: Peto OR 1.45, 95% CI 0.85 to 2.48; 51/1530 in biologic group; 18/878 in placebo; absolute difference: 1% (95% CI 0% to 2%). Using indirect comparison methodology, and one head-to-head study of etanercept versus infliximab, wide confidence intervals meant that results were inconclusive for evidence of differences in themajor outcomes between different anti-TNF agents. Regulatory agencies have published warnings about rare adverse events of serious infections, including tuberculosis, malignancies and lymphoma. Authors' conclusions There is moderate to high quality evidence that anti-TNF agents improve clinical symptoms in the treatment of ankylosing spondylitis. More participants withdrew due to adverse events when on an anti-TNF agent but we did not find evidence of an increase in serious adverse events, though event rates were low and trials had a short duration. The short-term toxicity profile appears acceptable. Based on indirect comparison methodology, we are uncertain whether there are differences between anti-TNF agents in terms of the key benefit or harm outcomes. C1 [Maxwell, Lara J.] Ottawa Hosp Res Inst, Ctr Practice Changing Res, Ottawa, ON K1H 8L6, Canada. [Zochling, Jane] Menzies Res Inst, Hobart, Tas, Australia. [Boonen, Annelies] Caphri Res Inst, Dept Rheumatol, NL-6202 AZ Maastricht, Netherlands. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Dept Med, Birmingham, AL USA. [Veras, Mirella M. S.] Univ Montreal, Ecole Readaptac, Montreal, PQ, Canada. [Ghogomu, Elizabeth Tanjong] Univ Ottawa, Bruyere Res Inst, Ottawa, ON, Canada. [Jandu, Maria Benkhalti] Univ Ottawa, Inst Populat Hlth, Ctr Global Hlth, Ottawa, ON, Canada. [Tugwell, Peter] Univ Ottawa, Dept Med, Fac Med, Ottawa, ON, Canada. [Wells, George A.] Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON, Canada. RP Maxwell, LJ (reprint author), Ottawa Hosp Res Inst, Ctr Practice Changing Res, Ottawa Hosp Gen Campus,501 Smyth Rd,Box 711, Ottawa, ON K1H 8L6, Canada. EM lmaxwell@uottawa.ca RI Veras, Mariana/D-8575-2012 OI Veras, Mariana/0000-0002-8363-4329; Tugwell, Peter/0000-0001-5062-0556 FU Institute of Population Health, University of Ottawa, Canada; Rheumazentrum Ruhrgebiet, Germany; NIHR Cochrane Incentive Award, UK FX Internal sources; Institute of Population Health, University of Ottawa, Canada.; Rheumazentrum Ruhrgebiet, Germany.; External sources; NIHR Cochrane Incentive Award 2013, UK.; Award to assist with completion of the review. NR 109 TC 11 Z9 12 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1469-493X EI 1361-6137 J9 COCHRANE DB SYST REV JI Cochrane Database Syst Rev. PY 2015 IS 4 AR CD005468 DI 10.1002/14651858.CD005468.pub2 PG 144 WC Medicine, General & Internal SC General & Internal Medicine GA CK1UQ UT WOS:000355993500018 PM 25887212 ER PT J AU Williams, DA Kogan, JR Hauer, KE Yamashita, T Aagaard, EM AF Williams, David A. Kogan, Jennifer R. Hauer, Karen E. Yamashita, Traci Aagaard, Eva M. TI The impact of exposure to shift-based schedules on medical students SO MEDICAL EDUCATION ONLINE LA English DT Article DE duty-hour reform; shift-based schedules; medical students; internal medicine clerkship; team fragmentation ID SURGICAL RESIDENTS; ROLE-MODELS; DUTY HOURS; CONTINUITY; EXPERIENCE; CLERKSHIP; TEACHERS; DESCRIBE; REFORM; CARE AB Background: With new resident duty-hour regulations, resident work schedules have progressively transitioned towards shift-based systems, sometimes resulting in increased team fragmentation. We hypothesized that exposure to shift-based schedules and subsequent team fragmentation would negatively affect medical student experiences during their third-year internal medicine clerkship. Design: As part of a larger national study on duty-hour reform, 67 of 150 eligible third-year medical students completed surveys about career choice, teaching and supervision, assessment, patient care, well-being, and attractiveness of a career in internal medicine after completing their internal medicine clerkship. Students who rotated to hospitals with shift-based systems were compared to those who did not. Non-demographic variables used a five-point Likert scale. Chi-squared and Fisher's exact tests were used to assess the relationships between exposure to shift-based schedules and student responses. Questions with univariate p50.1 were included in multivariable logistic regression models. Results: Thirty-six students (54%) were exposed to shift-based schedules. Students exposed to shift-based schedules were less likely to perceive that their attendings were committed to teaching (odds ratio [OR] 0.35, 95% confidence interval [CI]: 0.13-0.90, p = 0.01) or perceive that residents had sufficient exposure to assess their performance (OR 0.29, 95% CI: 0.09-0.91, p = 0.03). However, those students were more likely to feel their interns were able to observe them at the bedside (OR 1.89, 95% CI: 1.08-3.13, p = 0.02) and had sufficient exposure to assess their performance (OR 3.00, 95% CI: 1.01-8.86, p = 0.05). Conclusions: These findings suggest that shift-based schedules designed in response to duty-hour reform may have important broader implications for the teaching environment. C1 [Williams, David A.] Univ Colorado, Sch Med, Dept Internal Med, Denver Vet Affairs Med Ctr, Aurora, CO USA. [Kogan, Jennifer R.] Univ Penn, Dept Med, Perleman Sch Med, Philadelphia, PA 19104 USA. [Hauer, Karen E.] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA USA. [Yamashita, Traci; Aagaard, Eva M.] Univ Colorado, Sch Med, Dept Med, Aurora, CO USA. RP Williams, DA (reprint author), Denver Vet Affairs Med Ctr, 1055 Clermont St, Denver, CO 80220 USA. EM david.williams18@va.gov NR 27 TC 0 Z9 0 U1 1 U2 3 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 1087-2981 J9 MED EDUC ONLINE JI Med. Educ. Online PY 2015 VL 20 AR 27434 DI 10.3402/meo.v20.27434 PG 6 WC Education & Educational Research SC Education & Educational Research GA CK9ZG UT WOS:000356597500001 PM 26095587 ER PT B AU Kudsk, KA Pierre, JF AF Kudsk, Kenneth A. Pierre, Joseph F. BE Rothkopf, MM Nusbaum, MJ Haverstick, LP TI Nutrition and Immunity of the Gut SO METABOLIC MEDICINE AND SURGERY LA English DT Article; Book Chapter ID RESPIRATORY-TRACT IMMUNITY; MAJOR ABDOMINAL-TRAUMA; LYMPHOID-TISSUE; PARENTERAL-NUTRITION; MUCOSAL IMMUNITY; ENTERAL NUTRITION; BACTERIAL PNEUMONIA; SEPTIC MORBIDITY; INNATE IMMUNITY; SMALL-INTESTINE C1 [Kudsk, Kenneth A.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, Madison, WI USA. [Pierre, Joseph F.] Univ Chicago, Dept Med, Sect Gastroenterol Hepatol & Nutr, Chicago, IL 60637 USA. RP Kudsk, KA (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53706 USA. NR 55 TC 0 Z9 0 U1 0 U2 1 PU CRC PRESS-TAYLOR & FRANCIS GROUP PI BOCA RATON PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA BN 978-1-4665-6712-2; 978-1-4665-6711-5 PY 2015 BP 457 EP 468 PG 12 WC Endocrinology & Metabolism; Nutrition & Dietetics; Surgery SC Endocrinology & Metabolism; Nutrition & Dietetics; Surgery GA BC6XI UT WOS:000354561800027 ER PT J AU Stahlman, S Javanbakht, M Cochran, S Shoptaw, S Hamilton, AB Gorbach, PM AF Stahlman, Shauna Javanbakht, Marjan Cochran, Susan Shoptaw, Steven Hamilton, Alison B. Gorbach, Pamina M. TI A comparison of self-reported sexual risk behaviours between US civilian and active duty military women SO SEXUAL HEALTH LA English DT Article ID TRANSMITTED INFECTIONS; UNITED-STATES; SUBSTANCE USE; RECRUITS; TRENDS AB Women in the US military report a high prevalence of sexual risk behaviours, such as binge drinking and new or multiple sexual partnerships. However, demographical differences pose challenges to making comparisons with civilians. Two public-use datasets were used to compare prevalence of sexual risk behaviours between sexually active military and civilian women, after adjusting for demographic factors. It was found that women in the military reported a higher prevalence of binge drinking and new/multiple sexual partners as compared with civilians, which suggests that military women are a high-risk group and the military environment may at least partially facilitate these risk behaviours. C1 [Stahlman, Shauna; Javanbakht, Marjan; Cochran, Susan; Gorbach, Pamina M.] Univ Calif Los Angeles, Dept Epidemiol, Fielding Sch Publ Hlth, Los Angeles, CA 90095 USA. [Hamilton, Alison B.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Hamilton, Alison B.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Shoptaw, Steven] Univ Calif Los Angeles, Dept Family Med, Los Angeles, CA 90095 USA. RP Stahlman, S (reprint author), Univ Calif Los Angeles, Dept Epidemiol, Fielding Sch Publ Hlth, Los Angeles, CA 90095 USA. EM sstahlman@ucla.edu OI Shoptaw, Steven/0000-0002-3583-0026 FU NIMH NIH HHS [P30 MH058107] NR 16 TC 1 Z9 1 U1 0 U2 3 PU CSIRO PUBLISHING PI CLAYTON PA UNIPARK, BLDG 1, LEVEL 1, 195 WELLINGTON RD, LOCKED BAG 10, CLAYTON, VIC 3168, AUSTRALIA SN 1448-5028 EI 1449-8987 J9 SEX HEALTH JI Sex Health PY 2015 VL 12 IS 3 BP 272 EP 275 DI 10.1071/SH14211 PG 4 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CK7EV UT WOS:000356395300015 PM 25844558 ER PT J AU Matteucci, E Giampietro, O Covolan, V Giustarini, D Fanti, P Rossi, R AF Matteucci, Elena Giampietro, Ottavio Covolan, Vera Giustarini, Daniela Fanti, Paolo Rossi, Ranieri TI Insulin administration: present strategies and future directions for a noninvasive (possibly more physiological) delivery SO DRUG DESIGN DEVELOPMENT AND THERAPY LA English DT Review DE type 1 diabetes mellitus; drug formulations; drug administration routes; insulin; portal system; nanoparticles; biodegradable polymers ID TRANSDERMAL DRUG-DELIVERY; TIME-ACTION PROFILE; SUBCUTANEOUSLY INJECTED INSULIN; INHALED TECHNOSPHERE INSULIN; RANDOMIZED CONTROLLED-TRIAL; SOLID LIPID NANOPARTICLES; REGULAR HUMAN INSULIN; ORAL INSULIN; DIABETES-MELLITUS; IN-VIVO AB Insulin is a life-saving medication for people with type 1 diabetes, but traditional insulin replacement therapy is based on multiple daily subcutaneous injections or continuous subcutaneous pump-regulated infusion. Nonphysiologic delivery of subcutaneous insulin implies a rapid and sustained increase in systemic insulin levels due to the loss of concentration gradient between portal and systemic circulations. In fact, the liver degrades about half of the endogenous insulin secreted by the pancreas into the venous portal system. The reverse insulin distribution has short- and long-term effects on glucose metabolism. Thus, researchers have explored less-invasive administration routes based on innovative pharmaceutical formulations, which preserve hormone stability and ensure the therapeutic effectiveness. This review examines some of the recent proposals from clinical and material chemistry point of view, giving particular attention to patients' (and diabetologists') ideal requirements that organic chemistry could meet. C1 [Matteucci, Elena; Giampietro, Ottavio] Univ Pisa, Dept Clin & Expt Med, I-56100 Pisa, Italy. [Covolan, Vera] Univ Pisa, Dept Chem & Ind Chem, I-56100 Pisa, Italy. [Giustarini, Daniela; Rossi, Ranieri] Univ Siena, Lab Pharmacol & Toxicol, Dept Life Sci, I-53100 Siena, Italy. [Fanti, Paolo] Univ Texas Hlth Sci Ctr San Antonio, Div Nephrol, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Matteucci, E (reprint author), Dipartimento Med Clin & Sperimentale, Via Roma 67, I-56126 Pisa, Italy. EM elena.matteucci@med.unipi.it NR 75 TC 5 Z9 5 U1 2 U2 25 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1177-8881 J9 DRUG DES DEV THER JI Drug Des. Dev. Ther. PY 2015 VL 9 BP 3109 EP 3118 DI 10.2147/DDDT.S79322 PG 10 WC Chemistry, Medicinal; Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA CK6RA UT WOS:000356354100001 PM 26124635 ER PT J AU Asselin, P Knezevic, S Kornfeld, S Cirnigliaro, C Agranova-Breyter, I Bauman, WA Spungen, AM AF Asselin, Pierre Knezevic, Steven Kornfeld, Stephen Cirnigliaro, Christopher Agranova-Breyter, Irina Bauman, William A. Spungen, Ann M. TI Heart rate and oxygen demand of powered exoskeleton-assisted walking in persons with paraplegia SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE 6MWT; ambulatory device; energy expenditure; metabolic; overground walking; oxygen uptake; paraplegia; powered exoskeleton; reciprocating gait orthosis; RGO; spinal cord injury ID SPINAL-CORD-INJURY; RECIPROCATING-GAIT ORTHOSIS; QUALITY-OF-LIFE; ELECTRICAL-STIMULATION; ENERGY-EXPENDITURE; HYBRID ORTHOSIS; EXERCISE; INDIVIDUALS; PERFORMANCE; COST AB Historically, persons with paralysis have limited options for overground ambulation. Recently, powered exoskeletons, which are systems that translate the user's body movements to activate motors that move the lower limbs through a predetermined gait pattern, have become available. As part of an ongoing clinical study (NCT01454570), eight nonambulatory persons with paraplegia were trained to ambulate with a powered exoskeleton. Measurements of oxygen uptake (VO2) and heart rate (HR) were recorded for 6 mm each during each maneuver while sitting, standing, and walking. The average value of VO2 during walking (11.2 +/- 1.7 mL/kg/min) was significantly higher than for sitting and standing (3.5 +/- 0.4 and 4.3 +/- 0.9 mL/kg/min, respectively; p < 0.001). The HR response during walking was significantly greater than that of either sitting or standing (118 +/- 21 vs 70 +/- 10 and 81 +/- 12 beats per minute, respectively; p < 0.001). Persons with paraplegia were able to ambulate efficiently using the powered exoskeleton for overground ambulation, providing the potential for functional gain and improved fitness. C1 [Asselin, Pierre; Knezevic, Steven; Kornfeld, Stephen; Cirnigliaro, Christopher; Bauman, William A.; Spungen, Ann M.] Natl Ctr Excellence Med Consequences Spinal Cord, Dept Vet Affairs VA Rehabil Res & Dev, Bronx, NY USA. [Kornfeld, Stephen] Spinal Cord Injury Patient Care Ctr, Bronx, NY USA. [Agranova-Breyter, Irina] James J Peters VA Med Ctr, Rehabil Med, Bronx, NY USA. [Bauman, William A.; Spungen, Ann M.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [Bauman, William A.; Spungen, Ann M.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA. RP Spungen, AM (reprint author), 130 W Kingsbridge Rd,Rm 7A-13, Bronx, NY 10468 USA. EM Ann.spungen@va.gov FU VA Rehabilitation Research & Development National Center of Excellence for the Medical Consequences of Spinal Cord Injury [VA RRD B9212C] FX Funding/Support: This material was based on work supported by the VA Rehabilitation Research & Development National Center of Excellence for the Medical Consequences of Spinal Cord Injury (VA RR&D B9212C). Two of the four ReWalk devices were obtained on a loaner basis at no cost from Argo Medical Technologies (Marlborough, Massachusetts). Orthopedic shoes used in this trial were donated by Aetrex Worldwide Inc. (Teaneck, New Jersey). NR 55 TC 5 Z9 5 U1 0 U2 10 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 EI 1938-1352 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2015 VL 52 IS 2 BP 147 EP 158 DI 10.1682/JRRD.2014.02.0060 PG 12 WC Rehabilitation SC Rehabilitation GA CK6DB UT WOS:000356317600003 PM 26230182 ER PT J AU Littman, AJ Thompson, ML Arterburn, DE Bouldin, E Haselkorn, JK Sangeorzan, BJ Boyko, EJ AF Littman, Alyson J. Thompson, Mary Lou Arterburn, David E. Bouldin, Erin Haselkorn, Jodie K. Sangeorzan, Bruce J. Boyko, Edward J. TI Lower-limb amputation and body weight changes in men SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE adult; lower-limb amputation; men; obesity; partial foot amputation; toe amputation; transfemoral amputation; transtibial amputation; Veterans; weight change ID CARDIOVASCULAR-DISEASE; UNITED-STATES; PSYCHOSOCIAL ADJUSTMENT; RISK-ADJUSTMENT; PREVALENCE; MORTALITY; VETERANS; AMPUTEES; OBESITY; HEALTH AB Little is known about the relationship between lower-limb amputation (LLA) and subsequent changes in body weight. We conducted a retrospective cohort study using clinical and administrative databases to identify and follow weight changes in 759 males with amputation (partial foot amputation [PFA], n = 396; transtibial amputation [TTA], n = 267; and transfemoral amputation [TFA], n = 96) and 3,790 men without amputation frequency-matched (5:1) on age, body mass index, diabetes, and calendar year from eight Department of Veterans Affairs medical care facilities in the Pacific Northwest. We estimated and compared longitudinal percent weight change from baseline up to 39 mo of follow-up in men with and without amputation. Weight gain in the 2 yr after amputation was significantly more in men with an amputation than without, and in men with a TTA or TFA (8%-9% increase) than in men with a PFA (3%-6% increase). Generally, percent weight gain peaked at 2 yr and was followed by some weight loss in the third year. These findings indicate that LLA is often followed by clinically important weight gain. Future studies are needed to better understand the reasons for weight gain and to identify intervention strategies to prevent excess weight gain and the deleterious consequences that may ensue. C1 [Littman, Alyson J.; Thompson, Mary Lou; Bouldin, Erin; Boyko, Edward J.] Dept Vet Affairs VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA. [Littman, Alyson J.; Bouldin, Erin; Haselkorn, Jodie K.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Thompson, Mary Lou] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Arterburn, David E.] Grp Hlth Res Inst, Seattle, WA USA. [Haselkorn, Jodie K.] Univ Washington, VA Puget Sound Hlth Care Syst, Multiple Sclerosis Ctr Excellence West, Seattle, WA 98195 USA. [Haselkorn, Jodie K.] Univ Washington, Dept Rehabil, Seattle, WA 98195 USA. [Haselkorn, Jodie K.; Sangeorzan, Bruce J.] Univ Washington, Harborview Med Ctr, VA Puget Sound Hlth Care Syst, VA Ctr Excellence Limb Loss Prevent & Prosthet En, Seattle, WA 98104 USA. [Haselkorn, Jodie K.; Sangeorzan, Bruce J.] Univ Washington, Harborview Med Ctr, Dept Orthopaed & Sports Med, Seattle, WA 98104 USA. RP Littman, AJ (reprint author), VA Puget Sound Med Ctr, Seattle Epidemiol Res & Informat Ctr, 1100 Olive Way,Metropolitan Pk West,Suite 1400, Seattle, WA 98101 USA. EM alyson.littman@va.gov OI Bouldin, Erin/0000-0001-7550-309X; Boyko, Edward/0000-0002-3695-192X FU VA Office of Research and Development Cooperative Studies Program; Seattle Epidemiologic Research and Information Center of the VA; VA Rehabilitation Research and Development Career Development Award [6982] FX Funding/Support: This material was based on work supported in part by the VA Office of Research and Development Cooperative Studies Program. The Seattle Epidemiologic Research and Information Center of the VA provided support for this research. Dr. Littman's time was also supported by a VA Rehabilitation Research and Development Career Development Award (grant 6982). NR 20 TC 2 Z9 2 U1 1 U2 6 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 EI 1938-1352 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2015 VL 52 IS 2 BP 159 EP 169 DI 10.1682/JRRD.2014.07.0166 PG 11 WC Rehabilitation SC Rehabilitation GA CK6DB UT WOS:000356317600004 PM 26244755 ER PT J AU Barks, L Luther, SL Brown, LM Schulz, B Bowen, ME Powell-Cope, G AF Barks, Lelia Luther, Stephen L. Brown, Lisa M. Schulz, Brian Bowen, Mary Elizabeth Powell-Cope, Gail TI Development and initial validation of the Seated Posture Scale SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE elder; geriatric; long-term care; posture; reliability; seat; SPS; validity; Veteran; wheelchair ID WHEELCHAIR; RELIABILITY; RESIDENTS; PERFUSION; PRESSURE; CHILDREN AB Literature shows that some health outcomes (e.g., eating, breathing, and speaking) are directly related to posture. Evidence of outcomes mediated by wheelchair seated posture is limited to interface pressure, physical function, and wheelchair skills and safety. This study's purpose was to develop and validate a rapid, low-burden, paper-pencil assessment of wheelchair seated posture for research use and to test feasibility of its use with a sample of older adults. We used a prospective design and a convenience sample of older adults who were receiving rehabilitation services in a community living center. Forty-nine older wheelchair users participated. Main measures were the Seated Posture Scale (SPS), Modified Ashworth Scale, Barthel Index, Visual Descriptor Scale, scale-content validity index (S-CVI), Cronbach alpha, and test-retest reliability. Rating by six experts yielded the overall content validity score (S-CVI) of 0.744. Total SPS score correlated positively with physical function (Barthel Index, r = 0.46, p < 0.001) and negatively with muscle tone (Modified Ashworth Scale, r = -0.44, p = 0.001), supporting SPS construct validity. Internal consistency was 0.66 (Cronbach alpha). Test-retest reliability yielded Pearson product-moment correlations of 0.89 to 0.99. We conclude that the SPS has sufficient preliminary validity and reliability to support its use as an evaluation of wheelchair seated posture in outcomes research. C1 [Barks, Lelia; Luther, Stephen L.; Brown, Lisa M.; Bowen, Mary Elizabeth; Powell-Cope, Gail] James A Haley Vet Hosp, Ctr Innovat Disabil & Rehabil Res, Tampa, FL 33612 USA. [Barks, Lelia; Luther, Stephen L.; Brown, Lisa M.; Bowen, Mary Elizabeth; Powell-Cope, Gail] Dept Vet Affairs VA, Rehabil Res & Dev Serv, Washington, DC USA. [Brown, Lisa M.; Schulz, Brian] Univ S Florida, Sch Aging Studies, Tampa, FL USA. [Bowen, Mary Elizabeth] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Bowen, Mary Elizabeth] Ctr West Chester Univ, W Chester, PA USA. RP Barks, L (reprint author), Hlth Serv Res & Dev Rehabil Res & Dev Ctr Innovat, 8900 Grand Oak Cir, Tampa, FL 33637 USA. EM Lelia.Barks@va.gov OI Powell-Cope, Gail/0000-0002-4608-0128 FU VA Office of Academic Affiliations; VA Office of Research and Development, Rehabilitation Research and Development Service (Career Development Award) [07646-W, 2] FX Funding/Support: This material was based on work supported initially by the VA Office of Academic Affiliations (postdoctoral fellowship) and later by the VA Office of Research and Development, Rehabilitation Research and Development Service (Career Development Award 2 No. 07646-W). NR 27 TC 0 Z9 0 U1 0 U2 0 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 EI 1938-1352 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2015 VL 52 IS 2 BP 201 EP 210 DI 10.1682/JRRD.2014.04.0100 PG 10 WC Rehabilitation SC Rehabilitation GA CK6DB UT WOS:000356317600008 PM 26230339 ER PT J AU Wilson, R Anzueto, A Miravitlles, M Arvis, P Haverstock, D Trajanovic, M Sethi, S AF Wilson, Robert Anzueto, Antonio Miravitlles, Marc Arvis, Pierre Haverstock, Daniel Trajanovic, Mila Sethi, Sanjay TI Prognostic factors for clinical failure of exacerbations in elderly outpatients with moderate-to-severe COPD SO INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE LA English DT Article DE AECOPD; clinical failure; prognostic factor; long-term outcome; poor outcome ID OBSTRUCTIVE PULMONARY-DISEASE; RANDOMIZED CONTROLLED-TRIAL; LONG-TERM OUTCOMES; CHRONIC-BRONCHITIS; ANTIBIOTIC-TREATMENT; ORAL PREDNISONE; MORTALITY; RISK; CARE; CORTICOSTEROIDS AB Background: Acute exacerbations represent a significant burden for patients with moderate-to-severe chronic obstructive pulmonary disease. Each exacerbation episode is frequently associated with a lengthy recovery and impaired quality of life. Prognostic factors for outpatients that may predict poor outcome after treatment with antibiotics recommended in the guidelines, are not fully understood. We aimed to identify pretherapy factors predictive of clinical failure in elderly (>= 60 years old) outpatients with acute Anthonisen type 1 exacerbations. Trial registration: NCT00656747. Methods: Based on the moxifloxacin in AECOPDs (acute exacerbations of chronic obstructive pulmonary disease) trial (MAESTRAL) database, this study evaluated pretherapy demographic, clinical, sputum bacteriological factors using multivariate logistic regression analysis, with internal validation by bootstrap replicates, to investigate their possible association with clinical failure at end of therapy (EOT) and 8 weeks posttherapy. Results: The analyses found that the independent factors predicting clinical failure at EOT were more frequent exacerbations, increased respiratory rate and lower body temperature at exacerbation, treatment with long-acting anticholinergic drugs, and in vitro bacterial resistance to study drug. The independent factors predicting poor outcome at 8 weeks posttherapy included wheezing at preexacerbation, mild or moderate (vs extreme) sleep disturbances, lower body temperature at exacerbation, forced expiratory volume in 1 second <30%, lower body mass index, concomitant systemic corticosteroids for the current exacerbation, maintenance long-acting beta(2)-agonist and long-acting anticholinergic treatments, and positive sputum culture at EOT. Conclusion: Several bacteriological, historical, treatment-related factors were identified as predictors of early (EOT) and later (8 weeks posttherapy) clinical failure in this older outpatient population with moderate-to-severe chronic obstructive pulmonary disease. These patients should be closely monitored and sputum cultures considered before and after treatment. C1 [Wilson, Robert] Royal Brompton Hosp, Host Def Unit, London SW3 6NP, England. [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Miravitlles, Marc] Hosp Univ Vall dHebron, CIBER Enfermedades Resp CIBERES, Pneumol Dept, Barcelona, Spain. [Arvis, Pierre] Bayer HealthCare Pharmaceut, Loos, France. [Haverstock, Daniel] Bayer HealthCare Pharmaceut, Whippany, NJ USA. [Trajanovic, Mila] Bayer HealthCare Pharmaceut, Toronto, ON, Canada. [Sethi, Sanjay] SUNY Buffalo, Buffalo, NY 14260 USA. RP Wilson, R (reprint author), Royal Brompton Hosp, Host Def Unit, Sydney St, London SW3 6NP, England. EM r.wilson@rbht.nhs.uk OI Miravitlles, Marc/0000-0002-9850-9520 FU Bayer HealthCare, Germany; Bayer HealthCare FX This study was supported by Bayer HealthCare, Germany. Editorial assistance was provided by Highfield Communication, Oxford, UK, sponsored by Bayer HealthCare. The authors thank Mr Feng Zhan, inVentive Health, US, for his invaluable support in the bootstrapping and logistic regression analyses. NR 38 TC 0 Z9 1 U1 2 U2 4 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1178-2005 J9 INT J CHRONIC OBSTR JI Int. J. Chronic Obstr. Pulm. Dis. PY 2015 VL 10 DI 10.2147/COPD.S80926 PG 9 WC Respiratory System SC Respiratory System GA CJ9VG UT WOS:000355850700001 ER PT J AU Steinhauer, SR Condray, R Pless, ML AF Steinhauer, Stuart R. Condray, Ruth Pless, Misha L. TI Pharmacological Isolation of Cognitive Components Influencing the Pupillary Light Reflex SO JOURNAL OF OPHTHALMOLOGY LA English DT Article ID NORADRENERGIC LOCUS-COERULEUS; FUNCTIONAL NEUROANATOMY; SCHIZOPHRENIC-PATIENTS; DAPIPRAZOLE; MODULATION; AROUSAL; ROLES AB Cognitive operations can be detected by reduction of the pupillary light response. Neurophysiological pathways mediating this reduction have not been distinguished. We utilized selective blockade of pupillary sphincter or dilator muscles to isolate parasympathetic or sympathetic activity during cognition, without modifying central processes. Pupil diameter was measured during the light reaction in 29 normal adults under three processing levels: No Task, during an easy task (Add 1), or a difficult task (Subtract 7). At three separate sessions, the pupil was treated with placebo, tropicamide (blocking the muscarinic sphincter receptor), or dapiprazole (blocking the adrenergic dilator receptor). With placebo, pupil diameter increased with increasing task difficulty. The light reaction was reduced only in the Subtract 7 condition. Dapiprazole (which decreased overall diameter) showed similar task-related changes in diameter and light reflex as for placebo. Following tropicamide (which increased overall diameter), there was a further increase in diameter only in the difficult task. Findings suggest two separate inhibitory components at the parasympathetic oculomotor center. Changes in baseline diameter are likely related to reticular activation. Inhibition of the light reaction in the difficult task is likely associated with cortical afferents. Sustained sympathetic activity also was present during the difficult task. C1 [Steinhauer, Stuart R.; Condray, Ruth] VA Pittsburgh Healthcare Syst, Biometr Res Program, Pittsburgh, PA 15240 USA. [Steinhauer, Stuart R.] Univ Pittsburgh, Dept Psychiat, Sch Med, Pittsburgh, PA 15260 USA. [Pless, Misha L.] Luzerner Kantonsspital, Zentrum Neurol & Neurorehabil, Leitender Arzt Neuroophthalmol & Neurol Augenklin, CH-6000 Luzern 16, Switzerland. RP Steinhauer, SR (reprint author), VA Pittsburgh Healthcare Syst, Biometr Res Program, 151R,Univ Dr C, Pittsburgh, PA 15240 USA. EM sthauer@pitt.edu FU USPHS Grant [MH55762]; Medical Research Service of the United States Department of Veterans Affairs FX This work was supported by USPHS Grant MH55762 and by the Medical Research Service of the United States Department of Veterans Affairs. The authors thank Dr. Richard Rosen for additional ophthalmological screening, and the nursing and pharmacy services of the VA Pittsburgh Healthcare System for valuable assistance. NR 24 TC 0 Z9 0 U1 2 U2 3 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 2090-004X EI 2090-0058 J9 J OPHTHALMOL JI J. Ophthalmol. PY 2015 AR 179542 DI 10.1155/2015/179542 PG 7 WC Medicine, Research & Experimental; Ophthalmology SC Research & Experimental Medicine; Ophthalmology GA CJ9EZ UT WOS:000355806600001 ER PT J AU Marzec, LN Carey, EP Lambert-Kerzner, AC Del Giacco, EJ Melnyk, SD Bryson, CL Fahdi, IE Bosworth, HB Fiocchi, F Ho, PM AF Marzec, Lucas N. Carey, Evan P. Lambert-Kerzner, Anne C. Del Giacco, Eric J. Melnyk, Stephanie D. Bryson, Chris L. Fahdi, Ibrahim E. Bosworth, Hayden B. Fiocchi, Fran Ho, P. Michael TI Cognitive dysfunction and poor health literacy are common in veterans presenting with acute coronary syndrome: insights from the MEDICATION study SO PATIENT PREFERENCE AND ADHERENCE LA English DT Article DE medication adherence ID UNIVERSITY MENTAL STATUS; MYOCARDIAL-INFARCTION; HOSPITAL DISCHARGE; HEART-FAILURE; ADHERENCE; INTERVENTION; DEMENTIA; DISCONTINUATION; PREVALENCE; MORTALITY AB Background: Patient nonadherence to cardiac medications following acute coronary syndrome (ACS) is associated with increased risk of recurrent events. However, the prevalence of cognitive dysfunction and poor health literacy among ACS patients and their association with medication nonadherence are poorly understood. Methods: We assessed rates of cognitive dysfunction and poor health literacy among participants of a clinical trial that tested the effectiveness of an intervention to improve medication adherence in patients hospitalized with ACS. Of 254 patients, 249 completed the Rapid Estimate of Adult Literacy in Medicine, Revised (REALM-R) survey, an assessment of risk for poor literacy, and the St Louis University Mental Status (SLUMS) exam, a tool assessing for neurocognitive deficits, during ACS hospitalization. We assessed if SLUMS or REALM-R scores were associated with medication adherence. Results: Based on SLUMS score, 14% of patients were categorized as having dementia, and 52% with mild neurocognitive disorder (MNCD). Based on REALM-R score of. 6, 34% of patients were categorized as at risk for poor health literacy. There was no association between poor health literacy and medication nonadherence. Of those with MNCD, 35.5% were nonadherent, compared to 17.5% with normal cognitive function and 6.7% with dementia. In multivariable analysis, cognitive dysfunction was associated with medication nonadherence (P=0.007), mainly due to an association between MNCD and nonadherence (odds ratio = 12.2, 95% confidence interval = 1.9 to 243; P= 0.007). Cognitive status was not associated with adherence in patients randomized to the intervention. Conclusion: Cognitive dysfunction and risk for poor health literacy are common in patients hospitalized with ACS. We found an association between MNCD and medication nonadherence in the usual care group but not in the intervention group. These findings suggest efforts to screen for MNCD are needed during ACS hospitalization to identify patients at risk for nonadherence and who may benefit from an adherence intervention. C1 [Marzec, Lucas N.; Carey, Evan P.; Lambert-Kerzner, Anne C.; Ho, P. Michael] Denver VA Med Ctr, Div Cardiol, Denver, CO USA. [Del Giacco, Eric J.; Fahdi, Ibrahim E.] Little Rock VA Med Ctr, Dept Med, Little Rock, AR USA. [Melnyk, Stephanie D.; Bosworth, Hayden B.] Durham VA Med Ctr, Dept Med, Durham, NC USA. [Bryson, Chris L.] Puget Sound VA Med Ctr, Dept Med, Seattle, WA USA. [Fiocchi, Fran] Amer Coll Cardiol, Washington, DC USA. RP Marzec, LN (reprint author), Acad Off 1, Room 7104,12631 E 17th Ave,Campus Box B-130, Aurora, CO 80045 USA. EM lucas.marzec@ucdenver.edu NR 22 TC 0 Z9 0 U1 2 U2 2 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1177-889X J9 PATIENT PREFER ADHER JI Patient Prefer. Adherence PY 2015 VL 9 BP 745 EP 751 DI 10.2147/PPA.S75110 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA CJ9WW UT WOS:000355855000001 PM 26089651 ER PT J AU Martinez, J Harris, C Jalali, C Tung, J Meyer, R AF Martinez, Johanna Harris, Christina Jalali, Cathy Tung, Judy Meyer, Robert TI Using peer-assisted learning to teach and evaluate residents' musculoskeletal skills SO MEDICAL EDUCATION ONLINE LA English DT Article DE medical education; clinical skills; OSCE; peer learning; physical exam ID MEDICAL-STUDENTS; EDUCATION; IMPLEMENTATION; RHEUMATOLOGY; KNOWLEDGE; FACULTY; EXAM AB Although direct observation and corrective feedback are established methods of increasing select aspects of residents' musculoskeletal (MSK) clinical skills, the evaluation and management of patients with MSK complaints remains an underemphasized part of internal medicine training. This paper reports on the development of an innovative peer-assisted learning (PAL) model to teach five MSK areas (back, knee, shoulder, neck, or hip pain). Based on data from 42 participating interns and 44 senior residents from an urban US academic medical center, results from an objective structured clinical exam (OSCE) demonstrate gains in both knowledge and self-reported confidence in MSK skills. Moreover, subsequent focus group results reveal a strong preference for the PAL model. In conclusion, an educational module that utilizes the OSCE format holds much promise for teaching MSK skills to both intern and senior residents. C1 [Martinez, Johanna; Jalali, Cathy; Tung, Judy; Meyer, Robert] New York Presbyterian Weill Cornell Med Ctr, New York, NY 10021 USA. [Harris, Christina] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. RP Martinez, J (reprint author), New York Presbyterian Weill Cornell Med Ctr, 505 East 70th St,HT 4, New York, NY 10021 USA. EM jom9050@med.cornell.edu NR 21 TC 1 Z9 1 U1 1 U2 6 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 1087-2981 J9 MED EDUC ONLINE JI Med. Educ. Online PY 2015 VL 20 AR 27255 DI 10.3402/meo.v20.27255 PG 4 WC Education & Educational Research SC Education & Educational Research GA CJ3SP UT WOS:000355404500001 PM 26028495 ER PT J AU Zulman, DM Chee, CP Wagner, TH Yoon, J Cohen, DM Holmes, TH Ritchie, C Asch, SM AF Zulman, Donna M. Chee, Christine Pal Wagner, Todd H. Yoon, Jean Cohen, Danielle M. Holmes, Tyson H. Ritchie, Christine Asch, Steven M. TI Multimorbidity and healthcare utilisation among high-cost patients in the US Veterans Affairs Health Care System SO BMJ OPEN LA English DT Article ID COMORBID MENTAL-DISORDERS; AVERAGE COST; VA; BENEFICIARIES; PREVALENCE; DEPRESSION; PRINCIPLES; MANAGEMENT; STAYS AB Objectives: To investigate the relationship between multimorbidity and healthcare utilisation patterns among the highest cost patients in a large, integrated healthcare system. Design: In this retrospective cross-sectional study of all patients in the U.S. Veterans Affairs (VA) Health Care System, we aggregated costs of individuals' outpatient and inpatient care, pharmacy services and VA-sponsored contract care received in 2010. We assessed chronic condition prevalence, multimorbidity as measured by comorbidity count, and multisystem multimorbidity (number of body systems affected by chronic conditions) among the 5% highest cost patients. Using multivariate regression, we examined the association between multimorbidity and healthcare utilisation and costs, adjusting for age, sex, race/ethnicity, marital status, homelessness and health insurance status. Setting: USAVA Health Care System. Participants: 5.2 million VA patients. Measures: Annual total costs; absolute and share of costs generated through outpatient, inpatient, pharmacy and VA-sponsored contract care; number of visits to primary, specialty and mental healthcare; number of emergency department visits and hospitalisations. Results: The 5% highest cost patients (n=261 699) accounted for 47% of total VA costs. Approximately two-thirds of these patients had chronic conditions affecting >= 3 body systems. Patients with cancer and schizophrenia were less likely to have documented comorbid conditions than other high-cost patients. Multimorbidity was generally associated with greater outpatient and inpatient utilisation. However, increased multisystem multimorbidity was associated with a higher outpatient share of total costs (1.6 percentage points per affected body system, p<0.01) but a lower inpatient share of total costs (-0.6 percentage points per affected body system, p<0.01). Conclusions: Multisystem multimorbidity is common among high-cost VA patients. While some patients might benefit from disease-specific programmes, for most patients with multimorbidity there is a need for interventions that coordinate and maximise efficiency of outpatient services across multiple conditions. C1 [Zulman, Donna M.; Chee, Christine Pal; Wagner, Todd H.; Yoon, Jean; Asch, Steven M.] VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, Menlo Pk, CA 94025 USA. [Zulman, Donna M.; Cohen, Danielle M.; Asch, Steven M.] Stanford Univ, Div Gen Med Disciplines, Stanford, CA 94305 USA. [Chee, Christine Pal; Wagner, Todd H.; Yoon, Jean] VA Palo Alto Hlth Care Syst, Hlth Econ Resource Ctr, Menlo Pk, CA USA. [Wagner, Todd H.] Stanford Univ, Hlth Res & Policy, Stanford, CA 94305 USA. [Holmes, Tyson H.] Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. [Ritchie, Christine] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Ritchie, Christine] San Francisco VA Med Ctr, San Francisco, CA USA. RP Zulman, DM (reprint author), VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, Menlo Pk, CA 94025 USA. EM dzulman@stanford.edu FU U.S. Department of Veterans Affairs (VA) HSR&D Career Development Award [CDA 12-173]; VA Office of Specialty Care Services (Specialty/Surgical Care Neighborhood Team Based Model Pilot Program); Advanced Illness and Multimorbidity Geriatric Academic Leadership Award [1K07AG31779]; [SDR-ECN-99017-1] FX DMZ is supported by a U.S. Department of Veterans Affairs (VA) HSR&D Career Development Award (CDA 12-173). CPC, THW, and JY received core funding SDR-ECN-99017-1 to the VA Health Economics Resource Center. THH and DMC are supported in part by the VA Office of Specialty Care Services (Specialty/Surgical Care Neighborhood Team Based Model Pilot Program). CR is supported by the Advanced Illness and Multimorbidity Geriatric Academic Leadership Award (1K07AG31779). NR 34 TC 12 Z9 12 U1 0 U2 3 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-6055 J9 BMJ OPEN JI BMJ Open PY 2015 VL 5 IS 4 AR e007771 DI 10.1136/bmjopen-2015-007771 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA CI4GB UT WOS:000354705000122 PM 25882486 ER PT J AU Morgan, P Embry, A Perry, L Holthaus, K Gregory, CM AF Morgan, Patrick Embry, Aaron Perry, Lindsay Holthaus, Katy Gregory, Chris M. TI Feasibility of lower-limb muscle power training to enhance locomotor function poststroke SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE exercise; locomotion; locomotor function; muscle; optimization of walking; poststroke; rehabilitation; strengthening; stroke; walking ID LEG POWER; CHRONIC STROKE; GAIT SPEED; PHYSICAL PERFORMANCE; KNEE EXTENSION; OLDER WOMEN; REHABILITATION; STRENGTH; MOBILITY; INDIVIDUALS AB Poststroke motor control is characterized by greatly reduced muscle power generation. To date, the extent to which muscle power limits walking performance or whether its remediation should be a primary component of locomotor rehabilitation has yet to be established. The purpose of this study was to examine the feasibility and the effects of Poststroke Optimization of Walking using Explosive Resistance training, an intervention aimed at improving poststroke muscular and locomotor function. Twelve subjects (6-60 mo poststroke) participated in 24 training sessions (3 sessions/wk for 8 wk). Exercises included leg press, calf raises, and jump training, all performed at high concentric velocity, as well as trials of fast walking. We measured self-selected and fastest comfortable walking speeds as well as knee extensor and plantar flexor strength and power at pretraining, posttraining, and 8 wk follow-up time points. In addition, we also performed a number of clinical assessments commonly used in poststroke rehabilitation trials. Following training, significant improvements in lower-limb muscle strength and power were realized and accompanied by improvements in self-selected as well as fastest comfortable walking speeds. No changes in clinical assessments resulted from training. C1 [Morgan, Patrick; Embry, Aaron; Perry, Lindsay; Holthaus, Katy; Gregory, Chris M.] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA. [Embry, Aaron; Perry, Lindsay; Gregory, Chris M.] Med Univ S Carolina, Div Phys Therapy, Charleston, SC 29425 USA. [Gregory, Chris M.] Vet Affairs Med Ctr, Ralph H Johnson Dept, Charleston, SC 29403 USA. RP Gregory, CM (reprint author), Med Univ S Carolina, Dept Hlth Sci & Res, 77 President St,MSC 700, Charleston, SC 29425 USA. EM gregoryc@musc.edu FU Department of Veterans Affairs (VA), Office of Research and Development, Rehabilitation Research and Development Service [AHA-11BGIA7450016]; Ralph H. Johnson VA Medical Center, Charleston, South Carolina FX Funding/Support: This material was based on work supported by the Department of Veterans Affairs (VA), Office of Research and Development, Rehabilitation Research and Development Service (grant AHA-11BGIA7450016) and the Ralph H. Johnson VA Medical Center, Charleston, South Carolina. NR 31 TC 2 Z9 2 U1 2 U2 8 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 EI 1938-1352 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2015 VL 52 IS 1 BP 77 EP 84 DI 10.1682/JRRD.2014.04.0109 PG 8 WC Rehabilitation SC Rehabilitation GA CI8YI UT WOS:000355057200008 PM 26186176 ER PT J AU Zhu, LX Davoodi, M Srivastava, MK Kachroo, P Lee, JM John, MS Harris-White, M Huang, M Strieter, RM Dubinett, S Sharma, S AF Zhu, Li X. Davoodi, Michael Srivastava, Minu K. Kachroo, Puja Lee, Jay M. John, Maie St. Harris-White, Marni Huang, Min Strieter, Robert M. Dubinett, Steven Sharma, Sherven TI GITR agonist enhances vaccination responses in lung cancer SO ONCOIMMUNOLOGY LA English DT Article DE APC; lung cancer; NK; T cell activation; vaccination responses ID INDUCED TNF RECEPTOR; T-CELLS; COSTIMULATORY RECEPTOR; TUMOR; SUPERFAMILY; ACTIVATION; IPILIMUMAB; CARCINOMA; MELANOMA; SURVIVAL AB An immune tolerant tumor microenvironment promotes immune evasion of lung cancer. Agents that antagonize immune tolerance will thus aid the fight against this devastating disease. Members of the tumor necrosis factor receptor (TNFR) family modulate the magnitude, duration and phenotype of immune responsiveness to antigens. Among these, GITR expressed on immune cells functions as a key regulator in inflammatory and immune responses. Here, we evaluate the GITR agonistic antibody (DTA-1) as a mono-therapy and in combination with therapeutic vaccination in murine lung cancer models. We found that DTA-1 treatment of tumor-bearing mice increased: (i) the frequency and activation of intratumoral natural killer (NK) cells and T lymphocytes, (ii) the antigen presenting cell (APC) activity in the tumor, and (iii) systemic T-cell specific tumor cell cytolysis. DTA-1 treatment enhanced tumor cell apoptosis as quantified by cleaved caspase-3 staining in the tumors. DTA-1 treatment increased expression of IFN gamma, TNF alpha and IL-12 but reduced IL-10 levels in tumors. Furthermore, increased anti-angiogenic chemokines corresponding with decreased pro-angiogenic chemokine levels correlated with reduced expression of the endothelial cell marker Meca 32 in the tumors of DTA-1 treated mice. In accordance, there was reduced tumor growth (8-fold by weight) in the DTA-1 treatment group. NK cell depletion markedly inhibited the antitumor response elicited by DTA-1. DTA-1 combined with therapeutic vaccination caused tumor rejection in 38% of mice and a 20-fold reduction in tumor burden in the remaining mice relative to control. Mice that rejected tumors following therapy developed immunological memory against subsequent re-challenge. Our data demonstrates GITR agonist antibody activated NK cell and T lymphocyte activity, and enhanced therapeutic vaccination responses against lung cancer. C1 [Zhu, Li X.; Srivastava, Minu K.; Kachroo, Puja; Lee, Jay M.; John, Maie St.; Huang, Min; Dubinett, Steven; Sharma, Sherven] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Lung Canc Res Program, Dept Med, Los Angeles, CA 90095 USA. [Zhu, Li X.; Davoodi, Michael; Srivastava, Minu K.; Lee, Jay M.; Harris-White, Marni; Huang, Min; Dubinett, Steven; Sharma, Sherven] Vet Affairs Greater Los Angeles Healthcare Syst, Mol Gene Med Lab, Los Angeles, CA USA. [Kachroo, Puja; Lee, Jay M.; John, Maie St.; Dubinett, Steven; Sharma, Sherven] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA. [Strieter, Robert M.] Univ Virginia, Dept Med, Charlottesville, VA USA. RP Sharma, S (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, UCLA Lung Canc Res Program, Dept Med, Los Angeles, CA 90095 USA. EM ssharma@mednet.ucla.edu FU University of California Los Angeles Lung Cancer Program, Department of Veterans Affairs Medical Research Funds, NIH [RO1 CA95686, RO1 CA126944, P50 CA90388]; National Center for Research Resources [UL1RR033176]; National Center for Advancing Translational Sciences [UL1TR000124]; Tobacco Related Disease Program Award Program of University of California [15RT-0207, 20FT0082] FX This work was supported by the: University of California Los Angeles Lung Cancer Program, Department of Veterans Affairs Medical Research Funds, NIH Grants (RO1 CA95686, RO1 CA126944 and P50 CA90388), National Center for Research Resources, Grant UL1RR033176, and is now at the National Center for Advancing Translational Sciences, Grant UL1TR000124 and Tobacco Related Disease Program Award Program of University of California (15RT-0207 and 20FT0082). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. NR 23 TC 1 Z9 1 U1 2 U2 3 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 2162-402X J9 ONCOIMMUNOLOGY JI OncoImmunology PY 2015 VL 4 IS 4 AR e992237 DI 10.4161/2162402X.2014.992237 PG 12 WC Oncology; Immunology SC Oncology; Immunology GA CH7NS UT WOS:000354224400011 ER PT J AU Shad, MU Prasad, K Forman, SD Haas, GL Walker, JD Pisarov, LA Goldstein, G AF Shad, Mujeeb U. Prasad, Konasale Forman, Steven D. Haas, Gretchen L. Walker, Jon D. Pisarov, Liubomir A. Goldstein, Gerald TI Insight and neurocognitive functioning in bipolar subjects SO COMPREHENSIVE PSYCHIATRY LA English DT Article ID MOOD DISORDERS; CHRONIC-ALCOHOLICS; CORPUS-CALLOSUM; EXECUTIVE FUNCTION; GRAY-MATTER; SCHIZOPHRENIA; ABNORMALITIES; PSYCHOSIS; ILLNESS; WHITE AB Background: Insight concerning having a mental illness has been found to influence outcome and effectiveness of treatment. It has been studied mainly in the area of schizophrenia with few studies addressing other disorders. This study evaluates insight in individuals with bipolar disorder using the Scale to Assess Unawareness of Mental Disorder (SUMD), a comprehensive interview for evaluation of awareness of illness and attribution of symptoms. The hypothesis was that in bipolar disorder level of awareness may be associated with numerous factors including neurocognitive function, structural changes in the frontal lobes and hippocampus evaluated by MRI, neurocognitive status, severity of mania and other psychiatric symptoms and comorbid alcoholism. Method: In order to evaluate this hypothesis 33 individuals with DSM-IV diagnosed bipolar disorder, some with and some without comorbid alcoholism, were administered the SUMD and a number of other procedures including a quantitative MR' measuring volume of the frontal lobes and hippocampus, a brief battery of neurocognitive tests, the Brief Psychiatric Rating Scale, and the Young Mania Rating Scale. The data were analyzed by comparing participants with and without alcoholism on these procedures using t tests and by linear multiple regression, with SUMD ratings of awareness and attribution as the dependent variables and variable sets from the other procedures administered as multivariate independent variables. Results: The median score obtained from the SUMD for current awareness was in a range between full awareness and uncertainty concerning presence of a mental disorder. For attribution, the median score indicated that attribution was usually made to the illness itself. None of the differences between participants with and without comorbid alcoholism were significant for the SUMD awareness and attribution scores, neurocognitive or MRI variables. The multiple regression analyses only showed a significant degree of association between the SUMD awareness score and the Young Mania Rating Scale (r(2) = .632, p < .05). A stepwise analysis indicated that items assessing degree of insight, irritability, and sleep disturbance met criteria for entry into the regression equation. None of the regression analyses for the SUMD attribution item were significant. Conclusions: Apparently unlike the case for schizophrenia, most of the participants, all of whom had bipolar disorder, were aware of their symptoms and correctly related them to a mental disorder. Hypotheses concerning the relationships between degree of unawareness and possible contributors to its development including comorbid alcoholism, cognitive dysfunction and structural reduction of gray matter in the frontal region and hippocampus, were not associated with degree of unawareness but symptoms of mania were significantly associated. The apparent reason for this result is that the sample obtained a SUMD modal awareness score of 1 or 2, reflecting the area between full awareness and uncertainty about having a mental disorder. None of the participants were rated as having a 5 response reflecting the belief that s/he does not have a mental disorder. Published by Elsevier Inc. C1 [Shad, Mujeeb U.] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA 15206 USA. [Prasad, Konasale; Forman, Steven D.; Haas, Gretchen L.; Goldstein, Gerald] Univ Pittsburgh, Sch Med, Dept Psychiat, Educ & Clin Ctr,VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Forman, Steven D.; Haas, Gretchen L.; Walker, Jon D.; Pisarov, Liubomir A.; Goldstein, Gerald] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr 4, Pittsburgh, PA 15206 USA. RP Goldstein, G (reprint author), VA Pittsburgh Healthcare Syst, 7180 Highland Dr 151R, Pittsburgh, PA 15206 USA. EM ggold@nb.net OI Prasad, Konasale/0000-0003-0245-1393 FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development; VISN 4 Mental Illness Research, Education, and Clinical Center (MIRECC), VA Pittsburgh Healthcare System FX This material is based upon work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development. The project was funded by infrastructure support funding from the VISN 4 Mental Illness Research, Education, and Clinical Center (MIRECC, Director: D. Oslin; Pittsburgh Site Director: G. Haas), VA Pittsburgh Healthcare System. NR 39 TC 0 Z9 0 U1 1 U2 7 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0010-440X EI 1532-8384 J9 COMPR PSYCHIAT JI Compr. Psychiat. PY 2015 VL 56 BP 112 EP 120 DI 10.1016/j.comppsych.2014.04.016 PG 9 WC Psychiatry SC Psychiatry GA CH2PM UT WOS:000353867100014 PM 25439524 ER PT S AU Abdallah, CG Averill, LA Krystal, JH AF Abdallah, Chadi G. Averill, Lynnette A. Krystal, John H. GP New York Acad Sci TI Ketamine as a promising prototype for a new generation of rapid-acting antidepressants SO TRANSLATIONAL NEUROSCIENCE IN PSYCHIATRY SE Annals of the New York Academy of Sciences LA English DT Article; Proceedings Paper CT Conference on Translational Psychiatry - Light at the End of the Tunnel CY APR 08, 2014 CL New York Acad Sci, New York, NY HO New York Acad Sci DE ketamine; depression; antidepressant; treatment mechanisms; neurobiology ID TREATMENT-RESISTANT DEPRESSION; D-ASPARTATE ANTAGONIST; POSTTRAUMATIC-STRESS-DISORDER; NMDA RECEPTOR BLOCKADE; LOW-DOSE KETAMINE; ADD-ON TRIAL; MAJOR DEPRESSION; ELECTROCONVULSIVE-THERAPY; INTRAVENOUS KETAMINE; BIPOLAR DEPRESSION AB The discovery of ketamine's rapid and robust antidepressant effects opened a window into a new generation of antidepressants. Multiple controlled trials and open-label studies have demonstrated these effects across a variety of patient populations known to often achieve little to no response from traditional antidepressants. Ketamine has been generally well tolerated across patient groups, with transient mild-to-moderate adverse effects during infusion. However, the optimal dosing and route of administration and the safety of chronic treatment are not fully known. This review summarizes the clinical effects of ketamine and its neurobiological underpinnings and mechanisms of action, which may provide insight into the neurobiology of depression, relevant biomarkers, and treatment targets. Moreover, we offer suggestions for future research that may continue to advance the field forward and ultimately improve the psychopharmacologic interventions available for those individuals struggling with depressive and trauma-related disorders. C1 [Abdallah, Chadi G.; Averill, Lynnette A.; Krystal, John H.] US Dept Vet Affairs, Clin Neurosci Div, Natl Ctr Posttraumat Stress Disorder, VA Connecticut Healthcare Syst, West Haven, CT USA. [Abdallah, Chadi G.; Averill, Lynnette A.; Krystal, John H.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. RP Abdallah, CG (reprint author), US Dept Vet Affairs, Clin Neurosci Div, Natl Ctr Posttraumat Stress Disorder, VA Natl Ctr PTSD, 950 Campbell Ave 151E, West Haven, CT 06516 USA. EM chadi.abdallah@yale.edu OI Abdallah, Chadi/0000-0001-5783-6181 FU Brain and Behavior Research Foundation (NARSAD); American Psychiatric Foundation; Genentech FX Dr. Averill declares no conflicts of interest. Dr. Abdallah has received research funding or consultation fees from the Brain and Behavior Research Foundation (NARSAD), the American Psychiatric Foundation, and Genentech. Dr. Krystal has served as a scientific consultant to the following companies (the individual consultant agreements listed are less than $10000/year): Aisling Capital, Astellas Pharma Global Development, AstraZeneca Pharmaceuticals, Biocortech, Brintnall & Nicolini, Easton Associates, Gilead Sciences, GlaxoSmithKline, Janssen Pharmaceuticals, Lundbeck Research USA, Medivation, Merz Pharmaceuticals, MK Medical Communications, Hoffmann-La Roche, SK Holdings, Sunovion Pharmaceuticals, Takeda Industries, and Teva Pharmaceutical Industries. He is on the Scientific Advisory Board for the following companies: Abbott Laboratories, Bristol-Myers Squibb, Eisai, Eli Lilly, Forest Laboratories, Lohocla Research Corporation, Mnemosyne Pharmaceuticals, Naurex, Pfizer Pharmaceuticals, and Shire Pharmaceuticals. He holds less than $150 in exercisable warrant options with Tetragenex Pharmaceuticals. He is also on the Board of Directors of the Coalition for Translational Research in Alcohol and Substance Use Disorders and was the principal investigator of a multicenter study in which Janssen Research Foundation provided drug and some support to the Department of Veterans Affairs. He is Editor of Biological Psychiatry. In addition, he has a patent on dopamine and noradrenergic reuptake inhibitors in the treatment of schizophrenia (patent number 5447948) and is a coinventor with Dr. Gerard Sanacora on a filed patent application by Yale University related to targeting the glutamatergic system for the treatment of neuropsychiatric disorders (PCTWO06108055A1). He has a patent pending on intranasal administration of ketamine to treat depression. NR 88 TC 30 Z9 31 U1 3 U2 13 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND SN 0077-8923 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2015 VL 1344 BP 66 EP 77 DI 10.1111/nyas.12718 PG 12 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA BC5PU UT WOS:000353469600006 PM 25727103 ER PT J AU Connelly, KJ Larson, EA Marks, DL Klein, RF AF Connelly, Kara J. Larson, Emily A. Marks, Daniel L. Klein, Robert F. TI Neonatal Estrogen Exposure Results in Biphasic Age-Dependent Effects on the Skeletal Development of Male Mice SO ENDOCRINOLOGY LA English DT Article ID HORMONE-RELEASING-HORMONE; SOMATOSTATIN GENE-EXPRESSION; PEAK BONE MASS; GROWTH-HORMONE; SEX STEROIDS; ANDROGEN INSENSITIVITY; SECRETORY PATTERNS; GONADAL-STEROIDS; CORTICAL BONE; MALE-RATS AB Peak bone mass, one of the most important predictors for fracture risk later in life, is attained during puberty and adolescence and influenced by neonatal and pubertal sex-specific gonadal hormones and GH-IGF-I secretion patterns. This study examined the effects of brief neonatal estrogen (NE) exposure on growth and skeletal development in C57BL/6J mice. A single injection of 100-mu g estradiol or vehicle was administered on the first day of life. Growth parameters were monitored and skeletal phenotyping performed at 16 weeks in female mice and at 4 and 16 weeks in male mice. NE exposure negatively impacted adult femoral length in both sexes, but adult body weight, areal bone density, and bone strength in female mice were unaffected. In contrast, somatic growth was attenuated in estrogen-exposed male mice throughout the study period. At the prepubertal time point, the estrogen-exposed males exhibited higher bone mineral density, cortical volume, and cortical thickness compared with controls. However, by the time of peak bone mass acquisition, the early skeletal findings had reversed; estrogen-exposed mice had lower bone density with reduced cross-sectional area, cortical volume, and cortical thickness, resulting in cortical bones that were less resistant to fracture. NE exposure also resulted in reduced testicular volume and lower circulating IGF-I. Male mice exposed to estrogen on the first day of life experience age-dependent changes in skeletal development. Prepubertal animals experience greater endocortical bone acquisition as a result of estrogen exposure. However, by adulthood, continued developmental changes result in overall reduced skeletal integrity. C1 [Connelly, Kara J.; Marks, Daniel L.] Oregon Hlth & Sci Univ, Doernbecher Childrens Hosp, Div Pediat Endocrinol, Dept Pediat, Portland, OR 97239 USA. [Larson, Emily A.; Klein, Robert F.] Oregon Hlth & Sci Univ, Bone & Mineral Res Unit, Dept Med, Portland, OR 97239 USA. [Marks, Daniel L.] Oregon Hlth & Sci Univ, Pape Pediat Res Inst, Portland, OR 97239 USA. [Klein, Robert F.] Portland VA Med Ctr, Portland, OR 97239 USA. RP Connelly, KJ (reprint author), Oregon Hlth & Sci Univ, Doernbecher Childrens Hosp, Child Dev & Rehabil Ctr Pediat CDRC P, 707 Southwest Gaines St, Portland, OR 97239 USA. EM connellk@ohsu.edu FU National Institutes of Health Grant [R01 AR44659, R01 DK070333, T32 DK7674-19]; Veterans Affairs Medical Research Service FX This work was supported by National Institutes of Health Grants R01 AR44659 (to R.F.K.) and R01 DK070333 (to D.L.M.), T32 DK7674-19 (to K.J.C.), and by the Veterans Affairs Medical Research Service (R.F.K.). NR 42 TC 2 Z9 2 U1 0 U2 1 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0013-7227 EI 1945-7170 J9 ENDOCRINOLOGY JI Endocrinology PD JAN PY 2015 VL 156 IS 1 BP 193 EP 202 DI 10.1210/en.2014-1324 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CG2TA UT WOS:000353126800021 PM 25330099 ER PT J AU Lombardi, A Inabnet, WB Owen, R Farenholtz, KE Tomer, Y AF Lombardi, Angela Inabnet, William Barlow, III Owen, Randall Farenholtz, Kaitlyn Ellen Tomer, Yaron TI Endoplasmic Reticulum Stress as a Novel Mechanism in Amiodarone-Induced Destructive Thyroiditis SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID UNFOLDED PROTEIN RESPONSE; ATRIAL-FIBRILLATION; ER STRESS; INDUCED THYROTOXICOSIS; RHEUMATOID-ARTHRITIS; HEART-FAILURE; MESSENGER-RNA; DISEASE; DEGRADATION; CHAPERONES AB Context: Amiodarone (AMIO) is one of the most effective antiarrhythmic drugs available; however, its use is limited by a serious side effect profile, including thyroiditis. The mechanisms underlying AMIO thyroid toxicity have been elusive; thus, identification of novel approaches in order to prevent thyroiditis is essential in patients treated with AMIO. Objective: Our aim was to evaluate whether AMIO treatment could induce endoplasmic reticulum (ER) stress in human thyroid cells and the possible implications of this effect in AMIO-induced destructive thyroiditis. Results: Here we report that AMIO, but not iodine, significantly induced the expression of ER stress markers including Ig heavy chain-binding protein (BiP), phosphoeukaryotic translation initiation factor 2 alpha (eIF2 alpha), CCAAT/enhancer-binding protein homologous protein (CHOP) and spliced X-box binding protein-1 (XBP-1) in human thyroid ML-1 cells and human primary thyrocytes. In both experimental systems AMIO down-regulated thyroglobulin (Tg) protein but had little effect on Tg mRNA levels, suggesting a mechanism involving Tg protein degradation. Indeed, pretreatment with the specific proteasome inhibitor MG132 reversed AMIO-induced down-regulation of Tg protein levels, confirming a proteasome-dependent degradation of Tg protein. Corroborating our findings, pretreatment of ML-1 cells and human primary thyrocytes with the chemical chaperone 4-phenylbutyric acid completely prevented the effect of AMIO on both ER stress induction and Tg down-regulation. Conclusions: We identified ER stress as a novel mechanism contributing to AMIO-induced destructive thyroiditis. Our data establish that AMIO-induced ER stress impairs Tg expression via proteasome activation, providing a valuable therapeutic avenue for the treatment of AMIO-induced destructive thyroiditis. C1 [Lombardi, Angela; Farenholtz, Kaitlyn Ellen; Tomer, Yaron] Icahn Sch Med Mt Sinai, Div Endocrinol, New York, NY 10029 USA. [Inabnet, William Barlow, III; Owen, Randall] Icahn Sch Med Mt Sinai, Dept Surg, New York, NY 10029 USA. [Tomer, Yaron] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA. RP Lombardi, A (reprint author), Icahn Sch Med Mt Sinai, Div Endocrinol, Box 1055,One Gustave L Levy Pl, New York, NY 10029 USA. EM angela.lombardi@mssm.edu; yaron.tomer@mssm.edu FU NIH from the National Institute of Diabetes and Digestive and Kidney Diseases [DK061659, DK067555, DK073681]; Department of Veterans Affairs FX This work was supported by NIH Grants DK061659, DK067555, and DK073681 from the National Institute of Diabetes and Digestive and Kidney Diseases In addition, this material is based upon work supported in part by the Department of Veterans Affairs. NR 51 TC 2 Z9 2 U1 1 U2 2 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD JAN PY 2015 VL 100 IS 1 BP E1 EP E10 DI 10.1210/jc.2014-2745 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CG4UA UT WOS:000353281300014 PM 25295624 ER PT J AU Koontz, AM Ding, D Jan, YK de Groot, S Hansen, A AF Koontz, Alicia M. Ding, Dan Jan, Yih-Kuen de Groot, Sonja Hansen, Andrew TI Wheeled Mobility SO BIOMED RESEARCH INTERNATIONAL LA English DT Editorial Material C1 [Koontz, Alicia M.; Ding, Dan] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA 15206 USA. [Koontz, Alicia M.; Ding, Dan] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA 15260 USA. [Jan, Yih-Kuen] Univ Illinois, Dept Kinesiol & Community Hlth, Champaign, IL 61820 USA. [de Groot, Sonja] Reade, Amsterdam Rehabil Res Ctr, NL-1040 HG Amsterdam, Netherlands. [de Groot, Sonja] Univ Groningen, Univ Med Ctr Groningen, Ctr Human Movement Sci, NL-9700 AB Groningen, Netherlands. [Hansen, Andrew] Minneapolis VA Healthcare Syst, Rehabil Engn Res Program, Minneapolis, MN 55417 USA. [Hansen, Andrew] Univ Minnesota, Program Rehabil Sci, Dept Phys Med & Rehabil, Minneapolis, MN 55455 USA. RP Koontz, AM (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA 15206 USA. EM akoontz@pitt.edu OI Jan, Yih-Kuen/0000-0001-7149-4034 NR 3 TC 0 Z9 0 U1 1 U2 3 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 2314-6133 EI 2314-6141 J9 BIOMED RES INT JI Biomed Res. Int. PY 2015 AR 138176 DI 10.1155/2015/138176 PG 2 WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Research & Experimental Medicine GA CF9LK UT WOS:000352886000001 ER PT B AU Felsenfeld, AJ Levine, BS AF Felsenfeld, Arnold J. Levine, Barton S. BE Kimmel, PL Rosenberg, ME TI Pathophysiology of Calcium, Phosphorus, and Magnesium in Chronic Kidney Disease SO CHRONIC RENAL DISEASE LA English DT Article; Book Chapter ID CHRONIC-RENAL-FAILURE; PARATHYROID-HORMONE LEVELS; GROWTH-FACTOR 23; LEFT-VENTRICULAR HYPERTROPHY; SERUM PHOSPHATE LEVELS; TRADE-OFF HYPOTHESIS; INTACT PTH LEVELS; HEMODIALYSIS-PATIENTS; VITAMIN-D; MINERAL METABOLISM C1 [Felsenfeld, Arnold J.; Levine, Barton S.] VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA 90073 USA. [Felsenfeld, Arnold J.; Levine, Barton S.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Felsenfeld, AJ (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA 90073 USA. NR 139 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND BN 978-0-12-411616-0; 978-0-12-411602-3 PY 2015 BP 391 EP 405 DI 10.1016/B978-0-12-411602-3.00033-0 PG 15 WC Primary Health Care; Urology & Nephrology SC General & Internal Medicine; Urology & Nephrology GA BC2OW UT WOS:000351158600033 ER PT J AU Khan, M Dhammu, TS Matsuda, F Baarine, M Dhindsa, TS Singh, I Singh, AK AF Khan, Mushfiquddin Dhammu, Tajinder S. Matsuda, Fumiyo Baarine, Mauhammad Dhindsa, Tejbir Singh Singh, Inderjit Singh, Avtar K. TI Promoting endothelial function by S-nitrosoglutathione through the HIF-1 alpha/VEGF pathway stimulates neurorepair and functional recovery following experimental stroke in rats SO DRUG DESIGN DEVELOPMENT AND THERAPY LA English DT Article DE GSNO; IR; HIF-1 alpha; VEGF; motor function; subtle behavior; neuroprotection; neurorepair; angiogenesis; S-nitrosylation; stroke ID TRAUMATIC BRAIN-INJURY; INDUCIBLE FACTOR-I; AMERICAN-HEART-ASSOCIATION; FOCAL CEREBRAL-ISCHEMIA; NITRIC-OXIDE DONORS; NEUROVASCULAR UNIT; LIQUID-CHROMATOGRAPHY; COGNITIVE IMPAIRMENT; PROTECTS BRAIN; CELL MIGRATION AB Background: For stroke patients, stimulating neurorepair mechanisms is necessary to reduce morbidity and disability. Our previous studies on brain and spinal cord trauma show that exogenous treatment with the S-nitrosylating agent S-nitrosoglutathione (GSNO) - a nitric oxide and glutathione metabolite of the human body - stimulates neurorepair and aids functional recovery. Using a rat model of cerebral ischemia and reperfusion (IR) in this study, we tested the hypothesis that GSNO invokes the neurorepair process and improves neurobehavioral functions through the angiogenic HIF-1 alpha/VEGF pathway. Methods: Stroke was induced by middle cerebral artery occlusion for 60 minutes followed by reperfusion in adult male rats. The injured animals were treated with saline (IR group, n=7), GSNO (0.25 mg/kg, GSNO group, n=7), and GSNO plus the HIF-1 alpha inhibitor 2-methoxyestradiol (2-ME) (0.25 mg/kg GSNO + 5.0 mg/kg 2-ME, GSNO + 2-ME group, n=7). The groups were studied for either 7 or 14 days to determine neurorepair mediators and functional recovery. Brain capillary endothelial cells were used to show that GSNO promotes angiogenesis and that GSNO-mediated induction of VEGF and the stimulation of angiogenesis are dependent on HIF-1 alpha activity. Results: IR injury increased the expression of neurorepair mediators HIF-1 alpha, VEGF, and PECAM-1 and vessel markers to a limited degree that correlate well with significantly compromised neurobehavioral functions compared with sham animals. GSNO treatment of IR not only remarkably enhanced further the expression of HIF-1 alpha, VEGF, and PECAM-1 but also improved functioning compared with IR. The GSNO group also had a higher degree of vessel density than the IR group. Increased expression of VEGF and the degree of tube formation (angiogenesis) by GSNO were reduced after the inhibition of HIF-1 alpha by 2-ME in an endothelial cell culture model. 2-ME treatment of the GSNO group also blocked not only GSNO's effect of reduced infarct volume, decreased neuronal loss, and enhanced expression of PECAM-1 (P<0.001), but also its improvement of motor and neurological functions (P<0.001). Conclusion: GSNO stimulates the process of neurorepair, promotes angiogenesis, and aids functional recovery through the HIF-1 alpha-dependent pathway, showing therapeutic and translational promise for stroke. C1 [Khan, Mushfiquddin; Dhammu, Tajinder S.; Matsuda, Fumiyo; Dhindsa, Tejbir Singh; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. [Matsuda, Fumiyo] Kagoshima Univ, Sch Hlth Sci, Kagoshima 890, Japan. [Baarine, Mauhammad; Singh, Avtar K.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. [Singh, Avtar K.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Singh, AK (reprint author), Med Univ S Carolina, Dept Pathol & Lab Med, 513 Childrens Res Inst,173 Ashley Ave, Charleston, SC 29425 USA. EM khanm@musc.edu; singha@musc.edu FU NIH [NS-72511]; VA merit award [BX001062]; NIH from the Extramural Research Facilities Program of the National Center for Research Resources [C06 RR018823, C06 RR015455] FX This work was supported by grants from NIH (NS-72511) and VA merit award (BX001062). This work was also supported by the NIH, Grants C06 RR018823 and No C06 RR015455 from the Extramural Research Facilities Program of the National Center for Research Resources. We thank Ms Joyce Bryan and Ms Terry Hope for their technical help and secretarial assistance. We are grateful to Dr Harutoshi Sakakima and Dr Yoshihiro Yoshida for their valuable input. We also acknowledge Dr Tom Smith and Dr Lisa Kerr from the MUSC Writing Center for their valuable editing of the manuscript. NR 76 TC 5 Z9 5 U1 3 U2 10 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1177-8881 J9 DRUG DES DEV THER JI Drug Des. Dev. Ther. PY 2015 VL 9 BP 2233 EP 2247 DI 10.2147/DDDT.S77115 PG 15 WC Chemistry, Medicinal; Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA CG1SN UT WOS:000353054400001 PM 25945035 ER PT J AU Batki, SL Schmeling, B Lasher, B Pennington, D Herbst, E Plaut, Z Striebel, J Vrana, S Straznickas, J AF Batki, Steven L. Schmeling, Brandi Lasher, Brooke Pennington, David Herbst, Ellen Plaut, Zachary Striebel, Joan Vrana, Sally Straznickas, John TI Combined Naltrexone and Topiramate Treatment of Veterans with Alcohol Use Disorder: A Case Series SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Meeting Abstract C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1055-0496 EI 1521-0391 J9 AM J ADDICTION JI Am. J. Addict. PD JAN PY 2015 VL 24 IS 1 BP 63 EP 64 PG 2 WC Substance Abuse SC Substance Abuse GA CE7NZ UT WOS:000352029900027 ER PT J AU Jha, MK Abele, M Brown, J AF Jha, Manish K. Abele, Misoo Brown, Julie TI Motivational Interviewing Education of General Psychiatry Residents SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Meeting Abstract C1 [Jha, Manish K.] North Texas State Hosp, BMT Program, Vernon, TX USA. [Abele, Misoo] Portland VA Med Ctr, Portland, OR USA. [Brown, Julie] VA North Texas Med Ctr, Dallas, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1055-0496 EI 1521-0391 J9 AM J ADDICTION JI Am. J. Addict. PD JAN PY 2015 VL 24 IS 1 BP 73 EP 73 PG 1 WC Substance Abuse SC Substance Abuse GA CE7NZ UT WOS:000352029900046 ER PT J AU Lache, D Ascher, M Wassef, T Dhopesh, V AF Lache, Daniel Ascher, Michael Wassef, Tamer Dhopesh, Vasant TI Prognosis of Cerebellar Ataxia in Alcohol Dependent Patients: A Case Report SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Meeting Abstract C1 Univ Penn, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1055-0496 EI 1521-0391 J9 AM J ADDICTION JI Am. J. Addict. PD JAN PY 2015 VL 24 IS 1 BP 75 EP 76 PG 2 WC Substance Abuse SC Substance Abuse GA CE7NZ UT WOS:000352029900051 ER PT J AU Santa Ana, E LaRowe, S Lamb, K Tompkins, M Hartwell, K AF Santa Ana, Elizabeth LaRowe, Steve Lamb, Kayla Tompkins, Michelle Hartwell, Karen TI Impact of Group Motivational Interviewing on Enhancing Treatment Engagement for Homeless Veterans with Nicotine Dependence and other Substance Use Disorders: A Pilot Investigation SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Meeting Abstract C1 Ralph H Johnson VA Med Ctr, Charleston, SC USA. Med Univ S Carolina, Charleston, SC USA. FU American Cancer Society, Institutional Research Grant [IRG-97-219-14] FX American Cancer Society, Institutional Research Grant #IRG-97-219-14. NR 0 TC 0 Z9 0 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1055-0496 EI 1521-0391 J9 AM J ADDICTION JI Am. J. Addict. PD JAN PY 2015 VL 24 IS 1 BP 81 EP 82 PG 2 WC Substance Abuse SC Substance Abuse GA CE7NZ UT WOS:000352029900063 ER PT J AU Liu, G Sprenger, C Wu, PJ Sun, SH Uo, T Haugk, K Epilepsia, KS Plymate, S AF Liu, Gang Sprenger, Cynthia Wu, Pin-Jou Sun, Shihua Uo, Takuma Haugk, Kathleen Epilepsia, Kathryn Soriano Plymate, Stephen TI MED1 mediates androgen receptor splice variant induced gene expression in the absence of ligand SO ONCOTARGET LA English DT Article ID RESISTANT PROSTATE-CANCER; ACTIVATED PROTEIN-KINASE; CELL-PROLIFERATION; COREGULATORY ROLE; BREAST-CANCER; T-ANTIGEN; CASTRATION; OVEREXPRESSION; PROGRESSION; GROWTH AB The appearance of constitutively active androgen receptor splice variants (AR-Vs) has been proposed as one of the causes of castration-resistant prostate cancer (CRPC). However, the underlying mechanism of AR-Vs in CRPC transcriptional regulation has not been defined. A distinct transcriptome enriched with cell cycle genes, e.g. UBE2C, has been associated with AR-Vs, which indicates the possibility of an altered transcriptional mechanism when compared to full-length wild-type AR (AR(fl)). Importantly, a recent study reported the critical role of p-MED1 in enhancing UBE2C expression through a locus looping pattern, which only occurs in CRPC but not in androgen-dependent prostate cancer (ADPC). To investigate the potential correlation between AR-V and MED1, in the present study we performed protein co-immunoprecipitation, chromatin immunoprecipitation, and cell proliferation assays and found that MED1 is necessary for AR(v567es) induced UBE2C up-regulation and subsequent prostate cancer cell growth. Furthermore, p-MED1 is bound to AR(v567es) independent of full-length AR; p-MED1 has higher recruitment to UBE2C promoter and enhancer regions in the presence of AR(v567es). Our data indicate that p-MED1 serves as a key mediator in AR(v567es) induced gene expression and suggests a mechanism by which AR-Vs promote the development and progression of CRPC. C1 [Liu, Gang; Sprenger, Cynthia; Wu, Pin-Jou; Sun, Shihua; Uo, Takuma; Epilepsia, Kathryn Soriano; Plymate, Stephen] Univ Washington, Dept Med, Seattle, WA 98104 USA. [Sprenger, Cynthia; Haugk, Kathleen; Plymate, Stephen] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98104 USA. RP Plymate, S (reprint author), Univ Washington, Dept Med, Seattle, WA 98104 USA. EM splymate@u.washington.edu FU National Cancer Institute Pacific Northwest Prostate Cancer Specialized Program of Research Excellence (SPORE) [2 P50 CA 097186-07]; US Army Medical Research and Materiel Command Prostate Cancer Research Programs [W81XWH-11-1-0551, W81XWH-13-2-0093]; Department of Veterans Affairs; [PO1 CA85859]; [P01 CA163227] FX We would like to thank Dr. Qianben Wang for providing the UBE2C luciferase reporter constructs and p-MED1 antibody. This work was supported by the National Cancer Institute Pacific Northwest Prostate Cancer Specialized Program of Research Excellence (SPORE; 2 P50 CA 097186-07 Project 5), PO1 CA85859, P01 CA163227, US Army Medical Research and Materiel Command Prostate Cancer Research Programs (W81XWH-11-1-0551 and W81XWH-13-2-0093), and Department of Veterans Affairs, to S.R.P. NR 55 TC 8 Z9 9 U1 0 U2 1 PU IMPACT JOURNALS LLC PI ALBANY PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA SN 1949-2553 J9 ONCOTARGET JI Oncotarget PD JAN 1 PY 2015 VL 6 IS 1 BP 288 EP 304 PG 17 WC Oncology; Cell Biology SC Oncology; Cell Biology GA CE8BE UT WOS:000352065200024 PM 25481872 ER PT J AU Almario, CV Chey, W Kaung, A Whitman, C Fuller, G Reid, M Nguyen, K Bolus, R Dennis, B Encarnacion, R Martinez, B Talley, J Modi, R Agarwal, N Lee, A Kubomoto, S Sharma, G Bolus, S Chang, L Spiegel, BMR AF Almario, Christopher V. Chey, William Kaung, Aung Whitman, Cynthia Fuller, Garth Reid, Mark Nguyen, Ken Bolus, Roger Dennis, Buddy Encarnacion, Rey Martinez, Bibiana Talley, Jennifer Modi, Rushaba Agarwal, Nikhil Lee, Aaron Kubomoto, Scott Sharma, Gobind Bolus, Sally Chang, Lin Spiegel, Brennan M. R. TI Computer-Generated Vs. Physician-Documented History of Present Illness (HPI): Results of a Blinded Comparison SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID PATIENT-REPORTED OUTCOMES; GASTROINTESTINAL SYMPTOM SCALES; RECORDS AB OBJECTIVES: Healthcare delivery now mandates shorter visits with higher documentation requirements, undermining the patient-provider interaction. To improve clinic visit efficiency, we developed a patient-provider portal that systematically collects patient symptoms using a computer algorithm called Automated Evaluation of Gastrointestinal Symptoms (AEGIS). AEGIS also automatically "translates" the patient report into a full narrative history of present illness (HPI). We aimed to compare the quality of computer-generated vs. physician-documented HPIs. METHODS: We performed a cross-sectional study with a paired sample design among individuals visiting outpatient adult gastrointestinal (GI) clinics for evaluation of active GI symptoms. Participants first underwent usual care and then subsequently completed AEGIS. Each individual thereby had both a physician-documented and a computer-generated HPI. Forty-eight blinded physicians assessed HPI quality across six domains using 5-point scales: (i) overall impression, (ii) thoroughness, (iii) usefulness, (iv) organization, (v) succinctness, and (vi) comprehensibility. We compared HPI scores within patient using a repeated measures model. RESULTS: Seventy-five patients had both computer-generated and physician-documented HPIs. The mean overall impression score for computer-generated HPIs was higher than physician HPIs (3.68 vs. 2.80; P < 0.001), even after adjusting for physician and visit type, location, mode of transcription, and demographics. Computer-generated HPIs were also judged more complete (3.70 vs. 2.73; P < 0.001), more useful (3.82 vs. 3.04; P < 0.001), better organized (3.66 vs. 2.80; P < 0.001), more succinct (3.55 vs. 3.17; P < 0.001), and more comprehensible (3.66 vs. 2.97; P < 0.001). CONCLUSIONS: Computer-generated HPIs were of higher overall quality, better organized, and more succinct, comprehensible, complete, and useful compared with HPIs written by physicians during usual care in GI clinics. C1 [Almario, Christopher V.; Kaung, Aung; Whitman, Cynthia; Fuller, Garth; Nguyen, Ken; Martinez, Bibiana; Talley, Jennifer; Modi, Rushaba; Agarwal, Nikhil; Lee, Aaron; Kubomoto, Scott; Sharma, Gobind; Spiegel, Brennan M. R.] Cedars Sinai Med Ctr, Div Gastroenterol, Los Angeles, CA 90048 USA. [Almario, Christopher V.; Kaung, Aung; Reid, Mark; Martinez, Bibiana; Talley, Jennifer; Modi, Rushaba; Agarwal, Nikhil; Spiegel, Brennan M. R.] VA Greater Angeles Healthcare Syst, Div Gastroenterol, Los Angeles, CA USA. [Almario, Christopher V.; Modi, Rushaba; Agarwal, Nikhil; Chang, Lin] Univ Calif Los Angeles, Div Digest Dis, Los Angeles, CA USA. [Almario, Christopher V.; Whitman, Cynthia; Fuller, Garth; Reid, Mark; Nguyen, Ken; Bolus, Roger; Martinez, Bibiana; Talley, Jennifer; Bolus, Sally; Spiegel, Brennan M. R.] Cedars Sinai Ctr Outcomes Res & Educ, Los Angeles, CA 90048 USA. [Chey, William] Univ Michigan, Div Gastroenterol, Ann Arbor, MI 48109 USA. [Dennis, Buddy; Encarnacion, Rey] Univ Calif Los Angeles, Comp Technol Res Lab, Los Angeles, CA USA. RP Spiegel, BMR (reprint author), Cedars Sinai Ctr Outcomes Res & Educ, Cedars Sinai Hlth Syst, Hlth Serv Res, Pacific Theaters Bldg,116 North Robertson Blvd, Los Angeles, CA 90048 USA. EM brennan.spiegel@cshs.org FU NIH/NIAMS [U01 AR057936A]; National Institutes of Health through the NIH Roadmap for Medical Research Grant [AR052177]; National Institutes of Health [NIH T32DK07180-39]; Ironwood Pharmaceuticals FX This study was supported by NIH/NIAMS U01 AR057936A, the National Institutes of Health through the NIH Roadmap for Medical Research Grant (AR052177). Dr Almario was supported by a National Institutes of Health T32 training grant (NIH T32DK07180-39) during his gastroenterology and health services research training at UCLA. Support for the My GI Health portal used in this study was obtained from Ironwood Pharmaceuticals. NR 23 TC 5 Z9 5 U1 1 U2 3 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD JAN PY 2015 VL 110 IS 1 BP 170 EP 179 DI 10.1038/ajg.2014.356 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CE5ZJ UT WOS:000351914700017 PM 25461620 ER PT J AU Anaya, HD Butler, JN Knapp, H Chan, K Conners, EE Rumanes, SF AF Anaya, Henry D. Butler, Jaimi N. Knapp, Herschel Chan, Kee Conners, Erin E. Rumanes, Sophia F. TI Implementing an HIV Rapid Testing-Linkage-to-Care Project Among Homeless Individuals in Los Angeles County: A Collaborative Effort Between Federal, County, and City Government SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID NEW-YORK-CITY; INJECTION-DRUG USERS; TUBERCULOSIS INFECTION; EMERGENCY-DEPARTMENT; SAN-FRANCISCO; UNITED-STATES; SEROPREVALENCE; ADULTS; RISK; PREVALENCE AB Objectives. We developed and implemented an HIV rapid testing-linkage-to-care initiative between federal and local government. Methods. We used mixed methodology; HIV testing data were collected on-site, and qualitative data were collected via telephone. We used postintervention stakeholder and staff interviews to evaluate barriers and facilitators to this initiative. Results. We tested 817 individuals. We identified and confirmed 7 preliminary HIV positive individuals (0.86% seropositivity), 5 of whom were linked to care. Mean testing cost was $ 48.95 per client; cost per positive result was $ 5714. Conclusions. This initiative can be used as a template for other health departments and research teams focusing on homelessness and mitigation of the HIV/ AIDS epidemic. C1 [Anaya, Henry D.; Butler, Jaimi N.; Knapp, Herschel; Conners, Erin E.] VA Greater Los Angeles Healthcare Syst, VA Greater Los Angeles Hlth Serv Res & Dev IISR&D, Vet Affairs VA Qual Enhancement Res Initiat HIV &, Los Angeles, CA USA. [Anaya, Henry D.; Butler, Jaimi N.; Knapp, Herschel; Conners, Erin E.] VA Greater Los Angeles Healthcare Syst, VA Greater Los Angeles Hlth Serv Res & Dev IISR&D, Ctr Study Healthcare Provider Behav, Los Angeles, CA USA. [Chan, Kee] Boston Univ, Dept Hlth Sci, Coll Hlth & Rehabil Sci, Sargent Coll, Boston, MA 02215 USA. [Rumanes, Sophia F.] Cty Los Angeles Dept Publ Hlth, Div HIV & STD Programs, Los Angeles, CA USA. RP Anaya, HD (reprint author), 11301 Wilshire Blvd 111G, Los Angeles, CA 90073 USA. EM hanaya@ucla.edu FU Gilead Sciences; David Geffen School of Medicine at the University of California, Los Angeles; University of California FX This research was funded by a Gilead Sciences grant awarded to H. D. Anaya and supported by the David Geffen School of Medicine at the University of California, Los Angeles.; The views and opinions expressed in this article are those of the authors and do not necessarily represent the views of Gilead Sciences or the University of California. Gilead Sciences and the University of California supported this study but had no input in the design or reporting or in the decision to submit this article for publication. NR 36 TC 2 Z9 2 U1 1 U2 2 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD JAN PY 2015 VL 105 IS 1 BP 85 EP 90 DI 10.2105/AJPH.2014.302213 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CE6BG UT WOS:000351920100031 PM 25393202 ER PT J AU Wang, XL Zhou, XH AF Wang, Xueli Zhou, Xiao-Hua TI Some Results About Standardization for a Non Confounder in Estimators of (log) Relative Risk SO COMMUNICATIONS IN STATISTICS-THEORY AND METHODS LA English DT Article DE Confounding; Non confounder; Precision; Relative risk; Standardization ID COLLAPSIBILITY; HOMOGENEITY AB Confounding is very fundamental to the design and analysis of studies of causal effects. A variable is not a confounder if it is not a risk factor to disease or if it has the same distribution in the exposed and unexposed population. Whether or not to adjust for a non confounder to improve the precision of estimation has been argued by many authors. This article shows that if C is a non confounder, the pooled and standardized (log) relative risk estimators are asymptotic normal distributions with the mean being the true (log) relative risk, and that the asymptotic variance of the pooled (log) relative risk estimator is less than that of the stratified estimator. C1 [Wang, Xueli] Beijing Univ Posts & Telecommun, Sch Sci, Beijing 100876, Peoples R China. [Wang, Xueli; Zhou, Xiao-Hua] VA Puget Sound Hlth Care Syst, HSR&D, Seattle, WA USA. [Wang, Xueli; Zhou, Xiao-Hua] Univ Washington, Dept Biostat, Washington, DC USA. [Zhou, Xiao-Hua] Peking Univ, Beijing Int Ctr Math Res, Beijing 100871, Peoples R China. RP Wang, XL (reprint author), Beijing Univ Posts & Telecommun, Sch Sci, Beijing 100876, Peoples R China. EM wangxl@bupt.edu.cn FU National Natural Science Foundation of China [NSFC 10801019, 11471053, 11401037]; Fundamental Research Funds for the Central Universities [BUPT 2012RC0708, 2014RC0905] FX This research was supported by the National Natural Science Foundation of China (NSFC 10801019, 11471053, and 11401037) and the Fundamental Research Funds for the Central Universities (BUPT 2012RC0708 and 2014RC0905). NR 21 TC 0 Z9 0 U1 1 U2 2 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0361-0926 EI 1532-415X J9 COMMUN STAT-THEOR M JI Commun. Stat.-Theory Methods PY 2015 VL 44 IS 7 BP 1497 EP 1507 DI 10.1080/03610926.2013.769599 PG 11 WC Statistics & Probability SC Mathematics GA CE7GF UT WOS:000352005700013 ER PT J AU Leff, B Carlson, CM Saliba, D Ritchie, C AF Leff, Bruce Carlson, Charlotte M. Saliba, Debra Ritchie, Christine TI The Invisible Homebound: Setting Quality-Of-Care Standards For Home-Based Primary And Palliative Care SO HEALTH AFFAIRS LA English DT Article ID OLDER-ADULTS; HOUSE CALLS; HEALTH; BENEFICIARIES; POPULATION; MANAGEMENT; VETERANS; DEATH; COST AB Approximately four million adults in the United States are homebound, and many of them cannot access office-based primary care. Home-based medical care can improve outcomes and reduce health care costs, but this care operates in a quality measurement desert, having been largely left out of the national conversation on care quality. To address this shortcoming, two of the authors created the National Home-Based Primary and Palliative Care Network, an organization whose members include exemplary home-based medical practices, professional societies, and patient advocacy groups. This article describes the current status of home-based medical care in the United States and offers a brief narrative of a fictional homebound patient and the health events and fragmented care she faces. The article then describes the network's quality-of-care framework, which includes ten quality-of-care domains, thirty-two standards, and twenty quality indicators that are being tested in the field. The same two authors also developed a practice-based registry that will be used for quality-of-care benchmarking, practice-based quality improvement, performance reporting, and comparative effectiveness research. Together, these steps should help bring home-based medical care further into the mainstream of US health care. C1 [Leff, Bruce] Johns Hopkins Univ, Sch Med, Med, Baltimore, MD 21205 USA. [Carlson, Charlotte M.] On Lok Senior Hlth Serv, San Francisco, CA USA. [Saliba, Debra] Univ Calif Los Angeles, Borun Ctr, Los Angeles, CA 90024 USA. [Saliba, Debra] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Ritchie, Christine] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. RP Leff, B (reprint author), Johns Hopkins Univ, Sch Med, Med, Baltimore, MD 21205 USA. EM bleff@jhmi.edu FU Retirement Research Foundation; Commonwealth Fund; California HealthCare Foundation; National Institutes of Health; Agency for Healthcare Research and Quality; John A. Hartford Foundation FX Portions of this work were presented at the annual meeting of the American Academy of Home Care Medicine, in Orlando, Florida, May 14, 2014. This work was supported by the Retirement Research Foundation, the Commonwealth Fund, and the California HealthCare Foundation. The views presented here are those of the authors and not necessarily those of the Commonwealth Fund, its directors, officers, or staff. Bruce Leff is a current member of the board of directors and past president of the American Academy of Home Care Medicine. He and Debra Saliba are members of the PostAcute Care/Long-Term Care Workgroup of the Measure Application Partnership at the National Quality Forum. Christine Ritchie is president-elect of the American Academy of Hospice and Palliative Medicine. She is a section editor for UpToDate, Inc. Leff and Ritchie have received grant funding from the Commonwealth Fund, the Retirement Research Foundation, the California HealthCare Foundation, the National Institutes of Health, and the Agency for Healthcare Research and Quality. Leff has also received funding from the John A. Hartford Foundation. The authors thank Diane Meier for her thoughtful review of the manuscript and Debbie Statom for her assistance in preparing the manuscript. NR 35 TC 14 Z9 14 U1 0 U2 7 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD JAN PY 2015 VL 34 IS 1 BP 21 EP 29 DI 10.1377/hlthaff.2014.1008 PG 9 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA CE3GZ UT WOS:000351716000005 PM 25561640 ER PT J AU Brommelhoff, JA Sultzer, DL AF Brommelhoff, Jessica A. Sultzer, David L. TI Brain Structure and Function Related to Depression in Alzheimer's Disease: Contributions from Neuroimaging Research SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Review DE Alzheimer's disease; depression; late-life depression; neuroimaging ID LATE-LIFE DEPRESSION; MILD COGNITIVE IMPAIRMENT; DORSOLATERAL PREFRONTAL CORTEX; EMISSION COMPUTED-TOMOGRAPHY; VOXEL-BASED MORPHOMETRY; DEFAULT-MODE NETWORK; WHITE-MATTER CHANGES; GERIATRIC DEPRESSION; RATING-SCALE; HIPPOCAMPAL VOLUME AB The development of minimally invasive in vivo methods for imaging the brain has allowed for unprecedented advancement in our understanding of brain-behavior relationships. Structural, functional, and multimodal neuroimaging techniques have become more sophisticated in detecting structural and physiological abnormalities that may underlie various affective disorders and neurological illnesses such as depression in Alzheimer's disease (AD). In general, neuroimaging studies of depression in AD investigate whether depression is associated with damage to structures in specific neural networks involving frontal and subcortical structures or with functional disruption of cortical neural systems. This review provides an overview of how various imaging modalities have contributed to our understanding of the neurobiology of depression in AD. At present, the literature does not conclusively support any specific pathogenesis for depression, and it is not clear whether patients with AD and depression have histopathological and neurochemical characteristics that contribute to mood symptoms that are different from cognitively intact individuals with depression. Neuroimaging studies suggest that atrophy of temporal or frontal structures, white matter lesions in frontal lobe or subcortical systems, reduced activity in dorsolateral frontal cortex, or small vessel cerebrovascular disease may be associated with depression in AD. Conceptual, clinical, and methodological challenges in studying this relationship are discussed. Further work is needed to understand the specific brain structures, relevant white matter tracts, and interactions among them that are most important. This review concludes with potential directions for future research. C1 [Brommelhoff, Jessica A.; Sultzer, David L.] Univ Calif Los Angeles, David Geffen Sch Med, Mental Hlth Serv, VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA 90095 USA. [Brommelhoff, Jessica A.; Sultzer, David L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. RP Sultzer, DL (reprint author), VA Greater Los Angeles Hlth Care Syst, 11301 Wilshire Blvd,Bldg 401,116AE, Los Angeles, CA 90073 USA. EM dsultzer@ucla.edu FU Department of Veteran Affairs (MIRECC Advanced Fellowship); Department of Veteran Affairs (Merit Review Research Grant) FX Supported in part by the Department of Veteran Affairs (MIRECC Advanced Fellowship, Dr. Brommelhoff; Merit Review Research Grant, Dr. Sultzer). NR 96 TC 5 Z9 6 U1 4 U2 11 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2015 VL 45 IS 3 BP 689 EP 703 DI 10.3233/JAD-148007 PG 15 WC Neurosciences SC Neurosciences & Neurology GA CE1YK UT WOS:000351608700002 PM 25633682 ER PT J AU Pan, C Korff, A Galasko, D Ginghina, C Peskind, E Li, G Quinn, J Montine, TJ Cain, K Shi, M Zhang, J AF Pan, Catherine Korff, Ane Galasko, Douglas Ginghina, Carmen Peskind, Elaine Li, Ge Quinn, Joseph Montine, Thomas J. Cain, Kevin Shi, Min Zhang, Jing TI Diagnostic Values of Cerebrospinal Fluid T-Tau and A beta(42) using Meso Scale Discovery Assays for Alzheimer's Disease SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE A beta(42); Alzheimer's disease; cerebrospinal fluid; Meso Scale Discovery; tau ID QUALITY-CONTROL PROGRAM; CSF ALPHA-SYNUCLEIN; BETA-AMYLOID 1-42; APOLIPOPROTEIN-E; ASSOCIATION WORKGROUPS; ANALYTICAL PLATFORMS; PARKINSONS-DISEASE; NATIONAL INSTITUTE; CONFIRMED DEMENTIA; VASCULAR DEMENTIA AB Background: Meso Scale Discovery (MSD) recently established electrochemiluminescence-based assays to measure cerebrospinal fluid (CSF) levels of total tau (t-tau) and amyloid-beta 1-42 peptide (A beta(42)) that can aid in the diagnosis of Alzheimer's disease (AD). The goal of this investigation is to independently evaluate this platform and establish cut-off values of these biomarkers for AD diagnosis. Objective: To validate the analytical and clinical performance of the MSD t-tau and A beta(42) kits and propose diagnostic cut-off values for the field. Methods: The analytical performance of the CSF t-tau and A beta(42) assays was determined, followed by assessment of diagnostic performance of CSF t-tau, A beta(42), and t-tau/A beta(42) in three clinically characterized cohorts. Results: Both MSD assays demonstrated consistent and stable analytical performance, as well as resistance to several important pre-analytic variables. Diagnostically, t-tau/A beta(42) performed the best. Conclusions: Our results independently confirm the analytical and clinical performance of the MSD CSF t-tau and A beta(42) assays. Based on a large, multi-center, clinically-diagnosed cohort, we propose for the first time candidate diagnostic cut-offs for MSD measured CSF t-tau, A beta(42), and t-tau/A beta(42). However, these values needs to be refined as more subjects are included and the assays are tested by other laboratories. C1 [Pan, Catherine; Korff, Ane; Ginghina, Carmen; Montine, Thomas J.; Shi, Min; Zhang, Jing] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98104 USA. [Galasko, Douglas] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA. [Peskind, Elaine] VA Puget Sound Hlth Care Syst, Northwest Network VISN 20, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. [Peskind, Elaine; Li, Ge] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Li, Ge] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Quinn, Joseph] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Quinn, Joseph] Portland VA Med Ctr, Portland, OR USA. [Cain, Kevin] Univ Washington, Sch Med, Dept Biostat, Seattle, WA 98195 USA. RP Zhang, J (reprint author), Univ Washington, Sch Med, Dept Pathol, HMC Box 359635,325 9th Ave, Seattle, WA 98104 USA. EM zhangj@uw.edu RI Shi, Min/G-6165-2012 OI Shi, Min/0000-0002-6901-2558 FU [NINDS: U01 NS082137 03]; [NIA: P50 AG005131 31]; [NIA: P30 AG008017 25]; [NIA: P50 AG005136 31] FX The authors' efforts were supported by the NINDS: U01 NS082137 03 and NIA: P50 AG005131 31, P30 AG008017 25, and P50 AG005136 31. The authors would also like to thank the Friends of Alzheimer's research and the Department of Veterans Affairs. MSD had no role in the design, conduct, or analysis of results of the current study. NR 52 TC 2 Z9 3 U1 0 U2 3 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2015 VL 45 IS 3 BP 709 EP 719 DI 10.3233/JAD-143099 PG 11 WC Neurosciences SC Neurosciences & Neurology GA CE1YK UT WOS:000351608700004 PM 25613100 ER PT J AU Gray, NE Sampath, H Zweig, JA Quinn, JF Soumyanath, A AF Gray, Nora E. Sampath, Harini Zweig, Jonathan A. Quinn, Joseph F. Soumyanath, Amala TI Centella asiatica Attenuates Amyloid-beta-Induced Oxidative Stress and Mitochondrial Dysfunction SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Amyloid-beta toxicity; calcium homeostasis; Centella asiatica; mitochondrial dysfunction; neuroprotection; reactive oxygen species ID ALZHEIMERS-DISEASE; SH-SY5Y CELLS; MOUSE MODEL; INDUCED NEUROTOXICITY; CAFFEOYLQUINIC ACIDS; CEREBRAL-CORTEX; IN-VIVO; NEURONS; PROTEIN; RATS AB Background: We previously showed that a water extract of the medicinal plant Centella asiatica (CAW) attenuates amyloid-beta (A beta)-induced cognitive deficits in vivo, and prevents A beta-induced cytotoxicity in vitro. Yet the neuroprotective mechanism of CAW is unknown. Objective: The goal of this study was to identify biochemical pathways altered by CAW using in vitro models of A beta toxicity. Methods: The effects of CAW on aberrations in antioxidant response, calcium homeostasis, and mitochondrial function induced by A beta were evaluated in MC65 and SH-SY5Y neuroblastoma cells. Results: CAW decreased intracellular reactive oxygen species and calcium levels elevated in response to A beta, and induced the expression of antioxidant response genes in both cell lines. In SH-SY5Y cells, CAW increased basal and maximal oxygen consumption without altering spare capacity, and attenuated A beta-induced decreases in mitochondrial respiration. CAW also prevented A beta-induced decreases in ATP and induced the expression of mitochondrial genes and proteins in both cell types. Caffeoylquinic acids from CAW were shown to have a similar effect on antioxidant and mitochondrial gene expression in neuroblastoma cells. Primary rat hippocampal neurons treated with CAW also showed an increase in mitochondrial and antioxidant gene expression. Conclusions: These data suggest an effect of CAW on mitochondrial biogenesis, which in conjunction with activation of antioxidant response genes and normalizing calcium homeostasis, likely contributes to its neuroprotective action against A beta toxicity. C1 [Gray, Nora E.; Quinn, Joseph F.; Soumyanath, Amala] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Sampath, Harini] Oregon Hlth & Sci Univ, Oregon Inst Occupat Hlth Sci, Portland, OR 97201 USA. [Zweig, Jonathan A.] Oregon Hlth & Sci Univ, Dept Cell Dev & Canc Biol, Portland, OR 97201 USA. [Quinn, Joseph F.] Portland VA Med Ctr, Dept Neurol, Portland, OR USA. [Quinn, Joseph F.] Portland VA Med Ctr, Parkinsons Dis Res Educ & Clin Care Ctr PADRECC, Portland, OR USA. RP Gray, NE (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA. EM grayn@ohsu.edu FU NIH-NCCAM grant [R01AT008099]; Oregon Alzheimer's Disease Center (OADC) [3P30-AG008017 24 S1]; OADC [5 P30 AG008017 24]; T32 grant from NIH-NCCAM [AT002688]; K99 grant [K99DK100640]; Department of Veterans Affairs Merit Review grant FX This work was funded by NIH-NCCAM grant R01AT008099, a grant awarded to A. Soumyanath from the Oregon Alzheimer's Disease Center (OADC) 3P30-AG008017 24 S1 and one to N. Gray from the OADC 5 P30 AG008017 24, a T32 grant on which N. Gray was a trainee from NIH-NCCAM AT002688, a K99 grant to H. Sampath K99DK100640 and by a Department of Veterans Affairs Merit Review grant awarded to J. Quinn. The authors acknowledge Dr. Stephen Lloyd for his assistance with the Seahorse XF Analyzer experiments and Barbara Smoody for her help with the primary neuron experiments. MC65 cells were generously provided by Randy Woltjer, MD, PhD. NR 53 TC 8 Z9 9 U1 0 U2 8 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2015 VL 45 IS 3 BP 933 EP 946 DI 10.3233/JAD-142217 PG 14 WC Neurosciences SC Neurosciences & Neurology GA CE1YK UT WOS:000351608700022 PM 25633675 ER PT J AU Trygstad, LN Buccheri, RK Buffum, MD Ju, DS Dowling, GA AF Trygstad, Louise Nigh Buccheri, Robin K. Buffum, Martha D. Ju, Dau-shen Dowling, Glenna A. TI Auditory Hallucinations Interview Guide Promoting Recovery with an Interactive Assessment Tool SO JOURNAL OF PSYCHOSOCIAL NURSING AND MENTAL HEALTH SERVICES LA English DT Article ID COMMAND HALLUCINATIONS; BEHAVIORAL-MANAGEMENT; SELF-MANAGEMENT; HARM AB The Auditory Hallucinations Interview Guide (AHIG) is a 32-item tool that helps psychiatric-mental health (PMH) nurses assess past and current experiences of voice hearers so they can provide more individualized care. The AHIG was developed as a research tool but has also been found to be clinically useful in both inpatient and outpatient settings to help voice hearers and nurses develop a shared terminology of auditory hallucinations (AH). Using the AHIG, voice hearers are able to tell their stories in a structured and safe environment, thus encouraging recovery. Through respect and active listening, PMH nurses can communicate unconditional acceptance, caring, and hope for recovery, which helps develop rapport and promote trust in the nurse-patient relationship. Once trust is developed, voice hearers and PMH nurses can work together to find effective strategies for managing AH, including commands to harm self and others. C1 [Trygstad, Louise Nigh; Buccheri, Robin K.] Univ San Francisco, DNP Dept, Sch Nursing & Hlth Profess, San Francisco, CA 94117 USA. [Buffum, Martha D.] Univ Calif San Francisco, Sch Nursing, Dept Community Hlth Syst, San Francisco, CA 94143 USA. [Dowling, Glenna A.] Univ Calif San Francisco, Sch Nursing, Dept Physiol Nursing, San Francisco, CA 94143 USA. [Ju, Dau-shen] Iowa City Vet Affairs Hlth Care Syst, Mental Hlth Serv Line, Iowa City, IA USA. [Buffum, Martha D.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Buccheri, RK (reprint author), Univ San Francisco, DNP Dept, Sch Nursing & Hlth Profess, Cowell Hall 222,2130 Fulton St, San Francisco, CA 94117 USA. EM buccherir@usfca.edu FU University of San Francisco Faculty Development Funds FX The authors have disclosed no potential conflicts of interest, financial or otherwise. This project was funded by a grant from the University of San Francisco Faculty Development Funds. This material is the result of work supported with resources and the use of facilities at the San Francisco Veterans Affairs Medical Center, San Francisco, California, and Iowa City Veterans Affairs Health Care System, Iowa City, Iowa. This article is dedicated to all of the psychiatric-mental health nurses and other mental health clinicians who work diligently to help their patients learn how to manage their auditory hallucinations and stay safe. NR 16 TC 0 Z9 0 U1 4 U2 5 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0279-3695 EI 1938-2413 J9 J PSYCHOSOC NURS MEN JI J. Psychosoc. Nurs. Ment. Health Serv. PD JAN PY 2015 VL 53 IS 1 BP 20 EP 28 DI 10.3928/02793695-20141203-01 PG 9 WC Nursing SC Nursing GA CE7IL UT WOS:000352012500009 PM 25490776 ER PT J AU Ehret, PJ LaBrie, JW Santerre, C Sherman, DK AF Ehret, Phillip J. LaBrie, Joseph W. Santerre, Craig Sherman, David K. TI Self-affirmation and motivational interviewing: integrating perspectives to reduce resistance and increase efficacy of alcohol interventions SO HEALTH PSYCHOLOGY REVIEW LA English DT Article DE message processing; intervention efficacy; self-affirmation theory; resistance; alcohol interventions; motivational interviewing ID HEALTH-RISK INFORMATION; RANDOMIZED CONTROLLED-TRIAL; POSITIVE-AFFECT; PHYSICAL-ACTIVITY; BEHAVIOR-CHANGE; DISSONANCE; STRESS; DEFENSIVENESS; VULNERABILITY; CONSEQUENCES AB To promote efforts at reducing problematic alcohol use and improving health outcomes, the present review proposes an integration of a social psychological approach - self-affirmation theory - with a clinical psychology intervention - motivational interviewing. Motivational interviewing (MI) is a popular empirically-designed treatment approach that has shown moderate success at reducing drinking and improving health, especially with resistant drinkers. Experiments informed by self-affirmation theory have found that people exhibit reduced defensiveness to threatening health messages and increased intentions to reduce alcohol consumption when affirmed. This review focuses on the mechanisms by which self-affirmation reduces resistance and how these mechanisms are complementary to the MI approach. Further, the review outlines suggestions for conducting and integrating self-affirmation into a MI intervention and provides recommendations for future empirical research. C1 [Ehret, Phillip J.; Sherman, David K.] Univ Calif Santa Barbara, Dept Psychol & Brain Sci, Santa Barbara, CA 93106 USA. [LaBrie, Joseph W.] Loyola Marymount Univ, Dept Psychol, Los Angeles, CA 90045 USA. [Santerre, Craig] Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA 98108 USA. RP Ehret, PJ (reprint author), Univ Calif Santa Barbara, Dept Psychol & Brain Sci, Santa Barbara, CA 93106 USA. EM ehret@psych.ucsb.edu NR 80 TC 2 Z9 2 U1 3 U2 16 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1743-7199 EI 1743-7202 J9 HEALTH PSYCHOL REV JI Health Psychol. Rev. PD JAN 1 PY 2015 VL 9 IS 1 BP 83 EP 102 DI 10.1080/17437199.2013.840953 PG 20 WC Psychology, Clinical SC Psychology GA CE3SJ UT WOS:000351748500010 PM 25793492 ER PT J AU Cummings, J Mintzer, J Brodaty, H Sano, M Banerjee, S Devanand, DP Gauthier, S Howard, R Lanctot, K Lyketsos, CG Peskind, E Porsteinsson, AP Reich, E Sampaio, C Steffens, D Wortmann, M Zhong, K AF Cummings, Jeffrey Mintzer, Jacobo Brodaty, Henry Sano, Mary Banerjee, Sube Devanand, D. P. Gauthier, Serge Howard, Robert Lanctot, Krista Lyketsos, Constantine G. Peskind, Elaine Porsteinsson, Anton P. Reich, Edgardo Sampaio, Cristina Steffens, David Wortmann, Marc Zhong, Kate TI Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition SO INTERNATIONAL PSYCHOGERIATRICS LA English DT Article DE Alzheimer's disease; agitation; cognitive impairment; aggression; International Psychogeriatric Association; Food and Drug Administration; clinical trials; intervention; epidemiology ID NEUROPSYCHIATRIC SYMPTOMS; ALZHEIMERS-DISEASE; BEHAVIORAL SYMPTOMS; NURSING-HOME; DEMENTIA; MANAGEMENT; EFFICACY; MEMORY AB Background: Agitation is common across neuropsychiatric disorders and contributes to disability, institutionalization, and diminished quality of life for patients and their caregivers. There is no consensus definition of agitation and no widespread agreement on what elements should be included in the syndrome. The International Psychogeriatric Association formed an Agitation Definition Work Group (ADWG) to develop a provisional consensus definition of agitation in patients with cognitive disorders that can be applied in epidemiologic, non-interventional clinical, pharmacologic, non-pharmacologic interventional, and neurobiological studies. A consensus definition will facilitate communication and cross-study comparison and may have regulatory applications in drug development programs. Methods: The ADWG developed a transparent process using a combination of electronic, face-to-face, and survey-based strategies to develop a consensus based on agreement of a majority of participants. Nine-hundred twenty-eight respondents participated in the different phases of the process. Results: Agitation was defined broadly as: (1) occurring in patients with a cognitive impairment or dementia syndrome; (2) exhibiting behavior consistent with emotional distress; (3) manifesting excessive motor activity, verbal aggression, or physical aggression; and (4) evidencing behaviors that cause excess disability and are not solely attributable to another disorder (psychiatric, medical, or substance-related). A majority of the respondents rated all surveyed elements of the definition as "strongly agree" or "somewhat agree" (68-88% across elements). A majority of the respondents agreed that the definition is appropriate for clinical and research applications. Conclusions: A provisional consensus definition of agitation has been developed. This definition can be used to advance interventional and non-interventional research of agitation in patients with cognitive impairment. C1 [Cummings, Jeffrey; Zhong, Kate] Cleveland Clin, Lou Ruvo Ctr Brain Hlth, Las Vegas, NV 89106 USA. [Mintzer, Jacobo] Roper St Francis Hosp, Clin Biotechnol Res Inst, Charleston, SC USA. [Brodaty, Henry] Univ New S Wales, Ctr Hlth Brain Ageing, Sydney, NSW, Australia. [Sano, Mary] Mt Sinai Sch Med, New York, NY USA. [Banerjee, Sube] Univ Sussex, Trafford Ctr Med Res, Brighton & Sussex Med Sch, Brighton, E Sussex, England. [Devanand, D. P.] New York State Psychiat Inst & Hosp, New York, NY 10032 USA. [Gauthier, Serge] Douglas Mental Hlth Univ Inst Montreal, McGill Ctr Studies Aging, Montreal, PQ, Canada. [Howard, Robert] Kings Coll London, Inst Psychiat, London WC2R 2LS, England. [Lanctot, Krista] Univ Toronto, Sunnybrook Res Inst, Toronto, ON, Canada. [Lyketsos, Constantine G.] Johns Hopkins Bayview Med Ctr, Johns Hopkins Memory & Alzheimers Treatment Ctr, Baltimore, MD USA. [Peskind, Elaine] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Porsteinsson, Anton P.] Monroe Community Hosp, Rochester, NY USA. [Reich, Edgardo] Univ Buenos Aires, Hosp Julio Mendez, Dept Neurosci, Buenos Aires, DF, Argentina. [Sampaio, Cristina] CHDI Fdn, Princeton, NJ USA. [Steffens, David] Univ Connecticut, Ctr Hlth, Dept Psychiat, Farmington, CT 06032 USA. [Wortmann, Marc] Alzheimers Dis Int, London, England. RP Cummings, J (reprint author), Cleveland Clin, Lou Ruvo Ctr Brain Hlth, 888 W Bonneville Ave, Las Vegas, NV 89106 USA. EM cumminj@ccf.org FU Otsuka and Avanir Pharmaceutricals; Eli Lilly; Associated Jewish Federation of Baltimore; Weinberg Foundation; Forest; GlaxoSmithKline; Eisai; Pfizer; Astra-Zeneca; Lilly; Ortho-McNeil; Bristol-Myers; Novartis; National Football League; Elan; Functional Neuromodulation; Takeda Global Research and Development Center; Genentech; Merck; Accera; Avanir; F. Hoffmann-La Roche; Baxter; Wyeth; Janssen Alzheimer Initiative; Genentech/Roche; Toyama; Bayer; MerckSerono; Mertz; Teva; National Institute of Mental Health; American Psychiatric Press FX The sponsors, Otsuka and Avanir Pharmaceutricals, gave unrestricted education grants to help support the international meeting that was part of the definition-building process.; Dr. Jeffrey Cummings has provided consultation to Acadia, ADAMAS, Anavex, Avanir, Boehinger-Ingelheim, Eisai, EnVivo, GE Healthcare, Genentech, Lilly, Lundbeck, Medavante, Merck, Novartis, Otsuka, Pfizer, Prana, QR Pharma, Resverlogix, Roche, Sonexa, Suven, Takeda, and Toyoma companies. Dr. Cummings owns the copyright of the Neuropsychiatric Inventory.; Professor Sube Banerjee has received consultancy fees, honoraria for speaking, and support in attending conferences from the makers of anti-dementia medication and other psychotropics, including Abbvie, Eisai, Pfizer, Novartis, Lilly, and Shire.; Professor Henry Brodaty has served as investigator for Janssen, Lilly, Medivation, Merck, Sanofi, Servier, and Tau Therapeutics, and has been on the advisory boards of Pfizer, Novartis, Janssen, Lundbeck, and Nutricia. Dr. Brodaty has provided consultation to Baxter, Lilly, Merck, and Nutricia.; D.P. Devanand has received research support from Eli Lilly, and has provided consultation to AbbVie.; Dr. Serge Gauthier has been on the scientific advisory board or investigator with Abbvie, Affiris, Eisai, Lilly, Navidea, Novartis, Pfizer, Sanofi-Synthelabo, Servier, and TauRx.; Professor Robert Howard reports that he has no relevant disclosures to make.; Dr. Krista Lanctot has had research support and/or speaker's honoraria from Abbvie Canada, Lundbeck Canada Inc., Pfizer Canada Inc., Janssen Ortho, and Rocheand Wyeth.; Dr. Constantine Lyketsos has received grant support (research or CME) from Associated Jewish Federation of Baltimore, Weinberg Foundation, Forest, GlaxoSmithKline, Eisai, Pfizer, Astra-Zeneca, Lilly, Ortho-McNeil, Bristol-Myers, Novartis, National Football League, Elan, and Functional Neuromodulation. Dr. Lyketsos has been a consultant or advisor to Astra-Zeneca, GlaxoSmithKline, Eisai, Novartis, Forest, Supernus, Adlyfe, Takeda, Wyeth, Lundbeck, Merz, Lilly, Pfizer, Genentech, Elan, NFL Players Association, NFL Benefits Office, Avanir, Zinfandel, BMS, Abvie, Janssen, and Orion. Honorarium or travel support has been received from Pfizer, Forest, GlaxoSmithKline, and Health Monitor.; Dr. Jacobo Mintzer reports receipt of grants to his institution from Takeda Global Research and Development Center, Pfizer, Genentech, Merck, Accera, Elan, Avanir, F. Hoffmann-La Roche, Novartis, Baxter, Eli Lilly, Wyeth, and Janssen Alzheimer Initiative; and employment with NeuroQuest, and BioPharma Connex.; Dr. Elaine Peskind has been on the speakers' bureau for Forest Pharmaceuticals and on the Advisory Committee for Avanir. Dr. Peskind served on the Adjudication Committee for Takeda Pharmaceuticals.; Dr. Anton Porsteinsson has received a grant for his institution from Avanir, Eisai, Elan, Genentech/Roche, Janssen Alzheimer Initiative, Merck, Pfizer, and Toyama. He has provided consultation for Elan, Janssen Alzheimer Initiative, and TransTech Pharma. Dr. Porsteinsson has membership on data safety and monitoring boards for Quintiles.; Dr. Edgardo Reich has participated as investigator in different pharmaceutical-sponsored trials for Ely Lilly, Glaxo, Forest, Mertz. Astra Zeneca, Novartis, Roche, and Janssen. He has received travel grants from Bayer, MerckSerono, Novartis, Mertz, and Teva.; Dr. Cristina Sampaio has been a consultant for Abbvie, Alkermes, AstraZeneca, Avanir, Biogen, BMS, Chelsea, Genzyme, Lilly, Lundbeck, Otsuka, Pfizer, Roche, Sanofi, Servier, Takeda, and Teva.; Dr. Mary Sano has been on the Scientific Advisory Board for Medication and as a consultant for Bayer Schering Pharma, Bristol-Meyers Squibb, Elan, Genentech, Medivation, Medpace, Pfizer, Janssen, Takeda, and United Biosource.; Dr. David Steffens is supported through grants from the National Institute of Mental Health, and he receives textbook royalties from the American Psychiatric Press.; Dr. Marc Wortmann reports no other salaries than from Alzheimer's Disease International.; Dr. Kate Zhong has provided consultation to Avanir, Pfizer, Janssen, and Wyeth Pharmaceuticals. NR 31 TC 27 Z9 27 U1 2 U2 11 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1041-6102 EI 1741-203X J9 INT PSYCHOGERIATR JI Int. Psychogeriatr. PD JAN PY 2015 VL 27 IS 1 BP 7 EP 17 DI 10.1017/S1041610214001963 PG 11 WC Psychology, Clinical; Geriatrics & Gerontology; Gerontology; Psychiatry; Psychology SC Psychology; Geriatrics & Gerontology; Psychiatry GA CD4LX UT WOS:000351055400003 PM 25311499 ER PT J AU Meeker, KD Meabon, JS Cook, DG AF Meeker, Kole D. Meabon, James S. Cook, David G. TI Partial Loss of the Glutamate Transporter GLT-1 Alters Brain Akt and Insulin Signaling in a Mouse Model of Alzheimer's Disease SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Amyloid-beta; EAAT2; excitotoxicity; GLT1; metabolism; SLC1A2 ID SYNAPTICALLY RELEASED GLUTAMATE; AMYOTROPHIC-LATERAL-SCLEROSIS; DEGRADING ENZYME; NEURODEGENERATIVE DISORDERS; HUNTINGTONS-DISEASE; COGNITIVE DECLINE; BETA-PEPTIDE; MICE LACKING; S6 KINASE; IN-VIVO AB The glutamate transporter GLT-1 (also called EAAT2 in humans) plays a critical role in regulating extracellular glutamate levels in the central nervous system (CNS). In Alzheimer's disease (AD), EAAT2 loss is associated with neuropathology and cognitive impairment. In keeping with this, we have reported that partial GLT-1 loss (GLT-1+/-) causes early-occurring cognitive deficits in mice harboring familial AD A beta PPswe/PS1 Delta E9 mutations. GLT-1 plays important roles in several molecular pathways that regulate brain metabolism, including Akt and insulin signaling in astrocytes. Significantly, AD pathogenesis also involves chronic Akt activation and reduced insulin signaling in the CNS. In this report we tested the hypothesis that GLT-1 heterozygosity (which reduces GLT-1 to levels that are comparable to losses in AD patients) in A beta PPswe/PS1 Delta E9 mice would induce sustained activation of Akt and disturb components of the CNS insulin signaling cascade. We found that partial GLT-1 loss chronically increased Akt activation (reflected by increased phosphorylation at serine 473), impaired insulin signaling (reflected by decreased IR beta phosphorylation of tyrosines 1150/1151 and increased IRS-1 phosphorylation at serines 632/635 - denoted as 636/639 in humans), and reduced insulin degrading enzyme (IDE) activity in brains of mice expressing familial A beta PPswe/PS1 Delta E9 AD mutations. GLT-1 loss also caused an apparent compensatory increase in IDE activity in the liver, an organ that has been shown to regulate peripheral amyloid-beta levels and expresses GLT-1. Taken together, these findings demonstrate that partial GLT-1 loss can cause insulin/Akt signaling abnormalities that are in keeping with those observed in AD. C1 [Meeker, Kole D.; Cook, David G.] Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA. [Meeker, Kole D.; Cook, David G.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Meabon, James S.] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Meabon, James S.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Cook, David G.] Univ Washington, Sch Med, Dept Med, Div Gerontol, Seattle, WA 98195 USA. RP Cook, DG (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, 1660 S Columbian Way, Seattle, WA 98108 USA. EM dgcook@u.washington.edu FU Veteran's Affairs Office of Research and Development Medical Research Service; NIH Pharmacological Sciences training grant [5T32GM00775033]; NIH [T32 AG000258]; Cellular Functional Analysis Core of the University of Washington Diabetes Research Center [PO1 DK17047] FX This work was supported by funding from the Veteran's Affairs Office of Research and Development Medical Research Service (DGC), an NIH Pharmacological Sciences training grant [5T32GM00775033] (KDM), an NIH institutional fellowship [T32 AG000258] (JSM), and services by the Cellular Functional Analysis Core of the University of Washington Diabetes Research Center (PO1 DK17047). Original GLT-1 (+/-) mice were graciously made availabe by Kohichi Tanaka (Tokyo Medical and Dental University). NR 75 TC 8 Z9 8 U1 0 U2 5 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2015 VL 45 IS 2 BP 509 EP 520 DI 10.3233/JAD-142304 PG 12 WC Neurosciences SC Neurosciences & Neurology GA CE1PL UT WOS:000351583900017 PM 25589729 ER PT J AU Wang, XB Lopez, O Sweet, RA Becker, JT DeKosky, ST Barmada, MM Feingold, E Demirci, FY Kamboh, MI AF Wang, Xingbin Lopez, Oscar Sweet, Robert A. Becker, James T. DeKosky, Steven T. Barmada, Mahmud M. Feingold, Eleanor Demirci, F. Yesim Kamboh, M. Ilyas TI Genetic Determinants of Survival in Patients with Alzheimer's Disease SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Gene-based analysis; genome-wide association studies; late-onset Alzheimer's disease; survival ID GENOME-WIDE ASSOCIATION; APOLIPOPROTEIN-E; INCREASED RISK; PROMOTER POLYMORPHISM; INTERLEUKIN-10 GENE; IDENTIFIES VARIANTS; COMMON VARIANTS; POPULATION; DEMENTIA; MORTALITY AB There is a strong genetic basis for late-onset of Alzheimer's disease (LOAD), and thus far >20 genes/loci have been identified that affect the risk of LOAD. In addition to disease risk, genetic variation at these loci may also affect components of the natural history of AD, such as survival in AD. In this study, we first examined the role of known LOAD genes with survival time in 983 AD patients. We then performed genome-wide single-nucleotide polymorphism (SNP) and gene-based association analyses to identify novel loci that may influence survival of AD. Survival analysis was conducted using Cox proportional hazards regression under an additive genetics model. We found multiple nominally significant associations (p < 0.01) either within or adjacent to known LOAD genes. Genome-wide SNP analysis identified multiple suggestive novel loci and two of them were also significant in gene-based analysis (CCDC85C and NARS2) that survived after controlling for false-discovery rate at 0.05. In summary, we have identified two novel genes for survival in AD that need to be replicated in independent samples. Our findings highlight the importance of focusing on AD-related phenotypes that may help to identify additional genes relevant to AD. C1 [Wang, Xingbin; Barmada, Mahmud M.; Feingold, Eleanor; Demirci, F. Yesim; Kamboh, M. Ilyas] Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA 15261 USA. [Wang, Xingbin; Feingold, Eleanor] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA. [Lopez, Oscar; Sweet, Robert A.; Becker, James T.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15261 USA. [Lopez, Oscar; Sweet, Robert A.; Becker, James T.; Kamboh, M. Ilyas] Univ Pittsburgh, Alzheimers Dis Res Ctr, Pittsburgh, PA 15261 USA. [Sweet, Robert A.; Kamboh, M. Ilyas] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15261 USA. [DeKosky, Steven T.] Univ Virginia, Sch Med, Dept Neurol, Charlottesville, VA 22908 USA. [Sweet, Robert A.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 4, Pittsburgh, PA 15261 USA. RP Kamboh, MI (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA. EM kamboh@pitt.edu OI Feingold, Eleanor/0000-0003-2898-6484; Demirci, F. Yesim/0000-0001-6907-9843; Kamboh, M. Ilyas/0000-0002-3453-1438; Barmada, M Michael/0000-0002-3604-6460 FU National Institutes of Health [AG030653, AG041718, AG005133, AG027224] FX This study was supported by the National Institutes of Health grants AG030653, AG041718, AG005133, and AG027224. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Department of Veterans Affairs, the National Institutes of Health, or the United States Government. NR 51 TC 0 Z9 0 U1 0 U2 3 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2015 VL 45 IS 2 BP 651 EP 658 DI 10.3233/JAD-142442 PG 8 WC Neurosciences SC Neurosciences & Neurology GA CE1PL UT WOS:000351583900029 PM 25649651 ER EF